



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## **Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis (Review)**

Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, Maxwell LJ, Shah NP, Tugwell P, Wells GA

Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, Maxwell LJ, Shah NP, Tugwell P, Wells GA. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. *Cochrane Database of Systematic Reviews* 2016, Issue 5. Art. No.: CD012183. DOI: [10.1002/14651858.CD012183](https://doi.org/10.1002/14651858.CD012183).

[www.cochranelibrary.com](http://www.cochranelibrary.com)

**Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis (Review)**

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**WILEY**

**TABLE OF CONTENTS**

HEADER .....	1
ABSTRACT .....	1
PLAIN LANGUAGE SUMMARY .....	2
BACKGROUND .....	5
OBJECTIVES .....	6
METHODS .....	6
Figure 1. ....	8
RESULTS .....	10
Figure 2. ....	12
Figure 3. ....	14
Figure 4. ....	16
Figure 5. ....	18
Figure 6. ....	19
Figure 7. ....	20
Figure 8. ....	21
Figure 9. ....	22
Figure 10. ....	24
Figure 11. ....	25
Figure 12. ....	27
Figure 13. ....	29
Figure 14. ....	31
Figure 15. ....	32
DISCUSSION .....	35
AUTHORS' CONCLUSIONS .....	39
ACKNOWLEDGEMENTS .....	39
REFERENCES .....	40
ADDITIONAL TABLES .....	57
APPENDICES .....	65
WHAT'S NEW .....	585
HISTORY .....	585
CONTRIBUTIONS OF AUTHORS .....	585
DECLARATIONS OF INTEREST .....	585
SOURCES OF SUPPORT .....	586
NOTES .....	586
INDEX TERMS .....	586

## [Overview of Reviews]

# Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis

Jasvinder A Singh<sup>1</sup>, Alomgir Hossain<sup>2</sup>, Elizabeth Tanjong Ghogomu<sup>3</sup>, Ahmed Kotb<sup>2</sup>, Robin Christensen<sup>4</sup>, Amy S Mudano<sup>5</sup>, Lara J Maxwell<sup>6</sup>, Nipam P Shah<sup>7</sup>, Peter Tugwell<sup>8</sup>, George A Wells<sup>9</sup>

<sup>1</sup>Department of Medicine, Birmingham VA Medical Center, Birmingham, AL, USA. <sup>2</sup>Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Canada. <sup>3</sup>Bruyère Research Institute, University of Ottawa, Ottawa, Canada. <sup>4</sup>Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg og Frederiksberg, Copenhagen, Denmark. <sup>5</sup>Department of Medicine - Rheumatology, University of Alabama at Birmingham, Birmingham, USA. <sup>6</sup>Centre for Practice-Changing Research (CPCR), Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital - General Campus, Ottawa, Canada. <sup>7</sup>Department of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA. <sup>8</sup>Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada. <sup>9</sup>Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada

**Contact address:** Jasvinder A Singh, Department of Medicine, Birmingham VA Medical Center, Faculty Office Tower 805B, 510 20th Street South, Birmingham, AL, 35294, USA. [jasvinder.md@gmail.com](mailto:jasvinder.md@gmail.com).

**Editorial group:** Cochrane Musculoskeletal Group.

**Publication status and date:** New, published in Issue 5, 2016.

**Citation:** Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, Maxwell LJ, Shah NP, Tugwell P, Wells GA. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. *Cochrane Database of Systematic Reviews* 2016, Issue 5. Art. No.: CD012183. DOI: [10.1002/14651858.CD012183](https://doi.org/10.1002/14651858.CD012183).

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

This is an update of the 2009 Cochrane overview and network meta-analysis (NMA) of biologics for rheumatoid arthritis (RA).

### Objectives

To assess the benefits and harms of nine biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) and small molecule tofacitinib, versus comparator (MTX, DMARD, placebo (PL), or a combination) in adults with rheumatoid arthritis who have failed to respond to methotrexate (MTX) or other disease-modifying anti-rheumatic drugs (DMARDs), i.e., MTX/DMARD incomplete responders (MTX/DMARD-IR).

### Methods

We searched for randomized controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL) (via *The Cochrane Library* Issue 6, June 2015), MEDLINE (via OVID 1946 to June 2015), and EMBASE (via OVID 1947 to June 2015). Data extraction, risk of bias and GRADE assessments were done in duplicate. We calculated both direct estimates using standard meta-analysis and used Bayesian mixed treatment comparisons approach for NMA estimates to calculate odds ratios (OR) and 95% credible intervals (CrI). We converted OR to risk ratios (RR) which are reported in the abstract for the ease of interpretation.

## Main results

This update included 73 new RCTs for a total of 90 RCTs; 79 RCTs with 32,874 participants provided usable data. Few trials were at high risk of bias for blinding of assessors/participants (13% to 21%), selective reporting (4%) or major baseline imbalance (8%); a large number had unclear risk of bias for random sequence generation (68%) or allocation concealment (74%).

Based on direct evidence of moderate quality (downgraded for inconsistency), biologic+MTX/DMARD was associated with a statistically significant and clinically meaningful improvement in ACR50 versus comparator (RR 2.71 (95% confidence interval (CI) 2.36 to 3.10); absolute benefit 24% more patients (95% CI 19% to 29%), number needed to treat for an additional beneficial outcome (NNTB) = 5 (4 to 6). NMA estimates for ACR50 in tumor necrosis factor (TNF) biologic+MTX/DMARD (RR 3.23 (95% credible interval (CrI) 2.75 to 3.79), non-TNF biologic+MTX/DMARD (RR 2.99; 95% CrI 2.36 to 3.74), and anakinra + MTX/DMARD (RR 2.37 (95% CrI 1.00 to 4.70) were similar to the direct estimates.

Based on direct evidence of moderate quality (downgraded for inconsistency), biologic+MTX/DMARD was associated with a clinically and statistically important improvement in function measured by the Health Assessment Questionnaire (0 to 3 scale, higher = worse function) with a mean difference (MD) based on direct evidence of -0.25 (95% CI -0.28 to -0.22); absolute benefit of -8.3% (95% CI -9.3% to -7.3%), NNTB = 3 (95% CI 2 to 4). NMA estimates for TNF biologic+MTX/DMARD (absolute benefit, -10.3% (95% CrI -14% to -6.7%) and non-TNF biologic+MTX/DMARD (absolute benefit, -7.3% (95% CrI -13.6% to -0.67%) were similar to respective direct estimates.

Based on direct evidence of moderate quality (downgraded for inconsistency), biologic+MTX/DMARD was associated with clinically and statistically significantly greater proportion of participants achieving remission in RA (defined by disease activity score DAS < 1.6 or DAS28 < 2.6) versus comparator (RR 2.81 (95% CI, 2.23 to 3.53); absolute benefit 18% more patients (95% CI 12% to 25%), NNTB = 6 (4 to 9)). NMA estimates for TNF biologic+MTX/DMARD (absolute improvement 17% (95% CrI 11% to 23%)) and non-TNF biologic+MTX/DMARD (absolute improvement 19% (95% CrI 12% to 28%)) were similar to respective direct estimates.

Based on direct evidence of moderate quality (downgraded for inconsistency), radiographic progression (scale 0 to 448) was statistically significantly reduced in those on biologics + MTX/DMARDs versus comparator, MD -2.61 (95% CI -4.08 to -1.14). The absolute reduction was small, -0.58% (95% CI -0.91% to -0.25%) and we are unsure of the clinical relevance of this reduction. NMA estimates of TNF biologic+MTX/DMARD (absolute reduction -0.67% (95% CrI -1.4% to -0.12%) and non-TNF biologic+MTX/DMARD (absolute reduction, -0.68% (95% CrI -2.36% to 0.92%)) were similar to respective direct estimates.

Based on direct evidence of moderate quality (downgraded for imprecision), results for withdrawals due to adverse events were inconclusive, with wide confidence intervals encompassing the null effect and evidence of an important increase in withdrawals, RR 1.11 (95% CI 0.96 to 1.30). The NMA estimates of TNF biologic+MTX/DMARD (RR 1.24 (95% CrI 0.99 to 1.57)) and non-TNF biologic+MTX/DMARD (RR 1.20 (95% CrI 0.87 to 1.67)) were similarly inconclusive and downgraded to low for both imprecision and indirectness.

Based on direct evidence of high quality, biologic+MTX/DMARD was associated with clinically significantly increased risk (statistically borderline significant) of serious adverse events on biologic+MTX/DMARD (Peto OR [can be interpreted as RR due to low event rate] 1.12 (95% CI 0.99 to 1.27); absolute risk 1% (0% to 2%). As well, the NMA estimate for TNF biologic+MTX/DMARD (Peto OR 1.20 (95% CrI 1.01 to 1.43)) showed moderate quality evidence of an increase in the risk of serious adverse events. The other two NMA estimates were downgraded to low quality due to imprecision and indirectness and had wide confidence intervals resulting in uncertainty around the estimates: non-TNF biologics + MTX/DMARD: 1.07 (95% CrI 0.89 to 1.29) and anakinra: RR 1.06 (95% CrI 0.65 to 1.75).

Based on direct evidence of low quality (downgraded for serious imprecision), results were inconclusive for cancer (Peto OR 1.07 (95% CI 0.68 to 1.68) for all biologic+MTX/DMARD combinations. The NMA estimates of TNF biologic+MTX/DMARD (Peto OR 1.21 (95% CrI 0.63 to 2.38) and non-TNF biologic+MTX/DMARD (Peto OR 0.99 (95% CrI 0.58 to 1.78)) were similarly inconclusive and downgraded to low quality for both imprecision and indirectness.

Main results text shows the results for tofacitinib and differences between medications.

## Authors' conclusions

Based primarily on RCTs of 6 months' to 12 months' duration, there is moderate quality evidence that the use of biologic+MTX/DMARD in people with rheumatoid arthritis who have failed to respond to MTX or other DMARDs results in clinically important improvement in function and higher ACR50 and remission rates, and increased risk of serious adverse events than the comparator (MTX/DMARD/PL; high quality evidence). Radiographic progression is slowed but its clinical relevance is uncertain. Results were inconclusive for whether biologics + MTX/DMARDs are associated with an increased risk of cancer or withdrawals due to adverse events.

## PLAIN LANGUAGE SUMMARY

### Biologics or tofacitinib for rheumatoid arthritis not improved by treatment with methotrexate or other disease-modifying anti-rheumatic drugs

#### What is rheumatoid arthritis and what are biologics?

When people have rheumatoid arthritis (RA), their immune system, which normally fights infection, attacks the joint lining. This makes their joints swollen, stiff and painful. If the inflammation goes on without treatment, joint damage and disability may result. Biologics and tofacitinib are medications that work by blocking different types of immune cells in the body that cause swelling and joint damage in people who have RA.

This is an update of a review published in 2009. We have split the original review into four reviews based on patient population. We looked at trials done until June 2015 on the benefits and harms of biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab and tocilizumab) and tofacitinib on people with RA who had not improved with treatment of methotrexate or other DMARDs.

### **The review shows that in people with rheumatoid arthritis:**

Biologics in combination with methotrexate (MTX) or other DMARDs:

- probably improve signs and symptoms of RA (tender or swollen joints), function, the chances of RA remission (disappearance of symptoms) and slow down X-ray disease progression. However, we are not sure of the importance of the amount of slowing of disease progression as seen on X-rays. We downgraded our confidence in the results because of concerns about the inconsistency of some results.
- probably slightly increase the number of serious adverse events, though there are few events.

We often do not have precise information about side effects and complications. This is particularly true for rare but serious side effects. Because of the lack of data, we are uncertain of the effect of biologics on the risk of cancer and withdrawals due to adverse events.

### **Best estimate of what happens to people with RA taking biologics**

#### **ACR50 (number of tender or swollen joints and other doctor/patient assessed aspects)**

Twenty-four more people out of 100 experienced improvement in the symptoms of their rheumatoid arthritis with biologics + MTX/DMARD (24% absolute improvement).

Thirty-eight people out of 100 who were on biologic+ MTX experienced improvement compared to 14 people out of 100 who were on MTX/DMARD/placebo.

#### **Function improvement by Health Assessment Questionnaire (0 to 3 scale, lower score or more reduction = better function)**

People who took biologics + MTX/DMARDs rated their improvement in function to be 0.25 points more on a scale of 0 to 3 (-8% absolute improvement).

People who took biologics + MTX/DMARDs rated their function improved by 0.39 points on a scale of 0 to 3.

People who took a MTX/DMARD/placebo rated their function improved by 0.14 points on a scale of 0 to 3.

#### **Remission**

Eighteen more people out of 100 experienced no symptoms of their rheumatoid arthritis with biologics + MTX/DMARDs (18% absolute improvement).

Twenty-eight patients out of 100 who were on biologic+ MTX experienced no symptoms compared to 10 people out of 100 who were on MTX/DMARD/placebo.

#### **Progression of disease damage as measured on X-rays (on a scale of 0 to 448)**

The damage to joints of people who took biologics + MTX/DMARDs was 2.6 points lower (-0.58% absolute improvement).

The damage to joints of people who took a MTX/DMARD/placebo was 3.7 points.

#### **Withdrawal from study due to adverse events**

Ten more people out of 1000 who took biologics + MTX/DMARD withdrew from the study due to adverse events (1% more withdrawals).

Fifty-five patients out of 1000 who took biologics + MTX/DMARD withdrew from the study compared to 45 people out of 1000 who were on MTX/DMARD/placebo.

#### **Serious Adverse Events**

Ten more people out of 1000 who took biologics + MTX/DMARD had serious adverse events (1% more serious adverse events).

---

Seventy-eight patients out of 1000 who took biologics + MTX/DMARD had serious adverse events compared to 68 people out of 1000 who were on MTX/DMARD/placebo; most common were infections.

### **Cancer**

The same number of people (14 out of 1000) who took biologics + MTX/DMARDs compared to those on MTX/DMARD/placebo had cancer. However, we are cautious about this estimate as there were few events of cancer in the studies.

Results for tofacitinib are provided in the results section.

## BACKGROUND

### Description of the condition

Our previous overview and NMA of biologics for RA was performed in 2009 (Singh 2009) and is ready for an update. Due to feasibility issues, an a priori decision was made to examine use of biologics or tofacitinib in three RA populations separately, according to their previous drug exposure/experience: (1) MTX/DMARD-naive; (2) MTX/DMARD-experienced; and (3) biologic-experienced:

1. methotrexate/disease-modifying anti-rheumatic drug incomplete [inadequate] responder (MTX/DMARD-IR, i.e. patients who failed MTX/DMARDs due to lack of efficacy (primary or secondary), adverse event, patient preference etc. or a combination of these reasons), assessing the effect of biologic +MTX/DMARD (this publication);
2. methotrexate/disease-modifying anti-rheumatic drug incomplete [inadequate] responder, assessing the effect of biologic monotherapy;
3. methotrexate-naive (patients who have not experienced methotrexate as a treatment; MTX-naive); and
4. biologic-experienced (patients who failed biologic due to lack of efficacy (primary or secondary), adverse event, cost, patient preference etc. or a combination of these reasons)

This review will focus on RA patients who are MTX/DMARD-experienced (i.e., MTX/DMARD-incomplete responders (IR)) patients and will only address the benefits and risks of biologics when used in combination with MTX/DMARD. Analyses for biologic monotherapy in these patients will be published as a separate Cochrane NMA and systematic review. The other two RA populations will be analyzed separately and reported in separate Cochrane reviews.

Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by inflammation of the synovial lining of the joints, tendons and periarticular structures (Lee 2001). RA affects 0.5% to 1.0% of the population in Western countries (Kvien 2004). Untreated, RA leads to joint destruction, functional limitation and severe disability (Odegard 2005; Yelin 2007) and has a significant impact on health-related quality of life (HRQoL) (Kvien 2005; Lubeck 2004).

Treatment options for RA include symptomatic treatments such as non-steroidal anti-inflammatory drugs (NSAIDs). Definitive treatments that have disease-modifying potential include glucocorticoids, traditional disease-modifying anti-rheumatic drugs (DMARDs, such as methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, cyclosporine etc.), biologic DMARDs (referred to as biologics from here on) or oral small molecule drug, such as tofacitinib. The use of DMARDs leads to an improvement in pain and functioning for patients with RA as well as more long-term outcomes such as reduced radiographic progression (Finckh 2006; Pincus 2002) and disability (Cash 1994; Strand 2008).

Traditional DMARDs (referred to as DMARDs from here on), including methotrexate (MTX), are usually the first choice drug for people with RA (Singh 2012; Singh 2016; Smolen 2014a). When traditional DMARDs, including MTX, have either been

ineffective or partially effective (i.e. incomplete responders (DMARD-IR/MTX-IR) (Tugwell 2000)), or have had associated side effects, treatment options include other traditional DMARDs, biologics or tofacitinib (Singh 2012; Singh 2016; Smolen 2014a). The DMARD/MTX-IR patient population is one of the most commonly studied RA patient populations (Hochberg 2001; Maini 2006a; Saevarsdottir 2011). This patient population is the focus of this review and will be referred to as DMARD/MTX-experienced (or DMARD/MTX-IR), indicating that they were incomplete responders to one or more traditional DMARDs (including but not limited to sulfasalazine, hydroxychloroquine, leflunomide etc.) or methotrexate, respectively, due to the lack of efficacy, the occurrence of adverse events, or other reasons.

### Description of the interventions

The introduction of biologics has revolutionized the management of RA. Biologics provide clinically important and statistically significant improvements in pain and function in patients not responding to traditional DMARDs such as methotrexate (MTX). While biologics appear to have fewer side-effects and much greater success in slowing structural joint destruction than MTX, they are much more costly than traditional DMARDs.

Biologics are commonly used for patients with suboptimal response or intolerance to traditional DMARDs, such as MTX.

In these DMARD/MTX-incomplete responders (DMARD/MTX-IR), biologics or other DMARDs (double or triple-DMARD therapy) are used in combination with MTX. The biologics include:

1. tumor necrosis factor (TNF) inhibitors (Scott 2006):
  - a. infliximab (REMICADE, approved 1998 in the U.S.A) (FDA 1999),
  - b. etanercept (ENBREL, approved 1998) (FDA 1998),
  - c. adalimumab (HUMIRA, approved 2002) (FDA 2002),
  - d. certolizumab pegol (CIMZIA, approved 2008) (FDA 2008d),
  - e. golimumab (SIMPONI, approved 2009) (FDA 2008a);
2. anti-CD28 therapy:
  - a. abatacept (ORENCIA, approved 2005) (FDA 2005; FDA 2008b);
3. anti-IL1 therapy:
  - a. anakinra (KINERET, approved 2001) (FDA 2001);
4. anti-B-cell therapy: rituximab (RITUXAN/MABTHERA, approved 1997 for lymphoma and 2006 for RA) (Drugs 2006); and
5. anti-IL 6 therapy: tocilizumab (ACTEMRA, approved 2010) (FDA 2010).

In addition, more recently, the oral small molecule drug, tofacitinib (XELJANZ) (FDA 2012), was approved in 2012 for use in RA patients. Most biologics and tofacitinib are approved for use in RA internationally, although the indications for use differ slightly between countries.

### How the intervention might work

The systemic and joint inflammation in RA is mediated by activation of T-cells (Cope 2008), B-cells, macrophages (Szekanecz 2007), and other immune cells (Woolley 2003). These interactions lead to expression of chemokines, metalloproteinases and inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and various interleukins (IL) (Brennan 2008; Choy 2001). Interaction of lymphocytes and inflammatory cytokines with host cells such as fibroblasts, osteoclasts and chondrocytes leads to bone and



cartilage destruction, a hallmark of RA (Brennan 2008; Connell 2006). As briefly mentioned in the section above (Description of the interventions), the mechanism of action differs between the biologics, i.e. inhibition of TNF-alpha versus interleukin-1 versus interleukin-6 versus B-cells versus T-cell co-stimulatory molecule, CD28). It is possible that, due to different contributions of these cytokines and processes to the disease expression, the use of therapy targeting one cytokine may be more efficacious or safer than therapy targeting another cytokine/mechanism.

### Why it is important to do this overview

As shown in the Cochrane systematic reviews for these biologics and tofacitinib published in *The Cochrane Library*, these medications provide clinically important improvements in pain and disability in treating RA compared to MTX/DMARD/placebo (Lethaby 2013; Maxwell 2010a; Maxwell 2010b; Ruiz Garcia 2014; Singh 2010a; Singh 2010b; Mertens 2009; Navarro-Sarabia 2005; Lopez-Olivo 2015). The existing Cochrane systematic reviews, however, only reviewed each agent on its own, that is they are systematic reviews of each of the biologics. Treatment guidelines published recently (Saag 2008; Singh 2012; Singh 2016; Smolen 2014a) as well as consensus statements (Furst 2008; Furst 2010; Furst 2012) have also conducted systematic reviews of these interventions, but most are outdated and none performed indirect comparisons, to our knowledge. This was primarily due to the relative lack of head-to-head comparative effectiveness trials, which has been a barrier in comparing effectiveness of one biologic to another biologic. Therefore, a review summarizing all evidence to date is needed.

Patients, clinicians and policy-makers need to know if there are any important differences between the different biologics in terms of benefits and harms. Ideally, this requires head-to-head comparison studies. Few studies to date have compared two biologics including, but not limited to, Gabay 2013; Schiff 2008; Weinblatt 2013a. In the absence of head-to-head studies, indirect comparisons provide the best evidence for demonstrating any differences between the available biologics (Kristensen 2007; Kristensen 2011). When randomized trials fail to make head-to-head comparisons, a common comparator can be used to make an indirect comparison (Song 2003). A major limitation of previous systematic reviews was the lack of use of state-of-the-art methods to utilize indirect comparisons.

Using both direct and indirect comparisons is the essence of network meta-analysis (NMA) and the resulting review differs from the usual review, such that it is not intended to examine only one intervention for RA but aims to systematically review and simultaneously compare the existing randomized trials of biologics or small molecule tofacitinib for RA (Becker 2011; Puhan 2014).

### OBJECTIVES

To assess the benefits and harms of nine biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) and tofacitinib (an oral small molecule drug), versus comparator (MTX, DMARD, placebo (PL), or a combination) in adults with rheumatoid arthritis who have failed to respond to methotrexate (MTX) or other disease-modifying anti-rheumatic drugs (DMARDs), i.e., MTX/DMARD incomplete responders (MTX/DMARD-IR).

## METHODS

### Criteria for considering reviews for inclusion

Randomized controlled trials (RCTs) of biologics or tofacitinib for RA patients who are MTX/DMARD-incomplete responders (MTX/DMARD-IR).

### Search methods for identification of reviews

For the 2015 update, we searched for individual RCTs rather than for systematic reviews as was done in the original review. Cochrane Musculoskeletal's Trials Search Co-ordinator conducted a search to identify the individual studies in the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (via *The Cochrane Library* Issue 6, June 2015), MEDLINE (via OVID 1946-June 2015), and EMBASE (via OVID 1947-June 2015).

We considered 31 studies from the 2009 version, which were obtained by searching *The Cochrane Database of Systematic Reviews* using the search term 'Rheumatoid' in the title (Singh 2009). The 2009 version was completed by obtaining updated reviews for six biologics and including RCTs from these reviews, for this review as long as it mapped to the current review.

### Types of studies

For the 2015 update, we expanded from including only studies with standard dose biologics that were considered in the original 2009 version to the inclusion of studies with any dose of biologic in people with RA, if they had clinically relevant outcomes. We included all nine approved biologics for RA and in addition, included tofacitinib.

We defined the standard doses of biologics similarly to the 2009 version, and expanded to include definitions for the newer biologics and tofacitinib, as follows.

1. Abatacept intravenous: every four weeks intravenously at 500 mg dose in patients < 60 kg, 750 mg in patients 60 kg to 100 kg and 1000 mg in patients >100 kg, after the initial dosing regimen of baseline, two- and four-week infusions.
2. Abatacept subcutaneous: 125 mg subcutaneous weekly.
3. Adalimumab: 40 mg subcutaneous every two weeks.
4. Anakinra: 100 mg subcutaneous every day.
5. Certolizumab pegol: 400 mg initially and at weeks two and four, followed by 200 mg every other week (for maintenance dosing, 400 mg every four weeks can be considered).
6. Etanercept: 25 mg subcutaneous twice weekly or 50 mg subcutaneous once weekly.
7. Golimumab: 50 mg administered by subcutaneous injection once a month.
8. Infliximab: 3 mg/kg intravenous every eight weeks after initial dosing at zero, two and six weeks;
9. Rituximab: two 1000 mg intravenous doses two weeks apart.
10. Tocilizumab intravenous: starting dose is 4 mg per kg every four weeks followed by an increase to 8 mg per kg every four weeks based on clinical response;
11. Tocilizumab subcutaneous: 162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response for patients < 100 kg and



162 mg administered subcutaneously every week for patients  $\geq 100$  kg body weight.

12. Tofacitinib: 5 mg orally twice a day.

We recognize that RCTs included in this NMA and systematic review are limited in their ability to assess long-term safety, since rare or delayed effects will not be detected. We therefore also searched the U.S. Food and Drug Administration (FDA) website for labels and warnings. We also searched other regulatory agencies' websites from Canada (Health Canada) and Europe (European Medicines Agency (EMA)) to summarize warnings related to each of the biologics.

### Types of participants

Adults, 18 years or older, with RA meeting the 1987 American College of Rheumatology (ACR) classification criteria for RA (Arnett 1988) or the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria for RA (Aletaha 2010) and who were MTX/DMARD-experienced (including MTX/DMARD-IR).

### Types of interventions

Biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) or tofacitinib used alone or in combination with traditional DMARD/other biologics compared to placebo (PL) alone or to PL plus traditional DMARDs or biologics or combinations of DMARDs.

### Types of outcome measures

#### Primary outcomes

1. ACR50 defined as 50% improvement in both tender and swollen joint counts and 50% improvement in at least three of the following five variables: patient global assessment, physician global assessment, pain score, Health Assessment Questionnaire (HAQ) score, and acute phase reactant (Erythrocyte Sedimentation Rate (ESR) or C-Reactive Protein (CRP) (Chung 2006; Felson 1995). ACR50 was chosen, as clinical and statistical evidence supports this as the preferred endpoint for contemporary RA clinical trials (Ghogomu 2014).
2. RA disease remission defined as DAS  $< 1.6$  or DAS28  $< 2.6$  (Fransen 2005; Prevoo 1996).
3. Function measured by HAQ score or modified HAQ calculated as score changes (Fries 1980; Pincus 1983) and the proportion

achieving minimal clinically important difference on HAQ  $\leq 0.22$  (Wells 1993).

4. Radiographic progression, as measured by Larsen/Sharp/modified Sharp scores (Larsen 1977; Sharp 1971; Van der Heijde 1989).
5. Withdrawals due to adverse events (Ioannidis 2004)
6. Serious adverse events (SAEs) (Ioannidis 2004)
7. Cancer

### Data collection and analysis

#### Selection of reviews

For the 2015 update, we only included RCTs, not systematic reviews. We conducted a search of the databases from inception to June 2015 (one update to February 2014 and a second one to June 2015). We had previously included all Cochrane systematic reviews of biologics for RA for the 2009 version (that included all studies to 2009), if they had been completed and submitted for review or updated by 30 May 2009, or both.


After performing a common search, we split this update into four NMAs and systematic reviews based on three patient populations, according to their previous drug exposure/experience, for reasons of clinical relevance and feasibility:

1. methotrexate/disease-modifying anti-rheumatic drug incomplete responder (MTX/DMARD-IR), assessing the effect of biologic + MTX/DMARD, this publication;
2. methotrexate/disease-modifying anti-rheumatic drug incomplete responder, assessing the effect of biologic monotherapy;
3. MTX-naïve; and
4. biologic-experienced.

NMAs and systematic reviews addressing these other patient populations will be published as separate reviews.

Two authors (JS and RC for the original search; SN and TC for first search update; NS and JS for the second search update) independently reviewed the results of the search (titles and abstracts), and obtained the full text of articles identified as relevant for this update. Figure 1 shows the PRISMA flow chart for study selection (Moher 2009).

**Figure 1. Study flow diagram.**



**Data extraction and management**

For this updated NMA we abstracted only studies including RA patients who were MTX- or DMARD-experienced, i.e., incomplete responders and had been treated with biologics + MTX/DMARDs or tofacitinib + MTX/DMARDs. This was done for feasibility reasons since the original 2009 overview and NMA included RA patients regardless of current medication status (MTX-naive, MTX-experienced, DMARD-experienced and biologic-experienced).

For the 2015 update, we report the results for three separate RA patient populations in four separate reviews: (1) MTX- or DMARD-experienced, i.e., MTX/DMARD incomplete responders, on biologic + MTX/DMARD combination; (2) MTX/DMARD incomplete responders, on biologic monotherapy; (3) MTX-naive; and (4) biologic-experienced.

Two review authors (JS and GW for the original review; SN, JS and TC for the first update; NS and JS for the second search update) independently extracted data from the reviews using a predefined data extraction form created as a Microsoft Excel® spreadsheet for the 2015 update. Even for the RCT data abstracted for the 2009 original overview, two abstractors independently abstracted additional data for all doses (SN, JS) and concomitant MTX/DMARD, since the original review only included standard doses of biologics. TC double-checked all data for accuracy after the initial abstraction. We resolved disagreements by discussion with JS or GW. We obtained additional information from the original RCTs where necessary, from the online supplementary materials or by contacting study authors. AM designed the spreadsheets.

### Assessment of methodological quality of included reviews

Two review authors in three teams (SN/JS; TC/JS; JS/NS) independently evaluated the methodological quality of the included studies, as summarized below.

#### Quality of included trials for the 2015 update

For the 2015 update, the study quality was assessed using the Cochrane 'Risk of bias' tool by review authors (TC/NS/JS/TC) who independently assessed the risk of bias for each included trial. We assessed the risk of bias on each of the following criteria: random sequence generation, allocation concealment, presence of blinding (participants, personnel, and outcome assessors) in the studies, incomplete outcome data, selective outcome reporting and baseline imbalance (Higgins 2011). The risk of bias was assessed as recommended: low risk, high risk, or unclear risk (either lack of information or uncertainty over the potential for bias). The review authors resolved disagreements by discussion.

#### Quality of evidence

Two review authors (LM and RC) independently assessed the overall quality of the evidence for each outcome using the GRADE approach for both direct and NMA estimates (Guyatt 2008; Puhan 2014). The GRADE approach improves reliability in comparison to intuitive judgments about the certainty of a body of evidence (Mustafa 2013). The GRADE system specifies four levels of quality of evidence.

1. High quality for randomized trials; or double-upgraded observational studies.
2. Moderate quality for downgraded randomized trials; or upgraded observational studies.
3. Low quality for double-downgraded randomized trials; or observational studies and
4. Very low quality for triple-downgraded randomized trials; or downgraded observational studies; or case series/case reports.

Randomized trial evidence could be downgraded by one or two levels depending on the presence of five factors.

1. Serious (-1) or very serious (-2) limitation to study quality.
2. Important inconsistency (-1).
3. Some (-1) or major (-2) uncertainty about directness.
4. Imprecise or sparse data (-1).
5. High probability of reporting bias (-1).

### Data synthesis

#### Statistical analyses

For the 2015 update, we performed the main analyses considering important factors including the route of biologic (intravenous vs. subcutaneous), dose (low dose (LD), standard dose (SD) and high dose (HD)), and the use of concomitant MTX/DMARD as important variables/characteristics that might contribute to benefit and harm. Analyses for biologic monotherapy in this patient population will be published separately. We postulated that some of these factors might potentially impact benefits from the biologics or tofacitinib, and therefore we performed pre-specified analyses for several subgroups (see section for subgroup analysis).

We decided a priori (before any analyses were undertaken for the 2015 update) that benefit/harms would likely be different by prior DMARD/biologic experience (indicating disease severity/duration etc.). We separated the studies by prior DMARD/biologic experience (MTX-naive, MTX/DMARD-experienced or incomplete responders, biologic-experienced), which are different treatment populations in clinical practice and offer different efficacy for any treatment strategy. This was also done for reasons of feasibility, given the large amount of literature published in the six years since the previous version of the review was published.

We anticipated that harms would not be provided by all studies and would occur uncommonly or rarely. Therefore, dividing data into two groups by previous DMARD-experience vs. MTX-experience would likely lead to low power and the analyses would likely miss important differences regarding harms. Therefore, we decided to analyze MTX- and DMARD-experienced patients together for this NMA and systematic review. All results are therefore provided for this population, MTX/DMARD-experienced i.e., incomplete responders.

#### Network meta-analysis methods

We conducted network meta analysis (NMA) using a Bayesian mixed treatment comparison (MTC) approach, and traditional meta-analysis to determine the effectiveness of treatments compared to each other. We used WinBUGS statistical software for Bayesian analysis (MRC Biostatistics Unit, Cambridge, UK) (Spiegelhalter 2003), and Review Manager 5.3 (RevMan) (RevMan 2014) to conduct the NMA and traditional meta-analysis respectively. We based assessment of model fit on deviance information criterion (DIC) and comparison of residual deviance (Spiegelhalter 2003). To ensure convergence was reached, we assessed trace plots and the Brooks-Gelman-Rubin statistic (Spiegelhalter 2003). We used the continuity correction approach for zero event cells to make non-zero cells where needed. We derived the corresponding 95% credible intervals using Markov Chain Monte Carlo (MCMC) simulation approach with at least 5,000 or more iterations as needed. We used informative priors for the variance parameters (Turner 2012) but where considered more suitable, we used vague priors for basic parameters. To assess inconsistency (conflict between direct and indirect evidence) (Wells 2009), we compared deviance and DIC statistics in fitted consistency and inconsistency models (Dias 2011). We also drew the inconsistency plot. The random-effects model and the fixed-effect model were chosen based on the assessment of the deviance information criteria (DIC) and comparison of residual deviance to number of unconstrained data points.

Heterogeneity is a common issue encountered while performing meta-analyses (Higgins 2002; Thompson 1999). We used the  $I^2$  statistic for quantifying inconsistency of the results in individual treatment reviews (Higgins 2003); this statistic combines the  $\text{Chi}^2$  statistic and the number of studies contributing to each summary estimate in the figure. We evaluated heterogeneity for the indirect comparison analyses using  $\text{Tau}^2$ , which quantifies heterogeneity via the variance resulting from the interaction between study and drug (study and study  $\times$  drug interaction). We assessed clinical heterogeneity across PICO, i.e., assessed differences in patient populations (disease duration, number of DMARDs failed, type of DMARDs used etc.), intervention (dose, route, schedule), comparator (one vs. multiple DMARDs vs. PL), and outcome (time of assessment).

On the basis of the derived odds ratio (OR) comparing treatment to control, and considering the overall event rate in the placebo group as a proxy for the community baseline event rate, we estimated the number needed to treat for an additional beneficial outcome (NNTB) and number needed to treat for an additional harmful outcome (NNTH), with 95% confidence intervals (CIs). This method enables direct translation into clinical practice (Osiri 2003), using Visual Rx with the overall (pooled) number of responders within the available studies as proxy for the expected rate of responders in a given RA population (Cates 2009).

We considered P values less than 0.05 and 95% CIs or credible intervals that did not include 1 to be statistically significant. In all the forest plots presenting effect measure data per treatment, the random-effects model was applied as the default option (Dersimonian 2007) for illustrative purposes, and we used  $I^2$  statistic values to evaluate heterogeneity.

For dichotomous outcomes (i.e. the number of patients achieving more than 50% symptomatic improvement (ACR50) and withdrawal due to adverse events), we performed the meta-analysis by combining trials of various drugs versus placebo to obtain mutually independent estimates using odds ratios (OR) as effect measures. For data on cancer and serious adverse events, we anticipated that events would be rare (Sweeting 2004), and therefore used Peto Odds ratio for these effect estimates. In order to handle these expected sparse data, we applied an empirical Bayes (treatment arm-based) (Salanti 2008) approach. AK and AH performed data analyses under the supervision of GW.

Since clinicians may find it easier to interpret relative risk (RR) compared to odds ratios, we converted the odds ratios obtained from the NMA into relative risk for the 'Summary of findings' table, the Abstract and the Plain Language Summary. The NMA produces odds ratios, which are presented in most of the tables and the text of this review.

### Sub-group analyses/planned comparisons

We compared the nine biologics and tofacitinib with regard to benefits and harms as the main analysis (analysis 1 in appendices). In addition, we performed the following subgroup analyses.

1. Trial duration: short duration ( $\leq 6$  months), intermediate duration ( $> 6$  to 12 months) or long duration ( $> 12$  months).
2. RA disease duration: early RA (mean/median duration of  $< 2$  years) (Boers 2001), established RA (mean/median duration 2 to

10 years) or late RA (mean/median duration  $> 10$  years) (Barlow 1999).

In addition, we specified *a priori* that we would calculate the odds ratios for the following.

1. Overall biologic versus comparator placebo/control.
2. Type of medication (by mechanism): TNF inhibitors (etanercept (ETN), adalimumab (ADA), certolizumab pegol (CERT), golimumab (GOLI), infliximab (INF)) vs. non-TNF-inhibitors (abatacept (ABA), rituximab (RITUX), tocilizumab (TOCI), ) vs. anakinra (ANA) vs. tofacitinib (TOFA) (analysis 2 in appendices).
3. Type of biologic (antibody vs. receptor): medications targeting TNF receptor (etanercept (ETN)) versus monoclonal antibodies against TNF (adalimumab, certolizumab pegol, golimumab, infliximab) vs. non-TNF (abatacept, rituximab, tocilizumab) vs. anakinra vs. tofacitinib (analysis 3 in appendices).
4. Dose: high-dose (HD) vs. standard dose (SD) vs. low-dose (LD) biologic (analysis 3 in appendices).

## RESULTS

Given that the number of included studies has increased significantly and our analyses were much more detailed for this 2015 update, we split the update into four reviews. Our current review also included a subset of studies from the original 31 RCTs from the 2009 version that were in the MTX/DMARD-IR category, that mapped to our current review for patient population and intervention. We focused on describing the updated results in this review, rather than pointing out similarities and differences of the 2015 updated analyses compared to the original 2009 version. We prioritized the ease of readability over comprehensiveness (which would have lengthened this review further). There were several reasons to focus on the current, most updated evidence. Significant advances in drug therapy for RA in the last six years have occurred and many trials with new evidence are now available with availability of new evidence. In addition, methods for evidence synthesis have evolved and become more sophisticated over time, a particular example is the use of NMA methodology.

### Description of included reviews

NOTE: this update uses individual studies, not reviews, for the basis of all analyses

Figure 1 shows the overall study selection process that included the studies identified for inclusion in the 2015 update. With the 2015 update, we identified a total of 90 studies (73 studies from 8771 titles and 17 of the 31 RCTs from the seven Cochrane reviews in the original 2009 version), of which 79 studies with 32,874 patients provided data for analyses. Eleven studies (Emery 2006b; Gashi 2014; Heimans 2013; Van der Kooij 2009; Kremer 2011; Lisbona 2008; Maclsaac 2014; Moreland 2012; Ohta 2014; Pavelka 2009; Van Riel 2008) did not provide data or usable data for the analyses including the NMA. Of the 79 trials that provided usable data, the study duration was 12 months or less in 87% of the RCTs and more than 12 months in 13% of the RCTs.

## Methodological quality of included reviews

For the 2015 update, two reviewers independently abstracted the study characteristics below from the published reports of the individual trials.

### Risk of bias in included trials:

Detailed risk of bias assessments for each trial including the reasons for each judgment are available at the Cochrane Musculoskeletal Group web site. ([Risk of Bias Assessment A](#) and [Risk of Bias Assessment B](#)).

#### **Allocation (selection bias)**

All trials were described as randomized, however, only 29 of 90 (32%) reported adequate sequence generation and were assessed as low risk, while 61 (68%) did not describe the method used and were assessed as unclear risk. Allocation concealment was assessed as low risk in 23 (26%) trials and unclear in 67 (74%) trials.

#### **Blinding (performance and detection bias)**

A total of 38 (42%) trials were judged at low risk of performance bias and 40 (45%) at unclear risk of bias. In 12 (13%) trials, participants were not blinded and these trials were at high risk of performance bias.

We assessed low risk of detection bias in 34 (38%) trials, high risk of detection bias in 19 (21%) and unclear risk in 37 (41%) trials.

#### **Incomplete outcome data (attrition bias)**

Most trials (48 out of 90; 53%) were judged at high risk of attrition bias because > 20% of participants dropped out. Thirty-seven (41%) trials had low risk of attrition bias and five (6%) trials were at unclear risk of attrition bias.

#### **Selective reporting (reporting bias)**

Ten trials (11%) had a protocol and were judged as low risk of selective reporting. Four trials (4%) were at high risk of selective reporting and 76 trials (85%) were judged as unclear risk since the study protocols were not available and we did not have enough information in the study report to assess selective reporting.


#### **Other potential sources of bias**

Major baseline imbalance was assessed and 82 (91%) trials had low risk of bias, seven (8%) had high risk of bias and one (1%) trial had unclear risk of bias.

Study characteristics of 79 included studies with data available for analysis is provided in [Table 1](#). From here on, all proportions and discussions are related to the 79 included studies with data. [Figure 2](#) shows the network diagram for cancer, as an example of network diagrams.



**Figure 2. Network Diagram for Cancer**



**Effect of interventions**

For the 2015 version, we extracted all relevant data from the included RCTs.

We pre-specified seven outcomes, four benefit and three harms outcomes. Analyses and comparisons for these outcomes were done when possible. When analysis was not possible due to lack of data for comparisons, results were simply described in the text or depicted in tables.

**Primary Benefit Outcomes**

ACR50, HAQ, RA disease remission and radiographic progression

**Primary Harms Outcomes**

Withdrawals due to adverse events, serious adverse events (SAEs), and cancer.

In comparison to the original 2009 version, the 2015 update has several new key aspects:

1. instead of six biologics in the 2009 review, we included all nine biologics and tofacitinib (oral small molecule drug) in this review;
2. we included cancer and serious adverse events as outcomes, which were limited to seven primary outcomes, as per Cochrane Musculoskeletal group guidance;



3. we included all doses of biologics and tofacitinib and analyzed by dose;
4. we analyzed outcomes by whether MTX/DMARD was used concomitantly or not. This NMA presents results of analyses of Biologic + MTX/DMARD versus comparator. A separate NMA will describe results of biologic monotherapy versus comparator; and
5. we used a Bayesian approach rather than a frequentist approach for analyses and reported odds ratios (OR) and 95% credible intervals (CrI). Another major difference was that we examined the main results separately by prior MTX/DMARD/biologic-experience in three categories in separate reviews (MTX-naïve, MTX/DMARD-incomplete responder, biologic-experienced). The current review is focused on MTX/DMARD-incomplete responder and presents the benefits and harms of biologic + MTX/DMARD versus comparator (MTX, DMARD or PL); a separate review will summarize the data for biologic monotherapy versus comparator.

### How to navigate this review?

We followed the principles below while describing results to keep this review as comprehensive as possible.

1. We first present the overall odds ratio for the entire group in the results section, followed by pre-specified comparisons (e.g. TNF vs. non-TNF vs. anakinra vs. tofacitinib; Analyses 2-4 in appendices), followed by subgroup analyses, where data were available. The abstract, 'Summary of findings' table and Plain Language Summary provide these data transformed into relative risk, since relative risk data are easier for clinicians to understand compared to odds ratios. Except for the abstract, 'Summary of findings' table and Plain Language Summary, i.e., everywhere else in the review, we present odds ratios for comparisons.
2. In the overall odds ratio analyses, only the last set of odds ratios compare the biologic by dose; other analyses prior to the dose analysis include all doses and provide comparison by a different characteristic of interest, e.g., the type of biologic.
3. The main analysis shows estimates from the overall network that includes both biologic + MTX/DMARD as well as biologic monotherapy arms, since the analysis was done with a single network for each of the seven outcomes. We describe and discuss only the results for biologic + MTX/DMARD in the text, since the results for biologic monotherapy will be described in a separate published review. This analysis provides the most detailed individual biologic direct comparisons to each other and every other treatment (Analysis 1 in appendices).
4. In the main analyses, when not specified, the biologic or tofacitinib is in standard dose. We specify 'high-dose' and 'low-dose' other than when standard dose was used.
5. For biologics that are approved for only one route of administration (i.e. intravenous or subcutaneous), the route is not specified. The mention of the drug without the route implies the only approved route for the drug: subcutaneous route for adalimumab, anakinra, certolizumab pegol, etanercept and golimumab; intravenous route for infliximab and rituximab. Since only two biologics are approved for both subcutaneous and intravenous use (tocilizumab and abatacept), we specify one of these two routes when describing results for these two

medications. The small molecule drug, tofacitinib, is approved only for oral use.

6. Due to our attempt to keep the narrative short, we summarize statistically significant results in the text. The tables represent the entire comparison, for interested readers, as well as comparisons for *a priori* specified subgroup analyses.

### 'Summary of findings' table

The 'Summary of findings' table was made for MTX/DMARD-IR patients (Table 2). The table presents both the direct estimates of biologic + MTX/DMARD versus comparator (in most cases MTX/DMARD; in some cases placebo) with the quality of evidence followed by estimates from the NMA with the quality of evidence. Absolute risk difference as well as relative difference (converted from odds ratio in the NMA to risk ratio for ease of interpretation for clinicians) are provided for each estimate. As is evident, direct estimates were consistent with NMA estimates for all seven outcomes. Biologics + MTX/DMARD was associated with statistically significant and clinically meaningful improvement (versus comparator) in: (1) ACR50; (2) function as measured by the Health Assessment Questionnaire; (3) RA disease remission (all with moderate quality evidence). Radiographic progression was statistically significantly reduced in those on biologics + MTX/DMARDs versus comparator (scale 0 to 448), though the absolute reduction was small and therefore we are not sure of the clinical relevance of this reduction (moderate quality evidence). Results for withdrawals due to adverse events were inconclusive, with wide confidence intervals encompassing the null effect and evidence of an important increase in withdrawals (moderate quality evidence for direct and low quality evidence for NMA estimates). There was high quality, direct evidence of a clinically meaningful increase in the risk of serious adverse events with biologics, which almost achieved statistical significance. There was low quality evidence of inconclusive results for cancer.

### Number needed to treat for an additional beneficial outcome (NNTB) and number needed to treat for an additional harmful outcome (NNTH)


We derived NNTB values by comparing biologics + MTX/DMARDs to comparator. The comparator was MTX or DMARD, or a combination of MTX/DMARDs for most of the studies for the seven outcomes; placebo (PL) was the only comparator in just 18% studies. More specifically the proportion of studies with PL as comparator were as follows: 15% for ACR50; 20% for HAQ; 3% for remission; 0% for radiographic progression; 17% for serious adverse events; 18% for withdrawals due to adverse events; and 6% for cancer. We used the control event rates as observed in the comparator group in the trials.

### Primary benefit outcome: ACR50

Seventy-nine studies with 30,229 participants reported ACR50. Of these, 56 studies included at least one arm with participants on a biologic with concomitant MTX/DMARD (most often MTX). The 23 studies that included only biologic (no concomitant MTX/DMARD therapy) are presented in a separate review/NMA.

Biologics + MTX/DMARD were associated with the higher odds of ACR50 versus comparator, OR 3.80 (95% CI 3.24 to 4.44),  $I^2$  of 65% representing moderate heterogeneity (50 studies; Figure 3).

**Figure 3. Forest plot of biologics + MTX/DMARD vs comparator (MTX/DMARD/PL), outcome: ACR50.**



The overall rate of ACR50 by the type of biologic and the dose were as follows:

1. Type of medication: TNF biologic vs. non-TNF biologic vs. anakinra vs. tofacitinib (74 studies, 28,065 participants) (Appendix 1; bottom rows have biologic with concomitant MTX/DMARDs vs. control; Analysis 2)
  - a. Compared to TNF biologic + MTX/DMARD, none of the following were associated with any difference in the odds ratio (95% credible interval (CrI)) of ACR50: non-TNF (tocilizumab, rituximab, abatacept) + MTX/DMARD, OR 0.89 (95% CrI 0.60 to 1.31); anakinra + MTX, OR 0.64 (95% CrI 0.22

to 1.96); and tofacitinib + MTX/DMARD, OR 1.28 (95% CrI 0.61 to 2.71).

2. Type of biologic: monoclonal TNF antibody vs. TNF receptor vs. non-TNF vs. anakinra vs. tofacitinib (74 studies, 28,065 participants) (Appendix 2; bottom rows show biologic with concomitant MTX/DMARDs comparisons; Analysis 3)
  - a. Compared to monoclonal antibodies against TNF (adalimumab, certolizumab pegol, golimumab, infliximab) + MTX/DMARD, none of the following were associated with differences in odds of ACR50 rates: non-TNF (tocilizumab, rituximab, abatacept) + MTX/DMARD, OR 0.89 (95% CrI 0.59 to 1.34); etanercept + MTX/DMARD, OR 0.95 (95% CrI 0.57 to 1.59); OR anakinra + MTX/DMARD, OR 0.63 (95% CrI 0.21 to

- 1.93); and tofacitinib + MTX/DMARD, OR 1.25 (95% CrI 0.58 to 2.70).
3. By dose: standard-dose vs. high-dose vs. low-dose (68 studies, 25,224 participants) ([Appendix 3](#); bottom rows show comparisons of biologic with concomitant MTX/DMARDs vs. control; Analysis 3)
- a. Compared to standard-dose biologic + MTX/DMARD, low-dose biologic + MTX/DMARD was associated with lower odds of ACR50 with odds ratio of 0.73 (95% CrI, 0.54 to 0.97)

and high-dose biologic + MTX/DMARD with similar/possibly higher odds that were not statistically significant, odds ratio of 1.26 (95% CrI, 0.97 to 1.65), respectively. Low-dose biologic + MTX/DMARD was less likely than high-dose biologic + MTX/DMARD to be associated with ACR50, odds ratio of 0.58 (95% CrI, 0.40 to 0.82).

Direct estimates for ACR50 by the type of biologic, i.e., TNF biologic vs. non-TNF biologic vs. anakinra, are shown in [Figure 4](#).

**Figure 4. Forest plot Biologics + MTX/DMARD vs comparator (MTX/DMARD/PL), subgroup estimates for ACR50**




Figure 4. (Continued)



**Main analyses**

Seventy-nine studies (38 two-arm, 33 three-arm trials, 6 four-arm, 1 five-arm and 1 seven-arm trials) with 30,229 participants provided data for all dose analyses in MTX/DMARD-experienced patients (Appendix 4; Analysis 1), including biologic + MTX/DMARD as well as biologic monotherapy arms (interpretation of these analyses is presented in a separate review). All nine biologics, in combination with MTX, in low-dose, standard-dose or high-dose, were superior to placebo in achieving ACR50. MTX was 3.7 times and MTX + DMARD 5.6 times superior to placebo in achieving ACR50. Compared to MTX + PL, each of the nine standard-dose biologic + MTX/DMARD were 2.54 to 6.49 times as likely to achieve ACR50, and most low-dose biologics (rituximab, abatacept, certolizumab, etanercept) + MTX, or tofacitinib + MTX were 2.22 to 4.12 times as likely to achieve ACR50. Similarly, high-dose biologic (golimumab, infliximab, certolizumab, tocilizumab, adalimumab) + MTX or Tofacitinib + MTX were associated with 4.85 to 6.96 times higher odds of ACR50 compared to MTX + PL. Compared to MTX + DMARD, several biologic + MTX (standard-dose and high-dose) combinations were associated with higher odds of ACR50, OR ranging 2.0 to 4.47.

We found several other clinically and statistically significant differences (Appendix 4), namely that

1. high-dose biologic + MTX was clinically and statistically significantly more effective in achieving ACR50 compared to standard-dose biologic (same or other biologic) + MTX across most biologics,
2. low-dose biologic of most biologics was often less effective in achieving ACR50 compared to standard-dose biologic (same or other biologic) and compared to standard-dose tofacitinib, and
3. biologic in combination with MTX was more effective in achieving ACR50 than biologic in combination with other DMARDs (such as sulfasalazine etc.).

**Subgroup analyses by disease duration (early vs. established vs. late RA)**

**Early RA (RA disease duration less than two years)**

There were not enough data to perform NMA.

**Established RA (disease duration two to 10 years)**

Sixty trials with 24,984 participants (Appendix 5): compared to PL, all biologic and tofacitinib comparators in standard-dose and high-dose, with concomitant MTX, were associated with higher odds of ACR50, ranging from 3.01 to 20.7. Compared to MTX, most biologics + MTX, were associated with higher odds of ACR50, ranging from 2.12 to 6.93. Compared to DMARD, most biologics + DMARD, were associated with higher odds of ACR50, ranging from 3.2 to 24.5. Compared to MTX + DMARD, most standard-dose and high-dose biologics + MTX were associated with higher odds of ACR50, ranging from 2.2 to 5.1.

Compared to standard-dose biologic, standard-dose biologic + MTX or high-dose biologic + MTX, were associated with higher odds of ACR50 in the 2 to 6-fold range. Biologic + DMARD was associated with lower odds of ACR50 compared to biologic + MTX, ranging from 0.13 to 0.31. In general, high-dose biologics + MTX were associated with higher odds of ACR50 compared to standard-dose + MTX.

**Late RA (disease duration more than 10 years)**

Twelve trials with 3481 participants (Appendix 6): compared to PL + MTX, standard-dose biologic + MTX and high-dose biologic + MTX were associated with higher odds of ACR50, in most cases. Compared to low-dose biologic, low-dose biologic + MTX was associated with higher odds of ACR50, ranging from 4.5 to 5.9.

**Subgroup analyses by trial duration**

**Trial duration, six months or less**

Sixty-six trials with 24,122 participants (Appendix 7): compared to MTX, the standard-, high- and low-dose biologics + MTX were associated with higher odds of ACR50, ranging from 2.4 to 6.9. Compared to MTX + DMARD, standard-dose biologics + MTX were associated with higher odds of ACR50, ranging from 2.8 to 3.8. Compared to standard-dose biologic, standard-dose biologic + MTX or high-dose biologic + MTX, were associated with higher odds of ACR50 in the 2 to 6-fold range. Compared to standard-dose biologic + MTX, low-dose biologic with MTX, was associated with lower odds ratio of ACR50 in the 0.2 to 0.4 range. High-dose biologic + MTX was associated with higher odds ratio ranging from 3 to 6 compared to low-dose biologics + MTX.

**Trial duration, six to 12 months**

Six trials with 3209 participants (Appendix 8): compared to PL + MTX, most biologics (low-, standard- or high-dose) + MTX combinations were associated with higher odds of ACR50, odds ratios ranging from 2.8 to 6.0. Low-dose biologic + MTX was less efficacious than standard- or high-dose biologic + MTX in achieving ACR50, with odds ranging from 0.14 to 0.21.

**Trial duration, more than 12 months**

There were not enough data to perform NMA.

**Primary efficacy outcome: Function as assessed by Health Assessment Questionnaire (HAQ)**


Forty-eight studies with 16,355 patients reported data on HAQ scores. Of these, 35 studies included at least one arm with patients on a biologic with concomitant MTX/DMARD (most often MTX). The 13 studies that had only biologic (no concomitant MTX/DMARD therapy) are presented in a separate review. Lower HAQ scores denote better function and therefore a greater reduction with treatment indicates more improvement in function vs. comparator.

The use of biologic therapy was associated with statistically significant improvement in HAQ scores vs. comparator, in patients taking biologic with concomitant MTX/DMARD (29 studies) with a mean difference (MD) of -0.25 (95% CI -0.28 to -0.22), I<sup>2</sup> 95%,



i.e., considerable heterogeneity (Figure 5). One potential reason for heterogeneity might be that we combined change in HAQ (negative change) with HAQ scores (positive), as decided *a priori*, as performed commonly in systematic reviews.

**Figure 5. Forest plot of biologics + MTX/DMARD vs comparator (MTX/DMARD/PL), outcome: HAQ**



The HAQ scores differed by the type of medication and the dose as follows.


1. Type of medication: TNF biologic vs. non-TNF biologic vs. anakinra vs. tofacitinib (48 studies, 15,865 participants) (Appendix 9).
  - a. On background MTX: compared to TNF biologic + MTX/DMARD, none of the following were associated with any difference in HAQ scores (95% credible interval (CrI)): non-TNF (tocilizumab, rituximab, abatacept) + MTX/DMARD, MD 0.10 (95% CrI -0.13 to 0.32) and tofacitinib + MTX/DMARD, MD -0.12 (95% CrI -0.65 to 0.40). Compared to non-TNF biologic + MTX/DMARD, HAQ scores did not differ for tofacitinib + MTX/DMARD, MD -0.22 (95% CrI -0.76 to 0.33).
2. Type of biologic: monoclonal TNF antibody vs. TNF receptor vs. non-TNF vs. anakinra vs. tofacitinib (48 studies, 16,124 participants) (Appendix 10).
  - a. On background MTX: compared to monoclonal antibodies against TNF (adalimumab, certolizumab pegol, golimumab, infliximab) + MTX/DMARD, none of the following were associated with any difference in HAQ scores (95% CrI): non-

- TNF (tocilizumab, rituximab, abatacept) + MTX/DMARD, MD 0.00 (95% CrI -0.23 to 0.23); or tofacitinib + MTX/DMARD, MD -0.22 (95% CrI -0.72 to 0.28). No comparisons could be made to anakinra. Compared to monoclonal antibodies against TNF, etanercept + MTX/DMARD was associated with significantly more improvement in HAQ scores, MD -0.25 (95% CrI -0.48 to -0.03).
3. By dose: standard-dose vs. high-dose vs. low-dose (43 studies, 14,638 participants) (Appendix 11).
  - a. On background MTX/DMARD: compared to standard-dose biologic + MTX/DMARD, no significant differences were seen in HAQ scores (95% CrI) with low-dose biologic + MTX/DMARD or high-dose biologic + MTX/DMARD, MD 0.09 (95% CrI -0.07 to 0.24) and MD 0.01 (95% CrI -0.13 to 0.14), respectively. Low-dose biologic + MTX/DMARD was not significantly different than high-dose biologic + MTX/DMARD to be associated with withdrawals due to adverse events, MD 0.08 (95% CrI -0.10 to 0.26).

Direct estimates for HAQ by the type of biologic, TNF biologic vs. non-TNF biologic vs. anakinra, are shown in Figure 6.



Figure 6. Forest plot of biologics + MTX/DMARD vs comparator (MTX/DMARD/PL), subgroup estimates for HAQ



Main analyses

Forty-eight studies (25 two-arm, 15 three-arm and 8 four-arm trials) with 16,355 participants provided HAQ data in MTX/DMARD-experienced patients (Appendix 12), including biologic + MTX/DMARD as well as biologic monotherapy arms (interpretation of these analyses is presented in a separate review). Compared to PL, the following treatments were associated with better/lower HAQ scores or greater reduction in HAQ scores with treatment (i.e., more improvement in function): (1) Standard-dose adalimumab, -0.29; (2) Standard-dose tofacitinib, -0.40; (3) Standard-dose etanercept + MTX, -0.58; (4) low-dose adalimumab, -0.32; (5) high-dose tofacitinib, -0.52; and (6) high-dose adalimumab -0.43.

Compared to MTX, standard and high-dose biologic in combination with MTX/DMARD were associated with better HAQ scores with differences between groups ranging from -0.27 to -0.62: (1) standard-dose certolizumab + MTX, -0.29; (2) standard-dose adalimumab + MTX, -0.32; (3) standard-dose etanercept + MTX, -0.62; (4) standard-dose tofacitinib + MTX, -0.44; (5) low-dose adalimumab + MTX, -0.27; (6) high-dose tocilizumab -0.32; (7) high-dose tofacitinib, -0.56; (8) high-dose tocilizumab intravenous + MTX, -0.30; (9) high-dose certolizumab + MTX, -0.33; and (10) high-dose tofacitinib + MTX, -0.51.

Compared to DMARD, the following were associated with better HAQ scores: (1) standard-dose etanercept, -0.38; (2) standard-dose etanercept + MTX, -0.62; and (3) high-dose tofacitinib, -0.56.

Compared to standard-dose etanercept, standard-dose etanercept + MTX was associated with better HAQ scores, by -0.24.

Golimumab comparisons: compared to standard-dose golimumab intravenous + MTX, most biologics (standard-, low- or high-dose) + MTX were associated with better HAQ scores by -0.52 to -0.87.

Subgroup analyses by disease duration (early vs. established vs. late RA)

Early RA (RA disease duration less than two years)

There were not enough data to perform NMA.

Established RA (disease duration two to 10 years)

Thirty-nine studies (22 two-arm, 11 three-arm and 6 four-arm trials) with 14,018 participants provided HAQ data (Appendix 13).

Compared to MTX, standard- and high-dose biologics + MTX were associated with more significant improvements of HAQ scores, mean difference ranging from -0.29 to -0.63. Compared to standard-dose biologic + MTX, high-dose biologics + MTX were associated with greater improvements in HAQ scores, mean difference ranging -0.60 to -0.82.

Late RA (disease duration more than 10 years)

Seven studies (1 two-arm, 4 three-arm and 2 four-arm trials) with 2084 participants provided HAQ data (Appendix 14): compared to MTX, standard- and high-dose biologics + MTX were associated

with more significant improvements of HAQ scores, with mean difference between comparators ranging -0.25 to -0.44.

**Subgroup analyses by trial duration**

**Trial duration, six months or less**

Forty-two studies (23 two-arm, 11 three-arm and 8 four-arm trials) with 13,213 participants provided HAQ data (Appendix 15); there were no statistically significant differences between various treatments.

**Trial duration, six to 12 months**

There were not enough data to perform NMA.

**Trial duration, more than 12 months**


There were not enough data to perform NMA.

**Primary efficacy outcome: Remission**

Thirty studies with 14,125 patients reported data on remission. Of these, 28 studies included at least one arm with participants on a biologic with concomitant MTX/DMARD (most often MTX). The two studies that had only biologic (no concomitant MTX/DMARD therapy) are presented in a separate review.

Participants receiving biologic + MTX/DMARD had higher odds of remission with an OR of 3.81 (95% CI, 2.90 to 5.00; I<sup>2</sup> 60%; 21 studies) vs. comparator, denoting substantial heterogeneity (Figure 7).

**Figure 7. Forest plot biologics + MTX/DMARD vs comparator (MTX/DMARD/PL), outcome: Remission**



The overall rate of remission by the type of biologic and the dose as follows:


1. Type of medication: TNF biologic vs. non-TNF biologic vs. anakinra vs. tofacitinib (29 studies, 12,668 participants) (Appendix 16).
  - a. On background MTX/DMARD studies): compared to TNF biologic, neither non-TNF biologic nor tofacitinib were associated with any differences in the odds (95% CrI) of remission, OR 1.15 (95% CrI 0.69 to 1.93) and OR 1.99 (95% CrI 0.39 to 12.55); compared to non-TNF biologic, tofacitinib was not significantly different, OR 1.73 (95% CrI 0.33 to 11.10).
2. Type of biologic: monoclonal TNF antibody vs. TNF receptor vs. non-TNF vs. anakinra vs. tofacitinib (29 studies, 12,668 participants) (Appendix 17).
  - a. On background MTX/DMARD: compared to non-TNF biologic, neither etanercept nor tofacitinib were associated with any

differences in odds (95% CrI) of remission rates, OR 1.61 (95% CrI 0.29 to 10.92) and OR 2.14 (95% CrI 0.37 to 15.21), respectively. Compared to monoclonal TNF antibody biologic, etanercept was not associated with any difference in the odds of remission OR 1.75 (95% CrI 0.32 to 11.67).

3. By dose: standard-dose vs. high-dose vs. low-dose (27 studies, 11,225 participants) (Appendix 18).
  - a. On background MTX: compared to standard-dose, neither high-dose nor low-dose biologic were associated with any difference in the odds (95% CrI) of remission, OR 1.40 (95% CrI 0.86 to 2.35) and OR 0.55 (95% CrI 0.31 to 0.93). Compared to high-dose biologic, low-dose biologic was associated with statistically significantly lower rate of RA remission, OR 0.39 (95% CrI 0.19 to 0.78).

Direct estimates for remission by type of biologic, TNF biologic vs. non-TNF biologic vs. anakinra, are shown in Figure 8.

Figure 8. Forest plot Biologics + MTX/DMARD vs comparator (MTX/DMARD/PL), subgroup estimates for Remission



**Main analyses**

Thirty studies (17 two-arm, 11 three-arm, 1 four-arm and 1 five-arm trials) with 14,125 participants provided data for MTX/DMARD-experienced patients for remission (Appendix 19), including biologic + MTX/DMARD as well as biologic monotherapy arms (interpretation of these analyses for monotherapy is presented in a separate review).

Compared to MTX/DMARD, most standard-dose biologic + MTX were associated with 3.18 to 10.48 times odd of remission and most high-dose biologic + MTX combinations with 3.52 to 12.77 times odds of remission; high-dose tofacitinib + MTX was associated with 11.09 times odds of remission. Similarly compared to MTX + DMARD, the corresponding odds ratios were 4.59 to 15.18 for standard-dose biologic + MTX and 5.02 to 18.27 for high-dose biologic + MTX.

**High-dose biologic (higher remission) vs. standard- or low-dose biologic**

In general, compared to standard- or low-dose biologic + MTX, most high-dose biologics + MTX and tofacitinib + MTX were associated with higher rates of remission. Compared to standard-dose adalimumab, the following were each associated with higher odds of RA disease remission: (1) standard-dose golimumab + MTX, 8.85; (2) high-dose tocilizumab intravenous + MTX, 10.69.

Compared to standard-dose etanercept + MTX, high-dose tocilizumab intravenous + MTX was associated with 3.98 times odds of remission. Compared to standard-dose golimumab + MTX, the following treatments were associated with lower odds of disease remission: (1) standard-dose rituximab + MTX, 0.21; (2) low-dose rituximab + MTX, 0.14; and (3) low-dose golimumab intravenous + MTX, 0.13. Compared to low-dose golimumab intravenous, high-dose tocilizumab + MTX was associated with 5.98 times odds of remission. Compared to low-dose rituximab + MTX, high-dose tocilizumab intravenous + MTX and high-dose golimumab + MTX were associated with higher odds of disease remission, 5.62 and 4.11, respectively. Compared to low-dose golimumab intravenous + MTX, the following treatments were associated with higher odds of disease remission: (1) high-dose tocilizumab intravenous + MTX, 9.49; (2) high-dose golimumab + MTX, 6.98; and (3) high-dose tofacitinib + MTX, 8.33.

**Subgroup analyses by disease duration (early vs. established vs. late RA)**

**Early RA (RA disease duration less than two years)**

There were not enough data to perform NMA.

**Established RA (disease duration two to 10 years)**

Twenty nine studies with 13,479 participants (Appendix 20)

Compared to MTX, most standard-dose biologic + MTX combinations were associated with 3.2 to 10.7 times higher odds of RA remission. Compared to MTX + DMARD, standard- or high-dose biologic + MTX were associated with 4.6 to 18.6 times higher odds of remission, respectively. Compared to standard-dose biologics, standard- or high-dose biologics + MTX were associated with higher odds of remission, ranging 5.9 to 10.5. Compared to low-dose biologic + MTX, high-dose biologic + MTX was associated with lower odds of remission, ranging 6.3 to 9.9.

**Late RA (disease duration more than 10 years)**

There were no studies for late RA to conduct any analyses.

**Subgroup analyses by trial duration**

**Trial duration, six months or less**

Two networks were created, one with 20 studies and 9626 participants (Appendix 21) and the other with five studies and 1392 participants (Appendix 22).

Compared to MTX + PL, standard-dose golimumab subcutaneous + MTX, standard-dose golimumab intravenous + MTX, high-dose tocilizumab intravenous, high-dose tocilizumab intravenous + MTX and high-dose golimumab subcutaneous + MTX were associated

with higher odds ratios for remission, ranging from 3.6 to 13.0 . Compared to standard-dose adalimumab subcutaneous, standard-dose golimumab subcutaneous + MTX, high-dose tocilizumab intravenous and high-dose tocilizumab intravenous + MTX were associated with 8.3, 5.9 and 10.1 times odds of remission.

**Trial duration, six to 12 months**

There were not enough data to perform NMA.

**Trial duration, more than 12 months**


There were not enough data to perform NMA.

**Primary efficacy outcome: Radiographic progression**

Eight studies with 3,267 participants reported data on radiographic progression. All studies had at least one arm with participants on a biologic with concomitant MTX/DMARD (most often MTX).

The use of biologic + MTX/DMARD therapy was associated with significantly less radiographic progression compared to MTX/DMARD, with a mean difference (MD) of -2.61 (95% CI, -4.08 to -1.14; 7 studies) Sharp or modified Sharp units (scale 0 to 448) although based on results with a considerable degree of heterogeneity, with I<sup>2</sup> of 85% (Figure 9) .

**Figure 9. Forest plot of biologics + MTX/DMARD vs comparator (MTX/DMARD/PL), outcome: Radiographic progression**



The overall radiographic progression differed by the type of biologic and the dose as follows.

1. With concomitant MTX/DMARD (eight studies, 3267 participants) (Appendix 23): compared to anti-TNF biologic, non-TNF biologic was associated with no statistically significant difference in radiographic progression, MD 0.19 (95% CrI, -6.54 to 7.01).
2. With concomitant MTX/DMARD (eight studies, 3267 participants) (Appendix 24): compared to anti-TNF monoclonal antibody, non-TNF or etanercept were not associated with any statistically significant difference in radiographic progression, MD 0.21 (95% CrI, -6.67 to 6.88) and MD -3.80 (95% CrI, -11.2 to 4.54). Compared to non-TNF biologic, etanercept was not associated with any statistically significant difference in radiographic progression, MD -3.96 (95% CrI -13.74 to 7.10).
3. With concomitant MTX/DMARD (seven studies, 2621 participants) (Appendix 25): compared to standard dose biologic (reference category), high-dose biologic and low-dose biologic, MD -0.88 (95% CrI, -5.18 to 2.72) and MD 0.80 (95% CrI, -4.47 to 6.38), were not associated with a difference in

radiographic progression. Compared to high-dose biologic, low-dose biologic was not associated with any difference in radiographic progression, MD 1.68 (95% CrI, -4.27 to 8.66).

Data for radiographic progression by type of biologic was only available for TNF biologics (Figure 9).

**Main analyses**

Eight studies (4 two-arm, 4 three-arm trials) with 3,267 participants provided data for all dose analyses for radiographic progression (Appendix 26), including biologic + MTX/DMARD as well as biologic monotherapy arms (interpretation of these analyses for biologic monotherapy is presented in a separate review).

Compared to MTX, all treatments except low-dose certolizumab + MTX were associated with slower radiographic progression, but only two differences were statistically significant (clinical significance unclear since it hasn't been established), i.e., standard-dose infliximab + MTX and high-dose infliximab + MTX were associated with slower radiographic progression than MTX, with

mean differences of -6.43 (95% CrI -13.22 to -0.37) and -6.75 (95% CrI -13.30 to -1.60), respectively.

**Subgroup analyses by disease duration (early vs. established vs. late RA)**

**Early RA (RA disease duration less than two years)**

There were not enough data to perform NMA.

**Established RA (disease duration two to 10 years)**

There were not enough data to perform NMA.

**Late RA (disease duration more than 10 years)**

There were not enough data to perform NMA.

**Subgroup analyses by trial duration**

**Trial duration, six months or less**

There were not enough data to perform NMA.

**Trial duration, six to 12 months**

There were not enough data to perform NMA.

**Trial duration, more than 12 months**

There were not enough data to perform NMA.


**Primary safety/harms outcome: Withdrawals due to adverse events (AEs)**

Seventy studies with 29,062 participants reported withdrawals due to adverse events (AEs). Of these, 52 studies included at least one arm with participants on a biologic with concomitant MTX/DMARD (most often MTX; this review) and 18 studies had only biologic monotherapy (presented and discussed in a separate review).

The use of biologic therapy was associated with no statistically significant increase in the likelihood of withdrawals due to adverse events, vs. comparator, in patients taking biologic with concomitant MTX/DMARD (42 studies) with an OR of 1.14 (95% CI, 0.97 to 1.35) with an  $I^2$  of 0% (Figure 10).



**Figure 10. Forest plot of biologics + MTX/DMARD vs comparator (MTX/DMARD/PL), outcome: Withdrawals due to adverse events**



The overall rate of withdrawals by the type of biologic and the dose were as follows.

1. Type of medication: TNF biologic vs. non-TNF biologic vs. anakinra vs. tofacitinib (67 studies, 26,273 participants) (Appendix 27).
  - a. On background MTX: compared to TNF biologic + MTX/DMARD, none of the following were associated with any difference in the odds ratio of withdrawals due to adverse events: non-TNF (tocilizumab, rituximab, abatacept) + MTX/DMARD, OR 0.97 (95% CrI 0.65 to 1.42) and tofacitinib + MTX/DMARD, OR 1.25 (95% CrI 0.64 to 2.46). Compared to non-TNF biologic + MTX/DMARD, withdrawal rates did not differ for tofacitinib + MTX/DMARD, OR 1.29 (95% CrI 0.63 to 2.69).

2. Type of biologic: monoclonal TNF antibody vs. TNF receptor vs. non-TNF vs. anakinra vs. tofacitinib (67 studies, 26,273 participants) (Appendix 28).
  - a. On background MTX: compared to monoclonal antibodies against TNF (adalimumab, certolizumab pegol, golimumab, infliximab) + MTX/DMARD, etanercept + MTX/DMARD was associated with lower odds of withdrawals due to adverse events, OR 0.51 (95% CrI 0.32 to 0.80), but non-TNF (tocilizumab, rituximab, abatacept) + MTX/DMARD, OR 0.79 (95% CrI 0.54 to 1.18) or tofacitinib + MTX/DMARD, OR 1.07 (95% CrI 0.58 to 1.98) did not differ significantly. No comparisons could be made to anakinra.




3. By dose: standard-dose vs. high-dose vs. low-dose (62 studies, 24,137 participants) (Appendix 29).
  - a. On background MTX/DMARD: compared to standard-dose biologic + MTX/DMARD, no significant differences were seen in the odds of withdrawals due to adverse events with low-dose biologic + MTX/DMARD or high-dose biologic + MTX/DMARD, OR 0.95 (95% CrI 0.58 to 1.56) and OR 1.25 (95% CrI

0.89 to 1.72), respectively. Low-dose biologic + MTX/DMARD was not different than high-dose biologic + MTX/DMARD regarding withdrawals due to adverse events, OR 0.76 (95% CrI 0.45 to 1.30).

Direct estimates for withdrawals by type of biologic, TNF biologic vs. non-TNF biologic vs. anakinra, are shown in Figure 11.

**Figure 11. Forest plot of biologics + MTX/DMARD vs comparator (MTX/DMARD/PL), subgroup estimates for Withdrawals due to adverse events.**



## Main analyses

Seventy studies (42 two-arm, 20 three-arm, 7 four-arm trials and 1 seven-arm trial) with 29,062 participants provided data for all dose analyses (Appendix 30), including biologic + MTX/DMARD as well as biologic monotherapy arms (interpretation of these biologic monotherapy analyses is presented in a separate review).

Compared to PL, we found that MTX, MTX + DMARD, and most biologic + MTX combinations (standard- or high-dose) were associated with higher odds of withdrawals due to adverse events, with odds ratios ranging from 3.17 to 17.34, including the following: standard-dose adalimumab + MTX, standard-dose infliximab + MTX, standard-dose rituximab + MTX, standard-dose certolizumab + MTX, standard-dose tofacitinib + MTX, high-dose tocilizumab + MTX, high-dose golimumab + MTX, high-dose infliximab + MTX, high-dose certolizumab + MTX, and high-dose tofacitinib + MTX.

Compared to MTX, we noted that MTX + DMARD, standard-dose infliximab + MTX, standard-dose tofacitinib + MTX, were associated with higher odds of withdrawals due to adverse events, with odds ratios ranging from 1.90 to 2.33.

Compared to DMARD, DMARD + MTX was associated with 5.53 times odds, standard-dose biologics + MTX with 3.30 to 4.60 times odds, high-dose biologics + MTX with 1.95 to 4.14 times odds and tofacitinib + MTX with 3.54 times odds of withdrawals due to adverse events. Compared to MTX + DMARD, most biologic + MTX regimens were associated with lower odds of withdrawals due to adverse events of 0.04 to 0.37.

Compared to standard-dose etanercept + MTX, standard-dose infliximab + MTX and standard-dose tofacitinib + MTX, were associated with higher odds of withdrawals, 2.28 times each.

### Adalimumab and infliximab comparisons

Compared to standard-dose adalimumab + MTX or standard-dose infliximab + MTX, several treatments were associated with lower OR of withdrawals due to adverse events with OR ranging 0.13 to 0.40: standard-dose abatacept + MTX, standard-dose etanercept + DMARD, low-dose adalimumab and high-dose adalimumab. Compared to low-dose adalimumab, most high-dose biologics + MTX as well as tofacitinib + MTX were associated with higher odds of withdrawals due to adverse events with OR ranging 4.59 to 7.41.

Compared to standard-dose certolizumab + MTX, we found that standard-dose tocilizumab + MTX, standard-dose etanercept + DMARD, low dose adalimumab and high-dose adalimumab were associated with lower odds of withdrawals due to adverse events, 0.17 to 0.74.

Compared to standard-dose tofacitinib + MTX, standard-dose abatacept + MTX, standard-dose etanercept + DMARD, low-dose etanercept, low-dose adalimumab and high-dose adalimumab were associated with lower odds of withdrawals due to adverse events, 0.12 to 0.28.

Compared to standard-dose abatacept + MTX, we found that low-dose rituximab + MTX, high-dose golimumab + MTX, low-dose infliximab + MTX, and high-dose tofacitinib were associated with higher odds of withdrawals due to adverse events, 2.82 to 3.86.

Compared to high-dose golimumab, several treatments were associated with higher odds of withdrawals due to adverse events:

high-dose infliximab + MTX, high-dose tofacitinib + MTX, high-dose golimumab + MTX. Compared to high-dose adalimumab subcutaneous, high-dose tofacitinib + MTX was associated with 3.54 times odds of withdrawals due to adverse events. Compared to high-dose infliximab + MTX, high-dose tocilizumab + MTX and high-dose tocilizumab intravenous + DMARD, were associated with lower odds of withdrawals due to adverse events, 0.30 to 0.39.

### Subgroup analyses by disease duration (early vs. established vs. late RA)

#### Early RA (RA disease duration less than two years)

There were not enough data to perform NMA.

#### Established RA (disease duration two to 10 years)

Forty-eight studies (30 two-arm, 13 three-arm, and 5 four-arm trials) with 20,301 participants (Appendix 31). Compared to PL, MTX + DMARD, standard- and high-dose biologics + MTX were associated with higher odds of withdrawals due to AEs, with odds ranging from 4.0 to 11.5. Compared to DMARDs alone, standard- and high-dose biologics + MTX, were associated with higher odds of withdrawals due to AEs, with odds ranging from 3.6 to 10.4. Compared to MTX + DMARDs, standard and high-dose biologics + MTX, were associated with lower odds of withdrawals due to AEs, with odds ranging from 0.10 to 0.32. Compared to standard-dose biologics, standard- or high-dose biologics + MTX, were associated with higher odds of withdrawals due to AEs, with odds ranging from 4.4 to 16.2. Compared to standard-dose infliximab + MTX, several standard- or high-dose biologics + MTX were associated with lower odds of withdrawals due to AEs, ranging from 0.12 to 0.37. Compared to high-dose biologics, high-dose biologics + MTX were associated with higher odds of withdrawals due to AEs, ranging from 8.8 to 18.0.

#### Late RA (disease duration more than 10 years)

Nine studies (4 two-arm, 4 three-arm and 1 four-arm trials) with 3276 participants (Appendix 32). Compared to standard-dose etanercept, standard-dose rituximab and standard-dose rituximab + MTX, were each associated with higher odds of withdrawals due to adverse events with odds of 26.6 and 7.4, respectively.

### Subgroup analyses by trial duration

#### Trial duration, six months or less

Fifty-two studies with 20,850 participants (Appendix 33). Compared to MTX + DMARD, standard-dose etanercept + MTX was associated with 0.34 times lower odds of withdrawals due to AEs. Compared to standard-dose adalimumab subcutaneous, low-dose adalimumab subcutaneous was associated with 0.34 times odds and high-dose adalimumab subcutaneous with 0.35 times odds of withdrawals due to AEs. standard-dose abatacept subcutaneous + MTX was associated with 0.23 times odds compared to standard-dose adalimumab + MTX, and 0.17 times compared to standard-dose infliximab + MTX. Compared to standard-dose tofacitinib, high-dose tofacitinib was associated with 7.62 higher odds of withdrawals due to AEs.

#### Trial duration, six to 12 months

Seven studies with 3279 participants (Appendix 34). Standard-dose infliximab + MTX was more likely to be associated with withdrawals due to AEs compared to MTX and standard-dose etanercept, with odds of 2.60 and 3.83, respectively. Compared

to standard-dose etanercept + MTX, standard-dose tofacitinib + MTX, high-dose infliximab + MTX and high-dose golimumab + MTX, were each associated with higher odds of withdrawals due to AEs, with odds ranging from 3.35 to 3.65. Compared to standard-dose adalimumab subcutaneous + MTX, standard-dose etanercept + MTX was associated with 0.38 odds of withdrawals due to AEs. Compared to standard-dose infliximab intravenous + MTX, several regimens were associated with significantly lower odds of withdrawals due to AEs: standard-dose etanercept + MTX, standard-dose rituximab + MTX, low-dose etanercept, low-dose etanercept + MTX and high-dose golimumab, with odds ranging from 0.15 to 0.78. Compared to standard-dose tofacitinib + MTX, high-dose golimumab was associated with 0.19 odds of withdrawals due to adverse events. Compared to high-dose golimumab, high-dose infliximab + MTX and high-dose golimumab + MTX were associated with 5.44 and 4.74 times odds of withdrawals due to AEs.

**Trial duration, more than 12 months**


There were not enough data to perform NMA.

**Primary safety/harms outcome: Serious adverse events (SAEs)**

Sixty-one studies with 28,661 participants reported serious adverse events (SAEs). Of these, 46 studies included at least one arm with participants on a biologic with concomitant MTX/DMARD (most often MTX). Fifteen studies had only biologic vs. comparator (no concomitant MTX/DMARD therapy), which is presented in a separate review.

The use of biologic therapy was associated with an increase in odds of SAEs versus comparator, in participants with biologic with concomitant MTX/DMARD with a Peto OR 1.12 (95% CI 0.99 to 1.27, I<sup>2</sup> of 12%; 39 studies) with heterogeneity that might not be important (Figure 12). Peto OR was used due to the low event rate for serious adverse events, and can be interpreted as relative risk.

**Figure 12. Forest plot of biologics + MTX/DMARD vs comparator (MTX/DMARD/PL), outcome: Serious adverse events.**




The overall SAEs differed by the type of biologic and the dose as follows:

1. Type of biologic: (58 studies, 25,872 participants) ([Appendix 35](#)).
  - a. In participants receiving concomitant MTX: compared to TNF inhibitors, the odds of SAEs were not significantly different with non-TNF biologic, OR 0.89 (95% CrI, 0.69 to 1.14); anakinra, OR 0.88 (95% CrI, 0.51 to 1.55); and tofacitinib, OR 1.70 (95% CrI, 0.85 to 3.60).
2. Type of biologic: (58 studies, 25,872 participants) ([Appendix 36](#)).
  - a. In participants receiving concomitant MTX: compared to monoclonal antibodies against TNF receptor, the odds of SAEs were not significantly different with comparators as follows: non-TNF biologic (tocilizumab, rituximab, abatacept) OR 0.90 (95% CrI, 0.69 to 1.18); etanercept, OR 1.13 (95% CrI, 0.72 to 1.78); tofacitinib, OR 1.72 (95% CrI, 0.87 to 3.74); and anakinra, OR 0.90 (95% CrI, 0.52 to 1.61).
3. By dose: (53 studies, 22,337 participants) ([Appendix 37](#)).
  - a. In participants receiving concomitant MTX: compared to standard dose biologic, the odds of SAEs were not significantly different with comparators as follows: low-dose biologic OR 0.98 (95% CrI, 0.73 to 1.33); and high-dose biologic, OR 1.20 (95% CrI, 0.91 to 1.59).

Inconsistency was noted for several of these analyses.

Direct estimates for serious adverse events by type of biologic, TNF biologic vs. non-TNF biologic vs. anakinra, are shown in [Figure 13](#).

**Figure 13. Forest plot of biologics + MTX/DMARD vs comparator (MTX/DMARD/PL), Subgroup estimates for Serious adverse events.**



**Main analyses**

Sixty-one studies (38 two-arm, 16 three-arm, 6 four-arm, and one 5-arm trials) with 28,661 participants provided data for all dose analyses for SAEs (Appendix 38), including biologic + MTX/DMARD as well as biologic monotherapy arms (interpretation of these analyses is presented in a separate review). Main findings are summarized in the section below. None of the

treatments were significantly different from PL, except standard-dose certolizumab pegol and low-dose golimumab intravenous, which were associated with 4.67- and 6.90 times odds of SAEs (Appendix 38). In summary, golimumab and certolizumab pegol were associated with higher odds and abatacept and adalimumab with lower odds of SAEs compared to each other, other biologics or tofacitinib.



### MTX/DMARD comparisons (lower odds)

Compared to MTX, none of the comparators were clinically or statistically significant different. Compared to DMARDs, several standard-dose and high-dose biologic + MTX combination treatments were associated with higher odds of SAEs, ranging from 2.01 to 10.93. Compared to MTX + DMARD combination, we found that low-dose golimumab intravenous and high-dose golimumab + MTX, were each associated with higher odds of SAEs, 8.93 and 5.02, respectively.

### Tofacitinib comparisons

Compared to standard-dose tofacitinib, several biologic + MTX as well as tofacitinib + MTX combinations were associated with higher odds of SAEs, ranging from 5.42 to 12.27. Compared to standard-dose tofacitinib + MTX, several biologic + DMARD combinations were associated with lower odds of SAEs: standard-dose abatacept + DMARD, 0.26; standard-dose adalimumab + DMARD, 0.17; standard-dose anakinra + DMARD, 0.24; and standard-dose certolizumab + DMARD, 0.17.

### Golimumab comparisons (higher odds)

Low-dose golimumab intravenous was associated with higher odds of SAEs compared to several treatments: (1) standard-dose adalimumab, 6.29; (2) standard-dose tofacitinib, 18.17; (3) standard-dose golimumab intravenous, 4.58; (4) standard-dose rituximab, 12.36; (5) standard-dose infliximab + MTX, 5.64; (6) standard-dose adalimumab subcutaneous + MTX, 5.68; (7) standard-dose abatacept + MTX, 6.30; (8) standard-dose abatacept intravenous + DMARD, 10.09; (9) standard-dose adalimumab subcutaneous + DMARD, 16.15; (10) standard-dose anakinra + DMARD, 11.02; (11) standard-dose certolizumab + DMARD, 16.49; (12) low-dose adalimumab, 10.84; and (13) low-dose etanercept, 6.83. Several treatments were associated with lower odds of SAEs compared to low-dose golimumab intravenous: low-dose etanercept + MTX, 0.09; high-dose tofacitinib, 0.08; high-dose adalimumab, 0.14; and high-dose tocilizumab intravenous + DMARD, 0.14. High-dose golimumab subcutaneous + MTX was associated with higher odds of SAEs compared to: standard-dose infliximab + MTX, 3.15; standard-dose abatacept intravenous + MTX, 3.46; standard-dose abatacept subcutaneous + MTX, 4.09; standard-dose abatacept intravenous + DMARD, 5.69; standard-dose adalimumab + DMARD, 8.53; standard-dose anakinra + DMARD, 6.05; standard-dose certolizumab subcutaneous + DMARD, 8.51; low-dose etanercept + MTX, 5.83; high-dose tofacitinib, 7.54.

### Certolizumab pegol comparisons (higher odds)

High-dose certolizumab pegol subcutaneous + MTX was associated with higher odds of SAEs compared to several treatments: (1) standard-dose certolizumab subcutaneous + DMARD, 5.91; (2) standard-dose anakinra + DMARD, 6.05; (3) standard-dose adalimumab + DMARD, 5.81; (4) standard-dose abatacept subcutaneous + DMARD, 3.91; (5) standard-dose abatacept subcutaneous + MTX, 2.81; (6) standard-dose abatacept intravenous + DMARD, 1.94; and (7) low-dose etanercept, 3.95. Several treatments were associated with lower odds of SAEs compared to standard-dose certolizumab pegol subcutaneous: (1) standard-dose adalimumab + DMARD, 0.09; (2) low-dose adalimumab, 0.14; and (3) high-dose tofacitinib, 0.11.

### Abatacept + MTX comparisons (lower odds)

Compared to standard-dose abatacept + MTX (intravenous or subcutaneous), the following were associated with higher odds for SAEs ranging from 1.94 to 7.54: standard-dose certolizumab subcutaneous + MTX; standard-dose tofacitinib + MTX; low-dose golimumab intravenous; and high-dose golimumab subcutaneous + MTX. Compared to standard-dose abatacept intravenous + DMARD, the following were associated with higher odds for SAEs ranging from 3.91 to 10.09: low-dose golimumab intravenous; high-dose golimumab subcutaneous + MTX; and high-dose certolizumab subcutaneous + MTX.

### Adalimumab + DMARD comparisons (lower odds)

Compared to standard-dose adalimumab + DMARD, the following were associated with odds or SAEs ranging from 4.88 to 16.15: low-dose golimumab intravenous, low-dose golimumab intravenous + MTX, low-dose golimumab subcutaneous + MTX, high-dose tofacitinib + MTX, and high-dose certolizumab pegol subcutaneous + MTX.

### Subgroup analyses by disease duration (early vs. established vs. late RA)

#### Early RA (RA disease duration less than two years)

There were not enough data to perform NMA.

#### Established RA (disease duration two to 10 years)

Fifty studies with 22,022 participants ([Appendix 39](#)): compared to DMARD + PL, most biologics in standard-dose with MTX, were not associated with any differences in the rates of SAEs, except standard-dose certolizumab pegol and high-dose golimumab + MTX, which was associated with 4.5-fold and 3.0-fold higher odds of SAEs, respectively. Compared to DMARD, standard- and high-dose biologic + MTX were associated with higher odds of SAEs, ranging from 2.7 to 7.2. Compared to standard-dose biologic + MTX, high-dose biologic + MTX was associated with higher odds of SAEs, ranging from 2.4 to 4.9. Compared to standard-dose tofacitinib, several biologics + MTX combinations were associated with higher odds of SAEs, ranging from 5.7 to 24.1.

#### Late RA (disease duration more than 10 years)

Four studies (1 two-arm, 2 three-arm and 1 four-arm trials) with 1390 participants provided data. ([Appendix 40](#)): there were no statistically significant differences.

### Subgroup analyses by trial duration

#### Trial duration, six months or less

We created two networks, one with 23 studies and 11,146 participants ([Appendix 41](#)), and the other with 26 studies and 12,263 participants ([Appendix 42](#)).

In the first network with 23 studies and 11,146 participants, compared to standard-dose tofacitinib, high-dose abatacept subcutaneous was associated with 14.5 higher odds of SAEs. Compared to high-dose adalimumab, standard-dose tofacitinib was associated with 0.06 lower odds of SAEs. Compared to standard-dose adalimumab, standard-dose tofacitinib was associated with 0.06 lower odds of SAEs.

The second network had 26 studies with 12,263 participants. Compared to standard-dose infliximab + MTX, several biologics



were associated with higher rates of SAEs: standard-dose rituximab + MTX, 6.06; low-dose tocilizumab, 6.14; low-dose rituximab + MTX, 6.27; and high-dose tocilizumab + MTX, 3.74. Compared to standard-dose abatacept intravenous + MTX, several biologics were associated with higher rates of SAEs: standard-dose rituximab + MTX, 4.89; low-dose tocilizumab, 5.03; low-dose rituximab + MTX, 5.20; high-dose tocilizumab + MTX, 3.00. Compared to standard-dose abatacept subcutaneous + MTX, several biologics were associated with higher rates of SAEs: standard-dose rituximab + MTX, 6.28; low-dose tocilizumab, 6.31; low-dose rituximab + MTX, 6.63; high-dose tocilizumab + MTX, 3.76. Compared to standard-dose tocilizumab + MTX, low-dose tocilizumab intravenous and low-dose rituximab + MTX, were also associated with higher odds of SAEs, with odds ratios of 15.30 and 13.67.

**Trial duration, six to 12 months**

Six studies (10 two-arm, 12 three-arm, 3 four-arm and 1 five-arm trials) with 2277 participants (Appendix 43). Compared to MTX + PL, standard-dose tofacitinib + MTX and low-dose golimumab intravenous were associated with higher odds ranging from 10.7 to 13.23, and 6.27 to 7.61 compared to standard-dose rituximab intravenous and standard-dose adalimumab + MTX, respectively.

Low-dose golimumab intravenous was associated with higher rates of SAEs, compared to the following: (1) standard-dose rituximab + MTX, 5.41; (2) standard-dose abatacept intravenous + MTX, 5.80; (3) standard-dose abatacept intravenous + MTX, 7.47; and (4) low-dose etanercept, 7.57. High-dose tofacitinib + MTX was associated with higher odds compared to low-dose etanercept + MTX, odds of 7.40.

**Trial duration, more than 12 months**


There were not enough data to perform NMA.

**Primary safety outcome: Cancer**

Twenty-four studies with 10,843 participants reported cancer. Of these, 19 studies included at least one arm with participants on a biologic with concomitant MTX/DMARD (most often MTX). Five studies had only biologic vs. comparator (no concomitant MTX/DMARD therapy), which is presented in a separate review.

The use of biologic therapy is inconclusive in the risk of cancer due to few events and resulting wide confidence intervals, compared to comparator in patients on biologic with concomitant MTX/DMARD (15 studies) with Peto OR of 1.07 (95% CI 0.68 to 1.68;  $I^2$  of 0%) (Figure 14).

**Figure 14. Forest plot of biologics + MTX/DMARD vs comparator (MTX/DMARD/PL), outcome: Cancer**



The overall rate of cancer by the type of biologic and the dose were as follows.


1. Type of biologic: (23 studies, 9386 participants) (Appendix 44).
  - a. In participants receiving MTX/DMARD, compared to TNF inhibitors, the odds of cancer with non-TNF biologic were no different, Peto OR was 0.83 (95% CrI 0.38 to 1.71).
2. Type of biologic: receptor vs. antibody (23 studies, 9386 participants) (Appendix 45).
  - a. In participants receiving MTX, compared to non-TNF biologic, neither etanercept nor monoclonal TNF antibodies, were

associated with any significant differences in the odds of cancer, Peto OR 1.54 (95% CrI 0.56 to 4.51) and 1.00 (95% CrI 0.38 to 2.62), respectively.

3. By dose: (22 studies, 8740 participants) (Appendix 46).
  - a. In participants receiving MTX, compared to standard-dose biologic, the odds of cancer were no different with low-dose biologic, Peto OR 1.31 (95% CrI 0.40 to 3.77).

Direct estimates for cancer by type of biologic, TNF biologic vs. non-TNF biologic vs. anakinra, are shown in Figure 15

Figure 15. Forest plot of biologics + MTX/DMARD vs comparator (MTX/DMARD/PL), subgroup estimates for Cancer



**Main analyses**

Twenty-four studies (16 two-arm and 8 three-arm trials) with 10,843 participants provided data for all dose analyses (Appendix 47), including biologic + MTX/DMARD as well as biologic monotherapy arms (interpretation of these analyses for biologic monotherapy is presented in a separate review).

Most ORs ranged 16-47 with wide confidence intervals, related to few cancer events in most trials. Compared to DMARD, the following treatments were associated with higher odds of cancer: standard-dose etanercept, 13.86; standard-dose etanercept + MTX, 18.62; low-dose etanercept + MTX, 40.81. Low-dose etanercept + MTX was associated with higher odds of cancer compared to standard-dose etanercept + DMARD and standard-dose abatacept intravenous + MTX with odds ratios of 47.44 and 40.87, respectively. Compared to standard-dose etanercept + MTX, standard-dose etanercept + DMARD and standard-dose abatacept + DMARD were associated with lower odds of cancer, odds of 0.05 and 0.05 respectively. Compared to standard-dose etanercept, standard-dose etanercept + DMARD and standard-dose abatacept intravenous + DMARD were associated with lower odds of cancer, odds of 0.06 and 0.07 respectively.

**Subgroup analyses by disease duration (early vs. established vs. late RA)**

**Early RA (RA disease duration less than two years)**

There were not enough data to perform NMA

**Established RA (disease duration two to 10 years)**

Thirteen studies with 5,853 participants (Appendix 48): no statistically significant differences in cancer rates were noted between treatments.

**Late RA (disease duration more than 10 years)**

There were not enough data to perform NMA.

**Subgroup analyses by trial duration**

**Trial duration, six months or less**

Eight studies with 3895 participants (Appendix 49): no statistically significant differences in cancer rates were noted between treatments.

**Trial duration, six to 12 months**

There were not enough data to perform NMA.

**Trial duration, more than 12 months**

There were not enough data to perform NMA.

**Summary of safety warnings from regulatory agencies**

Evidence from RCTs is limited in informing patients and physicians regarding uncommon or rare adverse events. In the section below, we summarize warnings from the FDA, EMA and Health Canada, the regulatory agencies in the USA, Europe and Canada, respectively.

**Abatacept**

No recent warnings have been issued with regard to abatacept. On the product label of abatacept, the FDA warns against known safety implications reporting, "In controlled clinical trials, patients receiving concomitant abatacept and TNF antagonist therapy experienced more infections (63%) and serious infections (4.4%) compared to patients treated with only TNF antagonists (43% and 0.8%, respectively). Concurrent administration of a TNF antagonist with abatacept has been associated with an increased risk of serious infections and no statistically significant additional benefit over use of the TNF antagonists alone" (FDA

2007). Furthermore, the FDA reports that, "rare occurrences of anaphylaxis or anaphylactoid reactions have been observed in two of 2,688 patients treated with abatacept in clinical trials" (FDA 2007). Trials have also shown that, "COPD [ chronic obstructive pulmonary disease] patients treated with abatacept developed adverse events more frequently than those treated with placebo, including COPD exacerbations, cough, rhonchi, and dyspnea" (FDA 2007).

The effects of abatacept on pregnant women, pediatric patients, and the development of malignancies is "not yet fully understood" (FDA 2007). The European Medicines Agency (EMA) reports the adverse reactions in patients treated with abatacept, ranking the occurrences of such reactions as very common ( $\leq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); and very rare ( $< 1/10,000$ ). EMA 2009a reports increase in blood pressure, abnormal liver function test (transaminases increased) and headaches are very common adverse reactions. Dizziness, cough, rash including dermatitis, diarrhea, nausea, dyspepsia, abdominal pain, lower respiratory tract infection (including bronchitis), urinary tract infection, herpes simplex, upper respiratory tract infection, hypertension, flushing, fatigue and asthenia are common (EMA 2009a). Overall, "the most commonly reported adverse events (occurring in 10% or more of patients) were headaches, upper respiratory tract infection, nasopharyngitis, and nausea. The adverse events most commonly resulting in clinical intervention were due to infection" (FDA 2007).

#### **Adalimumab**

The updated 2008 FDA label for adalimumab reports "Serious infections, sepsis, tuberculosis and cases of opportunistic infections, including fatalities, have been reported with the use of TNF blocking agents including Humira® [adalimumab]" (FDA 2008a). "Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and septicemia. Hospitalization or fatal outcomes associated with infections have been reported" (EMA 2009b). Furthermore, hepatitis B reactivation has been shown to be associated with adalimumab treatment (Health Canada 2006a). The FDA reports, "As observed with other TNF blocking agents, tuberculosis associated with the administration of Humira® in clinical trials has been reported" (FDA 2008a).

In rare instances, adalimumab has been associated with, "new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease including multiple sclerosis" (EMA 2009b). Furthermore, "In the controlled portions of clinical trials of some TNF-blocking agents, including Humira, more cases of malignancies have been observed among patients receiving those TNF blockers compared to control patients" (FDA 2008a).

"Some of these hepatosplenic T-cell lymphomas have occurred in young adult patients on concomitant treatment with azathioprine or 6-mercaptopurine used for Crohn's disease". Thus, the risk of the development of hepatosplenic T-cell lymphoma cannot be excluded for patients treated with adalimumab (EMA 2009b). Though the causal relationship of hematological reactions and the use of adalimumab remain unclear as of 2008, the FDA label states, "Rare reports of pancytopenia including aplastic anemia have been reported with TNF blocking agents". Furthermore, the FDA reports "Treatment with Humira® [adalimumab] may result in

the formation of autoantibodies and rarely in the development of a lupus-like syndrome" (FDA 2008a).

#### **Anakinra**

Anakinra leads to an increased rate of infections (2%) versus placebo (less than 1%). Following the EMA standard of classification of frequency of the occurrence of "undesirable effects" mentioned above, neutropenia and serious infection requiring hospitalization were common (between 1/10 and 1/100) and headaches and injection site reactions were very common occurring in 1/10 or more patients treated with anakinra (EMA 2009). "A... clinical trial sponsored by Amgen Inc. showed a higher incidence of serious infection and of neutropenia in anakinra and etanercept combination group than patients receiving Enbrel [etanercept] alone and higher than observed in previous trials where Kineret [anakinra] was used alone (EMA 2003), therefore, the use of etanercept and anakinra is not recommended as it leads to safety complications". Furthermore, the FDA reports in its most recent report on anakinra that "Hypersensitivity reactions associated with Kineret [anakinra] administration are rare" (FDA 2001). Moreover, the FDA reports the effects of anakinra on the hematologic conditions of patients stating that, "In placebo-controlled studies with Kineret® [anakinra], treatment was associated with small reductions in the mean values for total white blood count, platelets, and absolute neutrophil count (ANC), and a small increase in the mean eosinophil differential percentage" (FDA 2001). With regard to the development of malignancies for patients treated with anakinra, trials show that, "among 5300 RA patients treated with Kineret [anakinra] clinical trials for a mean of 15 months (approximately 6400 patient years of treatment), lymphomas were observed for a rate of 0.12 cases per 100 patient years. This is 3.6 fold higher than the rate of lymphomas expected in the general population, based on the National Cancer Institutes Surveillance Epidemiology and End Results (SEER) database" (FDA 2001).

#### **Etanercept**

In the post-marketing reports of etanercept, "Infections, including serious infections leading to hospitalization or death, have been observed in patients treated with Enbrel® [etanercept]" (FDA 2008c). Furthermore, "Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with Enbrel® than with TNF-blocking monoclonal antibodies. Nonetheless, post-marketing cases of tuberculosis reactivation have been reported for TNF blockers, including Enbrel® [etanercept]. Patients receiving Enbrel® should be monitored closely for signs and symptoms of active tuberculosis. The possibility of tuberculosis should be considered, especially in patients who have travelled to countries with a high prevalence of tuberculosis or had close contact with a person with active tuberculosis. All patients treated with Enbrel® should have a thorough history taken prior to initiating therapy" (FDA 2008c). This finding is also stated in an important health warning issued by Health Canada in 2006 (Health Canada 2006a).

Furthermore, etanercept has been associated with the risk of histoplasmosis and other invasive fungal infections. Health Canada 2009 states, "...although no histoplasmosis infections were reported among 17,696 patients from the United States and Canada who were treated with Enbrel®, in 38 clinical trials and four cohort studies involving all authorized indications, post marketing cases of serious and sometimes fatal fungal infections,

including histoplasmosis, have been reported with TNF blockers, including Enbrel®. The FDA also outlines the risk of nervous system complications stating, "nervous system complications such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes have occurred in rare cases" (FDA 2008c).

Infections, including serious infections leading to hospitalization or death, have been observed in patients treated with Enbrel® [etanercept] (FDA 2008c). The FDA reports on the risk of malignancies for patients on etanercept treatment, stating "Patients have been observed in clinical trials with Enbrel® for over five years. Among 4462 rheumatoid arthritis patients treated with Enbrel® in clinical trials for a mean of 27 months (approximately 10,000 patient-years of therapy), lymphomas were observed for a rate of 0.09 cases per 100 patient-years. This is 3-fold higher than the rate of lymphomas expected in the general population based on the Surveillance, Epidemiology, and End Results Database. Rare reports of pancytopenia including aplastic anaemia, some with a fatal outcome, have been reported in patients treated with Enbrel®" (FDA 2008c). The FDA also reports, "Treatment with Enbrel® may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome or autoimmune hepatitis which may resolve following withdrawal of Enbrel®" (FDA 2008c).

The use of etanercept has also been associated with the relapse of hepatitis B (Health Canada 2006a).

### **Infliximab**

In its recent revised report on infliximab, the EMA reports on the risk of infusion reactions and hypersensitivity, stating, "An infusion-related reaction was defined in clinical studies as any adverse event occurring during an infusion or within 1 to 2 hours after an infusion. In clinical studies, approximately 20% of infliximab-treated patients compared with approximately 10% of placebo-treated patients experienced an infusion-related effect. Approximately 3% of patients discontinued treatment due to infusions reactions" (EMA 2009a). Infliximab is also associated with the relapse of hepatitis B as reported by Health Canada in 2006 (Health Canada 2006a). "Opportunistic infections have been reported in patients treated with infliximab, suggesting that host defence against infection is compromised. It should be noted that suppression of TNF-alpha may also mask symptoms of infection such as fever." There is also a possible association between infliximab and heptosplenix T-Cell lymphoma in pediatric and young adult patients with Crohn's disease (Health Canada 2006b).

"In a study designed to evaluate Remicade® [infliximab] in congestive heart failure (CHF), 150 patients with moderate to severe (NYHA class II-intravenous) CHF were treated with three infusions of Remicade 5mg/kg, or placebo over six weeks. Higher incidences of mortality and hospitalization for worsening heart failure were seen in those patients treated with Remicade®, especially (those) treated with the higher dose of 10mg/kg. At present 7 out of 101 patients treated with Remicade® have died compared to no deaths among 49 patients on placebo" (EMA 2001). In a May 2009 revision of the Remicade label, the FDA warns, "Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving TNF- blocking agents. Among opportunistic infections, tuberculosis, histoplasmosis, aspergillosis, candidiasis, coccidioidomycosis, listeriosis, and pneumocystosis were the

most commonly reported. Patients have frequently presented with disseminated rather than localized disease, and are often taking concomitant immunosuppressants such as methotrexate or corticosteroids with Remicade®" (FDA 2009a). In an investigation of neurological events, EMA reports "Infliximab and other agents that inhibit TNF-alpha have been associated in rare cases with optic neuritis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis, and peripheral demyelinating disorders, including Guillain-Barré syndrome" (EMA 2009a).

The increased risk of developing lymphoma is also reported. FDA archived report from October 2004 on infliximab safety alerts notifies that "During the controlled portions of REMICADE trials in patients with moderately to severely active rheumatoid arthritis and Crohn's disease, 1 patient developed lymphoma among 1389 REMICADE-treated patients versus 0 among 483 control patients (median duration of follow-up 1.1 years)." " In the controlled and open-label portions of these clinical trials of REMICADE, 3 patients developed lymphomas (1 patient with rheumatoid arthritis and 2 patients with Crohn's disease) among 2410 patients (median duration of follow-up 1.1 years)." "As a result of this evaluation, a warning concerning malignancy has been added to the labelling for all therapeutic agents that block TNF."(FDA 2004).

Another evidence of infliximab associated with lymphoma states that "In the controlled portions of clinical trials of all the TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared with control patients... In the combined clinical trial population for rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and plaque psoriasis, lymphomas were observed for a rate of 0.10 cases per 100 patient-years of follow-up, which is approximately 4-fold higher than expected in the general population. Patients with Crohn's disease, rheumatoid arthritis or plaque psoriasis, particularly patients with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to several fold) than the general population for the development of lymphoma, even in the absence of TNF-blocking therapy" (EMA 2009a).

### **TNF-blockers as a group**

In 2008, the FDA issued a safety alert regarding anti-TNF biologics, which stated that the risk of pulmonary and disseminated histoplasmosis, coccidioidomycosis, blastomycosis and other opportunistic infections were not consistently recognized in patients taking tumor necrosis factor-alpha blockers (TNF blockers including etanercept, adalimumab, infliximab or certolizumab), which resulted in the delay of proper antifungal treatment and at times led to death (FDA 2008b). The FDA reviewed 240 reports of histoplasmosis, an infection caused by the fungus *Histoplasma capsulatum*, in patients being treated with Enbrel, Humira, or Remicade. The majority of the reports involved people in the Ohio River and Mississippi River valleys (the fungus is commonly found in those areas). In at least 21 of the reports, histoplasmosis was initially not recognized by healthcare professionals, and antifungal treatment was delayed. Twelve of those patients died. The FDA recommended that for patients at risk of histoplasmosis and other invasive fungal infections, clinicians should consider empiric antifungal treatment until the pathogen(s) are identified.



## Rituximab

While no reviews exist for rituximab on the EMA web site and Health Canada's reviews are outdated, the FDA provides its most recent safety information for Rituxan® [rituximab] from 2009. Rituxan was found to be associated with progressive multifocal leukoencephalopathy. FDA and Genetech notified: "A third case of progressive multifocal leukoencephalopathy (PML) has been reported in a patient with rheumatoid arthritis treated with Rituxan." In view of this event, Genetech has advised physicians to have high index of suspicion for PML stated as "Physicians should consider PML in any patient being treated with Rituxan who presents with new onset neurologic manifestations. Consultation with a neurologist, brain MRI, and lumbar puncture should be considered as clinically indicated. In patients who develop PML, Rituxan should be discontinued." (FDA 2009b). Another event associated with Rituxan was notified in a FDA label from 2008. In this label, the possible safety complications of Rituxan® use included "tumor lysis syndrome which necessitates clinicians to administer prophylaxis and monitor patients' renal function, hepatitis B reactivation with fulminant hepatitis, which can sometimes [be] fatal and the risk of progressive multifocal leukoencephalopathy" (Drugs 2006).

FDA and Genetech informed healthcare professionals of important emerging safety information about Rituxan®. "Two patients died after being treated with Rituxan® for systemic lupus erythematosus (SLE). Rituxan® is approved for the above indication and is prescribed off-label for other serious diseases and conditions such as SLE. The cause of death was progressive multifocal leukoencephalopathy, a viral infection of the brain (that is caused by reactivated JC virus which is present in about 80% of adults" (FDA 2006). Further risks include "cardiac arrhythmias and angina" which can be life threatening, and "bowel obstruction and perforation" (FDA 2008c). Health Canada 2006a also provided warnings of bowel obstruction and perforation, "Reports of abdominal pain, bowel obstruction, and perforation, in some cases leading to death, have been observed in patients receiving Rituxan®. The majority of reports, including all deaths, have occurred in patients receiving Rituxan in combination with chemotherapy for NHL [non-Hodgkin's Lymphoma] indication. A causal relationship has not been established".

## Tofacitinib

The FDA issued a Risk Evaluation and Mitigation Strategy (REMS) document, a modification in February 2015 to the original 11/2012 document, highlighting the known concerns with tofacitinib, instructing the pharmaceutical company to send information to physicians and pharmacists regarding the risk of serious infections, malignancies, decreases in peripheral lymphocyte counts, neutrophil counts, hemoglobin, and increases in lipid parameters in peripheral blood with XELJANZ (tofacitinib) (FDA 2015).

No warnings were found for the other drugs included in this systematic review and NMA.

## DISCUSSION

### Summary of main results

This study examines benefits and harms of biologic + MTX/DMARDs in people with incomplete response to MTX/DMARD (Hochberg

2001; Maini 2006b; Saevarsdottir 2011; Tugwell 2000). We provide both NMA and direct estimates of comparisons of various biologic categories and biologics to each other, and to DMARDs. This review includes the details of the process of this systematic review, in accordance with recent suggestions for conducting NMA (Horlund 2013). The summary of findings table provides NMA vs. Direct estimates side-by-side. Several *a priori* planned subgroup analyses were conducted. We also provide comparisons of biologics by mechanism of action to examine potential differences in benefits and harms. This should give greater confidence to the reader.

Biologic + MTX/DMARD use probably improves the functional improvement as assessed by HAQ and ACR50 and RA disease remission rates, but leads to a higher risk of serious adverse events, versus comparator (MTX/DMARD/PL). Radiographic progression is probably decreased with biologic + MTX/DMARD use, but its clinical significance is unclear. Results were inconclusive regarding the risk of withdrawals due to adverse events or cancer with biologic + MTX/DMARD use.

### ACR50

Biologic + MTX/DMARD use was associated with higher RR of ACR50 versus comparator (usually MTX + Placebo) with RR 2.71 (95% CI, 2.36 to 3.10; quality of evidence, moderate), a clinically important and statistically significant improvement. Specifically, TNF, non-TNF, and anakinra in combination with MTX/DMARD were associated with RR of 2.83 (95% CI, 2.38 to 3.37; quality of evidence, moderate), RR 2.49 (95% CI, 1.88 to 3.30; quality of evidence, moderate) and RR 2.26 (95% CI, 1.41 to 3.63; quality of evidence, moderate) of ACR50 versus comparator in direct comparisons; respective RRs from NMA were RR 3.23 (95% CrI, 2.75 to 3.79; quality of evidence, moderate), RR 2.99 (95% CrI, 2.36 to 3.74; quality of evidence, moderate) and RR 2.37 (95% CrI, 1.00 to 4.70; quality of evidence, moderate).

With respect to the type of biologic, TNF biologics did not differ from non-TNF biologics and monoclonal TNF antibody biologic did not differ from TNF-receptor biologic in the ACR50 rates. Compared to standard-dose biologic + MTX/DMARD, low-dose biologic + MTX/DMARD was associated with lower OR 0.73 (95% CrI, 0.54 to 0.97) and high-dose biologic + MTX/DMARD with similar/possibly higher OR 1.26 (95% CrI, 0.97 to 1.65) that was not statistically significant. Low-dose biologic + MTX/DMARD was less likely than high-dose biologic + MTX/DMARD to be associated with ACR50, OR 0.58 (95% CrI, 0.40 to 0.82).

In individual comparisons, several biologics differed from each other slightly in ACR50 rates. Biologic in combination with MTX was more effective in achieving ACR50 than biologic in combination with DMARDs. High-dose biologic + MTX was more effective in achieving ACR50 compared to standard-dose biologic (same or other biologic) + MTX across most biologics.

### Function assessed by HAQ

Biologic + MTX/DMARD use was associated with a clinically important and statistically significant improvement in function, as indicated by lower HAQ scores (or a greater decrease in HAQ scores) with a mean difference of -0.25 (95% CI, -0.28 to -0.22; quality of evidence, moderate). Specifically, TNF, non-TNF in combination with MTX/DMARD were associated with mean difference of -0.23 (95% CI, -0.26 to -0.20; quality of evidence, moderate) and -0.21 (95% CI, -0.30 to -0.12; quality of evidence, moderate) for HAQ



scores versus comparator in direct comparisons; respective mean differences from NMA were -0.31 (95% CrI, -0.42 to -0.20; quality of evidence, moderate) and -0.22 (95% CrI, -0.41 to -0.02; Quality of evidence, moderate).

We noted no differences in HAQ scores by the type of biologic (TNF vs. non-TNF biologics). Compared to monoclonal TNF antibody biologic + MTX/DMARD, TNF-receptor biologic + MTX/DMARD use was associated with significantly more HAQ improvement, MD -0.25 (95% CrI, -0.48 to -0.03).

In individual comparisons, compared to MTX/DMARD, biologic + MTX/DMARD were associated with better HAQ scores. Several between-biologic differences were noted.

### Remission

Biologic + MTX/DMARD was associated with a higher remission rate vs. comparator, with RR of 2.81 (95% CI, 2.23 to 3.53; quality of evidence, moderate), which was clinically important and statistically significant improvement. Both TNF + MTX/DMARD and non-TNF + MTX/DMARD were associated with a higher remission rate versus comparator.

TNF biologic did not differ from non-TNF biologic with regards to the remission rates. Similarly, monoclonal TNF antibody biologic did not differ from TNF-receptor biologic regarding remission rates. High-dose biologic + MTX/DMARD was more effective in achieving remission compared to low-dose biologic + MTX/DMARD, but no differences were noted between standard-dose biologic + MTX/DMARD vs. low or high-dose biologic + MTX/DMARD.

### Radiographic Progression

Biologic + MTX/DMARD was associated with significantly less radiographic progression versus comparator, with a mean difference of -2.61 (95% CI -4.08 to -1.14) Sharp score units. Since the absolute reduction was small, -0.58% (95% CI -0.91% to -0.25%), we are not sure of the clinical relevance of this reduction. Most trials provided data for TNF biologics + MTX/DMARD (absolute reduction -0.67% (95% CrI -1.4% to -0.12%), which was statistically significant; comparison of non-TNF biologics + MTX/DMARD (absolute reduction, -0.68% (95% CrI -2.36% to 0.92%)) was not statistically significant.

No statistically significant differences were noted by the type of biologic (TNF vs. non-TNF biologic), biologic dose (standard-dose vs. high-dose vs. low-dose) or by receptor versus antibody TNF-biologic.

Compared to MTX, standard-dose etanercept + MTX and high-dose infliximab + MTX or standard-dose infliximab + MTX were associated with slower rates of radiographic progression with differences ranging from -4.05 to -6.12 Sharp score units.

### Withdrawals due to adverse events

The results were inconclusive, with wide confidence intervals encompassing the null effect and evidence of an important increase in withdrawals due to adverse events. Results for TNF biologics + MTX/DMARD (RR 1.24 (95% CrI 0.99 to 1.57)) and non-TNF biologics + MTX/DMARD (RR 1.20 (95% CrI 0.87 to 1.67)) versus comparator were similarly inconclusive.

There was no difference in this outcome when compared by the type of biologic (TNF vs. non-TNF biologic), biologic dose (standard-dose vs. high-dose vs. low-dose). Compared to monoclonal antibodies against TNF + MTX/DMARD, etanercept + MTX/DMARD was associated with lower odds of withdrawals due to adverse events, but non-TNF + MTX/DMARD was not statistically significantly different.

Compared to DMARD + MTX, most biologic + MTX combinations (in standard-dose, low-dose or high-dose) were less likely to be associated with withdrawals. Several between-biologic differences were noted in monotherapy and combination therapy, when compared to each other, with higher withdrawal rates in general for infliximab, and lower rates for etanercept.

### Serious adverse events (SAEs)

The odds of SAEs were higher in patients comparing biologic combination therapy versus comparator (MTX/DMARD/PL), Peto OR 1.12 (95% CI 0.99 to 1.27), which almost achieved statistical significance. *Peto OR can be interpreted as an RR due to the low event rate.* The NMA estimate for TNF biologics + MTX/DMARD (Peto OR 1.20 (95% CrI 1.01 to 1.43)) showed moderate quality evidence of an increase in the risk of serious adverse events. The other two NMA estimates were downgraded to low quality for concerns about imprecision and indirectness and had wide confidence intervals resulting in uncertainty around the estimates: non-TNF biologics + MTX/DMARD: Peto OR 1.07 (95% CrI 0.89 to 1.29) and anakinra: Peto OR 1.06 (95% CrI 0.65 to 1.75).

With respect to the type of biologics, TNF biologics did not differ from non-TNF biologics in the SAE rates (results for these were inconclusive with wide confidence intervals). Also, the odds of SAEs were no different when standard-dose biologic was compared with the high-dose and low-dose biologic. Compared to monoclonal TNF antibody biologic, TNF-receptor biologic was associated with lower OR of SAEs, 0.51 (95% CrI 0.32 to 0.80), but non-TNF biologic or tofacitinib were not significantly different.

In individual comparisons, compared to other biologic + MTX combinations, golimumab + MTX and certolizumab pegol + MTX combinations were associated with higher odds of SAEs and abatacept + MTX combinations were associated with lower odds of SAEs. Several between-biologic differences were noted (described in the main text).

### Cancer

The odds of cancer with Biologic + MTX/DMARD vs. comparator (MTX/DMARD/PL) was inconclusive (Peto OR 1.07, 95% CI 0.68 to 1.68) in direct estimates, as the 95% CI includes both a null effect and an important increase and decrease in the odds of cancer. The results were also inconclusive for TNF biologics + MTX/DMARD and non-TNF biologics + MTX/DMARD. The quality of evidence was low due to serious imprecision. *Peto OR can be interpreted as an RR due to the low event rate.*

With respect to the type of biologics, TNF biologics did not differ from non-TNF biologics in the risk of cancer. Also, the odds of cancer did not differ between standard-dose, high-dose and low-dose biologics in participants with biologic + MTX/DMARD.

Among the biologics, rituximab or abatacept in combination with MTX were associated with lower odds of cancer than low-dose

etanercept in combination with MTX (Peto OR ranging from 0.06 to 0.13) and standard-dose abatacept + DMARD was associated with Peto OR of 0.14 for cancer compared to standard-dose etanercept.

### Overall completeness and applicability of evidence

The evidence report is up to date and current, with this 2015 update. Due to the rarity of trials with direct comparisons, this study provides NMA estimates that also incorporate indirect comparisons of biologic + MTX/DMARD to each other and to traditional DMARDs/MTX.

### Quality of the evidence

For the updated 2015 review, the quality of included trials was reasonably good. Poor reporting of the conduct of included trials was a major issue, as all were described as double-blind, randomized but only 32% reported adequate sequence generation, 26% of trials were judged to be at low risk for allocation concealment, 42% trials were judged at low risk of performance bias (blinding), 38% at low risk of detection bias (blinding), 41% of trials had low risk of attrition bias and 87% trials had low risk of major baseline imbalance. Selective reporting bias could not be assessed since for several trials, we could not find published protocols.

The overall quality of the evidence for all outcomes was downgraded to moderate due to limitations in the study designs of the included studies, inconsistency of effect and indirectness with few head-to-head comparisons. We did not detect publication bias. Wide credible intervals were only found in some subgroup analyses.

The quality of evidence reflects the extent to which we are confident that an estimate of the effect is correct. It was assessed for each important outcome in this review. The Cochrane Collaboration recommends the use of GRADE in assessing quality of evidence (Schünemann 2011).

Outcome measures for this overview of reviews were selected following the general recommendations of the Outcome Measures in Rheumatology (OMERACT) group that outcomes need to be relevant to patients (www.omeract.org). Data on several core outcomes such as HAQ and radiographic scores were not reported in all the included reviews. Some measurements varied across the reviews and meta-analysis was not possible.

### Potential biases in the overview process

Our review has several limitations. Lack of reporting of many important outcomes from RCTs (radiographic scores, cancer, etc.) limited our ability to analyze and compare them between biologics due to few data points available.

To our knowledge there are only a few head-to-head comparisons of benefit and safety of various biologics or of biologics and tofacitinib in patients with RA: Gabay 2013; Schiff 2008; Weinblatt 2013a are some of the most well-known trials. We included these direct comparator studies in our analyses. However, the majority of the studies compared biologic or tofacitinib to MTX, or another traditional DMARD (such as sulfasalazine, etc.), or MTX + DMARD, and a few to placebo (18% or fewer). With the availability of multiple biologics whose benefits have yet to be compared to one another, it is unclear which biologic is most beneficial, safest, and best-tailored to a given patient, since different subgroups of people

suffering from RA may benefit differently from these medications. In the absence of such direct comparisons, NMA that includes direct and indirect comparisons such as ours can provide useful information.

Indirect comparisons have several limitations. RCTs differ in patient population characteristics, most prominently in prior failed therapy, biologic dose, concomitant use of DMARDs, mean RA disease duration, and trial duration. To overcome this limitation, we analyzed in the categories of previous DMARD/biologic history (MTX-naive, MTX/DMARD-experienced, and biologic-experienced) in three separate reviews- this current review focuses on the MTX/DMARD-experienced population. We separated reviews by concomitant MTX/DMARD use (yes/no) for MTX/DMARD-experienced population- this review analyzed biologic +MTX/DMARD combination. We also carefully analyzed data by dose (standard-dose, high-dose, low-dose).

We observed several novel findings when these analyses were performed, which make the results of this NMA and overview comprehensive. We also performed *a priori*-specified subgroup analyses by the duration of RA (early, established, late) and duration of the trial (< 6, 6-12 and > 12 months) as a surrogate of biologic exposure. These analyses also provide interesting results in specific subpopulations of RA patients. However, subgroup analyses are subject to low power and type II error, such as missing significant results, by chance, due to lower numbers of studies and patients. Therefore, results of subgroup analyses must be interpreted with caution.

Additionally, some studies presented data on safety for all doses of the biologic together, not just the recommended dose and in some cases presented data for the entire study duration, including the open-label phase. This limited our ability to get the data for the randomized phase or by dose. Several studies allowed continuation of DMARDs such as methotrexate in a proportion of the participants, but not all participants - 58% of participants in an anakinra study (Fleischman 2003) and 78% in an abatacept study continued on methotrexate (Genovese 2005). Such studies make the placebo group heterogeneous compared to other studies, where participants are usually randomized to placebo + methotrexate or placebo alone.

One must be careful in interpreting the odds ratios and risk ratios that may look slightly different from each other numerically, but not statistically. It is very important to consider the 95% confidence intervals while interpreting these numbers. Due to a large number of comparisons and the challenge of interpreting these tables, we summarized all statistically significant odds ratios to the extent possible in the main text. This should make it easier for readers to interpret the results.

There is also the possibility of type I error, due to multiple comparisons. Up to five differences per 100 comparisons may be due to chance. However, given the limited data for most outcomes, short trial duration and rarity of harms outcomes, our main concern with most of these analyses is type II error (i.e., missing an important difference due to the small number of events) and not type I error.

Two review authors abstracted all data independently for this updated review. This, we believe, minimizes errors in data abstractions, and biases due to this error. The quality of RCTs was

reasonably good, although some RCTs did not report certain quality characteristics. Abstracts and titles were also reviewed in duplicate, independently, to avoid errors as a part of the systematic review.

### Agreements and disagreements with other studies or reviews

Our NMA and systematic review was performed using a comprehensive strategy, accounting for many potential factors that differed between trials and trial arms. Therefore, direct comparison of results to most published NMAs is not possible, particularly those that have not stratified participants by these important characteristics.

In general, many results agree with several similar analyses in the past. However, since our review has several more included studies than the previous reviews and overviews, some findings differ, as expected. Additionally, our review includes nine biologics and tofacitinib, while most previous reviews have focused on anti-TNF biologics, with few exceptions.

In a meta-analysis ([Orme 2012](#)), RCTs of biologics that measured outcomes between 12 weeks and 30 weeks from baseline in patients previously treated with an incomplete response to conventional DMARDs were included. Forty-three RCTs were included. All licensed biologic combinations had significantly higher odds of ACR20, ACR50 or ACR70 compared to DMARDs alone, except for the rituximab comparison, which did not reach significance. The etanercept combination was significantly better than two other TNF biologics, adalimumab and infliximab, in improving ACR20, ACR50 and ACR70 outcomes. Our study confirms the first finding of better benefit of biologic combination therapy. We found few significant comparisons between-drugs, and confirmed the second finding to some extent.

In another meta-analysis of 44 trials published in 2012, compared to placebo, withdrawals due of adverse event were more common for biologics (OR 1.41, 95% CI 1.16 to 1.70) and lower withdrawal rates due to adverse events were found for abatacept, etanercept, and rituximab compared to most other drugs ([Desai 2012](#)). Our analyses including more studies, confirmed the finding of lower withdrawal rates due to adverse events with etanercept, abatacept and rituximab in several comparisons to other biologics. We also provide this analysis by biologic + MTX/DMARD, as well as separately by the dose, and where applicable the route of administration.

In a meta-analysis of RCTs of anti-TNF biologics for RA ([Alonso-Ruiz 2008](#)), compared to control treatment, the risk ratio of achieving ACR50 was 2.6 for adalimumab, 2.1 for infliximab and 2.6 for etanercept. These risk ratios are very similar to those reported in our study.

In a systematic review of four biologics for RA, TNF-inhibitors were similar to each other in benefit, but seemed to be better than anakinra ([Gartlehner 2006](#)). Our study shows that for several outcomes, TNF inhibitors were similar to each other. We also found the superiority of TNF-inhibitors to anakinra and this finding extends to comparisons of nine biologics, and tofacitinib.

[Kristensen 2007](#) examined patients with established RA treated for one year, estimated the NNTB for ACR50 to be 8 (95% CI, 5 to 38) for infliximab, 4 (3 to 6) for etanercept and 4 (3 to 6) for adalimumab.

Our NNTB estimates for achieving ACR50 were very similar to this previous study ranging from 4 to 6.

[Lee 2008](#) indirectly compared TNF-inhibitors (etanercept, infliximab and adalimumab) to each other in RCTs of 50 weeks or longer in RA. Three studies, [Lipsky 2000](#) (infliximab), [Klareskog 2004](#) (etanercept) and [Keystone 2004](#) (adalimumab) qualified and were included. The RR (95% CI, P value) of achieving ACR50 were as follows: etanercept versus infliximab, RR 0.59 (95% CI 0.27 to 1.29, P = 0.19); etanercept versus adalimumab, RR 0.37 (95% CI 0.22 to 0.60, P < 0.0001); and infliximab versus adalimumab, RR 0.62 (95% CI 0.25 to 1.49, P = 0.28). However, the authors failed to address the between-study variation, and did not interpret their data in absolute terms. Withdrawals due to adverse events among the three TNF inhibitors were as follows: etanercept versus infliximab, RR 1.01 (95% CI 0.30 to 3.42, P = 0.98); etanercept versus adalimumab, RR 0.38 (95% CI 0.17 to 0.86, P = 0.02); and infliximab versus adalimumab, RR 0.37 (95% CI 0.11 to 1.36, P = 0.14). Our estimates differ from this study such that ACR50 was not significantly different among the three TNF-inhibitors. In our study, withdrawals due to adverse events were significantly lower in etanercept compared to adalimumab and infliximab. This is likely due to inclusion of more RCTs and RCTs of any length in our study, including those RCTs of 50 weeks or more, as in [Lee 2008](#).

[Nixon 2007](#) performed indirect comparisons of TNF-inhibitors and anakinra for RA including RCTs with both standard approved doses as well as RCTs with non-standardized doses. Similar to our study, they found that ACR50 was similar between the various TNF-blockers, with odds ratios (95% CI) as follows: infliximab/etanercept, OR 0.98 (95% CI 0.45 to 1.93); adalimumab/etanercept, OR 0.94 (95% CI 0.51 to 1.62); and adalimumab/infliximab, OR 0.96 (95% CI 0.48 to 1.90).

[Donahue 2008](#) performed a qualitative synthesis of RCTs and observational studies and meta-analyses (when possible) of traditional DMARDs and biologics for RA. They reported that anakinra led to lower ACR50 compared to anti-TNF drugs and similar ACR50 among the anti-TNF drugs. These findings are in agreement with our quantitative approach.

Previous studies have analyzed the risk of malignancy and serious adverse events from RCTs of infliximab and adalimumab ([Bongartz 2006](#)) and etanercept ([Bongartz 2009](#)). Odds ratio of malignancy was 3.3 (95% CI 1.2 to 9.1) for all doses of infliximab and adalimumab and OR 2.0 (95% CI 1.3 to 3.1) for serious infections, when compared to control treatment. The risk of malignancy was OR 1.87 (95% CI 0.75 to 5.59) in a patient-level meta-analysis of etanercept versus control treatment ([Bongartz 2009](#)). Our results were inconclusive for cancer risk for anti-TNF biologics as a group; we did not examine serious infection in this systematic review, but a separately published review on serious infections reported an association of biologic dose with the risk of serious infection ([Singh 2015](#)).

In a NMA, [Lopez-Olivo 2012](#) concluded that biologics were not associated with higher risk of cancer compared to DMARDs or PL. Our findings are inconclusive due to few events and resulting wide confidence intervals, despite inclusion of data to 2015.

## AUTHORS' CONCLUSIONS

### Implications for practice

In the presence of very few direct head-to-head comparator trials of biologics in people with RA, practitioners are faced with a dilemma when choosing biologics or tofacitinib, for people who have had unsuccessful treatment with traditional MTX or other DMARDs. This review provides summarization of direct and NMA comparisons (includes indirect and direct comparison data) of data regarding these biologics or tofacitinib, in combination with MTX or DMARDs (in biologic drug categories by mechanism of action in summary of findings tables; and individually in main text and appendices). We realize that NMA, that incorporates direct and indirect evidence, relies a lot on indirect evidence (especially for between biologic comparisons), since direct head-to-head comparator trials of biologics are few. However, we found great concordance between direct and NMA estimates, as shown in the SOF tables, which confirms the robustness of this analysis. More data are needed however, to add clarity to the comparative effectiveness of biologics + MTX/DMARD compared to MTX/DMARD regarding harms such as cancer and infections, as well as between categories of biologics and individual biologics, with regards to comparative benefits and harms.

### Implications for research

We believe that more RCTs of direct head-to-head comparisons of biologic agents in people with RA are needed. As evident from our

analyses to date, data are few, especially for harms. Availability of new data from direct comparator trials of various biologics could provide additional insights into comparative benefits of each biologic to each other, in various clinical situations, and could add to the current knowledge. These RCTs should examine the relative benefit and safety of biologics for various stages of the disease (early, established and late RA), various levels of functional limitation (mild, moderate and severe limitation) and the nature of prior treatment (traditional DMARD- incomplete responder vs. MTX- incomplete responder vs. both). More long-term observational studies are needed to study harms and side effects of biologics, a study design which might allow for a better study, compared to RCTs. Issues related to channeling bias and confounding bias need to be handled carefully in such studies.

## ACKNOWLEDGEMENTS

We acknowledge the valuable contributions of Dr. Buchbinder from the Monash University, Malvern, Australia and Dr. Suarez-Almazor and Dr. Lopez-Olivo from the MD Anderson Cancer Center, Houston, Texas, USA for their contributions to the original 2009 version of this review. We thank Shahrzad Noorbalooshi and Tyler Cullis at Boston University for contributing to abstract/title review and data abstraction; Tamara Rader of University of Ottawa for performing the searches; and Dr. Aseem Bharat of University of Alabama at Birmingham (UAB) for proofing the article.



## REFERENCES

### References to included reviews

#### Abe 2006

Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. *The Journal of Rheumatology* 2006;**33**:37-44.

#### Bae 2013

Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig AS, et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. *BMC Musculoskeletal Disorders* 2013;**14**:13.

#### Chen 2009

Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, et al. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. *Journal of the Formosan Medical Association* 2009;**108**:310-9.

#### Choy 2012

Choy E, McKenna F, Vencovsky J, Valente R, Goel N, Vanlunen B, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. *Rheumatology* 2012;**51**:1226-34.

#### Cohen 2002

Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatology* 2002;**46**:614-24.

#### Cohen 2004

Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. *Annals of the Rheumatic Diseases* 2004;**63**:1062-8.

#### Combe 2006

Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. *Annals of the Rheumatic Diseases* 2006;**65**:1357-62.

#### Combe 2009

Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. *Annals of the Rheumatic Diseases* 2009;**68**:1146-52.

#### Conaghan 2013

Conaghan PG, Durez P, Alten RE, Burmester GR, Tak PP, Klareskog L, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. *Annals of the Rheumatic Diseases* 2013;**72**:1287-94.

#### Dougados 2013

Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). *Annals of the Rheumatic Diseases* 2013;**72**:43-50.

#### Edwards 2004

Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *New England Journal of Medicine* 2004;**350**:2572-81.

#### Emery 2006a

Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. *Arthritis and Rheumatology* 2006;**54**:1390-400.

#### Emery 2006b

Emery P, Kosinski M, Li T, Martin M, Williams GR, Becker JC, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. *Journal of Rheumatology* 2006;**33**(4):681-9.

#### Emery 2010

Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). *Annals of the Rheumatic Diseases* 2010;**69**:1629-35.

#### Fleischmann 2003

Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. *Arthritis and Rheumatology* 2003;**48**:927-34.

#### Fleischmann 2009

Fleischmann R, Vencovsky J, Van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic



therapy: the FAST4WARD study. *Annals of the Rheumatic Diseases* 2009;**68**:805-11.

#### Furst 2003

Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). *Journal of Rheumatology* 2003;**30**:2563-71.

#### Gashi 2014

Gashi AA, Rexhepi S, Berisha I, Kryeziu A, Ismaili J, Krasniqi G. Treatment of rheumatoid arthritis with biologic DMARDs (Rituximab and Etanercept). *Medical Archives* 2014;**68**(1):51-3.

#### Genovese 2004

Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. *Arthritis and Rheumatology* 2004;**50**:1412-9.

#### Genovese 2008

Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis and Rheumatology* 2008;**58**:2968-80.

#### Genovese 2011

Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. *Arthritis and Rheumatology* 2011;**63**:2854-64.

#### Goekoop-Ruiterman 2007

Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, Van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. *Annals of Internal Medicine* 2007;**146**:406-15.

#### Heimans 2013

Heimans L, Wevers-de Boer KV, Koudijs KK, Visser K, Goekoop-Ruiterman YP, Harbers JB, et al. Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study. *Arthritis Research and Therapy* 2013 Oct 31;**15**(5):R173.

#### Huizinga 2015

Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. *Annals of the Rheumatic Diseases* 2015;**74**:35-43.

#### Jobanputra 2012

Jobanputra P, Maggs F, Deeming A, Carruthers D, Rankin E, Jordan AC, et al. A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. *BMJ Open* 2012;**2**(6):e001395.

#### Kaine 2012

Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIb ALLOW study). *Annals of the Rheumatic Diseases* 2012;**71**:38-44.

#### Kameda 2010

Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. *Modern Rheumatology* 2010;**20**:531-8.

#### Kay 2008

Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. *Arthritis and Rheumatology* 2008;**58**:964-75.

#### Keystone 2004a

Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatology* 2004;**50**:353-63.

#### Keystone 2004b

Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis and Rheumatology* 2004;**50**:1400-11.

#### Keystone 2008

Keystone E, Heijde DV, Mason D, Landewe R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis and Rheumatology* 2008;**58**:3319-29.

#### Keystone 2009

Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate

therapy: the GO-FORWARD Study. *Annals of the Rheumatic Diseases* 2009;**68**:789-96.

#### Kim 2007

Kim HY, Lee SK, Song YW, Yoo DH, Koh EM, Yoo B, et al. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. *APLAR Journal of Rheumatology* 2007;**10**:9-16.

#### Kim 2012

Kim HY, Hsu PN, Barba M, Sulaiman W, Robertson D, Vlahos B, et al. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. *International Journal of Rheumatic Diseases* 2012;**15**:188-96.

#### Kim 2013

Kim J, Ryu H, Yoo DH, Park SH, Song GG, Park W, et al. A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment. *Journal of Korean Medical Science* 2013;**28**:1716-22.

#### Kivitz 2014

Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. *Arthritis Care and Research* 2014;**66**:1653-61.

#### Kremer 2003

Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. *New England Journal of Medicine* 2003;**349**:1907-15.

#### Kremer 2005

Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. *Arthritis and Rheumatology* 2005;**52**:2263-71.

#### Kremer 2006

Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. *Annals of Internal Medicine* 2006;**144**:865-76.

#### Kremer 2010

Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. *Arthritis and Rheumatology* 2010;**62**:917-28.

#### Kremer 2011

Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage

in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. *Arthritis and Rheumatology* 2011 March;**63**(3):609-21.

#### Kremer 2012

Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. *Arthritis and Rheumatology* 2012;**64**:970-81.

#### Lan 2004

Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. *Journal of the Formosan Medical Association* 2004;**103**:618-23.

#### Lipsky 2000a

Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. *New England Journal of Medicine* 2000;**343**:1594-602.

#### Lisbona 2008

Lisbona MP, Maymo J, Perich J, Almirall M, Pérez-García C, Carbonell J. Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks. *Journal of Rheumatology* 2008 Mar;**35**(3):394-7.

#### Lisbona 2010

Lisbona MP, Maymo J, Perich J, Almirall M, Carbonell J. Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept. *Annals of the Rheumatic Diseases* 2010;**69**:1117-22.

#### Machado 2014

Machado DA, Guzman RM, Xavier RM, Simon JA, Mele L, Pedersen R, et al. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. *Journal of Clinical Rheumatology* 2014;**20**:25-33.

#### MacIsaac 2014

MacIsaac KD, Baumgartner R, Kang J, Loboda A, Peterfy C, DiCarlo J, et al. Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients. *PLoS One* 2014 Dec 12;**9**(12):e113937.

**Maini 1998**

Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. *Arthritis and Rheumatology* 1998;**41**:1552-63.

**Maini 2006a**

Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. *Arthritis and Rheumatology* 2006;**54**:2817-29.

**Moreland 2012**

Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis and Rheumatology* 2012;**64**(9):2824-35.

**Nishimoto 2009**

Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. *Modern Rheumatology* 2009;**19**:12-9.

**O'Dell 2013**

O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. *New England Journal of Medicine* 2013;**369**:307-18.

**Ohta 2014**

Ohta SI, Tsuru T, Terao K, Mogi S, Suzuki M, Shono E, Ishida Y, Tarumi E, Imai M. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). *Journal of Clinical Pharmacology* 2014 Jan;**54**(1):109-19.

**Pavelka 2009**

Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. *Annals of the Rheumatic Diseases* 2009 Aug;**68**(8):1285-9.

**Pope 2014**

Pope JE, Haraoui B, Thorne JC, Vieira A, Poulin-Costello M, Keystone EC. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2014;**73**:2144-51.

**Rau 2004**

Rau R, Simianer S, Van Riel PL, Van de Putte LB, Kruger K, Schattenkirchner M, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. *Scandinavian Journal of Rheumatology* 2004;**33**:145-53.

**Rubbert-Roth 2010**

Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). *Rheumatology* 2010;**49**:1683-93.

**Schiff 2008**

Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Annals of the Rheumatic Diseases* 2008;**67**:1096-103.

**Schiff 2014**

Schiff M, Weinblatt ME, Valente R, Van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. *Annals of the Rheumatic Diseases* 2014;**73**:86-94.

**Smolen 2008**

Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet* 2008;**371**:987-97.

**Smolen 2009**

Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijckens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. *Annals of the Rheumatic Diseases* 2009;**68**:797-804.

**Smolen 2013**

Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. *Lancet* 2013;**381**:918-29.

**Smolen 2015**

Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. *Annals of the Rheumatic Diseases* 2015;**74**:843-50.

### Strand 2006

Strand V, Balbir-Gurman A, Pavelka K, Emery P, Li N, Yin M, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. *Rheumatology* 2006;**45**:1505-13.

### Strand 2012

Strand V, Burmester GR, Ogale S, Devenport J, John A, Emery P. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. *Rheumatology* 2012;**51**:1860-9.

### Tanaka 2011

Tanaka Y, Suzuki M, Nakamura H, Toyozumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Arthritis Care and Research* 2011;**63**:1150-8.

### Tanaka 2012

Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. *Annals of the Rheumatic Diseases* 2012;**71**:817-24.

### Taylor 2004

Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. *Arthritis and Rheumatology* 2004;**50**:1107-16.

### Taylor 2006

Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, Blomley MJ, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. *Arthritis and Rheumatology* 2006;**54**:47-53.

### Van der Heijde 2006

Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis and Rheumatology* 2006;**54**:1063-74.

### Van der Heijde 2007

Van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. *Arthritis and Rheumatology* 2007;**56**:3928-39.

### Van der Heijde 2013

Van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. *Arthritis and Rheumatology* 2013;**65**:559-70.

### Van der Kooij 2009

Van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Zeben D, Kerstens PJ, Hazes JM, van Schaardenburg D, Breedveld FC, Dijkmans BA, Allaart CF. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. *Ann Rheum Dis* 2009 July;**68**(7):1153-8.

### Van Riel 2006

Van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. *Annals of the Rheumatic Diseases* 2006;**65**:1478-83.

### Van Riel 2008

Van Riel PL, Freundlich B, MacPeck D, Pedersen R, Foehl JR, Singh A. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. *Annals of the Rheumatic Diseases* 2008 Aug;**67**(8):1104-10.

### Van Vollenhoven 2012a

Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *New England Journal of Medicine* 2012;**367**:508-19.

### Van Vollenhoven 2012b

Van Vollenhoven RF, Geborek P, Forslund K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. *Lancet* 2012;**379**:1712-20.

### Weinblatt 1999

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *New England Journal of Medicine* 1999;**340**:253-9.

### Weinblatt 2003

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis and Rheumatology* 2003;**48**:35-45.



**Weinblatt 2006**

Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. *Arthritis and Rheumatology* 2006;**54**:2807-16.

**Weinblatt 2012**

Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. *Rheumatology* 2012;**51**:2204-14.

**Weinblatt 2013a**

Weinblatt ME, Schiff M, Valente R, Van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. *Arthritis and Rheumatology* 2013;**65**:28-38.

**Weinblatt 2013b**

Weinblatt ME, Bingham CO, Mendelsohn AM, Kim L, Mack M, Lu J, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. *Annals of the Rheumatic Diseases* 2013;**72**:381-9.

**Weisman 2003**

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. *Clinical Therapeutics* 2003;**25**:1700-21.

**Weisman 2007**

Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, et al. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. *Rheumatology* 2007;**46**:1122-5.

**Westhovens 2006**

Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. *Arthritis and Rheumatology* 2006;**54**:1075-86.

**Yamamoto 2014a**

Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. *Modern Rheumatology* 2014;**24**:552-60.

**Yazici 2012**

Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. *Annals of the Rheumatic Diseases* 2012;**71**:198-205.

**Zhang 2006**

Zhang F, Hou Y, Huang F, Wu D, Bao C, Ni L, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. *APLAR Journal of Rheumatology* 2006;**9**:127-30.

**References to excluded reviews**
**Axelsen 2015**

Axelsen MB, Eshed I, Hørslev-Petersen K, Stengaard-Pedersen K, Hetland ML, Møller J, et al. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. *Annals of the Rheumatic Diseases* 2015;**74**:867-75.

**Bathon 2000**

Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. *New England Journal of Medicine* 2000;**343**(22):1586-93.

**Bejarano 2008**

Bejarano V, Quinn MA, Conaghan PG, Reece R, Keenan AM, Walker D, et al. Effect of the Early Use of the Anti-Tumor Necrosis Factor Adalimumab on the Prevention of Job Loss in Patients With Early Rheumatoid Arthritis. *Arthritis and Rheumatism* 2008;**59**(10):1467-74.

**Bonafede 2015**

Bonafede M, Johnson BH, Tang DH, Shah N, Harrison DJ, Collier DH. Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis. *Arthritis Care and Research (Hoboken)* 2015;**67**(12):1656-63.

**Boyle 2015**

Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2015;**74**(6):1311-6.

**Breedveld 2006**

Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis and Rheumatism* 2006;**54**:26-37.



**Bresnihan 1998**

Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. *Arthritis and Rheumatism* 1998;**41**(12):2196-204.

**Burmester 2014**

Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). *Annals of the Rheumatic Diseases* 2014;**73**(1):69-74.

**Burmester 2015**

Burmester GR, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. *Annals of the Rheumatic Diseases* 2015;**74**(6):1037-44.

**Cheng 2014**

Cheng T, Wang M, Chen Z, Eisenberg RA, Zhang Y, Zou Y, et al. Tartrate-resistant acid phosphatase 5b is a potential biomarker for rheumatoid arthritis: a pilot study in Han Chinese. *Chinese Medical Journal* 2014;**127**(16):2894-9.

**Cohen 2003**

Cohen M, Wolfe R, Mai T, Lewis D. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. *Journal of Rheumatology* 2003;**30**(3):523-8.

**Cohen 2006**

Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. *Arthritis and Rheumatism* 2006;**54**(9):2793-806.

**Conaghan 2014**

Conaghan PG, Peterfy C, Olech E, Kaine J, Ridley D, Dicarlo J, et al. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. *Annals of the Rheumatic Diseases* 2014;**73**(5):810-6.

**Coombs 2010**

Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. *Annals of the Rheumatic Diseases* 2010;**69**(2):413-6.

**Dougados 2014**

Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. *Annals of the Rheumatic Diseases* 2014;**73**(5):803-9.

**Doyle 2013**

Doyle MK, Rahman MU, Frederick B, Birbara CA, de Vries D, Toedter G, et al. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. *Rheumatology (Oxford)* 2013;**52**(7):1214-9.

**Durez 2004**

Durez P, Nzeusseu Toukap A, Lauwerys BR, Manicourt DH, Verschueren P, Westhovens R, et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. *Arthritis and Rheumatism* 2004;**63**:1069-74.

**Emery 2008**

Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. *Lancet* 2008;**372**:375-82.

**Emery 2014a**

Emery P, Fleischmann RM, Hsia EC, Xu S, Zhou Y, Baker D. Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis. *Clinical Rheumatology* 2014;**33**(9):1239-46.

**Emery 2014b**

Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch MH, et al. Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. *New England Journal of Medicine* 2014;**371**(19):1781-92.

**Ericksson 2015**

Ericksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, et al. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. *Annals of the Rheumatic Disease* 2015;**74**(6):1094-101.

**Fleischmann 2012a**

Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadi S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. *Arthritis and Rheumatism* 2012;**64**(3):617-29.

**Fleischmann 2012b**

Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-Controlled Trial of Tofacitinib

Monotherapy in Rheumatoid Arthritis. *New England Journal of Medicine* 2012;**367**(6):495-507.

#### **Fleischmann 2013**

Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A, et al. 2-Year results from the Ample (Abatacept versus adalimumab comparison in biologic-naïve RA patients with background Methotrexate) trial: changes in patient-reported outcomes in response to subcutaneous abatacept or adalimumab in rheumatoid arthritis. *Arthritis and Rheumatism* 2013;**65**(Suppl 10):S577.

#### **Furst 2015**

Furst DE, Shaikh SA, Greenwald M, Bennett B, Davies O, Luijckens K, et al. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis. *Arthritis Care and Research (Hoboken)*. 2015;**67**(2):151-60.

#### **Gabay 2013**

Gabay C, Emery P, Van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet* 2013;**381**(9877):1541-50.

#### **Genovese 2002**

Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. *Arthritis and Rheumatism* 2002;**46**(6):1443-50.

#### **Genovese 2005**

Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. *New England Journal of Medicine* 2005;**353**(11):1114-23.

#### **Gherge 2014**

Gherge AM, Ramiro S, Landewé R, Mihai C, Van der Heidje D. THU0229 Association of Radiographic Damage with Physical Function in Patients with Rheumatoid Arthritis – Results from the RAPID1 Trial. *Annals of the Rheumatic Diseases* 2014;**73**(Suppl 2):261.

#### **Haroui 2014**

Haraoui B, Thorne JC, Keystone EC, Poulin-Costello M, Trottier E, Vieira A, Pope JE. Clinical And Radiographic Outcomes With Etanercept And EtanerceptAnd Methotrexate In Patients With Rheumatoid Arthritis: Two-YearResults From The Canadian Methotrexate And Etanercept OutcomeStudy (CAMEO). *Arthritis and Rheumatism* 2014;**65**(Suppl 10):1464.

#### **Heimans 2014**

Heimans L, Wevers-de Boer KV, Visser K, Goekoop RJ, van Oosterhout M, Harbers JB, et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. *Annals of the Rheumatic Diseases* 2014;**73**(7):1356-61.

#### **Hobbs 2015**

Hobbs K, Deodhar A, Wang B, Bitman B, Nussbaum J, Chung J, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy. *Springerplus* 2015;**5**(4):113.

#### **Hørslev-Petersen 2014**

Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. *Annals of the Rheumatic Diseases* 2014;**73**(4):654-61.

#### **Iannone 2014**

Iannone F, La Montagna G, Bagnato G, Gremese E, Giardina A, Lapadula G. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. *Journal of Rheumatology* 2014;**41**(2):286-92.

#### **Johnsen 2006**

Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. *Journal of Rheumatology* 2006;**33**:659-64.

#### **Jones 2010**

Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. *Annals of the Rheumatic Diseases* 2010;**69**:88-96.

#### **Kameda 2011**

Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. *Journal of Rheumatology* 2011;**38**(8):1585-92.

#### **Kavanaugh 2014**

Kavanaugh A, Mease PJ, Strand V, Purcaru O, Curtis JR. Effect of certolizumab pegol on workplace and household productivity in us patients with rheumatoid arthritis with or without prior anti-tumor necrosis factor exposure: Results from the predict study. *Annals of the Rheumatic Diseases* 2014;**73**(Suppl 2):927-8.

#### **Kennedy 2014**

Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, et al. Efficacy and safety of pateclizumab (anti-lymphotoxin-alpha) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). *Arthritis Research and Therapy* 2014;**16**(5):467.

**Keystone 2014**

Keystone EC, Anisfeld A, Ogale S, Devenport JN, Curtis JR. Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment. *Journal of Rheumatology* 2014;**41**(2):216-26.

**Koroleva 2014a**

Koroleva MV, Raskina TA. Effect of rituximab therapy on life quality with rheumatoid arthritis patients. *Osteoporosis International* 2014;**25**:S365-S366.

**Koroleva 2014b**

Koroleva MV, Raskina TA. The effect of rituximab therapy on bone mineral density with rheumatoid arthritis patients. *Osteoporosis International* 2014;**25**:S374.

**Kremer 2015**

Kremer JM, Kivitz AJ, Simon-Campos JA, Nasonov EL, Tony HP, Lee SK, et al. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. *Arthritis Research & Therapy* 2015;**17**(95):1-11.

**Kremer 2009**

Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. *Arthritis and Rheumatism* 2009;**60**(7):1895-905.

**Kremer 2013**

Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. *Annals of Internal Medicine* 2013;**159**(4):253-61.

**Landewe 2015**

Landewé R, Smolen JS, Florentinus S, Chen S, Guérette B, van der Heijde D. Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. *Arthritis Research and Therapy* 2015;**17**:133.

**Manders 2015**

Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. *Arthritis Research and Therapy* 2015;**17**(1):134.

**Mathias 2000**

Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. *Clinical Therapeutics* 2000;**22**(1):128-39.

**McInnes 2015**

McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. *Annals of the Rheumatic Diseases* 2015;**74**(4):694-702.

**Miyasaka 2008**

Miyasaka N, Change Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. *Modern Rheumatology* 2008;**18**(3):252-62.

**Moreland 1999**

Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. *Annals of Internal Medicine* 1999;**130**(6):478-86.

**Moreland 2002**

Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. *Arthritis and Rheumatism* 2002;**46**(6):1470-9.

**Navarro 2014**

Navarro Coy NC, Brown S, Bosworth A, Davies CT, Emery P, Everett CC, et al. The 'Switch' study protocol: a randomised controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. *BMC Musculoskeletal Disorders* 2014;**15**:452.

**Nishimoto 2004**

Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. *Arthritis and Rheumatism* 2004;**50**(6):1761-9.

**Nishimoto 2007**

Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumab. *Annals of the Rheumatic Diseases* 2007;**66**(9):1162-7.

**Oakley 2014**

Oakley S, Esmaili N, Major G, Mathers D, Ratnarajah S, Van der Kallen J, et al. A randomised controlled trial evaluating the effect of humira upon endothelial function in ACPA positive rheumatoid arthritis – an interim analysis. *Arthritis and Rheumatology* 2014;**66**:S211.

**Ostergaard 2015**

Østergaard M, Jacobsson LT, Schaufelberger C, Hansen MS, Bijlsma JW, Dudek A, et al. MRI assessment of early

response to certolizumabpegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. *Annals of the Rheumatic Diseases* 2015;**74**:1156–63.

#### **Pavelka 2013**

Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, et al. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. *Clinical Rheumatology* 2013;**32**(9):1275–81.

#### **Quinn 2005**

Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatism* 2005;**52**(1):27–35.

#### **Smolen 2014b**

Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. *Lancet* 2014;**383**(9914):321–32.

#### **Sonomoto 2014**

Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, et al. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. *Rheumatology (Oxford)* 2014;**53**(5):914–8.

#### **St Clair 2004**

St Clair EW, Van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis and Rheumatism* 2004;**50**(11):3432–43.

#### **Tada 2012**

Tada M, Koike T, Okano T, Sugioka Y, Wakitani S, Fukushima K, et al. Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study. *Rheumatology (Oxford)* 2012;**51**(12):2164–9.

#### **Takeuchi 2013a**

Takeuchi T, Matsubara T, Nitobe T, Suematsu E, Ohta S, Honjo S, et al. Phase II dose–response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. *Modern Rheumatology* 2013;**23**(2):226–35.

#### **Takeuchi 2013b**

Takeuchi T, Miyasaka N, Zang C, Alvarez D, Fletcher T, Wajdula J, et al. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus

methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. *Modern Rheumatology* 2013;**23**(4):623–33.

#### **Takeuchi 2013c**

Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. *Annals of the Rheumatic Diseases* 2013;**72**(9):1488–95.

#### **Takeuchi 2014**

Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. *Annals of the Rheumatic Diseases* 2014;**73**(3):536–43.

#### **Van de Putte 2003**

Van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, Van Riel PL, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. *Annals of the Rheumatic Diseases* 2003;**62**(12):1168–77.

#### **Van de Putte 2004**

Van de Putte L B, Atkins C, Malaise M, Sany J, Russell A S, Van Riel P L, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. *Annals of the Rheumatic Diseases* 2004;**63**(5):508–16.

#### **Van Vollenhoven 2009**

Van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. *Lancet* 2009;**374**(9688):459–66.

#### **Vital 2015**

Vital EM, Dass S, Buch MH, Rawstron AC, Emery P. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. *Annals of the Rheumatic Diseases* 2015;**74**:1195–1201.

#### **Weinblatt 2007**

Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. *Annals of the Rheumatic Diseases* 2007;**66**:228–34.

#### **Weinblatt 2014**

Weinblatt ME, Westhovens R, Mendelsohn AM, Kim L, Lo KH, Sheng S, et al. Radiographic benefit and maintenance of clinical



benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. *Annals of the Rheumatic Diseases* 2014;**73**(12):2152-9.

#### Westhovens 2014

Westhovens R, Weinblatt ME, Han C, Kim L, Mack M, Lu J, et al. Health-related quality of life of patients with rheumatoid arthritis achieving DAS28 remission, improvement in physical function and no radiographic progression. *Annals of the Rheumatic Diseases* 2014;**73**:479-80.

#### Yamamoto 2014b

Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. *Modern Rheumatology* 2014;**24**(4):552-60.

#### Yamanaka 2014

Yamanaka H, Ishiguro N, Takeuchi T, Miyasaka N, Mukai M, Matsubara T, et al. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. *Rheumatology (Oxford)* 2014;**53**(5):904-13.

### Additional references

#### Aletaha 2010

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis and Rheumatology* 2010;**62**(9):2569-81.

#### Alonso-Ruiz 2008

Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and meta analysis of efficacy and safety. *BMC Musculoskeletal Disorders* 2008;**9**:52.

#### Arnett 1988

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis and Rheumatism* 1988;**31**(3):315-24.

#### Barlow 1999

Barlow JH, Cullen LA, Rowe IF. Comparison of knowledge and psychological well-being between patients with a short disease duration (< or = 1 year) and patients with more established rheumatoid arthritis (> or = 10 years duration). *Patient Education and Counseling* 1999;**38**:195-203.

#### Becker 2011

Becker LA, Oxman AD. Chapter 22: Overviews of reviews. In: Higgins JPT, Green S (editors), *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated

March 2011). The Cochrane Collaboration, 2011.. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

#### Boers 2001

Boers M. Treatment of early disease. *Rheumatic Diseases Clinics of North America* 2001;**27**:405-14, x.

#### Bongartz 2006

Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA* 2006;**295**(19):2275-85.

#### Bongartz 2009

Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. *Annals of the Rheumatic Diseases* 2009;**68**(7):1177-83.

#### Brennan 2008

Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. *Journal of Clinical Investigation* 2008;**118**(11):3537-45.

#### Cash 1994

Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. *New England Journal of Medicine* 1994;**330**(19):1368-75.

#### Cates 2009 [Computer program]

Dr Chris Cates' EBM web site. Available from <http://www.Nntonline.Net/visualrx/>. Visual Rx NNT Calculator version 3. Dr Chris Cates' EBM web site. Available from <http://www.Nntonline.Net/visualrx/>, Accessed 13 February 2009.

#### Choy 2001

Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. *New England Journal of Medicine* 2001;**344**(12):907-16.

#### Chung 2006

Chung CP, Thompson JL, Koch GG, Amara I, Strand V, Pincus T. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. *Annals of the Rheumatic Diseases* 2006;**65**(12):1602-7.

#### Connell 2006

Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases. *Best Practice and Research Clinical Rheumatology* 2006;**20**(5):865-78.

#### Cope 2008

Cope AP. T cells in rheumatoid arthritis. *Arthritis Research and Therapy* 2008;**10** Suppl 1:S1.



**Dersimonian 2007**

Dersimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. *Contemporary Clinical Trials* 2007;**28**(2):105-14.

**Desai 2012**

Desai RJ, Hansen RA, Rao JK, Wilkins TM, Harden EA, Yuen A, et al. Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis. *Annals of Pharmacotherapy* 2012;**46**(11):1491-505.

**Dias 2011**

Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. 1-39 (2011). Available at [www.nicedsu.org.uk](http://www.nicedsu.org.uk).

**Donahue 2008**

Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. *Annals of Internal Medicine* 2008;**148**(2):124-34.

**Drugs 2006**

Drug Information Online. Drugs.com. FDA approves first rheumatoid arthritis indication for Rituxan. <http://www.drugs.com/news/fda-approves-first-rheumatoid-arthritis-indication-rituxan-1745.html> 03/01/2006.

**EMA 2001**

European Medicines Agency. EMA public statement on infliximab (Remicade): Increased incidence of mortality and hospitalization for worsening congestive heart failure. <http://www.emea.europa.eu/pdfs/human/press/pus/325701en.pdf>.

**EMA 2003**

European Medicines Agency. EMA public statement: Increased risk of serious infection and neutropenia in patients treated concurrently with Kineret (anakinra) and Enbrel (etanercept). <http://www.emea.europa.eu/humandocs/PDFs/EPAR/kineret/3163102en.pdf>.

**EMA 2009**

European Medicines Agency. EPARs for authorized medicinal products for human use: Anakinra: European Public Assessment Report. <http://www.emea.europa.eu/humandocs/Humans/EPAR/kineret/kineret.htm> Revision 11, published 27/01/09.

**EMA 2009a**

European Medicines Agency. Remicade (infliximab). <http://www.emea.europa.eu/humandocs/PDFs/EPAR/Remicade/H-240-PI-en.pdf>.

**EMA 2009b**

European Medicines Agency. EPARs for authorized medicinal products for human use: Humira: European Public Assessment Report. <http://www.emea.europa.eu/humandocs/Humans/EPAR/humira/humira.htm> Revision 15, Published 11/05/09.

**FDA 1998**

Food, Drug Administration. Etanercept Product Approval Information- Licensing Action 12/2/1998. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080536.htm> 1998.

**FDA 1999**

Food, Drug Administration. Remicade® (infliximab) for IV Injection. <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm107722.pdf> 1999.

**FDA 2001**

Food, Drug Administration. Kineret® (anakinra) Physician packet insert: Kineret® (anakinra) prescribing information. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080650.htm> 2001.

**FDA 2002**

Food, Drug Administration. Package Insert. HUMIRA® (adalimumab). Abbott Laboratories. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080610.htm> 2002.

**FDA 2004**

Food, Drug Administration. Safety information. October 2004. <http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM166515.pdf>.

**FDA 2005**

Food, Drug Administration. Patient Information Sheet. Abatacept (marketed as Orencia®). <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/FastTrackApprovalReports/ucm082380.htm> 2005.

**FDA 2006**

Food, Drug Administration. Rituxan® (rituximab). <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150747.htm>.

**FDA 2007**

Food, Drug Administration. Drug details: Orencia. <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails>.

**FDA 2008a**

Food, Drug Administration. Humira (adalimumab): Highlights of prescribing information. [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/125057s114lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s114lbl.pdf).

**FDA 2008b**

Food, Drug Administration. FDA: Manufacturers of TNF-blocker drugs must highlight risk of fungal

infections. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116942.htm>.

#### FDA 2008c

Food, Drug Administration. Medication Guide: Enbrel® (etanercept). [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/103795s53591bl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103795s53591bl.pdf).

#### FDA 2008d

Food, Drug Administration. CDER New Molecular Entity (NME) Drug and New Biologic Approvals for Calendar Year 2008. CDER report. Application number:125160. <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM081805.pdf> December 31, 2008.

#### FDA 2009a

Food, Drug Administration. Remicade® (infliximab) for IV Injection. [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/103772s52341bl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103772s52341bl.pdf).

#### FDA 2009b

Food, Drug Administration. Safety information. Rituxan (Ritiximab). <http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM187792.pdf> 2009.

#### FDA 2010

Food and Drug Administration. CDER report. Application number: L 125276/0.0, December 31, 2010. CDER New Molecular Entity (NME) & New BLA Calendar Year Approvals. As of December 31, 2010. <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM242677.pdf> 2010.

#### FDA 2012

Food, Drug Administration. CDER New Molecular Entity (NME) & New BLA Calendar Year Approvals As of December 31, 2012. <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM342733.pdf> 2012.

#### FDA 2015

Food, Drug Administration. RISK EVALUATION AND MITIGATION STRATEGY (REMS). NDA 203,214 XELJANZ® (TOFACITINIB). <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM330290.pdf>.

#### Felson 1995

Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. *Arthritis and Rheumatism* 1995;**38**(6):727-35.

#### Finckh 2006

Finckh A, Liang MH, Van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in

rheumatoid arthritis: A meta-analysis. *Arthritis and Rheumatism* 2006;**55**(6):86-72.

#### Fleischman 2003

Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. *Arthritis and Rheumatism* 2003;**48**(4):927-34.

#### Fransen 2005

Fransen J, Van Riel PL. The Disease Activity Score and the EULAR response criteria. *Clinical and Experimental Rheumatology* 2005;**23**(5 Suppl 39):S93-9.

#### Fries 1980

Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis and Rheumatism* 1980;**23**(2):137-45.

#### Furst 2008

Furst DE, Keystone EC, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. *Annals of the Rheumatic Diseases* 2008;**67** Suppl 3(Suppl 3):iii2-25.

#### Furst 2010

Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases 2009. *Annals of the Rheumatic Diseases* 2010;**69**:Suppl 1:i2-29.

#### Furst 2012

Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases 2011. *Annals of the rheumatic diseases* 2012;**71**(Suppl 2):i2-45.

#### Gartlehner 2006

Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. *The Journal of Rheumatology* 2006;**33**(12):2398-408.

#### Ghogomu 2014

Ghogomu EA, Maxwell LJ, Buchbinder R, Rader T, Pardo Pardo J, Johnston RV, et al. Updated method guidelines for Cochrane Musculoskeletal Group systematic reviews and meta-analyses. *The Journal of Rheumatology* 2014;**41**(2):194-205.

#### Guyatt 2008

Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is "quality of evidence" and why is it important to clinicians?. *BMJ* May 3, 2008;**336**(7651):995-8.

#### Health Canada 2006a

Health Canada. Important Safety Information on anti-TNFα Therapy: Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab) - For Health Professionals. <http://>

www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/\_2006/anti-tnf\_therap\_hpc-cps-eng.php.

#### Health Canada 2006b

Health Canada. Possible association of Remicade (infliximab) with hepatosplenic T-cell lymphoma in pediatric and young adult patients with Crohn's disease - For Health Professionals. [http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/\\_2006/remicade\\_3\\_hpc-cps-eng.php](http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2006/remicade_3_hpc-cps-eng.php).

#### Health Canada 2009

Health Canada. Association of Enbrel (etanercept) with histoplasmosis and other invasive fungal infections - for health professionals. [http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/\\_2009/enbrel\\_hpc-cps-eng.php](http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2009/enbrel_hpc-cps-eng.php).

#### Higgins 2002

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* 2002;**21**:1539-58.

#### Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557-60.

#### Higgins 2011

Higgins JP, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors) editor(s). *Cochrane Handbook for Systematic Reviews of Interventions*. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org). Vol. **Version 5.1.0 (updated March 2011)**, The Cochrane Collaboration, 2011.

#### Hochberg 2001

Hochberg MC, Tracy JK, Flores RH. "Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate. *Annals of the Rheumatic Diseases* 2001;**60**:iii51-iii54.

#### Horlund 2013

Horlund K, Druyts E, Aviña-Zubieta JA, Wu P, Mills EJ. Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. *Annals of the Rheumatic Diseases* 2013;**72**:1524-35.

#### Ioannidis 2004

Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Annals of internal medicine* 2004;**141**(10):781-8.

#### Keystone 2004

Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis and Rheumatology* 2004;**50**(5):1400-11.

#### Klareskog 2004

Klareskog L, Van der Heijde D, De Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 2004;**363**(9410):675-81.

#### Kristensen 2011

Kristensen LE, Jakobsen AK, Bartels EM, Geborek P, Bliddal H, Saxne T, et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. *Scandinavian Journal of Rheumatology* 2011;**40**(1):1-7.

#### Kristensen 2007

Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. *Scandinavian Journal of Rheumatology* 2007;**36**:411-7.

#### Kvien 2004

Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. *Pharmacoeconomics* 2004;**22**(2 Suppl 1):1-12.

#### Kvien 2005

Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. *Scandinavian Journal of Rheumatology* 2005;**34**(5):333-41.

#### Larsen 1977

Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. *Acta Radiologica: Diagnosis (Stockholm)* 1977;**4**:481-91.

#### Lee 2001

Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet* 2001;**358**(9285):903-11.

#### Lee 2008

Lee YH, Woo JH, Rho YH, Choi SJ, Ji JD, Song GG. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. *Rheumatology International* 2008;**28**(6):553-9.

#### Lethaby 2013

Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2013, Issue 5. [DOI: [10.1002/14651858.CD004525](https://doi.org/10.1002/14651858.CD004525)]

#### Lipsky 2000

Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. *New England Journal of Medicine* 2000;**343**(22):1594-602.

**Lopez-Olivo 2012**

Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. *JAMA* 2012;**308**(9):898-908.

**Lopez-Olivo 2015**

Lopez-Olivo MA, Amezcua Urruela M, McGahan L, Pollono EN, Suarez-Almazor ME. Rituximab for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2015, Issue 1. [DOI: [10.1002/14651858.CD007356](https://doi.org/10.1002/14651858.CD007356)]

**Lubeck 2004**

Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. *Pharmacoeconomics* 2004;**22**(2 Suppl 1):27-38.

**Maini 2006b**

Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. *Arthritis and Rheumatology* 2006;**54**(9):2817-29.

**Maxwell 2010a**

Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2009, Issue 4. [DOI: [10.1002/14651858.CD007277.pub2](https://doi.org/10.1002/14651858.CD007277.pub2)]

**Maxwell 2010b**

Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. *Journal of Rheumatology* 2010;**37**(2):234-45.

**Mertens 2009**

Mertens M, Singh JA. Anakinra for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2009, Issue 1. [DOI: [10.1002/14651858.CD005121](https://doi.org/10.1002/14651858.CD005121)]

**Moher 2009**

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. *Plos medicine* 2009;**6**(7):e1000097. [DOI: [10.1371/journal.pmed.1000097](https://doi.org/10.1371/journal.pmed.1000097)]

**Mustafa 2013**

Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. *Journal of Clinical Epidemiology* 2013;**66**(7):736-42.

**Navarro-Sarabia 2005**

Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2005, Issue 3. [DOI: [10.1002/14651858.CD005113](https://doi.org/10.1002/14651858.CD005113)]

**Nixon 2007**

Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect

comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. *Statistics in Medicine* 2007;**26**(6):1237-54.

**Odegard 2005**

Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. *Scandinavian Journal of Rheumatology* 2005;**34**(6):441-7.

**Orme 2012**

Orme ME, Macgilchrist KS, Mitchell S, Spurden D, Bird A. Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. *Biologics: Targets & Therapy* 2012;**6**:429-64.

**Osiri 2003**

Osiri M, Suarez-Almazor ME, Wells GA, Robinson V, Tugwell P. Number needed to treat (NNT): implication in rheumatology clinical practice. *Annals of the Rheumatic Diseases* 2003;**62**:316-21.

**Pincus 1983**

Pincus T, Summey JA, Soraci SA, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. *Arthritis and Rheumatism* 1983;**26**(11):1346-53.

**Pincus 2002**

Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. *Rheumatology (Oxford)* 2002;**41**(12):1346-56.

**Prevoo 1996**

Prevoo ML, Van Gestel AM, Van't Hoff MA, Van Rijswijk MH, Van de Putte LB, Van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. *British Journal of Rheumatology* 1996;**35**(11):1101-5.

**Puhan 2014**

Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. *BMJ* 2014;**349**:g5630.

**RevMan 2014 [Computer program]**

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

**Ruiz Garcia 2014**

Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Vela Casasempere P, Bort-Martí S, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. *Cochrane*



Database of Systematic Reviews 2014, Issue 9. [DOI:  
[10.1002/14651858.CD007649](https://doi.org/10.1002/14651858.CD007649)]

### Saag 2008

Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis and Rheumatology* 2008;**59**(6):762-84.

### Saevarsdottir 2011

Saevarsdottir S, Wallin H, Seddighzadeh M, Ernestam S, Geborek P, Petersson IF, et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. *Annals of the Rheumatic Diseases* 2011;**70**(3):469-75.

### Salanti 2008

Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. *Statistical Methods in Medical Research* 2008;**17**(3):279-301.

### Schünemann 2011

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

### Scott 2006

Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. *New England Journal of Medicine* 2006;**355**(7):704-12.

### Sharp 1971

Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. *Arthritis and Rheumatism* 1971;**14**(6):706-20.

### Shea 2007

Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Medical Research Methodology* 2007;**7**:10.

### Singh 2009

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo M, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. *Cochrane Database of Systematic Reviews* 2009, Issue 10. [DOI:  
[10.1002/14651858.CD007848](https://doi.org/10.1002/14651858.CD007848)]

### Singh 2010a

Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. *Cochrane Database Syst Rev* 2010;**1**:CD008341.

### Singh 2010b

Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. *Cochrane Database Syst Rev* 2010;**7**:CD008331.

### Singh 2012

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2012;**64**(5):625-39.

### Singh 2015

Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. *Lancet* 2015;**386**(9990):258-65.

### Singh 2016

Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis and Rheumatology* 2016;**68**(1):1-26.

### Smolen 2014a

Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Annals of the Rheumatic Diseases* 2014;**73**(3):492-509.

### Song 2003

Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses. *BMJ* 2003;**326**:472.

### Spiegelhalter 2003

Spiegelhalter D, Thomas A, Best N. WinBUGS user manual. Version 1.4, January 2003.. MRC Biostat. Unit 2. <https://faculty.washington.edu/jmiyamot/p548/spiegelhalter%20winbugs%20user%20manual.pdf>. 2003.

### Strand 2008

Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. *American Journal of Managed Care* 2008;**14** (4):234-54.

### Sweeting 2004

Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Statistics in Medicine* 2004;**23**:1351-75.

### Szekanecz 2007

Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. *Current Opinion in Rheumatology* 2007;**19**(3):289-95.

### Thompson 1999

Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. *Statistics in Medicine* 1999;**18**(20):2693-708.



**Tugwell 2000**

Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, et al. "Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis. *New England Journal of Medicine* 2000;**343**(21):1520-8.

**Turner 2012**

Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. *International Journal of Epidemiology* 2012;**41**(3):818-27.

**Van der Heijde 1989**

Van der Heijde DM, Van Riel PL, Nuver-Zwart IH, Gribnau FW, Van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. *Lancet* 1989;**1**(8646):1036-8.

**Wells 1993**

Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with

rheumatoid arthritis: the patient's perspective. *The Journal of Rheumatology* 1993;**20**(3):557-60.

**Wells 2009**

Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect evidence: indirect treatment comparisons in meta-analysis. Canadian Agency for Drugs and Technologies in Health. Ottawa 2009.

**Woolley 2003**

Woolley DE. The mast cell in inflammatory arthritis. *New England Journal of Medicine* 2003;**348**(17):1709-11.

**Yelin 2007**

Yelin E. Work disability in rheumatic diseases. *Current Opinion in Rheumatology* 2007;**19**(2):91-6.

**References to other published versions of this review****Singh 2009a**

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo M, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. *Cochrane Database of Systematic Reviews* 2009, Issue 10. [DOI: [10.1002/14651858.CD007848](https://doi.org/10.1002/14651858.CD007848)]

## ADDITIONAL TABLES

**Table 1. Characteristics of 79 included studies with usable data**

Study name	Year	Biologic(s)	Biologic dose(s)	Number of study arms	Non-biologic comparator	Concomitant use of MTX	Trial duration	RA duration	Incomplete response to which medication?	Total number of participants
Abe	2006	Infliximab	std, high	3	MTX + PL	yes	3 months	Established	MTX	147
Bae (APPEAL)	2013	Etanercept	std	2	MTX + DMARD	yes	4 months	Established	MTX	300
Chen	2009	Adalimumab	std	2	MTX + PL	yes	3 months	Established	DMARD	47
Choy	2012	Certolizumab	std	2	MTX + PL	yes	6 months	Established	MTX	247
Cohen	2002	Anakinra	std, low	6	MTX + PL	yes	6 months	Established	MTX	317
Cohen	2004	Anakinra	std	2	MTX + PL	yes	6 months	Late	MTX	501
Combe	2006	Etanercept	std	2	DMARD	yes	6 months	Established	DMARD	151
Combe	2009	Etanercept	std	3	DMARD	yes	24 months	Established	DMARD	254
Conaghan	2013	Abatacept	std	2	MTX + PL	yes	4 months	Established	MTX	50
Dougados	2013	Tocilizumab (+/- MTX)	high	2	none	yes	6 months	Established	MTX	556
Edwards	2004	Rituximab	std, low	4	MTX + PL	yes	12 months	Late	MTX	161
Emery (DANCER)	2006a	Rituximab	std, low	3	MTX + PL	yes	6 months	Late	DMARD or Biologic	465
EMERY (SERENE)	2010a	Rituximab	std, low	3	MTX + PL	yes	11 months	Established	MTX	512
Fleischman	2003	Anakinra	std	2	DMARD + PL	yes	6 months	Late	DMARD	1399
Fleischmann (FAST4WARD)	2009	Certolizumab	std	2	PL	yes	6 months	Established	DMARD	220

**Table 1. Characteristics of 79 included studies with usable data** *(Continued)*

Furst	2003	Adalimumab	std	2	DMARD + PL	yes	6 months	Established	DMARD	531
Genovese	2004	Anakinra, Etanercept (combination)	std, low	3	none	yes	6 months	Established	MTX	242
Genovese	2011	Abatacept, Adalimumab	std	2	none	yes	6 months	Established	MTX	1457
Genovese (TOWARD)	2008	Tocilizumab	high	2	DMARD + PL	yes	6 months	Established	DMARD	1220
Goekoop Rulterman (BeST)	2007	Infliximab	std	2	MTX + DMARD	yes	3 months	Established	DMARD	261
Heijde (TEM-PO)	2006	Etanercept	std	3	MTX	yes	24 months	Established	DMARD	682
Heijde (TEM-PO)	2007	Etanercept	std	3	MTX	yes	36 months	Established	DMARD	682
Huizinga	2015	Tocilizumab (+/- MTX)	high	2	none	yes	24 months	Established	MTX	553
Jobanputra	2013	Adalimumab, Etanercept	std	2	none	yes	12 months	Established	MTX	125
Kaine	2011	Abatacept	std	2	MTX + PL	yes	9 months	Established	MTX	120
Kameda (JESMR)	2010	Etanercept (+/- MTX)	std	2	none	yes	6 months	Established	MTX	151
Kay	2008	Golimumab	std, high	5	MTX + PL	yes	11 months	Established	MTX	172
Keystone	2004	Adalimumab	std, low	3	MTX + PL	yes	12 months	Late	MTX	619
Keystone	2008	Certolizumab	std, high	3	MTX + PL	yes	12 months	Established	MTX	982
Keystone	2004a	Etanercept	std	3	MTX + PL	yes	4 months	Established	MTX	420
Keystone (GO-FORWARD)	2009	Golimumab	std, high	4	MTX + PL	yes	12 months	Established	MTX	444

**Table 1. Characteristics of 79 included studies with usable data** *(Continued)*

Kim	2007	Adalimumab	std	2	MTX + PL	yes	6 months	Established	DMARD	128
Kim	2012	Etanercept	std	2	MTX + DMARD	yes	4 months	Established	MTX	300
Kim	2013	Infliximab	std	2	MTX + PL	yes	7 months	Established	MTX	143
Kivitz	2014	Tocilizumab	std	2	DMARD + PL	yes	6 months	Late	DMARD	655
Kremer	2003	Abatacept	std, low	3	MTX + PL	yes	6 months	Established	MTX	339
Kremer	2005	Abatacept	std, low	3	MTX + PL	yes	12 months	Established	DMARD	339
Kremer	2006	Abatacept	std	2	MTX + PL	yes	12 months	Established	MTX	638
Kremer	2010	Golimumab	std, low	5	MTX + PL	yes	11 months	Established	MTX	643
Kremer	2012	Tofacitinib	std, high	3	MTX + PL	yes	6 months	Established	MTX	215
Lan	2004	Etanercept	std	2	MTX + PL	yes	3 months	Established	MTX	58
Lipsky	2000	Infliximab	std	3	MTX + PL	yes	12 months	Late	MTX	261
Lisbona	2010	Etanercept	std	2	DMARD	yes	2 months	Late	DMARD	31
Machado	2014	Etanercept	std	2	MTX + DMARD	yes	6 months	Established	MTX	423
Maini	1998	Infliximab	std	2	MTX + PL	yes	6 months	Established	MTX	101
Maini (CHARISMA)	2006	Tocilizumab	std, low, high	7	MTX + PL	yes	5 months	Established	MTX	359
Nishimoto (SATORI)	2009	Tocilizumab	high	2	MTX + PL	yes	6 months	Established	MTX	127
O'Dell	2013	Etanercept	std	2	MTX + DMARD	yes	6 months	Established	MTX	353
Pope (CAMEO)	2014	Etanercept (+/- MTX)	std	2	none	yes	6 months	Established	MTX	205
Rau	2004	Adalimumab	low	3	MTX + PL	yes	1 month	Late	MTX	54

**Table 1. Characteristics of 79 included studies with usable data** *(Continued)*

Rubbert-Roth	2010	Rituximab	std, low	3	MTX + PL	yes	11 months	Established	MTX	378
Schiff (AMPLE)	2013	Abatacept, Adalimumab	std	2	none	yes	24 months	Early	MTX	646
Schiff (AT-TEST)	2008	Abatacept, Infliximab	std	3	MTX + PL	yes	6 months	Established	MTX	431
Smolen	2013	Etanercept	std, low	3	MTX + PL	yes	12 months	Established	MTX	604
Smolen (CERTAIN)	2015	Certolizumab	std	2	DMARD + PL	yes	12 months	Established	MTX	194
Smolen (OPTION)	2008	Tocilizumab	std, high	3	MTX + PL	yes	8 months	Established	MTX	623
Smolen (RAPID 2)	2009	Certolizumab	std, high	3	MTX + PL	yes	12 months	Established	MTX	619
Strand	2006	Rituximab	std	4	MTX + PL	yes	24 months	Late	MTX	161
Strand (RADIATE)	2012	Tocilizumab	std, high	3	MTX + PL	yes	6 months	Late	MTX	489
Tanaka	2011	Tofacitinib	std, low, high	4	MTX + PL	yes	3 months	Established	MTX	112
Tanaka (GOFORTH)	2012	Golimumab	std, high	3	MTX + PL	yes	6 months	Established	MTX	269
Taylor	2004	Infliximab	high	2	MTX + PL	yes	12 months	Early	MTX	24
Taylor	2006	Infliximab	high	2	MTX + PL	yes	24 months	Early	MTX	24
van der Heijde	2013	Tofacitinib	std, high	3	MTX + PL	yes	12 months	Established	MTX	797
Van Riel (ADORE)	2006	Etanercept (+/- MTX)	std	2	none	yes	4 months	Established	MTX	315
van Vollenhoven	2012	Infliximab	std	2	MTX + DMARD	yes	24 months	Established	MTX	258



**Table 1. Characteristics of 79 included studies with usable data** (Continued)

van Vollenhoven	2012a	Adalimumab, Tofacitinib	std, high	4	MTX + PL	yes	12 months	Established	MTX	717
Weinblatt	1999	Etanercept	std	2	MTX + PL	yes	6 months	Late	MTX	89
Weinblatt	2012	Certolizumab	std	2	MTX + PL	yes	9 months	Established	DMARD	1063
Weinblatt (AMPLE)	2013	Abatacept, Adalimumab	std	2	none	yes	12 months	Early	MTX	646
Weinblatt (AR-MADA)	2003	Adalimumab	std, low, high	4	MTX + PL	yes	6 months	Late	DMARD	271
Weinblatt (ASSURE)	2006	Abatacept	std	2	DMARD + PL	yes	12 months	Late	DMARD or Biologic	1441
Weinblatt (GO-FURTHER)	2013	Golimumab	std	2	MTX + PL	yes	6 months	Established	MTX	592
Weisman	2003	Adalimumab	low	2	MTX + PL	yes	26 months	Late	MTX	24
Weisman	2007	Etanercept	std	2	DMARD + PL	yes	4 months	Late	DMARD	535
Westhovens (START)	2006	Infliximab	std, high	3	MTX + PL	yes	24 months	Established	MTX	1084
Yamamoto	2014a	Certolizumab	std, low, high	4	MTX + PL	yes	6 months	Established	MTX	316
Yazici	2012	Tocilizumab	high	2	DMARD + PL	yes	6 months	Established	DMARD	619
Zhang	2006	Infliximab	std	2	MTX + PL	yes	4 months	Established	MTX	173

**Table 2. Summary of findings table for biologics + MTX/DMARD vs. Comparator\* in MTX/DMARD-experienced patients (MTX/DMARD incomplete-responders)**

Comparison	Direct evidence			Network meta-analysis		
	Effect estimate	Absolute risk difference, NNTB	Quality of Evidence (GRADE)		Absolute risk difference, NNTB	Quality of evidence (GRADE)
<b>Outcome: ACR50</b>	<b>RR (95% CI)</b>			<b>RR (95% CrI)</b>		
All biologics + MTX/DMARD	2.71 (2.36, 3.10)	24% (19% to 29%), NNT = 5 (4 to 6)	⊕⊕⊕○ moderate [downgraded for inconsistency] <sup>1</sup>	n/a		
TNF + MTX/DMARD	2.83 (2.38, 3.37)	24% (20% to 27%), NNT = 4 (4 to 5)	⊕⊕⊕○ moderate [downgraded for inconsistency] <sup>2</sup>	3.23 (2.75 to 3.79)	25% (20 to 30%), NNT = 4 (3 to 5)	⊕⊕⊕○ moderate (downgraded for indirectness) <sup>5</sup>
Non-TNF + MTX/DMARD	2.49 (1.88, 3.30)	21% (16% to 26%), NNT = 5 (4 to 6)	⊕⊕⊕○ moderate [downgraded for inconsistency] <sup>3</sup>	2.99 (2.36 to 3.74)	22% (15 to 30), NNT = 5 (3 to 7)	⊕⊕⊕○ moderate (downgraded for indirectness) <sup>5</sup>
Anakinra + MTX/DMARD	2.26 (1.41, 3.63)	9% (5% to 14%), NNT = 11 (7 to 20)	⊕⊕⊕○ moderate [downgraded for imprecision] <sup>4</sup>	2.37 (1.00 to 4.70)	15% (0 to 40%), NNT = n/a	⊕⊕⊕○ moderate (downgraded for indirectness) <sup>5</sup>
<b>Outcome: Health Assessment Questionnaire (HAQ) score, 0-3 (higher = worse): a measure of function</b>	<b>MD (95% CI)</b>			<b>MD (95% CrI)</b>		
All biologics + MTX/DMARD	-0.25 (95% CI -0.28 to -0.22)	-8.3% (-9.3% to -7.3%), NNT = 3 (2 to 4)	⊕⊕⊕○ moderate (downgraded for inconsistency) <sup>6</sup>	n/a		
TNF + MTX/DMARD	-0.23 (-0.26 to -0.20)	-8.6% (-10% to -7.3%), NNT = 2 (2 to 4)	⊕⊕⊕○ moderate (downgraded for inconsistency) <sup>6</sup>	-0.31 (-0.42 to -0.20)	-10.3% (-14% to -6.7%)	⊕⊕⊕○ moderate (downgraded for indirectness) <sup>5</sup>
Non-TNF + MTX/DMARD	-0.21 (-0.30 to -0.12)	-7% (-10% to -4%), NNT = 3 (2 to 16)	⊕⊕⊕○ moderate (downgraded for inconsistency) <sup>7</sup>	-0.22 (-0.41 to -0.02)	-7.3% (-13.6% to -0.67%)	⊕⊕⊕○ moderate (downgraded for indirectness) <sup>5</sup>

**Table 2. Summary of findings table for biologics + MTX/DMARD vs. Comparator\* in MTX/DMARD-experienced patients (MTX/DMARD incomplete-responders)** (Continued)

Anakinra + MTX/DMARD	n/a			n/a		
<b>Outcome: Remission (defined as DAS &lt; 1.6 or DAS28 &lt; 2.6)</b>	<b>RR (95% CI)</b>			<b>RR (95% CrI)</b>		
All biologics + MTX/DMARD	2.81 (2.23 to 3.53)	18% (12% to 25%), NNT = 6 (4 to 9)	⊕⊕⊕○ moderate (downgraded for inconsistency) <sup>8</sup>	n/a		
TNF + MTX/DMARD	2.61 (2.08 to 3.27)	16% (8% to 24%), NNT = 6 (4 to 13)	⊕⊕⊕○ moderate (downgraded for inconsistency) <sup>9</sup>	3.36 (2.54 to 4.50)	17% (11% to 23%), NNT = 5 (4 to 7)	⊕⊕⊕○ moderate (downgraded for indirectness) <sup>5</sup>
Non-TNF + MTX/DMARD	3.56 (1.81, 7.01)	15% (11% to 19%); NNT = 7 (5 to 9)	⊕⊕⊕○ moderate (downgraded for inconsistency) <sup>10</sup>	3.73 (2.62 to 5.32)	19% (12% to 28%), NNT = 5 (3 to 7)	⊕⊕⊕○ moderate (downgraded for indirectness) <sup>5</sup>
Anakinra + MTX/DMARD	n/a			n/a		
<b>Outcome: Radiographic progression on Sharp/van Der Heijde modification (0 - 448 points)</b>	<b>MD (95% CI)</b>			<b>MD (95% CrI)</b>		
All biologics + MTX/DMARD	-2.61 (-4.08 to -1.14)	-0.58% (-0.91% to -0.25%), NNT = 7 (5 to 14)	⊕⊕⊕○ moderate [downgraded for inconsistency] <sup>11</sup>	n/a		
TNF + MTX/DMARD	-2.61 (-4.08 to -1.14)	-0.58% (-0.91% to -0.25%), NNT = 7 (5 to 14)	⊕⊕⊕○ moderate [downgraded for inconsistency] <sup>11</sup>	-2.99 (-6.30 to -0.55)	-0.67% (-1.4% to -0.12%)	⊕⊕⊕○ moderate (downgraded for indirectness) <sup>5</sup>
Non-TNF + MTX/DMARD	n/a			-2.76 (-10.58 to 4.12)	-0.68% (-2.36% to 0.92%)	⊕⊕⊕○ moderate (downgraded for indirectness) <sup>5</sup>
Anakinra + MTX/DMARD	n/a			n/a		
<b>Outcome: Withdrawals due to adverse events</b>	<b>RR (95% CI)</b>			<b>RR (95% CrI)</b>		
All biologics + MTX/DMARD	1.11 (0.96 to 1.30)	1% (0% to 2%), NNT = n/a	⊕⊕⊕○	n/a		

**Table 2. Summary of findings table for biologics + MTX/DMARD vs. Comparator\* in MTX/DMARD-experienced patients (MTX/DMARD incomplete-responders)** (Continued)

			moderate [downgraded for imprecision] <sup>12</sup>			
TNF + MTX/DMARD	1.04 (0.87 to 1.25)	1% (0 to 2%) NNT = n/a	⊕⊕⊕○  moderate [downgraded for imprecision] <sup>12</sup>	1.24 (0.99 to 1.57)	1% (0 to 2%) NNT = n/a	⊕⊕○○  low (downgraded for imprecision and indirectness) <sup>5,12</sup>
Non-TNF + MTX/DMARD	1.37 (1.03 to 1.82)	1% (1% to 2%), NNT = 100 (50 to 100)	high	1.20 (0.87 to 1.67)	0% (0% to 2%), NNT = n/a	⊕⊕○○  low (downgraded for imprecision and indirectness) <sup>5,12</sup>
Anakinra + MTX/DMARD	n/a			n/a		
<b>Outcome: Serious adverse events (report Peto OR which can be interpreted as an RR due to the low event rate)</b>	<b>RR (95% CI)</b>			<b>RR (95% CrI)</b>		
All biologics + MTX/DMARD	1.12 (0.99 to 1.27)	1% (0% to 2%), NNT = n/a	high	n/a		
TNF + MTX/DMARD	1.16 (0.96 to 1.39)	1% (0% to 2%), NNT = n/a	⊕⊕⊕○  moderate [downgraded for imprecision] <sup>12</sup>	1.20 (1.01 to 1.43)	1% (0% to 2%), NNT = n/a	⊕⊕⊕○  moderate (downgraded for indirectness) <sup>5</sup>
Non-TNF + MTX/DMARD	1.08 (0.91, 1.29)	1% (-1% to 2%), NNT = n/a	⊕⊕⊕○  moderate [downgraded for imprecision] <sup>12</sup>	1.07 (0.89 to 1.29)	0% (-1% to 1%), NNT = n/a	⊕⊕○○  low (downgraded for imprecision and indirectness) <sup>5,12</sup>
Anakinra + MTX/DMARD	1.04 (0.68, 1.61)	0% (-1% to 3%), NNT = n/a	⊕⊕⊕○  moderate [downgraded for imprecision] <sup>12</sup>	1.06 (0.65 to 1.75)	0% (-2% to 4%), NNT = n/a	⊕⊕○○  low (downgraded for imprecision and indirectness) <sup>5,12</sup>
<b>Outcome: Cancer (report Peto OR which can be interpreted as an RR due to the low event rate)</b>	<b>RR (95% CI)</b>			<b>RR (95% CrI)</b>		
All biologics + MTX/DMARD	1.07 (0.68 to 1.68)	0% (-1% to 1%), NNT = n/a	⊕⊕⊕○	n/a		

**Table 2. Summary of findings table for biologics + MTX/DMARD vs. Comparator\* in MTX/DMARD-experienced patients (MTX/DMARD incomplete-responders)** (Continued)

			low - downgraded for serious imprecision <sup>13</sup>			
TNF + MTX/DMARD	1.44 (0.62 to 3.34)	0% (-1% to 1%), NNT = n/a	⊕⊕⊕○ low - downgraded for serious imprecision <sup>13</sup>	1.21 (0.63 to 2.38)	0% (0 to 1%) NNT = n/a	⊕⊕○○ low (downgraded for imprecision and indirectness) <sup>5,12</sup>
Non-TNF + MTX/DMARD	0.95 (0.56 to 1.61)	0% (-1% to 1%), NNT = n/a	⊕⊕⊕○ low - downgraded for serious imprecision <sup>13</sup>	0.99 (0.58 to 1.78)	0% (0 to 1%) NNT=n/a	⊕⊕○○ low (downgraded for imprecision and indirectness) <sup>5,12</sup>
Anakinra + MTX/DMARD	n/a			n/a		

High quality (⊕⊕⊕⊕) : we are very confident that the true effect lies close to that of the estimate of the effect  
 Moderate quality (⊕⊕⊕○) : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different  
 Low quality (⊕⊕○○) : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect  
 Very low quality (⊕○○○) : we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

The assumed risk is based on the comparator group risk in the included studies.

\*Comparator = placebo and/or MTX and/or DMARD

NNTB calculated as 1/absolute risk difference

n/a = not available; DAS = Disease Activity Score; DMARD = disease-modifying anti-rheumatic drug; MTX = methotrexate; TNF = tumor necrosis factor

1. I<sup>2</sup> = 75% - downgraded for inconsistency
2. I<sup>2</sup> = 73% - downgraded for inconsistency
3. I<sup>2</sup> = 83% - downgraded for inconsistency
4. Only two studies and 79 events - downgraded for rule of thumb less than 300 events
5. Downgraded for indirectness/intransitivity due to differing patient characteristics (e.g. established vs late RA); differing biologic doses and co-interventions; and differing comparators
6. I<sup>2</sup>=95% - downgraded for inconsistency
7. I<sup>2</sup>=79% - downgraded for inconsistency
8. I<sup>2</sup>=66% - downgraded for inconsistency
9. I<sup>2</sup>=51% - downgraded for inconsistency
10. I<sup>2</sup>=81% - downgraded for inconsistency
11. I<sup>2</sup>=85% - downgraded for inconsistency
12. Downgraded for imprecision - 95% CI estimate includes both null effect and appreciable benefit or harm
13. Downgraded twice for serious imprecision - few events (<300) and 95% CI estimate includes both null effect and appreciable benefit or harm

## APPENDICES

### Appendix 1. ACR50: Type of medication (TNF vs non-TNF vs anakinra vs tofacitinib (TOFA))



## ACR50 Analysis 2: Odds Ratios, Risk ratios and Risk Difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
TNF	PL	2.90 (2.12,4.08)	2.40 (1.88,3.07)	0.15 (0.10,0.22)
non-TNF		3.79 (2.36,6.14)	2.90 (2.05,3.96)	0.21 (0.12,0.32)
TOFA		8.50 (3.73,19.74)	4.65 (2.86,6.55)	0.40 (0.21,0.60)
MTXTNF		4.46 (3.55,5.64)	3.23 (2.75,3.79)	0.25 (0.20,0.30)
MTXnon-TNF		3.97 (2.85,5.57)	2.99 (2.36,3.74)	0.22 (0.15,0.30)
MTXTOFA		5.68 (2.82,11.71)	3.75 (2.35,5.43)	0.30 (0.15,0.48)
MTXANA		2.85 (1.00,8.53)	2.37 (1.00,4.70)	0.15 (0.00,0.40)
non-TNF	TNF	1.31 (0.75,2.26)	1.21 (0.81,1.75)	0.05 (-0.06,0.17)
TOFA		2.92 (1.24,6.89)	1.93 (1.16,2.85)	0.25 (0.05,0.44)
MTXTNF		1.54 (1.07,2.18)	1.35 (1.05,1.73)	0.09 (0.02,0.16)
MTXnon-TNF		1.37 (0.86,2.15)	1.25 (0.90,1.71)	0.07 (-0.03,0.16)
MTXTOFA		1.96 (0.91,4.30)	1.56 (0.93,2.42)	0.15 (-0.02,0.33)
MTXANA		0.98 (0.33,3.06)	0.99 (0.40,2.03)	0.00 (-0.17,0.25)
TOFA	non-TNF	2.23 (0.87,5.84)	1.60 (0.91,2.59)	0.19 (-0.03,0.41)
MTXTNF		1.17 (0.70,1.98)	1.11 (0.80,1.61)	0.04 (-0.08,0.14)
MTXnon-TNF		1.05 (0.62,1.76)	1.03 (0.73,1.49)	0.01 (-0.11,0.12)
MTXTOFA		1.50 (0.64,3.51)	1.29 (0.74,2.13)	0.09 (-0.10,0.29)
MTXANA		0.75 (0.24,2.50)	0.82 (0.33,1.76)	-0.06 (-0.25,0.21)
MTXTNF	TOFA	0.53 (0.22,1.22)	0.69 (0.49,1.14)	-0.16 (-0.36,0.05)
MTXnon-TNF		0.47 (0.19,1.12)	0.65 (0.43,1.08)	-0.18 (-0.39,0.03)
MTXTOFA		0.67 (0.22,2.01)	0.81 (0.45,1.48)	-0.10 (-0.36,0.17)
MTXANA		0.34 (0.09,1.33)	0.51 (0.20,1.17)	-0.24 (-0.51,0.07)
MTXnon-TNF	MTXTNF	0.89 (0.60,1.31)	0.93 (0.71,1.19)	-0.03 (-0.11,0.06)
MTXTOFA		1.28 (0.61,2.71)	1.16 (0.71,1.72)	0.06 (-0.11,0.24)
MTXANA		0.64 (0.22,1.96)	0.73 (0.31,1.47)	-0.09 (-0.25,0.16)
MTXTOFA	MTXnon-TNF	1.43 (0.66,3.16)	1.25 (0.75,1.93)	0.08 (-0.09,0.27)

(Continued)

MTXANA		0.72 (0.24,2.28)	0.79 (0.33,1.63)	-0.07 (-0.24,0.19)
MTXANA	MTXTOFA	0.50 (0.14,1.86)	0.64 (0.25,1.46)	-0.15 (-0.39,0.14)
Random-effects model	Residual Deviance	156.1 vs 155 data points		
	Deviance Information Criteria	1030.28		
Fixed-effect model	Residual Deviance	404 vs 155 data points		
	Deviance Information Criteria	1226.22		
Note:				
Total participants	28065			
Total studies	74			
2-arm	67			
3-arm	7			

## Appendix 2. ACR50: Type of biologic

ACR50 Analysis 3: Odds Ratios, Risk ratios and Risk Difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
Monoclonal antibodies against TNF	PL	3.47 (2.18,5.55)	2.73 (1.93,3.74)	0.19 (0.10,0.29)
Medications targeting TNF receptor		2.44 (1.53,3.98)	2.11 (1.44,3.02)	0.12 (0.05,0.22)
Non-TNF		3.91 (2.43,6.36)	2.97 (2.10,4.04)	0.22 (0.12,0.33)
TOFA		8.99 (3.93,21.23)	4.79 (2.97,6.71)	0.42 (0.22,0.61)
(MTX or DMARD) + Monoclonal antibodies against TNF		4.50 (3.42,5.92)	3.25 (2.69,3.90)	0.25 (0.19,0.31)
(MTX or DMARD) + non-TNF		4.01 (2.87,5.57)	3.01 (2.38,3.75)	0.22 (0.15,0.30)
(MTX or DMARD) + Medications targeting TNF receptor		4.24 (2.79,6.62)	3.13 (2.33,4.14)	0.23 (0.15,0.34)

(Continued)

(MTX or DMARD) + TOFA		5.63 (2.80,11.50)	3.74 (2.33,5.42)	0.30 (0.15,0.47)
(MTX or DMARD) + ANA		2.83 (1.01,8.37)	2.36 (1.01,4.66)	0.15 (0.00,0.40)
Medications targeting TNF receptor	Monoclonal anti- bodies against TNF	0.70 (0.36,1.37)	0.77 (0.47,1.26)	-0.07 (-0.19,0.06)
Non-TNF		1.13 (0.61,2.09)	1.09 (0.71,1.65)	0.03 (-0.11,0.16)
TOFA		2.60 (1.09,6.27)	1.75 (1.06,2.69)	0.22 (0.02,0.42)
(MTX or DMARD) + Monoclonal anti- bodies against TNF		1.29 (0.77,2.15)	1.19 (0.85,1.71)	0.06 (-0.06,0.16)
(MTX or DMARD) + non-TNF		1.15 (0.65,2.01)	1.10 (0.75,1.64)	0.03 (-0.09,0.14)
(MTX or DMARD) + Medications target- ing TNF receptor		1.22 (0.66,2.31)	1.15 (0.75,1.77)	0.04 (-0.09,0.18)
(MTX or DMARD) + TOFA		1.61 (0.69,3.80)	1.36 (0.78,2.26)	0.11 (-0.08,0.31)
(MTX or DMARD) + ANA		0.82 (0.26,2.67)	0.87 (0.35,1.85)	-0.04 (-0.22,0.22)
Non-TNF	Medications target- ing TNF re- ceptor	1.60 (0.82,3.15)	1.41 (0.86,2.29)	0.09 (-0.04,0.23)
TOFA		3.70 (1.41,9.78)	2.26 (1.26,3.78)	0.29 (0.07,0.50)
(MTX or DMARD) + Monoclonal anti- bodies against TNF		1.84 (1.06,3.18)	1.54 (1.04,2.34)	0.12 (0.01,0.22)
(MTX or DMARD) + non-TNF		1.64 (0.91,2.92)	1.43 (0.93,2.21)	0.10 (-0.02,0.21)
(MTX or DMARD) + Medications target- ing TNF receptor		1.74 (1.05,2.89)	1.49 (1.03,2.16)	0.11 (0.01,0.21)
(MTX or DMARD) + TOFA		2.31 (0.97,5.37)	1.77 (0.98,2.99)	0.18 (-0.01,0.37)
(MTX or DMARD) + ANA		1.16 (0.37,3.82)	1.12 (0.44,2.47)	0.03 (-0.15,0.29)
TOFA	non-TNF	2.30 (0.88,6.09)	1.61 (0.93,2.59)	0.20 (-0.03,0.42)
(MTX or DMARD) + Monoclonal anti- bodies against TNF		1.15 (0.67,1.98)	1.10 (0.78,1.60)	0.03 (-0.09,0.14)
(MTX or DMARD) + non-TNF		1.02 (0.61,1.72)	1.01 (0.72,1.46)	0.00 (-0.11,0.11)
(MTX or DMARD) + Medications target- ing TNF receptor		1.09 (0.57,2.08)	1.06 (0.69,1.63)	0.02 (-0.13,0.16)
(MTX or DMARD) + TOFA		1.44 (0.60,3.39)	1.26 (0.71,2.08)	0.08 (-0.11,0.28)
(MTX or DMARD) + ANA		0.73 (0.23,2.37)	0.80 (0.32,1.71)	-0.06 (-0.26,0.20)

(Continued)

(MTX or DMARD) + Monoclonal anti-bodies against TNF	TOFA	0.50 (0.21,1.18)	0.68 (0.47,1.12)	-0.17 (-0.37,0.04)
(MTX or DMARD) + non-TNF		0.45 (0.18,1.09)	0.63 (0.42,1.06)	-0.19 (-0.40,0.02)
(MTX or DMARD) + Medications targeting TNF receptor		0.47 (0.18,1.22)	0.65 (0.42,1.13)	-0.18 (-0.40,0.05)
(MTX or DMARD) + TOFA		0.62 (0.21,1.86)	0.78 (0.44,1.41)	-0.11 (-0.37,0.15)
(MTX or DMARD) + ANA		0.31 (0.08,1.25)	0.50 (0.20,1.13)	-0.26 (-0.52,0.05)
(MTX or DMARD) + non-TNF	(MTX or DMARD) + Monoclonal anti-bodies against TNF	0.89 (0.59,1.34)	0.93 (0.70,1.21)	-0.03 (-0.12,0.07)
(MTX or DMARD) + Medications targeting TNF receptor		0.95 (0.57,1.59)	0.96 (0.69,1.33)	-0.01 (-0.12,0.11)
(MTX or DMARD) + TOFA		1.25 (0.58,2.70)	1.15 (0.69,1.73)	0.05 (-0.12,0.24)
(MTX or DMARD) + ANA		0.63 (0.21,1.93)	0.73 (0.30,1.47)	-0.10 (-0.26,0.16)
(MTX or DMARD) + Medications targeting TNF receptor	(MTX or DMARD) + non-TNF	1.06 (0.62,1.84)	1.04 (0.72,1.49)	0.01 (-0.10,0.14)
(MTX or DMARD) + TOFA		1.41 (0.64,3.10)	1.24 (0.74,1.91)	0.08 (-0.09,0.27)
(MTX or DMARD) + ANA		0.71 (0.23,2.22)	0.78 (0.32,1.62)	-0.07 (-0.24,0.19)
(MTX or DMARD) + TOFA	(MTX or DMARD) + Medications targeting TNF receptor	1.33 (0.57,3.04)	1.19 (0.69,1.91)	0.07 (-0.12,0.26)
(MTX or DMARD) + ANA		0.67 (0.21,2.13)	0.76 (0.30,1.58)	-0.08 (-0.27,0.18)
(MTX or DMARD) + ANA	(MTX or DMARD) + TOFA	0.51 (0.14,1.85)	0.64 (0.25,1.46)	-0.15 (-0.38,0.14)
Random-effects model	Residual deviance	156.1 vs 155 data points		
	Deviance information criteria	1030.52		
Fixed-effect model	Residual deviance	393.8 vs 155 data points		
	Deviance information criteria	1218.07		

Note:

(Continued)

Total participants	28065
Total studies	74
2-arm	67
3-arm	7

### Appendix 3. ACR50: By dose

ACR50 (Analysis-4): Odds Ratios, Risk Ratios and Risk Difference for all treatment comparisons - random-effects model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD	PL	3.00 (2.32,3.94)	2.37 (1.96,2.85)	0.18 (0.13,0.24)
HD		4.08 (3.01,5.60)	2.88 (2.36,3.50)	0.25 (0.19,0.33)
LD		1.58 (1.03,2.44)	1.47 (1.03,2.05)	0.06 (0.00,0.14)
MTXSD		4.19 (3.54,5.01)	2.93 (2.62,3.30)	0.26 (0.22,0.30)
MTXHD		5.28 (4.08,6.91)	3.35 (2.86,3.90)	0.32 (0.26,0.38)
MTXLD		3.05 (2.29,4.08)	2.39 (1.95,2.91)	0.19 (0.13,0.25)
HD	SD	1.36 (0.99,1.87)	1.22 (0.99,1.49)	0.07 (0.00,0.14)
LD		0.53 (0.34,0.81)	0.62 (0.44,0.86)	-0.12 (-0.19,-0.04)
MTXSD		1.40 (1.06,1.85)	1.24 (1.03,1.50)	0.08 (0.01,0.14)
MTXHD		1.76 (1.25,2.49)	1.42 (1.14,1.76)	0.13 (0.05,0.21)
MTXLD		1.02 (0.70,1.47)	1.01 (0.79,1.30)	0.00 (-0.08,0.08)
LD	HD	0.39 (0.24,0.62)	0.51 (0.35,0.72)	-0.19 (-0.28,-0.10)
MTXSD		1.03 (0.74,1.43)	1.02 (0.84,1.25)	0.01 (-0.07,0.08)
MTXHD		1.30 (0.90,1.87)	1.16 (0.94,1.45)	0.06 (-0.03,0.15)
MTXLD		0.75 (0.50,1.12)	0.83 (0.64,1.07)	-0.07 (-0.16,0.03)
MTXSD	LD	2.65 (1.70,4.13)	2.00 (1.43,2.86)	0.20 (0.11,0.27)
MTXHD		3.34 (2.06,5.43)	2.29 (1.61,3.32)	0.25 (0.16,0.34)
MTXLD		1.93 (1.18,3.16)	1.63 (1.13,2.39)	0.12 (0.03,0.21)



(Continued)

MTXHD	MTXSD	1.26 (0.97,1.65)	1.14 (0.98,1.33)	0.06 (-0.01,0.12)
MTXLD		0.73 (0.54,0.97)	0.82 (0.67,0.98)	-0.07 (-0.14,-0.01)
MTXLD	MTXHD	0.58 (0.40,0.82)	0.71 (0.57,0.89)	-0.13 (-0.21,-0.05)
Random-effects model	Residual deviance	185.2 vs 178 data points		
	Deviance information criteria	1149.95		
Fixed-effect model	Residual deviance	402.1 vs 178 data points		
	Deviance information criteria	1302.36		
Note:				
Total participants	25224			
Total studies	68			
2-arm	37			
3-arm	24			
4-arm	5			
5-arm	1			
7-arm	1			

#### Appendix 4. ACR50: Main analysis

ACR50 (Analysis 1): Odds Ratios, Risk Ratios and Risk Difference for all treatment comparisons - random-effects model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
PL + MTX/MTX	PL	3.66 (1.69,6.81)	3.15 (1.62,5.14)	0.13 (0.04,0.24)
DMARD/DMARD + PL		0.98 (0.37,2.38)	0.98 (0.38,2.20)	0.00 (-0.04,0.07)
MTX + DMARD		5.57 (2.31,13.66)	4.36 (2.11,8.02)	0.20 (0.07,0.39)
SD ETN SC		6.94 (3.38,13.10)	5.09 (2.90,7.94)	0.25 (0.13,0.38)

(Continued)

SD ADA SC	3.69 (2.13,6.72)	3.16 (1.98,5.13)	0.13 (0.07,0.23)
SD TOFA PO	6.44 (3.31,13.07)	4.82 (2.87,7.77)	0.23 (0.12,0.39)
SD GOLII SC	8.10 (3.04,22.03)	5.65 (2.70,10.08)	0.28 (0.11,0.52)
SD GOLII IV	6.49 (2.15,18.77)	4.85 (2.00,9.34)	0.23 (0.06,0.48)
SD TOCI IV	5.43 (2.12,13.52)	4.26 (1.97,8.06)	0.20 (0.06,0.39)
SD RITUX IV	2.52 (0.29,13.36)	2.30 (0.30,7.87)	0.08 (-0.04,0.39)
SD ABA SC	9.95 (2.69,46.12)	6.40 (2.43,13.14)	0.33 (0.09,0.68)
SD CERTO SC	9.56 (3.04,34.80)	6.26 (2.70,11.93)	0.32 (0.10,0.63)
SD ETN SC + MTX	14.81 (6.84,31.08)	8.01 (4.78,12.05)	0.43 (0.26,0.59)
SD INF IV + MTX	11.26 (4.80,24.64)	6.94 (3.82,10.64)	0.36 (0.19,0.54)
SD ABA IV + MTX	14.62 (6.12,33.05)	7.97 (4.48,12.16)	0.43 (0.23,0.61)
SD ADA SC + MTX	23.24 (9.03,57.59)	9.75 (5.74,14.38)	0.54 (0.32,0.72)
SD CERTO SC + MTX/ CERTO+ MTX	21.19 (8.18,46.26)	9.46 (5.51,13.45)	0.52 (0.30,0.69)
SD RITUX IV + MTX	9.14 (3.91,21.04)	6.08 (3.26,9.92)	0.31 (0.14,0.51)
SD TOFA PO + MTX	23.26 (9.75,57.30)	9.82 (6.11,14.14)	0.54 (0.34,0.72)
SD GOLII SC + MTX	23.12 (8.75,58.38)	9.79 (5.68,14.19)	0.54 (0.32,0.72)
SD ABA SC + MTX	18.02 (6.44,49.02)	8.78 (4.70,13.72)	0.48 (0.25,0.68)
SD GOLII IV + MTX	8.64 (3.20,22.14)	5.88 (2.79,10.06)	0.30 (0.12,0.52)
SD ANA SC + MTX	10.68 (3.49,30.43)	6.67 (3.01,11.55)	0.35 (0.13,0.59)
SD TOCI IV + MTX	7.50 (2.32,22.43)	5.36 (2.13,10.30)	0.27 (0.08,0.52)
SD CERTO SC + DMARD	5.17 (1.87,14.27)	4.12 (1.77,8.03)	0.19 (0.05,0.41)
SD ADA SC + DMARD	3.09 (0.76,11.16)	2.74 (0.78,6.94)	0.11 (-0.01,0.35)
SD ETN SC + DMARD	12.68 (4.15,38.46)	7.36 (3.45,12.62)	0.39 (0.16,0.65)
SD TOCI SC + DMARD	4.91 (1.24,18.43)	3.95 (1.22,9.00)	0.18 (0.01,0.48)
LD ADA SC	3.33 (1.59,7.53)	2.92 (1.53,5.52)	0.12 (0.03,0.26)
LD ETN SC	3.51 (1.56,7.76)	3.04 (1.50,5.60)	0.12 (0.03,0.27)
LD GOLII IV	3.85 (1.15,12.60)	3.27 (1.14,7.53)	0.14 (0.01,0.38)
LD TOCI IV	0.65 (0.11,2.67)	0.67 (0.12,2.43)	-0.02 (-0.06,0.08)

(Continued)

LD ADA SC + MTX		16.49 (6.28,46.62)	8.42 (4.58,13.41)	0.46 (0.24,0.68)
LD RITUX IV + MTX		8.07 (3.19,18.75)	5.62 (2.79,9.50)	0.28 (0.12,0.48)
LD ADA IV + MTX		14.69 (2.25,82.04)	7.93 (2.08,15.00)	0.43 (0.07,0.78)
LD ABA IV + MTX		7.85 (2.93,21.08)	5.52 (2.62,9.82)	0.28 (0.10,0.50)
LD ANA SC + MTX		7.33 (1.54,32.97)	5.26 (1.49,11.70)	0.26 (0.03,0.61)
LD CERTO SC + MTX		14.70 (4.41,47.72)	7.99 (3.58,13.38)	0.43 (0.17,0.69)
LD ETN SC + MTX		12.99 (4.49,37.72)	7.49 (3.65,12.44)	0.40 (0.18,0.64)
LD GOLI IV + MTX		7.58 (2.45,24.09)	5.38 (2.22,10.42)	0.27 (0.08,0.54)
LD TOCI IV + MTX		6.08 (1.95,18.19)	4.64 (1.83,9.22)	0.22 (0.05,0.46)
LD TOFA PO + MTX		12.84 (2.98,48.04)	7.40 (2.66,13.00)	0.39 (0.11,0.70)
HD TOCI IV		9.85 (4.54,19.49)	6.40 (3.64,9.73)	0.33 (0.18,0.48)
HD TOFA PO		10.26 (5.02,20.82)	6.53 (3.97,9.90)	0.34 (0.19,0.50)
HD ADA SC		4.69 (2.28,10.74)	3.82 (2.09,7.00)	0.17 (0.07,0.34)
HD ETN SC		7.12 (2.81,17.55)	5.19 (data points,9.25)	0.25 (0.10,0.47)
HD GOLI SC		9.57 (3.90,21.77)	6.26 (3.25,10.12)	0.32 (0.15,0.52)
HD ABA SC		14.48 (3.81,62.31)	7.86 (3.20,14.09)	0.42 (0.14,0.74)
HD INF IV + MTX		18.36 (7.49,43.86)	8.92 (5.14,13.22)	0.48 (0.28,0.67)
HD TOCI IV + MTX		17.54 (7.25,37.88)	8.70 (5.10,12.70)	0.47 (0.27,0.64)
HD TOFA PO + MTX		18.47 (7.83,45.79)	8.90 (5.26,13.32)	0.49 (0.29,0.68)
HD GOLI SC + MTX		17.77 (6.82,47.15)	8.77 (4.86,13.44)	0.48 (0.26,0.68)
HD CERTO SC + MTX		24.79 (10.00,59.86)	10.08 (6.17,14.60)	0.56 (0.35,0.73)
HD ADA SC + MTX		20.68 (6.34,70.20)	9.33 (4.67,14.68)	0.51 (0.24,0.75)
HD TOCI IV + DMARD		3.61 (1.09,11.27)	3.11 (1.08,7.06)	0.13 (0.01,0.35)
SD ANA SC + SD ETN SC + MTX		9.29 (2.84,33.61)	6.10 (2.51,11.95)	0.32 (0.10,0.62)
SD ANA SC + LD ETN SC + MTX		14.26 (4.13,48.43)	7.82 (3.39,13.56)	0.42 (0.16,0.69)
DMARD/DMARD + PL	PL + MTX/MTX	0.27 (0.12,0.63)	0.31 (0.15,0.68)	-0.13 (-0.23,-0.05)
MTX + DMARD		1.57 (0.88,2.82)	1.41 (0.90,2.15)	0.08 (-0.02,0.21)

(Continued)

SD ETN SC	1.91 (1.28,2.89)	1.63 (1.19,2.29)	0.12 (0.04,0.20)
SD ADA SC	1.03 (0.50,2.31)	1.03 (0.58,2.00)	0.00 (-0.11,0.13)
SD TOFA PO	1.80 (0.72,4.69)	1.56 (0.78,3.18)	0.11 (-0.06,0.29)
SD GOLI SC	2.27 (0.89,6.00)	1.82 (0.91,3.47)	0.15 (-0.02,0.37)
SD GOLI IV	1.81 (0.74,4.28)	1.57 (0.78,2.76)	0.10 (-0.05,0.31)
SD TOCI IV	1.52 (0.69,3.30)	1.38 (0.74,2.45)	0.07 (-0.06,0.23)
SD RITUX IV	0.71 (0.10,3.42)	0.75 (0.12,2.35)	-0.05 (-0.19,0.24)
SD ABA SC	2.80 (0.61,14.74)	2.05 (0.67,5.45)	0.20 (-0.08,0.57)
SD CERTO SC	2.61 (0.70,13.42)	1.99 (0.75,5.34)	0.19 (-0.06,0.53)
SD ETN SC + MTX	4.16 (2.76,6.35)	2.56 (1.93,3.64)	0.30 (0.19,0.40)
SD INF IV + MTX	3.11 (2.05,4.77)	2.19 (1.68,2.99)	0.23 (0.12,0.34)
SD ABA IV + MTX	4.07 (2.66,6.22)	2.53 (1.93,3.43)	0.29 (0.17,0.41)
SD ADA SC + MTX	6.35 (3.76,11.26)	3.10 (2.31,4.37)	0.40 (0.26,0.54)
SD CERTO SC + MTX/ CERTO+ MTX	5.80 (3.65,9.41)	2.99 (2.25,4.21)	0.38 (0.24,0.50)
SD RITUX IV + MTX	2.54 (1.53,4.27)	1.95 (1.37,2.78)	0.18 (0.07,0.31)
SD TOFA PO + MTX	6.49 (3.80,11.61)	3.11 (2.28,4.56)	0.41 (0.26,0.54)
SD GOLI SC + MTX	6.39 (3.32,12.48)	3.10 (2.14,4.71)	0.40 (0.24,0.54)
SD ABA SC + MTX	5.06 (2.49,10.03)	2.81 (1.88,4.20)	0.35 (0.17,0.51)
SD GOLI IV + MTX	2.37 (1.22,4.82)	1.87 (1.16,2.88)	0.17 (0.03,0.34)
SD ANA SC + MTX	2.99 (1.27,6.77)	2.14 (1.21,3.49)	0.22 (0.04,0.42)
SD TOCI IV + MTX	2.10 (0.78,5.43)	1.74 (0.81,3.13)	0.14 (-0.04,0.36)
SD CERTO SC + DMARD	1.45 (0.47,4.57)	1.34 (0.55,3.01)	0.06 (-0.12,0.30)
SD ADA SC + DMARD	0.87 (0.26,3.00)	0.89 (0.30,2.27)	-0.02 (-0.16,0.21)
SD ETN SC + DMARD	3.56 (1.36,9.54)	2.37 (1.25,4.09)	0.26 (0.05,0.49)
SD TOCI SC + DMARD	1.37 (0.41,4.84)	1.28 (0.47,2.92)	0.05 (-0.12,0.33)
LD ADA SC	0.95 (0.37,2.61)	0.96 (0.44,2.15)	-0.01 (-0.14,0.15)
LD ETN SC	0.98 (0.50,1.88)	0.98 (0.57,1.64)	0.00 (-0.10,0.11)
LD GOLI IV	1.08 (0.37,2.92)	1.06 (0.43,2.13)	0.01 (-0.12,0.21)

(Continued)

LD TOCI IV		0.18 (0.03,0.66)	0.22 (0.04,0.71)	-0.14 (-0.25,-0.04)
LD ADA SC + MTX		4.55 (2.36,9.09)	2.67 (1.83,3.95)	0.32 (0.16,0.49)
LD RITUX IV + MTX		2.22 (1.29,3.78)	1.78 (1.22,2.57)	0.15 (0.04,0.29)
LD ADA IV + MTX		4.07 (0.70,20.43)	2.52 (0.75,4.91)	0.29 (-0.05,0.63)
LD ABA IV + MTX		2.19 (1.15,4.20)	1.78 (1.11,2.65)	0.15 (0.02,0.31)
LD ANA SC + MTX		2.01 (0.54,8.21)	1.67 (0.59,3.74)	0.13 (-0.07,0.46)
LD CERTO SC + MTX		4.12 (1.67,10.42)	2.54 (1.49,4.24)	0.30 (0.08,0.52)
LD ETN SC + MTX		3.66 (1.61,8.16)	2.40 (1.43,3.82)	0.27 (0.08,0.47)
LD GOLI IV + MTX		2.13 (0.83,5.69)	1.75 (0.85,3.06)	0.14 (-0.03,0.38)
LD TOCI IV + MTX		1.71 (0.63,4.45)	1.50 (0.68,2.88)	0.09 (-0.07,0.30)
LD TOFA PO + MTX		3.54 (1.05,10.97)	2.35 (1.05,4.11)	0.26 (0.01,0.53)
HD TOCI IV		2.69 (1.64,4.53)	2.02 (1.42,3.00)	0.19 (0.09,0.30)
HD TOFA PO		2.91 (1.13,6.96)	2.11 (1.09,3.99)	0.21 (0.02,0.39)
HD ADA SC		1.31 (0.53,3.66)	1.23 (0.61,2.74)	0.04 (-0.10,0.23)
HD ETN SC		2.00 (0.98,4.13)	1.68 (0.98,2.69)	0.13 (0.00,0.30)
HD GOLI SC		2.66 (1.32,5.56)	2.01 (1.22,3.29)	0.19 (0.05,0.36)
HD ABA SC		3.98 (0.87,21.43)	2.48 (0.90,6.26)	0.29 (-0.02,0.63)
HD INF IV + MTX		5.06 (2.95,8.88)	2.80 (2.04,4.07)	0.35 (0.20,0.48)
HD TOCI IV + MTX		4.85 (2.84,8.32)	2.77 (1.98,4.06)	0.34 (0.20,0.46)
HD TOFA PO + MTX		5.23 (2.96,9.43)	2.84 (2.08,4.16)	0.35 (0.20,0.50)
HD GOLI SC + MTX		4.96 (2.55,10.15)	2.78 (1.90,4.24)	0.34 (0.17,0.51)
HD CERTO SC + MTX		6.96 (4.03,12.34)	3.21 (2.38,4.77)	0.42 (0.28,0.55)
HD ADA SC + MTX		5.77 (2.26,15.13)	2.96 (1.80,4.72)	0.38 (0.15,0.58)
HD TOCI IV + DMARD		0.99 (0.37,2.99)	1.00 (0.43,2.21)	0.00 (-0.13,0.21)
SD ANA SC + SD ETN SC + MTX		2.65 (0.91,7.95)	1.99 (0.92,3.62)	0.19 (-0.01,0.45)
SD ANA SC + LD ETN SC + MTX		3.92 (1.35,11.55)	2.48 (1.27,4.39)	0.28 (0.05,0.53)
MTX + DMARD	DMARD/DMARD + PL	5.73 (2.15,15.44)	4.44 (1.92,10.18)	0.20 (0.08,0.38)



(Continued)

SD ETN SC	7.00 (3.18,16.12)	5.12 (2.54,10.99)	0.24 (0.15,0.37)
SD ADA SC	3.82 (1.49,10.43)	3.24 (1.41,8.32)	0.13 (0.04,0.23)
SD TOFA PO	6.69 (2.23,20.71)	4.95 (1.94,13.32)	0.23 (0.10,0.39)
SD GOL I SC	8.45 (2.52,28.38)	5.74 (2.18,14.79)	0.28 (0.11,0.51)
SD GOL I IV	6.69 (2.03,21.73)	4.90 (1.84,12.38)	0.23 (0.07,0.47)
SD TOCI IV	5.54 (1.99,15.19)	4.30 (1.81,10.25)	0.20 (0.07,0.38)
SD RITUX IV	2.62 (0.35,14.24)	2.37 (0.36,9.12)	0.08 (-0.04,0.38)
SD ABA SC	10.22 (1.96,67.26)	6.42 (1.78,21.42)	0.33 (0.07,0.68)
SD CERTO SC	9.52 (2.41,55.12)	6.21 (2.11,20.67)	0.32 (0.09,0.64)
SD ETN SC + MTX	15.43 (6.09,36.84)	8.16 (3.82,17.50)	0.43 (0.27,0.58)
SD INF IV + MTX	11.55 (4.44,28.43)	6.97 (3.19,15.12)	0.36 (0.20,0.53)
SD ABA IV + MTX	14.98 (5.67,38.74)	8.01 (3.80,17.66)	0.42 (0.25,0.60)
SD ADA SC + MTX	23.75 (8.83,64.04)	9.87 (4.67,22.02)	0.54 (0.33,0.71)
SD CERTO SC + MTX/ CERTO+ MTX	21.40 (8.90,54.77)	9.45 (4.58,21.00)	0.51 (0.32,0.67)
SD RITUX IV + MTX	9.36 (3.71,24.79)	6.17 (2.85,13.68)	0.31 (0.16,0.49)
SD TOFA PO + MTX	24.16 (8.45,63.98)	9.85 (4.53,22.14)	0.54 (0.35,0.71)
SD GOL I SC + MTX	23.37 (8.62,68.20)	9.78 (4.66,22.22)	0.53 (0.34,0.72)
SD ABA SC + MTX	18.79 (6.14,55.73)	8.88 (3.96,20.29)	0.48 (0.26,0.68)
SD GOL I IV + MTX	8.82 (3.13,25.00)	5.96 (2.52,13.35)	0.29 (0.13,0.51)
SD ANA SC + MTX	10.76 (3.51,34.96)	6.68 (2.78,15.97)	0.35 (0.14,0.58)
SD TOCI IV + MTX	7.72 (2.37,24.38)	5.42 (2.08,13.15)	0.26 (0.09,0.50)
SD CERTO SC + DMARD	5.29 (2.04,14.40)	4.16 (1.83,9.28)	0.19 (0.06,0.40)
SD ADA SC + DMARD	3.17 (1.27,7.97)	2.78 (1.24,5.67)	0.11 (0.01,0.32)
SD ETN SC + DMARD	13.15 (4.43,40.09)	7.44 (3.25,16.84)	0.39 (0.18,0.63)
SD TOCI SC + DMARD	5.09 (2.05,12.60)	3.99 (1.93,7.58)	0.18 (0.04,0.43)
LD ADA SC	3.51 (1.11,11.39)	3.02 (1.10,8.87)	0.12 (0.01,0.26)
LD ETN SC	3.57 (1.35,9.68)	3.07 (1.30,7.43)	0.12 (0.03,0.26)
LD GOL I IV	3.95 (1.07,14.06)	3.33 (1.06,9.32)	0.14 (0.01,0.36)

(Continued)

LD TOCI IV		0.66 (0.12,3.03)	0.67 (0.13,2.77)	-0.02 (-0.09,0.08)
LD ADA SC + MTX		17.11 (5.62,50.08)	8.52 (3.75,19.41)	0.45 (0.25,0.66)
LD RITUX IV + MTX		8.19 (3.22,20.68)	5.65 (2.63,12.55)	0.28 (0.13,0.47)
LD ADA IV + MTX		14.37 (2.12,93.58)	7.65 (1.97,22.26)	0.42 (0.06,0.78)
LD ABA IV + MTX		8.07 (2.70,22.51)	5.62 (2.32,12.95)	0.27 (0.11,0.48)
LD ANA SC + MTX		7.55 (1.67,34.99)	5.28 (1.59,14.89)	0.26 (0.04,0.60)
LD CERTO SC + MTX		15.23 (4.36,51.01)	8.03 (3.36,18.78)	0.43 (0.18,0.68)
LD ETN SC + MTX		13.60 (4.08,41.18)	7.57 (3.08,17.26)	0.40 (0.18,0.63)
LD GOLI IV + MTX		7.88 (2.31,27.60)	5.58 (2.03,13.62)	0.27 (0.09,0.53)
LD TOCI IV + MTX		6.21 (2.01,20.21)	4.64 (1.83,11.75)	0.22 (0.06,0.46)
LD TOFA PO + MTX		13.09 (3.10,53.35)	7.35 (2.61,18.10)	0.39 (0.11,0.68)
HD TOCI IV		10.02 (4.58,21.22)	6.44 (3.23,13.55)	0.32 (0.20,0.45)
HD TOFA PO		10.64 (3.51,31.38)	6.67 (2.69,17.25)	0.34 (0.17,0.50)
HD ADA SC		4.92 (1.56,16.41)	3.95 (1.46,11.38)	0.17 (0.05,0.34)
HD ETN SC		7.30 (2.73,21.44)	5.23 (2.30,12.42)	0.25 (0.10,0.47)
HD GOLI SC		9.78 (3.41,28.72)	6.38 (2.68,15.33)	0.32 (0.16,0.52)
HD ABA SC		14.60 (3.02,89.72)	7.82 (2.52,24.97)	0.42 (0.13,0.74)
HD INF IV + MTX		18.86 (7.03,48.19)	8.96 (4.12,19.83)	0.48 (0.29,0.65)
HD TOCI IV + MTX		17.95 (7.14,42.71)	8.77 (4.14,18.85)	0.47 (0.30,0.63)
HD TOFA PO + MTX		19.49 (6.68,52.18)	9.08 (4.03,20.32)	0.48 (0.29,0.67)
HD GOLI SC + MTX		18.31 (6.35,54.48)	8.80 (3.96,20.53)	0.47 (0.27,0.67)
HD CERTO SC + MTX		25.75 (9.86,68.31)	10.24 (4.85,22.45)	0.56 (0.37,0.72)
HD ADA SC + MTX		21.47 (6.23,78.69)	9.39 (4.00,22.26)	0.51 (0.25,0.75)
HD TOCI IV + DMARD		3.74 (1.94,6.85)	3.16 (1.83,5.11)	0.13 (0.04,0.30)
SD ANA SC + SD ETN SC + MTX		9.84 (2.56,36.96)	6.33 (2.21,15.71)	0.32 (0.10,0.60)
SD ANA SC + LD ETN SC + MTX		14.70 (3.90,54.42)	7.81 (2.97,19.10)	0.42 (0.16,0.68)
SD ETN SC	MTX + DMARD	1.23 (0.66,2.37)	1.16 (0.76,1.91)	0.04 (-0.09,0.16)

(Continued)

SD ADA SC	0.67 (0.28,1.68)	0.74 (0.39,1.50)	-0.07 (-0.26,0.08)
SD TOFA PO	1.16 (0.39,3.34)	1.11 (0.52,2.43)	0.03 (-0.19,0.23)
SD GOL I SC	1.46 (0.48,4.22)	1.29 (0.59,2.64)	0.08 (-0.15,0.32)
SD GOL I IV	1.15 (0.38,3.37)	1.10 (0.48,2.27)	0.03 (-0.19,0.26)
SD TOCI IV	0.97 (0.38,2.54)	0.98 (0.47,1.95)	-0.01 (-0.19,0.18)
SD RITUX IV	0.45 (0.06,2.33)	0.54 (0.08,1.75)	-0.12 (-0.33,0.17)
SD ABA SC	1.81 (0.36,10.65)	1.48 (0.47,4.03)	0.13 (-0.19,0.51)
SD CERTO SC	1.71 (0.39,8.34)	1.43 (0.51,3.69)	0.11 (-0.18,0.46)
SD ETN SC + MTX	2.67 (1.63,4.24)	1.83 (1.30,2.72)	0.22 (0.11,0.32)
SD INF IV + MTX	2.00 (1.05,3.70)	1.56 (1.03,2.49)	0.15 (0.01,0.28)
SD ABA IV + MTX	2.61 (1.28,5.27)	1.80 (1.15,2.99)	0.21 (0.06,0.37)
SD ADA SC + MTX	4.11 (1.87,9.46)	2.22 (1.38,3.82)	0.32 (0.14,0.50)
SD CERTO SC + MTX/ CERTO+ MTX	3.71 (1.76,7.84)	2.13 (1.36,3.57)	0.30 (0.13,0.46)
SD RITUX IV + MTX	1.62 (0.75,3.65)	1.39 (0.81,2.43)	0.10 (-0.06,0.28)
SD TOFA PO + MTX	4.17 (1.85,9.68)	2.22 (1.39,3.87)	0.33 (0.14,0.50)
SD GOL I SC + MTX	4.13 (1.65,9.80)	2.22 (1.31,3.91)	0.32 (0.12,0.50)
SD ABA SC + MTX	3.24 (1.27,8.10)	2.00 (1.16,3.54)	0.26 (0.05,0.46)
SD GOL I IV + MTX	1.51 (0.63,3.81)	1.32 (0.73,2.48)	0.08 (-0.09,0.29)
SD ANA SC + MTX	1.92 (0.67,5.09)	1.53 (0.75,2.85)	0.14 (-0.08,0.36)
SD TOCI IV + MTX	1.35 (0.45,4.09)	1.23 (0.55,2.57)	0.06 (-0.15,0.30)
SD CERTO SC + DMARD	0.94 (0.27,3.22)	0.96 (0.37,2.30)	-0.01 (-0.25,0.24)
SD ADA SC + DMARD	0.56 (0.15,2.14)	0.63 (0.20,1.73)	-0.09 (-0.30,0.14)
SD ETN SC + DMARD	2.27 (0.78,6.68)	1.67 (0.85,3.24)	0.18 (-0.05,0.43)
SD TOCI SC + DMARD	0.88 (0.23,3.44)	0.91 (0.31,2.25)	-0.02 (-0.25,0.27)
LD ADA SC	0.61 (0.21,1.83)	0.68 (0.30,1.61)	-0.08 (-0.29,0.11)
LD ETN SC	0.62 (0.28,1.46)	0.70 (0.37,1.36)	-0.08 (-0.24,0.06)
LD GOL I IV	0.69 (0.21,2.31)	0.75 (0.28,1.80)	-0.06 (-0.26,0.17)
LD TOCI IV	0.12 (0.02,0.51)	0.15 (0.03,0.56)	-0.22 (-0.40,-0.08)

(Continued)

LD ADA SC + MTX		2.88 (1.20,7.42)	1.90 (1.13,3.38)	0.24 (0.04,0.45)
LD RITUX IV + MTX		1.42 (0.65,3.15)	1.27 (0.74,2.21)	0.07 (-0.09,0.24)
LD ADA IV + MTX		2.62 (0.40,15.12)	1.79 (0.48,4.13)	0.21 (-0.15,0.58)
LD ABA IV + MTX		1.40 (0.56,3.39)	1.26 (0.67,2.30)	0.07 (-0.12,0.26)
LD ANA SC + MTX		1.30 (0.30,5.78)	1.20 (0.38,2.85)	0.05 (-0.19,0.39)
LD CERTO SC + MTX		2.63 (0.91,8.27)	1.80 (0.94,3.44)	0.22 (-0.02,0.47)
LD ETN SC + MTX		2.36 (0.92,5.64)	1.70 (0.95,2.92)	0.19 (-0.02,0.39)
LD GOLI IV + MTX		1.37 (0.45,4.14)	1.24 (0.54,2.52)	0.06 (-0.15,0.30)
LD TOCI IV + MTX		1.09 (0.34,3.27)	1.06 (0.45,2.25)	0.02 (-0.20,0.25)
LD TOFA PO + MTX		2.25 (0.57,8.33)	1.66 (0.67,3.40)	0.18 (-0.10,0.47)
HD TOCI IV		1.74 (0.81,3.70)	1.45 (0.88,2.56)	0.12 (-0.05,0.27)
HD TOFA PO		1.85 (0.61,5.04)	1.51 (0.73,3.04)	0.13 (-0.11,0.34)
HD ADA SC		0.85 (0.28,2.57)	0.89 (0.40,2.03)	-0.03 (-0.24,0.18)
HD ETN SC		1.27 (0.53,3.13)	1.18 (0.65,2.24)	0.05 (-0.13,0.24)
HD GOLI SC		1.70 (0.67,4.28)	1.42 (0.77,2.71)	0.11 (-0.09,0.31)
HD ABA SC		2.57 (0.53,14.69)	1.79 (0.65,4.51)	0.21 (-0.13,0.57)
HD INF IV + MTX		3.24 (1.55,7.05)	2.01 (1.28,3.40)	0.27 (0.10,0.43)
HD TOCI IV + MTX		3.12 (1.42,6.58)	1.97 (1.22,3.35)	0.26 (0.08,0.42)
HD TOFA PO + MTX		3.35 (1.44,7.78)	2.04 (1.23,3.57)	0.27 (0.09,0.46)
HD GOLI SC + MTX		3.20 (1.30,7.77)	1.99 (1.17,3.54)	0.26 (0.06,0.45)
HD CERTO SC + MTX		4.47 (1.96,10.26)	2.28 (1.43,4.03)	0.34 (0.15,0.51)
HD ADA SC + MTX		3.73 (1.27,11.82)	2.11 (1.15,3.91)	0.30 (0.05,0.54)
HD TOCI IV + DMARD		0.65 (0.20,2.05)	0.72 (0.28,1.69)	-0.07 (-0.26,0.15)
SD ANA SC + SD ETN SC + MTX		1.69 (0.56,5.21)	1.41 (0.65,2.74)	0.11 (-0.11,0.38)
SD ANA SC + LD ETN SC + MTX		2.53 (0.87,7.62)	1.76 (0.91,3.26)	0.20 (-0.03,0.45)
SD ADA SC	SD ETN SC	0.54 (0.26,1.21)	0.63 (0.37,1.15)	-0.11 (-0.26,0.03)
SD TOFA PO		0.94 (0.39,2.37)	0.96 (0.51,1.81)	-0.01 (-0.20,0.18)

(Continued)

SD GOLI SC	1.19 (0.45,3.22)	1.13 (0.57,2.06)	0.04 (-0.16,0.27)
SD GOLI IV	0.94 (0.35,2.46)	0.96 (0.44,1.73)	-0.01 (-0.19,0.21)
SD TOCI IV	0.80 (0.33,1.87)	0.85 (0.42,1.50)	-0.04 (-0.21,0.14)
SD RITUX IV	0.37 (0.05,1.82)	0.46 (0.07,1.45)	-0.16 (-0.33,0.14)
SD ABA SC	1.47 (0.32,7.50)	1.28 (0.44,3.01)	0.09 (-0.21,0.46)
SD CERTO SC	1.39 (0.37,6.41)	1.24 (0.48,2.90)	0.07 (-0.20,0.42)
SD ETN SC + MTX	2.17 (1.40,3.36)	1.58 (1.23,2.08)	0.18 (0.08,0.29)
SD INF IV + MTX	1.64 (0.92,2.82)	1.36 (0.95,1.89)	0.11 (-0.02,0.24)
SD ABA IV + MTX	2.12 (1.15,3.75)	1.56 (1.10,2.16)	0.17 (0.03,0.31)
SD ADA SC + MTX	3.31 (1.70,6.75)	1.91 (1.35,2.69)	0.28 (0.12,0.44)
SD CERTO SC + MTX/ CERTO+ MTX	3.04 (1.63,5.70)	1.84 (1.34,2.61)	0.26 (0.11,0.41)
SD RITUX IV + MTX	1.32 (0.71,2.58)	1.20 (0.78,1.80)	0.06 (-0.07,0.22)
SD TOFA PO + MTX	3.40 (1.68,7.11)	1.93 (1.35,2.80)	0.29 (0.12,0.45)
SD GOLI SC + MTX	3.32 (1.58,7.24)	1.91 (1.31,2.84)	0.28 (0.10,0.45)
SD ABA SC + MTX	2.64 (1.14,5.82)	1.73 (1.08,2.55)	0.23 (0.03,0.41)
SD GOLI IV + MTX	1.25 (0.57,2.80)	1.15 (0.67,1.88)	0.05 (-0.11,0.24)
SD ANA SC + MTX	1.57 (0.61,3.87)	1.34 (0.69,2.14)	0.10 (-0.10,0.31)
SD TOCI IV + MTX	1.11 (0.38,2.98)	1.07 (0.48,1.95)	0.02 (-0.18,0.25)
SD CERTO SC + DMARD	0.76 (0.25,2.22)	0.82 (0.35,1.67)	-0.05 (-0.25,0.18)
SD ADA SC + DMARD	0.45 (0.13,1.55)	0.54 (0.19,1.34)	-0.14 (-0.30,0.09)
SD ETN SC + DMARD	1.85 (0.75,4.62)	1.45 (0.83,2.34)	0.14 (-0.06,0.36)
SD TOCI SC + DMARD	0.72 (0.21,2.47)	0.79 (0.29,1.73)	-0.06 (-0.25,0.21)
LD ADA SC	0.49 (0.19,1.33)	0.59 (0.28,1.23)	-0.13 (-0.29,0.05)
LD ETN SC	0.51 (0.27,0.93)	0.61 (0.37,0.95)	-0.12 (-0.23,-0.01)
LD GOLI IV	0.57 (0.18,1.64)	0.66 (0.26,1.38)	-0.10 (-0.26,0.10)
LD TOCI IV	0.09 (0.02,0.36)	0.13 (0.03,0.45)	-0.26 (-0.39,-0.14)
LD ADA SC + MTX	2.39 (1.11,5.53)	1.65 (1.07,2.47)	0.20 (0.02,0.40)
LD RITUX IV + MTX	1.17 (0.58,2.22)	1.11 (0.68,1.66)	0.03 (-0.11,0.18)

(Continued)

LD ADA IV + MTX		2.15 (0.35,11.91)	1.57 (0.44,3.05)	0.18 (-0.17,0.53)
LD ABA IV + MTX		1.13 (0.52,2.52)	1.09 (0.62,1.74)	0.03 (-0.12,0.21)
LD ANA SC + MTX		1.07 (0.27,4.40)	1.05 (0.34,2.22)	0.01 (-0.22,0.35)
LD CERTO SC + MTX		2.15 (0.78,5.93)	1.57 (0.84,2.51)	0.18 (-0.05,0.41)
LD ETN SC + MTX		1.92 (0.79,4.40)	1.48 (0.85,2.26)	0.15 (-0.05,0.35)
LD GOLI IV + MTX		1.11 (0.40,3.11)	1.07 (0.50,1.95)	0.02 (-0.17,0.27)
LD TOCI IV + MTX		0.88 (0.31,2.38)	0.92 (0.40,1.72)	-0.03 (-0.21,0.20)
LD TOFA PO + MTX		1.87 (0.52,6.29)	1.46 (0.61,2.61)	0.14 (-0.12,0.42)
HD TOCI IV		1.41 (0.79,2.48)	1.25 (0.86,1.82)	0.08 (-0.05,0.21)
HD TOFA PO		1.52 (0.60,3.60)	1.31 (0.71,2.27)	0.09 (-0.11,0.29)
HD ADA SC		0.69 (0.28,1.87)	0.76 (0.40,1.56)	-0.07 (-0.25,0.13)
HD ETN SC		1.04 (0.53,2.06)	1.03 (0.63,1.57)	0.01 (-0.12,0.17)
HD GOLI SC		1.38 (0.63,3.12)	1.23 (0.72,2.01)	0.07 (-0.10,0.26)
HD ABA SC		2.11 (0.46,10.73)	1.56 (0.58,3.37)	0.17 (-0.16,0.52)
HD INF IV + MTX		2.66 (1.38,5.23)	1.74 (1.21,2.50)	0.23 (0.07,0.38)
HD TOCI IV + MTX		2.51 (1.36,4.86)	1.70 (1.20,2.49)	0.22 (0.07,0.36)
HD TOFA PO + MTX		2.73 (1.35,5.74)	1.76 (1.21,2.59)	0.23 (0.07,0.40)
HD GOLI SC + MTX		2.60 (1.22,5.76)	1.72 (1.14,2.58)	0.22 (0.04,0.41)
HD CERTO SC + MTX		3.63 (1.87,7.36)	1.98 (1.42,2.86)	0.31 (0.14,0.45)
HD ADA SC + MTX		3.03 (1.06,8.85)	1.84 (1.03,2.87)	0.26 (0.01,0.48)
HD TOCI IV + DMARD		0.52 (0.19,1.50)	0.62 (0.26,1.31)	-0.11 (-0.27,0.09)
SD ANA SC + SD ETN SC + MTX		1.36 (0.47,4.22)	1.22 (0.57,2.16)	0.07 (-0.14,0.34)
SD ANA SC + LD ETN SC + MTX		2.05 (0.69,5.80)	1.53 (0.77,2.52)	0.17 (-0.07,0.40)
SD TOFA PO	SD ADA SC	1.73 (0.80,3.81)	1.51 (0.85,2.66)	0.10 (-0.04,0.26)
SD GOLI SC		2.16 (0.74,6.48)	1.75 (0.78,3.50)	0.15 (-0.05,0.39)
SD GOLI IV		1.73 (0.54,5.57)	1.51 (0.61,3.22)	0.10 (-0.09,0.35)
SD TOCI IV		1.46 (0.57,3.69)	1.34 (0.63,2.60)	0.07 (-0.09,0.26)



(Continued)

SD RITUX IV	0.67 (0.08,3.59)	0.72 (0.09,2.47)	-0.05 (-0.20,0.26)
SD ABA SC	2.74 (0.62,13.53)	2.03 (0.68,4.74)	0.20 (-0.07,0.55)
SD CERTO SC	2.59 (0.71,10.10)	1.98 (0.76,4.10)	0.19 (-0.06,0.50)
SD ETN SC + MTX	3.97 (1.77,8.94)	2.49 (1.47,4.16)	0.29 (0.12,0.47)
SD INF IV + MTX	3.00 (1.21,7.15)	2.13 (1.16,3.72)	0.22 (0.04,0.42)
SD ABA IV + MTX	3.88 (1.60,9.17)	2.46 (1.40,4.19)	0.29 (0.09,0.47)
SD ADA SC + MTX	6.24 (2.30,15.44)	3.04 (1.70,4.99)	0.41 (0.17,0.58)
SD CERTO SC + MTX/ CERTO+ MTX	5.69 (2.20,14.03)	2.92 (1.70,4.87)	0.38 (0.16,0.56)
SD RITUX IV + MTX	2.46 (0.94,5.83)	1.91 (0.95,3.29)	0.18 (-0.01,0.37)
SD TOFA PO + MTX	6.34 (2.41,15.58)	3.06 (1.76,4.98)	0.41 (0.19,0.59)
SD GOLI SC + MTX	6.17 (2.25,17.16)	3.03 (1.73,5.10)	0.40 (0.17,0.60)
SD ABA SC + MTX	4.84 (1.63,13.02)	2.74 (1.41,4.62)	0.34 (0.10,0.55)
SD GOLI IV + MTX	2.29 (0.81,6.37)	1.82 (0.85,3.44)	0.16 (-0.03,0.39)
SD ANA SC + MTX	2.90 (0.91,8.36)	2.10 (0.93,3.88)	0.22 (-0.02,0.46)
SD TOCI IV + MTX	2.01 (0.67,6.11)	1.67 (0.72,3.44)	0.13 (-0.06,0.39)
SD CERTO SC + DMARD	1.37 (0.47,4.26)	1.27 (0.53,2.75)	0.05 (-0.11,0.29)
SD ADA SC + DMARD	0.83 (0.20,3.18)	0.86 (0.24,2.33)	-0.03 (-0.18,0.22)
SD ETN SC + DMARD	3.42 (1.09,10.90)	2.31 (1.06,4.23)	0.26 (0.01,0.51)
SD TOCI SC + DMARD	1.32 (0.33,5.23)	1.25 (0.39,3.03)	0.05 (-0.14,0.35)
LD ADA SC	0.91 (0.44,1.87)	0.92 (0.50,1.63)	-0.01 (-0.11,0.11)
LD ETN SC	0.94 (0.37,2.19)	0.95 (0.44,1.85)	-0.01 (-0.14,0.14)
LD GOLI IV	1.03 (0.29,3.53)	1.03 (0.35,2.47)	0.01 (-0.15,0.25)
LD TOCI IV	0.18 (0.03,0.73)	0.21 (0.04,0.76)	-0.15 (-0.25,-0.04)
LD ADA SC + MTX	4.38 (1.60,12.11)	2.63 (1.40,4.53)	0.32 (0.10,0.54)
LD RITUX IV + MTX	2.15 (0.81,5.17)	1.74 (0.85,3.15)	0.15 (-0.04,0.34)
LD ADA IV + MTX	3.98 (0.57,20.80)	2.50 (0.63,4.94)	0.29 (-0.08,0.63)
LD ABA IV + MTX	2.09 (0.73,5.57)	1.72 (0.78,3.24)	0.14 (-0.05,0.36)
LD ANA SC + MTX	1.93 (0.41,8.78)	1.63 (0.47,3.77)	0.12 (-0.11,0.47)

(Continued)

LD CERTO SC + MTX		3.97 (1.19,13.41)	2.50 (1.13,4.56)	0.29 (0.03,0.56)
LD ETN SC + MTX		3.49 (1.19,10.53)	2.34 (1.14,4.20)	0.26 (0.03,0.52)
LD GOLI IV + MTX		2.02 (0.65,6.88)	1.67 (0.71,3.59)	0.13 (-0.06,0.41)
LD TOCI IV + MTX		1.63 (0.51,4.73)	1.45 (0.57,3.02)	0.09 (-0.10,0.32)
LD TOFA PO + MTX		3.39 (0.77,13.20)	2.30 (0.81,4.47)	0.26 (-0.04,0.56)
HD TOCI IV		2.61 (1.25,5.23)	1.98 (1.18,3.19)	0.19 (0.04,0.34)
HD TOFA PO		2.75 (1.23,5.94)	2.05 (1.17,3.40)	0.20 (0.04,0.37)
HD ADA SC		1.28 (0.63,2.69)	1.21 (0.69,2.09)	0.04 (-0.07,0.19)
HD ETN SC		1.93 (0.72,5.18)	1.63 (0.77,3.17)	0.12 (-0.05,0.34)
HD GOLI SC		2.56 (0.98,6.77)	1.94 (0.98,3.62)	0.19 (0.00,0.40)
HD ABA SC		3.84 (0.91,19.43)	2.44 (0.94,5.29)	0.28 (-0.02,0.62)
HD INF IV + MTX		4.86 (1.92,12.96)	2.74 (1.57,4.72)	0.34 (0.13,0.55)
HD TOCI IV + MTX		4.65 (1.91,10.77)	2.70 (1.56,4.51)	0.33 (0.13,0.51)
HD TOFA PO + MTX		5.09 (1.99,12.40)	2.81 (1.58,4.58)	0.35 (0.14,0.54)
HD GOLI SC + MTX		4.81 (1.72,13.21)	2.73 (1.46,4.72)	0.34 (0.11,0.55)
HD CERTO SC + MTX		6.80 (2.61,16.93)	3.14 (1.85,5.20)	0.42 (0.20,0.60)
HD ADA SC + MTX		5.60 (1.70,19.32)	2.92 (1.47,5.02)	0.38 (0.10,0.62)
HD TOCI IV + DMARD		0.97 (0.30,3.08)	0.98 (0.36,2.26)	0.00 (-0.15,0.22)
SD ANA SC + SD ETN SC + MTX		2.57 (0.75,9.10)	1.94 (0.80,3.91)	0.19 (-0.05,0.47)
SD ANA SC + LD ETN SC + MTX		3.84 (1.10,12.87)	2.46 (1.08,4.53)	0.28 (0.02,0.55)
SD GOLI SC	SD TOFA PO	1.28 (0.39,3.96)	1.18 (0.51,2.41)	0.05 (-0.19,0.31)
SD GOLI IV		1.00 (0.28,3.34)	1.00 (0.38,2.20)	0.00 (-0.23,0.27)
SD TOCI IV		0.83 (0.26,2.48)	0.88 (0.37,1.86)	-0.04 (-0.25,0.19)
SD RITUX IV		0.39 (0.04,2.29)	0.48 (0.06,1.74)	-0.15 (-0.36,0.17)
SD ABA SC		1.58 (0.33,8.35)	1.34 (0.44,3.11)	0.10 (-0.21,0.48)
SD CERTO SC		1.51 (0.38,6.32)	1.31 (0.50,2.84)	0.09 (-0.19,0.42)
SD ETN SC + MTX		2.31 (0.88,6.26)	1.66 (0.93,3.01)	0.19 (-0.03,0.41)

(Continued)

SD INF IV + MTX	1.72 (0.62,4.76)	1.41 (0.73,2.69)	0.12 (-0.11,0.35)
SD ABA IV + MTX	2.24 (0.80,6.24)	1.63 (0.86,3.03)	0.19 (-0.05,0.41)
SD ADA SC + MTX	3.55 (1.17,10.48)	2.01 (1.10,3.61)	0.30 (0.04,0.52)
SD CERTO SC + MTX/ CERTO+ MTX	3.21 (1.12,9.16)	1.92 (1.07,3.46)	0.28 (0.03,0.50)
SD RITUX IV + MTX	1.42 (0.46,3.90)	1.26 (0.59,2.42)	0.08 (-0.16,0.30)
SD TOFA PO + MTX	3.60 (1.19,10.34)	2.02 (1.11,3.62)	0.30 (0.04,0.52)
SD GOLI SC + MTX	3.58 (1.17,10.70)	2.01 (1.09,3.64)	0.30 (0.04,0.52)
SD ABA SC + MTX	2.78 (0.88,8.76)	1.81 (0.92,3.33)	0.24 (-0.03,0.49)
SD GOLI IV + MTX	1.31 (0.42,4.18)	1.19 (0.54,2.50)	0.06 (-0.18,0.32)
SD ANA SC + MTX	1.64 (0.51,5.60)	1.36 (0.62,2.80)	0.11 (-0.14,0.39)
SD TOCI IV + MTX	1.17 (0.33,4.14)	1.11 (0.44,2.43)	0.03 (-0.21,0.32)
SD CERTO SC + DMARD	0.79 (0.24,2.75)	0.85 (0.35,1.98)	-0.04 (-0.26,0.22)
SD ADA SC + DMARD	0.47 (0.11,2.03)	0.56 (0.16,1.63)	-0.13 (-0.33,0.15)
SD ETN SC + DMARD	1.95 (0.56,7.17)	1.52 (0.68,3.07)	0.15 (-0.13,0.44)
SD TOCI SC + DMARD	0.77 (0.18,3.11)	0.83 (0.25,2.09)	-0.05 (-0.28,0.25)
LD ADA SC	0.52 (0.20,1.40)	0.61 (0.29,1.29)	-0.11 (-0.29,0.06)
LD ETN SC	0.54 (0.19,1.54)	0.63 (0.28,1.37)	-0.11 (-0.29,0.08)
LD GOLI IV	0.59 (0.15,2.28)	0.68 (0.22,1.74)	-0.09 (-0.31,0.17)
LD TOCI IV	0.10 (0.01,0.46)	0.14 (0.02,0.53)	-0.25 (-0.41,-0.10)
LD ADA SC + MTX	2.57 (0.85,8.46)	1.74 (0.90,3.31)	0.22 (-0.04,0.48)
LD RITUX IV + MTX	1.24 (0.40,3.55)	1.16 (0.52,2.31)	0.05 (-0.18,0.28)
LD ADA IV + MTX	2.27 (0.32,14.64)	1.64 (0.43,3.55)	0.19 (-0.20,0.57)
LD ABA IV + MTX	1.21 (0.37,3.79)	1.14 (0.50,2.34)	0.04 (-0.19,0.30)
LD ANA SC + MTX	1.12 (0.22,5.62)	1.08 (0.31,2.73)	0.02 (-0.25,0.40)
LD CERTO SC + MTX	2.25 (0.63,9.29)	1.62 (0.73,3.32)	0.19 (-0.10,0.50)
LD ETN SC + MTX	2.03 (0.62,7.04)	1.55 (0.72,3.06)	0.16 (-0.10,0.44)
LD GOLI IV + MTX	1.17 (0.32,4.45)	1.11 (0.43,2.48)	0.03 (-0.21,0.33)
LD TOCI IV + MTX	0.94 (0.26,3.11)	0.96 (0.36,2.11)	-0.01 (-0.24,0.25)

(Continued)

LD TOFA PO + MTX		1.95 (0.43,8.36)	1.52 (0.52,3.23)	0.15 (-0.16,0.48)
HD TOCI IV		1.49 (0.60,3.77)	1.30 (0.71,2.41)	0.09 (-0.12,0.29)
HD TOFA PO		1.59 (0.88,2.79)	1.35 (0.92,1.97)	0.10 (-0.03,0.23)
HD ADA SC		0.74 (0.27,2.01)	0.80 (0.38,1.65)	-0.06 (-0.25,0.14)
HD ETN SC		1.09 (0.37,3.48)	1.06 (0.49,2.27)	0.02 (-0.19,0.27)
HD GOLI SC		1.49 (0.49,4.16)	1.30 (0.61,2.50)	0.09 (-0.15,0.32)
HD ABA SC		2.25 (0.47,11.73)	1.63 (0.60,3.46)	0.19 (-0.15,0.54)
HD INF IV + MTX		2.79 (0.94,8.38)	1.80 (0.96,3.31)	0.24 (-0.01,0.48)
HD TOCI IV + MTX		2.70 (1.00,7.10)	1.77 (1.00,3.19)	0.23 (0.00,0.44)
HD TOFA PO + MTX		2.92 (1.00,8.04)	1.84 (1.00,3.29)	0.25 (0.00,0.47)
HD GOLI SC + MTX		2.76 (0.89,8.24)	1.80 (0.93,3.29)	0.24 (-0.03,0.47)
HD CERTO SC + MTX		3.88 (1.33,11.44)	2.07 (1.18,3.68)	0.32 (0.07,0.54)
HD ADA SC + MTX		3.20 (0.82,13.02)	1.91 (0.88,3.63)	0.27 (-0.05,0.56)
HD TOCI IV + DMARD		0.56 (0.15,2.04)	0.65 (0.22,1.67)	-0.10 (-0.31,0.15)
SD ANA SC + SD ETN SC + MTX		1.47 (0.37,6.12)	1.29 (0.49,2.85)	0.09 (-0.19,0.41)
SD ANA SC + LD ETN SC + MTX		2.15 (0.57,8.30)	1.59 (0.67,3.30)	0.18 (-0.12,0.48)
SD GOLI IV	SD GOLI SC	0.79 (0.27,2.32)	0.86 (0.40,1.74)	-0.05 (-0.27,0.18)
SD TOCI IV		0.66 (0.21,2.27)	0.75 (0.34,1.81)	-0.09 (-0.34,0.16)
SD RITUX IV		0.31 (0.04,1.82)	0.41 (0.06,1.50)	-0.19 (-0.45,0.12)
SD ABA SC		1.23 (0.23,7.46)	1.14 (0.37,3.15)	0.05 (-0.31,0.46)
SD CERTO SC		1.17 (0.27,5.93)	1.11 (0.42,2.89)	0.04 (-0.29,0.40)
SD ETN SC + MTX		1.83 (0.66,5.08)	1.42 (0.80,2.76)	0.14 (-0.10,0.36)
SD INF IV + MTX		1.38 (0.48,3.74)	1.21 (0.65,2.39)	0.07 (-0.17,0.29)
SD ABA IV + MTX		1.81 (0.63,4.85)	1.40 (0.78,2.69)	0.14 (-0.11,0.36)
SD ADA SC + MTX		2.82 (0.93,8.79)	1.71 (0.96,3.35)	0.24 (-0.02,0.49)
SD CERTO SC + MTX/ CERTO+ MTX		2.60 (0.90,7.38)	1.65 (0.95,3.25)	0.22 (-0.03,0.45)
SD RITUX IV + MTX		1.12 (0.38,3.30)	1.07 (0.55,2.20)	0.02 (-0.22,0.26)

(Continued)

SD TOFA PO + MTX	2.85 (0.96,8.93)	1.72 (0.98,3.43)	0.25 (-0.01,0.49)
SD GOLI SC + MTX	2.81 (1.00,8.35)	1.71 (1.00,3.33)	0.24 (0.00,0.48)
SD ABA SC + MTX	2.22 (0.68,7.31)	1.55 (0.81,3.11)	0.19 (-0.09,0.45)
SD GOLI IV + MTX	1.05 (0.36,3.21)	1.03 (0.51,2.15)	0.01 (-0.23,0.25)
SD ANA SC + MTX	1.31 (0.35,4.50)	1.18 (0.52,2.57)	0.06 (-0.23,0.34)
SD TOCI IV + MTX	0.93 (0.24,3.45)	0.96 (0.37,2.25)	-0.02 (-0.31,0.28)
SD CERTO SC + DMARD	0.64 (0.17,2.49)	0.74 (0.29,1.85)	-0.09 (-0.37,0.19)
SD ADA SC + DMARD	0.37 (0.08,1.82)	0.48 (0.14,1.52)	-0.17 (-0.43,0.12)
SD ETN SC + DMARD	1.57 (0.42,6.01)	1.30 (0.58,2.82)	0.10 (-0.20,0.41)
SD TOCI SC + DMARD	0.61 (0.13,2.73)	0.71 (0.22,1.87)	-0.10 (-0.37,0.21)
LD ADA SC	0.41 (0.13,1.46)	0.52 (0.23,1.33)	-0.16 (-0.42,0.06)
LD ETN SC	0.43 (0.14,1.26)	0.54 (0.26,1.19)	-0.16 (-0.39,0.04)
LD GOLI IV	0.48 (0.13,1.70)	0.59 (0.22,1.45)	-0.14 (-0.38,0.11)
LD TOCI IV	0.08 (0.01,0.41)	0.12 (0.02,0.49)	-0.30 (-0.53,-0.11)
LD ADA SC + MTX	2.00 (0.62,6.80)	1.47 (0.77,3.04)	0.16 (-0.11,0.43)
LD RITUX IV + MTX	0.99 (0.32,2.88)	0.99 (0.49,2.06)	0.00 (-0.26,0.23)
LD ADA IV + MTX	1.79 (0.24,12.52)	1.39 (0.34,3.44)	0.13 (-0.27,0.55)
LD ABA IV + MTX	0.97 (0.31,2.94)	0.98 (0.46,2.08)	-0.01 (-0.27,0.24)
LD ANA SC + MTX	0.91 (0.17,4.98)	0.94 (0.27,2.51)	-0.02 (-0.34,0.36)
LD CERTO SC + MTX	1.81 (0.47,7.41)	1.40 (0.63,3.14)	0.14 (-0.17,0.45)
LD ETN SC + MTX	1.61 (0.48,5.33)	1.32 (0.64,2.73)	0.11 (-0.17,0.38)
LD GOLI IV + MTX	0.94 (0.29,3.21)	0.96 (0.42,2.09)	-0.01 (-0.26,0.27)
LD TOCI IV + MTX	0.74 (0.20,2.81)	0.81 (0.32,2.03)	-0.06 (-0.33,0.22)
LD TOFA PO + MTX	1.58 (0.33,6.53)	1.30 (0.48,2.88)	0.10 (-0.23,0.43)
HD TOCI IV	1.20 (0.41,3.21)	1.12 (0.60,2.24)	0.04 (-0.21,0.25)
HD TOFA PO	1.26 (0.41,4.19)	1.15 (0.59,2.63)	0.05 (-0.22,0.30)
HD ADA SC	0.58 (0.18,2.03)	0.69 (0.31,1.68)	-0.11 (-0.37,0.14)
HD ETN SC	0.87 (0.28,2.82)	0.91 (0.44,2.00)	-0.03 (-0.28,0.23)

(Continued)

HD GOLI SC		1.18 (0.48,2.78)	1.10 (0.64,1.98)	0.04 (-0.17,0.22)
HD ABA SC		1.76 (0.34,10.96)	1.38 (0.50,3.52)	0.13 (-0.25,0.52)
HD INF IV + MTX		2.25 (0.72,6.53)	1.56 (0.84,3.12)	0.19 (-0.08,0.42)
HD TOCI IV + MTX		2.13 (0.73,6.30)	1.52 (0.85,3.04)	0.18 (-0.08,0.41)
HD TOFA PO + MTX		2.28 (0.77,7.15)	1.57 (0.87,3.11)	0.20 (-0.06,0.44)
HD GOLI SC + MTX		2.16 (0.72,6.83)	1.52 (0.84,3.02)	0.18 (-0.08,0.44)
HD CERTO SC + MTX		3.09 (1.03,9.34)	1.78 (1.01,3.48)	0.27 (0.01,0.49)
HD ADA SC + MTX		2.52 (0.70,9.68)	1.63 (0.81,3.35)	0.22 (-0.09,0.51)
HD TOCI IV + DMARD		0.44 (0.11,1.76)	0.55 (0.20,1.47)	-0.15 (-0.41,0.11)
SD ANA SC + SD ETN SC + MTX		1.16 (0.27,4.95)	1.10 (0.42,2.57)	0.03 (-0.28,0.36)
SD ANA SC + LD ETN SC + MTX		1.79 (0.40,7.49)	1.38 (0.56,3.08)	0.13 (-0.20,0.45)
SD TOCI IV	SD GOLI IV	0.83 (0.26,2.80)	0.87 (0.39,2.13)	-0.04 (-0.29,0.19)
SD RITUX IV		0.39 (0.05,2.29)	0.48 (0.07,1.73)	-0.14 (-0.40,0.16)
SD ABA SC		1.63 (0.26,9.41)	1.37 (0.40,3.98)	0.10 (-0.27,0.49)
SD CERTO SC		1.48 (0.32,8.09)	1.29 (0.46,3.71)	0.09 (-0.24,0.44)
SD ETN SC + MTX		2.28 (0.88,6.42)	1.64 (0.94,3.63)	0.19 (-0.03,0.39)
SD INF IV + MTX		1.70 (0.67,4.67)	1.40 (0.79,2.89)	0.12 (-0.10,0.33)
SD ABA IV + MTX		2.24 (0.87,6.17)	1.63 (0.93,3.39)	0.18 (-0.03,0.39)
SD ADA SC + MTX		3.55 (1.26,10.41)	1.99 (1.12,4.15)	0.29 (0.06,0.51)
SD CERTO SC + MTX/ CERTO+ MTX		3.21 (1.20,8.69)	1.92 (1.09,4.00)	0.27 (0.04,0.47)
SD RITUX IV + MTX		1.41 (0.50,4.00)	1.26 (0.65,2.66)	0.07 (-0.16,0.28)
SD TOFA PO + MTX		3.55 (1.29,10.77)	2.00 (1.12,4.38)	0.29 (0.06,0.51)
SD GOLI SC + MTX		3.56 (1.23,10.36)	1.99 (1.11,4.27)	0.29 (0.05,0.51)
SD ABA SC + MTX		2.72 (0.91,9.50)	1.79 (0.94,3.99)	0.23 (-0.02,0.49)
SD GOLI IV + MTX		1.31 (0.54,3.34)	1.19 (0.68,2.33)	0.06 (-0.13,0.25)
SD ANA SC + MTX		1.67 (0.49,5.35)	1.37 (0.64,3.00)	0.11 (-0.16,0.36)
SD TOCI IV + MTX		1.19 (0.31,4.64)	1.12 (0.44,2.77)	0.03 (-0.24,0.32)



(Continued)

SD CERTO SC + DMARD	0.79 (0.20,3.39)	0.85 (0.32,2.40)	-0.04 (-0.33,0.24)
SD ADA SC + DMARD	0.48 (0.11,2.21)	0.58 (0.17,1.78)	-0.12 (-0.39,0.15)
SD ETN SC + DMARD	1.96 (0.55,7.94)	1.51 (0.68,3.70)	0.15 (-0.13,0.44)
SD TOCI SC + DMARD	0.79 (0.17,3.47)	0.84 (0.25,2.36)	-0.04 (-0.33,0.26)
LD ADA SC	0.52 (0.14,1.85)	0.61 (0.25,1.66)	-0.11 (-0.38,0.10)
LD ETN SC	0.54 (0.19,1.60)	0.63 (0.30,1.47)	-0.11 (-0.33,0.07)
LD GOLIV	0.59 (0.21,1.72)	0.68 (0.29,1.48)	-0.09 (-0.29,0.10)
LD TOCI IV	0.10 (0.02,0.49)	0.14 (0.03,0.56)	-0.25 (-0.49,-0.07)
LD ADA SC + MTX	2.49 (0.83,7.83)	1.72 (0.90,3.79)	0.21 (-0.04,0.45)
LD RITUX IV + MTX	1.24 (0.43,3.66)	1.16 (0.59,2.45)	0.04 (-0.19,0.26)
LD ADA IV + MTX	2.30 (0.30,14.83)	1.62 (0.41,4.17)	0.18 (-0.23,0.57)
LD ABA IV + MTX	1.21 (0.41,3.57)	1.13 (0.56,2.47)	0.04 (-0.19,0.26)
LD ANA SC + MTX	1.12 (0.23,5.89)	1.07 (0.34,2.99)	0.02 (-0.27,0.39)
LD CERTO SC + MTX	2.26 (0.63,8.62)	1.62 (0.75,3.71)	0.18 (-0.10,0.47)
LD ETN SC + MTX	2.03 (0.63,7.01)	1.53 (0.76,3.42)	0.16 (-0.10,0.41)
LD GOLIV + MTX	1.18 (0.46,3.15)	1.12 (0.57,2.25)	0.03 (-0.16,0.25)
LD TOCI IV + MTX	0.94 (0.26,3.34)	0.96 (0.38,2.39)	-0.01 (-0.27,0.25)
LD TOFA PO + MTX	2.02 (0.44,8.07)	1.51 (0.56,3.52)	0.15 (-0.17,0.46)
HD TOCI IV	1.50 (0.54,4.28)	1.30 (0.71,2.87)	0.09 (-0.14,0.29)
HD TOFA PO	1.60 (0.48,5.54)	1.36 (0.65,3.33)	0.10 (-0.17,0.34)
HD ADA SC	0.73 (0.21,2.66)	0.80 (0.34,2.12)	-0.06 (-0.33,0.17)
HD ETN SC	1.09 (0.37,3.65)	1.06 (0.52,2.44)	0.02 (-0.22,0.26)
HD GOLIV	1.47 (0.51,4.28)	1.29 (0.67,2.79)	0.08 (-0.15,0.30)
HD ABA SC	2.28 (0.36,13.60)	1.62 (0.52,4.64)	0.18 (-0.22,0.56)
HD INF IV + MTX	2.77 (1.02,8.60)	1.80 (1.01,3.88)	0.23 (0.01,0.46)
HD TOCI IV + MTX	2.69 (0.97,7.55)	1.78 (0.99,3.80)	0.23 (-0.01,0.44)
HD TOFA PO + MTX	2.88 (1.00,8.48)	1.83 (1.00,3.88)	0.24 (0.00,0.47)
HD GOLIV + MTX	2.74 (0.95,8.32)	1.78 (0.97,3.84)	0.23 (-0.01,0.47)

(Continued)

HD CERTO SC + MTX		3.91 (1.39,11.12)	2.06 (1.18,4.46)	0.31 (0.08,0.52)
HD ADA SC + MTX		3.20 (0.89,12.30)	1.90 (0.93,4.33)	0.26 (-0.03,0.54)
HD TOCI IV + DMARD		0.55 (0.14,2.36)	0.64 (0.23,1.86)	-0.10 (-0.36,0.15)
SD ANA SC + SD ETN SC + MTX		1.46 (0.38,6.28)	1.28 (0.50,3.21)	0.08 (-0.21,0.40)
SD ANA SC + LD ETN SC + MTX		2.17 (0.55,8.79)	1.59 (0.66,3.83)	0.18 (-0.13,0.47)
SD RITUX IV	SD TOCI IV	0.45 (0.06,2.62)	0.54 (0.08,1.98)	-0.12 (-0.33,0.20)
SD ABA SC		1.83 (0.36,11.86)	1.48 (0.46,4.33)	0.13 (-0.20,0.53)
SD CERTO SC		1.75 (0.41,9.08)	1.45 (0.52,3.98)	0.12 (-0.18,0.47)
SD ETN SC + MTX		2.71 (1.13,6.78)	1.86 (1.08,3.65)	0.22 (0.03,0.40)
SD INF IV + MTX		2.07 (0.83,5.17)	1.60 (0.89,3.10)	0.16 (-0.04,0.34)
SD ABA IV + MTX		2.66 (1.08,6.74)	1.83 (1.05,3.55)	0.22 (0.02,0.41)
SD ADA SC + MTX		4.19 (1.58,11.07)	2.25 (1.29,4.30)	0.32 (0.11,0.53)
SD CERTO SC + MTX/ CERTO+ MTX		3.84 (1.57,9.46)	2.17 (1.27,4.19)	0.31 (0.10,0.49)
SD RITUX IV + MTX		1.67 (0.63,4.23)	1.42 (0.73,2.79)	0.11 (-0.09,0.30)
SD TOFA PO + MTX		4.31 (1.65,11.31)	2.27 (1.30,4.39)	0.33 (0.12,0.52)
SD GOLI SC + MTX		4.24 (1.56,11.54)	2.27 (1.29,4.37)	0.33 (0.10,0.53)
SD ABA SC + MTX		3.33 (1.10,9.34)	2.05 (1.06,3.99)	0.27 (0.02,0.49)
SD GOLI IV + MTX		1.58 (0.54,4.50)	1.36 (0.65,2.81)	0.09 (-0.13,0.32)
SD ANA SC + MTX		1.98 (0.63,5.86)	1.56 (0.72,3.19)	0.14 (-0.10,0.39)
SD TOCI IV + MTX		1.40 (0.50,3.81)	1.25 (0.60,2.54)	0.07 (-0.14,0.29)
SD CERTO SC + DMARD		0.95 (0.28,3.40)	0.96 (0.39,2.42)	-0.01 (-0.24,0.24)
SD ADA SC + DMARD		0.56 (0.14,2.34)	0.64 (0.20,1.82)	-0.09 (-0.30,0.16)
SD ETN SC + DMARD		2.36 (0.67,8.14)	1.72 (0.76,3.69)	0.19 (-0.08,0.46)
SD TOCI SC + DMARD		0.90 (0.23,3.50)	0.92 (0.31,2.34)	-0.02 (-0.24,0.26)
LD ADA SC		0.62 (0.21,2.00)	0.69 (0.30,1.73)	-0.08 (-0.28,0.11)
LD ETN SC		0.65 (0.24,1.74)	0.71 (0.35,1.55)	-0.07 (-0.26,0.09)
LD GOLI IV		0.71 (0.18,2.55)	0.77 (0.25,1.98)	-0.06 (-0.27,0.18)

(Continued)

LD TOCI IV	0.12 (0.02,0.49)	0.16 (0.03,0.56)	-0.21 (-0.39,-0.08)	
LD ADA SC + MTX	3.01 (1.09,8.51)	1.94 (1.06,3.83)	0.25 (0.02,0.46)	
LD RITUX IV + MTX	1.46 (0.56,3.80)	1.29 (0.67,2.59)	0.08 (-0.12,0.27)	
LD ADA IV + MTX	2.72 (0.38,15.97)	1.84 (0.47,4.52)	0.22 (-0.16,0.59)	
LD ABA IV + MTX	1.44 (0.51,3.84)	1.28 (0.61,2.59)	0.07 (-0.14,0.29)	
LD ANA SC + MTX	1.33 (0.29,6.67)	1.21 (0.39,3.19)	0.06 (-0.21,0.42)	
LD CERTO SC + MTX	2.71 (0.81,8.99)	1.85 (0.86,3.92)	0.22 (-0.05,0.48)	
LD ETN SC + MTX	2.42 (0.75,7.25)	1.74 (0.82,3.62)	0.19 (-0.06,0.43)	
LD GOLI IV + MTX	1.40 (0.40,4.77)	1.27 (0.52,2.90)	0.07 (-0.18,0.34)	
LD TOCI IV + MTX	1.12 (0.39,3.10)	1.08 (0.49,2.23)	0.02 (-0.17,0.24)	
LD TOFA PO + MTX	2.34 (0.53,9.11)	1.71 (0.64,3.72)	0.19 (-0.12,0.49)	
HD TOCI IV	1.79 (0.85,3.71)	1.48 (0.91,2.63)	0.12 (-0.04,0.26)	
HD TOFA PO	1.91 (0.63,5.76)	1.53 (0.75,3.39)	0.14 (-0.10,0.35)	
HD ADA SC	0.88 (0.29,2.73)	0.91 (0.40,2.16)	-0.02 (-0.24,0.18)	
HD ETN SC	1.29 (0.46,4.11)	1.20 (0.57,2.74)	0.05 (-0.16,0.29)	
HD GOLI SC	1.75 (0.59,4.93)	1.46 (0.71,3.02)	0.12 (-0.11,0.33)	
HD ABA SC	2.61 (0.48,16.78)	1.80 (0.61,5.00)	0.21 (-0.15,0.59)	
HD INF IV + MTX	3.35 (1.30,8.69)	2.04 (1.17,3.95)	0.27 (0.06,0.47)	
HD TOCI IV + MTX	3.21 (1.43,7.28)	2.00 (1.23,3.67)	0.26 (0.09,0.43)	
HD TOFA PO + MTX	3.44 (1.27,9.02)	2.07 (1.15,4.09)	0.28 (0.06,0.48)	
HD GOLI SC + MTX	3.33 (1.18,9.47)	2.03 (1.10,4.00)	0.27 (0.04,0.49)	
HD CERTO SC + MTX	4.62 (1.78,11.81)	2.33 (1.35,4.50)	0.35 (0.14,0.54)	
HD ADA SC + MTX	3.85 (1.10,12.74)	2.16 (1.06,4.37)	0.30 (0.02,0.55)	
HD TOCI IV + DMARD	0.66 (0.21,2.26)	0.72 (0.28,1.82)	-0.07 (-0.27,0.16)	
SD ANA SC + SD ETN SC + MTX	1.74 (0.48,6.36)	1.46 (0.59,3.25)	0.12 (-0.14,0.41)	
SD ANA SC + LD ETN SC + MTX	2.63 (0.69,9.59)	1.82 (0.77,3.86)	0.21 (-0.08,0.48)	
SD ABA SC	SD RITUX IV	4.21 (0.44,42.54)	2.76 (0.56,19.85)	0.25 (-0.16,0.61)

(Continued)

SD CERTO SC	3.74 (0.53,50.05)	2.65 (0.64,23.72)	0.23 (-0.13,0.57)
SD ETN SC + MTX	5.89 (1.18,42.29)	3.44 (1.09,22.67)	0.34 (0.04,0.53)
SD INF IV + MTX	4.43 (0.91,31.70)	2.94 (0.95,18.79)	0.26 (-0.02,0.47)
SD ABA IV + MTX	5.80 (1.18,40.44)	3.41 (1.10,21.64)	0.33 (0.04,0.55)
SD ADA SC + MTX	8.90 (1.82,65.79)	4.09 (1.35,26.12)	0.43 (0.14,0.66)
SD CERTO SC + MTX/ CERTO+ MTX	8.30 (1.68,59.65)	4.00 (1.29,26.59)	0.42 (0.12,0.62)
SD RITUX IV + MTX	3.56 (0.84,23.14)	2.57 (0.90,15.84)	0.22 (-0.04,0.42)
SD TOFA PO + MTX	9.40 (1.74,68.15)	4.19 (1.31,28.09)	0.44 (0.13,0.65)
SD GOLI SC + MTX	9.13 (1.73,70.86)	4.15 (1.30,28.21)	0.44 (0.13,0.66)
SD ABA SC + MTX	7.12 (1.31,53.91)	3.73 (1.18,24.59)	0.37 (0.06,0.62)
SD GOLI IV + MTX	3.47 (0.62,25.53)	2.49 (0.73,16.35)	0.21 (-0.10,0.45)
SD ANA SC + MTX	4.30 (0.69,35.24)	2.88 (0.81,19.26)	0.26 (-0.08,0.51)
SD TOCI IV + MTX	3.03 (0.48,24.29)	2.31 (0.60,15.65)	0.18 (-0.15,0.46)
SD CERTO SC + DMARD	2.06 (0.34,19.39)	1.77 (0.45,13.85)	0.11 (-0.22,0.35)
SD ADA SC + DMARD	1.26 (0.18,10.65)	1.21 (0.25,8.40)	0.03 (-0.28,0.27)
SD ETN SC + DMARD	5.13 (0.82,40.39)	3.16 (0.90,22.15)	0.29 (-0.04,0.58)
SD TOCI SC + DMARD	1.96 (0.28,17.69)	1.69 (0.38,11.57)	0.09 (-0.22,0.40)
LD ADA SC	1.34 (0.23,11.47)	1.27 (0.33,9.14)	0.04 (-0.28,0.22)
LD ETN SC	1.39 (0.26,10.49)	1.31 (0.38,8.58)	0.04 (-0.26,0.21)
LD GOLI IV	1.55 (0.24,12.86)	1.43 (0.34,9.67)	0.06 (-0.25,0.30)
LD TOCI IV	0.26 (0.03,2.85)	0.30 (0.04,2.65)	-0.09 (-0.40,0.05)
LD ADA SC + MTX	6.43 (1.26,49.13)	3.54 (1.14,24.27)	0.36 (0.05,0.61)
LD RITUX IV + MTX	3.16 (0.66,21.59)	2.40 (0.77,15.27)	0.19 (-0.09,0.39)
LD ADA IV + MTX	5.98 (0.47,90.52)	3.31 (0.58,25.83)	0.33 (-0.13,0.73)
LD ABA IV + MTX	3.14 (0.60,22.91)	2.37 (0.71,15.40)	0.19 (-0.11,0.42)
LD ANA SC + MTX	2.97 (0.35,27.99)	2.24 (0.47,15.55)	0.17 (-0.18,0.53)
LD CERTO SC + MTX	6.02 (0.94,48.13)	3.42 (0.97,23.32)	0.33 (-0.01,0.61)
LD ETN SC + MTX	5.25 (0.87,42.64)	3.19 (0.92,22.59)	0.30 (-0.03,0.56)

(Continued)

LD GOLI IV + MTX		3.07 (0.50,25.30)	2.31 (0.62,16.01)	0.18 (-0.14,0.46)
LD TOCI IV + MTX		2.37 (0.42,19.76)	1.96 (0.53,13.70)	0.13 (-0.17,0.41)
LD TOFA PO + MTX		5.16 (0.70,44.64)	3.14 (0.79,21.06)	0.29 (-0.07,0.61)
HD TOCI IV		3.77 (0.81,28.69)	2.71 (0.88,17.89)	0.23 (-0.05,0.42)
HD TOFA PO		4.12 (0.70,39.19)	2.85 (0.81,21.72)	0.25 (-0.08,0.47)
HD ADA SC		1.90 (0.32,18.13)	1.67 (0.46,13.74)	0.09 (-0.22,0.30)
HD ETN SC		2.85 (0.49,21.62)	2.25 (0.63,14.83)	0.17 (-0.15,0.39)
HD GOLI SC		3.77 (0.70,28.57)	2.68 (0.81,18.53)	0.23 (-0.08,0.45)
HD ABA SC		6.03 (0.63,63.43)	3.37 (0.73,24.85)	0.33 (-0.10,0.67)
HD INF IV + MTX		7.28 (1.39,51.14)	3.77 (1.19,23.86)	0.39 (0.07,0.60)
HD TOCI IV + MTX		6.83 (1.35,52.63)	3.68 (1.17,25.31)	0.37 (0.07,0.58)
HD TOFA PO + MTX		7.46 (1.37,56.14)	3.85 (1.18,26.06)	0.39 (0.07,0.61)
HD GOLI SC + MTX		7.03 (1.24,55.18)	3.72 (1.12,25.45)	0.38 (0.05,0.62)
HD CERTO SC + MTX		10.00 (1.95,75.46)	4.32 (1.39,30.12)	0.46 (0.16,0.67)
HD ADA SC + MTX		8.21 (1.51,71.89)	3.95 (1.21,26.17)	0.41 (0.09,0.69)
HD TOCI IV + DMARD		1.42 (0.23,11.64)	1.33 (0.32,9.34)	0.05 (-0.27,0.27)
SD ANA SC + SD ETN SC + MTX		3.78 (0.55,31.04)	2.64 (0.68,18.20)	0.22 (-0.11,0.54)
SD ANA SC + LD ETN SC + MTX		5.70 (0.81,44.18)	3.32 (0.88,21.37)	0.32 (-0.05,0.62)
SD CERTO SC	SD ABA SC	0.95 (0.15,6.00)	0.97 (0.34,3.23)	-0.01 (-0.43,0.39)
SD ETN SC + MTX		1.47 (0.27,6.88)	1.23 (0.55,3.54)	0.09 (-0.31,0.42)
SD INF IV + MTX		1.12 (0.19,5.26)	1.07 (0.45,3.10)	0.03 (-0.38,0.35)
SD ABA IV + MTX		1.44 (0.26,7.18)	1.22 (0.52,3.63)	0.09 (-0.32,0.42)
SD ADA SC + MTX		2.31 (0.39,11.64)	1.50 (0.68,4.33)	0.20 (-0.22,0.54)
SD CERTO SC + MTX/ CERTO+ MTX		2.07 (0.36,10.29)	1.45 (0.64,4.08)	0.18 (-0.24,0.51)
SD RITUX IV + MTX		0.90 (0.16,4.50)	0.94 (0.37,2.87)	-0.02 (-0.42,0.31)
SD TOFA PO + MTX		2.36 (0.39,12.22)	1.52 (0.68,4.38)	0.20 (-0.21,0.54)
SD GOLI SC + MTX		2.32 (0.39,11.59)	1.49 (0.67,4.31)	0.20 (-0.22,0.53)

(Continued)

SD ABA SC + MTX	1.80 (0.30,9.81)	1.35 (0.58,3.94)	0.14 (-0.29,0.50)
SD GOLI IV + MTX	0.86 (0.14,4.71)	0.91 (0.33,2.85)	-0.03 (-0.44,0.32)
SD ANA SC + MTX	1.05 (0.16,6.47)	1.03 (0.37,3.30)	0.01 (-0.42,0.39)
SD TOCI IV + MTX	0.75 (0.11,4.27)	0.83 (0.28,2.71)	-0.06 (-0.48,0.31)
SD CERTO SC + DMARD	0.52 (0.08,2.85)	0.64 (0.22,2.10)	-0.14 (-0.53,0.20)
SD ADA SC + DMARD	0.30 (0.04,2.06)	0.43 (0.09,1.69)	-0.22 (-0.59,0.14)
SD ETN SC + DMARD	1.27 (0.19,7.51)	1.14 (0.42,3.60)	0.06 (-0.37,0.44)
SD TOCI SC + DMARD	0.49 (0.06,3.27)	0.62 (0.16,2.25)	-0.14 (-0.56,0.25)
LD ADA SC	0.34 (0.06,1.56)	0.46 (0.18,1.42)	-0.21 (-0.57,0.07)
LD ETN SC	0.35 (0.06,1.72)	0.48 (0.18,1.52)	-0.20 (-0.57,0.09)
LD GOLI IV	0.38 (0.05,2.21)	0.51 (0.14,1.80)	-0.19 (-0.59,0.15)
LD TOCI IV	0.06 (0.01,0.47)	0.10 (0.02,0.54)	-0.35 (-0.69,-0.08)
LD ADA SC + MTX	1.60 (0.27,8.88)	1.29 (0.55,3.76)	0.11 (-0.31,0.47)
LD RITUX IV + MTX	0.81 (0.14,4.00)	0.87 (0.33,2.63)	-0.05 (-0.44,0.28)
LD ADA IV + MTX	1.49 (0.12,14.01)	1.23 (0.26,4.12)	0.09 (-0.45,0.56)
LD ABA IV + MTX	0.79 (0.12,4.23)	0.86 (0.30,2.68)	-0.05 (-0.46,0.31)
LD ANA SC + MTX	0.72 (0.09,6.25)	0.82 (0.19,3.03)	-0.07 (-0.52,0.40)
LD CERTO SC + MTX	1.44 (0.22,9.13)	1.21 (0.44,3.75)	0.09 (-0.35,0.48)
LD ETN SC + MTX	1.30 (0.21,7.28)	1.15 (0.45,3.50)	0.06 (-0.36,0.42)
LD GOLI IV + MTX	0.75 (0.11,4.54)	0.84 (0.28,2.79)	-0.06 (-0.47,0.32)
LD TOCI IV + MTX	0.60 (0.09,3.57)	0.72 (0.23,2.38)	-0.11 (-0.52,0.26)
LD TOFA PO + MTX	1.25 (0.16,9.65)	1.13 (0.34,3.72)	0.05 (-0.42,0.48)
HD TOCI IV	0.96 (0.17,4.48)	0.98 (0.41,2.89)	-0.01 (-0.41,0.30)
HD TOFA PO	1.02 (0.20,4.82)	1.01 (0.45,2.95)	0.00 (-0.37,0.32)
HD ADA SC	0.47 (0.09,2.27)	0.59 (0.24,1.83)	-0.16 (-0.53,0.15)
HD ETN SC	0.69 (0.12,3.76)	0.79 (0.30,2.55)	-0.08 (-0.46,0.27)
HD GOLI SC	0.96 (0.16,4.86)	0.97 (0.38,2.96)	-0.01 (-0.42,0.33)
HD ABA SC	1.41 (0.50,4.38)	1.19 (0.67,2.49)	0.08 (-0.16,0.33)



(Continued)

HD INF IV + MTX		1.83 (0.31,9.05)	1.36 (0.59,3.92)	0.14 (-0.28,0.48)
HD TOCI IV + MTX		1.75 (0.29,8.75)	1.34 (0.57,3.87)	0.13 (-0.29,0.46)
HD TOFA PO + MTX		1.86 (0.31,9.51)	1.38 (0.60,3.99)	0.15 (-0.28,0.49)
HD GOLI SC + MTX		1.78 (0.29,9.95)	1.35 (0.57,4.08)	0.14 (-0.29,0.48)
HD CERTO SC + MTX		2.46 (0.44,13.05)	1.55 (0.72,4.43)	0.22 (-0.19,0.55)
HD ADA SC + MTX		2.07 (0.31,11.93)	1.43 (0.57,4.07)	0.17 (-0.27,0.54)
HD TOCI IV + DMARD		0.36 (0.05,2.15)	0.49 (0.13,1.73)	-0.19 (-0.59,0.15)
SD ANA SC + SD ETN SC + MTX		0.95 (0.14,5.66)	0.97 (0.32,2.91)	-0.01 (-0.43,0.38)
SD ANA SC + LD ETN SC + MTX		1.40 (0.21,8.53)	1.20 (0.43,3.59)	0.08 (-0.36,0.47)
SD ETN SC + MTX	SD CERTO SC	1.55 (0.35,6.31)	1.28 (0.58,3.21)	0.10 (-0.26,0.41)
SD INF IV + MTX		1.18 (0.23,4.70)	1.10 (0.45,2.78)	0.04 (-0.35,0.33)
SD ABA IV + MTX		1.55 (0.28,6.56)	1.28 (0.53,3.25)	0.10 (-0.30,0.41)
SD ADA SC + MTX		2.43 (0.44,10.13)	1.55 (0.69,3.86)	0.21 (-0.20,0.51)
SD CERTO SC + MTX/ CERTO+ MTX		2.25 (0.41,9.25)	1.51 (0.67,3.78)	0.19 (-0.21,0.49)
SD RITUX IV + MTX		0.95 (0.19,3.97)	0.97 (0.39,2.56)	-0.01 (-0.38,0.29)
SD TOFA PO + MTX		2.46 (0.45,10.50)	1.56 (0.71,3.83)	0.22 (-0.19,0.52)
SD GOLI SC + MTX		2.43 (0.47,10.61)	1.56 (0.72,3.91)	0.21 (-0.18,0.51)
SD ABA SC + MTX		1.90 (0.35,8.57)	1.40 (0.59,3.58)	0.15 (-0.25,0.47)
SD GOLI IV + MTX		0.91 (0.17,3.93)	0.94 (0.35,2.50)	-0.02 (-0.41,0.29)
SD ANA SC + MTX		1.13 (0.19,5.17)	1.07 (0.38,2.87)	0.03 (-0.38,0.36)
SD TOCI IV + MTX		0.79 (0.14,4.01)	0.86 (0.29,2.49)	-0.05 (-0.44,0.31)
SD CERTO SC + DMARD		0.54 (0.11,2.40)	0.66 (0.24,1.83)	-0.13 (-0.48,0.18)
SD ADA SC + DMARD		0.33 (0.04,1.71)	0.45 (0.10,1.48)	-0.20 (-0.56,0.10)
SD ETN SC + DMARD		1.34 (0.22,6.51)	1.18 (0.45,3.07)	0.07 (-0.34,0.41)
SD TOCI SC + DMARD		0.54 (0.07,2.78)	0.65 (0.17,1.93)	-0.13 (-0.52,0.21)
LD ADA SC		0.35 (0.08,1.39)	0.47 (0.20,1.29)	-0.20 (-0.52,0.06)
LD ETN SC		0.37 (0.08,1.51)	0.49 (0.18,1.36)	-0.19 (-0.52,0.07)

(Continued)

LD GOLI IV	0.40 (0.07,2.05)	0.54 (0.16,1.66)	-0.18 (-0.52,0.15)
LD TOCI IV	0.07 (0.01,0.43)	0.11 (0.02,0.51)	-0.34 (-0.64,-0.10)
LD ADA SC + MTX	1.71 (0.30,7.31)	1.34 (0.56,3.27)	0.13 (-0.28,0.44)
LD RITUX IV + MTX	0.85 (0.15,3.42)	0.90 (0.34,2.34)	-0.04 (-0.42,0.26)
LD ADA IV + MTX	1.55 (0.14,13.76)	1.26 (0.27,3.74)	0.10 (-0.42,0.56)
LD ABA IV + MTX	0.83 (0.15,3.60)	0.89 (0.31,2.39)	-0.04 (-0.43,0.27)
LD ANA SC + MTX	0.79 (0.09,5.35)	0.86 (0.20,2.60)	-0.05 (-0.47,0.37)
LD CERTO SC + MTX	1.57 (0.25,7.88)	1.28 (0.47,3.40)	0.11 (-0.32,0.46)
LD ETN SC + MTX	1.37 (0.24,6.67)	1.20 (0.45,3.19)	0.07 (-0.33,0.42)
LD GOLI IV + MTX	0.79 (0.13,3.92)	0.87 (0.29,2.49)	-0.05 (-0.44,0.30)
LD TOCI IV + MTX	0.65 (0.11,3.09)	0.75 (0.24,2.14)	-0.09 (-0.47,0.24)
LD TOFA PO + MTX	1.38 (0.18,7.25)	1.19 (0.37,3.12)	0.07 (-0.38,0.44)
HD TOCI IV	1.03 (0.22,3.76)	1.02 (0.45,2.52)	0.01 (-0.36,0.27)
HD TOFA PO	1.06 (0.26,4.30)	1.04 (0.50,2.66)	0.01 (-0.32,0.30)
HD ADA SC	0.49 (0.12,2.09)	0.62 (0.27,1.69)	-0.15 (-0.46,0.14)
HD ETN SC	0.75 (0.14,3.26)	0.83 (0.31,2.31)	-0.06 (-0.44,0.24)
HD GOLI SC	1.01 (0.20,4.04)	1.01 (0.41,2.60)	0.00 (-0.37,0.30)
HD ABA SC	1.49 (0.25,9.40)	1.25 (0.44,3.33)	0.09 (-0.31,0.50)
HD INF IV + MTX	1.89 (0.38,7.69)	1.40 (0.63,3.47)	0.15 (-0.24,0.45)
HD TOCI IV + MTX	1.79 (0.38,7.48)	1.37 (0.63,3.45)	0.14 (-0.23,0.44)
HD TOFA PO + MTX	1.95 (0.38,8.22)	1.42 (0.63,3.60)	0.16 (-0.23,0.47)
HD GOLI SC + MTX	1.87 (0.33,8.17)	1.39 (0.58,3.65)	0.15 (-0.26,0.46)
HD CERTO SC + MTX	2.68 (0.51,11.20)	1.61 (0.75,4.02)	0.24 (-0.15,0.53)
HD ADA SC + MTX	2.17 (0.38,11.15)	1.48 (0.61,3.82)	0.18 (-0.23,0.52)
HD TOCI IV + DMARD	0.38 (0.06,1.85)	0.51 (0.15,1.56)	-0.18 (-0.55,0.12)
SD ANA SC + SD ETN SC + MTX	1.01 (0.16,5.44)	1.01 (0.34,2.81)	0.00 (-0.40,0.38)
SD ANA SC + LD ETN SC + MTX	1.49 (0.24,7.93)	1.25 (0.44,3.35)	0.09 (-0.33,0.47)

(Continued)

SD INF IV + MTX	SD ETN SC + MTX	0.76 (0.43,1.28)	0.86 (0.60,1.14)	-0.07 (-0.20,0.06)
SD ABA IV + MTX		0.98 (0.54,1.79)	0.99 (0.71,1.33)	0.00 (-0.15,0.14)
SD ADA SC + MTX		1.52 (0.78,3.23)	1.21 (0.88,1.65)	0.10 (-0.06,0.27)
SD CERTO SC + MTX/ CERTO+ MTX		1.39 (0.76,2.70)	1.16 (0.88,1.59)	0.08 (-0.07,0.24)
SD RITUX IV + MTX		0.61 (0.31,1.21)	0.76 (0.49,1.11)	-0.12 (-0.27,0.05)
SD TOFA PO + MTX		1.57 (0.77,3.31)	1.22 (0.89,1.69)	0.11 (-0.06,0.28)
SD GOL I SC + MTX		1.55 (0.70,3.44)	1.21 (0.83,1.73)	0.10 (-0.09,0.28)
SD ABA SC + MTX		1.21 (0.53,2.65)	1.10 (0.70,1.54)	0.05 (-0.15,0.23)
SD GOL I IV + MTX		0.57 (0.26,1.31)	0.73 (0.43,1.15)	-0.13 (-0.30,0.07)
SD ANA SC + MTX		0.72 (0.26,1.81)	0.84 (0.44,1.33)	-0.08 (-0.30,0.14)
SD TOCI IV + MTX		0.51 (0.18,1.39)	0.68 (0.32,1.19)	-0.16 (-0.38,0.08)
SD CERTO SC + DMARD		0.35 (0.11,1.14)	0.52 (0.22,1.08)	-0.23 (-0.47,0.03)
SD ADA SC + DMARD		0.21 (0.06,0.76)	0.34 (0.11,0.85)	-0.31 (-0.51,-0.06)
SD ETN SC + DMARD		0.86 (0.33,2.27)	0.93 (0.50,1.47)	-0.04 (-0.26,0.20)
SD TOCI SC + DMARD		0.33 (0.10,1.24)	0.50 (0.18,1.12)	-0.24 (-0.45,0.05)
LD ADA SC		0.23 (0.08,0.64)	0.37 (0.18,0.74)	-0.31 (-0.50,-0.10)
LD ETN SC		0.23 (0.12,0.48)	0.38 (0.23,0.63)	-0.30 (-0.45,-0.15)
LD GOL I IV		0.26 (0.08,0.80)	0.41 (0.16,0.88)	-0.28 (-0.47,-0.05)
LD TOCI IV		0.04 (0.01,0.17)	0.08 (0.02,0.28)	-0.44 (-0.60,-0.28)
LD ADA SC + MTX		1.10 (0.50,2.53)	1.05 (0.68,1.51)	0.02 (-0.16,0.22)
LD RITUX IV + MTX		0.54 (0.27,1.04)	0.70 (0.44,1.02)	-0.14 (-0.30,0.01)
LD ADA IV + MTX		0.98 (0.16,5.36)	0.99 (0.28,1.89)	0.00 (-0.36,0.36)
LD ABA IV + MTX		0.52 (0.24,1.15)	0.69 (0.40,1.08)	-0.15 (-0.32,0.04)
LD ANA SC + MTX		0.49 (0.12,2.12)	0.66 (0.21,1.38)	-0.16 (-0.41,0.18)
LD CERTO SC + MTX		1.00 (0.36,2.80)	1.00 (0.53,1.57)	0.00 (-0.23,0.24)
LD ETN SC + MTX		0.88 (0.40,1.93)	0.93 (0.57,1.33)	-0.03 (-0.22,0.15)
LD GOL I IV + MTX		0.52 (0.18,1.45)	0.68 (0.32,1.19)	-0.15 (-0.36,0.09)
LD TOCI IV + MTX		0.41 (0.14,1.14)	0.59 (0.25,1.08)	-0.20 (-0.42,0.03)

(Continued)

LD TOFA PO + MTX		0.85 (0.24,2.97)	0.92 (0.38,1.60)	-0.04 (-0.30,0.25)
HD TOCI IV		0.65 (0.36,1.23)	0.79 (0.56,1.12)	-0.10 (-0.25,0.05)
HD TOFA PO		0.70 (0.26,1.68)	0.82 (0.47,1.34)	-0.09 (-0.32,0.13)
HD ADA SC		0.32 (0.12,0.92)	0.48 (0.25,0.95)	-0.25 (-0.46,-0.02)
HD ETN SC		0.48 (0.22,1.04)	0.65 (0.38,1.02)	-0.17 (-0.34,0.01)
HD GOLI SC		0.64 (0.28,1.48)	0.78 (0.47,1.24)	-0.11 (-0.29,0.09)
HD ABA SC		0.96 (0.21,5.15)	0.98 (0.37,2.00)	-0.01 (-0.35,0.37)
HD INF IV + MTX		1.23 (0.63,2.38)	1.10 (0.78,1.51)	0.05 (-0.11,0.21)
HD TOCI IV + MTX		1.17 (0.59,2.28)	1.08 (0.76,1.49)	0.04 (-0.13,0.20)
HD TOFA PO + MTX		1.26 (0.62,2.64)	1.11 (0.78,1.55)	0.06 (-0.12,0.23)
HD GOLI SC + MTX		1.20 (0.54,2.74)	1.09 (0.71,1.57)	0.04 (-0.15,0.23)
HD CERTO SC + MTX		1.69 (0.83,3.46)	1.25 (0.91,1.73)	0.12 (-0.05,0.29)
HD ADA SC + MTX		1.39 (0.51,3.97)	1.16 (0.68,1.75)	0.08 (-0.16,0.31)
HD TOCI IV + DMARD		0.24 (0.09,0.77)	0.39 (0.16,0.86)	-0.29 (-0.48,-0.06)
SD ANA SC + SD ETN SC + MTX		0.63 (0.24,1.71)	0.78 (0.38,1.26)	-0.11 (-0.31,0.13)
SD ANA SC + LD ETN SC + MTX		0.95 (0.37,2.58)	0.97 (0.52,1.47)	-0.01 (-0.22,0.22)
SD ABA IV + MTX	SD INF IV + MTX	1.30 (0.75,2.23)	1.15 (0.85,1.58)	0.06 (-0.07,0.19)
SD ADA SC + MTX		2.06 (1.02,4.14)	1.41 (1.01,2.07)	0.17 (0.00,0.33)
SD CERTO SC + MTX/ CERTO+ MTX		1.85 (1.00,3.55)	1.35 (1.00,1.92)	0.15 (0.00,0.30)
SD RITUX IV + MTX		0.82 (0.42,1.59)	0.89 (0.58,1.31)	-0.04 (-0.20,0.11)
SD TOFA PO + MTX		2.08 (1.04,4.31)	1.42 (1.02,2.10)	0.18 (0.01,0.34)
SD GOLI SC + MTX		2.04 (0.93,4.39)	1.42 (0.96,2.10)	0.17 (-0.02,0.35)
SD ABA SC + MTX		1.63 (0.72,3.47)	1.28 (0.83,1.89)	0.12 (-0.08,0.29)
SD GOLI IV + MTX		0.77 (0.34,1.71)	0.86 (0.50,1.36)	-0.06 (-0.24,0.13)
SD ANA SC + MTX		0.96 (0.36,2.42)	0.97 (0.52,1.62)	-0.01 (-0.22,0.21)
SD TOCI IV + MTX		0.68 (0.23,1.82)	0.79 (0.37,1.41)	-0.09 (-0.30,0.15)
SD CERTO SC + DMARD		0.46 (0.14,1.58)	0.60 (0.26,1.34)	-0.16 (-0.40,0.10)

(Continued)

SD ADA SC + DMARD	0.28 (0.08,1.04)	0.40 (0.14,1.02)	-0.24 (-0.44,0.01)
SD ETN SC + DMARD	1.14 (0.39,3.45)	1.08 (0.56,1.87)	0.03 (-0.21,0.29)
SD TOCI SC + DMARD	0.44 (0.12,1.72)	0.58 (0.20,1.34)	-0.17 (-0.40,0.13)
LD ADA SC	0.30 (0.11,0.91)	0.43 (0.21,0.94)	-0.24 (-0.44,-0.02)
LD ETN SC	0.31 (0.15,0.68)	0.44 (0.25,0.76)	-0.23 (-0.39,-0.08)
LD GOLIV	0.35 (0.11,1.01)	0.48 (0.19,1.01)	-0.21 (-0.41,0.00)
LD TOCI IV	0.06 (0.01,0.23)	0.10 (0.02,0.33)	-0.37 (-0.56,-0.21)
LD ADA SC + MTX	1.46 (0.70,3.34)	1.21 (0.81,1.83)	0.09 (-0.09,0.28)
LD RITUX IV + MTX	0.71 (0.36,1.41)	0.82 (0.51,1.23)	-0.08 (-0.23,0.08)
LD ADA IV + MTX	1.30 (0.21,7.03)	1.15 (0.32,2.23)	0.06 (-0.29,0.42)
LD ABA IV + MTX	0.70 (0.33,1.51)	0.81 (0.47,1.27)	-0.08 (-0.25,0.10)
LD ANA SC + MTX	0.65 (0.16,2.68)	0.77 (0.25,1.63)	-0.09 (-0.34,0.23)
LD CERTO SC + MTX	1.32 (0.49,3.72)	1.16 (0.64,1.91)	0.07 (-0.16,0.31)
LD ETN SC + MTX	1.18 (0.48,2.76)	1.09 (0.64,1.72)	0.04 (-0.17,0.24)
LD GOLIV + MTX	0.68 (0.24,1.89)	0.80 (0.38,1.43)	-0.08 (-0.29,0.15)
LD TOCI IV + MTX	0.55 (0.18,1.51)	0.68 (0.30,1.28)	-0.13 (-0.35,0.10)
LD TOFA PO + MTX	1.14 (0.33,3.94)	1.07 (0.46,1.90)	0.03 (-0.24,0.32)
HD TOCI IV	0.87 (0.46,1.66)	0.92 (0.65,1.38)	-0.03 (-0.19,0.12)
HD TOFA PO	0.94 (0.33,2.50)	0.96 (0.52,1.73)	-0.02 (-0.26,0.21)
HD ADA SC	0.43 (0.15,1.27)	0.56 (0.28,1.17)	-0.18 (-0.40,0.05)
HD ETN SC	0.65 (0.28,1.51)	0.76 (0.43,1.27)	-0.10 (-0.28,0.10)
HD GOLIV SC	0.85 (0.38,2.01)	0.91 (0.54,1.52)	-0.04 (-0.23,0.17)
HD ABA SC	1.28 (0.27,7.19)	1.14 (0.44,2.59)	0.06 (-0.29,0.45)
HD INF IV + MTX	1.63 (0.96,2.74)	1.28 (0.98,1.73)	0.12 (-0.01,0.24)
HD TOCI IV + MTX	1.56 (0.79,3.03)	1.26 (0.88,1.85)	0.11 (-0.05,0.26)
HD TOFA PO + MTX	1.67 (0.82,3.47)	1.29 (0.90,1.91)	0.12 (-0.05,0.30)
HD GOLIV SC + MTX	1.60 (0.73,3.62)	1.27 (0.84,1.94)	0.11 (-0.08,0.31)
HD CERTO SC + MTX	2.24 (1.11,4.53)	1.46 (1.06,2.13)	0.19 (0.03,0.35)

(Continued)

HD ADA SC + MTX		1.85 (0.66,5.21)	1.35 (0.79,2.16)	0.15 (-0.10,0.37)
HD TOCI IV + DMARD		0.32 (0.11,1.03)	0.45 (0.19,1.02)	-0.22 (-0.42,0.01)
SD ANA SC + SD ETN SC + MTX		0.84 (0.28,2.68)	0.91 (0.41,1.67)	-0.04 (-0.27,0.23)
SD ANA SC + LD ETN SC + MTX		1.28 (0.42,3.77)	1.14 (0.56,1.93)	0.06 (-0.19,0.31)
SD ADA SC + MTX	SD ABA IV + MTX	1.57 (0.80,3.04)	1.22 (0.91,1.67)	0.11 (-0.06,0.26)
SD CERTO SC + MTX/ CERTO+ MTX		1.42 (0.77,2.72)	1.17 (0.88,1.65)	0.08 (-0.06,0.24)
SD RITUX IV + MTX		0.63 (0.32,1.21)	0.77 (0.50,1.11)	-0.11 (-0.26,0.05)
SD TOFA PO + MTX		1.62 (0.79,3.31)	1.23 (0.89,1.78)	0.12 (-0.06,0.28)
SD GOLI SC + MTX		1.58 (0.71,3.44)	1.22 (0.86,1.80)	0.11 (-0.08,0.29)
SD ABA SC + MTX		1.25 (0.62,2.46)	1.11 (0.77,1.49)	0.05 (-0.11,0.21)
SD GOLI IV + MTX		0.59 (0.27,1.35)	0.74 (0.43,1.17)	-0.12 (-0.30,0.07)
SD ANA SC + MTX		0.73 (0.28,1.97)	0.85 (0.45,1.40)	-0.08 (-0.29,0.16)
SD TOCI IV + MTX		0.52 (0.18,1.42)	0.68 (0.32,1.21)	-0.15 (-0.37,0.08)
SD CERTO SC + DMARD		0.36 (0.11,1.20)	0.52 (0.22,1.12)	-0.22 (-0.47,0.04)
SD ADA SC + DMARD		0.21 (0.06,0.81)	0.35 (0.12,0.88)	-0.31 (-0.52,-0.05)
SD ETN SC + DMARD		0.88 (0.30,2.58)	0.93 (0.49,1.59)	-0.03 (-0.28,0.22)
SD TOCI SC + DMARD		0.34 (0.09,1.33)	0.51 (0.18,1.16)	-0.24 (-0.46,0.07)
LD ADA SC		0.23 (0.08,0.73)	0.38 (0.18,0.81)	-0.30 (-0.51,-0.07)
LD ETN SC		0.24 (0.11,0.53)	0.39 (0.22,0.65)	-0.30 (-0.46,-0.13)
LD GOLI IV		0.27 (0.09,0.77)	0.42 (0.16,0.86)	-0.27 (-0.47,-0.06)
LD TOCI IV		0.05 (0.01,0.17)	0.09 (0.02,0.28)	-0.44 (-0.62,-0.25)
LD ADA SC + MTX		1.13 (0.52,2.45)	1.06 (0.69,1.52)	0.03 (-0.16,0.21)
LD RITUX IV + MTX		0.55 (0.27,1.09)	0.71 (0.45,1.05)	-0.14 (-0.30,0.02)
LD ADA IV + MTX		1.02 (0.16,5.57)	1.01 (0.27,1.87)	0.01 (-0.36,0.36)
LD ABA IV + MTX		0.54 (0.28,1.03)	0.70 (0.44,1.01)	-0.14 (-0.28,0.01)
LD ANA SC + MTX		0.49 (0.12,2.19)	0.66 (0.21,1.45)	-0.16 (-0.40,0.19)
LD CERTO SC + MTX		1.01 (0.37,2.97)	1.01 (0.55,1.63)	0.00 (-0.23,0.25)



(Continued)

LD ETN SC + MTX		0.92 (0.34,2.19)	0.95 (0.54,1.46)	-0.02 (-0.24,0.19)
LD GOLI IV + MTX		0.53 (0.19,1.50)	0.69 (0.33,1.22)	-0.15 (-0.36,0.09)
LD TOCI IV + MTX		0.41 (0.14,1.18)	0.59 (0.27,1.10)	-0.20 (-0.41,0.04)
LD TOFA PO + MTX		0.86 (0.25,3.13)	0.93 (0.40,1.64)	-0.04 (-0.29,0.26)
HD TOCI IV		0.67 (0.34,1.33)	0.80 (0.57,1.18)	-0.10 (-0.26,0.07)
HD TOFA PO		0.72 (0.25,1.95)	0.84 (0.46,1.49)	-0.08 (-0.32,0.16)
HD ADA SC		0.32 (0.12,0.96)	0.49 (0.25,0.97)	-0.25 (-0.46,-0.01)
HD ETN SC		0.49 (0.22,1.16)	0.66 (0.38,1.08)	-0.16 (-0.34,0.03)
HD GOLI SC		0.65 (0.29,1.57)	0.78 (0.47,1.28)	-0.10 (-0.30,0.11)
HD ABA SC		0.98 (0.20,5.58)	0.99 (0.37,2.16)	-0.01 (-0.36,0.39)
HD INF IV + MTX		1.26 (0.64,2.52)	1.11 (0.80,1.58)	0.06 (-0.11,0.22)
HD TOCI IV + MTX		1.20 (0.60,2.35)	1.09 (0.78,1.57)	0.04 (-0.12,0.20)
HD TOFA PO + MTX		1.29 (0.63,2.67)	1.13 (0.79,1.61)	0.06 (-0.11,0.23)
HD GOLI SC + MTX		1.23 (0.54,2.75)	1.10 (0.72,1.65)	0.05 (-0.15,0.24)
HD CERTO SC + MTX		1.73 (0.85,3.54)	1.26 (0.93,1.85)	0.13 (-0.04,0.30)
HD ADA SC + MTX		1.43 (0.51,3.93)	1.18 (0.69,1.77)	0.09 (-0.16,0.31)
HD TOCI IV + DMARD		0.25 (0.08,0.80)	0.39 (0.16,0.88)	-0.29 (-0.49,-0.05)
SD ANA SC + SD ETN SC + MTX		0.65 (0.20,2.08)	0.79 (0.36,1.45)	-0.10 (-0.34,0.18)
SD ANA SC + LD ETN SC + MTX		0.97 (0.31,3.09)	0.99 (0.49,1.63)	-0.01 (-0.26,0.26)
SD CERTO SC + MTX/ CERTO+ MTX	SD ADA SC + MTX	0.91 (0.44,1.81)	0.96 (0.72,1.32)	-0.02 (-0.19,0.14)
SD RITUX IV + MTX		0.40 (0.19,0.83)	0.63 (0.41,0.91)	-0.22 (-0.39,-0.05)
SD TOFA PO + MTX		1.03 (0.46,2.14)	1.01 (0.73,1.40)	0.01 (-0.18,0.17)
SD GOLI SC + MTX		0.99 (0.43,2.34)	1.00 (0.71,1.43)	0.00 (-0.19,0.20)
SD ABA SC + MTX		0.79 (0.39,1.57)	0.91 (0.63,1.20)	-0.06 (-0.22,0.10)
SD GOLI IV + MTX		0.38 (0.16,0.89)	0.61 (0.36,0.94)	-0.23 (-0.42,-0.03)
SD ANA SC + MTX		0.47 (0.17,1.27)	0.70 (0.36,1.10)	-0.18 (-0.41,0.05)
SD TOCI IV + MTX		0.33 (0.11,1.02)	0.56 (0.26,1.01)	-0.26 (-0.49,0.00)

(Continued)

SD CERTO SC + DMARD	0.23 (0.06,0.84)	0.43 (0.19,0.91)	-0.34 (-0.59,-0.04)
SD ADA SC + DMARD	0.13 (0.04,0.52)	0.29 (0.09,0.70)	-0.42 (-0.63,-0.15)
SD ETN SC + DMARD	0.56 (0.19,1.62)	0.77 (0.41,1.24)	-0.14 (-0.38,0.11)
SD TOCI SC + DMARD	0.21 (0.05,0.85)	0.41 (0.15,0.92)	-0.34 (-0.58,-0.04)
LD ADA SC	0.15 (0.05,0.48)	0.31 (0.15,0.62)	-0.41 (-0.62,-0.16)
LD ETN SC	0.15 (0.06,0.36)	0.32 (0.18,0.54)	-0.40 (-0.58,-0.22)
LD GOLIV	0.17 (0.05,0.51)	0.34 (0.13,0.70)	-0.38 (-0.58,-0.16)
LD TOCI IV	0.03 (0.00,0.13)	0.07 (0.01,0.24)	-0.55 (-0.73,-0.34)
LD ADA SC + MTX	0.71 (0.38,1.36)	0.87 (0.62,1.14)	-0.08 (-0.22,0.07)
LD RITUX IV + MTX	0.35 (0.16,0.74)	0.58 (0.36,0.85)	-0.25 (-0.42,-0.07)
LD ADA IV + MTX	0.65 (0.10,3.48)	0.82 (0.23,1.52)	-0.10 (-0.47,0.26)
LD ABA IV + MTX	0.34 (0.15,0.77)	0.58 (0.33,0.88)	-0.25 (-0.43,-0.06)
LD ANA SC + MTX	0.32 (0.07,1.39)	0.54 (0.18,1.15)	-0.26 (-0.53,0.08)
LD CERTO SC + MTX	0.65 (0.22,1.91)	0.83 (0.44,1.29)	-0.10 (-0.35,0.14)
LD ETN SC + MTX	0.57 (0.21,1.54)	0.78 (0.44,1.20)	-0.13 (-0.36,0.10)
LD GOLIV + MTX	0.34 (0.11,0.99)	0.56 (0.27,1.00)	-0.26 (-0.48,0.00)
LD TOCI IV + MTX	0.27 (0.08,0.78)	0.48 (0.22,0.88)	-0.30 (-0.53,-0.06)
LD TOFA PO + MTX	0.56 (0.14,1.95)	0.77 (0.31,1.31)	-0.14 (-0.42,0.16)
HD TOCI IV	0.42 (0.20,0.90)	0.65 (0.46,0.94)	-0.21 (-0.37,-0.03)
HD TOFA PO	0.45 (0.15,1.33)	0.68 (0.39,1.16)	-0.19 (-0.43,0.07)
HD ADA SC	0.21 (0.07,0.65)	0.40 (0.21,0.77)	-0.36 (-0.57,-0.10)
HD ETN SC	0.32 (0.12,0.80)	0.54 (0.30,0.89)	-0.27 (-0.47,-0.05)
HD GOLIV	0.42 (0.16,1.06)	0.65 (0.38,1.04)	-0.21 (-0.42,0.01)
HD ABA SC	0.62 (0.12,3.54)	0.81 (0.32,1.66)	-0.11 (-0.47,0.28)
HD INF IV + MTX	0.80 (0.36,1.74)	0.91 (0.64,1.28)	-0.05 (-0.24,0.13)
HD TOCI IV + MTX	0.76 (0.36,1.61)	0.89 (0.63,1.25)	-0.06 (-0.24,0.11)
HD TOFA PO + MTX	0.83 (0.38,1.77)	0.92 (0.64,1.28)	-0.04 (-0.23,0.13)
HD GOLIV + MTX	0.78 (0.33,1.82)	0.90 (0.60,1.31)	-0.06 (-0.25,0.14)

(Continued)

HD CERTO SC + MTX		1.11 (0.49,2.40)	1.04 (0.75,1.45)	0.02 (-0.17,0.20)
HD ADA SC + MTX		0.92 (0.37,2.26)	0.96 (0.61,1.33)	-0.02 (-0.23,0.17)
HD TOCI IV + DMARD		0.16 (0.05,0.54)	0.32 (0.13,0.71)	-0.39 (-0.60,-0.15)
SD ANA SC + SD ETN SC + MTX		0.42 (0.12,1.41)	0.65 (0.30,1.16)	-0.21 (-0.46,0.08)
SD ANA SC + LD ETN SC + MTX		0.62 (0.19,2.04)	0.81 (0.40,1.33)	-0.11 (-0.38,0.16)
SD RITUX IV + MTX	SD CERTO SC +	0.44 (0.21,0.90)	0.66 (0.42,0.94)	-0.20 (-0.36,-0.03)
SD TOFA PO + MTX		1.12 (0.55,2.38)	1.05 (0.76,1.42)	0.03 (-0.14,0.19)
SD GOLI SC + MTX		1.10 (0.50,2.45)	1.04 (0.74,1.45)	0.02 (-0.16,0.20)
SD ABA SC + MTX		0.87 (0.37,1.95)	0.94 (0.60,1.33)	-0.03 (-0.24,0.15)
SD GOLI IV + MTX		0.42 (0.18,0.93)	0.63 (0.36,0.97)	-0.21 (-0.39,-0.02)
SD ANA SC + MTX		0.51 (0.20,1.29)	0.72 (0.38,1.13)	-0.16 (-0.37,0.06)
SD TOCI IV + MTX		0.36 (0.12,1.04)	0.58 (0.27,1.02)	-0.24 (-0.46,0.01)
SD CERTO SC + DMARD		0.25 (0.07,0.83)	0.44 (0.19,0.90)	-0.31 (-0.55,-0.05)
SD ADA SC + DMARD		0.15 (0.04,0.54)	0.29 (0.10,0.72)	-0.39 (-0.59,-0.14)
SD ETN SC + DMARD		0.61 (0.21,1.83)	0.79 (0.42,1.29)	-0.12 (-0.37,0.14)
SD TOCI SC + DMARD		0.23 (0.07,0.87)	0.43 (0.15,0.93)	-0.32 (-0.55,-0.03)
LD ADA SC		0.16 (0.06,0.51)	0.32 (0.16,0.65)	-0.40 (-0.59,-0.15)
LD ETN SC		0.17 (0.08,0.37)	0.33 (0.19,0.55)	-0.38 (-0.54,-0.21)
LD GOLI IV		0.19 (0.06,0.55)	0.35 (0.14,0.73)	-0.36 (-0.56,-0.14)
LD TOCI IV		0.03 (0.01,0.13)	0.07 (0.01,0.24)	-0.53 (-0.69,-0.33)
LD ADA SC + MTX		0.78 (0.37,1.77)	0.90 (0.59,1.28)	-0.06 (-0.24,0.13)
LD RITUX IV + MTX		0.39 (0.18,0.77)	0.60 (0.37,0.88)	-0.23 (-0.39,-0.06)
LD ADA IV + MTX		0.69 (0.12,3.87)	0.85 (0.23,1.58)	-0.09 (-0.44,0.28)
LD ABA IV + MTX		0.37 (0.17,0.81)	0.59 (0.34,0.90)	-0.23 (-0.41,-0.05)
LD ANA SC + MTX		0.35 (0.09,1.48)	0.56 (0.18,1.18)	-0.24 (-0.49,0.09)
LD CERTO SC + MTX		0.70 (0.29,1.84)	0.85 (0.49,1.27)	-0.08 (-0.28,0.14)
LD ETN SC + MTX		0.63 (0.24,1.55)	0.81 (0.46,1.21)	-0.11 (-0.33,0.10)

(Continued)

LD GOLI IV + MTX		0.37 (0.13,1.04)	0.58 (0.27,1.02)	-0.23 (-0.45,0.01)
LD TOCI IV + MTX		0.29 (0.10,0.83)	0.50 (0.22,0.91)	-0.28 (-0.50,-0.04)
LD TOFA PO + MTX		0.60 (0.18,2.09)	0.79 (0.34,1.34)	-0.12 (-0.38,0.17)
HD TOCI IV		0.47 (0.24,0.90)	0.68 (0.48,0.94)	-0.18 (-0.34,-0.03)
HD TOFA PO		0.50 (0.17,1.37)	0.71 (0.41,1.19)	-0.17 (-0.40,0.08)
HD ADA SC		0.22 (0.08,0.72)	0.41 (0.22,0.82)	-0.34 (-0.54,-0.07)
HD ETN SC		0.34 (0.15,0.83)	0.56 (0.32,0.91)	-0.25 (-0.43,-0.05)
HD GOLI SC		0.46 (0.19,1.06)	0.67 (0.41,1.03)	-0.19 (-0.38,0.01)
HD ABA SC		0.69 (0.14,4.04)	0.84 (0.33,1.75)	-0.09 (-0.45,0.31)
HD INF IV + MTX		0.88 (0.43,1.77)	0.94 (0.68,1.29)	-0.03 (-0.20,0.13)
HD TOCI IV + MTX		0.84 (0.41,1.64)	0.93 (0.67,1.25)	-0.04 (-0.21,0.12)
HD TOFA PO + MTX		0.89 (0.43,1.90)	0.95 (0.66,1.33)	-0.03 (-0.20,0.15)
HD GOLI SC + MTX		0.85 (0.38,1.96)	0.93 (0.62,1.32)	-0.04 (-0.23,0.16)
HD CERTO SC + MTX		1.20 (0.71,1.99)	1.07 (0.86,1.35)	0.04 (-0.08,0.16)
HD ADA SC + MTX		1.00 (0.33,2.94)	1.00 (0.58,1.50)	0.00 (-0.26,0.23)
HD TOCI IV + DMARD		0.17 (0.06,0.51)	0.34 (0.13,0.70)	-0.37 (-0.56,-0.16)
SD ANA SC + SD ETN SC + MTX		0.46 (0.14,1.41)	0.67 (0.31,1.16)	-0.19 (-0.43,0.08)
SD ANA SC + LD ETN SC + MTX		0.68 (0.21,2.11)	0.84 (0.41,1.34)	-0.09 (-0.36,0.17)
SD TOFA PO + MTX	SD RITUX IV + MTX	2.55 (1.21,5.49)	1.60 (1.10,2.49)	0.22 (0.05,0.40)
SD GOLI SC + MTX		2.52 (1.10,5.87)	1.59 (1.05,2.58)	0.22 (0.02,0.41)
SD ABA SC + MTX		1.99 (0.85,4.70)	1.44 (0.91,2.34)	0.16 (-0.04,0.36)
SD GOLI IV + MTX		0.93 (0.39,2.25)	0.96 (0.54,1.63)	-0.01 (-0.20,0.19)
SD ANA SC + MTX		1.18 (0.43,3.10)	1.10 (0.58,1.90)	0.04 (-0.18,0.27)
SD TOCI IV + MTX		0.83 (0.27,2.38)	0.89 (0.41,1.67)	-0.04 (-0.27,0.20)
SD CERTO SC + DMARD		0.58 (0.17,1.88)	0.69 (0.28,1.51)	-0.11 (-0.36,0.14)
SD ADA SC + DMARD		0.34 (0.09,1.22)	0.46 (0.15,1.14)	-0.19 (-0.40,0.04)
SD ETN SC + DMARD		1.41 (0.45,4.13)	1.21 (0.61,2.20)	0.08 (-0.18,0.33)

(Continued)

SD TOCI SC + DMARD	0.54 (0.14,2.01)	0.66 (0.23,1.53)	-0.12 (-0.36,0.16)
LD ADA SC	0.37 (0.13,1.14)	0.49 (0.23,1.10)	-0.19 (-0.41,0.03)
LD ETN SC	0.39 (0.17,0.86)	0.51 (0.27,0.90)	-0.18 (-0.36,-0.02)
LD GOL I V	0.42 (0.13,1.28)	0.55 (0.21,1.17)	-0.16 (-0.37,0.05)
LD TOCI IV	0.07 (0.01,0.29)	0.11 (0.02,0.39)	-0.32 (-0.52,-0.16)
LD ADA SC + MTX	1.80 (0.79,4.27)	1.37 (0.86,2.21)	0.14 (-0.06,0.34)
LD RITUX IV + MTX	0.88 (0.51,1.51)	0.92 (0.63,1.31)	-0.03 (-0.15,0.09)
LD ADA IV + MTX	1.62 (0.24,9.49)	1.30 (0.35,2.76)	0.11 (-0.27,0.49)
LD ABA IV + MTX	0.85 (0.37,1.95)	0.90 (0.52,1.50)	-0.04 (-0.21,0.16)
LD ANA SC + MTX	0.80 (0.18,3.55)	0.87 (0.28,1.94)	-0.05 (-0.30,0.30)
LD CERTO SC + MTX	1.61 (0.57,4.78)	1.30 (0.70,2.29)	0.11 (-0.12,0.36)
LD ETN SC + MTX	1.44 (0.56,3.77)	1.23 (0.70,2.10)	0.08 (-0.13,0.31)
LD GOL I V + MTX	0.84 (0.29,2.50)	0.89 (0.41,1.69)	-0.04 (-0.26,0.22)
LD TOCI IV + MTX	0.67 (0.22,1.89)	0.77 (0.33,1.52)	-0.08 (-0.30,0.15)
LD TOFA PO + MTX	1.39 (0.38,5.07)	1.20 (0.51,2.24)	0.08 (-0.20,0.37)
HD TOCI IV	1.05 (0.53,2.18)	1.03 (0.69,1.66)	0.01 (-0.15,0.17)
HD TOFA PO	1.13 (0.40,3.21)	1.07 (0.57,2.12)	0.03 (-0.21,0.26)
HD ADA SC	0.53 (0.18,1.60)	0.64 (0.31,1.40)	-0.13 (-0.36,0.09)
HD ETN SC	0.79 (0.34,1.90)	0.86 (0.48,1.50)	-0.05 (-0.24,0.15)
HD GOL I SC	1.05 (0.42,2.59)	1.03 (0.59,1.82)	0.01 (-0.20,0.21)
HD ABA SC	1.58 (0.32,8.91)	1.29 (0.47,3.02)	0.11 (-0.25,0.49)
HD INF IV + MTX	2.00 (0.96,4.27)	1.45 (0.98,2.27)	0.16 (-0.01,0.33)
HD TOCI IV + MTX	1.91 (0.92,3.98)	1.42 (0.96,2.24)	0.15 (-0.02,0.32)
HD TOFA PO + MTX	2.08 (0.94,4.43)	1.47 (0.97,2.29)	0.17 (-0.01,0.35)
HD GOL I SC + MTX	1.95 (0.83,4.69)	1.42 (0.90,2.35)	0.16 (-0.04,0.36)
HD CERTO SC + MTX	2.74 (1.30,5.90)	1.64 (1.13,2.61)	0.24 (0.06,0.41)
HD ADA SC + MTX	2.29 (0.79,6.68)	1.52 (0.87,2.54)	0.20 (-0.05,0.43)
HD TOCI IV + DMARD	0.39 (0.13,1.27)	0.51 (0.21,1.16)	-0.18 (-0.37,0.05)

(Continued)

SD ANA SC + SD ETN SC + MTX		1.03 (0.34,3.46)	1.02 (0.46,1.94)	0.01 (-0.23,0.30)
SD ANA SC + LD ETN SC + MTX		1.55 (0.49,5.05)	1.27 (0.62,2.33)	0.10 (-0.16,0.37)
SD GOLI SC + MTX	SD TOFA PO + MTX	0.97 (0.41,2.39)	0.99 (0.69,1.43)	-0.01 (-0.21,0.20)
SD ABA SC + MTX		0.78 (0.31,1.85)	0.90 (0.57,1.29)	-0.06 (-0.27,0.14)
SD GOLI IV + MTX		0.37 (0.14,0.93)	0.60 (0.34,0.96)	-0.24 (-0.44,-0.02)
SD ANA SC + MTX		0.46 (0.16,1.29)	0.69 (0.35,1.12)	-0.18 (-0.42,0.06)
SD TOCI IV + MTX		0.32 (0.10,0.97)	0.55 (0.25,0.99)	-0.27 (-0.49,-0.01)
SD CERTO SC + DMARD		0.22 (0.06,0.78)	0.42 (0.19,0.87)	-0.34 (-0.59,-0.06)
SD ADA SC + DMARD		0.13 (0.03,0.53)	0.28 (0.09,0.70)	-0.42 (-0.63,-0.15)
SD ETN SC + DMARD		0.55 (0.17,1.73)	0.76 (0.40,1.26)	-0.14 (-0.41,0.13)
SD TOCI SC + DMARD		0.21 (0.06,0.84)	0.41 (0.14,0.92)	-0.35 (-0.58,-0.04)
LD ADA SC		0.14 (0.05,0.44)	0.30 (0.15,0.60)	-0.42 (-0.61,-0.18)
LD ETN SC		0.15 (0.06,0.36)	0.31 (0.18,0.54)	-0.41 (-0.59,-0.22)
LD GOLI IV		0.17 (0.05,0.53)	0.34 (0.13,0.73)	-0.39 (-0.60,-0.15)
LD TOCI IV		0.03 (0.00,0.12)	0.07 (0.01,0.24)	-0.55 (-0.73,-0.35)
LD ADA SC + MTX		0.70 (0.30,1.72)	0.86 (0.56,1.26)	-0.08 (-0.28,0.13)
LD RITUX IV + MTX		0.34 (0.16,0.74)	0.57 (0.35,0.86)	-0.25 (-0.42,-0.07)
LD ADA IV + MTX		0.63 (0.10,3.41)	0.81 (0.22,1.47)	-0.11 (-0.47,0.25)
LD ABA IV + MTX		0.33 (0.14,0.79)	0.57 (0.33,0.90)	-0.26 (-0.44,-0.06)
LD ANA SC + MTX		0.31 (0.07,1.42)	0.54 (0.17,1.16)	-0.27 (-0.53,0.08)
LD CERTO SC + MTX		0.63 (0.22,1.81)	0.82 (0.43,1.27)	-0.11 (-0.35,0.13)
LD ETN SC + MTX		0.56 (0.20,1.50)	0.77 (0.44,1.19)	-0.14 (-0.37,0.09)
LD GOLI IV + MTX		0.33 (0.10,1.07)	0.55 (0.26,1.03)	-0.26 (-0.49,0.02)
LD TOCI IV + MTX		0.26 (0.08,0.77)	0.48 (0.21,0.88)	-0.31 (-0.52,-0.06)
LD TOFA PO + MTX		0.55 (0.17,1.67)	0.76 (0.34,1.20)	-0.14 (-0.39,0.11)
HD TOCI IV		0.41 (0.20,0.91)	0.65 (0.45,0.95)	-0.21 (-0.37,-0.02)
HD TOFA PO		0.44 (0.15,1.23)	0.67 (0.39,1.12)	-0.20 (-0.43,0.05)



(Continued)

HD ADA SC		0.20 (0.07,0.63)	0.40 (0.21,0.76)	-0.36 (-0.57,-0.10)
HD ETN SC		0.31 (0.12,0.76)	0.53 (0.30,0.87)	-0.28 (-0.47,-0.06)
HD GOLI SC		0.41 (0.16,1.05)	0.64 (0.39,1.02)	-0.21 (-0.42,0.01)
HD ABA SC		0.61 (0.12,3.64)	0.81 (0.31,1.63)	-0.12 (-0.48,0.29)
HD INF IV + MTX		0.79 (0.36,1.73)	0.91 (0.63,1.26)	-0.06 (-0.24,0.13)
HD TOCI IV + MTX		0.74 (0.34,1.59)	0.88 (0.62,1.24)	-0.07 (-0.25,0.11)
HD TOFA PO + MTX		0.80 (0.48,1.30)	0.92 (0.72,1.12)	-0.05 (-0.17,0.06)
HD GOLI SC + MTX		0.76 (0.32,1.91)	0.90 (0.58,1.30)	-0.06 (-0.27,0.15)
HD CERTO SC + MTX		1.07 (0.50,2.42)	1.03 (0.75,1.45)	0.02 (-0.16,0.20)
HD ADA SC + MTX		0.88 (0.32,2.70)	0.95 (0.55,1.43)	-0.03 (-0.27,0.22)
HD TOCI IV + DMARD		0.15 (0.05,0.52)	0.32 (0.13,0.71)	-0.40 (-0.60,-0.15)
SD ANA SC + SD ETN SC + MTX		0.40 (0.12,1.45)	0.64 (0.28,1.17)	-0.21 (-0.48,0.09)
SD ANA SC + LD ETN SC + MTX		0.60 (0.18,2.12)	0.80 (0.38,1.33)	-0.12 (-0.39,0.17)
SD ABA SC + MTX	SD GOLI SC + MTX	0.79 (0.30,1.98)	0.91 (0.56,1.35)	-0.06 (-0.28,0.16)
SD GOLI IV + MTX		0.37 (0.14,0.96)	0.60 (0.34,0.98)	-0.23 (-0.44,-0.01)
SD ANA SC + MTX		0.47 (0.16,1.31)	0.69 (0.36,1.12)	-0.18 (-0.42,0.06)
SD TOCI IV + MTX		0.33 (0.10,1.03)	0.56 (0.25,1.02)	-0.26 (-0.51,0.01)
SD CERTO SC + DMARD		0.23 (0.06,0.79)	0.43 (0.19,0.89)	-0.33 (-0.59,-0.05)
SD ADA SC + DMARD		0.14 (0.03,0.53)	0.28 (0.09,0.71)	-0.42 (-0.64,-0.14)
SD ETN SC + DMARD		0.56 (0.17,1.79)	0.77 (0.38,1.28)	-0.14 (-0.41,0.14)
SD TOCI SC + DMARD		0.21 (0.06,0.83)	0.41 (0.14,0.91)	-0.34 (-0.58,-0.05)
LD ADA SC		0.15 (0.05,0.49)	0.30 (0.15,0.63)	-0.41 (-0.63,-0.16)
LD ETN SC		0.15 (0.06,0.37)	0.32 (0.18,0.54)	-0.40 (-0.59,-0.21)
LD GOLI IV		0.17 (0.05,0.55)	0.34 (0.13,0.73)	-0.38 (-0.59,-0.14)
LD TOCI IV		0.03 (0.00,0.13)	0.07 (0.01,0.25)	-0.55 (-0.74,-0.33)
LD ADA SC + MTX		0.73 (0.29,1.78)	0.87 (0.54,1.27)	-0.08 (-0.29,0.13)
LD RITUX IV + MTX		0.34 (0.15,0.82)	0.58 (0.35,0.91)	-0.25 (-0.43,-0.05)

(Continued)

LD ADA IV + MTX		0.64 (0.10,3.52)	0.82 (0.22,1.51)	-0.10 (-0.48,0.26)
LD ABA IV + MTX		0.34 (0.14,0.86)	0.57 (0.32,0.93)	-0.25 (-0.44,-0.04)
LD ANA SC + MTX		0.32 (0.07,1.48)	0.55 (0.17,1.17)	-0.26 (-0.55,0.09)
LD CERTO SC + MTX		0.65 (0.21,2.08)	0.83 (0.43,1.35)	-0.10 (-0.36,0.17)
LD ETN SC + MTX		0.57 (0.19,1.66)	0.78 (0.42,1.24)	-0.13 (-0.38,0.12)
LD GOLI IV + MTX		0.33 (0.11,1.06)	0.57 (0.25,1.03)	-0.26 (-0.49,0.01)
LD TOCI IV + MTX		0.27 (0.08,0.84)	0.48 (0.22,0.92)	-0.30 (-0.53,-0.04)
LD TOFA PO + MTX		0.56 (0.14,2.01)	0.76 (0.31,1.35)	-0.14 (-0.43,0.16)
HD TOCI IV		0.43 (0.18,0.92)	0.66 (0.44,0.96)	-0.20 (-0.39,-0.02)
HD TOFA PO		0.45 (0.15,1.37)	0.68 (0.39,1.18)	-0.19 (-0.43,0.08)
HD ADA SC		0.21 (0.06,0.69)	0.40 (0.21,0.80)	-0.36 (-0.59,-0.08)
HD ETN SC		0.31 (0.12,0.81)	0.53 (0.30,0.90)	-0.27 (-0.48,-0.05)
HD GOLI SC		0.42 (0.18,0.96)	0.65 (0.41,0.98)	-0.21 (-0.39,-0.01)
HD ABA SC		0.63 (0.12,3.59)	0.81 (0.32,1.67)	-0.11 (-0.47,0.28)
HD INF IV + MTX		0.80 (0.34,1.90)	0.91 (0.62,1.34)	-0.05 (-0.25,0.15)
HD TOCI IV + MTX		0.76 (0.32,1.72)	0.89 (0.62,1.30)	-0.07 (-0.26,0.13)
HD TOFA PO + MTX		0.82 (0.34,1.98)	0.92 (0.62,1.35)	-0.05 (-0.25,0.16)
HD GOLI SC + MTX		0.78 (0.42,1.45)	0.90 (0.66,1.16)	-0.06 (-0.20,0.09)
HD CERTO SC + MTX		1.11 (0.45,2.57)	1.04 (0.74,1.48)	0.02 (-0.18,0.22)
HD ADA SC + MTX		0.91 (0.28,2.80)	0.96 (0.53,1.48)	-0.02 (-0.30,0.23)
HD TOCI IV + DMARD		0.16 (0.05,0.53)	0.32 (0.13,0.70)	-0.39 (-0.61,-0.15)
SD ANA SC + SD ETN SC + MTX		0.41 (0.12,1.56)	0.65 (0.28,1.23)	-0.21 (-0.48,0.10)
SD ANA SC + LD ETN SC + MTX		0.62 (0.17,2.19)	0.81 (0.38,1.38)	-0.11 (-0.41,0.18)
SD GOLI IV + MTX	SD ABA SC + MTX	0.47 (0.18,1.28)	0.67 (0.38,1.13)	-0.18 (-0.39,0.06)
SD ANA SC + MTX		0.58 (0.20,1.86)	0.76 (0.39,1.39)	-0.13 (-0.37,0.15)
SD TOCI IV + MTX		0.41 (0.13,1.36)	0.61 (0.28,1.18)	-0.21 (-0.45,0.07)
SD CERTO SC + DMARD		0.29 (0.08,1.13)	0.48 (0.20,1.07)	-0.28 (-0.55,0.03)

(Continued)

SD ADA SC + DMARD	0.17 (0.04,0.76)	0.32 (0.10,0.84)	-0.36 (-0.59,-0.06)
SD ETN SC + DMARD	0.71 (0.21,2.38)	0.84 (0.43,1.51)	-0.08 (-0.37,0.21)
SD TOCI SC + DMARD	0.28 (0.07,1.15)	0.47 (0.16,1.08)	-0.28 (-0.54,0.03)
LD ADA SC	0.19 (0.06,0.64)	0.34 (0.17,0.75)	-0.35 (-0.58,-0.09)
LD ETN SC	0.19 (0.07,0.49)	0.35 (0.19,0.63)	-0.35 (-0.55,-0.14)
LD GOLIV	0.21 (0.06,0.70)	0.38 (0.15,0.82)	-0.33 (-0.56,-0.08)
LD TOCI IV	0.04 (0.01,0.17)	0.08 (0.01,0.27)	-0.49 (-0.69,-0.26)
LD ADA SC + MTX	0.91 (0.39,2.24)	0.96 (0.63,1.44)	-0.02 (-0.22,0.19)
LD RITUX IV + MTX	0.44 (0.19,1.08)	0.64 (0.38,1.04)	-0.19 (-0.39,0.02)
LD ADA IV + MTX	0.82 (0.13,4.51)	0.92 (0.25,1.83)	-0.05 (-0.42,0.33)
LD ABA IV + MTX	0.43 (0.18,1.07)	0.63 (0.36,1.04)	-0.20 (-0.40,0.02)
LD ANA SC + MTX	0.40 (0.09,1.99)	0.60 (0.19,1.37)	-0.21 (-0.49,0.16)
LD CERTO SC + MTX	0.81 (0.27,2.63)	0.91 (0.48,1.61)	-0.05 (-0.30,0.23)
LD ETN SC + MTX	0.72 (0.25,2.12)	0.86 (0.47,1.45)	-0.08 (-0.32,0.18)
LD GOLIV + MTX	0.42 (0.14,1.37)	0.62 (0.29,1.18)	-0.20 (-0.44,0.08)
LD TOCI IV + MTX	0.33 (0.10,1.12)	0.53 (0.24,1.06)	-0.25 (-0.49,0.03)
LD TOFA PO + MTX	0.70 (0.18,2.71)	0.84 (0.34,1.58)	-0.09 (-0.38,0.23)
HD TOCI IV	0.54 (0.23,1.29)	0.72 (0.48,1.16)	-0.15 (-0.35,0.06)
HD TOFA PO	0.58 (0.19,1.81)	0.75 (0.42,1.40)	-0.13 (-0.39,0.14)
HD ADA SC	0.26 (0.08,0.88)	0.44 (0.23,0.92)	-0.30 (-0.53,-0.03)
HD ETN SC	0.39 (0.15,1.05)	0.60 (0.33,1.03)	-0.22 (-0.43,0.01)
HD GOLIV SC	0.54 (0.19,1.44)	0.72 (0.41,1.23)	-0.15 (-0.39,0.08)
HD ABA SC	0.80 (0.15,4.83)	0.90 (0.34,2.00)	-0.05 (-0.43,0.35)
HD INF IV + MTX	1.01 (0.42,2.46)	1.01 (0.68,1.58)	0.00 (-0.20,0.21)
HD TOCI IV + MTX	0.96 (0.41,2.31)	0.98 (0.67,1.56)	-0.01 (-0.21,0.20)
HD TOFA PO + MTX	1.02 (0.42,2.59)	1.01 (0.68,1.61)	0.01 (-0.20,0.23)
HD GOLIV SC + MTX	0.98 (0.38,2.69)	0.99 (0.64,1.61)	0.00 (-0.23,0.23)
HD CERTO SC + MTX	1.37 (0.59,3.51)	1.14 (0.81,1.83)	0.07 (-0.12,0.29)

(Continued)

HD ADA SC + MTX		1.15 (0.40,3.40)	1.07 (0.63,1.69)	0.03 (-0.22,0.27)
HD TOCI IV + DMARD		0.20 (0.06,0.73)	0.36 (0.14,0.83)	-0.34 (-0.57,-0.07)
SD ANA SC + SD ETN SC + MTX		0.52 (0.15,1.89)	0.71 (0.32,1.35)	-0.15 (-0.42,0.15)
SD ANA SC + LD ETN SC + MTX		0.78 (0.24,2.91)	0.89 (0.44,1.60)	-0.06 (-0.32,0.25)
SD ANA SC + MTX	SD GOL I IV + MTX	1.25 (0.43,3.50)	1.14 (0.58,2.11)	0.05 (-0.19,0.29)
SD TOCI IV + MTX		0.88 (0.28,2.81)	0.92 (0.41,1.93)	-0.03 (-0.28,0.24)
SD CERTO SC + DMARD		0.60 (0.17,2.29)	0.71 (0.29,1.72)	-0.10 (-0.36,0.19)
SD ADA SC + DMARD		0.36 (0.09,1.41)	0.48 (0.15,1.26)	-0.18 (-0.43,0.07)
SD ETN SC + DMARD		1.48 (0.46,4.78)	1.26 (0.63,2.44)	0.09 (-0.17,0.36)
SD TOCI SC + DMARD		0.58 (0.14,2.34)	0.68 (0.23,1.72)	-0.11 (-0.36,0.20)
LD ADA SC		0.39 (0.12,1.34)	0.51 (0.22,1.23)	-0.18 (-0.42,0.06)
LD ETN SC		0.41 (0.16,1.00)	0.52 (0.27,1.00)	-0.17 (-0.38,0.00)
LD GOL I IV		0.45 (0.17,1.17)	0.57 (0.24,1.11)	-0.15 (-0.34,0.03)
LD TOCI IV		0.08 (0.01,0.34)	0.12 (0.02,0.42)	-0.31 (-0.53,-0.13)
LD ADA SC + MTX		1.90 (0.74,5.11)	1.43 (0.85,2.58)	0.15 (-0.07,0.37)
LD RITUX IV + MTX		0.94 (0.39,2.24)	0.96 (0.55,1.70)	-0.01 (-0.22,0.17)
LD ADA IV + MTX		1.76 (0.23,10.18)	1.36 (0.35,3.06)	0.13 (-0.27,0.50)
LD ABA IV + MTX		0.92 (0.35,2.27)	0.95 (0.52,1.66)	-0.02 (-0.23,0.18)
LD ANA SC + MTX		0.84 (0.19,4.05)	0.90 (0.30,2.20)	-0.04 (-0.31,0.32)
LD CERTO SC + MTX		1.73 (0.55,5.37)	1.35 (0.69,2.63)	0.13 (-0.14,0.38)
LD ETN SC + MTX		1.52 (0.52,4.45)	1.27 (0.68,2.43)	0.10 (-0.15,0.34)
LD GOL I IV + MTX		0.89 (0.36,2.24)	0.93 (0.49,1.66)	-0.02 (-0.22,0.19)
LD TOCI IV + MTX		0.72 (0.21,2.28)	0.80 (0.34,1.75)	-0.07 (-0.33,0.18)
LD TOFA PO + MTX		1.50 (0.37,5.83)	1.26 (0.51,2.57)	0.09 (-0.21,0.40)
HD TOCI IV		1.13 (0.47,2.63)	1.08 (0.66,1.95)	0.03 (-0.18,0.21)
HD TOFA PO		1.22 (0.38,3.66)	1.13 (0.56,2.37)	0.05 (-0.23,0.28)
HD ADA SC		0.55 (0.18,1.87)	0.66 (0.31,1.57)	-0.12 (-0.36,0.12)

(Continued)

HD ETN SC		0.84 (0.31,2.23)	0.89 (0.46,1.71)	-0.04 (-0.26,0.18)
HD GOLI SC		1.12 (0.42,2.87)	1.07 (0.59,1.99)	0.02 (-0.20,0.23)
HD ABA SC		1.69 (0.31,10.13)	1.34 (0.46,3.48)	0.12 (-0.26,0.51)
HD INF IV + MTX		2.13 (0.87,5.23)	1.51 (0.92,2.69)	0.18 (-0.03,0.37)
HD TOCI IV + MTX		2.05 (0.82,4.82)	1.48 (0.91,2.61)	0.17 (-0.05,0.36)
HD TOFA PO + MTX		2.19 (0.87,5.57)	1.53 (0.93,2.69)	0.18 (-0.03,0.39)
HD GOLI SC + MTX		2.07 (0.80,5.42)	1.48 (0.89,2.70)	0.17 (-0.05,0.39)
HD CERTO SC + MTX		2.92 (1.21,7.21)	1.70 (1.08,3.06)	0.25 (0.05,0.45)
HD ADA SC + MTX		2.44 (0.73,7.73)	1.59 (0.85,3.00)	0.21 (-0.07,0.46)
HD TOCI IV + DMARD		0.41 (0.12,1.43)	0.53 (0.21,1.28)	-0.16 (-0.41,0.07)
SD ANA SC + SD ETN SC + MTX		1.10 (0.30,3.93)	1.06 (0.45,2.20)	0.02 (-0.25,0.31)
SD ANA SC + LD ETN SC + MTX		1.66 (0.45,5.64)	1.33 (0.61,2.64)	0.12 (-0.17,0.40)
SD TOCI IV + MTX	SD ANA SC + MTX	0.70 (0.20,2.50)	0.80 (0.36,1.77)	-0.08 (-0.35,0.20)
SD CERTO SC + DMARD		0.50 (0.12,1.96)	0.63 (0.24,1.59)	-0.15 (-0.44,0.14)
SD ADA SC + DMARD		0.29 (0.07,1.32)	0.42 (0.13,1.20)	-0.23 (-0.49,0.06)
SD ETN SC + DMARD		1.19 (0.34,4.17)	1.10 (0.54,2.30)	0.04 (-0.25,0.33)
SD TOCI SC + DMARD		0.46 (0.11,1.92)	0.60 (0.20,1.48)	-0.16 (-0.44,0.14)
LD ADA SC		0.31 (0.09,1.15)	0.44 (0.20,1.11)	-0.23 (-0.49,0.02)
LD ETN SC		0.33 (0.11,0.96)	0.46 (0.23,0.96)	-0.22 (-0.46,-0.01)
LD GOLI IV		0.36 (0.10,1.24)	0.50 (0.19,1.16)	-0.20 (-0.45,0.04)
LD TOCI IV		0.06 (0.01,0.30)	0.10 (0.02,0.38)	-0.36 (-0.60,-0.14)
LD ADA SC + MTX		1.53 (0.54,4.58)	1.25 (0.73,2.43)	0.10 (-0.15,0.35)
LD RITUX IV + MTX		0.74 (0.28,2.00)	0.83 (0.47,1.62)	-0.07 (-0.29,0.15)
LD ADA IV + MTX		1.40 (0.18,9.16)	1.19 (0.30,2.80)	0.08 (-0.33,0.48)
LD ABA IV + MTX		0.73 (0.24,2.19)	0.83 (0.41,1.67)	-0.07 (-0.32,0.17)
LD ANA SC + MTX		0.68 (0.18,2.54)	0.80 (0.29,1.65)	-0.08 (-0.33,0.22)
LD CERTO SC + MTX		1.38 (0.42,4.91)	1.19 (0.60,2.37)	0.08 (-0.21,0.36)

(Continued)

LD ETN SC + MTX		1.23 (0.38,4.08)	1.12 (0.59,2.30)	0.05 (-0.22,0.32)
LD GOLI IV + MTX		0.71 (0.22,2.47)	0.82 (0.37,1.72)	-0.08 (-0.34,0.21)
LD TOCI IV + MTX		0.57 (0.16,2.01)	0.70 (0.30,1.59)	-0.12 (-0.39,0.16)
LD TOFA PO + MTX		1.18 (0.26,4.90)	1.10 (0.42,2.37)	0.04 (-0.29,0.36)
HD TOCI IV		0.90 (0.35,2.35)	0.94 (0.57,1.81)	-0.02 (-0.25,0.19)
HD TOFA PO		0.98 (0.29,3.14)	0.99 (0.50,2.13)	-0.01 (-0.29,0.25)
HD ADA SC		0.44 (0.13,1.65)	0.58 (0.27,1.45)	-0.17 (-0.44,0.10)
HD ETN SC		0.66 (0.22,2.12)	0.77 (0.40,1.62)	-0.09 (-0.34,0.16)
HD GOLI SC		0.89 (0.31,2.72)	0.94 (0.51,1.90)	-0.03 (-0.27,0.22)
HD ABA SC		1.34 (0.24,8.97)	1.17 (0.41,3.20)	0.07 (-0.33,0.49)
HD INF IV + MTX		1.69 (0.62,4.76)	1.31 (0.80,2.53)	0.13 (-0.11,0.36)
HD TOCI IV + MTX		1.61 (0.61,4.65)	1.28 (0.79,2.51)	0.11 (-0.12,0.35)
HD TOFA PO + MTX		1.73 (0.63,5.21)	1.32 (0.79,2.67)	0.13 (-0.11,0.38)
HD GOLI SC + MTX		1.65 (0.58,5.18)	1.28 (0.76,2.51)	0.12 (-0.13,0.37)
HD CERTO SC + MTX		2.34 (0.90,6.51)	1.49 (0.96,2.81)	0.20 (-0.02,0.42)
HD ADA SC + MTX		1.94 (0.57,7.07)	1.37 (0.74,2.82)	0.16 (-0.13,0.44)
HD TOCI IV + DMARD		0.34 (0.10,1.28)	0.47 (0.18,1.18)	-0.21 (-0.47,0.05)
SD ANA SC + SD ETN SC + MTX		0.89 (0.25,3.60)	0.93 (0.40,2.08)	-0.03 (-0.32,0.30)
SD ANA SC + LD ETN SC + MTX		1.31 (0.35,5.32)	1.16 (0.53,2.44)	0.06 (-0.24,0.38)
SD CERTO SC + DMARD	SD TOCI IV + MTX	0.69 (0.17,2.87)	0.77 (0.30,2.15)	-0.07 (-0.36,0.20)
SD ADA SC + DMARD		0.40 (0.09,1.87)	0.51 (0.15,1.58)	-0.16 (-0.42,0.12)
SD ETN SC + DMARD		1.72 (0.44,6.77)	1.38 (0.61,3.23)	0.12 (-0.19,0.42)
SD TOCI SC + DMARD		0.65 (0.15,2.82)	0.74 (0.25,2.02)	-0.08 (-0.36,0.22)
LD ADA SC		0.45 (0.13,1.65)	0.56 (0.24,1.49)	-0.14 (-0.41,0.08)
LD ETN SC		0.46 (0.16,1.50)	0.57 (0.27,1.37)	-0.14 (-0.38,0.07)
LD GOLI IV		0.51 (0.13,2.07)	0.62 (0.21,1.70)	-0.12 (-0.39,0.14)
LD TOCI IV		0.09 (0.01,0.40)	0.13 (0.02,0.46)	-0.28 (-0.51,-0.10)



(Continued)

LD ADA SC + MTX		2.17 (0.70,7.11)	1.55 (0.83,3.37)	0.18 (-0.08,0.43)
LD RITUX IV + MTX		1.06 (0.37,3.23)	1.04 (0.53,2.28)	0.01 (-0.22,0.24)
LD ADA IV + MTX		1.98 (0.23,13.19)	1.46 (0.34,3.71)	0.16 (-0.26,0.54)
LD ABA IV + MTX		1.03 (0.33,3.27)	1.02 (0.48,2.30)	0.01 (-0.25,0.25)
LD ANA SC + MTX		0.95 (0.19,5.03)	0.97 (0.29,2.74)	-0.01 (-0.31,0.36)
LD CERTO SC + MTX		1.96 (0.52,7.60)	1.47 (0.68,3.41)	0.15 (-0.15,0.45)
LD ETN SC + MTX		1.74 (0.48,6.39)	1.39 (0.65,3.29)	0.13 (-0.17,0.40)
LD GOLI IV + MTX		1.02 (0.25,3.92)	1.01 (0.39,2.49)	0.00 (-0.29,0.29)
LD TOCI IV + MTX		0.81 (0.26,2.44)	0.86 (0.39,1.85)	-0.04 (-0.28,0.18)
LD TOFA PO + MTX		1.69 (0.34,7.74)	1.36 (0.50,3.23)	0.12 (-0.23,0.45)
HD TOCI IV		1.29 (0.51,3.31)	1.17 (0.69,2.40)	0.06 (-0.16,0.24)
HD TOFA PO		1.38 (0.37,4.61)	1.22 (0.56,2.95)	0.07 (-0.23,0.32)
HD ADA SC		0.64 (0.18,2.34)	0.73 (0.33,1.88)	-0.09 (-0.36,0.15)
HD ETN SC		0.94 (0.29,3.21)	0.96 (0.46,2.27)	-0.01 (-0.27,0.24)
HD GOLI SC		1.26 (0.39,4.32)	1.16 (0.57,2.76)	0.05 (-0.22,0.31)
HD ABA SC		1.90 (0.35,11.83)	1.45 (0.51,4.05)	0.14 (-0.23,0.54)
HD INF IV + MTX		2.42 (0.81,7.42)	1.63 (0.90,3.53)	0.21 (-0.05,0.44)
HD TOCI IV + MTX		2.33 (0.88,6.34)	1.61 (0.94,3.39)	0.20 (-0.03,0.40)
HD TOFA PO + MTX		2.51 (0.77,8.00)	1.65 (0.88,3.62)	0.21 (-0.06,0.45)
HD GOLI SC + MTX		2.34 (0.71,8.13)	1.60 (0.83,3.76)	0.20 (-0.08,0.46)
HD CERTO SC + MTX		3.34 (1.08,10.66)	1.87 (1.03,4.06)	0.28 (0.02,0.51)
HD ADA SC + MTX		2.76 (0.73,10.83)	1.71 (0.84,3.87)	0.24 (-0.07,0.52)
HD TOCI IV + DMARD		0.48 (0.13,1.88)	0.58 (0.22,1.57)	-0.13 (-0.39,0.12)
SD ANA SC + SD ETN SC + MTX		1.27 (0.32,5.18)	1.16 (0.47,2.80)	0.05 (-0.25,0.36)
SD ANA SC + LD ETN SC + MTX		1.89 (0.47,7.69)	1.44 (0.63,3.35)	0.14 (-0.17,0.45)
SD ADA SC + DMARD	SD CERTO SC + DMARD	0.60 (0.16,2.21)	0.67 (0.22,1.78)	-0.08 (-0.30,0.15)
SD ETN SC + DMARD		2.43 (0.66,9.99)	1.75 (0.76,4.25)	0.19 (-0.09,0.50)

(Continued)

SD TOCI SC + DMARD	0.96 (0.24,3.63)	0.97 (0.33,2.46)	-0.01 (-0.25,0.27)
LD ADA SC	0.65 (0.18,2.32)	0.72 (0.28,1.93)	-0.07 (-0.32,0.13)
LD ETN SC	0.68 (0.21,2.24)	0.74 (0.32,1.86)	-0.06 (-0.30,0.13)
LD GOL I V	0.75 (0.16,3.15)	0.80 (0.24,2.39)	-0.05 (-0.32,0.22)
LD TOCI IV	0.12 (0.02,0.64)	0.16 (0.03,0.68)	-0.20 (-0.43,-0.05)
LD ADA SC + MTX	3.14 (0.82,12.22)	2.02 (0.89,4.88)	0.25 (-0.05,0.52)
LD RITUX IV + MTX	1.52 (0.46,5.28)	1.34 (0.59,3.28)	0.08 (-0.17,0.33)
LD ADA IV + MTX	2.77 (0.33,19.55)	1.85 (0.43,5.19)	0.22 (-0.17,0.62)
LD ABA IV + MTX	1.50 (0.41,5.47)	1.32 (0.54,3.32)	0.08 (-0.18,0.35)
LD ANA SC + MTX	1.39 (0.25,7.96)	1.26 (0.35,3.73)	0.06 (-0.24,0.44)
LD CERTO SC + MTX	2.84 (0.67,12.21)	1.90 (0.77,4.65)	0.23 (-0.08,0.54)
LD ETN SC + MTX	2.54 (0.64,9.87)	1.80 (0.76,4.44)	0.20 (-0.09,0.49)
LD GOL I V + MTX	1.50 (0.35,6.23)	1.32 (0.46,3.53)	0.08 (-0.21,0.38)
LD TOCI IV + MTX	1.15 (0.30,4.82)	1.10 (0.41,3.01)	0.03 (-0.23,0.31)
LD TOFA PO + MTX	2.41 (0.44,12.35)	1.76 (0.56,4.60)	0.19 (-0.16,0.53)
HD TOCI IV	1.87 (0.64,5.60)	1.53 (0.75,3.52)	0.13 (-0.10,0.33)
HD TOFA PO	1.98 (0.59,6.42)	1.58 (0.72,3.76)	0.15 (-0.12,0.37)
HD ADA SC	0.92 (0.26,3.13)	0.94 (0.38,2.46)	-0.01 (-0.26,0.20)
HD ETN SC	1.36 (0.40,4.99)	1.25 (0.53,3.13)	0.06 (-0.19,0.32)
HD GOL I SC	1.83 (0.50,6.69)	1.51 (0.65,3.81)	0.13 (-0.15,0.38)
HD ABA SC	2.77 (0.51,16.05)	1.90 (0.64,5.14)	0.22 (-0.14,0.58)
HD INF IV + MTX	3.49 (1.03,12.10)	2.11 (1.02,4.80)	0.28 (0.01,0.53)
HD TOCI IV + MTX	3.33 (1.03,11.15)	2.08 (1.02,4.74)	0.27 (0.01,0.50)
HD TOFA PO + MTX	3.59 (1.01,12.56)	2.14 (1.01,4.94)	0.29 (0.00,0.54)
HD GOL I SC + MTX	3.41 (1.00,13.70)	2.08 (1.00,5.04)	0.27 (0.00,0.55)
HD CERTO SC + MTX	4.76 (1.39,17.80)	2.42 (1.20,5.58)	0.35 (0.08,0.60)
HD ADA SC + MTX	3.98 (0.87,18.35)	2.22 (0.92,5.31)	0.31 (-0.03,0.61)
HD TOCI IV + DMARD	0.69 (0.22,2.34)	0.75 (0.30,1.91)	-0.06 (-0.27,0.16)

(Continued)

SD ANA SC + SD ETN SC + MTX		1.83 (0.40,8.62)	1.50 (0.52,4.00)	0.13 (-0.19,0.45)
SD ANA SC + LD ETN SC + MTX		2.73 (0.58,12.40)	1.86 (0.70,4.57)	0.22 (-0.11,0.54)
SD ETN SC + DMARD	SD ADA SC + DMARD	4.19 (1.03,16.78)	2.67 (1.02,7.96)	0.27 (0.01,0.53)
SD TOCI SC + DMARD		1.61 (0.45,5.68)	1.44 (0.53,3.88)	0.07 (-0.13,0.31)
LD ADA SC		1.10 (0.25,5.16)	1.08 (0.34,4.15)	0.01 (-0.25,0.19)
LD ETN SC		1.12 (0.30,4.34)	1.10 (0.40,3.61)	0.02 (-0.22,0.19)
LD GOL I IV		1.26 (0.25,6.03)	1.21 (0.34,4.43)	0.03 (-0.23,0.28)
LD TOCI IV		0.21 (0.03,1.31)	0.25 (0.04,1.28)	-0.12 (-0.36,0.02)
LD ADA SC + MTX		5.32 (1.22,21.84)	3.02 (1.15,9.46)	0.34 (0.04,0.57)
LD RITUX IV + MTX		2.61 (0.71,9.79)	2.03 (0.79,6.26)	0.17 (-0.07,0.37)
LD ADA IV + MTX		4.64 (0.55,36.88)	2.76 (0.64,9.90)	0.30 (-0.09,0.69)
LD ABA IV + MTX		2.57 (0.61,9.99)	2.01 (0.71,6.28)	0.16 (-0.10,0.39)
LD ANA SC + MTX		2.33 (0.39,15.09)	1.86 (0.49,6.95)	0.15 (-0.15,0.52)
LD CERTO SC + MTX		4.80 (1.03,20.93)	2.84 (1.02,8.79)	0.31 (0.00,0.58)
LD ETN SC + MTX		4.24 (0.92,18.33)	2.70 (0.95,8.61)	0.28 (-0.02,0.54)
LD GOL I IV + MTX		2.50 (0.53,11.38)	1.98 (0.63,6.55)	0.15 (-0.11,0.44)
LD TOCI IV + MTX		1.96 (0.44,8.68)	1.69 (0.55,5.53)	0.11 (-0.15,0.37)
LD TOFA PO + MTX		4.02 (0.75,22.03)	2.58 (0.82,8.69)	0.27 (-0.05,0.59)
HD TOCI IV		3.12 (0.93,10.30)	2.29 (0.95,6.72)	0.21 (-0.02,0.37)
HD TOFA PO		3.34 (0.77,14.33)	2.38 (0.84,8.27)	0.23 (-0.06,0.44)
HD ADA SC		1.53 (0.37,7.20)	1.41 (0.48,5.23)	0.07 (-0.20,0.27)
HD ETN SC		2.29 (0.55,9.79)	1.86 (0.67,5.97)	0.14 (-0.12,0.38)
HD GOL I SC		3.15 (0.75,12.83)	2.30 (0.82,7.36)	0.21 (-0.06,0.44)
HD ABA SC		4.68 (0.73,35.39)	2.80 (0.79,11.14)	0.30 (-0.07,0.66)
HD INF IV + MTX		5.90 (1.53,22.18)	3.21 (1.28,9.75)	0.36 (0.10,0.58)
HD TOCI IV + MTX		5.62 (1.49,20.38)	3.15 (1.26,9.32)	0.35 (0.09,0.55)
HD TOFA PO + MTX		6.10 (1.44,22.51)	3.25 (1.25,9.98)	0.37 (0.09,0.59)

(Continued)

HD GOLI SC + MTX		5.85 (1.36,23.34)	3.15 (1.20,10.00)	0.36 (0.07,0.59)
HD CERTO SC + MTX		8.25 (2.16,30.92)	3.66 (1.48,11.08)	0.44 (0.17,0.65)
HD ADA SC + MTX		6.84 (1.41,32.79)	3.36 (1.23,10.84)	0.39 (0.07,0.67)
HD TOCI IV + DMARD		1.17 (0.38,3.50)	1.14 (0.47,2.90)	0.02 (-0.16,0.19)
SD ANA SC + SD ETN SC + MTX		3.13 (0.63,15.56)	2.26 (0.72,7.46)	0.20 (-0.09,0.50)
SD ANA SC + LD ETN SC + MTX		4.64 (0.94,21.72)	2.83 (0.96,8.93)	0.30 (-0.01,0.59)
SD TOCI SC + DMARD	SD ETN SC + DMARD	0.39 (0.09,1.50)	0.55 (0.19,1.27)	-0.20 (-0.48,0.09)
LD ADA SC		0.26 (0.07,1.01)	0.40 (0.18,1.01)	-0.27 (-0.54,0.00)
LD ETN SC		0.27 (0.09,0.82)	0.42 (0.21,0.87)	-0.26 (-0.51,-0.04)
LD GOLI IV		0.30 (0.07,1.17)	0.45 (0.16,1.11)	-0.24 (-0.51,0.04)
LD TOCI IV		0.05 (0.01,0.26)	0.09 (0.02,0.36)	-0.40 (-0.66,-0.17)
LD ADA SC + MTX		1.29 (0.41,4.09)	1.13 (0.64,2.23)	0.06 (-0.21,0.33)
LD RITUX IV + MTX		0.62 (0.21,1.88)	0.76 (0.40,1.50)	-0.11 (-0.37,0.14)
LD ADA IV + MTX		1.16 (0.15,7.23)	1.08 (0.28,2.45)	0.03 (-0.38,0.44)
LD ABA IV + MTX		0.61 (0.18,1.97)	0.75 (0.36,1.54)	-0.11 (-0.39,0.16)
LD ANA SC + MTX		0.56 (0.10,3.09)	0.71 (0.21,1.89)	-0.13 (-0.45,0.27)
LD CERTO SC + MTX		1.17 (0.29,4.63)	1.08 (0.51,2.27)	0.04 (-0.29,0.35)
LD ETN SC + MTX		1.03 (0.29,3.59)	1.02 (0.51,2.04)	0.01 (-0.29,0.30)
LD GOLI IV + MTX		0.61 (0.16,2.30)	0.74 (0.31,1.61)	-0.11 (-0.41,0.18)
LD TOCI IV + MTX		0.48 (0.12,1.70)	0.64 (0.25,1.41)	-0.16 (-0.45,0.12)
LD TOFA PO + MTX		1.00 (0.19,4.51)	1.00 (0.37,2.17)	0.00 (-0.36,0.35)
HD TOCI IV		0.77 (0.27,2.14)	0.86 (0.51,1.63)	-0.06 (-0.31,0.17)
HD TOFA PO		0.82 (0.22,2.74)	0.89 (0.46,1.91)	-0.05 (-0.35,0.23)
HD ADA SC		0.37 (0.10,1.42)	0.52 (0.25,1.27)	-0.21 (-0.49,0.07)
HD ETN SC		0.56 (0.18,1.70)	0.71 (0.36,1.41)	-0.13 (-0.39,0.11)
HD GOLI SC		0.75 (0.23,2.38)	0.85 (0.45,1.72)	-0.07 (-0.34,0.19)
HD ABA SC		1.14 (0.20,7.19)	1.07 (0.40,2.73)	0.03 (-0.37,0.44)

(Continued)

HD INF IV + MTX		1.43 (0.45,4.68)	1.19 (0.70,2.32)	0.09 (-0.19,0.36)
HD TOCI IV + MTX		1.35 (0.48,4.16)	1.16 (0.71,2.26)	0.07 (-0.17,0.33)
HD TOFA PO + MTX		1.46 (0.46,4.62)	1.21 (0.70,2.29)	0.09 (-0.19,0.35)
HD GOL I SC + MTX		1.38 (0.43,4.58)	1.17 (0.67,2.32)	0.08 (-0.20,0.36)
HD CERTO SC + MTX		1.98 (0.65,5.90)	1.36 (0.84,2.66)	0.16 (-0.10,0.41)
HD ADA SC + MTX		1.63 (0.45,6.67)	1.25 (0.65,2.55)	0.12 (-0.19,0.43)
HD TOCI IV + DMARD		0.28 (0.08,1.02)	0.43 (0.17,1.02)	-0.25 (-0.51,0.01)
SD ANA SC + SD ETN SC + MTX		0.73 (0.18,3.07)	0.84 (0.35,1.87)	-0.07 (-0.38,0.26)
SD ANA SC + LD ETN SC + MTX		1.10 (0.27,4.41)	1.05 (0.47,2.23)	0.02 (-0.30,0.34)
LD ADA SC	SD TOCI SC + DMARD	0.69 (0.15,2.89)	0.75 (0.26,2.49)	-0.06 (-0.37,0.15)
LD ETN SC		0.72 (0.18,2.77)	0.77 (0.30,2.35)	-0.05 (-0.34,0.14)
LD GOL I IV		0.77 (0.15,3.70)	0.82 (0.24,2.77)	-0.04 (-0.35,0.22)
LD TOCI IV		0.13 (0.02,0.74)	0.17 (0.03,0.76)	-0.19 (-0.49,-0.03)
LD ADA SC + MTX		3.34 (0.82,13.39)	2.09 (0.89,6.26)	0.26 (-0.05,0.52)
LD RITUX IV + MTX		1.60 (0.43,6.16)	1.39 (0.59,4.04)	0.09 (-0.19,0.32)
LD ADA IV + MTX		2.88 (0.34,24.83)	1.91 (0.45,6.86)	0.23 (-0.19,0.65)
LD ABA IV + MTX		1.59 (0.38,6.12)	1.39 (0.54,3.95)	0.09 (-0.22,0.34)
LD ANA SC + MTX		1.47 (0.28,8.57)	1.30 (0.38,4.59)	0.07 (-0.25,0.44)
LD CERTO SC + MTX		3.02 (0.67,13.54)	1.98 (0.78,5.72)	0.23 (-0.09,0.53)
LD ETN SC + MTX		2.65 (0.56,11.24)	1.85 (0.71,5.70)	0.21 (-0.13,0.48)
LD GOL I IV + MTX		1.53 (0.32,7.64)	1.35 (0.46,4.40)	0.08 (-0.24,0.40)
LD TOCI IV + MTX		1.23 (0.28,5.39)	1.16 (0.42,3.63)	0.04 (-0.25,0.31)
LD TOFA PO + MTX		2.59 (0.47,14.40)	1.82 (0.61,5.73)	0.20 (-0.16,0.54)
HD TOCI IV		1.97 (0.59,6.57)	1.59 (0.73,4.24)	0.14 (-0.13,0.33)
HD TOFA PO		2.09 (0.50,8.90)	1.64 (0.67,5.08)	0.16 (-0.16,0.39)
HD ADA SC		0.98 (0.22,4.20)	0.98 (0.36,3.28)	0.00 (-0.32,0.22)
HD ETN SC		1.47 (0.36,6.01)	1.31 (0.52,3.96)	0.07 (-0.22,0.32)

(Continued)

HD GOLI SC		1.94 (0.48,7.88)	1.57 (0.64,4.74)	0.13 (-0.17,0.38)
HD ABA SC		2.90 (0.46,23.04)	1.94 (0.61,7.28)	0.23 (-0.17,0.62)
HD INF IV + MTX		3.70 (0.92,14.22)	2.19 (0.95,6.30)	0.29 (-0.02,0.52)
HD TOCI IV + MTX		3.55 (0.95,12.45)	2.18 (0.97,6.02)	0.28 (-0.01,0.50)
HD TOFA PO + MTX		3.81 (0.95,14.85)	2.24 (0.97,6.42)	0.29 (-0.01,0.54)
HD GOLI SC + MTX		3.63 (0.90,14.77)	2.18 (0.94,6.34)	0.28 (-0.03,0.54)
HD CERTO SC + MTX		5.07 (1.33,19.89)	2.51 (1.15,7.28)	0.36 (0.07,0.60)
HD ADA SC + MTX		4.25 (0.84,20.80)	2.32 (0.91,6.75)	0.31 (-0.04,0.62)
HD TOCI IV + DMARD		0.72 (0.24,2.22)	0.78 (0.35,1.87)	-0.05 (-0.26,0.13)
SD ANA SC + SD ETN SC + MTX		1.97 (0.38,9.73)	1.57 (0.52,4.79)	0.13 (-0.20,0.45)
SD ANA SC + LD ETN SC + MTX		3.01 (0.56,12.97)	1.96 (0.69,5.90)	0.23 (-0.13,0.52)
LD ETN SC	LD ADA SC	1.04 (0.35,2.94)	1.03 (0.42,2.40)	0.01 (-0.16,0.16)
LD GOLI IV		1.15 (0.29,4.45)	1.12 (0.34,3.09)	0.02 (-0.18,0.27)
LD TOCI IV		0.19 (0.03,0.90)	0.23 (0.04,0.91)	-0.13 (-0.28,-0.01)
LD ADA SC + MTX		4.87 (1.49,15.92)	2.83 (1.31,5.92)	0.33 (0.08,0.56)
LD RITUX IV + MTX		2.36 (0.80,6.85)	1.89 (0.85,4.11)	0.16 (-0.04,0.37)
LD ADA IV + MTX		4.39 (0.62,26.94)	2.69 (0.67,6.30)	0.30 (-0.07,0.66)
LD ABA IV + MTX		2.31 (0.66,7.47)	1.86 (0.74,4.26)	0.15 (-0.07,0.39)
LD ANA SC + MTX		2.16 (0.39,11.29)	1.77 (0.46,4.90)	0.14 (-0.13,0.51)
LD CERTO SC + MTX		4.38 (1.11,17.68)	2.71 (1.08,5.91)	0.30 (0.02,0.59)
LD ETN SC + MTX		3.89 (1.08,13.39)	2.52 (1.06,5.44)	0.27 (0.02,0.54)
LD GOLI IV + MTX		2.28 (0.59,8.60)	1.83 (0.66,4.47)	0.15 (-0.09,0.44)
LD TOCI IV + MTX		1.81 (0.49,5.91)	1.57 (0.57,3.64)	0.10 (-0.11,0.35)
LD TOFA PO + MTX		3.79 (0.74,15.77)	2.50 (0.79,5.64)	0.27 (-0.05,0.57)
HD TOCI IV		2.90 (1.06,7.27)	2.15 (1.05,4.29)	0.21 (0.01,0.38)
HD TOFA PO		3.08 (1.11,8.05)	2.22 (1.08,4.53)	0.22 (0.02,0.40)
HD ADA SC		1.41 (0.67,2.96)	1.31 (0.73,2.36)	0.05 (-0.07,0.19)

(Continued)

HD ETN SC		2.12 (0.63,6.81)	1.76 (0.69,4.07)	0.13 (-0.08,0.37)
HD GOLI SC		2.88 (0.90,8.57)	2.12 (0.92,4.70)	0.20 (-0.02,0.42)
HD ABA SC		4.27 (0.90,22.60)	2.65 (0.93,6.40)	0.30 (-0.02,0.63)
HD INF IV + MTX		5.40 (1.69,16.10)	2.99 (1.40,6.04)	0.36 (0.11,0.57)
HD TOCI IV + MTX		5.22 (1.74,14.19)	2.94 (1.43,5.80)	0.35 (0.12,0.54)
HD TOFA PO + MTX		5.51 (1.82,16.31)	2.99 (1.48,6.04)	0.36 (0.13,0.57)
HD GOLI SC + MTX		5.32 (1.53,16.94)	2.96 (1.34,6.13)	0.35 (0.09,0.58)
HD CERTO SC + MTX		7.41 (2.25,23.01)	3.40 (1.66,6.78)	0.44 (0.18,0.64)
HD ADA SC + MTX		6.10 (1.57,24.34)	3.11 (1.37,6.65)	0.39 (0.09,0.65)
HD TOCI IV + DMARD		1.07 (0.28,3.93)	1.05 (0.34,2.76)	0.01 (-0.16,0.24)
SD ANA SC + SD ETN SC + MTX		2.81 (0.67,11.10)	2.09 (0.73,4.98)	0.20 (-0.07,0.50)
SD ANA SC + LD ETN SC + MTX		4.24 (0.97,16.58)	2.64 (0.98,5.85)	0.30 (-0.01,0.58)
LD GOLI IV	LD ETN SC	1.11 (0.33,3.54)	1.09 (0.39,2.59)	0.02 (-0.15,0.24)
LD TOCI IV		0.18 (0.03,0.79)	0.22 (0.04,0.81)	-0.14 (-0.28,-0.02)
LD ADA SC + MTX		4.67 (1.86,12.20)	2.73 (1.50,5.07)	0.32 (0.13,0.54)
LD RITUX IV + MTX		2.26 (0.97,5.21)	1.82 (0.98,3.37)	0.15 (0.00,0.34)
LD ADA IV + MTX		4.10 (0.66,25.89)	2.54 (0.71,5.84)	0.30 (-0.06,0.66)
LD ABA IV + MTX		2.21 (0.89,5.52)	1.80 (0.92,3.38)	0.14 (-0.02,0.35)
LD ANA SC + MTX		2.08 (0.48,9.29)	1.72 (0.54,4.08)	0.13 (-0.10,0.47)
LD CERTO SC + MTX		4.18 (1.39,13.73)	2.59 (1.27,5.14)	0.30 (0.06,0.55)
LD ETN SC + MTX		3.74 (1.36,10.23)	2.44 (1.24,4.59)	0.27 (0.06,0.49)
LD GOLI IV + MTX		2.14 (0.71,6.86)	1.76 (0.76,3.82)	0.14 (-0.06,0.40)
LD TOCI IV + MTX		1.75 (0.54,5.07)	1.53 (0.61,3.27)	0.10 (-0.10,0.33)
LD TOFA PO + MTX		3.63 (0.92,13.79)	2.37 (0.93,5.09)	0.26 (-0.01,0.55)
HD TOCI IV		2.75 (1.33,5.89)	2.06 (1.22,3.69)	0.20 (0.06,0.35)
HD TOFA PO		2.95 (1.04,7.65)	2.15 (1.03,4.40)	0.21 (0.01,0.40)
HD ADA SC		1.35 (0.49,4.07)	1.27 (0.57,3.00)	0.05 (-0.12,0.24)



(Continued)

HD ETN SC		2.03 (0.82,4.99)	1.69 (0.85,3.23)	0.13 (-0.03,0.32)
HD GOLI SC		2.72 (1.08,7.03)	2.06 (1.06,3.99)	0.19 (0.01,0.39)
HD ABA SC		4.14 (0.85,22.78)	2.53 (0.88,6.31)	0.30 (-0.03,0.63)
HD INF IV + MTX		5.17 (2.25,12.14)	2.87 (1.68,5.13)	0.35 (0.17,0.53)
HD TOCI IV + MTX		4.98 (2.21,11.49)	2.83 (1.64,5.15)	0.34 (0.17,0.51)
HD TOFA PO + MTX		5.30 (2.31,12.72)	2.91 (1.67,5.28)	0.35 (0.17,0.54)
HD GOLI SC + MTX		5.08 (2.05,12.85)	2.85 (1.59,5.23)	0.34 (0.15,0.54)
HD CERTO SC + MTX		7.09 (3.03,16.65)	3.29 (1.95,5.89)	0.43 (0.23,0.59)
HD ADA SC + MTX		5.98 (1.81,19.47)	3.02 (1.51,5.84)	0.38 (0.11,0.62)
HD TOCI IV + DMARD		1.02 (0.32,3.40)	1.02 (0.39,2.53)	0.00 (-0.16,0.23)
SD ANA SC + SD ETN SC + MTX		2.69 (0.82,9.62)	2.02 (0.86,4.34)	0.19 (-0.03,0.48)
SD ANA SC + LD ETN SC + MTX		4.01 (1.27,13.05)	2.54 (1.19,5.03)	0.29 (0.04,0.55)
LD TOCI IV	LD GOLI IV	0.17 (0.03,0.91)	0.20 (0.04,0.92)	-0.15 (-0.39,-0.01)
LD ADA SC + MTX		4.25 (1.31,14.65)	2.52 (1.19,6.45)	0.30 (0.06,0.53)
LD RITUX IV + MTX		2.07 (0.67,6.74)	1.70 (0.77,4.45)	0.13 (-0.09,0.34)
LD ADA IV + MTX		3.84 (0.48,26.26)	2.35 (0.55,7.55)	0.27 (-0.12,0.66)
LD ABA IV + MTX		2.02 (0.62,7.01)	1.67 (0.72,4.41)	0.13 (-0.10,0.35)
LD ANA SC + MTX		1.89 (0.36,10.40)	1.59 (0.45,5.05)	0.11 (-0.17,0.48)
LD CERTO SC + MTX		3.84 (1.04,16.07)	2.38 (1.03,6.81)	0.28 (0.01,0.56)
LD ETN SC + MTX		3.42 (0.94,12.61)	2.26 (0.96,6.13)	0.25 (-0.01,0.50)
LD GOLI IV + MTX		1.99 (0.74,5.68)	1.63 (0.81,3.78)	0.12 (-0.06,0.35)
LD TOCI IV + MTX		1.61 (0.39,6.55)	1.42 (0.50,4.14)	0.08 (-0.18,0.33)
LD TOFA PO + MTX		3.29 (0.72,15.29)	2.19 (0.80,6.39)	0.24 (-0.06,0.55)
HD TOCI IV		2.51 (0.84,7.85)	1.93 (0.91,5.00)	0.18 (-0.04,0.36)
HD TOFA PO		2.67 (0.72,9.88)	1.99 (0.81,5.75)	0.20 (-0.08,0.41)
HD ADA SC		1.24 (0.32,5.01)	1.17 (0.44,3.65)	0.03 (-0.22,0.25)
HD ETN SC		1.83 (0.54,6.74)	1.57 (0.65,4.33)	0.11 (-0.13,0.34)

(Continued)

HD GOLI SC		2.47 (0.75,8.14)	1.90 (0.83,5.01)	0.17 (-0.06,0.39)
HD ABA SC		3.74 (0.60,27.98)	2.34 (0.71,8.23)	0.27 (-0.10,0.65)
HD INF IV + MTX		4.69 (1.60,15.36)	2.65 (1.30,6.97)	0.33 (0.11,0.53)
HD TOCI IV + MTX		4.56 (1.52,13.83)	2.62 (1.27,6.60)	0.32 (0.09,0.51)
HD TOFA PO + MTX		4.81 (1.46,16.33)	2.67 (1.23,7.00)	0.33 (0.09,0.56)
HD GOLI SC + MTX		4.62 (1.46,15.62)	2.64 (1.23,6.90)	0.32 (0.08,0.55)
HD CERTO SC + MTX		6.52 (2.12,21.71)	3.02 (1.47,8.12)	0.41 (0.18,0.60)
HD ADA SC + MTX		5.35 (1.40,22.28)	2.80 (1.21,7.36)	0.36 (0.07,0.62)
HD TOCI IV + DMARD		0.93 (0.23,3.99)	0.94 (0.32,3.16)	-0.01 (-0.26,0.22)
SD ANA SC + SD ETN SC + MTX		2.41 (0.61,11.84)	1.87 (0.69,5.82)	0.17 (-0.10,0.48)
SD ANA SC + LD ETN SC + MTX		3.65 (0.85,16.59)	2.31 (0.90,6.80)	0.26 (-0.03,0.55)
LD ADA SC + MTX	LD TOCI IV	25.53 (5.70,150.60)	12.46 (3.50,66.43)	0.46 (0.25,0.68)
LD RITUX IV + MTX		12.12 (3.02,67.88)	8.24 (2.38,43.65)	0.29 (0.14,0.48)
LD ADA IV + MTX		23.04 (2.12,238.20)	11.12 (1.92,70.61)	0.44 (0.07,0.80)
LD ABA IV + MTX		11.85 (2.79,70.60)	8.06 (2.28,45.31)	0.29 (0.12,0.50)
LD ANA SC + MTX		11.47 (1.62,90.12)	7.71 (1.51,42.95)	0.27 (0.04,0.62)
LD CERTO SC + MTX		22.25 (4.67,152.50)	11.39 (3.16,62.75)	0.44 (0.19,0.70)
LD ETN SC + MTX		20.54 (4.45,112.80)	10.99 (3.07,57.41)	0.41 (0.19,0.64)
LD GOLI IV + MTX		11.71 (2.39,76.13)	8.05 (2.04,42.32)	0.28 (0.09,0.55)
LD TOCI IV + MTX		9.40 (2.06,49.65)	6.78 (1.84,32.50)	0.23 (0.07,0.47)
LD TOFA PO + MTX		19.86 (3.10,146.10)	10.62 (2.49,64.70)	0.40 (0.12,0.70)
HD TOCI IV		14.93 (3.90,75.23)	9.42 (2.87,47.66)	0.34 (0.20,0.48)
HD TOFA PO		15.66 (3.47,102.30)	9.71 (2.62,55.93)	0.35 (0.18,0.53)
HD ADA SC		7.35 (1.51,48.47)	5.80 (1.44,33.74)	0.19 (0.05,0.36)
HD ETN SC		11.19 (2.44,60.78)	7.80 (2.04,39.32)	0.27 (0.10,0.49)
HD GOLI SC		14.83 (3.29,82.73)	9.44 (2.55,47.97)	0.33 (0.15,0.53)
HD ABA SC		22.78 (3.05,200.40)	11.47 (2.48,66.75)	0.43 (0.14,0.75)

(Continued)

HD INF IV + MTX		28.18 (6.73,162.10)	13.13 (3.77,69.26)	0.49 (0.30,0.68)
HD TOCI IV + MTX		26.62 (6.91,137.90)	12.86 (3.88,65.61)	0.48 (0.30,0.65)
HD TOFA PO + MTX		28.74 (6.44,171.10)	13.26 (3.78,73.25)	0.50 (0.29,0.69)
HD GOLI SC + MTX		27.56 (5.96,166.40)	12.94 (3.59,69.76)	0.49 (0.27,0.69)
HD CERTO SC + MTX		38.93 (9.22,211.20)	15.06 (4.51,77.16)	0.57 (0.37,0.74)
HD ADA SC + MTX		32.21 (6.08,214.40)	13.87 (3.73,74.13)	0.52 (0.26,0.76)
HD TOCI IV + DMARD		5.61 (1.03,35.62)	4.66 (1.03,26.81)	0.14 (0.00,0.37)
SD ANA SC + SD ETN SC + MTX		15.09 (2.41,97.04)	9.22 (2.04,48.43)	0.33 (0.10,0.62)
SD ANA SC + LD ETN SC + MTX		22.49 (3.81,146.20)	11.54 (2.87,63.49)	0.44 (0.16,0.70)
LD RITUX IV + MTX	LD ADA SC + MTX	0.49 (0.20,1.16)	0.67 (0.41,1.09)	-0.17 (-0.37,0.04)
LD ADA IV + MTX		0.90 (0.15,4.77)	0.95 (0.27,1.84)	-0.02 (-0.38,0.34)
LD ABA IV + MTX		0.47 (0.19,1.20)	0.66 (0.37,1.11)	-0.17 (-0.37,0.04)
LD ANA SC + MTX		0.44 (0.10,2.00)	0.63 (0.21,1.39)	-0.18 (-0.47,0.16)
LD CERTO SC + MTX		0.90 (0.28,3.03)	0.95 (0.50,1.70)	-0.02 (-0.29,0.25)
LD ETN SC + MTX		0.80 (0.26,2.32)	0.90 (0.50,1.53)	-0.05 (-0.31,0.20)
LD GOLI IV + MTX		0.46 (0.15,1.53)	0.64 (0.30,1.24)	-0.18 (-0.43,0.10)
LD TOCI IV + MTX		0.37 (0.11,1.16)	0.56 (0.24,1.10)	-0.22 (-0.47,0.04)
LD TOFA PO + MTX		0.76 (0.19,2.96)	0.88 (0.36,1.62)	-0.06 (-0.36,0.25)
HD TOCI IV		0.59 (0.26,1.36)	0.75 (0.50,1.21)	-0.13 (-0.32,0.07)
HD TOFA PO		0.64 (0.20,1.86)	0.79 (0.43,1.44)	-0.11 (-0.37,0.15)
HD ADA SC		0.29 (0.09,0.98)	0.46 (0.23,0.98)	-0.27 (-0.52,-0.01)
HD ETN SC		0.44 (0.17,1.15)	0.62 (0.34,1.09)	-0.19 (-0.41,0.03)
HD GOLI SC		0.58 (0.21,1.64)	0.75 (0.44,1.31)	-0.13 (-0.36,0.12)
HD ABA SC		0.89 (0.16,4.91)	0.95 (0.36,2.08)	-0.03 (-0.41,0.37)
HD INF IV + MTX		1.11 (0.47,2.56)	1.05 (0.71,1.63)	0.03 (-0.18,0.23)
HD TOCI IV + MTX		1.05 (0.45,2.46)	1.02 (0.70,1.62)	0.01 (-0.18,0.22)
HD TOFA PO + MTX		1.15 (0.48,2.67)	1.06 (0.72,1.65)	0.03 (-0.18,0.23)

(Continued)

HD GOLI SC + MTX		1.07 (0.45,2.77)	1.03 (0.68,1.67)	0.02 (-0.19,0.24)
HD CERTO SC + MTX		1.55 (0.62,3.71)	1.20 (0.83,1.87)	0.10 (-0.11,0.30)
HD ADA SC + MTX		1.26 (0.50,3.32)	1.10 (0.70,1.67)	0.05 (-0.16,0.27)
HD TOCI IV + DMARD		0.22 (0.06,0.79)	0.37 (0.15,0.87)	-0.32 (-0.55,-0.05)
SD ANA SC + SD ETN SC + MTX		0.57 (0.17,2.15)	0.74 (0.34,1.46)	-0.13 (-0.40,0.18)
SD ANA SC + LD ETN SC + MTX		0.86 (0.25,2.99)	0.93 (0.46,1.64)	-0.04 (-0.32,0.26)
LD ADA IV + MTX	LD RITUX IV + MTX	1.85 (0.28,10.98)	1.41 (0.40,3.03)	0.14 (-0.22,0.52)
LD ABA IV + MTX		0.98 (0.43,2.26)	0.99 (0.56,1.67)	0.00 (-0.18,0.18)
LD ANA SC + MTX		0.91 (0.22,4.20)	0.94 (0.30,2.19)	-0.02 (-0.27,0.33)
LD CERTO SC + MTX		1.86 (0.65,5.46)	1.42 (0.75,2.53)	0.15 (-0.10,0.39)
LD ETN SC + MTX		1.62 (0.65,4.27)	1.33 (0.76,2.35)	0.11 (-0.10,0.33)
LD GOLI IV + MTX		0.96 (0.32,2.91)	0.97 (0.44,1.87)	-0.01 (-0.23,0.25)
LD TOCI IV + MTX		0.77 (0.26,2.21)	0.84 (0.37,1.70)	-0.05 (-0.27,0.17)
LD TOFA PO + MTX		1.58 (0.46,5.37)	1.31 (0.59,2.45)	0.11 (-0.16,0.39)
HD TOCI IV		1.21 (0.60,2.57)	1.12 (0.74,1.88)	0.04 (-0.12,0.21)
HD TOFA PO		1.30 (0.45,3.67)	1.17 (0.62,2.39)	0.06 (-0.19,0.28)
HD ADA SC		0.60 (0.21,1.86)	0.70 (0.33,1.58)	-0.10 (-0.32,0.12)
HD ETN SC		0.91 (0.36,2.17)	0.94 (0.51,1.66)	-0.02 (-0.22,0.17)
HD GOLI SC		1.19 (0.47,3.01)	1.12 (0.63,2.04)	0.04 (-0.17,0.25)
HD ABA SC		1.83 (0.37,10.53)	1.41 (0.52,3.31)	0.14 (-0.21,0.52)
HD INF IV + MTX		2.29 (1.04,5.06)	1.57 (1.02,2.56)	0.19 (0.01,0.37)
HD TOCI IV + MTX		2.19 (1.06,4.52)	1.55 (1.03,2.50)	0.18 (0.01,0.35)
HD TOFA PO + MTX		2.36 (1.10,5.07)	1.59 (1.05,2.61)	0.20 (0.02,0.37)
HD GOLI SC + MTX		2.24 (0.93,5.53)	1.56 (0.96,2.66)	0.19 (-0.02,0.39)
HD CERTO SC + MTX		3.14 (1.49,6.76)	1.77 (1.23,2.94)	0.27 (0.10,0.44)
HD ADA SC + MTX		2.59 (0.92,8.01)	1.65 (0.95,2.92)	0.22 (-0.02,0.47)
HD TOCI IV + DMARD		0.45 (0.15,1.41)	0.56 (0.22,1.26)	-0.14 (-0.34,0.07)

(Continued)

SD ANA SC + SD ETN SC + MTX		1.19 (0.38,4.01)	1.11 (0.50,2.21)	0.04 (-0.20,0.33)
SD ANA SC + LD ETN SC + MTX		1.78 (0.54,5.67)	1.40 (0.66,2.56)	0.13 (-0.13,0.40)
LD ABA IV + MTX	LD ADA IV + MTX	0.53 (0.09,3.69)	0.70 (0.32,2.65)	-0.15 (-0.52,0.24)
LD ANA SC + MTX		0.50 (0.06,4.61)	0.68 (0.19,2.88)	-0.15 (-0.59,0.29)
LD CERTO SC + MTX		1.01 (0.15,7.25)	1.00 (0.43,3.59)	0.00 (-0.42,0.41)
LD ETN SC + MTX		0.91 (0.13,6.17)	0.95 (0.41,3.56)	-0.02 (-0.43,0.37)
LD GOLI IV + MTX		0.53 (0.08,4.13)	0.69 (0.26,2.63)	-0.14 (-0.55,0.27)
LD TOCI IV + MTX		0.42 (0.07,3.01)	0.60 (0.23,2.37)	-0.19 (-0.57,0.20)
LD TOFA PO + MTX		0.86 (0.12,7.05)	0.93 (0.32,3.49)	-0.04 (-0.46,0.40)
HD TOCI IV		0.67 (0.12,4.36)	0.80 (0.42,2.94)	-0.10 (-0.46,0.26)
HD TOFA PO		0.70 (0.11,5.26)	0.83 (0.39,3.27)	-0.09 (-0.47,0.32)
HD ADA SC		0.32 (0.05,2.46)	0.49 (0.22,2.01)	-0.25 (-0.61,0.15)
HD ETN SC		0.50 (0.08,3.29)	0.67 (0.29,2.46)	-0.16 (-0.53,0.21)
HD GOLI SC		0.66 (0.11,4.61)	0.80 (0.37,2.91)	-0.10 (-0.48,0.28)
HD ABA SC		0.97 (0.11,12.73)	0.98 (0.34,4.67)	-0.01 (-0.49,0.52)
HD INF IV + MTX		1.25 (0.21,8.23)	1.11 (0.59,4.10)	0.05 (-0.33,0.42)
HD TOCI IV + MTX		1.18 (0.22,7.94)	1.08 (0.59,4.02)	0.04 (-0.32,0.42)
HD TOFA PO + MTX		1.29 (0.24,7.85)	1.12 (0.61,3.92)	0.06 (-0.30,0.42)
HD GOLI SC + MTX		1.21 (0.22,8.24)	1.09 (0.58,4.04)	0.05 (-0.32,0.42)
HD CERTO SC + MTX		1.73 (0.31,10.93)	1.27 (0.68,4.58)	0.13 (-0.24,0.49)
HD ADA SC + MTX		1.40 (0.23,12.60)	1.16 (0.55,4.66)	0.08 (-0.33,0.50)
HD TOCI IV + DMARD		0.26 (0.03,2.01)	0.41 (0.13,1.71)	-0.28 (-0.67,0.11)
SD ANA SC + SD ETN SC + MTX		0.67 (0.09,5.59)	0.80 (0.30,3.00)	-0.09 (-0.52,0.34)
SD ANA SC + LD ETN SC + MTX		0.99 (0.13,7.58)	1.00 (0.39,3.57)	0.00 (-0.44,0.42)
LD ANA SC + MTX	LD ABA IV + MTX	0.91 (0.20,4.66)	0.94 (0.29,2.52)	-0.02 (-0.29,0.34)
LD CERTO SC + MTX		1.91 (0.63,6.04)	1.45 (0.74,2.79)	0.15 (-0.10,0.41)

(Continued)

LD ETN SC + MTX		1.70 (0.57,4.75)	1.36 (0.71,2.52)	0.12 (-0.13,0.36)
LD GOLI IV + MTX		0.97 (0.32,2.95)	0.98 (0.45,1.98)	-0.01 (-0.24,0.24)
LD TOCI IV + MTX		0.78 (0.24,2.42)	0.84 (0.35,1.81)	-0.05 (-0.29,0.19)
LD TOFA PO + MTX		1.61 (0.43,6.11)	1.32 (0.56,2.75)	0.11 (-0.17,0.41)
HD TOCI IV		1.23 (0.55,2.86)	1.14 (0.71,2.11)	0.05 (-0.14,0.22)
HD TOFA PO		1.32 (0.42,3.99)	1.19 (0.60,2.58)	0.06 (-0.20,0.30)
HD ADA SC		0.61 (0.20,2.00)	0.70 (0.33,1.66)	-0.10 (-0.34,0.14)
HD ETN SC		0.91 (0.35,2.36)	0.94 (0.49,1.82)	-0.02 (-0.24,0.18)
HD GOLI SC		1.22 (0.46,3.29)	1.14 (0.62,2.17)	0.04 (-0.18,0.26)
HD ABA SC		1.78 (0.34,11.27)	1.40 (0.49,3.73)	0.13 (-0.24,0.53)
HD INF IV + MTX		2.33 (0.99,5.52)	1.59 (1.00,2.82)	0.20 (0.00,0.39)
HD TOCI IV + MTX		2.21 (0.98,5.30)	1.56 (0.99,2.86)	0.19 (0.00,0.37)
HD TOFA PO + MTX		2.39 (1.03,5.58)	1.61 (1.01,2.78)	0.20 (0.01,0.39)
HD GOLI SC + MTX		2.27 (0.91,5.99)	1.56 (0.95,2.89)	0.19 (-0.02,0.40)
HD CERTO SC + MTX		3.21 (1.37,7.60)	1.81 (1.17,3.32)	0.27 (0.08,0.46)
HD ADA SC + MTX		2.67 (0.86,8.46)	1.67 (0.92,3.16)	0.23 (-0.03,0.48)
HD TOCI IV + DMARD		0.45 (0.14,1.69)	0.57 (0.22,1.43)	-0.14 (-0.36,0.11)
SD ANA SC + SD ETN SC + MTX		1.20 (0.34,4.46)	1.12 (0.47,2.44)	0.04 (-0.23,0.34)
SD ANA SC + LD ETN SC + MTX		1.79 (0.53,6.53)	1.40 (0.67,2.80)	0.13 (-0.14,0.42)
LD CERTO SC + MTX	LD ANA SC + MTX	2.06 (0.40,9.99)	1.51 (0.63,4.88)	0.16 (-0.21,0.47)
LD ETN SC + MTX		1.78 (0.36,8.78)	1.41 (0.60,4.58)	0.13 (-0.24,0.43)
LD GOLI IV + MTX		1.04 (0.21,5.34)	1.03 (0.39,3.31)	0.01 (-0.35,0.33)
LD TOCI IV + MTX		0.84 (0.16,4.23)	0.89 (0.31,2.97)	-0.04 (-0.40,0.26)
LD TOFA PO + MTX		1.72 (0.27,11.39)	1.37 (0.46,5.08)	0.12 (-0.28,0.49)
HD TOCI IV		1.33 (0.33,5.28)	1.20 (0.57,3.73)	0.07 (-0.26,0.30)
HD TOFA PO		1.41 (0.29,6.98)	1.24 (0.52,4.38)	0.08 (-0.29,0.36)
HD ADA SC		0.65 (0.13,3.66)	0.74 (0.28,2.91)	-0.08 (-0.45,0.20)

(Continued)

HD ETN SC		0.98 (0.21,4.57)	0.99 (0.40,3.28)	0.00 (-0.35,0.28)
HD GOLI SC		1.30 (0.28,6.49)	1.18 (0.52,3.96)	0.06 (-0.30,0.35)
HD ABA SC		2.01 (0.23,17.30)	1.49 (0.43,5.94)	0.15 (-0.34,0.59)
HD INF IV + MTX		2.52 (0.57,10.48)	1.68 (0.78,5.22)	0.21 (-0.14,0.48)
HD TOCI IV + MTX		2.39 (0.53,10.14)	1.64 (0.76,5.12)	0.20 (-0.15,0.46)
HD TOFA PO + MTX		2.56 (0.57,11.78)	1.68 (0.78,5.35)	0.22 (-0.13,0.50)
HD GOLI SC + MTX		2.46 (0.52,11.41)	1.66 (0.73,5.36)	0.21 (-0.16,0.50)
HD CERTO SC + MTX		3.48 (0.80,14.93)	1.93 (0.93,5.96)	0.29 (-0.05,0.55)
HD ADA SC + MTX		2.87 (0.57,14.52)	1.73 (0.77,5.56)	0.24 (-0.14,0.55)
HD TOCI IV + DMARD		0.50 (0.09,2.44)	0.60 (0.19,2.03)	-0.12 (-0.48,0.14)
SD ANA SC + SD ETN SC + MTX		1.34 (0.24,7.63)	1.19 (0.43,4.02)	0.06 (-0.32,0.40)
SD ANA SC + LD ETN SC + MTX		1.96 (0.34,11.07)	1.46 (0.55,4.94)	0.15 (-0.25,0.49)
LD ETN SC + MTX	LD CERTO SC + MTX	0.87 (0.25,2.86)	0.93 (0.50,1.83)	-0.03 (-0.32,0.24)
LD GOLI IV + MTX		0.52 (0.14,1.99)	0.69 (0.30,1.49)	-0.15 (-0.43,0.16)
LD TOCI IV + MTX		0.41 (0.10,1.53)	0.59 (0.24,1.31)	-0.20 (-0.49,0.09)
LD TOFA PO + MTX		0.86 (0.19,3.62)	0.92 (0.37,1.95)	-0.04 (-0.36,0.29)
HD TOCI IV		0.66 (0.22,1.84)	0.80 (0.48,1.51)	-0.10 (-0.35,0.13)
HD TOFA PO		0.70 (0.17,2.49)	0.83 (0.42,1.81)	-0.09 (-0.41,0.20)
HD ADA SC		0.32 (0.08,1.30)	0.48 (0.23,1.19)	-0.25 (-0.54,0.05)
HD ETN SC		0.48 (0.16,1.57)	0.66 (0.34,1.35)	-0.16 (-0.42,0.10)
HD GOLI SC		0.64 (0.19,2.11)	0.79 (0.43,1.60)	-0.11 (-0.39,0.17)
HD ABA SC		0.98 (0.16,6.38)	0.99 (0.36,2.50)	0.00 (-0.41,0.42)
HD INF IV + MTX		1.22 (0.42,3.54)	1.10 (0.69,2.09)	0.05 (-0.20,0.29)
HD TOCI IV + MTX		1.18 (0.41,3.38)	1.09 (0.68,2.04)	0.04 (-0.21,0.28)
HD TOFA PO + MTX		1.27 (0.43,3.74)	1.12 (0.70,2.08)	0.06 (-0.20,0.30)
HD GOLI SC + MTX		1.20 (0.39,3.86)	1.09 (0.65,2.10)	0.04 (-0.22,0.32)
HD CERTO SC + MTX		1.70 (0.68,4.09)	1.26 (0.86,2.19)	0.13 (-0.09,0.33)



(Continued)

HD ADA SC + MTX		1.42 (0.37,5.40)	1.16 (0.62,2.27)	0.08 (-0.23,0.38)
HD TOCI IV + DMARD		0.24 (0.06,0.97)	0.40 (0.15,0.97)	-0.29 (-0.57,-0.01)
SD ANA SC + SD ETN SC + MTX		0.64 (0.15,2.60)	0.79 (0.33,1.71)	-0.10 (-0.42,0.22)
SD ANA SC + LD ETN SC + MTX		0.97 (0.22,3.75)	0.98 (0.45,1.98)	-0.01 (-0.34,0.31)
LD GOLI IV + MTX	LD ETN SC + MTX	0.58 (0.17,2.03)	0.73 (0.33,1.52)	-0.12 (-0.38,0.17)
LD TOCI IV + MTX		0.46 (0.13,1.54)	0.63 (0.26,1.33)	-0.17 (-0.43,0.10)
LD TOFA PO + MTX		0.98 (0.24,4.00)	0.99 (0.39,2.06)	0.00 (-0.32,0.32)
HD TOCI IV		0.74 (0.30,1.94)	0.84 (0.53,1.54)	-0.07 (-0.29,0.15)
HD TOFA PO		0.79 (0.21,2.56)	0.88 (0.45,1.77)	-0.06 (-0.36,0.22)
HD ADA SC		0.36 (0.10,1.25)	0.52 (0.25,1.17)	-0.22 (-0.49,0.05)
HD ETN SC		0.54 (0.19,1.60)	0.69 (0.38,1.35)	-0.14 (-0.37,0.10)
HD GOLI SC		0.73 (0.25,2.18)	0.84 (0.47,1.61)	-0.07 (-0.31,0.18)
HD ABA SC		1.11 (0.20,6.49)	1.06 (0.38,2.51)	0.03 (-0.37,0.42)
HD INF IV + MTX		1.40 (0.54,3.72)	1.18 (0.75,2.06)	0.08 (-0.15,0.31)
HD TOCI IV + MTX		1.33 (0.50,3.47)	1.15 (0.73,2.07)	0.07 (-0.16,0.29)
HD TOFA PO + MTX		1.44 (0.52,3.90)	1.19 (0.73,2.14)	0.09 (-0.16,0.32)
HD GOLI SC + MTX		1.37 (0.48,4.04)	1.16 (0.71,2.10)	0.08 (-0.17,0.33)
HD CERTO SC + MTX		1.92 (0.74,5.30)	1.34 (0.88,2.42)	0.16 (-0.07,0.38)
HD ADA SC + MTX		1.58 (0.46,5.79)	1.23 (0.68,2.37)	0.11 (-0.18,0.39)
HD TOCI IV + DMARD		0.27 (0.08,1.05)	0.42 (0.16,1.04)	-0.26 (-0.51,0.01)
SD ANA SC + SD ETN SC + MTX		0.73 (0.21,2.58)	0.83 (0.37,1.70)	-0.07 (-0.34,0.23)
SD ANA SC + LD ETN SC + MTX		1.08 (0.33,3.87)	1.04 (0.52,2.01)	0.02 (-0.26,0.31)
LD TOCI IV + MTX	LD GOLI IV + MTX	0.79 (0.20,3.00)	0.85 (0.33,2.15)	-0.05 (-0.33,0.22)
LD TOFA PO + MTX		1.68 (0.34,7.25)	1.36 (0.50,3.21)	0.12 (-0.23,0.44)
HD TOCI IV		1.27 (0.42,3.58)	1.17 (0.62,2.48)	0.05 (-0.21,0.26)
HD TOFA PO		1.35 (0.36,4.50)	1.20 (0.57,2.84)	0.07 (-0.24,0.31)

(Continued)

HD ADA SC		0.62 (0.16,2.42)	0.72 (0.30,1.92)	-0.09 (-0.39,0.16)
HD ETN SC		0.93 (0.28,3.25)	0.95 (0.46,2.26)	-0.02 (-0.29,0.23)
HD GOLI SC		1.24 (0.41,3.80)	1.15 (0.59,2.48)	0.05 (-0.21,0.28)
HD ABA SC		1.89 (0.32,12.68)	1.44 (0.49,4.06)	0.15 (-0.25,0.54)
HD INF IV + MTX		2.35 (0.82,7.16)	1.62 (0.90,3.50)	0.20 (-0.05,0.43)
HD TOCI IV + MTX		2.28 (0.77,6.69)	1.59 (0.88,3.39)	0.19 (-0.06,0.41)
HD TOFA PO + MTX		2.46 (0.75,7.74)	1.63 (0.87,3.64)	0.21 (-0.07,0.44)
HD GOLI SC + MTX		2.32 (0.75,7.19)	1.59 (0.87,3.49)	0.20 (-0.07,0.44)
HD CERTO SC + MTX		3.29 (1.08,10.01)	1.84 (1.03,4.04)	0.28 (0.02,0.50)
HD ADA SC + MTX		2.72 (0.72,9.55)	1.70 (0.84,3.75)	0.23 (-0.08,0.50)
HD TOCI IV + DMARD		0.46 (0.12,1.91)	0.57 (0.21,1.61)	-0.13 (-0.41,0.12)
SD ANA SC + SD ETN SC + MTX		1.25 (0.29,5.44)	1.15 (0.45,2.89)	0.05 (-0.26,0.38)
SD ANA SC + LD ETN SC + MTX		1.83 (0.46,7.74)	1.41 (0.62,3.45)	0.14 (-0.18,0.44)
LD TOFA PO + MTX	LD TOCI IV + MTX	2.10 (0.44,9.63)	1.57 (0.56,3.92)	0.16 (-0.16,0.49)
HD TOCI IV		1.60 (0.63,4.23)	1.36 (0.77,2.90)	0.10 (-0.11,0.28)
HD TOFA PO		1.70 (0.51,5.90)	1.41 (0.66,3.53)	0.12 (-0.16,0.35)
HD ADA SC		0.77 (0.23,2.91)	0.83 (0.35,2.29)	-0.05 (-0.30,0.19)
HD ETN SC		1.17 (0.38,4.05)	1.12 (0.52,2.73)	0.03 (-0.22,0.29)
HD GOLI SC		1.55 (0.49,5.07)	1.33 (0.63,3.18)	0.09 (-0.16,0.34)
HD ABA SC		2.40 (0.42,15.15)	1.68 (0.56,5.08)	0.19 (-0.19,0.57)
HD INF IV + MTX		2.99 (1.08,9.45)	1.88 (1.04,4.25)	0.25 (0.02,0.49)
HD TOCI IV + MTX		2.87 (1.08,7.82)	1.87 (1.04,3.99)	0.24 (0.02,0.43)
HD TOFA PO + MTX		3.07 (1.00,9.38)	1.90 (1.00,4.35)	0.26 (0.00,0.48)
HD GOLI SC + MTX		2.87 (0.89,10.00)	1.85 (0.94,4.31)	0.24 (-0.03,0.49)
HD CERTO SC + MTX		4.16 (1.36,12.90)	2.16 (1.15,4.86)	0.33 (0.07,0.55)
HD ADA SC + MTX		3.39 (0.89,13.77)	1.98 (0.93,4.69)	0.28 (-0.03,0.56)
HD TOCI IV + DMARD		0.60 (0.16,2.30)	0.68 (0.25,1.86)	-0.09 (-0.34,0.16)

(Continued)

SD ANA SC + SD ETN SC + MTX		1.57 (0.41,6.71)	1.33 (0.55,3.50)	0.09 (-0.19,0.42)
SD ANA SC + LD ETN SC + MTX		2.37 (0.60,10.10)	1.67 (0.71,4.07)	0.19 (-0.11,0.50)
HD TOCI IV	LD TOFA PO + MTX	0.76 (0.22,2.84)	0.85 (0.49,2.18)	-0.07 (-0.35,0.21)
HD TOFA PO		0.81 (0.19,3.83)	0.89 (0.44,2.52)	-0.05 (-0.38,0.27)
HD ADA SC		0.37 (0.09,1.85)	0.53 (0.23,1.57)	-0.21 (-0.52,0.11)
HD ETN SC		0.57 (0.15,2.26)	0.71 (0.35,1.77)	-0.13 (-0.43,0.17)
HD GOLI SC		0.74 (0.20,3.12)	0.85 (0.44,2.15)	-0.07 (-0.37,0.23)
HD ABA SC		1.16 (0.16,8.45)	1.08 (0.38,3.27)	0.03 (-0.41,0.47)
HD INF IV + MTX		1.45 (0.39,5.44)	1.20 (0.68,2.88)	0.09 (-0.21,0.37)
HD TOCI IV + MTX		1.35 (0.40,5.29)	1.16 (0.68,2.88)	0.07 (-0.21,0.36)
HD TOFA PO + MTX		1.48 (0.49,4.58)	1.20 (0.75,2.60)	0.09 (-0.16,0.33)
HD GOLI SC + MTX		1.40 (0.39,5.69)	1.18 (0.66,2.85)	0.08 (-0.22,0.39)
HD CERTO SC + MTX		2.01 (0.56,7.16)	1.37 (0.81,3.39)	0.17 (-0.13,0.43)
HD ADA SC + MTX		1.64 (0.37,7.93)	1.25 (0.64,3.23)	0.11 (-0.23,0.45)
HD TOCI IV + DMARD		0.28 (0.06,1.35)	0.43 (0.15,1.24)	-0.25 (-0.57,0.05)
SD ANA SC + SD ETN SC + MTX		0.75 (0.15,3.85)	0.85 (0.33,2.27)	-0.07 (-0.41,0.30)
SD ANA SC + LD ETN SC + MTX		1.14 (0.22,5.38)	1.07 (0.45,2.75)	0.03 (-0.34,0.37)
HD TOFA PO	HD TOCI IV	1.08 (0.41,2.57)	1.05 (0.57,1.78)	0.02 (-0.21,0.22)
HD ADA SC		0.48 (0.20,1.28)	0.61 (0.32,1.18)	-0.15 (-0.33,0.05)
HD ETN SC		0.74 (0.31,1.78)	0.82 (0.46,1.39)	-0.07 (-0.24,0.13)
HD GOLI SC		0.98 (0.42,2.30)	0.99 (0.57,1.63)	-0.01 (-0.19,0.20)
HD ABA SC		1.45 (0.34,7.89)	1.22 (0.48,2.68)	0.09 (-0.24,0.46)
HD INF IV + MTX		1.88 (0.93,3.87)	1.40 (0.96,2.00)	0.15 (-0.02,0.32)
HD TOCI IV + MTX		1.79 (1.03,3.11)	1.37 (1.02,1.82)	0.14 (0.01,0.27)
HD TOFA PO + MTX		1.94 (0.87,4.04)	1.41 (0.92,2.06)	0.16 (-0.03,0.33)
HD GOLI SC + MTX		1.84 (0.81,4.44)	1.37 (0.88,2.08)	0.15 (-0.05,0.35)

(Continued)

HD CERTO SC + MTX		2.57 (1.29,5.38)	1.59 (1.14,2.27)	0.23 (0.06,0.39)
HD ADA SC + MTX		2.17 (0.71,6.31)	1.48 (0.82,2.29)	0.19 (-0.08,0.41)
HD TOCI IV + DMARD		0.37 (0.14,1.05)	0.49 (0.21,1.03)	-0.19 (-0.35,0.01)
SD ANA SC + SD ETN SC + MTX		0.98 (0.31,3.04)	0.99 (0.44,1.80)	0.00 (-0.24,0.27)
SD ANA SC + LD ETN SC + MTX		1.46 (0.45,4.56)	1.24 (0.60,2.09)	0.09 (-0.17,0.35)
HD ADA SC	HD TOFA PO	0.46 (0.17,1.32)	0.59 (0.29,1.21)	-0.16 (-0.36,0.06)
HD ETN SC		0.68 (0.23,2.29)	0.78 (0.37,1.64)	-0.09 (-0.30,0.19)
HD GOLI SC		0.93 (0.33,2.63)	0.96 (0.50,1.81)	-0.02 (-0.25,0.23)
HD ABA SC		1.42 (0.31,7.05)	1.20 (0.47,2.49)	0.09 (-0.26,0.44)
HD INF IV + MTX		1.75 (0.64,5.29)	1.34 (0.78,2.41)	0.14 (-0.11,0.39)
HD TOCI IV + MTX		1.69 (0.62,4.72)	1.31 (0.77,2.28)	0.13 (-0.11,0.36)
HD TOFA PO + MTX		1.82 (0.65,5.22)	1.36 (0.79,2.36)	0.15 (-0.10,0.38)
HD GOLI SC + MTX		1.73 (0.57,5.23)	1.33 (0.72,2.37)	0.13 (-0.14,0.39)
HD CERTO SC + MTX		2.44 (0.87,7.25)	1.53 (0.93,2.65)	0.22 (-0.03,0.45)
HD ADA SC + MTX		2.00 (0.55,7.96)	1.42 (0.70,2.61)	0.17 (-0.14,0.46)
HD TOCI IV + DMARD		0.35 (0.09,1.29)	0.48 (0.17,1.17)	-0.21 (-0.41,0.05)
SD ANA SC + SD ETN SC + MTX		0.91 (0.24,3.71)	0.95 (0.38,1.96)	-0.02 (-0.30,0.31)
SD ANA SC + LD ETN SC + MTX		1.36 (0.35,5.27)	1.18 (0.51,2.29)	0.07 (-0.23,0.39)
HD ETN SC	HD ADA SC	1.54 (0.43,4.77)	1.36 (0.54,2.89)	0.08 (-0.16,0.32)
HD GOLI SC		2.03 (0.61,6.02)	1.63 (0.71,3.38)	0.15 (-0.10,0.38)
HD ABA SC		3.03 (0.62,15.42)	2.02 (0.72,4.66)	0.24 (-0.09,0.58)
HD INF IV + MTX		3.85 (1.22,11.95)	2.29 (1.13,4.47)	0.30 (0.04,0.53)
HD TOCI IV + MTX		3.68 (1.26,10.12)	2.24 (1.15,4.29)	0.29 (0.05,0.49)
HD TOFA PO + MTX		3.93 (1.33,11.68)	2.30 (1.19,4.49)	0.31 (0.07,0.53)
HD GOLI SC + MTX		3.78 (1.11,11.88)	2.26 (1.07,4.47)	0.30 (0.02,0.54)
HD CERTO SC + MTX		5.31 (1.67,15.81)	2.61 (1.36,4.92)	0.38 (0.12,0.59)

(Continued)

HD ADA SC + MTX		4.34 (1.09,16.97)	2.39 (1.06,4.78)	0.33 (0.02,0.60)
HD TOCI IV + DMARD		0.75 (0.21,2.89)	0.80 (0.28,2.17)	-0.05 (-0.24,0.21)
SD ANA SC + SD ETN SC + MTX		2.00 (0.46,7.90)	1.60 (0.56,3.66)	0.14 (-0.14,0.46)
SD ANA SC + LD ETN SC + MTX		3.04 (0.69,11.57)	2.01 (0.77,4.17)	0.24 (-0.07,0.54)
HD GOLI SC	HD ETN SC	1.34 (0.49,3.53)	1.21 (0.63,2.32)	0.06 (-0.16,0.29)
HD ABA SC		2.05 (0.39,11.60)	1.52 (0.54,3.72)	0.16 (-0.21,0.53)
HD INF IV + MTX		2.55 (1.06,6.32)	1.68 (1.03,3.03)	0.22 (0.01,0.41)
HD TOCI IV + MTX		2.44 (0.96,5.82)	1.66 (0.98,3.02)	0.21 (-0.01,0.39)
HD TOFA PO + MTX		2.62 (1.03,6.51)	1.72 (1.01,3.00)	0.22 (0.01,0.43)
HD GOLI SC + MTX		2.51 (0.93,6.81)	1.68 (0.96,3.12)	0.21 (-0.02,0.43)
HD CERTO SC + MTX		3.52 (1.39,8.85)	1.93 (1.19,3.43)	0.29 (0.08,0.49)
HD ADA SC + MTX		2.91 (0.85,9.56)	1.78 (0.91,3.37)	0.24 (-0.04,0.50)
HD TOCI IV + DMARD		0.51 (0.15,1.74)	0.61 (0.23,1.48)	-0.12 (-0.36,0.11)
SD ANA SC + SD ETN SC + MTX		1.31 (0.37,4.89)	1.19 (0.50,2.49)	0.06 (-0.20,0.35)
SD ANA SC + LD ETN SC + MTX		1.98 (0.56,6.95)	1.49 (0.69,2.97)	0.15 (-0.13,0.44)
HD ABA SC	HD GOLI SC	1.53 (0.30,8.55)	1.26 (0.47,2.95)	0.10 (-0.27,0.48)
HD INF IV + MTX		1.93 (0.76,4.66)	1.41 (0.87,2.35)	0.16 (-0.06,0.36)
HD TOCI IV + MTX		1.83 (0.77,4.34)	1.38 (0.86,2.35)	0.14 (-0.06,0.34)
HD TOFA PO + MTX		1.97 (0.74,4.83)	1.43 (0.85,2.41)	0.16 (-0.07,0.37)
HD GOLI SC + MTX		1.88 (0.78,4.38)	1.39 (0.88,2.23)	0.15 (-0.06,0.35)
HD CERTO SC + MTX		2.63 (1.05,6.51)	1.60 (1.02,2.68)	0.23 (0.01,0.43)
HD ADA SC + MTX		2.19 (0.68,7.50)	1.48 (0.80,2.66)	0.19 (-0.09,0.45)
HD TOCI IV + DMARD		0.38 (0.11,1.36)	0.50 (0.20,1.23)	-0.19 (-0.42,0.07)
SD ANA SC + SD ETN SC + MTX		0.98 (0.28,3.66)	0.99 (0.42,2.02)	0.00 (-0.27,0.31)
SD ANA SC + LD ETN SC + MTX		1.50 (0.41,5.27)	1.25 (0.58,2.36)	0.10 (-0.20,0.38)

(Continued)

HD INF IV + MTX	HD ABA SC	1.28 (0.24,6.28)	1.12 (0.54,2.82)	0.06 (-0.33,0.41)
HD TOCI IV + MTX		1.22 (0.21,5.94)	1.10 (0.51,2.87)	0.05 (-0.36,0.40)
HD TOFA PO + MTX		1.30 (0.24,6.77)	1.13 (0.55,2.99)	0.06 (-0.33,0.43)
HD GOLI SC + MTX		1.26 (0.22,6.45)	1.11 (0.50,2.97)	0.06 (-0.35,0.42)
HD CERTO SC + MTX		1.73 (0.30,8.54)	1.27 (0.65,3.26)	0.13 (-0.26,0.48)
HD ADA SC + MTX		1.43 (0.22,8.63)	1.17 (0.52,3.08)	0.08 (-0.34,0.48)
HD TOCI IV + DMARD		0.25 (0.04,1.54)	0.40 (0.12,1.32)	-0.28 (-0.65,0.09)
SD ANA SC + SD ETN SC + MTX		0.66 (0.09,3.85)	0.80 (0.28,2.18)	-0.10 (-0.52,0.31)
SD ANA SC + LD ETN SC + MTX		1.00 (0.14,5.90)	1.00 (0.38,2.72)	0.00 (-0.44,0.40)
HD TOCI IV + MTX	HD INF IV + MTX	0.95 (0.45,2.05)	0.98 (0.69,1.41)	-0.01 (-0.19,0.17)
HD TOFA PO + MTX		1.04 (0.45,2.32)	1.02 (0.69,1.49)	0.01 (-0.19,0.20)
HD GOLI SC + MTX		0.97 (0.40,2.34)	0.99 (0.64,1.48)	-0.01 (-0.22,0.20)
HD CERTO SC + MTX		1.38 (0.63,2.98)	1.14 (0.82,1.62)	0.08 (-0.11,0.25)
HD ADA SC + MTX		1.14 (0.38,3.46)	1.06 (0.61,1.65)	0.03 (-0.23,0.28)
HD TOCI IV + DMARD		0.19 (0.06,0.65)	0.35 (0.14,0.79)	-0.34 (-0.55,-0.10)
SD ANA SC + SD ETN SC + MTX		0.51 (0.16,1.69)	0.71 (0.32,1.29)	-0.16 (-0.40,0.12)
SD ANA SC + LD ETN SC + MTX		0.78 (0.26,2.44)	0.89 (0.44,1.47)	-0.06 (-0.31,0.21)
HD TOFA PO + MTX	HD TOCI IV + MTX	1.08 (0.50,2.43)	1.04 (0.70,1.49)	0.02 (-0.17,0.21)
HD GOLI SC + MTX		1.03 (0.44,2.50)	1.01 (0.66,1.50)	0.01 (-0.20,0.22)
HD CERTO SC + MTX		1.43 (0.67,3.18)	1.16 (0.84,1.65)	0.09 (-0.10,0.27)
HD ADA SC + MTX		1.19 (0.41,3.65)	1.08 (0.62,1.65)	0.04 (-0.21,0.28)
HD TOCI IV + DMARD		0.21 (0.07,0.66)	0.36 (0.15,0.79)	-0.33 (-0.52,-0.10)
SD ANA SC + SD ETN SC + MTX		0.55 (0.18,1.81)	0.73 (0.33,1.31)	-0.14 (-0.38,0.15)
SD ANA SC + LD ETN SC + MTX		0.81 (0.25,2.63)	0.91 (0.43,1.54)	-0.05 (-0.32,0.23)
HD GOLI SC + MTX	HD TOFA PO + MTX	0.95 (0.37,2.42)	0.98 (0.62,1.49)	-0.01 (-0.23,0.21)

(Continued)

HD CERTO SC + MTX		1.34 (0.62,2.99)	1.12 (0.81,1.63)	0.07 (-0.12,0.25)
HD ADA SC + MTX		1.09 (0.39,3.55)	1.04 (0.61,1.63)	0.02 (-0.22,0.28)
HD TOCI IV + DMARD		0.19 (0.06,0.68)	0.35 (0.14,0.80)	-0.35 (-0.56,-0.09)
SD ANA SC + SD ETN SC + MTX		0.51 (0.15,1.83)	0.70 (0.31,1.31)	-0.16 (-0.43,0.14)
SD ANA SC + LD ETN SC + MTX		0.76 (0.21,2.54)	0.88 (0.42,1.51)	-0.07 (-0.35,0.22)
HD CERTO SC + MTX	HD GOLI SC + MTX	1.42 (0.58,3.45)	1.15 (0.80,1.76)	0.08 (-0.13,0.29)
HD ADA SC + MTX		1.17 (0.37,3.71)	1.07 (0.59,1.75)	0.04 (-0.24,0.29)
HD TOCI IV + DMARD		0.20 (0.06,0.71)	0.36 (0.14,0.82)	-0.33 (-0.57,-0.08)
SD ANA SC + SD ETN SC + MTX		0.53 (0.15,1.94)	0.72 (0.31,1.39)	-0.15 (-0.42,0.15)
SD ANA SC + LD ETN SC + MTX		0.80 (0.23,2.79)	0.90 (0.42,1.57)	-0.05 (-0.34,0.23)
HD ADA SC + MTX	HD CERTO SC + MTX	0.82 (0.28,2.59)	0.93 (0.54,1.40)	-0.05 (-0.30,0.20)
HD TOCI IV + DMARD		0.14 (0.05,0.46)	0.31 (0.13,0.67)	-0.42 (-0.61,-0.18)
SD ANA SC + SD ETN SC + MTX		0.38 (0.11,1.26)	0.62 (0.28,1.11)	-0.23 (-0.49,0.05)
SD ANA SC + LD ETN SC + MTX		0.56 (0.17,1.96)	0.78 (0.38,1.28)	-0.14 (-0.41,0.15)
HD TOCI IV + DMARD	HD ADA SC + MTX	0.17 (0.04,0.77)	0.34 (0.13,0.85)	-0.37 (-0.63,-0.06)
SD ANA SC + SD ETN SC + MTX		0.46 (0.11,1.88)	0.67 (0.30,1.39)	-0.18 (-0.48,0.15)
SD ANA SC + LD ETN SC + MTX		0.69 (0.17,2.78)	0.84 (0.40,1.62)	-0.08 (-0.40,0.24)
SD ANA SC + SD ETN SC + MTX	HD TOCI IV + DMARD	2.66 (0.61,11.12)	1.99 (0.70,5.51)	0.18 (-0.10,0.48)
SD ANA SC + LD ETN SC + MTX		3.96 (0.90,15.38)	2.47 (0.94,6.49)	0.28 (-0.02,0.56)
SD ANA SC + LD ETN SC + MTX	SD ANA SC + SD ETN SC + MTX	1.49 (0.55,4.14)	1.24 (0.72,2.35)	0.09 (-0.13,0.32)
Random-Effect Model	Residual Deviance	212.5 vs 213 data points		



(Continued)

	Deviance Information Criteria	1368.54
Fixed-Effect Model	Residual Deviance	333.4 vs 213 data points
	Deviance Information Criteria	1449.97
Note:		
Total Patients	30229	
Total Studies	79	
2-arm	38	
3-arm	33	
4-arm	6	
5-arm	1	
7-arm	1	

### Appendix 5. ACR50: Subgroup - Established RA (2 to 10 years)

ACR50 in Established RA: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX	PL	3.01 (1.47,6.08)	2.68 (1.43,4.76)	0.10 (0.03,0.21)
DMARD		0.84 (0.34,2.09)	0.85 (0.36,1.97)	-0.01 (-0.04,0.05)
MTX + DMARD		4.04 (1.64,9.92)	3.40 (1.57,6.61)	0.14 (0.04,0.32)
SD ETN SC		5.37 (2.65,11.01)	4.25 (2.40,7.11)	0.20 (0.09,0.34)
SD ADA SC		3.77 (1.96,7.47)	3.23 (1.84,5.56)	0.13 (0.05,0.25)
SD TOFA PO		6.61 (3.30,13.96)	4.94 (2.87,8.12)	0.24 (0.12,0.40)
SD TOCI IV		4.76 (1.89,11.98)	3.88 (1.78,7.41)	0.17 (0.05,0.37)
SD GOLI SC		7.48 (2.54,22.98)	5.37 (2.31,10.43)	0.26 (0.08,0.53)
SD GOLI IV		5.61 (1.70,18.79)	4.37 (1.63,9.29)	0.20 (0.04,0.48)
SD ABA SC		10.25 (2.56,47.10)	6.54 (2.33,13.59)	0.34 (0.08,0.68)

(Continued)

SD CERTO SC	9.70 (3.03,32.66)	6.33 (2.69,11.66)	0.32 (0.10,0.61)
SD ETN SC + MTX	10.23 (4.69,22.42)	6.55 (3.78,10.40)	0.34 (0.17,0.52)
SD INF IV + MTX	9.01 (3.97,20.72)	6.07 (3.35,10.05)	0.31 (0.15,0.50)
SD ABA IV + MTX	11.51 (4.85,26.93)	7.02 (3.90,11.23)	0.36 (0.18,0.56)
SD CERTO SC + MTX	17.37 (7.32,41.58)	8.68 (5.19,13.11)	0.47 (0.26,0.66)
SD TOFA PO + MTX	18.69 (7.47,51.23)	9.00 (5.23,13.94)	0.48 (0.26,0.70)
SD GOLI SC + MTX	20.69 (8.35,53.21)	9.39 (5.61,13.89)	0.51 (0.29,0.70)
SD ADA SC + MTX	12.42 (3.61,44.27)	7.34 (3.09,13.11)	0.38 (0.13,0.67)
SD RITUX IV + MTX	6.43 (2.42,18.59)	4.85 (2.22,9.41)	0.23 (0.07,0.47)
SD GOLI IV + MTX	7.23 (2.75,19.67)	5.24 (2.47,9.63)	0.26 (0.09,0.49)
SD ABA SC + MTX	12.38 (3.67,41.58)	7.30 (3.14,12.96)	0.38 (0.13,0.66)
SD ANA SC + MTX	15.95 (2.40,129.30)	8.35 (2.22,16.03)	0.44 (0.07,0.83)
SD TOCI IV + MTX	6.45 (1.99,20.90)	4.85 (1.87,9.96)	0.23 (0.05,0.50)
SD CERTO SC + DMARD	4.83 (1.75,13.91)	3.92 (1.67,8.05)	0.18 (0.04,0.40)
SD ADA SC + DMARD	2.67 (0.74,10.00)	2.42 (0.75,6.62)	0.09 (-0.02,0.32)
SD ETN SC + DMARD	10.60 (3.43,34.78)	6.67 (2.98,12.03)	0.34 (0.12,0.62)
LD ADA SC	3.47 (1.47,8.34)	3.02 (1.43,5.94)	0.12 (0.03,0.28)
LD GOLI IV	3.32 (0.95,11.16)	2.90 (0.96,7.10)	0.11 (0.00,0.35)
LD TOCI IV	0.59 (0.10,2.51)	0.61 (0.11,2.31)	-0.02 (-0.06,0.08)
LD RITUX IV + MTX	5.34 (2.00,15.20)	4.23 (1.89,8.52)	0.19 (0.06,0.42)
LD ABA IV + MTX	6.29 (2.28,17.23)	4.75 (2.12,9.10)	0.23 (0.07,0.45)
LD ANA SC + MTX	9.03 (1.29,76.76)	6.06 (1.27,14.67)	0.31 (0.02,0.77)
LD CERTO SC + MTX	12.43 (3.91,40.48)	7.33 (3.29,12.79)	0.38 (0.14,0.66)
LD ETN SC + MTX	9.76 (3.29,29.06)	6.36 (2.88,11.44)	0.32 (0.12,0.59)
LD GOLI IV + MTX	6.41 (1.98,21.30)	4.83 (1.87,10.01)	0.23 (0.05,0.51)
LD TOCI IV + MTX	5.41 (1.69,17.11)	4.26 (1.62,9.01)	0.20 (0.04,0.45)
LD TOFA PO + MTX	9.58 (2.42,38.84)	6.30 (2.24,12.60)	0.32 (0.08,0.65)
HD TOCI IV	8.54 (4.39,17.47)	5.86 (3.58,9.35)	0.29 (0.17,0.45)

(Continued)

HD TOFA PO		10.58 (5.28,22.12)	6.69 (4.12,10.32)	0.34 (0.20,0.52)
HD ADA SC		4.95 (2.16,11.79)	3.99 (2.01,7.44)	0.18 (0.06,0.36)
HD GOLI SC		8.87 (3.71,21.75)	6.00 (3.15,10.14)	0.30 (0.13,0.51)
HD ETN SC		5.94 (2.15,17.26)	4.57 (2.00,9.00)	0.22 (0.06,0.46)
HD ABA SC		14.79 (3.72,67.13)	8.02 (3.17,14.87)	0.43 (0.14,0.74)
HD TOCI IV + MTX		14.79 (6.72,33.84)	8.03 (4.89,12.34)	0.43 (0.25,0.61)
HD TOFA PO + MTX		15.00 (5.88,40.02)	8.08 (4.48,12.84)	0.43 (0.22,0.65)
HD GOLI SC + MTX		15.89 (6.41,40.49)	8.33 (4.74,12.87)	0.44 (0.24,0.65)
HD CERTO SC + MTX		20.66 (8.33,52.67)	9.39 (5.62,14.01)	0.51 (0.29,0.70)
HD INF IV + MTX		12.70 (4.73,34.29)	7.42 (3.82,12.28)	0.39 (0.18,0.62)
HD TOCI IV + DMARD		3.13 (1.03,9.52)	2.78 (1.03,6.40)	0.11 (0.00,0.31)
DMARD	MTX	0.28 (0.12,0.65)	0.32 (0.14,0.68)	-0.11 (-0.20,-0.04)
MTX + DMARD		1.35 (0.70,2.54)	1.28 (0.74,2.06)	0.04 (-0.05,0.17)
SD ETN SC		1.80 (1.09,2.94)	1.59 (1.07,2.36)	0.09 (0.01,0.19)
SD ADA SC		1.26 (0.56,2.91)	1.21 (0.62,2.42)	0.03 (-0.09,0.16)
SD TOFA PO		2.21 (0.85,5.98)	1.85 (0.88,3.90)	0.14 (-0.03,0.32)
SD TOCI IV		1.59 (0.70,3.60)	1.45 (0.74,2.67)	0.07 (-0.05,0.24)
SD GOLI SC		2.54 (0.79,8.01)	2.02 (0.82,4.35)	0.16 (-0.03,0.42)
SD GOLI IV		1.87 (0.69,5.16)	1.63 (0.72,3.14)	0.10 (-0.04,0.34)
SD ABA SC		3.42 (0.71,18.44)	2.43 (0.76,6.30)	0.23 (-0.05,0.59)
SD CERTO SC		3.22 (0.82,13.12)	2.35 (0.85,5.65)	0.22 (-0.03,0.52)
SD ETN SC + MTX		3.43 (2.12,5.48)	2.44 (1.72,3.44)	0.23 (0.12,0.36)
SD INF IV + MTX		3.02 (1.88,4.88)	2.25 (1.61,3.18)	0.20 (0.09,0.33)
SD ABA IV + MTX		3.83 (2.35,6.31)	2.60 (1.86,3.66)	0.26 (0.13,0.40)
SD CERTO SC + MTX		5.79 (3.56,9.50)	3.22 (2.33,4.53)	0.36 (0.21,0.49)
SD TOFA PO + MTX		6.29 (3.50,11.75)	3.33 (2.32,4.86)	0.38 (0.22,0.53)
SD GOLI SC + MTX		6.87 (3.42,14.35)	3.47 (2.27,5.52)	0.40 (0.23,0.56)
SD ADA SC + MTX		4.16 (1.46,11.69)	2.69 (1.35,4.71)	0.28 (0.05,0.53)

(Continued)

SD RITUX IV + MTX	2.16 (1.06,4.48)	1.81 (1.05,2.94)	0.13 (0.01,0.31)
SD GOLI IV + MTX	2.42 (1.19,5.00)	1.95 (1.15,3.11)	0.15 (0.02,0.33)
SD ABA SC + MTX	4.14 (1.52,11.20)	2.69 (1.40,4.63)	0.28 (0.06,0.52)
SD ANA SC + MTX	5.32 (0.89,36.66)	3.05 (0.91,6.36)	0.34 (-0.01,0.71)
SD TOCI IV + MTX	2.14 (0.77,6.09)	1.79 (0.81,3.51)	0.13 (-0.03,0.37)
SD CERTO SC + DMARD	1.60 (0.53,5.10)	1.46 (0.59,3.42)	0.07 (-0.09,0.30)
SD ADA SC + DMARD	0.90 (0.24,3.18)	0.92 (0.28,2.41)	-0.01 (-0.15,0.21)
SD ETN SC + DMARD	3.56 (1.26,10.16)	2.48 (1.20,4.62)	0.24 (0.03,0.49)
LD ADA SC	1.15 (0.42,3.28)	1.13 (0.48,2.61)	0.02 (-0.12,0.19)
LD GOLI IV	1.10 (0.39,3.08)	1.08 (0.43,2.31)	0.01 (-0.10,0.21)
LD TOCI IV	0.20 (0.04,0.77)	0.23 (0.04,0.79)	-0.12 (-0.22,-0.03)
LD RITUX IV + MTX	1.79 (0.88,3.78)	1.58 (0.90,2.65)	0.09 (-0.02,0.27)
LD ABA IV + MTX	2.10 (1.02,4.29)	1.77 (1.02,2.86)	0.12 (0.00,0.30)
LD ANA SC + MTX	3.05 (0.49,21.80)	2.25 (0.54,5.41)	0.20 (-0.08,0.64)
LD CERTO SC + MTX	4.17 (1.63,10.69)	2.71 (1.47,4.51)	0.28 (0.07,0.51)
LD ETN SC + MTX	3.28 (1.37,7.76)	2.37 (1.29,3.99)	0.22 (0.05,0.44)
LD GOLI IV + MTX	2.16 (0.81,5.70)	1.81 (0.83,3.36)	0.13 (-0.03,0.36)
LD TOCI IV + MTX	1.80 (0.65,5.01)	1.59 (0.70,3.19)	0.09 (-0.05,0.32)
LD TOFA PO + MTX	3.23 (0.98,10.73)	2.34 (0.99,4.42)	0.22 (0.00,0.51)
HD TOCI IV	2.85 (1.69,4.96)	2.18 (1.47,3.40)	0.19 (0.09,0.31)
HD TOFA PO	3.53 (1.37,9.55)	2.49 (1.26,5.07)	0.24 (0.06,0.43)
HD ADA SC	1.66 (0.60,4.70)	1.50 (0.66,3.33)	0.08 (-0.08,0.27)
HD GOLI SC	2.98 (1.30,6.71)	2.23 (1.22,3.97)	0.20 (0.04,0.38)
HD ETN SC	1.99 (0.85,4.71)	1.71 (0.87,3.06)	0.11 (-0.02,0.31)
HD ABA SC	4.88 (1.08,25.35)	2.95 (1.06,7.04)	0.32 (0.01,0.65)
HD TOCI IV + MTX	4.95 (2.86,8.78)	2.98 (2.04,4.57)	0.32 (0.19,0.46)
HD TOFA PO + MTX	5.01 (2.74,9.20)	2.99 (2.07,4.36)	0.33 (0.17,0.48)
HD GOLI SC + MTX	5.27 (2.59,10.98)	3.07 (1.96,4.88)	0.34 (0.17,0.51)

(Continued)

HD CERTO SC + MTX		6.93 (3.84,12.54)	3.48 (2.44,5.13)	0.40 (0.24,0.55)
HD INF IV + MTX		4.22 (2.12,8.71)	2.74 (1.76,4.23)	0.28 (0.12,0.46)
HD TOCI IV + DMARD		1.06 (0.35,3.00)	1.05 (0.41,2.33)	0.01 (-0.12,0.19)
MTX + DMARD	DMARD	4.75 (1.78,13.41)	3.95 (1.66,9.80)	0.15 (0.05,0.32)
SD ETN SC		6.38 (2.80,14.83)	4.94 (2.40,10.72)	0.20 (0.10,0.34)
SD ADA SC		4.48 (1.67,12.12)	3.78 (1.56,9.27)	0.14 (0.05,0.26)
SD TOFA PO		7.87 (2.58,23.95)	5.77 (2.21,14.80)	0.24 (0.11,0.41)
SD TOCI IV		5.63 (1.99,16.22)	4.50 (1.81,11.05)	0.18 (0.06,0.36)
SD GOLI SC		8.98 (2.33,33.68)	6.24 (2.07,17.07)	0.27 (0.08,0.53)
SD GOLI IV		6.59 (1.85,25.43)	5.06 (1.74,14.10)	0.21 (0.05,0.48)
SD ABA SC		12.25 (2.29,68.23)	7.60 (2.05,23.30)	0.34 (0.08,0.69)
SD CERTO SC		11.38 (2.59,51.27)	7.28 (2.25,21.19)	0.33 (0.10,0.62)
SD ETN SC + MTX		12.11 (4.99,31.14)	7.57 (3.60,17.11)	0.34 (0.19,0.51)
SD INF IV + MTX		10.67 (4.20,28.91)	7.00 (3.23,16.24)	0.31 (0.16,0.50)
SD ABA IV + MTX		13.55 (5.12,36.64)	8.10 (3.71,18.61)	0.37 (0.19,0.56)
SD CERTO SC + MTX		20.42 (7.69,56.02)	10.05 (4.70,22.73)	0.47 (0.28,0.66)
SD TOFA PO + MTX		22.07 (8.24,65.85)	10.39 (4.94,23.55)	0.49 (0.28,0.69)
SD GOLI SC + MTX		24.47 (8.47,73.59)	10.85 (4.87,25.08)	0.51 (0.30,0.70)
SD ADA SC + MTX		14.51 (3.93,56.13)	8.29 (3.16,21.02)	0.39 (0.14,0.67)
SD RITUX IV + MTX		7.60 (2.57,24.73)	5.60 (2.25,14.24)	0.24 (0.09,0.47)
SD GOLI IV + MTX		8.57 (2.81,26.42)	6.07 (2.41,14.87)	0.26 (0.10,0.49)
SD ABA SC + MTX		14.58 (4.01,54.98)	8.33 (3.18,20.84)	0.39 (0.14,0.66)
SD ANA SC + MTX		19.11 (2.64,157.80)	9.44 (2.33,25.66)	0.45 (0.08,0.83)
SD TOCI IV + MTX		7.57 (2.21,27.29)	5.55 (2.01,14.63)	0.24 (0.06,0.50)
SD CERTO SC + DMARD		5.76 (2.02,16.38)	4.55 (1.85,10.85)	0.18 (0.06,0.39)
SD ADA SC + DMARD		3.16 (1.20,8.26)	2.82 (1.19,6.08)	0.09 (0.01,0.30)
SD ETN SC + DMARD		12.48 (4.39,38.15)	7.64 (3.46,17.10)	0.35 (0.14,0.61)
LD ADA SC		4.09 (1.30,13.57)	3.51 (1.27,10.05)	0.13 (0.02,0.28)

(Continued)

LD GOLI IV		3.91 (0.99,15.51)	3.36 (1.00,10.37)	0.12 (0.00,0.35)
LD TOCI IV		0.69 (0.11,3.24)	0.70 (0.12,2.99)	-0.01 (-0.08,0.08)
LD RITUX IV + MTX		6.35 (2.10,20.24)	4.91 (1.92,12.60)	0.20 (0.06,0.42)
LD ABA IV + MTX		7.37 (2.47,22.77)	5.47 (2.20,13.79)	0.23 (0.08,0.45)
LD ANA SC + MTX		10.91 (1.38,88.88)	7.03 (1.34,21.59)	0.31 (0.02,0.77)
LD CERTO SC + MTX		14.73 (4.21,52.91)	8.40 (3.32,20.38)	0.39 (0.15,0.65)
LD ETN SC + MTX		11.52 (3.62,38.11)	7.30 (2.95,17.91)	0.33 (0.13,0.58)
LD GOLI IV + MTX		7.63 (2.08,28.74)	5.60 (1.91,15.06)	0.24 (0.06,0.51)
LD TOCI IV + MTX		6.40 (1.89,22.37)	4.91 (1.77,13.04)	0.20 (0.05,0.45)
LD TOFA PO + MTX		11.42 (2.71,50.51)	7.23 (2.39,19.59)	0.32 (0.09,0.64)
HD TOCI IV		10.13 (4.65,22.67)	6.81 (3.42,14.40)	0.30 (0.18,0.44)
HD TOFA PO		12.63 (4.20,38.26)	7.87 (3.14,19.74)	0.35 (0.19,0.53)
HD ADA SC		5.90 (1.89,19.18)	4.66 (1.74,12.78)	0.19 (0.06,0.36)
HD GOLI SC		10.52 (3.45,32.32)	6.98 (2.79,17.25)	0.31 (0.14,0.51)
HD ETN SC		7.02 (2.25,22.38)	5.27 (2.04,13.34)	0.22 (0.07,0.45)
HD ABA SC		17.57 (3.38,98.73)	9.21 (2.78,26.24)	0.43 (0.14,0.75)
HD TOCI IV + MTX		17.47 (7.19,45.59)	9.31 (4.54,20.47)	0.43 (0.27,0.61)
HD TOFA PO + MTX		17.73 (6.48,51.47)	9.30 (4.28,21.36)	0.43 (0.23,0.64)
HD GOLI SC + MTX		18.65 (6.40,57.05)	9.60 (4.21,22.52)	0.45 (0.25,0.65)
HD CERTO SC + MTX		24.36 (8.95,70.21)	10.84 (5.07,24.65)	0.51 (0.31,0.70)
HD INF IV + MTX		14.98 (5.23,46.24)	8.53 (3.75,20.19)	0.39 (0.19,0.61)
HD TOCI IV + DMARD		3.72 (1.91,7.08)	3.23 (1.81,5.45)	0.11 (0.03,0.27)
SD ETN SC	MTX + DMARD	1.34 (0.67,2.67)	1.25 (0.75,2.21)	0.05 (-0.08,0.16)
SD ADA SC		0.94 (0.35,2.57)	0.96 (0.45,2.18)	-0.01 (-0.19,0.14)
SD TOFA PO		1.66 (0.54,5.08)	1.46 (0.64,3.48)	0.09 (-0.12,0.29)
SD TOCI IV		1.18 (0.42,3.28)	1.14 (0.51,2.52)	0.03 (-0.15,0.21)
SD GOLI SC		1.89 (0.50,6.85)	1.58 (0.59,3.85)	0.12 (-0.12,0.39)
SD GOLI IV		1.39 (0.43,4.63)	1.28 (0.51,2.98)	0.06 (-0.13,0.31)

(Continued)

SD ABA SC	2.53 (0.48,15.15)	1.90 (0.58,5.57)	0.18 (-0.13,0.56)
SD CERTO SC	2.42 (0.52,11.13)	1.86 (0.62,4.92)	0.17 (-0.12,0.49)
SD ETN SC + MTX	2.55 (1.52,4.28)	1.92 (1.30,3.00)	0.18 (0.08,0.29)
SD INF IV + MTX	2.24 (1.16,4.47)	1.77 (1.10,3.04)	0.16 (0.03,0.30)
SD ABA IV + MTX	2.85 (1.30,6.33)	2.05 (1.19,3.73)	0.21 (0.05,0.38)
SD CERTO SC + MTX	4.31 (1.89,9.70)	2.53 (1.47,4.66)	0.31 (0.14,0.48)
SD TOFA PO + MTX	4.70 (1.97,11.52)	2.62 (1.50,4.93)	0.33 (0.14,0.52)
SD GOLI SC + MTX	5.12 (1.98,13.25)	2.74 (1.51,5.40)	0.35 (0.15,0.54)
SD ADA SC + MTX	3.08 (0.90,10.40)	2.11 (0.93,4.47)	0.23 (-0.02,0.50)
SD RITUX IV + MTX	1.61 (0.62,4.25)	1.43 (0.70,2.91)	0.08 (-0.08,0.29)
SD GOLI IV + MTX	1.80 (0.67,4.70)	1.54 (0.75,3.04)	0.11 (-0.07,0.31)
SD ABA SC + MTX	3.07 (0.94,9.88)	2.11 (0.96,4.40)	0.23 (-0.01,0.49)
SD ANA SC + MTX	3.97 (0.61,31.66)	2.38 (0.67,5.81)	0.29 (-0.07,0.67)
SD TOCI IV + MTX	1.59 (0.48,5.31)	1.41 (0.56,3.27)	0.08 (-0.11,0.34)
SD CERTO SC + DMARD	1.20 (0.34,4.28)	1.15 (0.43,3.01)	0.03 (-0.18,0.27)
SD ADA SC + DMARD	0.67 (0.16,2.64)	0.72 (0.21,2.11)	-0.05 (-0.24,0.17)
SD ETN SC + DMARD	2.66 (0.82,8.47)	1.95 (0.87,4.19)	0.19 (-0.04,0.45)
LD ADA SC	0.86 (0.27,2.82)	0.89 (0.35,2.29)	-0.02 (-0.22,0.16)
LD GOLI IV	0.82 (0.24,2.79)	0.86 (0.30,2.17)	-0.03 (-0.20,0.18)
LD TOCI IV	0.14 (0.02,0.66)	0.18 (0.03,0.69)	-0.16 (-0.34,-0.04)
LD RITUX IV + MTX	1.34 (0.52,3.60)	1.25 (0.60,2.59)	0.05 (-0.11,0.24)
LD ABA IV + MTX	1.56 (0.62,4.03)	1.39 (0.69,2.81)	0.08 (-0.09,0.27)
LD ANA SC + MTX	2.28 (0.32,17.50)	1.77 (0.40,4.90)	0.16 (-0.15,0.60)
LD CERTO SC + MTX	3.11 (1.00,9.77)	2.13 (1.00,4.41)	0.23 (0.00,0.49)
LD ETN SC + MTX	2.44 (0.92,6.48)	1.86 (0.94,3.60)	0.17 (-0.02,0.40)
LD GOLI IV + MTX	1.61 (0.50,5.06)	1.42 (0.58,3.17)	0.08 (-0.11,0.34)
LD TOCI IV + MTX	1.34 (0.40,4.50)	1.25 (0.49,2.99)	0.05 (-0.14,0.29)
LD TOFA PO + MTX	2.42 (0.62,9.38)	1.84 (0.69,4.16)	0.17 (-0.08,0.48)



(Continued)

HD TOCI IV		2.13 (0.95,4.91)	1.72 (0.97,3.35)	0.14 (-0.01,0.29)
HD TOFA PO		2.64 (0.85,8.04)	1.96 (0.89,4.50)	0.20 (-0.04,0.41)
HD ADA SC		1.25 (0.38,3.93)	1.19 (0.48,2.92)	0.04 (-0.17,0.24)
HD GOLI SC		2.22 (0.78,6.08)	1.76 (0.84,3.68)	0.15 (-0.05,0.36)
HD ETN SC		1.49 (0.54,4.17)	1.35 (0.62,2.84)	0.07 (-0.10,0.28)
HD ABA SC		3.63 (0.73,21.55)	2.32 (0.79,6.27)	0.27 (-0.06,0.63)
HD TOCI IV + MTX		3.69 (1.61,8.66)	2.35 (1.35,4.50)	0.27 (0.11,0.44)
HD TOFA PO + MTX		3.73 (1.59,9.16)	2.35 (1.34,4.45)	0.28 (0.09,0.47)
HD GOLI SC + MTX		3.92 (1.53,10.33)	2.41 (1.31,4.76)	0.29 (0.09,0.49)
HD CERTO SC + MTX		5.14 (2.18,12.37)	2.74 (1.57,5.11)	0.36 (0.17,0.53)
HD INF IV + MTX		3.15 (1.31,7.82)	2.15 (1.20,4.07)	0.23 (0.05,0.44)
HD TOCI IV + DMARD		0.78 (0.23,2.59)	0.82 (0.30,2.09)	-0.04 (-0.21,0.16)
SD ADA SC	SD ETN SC	0.71 (0.30,1.64)	0.77 (0.40,1.47)	-0.06 (-0.22,0.08)
SD TOFA PO		1.23 (0.46,3.30)	1.16 (0.57,2.33)	0.04 (-0.16,0.24)
SD TOCI IV		0.89 (0.35,2.17)	0.91 (0.44,1.75)	-0.02 (-0.18,0.16)
SD GOLI SC		1.41 (0.41,4.61)	1.27 (0.51,2.69)	0.07 (-0.16,0.34)
SD GOLI IV		1.04 (0.35,3.24)	1.03 (0.43,2.14)	0.01 (-0.17,0.26)
SD ABA SC		1.90 (0.39,10.18)	1.53 (0.50,3.77)	0.14 (-0.16,0.51)
SD CERTO SC		1.80 (0.44,7.39)	1.48 (0.54,3.40)	0.12 (-0.15,0.44)
SD ETN SC + MTX		1.90 (1.17,3.13)	1.53 (1.11,2.15)	0.14 (0.03,0.26)
SD INF IV + MTX		1.68 (0.88,3.25)	1.42 (0.91,2.20)	0.11 (-0.03,0.26)
SD ABA IV + MTX		2.13 (1.07,4.27)	1.64 (1.04,2.55)	0.16 (0.01,0.33)
SD CERTO SC + MTX		3.22 (1.60,6.62)	2.03 (1.33,3.13)	0.26 (0.10,0.43)
SD TOFA PO + MTX		3.48 (1.61,7.86)	2.10 (1.36,3.31)	0.28 (0.10,0.46)
SD GOLI SC + MTX		3.84 (1.64,9.05)	2.19 (1.35,3.59)	0.31 (0.11,0.49)
SD ADA SC + MTX		2.29 (0.73,7.27)	1.70 (0.79,3.12)	0.18 (-0.06,0.45)
SD RITUX IV + MTX		1.20 (0.51,2.93)	1.14 (0.60,2.05)	0.03 (-0.12,0.24)
SD GOLI IV + MTX		1.35 (0.57,3.21)	1.23 (0.65,2.16)	0.06 (-0.10,0.26)

(Continued)

SD ABA SC + MTX	2.29 (0.76,7.00)	1.70 (0.81,3.09)	0.18 (-0.05,0.44)
SD ANA SC + MTX	2.94 (0.47,22.26)	1.93 (0.55,4.06)	0.24 (-0.12,0.62)
SD TOCI IV + MTX	1.19 (0.40,3.67)	1.13 (0.48,2.31)	0.03 (-0.16,0.29)
SD CERTO SC + DMARD	0.89 (0.29,2.84)	0.92 (0.38,2.08)	-0.02 (-0.21,0.21)
SD ADA SC + DMARD	0.50 (0.14,1.78)	0.57 (0.19,1.50)	-0.10 (-0.26,0.11)
SD ETN SC + DMARD	1.99 (0.76,5.22)	1.57 (0.82,2.68)	0.15 (-0.05,0.38)
LD ADA SC	0.65 (0.23,1.85)	0.71 (0.31,1.59)	-0.07 (-0.25,0.11)
LD GOL I IV	0.61 (0.20,1.89)	0.68 (0.25,1.57)	-0.08 (-0.24,0.13)
LD TOCI IV	0.11 (0.02,0.46)	0.14 (0.03,0.52)	-0.21 (-0.36,-0.09)
LD RITUX IV + MTX	1.00 (0.42,2.44)	1.00 (0.50,1.83)	0.00 (-0.15,0.19)
LD ABA IV + MTX	1.16 (0.49,2.80)	1.11 (0.57,2.01)	0.03 (-0.12,0.22)
LD ANA SC + MTX	1.69 (0.26,12.73)	1.42 (0.33,3.49)	0.11 (-0.19,0.55)
LD CERTO SC + MTX	2.33 (0.81,6.73)	1.72 (0.85,3.04)	0.18 (-0.04,0.43)
LD ETN SC + MTX	1.82 (0.73,4.61)	1.49 (0.79,2.58)	0.12 (-0.06,0.35)
LD GOL I IV + MTX	1.19 (0.40,3.71)	1.14 (0.48,2.29)	0.03 (-0.15,0.29)
LD TOCI IV + MTX	1.00 (0.34,3.02)	1.00 (0.42,2.10)	0.00 (-0.18,0.24)
LD TOFA PO + MTX	1.80 (0.50,6.60)	1.48 (0.59,2.94)	0.12 (-0.12,0.42)
HD TOCI IV	1.58 (0.84,3.16)	1.37 (0.88,2.22)	0.09 (-0.04,0.24)
HD TOFA PO	1.97 (0.73,5.20)	1.57 (0.81,3.04)	0.15 (-0.07,0.35)
HD ADA SC	0.92 (0.33,2.65)	0.94 (0.42,2.05)	-0.01 (-0.20,0.19)
HD GOL I SC	1.66 (0.65,4.05)	1.41 (0.73,2.55)	0.10 (-0.09,0.31)
HD ETN SC	1.11 (0.48,2.65)	1.08 (0.56,1.89)	0.02 (-0.12,0.21)
HD ABA SC	2.74 (0.60,14.42)	1.87 (0.69,4.21)	0.23 (-0.10,0.57)
HD TOCI IV + MTX	2.75 (1.37,5.68)	1.88 (1.22,3.00)	0.23 (0.07,0.39)
HD TOFA PO + MTX	2.78 (1.31,6.13)	1.89 (1.20,3.01)	0.23 (0.06,0.41)
HD GOL I SC + MTX	2.95 (1.25,7.06)	1.94 (1.16,3.24)	0.24 (0.05,0.44)
HD CERTO SC + MTX	3.81 (1.78,8.36)	2.19 (1.42,3.46)	0.31 (0.13,0.48)
HD INF IV + MTX	2.34 (1.03,5.59)	1.72 (1.02,2.86)	0.19 (0.01,0.39)

(Continued)

HD TOCI IV + DMARD		0.59 (0.20,1.66)	0.66 (0.26,1.44)	-0.09 (-0.24,0.10)
SD TOFA PO	SD ADA SC	1.74 (0.76,4.14)	1.52 (0.82,2.83)	0.10 (-0.05,0.27)
SD TOCI IV		1.26 (0.45,3.46)	1.20 (0.53,2.52)	0.04 (-0.12,0.23)
SD GOLI SC		2.00 (0.55,6.90)	1.66 (0.63,3.70)	0.13 (-0.09,0.40)
SD GOLI IV		1.48 (0.41,5.41)	1.34 (0.48,3.20)	0.07 (-0.12,0.35)
SD ABA SC		2.70 (0.59,14.14)	2.02 (0.66,4.83)	0.20 (-0.08,0.56)
SD CERTO SC		2.55 (0.64,10.19)	1.95 (0.71,4.42)	0.18 (-0.07,0.49)
SD ETN SC + MTX		2.70 (1.11,6.73)	2.02 (1.08,3.72)	0.20 (0.02,0.39)
SD INF IV + MTX		2.38 (0.94,6.12)	1.86 (0.95,3.52)	0.17 (-0.01,0.37)
SD ABA IV + MTX		3.04 (1.15,7.85)	2.15 (1.11,4.00)	0.22 (0.02,0.43)
SD CERTO SC + MTX		4.60 (1.74,11.84)	2.67 (1.45,4.75)	0.33 (0.11,0.53)
SD TOFA PO + MTX		4.95 (1.80,13.82)	2.76 (1.48,4.99)	0.35 (0.12,0.56)
SD GOLI SC + MTX		5.47 (1.97,15.38)	2.88 (1.57,5.19)	0.37 (0.14,0.58)
SD ADA SC + MTX		3.27 (0.87,12.49)	2.23 (0.90,4.61)	0.24 (-0.02,0.54)
SD RITUX IV + MTX		1.71 (0.58,5.26)	1.50 (0.65,3.18)	0.10 (-0.09,0.34)
SD GOLI IV + MTX		1.92 (0.64,5.65)	1.62 (0.70,3.34)	0.12 (-0.07,0.36)
SD ABA SC + MTX		3.27 (0.87,11.74)	2.24 (0.90,4.53)	0.24 (-0.02,0.53)
SD ANA SC + MTX		4.23 (0.60,35.03)	2.55 (0.66,5.57)	0.30 (-0.07,0.70)
SD TOCI IV + MTX		1.71 (0.49,5.80)	1.50 (0.56,3.31)	0.10 (-0.11,0.36)
SD CERTO SC + DMARD		1.27 (0.40,4.21)	1.20 (0.47,2.86)	0.04 (-0.14,0.28)
SD ADA SC + DMARD		0.71 (0.18,2.78)	0.75 (0.22,2.15)	-0.05 (-0.20,0.19)
SD ETN SC + DMARD		2.82 (0.84,9.66)	2.06 (0.87,4.20)	0.21 (-0.03,0.49)
LD ADA SC		0.92 (0.42,1.98)	0.93 (0.49,1.70)	-0.01 (-0.12,0.12)
LD GOLI IV		0.87 (0.23,3.20)	0.89 (0.28,2.36)	-0.02 (-0.18,0.22)
LD TOCI IV		0.15 (0.03,0.70)	0.19 (0.04,0.74)	-0.15 (-0.27,-0.04)
LD RITUX IV + MTX		1.42 (0.48,4.34)	1.31 (0.55,2.87)	0.06 (-0.11,0.29)
LD ABA IV + MTX		1.65 (0.55,4.88)	1.46 (0.62,3.08)	0.09 (-0.09,0.32)
LD ANA SC + MTX		2.39 (0.32,20.29)	1.86 (0.39,4.88)	0.17 (-0.14,0.63)

(Continued)

LD CERTO SC + MTX		3.31 (0.95,11.76)	2.26 (0.96,4.52)	0.25 (-0.01,0.53)
LD ETN SC + MTX		2.58 (0.81,8.33)	1.96 (0.84,3.93)	0.19 (-0.04,0.45)
LD GOLI IV + MTX		1.71 (0.48,6.04)	1.49 (0.55,3.40)	0.10 (-0.11,0.37)
LD TOCI IV + MTX		1.43 (0.43,4.62)	1.32 (0.50,2.95)	0.06 (-0.12,0.31)
LD TOFA PO + MTX		2.54 (0.60,10.95)	1.94 (0.67,4.29)	0.18 (-0.08,0.51)
HD TOCI IV		2.26 (1.07,4.69)	1.81 (1.05,3.07)	0.16 (0.01,0.31)
HD TOFA PO		2.80 (1.21,6.50)	2.06 (1.14,3.67)	0.21 (0.04,0.39)
HD ADA SC		1.32 (0.62,2.79)	1.24 (0.68,2.15)	0.05 (-0.07,0.19)
HD GOLI SC		2.34 (0.84,6.67)	1.84 (0.87,3.71)	0.17 (-0.03,0.39)
HD ETN SC		1.58 (0.50,4.94)	1.41 (0.57,3.07)	0.08 (-0.11,0.32)
HD ABA SC		3.89 (0.85,20.41)	2.46 (0.89,5.43)	0.29 (-0.03,0.63)
HD TOCI IV + MTX		3.92 (1.62,9.54)	2.47 (1.38,4.38)	0.29 (0.10,0.48)
HD TOFA PO + MTX		3.95 (1.45,11.00)	2.48 (1.30,4.54)	0.29 (0.07,0.51)
HD GOLI SC + MTX		4.17 (1.48,12.15)	2.55 (1.32,4.76)	0.31 (0.08,0.53)
HD CERTO SC + MTX		5.46 (1.94,15.08)	2.87 (1.55,5.11)	0.37 (0.14,0.58)
HD INF IV + MTX		3.36 (1.12,9.87)	2.28 (1.09,4.36)	0.25 (0.02,0.49)
HD TOCI IV + DMARD		0.83 (0.25,2.67)	0.86 (0.30,2.11)	-0.03 (-0.18,0.18)
SD TOCI IV	SD TOFA PO	0.72 (0.23,2.22)	0.78 (0.33,1.76)	-0.06 (-0.27,0.16)
SD GOLI SC		1.13 (0.30,4.41)	1.09 (0.42,2.50)	0.03 (-0.23,0.33)
SD GOLI IV		0.86 (0.21,3.25)	0.90 (0.30,2.11)	-0.03 (-0.27,0.26)
SD ABA SC		1.53 (0.32,8.07)	1.32 (0.43,3.11)	0.09 (-0.21,0.47)
SD CERTO SC		1.45 (0.36,5.84)	1.28 (0.48,2.83)	0.08 (-0.20,0.40)
SD ETN SC + MTX		1.54 (0.55,4.24)	1.32 (0.67,2.58)	0.10 (-0.13,0.32)
SD INF IV + MTX		1.36 (0.46,3.95)	1.22 (0.59,2.42)	0.07 (-0.16,0.30)
SD ABA IV + MTX		1.74 (0.58,5.05)	1.42 (0.69,2.74)	0.12 (-0.12,0.36)
SD CERTO SC + MTX		2.63 (0.85,7.68)	1.76 (0.91,3.24)	0.23 (-0.04,0.46)
SD TOFA PO + MTX		2.83 (0.89,9.18)	1.81 (0.93,3.40)	0.24 (-0.03,0.50)
SD GOLI SC + MTX		3.13 (0.99,9.62)	1.90 (0.99,3.49)	0.27 (0.00,0.50)

(Continued)

SD ADA SC + MTX	1.87 (0.44,7.68)	1.47 (0.56,3.11)	0.14 (-0.17,0.46)
SD RITUX IV + MTX	0.98 (0.29,3.30)	0.98 (0.40,2.19)	0.00 (-0.24,0.26)
SD GOLIV IV + MTX	1.10 (0.33,3.54)	1.06 (0.45,2.25)	0.02 (-0.22,0.28)
SD ABA SC + MTX	1.88 (0.45,7.52)	1.48 (0.57,3.09)	0.14 (-0.16,0.46)
SD ANA SC + MTX	2.42 (0.31,21.34)	1.68 (0.41,3.78)	0.21 (-0.21,0.62)
SD TOCI IV + MTX	0.97 (0.25,3.75)	0.98 (0.35,2.31)	-0.01 (-0.25,0.30)
SD CERTO SC + DMARD	0.72 (0.21,2.59)	0.79 (0.31,1.91)	-0.06 (-0.28,0.20)
SD ADA SC + DMARD	0.40 (0.09,1.78)	0.49 (0.14,1.50)	-0.15 (-0.35,0.12)
SD ETN SC + DMARD	1.61 (0.44,6.20)	1.35 (0.56,2.86)	0.10 (-0.17,0.41)
LD ADA SC	0.53 (0.18,1.51)	0.61 (0.27,1.36)	-0.11 (-0.30,0.08)
LD GOLIV IV	0.50 (0.12,1.92)	0.59 (0.18,1.58)	-0.12 (-0.33,0.14)
LD TOCI IV	0.09 (0.01,0.42)	0.12 (0.02,0.49)	-0.25 (-0.43,-0.11)
LD RITUX IV + MTX	0.82 (0.24,2.76)	0.87 (0.34,1.97)	-0.04 (-0.26,0.22)
LD ABA IV + MTX	0.95 (0.28,3.09)	0.96 (0.39,2.12)	-0.01 (-0.24,0.25)
LD ANA SC + MTX	1.37 (0.17,12.35)	1.23 (0.25,3.38)	0.07 (-0.28,0.55)
LD CERTO SC + MTX	1.90 (0.48,7.42)	1.49 (0.60,3.09)	0.14 (-0.15,0.45)
LD ETN SC + MTX	1.47 (0.41,5.25)	1.29 (0.53,2.71)	0.08 (-0.18,0.37)
LD GOLIV IV + MTX	0.98 (0.25,3.70)	0.99 (0.35,2.27)	0.00 (-0.25,0.29)
LD TOCI IV + MTX	0.82 (0.21,3.06)	0.87 (0.31,2.07)	-0.04 (-0.27,0.25)
LD TOFA PO + MTX	1.44 (0.31,6.91)	1.27 (0.41,2.98)	0.08 (-0.22,0.44)
HD TOCI IV	1.30 (0.50,3.33)	1.19 (0.64,2.27)	0.06 (-0.15,0.26)
HD TOFA PO	1.60 (0.88,2.96)	1.35 (0.92,2.05)	0.10 (-0.03,0.24)
HD ADA SC	0.75 (0.27,2.15)	0.81 (0.38,1.71)	-0.05 (-0.25,0.16)
HD GOLIV SC	1.34 (0.42,4.06)	1.22 (0.55,2.47)	0.06 (-0.18,0.31)
HD ETN SC	0.90 (0.26,3.17)	0.93 (0.37,2.13)	-0.02 (-0.25,0.25)
HD ABA SC	2.21 (0.46,11.37)	1.61 (0.58,3.50)	0.18 (-0.16,0.53)
HD TOCI IV + MTX	2.24 (0.79,6.42)	1.63 (0.87,3.05)	0.19 (-0.05,0.42)
HD TOFA PO + MTX	2.24 (0.70,7.22)	1.63 (0.79,3.12)	0.19 (-0.08,0.45)

(Continued)

HD GOLI SC + MTX		2.38 (0.74,7.39)	1.67 (0.83,3.19)	0.20 (-0.07,0.45)
HD CERTO SC + MTX		3.15 (0.98,9.47)	1.91 (0.99,3.46)	0.27 (-0.01,0.50)
HD INF IV + MTX		1.92 (0.56,6.18)	1.50 (0.68,2.93)	0.15 (-0.12,0.41)
HD TOCI IV + DMARD		0.47 (0.13,1.67)	0.56 (0.19,1.45)	-0.13 (-0.33,0.10)
SD GOLI SC	SD TOCI IV	1.58 (0.41,6.09)	1.38 (0.51,3.54)	0.09 (-0.17,0.37)
SD GOLI IV		1.18 (0.32,4.30)	1.13 (0.41,2.74)	0.03 (-0.19,0.30)
SD ABA SC		2.18 (0.40,12.62)	1.68 (0.50,4.73)	0.16 (-0.17,0.54)
SD CERTO SC		2.05 (0.43,9.44)	1.63 (0.55,4.26)	0.15 (-0.16,0.47)
SD ETN SC + MTX		2.13 (0.85,5.52)	1.67 (0.90,3.42)	0.16 (-0.03,0.34)
SD INF IV + MTX		1.90 (0.75,4.83)	1.56 (0.82,3.13)	0.13 (-0.06,0.32)
SD ABA IV + MTX		2.42 (0.93,6.29)	1.79 (0.95,3.60)	0.19 (-0.02,0.38)
SD CERTO SC + MTX		3.63 (1.44,9.57)	2.22 (1.24,4.41)	0.28 (0.08,0.48)
SD TOFA PO + MTX		3.95 (1.45,11.20)	2.29 (1.25,4.69)	0.30 (0.08,0.51)
SD GOLI SC + MTX		4.34 (1.52,12.39)	2.40 (1.28,4.92)	0.33 (0.10,0.53)
SD ADA SC + MTX		2.62 (0.68,9.67)	1.87 (0.76,4.13)	0.20 (-0.07,0.49)
SD RITUX IV + MTX		1.36 (0.46,4.08)	1.25 (0.56,2.77)	0.06 (-0.15,0.29)
SD GOLI IV + MTX		1.53 (0.51,4.48)	1.35 (0.61,2.92)	0.08 (-0.13,0.30)
SD ABA SC + MTX		2.60 (0.71,9.32)	1.86 (0.78,4.17)	0.20 (-0.07,0.48)
SD ANA SC + MTX		3.39 (0.46,28.16)	2.10 (0.56,5.23)	0.26 (-0.12,0.66)
SD TOCI IV + MTX		1.35 (0.46,4.03)	1.24 (0.54,2.65)	0.06 (-0.14,0.29)
SD CERTO SC + DMARD		1.01 (0.27,3.77)	1.01 (0.37,2.68)	0.00 (-0.22,0.25)
SD ADA SC + DMARD		0.56 (0.14,2.28)	0.63 (0.19,1.89)	-0.08 (-0.29,0.15)
SD ETN SC + DMARD		2.22 (0.64,8.05)	1.71 (0.72,3.94)	0.16 (-0.09,0.44)
LD ADA SC		0.73 (0.22,2.48)	0.78 (0.31,2.06)	-0.05 (-0.26,0.15)
LD GOLI IV		0.69 (0.18,2.61)	0.75 (0.25,2.04)	-0.06 (-0.26,0.18)
LD TOCI IV		0.12 (0.02,0.52)	0.16 (0.03,0.57)	-0.19 (-0.37,-0.07)
LD RITUX IV + MTX		1.13 (0.37,3.40)	1.10 (0.47,2.45)	0.02 (-0.17,0.24)
LD ABA IV + MTX		1.32 (0.44,3.93)	1.22 (0.54,2.70)	0.05 (-0.16,0.27)

(Continued)

LD ANA SC + MTX		1.90 (0.25,16.32)	1.55 (0.33,4.45)	0.13 (-0.20,0.58)
LD CERTO SC + MTX		2.63 (0.76,9.00)	1.87 (0.83,4.07)	0.20 (-0.05,0.48)
LD ETN SC + MTX		2.03 (0.63,6.68)	1.62 (0.72,3.59)	0.14 (-0.09,0.40)
LD GOL I IV + MTX		1.36 (0.38,4.95)	1.25 (0.47,3.02)	0.06 (-0.17,0.33)
LD TOCI IV + MTX		1.13 (0.38,3.33)	1.10 (0.46,2.37)	0.02 (-0.17,0.24)
LD TOFA PO + MTX		2.01 (0.49,8.77)	1.61 (0.58,3.97)	0.14 (-0.13,0.47)
HD TOCI IV		1.80 (0.84,3.86)	1.51 (0.90,2.80)	0.12 (-0.04,0.26)
HD TOFA PO		2.23 (0.72,6.85)	1.72 (0.81,3.95)	0.17 (-0.07,0.38)
HD ADA SC		1.05 (0.31,3.42)	1.04 (0.41,2.58)	0.01 (-0.22,0.22)
HD GOL I SC		1.87 (0.61,5.68)	1.54 (0.71,3.46)	0.12 (-0.10,0.35)
HD ETN SC		1.25 (0.39,4.10)	1.18 (0.49,2.75)	0.04 (-0.17,0.28)
HD ABA SC		3.14 (0.60,18.06)	2.05 (0.69,5.37)	0.25 (-0.10,0.61)
HD TOCI IV + MTX		3.11 (1.37,7.40)	2.06 (1.21,3.96)	0.25 (0.07,0.42)
HD TOFA PO + MTX		3.14 (1.15,8.96)	2.06 (1.10,4.26)	0.25 (0.03,0.47)
HD GOL I SC + MTX		3.30 (1.14,9.73)	2.11 (1.08,4.46)	0.26 (0.03,0.48)
HD CERTO SC + MTX		4.34 (1.62,12.05)	2.39 (1.32,4.83)	0.33 (0.11,0.53)
HD INF IV + MTX		2.66 (0.94,7.79)	1.88 (0.96,3.94)	0.21 (-0.01,0.43)
HD TOCI IV + DMARD		0.66 (0.19,2.27)	0.72 (0.26,1.88)	-0.06 (-0.26,0.14)
SD GOL I IV	SD GOL I SC	0.74 (0.16,3.46)	0.81 (0.27,2.34)	-0.06 (-0.36,0.26)
SD ABA SC		1.35 (0.22,9.27)	1.21 (0.36,3.71)	0.07 (-0.31,0.48)
SD CERTO SC		1.30 (0.24,6.31)	1.18 (0.39,3.22)	0.06 (-0.31,0.40)
SD ETN SC + MTX		1.36 (0.40,4.70)	1.21 (0.59,2.91)	0.07 (-0.21,0.32)
SD INF IV + MTX		1.20 (0.34,4.27)	1.12 (0.53,2.72)	0.04 (-0.24,0.30)
SD ABA IV + MTX		1.52 (0.44,5.38)	1.29 (0.62,3.11)	0.10 (-0.19,0.36)
SD CERTO SC + MTX		2.27 (0.66,8.08)	1.59 (0.81,3.75)	0.19 (-0.10,0.45)
SD TOFA PO + MTX		2.48 (0.67,9.64)	1.65 (0.81,3.93)	0.21 (-0.10,0.49)
SD GOL I SC + MTX		2.73 (0.81,9.24)	1.73 (0.90,3.88)	0.23 (-0.05,0.48)
SD ADA SC + MTX		1.63 (0.36,7.86)	1.34 (0.51,3.51)	0.11 (-0.22,0.45)



(Continued)

SD RITUX IV + MTX	0.86 (0.22,3.33)	0.90 (0.36,2.32)	-0.03 (-0.32,0.25)
SD GOLI IV + MTX	0.95 (0.25,3.77)	0.97 (0.39,2.50)	-0.01 (-0.30,0.28)
SD ABA SC + MTX	1.63 (0.35,7.65)	1.34 (0.52,3.42)	0.11 (-0.23,0.44)
SD ANA SC + MTX	2.10 (0.26,20.11)	1.51 (0.38,4.26)	0.17 (-0.27,0.61)
SD TOCI IV + MTX	0.86 (0.19,3.78)	0.90 (0.32,2.46)	-0.03 (-0.34,0.28)
SD CERTO SC + DMARD	0.64 (0.14,2.84)	0.73 (0.26,2.10)	-0.09 (-0.39,0.20)
SD ADA SC + DMARD	0.35 (0.07,1.89)	0.45 (0.12,1.61)	-0.17 (-0.45,0.12)
SD ETN SC + DMARD	1.41 (0.32,6.53)	1.24 (0.49,3.31)	0.08 (-0.25,0.41)
LD ADA SC	0.46 (0.12,1.84)	0.56 (0.22,1.60)	-0.14 (-0.43,0.10)
LD GOLI IV	0.44 (0.09,2.02)	0.54 (0.16,1.68)	-0.14 (-0.43,0.13)
LD TOCI IV	0.08 (0.01,0.44)	0.11 (0.02,0.51)	-0.28 (-0.55,-0.09)
LD RITUX IV + MTX	0.71 (0.18,2.83)	0.79 (0.31,2.08)	-0.07 (-0.35,0.21)
LD ABA IV + MTX	0.82 (0.21,3.22)	0.88 (0.35,2.29)	-0.04 (-0.32,0.24)
LD ANA SC + MTX	1.20 (0.14,11.81)	1.12 (0.23,3.63)	0.04 (-0.35,0.53)
LD CERTO SC + MTX	1.65 (0.38,7.43)	1.35 (0.54,3.42)	0.11 (-0.21,0.44)
LD ETN SC + MTX	1.29 (0.31,5.46)	1.17 (0.48,2.98)	0.06 (-0.26,0.36)
LD GOLI IV + MTX	0.85 (0.19,3.97)	0.89 (0.31,2.52)	-0.03 (-0.33,0.29)
LD TOCI IV + MTX	0.72 (0.16,3.22)	0.79 (0.27,2.23)	-0.07 (-0.36,0.24)
LD TOFA PO + MTX	1.28 (0.25,6.87)	1.16 (0.39,3.21)	0.05 (-0.29,0.42)
HD TOCI IV	1.13 (0.35,3.78)	1.09 (0.54,2.60)	0.03 (-0.25,0.26)
HD TOFA PO	1.40 (0.38,5.44)	1.24 (0.58,3.18)	0.08 (-0.23,0.35)
HD ADA SC	0.66 (0.17,2.65)	0.75 (0.30,2.07)	-0.08 (-0.37,0.18)
HD GOLI SC	1.17 (0.44,3.25)	1.10 (0.60,2.31)	0.03 (-0.19,0.25)
HD ETN SC	0.79 (0.19,3.21)	0.85 (0.32,2.30)	-0.05 (-0.34,0.24)
HD ABA SC	1.92 (0.33,13.06)	1.46 (0.50,4.21)	0.15 (-0.24,0.55)
HD TOCI IV + MTX	1.97 (0.58,7.18)	1.48 (0.75,3.55)	0.16 (-0.13,0.42)
HD TOFA PO + MTX	1.96 (0.53,7.70)	1.48 (0.70,3.59)	0.16 (-0.15,0.44)
HD GOLI SC + MTX	2.07 (0.63,7.23)	1.52 (0.78,3.53)	0.17 (-0.11,0.43)

(Continued)

HD CERTO SC + MTX		2.74 (0.77,9.95)	1.73 (0.88,4.05)	0.24 (-0.06,0.50)
HD INF IV + MTX		1.69 (0.45,6.56)	1.36 (0.62,3.34)	0.12 (-0.19,0.41)
HD TOCI IV + DMARD		0.42 (0.10,1.83)	0.52 (0.17,1.57)	-0.15 (-0.44,0.11)
SD ABA SC	SD GOLI IV	1.83 (0.28,12.96)	1.48 (0.42,5.16)	0.13 (-0.26,0.53)
SD CERTO SC		1.72 (0.32,9.36)	1.43 (0.47,4.59)	0.11 (-0.24,0.46)
SD ETN SC + MTX		1.83 (0.59,5.58)	1.49 (0.74,3.61)	0.13 (-0.12,0.33)
SD INF IV + MTX		1.61 (0.53,4.83)	1.38 (0.68,3.31)	0.10 (-0.15,0.30)
SD ABA IV + MTX		2.05 (0.68,6.20)	1.59 (0.80,3.84)	0.15 (-0.09,0.36)
SD CERTO SC + MTX		3.09 (1.01,9.42)	1.97 (1.00,4.70)	0.25 (0.00,0.46)
SD TOFA PO + MTX		3.36 (1.09,10.84)	2.04 (1.05,4.86)	0.27 (0.02,0.50)
SD GOLI SC + MTX		3.67 (1.06,12.65)	2.12 (1.03,5.34)	0.29 (0.01,0.52)
SD ADA SC + MTX		2.23 (0.53,8.94)	1.65 (0.66,4.26)	0.17 (-0.14,0.47)
SD RITUX IV + MTX		1.16 (0.35,4.00)	1.11 (0.49,2.81)	0.03 (-0.22,0.26)
SD GOLI IV + MTX		1.29 (0.49,3.47)	1.19 (0.63,2.56)	0.05 (-0.15,0.24)
SD ABA SC + MTX		2.20 (0.55,9.17)	1.64 (0.68,4.41)	0.17 (-0.13,0.46)
SD ANA SC + MTX		2.86 (0.37,25.79)	1.85 (0.49,5.45)	0.23 (-0.19,0.65)
SD TOCI IV + MTX		1.15 (0.27,4.96)	1.11 (0.40,3.17)	0.03 (-0.27,0.31)
SD CERTO SC + DMARD		0.87 (0.19,3.86)	0.90 (0.31,2.80)	-0.03 (-0.33,0.24)
SD ADA SC + DMARD		0.48 (0.10,2.36)	0.56 (0.15,1.90)	-0.11 (-0.40,0.15)
SD ETN SC + DMARD		1.91 (0.44,8.10)	1.52 (0.58,4.19)	0.13 (-0.18,0.43)
LD ADA SC		0.62 (0.15,2.60)	0.70 (0.25,2.16)	-0.08 (-0.37,0.15)
LD GOLI IV		0.59 (0.20,1.75)	0.67 (0.28,1.54)	-0.08 (-0.29,0.10)
LD TOCI IV		0.11 (0.01,0.56)	0.14 (0.02,0.61)	-0.22 (-0.49,-0.05)
LD RITUX IV + MTX		0.96 (0.28,3.30)	0.97 (0.41,2.47)	-0.01 (-0.26,0.22)
LD ABA IV + MTX		1.12 (0.32,3.89)	1.08 (0.46,2.80)	0.02 (-0.24,0.25)
LD ANA SC + MTX		1.63 (0.20,14.91)	1.38 (0.29,4.58)	0.10 (-0.27,0.57)
LD CERTO SC + MTX		2.23 (0.55,8.94)	1.66 (0.69,4.28)	0.17 (-0.13,0.46)
LD ETN SC + MTX		1.74 (0.46,6.35)	1.44 (0.62,3.66)	0.11 (-0.17,0.38)

(Continued)

LD GOLI IV + MTX		1.15 (0.41,3.30)	1.10 (0.53,2.41)	0.03 (-0.18,0.24)
LD TOCI IV + MTX		0.97 (0.23,3.94)	0.97 (0.35,2.76)	-0.01 (-0.28,0.26)
LD TOFA PO + MTX		1.74 (0.38,8.13)	1.43 (0.51,3.92)	0.11 (-0.20,0.44)
HD TOCI IV		1.53 (0.49,4.82)	1.34 (0.66,3.34)	0.09 (-0.17,0.28)
HD TOFA PO		1.88 (0.49,7.57)	1.51 (0.67,4.29)	0.14 (-0.17,0.39)
HD ADA SC		0.90 (0.21,3.79)	0.93 (0.34,2.80)	-0.02 (-0.33,0.22)
HD GOLI SC		1.59 (0.44,5.81)	1.36 (0.60,3.66)	0.09 (-0.19,0.34)
HD ETN SC		1.06 (0.29,3.92)	1.04 (0.43,2.77)	0.01 (-0.26,0.26)
HD ABA SC		2.64 (0.42,18.45)	1.81 (0.57,5.79)	0.21 (-0.19,0.60)
HD TOCI IV + MTX		2.65 (0.83,8.23)	1.83 (0.91,4.49)	0.21 (-0.04,0.43)
HD TOFA PO + MTX		2.68 (0.86,8.46)	1.83 (0.92,4.35)	0.21 (-0.04,0.44)
HD GOLI SC + MTX		2.81 (0.81,9.90)	1.88 (0.90,4.77)	0.23 (-0.05,0.47)
HD CERTO SC + MTX		3.70 (1.18,11.73)	2.13 (1.08,5.12)	0.29 (0.04,0.51)
HD INF IV + MTX		2.26 (0.65,7.75)	1.67 (0.78,4.19)	0.17 (-0.10,0.42)
HD TOCI IV + DMARD		0.56 (0.13,2.32)	0.64 (0.21,1.96)	-0.09 (-0.38,0.13)
SD CERTO SC	SD ABA SC	0.94 (0.13,5.99)	0.96 (0.32,3.09)	-0.02 (-0.44,0.39)
SD ETN SC + MTX		1.01 (0.18,4.82)	1.01 (0.42,2.96)	0.00 (-0.39,0.33)
SD INF IV + MTX		0.88 (0.16,4.45)	0.93 (0.37,2.84)	-0.03 (-0.42,0.30)
SD ABA IV + MTX		1.13 (0.19,5.78)	1.07 (0.44,3.23)	0.03 (-0.38,0.37)
SD CERTO SC + MTX		1.70 (0.29,8.79)	1.33 (0.57,3.95)	0.13 (-0.29,0.46)
SD TOFA PO + MTX		1.84 (0.29,10.11)	1.37 (0.57,4.11)	0.15 (-0.29,0.50)
SD GOLI SC + MTX		2.00 (0.34,11.30)	1.42 (0.63,4.22)	0.17 (-0.25,0.52)
SD ADA SC + MTX		1.20 (0.17,7.97)	1.11 (0.37,3.53)	0.04 (-0.40,0.45)
SD RITUX IV + MTX		0.63 (0.10,3.75)	0.74 (0.26,2.54)	-0.10 (-0.49,0.26)
SD GOLI IV + MTX		0.71 (0.12,3.96)	0.80 (0.28,2.60)	-0.08 (-0.48,0.28)
SD ABA SC + MTX		1.21 (0.16,7.70)	1.11 (0.37,3.47)	0.04 (-0.41,0.44)
SD ANA SC + MTX		1.55 (0.13,19.67)	1.25 (0.29,4.21)	0.10 (-0.43,0.60)
SD TOCI IV + MTX		0.63 (0.09,3.71)	0.75 (0.23,2.50)	-0.10 (-0.51,0.28)

(Continued)

SD CERTO SC + DMARD		0.47 (0.08,2.70)	0.60 (0.21,2.06)	-0.15 (-0.54,0.19)
SD ADA SC + DMARD		0.26 (0.04,1.81)	0.38 (0.09,1.55)	-0.24 (-0.62,0.11)
SD ETN SC + DMARD		1.02 (0.16,6.39)	1.01 (0.36,3.22)	0.00 (-0.41,0.41)
LD ADA SC		0.34 (0.06,1.80)	0.46 (0.17,1.57)	-0.21 (-0.59,0.10)
LD GOLIV		0.32 (0.04,2.08)	0.45 (0.12,1.71)	-0.21 (-0.60,0.14)
LD TOCI IV		0.06 (0.01,0.45)	0.09 (0.01,0.51)	-0.35 (-0.70,-0.08)
LD RITUX IV + MTX		0.52 (0.09,3.10)	0.65 (0.22,2.26)	-0.14 (-0.52,0.22)
LD ABA IV + MTX		0.61 (0.10,3.44)	0.73 (0.25,2.41)	-0.10 (-0.50,0.24)
LD ANA SC + MTX		0.88 (0.07,11.24)	0.93 (0.16,3.56)	-0.03 (-0.51,0.52)
LD CERTO SC + MTX		1.23 (0.18,7.57)	1.12 (0.40,3.51)	0.05 (-0.39,0.44)
LD ETN SC + MTX		0.95 (0.15,5.58)	0.97 (0.34,3.10)	-0.01 (-0.43,0.37)
LD GOLIV + MTX		0.63 (0.09,3.98)	0.75 (0.23,2.54)	-0.10 (-0.51,0.29)
LD TOCI IV + MTX		0.52 (0.08,3.21)	0.65 (0.20,2.27)	-0.13 (-0.53,0.24)
LD TOFA PO + MTX		0.95 (0.12,6.83)	0.97 (0.27,3.23)	-0.01 (-0.45,0.42)
HD TOCI IV		0.83 (0.16,4.00)	0.89 (0.39,2.68)	-0.04 (-0.42,0.27)
HD TOFA PO		1.04 (0.20,4.89)	1.03 (0.46,3.00)	0.01 (-0.37,0.33)
HD ADA SC		0.48 (0.09,2.52)	0.61 (0.23,2.00)	-0.15 (-0.53,0.17)
HD GOLIV		0.87 (0.15,4.66)	0.92 (0.36,2.90)	-0.03 (-0.44,0.31)
HD ETN SC		0.58 (0.09,3.39)	0.70 (0.24,2.36)	-0.12 (-0.51,0.24)
HD ABA SC		1.44 (0.48,4.29)	1.20 (0.65,2.44)	0.08 (-0.17,0.33)
HD TOCI IV + MTX		1.45 (0.26,7.48)	1.22 (0.54,3.66)	0.09 (-0.31,0.42)
HD TOFA PO + MTX		1.47 (0.24,8.02)	1.23 (0.50,3.68)	0.09 (-0.33,0.45)
HD GOLIV + MTX		1.55 (0.25,8.58)	1.26 (0.52,3.83)	0.10 (-0.32,0.46)
HD CERTO SC + MTX		2.03 (0.34,10.70)	1.43 (0.64,4.20)	0.17 (-0.25,0.51)
HD INF IV + MTX		1.24 (0.20,6.94)	1.13 (0.44,3.45)	0.05 (-0.37,0.42)
HD TOCI IV + DMARD		0.30 (0.05,1.86)	0.43 (0.13,1.60)	-0.22 (-0.60,0.11)
SD ETN SC + MTX	SD CERTO SC	1.06 (0.25,4.54)	1.03 (0.47,2.76)	0.01 (-0.32,0.32)
SD INF IV + MTX		0.93 (0.21,4.09)	0.96 (0.42,2.58)	-0.02 (-0.36,0.29)

(Continued)

SD ABA IV + MTX	1.19 (0.27,5.16)	1.11 (0.49,2.90)	0.04 (-0.31,0.35)
SD CERTO SC + MTX	1.80 (0.40,7.80)	1.37 (0.63,3.49)	0.14 (-0.22,0.45)
SD TOFA PO + MTX	1.95 (0.42,9.15)	1.42 (0.65,3.65)	0.16 (-0.21,0.48)
SD GOL I SC + MTX	2.12 (0.48,9.77)	1.47 (0.71,3.77)	0.18 (-0.17,0.49)
SD ADA SC + MTX	1.27 (0.23,7.50)	1.15 (0.41,3.19)	0.06 (-0.33,0.45)
SD RITUX IV + MTX	0.67 (0.14,3.26)	0.77 (0.29,2.24)	-0.09 (-0.43,0.25)
SD GOL I IV + MTX	0.75 (0.16,3.52)	0.83 (0.32,2.32)	-0.06 (-0.40,0.26)
SD ABA SC + MTX	1.27 (0.23,7.04)	1.15 (0.41,3.12)	0.06 (-0.33,0.43)
SD ANA SC + MTX	1.64 (0.18,18.45)	1.29 (0.32,3.87)	0.11 (-0.36,0.59)
SD TOCI IV + MTX	0.66 (0.12,3.66)	0.77 (0.26,2.35)	-0.09 (-0.44,0.28)
SD CERTO SC + DMARD	0.50 (0.10,2.51)	0.62 (0.22,1.90)	-0.14 (-0.47,0.18)
SD ADA SC + DMARD	0.28 (0.05,1.65)	0.39 (0.10,1.42)	-0.22 (-0.55,0.10)
SD ETN SC + DMARD	1.10 (0.21,5.81)	1.06 (0.39,3.00)	0.02 (-0.36,0.39)
LD ADA SC	0.36 (0.08,1.59)	0.48 (0.18,1.42)	-0.20 (-0.51,0.08)
LD GOL I IV	0.34 (0.06,1.86)	0.46 (0.13,1.57)	-0.20 (-0.52,0.12)
LD TOCI IV	0.06 (0.01,0.42)	0.10 (0.02,0.49)	-0.34 (-0.64,-0.09)
LD RITUX IV + MTX	0.56 (0.11,2.76)	0.68 (0.24,2.04)	-0.12 (-0.46,0.20)
LD ABA IV + MTX	0.64 (0.13,3.13)	0.75 (0.28,2.21)	-0.09 (-0.44,0.24)
LD ANA SC + MTX	0.93 (0.10,10.84)	0.96 (0.19,3.34)	-0.01 (-0.44,0.51)
LD CERTO SC + MTX	1.30 (0.24,6.79)	1.16 (0.43,3.15)	0.06 (-0.32,0.43)
LD ETN SC + MTX	1.01 (0.20,5.38)	1.00 (0.38,2.87)	0.00 (-0.36,0.37)
LD GOL I IV + MTX	0.67 (0.13,3.52)	0.77 (0.26,2.31)	-0.09 (-0.43,0.27)
LD TOCI IV + MTX	0.56 (0.11,2.98)	0.68 (0.22,2.08)	-0.12 (-0.46,0.23)
LD TOFA PO + MTX	1.00 (0.16,6.21)	1.00 (0.30,3.00)	0.00 (-0.39,0.41)
HD TOCI IV	0.89 (0.22,3.58)	0.93 (0.43,2.46)	-0.03 (-0.35,0.26)
HD TOFA PO	1.09 (0.27,4.37)	1.06 (0.50,2.71)	0.02 (-0.31,0.31)
HD ADA SC	0.52 (0.12,2.29)	0.64 (0.26,1.83)	-0.14 (-0.46,0.16)
HD GOL I SC	0.92 (0.21,4.03)	0.95 (0.41,2.57)	-0.02 (-0.36,0.30)

(Continued)

HD ETN SC		0.62 (0.13,3.05)	0.73 (0.26,2.17)	-0.10 (-0.44,0.23)
HD ABA SC		1.53 (0.24,10.61)	1.26 (0.43,3.62)	0.10 (-0.32,0.51)
HD TOCI IV + MTX		1.55 (0.36,6.66)	1.27 (0.60,3.26)	0.10 (-0.25,0.41)
HD TOFA PO + MTX		1.55 (0.33,7.27)	1.28 (0.56,3.34)	0.10 (-0.26,0.43)
HD GOLI SC + MTX		1.63 (0.37,7.55)	1.31 (0.59,3.41)	0.11 (-0.24,0.44)
HD CERTO SC + MTX		2.15 (0.47,9.77)	1.48 (0.69,3.75)	0.18 (-0.18,0.50)
HD INF IV + MTX		1.31 (0.28,6.39)	1.17 (0.49,3.18)	0.06 (-0.30,0.40)
HD TOCI IV + DMARD		0.32 (0.06,1.61)	0.44 (0.14,1.43)	-0.21 (-0.53,0.09)
SD INF IV + MTX	SD ETN SC + MTX	0.88 (0.49,1.63)	0.93 (0.63,1.35)	-0.03 (-0.16,0.11)
SD ABA IV + MTX		1.12 (0.57,2.21)	1.07 (0.71,1.58)	0.03 (-0.13,0.19)
SD CERTO SC + MTX		1.69 (0.85,3.36)	1.32 (0.92,1.92)	0.13 (-0.04,0.29)
SD TOFA PO + MTX		1.82 (0.87,4.08)	1.36 (0.92,2.06)	0.14 (-0.03,0.33)
SD GOLI SC + MTX		2.01 (0.87,4.73)	1.42 (0.93,2.23)	0.17 (-0.04,0.36)
SD ADA SC + MTX		1.21 (0.39,3.85)	1.11 (0.52,1.95)	0.04 (-0.20,0.32)
SD RITUX IV + MTX		0.63 (0.27,1.51)	0.74 (0.40,1.28)	-0.10 (-0.27,0.10)
SD GOLI IV + MTX		0.71 (0.30,1.68)	0.80 (0.43,1.36)	-0.08 (-0.26,0.12)
SD ABA SC + MTX		1.20 (0.40,3.63)	1.11 (0.54,1.92)	0.04 (-0.19,0.30)
SD ANA SC + MTX		1.55 (0.25,11.52)	1.26 (0.37,2.55)	0.10 (-0.26,0.49)
SD TOCI IV + MTX		0.63 (0.21,1.91)	0.74 (0.31,1.47)	-0.10 (-0.31,0.15)
SD CERTO SC + DMARD		0.47 (0.15,1.57)	0.60 (0.25,1.34)	-0.16 (-0.38,0.10)
SD ADA SC + DMARD		0.26 (0.07,0.98)	0.38 (0.12,0.98)	-0.24 (-0.43,-0.01)
SD ETN SC + DMARD		1.04 (0.36,3.03)	1.02 (0.51,1.78)	0.01 (-0.22,0.26)
LD ADA SC		0.34 (0.11,1.02)	0.46 (0.21,1.01)	-0.21 (-0.42,0.00)
LD GOLI IV		0.32 (0.10,0.99)	0.45 (0.16,1.00)	-0.21 (-0.40,0.00)
LD TOCI IV		0.06 (0.01,0.24)	0.09 (0.02,0.34)	-0.35 (-0.53,-0.19)
LD RITUX IV + MTX		0.52 (0.22,1.26)	0.65 (0.34,1.15)	-0.13 (-0.30,0.05)
LD ABA IV + MTX		0.61 (0.26,1.46)	0.73 (0.38,1.25)	-0.10 (-0.28,0.09)
LD ANA SC + MTX		0.88 (0.14,6.69)	0.93 (0.22,2.20)	-0.03 (-0.34,0.42)

(Continued)

LD CERTO SC + MTX		1.22 (0.42,3.50)	1.12 (0.56,1.90)	0.05 (-0.19,0.29)
LD ETN SC + MTX		0.96 (0.41,2.27)	0.97 (0.54,1.55)	-0.01 (-0.19,0.20)
LD GOLI IV + MTX		0.63 (0.21,1.86)	0.74 (0.32,1.41)	-0.10 (-0.31,0.14)
LD TOCI IV + MTX		0.53 (0.18,1.61)	0.65 (0.28,1.34)	-0.13 (-0.34,0.11)
LD TOFA PO + MTX		0.94 (0.26,3.45)	0.96 (0.38,1.84)	-0.01 (-0.27,0.29)
HD TOCI IV		0.83 (0.43,1.70)	0.89 (0.60,1.41)	-0.04 (-0.20,0.12)
HD TOFA PO		1.04 (0.37,2.90)	1.02 (0.56,1.91)	0.01 (-0.23,0.25)
HD ADA SC		0.49 (0.16,1.46)	0.62 (0.29,1.29)	-0.15 (-0.37,0.08)
HD GOLI SC		0.87 (0.34,2.20)	0.92 (0.50,1.60)	-0.03 (-0.24,0.18)
HD ETN SC		0.58 (0.24,1.46)	0.70 (0.35,1.25)	-0.12 (-0.29,0.09)
HD ABA SC		1.42 (0.30,7.84)	1.21 (0.46,2.66)	0.08 (-0.26,0.46)
HD TOCI IV + MTX		1.45 (0.72,3.01)	1.22 (0.83,1.87)	0.09 (-0.08,0.26)
HD TOFA PO + MTX		1.46 (0.69,3.19)	1.23 (0.80,1.86)	0.09 (-0.09,0.27)
HD GOLI SC + MTX		1.53 (0.66,3.67)	1.26 (0.79,2.01)	0.10 (-0.10,0.31)
HD CERTO SC + MTX		2.02 (0.96,4.29)	1.43 (0.98,2.12)	0.17 (-0.01,0.34)
HD INF IV + MTX		1.23 (0.54,2.85)	1.13 (0.68,1.77)	0.05 (-0.14,0.25)
HD TOCI IV + DMARD		0.31 (0.10,0.91)	0.43 (0.17,0.94)	-0.22 (-0.41,-0.02)
SD ABA IV + MTX	SD INF IV + MTX	1.27 (0.68,2.35)	1.15 (0.79,1.68)	0.05 (-0.09,0.20)
SD CERTO SC + MTX		1.92 (0.97,3.79)	1.42 (0.99,2.14)	0.15 (-0.01,0.31)
SD TOFA PO + MTX		2.08 (0.98,4.52)	1.47 (0.99,2.28)	0.17 (0.00,0.35)
SD GOLI SC + MTX		2.28 (0.98,5.44)	1.54 (0.99,2.51)	0.20 (0.00,0.39)
SD ADA SC + MTX		1.37 (0.44,4.24)	1.20 (0.57,2.14)	0.07 (-0.18,0.34)
SD RITUX IV + MTX		0.72 (0.30,1.70)	0.80 (0.43,1.39)	-0.07 (-0.25,0.12)
SD GOLI IV + MTX		0.80 (0.33,1.94)	0.87 (0.47,1.51)	-0.05 (-0.23,0.15)
SD ABA SC + MTX		1.37 (0.47,3.92)	1.20 (0.60,2.08)	0.07 (-0.16,0.32)
SD ANA SC + MTX		1.78 (0.28,12.80)	1.37 (0.39,2.84)	0.14 (-0.24,0.52)
SD TOCI IV + MTX		0.71 (0.23,2.23)	0.80 (0.34,1.63)	-0.07 (-0.29,0.19)
SD CERTO SC + DMARD		0.54 (0.16,1.80)	0.65 (0.26,1.47)	-0.13 (-0.36,0.13)



(Continued)

SD ADA SC + DMARD		0.30 (0.07,1.13)	0.41 (0.12,1.08)	-0.21 (-0.42,0.03)
SD ETN SC + DMARD		1.18 (0.38,3.66)	1.10 (0.53,2.07)	0.04 (-0.20,0.30)
LD ADA SC		0.38 (0.12,1.19)	0.50 (0.22,1.13)	-0.18 (-0.40,0.03)
LD GOL I V		0.36 (0.12,1.15)	0.48 (0.18,1.09)	-0.18 (-0.37,0.03)
LD TOCI IV		0.07 (0.01,0.28)	0.10 (0.02,0.37)	-0.32 (-0.51,-0.16)
LD RITUX IV + MTX		0.60 (0.25,1.43)	0.71 (0.37,1.25)	-0.10 (-0.28,0.08)
LD ABA IV + MTX		0.69 (0.30,1.60)	0.79 (0.42,1.34)	-0.08 (-0.25,0.10)
LD ANA SC + MTX		1.00 (0.15,7.64)	1.00 (0.23,2.46)	0.00 (-0.32,0.44)
LD CERTO SC + MTX		1.38 (0.48,3.98)	1.21 (0.61,2.10)	0.07 (-0.16,0.32)
LD ETN SC + MTX		1.08 (0.42,2.77)	1.05 (0.55,1.81)	0.02 (-0.18,0.24)
LD GOL I V + MTX		0.71 (0.24,2.12)	0.80 (0.35,1.56)	-0.07 (-0.28,0.18)
LD TOCI IV + MTX		0.60 (0.20,1.81)	0.71 (0.29,1.47)	-0.10 (-0.31,0.13)
LD TOFA PO + MTX		1.07 (0.31,3.79)	1.04 (0.42,2.04)	0.02 (-0.24,0.31)
HD TOCI IV		0.95 (0.47,1.93)	0.97 (0.63,1.56)	-0.01 (-0.18,0.14)
HD TOFA PO		1.18 (0.41,3.43)	1.10 (0.59,2.17)	0.04 (-0.21,0.28)
HD ADA SC		0.55 (0.18,1.69)	0.66 (0.30,1.44)	-0.12 (-0.35,0.11)
HD GOL I SC		0.99 (0.39,2.52)	0.99 (0.54,1.78)	0.00 (-0.21,0.21)
HD ETN SC		0.66 (0.25,1.70)	0.76 (0.37,1.40)	-0.09 (-0.28,0.12)
HD ABA SC		1.61 (0.34,8.89)	1.31 (0.49,2.99)	0.11 (-0.23,0.49)
HD TOCI IV + MTX		1.64 (0.81,3.46)	1.32 (0.89,2.11)	0.12 (-0.05,0.29)
HD TOFA PO + MTX		1.66 (0.77,3.60)	1.33 (0.86,2.07)	0.12 (-0.06,0.30)
HD GOL I SC + MTX		1.74 (0.75,4.15)	1.36 (0.85,2.25)	0.13 (-0.07,0.33)
HD CERTO SC + MTX		2.29 (1.09,4.91)	1.54 (1.04,2.37)	0.20 (0.02,0.37)
HD INF IV + MTX		1.40 (0.72,2.77)	1.22 (0.81,1.78)	0.08 (-0.07,0.24)
HD TOCI IV + DMARD		0.35 (0.11,1.07)	0.46 (0.18,1.05)	-0.19 (-0.40,0.01)
SD CERTO SC + MTX	SD ABA IV + MTX	1.51 (0.75,3.04)	1.24 (0.86,1.84)	0.10 (-0.07,0.26)
SD TOFA PO + MTX		1.63 (0.77,3.60)	1.28 (0.87,1.95)	0.12 (-0.06,0.30)
SD GOL I SC + MTX		1.80 (0.77,4.27)	1.33 (0.88,2.12)	0.14 (-0.06,0.34)

(Continued)

SD ADA SC + MTX	1.08 (0.34,3.37)	1.04 (0.49,1.85)	0.02 (-0.23,0.29)
SD RITUX IV + MTX	0.56 (0.24,1.37)	0.70 (0.37,1.21)	-0.13 (-0.31,0.07)
SD GOLIV IV + MTX	0.63 (0.26,1.49)	0.76 (0.41,1.27)	-0.10 (-0.29,0.09)
SD ABA SC + MTX	1.07 (0.45,2.58)	1.04 (0.58,1.59)	0.02 (-0.17,0.22)
SD ANA SC + MTX	1.40 (0.22,10.19)	1.19 (0.34,2.43)	0.08 (-0.31,0.47)
SD TOCI IV + MTX	0.56 (0.18,1.75)	0.69 (0.30,1.39)	-0.13 (-0.35,0.13)
SD CERTO SC + DMARD	0.42 (0.12,1.47)	0.56 (0.23,1.28)	-0.18 (-0.42,0.09)
SD ADA SC + DMARD	0.24 (0.06,0.91)	0.35 (0.11,0.94)	-0.26 (-0.48,-0.02)
SD ETN SC + DMARD	0.92 (0.30,3.02)	0.95 (0.46,1.78)	-0.02 (-0.26,0.26)
LD ADA SC	0.30 (0.10,0.95)	0.43 (0.19,0.96)	-0.24 (-0.46,-0.01)
LD GOLIV IV	0.29 (0.09,0.89)	0.42 (0.15,0.93)	-0.24 (-0.43,-0.03)
LD TOCI IV	0.05 (0.01,0.23)	0.09 (0.02,0.32)	-0.38 (-0.58,-0.19)
LD RITUX IV + MTX	0.47 (0.19,1.13)	0.61 (0.31,1.08)	-0.16 (-0.34,0.03)
LD ABA IV + MTX	0.55 (0.27,1.07)	0.68 (0.40,1.04)	-0.13 (-0.28,0.02)
LD ANA SC + MTX	0.79 (0.12,5.87)	0.87 (0.20,2.05)	-0.05 (-0.38,0.38)
LD CERTO SC + MTX	1.09 (0.38,3.14)	1.05 (0.53,1.78)	0.02 (-0.22,0.27)
LD ETN SC + MTX	0.85 (0.32,2.23)	0.91 (0.48,1.54)	-0.04 (-0.25,0.19)
LD GOLIV IV + MTX	0.56 (0.19,1.68)	0.69 (0.31,1.35)	-0.12 (-0.34,0.12)
LD TOCI IV + MTX	0.47 (0.15,1.47)	0.61 (0.25,1.26)	-0.16 (-0.37,0.09)
LD TOFA PO + MTX	0.85 (0.24,3.02)	0.91 (0.37,1.74)	-0.04 (-0.30,0.26)
HD TOCI IV	0.75 (0.36,1.56)	0.84 (0.56,1.34)	-0.07 (-0.24,0.10)
HD TOFA PO	0.92 (0.32,2.80)	0.95 (0.53,1.87)	-0.02 (-0.27,0.24)
HD ADA SC	0.43 (0.14,1.33)	0.58 (0.27,1.21)	-0.18 (-0.42,0.06)
HD GOLIV SC	0.77 (0.30,2.00)	0.86 (0.47,1.51)	-0.06 (-0.28,0.16)
HD ETN SC	0.52 (0.19,1.38)	0.66 (0.32,1.21)	-0.14 (-0.34,0.07)
HD ABA SC	1.28 (0.26,7.22)	1.14 (0.43,2.53)	0.06 (-0.30,0.44)
HD TOCI IV + MTX	1.29 (0.62,2.77)	1.14 (0.78,1.81)	0.06 (-0.11,0.24)
HD TOFA PO + MTX	1.30 (0.61,2.88)	1.15 (0.75,1.75)	0.06 (-0.12,0.25)

(Continued)

HD GOLI SC + MTX		1.37 (0.59,3.31)	1.18 (0.75,1.89)	0.08 (-0.13,0.28)
HD CERTO SC + MTX		1.80 (0.86,3.88)	1.33 (0.92,2.04)	0.14 (-0.04,0.32)
HD INF IV + MTX		1.10 (0.49,2.51)	1.05 (0.65,1.65)	0.02 (-0.16,0.22)
HD TOCI IV + DMARD		0.27 (0.08,0.87)	0.40 (0.15,0.92)	-0.25 (-0.46,-0.03)
SD TOFA PO + MTX	SD CERTO SC + MTX	1.09 (0.51,2.36)	1.04 (0.72,1.49)	0.02 (-0.16,0.20)
SD GOLI SC + MTX		1.19 (0.51,2.86)	1.08 (0.72,1.61)	0.04 (-0.16,0.24)
SD ADA SC + MTX		0.71 (0.23,2.24)	0.84 (0.40,1.42)	-0.08 (-0.33,0.19)
SD RITUX IV + MTX		0.37 (0.16,0.90)	0.56 (0.30,0.95)	-0.22 (-0.41,-0.02)
SD GOLI IV + MTX		0.42 (0.17,0.99)	0.61 (0.33,0.99)	-0.20 (-0.38,0.00)
SD ABA SC + MTX		0.72 (0.24,2.13)	0.85 (0.41,1.40)	-0.08 (-0.33,0.18)
SD ANA SC + MTX		0.92 (0.15,6.65)	0.96 (0.27,1.86)	-0.02 (-0.39,0.37)
SD TOCI IV + MTX		0.37 (0.12,1.18)	0.56 (0.24,1.09)	-0.23 (-0.45,0.04)
SD CERTO SC + DMARD		0.28 (0.08,0.98)	0.45 (0.19,0.99)	-0.28 (-0.52,0.00)
SD ADA SC + DMARD		0.15 (0.04,0.62)	0.28 (0.09,0.75)	-0.37 (-0.58,-0.11)
SD ETN SC + DMARD		0.61 (0.19,1.95)	0.78 (0.37,1.37)	-0.12 (-0.37,0.16)
LD ADA SC		0.20 (0.07,0.63)	0.35 (0.16,0.74)	-0.34 (-0.55,-0.10)
LD GOLI IV		0.19 (0.06,0.59)	0.34 (0.13,0.74)	-0.34 (-0.53,-0.12)
LD TOCI IV		0.03 (0.01,0.15)	0.07 (0.01,0.25)	-0.48 (-0.67,-0.28)
LD RITUX IV + MTX		0.31 (0.13,0.76)	0.49 (0.26,0.86)	-0.26 (-0.44,-0.06)
LD ABA IV + MTX		0.36 (0.15,0.86)	0.55 (0.28,0.92)	-0.23 (-0.42,-0.04)
LD ANA SC + MTX		0.52 (0.08,4.01)	0.70 (0.16,1.64)	-0.15 (-0.48,0.29)
LD CERTO SC + MTX		0.72 (0.29,1.80)	0.85 (0.47,1.29)	-0.08 (-0.28,0.14)
LD ETN SC + MTX		0.57 (0.21,1.52)	0.74 (0.39,1.22)	-0.13 (-0.36,0.10)
LD GOLI IV + MTX		0.38 (0.13,1.13)	0.56 (0.25,1.06)	-0.22 (-0.44,0.03)
LD TOCI IV + MTX		0.31 (0.10,0.96)	0.49 (0.21,0.98)	-0.26 (-0.47,-0.01)
LD TOFA PO + MTX		0.56 (0.16,2.02)	0.73 (0.30,1.35)	-0.14 (-0.40,0.16)
HD TOCI IV		0.49 (0.24,1.02)	0.68 (0.46,1.01)	-0.17 (-0.34,0.00)
HD TOFA PO		0.61 (0.21,1.86)	0.77 (0.45,1.41)	-0.12 (-0.37,0.15)

(Continued)

HD ADA SC		0.29 (0.09,0.93)	0.46 (0.22,0.96)	-0.28 (-0.51,-0.02)
HD GOLI SC		0.51 (0.20,1.30)	0.70 (0.39,1.16)	-0.16 (-0.37,0.06)
HD ETN SC		0.34 (0.13,0.93)	0.53 (0.26,0.96)	-0.24 (-0.44,-0.02)
HD ABA SC		0.85 (0.17,4.69)	0.92 (0.35,1.92)	-0.04 (-0.40,0.35)
HD TOCI IV + MTX		0.86 (0.40,1.79)	0.93 (0.64,1.35)	-0.04 (-0.22,0.14)
HD TOFA PO + MTX		0.87 (0.40,1.85)	0.93 (0.62,1.34)	-0.03 (-0.22,0.14)
HD GOLI SC + MTX		0.91 (0.39,2.20)	0.96 (0.61,1.46)	-0.02 (-0.23,0.19)
HD CERTO SC + MTX		1.20 (0.70,2.03)	1.08 (0.85,1.38)	0.04 (-0.08,0.16)
HD INF IV + MTX		0.73 (0.31,1.70)	0.85 (0.52,1.29)	-0.08 (-0.27,0.13)
HD TOCI IV + DMARD		0.18 (0.05,0.58)	0.32 (0.13,0.72)	-0.35 (-0.56,-0.12)
SD GOLI SC + MTX	SD TOFA PO + MTX	1.10 (0.43,2.84)	1.04 (0.69,1.61)	0.02 (-0.20,0.24)
SD ADA SC + MTX		0.66 (0.19,2.18)	0.82 (0.38,1.42)	-0.10 (-0.37,0.18)
SD RITUX IV + MTX		0.34 (0.14,0.89)	0.55 (0.29,0.94)	-0.24 (-0.44,-0.03)
SD GOLI IV + MTX		0.39 (0.15,0.97)	0.59 (0.31,0.98)	-0.22 (-0.42,-0.01)
SD ABA SC + MTX		0.66 (0.21,2.09)	0.82 (0.39,1.39)	-0.10 (-0.36,0.17)
SD ANA SC + MTX		0.85 (0.13,6.50)	0.93 (0.27,1.83)	-0.04 (-0.43,0.36)
SD TOCI IV + MTX		0.34 (0.10,1.14)	0.54 (0.23,1.07)	-0.24 (-0.48,0.03)
SD CERTO SC + DMARD		0.26 (0.07,0.94)	0.44 (0.18,0.97)	-0.30 (-0.56,-0.01)
SD ADA SC + DMARD		0.14 (0.03,0.57)	0.28 (0.09,0.72)	-0.38 (-0.62,-0.13)
SD ETN SC + DMARD		0.57 (0.17,1.86)	0.75 (0.35,1.35)	-0.13 (-0.41,0.15)
LD ADA SC		0.19 (0.05,0.61)	0.34 (0.15,0.72)	-0.36 (-0.59,-0.10)
LD GOLI IV		0.18 (0.05,0.58)	0.33 (0.12,0.73)	-0.36 (-0.57,-0.12)
LD TOCI IV		0.03 (0.01,0.14)	0.07 (0.01,0.24)	-0.50 (-0.71,-0.29)
LD RITUX IV + MTX		0.29 (0.11,0.75)	0.48 (0.24,0.85)	-0.28 (-0.48,-0.07)
LD ABA IV + MTX		0.33 (0.13,0.84)	0.53 (0.28,0.91)	-0.25 (-0.45,-0.04)
LD ANA SC + MTX		0.48 (0.07,3.81)	0.68 (0.16,1.59)	-0.17 (-0.51,0.28)
LD CERTO SC + MTX		0.67 (0.22,2.03)	0.82 (0.41,1.38)	-0.10 (-0.35,0.17)
LD ETN SC + MTX		0.52 (0.18,1.47)	0.71 (0.37,1.21)	-0.15 (-0.39,0.09)

(Continued)

LD GOLI IV + MTX		0.35 (0.11,1.07)	0.55 (0.24,1.03)	-0.24 (-0.47,0.01)
LD TOCI IV + MTX		0.29 (0.09,0.94)	0.48 (0.20,0.96)	-0.28 (-0.51,-0.02)
LD TOFA PO + MTX		0.52 (0.16,1.63)	0.71 (0.30,1.23)	-0.15 (-0.40,0.11)
HD TOCI IV		0.46 (0.20,1.01)	0.65 (0.44,1.01)	-0.19 (-0.37,0.00)
HD TOFA PO		0.57 (0.17,1.77)	0.75 (0.42,1.37)	-0.14 (-0.41,0.13)
HD ADA SC		0.26 (0.08,0.89)	0.45 (0.21,0.93)	-0.30 (-0.55,-0.03)
HD GOLI SC		0.47 (0.16,1.31)	0.67 (0.36,1.16)	-0.18 (-0.41,0.06)
HD ETN SC		0.32 (0.11,0.89)	0.51 (0.25,0.94)	-0.26 (-0.48,-0.03)
HD ABA SC		0.78 (0.15,4.72)	0.89 (0.34,1.94)	-0.06 (-0.43,0.35)
HD TOCI IV + MTX		0.79 (0.34,1.79)	0.90 (0.61,1.36)	-0.06 (-0.25,0.14)
HD TOFA PO + MTX		0.80 (0.47,1.33)	0.90 (0.68,1.15)	-0.05 (-0.18,0.07)
HD GOLI SC + MTX		0.84 (0.33,2.18)	0.93 (0.58,1.45)	-0.04 (-0.26,0.18)
HD CERTO SC + MTX		1.10 (0.47,2.52)	1.04 (0.72,1.54)	0.02 (-0.17,0.22)
HD INF IV + MTX		0.67 (0.26,1.70)	0.83 (0.48,1.30)	-0.09 (-0.31,0.13)
HD TOCI IV + DMARD		0.17 (0.05,0.55)	0.31 (0.12,0.69)	-0.37 (-0.59,-0.13)
SD ADA SC + MTX	SD GOLI SC + MTX	0.60 (0.17,2.09)	0.78 (0.36,1.36)	-0.12 (-0.40,0.17)
SD RITUX IV + MTX		0.31 (0.11,0.87)	0.52 (0.26,0.93)	-0.27 (-0.48,-0.03)
SD GOLI IV + MTX		0.35 (0.13,0.95)	0.57 (0.29,0.97)	-0.24 (-0.46,-0.01)
SD ABA SC + MTX		0.60 (0.17,2.00)	0.78 (0.36,1.35)	-0.12 (-0.39,0.16)
SD ANA SC + MTX		0.77 (0.12,6.30)	0.89 (0.25,1.77)	-0.06 (-0.46,0.35)
SD TOCI IV + MTX		0.31 (0.09,1.07)	0.52 (0.21,1.03)	-0.27 (-0.51,0.02)
SD CERTO SC + DMARD		0.23 (0.06,0.87)	0.42 (0.17,0.93)	-0.32 (-0.57,-0.03)
SD ADA SC + DMARD		0.13 (0.03,0.53)	0.26 (0.08,0.70)	-0.41 (-0.63,-0.14)
SD ETN SC + DMARD		0.51 (0.15,1.84)	0.72 (0.33,1.33)	-0.16 (-0.43,0.14)
LD ADA SC		0.17 (0.05,0.57)	0.33 (0.15,0.70)	-0.38 (-0.60,-0.12)
LD GOLI IV		0.16 (0.05,0.55)	0.31 (0.11,0.72)	-0.38 (-0.59,-0.14)
LD TOCI IV		0.03 (0.00,0.13)	0.07 (0.01,0.24)	-0.52 (-0.72,-0.31)
LD RITUX IV + MTX		0.26 (0.10,0.71)	0.46 (0.22,0.84)	-0.30 (-0.51,-0.08)

(Continued)

LD ABA IV + MTX		0.30 (0.11,0.83)	0.51 (0.25,0.91)	-0.27 (-0.49,-0.04)
LD ANA SC + MTX		0.44 (0.06,3.62)	0.65 (0.15,1.55)	-0.19 (-0.54,0.26)
LD CERTO SC + MTX		0.60 (0.19,1.96)	0.79 (0.39,1.35)	-0.12 (-0.38,0.16)
LD ETN SC + MTX		0.48 (0.15,1.41)	0.69 (0.34,1.18)	-0.18 (-0.42,0.08)
LD GOL I IV + MTX		0.31 (0.09,1.04)	0.52 (0.22,1.02)	-0.27 (-0.50,0.01)
LD TOCI IV + MTX		0.26 (0.08,0.91)	0.46 (0.19,0.95)	-0.30 (-0.53,-0.02)
LD TOFA PO + MTX		0.47 (0.12,1.86)	0.68 (0.26,1.30)	-0.18 (-0.46,0.14)
HD TOCI IV		0.42 (0.18,0.97)	0.63 (0.41,0.98)	-0.21 (-0.40,-0.01)
HD TOFA PO		0.51 (0.17,1.62)	0.71 (0.41,1.30)	-0.16 (-0.41,0.12)
HD ADA SC		0.24 (0.07,0.80)	0.43 (0.20,0.87)	-0.32 (-0.56,-0.05)
HD GOL I SC		0.43 (0.18,1.00)	0.64 (0.38,1.00)	-0.20 (-0.39,0.00)
HD ETN SC		0.29 (0.10,0.89)	0.49 (0.23,0.94)	-0.28 (-0.50,-0.03)
HD ABA SC		0.71 (0.13,3.99)	0.86 (0.32,1.77)	-0.08 (-0.45,0.31)
HD TOCI IV + MTX		0.73 (0.30,1.75)	0.86 (0.57,1.32)	-0.08 (-0.28,0.13)
HD TOFA PO + MTX		0.72 (0.29,1.85)	0.86 (0.54,1.33)	-0.08 (-0.29,0.14)
HD GOL I SC + MTX		0.77 (0.40,1.45)	0.89 (0.63,1.19)	-0.06 (-0.22,0.09)
HD CERTO SC + MTX		1.00 (0.41,2.52)	1.00 (0.67,1.50)	0.00 (-0.21,0.21)
HD INF IV + MTX		0.61 (0.22,1.67)	0.79 (0.45,1.26)	-0.12 (-0.35,0.12)
HD TOCI IV + DMARD		0.15 (0.04,0.52)	0.30 (0.12,0.68)	-0.39 (-0.61,-0.14)
SD RITUX IV + MTX	SD ADA SC + MTX	0.52 (0.15,1.93)	0.67 (0.32,1.56)	-0.14 (-0.42,0.14)
SD GOL I IV + MTX		0.59 (0.16,2.07)	0.73 (0.34,1.63)	-0.12 (-0.41,0.15)
SD ABA SC + MTX		1.00 (0.24,4.20)	1.00 (0.44,2.30)	0.00 (-0.33,0.32)
SD ANA SC + MTX		1.29 (0.17,12.03)	1.13 (0.31,3.02)	0.06 (-0.38,0.51)
SD TOCI IV + MTX		0.52 (0.12,2.23)	0.67 (0.27,1.68)	-0.14 (-0.45,0.17)
SD CERTO SC + DMARD		0.39 (0.08,1.77)	0.54 (0.21,1.49)	-0.20 (-0.52,0.11)
SD ADA SC + DMARD		0.22 (0.04,1.13)	0.34 (0.10,1.09)	-0.28 (-0.59,0.02)
SD ETN SC + DMARD		0.86 (0.19,3.76)	0.92 (0.40,2.20)	-0.03 (-0.38,0.30)
LD ADA SC		0.28 (0.06,1.19)	0.42 (0.17,1.14)	-0.25 (-0.56,0.03)

(Continued)

LD GOLI IV		0.27 (0.06,1.20)	0.41 (0.14,1.14)	-0.25 (-0.55,0.03)
LD TOCI IV		0.05 (0.01,0.27)	0.09 (0.02,0.35)	-0.40 (-0.69,-0.14)
LD RITUX IV + MTX		0.44 (0.12,1.53)	0.59 (0.27,1.34)	-0.18 (-0.46,0.09)
LD ABA IV + MTX		0.51 (0.14,1.82)	0.66 (0.30,1.50)	-0.15 (-0.43,0.12)
LD ANA SC + MTX		0.74 (0.09,6.89)	0.84 (0.18,2.55)	-0.07 (-0.47,0.42)
LD CERTO SC + MTX		1.01 (0.26,4.08)	1.01 (0.47,2.30)	0.00 (-0.32,0.32)
LD ETN SC + MTX		0.79 (0.20,3.05)	0.88 (0.41,1.99)	-0.05 (-0.36,0.25)
LD GOLI IV + MTX		0.52 (0.12,2.20)	0.67 (0.27,1.66)	-0.14 (-0.45,0.17)
LD TOCI IV + MTX		0.44 (0.10,1.90)	0.59 (0.23,1.52)	-0.18 (-0.48,0.14)
LD TOFA PO + MTX		0.78 (0.16,3.86)	0.87 (0.32,2.17)	-0.06 (-0.40,0.31)
HD TOCI IV		0.69 (0.21,2.27)	0.80 (0.46,1.79)	-0.09 (-0.36,0.17)
HD TOFA PO		0.85 (0.21,3.69)	0.91 (0.46,2.34)	-0.04 (-0.36,0.28)
HD ADA SC		0.41 (0.09,1.76)	0.56 (0.23,1.51)	-0.19 (-0.51,0.11)
HD GOLI SC		0.72 (0.19,2.75)	0.83 (0.40,1.97)	-0.08 (-0.39,0.22)
HD ETN SC		0.48 (0.12,1.85)	0.64 (0.28,1.50)	-0.16 (-0.46,0.13)
HD ABA SC		1.20 (0.18,8.04)	1.10 (0.39,3.07)	0.04 (-0.39,0.46)
HD TOCI IV + MTX		1.19 (0.38,3.99)	1.09 (0.65,2.39)	0.04 (-0.23,0.31)
HD TOFA PO + MTX		1.20 (0.36,3.99)	1.10 (0.62,2.36)	0.04 (-0.24,0.31)
HD GOLI SC + MTX		1.28 (0.36,4.50)	1.13 (0.62,2.52)	0.06 (-0.24,0.34)
HD CERTO SC + MTX		1.67 (0.51,5.47)	1.28 (0.76,2.72)	0.12 (-0.15,0.39)
HD INF IV + MTX		1.02 (0.29,3.62)	1.01 (0.53,2.23)	0.00 (-0.29,0.29)
HD TOCI IV + DMARD		0.25 (0.06,1.09)	0.39 (0.14,1.07)	-0.26 (-0.56,0.02)
SD GOLI IV + MTX	SD RITUX IV + MTX	1.12 (0.40,3.04)	1.08 (0.54,2.17)	0.02 (-0.19,0.23)
SD ABA SC + MTX		1.92 (0.55,6.31)	1.49 (0.67,3.11)	0.14 (-0.13,0.41)
SD ANA SC + MTX		2.42 (0.37,19.71)	1.67 (0.47,4.05)	0.20 (-0.17,0.60)
SD TOCI IV + MTX		0.99 (0.28,3.48)	1.00 (0.39,2.34)	0.00 (-0.25,0.27)
SD CERTO SC + DMARD		0.74 (0.20,2.86)	0.81 (0.30,2.12)	-0.06 (-0.32,0.21)
SD ADA SC + DMARD		0.42 (0.09,1.81)	0.51 (0.14,1.55)	-0.14 (-0.39,0.11)



(Continued)

SD ETN SC + DMARD	1.64 (0.45,5.84)	1.37 (0.59,3.04)	0.11 (-0.17,0.39)	
LD ADA SC	0.54 (0.15,1.88)	0.62 (0.25,1.63)	-0.11 (-0.36,0.11)	
LD GOL I IV	0.51 (0.14,1.74)	0.60 (0.21,1.50)	-0.11 (-0.34,0.11)	
LD TOCI IV	0.09 (0.01,0.41)	0.13 (0.02,0.48)	-0.25 (-0.48,-0.09)	
LD RITUX IV + MTX	0.83 (0.41,1.69)	0.88 (0.52,1.45)	-0.03 (-0.18,0.10)	
LD ABA IV + MTX	0.97 (0.35,2.67)	0.98 (0.47,2.00)	-0.01 (-0.22,0.20)	
LD ANA SC + MTX	1.38 (0.20,11.43)	1.23 (0.28,3.45)	0.07 (-0.26,0.52)	
LD CERTO SC + MTX	1.93 (0.59,6.27)	1.50 (0.71,3.09)	0.14 (-0.11,0.41)	
LD ETN SC + MTX	1.52 (0.48,4.60)	1.31 (0.61,2.72)	0.09 (-0.15,0.33)	
LD GOL I IV + MTX	1.00 (0.29,3.25)	1.00 (0.41,2.20)	0.00 (-0.24,0.25)	
LD TOCI IV + MTX	0.83 (0.24,2.91)	0.88 (0.35,2.11)	-0.03 (-0.28,0.22)	
LD TOFA PO + MTX	1.49 (0.37,5.95)	1.30 (0.49,2.95)	0.08 (-0.20,0.39)	
HD TOCI IV	1.33 (0.53,3.25)	1.21 (0.69,2.38)	0.06 (-0.15,0.23)	
HD TOFA PO	1.65 (0.48,5.44)	1.38 (0.65,3.21)	0.11 (-0.17,0.35)	
HD ADA SC	0.77 (0.22,2.73)	0.83 (0.35,2.12)	-0.05 (-0.31,0.19)	
HD GOL I SC	1.38 (0.46,4.05)	1.24 (0.60,2.63)	0.07 (-0.18,0.29)	
HD ETN SC	0.92 (0.30,2.83)	0.94 (0.42,2.05)	-0.02 (-0.25,0.22)	
HD ABA SC	2.28 (0.40,13.35)	1.63 (0.55,4.36)	0.19 (-0.19,0.56)	
HD TOCI IV + MTX	2.30 (0.89,5.73)	1.65 (0.94,3.19)	0.19 (-0.03,0.38)	
HD TOFA PO + MTX	2.32 (0.89,5.86)	1.65 (0.93,3.13)	0.19 (-0.03,0.39)	
HD GOL I SC + MTX	2.44 (0.88,6.86)	1.70 (0.93,3.36)	0.20 (-0.03,0.42)	
HD CERTO SC + MTX	3.21 (1.26,8.19)	1.91 (1.12,3.64)	0.27 (0.05,0.46)	
HD INF IV + MTX	1.95 (0.71,5.37)	1.51 (0.82,2.92)	0.15 (-0.08,0.37)	
HD TOCI IV + DMARD	0.49 (0.13,1.74)	0.58 (0.20,1.51)	-0.12 (-0.36,0.10)	
SD ABA SC + MTX	SD GOL I IV + MTX	1.70 (0.50,5.91)	1.37 (0.63,2.89)	0.12 (-0.15,0.40)
SD ANA SC + MTX		2.19 (0.32,18.87)	1.57 (0.44,3.79)	0.18 (-0.22,0.59)
SD TOCI IV + MTX		0.89 (0.26,3.23)	0.92 (0.37,2.18)	-0.02 (-0.27,0.25)
SD CERTO SC + DMARD		0.66 (0.18,2.55)	0.74 (0.29,1.95)	-0.08 (-0.34,0.19)

(Continued)

SD ADA SC + DMARD		0.37 (0.09,1.65)	0.47 (0.14,1.43)	-0.16 (-0.41,0.09)
SD ETN SC + DMARD		1.47 (0.41,5.27)	1.27 (0.56,2.80)	0.08 (-0.19,0.37)
LD ADA SC		0.48 (0.14,1.71)	0.58 (0.24,1.51)	-0.13 (-0.38,0.09)
LD GOL I V		0.46 (0.16,1.26)	0.56 (0.24,1.17)	-0.13 (-0.32,0.04)
LD TOCI IV		0.08 (0.01,0.38)	0.12 (0.02,0.45)	-0.27 (-0.50,-0.10)
LD RITUX IV + MTX		0.74 (0.27,2.10)	0.81 (0.40,1.68)	-0.06 (-0.27,0.15)
LD ABA IV + MTX		0.87 (0.31,2.39)	0.91 (0.44,1.82)	-0.03 (-0.24,0.18)
LD ANA SC + MTX		1.25 (0.18,10.77)	1.15 (0.26,3.19)	0.05 (-0.30,0.50)
LD CERTO SC + MTX		1.73 (0.53,5.55)	1.39 (0.66,2.81)	0.12 (-0.14,0.39)
LD ETN SC + MTX		1.35 (0.45,4.08)	1.21 (0.59,2.47)	0.07 (-0.17,0.31)
LD GOL I V + MTX		0.89 (0.34,2.35)	0.92 (0.46,1.77)	-0.02 (-0.21,0.19)
LD TOCI IV + MTX		0.75 (0.22,2.65)	0.82 (0.32,1.94)	-0.06 (-0.30,0.20)
LD TOFA PO + MTX		1.34 (0.34,5.31)	1.20 (0.46,2.62)	0.06 (-0.21,0.37)
HD TOCI IV		1.18 (0.48,2.91)	1.12 (0.65,2.18)	0.04 (-0.17,0.21)
HD TOFA PO		1.45 (0.45,4.82)	1.27 (0.62,2.94)	0.08 (-0.19,0.33)
HD ADA SC		0.69 (0.19,2.43)	0.77 (0.32,1.91)	-0.07 (-0.34,0.17)
HD GOL I SC		1.24 (0.41,3.64)	1.15 (0.57,2.41)	0.05 (-0.20,0.27)
HD ETN SC		0.82 (0.28,2.54)	0.87 (0.40,1.89)	-0.04 (-0.26,0.20)
HD ABA SC		2.03 (0.38,12.21)	1.51 (0.53,3.94)	0.16 (-0.21,0.54)
HD TOCI IV + MTX		2.05 (0.82,5.14)	1.53 (0.90,2.94)	0.16 (-0.05,0.36)
HD TOFA PO + MTX		2.07 (0.81,5.27)	1.53 (0.89,2.84)	0.17 (-0.05,0.37)
HD GOL I SC + MTX		2.19 (0.81,6.05)	1.57 (0.89,3.11)	0.18 (-0.05,0.40)
HD CERTO SC + MTX		2.85 (1.15,7.15)	1.77 (1.08,3.32)	0.24 (0.03,0.44)
HD INF IV + MTX		1.74 (0.63,4.86)	1.40 (0.76,2.74)	0.12 (-0.11,0.35)
HD TOCI IV + DMARD		0.43 (0.12,1.55)	0.53 (0.19,1.38)	-0.14 (-0.38,0.08)
SD ANA SC + MTX	SD ABA SC + MTX	1.30 (0.17,11.09)	1.14 (0.31,2.89)	0.06 (-0.37,0.49)
SD TOCI IV + MTX		0.52 (0.12,2.16)	0.68 (0.26,1.63)	-0.14 (-0.44,0.17)
SD CERTO SC + DMARD		0.39 (0.09,1.75)	0.54 (0.20,1.47)	-0.20 (-0.52,0.11)

(Continued)

SD ADA SC + DMARD		0.22 (0.04,1.10)	0.34 (0.10,1.07)	-0.28 (-0.58,0.02)
SD ETN SC + DMARD		0.86 (0.21,3.58)	0.92 (0.40,2.13)	-0.04 (-0.35,0.29)
LD ADA SC		0.28 (0.07,1.19)	0.42 (0.17,1.14)	-0.25 (-0.55,0.03)
LD GOL I V		0.27 (0.06,1.10)	0.41 (0.14,1.07)	-0.25 (-0.54,0.02)
LD TOCI IV		0.05 (0.01,0.26)	0.09 (0.02,0.34)	-0.40 (-0.67,-0.15)
LD RITUX IV + MTX		0.43 (0.13,1.54)	0.59 (0.27,1.34)	-0.18 (-0.45,0.09)
LD ABA IV + MTX		0.51 (0.17,1.57)	0.66 (0.33,1.34)	-0.15 (-0.40,0.09)
LD ANA SC + MTX		0.73 (0.10,6.66)	0.84 (0.19,2.41)	-0.07 (-0.46,0.41)
LD CERTO SC + MTX		1.02 (0.26,4.03)	1.01 (0.46,2.22)	0.00 (-0.31,0.32)
LD ETN SC + MTX		0.79 (0.21,2.91)	0.88 (0.41,1.94)	-0.05 (-0.35,0.24)
LD GOL I V + MTX		0.52 (0.13,2.09)	0.67 (0.27,1.59)	-0.14 (-0.44,0.16)
LD TOCI IV + MTX		0.44 (0.11,1.82)	0.60 (0.23,1.47)	-0.18 (-0.47,0.13)
LD TOFA PO + MTX		0.78 (0.16,3.79)	0.87 (0.32,2.09)	-0.06 (-0.39,0.30)
HD TOCI IV		0.69 (0.23,2.20)	0.80 (0.47,1.75)	-0.09 (-0.35,0.16)
HD TOFA PO		0.86 (0.22,3.47)	0.91 (0.47,2.27)	-0.04 (-0.36,0.27)
HD ADA SC		0.40 (0.10,1.69)	0.55 (0.24,1.46)	-0.20 (-0.50,0.10)
HD GOL I SC		0.72 (0.20,2.62)	0.83 (0.41,1.90)	-0.08 (-0.37,0.21)
HD ETN SC		0.48 (0.13,1.80)	0.64 (0.28,1.48)	-0.16 (-0.44,0.12)
HD ABA SC		1.18 (0.20,8.27)	1.09 (0.40,3.03)	0.04 (-0.37,0.47)
HD TOCI IV + MTX		1.21 (0.39,3.85)	1.10 (0.65,2.32)	0.05 (-0.22,0.30)
HD TOFA PO + MTX		1.21 (0.38,3.92)	1.10 (0.63,2.31)	0.05 (-0.23,0.31)
HD GOL I SC + MTX		1.27 (0.38,4.38)	1.13 (0.63,2.42)	0.06 (-0.23,0.34)
HD CERTO SC + MTX		1.68 (0.54,5.38)	1.28 (0.76,2.69)	0.12 (-0.15,0.38)
HD INF IV + MTX		1.02 (0.32,3.46)	1.01 (0.55,2.13)	0.01 (-0.27,0.28)
HD TOCI IV + DMARD		0.26 (0.06,1.10)	0.39 (0.14,1.07)	-0.26 (-0.56,0.02)
SD TOCI IV + MTX	SD ANA SC + MTX	0.40 (0.04,3.21)	0.60 (0.21,2.32)	-0.20 (-0.63,0.22)
SD CERTO SC + DMARD		0.30 (0.03,2.48)	0.48 (0.16,1.99)	-0.26 (-0.69,0.16)
SD ADA SC + DMARD		0.17 (0.02,1.51)	0.31 (0.08,1.37)	-0.34 (-0.75,0.06)

(Continued)

SD ETN SC + DMARD	0.66 (0.07,5.14)	0.81 (0.32,2.99)	-0.10 (-0.53,0.33)	
LD ADA SC	0.22 (0.02,1.72)	0.37 (0.14,1.54)	-0.32 (-0.71,0.08)	
LD GOLI IV	0.21 (0.02,1.64)	0.36 (0.11,1.44)	-0.31 (-0.72,0.08)	
LD TOCI IV	0.04 (0.00,0.37)	0.08 (0.01,0.43)	-0.46 (-0.85,-0.09)	
LD RITUX IV + MTX	0.34 (0.04,2.28)	0.53 (0.21,1.86)	-0.24 (-0.63,0.14)	
LD ABA IV + MTX	0.39 (0.05,2.76)	0.58 (0.23,2.13)	-0.21 (-0.61,0.18)	
LD ANA SC + MTX	0.56 (0.13,2.39)	0.76 (0.26,1.64)	-0.11 (-0.42,0.18)	
LD CERTO SC + MTX	0.78 (0.09,5.84)	0.89 (0.35,3.12)	-0.06 (-0.49,0.37)	
LD ETN SC + MTX	0.61 (0.07,4.38)	0.77 (0.31,2.75)	-0.11 (-0.53,0.30)	
LD GOLI IV + MTX	0.41 (0.04,3.03)	0.60 (0.21,2.20)	-0.20 (-0.63,0.21)	
LD TOCI IV + MTX	0.34 (0.04,2.62)	0.53 (0.18,2.04)	-0.24 (-0.65,0.17)	
LD TOFA PO + MTX	0.61 (0.06,5.07)	0.78 (0.25,2.87)	-0.11 (-0.56,0.34)	
HD TOCI IV	0.54 (0.07,3.36)	0.71 (0.36,2.51)	-0.15 (-0.53,0.22)	
HD TOFA PO	0.66 (0.08,5.13)	0.80 (0.38,3.16)	-0.10 (-0.52,0.32)	
HD ADA SC	0.31 (0.03,2.47)	0.49 (0.20,2.01)	-0.26 (-0.66,0.15)	
HD GOLI SC	0.56 (0.07,3.89)	0.73 (0.32,2.67)	-0.14 (-0.55,0.25)	
HD ETN SC	0.37 (0.04,2.62)	0.56 (0.22,2.04)	-0.22 (-0.63,0.18)	
HD ABA SC	0.94 (0.08,10.52)	0.97 (0.32,3.99)	-0.01 (-0.53,0.50)	
HD TOCI IV + MTX	0.92 (0.12,5.90)	0.96 (0.50,3.40)	-0.02 (-0.41,0.36)	
HD TOFA PO + MTX	0.94 (0.12,5.88)	0.97 (0.47,3.32)	-0.01 (-0.42,0.37)	
HD GOLI SC + MTX	0.98 (0.13,6.73)	0.99 (0.48,3.61)	0.00 (-0.41,0.39)	
HD CERTO SC + MTX	1.30 (0.17,8.36)	1.12 (0.58,4.03)	0.06 (-0.33,0.45)	
HD INF IV + MTX	0.80 (0.10,5.40)	0.89 (0.41,3.15)	-0.05 (-0.46,0.35)	
HD TOCI IV + DMARD	0.20 (0.02,1.55)	0.35 (0.11,1.42)	-0.33 (-0.73,0.07)	
SD CERTO SC + DMARD	SD TOCI IV + MTX	0.75 (0.17,3.29)	0.82 (0.29,2.45)	-0.05 (-0.35,0.22)
SD ADA SC + DMARD		0.42 (0.09,2.00)	0.51 (0.14,1.70)	-0.13 (-0.42,0.12)
SD ETN SC + DMARD		1.65 (0.39,7.10)	1.38 (0.55,3.61)	0.11 (-0.21,0.41)
LD ADA SC		0.54 (0.13,2.21)	0.63 (0.24,1.88)	-0.11 (-0.39,0.12)

(Continued)

LD GOLIV		0.51 (0.12,2.20)	0.61 (0.19,1.81)	-0.11 (-0.39,0.14)
LD TOCI IV		0.09 (0.02,0.41)	0.13 (0.03,0.48)	-0.25 (-0.50,-0.08)
LD RITUX IV + MTX		0.84 (0.23,3.02)	0.88 (0.36,2.27)	-0.03 (-0.30,0.21)
LD ABA IV + MTX		0.97 (0.28,3.42)	0.98 (0.42,2.44)	-0.01 (-0.27,0.24)
LD ANA SC + MTX		1.41 (0.17,13.53)	1.25 (0.26,4.02)	0.07 (-0.31,0.55)
LD CERTO SC + MTX		1.95 (0.48,7.98)	1.51 (0.63,3.78)	0.15 (-0.16,0.45)
LD ETN SC + MTX		1.53 (0.40,5.83)	1.31 (0.56,3.28)	0.09 (-0.20,0.37)
LD GOLIV + MTX		0.99 (0.24,4.22)	1.00 (0.36,2.72)	0.00 (-0.29,0.29)
LD TOCI IV + MTX		0.85 (0.25,2.73)	0.89 (0.37,2.06)	-0.03 (-0.28,0.20)
LD TOFA PO + MTX		1.49 (0.31,7.21)	1.29 (0.45,3.49)	0.08 (-0.23,0.43)
HD TOCI IV		1.33 (0.49,3.66)	1.21 (0.66,2.67)	0.06 (-0.17,0.24)
HD TOFA PO		1.65 (0.44,6.31)	1.38 (0.62,3.73)	0.11 (-0.20,0.36)
HD ADA SC		0.77 (0.19,3.23)	0.83 (0.33,2.46)	-0.05 (-0.34,0.21)
HD GOLIV SC		1.37 (0.39,4.94)	1.23 (0.55,3.15)	0.07 (-0.22,0.32)
HD ETN SC		0.93 (0.24,3.53)	0.95 (0.38,2.54)	-0.01 (-0.29,0.24)
HD ABA SC		2.27 (0.39,15.04)	1.63 (0.55,4.95)	0.18 (-0.21,0.57)
HD TOCI IV + MTX		2.29 (0.83,6.50)	1.65 (0.91,3.72)	0.19 (-0.05,0.39)
HD TOFA PO + MTX		2.33 (0.70,7.71)	1.65 (0.82,3.92)	0.19 (-0.08,0.43)
HD GOLIV SC + MTX		2.45 (0.70,8.76)	1.70 (0.82,4.17)	0.20 (-0.08,0.46)
HD CERTO SC + MTX		3.22 (0.99,10.62)	1.92 (1.00,4.50)	0.27 (0.00,0.50)
HD INF IV + MTX		1.98 (0.57,6.85)	1.52 (0.71,3.69)	0.15 (-0.13,0.40)
HD TOCI IV + DMARD		0.49 (0.12,1.95)	0.58 (0.20,1.70)	-0.12 (-0.40,0.11)
SD ADA SC + DMARD	SD CERTO SC + DMARD	0.55 (0.13,2.34)	0.62 (0.19,1.90)	-0.08 (-0.31,0.15)
SD ETN SC + DMARD		2.20 (0.56,8.91)	1.69 (0.67,4.39)	0.16 (-0.12,0.46)
LD ADA SC		0.73 (0.19,2.64)	0.78 (0.28,2.19)	-0.05 (-0.30,0.15)
LD GOLIV		0.69 (0.14,3.18)	0.74 (0.21,2.43)	-0.06 (-0.31,0.20)
LD TOCI IV		0.12 (0.02,0.67)	0.15 (0.03,0.71)	-0.19 (-0.42,-0.04)
LD RITUX IV + MTX		1.12 (0.28,4.31)	1.09 (0.39,2.95)	0.02 (-0.24,0.28)

(Continued)

LD ABA IV + MTX		1.30 (0.34,5.01)	1.21 (0.45,3.27)	0.05 (-0.21,0.31)
LD ANA SC + MTX		1.85 (0.22,19.38)	1.52 (0.29,5.21)	0.12 (-0.23,0.61)
LD CERTO SC + MTX		2.59 (0.58,11.10)	1.86 (0.69,4.83)	0.20 (-0.11,0.50)
LD ETN SC + MTX		2.03 (0.50,8.17)	1.62 (0.61,4.22)	0.14 (-0.14,0.43)
LD GOLI IV + MTX		1.34 (0.30,6.07)	1.24 (0.41,3.55)	0.05 (-0.22,0.36)
LD TOCI IV + MTX		1.12 (0.26,4.84)	1.09 (0.36,3.17)	0.02 (-0.24,0.30)
LD TOFA PO + MTX		2.01 (0.38,10.64)	1.60 (0.50,4.60)	0.14 (-0.18,0.49)
HD TOCI IV		1.78 (0.58,5.38)	1.50 (0.70,3.58)	0.12 (-0.12,0.31)
HD TOFA PO		2.21 (0.63,7.63)	1.71 (0.74,4.28)	0.17 (-0.10,0.39)
HD ADA SC		1.04 (0.27,3.82)	1.03 (0.39,2.84)	0.01 (-0.26,0.23)
HD GOLI SC		1.85 (0.50,6.84)	1.53 (0.63,3.97)	0.12 (-0.15,0.38)
HD ETN SC		1.24 (0.31,4.88)	1.17 (0.42,3.22)	0.04 (-0.23,0.30)
HD ABA SC		3.07 (0.54,18.58)	2.03 (0.66,5.61)	0.24 (-0.13,0.61)
HD TOCI IV + MTX		3.08 (0.93,10.53)	2.05 (0.96,4.92)	0.24 (-0.02,0.47)
HD TOFA PO + MTX		3.11 (0.82,11.54)	2.05 (0.89,5.04)	0.25 (-0.04,0.51)
HD GOLI SC + MTX		3.28 (0.87,12.37)	2.11 (0.92,5.18)	0.26 (-0.03,0.52)
HD CERTO SC + MTX		4.31 (1.19,15.33)	2.39 (1.10,5.66)	0.33 (0.04,0.56)
HD INF IV + MTX		2.63 (0.70,10.14)	1.88 (0.79,4.71)	0.21 (-0.08,0.48)
HD TOCI IV + DMARD		0.65 (0.19,2.23)	0.71 (0.26,1.86)	-0.07 (-0.28,0.14)
SD ETN SC + DMARD	SD ADA SC + DMARD	3.96 (0.96,16.87)	2.69 (0.97,8.53)	0.24 (-0.01,0.51)
LD ADA SC		1.29 (0.28,6.03)	1.23 (0.38,4.70)	0.03 (-0.22,0.22)
LD GOLI IV		1.23 (0.23,6.37)	1.18 (0.30,4.70)	0.02 (-0.22,0.27)
LD TOCI IV		0.22 (0.03,1.35)	0.25 (0.04,1.30)	-0.10 (-0.34,0.02)
LD RITUX IV + MTX		2.00 (0.45,9.24)	1.72 (0.55,6.23)	0.10 (-0.14,0.34)
LD ABA IV + MTX		2.31 (0.55,10.35)	1.92 (0.64,6.71)	0.13 (-0.11,0.37)
LD ANA SC + MTX		3.43 (0.37,35.91)	2.44 (0.44,10.08)	0.21 (-0.14,0.68)
LD CERTO SC + MTX		4.66 (0.94,23.07)	2.95 (0.96,9.82)	0.28 (-0.01,0.57)
LD ETN SC + MTX		3.61 (0.83,17.21)	2.57 (0.88,8.68)	0.23 (-0.04,0.50)

(Continued)

LD GOLIV + MTX		2.40 (0.49,12.55)	1.96 (0.58,7.12)	0.14 (-0.12,0.42)
LD TOCI IV + MTX		2.01 (0.42,9.41)	1.74 (0.51,6.04)	0.10 (-0.15,0.37)
LD TOFA PO + MTX		3.59 (0.66,21.36)	2.52 (0.73,9.55)	0.22 (-0.07,0.56)
HD TOCI IV		3.20 (0.91,11.22)	2.40 (0.94,7.30)	0.20 (-0.02,0.37)
HD TOFA PO		3.97 (0.88,17.13)	2.75 (0.92,9.37)	0.25 (-0.03,0.46)
HD ADA SC		1.86 (0.42,8.53)	1.64 (0.52,5.97)	0.09 (-0.16,0.30)
HD GOLIV SC		3.32 (0.76,14.84)	2.44 (0.83,8.40)	0.21 (-0.06,0.44)
HD ETN SC		2.24 (0.51,9.86)	1.87 (0.61,6.43)	0.12 (-0.12,0.37)
HD ABA SC		5.51 (0.79,39.89)	3.24 (0.85,12.27)	0.32 (-0.05,0.68)
HD TOCI IV + MTX		5.51 (1.52,21.29)	3.29 (1.27,10.27)	0.33 (0.09,0.53)
HD TOFA PO + MTX		5.58 (1.39,23.39)	3.26 (1.23,10.64)	0.33 (0.07,0.57)
HD GOLIV SC + MTX		5.90 (1.41,25.44)	3.38 (1.24,10.98)	0.34 (0.07,0.58)
HD CERTO SC + MTX		7.71 (1.89,32.25)	3.80 (1.43,12.17)	0.41 (0.15,0.63)
HD INF IV + MTX		4.74 (1.13,21.25)	3.00 (1.08,9.94)	0.29 (0.02,0.54)
HD TOCI IV + DMARD		1.17 (0.36,3.79)	1.13 (0.45,3.11)	0.02 (-0.17,0.18)
LD ADA SC	SD ETN SC + DMARD	0.33 (0.08,1.31)	0.46 (0.19,1.23)	-0.22 (-0.51,0.05)
LD GOLIV IV		0.31 (0.07,1.40)	0.44 (0.14,1.27)	-0.22 (-0.51,0.06)
LD TOCI IV		0.05 (0.01,0.30)	0.09 (0.02,0.38)	-0.36 (-0.64,-0.14)
LD RITUX IV + MTX		0.51 (0.14,1.86)	0.64 (0.28,1.52)	-0.14 (-0.42,0.12)
LD ABA IV + MTX		0.59 (0.16,2.07)	0.71 (0.32,1.63)	-0.11 (-0.40,0.15)
LD ANA SC + MTX		0.85 (0.11,8.09)	0.91 (0.20,2.70)	-0.04 (-0.42,0.45)
LD CERTO SC + MTX		1.18 (0.28,4.75)	1.10 (0.47,2.45)	0.04 (-0.29,0.36)
LD ETN SC + MTX		0.92 (0.24,3.46)	0.95 (0.42,2.15)	-0.02 (-0.33,0.28)
LD GOLIV IV + MTX		0.61 (0.14,2.65)	0.73 (0.27,1.86)	-0.11 (-0.42,0.22)
LD TOCI IV + MTX		0.51 (0.12,2.09)	0.64 (0.24,1.64)	-0.14 (-0.43,0.16)
LD TOFA PO + MTX		0.91 (0.19,4.62)	0.95 (0.34,2.38)	-0.02 (-0.36,0.34)
HD TOCI IV		0.81 (0.27,2.37)	0.88 (0.50,1.82)	-0.05 (-0.31,0.18)
HD TOFA PO		1.01 (0.27,3.63)	1.00 (0.50,2.36)	0.00 (-0.31,0.28)



(Continued)

HD ADA SC		0.47 (0.12,1.82)	0.60 (0.26,1.55)	-0.16 (-0.46,0.12)
HD GOLI SC		0.84 (0.22,2.98)	0.90 (0.42,2.05)	-0.04 (-0.35,0.24)
HD ETN SC		0.56 (0.16,1.95)	0.69 (0.30,1.57)	-0.12 (-0.40,0.14)
HD ABA SC		1.40 (0.23,8.73)	1.20 (0.41,3.14)	0.08 (-0.34,0.48)
HD TOCI IV + MTX		1.39 (0.45,4.42)	1.19 (0.68,2.54)	0.08 (-0.19,0.33)
HD TOFA PO + MTX		1.41 (0.42,4.83)	1.20 (0.65,2.56)	0.08 (-0.20,0.36)
HD GOLI SC + MTX		1.49 (0.41,5.36)	1.23 (0.64,2.73)	0.09 (-0.21,0.38)
HD CERTO SC + MTX		1.94 (0.58,6.49)	1.39 (0.78,2.92)	0.16 (-0.13,0.42)
HD INF IV + MTX		1.19 (0.34,4.18)	1.10 (0.56,2.40)	0.04 (-0.25,0.32)
HD TOCI IV + DMARD		0.30 (0.08,1.01)	0.42 (0.16,1.01)	-0.23 (-0.49,0.00)
LD GOLI IV	LD ADA SC	0.95 (0.22,4.00)	0.96 (0.27,2.93)	-0.01 (-0.20,0.24)
LD TOCI IV		0.17 (0.03,0.88)	0.20 (0.03,0.89)	-0.14 (-0.30,-0.01)
LD RITUX IV + MTX		1.55 (0.45,5.33)	1.40 (0.52,3.56)	0.07 (-0.13,0.31)
LD ABA IV + MTX		1.80 (0.52,6.25)	1.56 (0.59,3.88)	0.10 (-0.11,0.34)
LD ANA SC + MTX		2.64 (0.32,23.26)	2.01 (0.38,6.04)	0.18 (-0.15,0.64)
LD CERTO SC + MTX		3.61 (0.88,14.55)	2.40 (0.91,5.72)	0.26 (-0.02,0.55)
LD ETN SC + MTX		2.80 (0.75,10.53)	2.09 (0.80,5.03)	0.20 (-0.05,0.47)
LD GOLI IV + MTX		1.85 (0.46,7.54)	1.59 (0.53,4.25)	0.11 (-0.12,0.40)
LD TOCI IV + MTX		1.57 (0.39,6.08)	1.42 (0.47,3.80)	0.07 (-0.14,0.34)
LD TOFA PO + MTX		2.77 (0.57,13.40)	2.06 (0.65,5.41)	0.19 (-0.09,0.54)
HD TOCI IV		2.46 (0.93,6.55)	1.93 (0.95,4.17)	0.17 (-0.02,0.34)
HD TOFA PO		3.07 (1.07,8.74)	2.21 (1.05,4.83)	0.22 (0.01,0.42)
HD ADA SC		1.44 (0.65,3.13)	1.33 (0.72,2.46)	0.06 (-0.07,0.20)
HD GOLI SC		2.56 (0.77,8.42)	1.97 (0.82,4.71)	0.18 (-0.05,0.41)
HD ETN SC		1.72 (0.47,6.28)	1.51 (0.56,3.89)	0.09 (-0.12,0.34)
HD ABA SC		4.23 (0.79,23.84)	2.62 (0.84,6.72)	0.30 (-0.04,0.64)
HD TOCI IV + MTX		4.25 (1.43,12.74)	2.64 (1.27,5.75)	0.30 (0.08,0.51)
HD TOFA PO + MTX		4.32 (1.32,14.45)	2.65 (1.20,5.93)	0.30 (0.06,0.54)

(Continued)

HD GOLI SC + MTX		4.57 (1.34,15.22)	2.74 (1.23,6.09)	0.32 (0.06,0.55)
HD CERTO SC + MTX		5.97 (1.79,19.51)	3.08 (1.46,6.70)	0.38 (0.12,0.60)
HD INF IV + MTX		3.69 (1.04,12.57)	2.44 (1.02,5.61)	0.26 (0.01,0.51)
HD TOCI IV + DMARD		0.91 (0.23,3.37)	0.92 (0.28,2.63)	-0.01 (-0.20,0.20)
LD TOCI IV	LD GOLI IV	0.18 (0.03,0.97)	0.21 (0.03,0.97)	-0.13 (-0.36,0.00)
LD RITUX IV + MTX		1.61 (0.48,5.91)	1.45 (0.58,4.17)	0.08 (-0.14,0.29)
LD ABA IV + MTX		1.91 (0.54,6.97)	1.63 (0.64,4.72)	0.11 (-0.11,0.32)
LD ANA SC + MTX		2.71 (0.34,26.19)	2.04 (0.42,7.72)	0.18 (-0.16,0.64)
LD CERTO SC + MTX		3.83 (0.97,14.94)	2.49 (0.97,7.05)	0.26 (-0.01,0.53)
LD ETN SC + MTX		2.95 (0.79,11.52)	2.15 (0.85,6.29)	0.20 (-0.05,0.46)
LD GOLI IV + MTX		1.96 (0.66,5.88)	1.65 (0.73,4.02)	0.11 (-0.07,0.32)
LD TOCI IV + MTX		1.63 (0.39,7.02)	1.46 (0.49,4.61)	0.08 (-0.16,0.33)
LD TOFA PO + MTX		2.93 (0.62,13.99)	2.13 (0.70,6.55)	0.20 (-0.08,0.52)
HD TOCI IV		2.61 (0.81,8.59)	2.01 (0.88,5.73)	0.17 (-0.05,0.34)
HD TOFA PO		3.19 (0.82,13.52)	2.28 (0.88,7.41)	0.22 (-0.04,0.45)
HD ADA SC		1.51 (0.35,6.45)	1.38 (0.46,4.69)	0.06 (-0.20,0.28)
HD GOLI SC		2.70 (0.72,10.22)	2.06 (0.80,6.15)	0.18 (-0.07,0.40)
HD ETN SC		1.81 (0.50,6.93)	1.58 (0.59,4.66)	0.09 (-0.13,0.33)
HD ABA SC		4.45 (0.70,31.35)	2.69 (0.78,9.79)	0.30 (-0.07,0.66)
HD TOCI IV + MTX		4.50 (1.38,15.12)	2.74 (1.20,7.77)	0.30 (0.07,0.50)
HD TOFA PO + MTX		4.55 (1.41,14.70)	2.75 (1.22,7.36)	0.30 (0.07,0.51)
HD GOLI SC + MTX		4.78 (1.38,17.07)	2.83 (1.22,7.96)	0.31 (0.07,0.54)
HD CERTO SC + MTX		6.28 (1.96,20.63)	3.22 (1.45,8.65)	0.38 (0.15,0.58)
HD INF IV + MTX		3.86 (1.13,13.52)	2.52 (1.08,6.99)	0.26 (0.03,0.49)
HD TOCI IV + DMARD		0.96 (0.21,4.24)	0.96 (0.29,3.35)	-0.01 (-0.25,0.20)
LD RITUX IV + MTX	LD TOCI IV	9.16 (1.99,56.51)	6.92 (1.78,37.78)	0.21 (0.07,0.43)
LD ABA IV + MTX		10.70 (2.29,67.10)	7.72 (2.00,42.78)	0.24 (0.08,0.46)
LD ANA SC + MTX		16.16 (1.40,200.30)	9.73 (1.35,63.50)	0.32 (0.02,0.78)

(Continued)

LD CERTO SC + MTX		21.02 (4.03,140.00)	11.70 (2.99,63.85)	0.40 (0.16,0.67)
LD ETN SC + MTX		16.69 (3.41,106.30)	10.26 (2.67,55.69)	0.34 (0.13,0.59)
LD GOLI IV + MTX		10.97 (2.10,75.57)	7.77 (1.86,44.20)	0.25 (0.07,0.52)
LD TOCI IV + MTX		9.20 (2.07,51.29)	6.87 (1.86,34.95)	0.21 (0.06,0.45)
LD TOFA PO + MTX		16.80 (2.68,125.80)	10.19 (2.27,58.61)	0.34 (0.09,0.66)
HD TOCI IV		14.50 (3.83,77.33)	9.64 (2.83,48.60)	0.31 (0.19,0.46)
HD TOFA PO		18.08 (3.77,117.20)	11.04 (2.79,61.95)	0.36 (0.20,0.54)
HD ADA SC		8.56 (1.64,53.20)	6.66 (1.53,37.47)	0.20 (0.05,0.38)
HD GOLI SC		15.01 (3.19,95.36)	9.76 (2.49,54.89)	0.32 (0.14,0.53)
HD ETN SC		10.17 (2.02,66.08)	7.45 (1.81,42.46)	0.23 (0.07,0.47)
HD ABA SC		25.35 (3.24,254.00)	12.86 (2.59,78.02)	0.44 (0.14,0.77)
HD TOCI IV + MTX		25.26 (6.42,138.30)	13.18 (3.84,67.50)	0.44 (0.27,0.62)
HD TOFA PO + MTX		25.35 (5.76,155.60)	13.11 (3.65,69.81)	0.44 (0.23,0.66)
HD GOLI SC + MTX		26.90 (5.82,164.10)	13.57 (3.64,74.17)	0.46 (0.25,0.67)
HD CERTO SC + MTX		35.15 (7.94,203.30)	15.25 (4.27,79.07)	0.52 (0.31,0.72)
HD INF IV + MTX		21.32 (4.76,131.90)	11.92 (3.27,63.50)	0.40 (0.19,0.63)
HD TOCI IV + DMARD		5.33 (1.01,36.04)	4.55 (1.01,27.50)	0.12 (0.00,0.33)
LD ABA IV + MTX	LD RITUX IV + MTX	1.16 (0.41,3.22)	1.11 (0.53,2.34)	0.03 (-0.17,0.23)
LD ANA SC + MTX		1.67 (0.25,13.36)	1.41 (0.33,3.97)	0.10 (-0.22,0.55)
LD CERTO SC + MTX		2.31 (0.71,7.65)	1.70 (0.79,3.69)	0.18 (-0.07,0.44)
LD ETN SC + MTX		1.82 (0.58,5.63)	1.49 (0.69,3.17)	0.12 (-0.11,0.37)
LD GOLI IV + MTX		1.21 (0.36,3.94)	1.14 (0.47,2.60)	0.04 (-0.19,0.29)
LD TOCI IV + MTX		1.00 (0.28,3.51)	1.00 (0.38,2.47)	0.00 (-0.23,0.25)
LD TOFA PO + MTX		1.80 (0.44,7.19)	1.48 (0.55,3.42)	0.12 (-0.16,0.43)
HD TOCI IV		1.60 (0.64,3.99)	1.38 (0.76,2.81)	0.09 (-0.10,0.26)
HD TOFA PO		1.97 (0.59,6.65)	1.57 (0.72,3.82)	0.14 (-0.12,0.38)
HD ADA SC		0.92 (0.27,3.29)	0.94 (0.38,2.48)	-0.02 (-0.26,0.21)
HD GOLI SC		1.65 (0.55,5.02)	1.40 (0.67,3.10)	0.10 (-0.13,0.33)

(Continued)

HD ETN SC		1.11 (0.37,3.39)	1.08 (0.48,2.41)	0.02 (-0.20,0.25)
HD ABA SC		2.76 (0.49,16.52)	1.88 (0.62,5.18)	0.22 (-0.15,0.59)
HD TOCI IV + MTX		2.76 (1.08,6.96)	1.88 (1.04,3.82)	0.22 (0.02,0.41)
HD TOFA PO + MTX		2.77 (1.07,7.21)	1.88 (1.04,3.72)	0.22 (0.01,0.42)
HD GOLI SC + MTX		2.92 (1.07,8.13)	1.94 (1.04,3.96)	0.24 (0.01,0.45)
HD CERTO SC + MTX		3.87 (1.50,9.95)	2.19 (1.24,4.33)	0.30 (0.09,0.49)
HD INF IV + MTX		2.35 (0.86,6.55)	1.73 (0.91,3.53)	0.18 (-0.03,0.40)
HD TOCI IV + DMARD		0.59 (0.15,2.10)	0.66 (0.22,1.76)	-0.08 (-0.32,0.13)
LD ANA SC + MTX	LD ABA IV + MTX	1.46 (0.20,11.51)	1.27 (0.28,3.57)	0.08 (-0.26,0.52)
LD CERTO SC + MTX		1.98 (0.60,6.52)	1.53 (0.72,3.21)	0.15 (-0.10,0.41)
LD ETN SC + MTX		1.56 (0.51,4.80)	1.33 (0.64,2.77)	0.09 (-0.14,0.34)
LD GOLI IV + MTX		1.03 (0.31,3.49)	1.02 (0.42,2.33)	0.01 (-0.23,0.27)
LD TOCI IV + MTX		0.87 (0.25,3.01)	0.90 (0.36,2.16)	-0.03 (-0.26,0.22)
LD TOFA PO + MTX		1.55 (0.38,6.29)	1.33 (0.50,3.09)	0.09 (-0.19,0.40)
HD TOCI IV		1.37 (0.56,3.39)	1.23 (0.71,2.48)	0.07 (-0.13,0.24)
HD TOFA PO		1.68 (0.50,5.83)	1.40 (0.66,3.41)	0.11 (-0.16,0.36)
HD ADA SC		0.80 (0.23,2.82)	0.85 (0.35,2.19)	-0.04 (-0.30,0.19)
HD GOLI SC		1.41 (0.47,4.22)	1.26 (0.62,2.72)	0.07 (-0.16,0.30)
HD ETN SC		0.95 (0.31,2.89)	0.97 (0.43,2.08)	-0.01 (-0.23,0.22)
HD ABA SC		2.33 (0.45,14.25)	1.65 (0.58,4.56)	0.19 (-0.17,0.57)
HD TOCI IV + MTX		2.37 (0.97,5.94)	1.68 (0.98,3.34)	0.19 (-0.01,0.38)
HD TOFA PO + MTX		2.38 (0.94,6.08)	1.68 (0.97,3.26)	0.19 (-0.01,0.40)
HD GOLI SC + MTX		2.49 (0.93,7.08)	1.73 (0.96,3.53)	0.21 (-0.02,0.43)
HD CERTO SC + MTX		3.30 (1.31,8.53)	1.96 (1.16,3.85)	0.27 (0.06,0.47)
HD INF IV + MTX		2.01 (0.75,5.50)	1.54 (0.84,3.05)	0.15 (-0.06,0.37)
HD TOCI IV + DMARD		0.50 (0.14,1.77)	0.59 (0.21,1.54)	-0.11 (-0.34,0.10)
LD CERTO SC + MTX	LD ANA SC + MTX	1.40 (0.15,10.56)	1.20 (0.42,5.41)	0.07 (-0.40,0.45)
LD ETN SC + MTX		1.08 (0.12,8.16)	1.05 (0.37,4.81)	0.02 (-0.46,0.39)

(Continued)

LD GOLI IV + MTX		0.72 (0.08,5.62)	0.81 (0.25,3.72)	-0.07 (-0.55,0.30)
LD TOCI IV + MTX		0.60 (0.06,4.73)	0.71 (0.21,3.39)	-0.10 (-0.58,0.26)
LD TOFA PO + MTX		1.06 (0.12,9.47)	1.04 (0.32,4.93)	0.01 (-0.46,0.43)
HD TOCI IV		0.95 (0.13,6.37)	0.97 (0.41,4.32)	-0.01 (-0.45,0.30)
HD TOFA PO		1.17 (0.13,9.01)	1.10 (0.42,5.38)	0.04 (-0.44,0.39)
HD ADA SC		0.55 (0.06,4.26)	0.66 (0.23,3.31)	-0.12 (-0.59,0.22)
HD GOLI SC		0.97 (0.12,7.08)	0.98 (0.37,4.51)	-0.01 (-0.47,0.34)
HD ETN SC		0.66 (0.08,4.83)	0.77 (0.25,3.45)	-0.08 (-0.55,0.26)
HD ABA SC		1.65 (0.13,20.12)	1.31 (0.38,7.09)	0.11 (-0.44,0.58)
HD TOCI IV + MTX		1.63 (0.22,11.26)	1.31 (0.57,5.77)	0.11 (-0.33,0.44)
HD TOFA PO + MTX		1.67 (0.21,11.09)	1.33 (0.56,5.73)	0.12 (-0.33,0.45)
HD GOLI SC + MTX		1.76 (0.21,12.43)	1.37 (0.56,6.10)	0.13 (-0.33,0.48)
HD CERTO SC + MTX		2.28 (0.29,15.46)	1.53 (0.65,6.73)	0.19 (-0.26,0.53)
HD INF IV + MTX		1.40 (0.17,9.75)	1.21 (0.48,5.32)	0.08 (-0.38,0.43)
HD TOCI IV + DMARD		0.34 (0.04,2.90)	0.47 (0.14,2.42)	-0.19 (-0.66,0.15)
LD ETN SC + MTX	LD CERTO SC + MTX	0.78 (0.22,2.80)	0.87 (0.41,1.85)	-0.06 (-0.35,0.23)
LD GOLI IV + MTX		0.52 (0.13,1.98)	0.67 (0.27,1.54)	-0.14 (-0.43,0.15)
LD TOCI IV + MTX		0.43 (0.11,1.68)	0.59 (0.24,1.40)	-0.18 (-0.47,0.11)
LD TOFA PO + MTX		0.77 (0.17,3.40)	0.87 (0.33,2.00)	-0.06 (-0.38,0.28)
HD TOCI IV		0.68 (0.23,2.04)	0.80 (0.47,1.64)	-0.09 (-0.34,0.15)
HD TOFA PO		0.85 (0.22,3.34)	0.91 (0.47,2.17)	-0.04 (-0.35,0.27)
HD ADA SC		0.40 (0.10,1.61)	0.55 (0.24,1.40)	-0.20 (-0.50,0.10)
HD GOLI SC		0.71 (0.20,2.44)	0.82 (0.41,1.79)	-0.08 (-0.37,0.20)
HD ETN SC		0.48 (0.13,1.73)	0.63 (0.28,1.42)	-0.16 (-0.44,0.12)
HD ABA SC		1.17 (0.20,7.79)	1.08 (0.39,2.89)	0.04 (-0.37,0.46)
HD TOCI IV + MTX		1.19 (0.40,3.58)	1.09 (0.65,2.21)	0.04 (-0.22,0.29)
HD TOFA PO + MTX		1.20 (0.40,3.68)	1.10 (0.64,2.20)	0.04 (-0.22,0.30)
HD GOLI SC + MTX		1.26 (0.39,4.12)	1.13 (0.64,2.31)	0.06 (-0.22,0.33)

(Continued)

HD CERTO SC + MTX		1.65 (0.64,4.28)	1.27 (0.83,2.38)	0.12 (-0.10,0.33)
HD INF IV + MTX		1.02 (0.31,3.28)	1.01 (0.54,2.05)	0.00 (-0.27,0.27)
HD TOCI IV + DMARD		0.25 (0.06,1.02)	0.38 (0.14,1.01)	-0.27 (-0.55,0.00)
LD GOLI IV + MTX	LD ETN SC + MTX	0.66 (0.18,2.42)	0.77 (0.31,1.74)	-0.09 (-0.36,0.19)
LD TOCI IV + MTX		0.55 (0.15,2.10)	0.67 (0.26,1.66)	-0.12 (-0.39,0.16)
LD TOFA PO + MTX		0.99 (0.22,4.31)	0.99 (0.37,2.32)	0.00 (-0.32,0.33)
HD TOCI IV		0.88 (0.32,2.37)	0.92 (0.54,1.85)	-0.03 (-0.27,0.18)
HD TOFA PO		1.08 (0.31,3.96)	1.05 (0.53,2.49)	0.02 (-0.28,0.29)
HD ADA SC		0.51 (0.14,1.90)	0.63 (0.27,1.59)	-0.14 (-0.42,0.13)
HD GOLI SC		0.91 (0.28,2.99)	0.94 (0.47,2.05)	-0.02 (-0.29,0.24)
HD ETN SC		0.61 (0.19,2.02)	0.72 (0.32,1.60)	-0.10 (-0.36,0.15)
HD ABA SC		1.50 (0.27,9.56)	1.24 (0.45,3.31)	0.09 (-0.30,0.49)
HD TOCI IV + MTX		1.52 (0.56,4.18)	1.26 (0.74,2.50)	0.10 (-0.14,0.31)
HD TOFA PO + MTX		1.53 (0.54,4.46)	1.27 (0.73,2.49)	0.10 (-0.14,0.33)
HD GOLI SC + MTX		1.61 (0.53,5.02)	1.30 (0.72,2.64)	0.11 (-0.15,0.36)
HD CERTO SC + MTX		2.11 (0.76,6.02)	1.46 (0.88,2.88)	0.18 (-0.07,0.41)
HD INF IV + MTX		1.30 (0.44,3.92)	1.16 (0.63,2.31)	0.06 (-0.19,0.31)
HD TOCI IV + DMARD		0.32 (0.08,1.21)	0.44 (0.16,1.15)	-0.21 (-0.47,0.04)
LD TOCI IV + MTX	LD GOLI IV + MTX	0.84 (0.20,3.41)	0.88 (0.32,2.42)	-0.03 (-0.31,0.24)
LD TOFA PO + MTX		1.49 (0.33,6.96)	1.29 (0.47,3.45)	0.08 (-0.23,0.42)
HD TOCI IV		1.33 (0.43,4.09)	1.21 (0.62,2.88)	0.06 (-0.20,0.26)
HD TOFA PO		1.63 (0.44,6.47)	1.38 (0.63,3.84)	0.11 (-0.19,0.37)
HD ADA SC		0.78 (0.19,3.21)	0.84 (0.32,2.43)	-0.05 (-0.35,0.20)
HD GOLI SC		1.37 (0.39,4.95)	1.23 (0.55,3.20)	0.07 (-0.22,0.32)
HD ETN SC		0.92 (0.26,3.33)	0.95 (0.40,2.44)	-0.01 (-0.29,0.23)
HD ABA SC		2.28 (0.36,15.71)	1.63 (0.53,5.06)	0.18 (-0.23,0.58)
HD TOCI IV + MTX		2.29 (0.74,7.20)	1.65 (0.86,3.92)	0.19 (-0.07,0.41)
HD TOFA PO + MTX		2.31 (0.75,7.41)	1.64 (0.85,3.78)	0.19 (-0.07,0.43)

(Continued)

HD GOLI SC + MTX		2.44 (0.73,8.26)	1.69 (0.85,4.07)	0.20 (-0.08,0.44)
HD CERTO SC + MTX		3.19 (1.02,10.06)	1.92 (1.01,4.44)	0.27 (0.01,0.49)
HD INF IV + MTX		1.97 (0.58,6.61)	1.52 (0.72,3.61)	0.15 (-0.13,0.40)
HD TOCI IV + DMARD		0.49 (0.11,2.04)	0.58 (0.19,1.74)	-0.12 (-0.41,0.12)
LD TOFA PO + MTX	LD TOCI IV + MTX	1.78 (0.37,8.74)	1.46 (0.50,4.09)	0.12 (-0.19,0.46)
HD TOCI IV		1.58 (0.60,4.37)	1.37 (0.73,3.10)	0.09 (-0.12,0.26)
HD TOFA PO		1.98 (0.53,7.29)	1.57 (0.68,4.29)	0.15 (-0.15,0.38)
HD ADA SC		0.92 (0.24,3.59)	0.94 (0.36,2.71)	-0.02 (-0.29,0.22)
HD GOLI SC		1.64 (0.46,6.05)	1.40 (0.61,3.68)	0.10 (-0.17,0.35)
HD ETN SC		1.10 (0.30,4.06)	1.07 (0.43,2.87)	0.02 (-0.24,0.27)
HD ABA SC		2.73 (0.45,17.79)	1.85 (0.60,5.61)	0.22 (-0.17,0.59)
HD TOCI IV + MTX		2.76 (1.01,7.82)	1.87 (1.01,4.30)	0.22 (0.00,0.42)
HD TOFA PO + MTX		2.78 (0.85,9.12)	1.88 (0.91,4.54)	0.22 (-0.04,0.46)
HD GOLI SC + MTX		2.92 (0.88,10.05)	1.93 (0.93,4.81)	0.24 (-0.03,0.48)
HD CERTO SC + MTX		3.83 (1.20,12.17)	2.19 (1.10,5.23)	0.30 (0.04,0.52)
HD INF IV + MTX		2.36 (0.68,7.90)	1.72 (0.79,4.23)	0.18 (-0.09,0.43)
HD TOCI IV + DMARD		0.58 (0.14,2.26)	0.66 (0.22,1.93)	-0.08 (-0.34,0.14)
HD TOCI IV	LD TOFA PO + MTX	0.89 (0.24,3.27)	0.93 (0.48,2.43)	-0.03 (-0.34,0.22)
HD TOFA PO		1.12 (0.23,5.17)	1.07 (0.48,3.16)	0.03 (-0.34,0.33)
HD ADA SC		0.52 (0.11,2.57)	0.64 (0.25,2.04)	-0.14 (-0.49,0.17)
HD GOLI SC		0.92 (0.21,3.85)	0.95 (0.43,2.59)	-0.02 (-0.36,0.27)
HD ETN SC		0.61 (0.14,2.71)	0.73 (0.30,2.05)	-0.10 (-0.43,0.19)
HD ABA SC		1.52 (0.22,11.95)	1.26 (0.42,4.11)	0.10 (-0.35,0.53)
HD TOCI IV + MTX		1.54 (0.41,5.65)	1.27 (0.67,3.22)	0.10 (-0.20,0.36)
HD TOFA PO + MTX		1.55 (0.49,4.96)	1.27 (0.72,2.95)	0.10 (-0.17,0.34)
HD GOLI SC + MTX		1.64 (0.41,6.37)	1.31 (0.66,3.36)	0.12 (-0.21,0.40)
HD CERTO SC + MTX		2.15 (0.57,8.03)	1.48 (0.79,3.70)	0.18 (-0.13,0.45)
HD INF IV + MTX		1.32 (0.33,5.21)	1.17 (0.57,3.00)	0.06 (-0.26,0.35)



(Continued)

HD TOCI IV + DMARD		0.33 (0.07,1.59)	0.45 (0.15,1.42)	-0.21 (-0.53,0.08)
HD TOFA PO	HD TOCI IV	1.24 (0.49,3.16)	1.14 (0.64,2.02)	0.05 (-0.17,0.27)
HD ADA SC		0.59 (0.22,1.55)	0.69 (0.33,1.34)	-0.11 (-0.30,0.09)
HD GOLI SC		1.03 (0.41,2.58)	1.02 (0.55,1.77)	0.01 (-0.19,0.22)
HD ETN SC		0.70 (0.26,1.86)	0.78 (0.37,1.45)	-0.08 (-0.26,0.15)
HD ABA SC		1.71 (0.38,8.82)	1.37 (0.51,2.83)	0.13 (-0.21,0.49)
HD TOCI IV + MTX		1.73 (0.98,3.14)	1.37 (0.99,1.90)	0.13 (-0.01,0.27)
HD TOFA PO + MTX		1.75 (0.77,3.95)	1.37 (0.85,2.08)	0.13 (-0.06,0.32)
HD GOLI SC + MTX		1.85 (0.78,4.44)	1.41 (0.86,2.22)	0.15 (-0.06,0.35)
HD CERTO SC + MTX		2.41 (1.09,5.50)	1.59 (1.05,2.36)	0.21 (0.02,0.39)
HD INF IV + MTX		1.48 (0.61,3.53)	1.26 (0.72,1.97)	0.09 (-0.11,0.30)
HD TOCI IV + DMARD		0.37 (0.13,1.02)	0.48 (0.19,1.01)	-0.18 (-0.34,0.00)
HD ADA SC	HD TOFA PO	0.47 (0.17,1.31)	0.60 (0.29,1.20)	-0.16 (-0.36,0.06)
HD GOLI SC		0.84 (0.27,2.54)	0.90 (0.43,1.73)	-0.04 (-0.29,0.22)
HD ETN SC		0.57 (0.16,1.98)	0.69 (0.28,1.51)	-0.12 (-0.37,0.16)
HD ABA SC		1.39 (0.30,7.02)	1.20 (0.45,2.42)	0.08 (-0.27,0.44)
HD TOCI IV + MTX		1.40 (0.50,4.03)	1.20 (0.67,2.13)	0.08 (-0.17,0.33)
HD TOFA PO + MTX		1.40 (0.44,4.57)	1.20 (0.62,2.20)	0.08 (-0.19,0.36)
HD GOLI SC + MTX		1.49 (0.47,4.61)	1.24 (0.65,2.22)	0.10 (-0.18,0.36)
HD CERTO SC + MTX		1.96 (0.61,5.87)	1.41 (0.77,2.41)	0.16 (-0.12,0.41)
HD INF IV + MTX		1.20 (0.36,3.87)	1.11 (0.53,2.05)	0.04 (-0.23,0.32)
HD TOCI IV + DMARD		0.29 (0.08,1.06)	0.41 (0.15,1.04)	-0.23 (-0.44,0.01)
HD GOLI SC	HD ADA SC	1.77 (0.55,5.82)	1.49 (0.66,3.38)	0.12 (-0.12,0.36)
HD ETN SC		1.20 (0.33,4.34)	1.14 (0.43,2.81)	0.03 (-0.20,0.30)
HD ABA SC		2.95 (0.58,16.90)	1.97 (0.69,4.88)	0.24 (-0.11,0.60)
HD TOCI IV + MTX		3.00 (1.00,9.18)	2.00 (1.00,4.20)	0.24 (0.00,0.47)
HD TOFA PO + MTX		3.04 (0.89,9.90)	2.01 (0.93,4.27)	0.24 (-0.02,0.49)
HD GOLI SC + MTX		3.17 (0.96,10.70)	2.06 (0.97,4.46)	0.26 (-0.01,0.51)

(Continued)

HD CERTO SC + MTX		4.17 (1.23,13.41)	2.33 (1.13,4.81)	0.32 (0.05,0.55)
HD INF IV + MTX		2.55 (0.74,8.89)	1.84 (0.81,4.06)	0.20 (-0.07,0.47)
HD TOCI IV + DMARD		0.63 (0.16,2.29)	0.70 (0.23,1.88)	-0.07 (-0.28,0.15)
HD ETN SC	HD GOLI SC	0.67 (0.21,2.21)	0.77 (0.33,1.67)	-0.08 (-0.32,0.17)
HD ABA SC		1.66 (0.32,9.56)	1.33 (0.48,3.10)	0.12 (-0.25,0.50)
HD TOCI IV + MTX		1.68 (0.65,4.45)	1.34 (0.79,2.46)	0.12 (-0.10,0.34)
HD TOFA PO + MTX		1.68 (0.61,4.95)	1.34 (0.75,2.48)	0.12 (-0.12,0.36)
HD GOLI SC + MTX		1.77 (0.76,4.30)	1.37 (0.86,2.34)	0.13 (-0.06,0.33)
HD CERTO SC + MTX		2.34 (0.87,6.39)	1.55 (0.93,2.81)	0.20 (-0.03,0.42)
HD INF IV + MTX		1.43 (0.50,4.21)	1.23 (0.65,2.32)	0.08 (-0.16,0.33)
HD TOCI IV + DMARD		0.35 (0.10,1.27)	0.47 (0.17,1.18)	-0.19 (-0.42,0.05)
HD ABA SC	HD ETN SC	2.47 (0.45,15.55)	1.72 (0.59,4.88)	0.20 (-0.17,0.58)
HD TOCI IV + MTX		2.50 (0.91,6.90)	1.75 (0.95,3.70)	0.20 (-0.02,0.41)
HD TOFA PO + MTX		2.52 (0.89,7.07)	1.75 (0.93,3.64)	0.21 (-0.03,0.42)
HD GOLI SC + MTX		2.64 (0.87,8.00)	1.79 (0.93,3.91)	0.22 (-0.03,0.45)
HD CERTO SC + MTX		3.47 (1.23,9.81)	2.03 (1.11,4.22)	0.28 (0.05,0.49)
HD INF IV + MTX		2.11 (0.72,6.50)	1.60 (0.82,3.44)	0.16 (-0.08,0.40)
HD TOCI IV + DMARD		0.52 (0.14,1.92)	0.61 (0.22,1.66)	-0.10 (-0.34,0.11)
HD TOCI IV + MTX	HD ABA SC	1.01 (0.18,4.85)	1.01 (0.49,2.61)	0.00 (-0.38,0.35)
HD TOFA PO + MTX		1.03 (0.17,5.35)	1.02 (0.45,2.69)	0.01 (-0.40,0.38)
HD GOLI SC + MTX		1.07 (0.18,5.66)	1.03 (0.47,2.79)	0.02 (-0.38,0.39)
HD CERTO SC + MTX		1.41 (0.24,7.32)	1.17 (0.57,3.04)	0.08 (-0.31,0.44)
HD INF IV + MTX		0.86 (0.14,4.62)	0.92 (0.40,2.50)	-0.04 (-0.43,0.35)
HD TOCI IV + DMARD		0.21 (0.03,1.24)	0.35 (0.11,1.17)	-0.31 (-0.66,0.04)
HD TOFA PO + MTX	HD TOCI IV + MTX	1.01 (0.44,2.30)	1.00 (0.64,1.50)	0.00 (-0.19,0.20)
HD GOLI SC + MTX		1.06 (0.44,2.61)	1.03 (0.64,1.61)	0.01 (-0.20,0.23)
HD CERTO SC + MTX		1.39 (0.62,3.13)	1.16 (0.79,1.71)	0.08 (-0.11,0.27)
HD INF IV + MTX		0.85 (0.35,2.08)	0.92 (0.54,1.44)	-0.04 (-0.25,0.17)

(Continued)

HD TOCI IV + DMARD		0.21 (0.07,0.64)	0.35 (0.14,0.75)	-0.31 (-0.51,-0.10)
HD GOLI SC + MTX	HD TOFA PO + MTX	1.05 (0.41,2.66)	1.03 (0.64,1.67)	0.01 (-0.21,0.23)
HD CERTO SC + MTX		1.38 (0.60,3.13)	1.16 (0.79,1.78)	0.08 (-0.12,0.27)
HD INF IV + MTX		0.84 (0.33,2.16)	0.92 (0.54,1.50)	-0.04 (-0.26,0.18)
HD TOCI IV + DMARD		0.21 (0.06,0.70)	0.35 (0.13,0.80)	-0.31 (-0.54,-0.07)
HD CERTO SC + MTX	HD GOLI SC + MTX	1.31 (0.53,3.32)	1.13 (0.74,1.79)	0.06 (-0.15,0.28)
HD INF IV + MTX		0.80 (0.30,2.17)	0.89 (0.51,1.50)	-0.05 (-0.29,0.19)
HD TOCI IV + DMARD		0.20 (0.06,0.69)	0.34 (0.13,0.79)	-0.33 (-0.56,-0.08)
HD INF IV + MTX	HD CERTO SC + MTX	0.61 (0.25,1.53)	0.79 (0.47,1.22)	-0.12 (-0.33,0.10)
HD TOCI IV + DMARD		0.15 (0.04,0.51)	0.30 (0.12,0.67)	-0.39 (-0.61,-0.15)
HD TOCI IV + DMARD	HD INF IV + MTX	0.25 (0.07,0.84)	0.38 (0.14,0.89)	-0.27 (-0.52,-0.03)
Random-Effect Model	Residual Deviance	165.2 vs 163 data points		
	Deviance Information Criteria	1084.66		
Fixed-Effect Model	Residual Deviance	vs data points		
	Deviance Information Criteria			
Note:				
Total Patients	24984			
Total Studies	60			
2-arm	28			
3-arm	25			
4-arm	5			
5-arm	1			
7-arm	1			

**Appendix 6. ACR50: Subgroup - Late RA (> 10 years)**

ACR50 in Late RA: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
PL + MTX	PL	9.03 (2.77,32.14)	5.98 (2.40,14.46)	0.31 (0.11,0.55)
SD ETN SC		12.36 (4.09,40.45)	7.19 (3.20,16.25)	0.38 (0.18,0.60)
SD ADA SC		3.25 (1.25,9.09)	2.84 (1.22,6.57)	0.11 (0.02,0.28)
SD RITUX IV		7.61 (1.05,48.91)	5.31 (1.05,15.48)	0.27 (0.00,0.67)
SD ADA SC + MTX		78.18 (21.30,316.50)	13.37 (7.38,25.96)	0.77 (0.56,0.89)
SD RITUX IV + MTX		29.22 (7.62,123.90)	10.42 (4.86,21.99)	0.59 (0.30,0.81)
SD INF IV + MTX		28.50 (5.64,150.40)	10.32 (4.06,21.95)	0.59 (0.24,0.84)
SD ANA SC + MTX		21.62 (5.29,100.60)	9.34 (3.88,20.73)	0.52 (0.22,0.78)
LD ETN SC		6.53 (2.15,21.87)	4.84 (1.95,12.08)	0.24 (0.08,0.45)
LD ADA SC + MTX		52.44 (14.07,203.40)	12.33 (6.47,24.47)	0.71 (0.45,0.86)
LD ADA IV + MTX		37.02 (4.69,310.40)	11.04 (3.64,24.02)	0.64 (0.19,0.89)
LD RITUX IV + MTX		29.07 (7.11,128.80)	10.41 (4.65,22.13)	0.59 (0.29,0.81)
HD ETN SC		11.74 (2.36,61.75)	6.95 (2.11,17.43)	0.37 (0.08,0.71)
HD INF IV + MTX		70.87 (14.10,366.00)	13.00 (6.55,25.50)	0.76 (0.46,0.90)
HD ADA SC + MTX		64.44 (15.62,288.90)	12.83 (6.77,25.34)	0.74 (0.47,0.88)
SD ETN SC	PL + MTX	1.38 (0.76,2.56)	1.20 (0.86,1.84)	0.07 (-0.06,0.21)
SD ADA SC		0.36 (0.07,1.79)	0.48 (0.15,1.54)	-0.19 (-0.49,0.11)
SD RITUX IV		0.85 (0.16,3.46)	0.91 (0.23,1.91)	-0.03 (-0.30,0.29)
SD ADA SC + MTX		8.66 (4.91,16.96)	2.24 (1.53,3.76)	0.45 (0.31,0.57)
SD RITUX IV + MTX		3.25 (1.67,6.41)	1.74 (1.27,2.63)	0.27 (0.11,0.41)
SD INF IV + MTX		3.14 (1.10,10.16)	1.70 (1.05,2.87)	0.26 (0.02,0.48)
SD ANA SC + MTX		2.43 (1.15,5.27)	1.55 (1.08,2.37)	0.21 (0.03,0.37)
LD ETN SC		0.73 (0.40,1.35)	0.82 (0.55,1.23)	-0.07 (-0.21,0.06)
LD ADA SC + MTX		5.81 (3.23,10.66)	2.06 (1.46,3.26)	0.39 (0.25,0.50)
LD ADA IV + MTX		4.10 (0.76,22.94)	1.81 (0.83,3.35)	0.32 (-0.06,0.58)

(Continued)

LD RITUX IV + MTX		3.25 (1.52,6.96)	1.73 (1.23,2.67)	0.27 (0.09,0.42)
HD ETN SC		1.30 (0.38,4.74)	1.16 (0.51,2.26)	0.06 (-0.20,0.35)
HD INF IV + MTX		7.73 (2.84,23.51)	2.15 (1.46,3.72)	0.43 (0.23,0.60)
HD ADA SC + MTX		7.10 (3.18,16.90)	2.14 (1.47,3.57)	0.42 (0.25,0.56)
SD ADA SC	SD ETN SC	0.26 (0.05,1.24)	0.40 (0.13,1.16)	-0.27 (-0.55,0.04)
SD RITUX IV		0.62 (0.10,2.82)	0.75 (0.18,1.61)	-0.11 (-0.40,0.24)
SD ADA SC + MTX		6.29 (2.78,15.30)	1.84 (1.36,2.85)	0.37 (0.22,0.53)
SD RITUX IV + MTX		2.38 (0.95,5.71)	1.44 (0.97,2.17)	0.20 (-0.01,0.38)
SD INF IV + MTX		2.30 (0.68,8.47)	1.42 (0.81,2.29)	0.19 (-0.09,0.43)
SD ANA SC + MTX		1.77 (0.66,4.65)	1.30 (0.79,1.97)	0.14 (-0.09,0.34)
LD ETN SC		0.53 (0.32,0.88)	0.68 (0.46,0.93)	-0.14 (-0.26,-0.03)
LD ADA SC + MTX		4.22 (1.81,9.69)	1.70 (1.25,2.56)	0.31 (0.14,0.47)
LD ADA IV + MTX		2.98 (0.48,17.74)	1.53 (0.64,2.60)	0.24 (-0.16,0.52)
LD RITUX IV + MTX		2.37 (0.88,6.08)	1.44 (0.93,2.18)	0.20 (-0.03,0.39)
HD ETN SC		0.95 (0.32,2.95)	0.97 (0.45,1.61)	-0.01 (-0.24,0.24)
HD INF IV + MTX		5.61 (1.73,19.73)	1.79 (1.24,2.83)	0.35 (0.13,0.54)
HD ADA SC + MTX		5.18 (1.90,14.64)	1.77 (1.27,2.74)	0.34 (0.15,0.51)
SD RITUX IV	SD ADA SC	2.31 (0.26,19.14)	1.86 (0.32,6.88)	0.15 (-0.19,0.59)
SD ADA SC + MTX		24.02 (4.41,138.70)	4.70 (2.08,11.58)	0.65 (0.35,0.84)
SD RITUX IV + MTX		8.97 (1.62,51.78)	3.68 (1.35,9.85)	0.47 (0.11,0.74)
SD INF IV + MTX		8.70 (1.25,61.66)	3.61 (1.16,9.86)	0.47 (0.05,0.76)
SD ANA SC + MTX		6.65 (1.16,40.42)	3.29 (1.11,9.28)	0.40 (0.03,0.71)
LD ETN SC		2.02 (0.43,9.84)	1.71 (0.53,5.65)	0.12 (-0.15,0.40)
LD ADA SC + MTX		15.95 (2.91,90.03)	4.33 (1.79,10.94)	0.59 (0.25,0.80)
LD ADA IV + MTX		11.47 (1.14,117.00)	3.86 (1.09,10.54)	0.52 (0.03,0.82)
LD RITUX IV + MTX		8.91 (1.55,53.22)	3.67 (1.32,9.84)	0.47 (0.09,0.75)
HD ETN SC		3.59 (0.53,25.06)	2.43 (0.62,7.85)	0.25 (-0.11,0.63)
HD INF IV + MTX		21.42 (3.13,149.10)	4.57 (1.86,11.37)	0.63 (0.26,0.84)

(Continued)

HD ADA SC + MTX		19.49 (3.30,119.80)	4.51 (1.91,11.25)	0.62 (0.28,0.83)
SD ADA SC + MTX	SD RITUX IV	10.16 (2.23,60.86)	2.46 (1.20,10.85)	0.48 (0.14,0.75)
SD RITUX IV + MTX		3.78 (0.98,19.16)	1.91 (1.00,7.58)	0.30 (0.00,0.57)
SD INF IV + MTX		3.74 (0.63,27.40)	1.88 (0.81,8.12)	0.29 (-0.11,0.64)
SD ANA SC + MTX		2.86 (0.57,17.81)	1.71 (0.78,7.20)	0.23 (-0.13,0.56)
LD ETN SC		0.86 (0.19,5.08)	0.90 (0.40,3.77)	-0.03 (-0.38,0.24)
LD ADA SC + MTX		6.77 (1.49,39.92)	2.26 (1.11,9.79)	0.42 (0.08,0.70)
LD ADA IV + MTX		4.91 (0.54,48.35)	1.98 (0.72,9.04)	0.33 (-0.14,0.72)
LD RITUX IV + MTX		3.77 (0.86,21.06)	1.90 (0.95,7.79)	0.30 (-0.03,0.59)
HD ETN SC		1.54 (0.23,13.15)	1.28 (0.43,6.03)	0.09 (-0.32,0.49)
HD INF IV + MTX		9.21 (1.56,66.83)	2.38 (1.13,10.47)	0.46 (0.09,0.76)
HD ADA SC + MTX		8.35 (1.68,54.98)	2.35 (1.15,10.26)	0.45 (0.10,0.74)
SD RITUX IV + MTX	SD ADA SC + MTX	0.37 (0.15,0.90)	0.79 (0.51,0.98)	-0.17 (-0.38,-0.02)
SD INF IV + MTX		0.36 (0.10,1.31)	0.79 (0.41,1.05)	-0.18 (-0.46,0.04)
SD ANA SC + MTX		0.28 (0.10,0.73)	0.71 (0.41,0.94)	-0.24 (-0.46,-0.05)
LD ETN SC		0.08 (0.03,0.19)	0.36 (0.21,0.56)	-0.52 (-0.65,-0.36)
LD ADA SC + MTX		0.67 (0.38,1.07)	0.93 (0.77,1.01)	-0.06 (-0.17,0.01)
LD ADA IV + MTX		0.47 (0.08,2.60)	0.85 (0.35,1.15)	-0.12 (-0.52,0.11)
LD RITUX IV + MTX		0.38 (0.13,0.94)	0.79 (0.49,0.99)	-0.17 (-0.40,-0.01)
HD ETN SC		0.15 (0.04,0.60)	0.53 (0.21,0.89)	-0.39 (-0.65,-0.09)
HD INF IV + MTX		0.89 (0.26,3.07)	0.98 (0.70,1.21)	-0.02 (-0.24,0.14)
HD ADA SC + MTX		0.82 (0.38,1.70)	0.97 (0.77,1.10)	-0.03 (-0.17,0.07)
SD INF IV + MTX	SD RITUX IV + MTX	0.96 (0.28,3.76)	0.99 (0.56,1.53)	-0.01 (-0.28,0.26)
SD ANA SC + MTX		0.74 (0.27,2.13)	0.90 (0.56,1.33)	-0.06 (-0.29,0.16)
LD ETN SC		0.22 (0.09,0.55)	0.47 (0.28,0.73)	-0.34 (-0.52,-0.13)
LD ADA SC + MTX		1.79 (0.74,4.31)	1.17 (0.92,1.72)	0.11 (-0.06,0.30)
LD ADA IV + MTX		1.26 (0.21,7.77)	1.07 (0.45,1.76)	0.05 (-0.35,0.35)
LD RITUX IV + MTX		0.99 (0.51,1.98)	1.00 (0.75,1.29)	0.00 (-0.15,0.14)

(Continued)

HD ETN SC		0.40 (0.10,1.73)	0.67 (0.28,1.24)	-0.21 (-0.50,0.12)
HD INF IV + MTX		2.36 (0.72,8.88)	1.23 (0.91,1.91)	0.15 (-0.06,0.38)
HD ADA SC + MTX		2.19 (0.76,6.44)	1.21 (0.93,1.86)	0.14 (-0.05,0.36)
SD ANA SC + MTX	SD INF IV + MTX	0.77 (0.19,2.90)	0.92 (0.53,1.63)	-0.05 (-0.34,0.24)
LD ETN SC		0.23 (0.06,0.77)	0.48 (0.27,0.86)	-0.34 (-0.57,-0.05)
LD ADA SC + MTX		1.85 (0.50,6.31)	1.18 (0.86,2.17)	0.12 (-0.11,0.39)
LD ADA IV + MTX		1.30 (0.17,9.16)	1.07 (0.44,2.07)	0.05 (-0.39,0.41)
LD RITUX IV + MTX		1.03 (0.25,3.75)	1.01 (0.63,1.79)	0.01 (-0.27,0.29)
HD ETN SC		0.41 (0.07,2.16)	0.69 (0.27,1.42)	-0.20 (-0.54,0.17)
HD INF IV + MTX		2.46 (1.05,5.75)	1.24 (1.01,2.01)	0.16 (0.01,0.36)
HD ADA SC + MTX		2.25 (0.55,8.92)	1.22 (0.87,2.31)	0.15 (-0.10,0.44)
LD ETN SC	SD ANA SC + MTX	0.30 (0.11,0.78)	0.53 (0.31,0.86)	-0.28 (-0.48,-0.05)
LD ADA SC + MTX		2.38 (0.91,6.30)	1.30 (0.98,2.18)	0.17 (-0.02,0.39)
LD ADA IV + MTX		1.67 (0.27,10.90)	1.17 (0.50,2.16)	0.10 (-0.30,0.43)
LD RITUX IV + MTX		1.34 (0.44,3.87)	1.11 (0.72,1.80)	0.06 (-0.18,0.29)
HD ETN SC		0.54 (0.13,2.43)	0.75 (0.31,1.49)	-0.14 (-0.45,0.20)
HD INF IV + MTX		3.16 (0.88,12.20)	1.36 (0.96,2.41)	0.21 (-0.02,0.47)
HD ADA SC + MTX		2.92 (0.96,9.18)	1.35 (0.99,2.34)	0.21 (-0.01,0.44)
LD ADA SC + MTX	LD ETN SC	7.94 (3.42,18.41)	2.52 (1.67,4.23)	0.46 (0.28,0.60)
LD ADA IV + MTX		5.61 (0.90,33.83)	2.23 (0.93,4.23)	0.39 (-0.02,0.65)
LD RITUX IV + MTX		4.46 (1.67,11.67)	2.12 (1.33,3.56)	0.34 (0.11,0.53)
HD ETN SC		1.79 (0.53,6.27)	1.42 (0.63,2.73)	0.13 (-0.12,0.41)
HD INF IV + MTX		10.54 (3.32,37.56)	2.65 (1.67,4.71)	0.50 (0.27,0.67)
HD ADA SC + MTX		9.76 (3.59,27.53)	2.62 (1.70,4.54)	0.49 (0.29,0.64)
LD ADA IV + MTX	LD ADA SC + MTX	0.70 (0.13,3.73)	0.92 (0.38,1.27)	-0.06 (-0.44,0.18)
LD RITUX IV + MTX		0.56 (0.21,1.44)	0.86 (0.55,1.10)	-0.11 (-0.32,0.07)
HD ETN SC		0.22 (0.06,0.93)	0.57 (0.23,0.98)	-0.32 (-0.59,-0.01)
HD INF IV + MTX		1.32 (0.40,4.66)	1.05 (0.77,1.40)	0.04 (-0.17,0.24)

(Continued)

HD ADA SC + MTX		1.22 (0.58,2.64)	1.04 (0.86,1.27)	0.03 (-0.10,0.16)
LD RITUX IV + MTX	LD ADA IV + MTX	0.79 (0.12,5.12)	0.94 (0.55,2.21)	-0.05 (-0.36,0.36)
HD ETN SC		0.32 (0.04,2.57)	0.65 (0.25,1.65)	-0.24 (-0.61,0.21)
HD INF IV + MTX		1.92 (0.27,14.27)	1.14 (0.77,2.87)	0.10 (-0.19,0.52)
HD ADA SC + MTX		1.75 (0.28,10.64)	1.13 (0.79,2.77)	0.09 (-0.18,0.49)
HD ETN SC	LD RITUX IV + MTX	0.40 (0.10,1.79)	0.68 (0.28,1.27)	-0.21 (-0.50,0.13)
HD INF IV + MTX		2.36 (0.69,9.30)	1.23 (0.90,2.00)	0.15 (-0.07,0.40)
HD ADA SC + MTX		2.19 (0.72,6.90)	1.21 (0.92,1.95)	0.14 (-0.06,0.37)
HD INF IV + MTX	HD ETN SC	5.95 (1.14,31.00)	1.83 (1.04,4.69)	0.36 (0.03,0.66)
HD ADA SC + MTX		5.45 (1.21,24.49)	1.82 (1.05,4.56)	0.35 (0.04,0.63)
HD ADA SC + MTX	HD INF IV + MTX	0.92 (0.23,3.55)	0.99 (0.73,1.38)	-0.01 (-0.22,0.22)

Random-Effect Model	Residual Deviance	31.33 vs 33 data points
---------------------	-------------------	-------------------------

	Deviance Information Criteria	198.481
--	-------------------------------	---------

Fixed-Effect Model	Residual Deviance	32.58 vs 33 data points
--------------------	-------------------	-------------------------

	Deviance Information Criteria	198.437
--	-------------------------------	---------

Note:

Total Patients	3481
----------------	------

Total Studies	12
---------------	----

2-arm	4
-------	---

3-arm	7
-------	---

4-arm	1
-------	---

## Appendix 7. ACR50: Subgroup - Trial duration ( $\leq 6$ months)



## ACR50, Short trial duration: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX	PL	2.55 (1.22,5.33)	2.33 (1.21,4.30)	0.08 (0.01,0.19)
DMARD + PL		2.23 (0.35,15.88)	2.07 (0.37,8.76)	0.07 (-0.04,0.43)
MTX + DMARD		4.87 (1.89,13.63)	3.93 (1.80,7.95)	0.18 (0.05,0.40)
SD ETN SC		7.47 (3.69,15.72)	5.33 (3.13,8.70)	0.27 (0.13,0.43)
SD ADA SC		3.51 (2.03,6.27)	3.04 (1.90,4.88)	0.13 (0.06,0.22)
SD TOFA PO		6.49 (3.24,13.34)	4.84 (2.82,7.90)	0.24 (0.12,0.40)
SD GOLI SC		6.87 (2.62,18.68)	5.04 (2.37,9.33)	0.25 (0.09,0.48)
SD GOLI IV		4.85 (1.73,13.91)	3.92 (1.65,7.98)	0.18 (0.04,0.41)
SD TOCI IV		4.06 (1.65,10.59)	3.42 (1.58,6.88)	0.15 (0.04,0.33)
SD ABA SC		9.70 (2.55,42.23)	6.30 (2.33,12.94)	0.33 (0.08,0.66)
SD CERTO SC		9.56 (3.10,31.95)	6.25 (2.73,11.67)	0.32 (0.11,0.61)
SD ETN SC + MTX		13.71 (6.17,32.64)	7.65 (4.60,12.03)	0.41 (0.23,0.61)
SD ABA IV + MTX		9.91 (4.17,23.64)	6.38 (3.46,10.53)	0.33 (0.16,0.54)
SD CERTO SC + MTX		14.70 (6.35,35.45)	7.94 (4.70,12.27)	0.43 (0.24,0.63)
SD INF IV + MTX		8.50 (3.54,20.49)	5.80 (3.03,9.91)	0.30 (0.13,0.50)
SD ADA SC + MTX		18.53 (6.63,55.31)	8.89 (4.84,13.93)	0.48 (0.25,0.71)
SD TOFA PO + MTX		17.33 (6.20,45.92)	8.60 (4.64,13.30)	0.47 (0.23,0.68)
SD GOLI SC + MTX		17.44 (6.73,46.14)	8.63 (4.89,13.52)	0.47 (0.25,0.68)
SD RITUX IV + MTX		9.11 (3.28,25.67)	6.05 (2.84,10.82)	0.31 (0.12,0.55)
SD GOLI IV + MTX		6.25 (2.39,16.37)	4.72 (2.18,8.78)	0.23 (0.07,0.44)
SD ANA SC + MTX		7.55 (2.54,21.72)	5.37 (2.32,10.03)	0.27 (0.08,0.51)
SD ABA SC + MTX		10.68 (3.19,35.56)	6.67 (2.80,12.04)	0.35 (0.11,0.63)
SD TOCI IV + MTX		5.36 (1.74,17.50)	4.23 (1.66,9.07)	0.20 (0.04,0.46)
SD CERTO SC + DMARD		8.22 (2.18,37.10)	5.67 (2.02,12.39)	0.29 (0.07,0.63)
SD ADA SC + DMARD		7.12 (0.90,64.70)	5.16 (0.91,14.25)	0.26 (-0.01,0.74)
SD TOCI SC + DMARD		11.64 (1.44,99.75)	6.98 (1.40,15.58)	0.37 (0.03,0.80)

(Continued)

LD ADA SC	3.30 (1.50,7.54)	2.89 (1.45,5.55)	0.12 (0.03,0.26)
LD ETN SC	4.15 (1.36,12.15)	3.49 (1.33,7.44)	0.15 (0.02,0.38)
LD GOLI IV	2.89 (0.87,9.18)	2.59 (0.87,6.21)	0.10 (-0.01,0.31)
LD TOCI IV	0.51 (0.08,2.31)	0.52 (0.09,2.15)	-0.03 (-0.06,0.07)
LD ADA SC + MTX	10.23 (3.07,34.66)	6.52 (2.71,12.01)	0.34 (0.11,0.62)
LD RITUX IV + MTX	8.96 (3.27,25.59)	6.00 (2.83,10.74)	0.31 (0.12,0.55)
LD ADA IV + MTX	9.05 (1.24,57.71)	6.05 (1.23,13.65)	0.31 (0.01,0.72)
LD ABA IV + MTX	5.37 (2.01,14.58)	4.21 (1.89,8.23)	0.20 (0.06,0.41)
LD ANA SC + MTX	5.03 (0.99,23.55)	4.03 (0.99,10.23)	0.19 (0.00,0.54)
LD CERTO SC + MTX	10.48 (3.40,34.48)	6.62 (2.93,12.00)	0.35 (0.12,0.63)
LD GOLI IV + MTX	5.57 (1.76,17.07)	4.33 (1.67,8.93)	0.20 (0.04,0.46)
LD TOCI IV + MTX	4.58 (1.48,14.58)	3.74 (1.44,8.24)	0.17 (0.03,0.41)
LD TOFA PO + MTX	7.70 (1.88,30.51)	5.44 (1.78,11.31)	0.27 (0.05,0.60)
HD TOCI IV	7.18 (3.51,15.04)	5.19 (3.00,8.55)	0.26 (0.13,0.42)
HD TOFA PO	10.26 (5.29,21.10)	6.53 (4.10,9.99)	0.34 (0.20,0.51)
HD ADA SC	4.74 (2.21,10.66)	3.85 (2.05,6.91)	0.17 (0.07,0.34)
HD GOLI SC	7.91 (3.29,18.94)	5.53 (2.85,9.48)	0.28 (0.12,0.48)
HD ETN SC	7.29 (1.60,31.99)	5.25 (1.54,11.43)	0.26 (0.03,0.61)
HD ABA SC	13.97 (3.81,59.84)	7.75 (3.21,14.13)	0.42 (0.14,0.73)
HD TOCI IV + MTX	12.46 (5.56,29.67)	7.28 (4.26,11.67)	0.39 (0.21,0.58)
HD INF IV + MTX	11.45 (4.40,31.21)	6.95 (3.60,11.69)	0.37 (0.17,0.60)
HD TOFA PO + MTX	9.77 (3.55,25.79)	6.33 (3.05,10.91)	0.33 (0.13,0.56)
HD GOLI SC + MTX	13.39 (5.17,35.25)	7.57 (4.09,12.40)	0.40 (0.19,0.63)
HD CERTO SC + MTX	17.57 (7.13,44.53)	8.69 (5.06,13.19)	0.47 (0.26,0.68)
HD ADA SC + MTX	14.67 (4.28,54.00)	7.94 (3.51,13.68)	0.43 (0.16,0.71)
HD TOCI IV + DMARD	8.38 (1.22,68.40)	5.74 (1.20,14.29)	0.29 (0.01,0.75)
SD ANA SC + SD ETN SC + MTX	8.79 (2.43,33.12)	5.93 (2.23,11.66)	0.30 (0.08,0.62)

(Continued)

SD ANA SC + LD ETN SC + MTX		12.92 (3.62,49.50)	7.40 (3.12,13.21)	0.39 (0.13,0.70)
DMARD + PL	MTX	0.89 (0.13,6.94)	0.91 (0.15,4.20)	-0.01 (-0.17,0.36)
MTX + DMARD		1.90 (0.80,4.89)	1.67 (0.82,3.39)	0.10 (-0.03,0.29)
SD ETN SC		2.90 (1.34,6.71)	2.26 (1.25,4.32)	0.18 (0.05,0.34)
SD ADA SC		1.36 (0.65,3.06)	1.30 (0.70,2.60)	0.04 (-0.07,0.15)
SD TOFA PO		2.51 (0.96,6.87)	2.05 (0.97,4.54)	0.15 (-0.01,0.32)
SD GOLI SC		2.67 (1.03,6.99)	2.14 (1.03,4.20)	0.16 (0.00,0.37)
SD GOLI IV		1.90 (0.80,4.49)	1.68 (0.83,3.13)	0.09 (-0.03,0.29)
SD TOCI IV		1.59 (0.71,3.59)	1.47 (0.75,2.75)	0.06 (-0.04,0.22)
SD ABA SC		3.84 (0.84,19.22)	2.70 (0.86,6.84)	0.24 (-0.03,0.59)
SD CERTO SC		3.76 (0.93,15.37)	2.67 (0.95,6.49)	0.24 (-0.01,0.54)
SD ETN SC + MTX		5.35 (2.71,11.94)	3.24 (2.05,5.68)	0.32 (0.17,0.50)
SD ABA IV + MTX		3.88 (2.45,6.23)	2.71 (1.97,3.80)	0.25 (0.13,0.38)
SD CERTO SC + MTX		5.77 (3.65,9.24)	3.37 (2.45,4.79)	0.34 (0.21,0.48)
SD INF IV + MTX		3.32 (2.03,5.43)	2.46 (1.73,3.49)	0.21 (0.10,0.35)
SD ADA SC + MTX		7.23 (3.37,16.26)	3.72 (2.39,6.02)	0.40 (0.20,0.58)
SD TOFA PO + MTX		6.75 (3.33,13.51)	3.62 (2.36,5.62)	0.38 (0.19,0.55)
SD GOLI SC + MTX		6.80 (3.52,13.59)	3.65 (2.41,5.68)	0.39 (0.21,0.55)
SD RITUX IV + MTX		3.55 (1.76,7.28)	2.56 (1.57,4.06)	0.23 (0.07,0.42)
SD GOLI IV + MTX		2.43 (1.24,4.79)	2.00 (1.20,3.22)	0.14 (0.03,0.31)
SD ANA SC + MTX		2.90 (1.32,6.64)	2.25 (1.26,3.85)	0.18 (0.03,0.39)
SD ABA SC + MTX		4.14 (1.60,10.51)	2.81 (1.46,4.80)	0.26 (0.06,0.50)
SD TOCI IV + MTX		2.12 (0.79,5.62)	1.81 (0.82,3.51)	0.11 (-0.03,0.34)
SD CERTO SC + DMARD		3.26 (0.72,17.46)	2.43 (0.76,6.58)	0.20 (-0.04,0.56)
SD ADA SC + DMARD		2.78 (0.33,28.96)	2.19 (0.37,7.38)	0.17 (-0.11,0.67)
SD TOCI SC + DMARD		4.59 (0.50,43.80)	2.96 (0.56,8.33)	0.29 (-0.07,0.73)
LD ADA SC		1.29 (0.47,3.56)	1.24 (0.53,2.86)	0.03 (-0.10,0.19)
LD ETN SC		1.62 (0.48,5.30)	1.49 (0.53,3.67)	0.07 (-0.09,0.29)

(Continued)

LD GOLI IV		1.13 (0.42,2.93)	1.11 (0.46,2.31)	0.01 (-0.09,0.18)
LD TOCI IV		0.20 (0.04,0.78)	0.23 (0.04,0.80)	-0.11 (-0.20,-0.03)
LD ADA SC + MTX		3.94 (1.54,11.17)	2.72 (1.42,4.93)	0.25 (0.06,0.50)
LD RITUX IV + MTX		3.50 (1.73,7.27)	2.53 (1.55,3.99)	0.22 (0.07,0.42)
LD ADA IV + MTX		3.51 (0.58,20.32)	2.53 (0.62,6.00)	0.22 (-0.05,0.62)
LD ABA IV + MTX		2.09 (1.08,4.13)	1.79 (1.06,2.91)	0.11 (0.01,0.28)
LD ANA SC + MTX		1.95 (0.46,7.82)	1.70 (0.50,4.07)	0.10 (-0.07,0.42)
LD CERTO SC + MTX		4.09 (1.68,10.25)	2.79 (1.52,4.80)	0.26 (0.07,0.49)
LD GOLI IV + MTX		2.17 (0.85,5.42)	1.84 (0.88,3.45)	0.12 (-0.02,0.33)
LD TOCI IV + MTX		1.79 (0.69,4.69)	1.60 (0.73,3.17)	0.09 (-0.04,0.29)
LD TOFA PO + MTX		2.99 (0.90,9.84)	2.30 (0.91,4.62)	0.19 (-0.01,0.48)
HD TOCI IV		2.79 (1.68,4.85)	2.21 (1.48,3.48)	0.17 (0.08,0.29)
HD TOFA PO		4.00 (1.56,10.84)	2.77 (1.39,5.90)	0.26 (0.08,0.44)
HD ADA SC		1.85 (0.69,5.13)	1.65 (0.73,3.71)	0.09 (-0.06,0.27)
HD GOLI SC		3.07 (1.46,6.49)	2.34 (1.35,4.05)	0.19 (0.06,0.36)
HD ETN SC		2.86 (0.63,12.73)	2.22 (0.68,5.46)	0.18 (-0.05,0.52)
HD ABA SC		5.45 (1.22,27.20)	3.29 (1.16,7.69)	0.33 (0.03,0.66)
HD TOCI IV + MTX		4.87 (2.87,8.65)	3.08 (2.13,4.75)	0.30 (0.17,0.45)
HD INF IV + MTX		4.46 (2.35,8.54)	2.92 (1.93,4.47)	0.28 (0.13,0.45)
HD TOFA PO + MTX		3.81 (1.87,7.74)	2.67 (1.64,4.23)	0.24 (0.09,0.43)
HD GOLI SC + MTX		5.23 (2.66,10.42)	3.19 (2.07,5.05)	0.32 (0.15,0.50)
HD CERTO SC + MTX		6.85 (3.97,12.00)	3.66 (2.58,5.37)	0.39 (0.23,0.53)
HD ADA SC + MTX		5.71 (2.09,16.60)	3.32 (1.79,5.83)	0.34 (0.11,0.59)
HD TOCI IV + DMARD		3.33 (0.43,29.84)	2.47 (0.49,7.72)	0.21 (-0.09,0.67)
SD ANA SC + SD ETN SC + MTX		3.39 (1.00,12.78)	2.49 (1.00,5.38)	0.22 (0.00,0.52)
SD ANA SC + LD ETN SC + MTX		5.03 (1.51,18.48)	3.12 (1.38,6.26)	0.31 (0.06,0.60)
MTX + DMARD	DMARD + PL	2.13 (0.26,17.12)	1.84 (0.39,11.46)	0.10 (-0.27,0.36)

(Continued)

SD ETN SC	3.28 (0.42,22.89)	2.51 (0.57,14.53)	0.19 (-0.20,0.40)
SD ADA SC	1.54 (0.21,10.73)	1.44 (0.34,8.66)	0.05 (-0.31,0.21)
SD TOFA PO	2.84 (0.38,20.69)	2.29 (0.53,13.86)	0.16 (-0.21,0.38)
SD GOLI SC	3.00 (0.36,23.68)	2.35 (0.50,14.38)	0.17 (-0.22,0.44)
SD GOLI IV	2.13 (0.24,17.08)	1.84 (0.36,11.35)	0.10 (-0.28,0.36)
SD TOCI IV	1.78 (0.21,13.15)	1.61 (0.33,9.66)	0.07 (-0.30,0.30)
SD ABA SC	4.23 (0.45,41.99)	2.89 (0.58,18.44)	0.24 (-0.16,0.61)
SD CERTO SC	4.23 (0.46,37.08)	2.93 (0.61,18.40)	0.24 (-0.16,0.57)
SD ETN SC + MTX	6.03 (0.81,44.15)	3.61 (0.88,20.24)	0.33 (-0.05,0.58)
SD ABA IV + MTX	4.31 (0.52,33.57)	2.98 (0.67,17.79)	0.25 (-0.14,0.51)
SD CERTO SC + MTX	6.38 (0.78,49.00)	3.72 (0.87,21.82)	0.35 (-0.06,0.60)
SD INF IV + MTX	3.73 (0.47,27.63)	2.72 (0.62,15.81)	0.22 (-0.17,0.47)
SD ADA SC + MTX	8.00 (0.89,72.65)	4.14 (0.94,25.18)	0.39 (-0.03,0.69)
SD TOFA PO + MTX	7.62 (0.84,60.65)	4.01 (0.90,23.12)	0.38 (-0.04,0.65)
SD GOLI SC + MTX	7.62 (0.87,62.09)	4.02 (0.93,23.87)	0.39 (-0.03,0.65)
SD RITUX IV + MTX	4.04 (0.43,31.73)	2.86 (0.58,16.82)	0.23 (-0.18,0.51)
SD GOLI IV + MTX	2.72 (0.32,21.26)	2.21 (0.47,13.52)	0.15 (-0.23,0.41)
SD ANA SC + MTX	3.24 (0.36,26.83)	2.47 (0.50,15.15)	0.18 (-0.21,0.48)
SD ABA SC + MTX	4.59 (0.48,41.94)	3.06 (0.63,19.18)	0.26 (-0.15,0.59)
SD TOCI IV + MTX	2.37 (0.25,20.03)	2.00 (0.37,12.81)	0.12 (-0.27,0.41)
SD CERTO SC + DMARD	3.61 (1.08,13.20)	2.60 (1.04,8.93)	0.20 (0.01,0.42)
SD ADA SC + DMARD	3.16 (1.27,8.05)	2.30 (1.21,4.97)	0.18 (0.02,0.43)
SD TOCI SC + DMARD	5.09 (2.01,12.61)	3.06 (1.52,6.63)	0.28 (0.05,0.52)
LD ADA SC	1.43 (0.19,11.26)	1.36 (0.30,8.78)	0.04 (-0.32,0.24)
LD ETN SC	1.79 (0.20,15.67)	1.61 (0.31,10.96)	0.07 (-0.30,0.34)
LD GOLI IV	1.26 (0.13,10.61)	1.22 (0.21,8.05)	0.03 (-0.34,0.27)
LD TOCI IV	0.22 (0.02,2.29)	0.25 (0.03,2.19)	-0.09 (-0.46,0.05)
LD ADA SC + MTX	4.42 (0.47,43.81)	2.98 (0.62,19.68)	0.25 (-0.16,0.58)

(Continued)

LD RITUX IV + MTX		3.96 (0.44,31.31)	2.81 (0.59,16.79)	0.23 (-0.18,0.51)
LD ADA IV + MTX		3.88 (0.28,53.46)	2.70 (0.38,19.90)	0.21 (-0.22,0.68)
LD ABA IV + MTX		2.30 (0.27,18.75)	1.95 (0.40,12.17)	0.12 (-0.27,0.38)
LD ANA SC + MTX		2.17 (0.18,24.21)	1.85 (0.27,13.25)	0.10 (-0.29,0.49)
LD CERTO SC + MTX		4.55 (0.52,41.05)	3.04 (0.66,19.40)	0.26 (-0.14,0.58)
LD GOLI IV + MTX		2.45 (0.27,20.29)	2.03 (0.39,12.75)	0.13 (-0.26,0.42)
LD TOCI IV + MTX		2.00 (0.22,16.94)	1.76 (0.33,11.51)	0.09 (-0.29,0.37)
LD TOFA PO + MTX		3.32 (0.29,32.80)	2.49 (0.42,16.29)	0.19 (-0.24,0.55)
HD TOCI IV		3.16 (0.40,23.05)	2.45 (0.56,14.82)	0.18 (-0.20,0.39)
HD TOFA PO		4.62 (0.60,33.78)	3.11 (0.73,18.54)	0.26 (-0.12,0.48)
HD ADA SC		2.07 (0.27,15.63)	1.80 (0.41,11.40)	0.10 (-0.27,0.32)
HD GOLI SC		3.49 (0.40,25.46)	2.62 (0.56,15.44)	0.20 (-0.20,0.45)
HD ETN SC		3.18 (0.27,31.90)	2.43 (0.39,15.19)	0.17 (-0.24,0.56)
HD ABA SC		6.06 (0.64,63.98)	3.54 (0.76,22.23)	0.32 (-0.10,0.68)
HD TOCI IV + MTX		5.44 (0.69,41.42)	3.41 (0.80,19.88)	0.31 (-0.09,0.56)
HD INF IV + MTX		5.01 (0.60,39.15)	3.23 (0.73,18.73)	0.28 (-0.12,0.56)
HD TOFA PO + MTX		4.32 (0.49,35.01)	2.97 (0.63,17.59)	0.25 (-0.16,0.52)
HD GOLI SC + MTX		5.91 (0.68,48.66)	3.54 (0.80,21.87)	0.32 (-0.09,0.60)
HD CERTO SC + MTX		7.64 (0.93,59.67)	4.05 (0.96,23.39)	0.39 (-0.02,0.65)
HD ADA SC + MTX		6.24 (0.67,64.15)	3.63 (0.77,23.11)	0.33 (-0.09,0.68)
HD TOCI IV + DMARD		3.73 (1.99,7.03)	2.60 (1.49,4.71)	0.22 (0.05,0.41)
SD ANA SC + SD ETN SC + MTX		3.76 (0.41,35.98)	2.69 (0.54,16.75)	0.21 (-0.18,0.58)
SD ANA SC + LD ETN SC + MTX		5.60 (0.62,54.38)	3.38 (0.75,20.57)	0.31 (-0.10,0.65)
SD ETN SC	MTX + DMARD	1.54 (0.64,3.39)	1.36 (0.75,2.52)	0.08 (-0.10,0.23)
SD ADA SC		0.72 (0.24,2.02)	0.77 (0.36,1.79)	-0.05 (-0.28,0.10)
SD TOFA PO		1.33 (0.40,4.19)	1.23 (0.53,2.97)	0.05 (-0.19,0.26)
SD GOLI SC		1.40 (0.40,4.68)	1.27 (0.52,3.04)	0.07 (-0.18,0.31)

(Continued)

SD GOL I IV	1.00 (0.28,3.27)	1.00 (0.37,2.43)	0.00 (-0.23,0.23)
SD TOCI IV	0.83 (0.25,2.62)	0.87 (0.35,2.11)	-0.03 (-0.25,0.17)
SD ABA SC	1.99 (0.38,11.67)	1.59 (0.49,4.61)	0.14 (-0.19,0.52)
SD CERTO SC	1.96 (0.42,9.09)	1.57 (0.53,4.20)	0.14 (-0.18,0.46)
SD ETN SC + MTX	2.82 (1.66,4.83)	1.94 (1.31,3.11)	0.22 (0.11,0.34)
SD ABA IV + MTX	2.04 (0.72,5.40)	1.62 (0.81,3.34)	0.15 (-0.07,0.35)
SD CERTO SC + MTX	3.04 (1.08,8.19)	2.01 (1.05,4.16)	0.24 (0.02,0.44)
SD INF IV + MTX	1.75 (0.62,4.68)	1.47 (0.72,3.08)	0.11 (-0.11,0.31)
SD ADA SC + MTX	3.82 (1.14,12.55)	2.23 (1.08,4.82)	0.30 (0.03,0.54)
SD TOFA PO + MTX	3.55 (1.10,10.34)	2.15 (1.06,4.52)	0.28 (0.02,0.50)
SD GOL I SC + MTX	3.59 (1.14,10.56)	2.17 (1.08,4.56)	0.28 (0.03,0.51)
SD RITUX IV + MTX	1.87 (0.58,5.74)	1.53 (0.68,3.32)	0.13 (-0.11,0.37)
SD GOL I IV + MTX	1.29 (0.39,3.85)	1.20 (0.51,2.69)	0.05 (-0.19,0.26)
SD ANA SC + MTX	1.53 (0.43,5.13)	1.35 (0.54,3.16)	0.08 (-0.16,0.33)
SD ABA SC + MTX	2.18 (0.58,7.72)	1.67 (0.68,3.80)	0.16 (-0.11,0.44)
SD TOCI IV + MTX	1.11 (0.29,4.07)	1.08 (0.39,2.74)	0.02 (-0.22,0.28)
SD CERTO SC + DMARD	1.68 (0.32,9.50)	1.44 (0.43,4.18)	0.10 (-0.21,0.48)
SD ADA SC + DMARD	1.46 (0.15,14.94)	1.31 (0.22,4.59)	0.07 (-0.28,0.57)
SD TOCI SC + DMARD	2.40 (0.23,23.89)	1.76 (0.32,5.23)	0.18 (-0.23,0.65)
LD ADA SC	0.67 (0.20,2.36)	0.73 (0.29,2.01)	-0.06 (-0.30,0.14)
LD ETN SC	0.85 (0.23,2.95)	0.88 (0.31,2.26)	-0.03 (-0.26,0.20)
LD GOL I IV	0.59 (0.15,2.15)	0.66 (0.21,1.80)	-0.08 (-0.30,0.13)
LD TOCI IV	0.10 (0.02,0.51)	0.13 (0.02,0.57)	-0.20 (-0.42,-0.06)
LD ADA SC + MTX	2.08 (0.56,7.92)	1.63 (0.67,3.84)	0.15 (-0.11,0.44)
LD RITUX IV + MTX	1.83 (0.57,5.64)	1.51 (0.68,3.33)	0.12 (-0.11,0.36)
LD ADA IV + MTX	1.83 (0.24,12.73)	1.50 (0.31,4.34)	0.12 (-0.22,0.54)
LD ABA IV + MTX	1.10 (0.35,3.33)	1.07 (0.46,2.42)	0.02 (-0.20,0.23)
LD ANA SC + MTX	1.02 (0.17,5.31)	1.02 (0.24,3.09)	0.00 (-0.27,0.36)

(Continued)

LD CERTO SC + MTX		2.14 (0.60,7.60)	1.66 (0.70,3.79)	0.16 (-0.10,0.43)
LD GOLI IV + MTX		1.15 (0.29,3.90)	1.11 (0.39,2.69)	0.02 (-0.22,0.27)
LD TOCI IV + MTX		0.93 (0.24,3.37)	0.95 (0.33,2.44)	-0.01 (-0.25,0.23)
LD TOFA PO + MTX		1.57 (0.33,6.88)	1.36 (0.43,3.49)	0.09 (-0.19,0.42)
HD TOCI IV		1.48 (0.54,3.99)	1.32 (0.66,2.87)	0.08 (-0.13,0.25)
HD TOFA PO		2.12 (0.64,6.62)	1.66 (0.75,3.86)	0.16 (-0.10,0.38)
HD ADA SC		0.96 (0.28,3.27)	0.97 (0.40,2.51)	-0.01 (-0.25,0.21)
HD GOLI SC		1.62 (0.51,4.77)	1.40 (0.63,3.11)	0.10 (-0.14,0.31)
HD ETN SC		1.49 (0.31,6.49)	1.32 (0.39,3.28)	0.08 (-0.19,0.41)
HD ABA SC		2.87 (0.53,16.08)	1.94 (0.65,5.25)	0.23 (-0.13,0.58)
HD TOCI IV + MTX		2.56 (0.88,7.15)	1.84 (0.93,3.90)	0.20 (-0.03,0.41)
HD INF IV + MTX		2.35 (0.76,7.02)	1.75 (0.84,3.79)	0.18 (-0.06,0.41)
HD TOFA PO + MTX		2.00 (0.62,6.01)	1.60 (0.72,3.48)	0.14 (-0.10,0.37)
HD GOLI SC + MTX		2.76 (0.86,8.32)	1.92 (0.91,4.03)	0.22 (-0.03,0.45)
HD CERTO SC + MTX		3.60 (1.23,10.18)	2.17 (1.13,4.55)	0.28 (0.05,0.49)
HD ADA SC + MTX		3.03 (0.76,11.72)	2.00 (0.82,4.54)	0.24 (-0.06,0.53)
HD TOCI IV + DMARD		1.76 (0.20,15.95)	1.47 (0.28,4.71)	0.11 (-0.25,0.58)
SD ANA SC + SD ETN SC + MTX		1.79 (0.56,5.67)	1.48 (0.64,3.06)	0.11 (-0.10,0.39)
SD ANA SC + LD ETN SC + MTX		2.65 (0.86,8.33)	1.85 (0.90,3.65)	0.21 (-0.03,0.46)
SD ADA SC	SD ETN SC	0.47 (0.19,1.12)	0.57 (0.31,1.09)	-0.14 (-0.32,0.02)
SD TOFA PO		0.87 (0.31,2.38)	0.91 (0.45,1.82)	-0.03 (-0.25,0.18)
SD GOLI SC		0.92 (0.30,2.85)	0.95 (0.42,1.95)	-0.02 (-0.25,0.23)
SD GOLI IV		0.65 (0.21,2.02)	0.74 (0.30,1.59)	-0.08 (-0.29,0.15)
SD TOCI IV		0.55 (0.19,1.60)	0.64 (0.29,1.39)	-0.12 (-0.31,0.09)
SD ABA SC		1.31 (0.29,6.76)	1.18 (0.41,2.80)	0.06 (-0.25,0.44)
SD CERTO SC		1.29 (0.33,5.22)	1.17 (0.46,2.57)	0.06 (-0.22,0.38)
SD ETN SC + MTX		1.85 (1.00,3.56)	1.43 (1.00,2.12)	0.14 (0.00,0.30)



(Continued)

SD ABA IV + MTX	1.33 (0.52,3.31)	1.20 (0.65,2.11)	0.06 (-0.14,0.27)
SD CERTO SC + MTX	1.99 (0.77,4.98)	1.49 (0.85,2.55)	0.16 (-0.06,0.37)
SD INF IV + MTX	1.15 (0.43,2.84)	1.09 (0.57,1.93)	0.03 (-0.18,0.24)
SD ADA SC + MTX	2.50 (0.82,7.64)	1.65 (0.89,2.96)	0.22 (-0.05,0.46)
SD TOFA PO + MTX	2.34 (0.78,6.42)	1.61 (0.86,2.83)	0.20 (-0.06,0.43)
SD GOL I SC + MTX	2.34 (0.85,6.53)	1.61 (0.91,2.83)	0.20 (-0.04,0.43)
SD RITUX IV + MTX	1.21 (0.42,3.54)	1.13 (0.54,2.15)	0.04 (-0.18,0.29)
SD GOL I IV + MTX	0.84 (0.29,2.25)	0.89 (0.40,1.70)	-0.04 (-0.25,0.18)
SD ANA SC + MTX	1.00 (0.31,3.17)	1.00 (0.43,2.06)	0.00 (-0.23,0.26)
SD ABA SC + MTX	1.42 (0.41,4.78)	1.25 (0.53,2.42)	0.08 (-0.18,0.36)
SD TOCI IV + MTX	0.72 (0.21,2.46)	0.80 (0.31,1.77)	-0.07 (-0.29,0.20)
SD CERTO SC + DMARD	1.09 (0.25,5.83)	1.06 (0.36,2.67)	0.02 (-0.26,0.40)
SD ADA SC + DMARD	0.95 (0.11,9.39)	0.97 (0.17,2.97)	-0.01 (-0.33,0.49)
SD TOCI SC + DMARD	1.58 (0.17,14.63)	1.32 (0.25,3.31)	0.10 (-0.29,0.56)
LD ADA SC	0.44 (0.15,1.29)	0.54 (0.24,1.21)	-0.15 (-0.34,0.05)
LD ETN SC	0.55 (0.20,1.50)	0.65 (0.28,1.31)	-0.11 (-0.28,0.09)
LD GOL I IV	0.38 (0.11,1.32)	0.49 (0.16,1.21)	-0.16 (-0.35,0.06)
LD TOCI IV	0.07 (0.01,0.31)	0.10 (0.02,0.39)	-0.29 (-0.46,-0.14)
LD ADA SC + MTX	1.35 (0.39,4.98)	1.20 (0.52,2.49)	0.07 (-0.19,0.37)
LD RITUX IV + MTX	1.20 (0.40,3.48)	1.12 (0.53,2.12)	0.04 (-0.19,0.29)
LD ADA IV + MTX	1.19 (0.16,8.17)	1.12 (0.24,2.83)	0.04 (-0.29,0.47)
LD ABA IV + MTX	0.72 (0.25,2.02)	0.80 (0.36,1.59)	-0.06 (-0.27,0.15)
LD ANA SC + MTX	0.67 (0.12,3.35)	0.75 (0.18,2.06)	-0.08 (-0.33,0.28)
LD CERTO SC + MTX	1.41 (0.42,4.72)	1.24 (0.55,2.41)	0.08 (-0.18,0.36)
LD GOL I IV + MTX	0.75 (0.21,2.45)	0.82 (0.31,1.77)	-0.06 (-0.28,0.20)
LD TOCI IV + MTX	0.61 (0.18,2.03)	0.70 (0.27,1.61)	-0.09 (-0.31,0.15)
LD TOFA PO + MTX	1.02 (0.24,4.31)	1.01 (0.34,2.29)	0.00 (-0.25,0.34)
HD TOCI IV	0.97 (0.39,2.30)	0.98 (0.54,1.75)	-0.01 (-0.20,0.18)

(Continued)

HD TOFA PO		1.38 (0.50,3.78)	1.22 (0.65,2.34)	0.07 (-0.16,0.30)
HD ADA SC		0.63 (0.23,1.84)	0.72 (0.34,1.55)	-0.09 (-0.30,0.13)
HD GOL I SC		1.06 (0.39,2.86)	1.04 (0.52,1.97)	0.01 (-0.20,0.24)
HD ETN SC		0.97 (0.27,3.52)	0.98 (0.35,1.97)	-0.01 (-0.22,0.29)
HD ABA SC		1.86 (0.41,9.56)	1.44 (0.54,3.12)	0.15 (-0.19,0.50)
HD TOCI IV + MTX		1.69 (0.64,4.20)	1.37 (0.76,2.40)	0.12 (-0.10,0.33)
HD INF IV + MTX		1.54 (0.53,4.27)	1.30 (0.67,2.34)	0.10 (-0.14,0.33)
HD TOFA PO + MTX		1.31 (0.44,3.69)	1.18 (0.57,2.20)	0.06 (-0.17,0.30)
HD GOL I SC + MTX		1.80 (0.65,5.05)	1.42 (0.75,2.55)	0.14 (-0.10,0.37)
HD CERTO SC + MTX		2.36 (0.89,6.34)	1.62 (0.93,2.81)	0.20 (-0.03,0.42)
HD ADA SC + MTX		1.96 (0.53,7.54)	1.48 (0.65,2.85)	0.16 (-0.13,0.46)
HD TOCI IV + DMARD		1.15 (0.15,9.90)	1.09 (0.22,3.02)	0.03 (-0.31,0.51)
SD ANA SC + SD ETN SC + MTX		1.17 (0.37,3.97)	1.10 (0.47,2.14)	0.03 (-0.19,0.32)
SD ANA SC + LD ETN SC + MTX		1.71 (0.54,5.87)	1.37 (0.65,2.47)	0.12 (-0.12,0.41)
SD TOFA PO	SD ADA SC	1.83 (0.84,4.08)	1.58 (0.87,2.81)	0.11 (-0.03,0.27)
SD GOL I SC		1.95 (0.68,5.74)	1.66 (0.73,3.35)	0.12 (-0.06,0.36)
SD GOL I IV		1.38 (0.45,4.18)	1.29 (0.51,2.78)	0.05 (-0.11,0.28)
SD TOCI IV		1.16 (0.44,3.05)	1.13 (0.51,2.32)	0.02 (-0.11,0.21)
SD ABA SC		2.76 (0.64,13.71)	2.07 (0.70,4.84)	0.20 (-0.07,0.55)
SD CERTO SC		2.75 (0.76,10.23)	2.07 (0.80,4.32)	0.20 (-0.05,0.50)
SD ETN SC + MTX		3.92 (1.59,10.02)	2.51 (1.40,4.41)	0.28 (0.09,0.49)
SD ABA IV + MTX		2.86 (1.13,6.78)	2.11 (1.10,3.65)	0.21 (0.02,0.41)
SD CERTO SC + MTX		4.23 (1.71,10.34)	2.61 (1.46,4.38)	0.30 (0.10,0.50)
SD INF IV + MTX		2.43 (0.95,6.12)	1.91 (0.96,3.45)	0.17 (-0.01,0.38)
SD ADA SC + MTX		5.24 (1.82,15.68)	2.90 (1.53,4.96)	0.36 (0.12,0.59)
SD TOFA PO + MTX		4.92 (1.66,13.45)	2.81 (1.44,4.83)	0.34 (0.10,0.56)
SD GOL I SC + MTX		4.98 (1.79,13.53)	2.82 (1.51,4.81)	0.34 (0.11,0.56)

(Continued)

SD RITUX IV + MTX	2.61 (0.87,7.53)	1.99 (0.89,3.76)	0.19 (-0.02,0.43)
SD GOLI IV + MTX	1.79 (0.63,4.89)	1.55 (0.69,3.06)	0.10 (-0.07,0.32)
SD ANA SC + MTX	2.14 (0.70,6.29)	1.76 (0.75,3.46)	0.14 (-0.05,0.39)
SD ABA SC + MTX	3.04 (0.88,9.99)	2.18 (0.90,4.19)	0.22 (-0.02,0.50)
SD TOCI IV + MTX	1.53 (0.48,4.91)	1.39 (0.54,3.00)	0.07 (-0.10,0.33)
SD CERTO SC + DMARD	2.35 (0.54,11.30)	1.87 (0.61,4.51)	0.16 (-0.09,0.52)
SD ADA SC + DMARD	2.04 (0.23,19.03)	1.71 (0.28,5.02)	0.13 (-0.16,0.62)
SD TOCI SC + DMARD	3.33 (0.37,30.29)	2.30 (0.43,5.62)	0.24 (-0.12,0.68)
LD ADA SC	0.94 (0.45,1.99)	0.95 (0.51,1.71)	-0.01 (-0.11,0.12)
LD ETN SC	1.18 (0.35,3.85)	1.14 (0.41,2.67)	0.03 (-0.14,0.26)
LD GOLI IV	0.82 (0.23,2.66)	0.85 (0.28,2.10)	-0.03 (-0.16,0.18)
LD TOCI IV	0.14 (0.02,0.64)	0.17 (0.03,0.69)	-0.15 (-0.24,-0.05)
LD ADA SC + MTX	2.92 (0.86,9.85)	2.12 (0.88,4.13)	0.21 (-0.02,0.49)
LD RITUX IV + MTX	2.56 (0.88,7.45)	1.97 (0.90,3.74)	0.18 (-0.02,0.42)
LD ADA IV + MTX	2.56 (0.36,16.19)	1.97 (0.41,4.74)	0.18 (-0.12,0.59)
LD ABA IV + MTX	1.55 (0.54,4.17)	1.40 (0.60,2.78)	0.07 (-0.09,0.29)
LD ANA SC + MTX	1.43 (0.27,6.74)	1.32 (0.32,3.43)	0.06 (-0.14,0.41)
LD CERTO SC + MTX	2.98 (0.93,9.80)	2.16 (0.94,4.12)	0.22 (-0.01,0.49)
LD GOLI IV + MTX	1.58 (0.48,5.13)	1.42 (0.55,3.14)	0.08 (-0.10,0.33)
LD TOCI IV + MTX	1.31 (0.41,4.03)	1.24 (0.47,2.68)	0.04 (-0.12,0.28)
LD TOFA PO + MTX	2.18 (0.50,8.90)	1.78 (0.56,3.90)	0.14 (-0.09,0.47)
HD TOCI IV	2.05 (1.00,4.19)	1.71 (1.00,2.83)	0.13 (0.00,0.28)
HD TOFA PO	2.92 (1.38,6.40)	2.14 (1.26,3.61)	0.21 (0.06,0.39)
HD ADA SC	1.35 (0.65,2.83)	1.26 (0.70,2.18)	0.05 (-0.06,0.20)
HD GOLI SC	2.25 (0.87,5.69)	1.81 (0.90,3.39)	0.15 (-0.02,0.36)
HD ETN SC	2.09 (0.41,9.89)	1.73 (0.47,4.11)	0.14 (-0.11,0.49)
HD ABA SC	3.97 (0.94,19.17)	2.52 (0.95,5.29)	0.29 (-0.01,0.62)
HD TOCI IV + MTX	3.55 (1.54,8.35)	2.39 (1.37,4.02)	0.26 (0.08,0.45)

(Continued)

HD INF IV + MTX		3.27 (1.17,8.74)	2.28 (1.13,4.07)	0.24 (0.03,0.47)
HD TOFA PO + MTX		2.80 (0.96,7.65)	2.08 (0.97,3.80)	0.20 (-0.01,0.43)
HD GOLI SC + MTX		3.86 (1.36,10.41)	2.50 (1.26,4.36)	0.28 (0.06,0.50)
HD CERTO SC + MTX		5.04 (1.93,13.17)	2.83 (1.59,4.73)	0.34 (0.13,0.55)
HD ADA SC + MTX		4.17 (1.17,15.23)	2.59 (1.12,4.81)	0.30 (0.03,0.58)
HD TOCI IV + DMARD		2.44 (0.31,20.12)	1.92 (0.37,5.12)	0.17 (-0.14,0.63)
SD ANA SC + SD ETN SC + MTX		2.50 (0.65,10.02)	1.94 (0.70,4.17)	0.18 (-0.06,0.49)
SD ANA SC + LD ETN SC + MTX		3.70 (0.95,14.48)	2.43 (0.96,4.71)	0.27 (-0.01,0.57)
SD GOLI SC	SD TOFA PO	1.07 (0.33,3.41)	1.05 (0.44,2.23)	0.01 (-0.22,0.27)
SD GOLI IV		0.76 (0.21,2.49)	0.82 (0.31,1.88)	-0.05 (-0.27,0.19)
SD TOCI IV		0.63 (0.21,1.98)	0.71 (0.30,1.64)	-0.09 (-0.28,0.14)
SD ABA SC		1.50 (0.33,7.50)	1.30 (0.44,3.08)	0.09 (-0.21,0.45)
SD CERTO SC		1.47 (0.40,6.07)	1.29 (0.52,2.88)	0.08 (-0.18,0.41)
SD ETN SC + MTX		2.13 (0.75,6.41)	1.59 (0.83,3.04)	0.17 (-0.06,0.42)
SD ABA IV + MTX		1.56 (0.50,4.36)	1.33 (0.62,2.54)	0.10 (-0.15,0.33)
SD CERTO SC + MTX		2.29 (0.77,6.57)	1.65 (0.85,3.06)	0.19 (-0.06,0.42)
SD INF IV + MTX		1.34 (0.43,3.79)	1.21 (0.55,2.39)	0.06 (-0.17,0.30)
SD ADA SC + MTX		2.88 (0.84,9.69)	1.84 (0.90,3.43)	0.25 (-0.04,0.51)
SD TOFA PO + MTX		2.68 (0.78,8.94)	1.78 (0.85,3.37)	0.23 (-0.05,0.49)
SD GOLI SC + MTX		2.72 (0.83,8.49)	1.78 (0.90,3.34)	0.23 (-0.04,0.48)
SD RITUX IV + MTX		1.41 (0.41,4.66)	1.25 (0.53,2.59)	0.08 (-0.18,0.35)
SD GOLI IV + MTX		0.97 (0.29,3.00)	0.98 (0.40,2.10)	-0.01 (-0.23,0.24)
SD ANA SC + MTX		1.17 (0.33,3.85)	1.11 (0.44,2.36)	0.03 (-0.21,0.30)
SD ABA SC + MTX		1.66 (0.41,6.23)	1.38 (0.53,2.88)	0.11 (-0.18,0.42)
SD TOCI IV + MTX		0.83 (0.23,3.18)	0.88 (0.32,2.12)	-0.04 (-0.26,0.25)
SD CERTO SC + DMARD		1.28 (0.28,6.58)	1.18 (0.38,2.94)	0.05 (-0.24,0.43)
SD ADA SC + DMARD		1.12 (0.12,10.72)	1.08 (0.17,3.24)	0.02 (-0.31,0.52)

(Continued)

SD TOCI SC + DMARD	1.81 (0.19,16.82)	1.45 (0.27,3.63)	0.13 (-0.26,0.59)
LD ADA SC	0.51 (0.18,1.45)	0.60 (0.27,1.32)	-0.12 (-0.30,0.07)
LD ETN SC	0.64 (0.17,2.38)	0.72 (0.25,1.81)	-0.08 (-0.30,0.18)
LD GOL I IV	0.45 (0.11,1.63)	0.54 (0.16,1.42)	-0.13 (-0.33,0.10)
LD TOCI IV	0.08 (0.01,0.41)	0.11 (0.02,0.48)	-0.26 (-0.42,-0.11)
LD ADA SC + MTX	1.58 (0.41,5.85)	1.34 (0.52,2.78)	0.10 (-0.18,0.40)
LD RITUX IV + MTX	1.38 (0.42,4.49)	1.24 (0.54,2.57)	0.07 (-0.18,0.34)
LD ADA IV + MTX	1.39 (0.19,9.58)	1.24 (0.27,3.23)	0.07 (-0.26,0.50)
LD ABA IV + MTX	0.83 (0.25,2.63)	0.88 (0.35,1.92)	-0.04 (-0.26,0.21)
LD ANA SC + MTX	0.78 (0.13,3.89)	0.84 (0.19,2.28)	-0.05 (-0.30,0.31)
LD CERTO SC + MTX	1.62 (0.44,6.17)	1.36 (0.55,2.88)	0.11 (-0.17,0.41)
LD GOL I IV + MTX	0.86 (0.22,3.03)	0.90 (0.32,2.10)	-0.03 (-0.26,0.24)
LD TOCI IV + MTX	0.70 (0.19,2.61)	0.77 (0.28,1.90)	-0.07 (-0.28,0.21)
LD TOFA PO + MTX	1.20 (0.25,5.45)	1.13 (0.34,2.69)	0.04 (-0.24,0.39)
HD TOCI IV	1.11 (0.43,2.87)	1.08 (0.56,2.10)	0.02 (-0.18,0.22)
HD TOFA PO	1.60 (0.90,2.88)	1.35 (0.93,2.00)	0.10 (-0.02,0.23)
HD ADA SC	0.73 (0.27,1.99)	0.80 (0.39,1.63)	-0.06 (-0.25,0.14)
HD GOL I SC	1.23 (0.40,3.50)	1.15 (0.53,2.29)	0.04 (-0.19,0.27)
HD ETN SC	1.13 (0.20,5.55)	1.09 (0.29,2.72)	0.03 (-0.27,0.39)
HD ABA SC	2.16 (0.48,10.85)	1.59 (0.61,3.46)	0.18 (-0.15,0.53)
HD TOCI IV + MTX	1.93 (0.68,5.49)	1.50 (0.77,2.88)	0.15 (-0.09,0.38)
HD INF IV + MTX	1.78 (0.55,5.55)	1.44 (0.66,2.83)	0.13 (-0.13,0.38)
HD TOFA PO + MTX	1.52 (0.45,4.85)	1.31 (0.58,2.68)	0.09 (-0.16,0.35)
HD GOL I SC + MTX	2.08 (0.64,6.48)	1.56 (0.75,3.02)	0.17 (-0.10,0.42)
HD CERTO SC + MTX	2.74 (0.88,8.31)	1.79 (0.92,3.32)	0.23 (-0.03,0.48)
HD ADA SC + MTX	2.28 (0.55,9.15)	1.64 (0.66,3.26)	0.19 (-0.12,0.50)
HD TOCI IV + DMARD	1.32 (0.16,11.50)	1.20 (0.23,3.30)	0.06 (-0.28,0.53)
SD ANA SC + SD ETN SC + MTX	1.37 (0.31,5.84)	1.23 (0.42,2.78)	0.07 (-0.21,0.40)

(Continued)

SD ANA SC + LD ETN SC + MTX		2.02 (0.47,8.79)	1.53 (0.59,3.25)	0.16 (-0.15,0.49)
SD GOLI IV	SD GOLI SC	0.71 (0.25,2.07)	0.78 (0.35,1.67)	-0.07 (-0.27,0.15)
SD TOCI IV		0.59 (0.18,1.91)	0.68 (0.29,1.62)	-0.10 (-0.33,0.12)
SD ABA SC		1.43 (0.28,7.98)	1.25 (0.41,3.36)	0.08 (-0.26,0.46)
SD CERTO SC		1.40 (0.31,6.48)	1.24 (0.45,3.20)	0.07 (-0.24,0.41)
SD ETN SC + MTX		2.01 (0.66,6.45)	1.52 (0.79,3.27)	0.16 (-0.10,0.41)
SD ABA IV + MTX		1.44 (0.51,4.14)	1.26 (0.66,2.63)	0.08 (-0.15,0.30)
SD CERTO SC + MTX		2.15 (0.75,6.13)	1.57 (0.85,3.21)	0.18 (-0.07,0.40)
SD INF IV + MTX		1.24 (0.42,3.63)	1.15 (0.58,2.41)	0.05 (-0.19,0.27)
SD ADA SC + MTX		2.73 (0.80,9.04)	1.75 (0.87,3.59)	0.23 (-0.05,0.49)
SD TOFA PO + MTX		2.52 (0.77,8.08)	1.69 (0.86,3.57)	0.21 (-0.06,0.46)
SD GOLI SC + MTX		2.54 (0.87,7.55)	1.70 (0.92,3.41)	0.22 (-0.03,0.45)
SD RITUX IV + MTX		1.33 (0.40,4.33)	1.20 (0.54,2.60)	0.06 (-0.20,0.32)
SD GOLI IV + MTX		0.91 (0.30,2.76)	0.93 (0.43,2.03)	-0.02 (-0.25,0.21)
SD ANA SC + MTX		1.09 (0.31,3.82)	1.05 (0.45,2.47)	0.02 (-0.24,0.29)
SD ABA SC + MTX		1.54 (0.40,5.88)	1.31 (0.54,2.99)	0.10 (-0.19,0.39)
SD TOCI IV + MTX		0.79 (0.21,3.01)	0.85 (0.32,2.10)	-0.05 (-0.30,0.23)
SD CERTO SC + DMARD		1.21 (0.23,6.88)	1.14 (0.35,3.20)	0.04 (-0.28,0.42)
SD ADA SC + DMARD		1.05 (0.11,11.51)	1.03 (0.18,3.58)	0.01 (-0.35,0.53)
SD TOCI SC + DMARD		1.72 (0.17,17.02)	1.39 (0.26,4.00)	0.12 (-0.30,0.59)
LD ADA SC		0.48 (0.14,1.64)	0.58 (0.24,1.46)	-0.13 (-0.38,0.08)
LD ETN SC		0.60 (0.15,2.48)	0.69 (0.24,1.93)	-0.09 (-0.36,0.18)
LD GOLI IV		0.42 (0.12,1.50)	0.51 (0.18,1.35)	-0.14 (-0.37,0.07)
LD TOCI IV		0.07 (0.01,0.39)	0.10 (0.02,0.45)	-0.27 (-0.50,-0.10)
LD ADA SC + MTX		1.47 (0.39,5.82)	1.28 (0.53,2.93)	0.08 (-0.20,0.39)
LD RITUX IV + MTX		1.31 (0.40,4.29)	1.19 (0.55,2.59)	0.06 (-0.20,0.32)
LD ADA IV + MTX		1.32 (0.17,9.67)	1.19 (0.25,3.34)	0.06 (-0.30,0.50)
LD ABA IV + MTX		0.78 (0.25,2.51)	0.84 (0.37,1.93)	-0.05 (-0.28,0.18)

(Continued)

LD ANA SC + MTX		0.73 (0.13,3.79)	0.80 (0.20,2.33)	-0.06 (-0.34,0.30)
LD CERTO SC + MTX		1.53 (0.42,5.72)	1.30 (0.56,2.95)	0.09 (-0.19,0.39)
LD GOLI IV + MTX		0.81 (0.24,2.74)	0.86 (0.34,2.01)	-0.04 (-0.28,0.21)
LD TOCI IV + MTX		0.66 (0.18,2.47)	0.74 (0.28,1.88)	-0.08 (-0.32,0.19)
LD TOFA PO + MTX		1.10 (0.25,5.05)	1.07 (0.36,2.69)	0.02 (-0.26,0.36)
HD TOCI IV		1.04 (0.38,2.96)	1.03 (0.54,2.19)	0.01 (-0.22,0.21)
HD TOFA PO		1.50 (0.48,4.82)	1.29 (0.65,2.92)	0.09 (-0.18,0.33)
HD ADA SC		0.69 (0.20,2.33)	0.76 (0.33,1.86)	-0.07 (-0.33,0.16)
HD GOLI SC		1.15 (0.48,2.78)	1.10 (0.61,2.05)	0.03 (-0.16,0.21)
HD ETN SC		1.06 (0.19,5.99)	1.04 (0.29,2.93)	0.01 (-0.30,0.40)
HD ABA SC		2.04 (0.39,11.51)	1.52 (0.54,3.83)	0.16 (-0.20,0.53)
HD TOCI IV + MTX		1.82 (0.61,5.33)	1.44 (0.75,3.01)	0.13 (-0.12,0.37)
HD INF IV + MTX		1.67 (0.54,5.22)	1.37 (0.67,2.88)	0.11 (-0.14,0.36)
HD TOFA PO + MTX		1.42 (0.44,4.60)	1.25 (0.59,2.72)	0.08 (-0.18,0.33)
HD GOLI SC + MTX		1.96 (0.68,5.76)	1.50 (0.79,3.02)	0.15 (-0.09,0.39)
HD CERTO SC + MTX		2.55 (0.85,7.57)	1.70 (0.92,3.50)	0.22 (-0.04,0.45)
HD ADA SC + MTX		2.14 (0.53,8.76)	1.56 (0.67,3.49)	0.17 (-0.14,0.48)
HD TOCI IV + DMARD		1.25 (0.15,11.99)	1.16 (0.22,3.70)	0.05 (-0.32,0.53)
SD ANA SC + SD ETN SC + MTX		1.28 (0.28,6.10)	1.17 (0.41,3.04)	0.05 (-0.25,0.40)
SD ANA SC + LD ETN SC + MTX		1.89 (0.42,8.64)	1.46 (0.56,3.47)	0.14 (-0.18,0.48)
SD TOCI IV	SD GOLI IV	0.84 (0.27,2.73)	0.88 (0.37,2.20)	-0.03 (-0.25,0.17)
SD ABA SC		2.03 (0.37,12.03)	1.60 (0.49,4.81)	0.14 (-0.20,0.52)
SD CERTO SC		1.97 (0.40,9.85)	1.59 (0.53,4.59)	0.14 (-0.19,0.47)
SD ETN SC + MTX		2.83 (0.95,9.18)	1.94 (0.97,4.54)	0.22 (-0.01,0.45)
SD ABA IV + MTX		2.04 (0.77,5.57)	1.62 (0.85,3.49)	0.15 (-0.06,0.34)
SD CERTO SC + MTX		3.04 (1.14,8.11)	2.01 (1.08,4.30)	0.24 (0.03,0.44)
SD INF IV + MTX		1.74 (0.65,4.76)	1.47 (0.75,3.13)	0.11 (-0.09,0.31)

(Continued)

SD ADA SC + MTX	3.83 (1.20,12.87)	2.23 (1.11,5.08)	0.29 (0.04,0.53)
SD TOFA PO + MTX	3.54 (1.17,10.64)	2.16 (1.09,4.73)	0.28 (0.03,0.50)
SD GOLJ SC + MTX	3.61 (1.25,10.53)	2.17 (1.13,4.72)	0.28 (0.05,0.50)
SD RITUX IV + MTX	1.87 (0.61,5.77)	1.53 (0.71,3.45)	0.13 (-0.10,0.36)
SD GOLJ IV + MTX	1.29 (0.53,3.09)	1.20 (0.63,2.34)	0.05 (-0.13,0.22)
SD ANA SC + MTX	1.53 (0.48,5.04)	1.35 (0.60,3.13)	0.08 (-0.14,0.33)
SD ABA SC + MTX	2.19 (0.62,7.85)	1.68 (0.72,3.95)	0.16 (-0.10,0.44)
SD TOCI IV + MTX	1.11 (0.31,4.10)	1.08 (0.41,2.78)	0.02 (-0.22,0.27)
SD CERTO SC + DMARD	1.70 (0.32,10.48)	1.44 (0.42,4.61)	0.11 (-0.22,0.49)
SD ADA SC + DMARD	1.48 (0.15,17.24)	1.32 (0.22,5.01)	0.07 (-0.28,0.59)
SD TOCI SC + DMARD	2.42 (0.24,26.07)	1.76 (0.32,5.68)	0.19 (-0.23,0.66)
LD ADA SC	0.68 (0.19,2.42)	0.74 (0.29,2.04)	-0.06 (-0.30,0.13)
LD ETN SC	0.86 (0.20,3.51)	0.89 (0.29,2.61)	-0.03 (-0.29,0.23)
LD GOLJ IV	0.59 (0.21,1.63)	0.66 (0.28,1.45)	-0.08 (-0.26,0.08)
LD TOCI IV	0.10 (0.02,0.54)	0.14 (0.02,0.58)	-0.20 (-0.42,-0.05)
LD ADA SC + MTX	2.07 (0.58,8.04)	1.62 (0.68,4.06)	0.15 (-0.11,0.44)
LD RITUX IV + MTX	1.85 (0.60,5.61)	1.51 (0.71,3.42)	0.12 (-0.10,0.35)
LD ADA IV + MTX	1.85 (0.25,12.96)	1.51 (0.32,4.48)	0.12 (-0.21,0.55)
LD ABA IV + MTX	1.10 (0.37,3.37)	1.07 (0.48,2.50)	0.02 (-0.19,0.23)
LD ANA SC + MTX	1.03 (0.20,5.24)	1.02 (0.26,3.06)	0.00 (-0.26,0.35)
LD CERTO SC + MTX	2.18 (0.63,7.71)	1.66 (0.73,3.93)	0.16 (-0.10,0.43)
LD GOLJ IV + MTX	1.15 (0.42,2.99)	1.11 (0.53,2.24)	0.02 (-0.16,0.22)
LD TOCI IV + MTX	0.94 (0.26,3.46)	0.96 (0.36,2.54)	-0.01 (-0.25,0.24)
LD TOFA PO + MTX	1.57 (0.36,6.71)	1.37 (0.46,3.51)	0.09 (-0.18,0.41)
HD TOCI IV	1.48 (0.55,4.06)	1.32 (0.67,2.96)	0.07 (-0.13,0.25)
HD TOFA PO	2.12 (0.65,7.37)	1.66 (0.76,4.24)	0.16 (-0.10,0.39)
HD ADA SC	0.97 (0.28,3.50)	0.98 (0.39,2.69)	-0.01 (-0.25,0.21)
HD GOLJ SC	1.63 (0.57,4.63)	1.41 (0.69,3.14)	0.09 (-0.12,0.30)



(Continued)

HD ETN SC		1.49 (0.28,8.50)	1.32 (0.36,4.08)	0.08 (-0.22,0.45)
HD ABA SC		2.92 (0.52,16.92)	1.96 (0.64,5.56)	0.23 (-0.14,0.58)
HD TOCI IV + MTX		2.56 (0.94,7.24)	1.84 (0.96,4.08)	0.20 (-0.01,0.41)
HD INF IV + MTX		2.34 (0.81,6.94)	1.75 (0.87,3.85)	0.18 (-0.05,0.40)
HD TOFA PO + MTX		2.01 (0.67,6.03)	1.60 (0.76,3.56)	0.14 (-0.09,0.37)
HD GOLI SC + MTX		2.76 (0.95,8.09)	1.91 (0.97,4.20)	0.22 (-0.01,0.44)
HD CERTO SC + MTX		3.63 (1.30,10.32)	2.18 (1.15,4.70)	0.28 (0.06,0.49)
HD ADA SC + MTX		3.02 (0.81,12.32)	1.99 (0.87,4.80)	0.24 (-0.04,0.53)
HD TOCI IV + DMARD		1.77 (0.20,17.84)	1.47 (0.28,5.19)	0.11 (-0.25,0.60)
SD ANA SC + SD ETN SC + MTX		1.79 (0.41,8.73)	1.48 (0.52,4.18)	0.11 (-0.17,0.45)
SD ANA SC + LD ETN SC + MTX		2.65 (0.61,12.84)	1.86 (0.71,4.88)	0.21 (-0.10,0.53)
SD ABA SC	SD TOCI IV	2.40 (0.47,13.22)	1.82 (0.56,5.15)	0.17 (-0.14,0.54)
SD CERTO SC		2.36 (0.52,10.79)	1.81 (0.62,4.78)	0.17 (-0.12,0.49)
SD ETN SC + MTX		3.37 (1.19,9.90)	2.22 (1.12,4.82)	0.26 (0.04,0.47)
SD ABA IV + MTX		2.44 (0.96,6.12)	1.85 (0.97,3.66)	0.18 (-0.01,0.37)
SD CERTO SC + MTX		3.62 (1.42,9.19)	2.31 (1.25,4.58)	0.27 (0.08,0.46)
SD INF IV + MTX		2.08 (0.81,5.33)	1.68 (0.86,3.40)	0.14 (-0.04,0.34)
SD ADA SC + MTX		4.53 (1.51,13.99)	2.55 (1.30,5.20)	0.33 (0.09,0.56)
SD TOFA PO + MTX		4.24 (1.43,12.16)	2.47 (1.25,4.99)	0.31 (0.08,0.53)
SD GOLI SC + MTX		4.29 (1.51,11.84)	2.50 (1.29,5.09)	0.31 (0.09,0.52)
SD RITUX IV + MTX		2.24 (0.76,6.40)	1.76 (0.82,3.72)	0.16 (-0.05,0.38)
SD GOLI IV + MTX		1.52 (0.53,4.29)	1.36 (0.62,2.96)	0.08 (-0.12,0.28)
SD ANA SC + MTX		1.83 (0.58,5.72)	1.55 (0.67,3.41)	0.11 (-0.10,0.35)
SD ABA SC + MTX		2.61 (0.73,8.75)	1.93 (0.80,4.20)	0.19 (-0.06,0.46)
SD TOCI IV + MTX		1.32 (0.45,3.81)	1.23 (0.53,2.64)	0.05 (-0.13,0.27)
SD CERTO SC + DMARD		2.01 (0.41,11.52)	1.64 (0.50,4.75)	0.13 (-0.15,0.51)
SD ADA SC + DMARD		1.76 (0.19,18.97)	1.50 (0.25,5.34)	0.10 (-0.22,0.61)

(Continued)

SD TOCI SC + DMARD	2.91 (0.31,29.40)	2.02 (0.38,6.03)	0.22 (-0.17,0.68)
LD ADA SC	0.81 (0.25,2.57)	0.84 (0.34,2.17)	-0.03 (-0.23,0.15)
LD ETN SC	1.02 (0.25,3.87)	1.02 (0.32,2.81)	0.00 (-0.22,0.24)
LD GOL I IV	0.70 (0.20,2.49)	0.75 (0.26,2.01)	-0.05 (-0.23,0.15)
LD TOCI IV	0.12 (0.02,0.51)	0.15 (0.03,0.57)	-0.17 (-0.34,-0.06)
LD ADA SC + MTX	2.48 (0.73,8.79)	1.86 (0.79,4.18)	0.18 (-0.06,0.46)
LD RITUX IV + MTX	2.19 (0.74,6.47)	1.73 (0.81,3.71)	0.15 (-0.06,0.38)
LD ADA IV + MTX	2.21 (0.31,14.42)	1.73 (0.38,4.79)	0.15 (-0.16,0.57)
LD ABA IV + MTX	1.32 (0.46,3.75)	1.23 (0.56,2.70)	0.05 (-0.14,0.25)
LD ANA SC + MTX	1.23 (0.23,6.10)	1.17 (0.29,3.36)	0.03 (-0.20,0.38)
LD CERTO SC + MTX	2.57 (0.76,8.78)	1.91 (0.82,4.19)	0.19 (-0.05,0.46)
LD GOL I IV + MTX	1.36 (0.40,4.50)	1.26 (0.49,3.02)	0.05 (-0.15,0.30)
LD TOCI IV + MTX	1.12 (0.39,3.15)	1.09 (0.46,2.36)	0.02 (-0.15,0.22)
LD TOFA PO + MTX	1.87 (0.43,7.90)	1.57 (0.51,3.91)	0.12 (-0.13,0.43)
HD TOCI IV	1.75 (0.85,3.68)	1.51 (0.90,2.75)	0.10 (-0.03,0.24)
HD TOFA PO	2.52 (0.81,7.62)	1.91 (0.87,4.35)	0.19 (-0.05,0.40)
HD ADA SC	1.16 (0.37,3.74)	1.12 (0.48,2.76)	0.03 (-0.18,0.22)
HD GOL I SC	1.93 (0.68,5.43)	1.60 (0.76,3.48)	0.13 (-0.08,0.33)
HD ETN SC	1.77 (0.33,9.17)	1.51 (0.41,4.25)	0.11 (-0.17,0.46)
HD ABA SC	3.44 (0.68,19.23)	2.23 (0.75,5.82)	0.26 (-0.07,0.61)
HD TOCI IV + MTX	3.05 (1.36,6.97)	2.10 (1.22,3.98)	0.23 (0.07,0.40)
HD INF IV + MTX	2.79 (1.00,7.89)	2.01 (1.00,4.14)	0.21 (0.00,0.43)
HD TOFA PO + MTX	2.38 (0.80,7.01)	1.83 (0.85,3.90)	0.17 (-0.04,0.40)
HD GOL I SC + MTX	3.29 (1.17,9.41)	2.19 (1.11,4.52)	0.25 (0.03,0.47)
HD CERTO SC + MTX	4.31 (1.60,11.61)	2.50 (1.34,5.06)	0.32 (0.10,0.51)
HD ADA SC + MTX	3.59 (1.00,13.30)	2.27 (1.00,4.96)	0.27 (0.00,0.55)
HD TOCI IV + DMARD	2.11 (0.26,19.54)	1.69 (0.33,5.43)	0.14 (-0.20,0.62)
SD ANA SC + SD ETN SC + MTX	2.14 (0.52,9.37)	1.70 (0.60,4.34)	0.15 (-0.12,0.47)

(Continued)

SD ANA SC + LD ETN SC + MTX		3.18 (0.72,13.73)	2.13 (0.79,5.13)	0.24 (-0.06,0.55)
SD CERTO SC	SD ABA SC	0.98 (0.16,5.86)	0.99 (0.35,3.01)	0.00 (-0.41,0.38)
SD ETN SC + MTX		1.42 (0.27,7.03)	1.21 (0.53,3.52)	0.08 (-0.31,0.42)
SD ABA IV + MTX		1.01 (0.19,5.06)	1.01 (0.42,3.03)	0.00 (-0.38,0.34)
SD CERTO SC + MTX		1.52 (0.27,7.46)	1.25 (0.55,3.56)	0.10 (-0.30,0.43)
SD INF IV + MTX		0.86 (0.16,4.39)	0.91 (0.37,2.72)	-0.03 (-0.42,0.31)
SD ADA SC + MTX		1.91 (0.32,10.24)	1.39 (0.59,3.94)	0.15 (-0.26,0.51)
SD TOFA PO + MTX		1.76 (0.31,9.04)	1.34 (0.57,3.86)	0.13 (-0.27,0.48)
SD GOLI SC + MTX		1.80 (0.31,9.37)	1.36 (0.59,3.88)	0.14 (-0.27,0.48)
SD RITUX IV + MTX		0.93 (0.16,5.22)	0.96 (0.36,2.96)	-0.02 (-0.41,0.35)
SD GOLI IV + MTX		0.64 (0.11,3.26)	0.75 (0.27,2.32)	-0.10 (-0.48,0.24)
SD ANA SC + MTX		0.76 (0.12,4.18)	0.85 (0.29,2.61)	-0.06 (-0.46,0.30)
SD ABA SC + MTX		1.09 (0.17,6.86)	1.05 (0.36,3.28)	0.02 (-0.40,0.41)
SD TOCI IV + MTX		0.55 (0.09,3.27)	0.67 (0.21,2.32)	-0.12 (-0.51,0.24)
SD CERTO SC + DMARD		0.86 (0.12,5.57)	0.91 (0.27,2.92)	-0.03 (-0.45,0.38)
SD ADA SC + DMARD		0.74 (0.06,8.62)	0.83 (0.14,3.14)	-0.06 (-0.51,0.47)
SD TOCI SC + DMARD		1.19 (0.10,13.54)	1.10 (0.20,3.70)	0.04 (-0.45,0.54)
LD ADA SC		0.34 (0.06,1.60)	0.47 (0.17,1.45)	-0.21 (-0.56,0.08)
LD ETN SC		0.42 (0.07,2.39)	0.55 (0.18,1.87)	-0.17 (-0.55,0.16)
LD GOLI IV		0.29 (0.05,1.74)	0.41 (0.12,1.51)	-0.22 (-0.58,0.10)
LD TOCI IV		0.05 (0.01,0.39)	0.08 (0.01,0.45)	-0.35 (-0.69,-0.09)
LD ADA SC + MTX		1.04 (0.17,6.22)	1.02 (0.35,3.17)	0.01 (-0.40,0.39)
LD RITUX IV + MTX		0.91 (0.16,5.00)	0.95 (0.36,2.91)	-0.02 (-0.41,0.34)
LD ADA IV + MTX		0.91 (0.09,9.57)	0.95 (0.18,3.49)	-0.02 (-0.47,0.49)
LD ABA IV + MTX		0.55 (0.10,2.93)	0.67 (0.24,2.19)	-0.13 (-0.50,0.22)
LD ANA SC + MTX		0.51 (0.06,3.92)	0.64 (0.14,2.39)	-0.13 (-0.54,0.29)
LD CERTO SC + MTX		1.07 (0.18,6.44)	1.04 (0.38,3.25)	0.01 (-0.39,0.41)
LD GOLI IV + MTX		0.57 (0.09,3.17)	0.69 (0.22,2.22)	-0.12 (-0.50,0.24)

(Continued)

LD TOCI IV + MTX		0.47 (0.07,2.80)	0.60 (0.18,2.10)	-0.15 (-0.53,0.20)
LD TOFA PO + MTX		0.78 (0.11,5.52)	0.86 (0.24,2.90)	-0.05 (-0.47,0.37)
HD TOCI IV		0.74 (0.14,3.42)	0.82 (0.35,2.46)	-0.07 (-0.44,0.24)
HD TOFA PO		1.06 (0.21,4.79)	1.04 (0.47,2.96)	0.01 (-0.36,0.32)
HD ADA SC		0.49 (0.09,2.32)	0.61 (0.24,1.88)	-0.15 (-0.51,0.15)
HD GOLI SC		0.80 (0.15,3.94)	0.87 (0.35,2.62)	-0.05 (-0.43,0.28)
HD ETN SC		0.75 (0.09,5.41)	0.84 (0.21,2.92)	-0.06 (-0.49,0.36)
HD ABA SC		1.43 (0.49,4.28)	1.20 (0.66,2.42)	0.08 (-0.16,0.32)
HD TOCI IV + MTX		1.28 (0.24,6.31)	1.15 (0.51,3.38)	0.06 (-0.33,0.39)
HD INF IV + MTX		1.16 (0.20,6.26)	1.09 (0.44,3.30)	0.03 (-0.37,0.40)
HD TOFA PO + MTX		0.99 (0.18,5.18)	0.99 (0.38,3.01)	0.00 (-0.39,0.35)
HD GOLI SC + MTX		1.39 (0.23,7.24)	1.20 (0.48,3.49)	0.08 (-0.34,0.43)
HD CERTO SC + MTX		1.79 (0.32,9.60)	1.36 (0.59,3.90)	0.14 (-0.27,0.49)
HD ADA SC + MTX		1.51 (0.24,9.19)	1.25 (0.45,3.67)	0.10 (-0.33,0.48)
HD TOCI IV + DMARD		0.88 (0.08,9.11)	0.93 (0.17,3.28)	-0.03 (-0.48,0.48)
SD ANA SC + SD ETN SC + MTX		0.89 (0.12,6.25)	0.94 (0.28,3.11)	-0.02 (-0.45,0.40)
SD ANA SC + LD ETN SC + MTX		1.34 (0.19,9.17)	1.18 (0.39,3.69)	0.07 (-0.38,0.48)
SD ETN SC + MTX	SD CERTO SC	1.44 (0.35,6.09)	1.23 (0.58,3.08)	0.09 (-0.25,0.39)
SD ABA IV + MTX		1.03 (0.24,4.46)	1.02 (0.44,2.67)	0.01 (-0.33,0.33)
SD CERTO SC + MTX		1.53 (0.35,6.74)	1.27 (0.59,3.20)	0.10 (-0.25,0.42)
SD INF IV + MTX		0.89 (0.20,3.86)	0.93 (0.39,2.47)	-0.03 (-0.37,0.29)
SD ADA SC + MTX		1.93 (0.39,9.53)	1.41 (0.62,3.56)	0.16 (-0.22,0.50)
SD TOFA PO + MTX		1.79 (0.36,8.51)	1.36 (0.60,3.41)	0.14 (-0.24,0.47)
SD GOLI SC + MTX		1.83 (0.40,8.16)	1.38 (0.62,3.47)	0.14 (-0.22,0.46)
SD RITUX IV + MTX		0.94 (0.20,4.53)	0.97 (0.37,2.62)	-0.01 (-0.37,0.33)
SD GOLI IV + MTX		0.64 (0.14,3.00)	0.75 (0.29,2.11)	-0.09 (-0.43,0.23)
SD ANA SC + MTX		0.77 (0.16,3.87)	0.85 (0.31,2.42)	-0.06 (-0.40,0.29)

(Continued)

SD ABA SC + MTX	1.10 (0.20,6.15)	1.06 (0.37,2.97)	0.02 (-0.35,0.41)
SD TOCI IV + MTX	0.56 (0.11,2.83)	0.68 (0.23,2.06)	-0.12 (-0.45,0.22)
SD CERTO SC + DMARD	0.86 (0.14,5.67)	0.91 (0.27,2.78)	-0.03 (-0.41,0.39)
SD ADA SC + DMARD	0.76 (0.07,8.49)	0.84 (0.14,2.99)	-0.06 (-0.48,0.47)
SD TOCI SC + DMARD	1.22 (0.11,13.82)	1.12 (0.21,3.48)	0.05 (-0.41,0.55)
LD ADA SC	0.34 (0.08,1.43)	0.46 (0.19,1.31)	-0.20 (-0.51,0.06)
LD ETN SC	0.44 (0.08,2.08)	0.56 (0.18,1.68)	-0.16 (-0.50,0.14)
LD GOL I IV	0.30 (0.05,1.55)	0.42 (0.12,1.38)	-0.22 (-0.54,0.08)
LD TOCI IV	0.05 (0.01,0.35)	0.09 (0.01,0.42)	-0.35 (-0.64,-0.11)
LD ADA SC + MTX	1.05 (0.20,5.69)	1.03 (0.37,2.84)	0.01 (-0.37,0.39)
LD RITUX IV + MTX	0.93 (0.19,4.42)	0.95 (0.37,2.61)	-0.02 (-0.37,0.32)
LD ADA IV + MTX	0.94 (0.10,8.31)	0.97 (0.19,3.04)	-0.01 (-0.44,0.47)
LD ABA IV + MTX	0.56 (0.12,2.65)	0.68 (0.25,1.99)	-0.12 (-0.45,0.20)
LD ANA SC + MTX	0.52 (0.07,3.42)	0.64 (0.14,2.16)	-0.13 (-0.49,0.27)
LD CERTO SC + MTX	1.09 (0.21,5.81)	1.05 (0.40,2.90)	0.02 (-0.35,0.39)
LD GOL I IV + MTX	0.58 (0.11,3.15)	0.70 (0.23,2.15)	-0.12 (-0.46,0.24)
LD TOCI IV + MTX	0.48 (0.09,2.36)	0.61 (0.20,1.82)	-0.15 (-0.49,0.18)
LD TOFA PO + MTX	0.80 (0.13,4.89)	0.87 (0.25,2.65)	-0.05 (-0.43,0.35)
HD TOCI IV	0.74 (0.19,3.03)	0.83 (0.38,2.18)	-0.07 (-0.39,0.22)
HD TOFA PO	1.07 (0.28,4.04)	1.04 (0.50,2.55)	0.02 (-0.31,0.30)
HD ADA SC	0.49 (0.12,2.01)	0.61 (0.26,1.69)	-0.15 (-0.46,0.13)
HD GOL I SC	0.82 (0.19,3.48)	0.88 (0.37,2.37)	-0.05 (-0.38,0.26)
HD ETN SC	0.76 (0.11,5.00)	0.85 (0.21,2.60)	-0.06 (-0.44,0.36)
HD ABA SC	1.44 (0.25,9.00)	1.22 (0.44,3.30)	0.09 (-0.32,0.48)
HD TOCI IV + MTX	1.30 (0.30,5.51)	1.16 (0.54,2.94)	0.06 (-0.28,0.37)
HD INF IV + MTX	1.18 (0.26,5.48)	1.10 (0.47,2.90)	0.04 (-0.31,0.38)
HD TOFA PO + MTX	1.02 (0.20,4.79)	1.01 (0.39,2.71)	0.00 (-0.36,0.34)
HD GOL I SC + MTX	1.40 (0.30,6.39)	1.21 (0.53,3.13)	0.08 (-0.28,0.41)

(Continued)

HD CERTO SC + MTX		1.82 (0.40,8.22)	1.37 (0.64,3.42)	0.14 (-0.21,0.47)
HD ADA SC + MTX		1.55 (0.27,8.61)	1.27 (0.47,3.34)	0.10 (-0.30,0.48)
HD TOCI IV + DMARD		0.89 (0.09,9.32)	0.93 (0.17,3.13)	-0.03 (-0.45,0.49)
SD ANA SC + SD ETN SC + MTX		0.91 (0.15,5.45)	0.95 (0.30,2.76)	-0.02 (-0.40,0.38)
SD ANA SC + LD ETN SC + MTX		1.35 (0.23,8.14)	1.19 (0.42,3.20)	0.07 (-0.33,0.46)
SD ABA IV + MTX	SD ETN SC + MTX	0.72 (0.29,1.63)	0.84 (0.48,1.32)	-0.08 (-0.29,0.12)
SD CERTO SC + MTX		1.08 (0.44,2.50)	1.04 (0.64,1.62)	0.02 (-0.20,0.22)
SD INF IV + MTX		0.62 (0.24,1.44)	0.76 (0.43,1.23)	-0.11 (-0.32,0.09)
SD ADA SC + MTX		1.35 (0.45,3.90)	1.15 (0.65,1.89)	0.07 (-0.19,0.31)
SD TOFA PO + MTX		1.26 (0.44,3.27)	1.12 (0.64,1.79)	0.05 (-0.20,0.28)
SD GOL I SC + MTX		1.27 (0.46,3.32)	1.12 (0.67,1.79)	0.06 (-0.19,0.29)
SD RITUX IV + MTX		0.66 (0.23,1.80)	0.79 (0.40,1.38)	-0.10 (-0.33,0.14)
SD GOL I IV + MTX		0.46 (0.15,1.19)	0.62 (0.29,1.11)	-0.18 (-0.40,0.04)
SD ANA SC + MTX		0.54 (0.17,1.61)	0.70 (0.32,1.30)	-0.14 (-0.38,0.11)
SD ABA SC + MTX		0.78 (0.22,2.46)	0.87 (0.39,1.55)	-0.06 (-0.33,0.21)
SD TOCI IV + MTX		0.39 (0.11,1.31)	0.56 (0.23,1.17)	-0.21 (-0.44,0.06)
SD CERTO SC + DMARD		0.60 (0.12,3.11)	0.74 (0.25,1.75)	-0.12 (-0.43,0.27)
SD ADA SC + DMARD		0.52 (0.06,4.99)	0.67 (0.12,1.95)	-0.15 (-0.50,0.36)
SD TOCI SC + DMARD		0.86 (0.09,7.91)	0.92 (0.18,2.18)	-0.04 (-0.45,0.43)
LD ADA SC		0.24 (0.08,0.74)	0.38 (0.18,0.82)	-0.29 (-0.52,-0.06)
LD ETN SC		0.30 (0.09,0.95)	0.45 (0.18,0.97)	-0.25 (-0.47,-0.01)
LD GOL I IV		0.21 (0.06,0.67)	0.34 (0.12,0.78)	-0.30 (-0.52,-0.09)
LD TOCI IV		0.04 (0.01,0.17)	0.07 (0.01,0.27)	-0.43 (-0.63,-0.25)
LD ADA SC + MTX		0.74 (0.21,2.46)	0.84 (0.38,1.57)	-0.07 (-0.34,0.21)
LD RITUX IV + MTX		0.65 (0.23,1.80)	0.78 (0.39,1.37)	-0.10 (-0.34,0.14)
LD ADA IV + MTX		0.65 (0.09,4.15)	0.78 (0.17,1.82)	-0.10 (-0.44,0.32)
LD ABA IV + MTX		0.39 (0.14,1.05)	0.55 (0.26,1.03)	-0.21 (-0.41,0.01)

(Continued)

LD ANA SC + MTX		0.36 (0.07,1.78)	0.52 (0.13,1.34)	-0.22 (-0.49,0.14)
LD CERTO SC + MTX		0.76 (0.23,2.42)	0.86 (0.40,1.55)	-0.07 (-0.32,0.21)
LD GOLI IV + MTX		0.41 (0.12,1.24)	0.57 (0.23,1.13)	-0.20 (-0.43,0.05)
LD TOCI IV + MTX		0.33 (0.09,1.08)	0.49 (0.19,1.05)	-0.24 (-0.47,0.02)
LD TOFA PO + MTX		0.55 (0.13,2.27)	0.71 (0.24,1.50)	-0.14 (-0.41,0.20)
HD TOCI IV		0.52 (0.22,1.20)	0.68 (0.40,1.12)	-0.15 (-0.35,0.04)
HD TOFA PO		0.75 (0.26,2.11)	0.85 (0.48,1.55)	-0.07 (-0.32,0.18)
HD ADA SC		0.34 (0.11,1.07)	0.50 (0.24,1.04)	-0.24 (-0.47,0.01)
HD GOLI SC		0.57 (0.20,1.49)	0.72 (0.38,1.27)	-0.13 (-0.36,0.10)
HD ETN SC		0.52 (0.12,2.08)	0.68 (0.22,1.43)	-0.15 (-0.41,0.18)
HD ABA SC		1.01 (0.21,5.24)	1.01 (0.39,2.09)	0.00 (-0.35,0.37)
HD TOCI IV + MTX		0.91 (0.36,2.18)	0.95 (0.57,1.53)	-0.02 (-0.24,0.19)
HD INF IV + MTX		0.83 (0.30,2.14)	0.91 (0.50,1.50)	-0.04 (-0.28,0.18)
HD TOFA PO + MTX		0.71 (0.25,1.87)	0.83 (0.42,1.41)	-0.08 (-0.31,0.15)
HD GOLI SC + MTX		0.97 (0.35,2.58)	0.99 (0.55,1.63)	-0.01 (-0.25,0.23)
HD CERTO SC + MTX		1.28 (0.49,3.17)	1.13 (0.69,1.77)	0.06 (-0.17,0.27)
HD ADA SC + MTX		1.07 (0.30,3.72)	1.03 (0.48,1.81)	0.02 (-0.28,0.30)
HD TOCI IV + DMARD		0.62 (0.08,5.30)	0.76 (0.16,1.99)	-0.11 (-0.47,0.37)
SD ANA SC + SD ETN SC + MTX		0.63 (0.23,1.77)	0.77 (0.35,1.30)	-0.11 (-0.31,0.14)
SD ANA SC + LD ETN SC + MTX		0.93 (0.35,2.55)	0.96 (0.49,1.49)	-0.02 (-0.24,0.21)
SD CERTO SC + MTX	SD ABA IV + MTX	1.48 (0.77,2.87)	1.24 (0.87,1.84)	0.09 (-0.06,0.25)
SD INF IV + MTX		0.85 (0.46,1.58)	0.91 (0.61,1.33)	-0.04 (-0.18,0.10)
SD ADA SC + MTX		1.87 (0.76,4.62)	1.37 (0.85,2.22)	0.15 (-0.07,0.36)
SD TOFA PO + MTX		1.73 (0.74,3.98)	1.33 (0.84,2.08)	0.13 (-0.07,0.32)
SD GOLI SC + MTX		1.75 (0.77,4.07)	1.34 (0.87,2.17)	0.13 (-0.06,0.33)
SD RITUX IV + MTX		0.91 (0.39,2.12)	0.95 (0.54,1.55)	-0.02 (-0.20,0.18)
SD GOLI IV + MTX		0.62 (0.28,1.41)	0.74 (0.41,1.24)	-0.10 (-0.27,0.08)

(Continued)

SD ANA SC + MTX	0.75 (0.29,1.92)	0.83 (0.42,1.47)	-0.06 (-0.26,0.15)
SD ABA SC + MTX	1.07 (0.47,2.38)	1.04 (0.60,1.58)	0.02 (-0.16,0.20)
SD TOCI IV + MTX	0.54 (0.19,1.59)	0.67 (0.29,1.33)	-0.13 (-0.34,0.11)
SD CERTO SC + DMARD	0.84 (0.17,4.57)	0.90 (0.29,2.25)	-0.04 (-0.36,0.36)
SD ADA SC + DMARD	0.72 (0.08,7.90)	0.81 (0.14,2.56)	-0.07 (-0.43,0.46)
SD TOCI SC + DMARD	1.18 (0.12,11.75)	1.10 (0.21,2.85)	0.04 (-0.38,0.52)
LD ADA SC	0.33 (0.11,1.00)	0.45 (0.21,1.00)	-0.21 (-0.43,0.00)
LD ETN SC	0.42 (0.11,1.47)	0.55 (0.20,1.30)	-0.17 (-0.41,0.08)
LD GOL I IV	0.29 (0.09,0.82)	0.41 (0.16,0.88)	-0.23 (-0.41,-0.04)
LD TOCI IV	0.05 (0.01,0.22)	0.08 (0.02,0.31)	-0.35 (-0.55,-0.18)
LD ADA SC + MTX	1.02 (0.35,3.10)	1.01 (0.49,1.84)	0.00 (-0.22,0.26)
LD RITUX IV + MTX	0.90 (0.39,2.11)	0.94 (0.54,1.54)	-0.02 (-0.21,0.18)
LD ADA IV + MTX	0.90 (0.14,5.40)	0.94 (0.22,2.18)	-0.02 (-0.34,0.38)
LD ABA IV + MTX	0.54 (0.28,1.04)	0.67 (0.40,1.02)	-0.13 (-0.26,0.01)
LD ANA SC + MTX	0.50 (0.11,2.13)	0.63 (0.18,1.53)	-0.14 (-0.37,0.18)
LD CERTO SC + MTX	1.06 (0.40,2.92)	1.03 (0.54,1.80)	0.01 (-0.20,0.25)
LD GOL I IV + MTX	0.56 (0.19,1.54)	0.68 (0.30,1.30)	-0.12 (-0.32,0.10)
LD TOCI IV + MTX	0.46 (0.16,1.33)	0.59 (0.26,1.20)	-0.16 (-0.36,0.06)
LD TOFA PO + MTX	0.77 (0.21,2.79)	0.85 (0.32,1.73)	-0.06 (-0.30,0.24)
HD TOCI IV	0.72 (0.36,1.49)	0.81 (0.53,1.31)	-0.07 (-0.24,0.08)
HD TOFA PO	1.03 (0.37,3.13)	1.02 (0.56,2.06)	0.01 (-0.24,0.26)
HD ADA SC	0.47 (0.16,1.49)	0.60 (0.29,1.32)	-0.16 (-0.38,0.08)
HD GOL I SC	0.79 (0.33,1.92)	0.86 (0.49,1.51)	-0.05 (-0.25,0.14)
HD ETN SC	0.73 (0.15,3.56)	0.82 (0.25,1.99)	-0.07 (-0.35,0.30)
HD ABA SC	1.41 (0.28,7.27)	1.21 (0.45,2.68)	0.08 (-0.28,0.45)
HD TOCI IV + MTX	1.26 (0.62,2.64)	1.14 (0.76,1.78)	0.05 (-0.12,0.23)
HD INF IV + MTX	1.15 (0.53,2.49)	1.08 (0.67,1.68)	0.03 (-0.14,0.21)
HD TOFA PO + MTX	0.98 (0.42,2.28)	0.99 (0.57,1.61)	0.00 (-0.20,0.20)



(Continued)

HD GOLI SC + MTX		1.35 (0.59,3.12)	1.18 (0.73,1.92)	0.07 (-0.12,0.27)
HD CERTO SC + MTX		1.77 (0.87,3.66)	1.34 (0.92,2.05)	0.14 (-0.03,0.30)
HD ADA SC + MTX		1.48 (0.47,4.65)	1.24 (0.62,2.18)	0.09 (-0.16,0.35)
HD TOCI IV + DMARD		0.86 (0.10,8.16)	0.91 (0.18,2.62)	-0.04 (-0.40,0.46)
SD ANA SC + SD ETN SC + MTX		0.88 (0.24,3.53)	0.92 (0.37,1.97)	-0.03 (-0.29,0.29)
SD ANA SC + LD ETN SC + MTX		1.30 (0.36,4.98)	1.15 (0.50,2.24)	0.06 (-0.22,0.37)
SD INF IV + MTX	SD CERTO SC + MTX	0.58 (0.29,1.14)	0.73 (0.47,1.07)	-0.13 (-0.29,0.03)
SD ADA SC + MTX		1.26 (0.51,3.23)	1.11 (0.70,1.71)	0.05 (-0.16,0.27)
SD TOFA PO + MTX		1.17 (0.49,2.73)	1.08 (0.69,1.62)	0.04 (-0.17,0.24)
SD GOLI SC + MTX		1.19 (0.52,2.71)	1.08 (0.71,1.62)	0.04 (-0.15,0.24)
SD RITUX IV + MTX		0.62 (0.26,1.44)	0.76 (0.43,1.21)	-0.11 (-0.30,0.09)
SD GOLI IV + MTX		0.42 (0.19,0.95)	0.60 (0.33,0.97)	-0.19 (-0.37,-0.01)
SD ANA SC + MTX		0.50 (0.20,1.32)	0.67 (0.35,1.15)	-0.16 (-0.35,0.07)
SD ABA SC + MTX		0.72 (0.25,2.00)	0.84 (0.41,1.39)	-0.08 (-0.31,0.17)
SD TOCI IV + MTX		0.37 (0.12,1.09)	0.54 (0.23,1.05)	-0.22 (-0.43,0.02)
SD CERTO SC + DMARD		0.56 (0.11,3.11)	0.72 (0.24,1.74)	-0.14 (-0.46,0.27)
SD ADA SC + DMARD		0.49 (0.05,5.17)	0.66 (0.12,1.93)	-0.16 (-0.52,0.36)
SD TOCI SC + DMARD		0.80 (0.08,7.86)	0.89 (0.17,2.15)	-0.05 (-0.48,0.43)
LD ADA SC		0.22 (0.07,0.68)	0.37 (0.17,0.77)	-0.31 (-0.53,-0.08)
LD ETN SC		0.28 (0.08,1.00)	0.44 (0.17,1.00)	-0.27 (-0.51,0.00)
LD GOLI IV		0.20 (0.06,0.56)	0.33 (0.13,0.70)	-0.32 (-0.51,-0.13)
LD TOCI IV		0.03 (0.01,0.14)	0.07 (0.01,0.24)	-0.45 (-0.64,-0.27)
LD ADA SC + MTX		0.68 (0.24,2.10)	0.82 (0.40,1.42)	-0.09 (-0.32,0.18)
LD RITUX IV + MTX		0.60 (0.26,1.43)	0.76 (0.43,1.21)	-0.12 (-0.30,0.09)
LD ADA IV + MTX		0.60 (0.09,3.69)	0.76 (0.17,1.69)	-0.12 (-0.44,0.29)
LD ABA IV + MTX		0.36 (0.16,0.83)	0.53 (0.29,0.90)	-0.22 (-0.39,-0.04)
LD ANA SC + MTX		0.34 (0.07,1.47)	0.51 (0.14,1.21)	-0.23 (-0.48,0.09)

(Continued)

LD CERTO SC + MTX		0.71 (0.30,1.75)	0.83 (0.46,1.30)	-0.08 (-0.27,0.13)
LD GOLI IV + MTX		0.38 (0.13,1.04)	0.55 (0.24,1.02)	-0.22 (-0.42,0.01)
LD TOCI IV + MTX		0.31 (0.10,0.89)	0.47 (0.20,0.94)	-0.25 (-0.46,-0.03)
LD TOFA PO + MTX		0.52 (0.14,1.87)	0.68 (0.26,1.34)	-0.15 (-0.40,0.15)
HD TOCI IV		0.49 (0.25,0.99)	0.66 (0.43,0.99)	-0.17 (-0.33,0.00)
HD TOFA PO		0.70 (0.24,2.03)	0.82 (0.47,1.52)	-0.09 (-0.33,0.17)
HD ADA SC		0.32 (0.11,0.98)	0.48 (0.24,0.99)	-0.25 (-0.48,0.00)
HD GOLI SC		0.53 (0.22,1.29)	0.70 (0.40,1.15)	-0.15 (-0.34,0.06)
HD ETN SC		0.50 (0.10,2.34)	0.67 (0.20,1.52)	-0.16 (-0.46,0.20)
HD ABA SC		0.94 (0.20,5.03)	0.97 (0.38,2.04)	-0.01 (-0.37,0.36)
HD TOCI IV + MTX		0.85 (0.42,1.78)	0.92 (0.62,1.37)	-0.04 (-0.21,0.14)
HD INF IV + MTX		0.78 (0.35,1.72)	0.88 (0.54,1.32)	-0.06 (-0.24,0.13)
HD TOFA PO + MTX		0.66 (0.28,1.53)	0.80 (0.46,1.25)	-0.10 (-0.29,0.10)
HD GOLI SC + MTX		0.91 (0.40,2.14)	0.95 (0.60,1.46)	-0.02 (-0.22,0.18)
HD CERTO SC + MTX		1.19 (0.73,1.95)	1.09 (0.85,1.39)	0.04 (-0.08,0.16)
HD ADA SC + MTX		0.99 (0.33,3.20)	1.00 (0.51,1.66)	0.00 (-0.25,0.27)
HD TOCI IV + DMARD		0.58 (0.07,5.40)	0.74 (0.15,2.00)	-0.13 (-0.50,0.38)
SD ANA SC + SD ETN SC + MTX		0.59 (0.16,2.30)	0.75 (0.30,1.49)	-0.12 (-0.39,0.20)
SD ANA SC + LD ETN SC + MTX		0.88 (0.24,3.37)	0.93 (0.41,1.72)	-0.03 (-0.32,0.28)
SD ADA SC + MTX	SD INF IV + MTX	2.18 (0.86,5.75)	1.51 (0.92,2.57)	0.18 (-0.04,0.40)
SD TOFA PO + MTX		2.03 (0.85,4.87)	1.46 (0.91,2.42)	0.17 (-0.04,0.37)
SD GOLI SC + MTX		2.06 (0.89,4.80)	1.48 (0.94,2.44)	0.17 (-0.03,0.36)
SD RITUX IV + MTX		1.06 (0.45,2.52)	1.04 (0.59,1.76)	0.01 (-0.17,0.21)
SD GOLI IV + MTX		0.73 (0.31,1.69)	0.81 (0.44,1.41)	-0.07 (-0.24,0.11)
SD ANA SC + MTX		0.87 (0.34,2.30)	0.91 (0.47,1.67)	-0.03 (-0.22,0.19)
SD ABA SC + MTX		1.25 (0.44,3.44)	1.14 (0.57,2.02)	0.05 (-0.17,0.29)
SD TOCI IV + MTX		0.63 (0.22,1.93)	0.73 (0.32,1.52)	-0.09 (-0.30,0.15)

(Continued)

SD CERTO SC + DMARD	0.97 (0.20,5.33)	0.98 (0.32,2.58)	-0.01 (-0.32,0.39)
SD ADA SC + DMARD	0.84 (0.10,8.93)	0.90 (0.16,2.89)	-0.04 (-0.39,0.48)
SD TOCI SC + DMARD	1.37 (0.15,14.07)	1.20 (0.23,3.21)	0.07 (-0.34,0.55)
LD ADA SC	0.39 (0.13,1.20)	0.50 (0.22,1.15)	-0.17 (-0.40,0.03)
LD ETN SC	0.48 (0.13,1.78)	0.60 (0.22,1.48)	-0.14 (-0.38,0.12)
LD GOLIV	0.34 (0.11,0.99)	0.45 (0.17,0.99)	-0.19 (-0.38,0.00)
LD TOCI IV	0.06 (0.01,0.25)	0.09 (0.02,0.34)	-0.32 (-0.51,-0.16)
LD ADA SC + MTX	1.18 (0.40,3.77)	1.10 (0.53,2.12)	0.04 (-0.19,0.31)
LD RITUX IV + MTX	1.05 (0.45,2.50)	1.03 (0.58,1.74)	0.01 (-0.17,0.21)
LD ADA IV + MTX	1.04 (0.17,6.64)	1.03 (0.24,2.47)	0.01 (-0.30,0.43)
LD ABA IV + MTX	0.63 (0.28,1.45)	0.73 (0.40,1.27)	-0.09 (-0.26,0.08)
LD ANA SC + MTX	0.59 (0.13,2.58)	0.70 (0.19,1.72)	-0.10 (-0.34,0.22)
LD CERTO SC + MTX	1.24 (0.45,3.54)	1.13 (0.58,2.06)	0.05 (-0.17,0.29)
LD GOLIV + MTX	0.66 (0.23,1.87)	0.75 (0.34,1.49)	-0.09 (-0.29,0.14)
LD TOCI IV + MTX	0.54 (0.18,1.62)	0.65 (0.28,1.36)	-0.12 (-0.32,0.10)
LD TOFA PO + MTX	0.90 (0.24,3.31)	0.94 (0.35,1.96)	-0.02 (-0.27,0.28)
HD TOCI IV	0.85 (0.41,1.80)	0.90 (0.57,1.51)	-0.04 (-0.21,0.12)
HD TOFA PO	1.20 (0.41,3.71)	1.12 (0.60,2.35)	0.04 (-0.21,0.29)
HD ADA SC	0.55 (0.18,1.77)	0.66 (0.31,1.51)	-0.12 (-0.36,0.12)
HD GOLIV SC	0.93 (0.38,2.26)	0.96 (0.53,1.70)	-0.02 (-0.22,0.18)
HD ETN SC	0.86 (0.18,4.11)	0.90 (0.27,2.21)	-0.03 (-0.32,0.33)
HD ABA SC	1.66 (0.34,8.63)	1.33 (0.50,3.05)	0.12 (-0.24,0.48)
HD TOCI IV + MTX	1.47 (0.70,3.18)	1.25 (0.81,2.06)	0.09 (-0.08,0.27)
HD INF IV + MTX	1.34 (0.72,2.58)	1.19 (0.81,1.76)	0.07 (-0.07,0.22)
HD TOFA PO + MTX	1.14 (0.49,2.74)	1.09 (0.63,1.85)	0.03 (-0.16,0.23)
HD GOLIV SC + MTX	1.58 (0.68,3.68)	1.30 (0.79,2.17)	0.11 (-0.09,0.30)
HD CERTO SC + MTX	2.07 (0.98,4.36)	1.48 (0.99,2.34)	0.17 (0.00,0.34)
HD ADA SC + MTX	1.72 (0.56,5.49)	1.36 (0.68,2.48)	0.13 (-0.13,0.39)

(Continued)

HD TOCI IV + DMARD		1.00 (0.12,9.28)	1.00 (0.20,2.94)	0.00 (-0.37,0.49)
SD ANA SC + SD ETN SC + MTX		1.03 (0.28,4.10)	1.02 (0.40,2.22)	0.01 (-0.26,0.33)
SD ANA SC + LD ETN SC + MTX		1.51 (0.41,5.90)	1.27 (0.55,2.56)	0.10 (-0.19,0.41)
SD TOFA PO + MTX	SD ADA SC + MTX	0.93 (0.32,2.60)	0.97 (0.58,1.61)	-0.02 (-0.26,0.23)
SD GOL I SC + MTX		0.94 (0.33,2.66)	0.97 (0.60,1.63)	-0.01 (-0.26,0.23)
SD RITUX IV + MTX		0.49 (0.16,1.39)	0.69 (0.36,1.20)	-0.17 (-0.41,0.08)
SD GOL I IV + MTX		0.33 (0.11,0.94)	0.54 (0.28,0.96)	-0.25 (-0.48,-0.02)
SD ANA SC + MTX		0.40 (0.13,1.26)	0.61 (0.29,1.13)	-0.21 (-0.45,0.05)
SD ABA SC + MTX		0.57 (0.17,1.94)	0.76 (0.35,1.38)	-0.13 (-0.40,0.16)
SD TOCI IV + MTX		0.29 (0.08,1.00)	0.49 (0.20,1.00)	-0.27 (-0.53,0.00)
SD CERTO SC + DMARD		0.45 (0.08,2.71)	0.65 (0.22,1.63)	-0.19 (-0.54,0.23)
SD ADA SC + DMARD		0.39 (0.04,4.54)	0.59 (0.10,1.81)	-0.22 (-0.61,0.33)
SD TOCI SC + DMARD		0.63 (0.06,6.86)	0.80 (0.15,2.04)	-0.11 (-0.57,0.40)
LD ADA SC		0.18 (0.05,0.62)	0.33 (0.15,0.72)	-0.36 (-0.61,-0.10)
LD ETN SC		0.22 (0.05,0.91)	0.40 (0.15,0.94)	-0.32 (-0.60,-0.02)
LD GOL I IV		0.15 (0.04,0.52)	0.30 (0.11,0.67)	-0.38 (-0.61,-0.13)
LD TOCI IV		0.03 (0.00,0.13)	0.06 (0.01,0.23)	-0.51 (-0.73,-0.27)
LD ADA SC + MTX		0.54 (0.21,1.44)	0.74 (0.39,1.19)	-0.14 (-0.35,0.09)
LD RITUX IV + MTX		0.48 (0.16,1.38)	0.68 (0.35,1.19)	-0.17 (-0.42,0.08)
LD ADA IV + MTX		0.48 (0.07,3.13)	0.69 (0.16,1.58)	-0.17 (-0.51,0.26)
LD ABA IV + MTX		0.29 (0.10,0.81)	0.48 (0.24,0.89)	-0.28 (-0.50,-0.05)
LD ANA SC + MTX		0.27 (0.05,1.29)	0.46 (0.12,1.14)	-0.28 (-0.57,0.06)
LD CERTO SC + MTX		0.57 (0.17,1.85)	0.75 (0.37,1.36)	-0.13 (-0.40,0.14)
LD GOL I IV + MTX		0.30 (0.09,0.98)	0.50 (0.21,0.99)	-0.27 (-0.51,-0.01)
LD TOCI IV + MTX		0.25 (0.07,0.83)	0.43 (0.18,0.90)	-0.30 (-0.55,-0.04)
LD TOFA PO + MTX		0.41 (0.09,1.73)	0.62 (0.22,1.30)	-0.20 (-0.50,0.13)
HD TOCI IV		0.39 (0.15,0.98)	0.59 (0.37,0.99)	-0.22 (-0.44,-0.01)

(Continued)

HD TOFA PO		0.55 (0.16,1.84)	0.74 (0.42,1.44)	-0.14 (-0.42,0.14)
HD ADA SC		0.26 (0.07,0.90)	0.44 (0.21,0.94)	-0.30 (-0.56,-0.02)
HD GOL I SC		0.42 (0.14,1.25)	0.63 (0.34,1.14)	-0.20 (-0.44,0.05)
HD ETN SC		0.39 (0.07,2.09)	0.60 (0.18,1.44)	-0.21 (-0.54,0.18)
HD ABA SC		0.75 (0.14,4.22)	0.87 (0.34,1.90)	-0.07 (-0.44,0.33)
HD TOCI IV + MTX		0.67 (0.25,1.75)	0.83 (0.52,1.36)	-0.10 (-0.32,0.13)
HD INF IV + MTX		0.62 (0.22,1.72)	0.79 (0.45,1.33)	-0.12 (-0.35,0.13)
HD TOFA PO + MTX		0.53 (0.18,1.46)	0.72 (0.39,1.24)	-0.15 (-0.39,0.09)
HD GOL I SC + MTX		0.72 (0.25,2.04)	0.86 (0.50,1.44)	-0.08 (-0.32,0.17)
HD CERTO SC + MTX		0.94 (0.36,2.41)	0.97 (0.63,1.58)	-0.01 (-0.24,0.21)
HD ADA SC + MTX		0.79 (0.30,2.09)	0.90 (0.50,1.38)	-0.05 (-0.28,0.17)
HD TOCI IV + DMARD		0.47 (0.05,4.71)	0.67 (0.13,1.86)	-0.18 (-0.58,0.34)
SD ANA SC + SD ETN SC + MTX		0.47 (0.11,2.11)	0.67 (0.26,1.44)	-0.18 (-0.48,0.18)
SD ANA SC + LD ETN SC + MTX		0.69 (0.16,3.13)	0.84 (0.36,1.67)	-0.09 (-0.41,0.26)
SD GOL I SC + MTX	SD TOFA PO + MTX	1.02 (0.39,2.62)	1.01 (0.64,1.63)	0.00 (-0.22,0.23)
SD RITUX IV + MTX		0.53 (0.19,1.44)	0.71 (0.38,1.21)	-0.15 (-0.38,0.09)
SD GOL I IV + MTX		0.36 (0.14,0.97)	0.56 (0.29,0.98)	-0.23 (-0.44,-0.01)
SD ANA SC + MTX		0.43 (0.15,1.31)	0.62 (0.31,1.16)	-0.20 (-0.42,0.06)
SD ABA SC + MTX		0.62 (0.19,2.01)	0.78 (0.37,1.41)	-0.11 (-0.37,0.17)
SD TOCI IV + MTX		0.31 (0.09,1.05)	0.50 (0.21,1.03)	-0.26 (-0.49,0.01)
SD CERTO SC + DMARD		0.48 (0.09,2.99)	0.67 (0.22,1.70)	-0.17 (-0.51,0.26)
SD ADA SC + DMARD		0.41 (0.04,4.67)	0.60 (0.10,1.92)	-0.21 (-0.58,0.34)
SD TOCI SC + DMARD		0.68 (0.07,7.40)	0.82 (0.16,2.18)	-0.09 (-0.53,0.42)
LD ADA SC		0.19 (0.06,0.67)	0.34 (0.16,0.76)	-0.35 (-0.58,-0.08)
LD ETN SC		0.24 (0.06,0.99)	0.41 (0.15,1.00)	-0.31 (-0.56,0.00)
LD GOL I IV		0.17 (0.05,0.54)	0.31 (0.11,0.69)	-0.36 (-0.58,-0.12)
LD TOCI IV		0.03 (0.00,0.14)	0.06 (0.01,0.24)	-0.49 (-0.70,-0.26)

(Continued)

LD ADA SC + MTX		0.59 (0.18,2.01)	0.76 (0.36,1.39)	-0.13 (-0.38,0.16)
LD RITUX IV + MTX		0.52 (0.19,1.41)	0.71 (0.38,1.20)	-0.15 (-0.38,0.08)
LD ADA IV + MTX		0.53 (0.08,3.36)	0.71 (0.16,1.66)	-0.15 (-0.49,0.27)
LD ABA IV + MTX		0.31 (0.12,0.83)	0.50 (0.26,0.90)	-0.26 (-0.47,-0.04)
LD ANA SC + MTX		0.29 (0.06,1.38)	0.47 (0.13,1.18)	-0.27 (-0.54,0.08)
LD CERTO SC + MTX		0.61 (0.20,1.91)	0.78 (0.38,1.39)	-0.12 (-0.37,0.15)
LD GOLIV IV + MTX		0.32 (0.10,1.01)	0.51 (0.22,1.00)	-0.25 (-0.48,0.00)
LD TOCI IV + MTX		0.26 (0.08,0.90)	0.44 (0.18,0.94)	-0.29 (-0.52,-0.02)
LD TOFA PO + MTX		0.45 (0.14,1.41)	0.64 (0.26,1.17)	-0.18 (-0.42,0.08)
HD TOCI IV		0.42 (0.18,1.04)	0.61 (0.38,1.02)	-0.21 (-0.40,0.01)
HD TOFA PO		0.60 (0.18,1.99)	0.76 (0.42,1.50)	-0.13 (-0.40,0.16)
HD ADA SC		0.27 (0.08,0.97)	0.45 (0.22,0.98)	-0.29 (-0.54,-0.01)
HD GOLIV SC		0.46 (0.17,1.26)	0.65 (0.36,1.14)	-0.18 (-0.41,0.05)
HD ETN SC		0.42 (0.08,2.30)	0.62 (0.18,1.51)	-0.20 (-0.50,0.20)
HD ABA SC		0.82 (0.16,4.55)	0.91 (0.35,1.97)	-0.05 (-0.42,0.34)
HD TOCI IV + MTX		0.73 (0.30,1.84)	0.85 (0.55,1.41)	-0.08 (-0.28,0.14)
HD INF IV + MTX		0.66 (0.26,1.74)	0.81 (0.48,1.34)	-0.10 (-0.31,0.13)
HD TOFA PO + MTX		0.57 (0.31,1.05)	0.74 (0.50,1.03)	-0.13 (-0.28,0.01)
HD GOLIV SC + MTX		0.78 (0.30,2.06)	0.89 (0.53,1.46)	-0.06 (-0.28,0.17)
HD CERTO SC + MTX		1.02 (0.42,2.56)	1.01 (0.67,1.61)	0.01 (-0.20,0.22)
HD ADA SC + MTX		0.86 (0.24,3.07)	0.93 (0.45,1.67)	-0.04 (-0.32,0.26)
HD TOCI IV + DMARD		0.50 (0.06,4.95)	0.68 (0.14,1.96)	-0.16 (-0.55,0.35)
SD ANA SC + SD ETN SC + MTX		0.51 (0.12,2.21)	0.70 (0.27,1.46)	-0.16 (-0.45,0.19)
SD ANA SC + LD ETN SC + MTX		0.75 (0.19,3.18)	0.87 (0.37,1.70)	-0.07 (-0.38,0.27)
SD RITUX IV + MTX	SD GOLIV SC + MTX	0.52 (0.19,1.41)	0.71 (0.38,1.19)	-0.15 (-0.38,0.08)
SD GOLIV IV + MTX		0.36 (0.14,0.92)	0.55 (0.29,0.95)	-0.23 (-0.44,-0.02)
SD ANA SC + MTX		0.43 (0.15,1.22)	0.62 (0.30,1.11)	-0.20 (-0.42,0.05)

(Continued)

SD ABA SC + MTX	0.61 (0.19,1.90)	0.78 (0.37,1.36)	-0.12 (-0.37,0.15)
SD TOCI IV + MTX	0.31 (0.09,1.02)	0.49 (0.21,1.01)	-0.26 (-0.50,0.00)
SD CERTO SC + DMARD	0.47 (0.09,2.81)	0.66 (0.22,1.66)	-0.18 (-0.50,0.25)
SD ADA SC + DMARD	0.41 (0.04,4.63)	0.60 (0.10,1.87)	-0.21 (-0.57,0.34)
SD TOCI SC + DMARD	0.67 (0.07,6.90)	0.82 (0.16,2.04)	-0.10 (-0.52,0.40)
LD ADA SC	0.19 (0.06,0.64)	0.34 (0.16,0.74)	-0.35 (-0.58,-0.09)
LD ETN SC	0.24 (0.06,0.89)	0.41 (0.15,0.93)	-0.31 (-0.57,-0.03)
LD GOL I IV	0.16 (0.05,0.52)	0.30 (0.11,0.67)	-0.36 (-0.57,-0.14)
LD TOCI IV	0.03 (0.00,0.14)	0.06 (0.01,0.24)	-0.49 (-0.70,-0.27)
LD ADA SC + MTX	0.58 (0.18,1.98)	0.75 (0.35,1.40)	-0.13 (-0.39,0.16)
LD RITUX IV + MTX	0.51 (0.19,1.37)	0.70 (0.37,1.19)	-0.16 (-0.38,0.08)
LD ADA IV + MTX	0.51 (0.07,3.30)	0.70 (0.16,1.65)	-0.15 (-0.50,0.27)
LD ABA IV + MTX	0.31 (0.12,0.80)	0.49 (0.25,0.88)	-0.26 (-0.46,-0.05)
LD ANA SC + MTX	0.28 (0.06,1.32)	0.47 (0.13,1.15)	-0.27 (-0.53,0.07)
LD CERTO SC + MTX	0.61 (0.20,1.83)	0.77 (0.38,1.34)	-0.12 (-0.37,0.14)
LD GOL I IV + MTX	0.32 (0.10,0.97)	0.51 (0.22,0.99)	-0.26 (-0.49,-0.01)
LD TOCI IV + MTX	0.26 (0.08,0.86)	0.44 (0.19,0.92)	-0.29 (-0.52,-0.03)
LD TOFA PO + MTX	0.44 (0.11,1.66)	0.64 (0.23,1.27)	-0.19 (-0.45,0.12)
HD TOCI IV	0.41 (0.18,0.97)	0.61 (0.38,0.98)	-0.21 (-0.40,-0.01)
HD TOFA PO	0.58 (0.19,1.91)	0.75 (0.43,1.46)	-0.13 (-0.39,0.15)
HD ADA SC	0.27 (0.08,0.90)	0.45 (0.22,0.94)	-0.29 (-0.53,-0.02)
HD GOL I SC	0.45 (0.20,1.02)	0.65 (0.39,1.02)	-0.19 (-0.37,0.01)
HD ETN SC	0.41 (0.08,2.13)	0.61 (0.18,1.44)	-0.20 (-0.51,0.18)
HD ABA SC	0.80 (0.16,4.44)	0.90 (0.35,1.94)	-0.05 (-0.42,0.34)
HD TOCI IV + MTX	0.71 (0.30,1.73)	0.85 (0.54,1.35)	-0.08 (-0.28,0.13)
HD INF IV + MTX	0.66 (0.26,1.65)	0.81 (0.47,1.29)	-0.10 (-0.32,0.12)
HD TOFA PO + MTX	0.56 (0.21,1.46)	0.74 (0.41,1.21)	-0.14 (-0.36,0.09)
HD GOL I SC + MTX	0.77 (0.41,1.44)	0.88 (0.62,1.20)	-0.06 (-0.21,0.09)

(Continued)

HD CERTO SC + MTX		1.01 (0.42,2.41)	1.00 (0.66,1.54)	0.00 (-0.21,0.21)
HD ADA SC + MTX		0.84 (0.24,2.97)	0.92 (0.44,1.62)	-0.04 (-0.33,0.25)
HD TOCI IV + DMARD		0.49 (0.05,4.87)	0.68 (0.14,1.91)	-0.17 (-0.55,0.35)
SD ANA SC + SD ETN SC + MTX		0.50 (0.12,2.19)	0.69 (0.26,1.45)	-0.16 (-0.45,0.18)
SD ANA SC + LD ETN SC + MTX		0.74 (0.18,3.07)	0.86 (0.37,1.65)	-0.07 (-0.38,0.26)
SD GOLI IV + MTX	SD RITUX IV + MTX	0.69 (0.25,1.77)	0.79 (0.40,1.48)	-0.08 (-0.30,0.12)
SD ANA SC + MTX		0.82 (0.28,2.52)	0.88 (0.42,1.80)	-0.04 (-0.28,0.20)
SD ABA SC + MTX		1.17 (0.36,3.75)	1.10 (0.51,2.18)	0.04 (-0.22,0.30)
SD TOCI IV + MTX		0.59 (0.18,1.97)	0.71 (0.29,1.56)	-0.11 (-0.35,0.15)
SD CERTO SC + DMARD		0.90 (0.17,5.65)	0.94 (0.30,2.70)	-0.02 (-0.36,0.39)
SD ADA SC + DMARD		0.78 (0.08,9.40)	0.86 (0.15,3.09)	-0.05 (-0.43,0.49)
SD TOCI SC + DMARD		1.27 (0.13,14.09)	1.15 (0.22,3.44)	0.06 (-0.37,0.56)
LD ADA SC		0.36 (0.11,1.28)	0.48 (0.21,1.21)	-0.19 (-0.45,0.04)
LD ETN SC		0.46 (0.11,1.83)	0.58 (0.21,1.50)	-0.15 (-0.43,0.12)
LD GOLI IV		0.32 (0.09,1.04)	0.43 (0.16,1.03)	-0.20 (-0.43,0.01)
LD TOCI IV		0.06 (0.01,0.26)	0.09 (0.02,0.34)	-0.33 (-0.57,-0.14)
LD ADA SC + MTX		1.11 (0.34,3.88)	1.06 (0.49,2.22)	0.02 (-0.24,0.31)
LD RITUX IV + MTX		0.99 (0.51,1.88)	0.99 (0.65,1.51)	0.00 (-0.15,0.14)
LD ADA IV + MTX		1.00 (0.14,6.65)	1.00 (0.23,2.57)	0.00 (-0.35,0.43)
LD ABA IV + MTX		0.59 (0.22,1.57)	0.70 (0.36,1.36)	-0.11 (-0.32,0.10)
LD ANA SC + MTX		0.54 (0.11,2.68)	0.66 (0.18,1.80)	-0.12 (-0.39,0.23)
LD CERTO SC + MTX		1.15 (0.37,3.69)	1.09 (0.53,2.17)	0.03 (-0.22,0.30)
LD GOLI IV + MTX		0.61 (0.19,1.96)	0.72 (0.31,1.55)	-0.10 (-0.34,0.14)
LD TOCI IV + MTX		0.50 (0.15,1.65)	0.62 (0.26,1.41)	-0.14 (-0.37,0.11)
LD TOFA PO + MTX		0.84 (0.21,3.37)	0.90 (0.33,2.03)	-0.04 (-0.31,0.28)
HD TOCI IV		0.79 (0.33,1.93)	0.86 (0.51,1.59)	-0.05 (-0.26,0.13)
HD TOFA PO		1.12 (0.34,3.93)	1.07 (0.54,2.48)	0.03 (-0.25,0.30)



(Continued)

HD ADA SC		0.52 (0.15,1.84)	0.64 (0.29,1.58)	-0.13 (-0.40,0.12)
HD GOLI SC		0.87 (0.31,2.43)	0.91 (0.48,1.82)	-0.03 (-0.26,0.19)
HD ETN SC		0.80 (0.15,4.28)	0.87 (0.26,2.31)	-0.05 (-0.37,0.33)
HD ABA SC		1.53 (0.28,9.04)	1.27 (0.46,3.25)	0.10 (-0.28,0.49)
HD TOCI IV + MTX		1.38 (0.56,3.47)	1.20 (0.73,2.24)	0.07 (-0.14,0.28)
HD INF IV + MTX		1.27 (0.48,3.24)	1.14 (0.64,2.10)	0.05 (-0.17,0.27)
HD TOFA PO + MTX		1.07 (0.39,2.89)	1.04 (0.55,1.96)	0.01 (-0.21,0.24)
HD GOLI SC + MTX		1.48 (0.54,3.96)	1.25 (0.71,2.34)	0.09 (-0.14,0.32)
HD CERTO SC + MTX		1.94 (0.79,4.73)	1.42 (0.89,2.54)	0.16 (-0.06,0.36)
HD ADA SC + MTX		1.62 (0.47,5.96)	1.30 (0.62,2.63)	0.11 (-0.17,0.40)
HD TOCI IV + DMARD		0.92 (0.11,9.66)	0.95 (0.19,3.11)	-0.02 (-0.40,0.49)
SD ANA SC + SD ETN SC + MTX		0.96 (0.23,4.34)	0.97 (0.37,2.35)	-0.01 (-0.31,0.34)
SD ANA SC + LD ETN SC + MTX		1.41 (0.34,6.29)	1.21 (0.51,2.72)	0.08 (-0.23,0.41)
SD ANA SC + MTX	SD GOLI IV + MTX	1.19 (0.42,3.49)	1.13 (0.54,2.32)	0.04 (-0.17,0.27)
SD ABA SC + MTX		1.71 (0.53,5.26)	1.41 (0.65,2.84)	0.12 (-0.13,0.37)
SD TOCI IV + MTX		0.86 (0.27,2.91)	0.90 (0.37,2.08)	-0.03 (-0.25,0.22)
SD CERTO SC + DMARD		1.33 (0.25,7.66)	1.21 (0.36,3.53)	0.06 (-0.26,0.44)
SD ADA SC + DMARD		1.16 (0.12,13.18)	1.11 (0.18,3.92)	0.03 (-0.33,0.56)
SD TOCI SC + DMARD		1.89 (0.19,19.88)	1.48 (0.28,4.42)	0.14 (-0.27,0.62)
LD ADA SC		0.53 (0.16,1.75)	0.62 (0.26,1.55)	-0.11 (-0.34,0.09)
LD ETN SC		0.66 (0.17,2.67)	0.74 (0.26,2.06)	-0.07 (-0.32,0.19)
LD GOLI IV		0.46 (0.17,1.20)	0.55 (0.24,1.14)	-0.12 (-0.30,0.03)
LD TOCI IV		0.08 (0.01,0.38)	0.11 (0.02,0.44)	-0.25 (-0.46,-0.10)
LD ADA SC + MTX		1.62 (0.51,5.62)	1.36 (0.62,2.92)	0.10 (-0.14,0.38)
LD RITUX IV + MTX		1.43 (0.55,3.95)	1.26 (0.66,2.51)	0.07 (-0.13,0.30)
LD ADA IV + MTX		1.44 (0.21,9.33)	1.27 (0.28,3.37)	0.08 (-0.25,0.49)
LD ABA IV + MTX		0.87 (0.33,2.24)	0.90 (0.45,1.79)	-0.03 (-0.22,0.16)

(Continued)

LD ANA SC + MTX		0.80 (0.16,3.82)	0.86 (0.22,2.32)	-0.04 (-0.30,0.30)
LD CERTO SC + MTX		1.68 (0.56,5.33)	1.39 (0.67,2.85)	0.11 (-0.12,0.37)
LD GOLI IV + MTX		0.89 (0.35,2.22)	0.92 (0.45,1.73)	-0.02 (-0.20,0.17)
LD TOCI IV + MTX		0.74 (0.23,2.42)	0.80 (0.32,1.86)	-0.06 (-0.27,0.18)
LD TOFA PO + MTX		1.22 (0.31,4.94)	1.15 (0.41,2.68)	0.04 (-0.21,0.36)
HD TOCI IV		1.15 (0.49,2.78)	1.10 (0.64,2.14)	0.03 (-0.16,0.20)
HD TOFA PO		1.64 (0.53,5.48)	1.38 (0.68,3.27)	0.11 (-0.15,0.35)
HD ADA SC		0.76 (0.23,2.52)	0.82 (0.35,2.04)	-0.05 (-0.30,0.17)
HD GOLI SC		1.26 (0.48,3.39)	1.17 (0.61,2.36)	0.05 (-0.16,0.25)
HD ETN SC		1.17 (0.22,6.09)	1.11 (0.31,3.07)	0.03 (-0.26,0.40)
HD ABA SC		2.26 (0.44,12.43)	1.63 (0.58,4.10)	0.18 (-0.18,0.55)
HD TOCI IV + MTX		1.99 (0.85,4.98)	1.54 (0.91,2.96)	0.15 (-0.04,0.35)
HD INF IV + MTX		1.83 (0.73,4.68)	1.46 (0.82,2.74)	0.13 (-0.07,0.34)
HD TOFA PO + MTX		1.57 (0.57,4.17)	1.34 (0.70,2.57)	0.10 (-0.12,0.31)
HD GOLI SC + MTX		2.16 (0.84,5.68)	1.59 (0.89,3.06)	0.17 (-0.04,0.38)
HD CERTO SC + MTX		2.82 (1.16,6.73)	1.82 (1.09,3.42)	0.24 (0.03,0.42)
HD ADA SC + MTX		2.36 (0.70,8.41)	1.66 (0.79,3.45)	0.19 (-0.08,0.47)
HD TOCI IV + DMARD		1.38 (0.16,13.49)	1.23 (0.23,3.99)	0.07 (-0.30,0.56)
SD ANA SC + SD ETN SC + MTX		1.39 (0.33,6.30)	1.24 (0.45,3.12)	0.07 (-0.21,0.41)
SD ANA SC + LD ETN SC + MTX		2.05 (0.51,8.91)	1.55 (0.63,3.58)	0.16 (-0.14,0.48)
SD ABA SC + MTX	SD ANA SC + MTX	1.43 (0.41,4.94)	1.24 (0.56,2.72)	0.08 (-0.19,0.35)
SD TOCI IV + MTX		0.72 (0.20,2.57)	0.80 (0.31,1.92)	-0.06 (-0.32,0.19)
SD CERTO SC + DMARD		1.11 (0.20,7.12)	1.07 (0.33,3.31)	0.02 (-0.32,0.43)
SD ADA SC + DMARD		0.97 (0.10,10.92)	0.98 (0.16,3.54)	-0.01 (-0.39,0.52)
SD TOCI SC + DMARD		1.57 (0.15,16.87)	1.31 (0.25,4.05)	0.10 (-0.34,0.59)
LD ADA SC		0.45 (0.12,1.63)	0.55 (0.23,1.47)	-0.15 (-0.41,0.08)
LD ETN SC		0.55 (0.13,2.41)	0.66 (0.22,1.90)	-0.11 (-0.39,0.17)

(Continued)

LD GOLI IV		0.39 (0.11,1.34)	0.49 (0.18,1.25)	-0.16 (-0.40,0.05)
LD TOCI IV		0.07 (0.01,0.34)	0.10 (0.02,0.41)	-0.29 (-0.53,-0.11)
LD ADA SC + MTX		1.36 (0.39,4.97)	1.20 (0.54,2.71)	0.07 (-0.20,0.36)
LD RITUX IV + MTX		1.20 (0.40,3.62)	1.12 (0.56,2.37)	0.04 (-0.20,0.27)
LD ADA IV + MTX		1.21 (0.17,8.02)	1.12 (0.26,3.10)	0.04 (-0.30,0.46)
LD ABA IV + MTX		0.72 (0.25,2.06)	0.80 (0.38,1.66)	-0.06 (-0.29,0.14)
LD ANA SC + MTX		0.67 (0.17,2.39)	0.76 (0.24,1.71)	-0.07 (-0.30,0.20)
LD CERTO SC + MTX		1.42 (0.41,4.80)	1.24 (0.57,2.68)	0.08 (-0.19,0.34)
LD GOLI IV + MTX		0.75 (0.21,2.52)	0.82 (0.33,1.87)	-0.06 (-0.32,0.19)
LD TOCI IV + MTX		0.61 (0.18,2.13)	0.71 (0.28,1.70)	-0.09 (-0.34,0.15)
LD TOFA PO + MTX		1.03 (0.24,4.37)	1.02 (0.35,2.48)	0.01 (-0.29,0.33)
HD TOCI IV		0.97 (0.37,2.52)	0.98 (0.54,1.98)	-0.01 (-0.23,0.18)
HD TOFA PO		1.39 (0.41,4.89)	1.23 (0.59,2.98)	0.07 (-0.21,0.32)
HD ADA SC		0.63 (0.18,2.29)	0.72 (0.32,1.88)	-0.09 (-0.36,0.15)
HD GOLI SC		1.05 (0.35,3.16)	1.03 (0.52,2.28)	0.01 (-0.23,0.24)
HD ETN SC		0.98 (0.17,5.43)	0.99 (0.27,2.84)	0.00 (-0.34,0.37)
HD ABA SC		1.86 (0.35,11.26)	1.43 (0.50,3.92)	0.14 (-0.23,0.52)
HD TOCI IV + MTX		1.66 (0.64,4.52)	1.36 (0.78,2.77)	0.12 (-0.11,0.32)
HD INF IV + MTX		1.55 (0.54,4.27)	1.30 (0.70,2.60)	0.10 (-0.14,0.32)
HD TOFA PO + MTX		1.32 (0.43,3.77)	1.19 (0.59,2.41)	0.06 (-0.18,0.29)
HD GOLI SC + MTX		1.80 (0.62,5.18)	1.41 (0.76,2.92)	0.13 (-0.11,0.36)
HD CERTO SC + MTX		2.38 (0.87,6.21)	1.62 (0.93,3.17)	0.20 (-0.03,0.41)
HD ADA SC + MTX		1.98 (0.52,7.37)	1.48 (0.66,3.27)	0.16 (-0.15,0.45)
HD TOCI IV + DMARD		1.15 (0.13,11.61)	1.09 (0.21,3.69)	0.03 (-0.36,0.53)
SD ANA SC + SD ETN SC + MTX		1.17 (0.26,5.61)	1.11 (0.40,2.91)	0.03 (-0.27,0.38)
SD ANA SC + LD ETN SC + MTX		1.74 (0.39,7.94)	1.39 (0.55,3.36)	0.13 (-0.21,0.46)
SD TOCI IV + MTX	SD ABA SC + MTX	0.50 (0.14,1.98)	0.64 (0.27,1.59)	-0.14 (-0.42,0.14)

(Continued)

SD CERTO SC + DMARD	0.79 (0.13,5.14)	0.86 (0.27,2.58)	-0.05 (-0.43,0.37)
SD ADA SC + DMARD	0.68 (0.06,8.08)	0.79 (0.13,2.79)	-0.08 (-0.50,0.46)
SD TOCI SC + DMARD	1.11 (0.10,12.55)	1.06 (0.19,3.28)	0.02 (-0.45,0.53)
LD ADA SC	0.31 (0.08,1.27)	0.44 (0.19,1.20)	-0.23 (-0.52,0.04)
LD ETN SC	0.39 (0.08,1.79)	0.53 (0.18,1.53)	-0.19 (-0.50,0.11)
LD GOL I IV	0.27 (0.07,1.04)	0.40 (0.14,1.03)	-0.24 (-0.51,0.01)
LD TOCI IV	0.05 (0.01,0.25)	0.08 (0.01,0.33)	-0.37 (-0.64,-0.14)
LD ADA SC + MTX	0.95 (0.25,3.82)	0.97 (0.43,2.22)	-0.01 (-0.31,0.30)
LD RITUX IV + MTX	0.83 (0.26,2.73)	0.90 (0.46,1.93)	-0.04 (-0.30,0.22)
LD ADA IV + MTX	0.85 (0.11,6.07)	0.91 (0.21,2.60)	-0.04 (-0.41,0.41)
LD ABA IV + MTX	0.50 (0.18,1.48)	0.64 (0.33,1.31)	-0.14 (-0.38,0.08)
LD ANA SC + MTX	0.47 (0.09,2.56)	0.61 (0.16,1.79)	-0.15 (-0.47,0.21)
LD CERTO SC + MTX	0.98 (0.28,3.71)	0.99 (0.47,2.22)	0.00 (-0.29,0.29)
LD GOL I IV + MTX	0.52 (0.14,1.92)	0.66 (0.28,1.53)	-0.14 (-0.41,0.14)
LD TOCI IV + MTX	0.42 (0.11,1.69)	0.57 (0.23,1.42)	-0.17 (-0.45,0.11)
LD TOFA PO + MTX	0.72 (0.16,3.37)	0.82 (0.28,2.06)	-0.07 (-0.39,0.27)
HD TOCI IV	0.67 (0.23,2.06)	0.78 (0.45,1.68)	-0.09 (-0.34,0.14)
HD TOFA PO	0.97 (0.26,3.87)	0.98 (0.50,2.46)	-0.01 (-0.32,0.29)
HD ADA SC	0.44 (0.12,1.81)	0.58 (0.26,1.55)	-0.17 (-0.47,0.11)
HD GOL I SC	0.74 (0.22,2.50)	0.83 (0.42,1.89)	-0.07 (-0.34,0.19)
HD ETN SC	0.69 (0.12,4.05)	0.80 (0.23,2.30)	-0.08 (-0.43,0.32)
HD ABA SC	1.33 (0.22,8.53)	1.16 (0.41,3.13)	0.07 (-0.34,0.47)
HD TOCI IV + MTX	1.16 (0.41,3.64)	1.09 (0.64,2.33)	0.04 (-0.21,0.28)
HD INF IV + MTX	1.08 (0.36,3.38)	1.04 (0.57,2.21)	0.02 (-0.24,0.27)
HD TOFA PO + MTX	0.93 (0.28,2.97)	0.96 (0.48,2.02)	-0.02 (-0.30,0.24)
HD GOL I SC + MTX	1.26 (0.41,4.13)	1.13 (0.62,2.42)	0.05 (-0.21,0.32)
HD CERTO SC + MTX	1.66 (0.56,5.01)	1.30 (0.76,2.69)	0.12 (-0.14,0.36)
HD ADA SC + MTX	1.39 (0.35,5.75)	1.19 (0.55,2.67)	0.08 (-0.24,0.39)

(Continued)

HD TOCI IV + DMARD		0.81 (0.08,8.56)	0.88 (0.17,2.85)	-0.05 (-0.47,0.47)
SD ANA SC + SD ETN SC + MTX		0.82 (0.18,4.16)	0.89 (0.32,2.30)	-0.04 (-0.38,0.32)
SD ANA SC + LD ETN SC + MTX		1.21 (0.26,5.77)	1.11 (0.45,2.70)	0.04 (-0.30,0.40)
SD CERTO SC + DMARD	SD TOCI IV + MTX	1.53 (0.27,10.01)	1.33 (0.39,4.46)	0.08 (-0.26,0.48)
SD ADA SC + DMARD		1.32 (0.13,16.60)	1.21 (0.19,4.93)	0.05 (-0.32,0.58)
SD TOCI SC + DMARD		2.13 (0.20,24.44)	1.61 (0.30,5.56)	0.16 (-0.27,0.65)
LD ADA SC		0.61 (0.17,2.33)	0.68 (0.27,1.99)	-0.08 (-0.35,0.13)
LD ETN SC		0.77 (0.16,3.43)	0.82 (0.25,2.57)	-0.05 (-0.33,0.22)
LD GOLI IV		0.53 (0.13,2.12)	0.61 (0.20,1.79)	-0.10 (-0.35,0.12)
LD TOCI IV		0.09 (0.02,0.42)	0.13 (0.02,0.48)	-0.22 (-0.47,-0.07)
LD ADA SC + MTX		1.90 (0.47,7.47)	1.51 (0.60,3.92)	0.13 (-0.16,0.42)
LD RITUX IV + MTX		1.67 (0.50,5.51)	1.41 (0.63,3.34)	0.10 (-0.15,0.35)
LD ADA IV + MTX		1.67 (0.21,12.25)	1.40 (0.29,4.38)	0.10 (-0.27,0.54)
LD ABA IV + MTX		0.99 (0.30,3.28)	0.99 (0.43,2.44)	0.00 (-0.24,0.22)
LD ANA SC + MTX		0.93 (0.16,4.97)	0.95 (0.23,2.98)	-0.01 (-0.30,0.34)
LD CERTO SC + MTX		1.93 (0.53,7.53)	1.53 (0.65,3.92)	0.14 (-0.14,0.42)
LD GOLI IV + MTX		1.03 (0.27,4.02)	1.02 (0.38,2.79)	0.00 (-0.25,0.27)
LD TOCI IV + MTX		0.85 (0.27,2.64)	0.89 (0.37,2.07)	-0.03 (-0.25,0.18)
LD TOFA PO + MTX		1.41 (0.30,6.84)	1.26 (0.40,3.66)	0.07 (-0.22,0.40)
HD TOCI IV		1.33 (0.52,3.52)	1.22 (0.67,2.70)	0.06 (-0.15,0.22)
HD TOFA PO		1.92 (0.50,7.06)	1.54 (0.66,4.14)	0.14 (-0.16,0.38)
HD ADA SC		0.88 (0.24,3.41)	0.91 (0.37,2.61)	-0.02 (-0.30,0.20)
HD GOLI SC		1.46 (0.44,4.96)	1.30 (0.58,3.30)	0.08 (-0.18,0.30)
HD ETN SC		1.36 (0.23,7.82)	1.23 (0.34,3.79)	0.06 (-0.27,0.43)
HD ABA SC		2.60 (0.44,16.75)	1.81 (0.58,5.41)	0.21 (-0.17,0.59)
HD TOCI IV + MTX		2.30 (0.87,6.38)	1.70 (0.93,3.76)	0.18 (-0.03,0.37)
HD INF IV + MTX		2.13 (0.64,6.85)	1.62 (0.76,3.81)	0.16 (-0.10,0.40)

(Continued)

HD TOFA PO + MTX		1.81 (0.55,6.06)	1.48 (0.69,3.56)	0.12 (-0.13,0.37)
HD GOLI SC + MTX		2.50 (0.77,8.24)	1.77 (0.85,4.23)	0.20 (-0.06,0.44)
HD CERTO SC + MTX		3.24 (1.07,10.27)	2.02 (1.04,4.72)	0.26 (0.02,0.48)
HD ADA SC + MTX		2.73 (0.65,11.85)	1.85 (0.76,4.70)	0.22 (-0.09,0.52)
HD TOCI IV + DMARD		1.57 (0.17,17.11)	1.35 (0.25,5.05)	0.09 (-0.30,0.59)
SD ANA SC + SD ETN SC + MTX		1.62 (0.35,8.40)	1.38 (0.47,4.07)	0.10 (-0.21,0.45)
SD ANA SC + LD ETN SC + MTX		2.41 (0.52,11.85)	1.73 (0.64,4.70)	0.19 (-0.14,0.52)
SD ADA SC + DMARD	SD CERTO SC + DMARD	0.88 (0.19,4.18)	0.92 (0.26,2.10)	-0.03 (-0.29,0.31)
SD TOCI SC + DMARD		1.42 (0.28,6.67)	1.20 (0.39,2.61)	0.07 (-0.22,0.41)
LD ADA SC		0.40 (0.08,1.98)	0.51 (0.19,1.72)	-0.17 (-0.52,0.11)
LD ETN SC		0.50 (0.08,2.87)	0.61 (0.18,2.17)	-0.13 (-0.51,0.19)
LD GOLI IV		0.35 (0.05,2.01)	0.46 (0.12,1.71)	-0.19 (-0.56,0.12)
LD TOCI IV		0.06 (0.01,0.46)	0.09 (0.01,0.52)	-0.31 (-0.66,-0.07)
LD ADA SC + MTX		1.22 (0.19,7.88)	1.13 (0.38,3.77)	0.04 (-0.37,0.43)
LD RITUX IV + MTX		1.09 (0.18,5.74)	1.05 (0.37,3.35)	0.02 (-0.39,0.36)
LD ADA IV + MTX		1.08 (0.10,11.13)	1.05 (0.20,3.96)	0.02 (-0.44,0.51)
LD ABA IV + MTX		0.64 (0.11,3.53)	0.74 (0.25,2.54)	-0.09 (-0.48,0.24)
LD ANA SC + MTX		0.60 (0.06,4.51)	0.71 (0.14,2.76)	-0.10 (-0.51,0.32)
LD CERTO SC + MTX		1.26 (0.20,7.79)	1.15 (0.40,3.74)	0.05 (-0.36,0.43)
LD GOLI IV + MTX		0.67 (0.10,3.90)	0.76 (0.23,2.61)	-0.08 (-0.47,0.27)
LD TOCI IV + MTX		0.56 (0.08,3.18)	0.67 (0.19,2.32)	-0.11 (-0.50,0.21)
LD TOFA PO + MTX		0.93 (0.11,6.43)	0.96 (0.24,3.33)	-0.01 (-0.45,0.40)
HD TOCI IV		0.87 (0.17,4.07)	0.91 (0.37,2.81)	-0.03 (-0.41,0.26)
HD TOFA PO		1.25 (0.24,5.67)	1.15 (0.48,3.41)	0.05 (-0.34,0.35)
HD ADA SC		0.57 (0.11,2.97)	0.67 (0.26,2.30)	-0.11 (-0.47,0.18)
HD GOLI SC		0.96 (0.16,4.71)	0.98 (0.35,3.07)	-0.01 (-0.41,0.30)
HD ETN SC		0.88 (0.11,6.45)	0.92 (0.22,3.38)	-0.03 (-0.46,0.40)

(Continued)

HD ABA SC		1.67 (0.25,11.35)	1.33 (0.45,4.24)	0.12 (-0.31,0.52)
HD TOCI IV + MTX		1.52 (0.28,7.23)	1.28 (0.53,3.83)	0.10 (-0.30,0.41)
HD INF IV + MTX		1.39 (0.23,7.23)	1.22 (0.45,3.76)	0.07 (-0.34,0.41)
HD TOFA PO + MTX		1.19 (0.19,6.29)	1.11 (0.39,3.47)	0.04 (-0.37,0.38)
HD GOLI SC + MTX		1.64 (0.27,8.62)	1.33 (0.51,4.00)	0.11 (-0.31,0.45)
HD CERTO SC + MTX		2.11 (0.38,10.95)	1.50 (0.63,4.48)	0.18 (-0.23,0.51)
HD ADA SC + MTX		1.76 (0.26,12.19)	1.37 (0.48,4.45)	0.13 (-0.30,0.53)
HD TOCI IV + DMARD		1.04 (0.25,4.07)	1.02 (0.34,2.14)	0.01 (-0.25,0.31)
SD ANA SC + SD ETN SC + MTX		1.05 (0.15,6.85)	1.03 (0.31,3.45)	0.01 (-0.41,0.41)
SD ANA SC + LD ETN SC + MTX		1.55 (0.23,9.96)	1.29 (0.43,4.04)	0.10 (-0.33,0.49)
SD TOCI SC + DMARD	SD ADA SC + DMARD	1.61 (0.43,5.86)	1.29 (0.59,3.28)	0.09 (-0.17,0.38)
LD ADA SC		0.46 (0.05,4.29)	0.56 (0.17,3.50)	-0.14 (-0.63,0.17)
LD ETN SC		0.58 (0.05,5.95)	0.68 (0.17,4.35)	-0.10 (-0.60,0.25)
LD GOLI IV		0.40 (0.03,3.89)	0.51 (0.11,3.14)	-0.15 (-0.66,0.18)
LD TOCI IV		0.07 (0.00,0.86)	0.10 (0.01,0.88)	-0.28 (-0.77,-0.01)
LD ADA SC + MTX		1.41 (0.11,16.29)	1.24 (0.34,7.81)	0.07 (-0.47,0.50)
LD RITUX IV + MTX		1.25 (0.11,12.11)	1.15 (0.33,6.71)	0.05 (-0.49,0.43)
LD ADA IV + MTX		1.22 (0.07,19.91)	1.13 (0.18,7.95)	0.04 (-0.53,0.57)
LD ABA IV + MTX		0.75 (0.07,7.20)	0.82 (0.22,4.96)	-0.06 (-0.58,0.30)
LD ANA SC + MTX		0.69 (0.04,9.40)	0.77 (0.14,5.34)	-0.07 (-0.60,0.39)
LD CERTO SC + MTX		1.46 (0.13,15.84)	1.27 (0.36,7.79)	0.08 (-0.45,0.49)
LD GOLI IV + MTX		0.79 (0.06,7.74)	0.85 (0.21,5.10)	-0.05 (-0.58,0.33)
LD TOCI IV + MTX		0.63 (0.05,6.70)	0.72 (0.18,4.74)	-0.09 (-0.60,0.28)
LD TOFA PO + MTX		1.07 (0.07,12.79)	1.04 (0.22,6.72)	0.01 (-0.54,0.46)
HD TOCI IV		1.00 (0.10,8.74)	1.00 (0.33,5.87)	0.00 (-0.51,0.32)
HD TOFA PO		1.44 (0.14,12.73)	1.26 (0.43,7.38)	0.08 (-0.43,0.41)
HD ADA SC		0.66 (0.07,6.25)	0.74 (0.23,4.65)	-0.08 (-0.58,0.24)

(Continued)

HD GOLI SC		1.12 (0.10,9.87)	1.08 (0.32,6.18)	0.02 (-0.51,0.36)
HD ETN SC		1.03 (0.07,11.56)	1.02 (0.21,6.08)	0.01 (-0.54,0.45)
HD ABA SC		1.94 (0.17,22.89)	1.47 (0.42,8.94)	0.14 (-0.39,0.58)
HD TOCI IV + MTX		1.73 (0.17,15.76)	1.40 (0.47,8.02)	0.12 (-0.39,0.48)
HD INF IV + MTX		1.59 (0.14,14.67)	1.33 (0.41,7.52)	0.10 (-0.43,0.47)
HD TOFA PO + MTX		1.39 (0.12,13.06)	1.23 (0.35,7.17)	0.07 (-0.47,0.44)
HD GOLI SC + MTX		1.87 (0.16,18.51)	1.45 (0.46,8.73)	0.14 (-0.40,0.51)
HD CERTO SC + MTX		2.45 (0.23,22.88)	1.66 (0.56,9.49)	0.21 (-0.32,0.57)
HD ADA SC + MTX		2.00 (0.16,24.85)	1.49 (0.43,9.38)	0.15 (-0.41,0.59)
HD TOCI IV + DMARD		1.19 (0.39,3.59)	1.10 (0.54,2.53)	0.03 (-0.20,0.26)
SD ANA SC + SD ETN SC + MTX		1.22 (0.10,13.91)	1.13 (0.29,7.02)	0.04 (-0.49,0.47)
SD ANA SC + LD ETN SC + MTX		1.79 (0.16,20.19)	1.40 (0.40,8.29)	0.13 (-0.41,0.56)
LD ADA SC	SD TOCI SC + DMARD	0.28 (0.03,2.70)	0.42 (0.15,2.32)	-0.25 (-0.70,0.13)
LD ETN SC		0.35 (0.03,3.77)	0.51 (0.14,2.86)	-0.21 (-0.67,0.21)
LD GOLI IV		0.25 (0.02,2.59)	0.38 (0.09,2.18)	-0.27 (-0.72,0.14)
LD TOCI IV		0.04 (0.00,0.55)	0.08 (0.01,0.60)	-0.39 (-0.83,-0.04)
LD ADA SC + MTX		0.87 (0.08,10.35)	0.93 (0.30,5.27)	-0.03 (-0.53,0.44)
LD RITUX IV + MTX		0.77 (0.07,7.57)	0.86 (0.29,4.52)	-0.06 (-0.56,0.37)
LD ADA IV + MTX		0.76 (0.05,13.19)	0.87 (0.16,5.25)	-0.06 (-0.60,0.51)
LD ABA IV + MTX		0.46 (0.04,4.68)	0.61 (0.20,3.34)	-0.17 (-0.64,0.25)
LD ANA SC + MTX		0.42 (0.03,5.99)	0.59 (0.11,3.69)	-0.17 (-0.67,0.32)
LD CERTO SC + MTX		0.89 (0.08,10.27)	0.94 (0.31,5.11)	-0.03 (-0.53,0.44)
LD GOLI IV + MTX		0.47 (0.04,5.09)	0.63 (0.18,3.50)	-0.16 (-0.64,0.27)
LD TOCI IV + MTX		0.38 (0.03,4.05)	0.54 (0.16,2.98)	-0.20 (-0.67,0.23)
LD TOFA PO + MTX		0.65 (0.05,7.86)	0.78 (0.19,4.34)	-0.09 (-0.62,0.39)
HD TOCI IV		0.61 (0.07,5.69)	0.74 (0.30,3.93)	-0.11 (-0.57,0.28)
HD TOFA PO		0.89 (0.10,8.27)	0.94 (0.39,4.87)	-0.03 (-0.49,0.37)



(Continued)

HD ADA SC		0.40 (0.04,3.86)	0.55 (0.21,3.03)	-0.19 (-0.64,0.20)
HD GOLI SC		0.68 (0.07,6.33)	0.79 (0.29,4.15)	-0.09 (-0.57,0.31)
HD ETN SC		0.62 (0.05,7.80)	0.76 (0.18,4.17)	-0.10 (-0.62,0.40)
HD ABA SC		1.19 (0.10,14.94)	1.09 (0.35,5.83)	0.04 (-0.48,0.53)
HD TOCI IV + MTX		1.07 (0.11,10.15)	1.03 (0.42,5.29)	0.01 (-0.46,0.43)
HD INF IV + MTX		0.98 (0.09,9.35)	0.99 (0.37,5.08)	0.00 (-0.50,0.42)
HD TOFA PO + MTX		0.85 (0.08,8.39)	0.91 (0.31,4.83)	-0.04 (-0.54,0.39)
HD GOLI SC + MTX		1.15 (0.11,11.85)	1.07 (0.41,5.66)	0.03 (-0.47,0.47)
HD CERTO SC + MTX		1.48 (0.15,15.21)	1.22 (0.51,6.46)	0.09 (-0.39,0.52)
HD ADA SC + MTX		1.22 (0.11,15.19)	1.11 (0.38,6.22)	0.05 (-0.47,0.53)
HD TOCI IV + DMARD		0.74 (0.24,2.21)	0.86 (0.41,1.71)	-0.06 (-0.31,0.16)
SD ANA SC + SD ETN SC + MTX		0.73 (0.07,8.86)	0.84 (0.25,4.60)	-0.07 (-0.56,0.42)
SD ANA SC + LD ETN SC + MTX		1.08 (0.10,13.00)	1.04 (0.35,5.48)	0.02 (-0.48,0.51)
LD ETN SC	LD ADA SC	1.27 (0.31,4.68)	1.20 (0.38,3.26)	0.04 (-0.16,0.27)
LD GOLI IV		0.87 (0.21,3.40)	0.89 (0.26,2.61)	-0.02 (-0.19,0.20)
LD TOCI IV		0.15 (0.02,0.78)	0.18 (0.03,0.81)	-0.14 (-0.29,-0.02)
LD ADA SC + MTX		3.08 (0.77,12.14)	2.22 (0.82,5.23)	0.22 (-0.04,0.52)
LD RITUX IV + MTX		2.71 (0.76,9.32)	2.06 (0.81,4.76)	0.19 (-0.05,0.45)
LD ADA IV + MTX		2.73 (0.34,19.06)	2.06 (0.40,5.83)	0.19 (-0.13,0.61)
LD ABA IV + MTX		1.63 (0.47,5.45)	1.46 (0.55,3.58)	0.08 (-0.12,0.31)
LD ANA SC + MTX		1.51 (0.26,8.30)	1.38 (0.31,4.20)	0.07 (-0.17,0.43)
LD CERTO SC + MTX		3.18 (0.83,12.39)	2.27 (0.86,5.26)	0.22 (-0.03,0.52)
LD GOLI IV + MTX		1.68 (0.44,6.31)	1.49 (0.51,3.85)	0.09 (-0.13,0.35)
LD TOCI IV + MTX		1.39 (0.38,4.91)	1.29 (0.45,3.30)	0.05 (-0.14,0.30)
LD TOFA PO + MTX		2.33 (0.47,10.82)	1.86 (0.54,4.86)	0.15 (-0.11,0.49)
HD TOCI IV		2.17 (0.81,5.72)	1.79 (0.86,3.80)	0.14 (-0.04,0.31)
HD TOFA PO		3.11 (1.16,8.68)	2.25 (1.11,4.86)	0.22 (0.03,0.41)

(Continued)

HD ADA SC		1.43 (0.67,3.15)	1.32 (0.72,2.50)	0.06 (-0.07,0.19)
HD GOLI SC		2.37 (0.77,7.38)	1.90 (0.82,4.35)	0.16 (-0.05,0.38)
HD ETN SC		2.21 (0.39,11.68)	1.80 (0.46,5.05)	0.14 (-0.13,0.50)
HD ABA SC		4.24 (0.90,21.81)	2.63 (0.92,6.43)	0.29 (-0.02,0.63)
HD TOCI IV + MTX		3.79 (1.30,10.94)	2.51 (1.20,5.31)	0.27 (0.05,0.48)
HD INF IV + MTX		3.45 (1.06,11.42)	2.37 (1.04,5.27)	0.24 (0.01,0.50)
HD TOFA PO + MTX		2.97 (0.84,9.82)	2.19 (0.88,4.93)	0.21 (-0.03,0.46)
HD GOLI SC + MTX		4.08 (1.21,13.31)	2.61 (1.14,5.69)	0.28 (0.04,0.52)
HD CERTO SC + MTX		5.32 (1.70,17.15)	2.98 (1.42,6.31)	0.35 (0.11,0.58)
HD ADA SC + MTX		4.45 (1.08,19.08)	2.70 (1.06,6.24)	0.31 (0.01,0.61)
HD TOCI IV + DMARD		2.62 (0.31,22.55)	2.01 (0.38,5.95)	0.18 (-0.15,0.64)
SD ANA SC + SD ETN SC + MTX		2.64 (0.59,12.25)	2.02 (0.66,5.25)	0.18 (-0.08,0.51)
SD ANA SC + LD ETN SC + MTX		3.89 (0.88,17.58)	2.53 (0.91,5.94)	0.27 (-0.02,0.59)
LD GOLI IV	LD ETN SC	0.70 (0.15,3.24)	0.75 (0.21,2.56)	-0.05 (-0.29,0.18)
LD TOCI IV		0.12 (0.02,0.76)	0.15 (0.02,0.78)	-0.17 (-0.40,-0.03)
LD ADA SC + MTX		2.45 (0.54,12.34)	1.84 (0.64,5.60)	0.18 (-0.12,0.50)
LD RITUX IV + MTX		2.15 (0.54,8.88)	1.71 (0.65,4.89)	0.15 (-0.12,0.42)
LD ADA IV + MTX		2.16 (0.25,18.72)	1.70 (0.33,5.98)	0.15 (-0.21,0.60)
LD ABA IV + MTX		1.29 (0.32,5.11)	1.21 (0.43,3.54)	0.04 (-0.21,0.29)
LD ANA SC + MTX		1.21 (0.18,7.76)	1.15 (0.25,4.17)	0.03 (-0.26,0.41)
LD CERTO SC + MTX		2.55 (0.57,11.64)	1.89 (0.67,5.41)	0.19 (-0.11,0.50)
LD GOLI IV + MTX		1.35 (0.30,6.06)	1.25 (0.40,3.89)	0.05 (-0.22,0.33)
LD TOCI IV + MTX		1.10 (0.25,5.00)	1.08 (0.34,3.40)	0.02 (-0.24,0.28)
LD TOFA PO + MTX		1.86 (0.34,10.20)	1.55 (0.44,4.90)	0.11 (-0.19,0.47)
HD TOCI IV		1.73 (0.52,6.13)	1.49 (0.65,4.15)	0.10 (-0.14,0.31)
HD TOFA PO		2.49 (0.68,9.22)	1.88 (0.78,5.19)	0.19 (-0.09,0.41)
HD ADA SC		1.14 (0.31,4.44)	1.11 (0.43,3.31)	0.02 (-0.22,0.24)

(Continued)

HD GOLI SC		1.89 (0.51,7.31)	1.58 (0.63,4.45)	0.12 (-0.14,0.37)
HD ETN SC		1.77 (0.32,8.88)	1.50 (0.42,4.43)	0.11 (-0.18,0.45)
HD ABA SC		3.37 (0.59,21.05)	2.20 (0.69,6.73)	0.25 (-0.11,0.62)
HD TOCI IV + MTX		3.00 (0.85,11.33)	2.09 (0.90,5.62)	0.23 (-0.04,0.47)
HD INF IV + MTX		2.76 (0.71,10.86)	1.98 (0.79,5.37)	0.21 (-0.07,0.47)
HD TOFA PO + MTX		2.37 (0.58,9.39)	1.81 (0.69,5.02)	0.17 (-0.11,0.43)
HD GOLI SC + MTX		3.23 (0.86,12.76)	2.16 (0.91,5.85)	0.24 (-0.03,0.51)
HD CERTO SC + MTX		4.24 (1.15,16.26)	2.47 (1.09,6.51)	0.31 (0.03,0.56)
HD ADA SC + MTX		3.54 (0.75,18.25)	2.24 (0.82,6.48)	0.27 (-0.06,0.59)
HD TOCI IV + DMARD		2.08 (0.22,20.49)	1.67 (0.29,6.32)	0.14 (-0.23,0.61)
SD ANA SC + SD ETN SC + MTX		2.10 (0.45,10.90)	1.67 (0.55,5.09)	0.14 (-0.15,0.48)
SD ANA SC + LD ETN SC + MTX		3.12 (0.68,15.79)	2.10 (0.76,5.94)	0.23 (-0.08,0.56)
LD TOCI IV	LD GOLI IV	0.17 (0.03,0.96)	0.20 (0.03,0.96)	-0.12 (-0.32,0.00)
LD ADA SC + MTX		3.49 (0.94,15.36)	2.44 (0.96,7.07)	0.23 (-0.01,0.51)
LD RITUX IV + MTX		3.11 (0.95,10.65)	2.29 (0.97,6.20)	0.20 (-0.01,0.43)
LD ADA IV + MTX		3.15 (0.43,23.07)	2.26 (0.49,8.01)	0.20 (-0.12,0.62)
LD ABA IV + MTX		1.86 (0.59,6.26)	1.63 (0.67,4.52)	0.09 (-0.09,0.30)
LD ANA SC + MTX		1.75 (0.31,9.20)	1.54 (0.37,5.29)	0.08 (-0.16,0.42)
LD CERTO SC + MTX		3.64 (0.99,14.23)	2.51 (1.00,7.11)	0.24 (0.00,0.51)
LD GOLI IV + MTX		1.93 (0.69,5.50)	1.66 (0.75,3.95)	0.10 (-0.06,0.30)
LD TOCI IV + MTX		1.60 (0.41,6.53)	1.45 (0.49,4.54)	0.07 (-0.14,0.31)
LD TOFA PO + MTX		2.65 (0.56,12.60)	2.06 (0.63,6.39)	0.16 (-0.09,0.49)
HD TOCI IV		2.49 (0.85,7.87)	2.00 (0.89,5.42)	0.16 (-0.03,0.32)
HD TOFA PO		3.52 (0.97,14.43)	2.49 (0.98,8.02)	0.24 (-0.01,0.45)
HD ADA SC		1.66 (0.43,6.78)	1.49 (0.53,4.98)	0.08 (-0.16,0.27)
HD GOLI SC		2.74 (0.85,9.01)	2.12 (0.89,5.90)	0.17 (-0.03,0.37)
HD ETN SC		2.53 (0.42,15.64)	1.98 (0.50,7.37)	0.16 (-0.13,0.52)

(Continued)

HD ABA SC		4.84 (0.84,30.92)	2.94 (0.88,9.98)	0.31 (-0.03,0.65)
HD TOCI IV + MTX		4.33 (1.46,14.12)	2.79 (1.26,7.54)	0.28 (0.08,0.48)
HD INF IV + MTX		3.98 (1.27,12.76)	2.65 (1.17,6.91)	0.26 (0.05,0.47)
HD TOFA PO + MTX		3.36 (1.05,11.84)	2.40 (1.03,6.55)	0.22 (0.01,0.45)
HD GOLI SC + MTX		4.66 (1.46,15.43)	2.89 (1.28,7.75)	0.30 (0.08,0.51)
HD CERTO SC + MTX		6.13 (2.02,18.97)	3.31 (1.52,8.79)	0.36 (0.15,0.56)
HD ADA SC + MTX		5.09 (1.28,22.23)	2.99 (1.18,8.64)	0.32 (0.04,0.60)
HD TOCI IV + DMARD		2.96 (0.32,33.53)	2.21 (0.39,9.52)	0.19 (-0.16,0.67)
SD ANA SC + SD ETN SC + MTX		3.02 (0.64,15.66)	2.25 (0.71,7.45)	0.19 (-0.07,0.52)
SD ANA SC + LD ETN SC + MTX		4.48 (0.95,23.21)	2.81 (0.96,8.96)	0.29 (-0.01,0.61)
LD ADA SC + MTX	LD TOCI IV	20.08 (3.82,137.60)	11.95 (2.95,69.30)	0.36 (0.14,0.64)
LD RITUX IV + MTX		17.68 (3.85,106.00)	11.21 (2.94,60.92)	0.33 (0.14,0.57)
LD ADA IV + MTX		17.82 (2.04,187.20)	10.83 (1.87,68.75)	0.33 (0.04,0.74)
LD ABA IV + MTX		10.78 (2.31,63.96)	8.05 (2.01,44.35)	0.22 (0.08,0.43)
LD ANA SC + MTX		9.99 (1.34,82.22)	7.51 (1.30,46.80)	0.21 (0.02,0.55)
LD CERTO SC + MTX		20.67 (4.15,138.30)	12.32 (3.09,70.88)	0.37 (0.15,0.64)
LD GOLI IV + MTX		11.13 (2.03,73.87)	8.17 (1.83,48.35)	0.23 (0.06,0.47)
LD TOCI IV + MTX		9.08 (2.05,51.80)	7.03 (1.86,37.56)	0.19 (0.06,0.41)
LD TOFA PO + MTX		15.36 (2.43,118.40)	9.98 (2.11,61.52)	0.29 (0.07,0.62)
HD TOCI IV		14.03 (3.83,77.39)	9.78 (2.87,53.02)	0.28 (0.16,0.42)
HD TOFA PO		20.22 (3.95,139.10)	12.31 (2.91,74.78)	0.36 (0.20,0.54)
HD ADA SC		9.39 (1.85,62.71)	7.31 (1.68,45.24)	0.20 (0.07,0.36)
HD GOLI SC		15.76 (3.27,98.50)	10.45 (2.61,59.14)	0.30 (0.14,0.49)
HD ETN SC		14.52 (1.92,131.90)	9.72 (1.76,65.53)	0.28 (0.05,0.63)
HD ABA SC		28.65 (3.64,268.10)	14.57 (2.89,92.29)	0.44 (0.15,0.76)
HD TOCI IV + MTX		24.32 (6.37,137.50)	13.61 (3.92,74.19)	0.41 (0.24,0.59)
HD INF IV + MTX		22.63 (5.08,140.80)	13.02 (3.43,74.04)	0.39 (0.19,0.61)

(Continued)

HD TOFA PO + MTX		19.19 (4.16,119.50)	11.85 (3.09,65.92)	0.35 (0.15,0.57)
HD GOLI SC + MTX		26.64 (5.66,168.80)	14.22 (3.68,81.14)	0.43 (0.22,0.64)
HD CERTO SC + MTX		34.59 (7.89,207.90)	16.15 (4.32,89.67)	0.49 (0.29,0.69)
HD ADA SC + MTX		29.29 (5.38,202.30)	14.69 (3.71,86.02)	0.45 (0.18,0.72)
HD TOCI IV + DMARD		17.18 (1.46,248.40)	10.89 (1.41,81.13)	0.32 (0.03,0.77)
SD ANA SC + SD ETN SC + MTX		17.47 (2.81,138.90)	11.06 (2.35,67.58)	0.33 (0.09,0.64)
SD ANA SC + LD ETN SC + MTX		25.95 (4.22,209.40)	13.76 (3.14,85.61)	0.42 (0.15,0.72)
LD RITUX IV + MTX	LD ADA SC + MTX	0.89 (0.25,2.93)	0.93 (0.44,2.01)	-0.03 (-0.32,0.23)
LD ADA IV + MTX		0.89 (0.14,5.17)	0.94 (0.23,2.28)	-0.03 (-0.37,0.37)
LD ABA IV + MTX		0.53 (0.16,1.77)	0.66 (0.30,1.49)	-0.13 (-0.41,0.11)
LD ANA SC + MTX		0.49 (0.08,2.68)	0.63 (0.16,1.83)	-0.14 (-0.47,0.21)
LD CERTO SC + MTX		1.04 (0.28,3.88)	1.02 (0.47,2.33)	0.01 (-0.29,0.31)
LD GOLI IV + MTX		0.55 (0.14,2.09)	0.68 (0.27,1.63)	-0.12 (-0.42,0.15)
LD TOCI IV + MTX		0.45 (0.11,1.74)	0.59 (0.23,1.45)	-0.16 (-0.45,0.11)
LD TOFA PO + MTX		0.76 (0.15,3.48)	0.85 (0.28,2.11)	-0.06 (-0.39,0.28)
HD TOCI IV		0.71 (0.23,2.08)	0.81 (0.45,1.70)	-0.08 (-0.34,0.15)
HD TOFA PO		1.01 (0.27,3.89)	1.00 (0.50,2.52)	0.00 (-0.31,0.29)
HD ADA SC		0.46 (0.12,1.87)	0.60 (0.27,1.59)	-0.16 (-0.47,0.12)
HD GOLI SC		0.78 (0.23,2.58)	0.86 (0.42,1.95)	-0.06 (-0.34,0.19)
HD ETN SC		0.72 (0.11,4.33)	0.82 (0.22,2.34)	-0.07 (-0.44,0.33)
HD ABA SC		1.39 (0.24,8.22)	1.19 (0.43,3.25)	0.08 (-0.33,0.47)
HD TOCI IV + MTX		1.23 (0.40,3.65)	1.13 (0.63,2.34)	0.05 (-0.22,0.29)
HD INF IV + MTX		1.13 (0.34,3.64)	1.07 (0.55,2.28)	0.03 (-0.25,0.29)
HD TOFA PO + MTX		0.96 (0.28,3.11)	0.98 (0.48,2.11)	-0.01 (-0.29,0.25)
HD GOLI SC + MTX		1.33 (0.38,4.31)	1.17 (0.60,2.52)	0.07 (-0.23,0.32)
HD CERTO SC + MTX		1.74 (0.55,5.24)	1.33 (0.76,2.75)	0.13 (-0.14,0.37)
HD ADA SC + MTX		1.44 (0.53,4.02)	1.21 (0.69,2.28)	0.08 (-0.15,0.32)

(Continued)

HD TOCI IV + DMARD		0.85 (0.08,8.81)	0.90 (0.16,3.01)	-0.04 (-0.47,0.48)
SD ANA SC + SD ETN SC + MTX		0.86 (0.18,4.25)	0.91 (0.33,2.40)	-0.03 (-0.37,0.32)
SD ANA SC + LD ETN SC + MTX		1.28 (0.27,6.13)	1.14 (0.46,2.84)	0.06 (-0.30,0.41)
LD ADA IV + MTX	LD RITUX IV + MTX	1.01 (0.14,6.86)	1.01 (0.23,2.59)	0.00 (-0.35,0.43)
LD ABA IV + MTX		0.60 (0.22,1.60)	0.71 (0.36,1.36)	-0.10 (-0.32,0.10)
LD ANA SC + MTX		0.56 (0.11,2.75)	0.67 (0.18,1.81)	-0.12 (-0.39,0.23)
LD CERTO SC + MTX		1.17 (0.37,3.73)	1.10 (0.53,2.17)	0.04 (-0.22,0.30)
LD GOLIV IV + MTX		0.62 (0.19,2.01)	0.73 (0.31,1.58)	-0.10 (-0.34,0.15)
LD TOCI IV + MTX		0.51 (0.16,1.69)	0.63 (0.26,1.43)	-0.13 (-0.37,0.11)
LD TOFA PO + MTX		0.86 (0.21,3.45)	0.91 (0.33,2.05)	-0.03 (-0.31,0.28)
HD TOCI IV		0.80 (0.33,1.98)	0.87 (0.52,1.63)	-0.05 (-0.26,0.14)
HD TOFA PO		1.15 (0.35,3.87)	1.09 (0.55,2.45)	0.03 (-0.25,0.29)
HD ADA SC		0.53 (0.16,1.87)	0.64 (0.29,1.57)	-0.13 (-0.40,0.12)
HD GOLIV SC		0.88 (0.31,2.45)	0.92 (0.49,1.84)	-0.03 (-0.26,0.19)
HD ETN SC		0.82 (0.16,4.34)	0.88 (0.26,2.35)	-0.04 (-0.36,0.33)
HD ABA SC		1.57 (0.30,9.12)	1.29 (0.46,3.23)	0.11 (-0.27,0.49)
HD TOCI IV + MTX		1.39 (0.57,3.48)	1.21 (0.74,2.23)	0.08 (-0.13,0.28)
HD INF IV + MTX		1.28 (0.49,3.35)	1.15 (0.65,2.14)	0.06 (-0.17,0.27)
HD TOFA PO + MTX		1.09 (0.39,2.93)	1.05 (0.56,1.98)	0.02 (-0.21,0.24)
HD GOLIV SC + MTX		1.51 (0.56,4.04)	1.26 (0.71,2.35)	0.09 (-0.14,0.32)
HD CERTO SC + MTX		1.97 (0.79,4.81)	1.44 (0.89,2.57)	0.16 (-0.06,0.36)
HD ADA SC + MTX		1.64 (0.49,6.07)	1.31 (0.64,2.73)	0.11 (-0.16,0.41)
HD TOCI IV + DMARD		0.95 (0.11,9.48)	0.97 (0.19,3.12)	-0.01 (-0.40,0.49)
SD ANA SC + SD ETN SC + MTX		0.98 (0.23,4.32)	0.99 (0.37,2.35)	0.00 (-0.30,0.34)
SD ANA SC + LD ETN SC + MTX		1.45 (0.35,6.17)	1.23 (0.51,2.71)	0.08 (-0.23,0.41)
LD ABA IV + MTX	LD ADA IV + MTX	0.59 (0.09,4.02)	0.71 (0.26,3.09)	-0.11 (-0.52,0.21)

(Continued)

LD ANA SC + MTX		0.55 (0.06,5.19)	0.68 (0.15,3.39)	-0.11 (-0.56,0.30)
LD CERTO SC + MTX		1.19 (0.16,8.73)	1.11 (0.40,4.77)	0.04 (-0.41,0.40)
LD GOLIV + MTX		0.61 (0.08,4.62)	0.73 (0.24,3.36)	-0.10 (-0.53,0.24)
LD TOCIV + MTX		0.51 (0.07,3.85)	0.63 (0.20,2.98)	-0.13 (-0.56,0.21)
LD TOFA PO + MTX		0.85 (0.10,7.52)	0.91 (0.26,4.28)	-0.03 (-0.49,0.38)
HD TOCIV		0.80 (0.14,5.08)	0.86 (0.38,3.73)	-0.05 (-0.45,0.25)
HD TOFA PO		1.14 (0.17,8.32)	1.08 (0.45,5.10)	0.03 (-0.40,0.37)
HD ADA SC		0.52 (0.08,4.11)	0.64 (0.24,3.18)	-0.13 (-0.56,0.20)
HD GOLIV SC		0.88 (0.13,6.38)	0.92 (0.36,4.23)	-0.03 (-0.45,0.31)
HD ETN SC		0.81 (0.08,8.04)	0.88 (0.21,4.52)	-0.04 (-0.53,0.40)
HD ABA SC		1.55 (0.16,16.31)	1.27 (0.39,6.59)	0.10 (-0.41,0.54)
HD TOCIV + MTX		1.39 (0.23,9.45)	1.21 (0.53,5.39)	0.08 (-0.33,0.40)
HD INF IV + MTX		1.28 (0.20,8.57)	1.15 (0.48,5.05)	0.06 (-0.37,0.39)
HD TOFA PO + MTX		1.08 (0.17,7.33)	1.05 (0.41,4.55)	0.02 (-0.41,0.36)
HD GOLIV SC + MTX		1.49 (0.22,10.58)	1.25 (0.52,5.58)	0.09 (-0.34,0.43)
HD CERTO SC + MTX		1.96 (0.32,13.10)	1.44 (0.63,6.28)	0.16 (-0.26,0.49)
HD ADA SC + MTX		1.63 (0.23,11.76)	1.29 (0.51,5.67)	0.11 (-0.33,0.48)
HD TOCIV + DMARD		0.98 (0.06,14.45)	0.99 (0.17,5.63)	0.00 (-0.55,0.54)
SD ANA SC + SD ETN SC + MTX		0.98 (0.12,8.38)	0.99 (0.30,4.75)	-0.01 (-0.46,0.41)
SD ANA SC + LD ETN SC + MTX		1.44 (0.19,12.99)	1.22 (0.41,5.84)	0.08 (-0.38,0.50)
LD ANA SC + MTX	LD ABA IV + MTX	0.92 (0.19,4.30)	0.94 (0.26,2.59)	-0.01 (-0.25,0.32)
LD CERTO SC + MTX		1.95 (0.64,6.17)	1.54 (0.74,3.25)	0.14 (-0.09,0.40)
LD GOLIV + MTX		1.04 (0.32,3.17)	1.03 (0.42,2.29)	0.01 (-0.21,0.23)
LD TOCIV + MTX		0.85 (0.27,2.78)	0.89 (0.36,2.11)	-0.03 (-0.24,0.20)
LD TOFA PO + MTX		1.43 (0.36,5.59)	1.28 (0.46,3.01)	0.07 (-0.18,0.38)
HD TOCIV		1.34 (0.58,3.23)	1.23 (0.70,2.45)	0.06 (-0.12,0.22)
HD TOFA PO		1.92 (0.61,6.50)	1.54 (0.74,3.75)	0.14 (-0.11,0.37)

(Continued)

HD ADA SC		0.88 (0.27,3.11)	0.91 (0.38,2.39)	-0.02 (-0.26,0.20)
HD GOLI SC		1.46 (0.54,3.92)	1.30 (0.66,2.69)	0.08 (-0.13,0.27)
HD ETN SC		1.35 (0.25,7.07)	1.23 (0.35,3.50)	0.06 (-0.24,0.42)
HD ABA SC		2.62 (0.50,14.41)	1.82 (0.61,4.86)	0.21 (-0.15,0.57)
HD TOCI IV + MTX		2.33 (0.98,5.70)	1.71 (0.99,3.36)	0.18 (0.00,0.37)
HD INF IV + MTX		2.13 (0.85,5.36)	1.62 (0.90,3.11)	0.16 (-0.04,0.36)
HD TOFA PO + MTX		1.81 (0.67,4.71)	1.48 (0.77,2.89)	0.12 (-0.08,0.33)
HD GOLI SC + MTX		2.50 (0.96,6.54)	1.78 (0.98,3.51)	0.20 (-0.01,0.40)
HD CERTO SC + MTX		3.27 (1.36,7.90)	2.03 (1.19,3.83)	0.26 (0.07,0.45)
HD ADA SC + MTX		2.75 (0.78,9.46)	1.85 (0.85,3.88)	0.22 (-0.05,0.49)
HD TOCI IV + DMARD		1.60 (0.18,16.02)	1.37 (0.27,4.57)	0.10 (-0.27,0.59)
SD ANA SC + SD ETN SC + MTX		1.61 (0.39,7.05)	1.38 (0.50,3.44)	0.10 (-0.18,0.42)
SD ANA SC + LD ETN SC + MTX		2.39 (0.60,10.16)	1.73 (0.70,4.03)	0.19 (-0.10,0.50)
LD CERTO SC + MTX	LD ANA SC + MTX	2.12 (0.39,11.79)	1.63 (0.57,6.33)	0.15 (-0.21,0.46)
LD GOLI IV + MTX		1.12 (0.20,6.14)	1.08 (0.34,4.18)	0.02 (-0.33,0.30)
LD TOCI IV + MTX		0.92 (0.17,5.10)	0.94 (0.29,3.72)	-0.01 (-0.36,0.26)
LD TOFA PO + MTX		1.52 (0.24,9.73)	1.34 (0.38,5.44)	0.08 (-0.29,0.44)
HD TOCI IV		1.44 (0.33,6.72)	1.29 (0.53,4.77)	0.07 (-0.26,0.29)
HD TOFA PO		2.04 (0.40,11.78)	1.61 (0.61,6.93)	0.15 (-0.22,0.41)
HD ADA SC		0.95 (0.18,5.59)	0.96 (0.32,4.19)	-0.01 (-0.37,0.24)
HD GOLI SC		1.57 (0.33,7.96)	1.36 (0.52,5.22)	0.09 (-0.25,0.34)
HD ETN SC		1.48 (0.18,11.79)	1.30 (0.29,6.00)	0.07 (-0.34,0.47)
HD ABA SC		2.79 (0.38,24.14)	1.89 (0.55,8.66)	0.22 (-0.22,0.61)
HD TOCI IV + MTX		2.50 (0.56,11.77)	1.80 (0.74,6.80)	0.20 (-0.14,0.44)
HD INF IV + MTX		2.28 (0.51,11.10)	1.71 (0.68,6.33)	0.17 (-0.16,0.44)
HD TOFA PO + MTX		1.95 (0.42,9.75)	1.56 (0.59,5.83)	0.13 (-0.21,0.40)
HD GOLI SC + MTX		2.69 (0.58,13.19)	1.87 (0.76,6.95)	0.21 (-0.13,0.47)



(Continued)

HD CERTO SC + MTX		3.52 (0.80,16.77)	2.14 (0.90,7.86)	0.27 (-0.05,0.53)
HD ADA SC + MTX		2.97 (0.52,17.42)	1.94 (0.68,7.53)	0.23 (-0.15,0.55)
HD TOCI IV + DMARD		1.72 (0.14,23.13)	1.44 (0.24,7.80)	0.11 (-0.35,0.61)
SD ANA SC + SD ETN SC + MTX		1.74 (0.28,12.85)	1.45 (0.43,6.32)	0.11 (-0.28,0.48)
SD ANA SC + LD ETN SC + MTX		2.59 (0.40,18.65)	1.82 (0.57,7.71)	0.20 (-0.20,0.56)
LD GOLI IV + MTX	LD CERTO SC + MTX	0.53 (0.14,1.88)	0.66 (0.28,1.51)	-0.13 (-0.41,0.13)
LD TOCI IV + MTX		0.43 (0.12,1.63)	0.57 (0.22,1.39)	-0.17 (-0.45,0.10)
LD TOFA PO + MTX		0.73 (0.16,3.21)	0.83 (0.29,1.96)	-0.07 (-0.38,0.26)
HD TOCI IV		0.68 (0.24,1.95)	0.79 (0.45,1.62)	-0.08 (-0.33,0.13)
HD TOFA PO		0.99 (0.26,3.66)	0.99 (0.50,2.37)	0.00 (-0.32,0.28)
HD ADA SC		0.45 (0.12,1.75)	0.58 (0.26,1.49)	-0.17 (-0.46,0.10)
HD GOLI SC		0.74 (0.23,2.43)	0.83 (0.43,1.82)	-0.07 (-0.33,0.19)
HD ETN SC		0.70 (0.12,3.91)	0.80 (0.22,2.18)	-0.08 (-0.43,0.31)
HD ABA SC		1.34 (0.23,8.00)	1.17 (0.42,2.99)	0.07 (-0.34,0.46)
HD TOCI IV + MTX		1.19 (0.42,3.47)	1.10 (0.64,2.21)	0.04 (-0.21,0.27)
HD INF IV + MTX		1.09 (0.36,3.29)	1.05 (0.57,2.10)	0.02 (-0.24,0.26)
HD TOFA PO + MTX		0.93 (0.30,2.82)	0.96 (0.50,1.95)	-0.02 (-0.28,0.23)
HD GOLI SC + MTX		1.28 (0.42,3.90)	1.14 (0.63,2.33)	0.06 (-0.21,0.31)
HD CERTO SC + MTX		1.66 (0.68,4.11)	1.30 (0.84,2.39)	0.12 (-0.09,0.32)
HD ADA SC + MTX		1.40 (0.36,5.68)	1.19 (0.55,2.57)	0.08 (-0.24,0.39)
HD TOCI IV + DMARD		0.82 (0.08,8.19)	0.89 (0.17,2.87)	-0.04 (-0.47,0.46)
SD ANA SC + SD ETN SC + MTX		0.83 (0.18,4.14)	0.90 (0.33,2.29)	-0.04 (-0.37,0.32)
SD ANA SC + LD ETN SC + MTX		1.23 (0.26,5.77)	1.12 (0.45,2.65)	0.05 (-0.30,0.40)
LD TOCI IV + MTX	LD GOLI IV + MTX	0.83 (0.22,3.17)	0.87 (0.32,2.38)	-0.03 (-0.29,0.21)
LD TOFA PO + MTX		1.37 (0.31,6.19)	1.24 (0.42,3.38)	0.06 (-0.22,0.39)
HD TOCI IV		1.30 (0.45,3.78)	1.20 (0.61,2.82)	0.05 (-0.18,0.24)

(Continued)

HD TOFA PO		1.85 (0.52,7.01)	1.50 (0.68,4.10)	0.13 (-0.15,0.37)
HD ADA SC		0.86 (0.23,3.36)	0.89 (0.36,2.56)	-0.03 (-0.30,0.20)
HD GOLI SC		1.41 (0.46,4.48)	1.26 (0.60,3.05)	0.07 (-0.17,0.29)
HD ETN SC		1.31 (0.23,7.51)	1.20 (0.33,3.81)	0.05 (-0.27,0.42)
HD ABA SC		2.52 (0.44,15.71)	1.76 (0.59,5.29)	0.20 (-0.18,0.57)
HD TOCI IV + MTX		2.25 (0.76,6.73)	1.67 (0.85,3.87)	0.18 (-0.06,0.39)
HD INF IV + MTX		2.04 (0.67,6.49)	1.58 (0.78,3.68)	0.15 (-0.09,0.38)
HD TOFA PO + MTX		1.75 (0.56,5.82)	1.44 (0.69,3.51)	0.12 (-0.13,0.36)
HD GOLI SC + MTX		2.42 (0.80,7.62)	1.73 (0.88,4.09)	0.19 (-0.05,0.42)
HD CERTO SC + MTX		3.17 (1.10,9.53)	1.98 (1.05,4.53)	0.26 (0.02,0.47)
HD ADA SC + MTX		2.63 (0.67,10.67)	1.80 (0.78,4.36)	0.21 (-0.09,0.51)
HD TOCI IV + DMARD		1.52 (0.17,15.87)	1.33 (0.25,4.95)	0.08 (-0.30,0.58)
SD ANA SC + SD ETN SC + MTX		1.56 (0.34,7.82)	1.34 (0.47,3.96)	0.09 (-0.21,0.43)
SD ANA SC + LD ETN SC + MTX		2.33 (0.51,11.57)	1.68 (0.64,4.61)	0.18 (-0.14,0.52)
LD TOFA PO + MTX	LD TOCI IV + MTX	1.67 (0.35,7.78)	1.43 (0.44,4.13)	0.10 (-0.19,0.42)
HD TOCI IV		1.57 (0.62,4.10)	1.38 (0.74,3.08)	0.09 (-0.11,0.24)
HD TOFA PO		2.27 (0.62,8.42)	1.75 (0.74,4.80)	0.17 (-0.11,0.40)
HD ADA SC		1.02 (0.29,3.86)	1.02 (0.42,2.94)	0.00 (-0.24,0.22)
HD GOLI SC		1.71 (0.53,5.66)	1.46 (0.65,3.65)	0.10 (-0.14,0.32)
HD ETN SC		1.58 (0.27,9.48)	1.38 (0.36,4.47)	0.09 (-0.23,0.46)
HD ABA SC		3.03 (0.53,19.91)	2.03 (0.66,6.26)	0.24 (-0.13,0.61)
HD TOCI IV + MTX		2.71 (1.04,7.39)	1.93 (1.03,4.31)	0.21 (0.01,0.40)
HD INF IV + MTX		2.49 (0.79,8.16)	1.83 (0.87,4.40)	0.19 (-0.05,0.42)
HD TOFA PO + MTX		2.14 (0.63,7.21)	1.67 (0.74,4.12)	0.15 (-0.10,0.39)
HD GOLI SC + MTX		2.95 (0.90,9.54)	2.01 (0.94,4.76)	0.23 (-0.02,0.46)
HD CERTO SC + MTX		3.84 (1.30,11.94)	2.29 (1.16,5.34)	0.29 (0.06,0.51)
HD ADA SC + MTX		3.24 (0.79,13.56)	2.08 (0.86,5.38)	0.25 (-0.05,0.54)

(Continued)

HD TOCI IV + DMARD		1.87 (0.20,19.42)	1.54 (0.28,5.80)	0.12 (-0.25,0.60)
SD ANA SC + SD ETN SC + MTX		1.90 (0.40,9.49)	1.56 (0.51,4.50)	0.12 (-0.18,0.46)
SD ANA SC + LD ETN SC + MTX		2.82 (0.60,13.84)	1.95 (0.71,5.41)	0.22 (-0.10,0.55)
HD TOCI IV	LD TOFA PO + MTX	0.94 (0.26,3.62)	0.96 (0.47,2.72)	-0.01 (-0.32,0.22)
HD TOFA PO		1.34 (0.29,6.55)	1.20 (0.53,3.89)	0.07 (-0.29,0.36)
HD ADA SC		0.62 (0.13,3.05)	0.71 (0.28,2.41)	-0.10 (-0.44,0.18)
HD GOLI SC		1.03 (0.25,4.19)	1.02 (0.46,2.93)	0.01 (-0.32,0.27)
HD ETN SC		0.95 (0.14,6.80)	0.97 (0.25,3.62)	-0.01 (-0.41,0.39)
HD ABA SC		1.84 (0.27,13.28)	1.42 (0.46,4.82)	0.14 (-0.30,0.54)
HD TOCI IV + MTX		1.63 (0.44,6.31)	1.34 (0.67,3.81)	0.11 (-0.19,0.37)
HD INF IV + MTX		1.51 (0.38,5.94)	1.28 (0.60,3.53)	0.09 (-0.23,0.36)
HD TOFA PO + MTX		1.27 (0.40,4.13)	1.16 (0.61,2.80)	0.05 (-0.21,0.28)
HD GOLI SC + MTX		1.75 (0.46,7.03)	1.39 (0.67,3.87)	0.13 (-0.18,0.40)
HD CERTO SC + MTX		2.30 (0.62,8.73)	1.59 (0.81,4.38)	0.19 (-0.11,0.45)
HD ADA SC + MTX		1.93 (0.39,10.08)	1.45 (0.58,4.30)	0.15 (-0.22,0.49)
HD TOCI IV + DMARD		1.14 (0.11,14.27)	1.09 (0.20,4.67)	0.03 (-0.42,0.55)
SD ANA SC + SD ETN SC + MTX		1.16 (0.20,6.79)	1.09 (0.36,3.57)	0.03 (-0.35,0.39)
SD ANA SC + LD ETN SC + MTX		1.71 (0.30,9.81)	1.36 (0.49,4.22)	0.12 (-0.27,0.48)
HD TOFA PO	HD TOCI IV	1.43 (0.56,3.74)	1.25 (0.69,2.33)	0.08 (-0.13,0.29)
HD ADA SC		0.66 (0.26,1.74)	0.74 (0.37,1.48)	-0.08 (-0.26,0.12)
HD GOLI SC		1.10 (0.46,2.61)	1.06 (0.58,1.85)	0.02 (-0.16,0.22)
HD ETN SC		1.01 (0.21,4.71)	1.01 (0.29,2.40)	0.00 (-0.26,0.36)
HD ABA SC		1.96 (0.43,9.65)	1.49 (0.56,3.17)	0.16 (-0.17,0.50)
HD TOCI IV + MTX		1.75 (0.99,3.08)	1.40 (0.99,1.98)	0.13 (0.00,0.26)
HD INF IV + MTX		1.59 (0.69,3.67)	1.33 (0.78,2.15)	0.10 (-0.08,0.30)
HD TOFA PO + MTX		1.36 (0.55,3.21)	1.21 (0.66,2.01)	0.07 (-0.12,0.27)

(Continued)

HD GOLI SC + MTX		1.88 (0.79,4.42)	1.45 (0.86,2.33)	0.15 (-0.05,0.35)
HD CERTO SC + MTX		2.45 (1.15,5.21)	1.66 (1.09,2.53)	0.21 (0.03,0.38)
HD ADA SC + MTX		2.04 (0.66,6.69)	1.51 (0.75,2.66)	0.17 (-0.09,0.43)
HD TOCI IV + DMARD		1.20 (0.15,10.25)	1.12 (0.22,3.10)	0.04 (-0.30,0.52)
SD ANA SC + SD ETN SC + MTX		1.21 (0.33,4.84)	1.13 (0.43,2.40)	0.04 (-0.21,0.36)
SD ANA SC + LD ETN SC + MTX		1.79 (0.48,6.85)	1.42 (0.59,2.73)	0.13 (-0.15,0.44)
HD ADA SC	HD TOFA PO	0.46 (0.17,1.22)	0.59 (0.29,1.14)	-0.16 (-0.36,0.04)
HD GOLI SC		0.77 (0.25,2.21)	0.85 (0.40,1.61)	-0.06 (-0.30,0.19)
HD ETN SC		0.70 (0.13,3.58)	0.80 (0.22,1.95)	-0.08 (-0.38,0.30)
HD ABA SC		1.35 (0.30,6.83)	1.18 (0.46,2.40)	0.07 (-0.26,0.43)
HD TOCI IV + MTX		1.21 (0.43,3.48)	1.12 (0.60,1.99)	0.05 (-0.20,0.29)
HD INF IV + MTX		1.12 (0.34,3.46)	1.07 (0.51,1.99)	0.03 (-0.25,0.29)
HD TOFA PO + MTX		0.95 (0.28,3.08)	0.97 (0.44,1.87)	-0.01 (-0.28,0.27)
HD GOLI SC + MTX		1.30 (0.40,4.07)	1.16 (0.57,2.11)	0.06 (-0.21,0.33)
HD CERTO SC + MTX		1.71 (0.55,5.12)	1.33 (0.71,2.31)	0.13 (-0.14,0.38)
HD ADA SC + MTX		1.44 (0.35,5.74)	1.22 (0.51,2.30)	0.09 (-0.23,0.40)
HD TOCI IV + DMARD		0.82 (0.10,7.14)	0.88 (0.17,2.34)	-0.05 (-0.40,0.43)
SD ANA SC + SD ETN SC + MTX		0.85 (0.20,3.81)	0.91 (0.33,1.97)	-0.04 (-0.33,0.31)
SD ANA SC + LD ETN SC + MTX		1.26 (0.30,5.48)	1.14 (0.45,2.26)	0.06 (-0.26,0.39)
HD GOLI SC	HD ADA SC	1.66 (0.53,5.13)	1.43 (0.63,3.11)	0.10 (-0.12,0.33)
HD ETN SC		1.54 (0.27,7.84)	1.36 (0.35,3.57)	0.08 (-0.20,0.45)
HD ABA SC		2.95 (0.62,15.08)	1.99 (0.71,4.63)	0.23 (-0.09,0.58)
HD TOCI IV + MTX		2.63 (0.90,7.64)	1.88 (0.93,3.82)	0.21 (-0.02,0.43)
HD INF IV + MTX		2.43 (0.72,7.91)	1.81 (0.80,3.81)	0.19 (-0.07,0.44)
HD TOFA PO + MTX		2.06 (0.60,6.84)	1.63 (0.69,3.58)	0.15 (-0.10,0.41)
HD GOLI SC + MTX		2.86 (0.85,9.26)	1.96 (0.89,4.07)	0.23 (-0.03,0.48)

(Continued)

HD CERTO SC + MTX		3.72 (1.17,11.58)	2.24 (1.11,4.50)	0.29 (0.04,0.53)
HD ADA SC + MTX		3.11 (0.74,13.00)	2.05 (0.81,4.44)	0.25 (-0.06,0.55)
HD TOCI IV + DMARD		1.81 (0.21,15.25)	1.51 (0.28,4.33)	0.12 (-0.22,0.58)
SD ANA SC + SD ETN SC + MTX		1.85 (0.42,8.59)	1.53 (0.52,3.79)	0.12 (-0.15,0.47)
SD ANA SC + LD ETN SC + MTX		2.74 (0.60,12.43)	1.93 (0.70,4.38)	0.22 (-0.10,0.54)
HD ETN SC	HD GOLI SC	0.92 (0.18,4.68)	0.95 (0.28,2.45)	-0.02 (-0.31,0.35)
HD ABA SC		1.78 (0.36,9.35)	1.39 (0.51,3.24)	0.13 (-0.22,0.50)
HD TOCI IV + MTX		1.59 (0.64,3.95)	1.31 (0.77,2.36)	0.11 (-0.10,0.31)
HD INF IV + MTX		1.45 (0.55,3.90)	1.25 (0.69,2.30)	0.09 (-0.13,0.31)
HD TOFA PO + MTX		1.24 (0.45,3.40)	1.14 (0.59,2.14)	0.05 (-0.17,0.28)
HD GOLI SC + MTX		1.70 (0.74,3.87)	1.36 (0.84,2.25)	0.12 (-0.07,0.31)
HD CERTO SC + MTX		2.25 (0.87,5.71)	1.56 (0.93,2.76)	0.19 (-0.03,0.40)
HD ADA SC + MTX		1.87 (0.53,6.68)	1.42 (0.66,2.80)	0.14 (-0.14,0.43)
HD TOCI IV + DMARD		1.08 (0.13,10.71)	1.05 (0.21,3.23)	0.02 (-0.34,0.52)
SD ANA SC + SD ETN SC + MTX		1.11 (0.27,4.84)	1.07 (0.39,2.47)	0.02 (-0.26,0.36)
SD ANA SC + LD ETN SC + MTX		1.65 (0.40,6.88)	1.34 (0.54,2.83)	0.11 (-0.19,0.44)
HD ABA SC	HD ETN SC	1.92 (0.27,15.51)	1.46 (0.46,5.62)	0.15 (-0.30,0.56)
HD TOCI IV + MTX		1.73 (0.36,8.34)	1.39 (0.59,4.64)	0.12 (-0.24,0.41)
HD INF IV + MTX		1.57 (0.31,8.12)	1.31 (0.53,4.47)	0.10 (-0.28,0.41)
HD TOFA PO + MTX		1.36 (0.24,6.81)	1.21 (0.45,4.06)	0.07 (-0.32,0.38)
HD GOLI SC + MTX		1.85 (0.36,9.57)	1.43 (0.60,4.86)	0.14 (-0.24,0.45)
HD CERTO SC + MTX		2.42 (0.49,12.49)	1.63 (0.72,5.55)	0.20 (-0.17,0.51)
HD ADA SC + MTX		2.05 (0.33,12.63)	1.50 (0.54,5.25)	0.16 (-0.25,0.52)
HD TOCI IV + DMARD		1.16 (0.11,14.39)	1.10 (0.20,5.07)	0.03 (-0.43,0.55)
SD ANA SC + SD ETN SC + MTX		1.21 (0.21,7.35)	1.13 (0.37,3.89)	0.04 (-0.35,0.41)

(Continued)

SD ANA SC + LD ETN SC + MTX		1.79 (0.32,10.19)	1.40 (0.52,4.57)	0.13 (-0.26,0.48)
HD TOCI IV + MTX	HD ABA SC	0.89 (0.17,4.27)	0.94 (0.45,2.44)	-0.03 (-0.40,0.32)
HD INF IV + MTX		0.81 (0.15,4.30)	0.89 (0.39,2.42)	-0.05 (-0.43,0.33)
HD TOFA PO + MTX		0.69 (0.13,3.64)	0.82 (0.34,2.24)	-0.09 (-0.46,0.29)
HD GOLI SC + MTX		0.96 (0.17,4.95)	0.98 (0.43,2.59)	-0.01 (-0.40,0.36)
HD CERTO SC + MTX		1.26 (0.23,6.53)	1.12 (0.53,2.89)	0.06 (-0.33,0.42)
HD ADA SC + MTX		1.04 (0.17,6.26)	1.02 (0.40,2.76)	0.01 (-0.40,0.42)
HD TOCI IV + DMARD		0.62 (0.05,6.51)	0.77 (0.14,2.50)	-0.11 (-0.56,0.42)
SD ANA SC + SD ETN SC + MTX		0.63 (0.09,4.31)	0.77 (0.25,2.32)	-0.11 (-0.52,0.33)
SD ANA SC + LD ETN SC + MTX		0.91 (0.14,6.39)	0.96 (0.34,2.73)	-0.02 (-0.44,0.42)
HD INF IV + MTX	HD TOCI IV + MTX	0.92 (0.38,2.17)	0.96 (0.56,1.51)	-0.02 (-0.22,0.19)
HD TOFA PO + MTX		0.78 (0.31,1.89)	0.87 (0.48,1.42)	-0.06 (-0.26,0.15)
HD GOLI SC + MTX		1.08 (0.44,2.58)	1.04 (0.62,1.64)	0.02 (-0.19,0.22)
HD CERTO SC + MTX		1.41 (0.64,3.07)	1.18 (0.79,1.78)	0.08 (-0.11,0.27)
HD ADA SC + MTX		1.17 (0.38,3.85)	1.08 (0.54,1.85)	0.04 (-0.22,0.31)
HD TOCI IV + DMARD		0.69 (0.09,6.07)	0.80 (0.17,2.20)	-0.09 (-0.45,0.40)
SD ANA SC + SD ETN SC + MTX		0.70 (0.19,2.89)	0.81 (0.32,1.69)	-0.08 (-0.35,0.25)
SD ANA SC + LD ETN SC + MTX		1.03 (0.28,4.07)	1.02 (0.44,1.95)	0.01 (-0.28,0.32)
HD TOFA PO + MTX	HD INF IV + MTX	0.86 (0.32,2.19)	0.92 (0.50,1.58)	-0.04 (-0.26,0.18)
HD GOLI SC + MTX		1.18 (0.46,2.98)	1.09 (0.65,1.86)	0.04 (-0.18,0.25)
HD CERTO SC + MTX		1.53 (0.66,3.63)	1.24 (0.81,2.05)	0.10 (-0.10,0.30)
HD ADA SC + MTX		1.29 (0.38,4.39)	1.14 (0.56,2.10)	0.06 (-0.22,0.34)
HD TOCI IV + DMARD		0.75 (0.09,6.98)	0.84 (0.17,2.50)	-0.06 (-0.45,0.44)
SD ANA SC + SD ETN SC + MTX		0.77 (0.19,3.21)	0.85 (0.33,1.85)	-0.06 (-0.35,0.27)
SD ANA SC + LD ETN SC + MTX		1.13 (0.29,4.59)	1.07 (0.45,2.18)	0.03 (-0.28,0.35)

(Continued)

HD GOLI SC + MTX	HD TOFA PO + MTX	1.38 (0.52,3.67)	1.19 (0.69,2.19)	0.07 (-0.15,0.30)
HD CERTO SC + MTX		1.80 (0.75,4.53)	1.36 (0.86,2.41)	0.14 (-0.07,0.35)
HD ADA SC + MTX		1.51 (0.43,5.51)	1.25 (0.60,2.48)	0.10 (-0.19,0.39)
HD TOCI IV + DMARD		0.87 (0.10,8.84)	0.92 (0.18,2.89)	-0.03 (-0.41,0.48)
SD ANA SC + SD ETN SC + MTX		0.90 (0.22,3.87)	0.94 (0.36,2.18)	-0.02 (-0.32,0.31)
SD ANA SC + LD ETN SC + MTX		1.33 (0.33,5.74)	1.17 (0.49,2.54)	0.07 (-0.24,0.39)
HD CERTO SC + MTX	HD GOLI SC + MTX	1.32 (0.53,3.14)	1.14 (0.74,1.85)	0.07 (-0.15,0.27)
HD ADA SC + MTX		1.09 (0.32,3.87)	1.04 (0.51,1.94)	0.02 (-0.26,0.31)
HD TOCI IV + DMARD		0.63 (0.07,6.39)	0.77 (0.15,2.23)	-0.11 (-0.50,0.41)
SD ANA SC + SD ETN SC + MTX		0.65 (0.16,2.81)	0.79 (0.30,1.70)	-0.10 (-0.39,0.24)
SD ANA SC + LD ETN SC + MTX		0.96 (0.24,4.08)	0.98 (0.42,1.97)	-0.01 (-0.32,0.32)
HD ADA SC + MTX	HD CERTO SC + MTX	0.84 (0.26,2.74)	0.92 (0.46,1.54)	-0.04 (-0.31,0.23)
HD TOCI IV + DMARD		0.49 (0.06,4.58)	0.68 (0.14,1.83)	-0.17 (-0.55,0.34)
SD ANA SC + SD ETN SC + MTX		0.49 (0.13,2.04)	0.69 (0.27,1.39)	-0.17 (-0.44,0.17)
SD ANA SC + LD ETN SC + MTX		0.74 (0.19,2.97)	0.86 (0.37,1.59)	-0.07 (-0.37,0.25)
HD TOCI IV + DMARD	HD ADA SC + MTX	0.61 (0.05,6.65)	0.76 (0.14,2.40)	-0.11 (-0.56,0.41)
SD ANA SC + SD ETN SC + MTX		0.59 (0.12,3.12)	0.75 (0.28,1.88)	-0.12 (-0.46,0.26)
SD ANA SC + LD ETN SC + MTX		0.87 (0.18,4.53)	0.93 (0.38,2.19)	-0.03 (-0.39,0.34)
SD ANA SC + SD ETN SC + MTX	HD TOCI IV + DMARD	1.01 (0.10,10.84)	1.00 (0.28,5.37)	0.00 (-0.50,0.45)
SD ANA SC + LD ETN SC + MTX		1.49 (0.15,15.67)	1.25 (0.38,6.50)	0.09 (-0.42,0.53)
SD ANA SC + LD ETN SC + MTX	SD ANA SC + SD ETN SC + MTX	1.47 (0.54,4.10)	1.24 (0.69,2.45)	0.08 (-0.14,0.31)

(Continued)

Random-Effect Model	Residual Deviance	180 vs 175 data points
	Deviance Information Criteria	1121.54
Fixed-Effect Model	Residual Deviance	251.8 vs 175 data points
	Deviance Information Criteria	1166.12
Note:		
Total Patients	24122	
Total Studies	66	
2-arm	35	
3-arm	23	
4-arm	6	
5-arm	1	
7-arm	1	

### Appendix 8. ACR50: Subgroup - Trial duration (> 6 to 12 months)

ACR50, Intermediate trial duration: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD ETN SC	PL + MTX	2.81 (1.01,7.87)	2.13 (1.01,3.59)	0.20 (0.00,0.45)
SD ETN SC + MTX		4.74 (1.71,13.91)	2.85 (1.52,4.32)	0.33 (0.09,0.57)
SD INF IV + MTX		3.14 (0.90,13.36)	2.28 (0.92,4.49)	0.23 (-0.01,0.56)
SD ADA SC + MTX		6.83 (2.41,20.66)	3.35 (1.92,4.83)	0.42 (0.17,0.64)
SD RITUX IV + MTX		1.42 (0.50,4.08)	1.32 (0.55,2.65)	0.06 (-0.08,0.29)
SD TOFA PO + MTX		5.57 (1.78,16.57)	3.08 (1.56,4.66)	0.37 (0.10,0.60)
LD ADA SC + MTX		5.79 (2.05,17.54)	3.13 (1.72,4.65)	0.38 (0.13,0.61)
LD RITUX IV + MTX		0.98 (0.35,2.82)	0.99 (0.39,2.13)	0.00 (-0.11,0.20)



(Continued)

LD ETN SC + MTX		3.84 (1.43,11.41)	2.56 (1.33,4.10)	0.27 (0.06,0.53)
HD ETN SC		2.51 (0.91,6.89)	1.98 (0.92,3.39)	0.17 (-0.01,0.42)
HD INF IV + MTX		7.84 (2.21,31.05)	3.54 (1.80,5.41)	0.45 (0.15,0.69)
HD TOFA PO + MTX		8.98 (2.97,27.44)	3.72 (2.17,5.17)	0.48 (0.22,0.68)
SD ETN SC + MTX	SD ETN SC	1.68 (0.41,7.67)	1.33 (0.62,3.05)	0.12 (-0.20,0.44)
SD INF IV + MTX		1.12 (0.22,6.35)	1.07 (0.39,2.80)	0.03 (-0.32,0.41)
SD ADA SC + MTX		2.43 (0.58,10.48)	1.57 (0.77,3.45)	0.21 (-0.12,0.50)
SD RITUX IV + MTX		0.50 (0.12,2.21)	0.62 (0.23,1.70)	-0.14 (-0.42,0.16)
SD TOFA PO + MTX		1.99 (0.41,8.74)	1.44 (0.62,3.22)	0.17 (-0.20,0.47)
LD ADA SC + MTX		2.06 (0.49,9.44)	1.47 (0.69,3.30)	0.17 (-0.16,0.47)
LD RITUX IV + MTX		0.35 (0.08,1.47)	0.47 (0.16,1.31)	-0.20 (-0.46,0.07)
LD ETN SC + MTX		1.36 (0.33,6.05)	1.20 (0.54,2.82)	0.07 (-0.24,0.38)
HD ETN SC		0.89 (0.32,2.50)	0.93 (0.49,1.75)	-0.03 (-0.23,0.19)
HD INF IV + MTX		2.80 (0.54,15.37)	1.66 (0.73,3.72)	0.25 (-0.14,0.57)
HD TOFA PO + MTX		3.22 (0.69,14.41)	1.74 (0.85,3.75)	0.28 (-0.08,0.56)
SD INF IV + MTX	SD ETN SC + MTX	0.66 (0.13,3.80)	0.80 (0.30,1.88)	-0.10 (-0.44,0.30)
SD ADA SC + MTX		1.45 (0.32,6.48)	1.18 (0.60,2.34)	0.09 (-0.25,0.40)
SD RITUX IV + MTX		0.30 (0.07,1.29)	0.47 (0.18,1.17)	-0.26 (-0.54,0.05)
SD TOFA PO + MTX		1.18 (0.23,5.09)	1.08 (0.50,2.19)	0.04 (-0.32,0.36)
LD ADA SC + MTX		1.23 (0.27,5.46)	1.10 (0.55,2.22)	0.05 (-0.28,0.37)
LD RITUX IV + MTX		0.21 (0.05,0.88)	0.35 (0.13,0.93)	-0.32 (-0.58,-0.02)
LD ETN SC + MTX		0.81 (0.29,2.29)	0.90 (0.53,1.52)	-0.05 (-0.27,0.18)
HD ETN SC		0.53 (0.12,2.17)	0.70 (0.30,1.53)	-0.15 (-0.45,0.17)
HD INF IV + MTX		1.66 (0.31,8.96)	1.24 (0.60,2.49)	0.12 (-0.26,0.46)
HD TOFA PO + MTX		1.90 (0.39,8.32)	1.30 (0.69,2.50)	0.15 (-0.20,0.45)
SD ADA SC + MTX	SD INF IV + MTX	2.17 (0.37,11.79)	1.46 (0.65,3.74)	0.19 (-0.22,0.53)
SD RITUX IV + MTX		0.45 (0.08,2.40)	0.58 (0.20,1.82)	-0.17 (-0.51,0.17)
SD TOFA PO + MTX		1.78 (0.28,9.05)	1.35 (0.55,3.48)	0.14 (-0.29,0.48)

(Continued)

LD ADA SC + MTX		1.82 (0.31,10.15)	1.36 (0.58,3.53)	0.14 (-0.27,0.50)
LD RITUX IV + MTX		0.31 (0.05,1.62)	0.44 (0.14,1.42)	-0.22 (-0.57,0.08)
LD ETN SC + MTX		1.23 (0.22,6.52)	1.12 (0.46,3.05)	0.05 (-0.34,0.40)
HD ETN SC		0.80 (0.14,3.96)	0.87 (0.33,2.41)	-0.05 (-0.42,0.29)
HD INF IV + MTX		2.47 (0.77,7.67)	1.52 (0.90,3.03)	0.21 (-0.05,0.44)
HD TOFA PO + MTX		2.85 (0.46,14.83)	1.62 (0.73,4.00)	0.25 (-0.17,0.56)
SD RITUX IV + MTX	SD ADA SC + MTX	0.21 (0.05,0.92)	0.40 (0.16,0.95)	-0.35 (-0.61,-0.02)
SD TOFA PO + MTX		0.82 (0.16,3.58)	0.92 (0.44,1.72)	-0.05 (-0.39,0.28)
LD ADA SC + MTX		0.85 (0.31,2.31)	0.94 (0.60,1.41)	-0.04 (-0.25,0.18)
LD RITUX IV + MTX		0.14 (0.03,0.64)	0.30 (0.11,0.77)	-0.41 (-0.66,-0.09)
LD ETN SC + MTX		0.56 (0.13,2.51)	0.76 (0.38,1.53)	-0.14 (-0.44,0.21)
HD ETN SC		0.37 (0.08,1.57)	0.59 (0.26,1.25)	-0.24 (-0.53,0.10)
HD INF IV + MTX		1.15 (0.20,6.47)	1.05 (0.51,2.00)	0.03 (-0.35,0.39)
HD TOFA PO + MTX		1.33 (0.27,5.83)	1.11 (0.61,1.99)	0.07 (-0.28,0.37)
SD TOFA PO + MTX	SD RITUX IV + MTX	3.95 (0.82,17.29)	2.32 (0.89,5.80)	0.31 (-0.04,0.57)
LD ADA SC + MTX		4.06 (0.91,18.89)	2.34 (0.95,5.90)	0.31 (-0.02,0.58)
LD RITUX IV + MTX		0.69 (0.24,1.98)	0.75 (0.33,1.68)	-0.06 (-0.24,0.11)
LD ETN SC + MTX		2.70 (0.63,11.96)	1.92 (0.76,4.98)	0.21 (-0.09,0.49)
HD ETN SC		1.77 (0.41,7.58)	1.49 (0.55,4.07)	0.11 (-0.17,0.39)
HD INF IV + MTX		5.54 (1.05,30.12)	2.65 (1.03,6.75)	0.39 (0.01,0.67)
HD TOFA PO + MTX		6.36 (1.35,28.09)	2.80 (1.17,6.76)	0.42 (0.06,0.66)
LD ADA SC + MTX	SD TOFA PO + MTX	1.03 (0.24,5.17)	1.01 (0.52,2.14)	0.01 (-0.32,0.36)
LD RITUX IV + MTX		0.17 (0.04,0.81)	0.32 (0.12,0.88)	-0.36 (-0.61,-0.04)
LD ETN SC + MTX		0.69 (0.16,3.41)	0.83 (0.40,1.84)	-0.09 (-0.40,0.27)
HD ETN SC		0.45 (0.10,2.11)	0.64 (0.28,1.50)	-0.19 (-0.49,0.17)
HD INF IV + MTX		1.40 (0.26,8.53)	1.15 (0.56,2.40)	0.08 (-0.30,0.45)
HD TOFA PO + MTX		1.61 (0.61,4.39)	1.20 (0.83,1.93)	0.11 (-0.10,0.31)

(Continued)

LD RITUX IV + MTX	LD ADA SC + MTX	0.17 (0.04,0.75)	0.32 (0.12,0.84)	-0.37 (-0.63,-0.05)
LD ETN SC + MTX		0.66 (0.15,2.95)	0.82 (0.39,1.68)	-0.10 (-0.41,0.24)
HD ETN SC		0.43 (0.10,1.87)	0.63 (0.28,1.38)	-0.20 (-0.49,0.14)
HD INF IV + MTX		1.36 (0.24,7.78)	1.13 (0.53,2.23)	0.07 (-0.32,0.43)
HD TOFA PO + MTX		1.56 (0.31,6.82)	1.19 (0.64,2.23)	0.10 (-0.25,0.41)
LD ETN SC + MTX	LD RITUX IV + MTX	3.91 (0.95,17.62)	2.58 (0.97,7.05)	0.27 (-0.01,0.54)
HD ETN SC		2.55 (0.60,11.03)	2.00 (0.69,5.81)	0.17 (-0.09,0.43)
HD INF IV + MTX		7.97 (1.55,44.08)	3.54 (1.29,9.51)	0.45 (0.09,0.71)
HD TOFA PO + MTX		9.20 (2.02,39.56)	3.75 (1.48,9.45)	0.48 (0.14,0.70)
HD ETN SC	LD ETN SC + MTX	0.65 (0.15,2.65)	0.78 (0.33,1.75)	-0.10 (-0.41,0.21)
HD INF IV + MTX		2.04 (0.40,10.79)	1.38 (0.64,2.88)	0.17 (-0.21,0.50)
HD TOFA PO + MTX		2.33 (0.49,10.00)	1.45 (0.74,2.89)	0.20 (-0.16,0.49)
HD INF IV + MTX	HD ETN SC	3.13 (0.60,16.97)	1.77 (0.77,4.04)	0.27 (-0.11,0.58)
HD TOFA PO + MTX		3.60 (0.77,15.84)	1.88 (0.89,4.11)	0.30 (-0.06,0.57)
HD TOFA PO + MTX	HD INF IV + MTX	1.15 (0.20,6.02)	1.05 (0.57,2.07)	0.03 (-0.33,0.38)
Random-Effect Model	Residual Deviance	18.31 vs 18 data points		
	Deviance Information Criteria	132.003		
Fixed-Effect Model	Residual Deviance	18.03 vs data points		
	Deviance Information Criteria	131.437		
Note:				
Total Patients	3209			
Total Studies	6			
3-arm	6			

**Appendix 9. HAQ: Type of medication**

HAQ Analysis 2: Mean Difference (MD) for All Treatment Comparisons-Random Effects Model		
Treatment	Reference	MD (95% CrI)
TNF	PL	-0.24 (-0.39,-0.08)
non-TNF		-0.32 (-0.59,-0.05)
TOFA		-0.45 (-0.79,-0.13)
ANA		-0.23 (-0.77,0.31)
MTXTNF		-0.31 (-0.42,-0.20)
MTXnon-TNF		-0.22 (-0.41,-0.02)
MTXTOFA		-0.44 (-0.94,0.07)
non-TNF	TNF	-0.08 (-0.39,0.22)
TOFA		-0.21 (-0.56,0.12)
ANA		0.00 (-0.56,0.57)
MTXTNF		-0.07 (-0.24,0.09)
MTXnon-TNF		0.02 (-0.23,0.27)
MTXTOFA		-0.20 (-0.73,0.33)
TOFA	non-TNF	-0.13 (-0.56,0.29)
ANA		0.09 (-0.52,0.69)
MTXTNF		0.01 (-0.28,0.30)
MTXnon-TNF		0.10 (-0.18,0.39)
MTXTOFA		-0.12 (-0.69,0.46)
ANA	TOFA	0.22 (-0.41,0.85)
MTXTNF		0.14 (-0.20,0.49)
MTXnon-TNF		0.24 (-0.14,0.62)
MTXTOFA		0.02 (-0.59,0.63)
MTXTNF	ANA	-0.08 (-0.63,0.47)
MTXnon-TNF		0.02 (-0.55,0.60)
MTXTOFA		-0.20 (-0.94,0.54)

(Continued)

MTXnon-TNF	MTXTNF	0.10 (-0.13,0.32)
MTXTOFA		-0.12 (-0.65,0.40)
MTXTOFA	MTXnon-TNF	-0.22 (-0.76,0.33)
Random-Effect Model	Total Residual Deviance	96.54 vs 99 data points
	Deviance Information Criteria	-207.722
Fixed-Effect Model	Total Residual Deviance	573.3 vs 99 data points
	Deviance Information Criteria	232.108
Note:		
Total Patients	15865	
Total Studies	48	
2-arm	45	
3-arm	3	

## Appendix 10. HAQ: Type of biologic

HAQ Analysis 3: Standardized Mean Difference (SMD) for All Treatment Comparisons-Random Effects Model

Treatment	Reference	MD (95% CrI)
Mono	PL	-0.27 (-0.47,-0.07)
TNF		-0.29 (-0.51,-0.06)
non-TNF		-0.32 (-0.57,-0.06)
TOFA		-0.46 (-0.78,-0.14)
ANA		-0.23 (-0.75,0.28)
MTXMono		-0.21 (-0.35,-0.08)
MTXTNF		-0.47 (-0.65,-0.29)
MTXnon-TNF		-0.22 (-0.40,-0.03)

(Continued)

MTXTOFA		-0.43 (-0.91,0.05)
TNF	Mono	-0.02 (-0.32,0.28)
non-TNF		-0.05 (-0.37,0.27)
TOFA		-0.19 (-0.54,0.15)
ANA		0.04 (-0.52,0.59)
MTXMono		0.06 (-0.18,0.29)
MTXTNF		-0.20 (-0.47,0.07)
MTXnon-TNF		0.05 (-0.22,0.32)
MTXTOFA		-0.16 (-0.68,0.35)
non-TNF	TNF	-0.03 (-0.37,0.31)
TOFA		-0.17 (-0.57,0.22)
ANA		0.05 (-0.51,0.61)
MTXMono		0.07 (-0.19,0.34)
MTXTNF		-0.18 (-0.40,0.03)
MTXnon-TNF		0.07 (-0.22,0.36)
MTXTOFA		-0.15 (-0.67,0.38)
TOFA	non-TNF	-0.14 (-0.55,0.26)
ANA		0.08 (-0.50,0.66)
MTXMono		0.10 (-0.18,0.39)
MTXTNF		-0.15 (-0.46,0.16)
MTXnon-TNF		0.10 (-0.17,0.37)
MTXTOFA		-0.11 (-0.66,0.43)
ANA	TOFA	0.23 (-0.38,0.84)
MTXMono		0.25 (-0.10,0.59)
MTXTNF		-0.01 (-0.37,0.36)
MTXnon-TNF		0.24 (-0.13,0.61)
MTXTOFA		0.03 (-0.55,0.60)
MTXMono	ANA	0.02 (-0.51,0.56)

(Continued)

MTXTNF		-0.23 (-0.78,0.31)
MTXnon-TNF		0.02 (-0.54,0.57)
MTXTOFA		-0.20 (-0.91,0.51)
MTXTNF	MTXMono	-0.25 (-0.48,-0.03)
MTXnon-TNF		0.00 (-0.23,0.23)
MTXTOFA		-0.22 (-0.72,0.28)
MTXnon-TNF	MTXTNF	0.25 (-0.01,0.51)
MTXTOFA		0.04 (-0.48,0.55)
MTXTOFA	MTXnon-TNF	-0.22 (-0.73,0.30)
<hr/>		
Random-Effect Model	Total Residual Deviance	96.91 vs 99 data points
	Deviance Information Criteria	-207.542
<hr/>		
Fixed-Effect Model	Total Residual Deviance	469.1 vs 99 data points
	Deviance Information Criteria	129.973
<hr/>		
Note:		
<hr/>		
Total Patients	16124	
Total Studies	48	
2-arm	45	
3-arm	3	

## Appendix 11. HAQ: By dose

HAQ Analysis 4: Standardized Mean Difference (SMD) for All Treatment Comparisons-Random Effects Model		
Treatment	Reference	MD (95% CrI)
SD	PL	-0.25 (-0.38,-0.13)
HD		-0.32 (-0.48,-0.16)

(Continued)

LD		-0.25 (-0.48,-0.03)
MTXSD		-0.29 (-0.38,-0.21)
MTXHD		-0.29 (-0.42,-0.16)
MTXLD		-0.21 (-0.36,-0.06)
HD	SD	-0.06 (-0.24,0.12)
LD		0.00 (-0.23,0.23)
MTXSD		-0.04 (-0.17,0.10)
MTXHD		-0.03 (-0.20,0.14)
MTXLD		0.05 (-0.14,0.23)
LD	HD	0.06 (-0.18,0.30)
MTXSD		0.02 (-0.15,0.20)
MTXHD		0.03 (-0.16,0.22)
MTXLD		0.11 (-0.10,0.32)
MTXSD	LD	-0.04 (-0.28,0.19)
MTXHD		-0.03 (-0.29,0.22)
MTXLD		0.05 (-0.22,0.31)
MTXHD	MTXSD	0.01 (-0.13,0.14)
MTXLD		0.09 (-0.07,0.24)
MTXLD	MTXHD	0.08 (-0.10,0.26)
Random-Effect Model	Total Residual Deviance	109.5 vs 110 data points
	Deviance Information Criteria	-267.724
Fixed-Effect Model	Total Residual Deviance	1429 vs 110 data points
	Deviance Information Criteria	998.821
Note:		
Total Patients	14638	



(Continued)

Total Studies	43
2-arm	26
3-arm	10
4-arm	7

## Appendix 12. HAQ: Main analysis

HAQ (Analysis 1): Mean Difference for All Treatments		
Treatment	Reference	MD (95% CrI)
MTX	PL	0.04 (-0.39,0.50)
DMARD		0.04 (-0.37,0.45)
MTX + DMARD		-0.30 (-0.83,0.23)
SD ETN SC		-0.34 (-0.70,0.03)
SD ADA SC		-0.29 (-0.51,-0.06)
SD TOFA PO		-0.40 (-0.68,-0.13)
SD CERTO		-0.33 (-0.66,0.01)
SD ANA		-0.20 (-0.63,0.23)
SD RITUX IV		-0.33 (-0.93,0.29)
SD ETN SC + MTX		-0.58 (-0.99,-0.16)
SD CERTO SC + MTX		-0.24 (-0.72,0.24)
SD RITUX IV + MTX		-0.14 (-0.64,0.39)
SD ADA SC + MTX		-0.27 (-0.77,0.25)
SD GOLI SC + MTX		0.04 (-0.49,0.59)
SD TOFA PO + MTX		-0.39 (-0.99,0.22)
SD TOCI IV + MTX		-0.16 (-0.67,0.37)
SD ABA SC + MTX		-0.18 (-0.83,0.49)
SD GOLI IV + MTX		0.35 (-0.25,0.97)
SD ETN SC + DMARD		-0.28 (-0.81,0.27)

(Continued)

SD CERTO + DMARD		-0.33 (-0.71,0.04)
LD ADA SC		-0.32 (-0.61,-0.03)
LD ANA		-0.20 (-0.62,0.22)
LD ADA SC + MTX		-0.23 (-0.74,0.30)
LD RITUX IV + MTX		-0.08 (-0.58,0.45)
LD ADA IV + MTX		-0.25 (-0.88,0.38)
LD CERTO SC + MTX		-0.16 (-0.75,0.44)
LD ETN SC + MTX		-0.32 (-0.87,0.23)
LD TOFA PO + MTX		-0.31 (-0.92,0.30)
HD TOCI IV		-0.28 (-0.74,0.20)
HD TOFA PO		-0.52 (-0.79,-0.25)
HD ADA SC		-0.43 (-0.72,-0.14)
HD ANA		-0.30 (-0.73,0.13)
HD GOLI SC		0.09 (-0.49,0.69)
HD TOCI IV + MTX		-0.26 (-0.73,0.23)
HD CERTO SC + MTX		-0.29 (-0.78,0.22)
HD TOFA PO + MTX		-0.47 (-1.07,0.14)
HD GOLI SC + MTX		0.08 (-0.46,0.62)
HD ADA SC + MTX		-0.27 (-0.85,0.33)
DMARD	MTX	-0.01 (-0.36,0.34)
MTX + DMARD		-0.35 (-0.75,0.05)
SD ETN SC		-0.38 (-0.65,-0.11)
SD ADA SC		-0.33 (-0.83,0.16)
SD TOFA PO		-0.45 (-0.97,0.07)
SD CERTO		-0.37 (-0.93,0.19)
SD ANA		-0.25 (-0.87,0.36)
SD RITUX IV		-0.37 (-0.79,0.05)
SD ETN SC + MTX		-0.62 (-0.86,-0.39)

(Continued)

SD CERTO SC + MTX	-0.29 (-0.48,-0.10)
SD RITUX IV + MTX	-0.18 (-0.44,0.07)
SD ADA SC + MTX	-0.32 (-0.56,-0.07)
SD GOLI SC + MTX	0.00 (-0.31,0.31)
SD TOFA PO + MTX	-0.44 (-0.85,-0.03)
SD TOCI IV + MTX	-0.20 (-0.48,0.08)
SD ABA SC + MTX	-0.22 (-0.70,0.27)
SD GOLI IV + MTX	0.31 (-0.11,0.73)
SD ETN SC + DMARD	-0.32 (-0.81,0.17)
SD CERTO + DMARD	-0.37 (-0.83,0.08)
LD ADA SC	-0.36 (-0.90,0.16)
LD ANA	-0.25 (-0.87,0.36)
LD ADA SC + MTX	-0.27 (-0.53,-0.01)
LD RITUX IV + MTX	-0.12 (-0.38,0.14)
LD ADA IV + MTX	-0.29 (-0.74,0.15)
LD CERTO SC + MTX	-0.20 (-0.60,0.20)
LD ETN SC + MTX	-0.36 (-0.75,0.02)
LD TOFA PO + MTX	-0.36 (-0.77,0.05)
HD TOCI IV	-0.32 (-0.60,-0.04)
HD TOFA PO	-0.56 (-1.09,-0.05)
HD ADA SC	-0.47 (-1.02,0.05)
HD ANA	-0.35 (-0.97,0.27)
HD GOLI SC	0.05 (-0.34,0.44)
HD TOCI IV + MTX	-0.30 (-0.53,-0.08)
HD CERTO SC + MTX	-0.33 (-0.56,-0.09)
HD TOFA PO + MTX	-0.51 (-0.93,-0.11)
HD GOLI SC + MTX	0.03 (-0.27,0.34)
HD ADA SC + MTX	-0.31 (-0.70,0.08)

(Continued)

MTX + DMARD	DMARD	-0.34 (-0.81,0.14)
SD ETN SC		-0.38 (-0.68,-0.06)
SD ADA SC		-0.33 (-0.80,0.14)
SD TOFA PO		-0.44 (-0.94,0.05)
SD CERTO		-0.37 (-0.89,0.17)
SD ANA		-0.24 (-0.83,0.35)
SD RITUX IV		-0.36 (-0.91,0.18)
SD ETN SC + MTX		-0.62 (-0.97,-0.27)
SD CERTO SC + MTX		-0.28 (-0.68,0.12)
SD RITUX IV + MTX		-0.17 (-0.61,0.27)
SD ADA SC + MTX		-0.31 (-0.74,0.13)
SD GOLI SC + MTX		0.01 (-0.46,0.48)
SD TOFA PO + MTX		-0.43 (-0.97,0.11)
SD TOCI IV + MTX		-0.20 (-0.63,0.24)
SD ABA SC + MTX		-0.21 (-0.81,0.39)
SD GOLI IV + MTX		0.32 (-0.23,0.86)
SD ETN SC + DMARD		-0.32 (-0.66,0.04)
SD CERTO + DMARD		-0.37 (-0.74,0.00)
LD ADA SC		-0.36 (-0.86,0.15)
LD ANA		-0.24 (-0.83,0.35)
LD ADA SC + MTX		-0.27 (-0.71,0.18)
LD RITUX IV + MTX		-0.11 (-0.55,0.33)
LD ADA IV + MTX		-0.29 (-0.85,0.28)
LD CERTO SC + MTX		-0.20 (-0.73,0.34)
LD ETN SC + MTX		-0.36 (-0.85,0.13)
LD TOFA PO + MTX		-0.35 (-0.89,0.19)
HD TOCI IV		-0.31 (-0.65,0.03)
HD TOFA PO		-0.56 (-1.05,-0.07)

(Continued)

HD ADA SC		-0.47 (-0.98,0.04)
HD ANA		-0.34 (-0.93,0.25)
HD GOLI SC		0.05 (-0.47,0.58)
HD TOCI IV + MTX		-0.30 (-0.68,0.09)
HD CERTO SC + MTX		-0.32 (-0.74,0.10)
HD TOFA PO + MTX		-0.51 (-1.05,0.03)
HD GOLI SC + MTX		0.04 (-0.42,0.51)
HD ADA SC + MTX		-0.31 (-0.82,0.22)
SD ETN SC	MTX + DMARD	-0.03 (-0.42,0.36)
SD ADA SC		0.02 (-0.56,0.59)
SD TOFA PO		-0.10 (-0.70,0.49)
SD CERTO		-0.03 (-0.65,0.61)
SD ANA		0.10 (-0.58,0.78)
SD RITUX IV		-0.02 (-0.61,0.56)
SD ETN SC + MTX		-0.28 (-0.60,0.05)
SD CERTO SC + MTX		0.06 (-0.38,0.50)
SD RITUX IV + MTX		0.17 (-0.30,0.64)
SD ADA SC + MTX		0.03 (-0.44,0.50)
SD GOLI SC + MTX		0.35 (-0.16,0.85)
SD TOFA PO + MTX		-0.09 (-0.66,0.48)
SD TOCI IV + MTX		0.15 (-0.34,0.63)
SD ABA SC + MTX		0.13 (-0.50,0.76)
SD GOLI IV + MTX		0.66 (0.08,1.24)
SD ETN SC + DMARD		0.02 (-0.56,0.61)
SD CERTO + DMARD		-0.03 (-0.58,0.52)
LD ADA SC		-0.01 (-0.62,0.59)
LD ANA		0.10 (-0.58,0.77)
LD ADA SC + MTX		0.07 (-0.40,0.55)

(Continued)

LD RITUX IV + MTX		0.23 (-0.25,0.71)
LD ADA IV + MTX		0.05 (-0.54,0.65)
LD CERTO SC + MTX		0.14 (-0.42,0.71)
LD ETN SC + MTX		-0.02 (-0.52,0.48)
LD TOFA PO + MTX		-0.01 (-0.58,0.57)
HD TOCI IV		0.03 (-0.44,0.49)
HD TOFA PO		-0.21 (-0.82,0.38)
HD ADA SC		-0.13 (-0.74,0.48)
HD ANA		0.00 (-0.68,0.68)
HD GOLI SC		0.40 (-0.17,0.95)
HD TOCI IV + MTX		0.04 (-0.40,0.50)
HD CERTO SC + MTX		0.02 (-0.45,0.48)
HD TOFA PO + MTX		-0.17 (-0.74,0.40)
HD GOLI SC + MTX		0.38 (-0.12,0.88)
HD ADA SC + MTX		0.04 (-0.52,0.60)
SD ADA SC	SD ETN SC	0.05 (-0.39,0.48)
SD TOFA PO		-0.07 (-0.53,0.39)
SD CERTO		0.01 (-0.49,0.51)
SD ANA		0.14 (-0.43,0.70)
SD RITUX IV		0.01 (-0.49,0.52)
SD ETN SC + MTX		-0.24 (-0.45,-0.03)
SD CERTO SC + MTX		0.09 (-0.23,0.43)
SD RITUX IV + MTX		0.20 (-0.17,0.58)
SD ADA SC + MTX		0.06 (-0.30,0.44)
SD GOLI SC + MTX		0.38 (-0.03,0.79)
SD TOFA PO + MTX		-0.06 (-0.54,0.43)
SD TOCI IV + MTX		0.18 (-0.20,0.56)
SD ABA SC + MTX		0.16 (-0.39,0.72)

(Continued)

SD GOLI IV + MTX		0.69 (0.20,1.19)
SD ETN SC + DMARD		0.06 (-0.41,0.53)
SD CERTO + DMARD		0.01 (-0.40,0.42)
LD ADA SC		0.02 (-0.45,0.49)
LD ANA		0.13 (-0.43,0.69)
LD ADA SC + MTX		0.11 (-0.26,0.49)
LD RITUX IV + MTX		0.26 (-0.11,0.64)
LD ADA IV + MTX		0.09 (-0.43,0.61)
LD CERTO SC + MTX		0.18 (-0.30,0.66)
LD ETN SC + MTX		0.02 (-0.40,0.44)
LD TOFA PO + MTX		0.02 (-0.47,0.52)
HD TOCI IV		0.06 (-0.28,0.41)
HD TOFA PO		-0.18 (-0.64,0.27)
HD ADA SC		-0.10 (-0.57,0.38)
HD ANA		0.03 (-0.53,0.60)
HD GOLI SC		0.43 (-0.04,0.91)
HD TOCI IV + MTX		0.08 (-0.26,0.42)
HD CERTO SC + MTX		0.05 (-0.30,0.41)
HD TOFA PO + MTX		-0.13 (-0.62,0.36)
HD GOLI SC + MTX		0.41 (0.01,0.82)
HD ADA SC + MTX		0.07 (-0.40,0.55)
SD TOFA PO	SD ADA SC	-0.12 (-0.43,0.19)
SD CERTO		-0.04 (-0.45,0.37)
SD ANA		0.09 (-0.40,0.57)
SD RITUX IV		-0.04 (-0.69,0.62)
SD ETN SC + MTX		-0.29 (-0.77,0.18)
SD CERTO SC + MTX		0.04 (-0.49,0.58)
SD RITUX IV + MTX		0.15 (-0.41,0.72)

(Continued)

SD ADA SC + MTX	0.01 (-0.54,0.57)	
SD GOLI SC + MTX	0.33 (-0.25,0.92)	
SD TOFA PO + MTX	-0.11 (-0.75,0.54)	
SD TOCI IV + MTX	0.13 (-0.43,0.70)	
SD ABA SC + MTX	0.11 (-0.58,0.82)	
SD GOLI IV + MTX	0.64 (-0.01,1.30)	
SD ETN SC + DMARD	0.01 (-0.57,0.60)	
SD CERTO + DMARD	-0.04 (-0.48,0.39)	
LD ADA SC	-0.03 (-0.32,0.26)	
LD ANA	0.08 (-0.40,0.56)	
LD ADA SC + MTX	0.06 (-0.50,0.62)	
LD RITUX IV + MTX	0.21 (-0.35,0.78)	
LD ADA IV + MTX	0.04 (-0.63,0.70)	
LD CERTO SC + MTX	0.13 (-0.51,0.77)	
LD ETN SC + MTX	-0.03 (-0.63,0.56)	
LD TOFA PO + MTX	-0.03 (-0.67,0.63)	
HD TOCI IV	0.01 (-0.51,0.54)	
HD TOFA PO	-0.23 (-0.54,0.08)	
HD ADA SC	-0.15 (-0.44,0.15)	
HD ANA	-0.02 (-0.51,0.47)	
HD GOLI SC	0.38 (-0.25,1.02)	
HD TOCI IV + MTX	0.03 (-0.50,0.56)	
HD CERTO SC + MTX	0.00 (-0.55,0.56)	
HD TOFA PO + MTX	-0.18 (-0.83,0.47)	
HD GOLI SC + MTX	0.36 (-0.22,0.95)	
HD ADA SC + MTX	0.02 (-0.61,0.65)	
SD CERTO	SD TOFA PO	0.07 (-0.36,0.52)
SD ANA		0.20 (-0.31,0.72)



(Continued)

SD RITUX IV	0.08 (-0.59,0.75)
SD ETN SC + MTX	-0.18 (-0.67,0.32)
SD CERTO SC + MTX	0.16 (-0.39,0.72)
SD RITUX IV + MTX	0.27 (-0.31,0.86)
SD ADA SC + MTX	0.13 (-0.44,0.71)
SD GOLI SC + MTX	0.44 (-0.16,1.06)
SD TOFA PO + MTX	0.01 (-0.65,0.68)
SD TOCI IV + MTX	0.25 (-0.33,0.84)
SD ABA SC + MTX	0.23 (-0.48,0.95)
SD GOLI IV + MTX	0.76 (0.09,1.44)
SD ETN SC + DMARD	0.12 (-0.47,0.74)
SD CERTO + DMARD	0.07 (-0.39,0.53)
LD ADA SC	0.09 (-0.29,0.47)
LD ANA	0.20 (-0.30,0.71)
LD ADA SC + MTX	0.17 (-0.40,0.76)
LD RITUX IV + MTX	0.33 (-0.25,0.92)
LD ADA IV + MTX	0.15 (-0.53,0.84)
LD CERTO SC + MTX	0.24 (-0.41,0.90)
LD ETN SC + MTX	0.08 (-0.53,0.70)
LD TOFA PO + MTX	0.09 (-0.57,0.77)
HD TOCI IV	0.13 (-0.42,0.68)
HD TOFA PO	-0.11 (-0.37,0.15)
HD ADA SC	-0.03 (-0.41,0.36)
HD ANA	0.10 (-0.41,0.61)
HD GOLI SC	0.50 (-0.15,1.15)
HD TOCI IV + MTX	0.15 (-0.40,0.70)
HD CERTO SC + MTX	0.12 (-0.45,0.69)
HD TOFA PO + MTX	-0.07 (-0.73,0.61)

(Continued)

HD GOLI SC + MTX		0.48 (-0.12,1.09)
HD ADA SC + MTX		0.14 (-0.50,0.79)
SD ANA	SD CERTO	0.13 (-0.43,0.67)
SD RITUX IV		0.00 (-0.70,0.70)
SD ETN SC + MTX		-0.25 (-0.80,0.28)
SD CERTO SC + MTX		0.09 (-0.51,0.67)
SD RITUX IV + MTX		0.19 (-0.42,0.81)
SD ADA SC + MTX		0.06 (-0.55,0.67)
SD GOLI SC + MTX		0.37 (-0.27,1.01)
SD TOFA PO + MTX		-0.06 (-0.75,0.63)
SD TOCI IV + MTX		0.17 (-0.45,0.79)
SD ABA SC + MTX		0.15 (-0.58,0.90)
SD GOLI IV + MTX		0.68 (-0.02,1.38)
SD ETN SC + DMARD		0.05 (-0.59,0.68)
SD CERTO + DMARD		0.00 (-0.51,0.50)
LD ADA SC		0.01 (-0.44,0.45)
LD ANA		0.13 (-0.42,0.66)
LD ADA SC + MTX		0.10 (-0.51,0.72)
LD RITUX IV + MTX		0.25 (-0.36,0.87)
LD ADA IV + MTX		0.08 (-0.63,0.79)
LD CERTO SC + MTX		0.17 (-0.51,0.86)
LD ETN SC + MTX		0.01 (-0.64,0.65)
LD TOFA PO + MTX		0.02 (-0.68,0.72)
HD TOCI IV		0.06 (-0.53,0.64)
HD TOFA PO		-0.19 (-0.63,0.24)
HD ADA SC		-0.10 (-0.56,0.35)
HD ANA		0.03 (-0.53,0.57)
HD GOLI SC		0.42 (-0.26,1.11)

(Continued)

HD TOCI IV + MTX		0.07 (-0.52,0.66)
HD CERTO SC + MTX		0.04 (-0.57,0.65)
HD TOFA PO + MTX		-0.14 (-0.84,0.56)
HD GOLI SC + MTX		0.41 (-0.23,1.04)
HD ADA SC + MTX		0.07 (-0.62,0.74)
SD RITUX IV	SD ANA	-0.12 (-0.86,0.63)
SD ETN SC + MTX		-0.38 (-0.97,0.22)
SD CERTO SC + MTX		-0.04 (-0.68,0.60)
SD RITUX IV + MTX		0.07 (-0.59,0.74)
SD ADA SC + MTX		-0.07 (-0.73,0.60)
SD GOLI SC + MTX		0.25 (-0.43,0.94)
SD TOFA PO + MTX		-0.19 (-0.92,0.55)
SD TOCI IV + MTX		0.05 (-0.62,0.72)
SD ABA SC + MTX		0.03 (-0.76,0.82)
SD GOLI IV + MTX		0.56 (-0.19,1.31)
SD ETN SC + DMARD		-0.07 (-0.75,0.61)
SD CERTO + DMARD		-0.13 (-0.70,0.43)
LD ADA SC		-0.12 (-0.63,0.40)
LD ANA		0.00 (-0.43,0.43)
LD ADA SC + MTX		-0.03 (-0.69,0.65)
LD RITUX IV + MTX		0.13 (-0.53,0.81)
LD ADA IV + MTX		-0.05 (-0.80,0.71)
LD CERTO SC + MTX		0.04 (-0.68,0.78)
LD ETN SC + MTX		-0.12 (-0.81,0.58)
LD TOFA PO + MTX		-0.11 (-0.85,0.64)
HD TOCI IV		-0.07 (-0.70,0.56)
HD TOFA PO		-0.31 (-0.83,0.19)
HD ADA SC		-0.23 (-0.75,0.29)

(Continued)

HD ANA		-0.10 (-0.54,0.33)
HD GOLI SC		0.29 (-0.43,1.02)
HD TOCI IV + MTX		-0.06 (-0.69,0.59)
HD CERTO SC + MTX		-0.08 (-0.74,0.58)
HD TOFA PO + MTX		-0.27 (-0.99,0.48)
HD GOLI SC + MTX		0.28 (-0.40,0.97)
HD ADA SC + MTX		-0.07 (-0.78,0.66)
SD ETN SC + MTX	SD RITUX IV	-0.25 (-0.74,0.23)
SD CERTO SC + MTX		0.08 (-0.38,0.54)
SD RITUX IV + MTX		0.19 (-0.23,0.61)
SD ADA SC + MTX		0.06 (-0.43,0.55)
SD GOLI SC + MTX		0.37 (-0.15,0.89)
SD TOFA PO + MTX		-0.07 (-0.65,0.52)
SD TOCI IV + MTX		0.17 (-0.33,0.67)
SD ABA SC + MTX		0.15 (-0.49,0.80)
SD GOLI IV + MTX		0.68 (0.08,1.27)
SD ETN SC + DMARD		0.05 (-0.60,0.71)
SD CERTO + DMARD		-0.01 (-0.63,0.61)
LD ADA SC		0.01 (-0.68,0.68)
LD ANA		0.13 (-0.64,0.86)
LD ADA SC + MTX		0.10 (-0.39,0.60)
LD RITUX IV + MTX		0.25 (-0.17,0.68)
LD ADA IV + MTX		0.08 (-0.53,0.69)
LD CERTO SC + MTX		0.17 (-0.41,0.74)
LD ETN SC + MTX		0.01 (-0.57,0.57)
LD TOFA PO + MTX		0.01 (-0.57,0.60)
HD TOCI IV		0.05 (-0.45,0.56)
HD TOFA PO		-0.19 (-0.86,0.47)

(Continued)

HD ADA SC		-0.10 (-0.80,0.57)
HD ANA		0.02 (-0.73,0.77)
HD GOLI SC		0.42 (-0.15,0.99)
HD TOCI IV + MTX		0.07 (-0.41,0.54)
HD CERTO SC + MTX		0.04 (-0.43,0.52)
HD TOFA PO + MTX		-0.14 (-0.73,0.44)
HD GOLI SC + MTX		0.40 (-0.11,0.92)
HD ADA SC + MTX		0.06 (-0.51,0.63)
SD CERTO SC + MTX	SD ETN SC + MTX	0.34 (0.03,0.64)
SD RITUX IV + MTX		0.44 (0.10,0.80)
SD ADA SC + MTX		0.31 (-0.03,0.65)
SD GOLI SC + MTX		0.62 (0.24,1.01)
SD TOFA PO + MTX		0.19 (-0.28,0.66)
SD TOCI IV + MTX		0.42 (0.06,0.79)
SD ABA SC + MTX		0.41 (-0.14,0.95)
SD GOLI IV + MTX		0.93 (0.45,1.42)
SD ETN SC + DMARD		0.30 (-0.19,0.80)
SD CERTO + DMARD		0.25 (-0.20,0.70)
LD ADA SC		0.26 (-0.25,0.77)
LD ANA		0.38 (-0.22,0.97)
LD ADA SC + MTX		0.35 (0.00,0.71)
LD RITUX IV + MTX		0.50 (0.16,0.86)
LD ADA IV + MTX		0.33 (-0.17,0.83)
LD CERTO SC + MTX		0.42 (-0.03,0.89)
LD ETN SC + MTX		0.26 (-0.12,0.64)
LD TOFA PO + MTX		0.27 (-0.21,0.74)
HD TOCI IV		0.30 (-0.03,0.64)
HD TOFA PO		0.06 (-0.43,0.55)

(Continued)

HD ADA SC		0.15 (-0.37,0.66)
HD ANA		0.28 (-0.32,0.88)
HD GOLI SC		0.67 (0.22,1.13)
HD TOCI IV + MTX		0.32 (0.01,0.64)
HD CERTO SC + MTX		0.30 (-0.03,0.63)
HD TOFA PO + MTX		0.11 (-0.36,0.59)
HD GOLI SC + MTX		0.66 (0.28,1.04)
HD ADA SC + MTX		0.31 (-0.13,0.77)
SD RITUX IV + MTX	SD CERTO SC + MTX	0.11 (-0.21,0.43)
SD ADA SC + MTX		-0.03 (-0.34,0.29)
SD GOLI SC + MTX		0.29 (-0.07,0.65)
SD TOFA PO + MTX		-0.15 (-0.60,0.30)
SD TOCI IV + MTX		0.09 (-0.26,0.43)
SD ABA SC + MTX		0.07 (-0.45,0.59)
SD GOLI IV + MTX		0.60 (0.14,1.06)
SD ETN SC + DMARD		-0.03 (-0.56,0.50)
SD CERTO + DMARD		-0.09 (-0.59,0.41)
LD ADA SC		-0.07 (-0.64,0.48)
LD ANA		0.04 (-0.61,0.68)
LD ADA SC + MTX		0.02 (-0.31,0.35)
LD RITUX IV + MTX		0.17 (-0.15,0.49)
LD ADA IV + MTX		-0.01 (-0.49,0.48)
LD CERTO SC + MTX		0.09 (-0.31,0.48)
LD ETN SC + MTX		-0.08 (-0.51,0.36)
LD TOFA PO + MTX		-0.07 (-0.52,0.38)
HD TOCI IV		-0.03 (-0.37,0.31)
HD TOFA PO		-0.27 (-0.83,0.27)
HD ADA SC		-0.19 (-0.76,0.38)

(Continued)

HD ANA		-0.06 (-0.71,0.59)
HD GOLI SC		0.34 (-0.10,0.77)
HD TOCI IV + MTX		-0.01 (-0.31,0.28)
HD CERTO SC + MTX		-0.04 (-0.27,0.19)
HD TOFA PO + MTX		-0.23 (-0.68,0.23)
HD GOLI SC + MTX		0.32 (-0.04,0.68)
HD ADA SC + MTX		-0.02 (-0.45,0.42)
SD ADA SC + MTX	SD RITUX IV + MTX	-0.14 (-0.49,0.22)
SD GOLI SC + MTX		0.18 (-0.22,0.58)
SD TOFA PO + MTX		-0.26 (-0.74,0.22)
SD TOCI IV + MTX		-0.02 (-0.40,0.36)
SD ABA SC + MTX		-0.04 (-0.59,0.52)
SD GOLI IV + MTX		0.49 (-0.01,0.98)
SD ETN SC + DMARD		-0.14 (-0.70,0.42)
SD CERTO + DMARD		-0.20 (-0.72,0.33)
LD ADA SC		-0.18 (-0.78,0.40)
LD ANA		-0.07 (-0.74,0.59)
LD ADA SC + MTX		-0.09 (-0.46,0.28)
LD RITUX IV + MTX		0.06 (-0.20,0.32)
LD ADA IV + MTX		-0.12 (-0.62,0.40)
LD CERTO SC + MTX		-0.02 (-0.50,0.45)
LD ETN SC + MTX		-0.19 (-0.65,0.28)
LD TOFA PO + MTX		-0.18 (-0.67,0.31)
HD TOCI IV		-0.14 (-0.52,0.24)
HD TOFA PO		-0.38 (-0.97,0.19)
HD ADA SC		-0.30 (-0.89,0.29)
HD ANA		-0.17 (-0.85,0.49)
HD GOLI SC		0.23 (-0.24,0.70)

(Continued)

HD TOCI IV + MTX		-0.12 (-0.46,0.22)
HD CERTO SC + MTX		-0.15 (-0.49,0.20)
HD TOFA PO + MTX		-0.34 (-0.82,0.15)
HD GOLI SC + MTX		0.21 (-0.19,0.61)
HD ADA SC + MTX		-0.13 (-0.59,0.34)
SD GOLI SC + MTX	SD ADA SC + MTX	0.32 (-0.09,0.71)
SD TOFA PO + MTX		-0.12 (-0.60,0.36)
SD TOCI IV + MTX		0.11 (-0.26,0.49)
SD ABA SC + MTX		0.10 (-0.45,0.65)
SD GOLI IV + MTX		0.62 (0.13,1.11)
SD ETN SC + DMARD		-0.01 (-0.56,0.55)
SD CERTO + DMARD		-0.06 (-0.58,0.45)
LD ADA SC		-0.05 (-0.64,0.54)
LD ANA		0.07 (-0.60,0.72)
LD ADA SC + MTX		0.04 (-0.24,0.33)
LD RITUX IV + MTX		0.20 (-0.17,0.55)
LD ADA IV + MTX		0.02 (-0.46,0.51)
LD CERTO SC + MTX		0.11 (-0.36,0.58)
LD ETN SC + MTX		-0.05 (-0.51,0.41)
LD TOFA PO + MTX		-0.04 (-0.53,0.44)
HD TOCI IV		0.00 (-0.39,0.37)
HD TOFA PO		-0.25 (-0.82,0.33)
HD ADA SC		-0.16 (-0.75,0.42)
HD ANA		-0.03 (-0.70,0.63)
HD GOLI SC		0.37 (-0.10,0.83)
HD TOCI IV + MTX		0.01 (-0.33,0.35)
HD CERTO SC + MTX		-0.01 (-0.36,0.33)
HD TOFA PO + MTX		-0.20 (-0.68,0.28)



(Continued)

HD GOLI SC + MTX		0.35 (-0.05,0.74)
HD ADA SC + MTX		0.00 (-0.39,0.40)
SD TOFA PO + MTX	SD GOLI SC + MTX	-0.44 (-0.95,0.07)
SD TOCI IV + MTX		-0.20 (-0.61,0.22)
SD ABA SC + MTX		-0.22 (-0.79,0.36)
SD GOLI IV + MTX		0.31 (-0.21,0.83)
SD ETN SC + DMARD		-0.32 (-0.90,0.27)
SD CERTO + DMARD		-0.38 (-0.93,0.18)
LD ADA SC		-0.36 (-0.98,0.25)
LD ANA		-0.25 (-0.93,0.44)
LD ADA SC + MTX		-0.27 (-0.67,0.14)
LD RITUX IV + MTX		-0.12 (-0.52,0.28)
LD ADA IV + MTX		-0.29 (-0.83,0.25)
LD CERTO SC + MTX		-0.20 (-0.70,0.30)
LD ETN SC + MTX		-0.36 (-0.86,0.13)
LD TOFA PO + MTX		-0.36 (-0.87,0.16)
HD TOCI IV		-0.32 (-0.74,0.09)
HD TOFA PO		-0.56 (-1.17,0.04)
HD ADA SC		-0.48 (-1.10,0.13)
HD ANA		-0.35 (-1.04,0.34)
HD GOLI SC		0.05 (-0.35,0.45)
HD TOCI IV + MTX		-0.30 (-0.68,0.08)
HD CERTO SC + MTX		-0.33 (-0.71,0.05)
HD TOFA PO + MTX		-0.51 (-1.03,-0.01)
HD GOLI SC + MTX		0.03 (-0.28,0.34)
HD ADA SC + MTX		-0.31 (-0.80,0.19)
SD TOCI IV + MTX	SD TOFA PO + MTX	0.24 (-0.26,0.73)
SD ABA SC + MTX		0.22 (-0.42,0.85)

(Continued)

SD GOLI IV + MTX		0.75 (0.16,1.34)
SD ETN SC + DMARD		0.11 (-0.52,0.76)
SD CERTO + DMARD		0.06 (-0.55,0.67)
LD ADA SC		0.08 (-0.60,0.74)
LD ANA		0.19 (-0.55,0.92)
LD ADA SC + MTX		0.17 (-0.32,0.66)
LD RITUX IV + MTX		0.32 (-0.16,0.80)
LD ADA IV + MTX		0.14 (-0.46,0.75)
LD CERTO SC + MTX		0.23 (-0.33,0.80)
LD ETN SC + MTX		0.07 (-0.49,0.63)
LD TOFA PO + MTX		0.08 (-0.33,0.49)
HD TOCI IV		0.12 (-0.38,0.61)
HD TOFA PO		-0.12 (-0.79,0.53)
HD ADA SC		-0.04 (-0.72,0.63)
HD ANA		0.09 (-0.65,0.82)
HD GOLI SC		0.49 (-0.08,1.05)
HD TOCI IV + MTX		0.13 (-0.33,0.60)
HD CERTO SC + MTX		0.11 (-0.36,0.58)
HD TOFA PO + MTX		-0.08 (-0.48,0.33)
HD GOLI SC + MTX		0.47 (-0.04,0.98)
HD ADA SC + MTX		0.12 (-0.43,0.69)
SD ABA SC + MTX	SD TOCI IV + MTX	-0.02 (-0.58,0.55)
SD GOLI IV + MTX		0.51 (0.00,1.02)
SD ETN SC + DMARD		-0.12 (-0.67,0.44)
SD CERTO + DMARD		-0.17 (-0.71,0.35)
LD ADA SC		-0.16 (-0.75,0.43)
LD ANA		-0.05 (-0.72,0.62)
LD ADA SC + MTX		-0.07 (-0.45,0.32)

(Continued)

LD RITUX IV + MTX		0.08 (-0.30,0.46)
LD ADA IV + MTX		-0.09 (-0.62,0.44)
LD CERTO SC + MTX		0.00 (-0.49,0.49)
LD ETN SC + MTX		-0.16 (-0.64,0.31)
LD TOFA PO + MTX		-0.16 (-0.66,0.34)
HD TOCI IV		-0.12 (-0.49,0.26)
HD TOFA PO		-0.36 (-0.94,0.21)
HD ADA SC		-0.28 (-0.87,0.31)
HD ANA		-0.15 (-0.82,0.52)
HD GOLI SC		0.25 (-0.23,0.73)
HD TOCI IV + MTX		-0.10 (-0.38,0.18)
HD CERTO SC + MTX		-0.13 (-0.49,0.24)
HD TOFA PO + MTX		-0.31 (-0.81,0.18)
HD GOLI SC + MTX		0.23 (-0.18,0.64)
HD ADA SC + MTX		-0.11 (-0.59,0.37)
SD GOLI IV + MTX	SD ABA SC + MTX	0.53 (-0.12,1.18)
SD ETN SC + DMARD		-0.10 (-0.79,0.59)
SD CERTO + DMARD		-0.16 (-0.83,0.51)
LD ADA SC		-0.14 (-0.87,0.57)
LD ANA		-0.03 (-0.82,0.75)
LD ADA SC + MTX		-0.05 (-0.61,0.51)
LD RITUX IV + MTX		0.10 (-0.45,0.65)
LD ADA IV + MTX		-0.08 (-0.73,0.59)
LD CERTO SC + MTX		0.02 (-0.61,0.65)
LD ETN SC + MTX		-0.14 (-0.76,0.48)
LD TOFA PO + MTX		-0.14 (-0.78,0.50)
HD TOCI IV		-0.10 (-0.67,0.46)
HD TOFA PO		-0.34 (-1.06,0.37)

(Continued)

HD ADA SC		-0.25 (-0.99,0.46)
HD ANA		-0.13 (-0.92,0.65)
HD GOLI SC		0.27 (-0.35,0.89)
HD TOCI IV + MTX		-0.08 (-0.62,0.45)
HD CERTO SC + MTX		-0.11 (-0.65,0.43)
HD TOFA PO + MTX		-0.30 (-0.93,0.34)
HD GOLI SC + MTX		0.25 (-0.32,0.82)
HD ADA SC + MTX		-0.09 (-0.72,0.54)
SD ETN SC + DMARD	SD GOLI IV + MTX	-0.63 (-1.28,0.02)
SD CERTO + DMARD		-0.69 (-1.31,-0.07)
LD ADA SC		-0.67 (-1.35,0.00)
LD ANA		-0.56 (-1.30,0.19)
LD ADA SC + MTX		-0.58 (-1.07,-0.08)
LD RITUX IV + MTX		-0.43 (-0.92,0.06)
LD ADA IV + MTX		-0.61 (-1.21,0.01)
LD CERTO SC + MTX		-0.51 (-1.09,0.06)
LD ETN SC + MTX		-0.68 (-1.24,-0.11)
LD TOFA PO + MTX		-0.67 (-1.26,-0.07)
HD TOCI IV		-0.63 (-1.14,-0.12)
HD TOFA PO		-0.87 (-1.55,-0.20)
HD ADA SC		-0.78 (-1.47,-0.11)
HD ANA		-0.66 (-1.41,0.09)
HD GOLI SC		-0.26 (-0.83,0.32)
HD TOCI IV + MTX		-0.61 (-1.09,-0.13)
HD CERTO SC + MTX		-0.64 (-1.12,-0.16)
HD TOFA PO + MTX		-0.82 (-1.42,-0.24)
HD GOLI SC + MTX		-0.28 (-0.79,0.25)
HD ADA SC + MTX		-0.62 (-1.19,-0.04)

(Continued)

SD CERTO + DMARD	SD ETN SC + DMARD	-0.05 (-0.56,0.45)
LD ADA SC		-0.04 (-0.66,0.57)
LD ANA		0.08 (-0.61,0.75)
LD ADA SC + MTX		0.05 (-0.52,0.61)
LD RITUX IV + MTX		0.20 (-0.36,0.76)
LD ADA IV + MTX		0.03 (-0.64,0.69)
LD CERTO SC + MTX		0.12 (-0.52,0.75)
LD ETN SC + MTX		-0.04 (-0.64,0.55)
LD TOFA PO + MTX		-0.04 (-0.69,0.60)
HD TOCI IV		0.00 (-0.49,0.48)
HD TOFA PO		-0.24 (-0.85,0.35)
HD ADA SC		-0.16 (-0.78,0.46)
HD ANA		-0.03 (-0.72,0.65)
HD GOLI SC		0.37 (-0.26,1.00)
HD TOCI IV + MTX		0.02 (-0.50,0.54)
HD CERTO SC + MTX		-0.01 (-0.56,0.54)
HD TOFA PO + MTX		-0.19 (-0.84,0.44)
HD GOLI SC + MTX		0.35 (-0.23,0.93)
HD ADA SC + MTX		0.01 (-0.62,0.64)
LD ADA SC	SD CERTO + DMARD	0.01 (-0.46,0.49)
LD ANA		0.13 (-0.43,0.69)
LD ADA SC + MTX		0.10 (-0.42,0.63)
LD RITUX IV + MTX		0.25 (-0.26,0.78)
LD ADA IV + MTX		0.08 (-0.56,0.72)
LD CERTO SC + MTX		0.17 (-0.43,0.78)
LD ETN SC + MTX		0.01 (-0.56,0.58)
LD TOFA PO + MTX		0.02 (-0.60,0.64)
HD TOCI IV		0.06 (-0.41,0.52)

(Continued)

HD TOFA PO		-0.19 (-0.64,0.27)
HD ADA SC		-0.10 (-0.57,0.37)
HD ANA		0.03 (-0.54,0.60)
HD GOLI SC		0.42 (-0.17,1.03)
HD TOCI IV + MTX		0.07 (-0.41,0.57)
HD CERTO SC + MTX		0.05 (-0.46,0.57)
HD TOFA PO + MTX		-0.14 (-0.75,0.48)
HD GOLI SC + MTX		0.41 (-0.14,0.96)
HD ADA SC + MTX		0.07 (-0.53,0.67)
LD ANA	LD ADA SC	0.11 (-0.40,0.63)
LD ADA SC + MTX		0.09 (-0.50,0.69)
LD RITUX IV + MTX		0.24 (-0.35,0.84)
LD ADA IV + MTX		0.07 (-0.62,0.76)
LD CERTO SC + MTX		0.16 (-0.50,0.82)
LD ETN SC + MTX		0.00 (-0.62,0.62)
LD TOFA PO + MTX		0.00 (-0.67,0.69)
HD TOCI IV		0.04 (-0.51,0.60)
HD TOFA PO		-0.20 (-0.58,0.18)
HD ADA SC		-0.12 (-0.43,0.20)
HD ANA		0.01 (-0.51,0.53)
HD GOLI SC		0.41 (-0.25,1.08)
HD TOCI IV + MTX		0.06 (-0.50,0.62)
HD CERTO SC + MTX		0.03 (-0.54,0.62)
HD TOFA PO + MTX		-0.15 (-0.82,0.53)
HD GOLI SC + MTX		0.39 (-0.21,1.01)
HD ADA SC + MTX		0.05 (-0.60,0.71)
LD ADA SC + MTX	LD ANA	-0.02 (-0.68,0.65)
LD RITUX IV + MTX		0.12 (-0.53,0.80)

(Continued)

LD ADA IV + MTX		-0.05 (-0.80,0.72)
LD CERTO SC + MTX		0.04 (-0.68,0.78)
LD ETN SC + MTX		-0.12 (-0.81,0.57)
LD TOFA PO + MTX		-0.11 (-0.85,0.64)
HD TOCI IV		-0.07 (-0.70,0.56)
HD TOFA PO		-0.31 (-0.82,0.19)
HD ADA SC		-0.23 (-0.74,0.29)
HD ANA		-0.10 (-0.53,0.33)
HD GOLI SC		0.30 (-0.42,1.02)
HD TOCI IV + MTX		-0.05 (-0.69,0.59)
HD CERTO SC + MTX		-0.08 (-0.73,0.58)
HD TOFA PO + MTX		-0.27 (-1.00,0.48)
HD GOLI SC + MTX		0.28 (-0.40,0.97)
HD ADA SC + MTX		-0.06 (-0.78,0.67)
LD RITUX IV + MTX	LD ADA SC + MTX	0.15 (-0.22,0.52)
LD ADA IV + MTX		-0.02 (-0.49,0.44)
LD CERTO SC + MTX		0.07 (-0.41,0.54)
LD ETN SC + MTX		-0.09 (-0.56,0.37)
LD TOFA PO + MTX		-0.09 (-0.58,0.40)
HD TOCI IV		-0.05 (-0.44,0.34)
HD TOFA PO		-0.29 (-0.88,0.28)
HD ADA SC		-0.20 (-0.81,0.38)
HD ANA		-0.08 (-0.75,0.59)
HD GOLI SC		0.32 (-0.16,0.79)
HD TOCI IV + MTX		-0.03 (-0.38,0.32)
HD CERTO SC + MTX		-0.06 (-0.42,0.30)
HD TOFA PO + MTX		-0.24 (-0.73,0.24)
HD GOLI SC + MTX		0.30 (-0.10,0.71)

(Continued)

HD ADA SC + MTX		-0.04 (-0.44,0.36)
LD ADA IV + MTX	LD RITUX IV + MTX	-0.17 (-0.68,0.34)
LD CERTO SC + MTX		-0.08 (-0.55,0.39)
LD ETN SC + MTX		-0.25 (-0.71,0.22)
LD TOFA PO + MTX		-0.24 (-0.72,0.25)
HD TOCI IV		-0.20 (-0.59,0.18)
HD TOFA PO		-0.44 (-1.03,0.14)
HD ADA SC		-0.36 (-0.96,0.23)
HD ANA		-0.23 (-0.91,0.44)
HD GOLI SC		0.17 (-0.30,0.64)
HD TOCI IV + MTX		-0.18 (-0.52,0.16)
HD CERTO SC + MTX		-0.21 (-0.56,0.14)
HD TOFA PO + MTX		-0.39 (-0.88,0.09)
HD GOLI SC + MTX		0.15 (-0.24,0.55)
HD ADA SC + MTX		-0.19 (-0.66,0.28)
LD CERTO SC + MTX	LD ADA IV + MTX	0.09 (-0.51,0.69)
LD ETN SC + MTX		-0.07 (-0.66,0.51)
LD TOFA PO + MTX		-0.06 (-0.68,0.54)
HD TOCI IV		-0.03 (-0.55,0.50)
HD TOFA PO		-0.27 (-0.95,0.41)
HD ADA SC		-0.18 (-0.88,0.51)
HD ANA		-0.06 (-0.82,0.70)
HD GOLI SC		0.34 (-0.25,0.93)
HD TOCI IV + MTX		-0.01 (-0.51,0.49)
HD CERTO SC + MTX		-0.04 (-0.54,0.47)
HD TOFA PO + MTX		-0.22 (-0.83,0.38)
HD GOLI SC + MTX		0.33 (-0.21,0.86)
HD ADA SC + MTX		-0.02 (-0.59,0.55)



(Continued)

LD ETN SC + MTX	LD CERTO SC + MTX	-0.16 (-0.71,0.39)
LD TOFA PO + MTX		-0.16 (-0.73,0.42)
HD TOCI IV		-0.11 (-0.61,0.37)
HD TOFA PO		-0.36 (-1.01,0.29)
HD ADA SC		-0.27 (-0.94,0.39)
HD ANA		-0.14 (-0.88,0.59)
HD GOLI SC		0.25 (-0.30,0.81)
HD TOCI IV + MTX		-0.10 (-0.56,0.36)
HD CERTO SC + MTX		-0.13 (-0.53,0.28)
HD TOFA PO + MTX		-0.31 (-0.88,0.26)
HD GOLI SC + MTX		0.23 (-0.26,0.74)
HD ADA SC + MTX		-0.11 (-0.66,0.45)
LD TOFA PO + MTX	LD ETN SC + MTX	0.00 (-0.55,0.57)
HD TOCI IV		0.05 (-0.42,0.51)
HD TOFA PO		-0.20 (-0.81,0.42)
HD ADA SC		-0.11 (-0.73,0.51)
HD ANA		0.02 (-0.69,0.71)
HD GOLI SC		0.41 (-0.13,0.96)
HD TOCI IV + MTX		0.06 (-0.38,0.50)
HD CERTO SC + MTX		0.04 (-0.42,0.49)
HD TOFA PO + MTX		-0.15 (-0.71,0.41)
HD GOLI SC + MTX		0.40 (-0.09,0.89)
HD ADA SC + MTX		0.05 (-0.49,0.60)
HD TOCI IV	LD TOFA PO + MTX	0.04 (-0.46,0.53)
HD TOFA PO		-0.20 (-0.88,0.46)
HD ADA SC		-0.12 (-0.80,0.55)
HD ANA		0.01 (-0.74,0.75)
HD GOLI SC		0.41 (-0.16,0.98)

(Continued)

HD TOCI IV + MTX		0.06 (-0.41,0.53)
HD CERTO SC + MTX		0.03 (-0.45,0.50)
HD TOFA PO + MTX		-0.16 (-0.57,0.26)
HD GOLI SC + MTX		0.39 (-0.12,0.91)
HD ADA SC + MTX		0.05 (-0.52,0.61)
HD TOFA PO	HD TOCI IV	-0.24 (-0.79,0.30)
HD ADA SC		-0.16 (-0.72,0.40)
HD ANA		-0.03 (-0.67,0.61)
HD GOLI SC		0.37 (-0.12,0.86)
HD TOCI IV + MTX		0.02 (-0.28,0.32)
HD CERTO SC + MTX		-0.01 (-0.38,0.36)
HD TOFA PO + MTX		-0.20 (-0.69,0.30)
HD GOLI SC + MTX		0.35 (-0.06,0.77)
HD ADA SC + MTX		0.01 (-0.47,0.49)
HD ADA SC	HD TOFA PO	0.09 (-0.30,0.47)
HD ANA		0.21 (-0.30,0.73)
HD GOLI SC		0.61 (-0.03,1.26)
HD TOCI IV + MTX		0.26 (-0.28,0.81)
HD CERTO SC + MTX		0.23 (-0.33,0.81)
HD TOFA PO + MTX		0.05 (-0.62,0.72)
HD GOLI SC + MTX		0.59 (0.00,1.20)
HD ADA SC + MTX		0.25 (-0.39,0.90)
HD ANA	HD ADA SC	0.13 (-0.39,0.65)
HD GOLI SC		0.53 (-0.13,1.19)
HD TOCI IV + MTX		0.17 (-0.38,0.74)
HD CERTO SC + MTX		0.15 (-0.43,0.73)
HD TOFA PO + MTX		-0.04 (-0.71,0.64)
HD GOLI SC + MTX		0.51 (-0.10,1.13)

(Continued)

HD ADA SC + MTX		0.17 (-0.48,0.82)
HD GOLI SC	HD ANA	0.40 (-0.32,1.13)
HD TOCI IV + MTX		0.05 (-0.59,0.69)
HD CERTO SC + MTX		0.02 (-0.64,0.68)
HD TOFA PO + MTX		-0.17 (-0.91,0.58)
HD GOLI SC + MTX		0.38 (-0.31,1.08)
HD ADA SC + MTX		0.04 (-0.68,0.78)
HD TOCI IV + MTX	HD GOLI SC	-0.35 (-0.80,0.10)
HD CERTO SC + MTX		-0.38 (-0.83,0.08)
HD TOFA PO + MTX		-0.56 (-1.13,0.00)
HD GOLI SC + MTX		-0.02 (-0.41,0.38)
HD ADA SC + MTX		-0.36 (-0.91,0.19)
HD CERTO SC + MTX	HD TOCI IV + MTX	-0.03 (-0.35,0.30)
HD TOFA PO + MTX		-0.21 (-0.68,0.26)
HD GOLI SC + MTX		0.33 (-0.04,0.71)
HD ADA SC + MTX		-0.01 (-0.46,0.45)
HD TOFA PO + MTX	HD CERTO SC + MTX	-0.18 (-0.66,0.29)
HD GOLI SC + MTX		0.36 (-0.02,0.74)
HD ADA SC + MTX		0.02 (-0.43,0.48)
HD GOLI SC + MTX	HD TOFA PO + MTX	0.55 (0.04,1.06)
HD ADA SC + MTX		0.21 (-0.36,0.77)
HD ADA SC + MTX	HD GOLI SC + MTX	-0.34 (-0.84,0.15)

Random-Effect Model

Total Residual Deviance

125.3 vs 127 data points

 Deviance Information  
 Criteria

-289.413

Note:

(Continued)

Total Patients	16355
Total Studies	48
2-arm	25
3-arm	15
4-arm	8

### Appendix 13. HAQ: Subgroup - Established RA (2 to 10 years)

HAQ in Established RA: Mean Difference (MD) for All Treatment Comparisons-Random Effects Model		
Treatment	Reference	MD (95% CrI)
MTX	PL	0.04 (-0.46,0.56)
DMARD		0.04 (-0.44,0.52)
MTX + DMARD		-0.31 (-0.92,0.31)
SD ETN SC		-0.34 (-0.76,0.09)
SD ADA SC		-0.27 (-0.58,0.04)
SD TOFA PO		-0.40 (-0.72,-0.09)
SD CERTO SC		-0.32 (-0.70,0.07)
SD ANA		-0.20 (-0.70,0.31)
SD ETN SC + MTX		-0.59 (-1.07,-0.09)
SD CERTO SC + MTX		-0.25 (-0.80,0.32)
SD GOL I SC + MTX		0.04 (-0.58,0.66)
SD TOFA PO + MTX		-0.39 (-1.09,0.31)
SD RITUX IV + MTX		0.04 (-0.66,0.77)
SD ADA SC + MTX		-0.26 (-0.97,0.48)
SD TOCI IV + MTX		-0.12 (-0.78,0.56)
SD ABA SC + MTX		-0.18 (-0.92,0.57)
SD GOL I IV + MTX		0.35 (-0.35,1.07)

(Continued)

SD CERTO SC + DMARD		-0.33 (-0.77,0.11)
SD ETN SC + DMARD		-0.46 (-1.17,0.24)
LD ADA SC		-0.31 (-0.66,0.04)
LD ANA		-0.20 (-0.69,0.30)
LD RITUX IV + MTX		0.14 (-0.56,0.87)
LD CERTO SC + MTX		-0.16 (-0.84,0.53)
LD ETN SC + MTX		-0.32 (-0.96,0.33)
LD TOFA PO + MTX		-0.31 (-1.01,0.39)
HD TOCI IV		-0.27 (-0.82,0.28)
HD TOFA PO		-0.52 (-0.84,-0.20)
HD ADA SC		-0.42 (-0.77,-0.07)
HD ANA		-0.30 (-0.81,0.21)
HD GOLI SC		0.09 (-0.58,0.78)
HD TOCI IV + MTX		-0.24 (-0.81,0.34)
HD CERTO SC + MTX		-0.29 (-0.86,0.30)
HD TOFA PO + MTX		-0.47 (-1.16,0.23)
HD GOLI SC + MTX		0.07 (-0.54,0.70)
DMARD	MTX	-0.01 (-0.41,0.40)
MTX + DMARD		-0.35 (-0.81,0.12)
SD ETN SC		-0.38 (-0.69,-0.07)
SD ADA SC		-0.31 (-0.91,0.27)
SD TOFA PO		-0.45 (-1.06,0.14)
SD CERTO SC		-0.36 (-1.00,0.28)
SD ANA		-0.24 (-0.96,0.46)
SD ETN SC + MTX		-0.63 (-0.90,-0.36)
SD CERTO SC + MTX		-0.29 (-0.51,-0.07)
SD GOLI SC + MTX		0.00 (-0.36,0.35)
SD TOFA PO + MTX		-0.43 (-0.91,0.05)

(Continued)

SD RITUX IV + MTX		0.00 (-0.50,0.51)
SD ADA SC + MTX		-0.30 (-0.82,0.22)
SD TOCI IV + MTX		-0.16 (-0.61,0.29)
SD ABA SC + MTX		-0.22 (-0.78,0.33)
SD GOLI IV + MTX		0.31 (-0.18,0.81)
SD CERTO SC + DMARD		-0.37 (-0.91,0.15)
SD ETN SC + DMARD		-0.51 (-1.17,0.16)
LD ADA SC		-0.35 (-0.98,0.26)
LD ANA		-0.24 (-0.96,0.47)
LD RITUX IV + MTX		0.10 (-0.41,0.61)
LD CERTO SC + MTX		-0.20 (-0.66,0.26)
LD ETN SC + MTX		-0.36 (-0.82,0.09)
LD TOFA PO + MTX		-0.35 (-0.84,0.13)
HD TOCI IV		-0.31 (-0.66,0.03)
HD TOFA PO		-0.56 (-1.17,0.03)
HD ADA SC		-0.47 (-1.09,0.14)
HD ANA		-0.34 (-1.06,0.36)
HD GOLI SC		0.05 (-0.40,0.51)
HD TOCI IV + MTX		-0.29 (-0.59,0.02)
HD CERTO SC + MTX		-0.33 (-0.60,-0.06)
HD TOFA PO + MTX		-0.51 (-0.98,-0.03)
HD GOLI SC + MTX		0.03 (-0.32,0.39)
MTX + DMARD	DMARD	-0.34 (-0.90,0.22)
SD ETN SC		-0.38 (-0.74,-0.01)
SD ADA SC		-0.31 (-0.89,0.26)
SD TOFA PO		-0.44 (-1.02,0.13)
SD CERTO SC		-0.35 (-0.97,0.27)
SD ANA		-0.23 (-0.93,0.46)

(Continued)

SD ETN SC + MTX		-0.62 (-1.03,-0.21)
SD CERTO SC + MTX		-0.28 (-0.75,0.19)
SD GOLI SC + MTX		0.00 (-0.54,0.55)
SD TOFA PO + MTX		-0.43 (-1.06,0.20)
SD RITUX IV + MTX		0.00 (-0.64,0.66)
SD ADA SC + MTX		-0.29 (-0.95,0.36)
SD TOCI IV + MTX		-0.15 (-0.74,0.44)
SD ABA SC + MTX		-0.22 (-0.90,0.47)
SD GOLI IV + MTX		0.32 (-0.32,0.95)
SD CERTO SC + DMARD		-0.37 (-0.80,0.06)
SD ETN SC + DMARD		-0.50 (-1.01,0.02)
LD ADA SC		-0.35 (-0.94,0.24)
LD ANA		-0.23 (-0.93,0.46)
LD RITUX IV + MTX		0.10 (-0.55,0.76)
LD CERTO SC + MTX		-0.20 (-0.81,0.42)
LD ETN SC + MTX		-0.36 (-0.93,0.22)
LD TOFA PO + MTX		-0.35 (-0.98,0.28)
HD TOCI IV		-0.31 (-0.70,0.09)
HD TOFA PO		-0.55 (-1.13,0.02)
HD ADA SC		-0.46 (-1.06,0.13)
HD ANA		-0.34 (-1.03,0.36)
HD GOLI SC		0.06 (-0.55,0.67)
HD TOCI IV + MTX		-0.28 (-0.75,0.19)
HD CERTO SC + MTX		-0.33 (-0.81,0.16)
HD TOFA PO + MTX		-0.51 (-1.13,0.12)
HD GOLI SC + MTX		0.04 (-0.50,0.57)
SD ETN SC	MTX + DMARD	-0.04 (-0.48,0.41)
SD ADA SC		0.03 (-0.66,0.72)

(Continued)

SD TOFA PO	-0.10 (-0.80,0.59)
SD CERTO SC	-0.01 (-0.74,0.71)
SD ANA	0.11 (-0.69,0.90)
SD ETN SC + MTX	-0.28 (-0.66,0.10)
SD CERTO SC + MTX	0.06 (-0.46,0.57)
SD GOLI SC + MTX	0.34 (-0.24,0.93)
SD TOFA PO + MTX	-0.09 (-0.75,0.58)
SD RITUX IV + MTX	0.35 (-0.33,1.03)
SD ADA SC + MTX	0.05 (-0.65,0.74)
SD TOCI IV + MTX	0.19 (-0.44,0.83)
SD ABA SC + MTX	0.13 (-0.60,0.84)
SD GOLI IV + MTX	0.66 (-0.01,1.34)
SD CERTO SC + DMARD	-0.03 (-0.67,0.61)
SD ETN SC + DMARD	-0.16 (-0.92,0.60)
LD ADA SC	0.00 (-0.72,0.70)
LD ANA	0.11 (-0.68,0.90)
LD RITUX IV + MTX	0.45 (-0.24,1.13)
LD CERTO SC + MTX	0.14 (-0.51,0.80)
LD ETN SC + MTX	-0.02 (-0.61,0.57)
LD TOFA PO + MTX	-0.01 (-0.68,0.67)
HD TOCI IV	0.03 (-0.51,0.59)
HD TOFA PO	-0.21 (-0.91,0.47)
HD ADA SC	-0.12 (-0.83,0.59)
HD ANA	0.01 (-0.79,0.80)
HD GOLI SC	0.40 (-0.25,1.05)
HD TOCI IV + MTX	0.06 (-0.48,0.61)
HD CERTO SC + MTX	0.01 (-0.52,0.55)
HD TOFA PO + MTX	-0.16 (-0.83,0.50)



(Continued)

HD GOLI SC + MTX		0.38 (-0.20,0.96)
SD ADA SC	SD ETN SC	0.07 (-0.46,0.59)
SD TOFA PO		-0.06 (-0.60,0.46)
SD CERTO SC		0.02 (-0.55,0.61)
SD ANA		0.14 (-0.52,0.80)
SD ETN SC + MTX		-0.25 (-0.49,0.00)
SD CERTO SC + MTX		0.09 (-0.29,0.48)
SD GOLI SC + MTX		0.38 (-0.09,0.85)
SD TOFA PO + MTX		-0.05 (-0.62,0.52)
SD RITUX IV + MTX		0.38 (-0.21,0.98)
SD ADA SC + MTX		0.08 (-0.52,0.69)
SD TOCI IV + MTX		0.22 (-0.31,0.77)
SD ABA SC + MTX		0.16 (-0.48,0.80)
SD GOLI IV + MTX		0.69 (0.11,1.28)
SD CERTO SC + DMARD		0.01 (-0.47,0.48)
SD ETN SC + DMARD		-0.12 (-0.76,0.51)
LD ADA SC		0.03 (-0.53,0.58)
LD ANA		0.14 (-0.52,0.80)
LD RITUX IV + MTX		0.48 (-0.11,1.08)
LD CERTO SC + MTX		0.18 (-0.37,0.74)
LD ETN SC + MTX		0.02 (-0.47,0.51)
LD TOFA PO + MTX		0.03 (-0.55,0.60)
HD TOCI IV		0.07 (-0.33,0.47)
HD TOFA PO		-0.18 (-0.71,0.35)
HD ADA SC		-0.08 (-0.64,0.47)
HD ANA		0.04 (-0.62,0.70)
HD GOLI SC		0.43 (-0.11,0.98)
HD TOCI IV + MTX		0.10 (-0.32,0.52)

(Continued)

HD CERTO SC + MTX		0.05 (-0.36,0.46)
HD TOFA PO + MTX		-0.13 (-0.69,0.44)
HD GOLI SC + MTX		0.41 (-0.06,0.89)
SD TOFA PO	SD ADA SC	-0.13 (-0.51,0.24)
SD CERTO SC		-0.04 (-0.54,0.45)
SD ANA		0.07 (-0.51,0.66)
SD ETN SC + MTX		-0.31 (-0.88,0.26)
SD CERTO SC + MTX		0.02 (-0.61,0.66)
SD GOLI SC + MTX		0.31 (-0.37,1.01)
SD TOFA PO + MTX		-0.12 (-0.88,0.65)
SD RITUX IV + MTX		0.31 (-0.45,1.10)
SD ADA SC + MTX		0.01 (-0.77,0.81)
SD TOCI IV + MTX		0.16 (-0.57,0.90)
SD ABA SC + MTX		0.09 (-0.72,0.90)
SD GOLI IV + MTX		0.62 (-0.13,1.40)
SD CERTO SC + DMARD		-0.06 (-0.59,0.47)
SD ETN SC + DMARD		-0.19 (-0.96,0.58)
LD ADA SC		-0.04 (-0.39,0.31)
LD ANA		0.07 (-0.51,0.66)
LD RITUX IV + MTX		0.41 (-0.36,1.20)
LD CERTO SC + MTX		0.11 (-0.64,0.87)
LD ETN SC + MTX		-0.05 (-0.75,0.66)
LD TOFA PO + MTX		-0.04 (-0.81,0.73)
HD TOCI IV		0.00 (-0.62,0.63)
HD TOFA PO		-0.24 (-0.62,0.12)
HD ADA SC		-0.15 (-0.50,0.20)
HD ANA		-0.03 (-0.62,0.56)
HD GOLI SC		0.36 (-0.37,1.12)

(Continued)

HD TOCI IV + MTX		0.03 (-0.61,0.69)
HD CERTO SC + MTX		-0.02 (-0.67,0.64)
HD TOFA PO + MTX		-0.20 (-0.95,0.57)
HD GOLI SC + MTX		0.35 (-0.34,1.04)
SD CERTO SC	SD TOFA PO	0.09 (-0.41,0.59)
SD ANA		0.21 (-0.38,0.81)
SD ETN SC + MTX		-0.18 (-0.75,0.41)
SD CERTO SC + MTX		0.16 (-0.48,0.81)
SD GOLI SC + MTX		0.44 (-0.25,1.15)
SD TOFA PO + MTX		0.01 (-0.75,0.78)
SD RITUX IV + MTX		0.44 (-0.32,1.24)
SD ADA SC + MTX		0.15 (-0.64,0.95)
SD TOCI IV + MTX		0.29 (-0.44,1.04)
SD ABA SC + MTX		0.22 (-0.59,1.04)
SD GOLI IV + MTX		0.76 (-0.01,1.54)
SD CERTO SC + DMARD		0.07 (-0.47,0.61)
SD ETN SC + DMARD		-0.06 (-0.83,0.72)
LD ADA SC		0.09 (-0.35,0.54)
LD ANA		0.21 (-0.39,0.80)
LD RITUX IV + MTX		0.54 (-0.23,1.33)
LD CERTO SC + MTX		0.24 (-0.51,1.01)
LD ETN SC + MTX		0.08 (-0.62,0.80)
LD TOFA PO + MTX		0.09 (-0.67,0.87)
HD TOCI IV		0.13 (-0.50,0.77)
HD TOFA PO		-0.11 (-0.42,0.19)
HD ADA SC		-0.02 (-0.46,0.43)
HD ANA		0.11 (-0.49,0.70)
HD GOLI SC		0.50 (-0.24,1.26)

(Continued)

HD TOCI IV + MTX		0.16 (-0.49,0.82)
HD CERTO SC + MTX		0.11 (-0.54,0.78)
HD TOFA PO + MTX		-0.06 (-0.82,0.70)
HD GOLI SC + MTX		0.48 (-0.21,1.18)
SD ANA	SD CERTO SC	0.12 (-0.52,0.75)
SD ETN SC + MTX		-0.27 (-0.89,0.35)
SD CERTO SC + MTX		0.07 (-0.61,0.75)
SD GOLI SC + MTX		0.36 (-0.38,1.08)
SD TOFA PO + MTX		-0.07 (-0.87,0.73)
SD RITUX IV + MTX		0.36 (-0.45,1.17)
SD ADA SC + MTX		0.06 (-0.76,0.88)
SD TOCI IV + MTX		0.20 (-0.57,0.98)
SD ABA SC + MTX		0.14 (-0.71,0.98)
SD GOLI IV + MTX		0.67 (-0.14,1.48)
SD CERTO SC + DMARD		-0.02 (-0.60,0.56)
SD ETN SC + DMARD		-0.15 (-0.97,0.66)
LD ADA SC		0.01 (-0.51,0.53)
LD ANA		0.12 (-0.52,0.75)
LD RITUX IV + MTX		0.46 (-0.35,1.27)
LD CERTO SC + MTX		0.16 (-0.63,0.94)
LD ETN SC + MTX		-0.01 (-0.76,0.75)
LD TOFA PO + MTX		0.00 (-0.80,0.81)
HD TOCI IV		0.05 (-0.63,0.72)
HD TOFA PO		-0.20 (-0.71,0.30)
HD ADA SC		-0.11 (-0.63,0.41)
HD ANA		0.02 (-0.62,0.65)
HD GOLI SC		0.41 (-0.37,1.20)
HD TOCI IV + MTX		0.07 (-0.62,0.77)

(Continued)

HD CERTO SC + MTX		0.03 (-0.67,0.72)
HD TOFA PO + MTX		-0.15 (-0.94,0.64)
HD GOLI SC + MTX		0.39 (-0.34,1.12)
SD ETN SC + MTX	SD ANA	-0.39 (-1.09,0.31)
SD CERTO SC + MTX		-0.05 (-0.79,0.70)
SD GOLI SC + MTX		0.24 (-0.56,1.04)
SD TOFA PO + MTX		-0.19 (-1.05,0.66)
SD RITUX IV + MTX		0.24 (-0.62,1.12)
SD ADA SC + MTX		-0.06 (-0.93,0.83)
SD TOCI IV + MTX		0.08 (-0.75,0.93)
SD ABA SC + MTX		0.02 (-0.89,0.93)
SD GOLI IV + MTX		0.55 (-0.31,1.43)
SD CERTO SC + DMARD		-0.13 (-0.81,0.53)
SD ETN SC + DMARD		-0.27 (-1.13,0.60)
LD ADA SC		-0.11 (-0.72,0.50)
LD ANA		0.00 (-0.50,0.50)
LD RITUX IV + MTX		0.34 (-0.53,1.22)
LD CERTO SC + MTX		0.04 (-0.80,0.89)
LD ETN SC + MTX		-0.13 (-0.94,0.70)
LD TOFA PO + MTX		-0.11 (-0.98,0.75)
HD TOCI IV		-0.07 (-0.81,0.67)
HD TOFA PO		-0.32 (-0.91,0.27)
HD ADA SC		-0.23 (-0.84,0.39)
HD ANA		-0.10 (-0.61,0.41)
HD GOLI SC		0.29 (-0.55,1.15)
HD TOCI IV + MTX		-0.05 (-0.81,0.72)
HD CERTO SC + MTX		-0.09 (-0.86,0.68)
HD TOFA PO + MTX		-0.27 (-1.13,0.60)

(Continued)

HD GOLI SC + MTX		0.27 (-0.52,1.08)
SD CERTO SC + MTX	SD ETN SC + MTX	0.34 (-0.01,0.69)
SD GOLI SC + MTX		0.62 (0.18,1.07)
SD TOFA PO + MTX		0.20 (-0.35,0.75)
SD RITUX IV + MTX		0.63 (0.06,1.20)
SD ADA SC + MTX		0.33 (-0.26,0.91)
SD TOCI IV + MTX		0.47 (-0.05,0.99)
SD ABA SC + MTX		0.41 (-0.21,1.02)
SD GOLI IV + MTX		0.94 (0.38,1.50)
SD CERTO SC + DMARD		0.25 (-0.27,0.77)
SD ETN SC + DMARD		0.12 (-0.54,0.78)
LD ADA SC		0.28 (-0.33,0.87)
LD ANA		0.39 (-0.31,1.08)
LD RITUX IV + MTX		0.73 (0.15,1.30)
LD CERTO SC + MTX		0.43 (-0.10,0.96)
LD ETN SC + MTX		0.26 (-0.19,0.72)
LD TOFA PO + MTX		0.27 (-0.28,0.83)
HD TOCI IV		0.31 (-0.08,0.72)
HD TOFA PO		0.07 (-0.52,0.64)
HD ADA SC		0.16 (-0.43,0.75)
HD ANA		0.29 (-0.42,0.98)
HD GOLI SC		0.68 (0.16,1.21)
HD TOCI IV + MTX		0.34 (-0.06,0.74)
HD CERTO SC + MTX		0.30 (-0.09,0.68)
HD TOFA PO + MTX		0.12 (-0.43,0.67)
HD GOLI SC + MTX		0.66 (0.22,1.11)
SD GOLI SC + MTX	SD CERTO SC + MTX	0.29 (-0.13,0.70)
SD TOFA PO + MTX		-0.14 (-0.67,0.39)

(Continued)

SD RITUX IV + MTX		0.29 (-0.26,0.84)
SD ADA SC + MTX		-0.01 (-0.57,0.56)
SD TOCI IV + MTX		0.13 (-0.37,0.64)
SD ABA SC + MTX		0.07 (-0.53,0.66)
SD GOLI IV + MTX		0.60 (0.06,1.15)
SD CERTO SC + DMARD		-0.08 (-0.67,0.49)
SD ETN SC + DMARD		-0.22 (-0.91,0.48)
LD ADA SC		-0.06 (-0.73,0.59)
LD ANA		0.05 (-0.70,0.79)
LD RITUX IV + MTX		0.39 (-0.17,0.94)
LD CERTO SC + MTX		0.09 (-0.37,0.55)
LD ETN SC + MTX		-0.07 (-0.59,0.43)
LD TOFA PO + MTX		-0.06 (-0.60,0.47)
HD TOCI IV		-0.02 (-0.43,0.39)
HD TOFA PO		-0.27 (-0.92,0.36)
HD ADA SC		-0.18 (-0.84,0.47)
HD ANA		-0.05 (-0.80,0.69)
HD GOLI SC		0.34 (-0.16,0.85)
HD TOCI IV + MTX		0.00 (-0.38,0.39)
HD CERTO SC + MTX		-0.04 (-0.32,0.23)
HD TOFA PO + MTX		-0.22 (-0.75,0.30)
HD GOLI SC + MTX		0.32 (-0.10,0.74)
SD TOFA PO + MTX	SD GOLI SC + MTX	-0.43 (-1.03,0.17)
SD RITUX IV + MTX		0.00 (-0.62,0.63)
SD ADA SC + MTX		-0.30 (-0.92,0.33)
SD TOCI IV + MTX		-0.15 (-0.73,0.42)
SD ABA SC + MTX		-0.22 (-0.88,0.44)
SD GOLI IV + MTX		0.31 (-0.30,0.92)

(Continued)

SD CERTO SC + DMARD		-0.37 (-1.01,0.26)
SD ETN SC + DMARD		-0.50 (-1.26,0.25)
LD ADA SC		-0.35 (-1.06,0.36)
LD ANA		-0.24 (-1.04,0.55)
LD RITUX IV + MTX		0.10 (-0.52,0.73)
LD CERTO SC + MTX		-0.20 (-0.78,0.38)
LD ETN SC + MTX		-0.36 (-0.93,0.21)
LD TOFA PO + MTX		-0.35 (-0.95,0.25)
HD TOCI IV		-0.31 (-0.80,0.18)
HD TOFA PO		-0.56 (-1.26,0.13)
HD ADA SC		-0.46 (-1.18,0.24)
HD ANA		-0.34 (-1.14,0.45)
HD GOLI SC		0.05 (-0.40,0.52)
HD TOCI IV + MTX		-0.28 (-0.75,0.19)
HD CERTO SC + MTX		-0.33 (-0.78,0.12)
HD TOFA PO + MTX		-0.51 (-1.10,0.09)
HD GOLI SC + MTX		0.03 (-0.32,0.40)
SD RITUX IV + MTX	SD TOFA PO + MTX	0.43 (-0.27,1.12)
SD ADA SC + MTX		0.13 (-0.57,0.84)
SD TOCI IV + MTX		0.27 (-0.38,0.93)
SD ABA SC + MTX		0.21 (-0.52,0.94)
SD GOLI IV + MTX		0.74 (0.05,1.43)
SD CERTO SC + DMARD		0.06 (-0.66,0.77)
SD ETN SC + DMARD		-0.07 (-0.89,0.74)
LD ADA SC		0.08 (-0.71,0.86)
LD ANA		0.19 (-0.67,1.05)
LD RITUX IV + MTX		0.53 (-0.17,1.24)
LD CERTO SC + MTX		0.23 (-0.44,0.89)



(Continued)

LD ETN SC + MTX		0.07 (-0.59,0.73)
LD TOFA PO + MTX		0.08 (-0.41,0.56)
HD TOCI IV		0.12 (-0.47,0.71)
HD TOFA PO		-0.13 (-0.90,0.64)
HD ADA SC		-0.03 (-0.82,0.75)
HD ANA		0.09 (-0.77,0.95)
HD GOLI SC		0.48 (-0.17,1.15)
HD TOCI IV + MTX		0.15 (-0.43,0.72)
HD CERTO SC + MTX		0.10 (-0.44,0.65)
HD TOFA PO + MTX		-0.08 (-0.55,0.41)
HD GOLI SC + MTX		0.46 (-0.13,1.06)
SD ADA SC + MTX	SD RITUX IV + MTX	-0.30 (-1.02,0.42)
SD TOCI IV + MTX		-0.16 (-0.83,0.52)
SD ABA SC + MTX		-0.22 (-0.97,0.53)
SD GOLI IV + MTX		0.31 (-0.39,1.02)
SD CERTO SC + DMARD		-0.37 (-1.11,0.36)
SD ETN SC + DMARD		-0.51 (-1.34,0.33)
LD ADA SC		-0.35 (-1.16,0.44)
LD ANA		-0.24 (-1.12,0.61)
LD RITUX IV + MTX		0.10 (-0.41,0.61)
LD CERTO SC + MTX		-0.20 (-0.89,0.49)
LD ETN SC + MTX		-0.36 (-1.04,0.32)
LD TOFA PO + MTX		-0.35 (-1.05,0.35)
HD TOCI IV		-0.31 (-0.92,0.29)
HD TOFA PO		-0.56 (-1.35,0.21)
HD ADA SC		-0.46 (-1.26,0.32)
HD ANA		-0.34 (-1.23,0.52)
HD GOLI SC		0.05 (-0.64,0.73)

(Continued)

HD TOCI IV + MTX		-0.29 (-0.88,0.30)
HD CERTO SC + MTX		-0.33 (-0.91,0.25)
HD TOFA PO + MTX		-0.51 (-1.20,0.19)
HD GOLI SC + MTX		0.03 (-0.59,0.65)
SD TOCI IV + MTX	SD ADA SC + MTX	0.14 (-0.54,0.82)
SD ABA SC + MTX		0.08 (-0.68,0.83)
SD GOLI IV + MTX		0.61 (-0.10,1.33)
SD CERTO SC + DMARD		-0.07 (-0.82,0.66)
SD ETN SC + DMARD		-0.21 (-1.05,0.63)
LD ADA SC		-0.05 (-0.87,0.75)
LD ANA		0.06 (-0.83,0.93)
LD RITUX IV + MTX		0.40 (-0.32,1.13)
LD CERTO SC + MTX		0.10 (-0.59,0.79)
LD ETN SC + MTX		-0.06 (-0.75,0.62)
LD TOFA PO + MTX		-0.05 (-0.76,0.65)
HD TOCI IV		-0.01 (-0.64,0.60)
HD TOFA PO		-0.26 (-1.06,0.53)
HD ADA SC		-0.17 (-0.99,0.64)
HD ANA		-0.04 (-0.93,0.83)
HD GOLI SC		0.35 (-0.34,1.04)
HD TOCI IV + MTX		0.01 (-0.59,0.62)
HD CERTO SC + MTX		-0.03 (-0.62,0.55)
HD TOFA PO + MTX		-0.21 (-0.91,0.49)
HD GOLI SC + MTX		0.33 (-0.30,0.96)
SD ABA SC + MTX	SD TOCI IV + MTX	-0.06 (-0.78,0.65)
SD GOLI IV + MTX		0.47 (-0.20,1.14)
SD CERTO SC + DMARD		-0.22 (-0.90,0.47)
SD ETN SC + DMARD		-0.35 (-1.13,0.43)

(Continued)

LD ADA SC		-0.19 (-0.96,0.55)
LD ANA		-0.08 (-0.92,0.75)
LD RITUX IV + MTX		0.26 (-0.42,0.94)
LD CERTO SC + MTX		-0.04 (-0.68,0.60)
LD ETN SC + MTX		-0.21 (-0.85,0.43)
LD TOFA PO + MTX		-0.20 (-0.86,0.46)
HD TOCI IV		-0.16 (-0.68,0.38)
HD TOFA PO		-0.40 (-1.15,0.33)
HD ADA SC		-0.31 (-1.07,0.44)
HD ANA		-0.18 (-1.03,0.65)
HD GOLI SC		0.21 (-0.43,0.85)
HD TOCI IV + MTX		-0.13 (-0.58,0.32)
HD CERTO SC + MTX		-0.17 (-0.70,0.35)
HD TOFA PO + MTX		-0.35 (-1.00,0.30)
HD GOLI SC + MTX		0.19 (-0.38,0.76)
SD GOLI IV + MTX	SD ABA SC + MTX	0.53 (-0.21,1.28)
SD CERTO SC + DMARD		-0.15 (-0.92,0.61)
SD ETN SC + DMARD		-0.29 (-1.15,0.58)
LD ADA SC		-0.13 (-0.95,0.70)
LD ANA		-0.02 (-0.92,0.88)
LD RITUX IV + MTX		0.32 (-0.43,1.07)
LD CERTO SC + MTX		0.02 (-0.70,0.75)
LD ETN SC + MTX		-0.14 (-0.86,0.58)
LD TOFA PO + MTX		-0.13 (-0.87,0.60)
HD TOCI IV		-0.09 (-0.74,0.56)
HD TOFA PO		-0.34 (-1.16,0.47)
HD ADA SC		-0.24 (-1.07,0.58)
HD ANA		-0.12 (-1.03,0.78)

(Continued)

HD GOLI SC		0.27 (-0.45,1.00)
HD TOCI IV + MTX		-0.07 (-0.69,0.58)
HD CERTO SC + MTX		-0.11 (-0.73,0.52)
HD TOFA PO + MTX		-0.29 (-1.02,0.45)
HD GOLI SC + MTX		0.25 (-0.40,0.91)
SD CERTO SC + DMARD	SD GOLI IV + MTX	-0.68 (-1.41,0.03)
SD ETN SC + DMARD		-0.82 (-1.63,0.01)
LD ADA SC		-0.66 (-1.46,0.12)
LD ANA		-0.55 (-1.43,0.30)
LD RITUX IV + MTX		-0.21 (-0.92,0.50)
LD CERTO SC + MTX		-0.51 (-1.19,0.17)
LD ETN SC + MTX		-0.68 (-1.34,0.00)
LD TOFA PO + MTX		-0.66 (-1.36,0.03)
HD TOCI IV		-0.62 (-1.22,-0.03)
HD TOFA PO		-0.87 (-1.65,-0.11)
HD ADA SC		-0.78 (-1.57,0.01)
HD ANA		-0.65 (-1.52,0.21)
HD GOLI SC		-0.26 (-0.93,0.41)
HD TOCI IV + MTX		-0.60 (-1.18,-0.02)
HD CERTO SC + MTX		-0.64 (-1.21,-0.08)
HD TOFA PO + MTX		-0.82 (-1.50,-0.13)
HD GOLI SC + MTX		-0.28 (-0.89,0.33)
SD ETN SC + DMARD	SD CERTO SC + DMARD	-0.13 (-0.81,0.55)
LD ADA SC		0.02 (-0.53,0.58)
LD ANA		0.13 (-0.53,0.80)
LD RITUX IV + MTX		0.47 (-0.26,1.21)
LD CERTO SC + MTX		0.17 (-0.52,0.88)
LD ETN SC + MTX		0.01 (-0.66,0.67)

(Continued)

LD TOFA PO + MTX		0.02 (-0.69,0.74)
HD TOCI IV		0.06 (-0.49,0.61)
HD TOFA PO		-0.18 (-0.72,0.35)
HD ADA SC		-0.09 (-0.65,0.47)
HD ANA		0.03 (-0.64,0.70)
HD GOLI SC		0.42 (-0.27,1.13)
HD TOCI IV + MTX		0.09 (-0.50,0.68)
HD CERTO SC + MTX		0.04 (-0.55,0.65)
HD TOFA PO + MTX		-0.14 (-0.85,0.57)
HD GOLI SC + MTX		0.41 (-0.23,1.05)
LD ADA SC	SD ETN SC + DMARD	0.16 (-0.64,0.94)
LD ANA		0.27 (-0.61,1.14)
LD RITUX IV + MTX		0.61 (-0.23,1.45)
LD CERTO SC + MTX		0.30 (-0.50,1.11)
LD ETN SC + MTX		0.14 (-0.64,0.92)
LD TOFA PO + MTX		0.15 (-0.66,0.97)
HD TOCI IV		0.19 (-0.46,0.85)
HD TOFA PO		-0.05 (-0.83,0.72)
HD ADA SC		0.04 (-0.75,0.83)
HD ANA		0.17 (-0.71,1.03)
HD GOLI SC		0.56 (-0.24,1.36)
HD TOCI IV + MTX		0.22 (-0.48,0.92)
HD CERTO SC + MTX		0.17 (-0.54,0.90)
HD TOFA PO + MTX		0.00 (-0.81,0.81)
HD GOLI SC + MTX		0.54 (-0.21,1.29)
LD ANA	LD ADA SC	0.11 (-0.50,0.72)
LD RITUX IV + MTX		0.45 (-0.34,1.25)
LD CERTO SC + MTX		0.15 (-0.62,0.92)

(Continued)

LD ETN SC + MTX		-0.01 (-0.74,0.73)
LD TOFA PO + MTX		0.00 (-0.79,0.79)
HD TOCI IV		0.04 (-0.61,0.69)
HD TOFA PO		-0.21 (-0.65,0.23)
HD ADA SC		-0.11 (-0.48,0.24)
HD ANA		0.01 (-0.61,0.62)
HD GOLI SC		0.40 (-0.36,1.18)
HD TOCI IV + MTX		0.06 (-0.60,0.75)
HD CERTO SC + MTX		0.02 (-0.65,0.71)
HD TOFA PO + MTX		-0.16 (-0.93,0.62)
HD GOLI SC + MTX		0.38 (-0.32,1.10)
LD RITUX IV + MTX	LD ANA	0.34 (-0.52,1.22)
LD CERTO SC + MTX		0.04 (-0.81,0.89)
LD ETN SC + MTX		-0.12 (-0.92,0.69)
LD TOFA PO + MTX		-0.11 (-0.97,0.75)
HD TOCI IV		-0.07 (-0.81,0.67)
HD TOFA PO		-0.32 (-0.91,0.27)
HD ADA SC		-0.23 (-0.83,0.39)
HD ANA		-0.10 (-0.60,0.40)
HD GOLI SC		0.29 (-0.55,1.14)
HD TOCI IV + MTX		-0.05 (-0.80,0.72)
HD CERTO SC + MTX		-0.09 (-0.85,0.68)
HD TOFA PO + MTX		-0.27 (-1.12,0.59)
HD GOLI SC + MTX		0.27 (-0.52,1.07)
LD CERTO SC + MTX	LD RITUX IV + MTX	-0.30 (-0.99,0.38)
LD ETN SC + MTX		-0.46 (-1.14,0.21)
LD TOFA PO + MTX		-0.45 (-1.15,0.25)
HD TOCI IV		-0.41 (-1.03,0.19)

(Continued)

HD TOFA PO		-0.66 (-1.45,0.12)
HD ADA SC		-0.56 (-1.37,0.23)
HD ANA		-0.44 (-1.32,0.43)
HD GOLI SC		-0.05 (-0.73,0.63)
HD TOCI IV + MTX		-0.39 (-0.98,0.21)
HD CERTO SC + MTX		-0.43 (-1.01,0.15)
HD TOFA PO + MTX		-0.61 (-1.30,0.09)
HD GOLI SC + MTX		-0.07 (-0.69,0.56)
LD ETN SC + MTX	LD CERTO SC + MTX	-0.16 (-0.81,0.48)
LD TOFA PO + MTX		-0.15 (-0.82,0.52)
HD TOCI IV		-0.11 (-0.68,0.46)
HD TOFA PO		-0.36 (-1.11,0.39)
HD ADA SC		-0.26 (-1.03,0.50)
HD ANA		-0.14 (-1.00,0.71)
HD GOLI SC		0.25 (-0.39,0.90)
HD TOCI IV + MTX		-0.08 (-0.64,0.47)
HD CERTO SC + MTX		-0.13 (-0.60,0.33)
HD TOFA PO + MTX		-0.31 (-0.97,0.36)
HD GOLI SC + MTX		0.23 (-0.35,0.82)
LD TOFA PO + MTX	LD ETN SC + MTX	0.01 (-0.65,0.67)
HD TOCI IV		0.05 (-0.50,0.61)
HD TOFA PO		-0.19 (-0.92,0.51)
HD ADA SC		-0.10 (-0.83,0.62)
HD ANA		0.02 (-0.80,0.83)
HD GOLI SC		0.41 (-0.23,1.06)
HD TOCI IV + MTX		0.08 (-0.46,0.63)
HD CERTO SC + MTX		0.03 (-0.49,0.56)
HD TOFA PO + MTX		-0.15 (-0.80,0.51)

(Continued)

HD GOLI SC + MTX		0.40 (-0.18,0.97)
HD TOCI IV	LD TOFA PO + MTX	0.04 (-0.55,0.64)
HD TOFA PO		-0.20 (-0.98,0.56)
HD ADA SC		-0.11 (-0.90,0.68)
HD ANA		0.01 (-0.86,0.88)
HD GOLI SC		0.40 (-0.26,1.07)
HD TOCI IV + MTX		0.07 (-0.50,0.65)
HD CERTO SC + MTX		0.02 (-0.54,0.58)
HD TOFA PO + MTX		-0.16 (-0.64,0.33)
HD GOLI SC + MTX		0.39 (-0.22,0.98)
HD TOFA PO	HD TOCI IV	-0.25 (-0.88,0.38)
HD ADA SC		-0.15 (-0.81,0.50)
HD ANA		-0.03 (-0.78,0.71)
HD GOLI SC		0.36 (-0.20,0.94)
HD TOCI IV + MTX		0.03 (-0.34,0.40)
HD CERTO SC + MTX		-0.02 (-0.46,0.42)
HD TOFA PO + MTX		-0.20 (-0.78,0.39)
HD GOLI SC + MTX		0.35 (-0.15,0.83)
HD ADA SC	HD TOFA PO	0.09 (-0.35,0.54)
HD ANA		0.22 (-0.37,0.82)
HD GOLI SC		0.61 (-0.13,1.37)
HD TOCI IV + MTX		0.27 (-0.38,0.94)
HD CERTO SC + MTX		0.23 (-0.42,0.89)
HD TOFA PO + MTX		0.05 (-0.71,0.82)
HD GOLI SC + MTX		0.59 (-0.09,1.29)
HD ANA	HD ADA SC	0.12 (-0.49,0.74)
HD GOLI SC		0.52 (-0.24,1.28)
HD TOCI IV + MTX		0.18 (-0.48,0.85)



(Continued)

HD CERTO SC + MTX		0.13 (-0.54,0.81)
HD TOFA PO + MTX		-0.05 (-0.82,0.74)
HD GOLI SC + MTX		0.50 (-0.20,1.21)
HD GOLI SC	HD ANA	0.39 (-0.45,1.24)
HD TOCI IV + MTX		0.05 (-0.71,0.83)
HD CERTO SC + MTX		0.01 (-0.75,0.78)
HD TOFA PO + MTX		-0.17 (-1.03,0.69)
HD GOLI SC + MTX		0.37 (-0.42,1.17)
HD TOCI IV + MTX	HD GOLI SC	-0.34 (-0.89,0.21)
HD CERTO SC + MTX		-0.38 (-0.91,0.15)
HD TOFA PO + MTX		-0.56 (-1.22,0.10)
HD GOLI SC + MTX		-0.02 (-0.49,0.44)
HD CERTO SC + MTX	HD TOCI IV + MTX	-0.05 (-0.46,0.36)
HD TOFA PO + MTX		-0.22 (-0.79,0.34)
HD GOLI SC + MTX		0.32 (-0.16,0.79)
HD TOFA PO + MTX	HD CERTO SC + MTX	-0.18 (-0.72,0.37)
HD GOLI SC + MTX		0.36 (-0.08,0.81)
HD GOLI SC + MTX	HD TOFA PO + MTX	0.54 (-0.05,1.14)
<hr/>		
Random-Effect Model	Total Residual Deviance	99.73
	Deviance Information Criteria	-252.066
<hr/>		
Fixed-Effect Model	Total Residual Deviance	322.3
	Deviance Information Criteria	-52.613
<hr/>		
Note:		
<hr/>		
Total Patients	14018	
Total Studies	39	

(Continued)

2-arm	22
3-arm	11
4-arm	6

**Appendix 14. HAQ: Subgroup - Late RA (> 10 years)**

HAQ in Late RA: Mean Difference (MD) for All Treatment Comparisons-Random Effects Model		
Treatment	Reference	MD (95% CrI)
SD RITUX IV	MTX + PL	-0.44 (-0.70,-0.18)
SD RITUX IV + MTX		-0.30 (-0.45,-0.11)
SD ADA SC + MTX		-0.33 (-0.49,-0.17)
SD TOCI IV + MTX		-0.26 (-0.48,-0.04)
LD ADA SC + MTX		-0.31 (-0.46,-0.15)
LD RITUX IV + MTX		-0.25 (-0.42,-0.07)
LD ADA IV + MTX		-0.32 (-0.67,0.03)
HD TOCI IV + MTX		-0.34 (-0.56,-0.12)
HD ADA SC + MTX		-0.33 (-0.55,-0.11)
SD RITUX IV + MTX	SD RITUX IV	0.14 (-0.12,0.42)
SD ADA SC + MTX		0.11 (-0.20,0.42)
SD TOCI IV + MTX		0.18 (-0.17,0.52)
LD ADA SC + MTX		0.13 (-0.17,0.44)
LD RITUX IV + MTX		0.19 (-0.08,0.47)
LD ADA IV + MTX		0.12 (-0.32,0.55)
HD TOCI IV + MTX		0.10 (-0.24,0.45)
HD ADA SC + MTX		0.11 (-0.24,0.47)
SD ADA SC + MTX	SD RITUX IV + MTX	-0.04 (-0.28,0.19)
SD TOCI IV + MTX		0.04 (-0.25,0.30)
LD ADA SC + MTX		-0.02 (-0.24,0.21)

(Continued)

LD RITUX IV + MTX		0.05 (-0.14,0.22)
LD ADA IV + MTX		-0.03 (-0.42,0.36)
HD TOCI IV + MTX		-0.04 (-0.34,0.22)
HD ADA SC + MTX		-0.04 (-0.33,0.24)
SD TOCI IV + MTX	SD ADA SC + MTX	0.07 (-0.20,0.35)
LD ADA SC + MTX		0.02 (-0.13,0.19)
LD RITUX IV + MTX		0.08 (-0.15,0.33)
LD ADA IV + MTX		0.01 (-0.36,0.38)
HD TOCI IV + MTX		-0.01 (-0.28,0.27)
HD ADA SC + MTX		0.00 (-0.23,0.23)
LD ADA SC + MTX	SD TOCI IV + MTX	-0.05 (-0.31,0.23)
LD RITUX IV + MTX		0.01 (-0.27,0.30)
LD ADA IV + MTX		-0.06 (-0.48,0.35)
HD TOCI IV + MTX		-0.08 (-0.30,0.14)
HD ADA SC + MTX		-0.07 (-0.38,0.24)
LD RITUX IV + MTX	LD ADA SC + MTX	0.06 (-0.17,0.29)
LD ADA IV + MTX		-0.01 (-0.38,0.35)
HD TOCI IV + MTX		-0.03 (-0.30,0.23)
HD ADA SC + MTX		-0.02 (-0.25,0.20)
LD ADA IV + MTX	LD RITUX IV + MTX	-0.07 (-0.47,0.31)
HD TOCI IV + MTX		-0.09 (-0.38,0.18)
HD ADA SC + MTX		-0.08 (-0.37,0.20)
HD TOCI IV + MTX	LD ADA IV + MTX	-0.02 (-0.42,0.40)
HD ADA SC + MTX		-0.01 (-0.41,0.40)
HD ADA SC + MTX	HD TOCI IV + MTX	0.01 (-0.31,0.32)
Random-Effect Model	Total Residual Deviance	19.24 vs 22 data point
	Deviance Information Criteria	-35.801

(Continued)

Fixed-Effect Model	Total Residual Deviance	19.04 vs 22 data point
	Deviance Information Criteria	-37.435
Note:		
Total Patients	2084	
Total Studies	7	
2-arm	1	
3-arm	4	
4-arm	2	

### Appendix 15. HAQ: Subgroup - Trial duration ( $\leq 6$ months)

HAQ, Short trial duration: Mean Difference (MD) for All Treatment Comparisons-Random Effects Model		
Treatment	Reference	MD (95% CrI)
MTX + PL	PL	1.08 (0.60,1.58)
DMARD + PL		-0.01 (-0.30,0.29)
MTX + DMARD		-0.15 (-0.56,0.25)
SD ETN SC		-0.31 (-0.57,-0.05)
SD ADA SC + PL		-0.30 (-0.45,-0.14)
SD TOFA PO		-0.39 (-0.59,-0.20)
SD CERTO SC		-0.36 (-0.60,-0.11)
SD ANA		-0.20 (-0.49,0.09)
SD RITUX IV		0.65 (0.08,1.23)
SD ETN SC + MTX		-0.42 (-0.74,-0.09)
SD CERTO SC + MTX		0.80 (0.30,1.31)
SD RITUX IV + MTX		0.80 (0.28,1.34)
SD ADA SC + MTX		0.77 (0.24,1.31)
SD GOLI SC + MTX		1.08 (0.56,1.62)

(Continued)

SD TOFA PO + MTX		0.65 (0.10,1.22)
SD TOCI IV + MTX		0.88 (0.37,1.41)
SD ABA SC + MTX		0.86 (0.25,1.47)
SD GOLI IV + MTX		1.40 (0.84,1.96)
SD ETN SC + DMARD		-0.36 (-0.75,0.04)
SD CERTO SC + DMARD		-0.35 (-0.61,-0.09)
LD ADA SC		-0.32 (-0.52,-0.12)
LD ANA		-0.20 (-0.48,0.08)
LD ADA SC + MTX		0.86 (0.33,1.42)
LD RITUX IV + MTX		0.84 (0.31,1.38)
LD ADA IV + MTX		0.80 (0.19,1.42)
LD CERTO SC + MTX		0.89 (0.33,1.46)
LD TOFA PO + MTX		0.73 (0.18,1.29)
HD TOFA PO		-0.51 (-0.70,-0.32)
HD ADA SC		-0.44 (-0.64,-0.23)
HD TOCI IV		0.88 (0.33,1.45)
HD ANA		-0.30 (-0.59,0.00)
HD GOLI SC		1.12 (0.58,1.68)
HD TOCI IV + MTX		0.77 (0.27,1.29)
HD CERTO SC + MTX		0.76 (0.26,1.28)
HD TOFA PO + MTX		0.57 (0.02,1.14)
HD GOLI SC + MTX		1.11 (0.59,1.65)
HD ADA SC + MTX		0.79 (0.23,1.37)
DMARD + PL	MTX + PL	-1.09 (-1.56,-0.63)
MTX + DMARD		-1.24 (-1.66,-0.82)
SD ETN SC		-1.39 (-1.79,-1.01)
SD ADA SC + PL		-1.38 (-1.89,-0.88)
SD TOFA PO		-1.48 (-2.01,-0.96)

(Continued)

SD CERTO SC	-1.45 (-1.99,-0.91)
SD ANA	-1.28 (-1.85,-0.73)
SD RITUX IV	-0.44 (-0.76,-0.11)
SD ETN SC + MTX	-1.50 (-1.84,-1.17)
SD CERTO SC + MTX	-0.28 (-0.41,-0.16)
SD RITUX IV + MTX	-0.28 (-0.50,-0.06)
SD ADA SC + MTX	-0.31 (-0.54,-0.09)
SD GOLI SC + MTX	0.00 (-0.21,0.20)
SD TOFA PO + MTX	-0.44 (-0.70,-0.17)
SD TOCI IV + MTX	-0.20 (-0.39,-0.01)
SD ABA SC + MTX	-0.22 (-0.59,0.15)
SD GOLI IV + MTX	0.31 (0.03,0.59)
SD ETN SC + DMARD	-1.44 (-1.97,-0.91)
SD CERTO SC + DMARD	-1.43 (-1.94,-0.94)
LD ADA SC	-1.41 (-1.93,-0.89)
LD ANA	-1.28 (-1.84,-0.73)
LD ADA SC + MTX	-0.22 (-0.49,0.04)
LD RITUX IV + MTX	-0.24 (-0.47,-0.01)
LD ADA IV + MTX	-0.29 (-0.69,0.11)
LD CERTO SC + MTX	-0.20 (-0.49,0.09)
LD TOFA PO + MTX	-0.36 (-0.62,-0.09)
HD TOFA PO	-1.59 (-2.12,-1.08)
HD ADA SC	-1.52 (-2.05,-1.00)
HD TOCI IV	-0.20 (-0.48,0.09)
HD ANA	-1.38 (-1.95,-0.82)
HD GOLI SC	0.04 (-0.23,0.30)
HD TOCI IV + MTX	-0.31 (-0.47,-0.14)
HD CERTO SC + MTX	-0.32 (-0.48,-0.17)

(Continued)

HD TOFA PO + MTX		-0.52 (-0.78,-0.25)
HD GOLI SC + MTX		0.03 (-0.18,0.23)
HD ADA SC + MTX		-0.29 (-0.59,0.00)
MTX + DMARD	DMARD + PL	-0.15 (-0.53,0.24)
SD ETN SC		-0.30 (-0.54,-0.06)
SD ADA SC + PL		-0.29 (-0.62,0.05)
SD TOFA PO		-0.39 (-0.74,-0.04)
SD CERTO SC		-0.36 (-0.73,0.03)
SD ANA		-0.19 (-0.60,0.23)
SD RITUX IV		0.65 (0.09,1.23)
SD ETN SC + MTX		-0.41 (-0.71,-0.11)
SD CERTO SC + MTX		0.81 (0.34,1.30)
SD RITUX IV + MTX		0.81 (0.30,1.34)
SD ADA SC + MTX		0.78 (0.26,1.30)
SD GOLI SC + MTX		1.09 (0.59,1.60)
SD TOFA PO + MTX		0.65 (0.13,1.21)
SD TOCI IV + MTX		0.89 (0.40,1.40)
SD ABA SC + MTX		0.87 (0.28,1.46)
SD GOLI IV + MTX		1.40 (0.87,1.95)
SD ETN SC + DMARD		-0.35 (-0.61,-0.08)
SD CERTO SC + DMARD		-0.34 (-0.60,-0.09)
LD ADA SC		-0.32 (-0.67,0.04)
LD ANA		-0.19 (-0.60,0.22)
LD ADA SC + MTX		0.87 (0.34,1.41)
LD RITUX IV + MTX		0.85 (0.34,1.38)
LD ADA IV + MTX		0.80 (0.21,1.42)
LD CERTO SC + MTX		0.89 (0.35,1.45)
LD TOFA PO + MTX		0.73 (0.20,1.28)

(Continued)

HD TOFA PO		-0.50 (-0.85,-0.15)
HD ADA SC		-0.43 (-0.78,-0.07)
HD TOCI IV		0.89 (0.36,1.44)
HD ANA		-0.29 (-0.71,0.13)
HD GOLI SC		1.13 (0.60,1.67)
HD TOCI IV + MTX		0.78 (0.29,1.28)
HD CERTO SC + MTX		0.77 (0.28,1.27)
HD TOFA PO + MTX		0.57 (0.05,1.12)
HD GOLI SC + MTX		1.12 (0.62,1.63)
HD ADA SC + MTX		0.80 (0.25,1.36)
SD ETN SC	MTX + DMARD	-0.16 (-0.46,0.14)
SD ADA SC + PL		-0.14 (-0.58,0.29)
SD TOFA PO		-0.24 (-0.69,0.20)
SD CERTO SC		-0.21 (-0.68,0.26)
SD ANA		-0.04 (-0.55,0.45)
SD RITUX IV		0.80 (0.27,1.33)
SD ETN SC + MTX		-0.27 (-0.51,-0.03)
SD CERTO SC + MTX		0.95 (0.52,1.39)
SD RITUX IV + MTX		0.96 (0.49,1.43)
SD ADA SC + MTX		0.92 (0.44,1.40)
SD GOLI SC + MTX		1.23 (0.77,1.70)
SD TOFA PO + MTX		0.80 (0.31,1.30)
SD TOCI IV + MTX		1.04 (0.58,1.50)
SD ABA SC + MTX		1.02 (0.46,1.57)
SD GOLI IV + MTX		1.55 (1.05,2.05)
SD ETN SC + DMARD		-0.20 (-0.67,0.26)
SD CERTO SC + DMARD		-0.20 (-0.62,0.22)
LD ADA SC		-0.17 (-0.62,0.28)



(Continued)

LD ANA		-0.04 (-0.54,0.44)
LD ADA SC + MTX		1.02 (0.52,1.51)
LD RITUX IV + MTX		1.00 (0.52,1.47)
LD ADA IV + MTX		0.95 (0.38,1.52)
LD CERTO SC + MTX		1.04 (0.53,1.55)
LD TOFA PO + MTX		0.88 (0.38,1.38)
HD TOFA PO		-0.35 (-0.80,0.09)
HD ADA SC		-0.28 (-0.73,0.17)
HD TOCI IV		1.04 (0.54,1.54)
HD ANA		-0.14 (-0.65,0.35)
HD GOLI SC		1.27 (0.78,1.77)
HD TOCI IV + MTX		0.93 (0.48,1.38)
HD CERTO SC + MTX		0.91 (0.47,1.36)
HD TOFA PO + MTX		0.72 (0.23,1.22)
HD GOLI SC + MTX		1.27 (0.81,1.74)
HD ADA SC + MTX		0.95 (0.43,1.46)
SD ADA SC + PL	SD ETN SC	0.01 (-0.29,0.31)
SD TOFA PO		-0.08 (-0.41,0.23)
SD CERTO SC		-0.05 (-0.40,0.31)
SD ANA		0.11 (-0.28,0.50)
SD RITUX IV		0.96 (0.45,1.47)
SD ETN SC + MTX		-0.11 (-0.30,0.08)
SD CERTO SC + MTX		1.11 (0.70,1.53)
SD RITUX IV + MTX		1.11 (0.67,1.57)
SD ADA SC + MTX		1.08 (0.62,1.53)
SD GOLI SC + MTX		1.39 (0.95,1.84)
SD TOFA PO + MTX		0.96 (0.49,1.44)
SD TOCI IV + MTX		1.19 (0.76,1.63)

(Continued)

SD ABA SC + MTX		1.17 (0.63,1.71)
SD GOLI IV + MTX		1.70 (1.22,2.19)
SD ETN SC + DMARD		-0.05 (-0.40,0.31)
SD CERTO SC + DMARD		-0.04 (-0.33,0.25)
LD ADA SC		-0.01 (-0.34,0.31)
LD ANA		0.11 (-0.27,0.49)
LD ADA SC + MTX		1.17 (0.70,1.65)
LD RITUX IV + MTX		1.15 (0.70,1.61)
LD ADA IV + MTX		1.11 (0.56,1.66)
LD CERTO SC + MTX		1.20 (0.71,1.69)
LD TOFA PO + MTX		1.04 (0.56,1.52)
HD TOFA PO		-0.20 (-0.52,0.12)
HD ADA SC		-0.13 (-0.46,0.20)
HD TOCI IV		1.19 (0.71,1.68)
HD ANA		0.01 (-0.38,0.40)
HD GOLI SC		1.43 (0.96,1.91)
HD TOCI IV + MTX		1.08 (0.66,1.51)
HD CERTO SC + MTX		1.07 (0.65,1.50)
HD TOFA PO + MTX		0.88 (0.41,1.36)
HD GOLI SC + MTX		1.42 (0.98,1.87)
HD ADA SC + MTX		1.10 (0.61,1.60)
SD TOFA PO	SD ADA SC + PL	-0.10 (-0.33,0.13)
SD CERTO SC		-0.07 (-0.36,0.23)
SD ANA		0.10 (-0.24,0.43)
SD RITUX IV		0.94 (0.35,1.55)
SD ETN SC + MTX		-0.12 (-0.48,0.24)
SD CERTO SC + MTX		1.10 (0.58,1.62)
SD RITUX IV + MTX		1.10 (0.55,1.66)

(Continued)

SD ADA SC + MTX	1.07 (0.51,1.63)	
SD GOL I SC + MTX	1.38 (0.83,1.93)	
SD TOFA PO + MTX	0.94 (0.37,1.54)	
SD TOCI IV + MTX	1.18 (0.65,1.73)	
SD ABA SC + MTX	1.16 (0.53,1.79)	
SD GOL I IV + MTX	1.69 (1.11,2.28)	
SD ETN SC + DMARD	-0.06 (-0.48,0.37)	
SD CERTO SC + DMARD	-0.05 (-0.36,0.25)	
LD ADA SC	-0.03 (-0.23,0.17)	
LD ANA	0.10 (-0.22,0.42)	
LD ADA SC + MTX	1.16 (0.60,1.74)	
LD RITUX IV + MTX	1.14 (0.59,1.70)	
LD ADA IV + MTX	1.09 (0.47,1.74)	
LD CERTO SC + MTX	1.18 (0.60,1.78)	
LD TOFA PO + MTX	1.02 (0.45,1.61)	
HD TOFA PO	-0.21 (-0.44,0.01)	
HD ADA SC	-0.14 (-0.34,0.06)	
HD TOCI IV	1.18 (0.61,1.77)	
HD ANA	0.00 (-0.34,0.34)	
HD GOL I SC	1.42 (0.86,2.00)	
HD TOCI IV + MTX	1.07 (0.54,1.61)	
HD CERTO SC + MTX	1.06 (0.53,1.60)	
HD TOFA PO + MTX	0.86 (0.30,1.46)	
HD GOL I SC + MTX	1.41 (0.87,1.96)	
HD ADA SC + MTX	1.09 (0.51,1.68)	
SD CERTO SC	SD TOFA PO	0.03 (-0.28,0.35)
SD ANA	0.19 (-0.16,0.55)	
SD RITUX IV	1.04 (0.43,1.66)	

(Continued)

SD ETN SC + MTX	-0.03 (-0.40,0.36)
SD CERTO SC + MTX	1.19 (0.66,1.74)
SD RITUX IV + MTX	1.20 (0.64,1.77)
SD ADA SC + MTX	1.16 (0.60,1.74)
SD GOLI SC + MTX	1.47 (0.92,2.05)
SD TOFA PO + MTX	1.04 (0.47,1.65)
SD TOCI IV + MTX	1.27 (0.73,1.84)
SD ABA SC + MTX	1.26 (0.62,1.90)
SD GOLI IV + MTX	1.79 (1.20,2.39)
SD ETN SC + DMARD	0.04 (-0.39,0.48)
SD CERTO SC + DMARD	0.04 (-0.28,0.37)
LD ADA SC	0.07 (-0.19,0.34)
LD ANA	0.19 (-0.14,0.54)
LD ADA SC + MTX	1.26 (0.69,1.85)
LD RITUX IV + MTX	1.24 (0.68,1.81)
LD ADA IV + MTX	1.19 (0.55,1.85)
LD CERTO SC + MTX	1.28 (0.69,1.89)
LD TOFA PO + MTX	1.12 (0.54,1.72)
HD TOFA PO	-0.11 (-0.30,0.07)
HD ADA SC	-0.04 (-0.31,0.23)
HD TOCI IV	1.28 (0.69,1.88)
HD ANA	0.10 (-0.26,0.46)
HD GOLI SC	1.51 (0.95,2.11)
HD TOCI IV + MTX	1.17 (0.63,1.73)
HD CERTO SC + MTX	1.15 (0.62,1.71)
HD TOFA PO + MTX	0.96 (0.39,1.57)
HD GOLI SC + MTX	1.50 (0.96,2.08)
HD ADA SC + MTX	1.18 (0.60,1.79)

(Continued)

SD ANA	SD CERTO SC	0.16 (-0.23,0.54)
SD RITUX IV		1.01 (0.38,1.64)
SD ETN SC + MTX		-0.06 (-0.47,0.35)
SD CERTO SC + MTX		1.16 (0.61,1.72)
SD RITUX IV + MTX		1.17 (0.58,1.75)
SD ADA SC + MTX		1.13 (0.55,1.71)
SD GOLI SC + MTX		1.44 (0.86,2.02)
SD TOFA PO + MTX		1.01 (0.41,1.62)
SD TOCI IV + MTX		1.25 (0.68,1.82)
SD ABA SC + MTX		1.23 (0.57,1.88)
SD GOLI IV + MTX		1.76 (1.15,2.37)
SD ETN SC + DMARD		0.01 (-0.46,0.47)
SD CERTO SC + DMARD		0.01 (-0.35,0.37)
LD ADA SC		0.04 (-0.28,0.35)
LD ANA		0.16 (-0.22,0.53)
LD ADA SC + MTX		1.23 (0.63,1.83)
LD RITUX IV + MTX		1.21 (0.62,1.79)
LD ADA IV + MTX		1.16 (0.49,1.83)
LD CERTO SC + MTX		1.25 (0.63,1.87)
LD TOFA PO + MTX		1.09 (0.49,1.70)
HD TOFA PO		-0.14 (-0.46,0.17)
HD ADA SC		-0.07 (-0.39,0.24)
HD TOCI IV		1.25 (0.64,1.86)
HD ANA		0.07 (-0.32,0.44)
HD GOLI SC		1.48 (0.89,2.08)
HD TOCI IV + MTX		1.14 (0.57,1.70)
HD CERTO SC + MTX		1.12 (0.56,1.69)
HD TOFA PO + MTX		0.93 (0.33,1.54)

(Continued)

HD GOLI SC + MTX		1.48 (0.90,2.06)
HD ADA SC + MTX		1.16 (0.54,1.77)
SD RITUX IV	SD ANA	0.85 (0.20,1.50)
SD ETN SC + MTX		-0.22 (-0.66,0.22)
SD CERTO SC + MTX		1.00 (0.43,1.58)
SD RITUX IV + MTX		1.00 (0.40,1.61)
SD ADA SC + MTX		0.97 (0.37,1.59)
SD GOLI SC + MTX		1.28 (0.68,1.89)
SD TOFA PO + MTX		0.85 (0.23,1.48)
SD TOCI IV + MTX		1.08 (0.50,1.68)
SD ABA SC + MTX		1.06 (0.39,1.74)
SD GOLI IV + MTX		1.59 (0.97,2.23)
SD ETN SC + DMARD		-0.16 (-0.65,0.34)
SD CERTO SC + DMARD		-0.15 (-0.55,0.24)
LD ADA SC		-0.12 (-0.48,0.23)
LD ANA		0.00 (-0.29,0.29)
LD ADA SC + MTX		1.06 (0.45,1.69)
LD RITUX IV + MTX		1.04 (0.44,1.65)
LD ADA IV + MTX		1.00 (0.32,1.69)
LD CERTO SC + MTX		1.09 (0.45,1.72)
LD TOFA PO + MTX		0.93 (0.31,1.56)
HD TOFA PO		-0.31 (-0.66,0.04)
HD ADA SC		-0.24 (-0.59,0.12)
HD TOCI IV		1.08 (0.46,1.72)
HD ANA		-0.10 (-0.40,0.20)
HD GOLI SC		1.32 (0.71,1.95)
HD TOCI IV + MTX		0.97 (0.40,1.57)
HD CERTO SC + MTX		0.96 (0.38,1.55)

(Continued)

HD TOFA PO + MTX		0.77 (0.15,1.41)
HD GOLI SC + MTX		1.31 (0.71,1.92)
HD ADA SC + MTX		0.99 (0.36,1.63)
SD ETN SC + MTX	SD RITUX IV	-1.07 (-1.54,-0.60)
SD CERTO SC + MTX		0.15 (-0.20,0.51)
SD RITUX IV + MTX		0.16 (-0.17,0.49)
SD ADA SC + MTX		0.12 (-0.27,0.52)
SD GOLI SC + MTX		0.43 (0.05,0.82)
SD TOFA PO + MTX		0.00 (-0.42,0.42)
SD TOCI IV + MTX		0.23 (-0.14,0.61)
SD ABA SC + MTX		0.22 (-0.27,0.71)
SD GOLI IV + MTX		0.75 (0.32,1.18)
SD ETN SC + DMARD		-1.00 (-1.63,-0.37)
SD CERTO SC + DMARD		-1.00 (-1.60,-0.40)
LD ADA SC		-0.97 (-1.59,-0.36)
LD ANA		-0.85 (-1.49,-0.21)
LD ADA SC + MTX		0.22 (-0.20,0.63)
LD RITUX IV + MTX		0.20 (-0.14,0.53)
LD ADA IV + MTX		0.15 (-0.37,0.67)
LD CERTO SC + MTX		0.24 (-0.20,0.68)
LD TOFA PO + MTX		0.08 (-0.34,0.50)
HD TOFA PO		-1.15 (-1.77,-0.55)
HD ADA SC		-1.08 (-1.70,-0.48)
HD TOCI IV		0.24 (-0.19,0.67)
HD ANA		-0.94 (-1.60,-0.30)
HD GOLI SC		0.47 (0.06,0.90)
HD TOCI IV + MTX		0.13 (-0.24,0.49)
HD CERTO SC + MTX		0.11 (-0.25,0.47)

(Continued)

HD TOFA PO + MTX		-0.08 (-0.50,0.34)
HD GOLI SC + MTX		0.46 (0.08,0.85)
HD ADA SC + MTX		0.14 (-0.30,0.58)
SD CERTO SC + MTX	SD ETN SC + MTX	1.22 (0.86,1.58)
SD RITUX IV + MTX		1.22 (0.82,1.63)
SD ADA SC + MTX		1.19 (0.78,1.60)
SD GOLI SC + MTX		1.50 (1.11,1.90)
SD TOFA PO + MTX		1.07 (0.64,1.51)
SD TOCI IV + MTX		1.30 (0.92,1.69)
SD ABA SC + MTX		1.28 (0.78,1.78)
SD GOLI IV + MTX		1.81 (1.38,2.25)
SD ETN SC + DMARD		0.06 (-0.34,0.47)
SD CERTO SC + DMARD		0.07 (-0.28,0.42)
LD ADA SC		0.10 (-0.28,0.48)
LD ANA		0.22 (-0.21,0.65)
LD ADA SC + MTX		1.28 (0.85,1.71)
LD RITUX IV + MTX		1.26 (0.86,1.67)
LD ADA IV + MTX		1.22 (0.70,1.74)
LD CERTO SC + MTX		1.31 (0.86,1.76)
LD TOFA PO + MTX		1.15 (0.72,1.58)
HD TOFA PO		-0.09 (-0.47,0.29)
HD ADA SC		-0.02 (-0.40,0.37)
HD TOCI IV		1.31 (0.87,1.75)
HD ANA		0.12 (-0.32,0.56)
HD GOLI SC		1.54 (1.12,1.98)
HD TOCI IV + MTX		1.19 (0.82,1.57)
HD CERTO SC + MTX		1.18 (0.81,1.55)
HD TOFA PO + MTX		0.99 (0.56,1.42)



(Continued)

HD GOLI SC + MTX	1.53 (1.14,1.93)
HD ADA SC + MTX	1.21 (0.76,1.66)
SD RITUX IV + MTX	SD CERTO SC + MTX 0.00 (-0.25,0.26)
SD ADA SC + MTX	-0.03 (-0.29,0.23)
SD GOLI SC + MTX	0.28 (0.03,0.52)
SD TOFA PO + MTX	-0.15 (-0.45,0.15)
SD TOCI IV + MTX	0.08 (-0.15,0.31)
SD ABA SC + MTX	0.06 (-0.33,0.45)
SD GOLI IV + MTX	0.59 (0.29,0.90)
SD ETN SC + DMARD	-1.16 (-1.71,-0.61)
SD CERTO SC + DMARD	-1.15 (-1.67,-0.64)
LD ADA SC	-1.12 (-1.66,-0.59)
LD ANA	-1.00 (-1.58,-0.43)
LD ADA SC + MTX	0.06 (-0.24,0.36)
LD RITUX IV + MTX	0.04 (-0.22,0.31)
LD ADA IV + MTX	0.00 (-0.42,0.42)
LD CERTO SC + MTX	0.09 (-0.21,0.38)
LD TOFA PO + MTX	-0.07 (-0.37,0.22)
HD TOFA PO	-1.31 (-1.85,-0.77)
HD ADA SC	-1.24 (-1.78,-0.70)
HD TOCI IV	0.08 (-0.23,0.40)
HD ANA	-1.10 (-1.68,-0.52)
HD GOLI SC	0.32 (0.03,0.62)
HD TOCI IV + MTX	-0.03 (-0.23,0.19)
HD CERTO SC + MTX	-0.04 (-0.19,0.11)
HD TOFA PO + MTX	-0.23 (-0.53,0.07)
HD GOLI SC + MTX	0.31 (0.07,0.56)
HD ADA SC + MTX	-0.01 (-0.33,0.31)

(Continued)

SD ADA SC + MTX	SD RITUX IV + MTX	-0.03 (-0.35,0.28)
SD GOLI SC + MTX		0.28 (-0.03,0.58)
SD TOFA PO + MTX		-0.16 (-0.50,0.19)
SD TOCI IV + MTX		0.08 (-0.21,0.37)
SD ABA SC + MTX		0.06 (-0.37,0.49)
SD GOLI IV + MTX		0.59 (0.23,0.95)
SD ETN SC + DMARD		-1.16 (-1.74,-0.58)
SD CERTO SC + DMARD		-1.15 (-1.71,-0.61)
LD ADA SC		-1.13 (-1.70,-0.56)
LD ANA		-1.00 (-1.60,-0.41)
LD ADA SC + MTX		0.06 (-0.29,0.40)
LD RITUX IV + MTX		0.04 (-0.20,0.27)
LD ADA IV + MTX		-0.01 (-0.46,0.45)
LD CERTO SC + MTX		0.08 (-0.29,0.45)
LD TOFA PO + MTX		-0.08 (-0.42,0.27)
HD TOFA PO		-1.31 (-1.89,-0.75)
HD ADA SC		-1.24 (-1.82,-0.68)
HD TOCI IV		0.08 (-0.28,0.44)
HD ANA		-1.10 (-1.71,-0.50)
HD GOLI SC		0.32 (-0.03,0.66)
HD TOCI IV + MTX		-0.03 (-0.31,0.25)
HD CERTO SC + MTX		-0.04 (-0.32,0.23)
HD TOFA PO + MTX		-0.24 (-0.58,0.11)
HD GOLI SC + MTX		0.31 (0.00,0.61)
HD ADA SC + MTX		-0.01 (-0.38,0.35)
SD GOLI SC + MTX	SD ADA SC + MTX	0.31 (0.00,0.62)
SD TOFA PO + MTX		-0.12 (-0.47,0.23)
SD TOCI IV + MTX		0.11 (-0.18,0.41)

(Continued)

SD ABA SC + MTX		0.09 (-0.34,0.53)
SD GOLI IV + MTX		0.62 (0.26,0.98)
SD ETN SC + DMARD		-1.13 (-1.71,-0.55)
SD CERTO SC + DMARD		-1.12 (-1.67,-0.57)
LD ADA SC		-1.09 (-1.67,-0.53)
LD ANA		-0.97 (-1.58,-0.37)
LD ADA SC + MTX		0.09 (-0.20,0.38)
LD RITUX IV + MTX		0.07 (-0.25,0.39)
LD ADA IV + MTX		0.03 (-0.42,0.47)
LD CERTO SC + MTX		0.12 (-0.25,0.48)
LD TOFA PO + MTX		-0.04 (-0.40,0.31)
HD TOFA PO		-1.28 (-1.86,-0.72)
HD ADA SC		-1.21 (-1.78,-0.64)
HD TOCI IV		0.11 (-0.25,0.48)
HD ANA		-1.07 (-1.68,-0.46)
HD GOLI SC		0.35 (0.00,0.70)
HD TOCI IV + MTX		0.00 (-0.28,0.29)
HD CERTO SC + MTX		-0.01 (-0.29,0.26)
HD TOFA PO + MTX		-0.20 (-0.55,0.15)
HD GOLI SC + MTX		0.34 (0.03,0.65)
HD ADA SC + MTX		0.02 (-0.28,0.32)
SD TOFA PO + MTX	SD GOLI SC + MTX	-0.43 (-0.77,-0.09)
SD TOCI IV + MTX		-0.20 (-0.48,0.08)
SD ABA SC + MTX		-0.22 (-0.64,0.21)
SD GOLI IV + MTX		0.32 (-0.03,0.66)
SD ETN SC + DMARD		-1.43 (-2.01,-0.87)
SD CERTO SC + DMARD		-1.43 (-1.98,-0.89)
LD ADA SC		-1.40 (-1.97,-0.85)

(Continued)

LD ANA		-1.28 (-1.88,-0.69)
LD ADA SC + MTX		-0.22 (-0.56,0.12)
LD RITUX IV + MTX		-0.24 (-0.55,0.07)
LD ADA IV + MTX		-0.28 (-0.73,0.17)
LD CERTO SC + MTX		-0.19 (-0.55,0.16)
LD TOFA PO + MTX		-0.35 (-0.69,-0.01)
HD TOFA PO		-1.58 (-2.16,-1.03)
HD ADA SC		-1.52 (-2.09,-0.96)
HD TOCI IV		-0.19 (-0.55,0.16)
HD ANA		-1.38 (-1.99,-0.78)
HD GOLI SC		0.04 (-0.23,0.32)
HD TOCI IV + MTX		-0.31 (-0.57,-0.04)
HD CERTO SC + MTX		-0.32 (-0.58,-0.06)
HD TOFA PO + MTX		-0.51 (-0.85,-0.17)
HD GOLI SC + MTX		0.03 (-0.18,0.25)
HD ADA SC + MTX		-0.29 (-0.65,0.07)
SD TOCI IV + MTX	SD TOFA PO + MTX	0.23 (-0.09,0.56)
SD ABA SC + MTX		0.22 (-0.24,0.67)
SD GOLI IV + MTX		0.75 (0.36,1.13)
SD ETN SC + DMARD		-1.00 (-1.61,-0.41)
SD CERTO SC + DMARD		-1.00 (-1.58,-0.44)
LD ADA SC		-0.97 (-1.57,-0.39)
LD ANA		-0.85 (-1.48,-0.24)
LD ADA SC + MTX		0.22 (-0.16,0.58)
LD RITUX IV + MTX		0.20 (-0.16,0.55)
LD ADA IV + MTX		0.15 (-0.33,0.63)
LD CERTO SC + MTX		0.24 (-0.15,0.63)
LD TOFA PO + MTX		0.08 (-0.19,0.34)

(Continued)

HD TOFA PO		-1.15 (-1.76,-0.58)
HD ADA SC		-1.08 (-1.69,-0.50)
HD TOCI IV		0.24 (-0.15,0.62)
HD ANA		-0.94 (-1.59,-0.33)
HD GOLI SC		0.47 (0.10,0.85)
HD TOCI IV + MTX		0.13 (-0.19,0.44)
HD CERTO SC + MTX		0.11 (-0.20,0.42)
HD TOFA PO + MTX		-0.08 (-0.34,0.19)
HD GOLI SC + MTX		0.46 (0.12,0.80)
HD ADA SC + MTX		0.14 (-0.25,0.54)
SD ABA SC + MTX	SD TOCI IV + MTX	-0.02 (-0.44,0.39)
SD GOLI IV + MTX		0.51 (0.17,0.85)
SD ETN SC + DMARD		-1.24 (-1.81,-0.68)
SD CERTO SC + DMARD		-1.23 (-1.78,-0.71)
LD ADA SC		-1.20 (-1.76,-0.66)
LD ANA		-1.08 (-1.67,-0.50)
LD ADA SC + MTX		-0.02 (-0.35,0.30)
LD RITUX IV + MTX		-0.04 (-0.34,0.26)
LD ADA IV + MTX		-0.09 (-0.53,0.36)
LD CERTO SC + MTX		0.00 (-0.34,0.35)
LD TOFA PO + MTX		-0.16 (-0.48,0.17)
HD TOFA PO		-1.39 (-1.95,-0.84)
HD ADA SC		-1.32 (-1.88,-0.77)
HD TOCI IV		0.00 (-0.34,0.34)
HD ANA		-1.18 (-1.78,-0.59)
HD GOLI SC		0.24 (-0.09,0.57)
HD TOCI IV + MTX		-0.11 (-0.30,0.08)
HD CERTO SC + MTX		-0.12 (-0.37,0.12)

(Continued)

HD TOFA PO + MTX		-0.31 (-0.64,0.01)
HD GOLI SC + MTX		0.23 (-0.05,0.51)
HD ADA SC + MTX		-0.09 (-0.44,0.25)
SD GOLI IV + MTX	SD ABA SC + MTX	0.53 (0.07,0.99)
SD ETN SC + DMARD		-1.22 (-1.86,-0.57)
SD CERTO SC + DMARD		-1.21 (-1.84,-0.59)
LD ADA SC		-1.18 (-1.82,-0.54)
LD ANA		-1.06 (-1.73,-0.39)
LD ADA SC + MTX		0.00 (-0.46,0.46)
LD RITUX IV + MTX		-0.02 (-0.45,0.42)
LD ADA IV + MTX		-0.07 (-0.61,0.48)
LD CERTO SC + MTX		0.02 (-0.45,0.50)
LD TOFA PO + MTX		-0.14 (-0.59,0.32)
HD TOFA PO		-1.37 (-2.01,-0.73)
HD ADA SC		-1.30 (-1.94,-0.66)
HD TOCI IV		0.02 (-0.44,0.49)
HD ANA		-1.16 (-1.84,-0.48)
HD GOLI SC		0.26 (-0.19,0.72)
HD TOCI IV + MTX		-0.09 (-0.49,0.32)
HD CERTO SC + MTX		-0.10 (-0.51,0.30)
HD TOFA PO + MTX		-0.29 (-0.75,0.16)
HD GOLI SC + MTX		0.25 (-0.18,0.68)
HD ADA SC + MTX		-0.07 (-0.54,0.40)
SD ETN SC + DMARD	SD GOLI IV + MTX	-1.75 (-2.35,-1.15)
SD CERTO SC + DMARD		-1.74 (-2.32,-1.18)
LD ADA SC		-1.72 (-2.31,-1.13)
LD ANA		-1.59 (-2.22,-0.98)
LD ADA SC + MTX		-0.53 (-0.92,-0.14)

(Continued)

LD RITUX IV + MTX		-0.55 (-0.91,-0.19)
LD ADA IV + MTX		-0.60 (-1.09,-0.11)
LD CERTO SC + MTX		-0.51 (-0.91,-0.11)
LD TOFA PO + MTX		-0.67 (-1.05,-0.28)
HD TOFA PO		-1.90 (-2.50,-1.31)
HD ADA SC		-1.83 (-2.43,-1.24)
HD TOCI IV		-0.51 (-0.91,-0.11)
HD ANA		-1.69 (-2.32,-1.07)
HD GOLI SC		-0.27 (-0.65,0.12)
HD TOCI IV + MTX		-0.62 (-0.95,-0.29)
HD CERTO SC + MTX		-0.63 (-0.95,-0.31)
HD TOFA PO + MTX		-0.83 (-1.21,-0.44)
HD GOLI SC + MTX		-0.28 (-0.63,0.06)
HD ADA SC + MTX		-0.60 (-1.01,-0.20)
SD CERTO SC + DMARD	SD ETN SC + DMARD	0.01 (-0.36,0.37)
LD ADA SC		0.03 (-0.41,0.47)
LD ANA		0.16 (-0.33,0.64)
LD ADA SC + MTX		1.22 (0.63,1.82)
LD RITUX IV + MTX		1.20 (0.62,1.78)
LD ADA IV + MTX		1.15 (0.50,1.82)
LD CERTO SC + MTX		1.24 (0.63,1.86)
LD TOFA PO + MTX		1.08 (0.49,1.69)
HD TOFA PO		-0.15 (-0.60,0.28)
HD ADA SC		-0.08 (-0.53,0.36)
HD TOCI IV		1.24 (0.64,1.84)
HD ANA		0.06 (-0.44,0.55)
HD GOLI SC		1.48 (0.89,2.07)
HD TOCI IV + MTX		1.13 (0.58,1.69)

(Continued)

HD CERTO SC + MTX		1.12 (0.56,1.67)
HD TOFA PO + MTX		0.92 (0.33,1.52)
HD GOLI SC + MTX		1.47 (0.90,2.04)
HD ADA SC + MTX		1.15 (0.54,1.76)
LD ADA SC	SD CERTO SC + DMARD	0.03 (-0.30,0.36)
LD ANA		0.15 (-0.24,0.54)
LD ADA SC + MTX		1.21 (0.65,1.79)
LD RITUX IV + MTX		1.19 (0.65,1.75)
LD ADA IV + MTX		1.15 (0.52,1.79)
LD CERTO SC + MTX		1.24 (0.66,1.83)
LD TOFA PO + MTX		1.08 (0.51,1.66)
HD TOFA PO		-0.16 (-0.48,0.17)
HD ADA SC		-0.09 (-0.42,0.25)
HD TOCI IV		1.23 (0.67,1.82)
HD ANA		0.05 (-0.34,0.45)
HD GOLI SC		1.47 (0.91,2.05)
HD TOCI IV + MTX		1.12 (0.60,1.66)
HD CERTO SC + MTX		1.11 (0.59,1.65)
HD TOFA PO + MTX		0.92 (0.35,1.50)
HD GOLI SC + MTX		1.46 (0.92,2.01)
HD ADA SC + MTX		1.14 (0.57,1.73)
LD ANA	LD ADA SC	0.12 (-0.22,0.47)
LD ADA SC + MTX		1.18 (0.61,1.78)
LD RITUX IV + MTX		1.16 (0.60,1.74)
LD ADA IV + MTX		1.12 (0.48,1.78)
LD CERTO SC + MTX		1.21 (0.61,1.82)
LD TOFA PO + MTX		1.05 (0.47,1.65)
HD TOFA PO		-0.18 (-0.45,0.08)



(Continued)

HD ADA SC		-0.11 (-0.33,0.10)
HD TOCI IV		1.21 (0.62,1.81)
HD ANA		0.02 (-0.33,0.38)
HD GOLI SC		1.44 (0.87,2.04)
HD TOCI IV + MTX		1.10 (0.56,1.65)
HD CERTO SC + MTX		1.08 (0.55,1.63)
HD TOFA PO + MTX		0.89 (0.31,1.49)
HD GOLI SC + MTX		1.43 (0.88,2.00)
HD ADA SC + MTX		1.11 (0.52,1.71)
LD ADA SC + MTX	LD ANA	1.06 (0.46,1.68)
LD RITUX IV + MTX		1.04 (0.45,1.65)
LD ADA IV + MTX		1.00 (0.32,1.69)
LD CERTO SC + MTX		1.09 (0.45,1.72)
LD TOFA PO + MTX		0.93 (0.31,1.56)
HD TOFA PO		-0.31 (-0.65,0.03)
HD ADA SC		-0.24 (-0.59,0.11)
HD TOCI IV		1.08 (0.47,1.72)
HD ANA		-0.10 (-0.40,0.20)
HD GOLI SC		1.32 (0.71,1.94)
HD TOCI IV + MTX		0.97 (0.40,1.56)
HD CERTO SC + MTX		0.96 (0.39,1.54)
HD TOFA PO + MTX		0.77 (0.15,1.40)
HD GOLI SC + MTX		1.31 (0.72,1.92)
HD ADA SC + MTX		0.99 (0.36,1.63)
LD RITUX IV + MTX	LD ADA SC + MTX	-0.02 (-0.37,0.33)
LD ADA IV + MTX		-0.07 (-0.49,0.36)
LD CERTO SC + MTX		0.02 (-0.37,0.42)
LD TOFA PO + MTX		-0.14 (-0.51,0.24)

(Continued)

HD TOFA PO		-1.37 (-1.97,-0.80)
HD ADA SC		-1.30 (-1.90,-0.73)
HD TOCI IV		0.02 (-0.36,0.41)
HD ANA		-1.16 (-1.79,-0.54)
HD GOLI SC		0.26 (-0.12,0.64)
HD TOCI IV + MTX		-0.09 (-0.40,0.23)
HD CERTO SC + MTX		-0.10 (-0.41,0.21)
HD TOFA PO + MTX		-0.29 (-0.67,0.08)
HD GOLI SC + MTX		0.25 (-0.09,0.59)
HD ADA SC + MTX		-0.07 (-0.38,0.24)
LD ADA IV + MTX	LD RITUX IV + MTX	-0.05 (-0.50,0.42)
LD CERTO SC + MTX		0.04 (-0.33,0.42)
LD TOFA PO + MTX		-0.12 (-0.47,0.24)
HD TOFA PO		-1.35 (-1.92,-0.79)
HD ADA SC		-1.28 (-1.86,-0.72)
HD TOCI IV		0.04 (-0.32,0.41)
HD ANA		-1.14 (-1.76,-0.53)
HD GOLI SC		0.28 (-0.07,0.63)
HD TOCI IV + MTX		-0.07 (-0.35,0.22)
HD CERTO SC + MTX		-0.08 (-0.36,0.19)
HD TOFA PO + MTX		-0.27 (-0.63,0.08)
HD GOLI SC + MTX		0.27 (-0.04,0.58)
HD ADA SC + MTX		-0.05 (-0.42,0.32)
LD CERTO SC + MTX	LD ADA IV + MTX	0.09 (-0.41,0.58)
LD TOFA PO + MTX		-0.07 (-0.55,0.41)
HD TOFA PO		-1.30 (-1.96,-0.66)
HD ADA SC		-1.23 (-1.90,-0.59)
HD TOCI IV		0.09 (-0.40,0.57)

(Continued)

HD ANA		-1.09 (-1.79,-0.41)
HD GOLI SC		0.32 (-0.15,0.81)
HD TOCI IV + MTX		-0.02 (-0.46,0.41)
HD CERTO SC + MTX		-0.04 (-0.46,0.39)
HD TOFA PO + MTX		-0.23 (-0.71,0.25)
HD GOLI SC + MTX		0.31 (-0.13,0.76)
HD ADA SC + MTX		-0.01 (-0.47,0.47)
LD TOFA PO + MTX	LD CERTO SC + MTX	-0.16 (-0.55,0.24)
HD TOFA PO		-1.39 (-2.00,-0.80)
HD ADA SC		-1.32 (-1.93,-0.73)
HD TOCI IV		0.00 (-0.41,0.41)
HD ANA		-1.18 (-1.83,-0.54)
HD GOLI SC		0.23 (-0.16,0.63)
HD TOCI IV + MTX		-0.11 (-0.44,0.23)
HD CERTO SC + MTX		-0.13 (-0.42,0.17)
HD TOFA PO + MTX		-0.32 (-0.71,0.08)
HD GOLI SC + MTX		0.23 (-0.13,0.58)
HD ADA SC + MTX		-0.09 (-0.50,0.32)
HD TOFA PO	LD TOFA PO + MTX	-1.23 (-1.83,-0.65)
HD ADA SC		-1.16 (-1.76,-0.58)
HD TOCI IV		0.16 (-0.23,0.54)
HD ANA		-1.02 (-1.66,-0.40)
HD GOLI SC		0.39 (0.02,0.77)
HD TOCI IV + MTX		0.05 (-0.27,0.37)
HD CERTO SC + MTX		0.03 (-0.28,0.34)
HD TOFA PO + MTX		-0.16 (-0.42,0.11)
HD GOLI SC + MTX		0.39 (0.05,0.72)
HD ADA SC + MTX		0.07 (-0.33,0.46)

(Continued)

HD ADA SC	HD TOFA PO	0.07 (-0.20,0.34)
HD TOCI IV		1.39 (0.81,1.99)
HD ANA		0.21 (-0.14,0.57)
HD GOLI SC		1.63 (1.06,2.22)
HD TOCI IV + MTX		1.28 (0.74,1.84)
HD CERTO SC + MTX		1.27 (0.73,1.82)
HD TOFA PO + MTX		1.07 (0.50,1.68)
HD GOLI SC + MTX		1.62 (1.07,2.19)
HD ADA SC + MTX		1.30 (0.71,1.91)
HD TOCI IV	HD ADA SC	1.32 (0.73,1.93)
HD ANA		0.14 (-0.22,0.50)
HD GOLI SC		1.56 (0.98,2.15)
HD TOCI IV + MTX		1.21 (0.67,1.77)
HD CERTO SC + MTX		1.20 (0.65,1.75)
HD TOFA PO + MTX		1.01 (0.43,1.61)
HD GOLI SC + MTX		1.55 (0.99,2.12)
HD ADA SC + MTX		1.23 (0.64,1.83)
HD ANA	HD TOCI IV	-1.18 (-1.82,-0.56)
HD GOLI SC		0.24 (-0.15,0.63)
HD TOCI IV + MTX		-0.11 (-0.44,0.22)
HD CERTO SC + MTX		-0.12 (-0.45,0.20)
HD TOFA PO + MTX		-0.32 (-0.71,0.07)
HD GOLI SC + MTX		0.23 (-0.12,0.58)
HD ADA SC + MTX		-0.09 (-0.50,0.31)
HD GOLI SC	HD ANA	1.42 (0.81,2.05)
HD TOCI IV + MTX		1.07 (0.49,1.67)
HD CERTO SC + MTX		1.06 (0.48,1.65)
HD TOFA PO + MTX		0.87 (0.24,1.50)

(Continued)

HD GOLI SC + MTX		1.41 (0.81,2.02)
HD ADA SC + MTX		1.09 (0.46,1.73)
HD TOCI IV + MTX	HD GOLI SC	-0.35 (-0.66,-0.03)
HD CERTO SC + MTX		-0.36 (-0.67,-0.05)
HD TOFA PO + MTX		-0.55 (-0.93,-0.18)
HD GOLI SC + MTX		-0.01 (-0.28,0.26)
HD ADA SC + MTX		-0.33 (-0.72,0.07)
HD CERTO SC + MTX	HD TOCI IV + MTX	-0.01 (-0.24,0.21)
HD TOFA PO + MTX		-0.21 (-0.52,0.11)
HD GOLI SC + MTX		0.34 (0.07,0.60)
HD ADA SC + MTX		0.02 (-0.32,0.35)
HD TOFA PO + MTX	HD CERTO SC + MTX	-0.19 (-0.50,0.12)
HD GOLI SC + MTX		0.35 (0.09,0.61)
HD ADA SC + MTX		0.03 (-0.30,0.37)
HD GOLI SC + MTX	HD TOFA PO + MTX	0.54 (0.21,0.88)
HD ADA SC + MTX		0.22 (-0.17,0.62)
HD ADA SC + MTX	HD GOLI SC + MTX	-0.32 (-0.68,0.04)
Random-Effect Model	Total Residual Deviance	108.9
	Deviance Information Criteria	-253.47
Fixed-Effect Model	Total Residual Deviance	443.8
	Deviance Information Criteria	188.147
Note:		
Total Patients	13213	
Total Studies	42	
2-arm	23	

(Continued)

3-arm 11

4-arm 8

**Appendix 16. Remission: Type of medication**

Remission Analysis 2 : Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
TNF	comp	2.11 (1.29,3.54)	1.96 (1.27,3.04)	0.07 (0.02,0.14)
non-TNF		4.59 (2.08,10.27)	3.66 (1.93,6.36)	0.19 (0.07,0.36)
MTXTNF		4.09 (2.91,5.93)	3.36 (2.54,4.50)	0.17 (0.11,0.23)
MTXnon-TNF		4.71 (3.02,7.60)	3.73 (2.62,5.32)	0.19 (0.12,0.28)
MTXTOFA		8.15 (1.66,49.85)	5.40 (1.58,11.79)	0.31 (0.04,0.71)
non-TNF	TNF	2.17 (0.94,4.93)	1.87 (0.95,3.38)	0.12 (-0.01,0.28)
MTXTNF		1.93 (1.22,3.09)	1.71 (1.17,2.56)	0.10 (0.03,0.16)
MTXnon-TNF		2.23 (1.20,4.17)	1.90 (1.16,3.17)	0.12 (0.03,0.23)
MTXTOFA		3.85 (0.72,25.04)	2.74 (0.76,6.70)	0.24 (-0.04,0.65)
MTXTNF	non-TNF	0.89 (0.40,2.05)	0.92 (0.53,1.78)	-0.02 (-0.20,0.11)
MTXnon-TNF		1.02 (0.48,2.23)	1.02 (0.61,1.88)	0.00 (-0.16,0.13)
MTXTOFA		1.78 (0.30,12.74)	1.47 (0.39,4.02)	0.12 (-0.21,0.55)
MTXnon-TNF	MTXTNF	1.15 (0.69,1.93)	1.11 (0.75,1.62)	0.03 (-0.07,0.13)
MTXTOFA		1.99 (0.39,12.55)	1.61 (0.46,3.60)	0.14 (-0.14,0.56)
MTXTOFA	MTXnon-TNF	1.73 (0.33,11.10)	1.45 (0.41,3.34)	0.12 (-0.17,0.53)
Random-Effect Model	Residual Deviance	64.66 vs 63 data points		
	Deviance Information Criteria	409.045		
Fixed-Effect Model	Residual Deviance	134.2 vs 63 data points		
	Deviance Information Criteria	459.699		

(Continued)

Note:

Total Patients	12668
Total Studies	29
2-arm	24
3-arm	5

### Appendix 17. Remission: Type of biologics

Remission Analysis 3 : Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
Mono	PL	2.00 (0.87,4.70)	1.96 (1.05,3.56)	0.07 (0.00,0.17)
TNF		4.64 (1.98,11.03)	1.87 (0.87,3.76)	0.06 (-0.01,0.19)
non-TNF		4.46 (2.86,7.27)	3.70 (1.85,6.65)	0.19 (0.06,0.37)
MTXMono		4.83 (3.02,8.00)	3.60 (2.51,5.22)	0.18 (0.11,0.27)
MTXnon-TNF		3.64 (1.93,7.01)	3.82 (2.63,5.54)	0.19 (0.12,0.29)
MTXTNF		7.78 (1.53,50.47)	3.08 (1.81,5.01)	0.14 (0.06,0.27)
MTXTOFA		0.95 (0.31,2.85)	5.29 (1.47,11.93)	0.30 (0.03,0.71)
TNF	Mono	2.21 (0.87,5.47)	0.96 (0.36,2.43)	-0.01 (-0.13,0.14)
non-TNF		2.12 (1.02,4.43)	1.89 (0.89,3.80)	0.12 (-0.02,0.29)
MTXMono		2.30 (1.05,5.07)	1.84 (1.02,3.48)	0.11 (0.00,0.21)
MTXnon-TNF		1.73 (0.66,4.49)	1.95 (1.04,3.81)	0.13 (0.01,0.24)
MTXTNF		3.72 (0.61,26.89)	1.57 (0.71,3.45)	0.08 (-0.06,0.22)
MTXTOFA		2.32 (0.69,7.63)	2.68 (0.66,7.56)	0.23 (-0.06,0.65)
non-TNF	TNF	2.23 (0.86,5.92)	1.97 (0.74,5.14)	0.12 (-0.06,0.33)
MTXMono		2.41 (0.92,6.44)	1.92 (0.89,4.52)	0.12 (-0.03,0.23)
MTXnon-TNF		1.82 (0.94,3.52)	2.03 (0.94,4.75)	0.13 (-0.01,0.26)
MTXTNF		3.90 (0.62,29.66)	1.64 (0.95,2.95)	0.08 (-0.01,0.17)

(Continued)

MTXTOFA		0.96 (0.39,2.43)	2.79 (0.67,8.70)	0.23 (-0.06,0.66)
MTXMono	non-TNF	1.04 (0.46,2.40)	0.97 (0.53,2.02)	-0.01 (-0.20,0.14)
MTXnon-TNF		0.79 (0.27,2.31)	1.03 (0.59,2.00)	0.01 (-0.17,0.14)
MTXTNF		1.69 (0.26,12.95)	0.83 (0.38,1.93)	-0.04 (-0.25,0.14)
MTXTOFA		1.08 (0.60,1.93)	1.42 (0.35,4.18)	0.11 (-0.22,0.55)
MTXnon-TNF	MTXMono	0.82 (0.36,1.79)	1.06 (0.69,1.62)	0.02 (-0.10,0.13)
MTXTNF		1.75 (0.32,11.67)	0.86 (0.45,1.54)	-0.04 (-0.17,0.11)
MTXTOFA		0.75 (0.33,1.68)	1.47 (0.39,3.48)	0.12 (-0.17,0.54)
MTXTNF	MTXnon-TNF	1.61 (0.29,10.92)	0.81 (0.42,1.46)	-0.05 (-0.19,0.10)
MTXTOFA		2.14 (0.37,15.21)	1.39 (0.37,3.32)	0.10 (-0.19,0.53)
MTXTOFA	MTXTNF		1.71 (0.44,4.56)	0.15 (-0.15,0.58)

Random-Effect Model	Residual Deviance	64.03 vs 63 data points
	Deviance Information Criteria	409.476
Fixed-Effect Model	Residual Deviance	135.9 vs 63 data points
	Deviance Information Criteria	463.334

Note:

Total Patients	12668
Total Studies	29
2-arm	24
3-arm	5

## Appendix 18. Remission: By dose

Remission Analysis 4 : Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
-----------	-----------	--------------	--------------	----------------

**Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis (Review)**

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.



(Continued)

SD	PL	1.90 (1.18,3.15)	1.78 (1.16,2.73)	0.06 (0.01,0.12)
HD		4.14 (2.25,7.68)	3.34 (2.05,5.22)	0.18 (0.08,0.30)
LD		2.79 (1.02,7.63)	2.45 (1.02,5.15)	0.11 (0.00,0.30)
MTXSD		4.15 (3.10,5.68)	3.35 (2.64,4.31)	0.18 (0.13,0.23)
MTXHD		5.82 (3.57,9.92)	4.27 (2.96,6.14)	0.25 (0.15,0.36)
MTXLD		2.26 (1.30,3.95)	2.07 (1.27,3.26)	0.08 (0.02,0.16)
HD	SD	2.17 (1.12,4.19)	1.87 (1.10,3.12)	0.12 (0.02,0.24)
LD		1.46 (0.52,4.11)	1.38 (0.56,3.02)	0.05 (-0.07,0.24)
MTXSD		2.17 (1.38,3.45)	1.88 (1.29,2.81)	0.12 (0.05,0.18)
MTXHD		3.06 (1.65,5.82)	2.39 (1.47,3.95)	0.19 (0.08,0.30)
MTXLD		1.19 (0.60,2.30)	1.16 (0.65,2.02)	0.02 (-0.06,0.11)
LD	HD	0.67 (0.22,2.10)	0.73 (0.28,1.72)	-0.07 (-0.23,0.14)
MTXSD		1.00 (0.54,1.85)	1.00 (0.65,1.63)	0.00 (-0.13,0.10)
MTXHD		1.41 (0.78,2.62)	1.27 (0.84,2.03)	0.07 (-0.05,0.19)
MTXLD		0.55 (0.25,1.20)	0.62 (0.33,1.16)	-0.10 (-0.23,0.03)
MTXSD	LD	1.49 (0.56,4.06)	1.36 (0.67,3.27)	0.07 (-0.12,0.18)
MTXHD		2.09 (0.71,6.32)	1.74 (0.79,4.39)	0.13 (-0.07,0.29)
MTXLD		0.81 (0.28,2.33)	0.84 (0.38,2.09)	-0.03 (-0.22,0.10)
MTXHD	MTXSD	1.40 (0.86,2.35)	1.27 (0.89,1.79)	0.07 (-0.03,0.18)
MTXLD		0.55 (0.31,0.93)	0.62 (0.38,0.95)	-0.10 (-0.17,-0.01)
MTXLD	MTXHD	0.39 (0.19,0.78)	0.48 (0.27,0.83)	-0.16 (-0.29,-0.04)
Random-Effect Model	Residual Deviance	68.24 vs 68 data points		
	Deviance Information Criteria	427.568		
Fixed-Effect Model	Residual Deviance	137.3 vs 68 data points		
	Deviance Information Criteria	475.55		

(Continued)

Note:

Total Patients	11225
Total Studies	27
2-arm	16
3-arm	9
4-arm	1
5-arm	1

### Appendix 19. Remission: Main analysis

Remission (Analysis 1): Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX + DMARD	MTX + PL	0.70 (0.21,2.15)	0.71 (0.22,2.05)	-0.01 (-0.04,0.05)
PL		0.98 (0.11,8.09)	0.98 (0.11,6.26)	0.00 (-0.04,0.22)
SD ETN SC		1.80 (0.77,4.19)	1.74 (0.77,3.68)	0.03 (-0.01,0.12)
SD ADA SC		1.19 (0.19,7.38)	1.18 (0.20,5.85)	0.01 (-0.04,0.20)
SD GOLI IV		1.45 (0.42,4.98)	1.42 (0.44,4.26)	0.02 (-0.03,0.14)
SD GOLI SC		3.40 (0.34,33.10)	3.07 (0.35,14.16)	0.09 (-0.03,0.55)
SD ETN SC + MTX		3.19 (1.51,6.77)	2.91 (1.48,5.42)	0.08 (0.02,0.19)
SD ABA IV + MTX		4.86 (2.53,9.91)	4.15 (2.36,7.26)	0.14 (0.06,0.26)
SD ABA SC + MTX		3.81 (1.63,9.06)	3.39 (1.59,6.76)	0.11 (0.03,0.24)
SD GOLI SC + MTX		10.48 (3.72,31.95)	7.37 (3.29,14.41)	0.28 (0.11,0.53)
SD ADA SC + MTX		4.68 (1.54,16.01)	4.02 (1.50,9.94)	0.13 (0.02,0.37)
SD INF IV + MTX		3.97 (1.79,9.33)	3.51 (1.73,6.90)	0.11 (0.03,0.25)
SD RITUX IV + MTX		2.26 (0.90,5.87)	2.14 (0.90,4.87)	0.05 (0.00,0.17)
SD GOLI IV + MTX		3.75 (1.42,10.74)	3.34 (1.39,7.59)	0.10 (0.02,0.28)
SD CERTO + MTX		3.18 (1.25,8.54)	2.90 (1.24,6.48)	0.08 (0.01,0.23)

(Continued)

SD TOFA PO + MTX		4.43 (0.95,27.56)	3.84 (0.96,13.18)	0.13 (0.00,0.50)
LD GOLI IV		2.24 (0.69,7.63)	2.13 (0.70,5.97)	0.05 (-0.01,0.21)
LD RITUX IV + MTX		1.50 (0.58,3.98)	1.47 (0.59,3.53)	0.02 (-0.02,0.11)
LD ETN SC + MTX		2.99 (1.04,8.23)	2.74 (1.04,6.27)	0.08 (0.00,0.23)
LD GOLI IV + MTX		1.35 (0.38,4.84)	1.33 (0.39,4.15)	0.01 (-0.03,0.14)
HD TOCI IV		6.93 (1.80,28.87)	5.48 (1.73,13.53)	0.20 (0.03,0.51)
HD GOLI SC		4.59 (1.15,19.15)	3.96 (1.14,11.02)	0.13 (0.01,0.41)
HD TOCI IV + MTX		12.77 (3.97,47.17)	8.35 (3.48,16.66)	0.33 (0.11,0.63)
HD GOLI SC + MTX		9.28 (3.29,27.72)	6.78 (2.97,13.56)	0.26 (0.09,0.50)
HD INF IV + MTX		3.52 (1.27,9.89)	3.16 (1.26,7.17)	0.10 (0.01,0.27)
HD TOFA PO + MTX		11.09 (2.48,65.57)	7.66 (2.32,18.02)	0.29 (0.06,0.70)
PL	MTX + DMARD	1.39 (0.12,16.02)	1.37 (0.13,12.69)	0.01 (-0.06,0.23)
SD ETN SC		2.59 (0.92,7.87)	2.46 (0.93,7.20)	0.04 (0.00,0.12)
SD ADA SC		1.72 (0.21,15.45)	1.68 (0.22,12.35)	0.02 (-0.05,0.21)
SD GOLI IV		2.08 (0.40,11.51)	2.01 (0.42,9.93)	0.03 (-0.04,0.15)
SD GOLI SC		4.89 (0.38,66.45)	4.29 (0.39,31.89)	0.10 (-0.03,0.56)
SD ETN SC + MTX		4.59 (1.94,11.53)	4.10 (1.82,10.14)	0.09 (0.04,0.18)
SD ABA IV + MTX		6.98 (1.93,28.27)	5.85 (1.79,21.70)	0.15 (0.06,0.27)
SD ABA SC + MTX		5.43 (1.36,24.12)	4.74 (1.33,18.88)	0.12 (0.02,0.26)
SD GOLI SC + MTX		15.18 (3.36,75.90)	10.34 (2.82,39.73)	0.29 (0.11,0.54)
SD ADA SC + MTX		6.74 (1.41,37.63)	5.66 (1.37,25.28)	0.14 (0.02,0.38)
SD INF IV + MTX		5.68 (1.47,25.34)	4.92 (1.42,19.65)	0.12 (0.03,0.27)
SD RITUX IV + MTX		3.26 (0.77,14.95)	3.03 (0.78,12.66)	0.06 (-0.02,0.18)
SD GOLI IV + MTX		5.39 (1.22,26.74)	4.71 (1.20,20.16)	0.11 (0.01,0.29)
SD CERTO + MTX		4.58 (1.05,22.26)	4.09 (1.05,17.58)	0.09 (0.00,0.25)
SD TOFA PO + MTX		6.41 (0.92,54.71)	5.41 (0.93,29.41)	0.13 (0.00,0.51)
LD GOLI IV		3.21 (0.63,18.15)	2.99 (0.65,14.50)	0.06 (-0.02,0.22)
LD RITUX IV + MTX		2.16 (0.49,10.31)	2.08 (0.51,9.23)	0.03 (-0.04,0.12)

(Continued)

LD ETN SC + MTX		4.26 (1.13,17.46)	3.83 (1.12,14.05)	0.09 (0.01,0.23)
LD GOLI IV + MTX		1.94 (0.36,11.09)	1.88 (0.38,9.70)	0.03 (-0.04,0.15)
HD TOCI IV		9.98 (1.77,63.04)	7.64 (1.67,33.66)	0.21 (0.04,0.52)
HD GOLI SC		6.58 (1.13,43.05)	5.55 (1.12,27.21)	0.14 (0.01,0.42)
HD TOCI IV + MTX		18.27 (3.69,107.80)	11.57 (3.07,46.42)	0.34 (0.12,0.64)
HD GOLI SC + MTX		13.37 (2.93,69.16)	9.54 (2.54,37.77)	0.27 (0.10,0.51)
HD INF IV + MTX		5.02 (1.13,25.11)	4.43 (1.12,18.99)	0.11 (0.01,0.28)
HD TOFA PO + MTX		16.14 (2.38,133.20)	10.64 (2.17,46.84)	0.30 (0.06,0.71)
SD ETN SC	PL	1.86 (0.19,18.82)	1.79 (0.23,16.93)	0.03 (-0.19,0.13)
SD ADA SC		1.22 (0.07,22.02)	1.21 (0.09,18.28)	0.01 (-0.21,0.20)
SD GOLI IV		1.48 (0.13,18.96)	1.45 (0.16,16.73)	0.02 (-0.20,0.15)
SD GOLI SC		3.51 (0.84,16.83)	3.00 (0.85,11.73)	0.08 (-0.01,0.43)
SD ETN SC + MTX		3.30 (0.36,33.04)	2.99 (0.43,27.70)	0.08 (-0.14,0.20)
SD ABA IV + MTX		5.01 (0.56,49.45)	4.24 (0.64,39.07)	0.13 (-0.09,0.27)
SD ABA SC + MTX		3.97 (0.40,40.40)	3.48 (0.48,32.69)	0.10 (-0.12,0.25)
SD GOLI SC + MTX		10.92 (1.52,87.02)	7.47 (1.35,56.90)	0.27 (0.06,0.50)
SD ADA SC + MTX		4.95 (0.45,57.22)	4.16 (0.52,41.03)	0.13 (-0.11,0.37)
SD INF IV + MTX		4.14 (0.44,42.18)	3.62 (0.51,33.82)	0.10 (-0.11,0.26)
SD RITUX IV + MTX		2.34 (0.23,25.19)	2.20 (0.28,21.68)	0.05 (-0.17,0.17)
SD GOLI IV + MTX		3.84 (0.39,43.24)	3.39 (0.45,34.05)	0.10 (-0.12,0.28)
SD CERTO + MTX		3.27 (0.32,37.80)	2.95 (0.38,30.52)	0.08 (-0.14,0.24)
SD TOFA PO + MTX		4.66 (0.34,72.48)	3.94 (0.40,43.94)	0.12 (-0.12,0.49)
LD GOLI IV		2.30 (0.21,29.17)	2.16 (0.25,24.49)	0.04 (-0.17,0.21)
LD RITUX IV + MTX		1.56 (0.15,16.84)	1.52 (0.19,15.35)	0.02 (-0.20,0.12)
LD ETN SC + MTX		3.07 (0.29,33.96)	2.79 (0.35,27.74)	0.07 (-0.15,0.24)
LD GOLI IV + MTX		1.36 (0.12,17.67)	1.33 (0.15,15.69)	0.01 (-0.20,0.14)
HD TOCI IV		7.14 (0.55,98.72)	5.54 (0.61,59.26)	0.19 (-0.08,0.51)
HD GOLI SC		4.68 (1.02,25.32)	3.94 (1.01,20.87)	0.12 (0.00,0.32)

(Continued)

HD TOCI IV + MTX		13.18 (1.15,172.20)	8.41 (1.11,84.04)	0.31 (0.02,0.63)
HD GOLI SC + MTX		9.64 (1.37,75.71)	6.86 (1.26,51.02)	0.24 (0.05,0.47)
HD INF IV + MTX		3.64 (0.36,40.20)	3.23 (0.42,31.55)	0.09 (-0.13,0.27)
HD TOFA PO + MTX		11.77 (0.84,177.10)	7.66 (0.88,76.14)	0.28 (-0.02,0.69)
SD ADA SC	SD ETN SC	0.66 (0.09,4.94)	0.68 (0.10,4.05)	-0.02 (-0.12,0.17)
SD GOLI IV		0.80 (0.18,3.60)	0.81 (0.20,3.20)	-0.01 (-0.11,0.11)
SD GOLI SC		1.90 (0.16,21.31)	1.77 (0.18,10.21)	0.06 (-0.09,0.52)
SD ETN SC + MTX		1.78 (0.99,3.19)	1.67 (0.99,2.87)	0.05 (0.00,0.12)
SD ABA IV + MTX		2.71 (0.95,8.10)	2.39 (0.96,6.32)	0.10 (-0.01,0.23)
SD ABA SC + MTX		2.11 (0.66,7.05)	1.94 (0.69,5.63)	0.07 (-0.04,0.22)
SD GOLI SC + MTX		5.87 (1.55,23.32)	4.22 (1.44,11.94)	0.25 (0.05,0.50)
SD ADA SC + MTX		2.61 (0.67,11.36)	2.31 (0.70,7.67)	0.10 (-0.04,0.34)
SD INF IV + MTX		2.21 (0.71,7.37)	2.02 (0.74,5.77)	0.08 (-0.03,0.22)
SD RITUX IV + MTX		1.26 (0.35,4.51)	1.23 (0.39,3.90)	0.02 (-0.08,0.14)
SD GOLI IV + MTX		2.08 (0.57,8.23)	1.91 (0.61,6.20)	0.07 (-0.05,0.25)
SD CERTO + MTX		1.77 (0.51,6.51)	1.67 (0.55,5.26)	0.05 (-0.06,0.21)
SD TOFA PO + MTX		2.45 (0.43,18.19)	2.19 (0.46,9.57)	0.09 (-0.06,0.47)
LD GOLI IV		1.25 (0.29,5.60)	1.23 (0.32,4.59)	0.02 (-0.09,0.18)
LD RITUX IV + MTX		0.84 (0.23,3.05)	0.85 (0.26,2.80)	-0.01 (-0.11,0.09)
LD ETN SC + MTX		1.66 (0.52,5.22)	1.57 (0.55,4.27)	0.04 (-0.05,0.19)
LD GOLI IV + MTX		0.75 (0.16,3.46)	0.76 (0.18,3.07)	-0.02 (-0.11,0.11)
HD TOCI IV		3.87 (0.80,19.79)	3.14 (0.82,10.47)	0.16 (-0.02,0.48)
HD GOLI SC		2.55 (0.51,13.26)	2.26 (0.55,8.27)	0.10 (-0.06,0.38)
HD TOCI IV + MTX		7.08 (1.71,33.40)	4.75 (1.56,13.93)	0.29 (0.06,0.60)
HD GOLI SC + MTX		5.19 (1.38,20.64)	3.89 (1.32,11.33)	0.22 (0.04,0.47)
HD INF IV + MTX		1.95 (0.53,7.41)	1.81 (0.56,5.71)	0.06 (-0.05,0.24)
HD TOFA PO + MTX		6.18 (1.09,43.57)	4.34 (1.08,14.33)	0.26 (0.01,0.66)
SD GOLI IV	SD ADA SC	1.21 (0.13,10.80)	1.20 (0.16,9.59)	0.01 (-0.19,0.14)

(Continued)

SD GOLI SC		2.89 (0.15,53.58)	2.56 (0.17,28.63)	0.08 (-0.15,0.53)
SD ETN SC + MTX		2.67 (0.37,19.12)	2.45 (0.43,15.83)	0.07 (-0.13,0.20)
SD ABA IV + MTX		4.09 (0.60,29.39)	3.50 (0.66,22.83)	0.13 (-0.08,0.26)
SD ABA SC + MTX		3.18 (0.43,24.47)	2.84 (0.49,19.34)	0.09 (-0.11,0.24)
SD GOLI SC + MTX		8.85 (1.06,76.90)	6.18 (1.04,42.23)	0.26 (0.01,0.53)
SD ADA SC + MTX		3.94 (0.47,35.70)	3.37 (0.53,24.92)	0.12 (-0.10,0.36)
SD INF IV + MTX		3.35 (0.47,25.34)	2.96 (0.53,19.92)	0.10 (-0.10,0.25)
SD RITUX IV + MTX		1.89 (0.24,14.91)	1.81 (0.29,12.88)	0.04 (-0.16,0.17)
SD GOLI IV + MTX		3.20 (0.38,25.90)	2.85 (0.44,19.93)	0.09 (-0.12,0.27)
SD CERTO + MTX		2.67 (0.35,21.18)	2.45 (0.41,17.27)	0.07 (-0.13,0.23)
SD TOFA PO + MTX		3.73 (0.35,48.40)	3.19 (0.40,28.58)	0.11 (-0.11,0.49)
LD GOLI IV		1.90 (0.21,16.63)	1.80 (0.25,13.84)	0.04 (-0.16,0.21)
LD RITUX IV + MTX		1.26 (0.16,10.02)	1.24 (0.20,9.04)	0.01 (-0.18,0.11)
LD ETN SC + MTX		2.50 (0.30,20.34)	2.30 (0.36,16.43)	0.06 (-0.14,0.23)
LD GOLI IV + MTX		1.13 (0.12,10.41)	1.12 (0.15,9.19)	0.01 (-0.19,0.14)
HD TOCI IV		5.81 (1.78,19.48)	4.50 (1.54,15.03)	0.18 (0.05,0.40)
HD GOLI SC		3.86 (0.38,38.51)	3.30 (0.44,25.76)	0.11 (-0.11,0.40)
HD TOCI IV + MTX		10.69 (2.61,48.07)	6.85 (1.93,30.17)	0.30 (0.12,0.54)
HD GOLI SC + MTX		7.83 (0.97,65.92)	5.66 (0.98,38.74)	0.24 (-0.01,0.49)
HD INF IV + MTX		2.95 (0.37,24.65)	2.66 (0.43,19.04)	0.08 (-0.12,0.27)
HD TOFA PO + MTX		9.32 (0.87,117.10)	6.23 (0.90,46.60)	0.27 (-0.02,0.69)
SD GOLI SC	SD GOLI IV	2.40 (0.17,30.12)	2.18 (0.19,15.31)	0.07 (-0.11,0.53)
SD ETN SC + MTX		2.22 (0.52,9.29)	2.06 (0.56,7.76)	0.06 (-0.07,0.18)
SD ABA IV + MTX		3.39 (0.84,14.08)	2.93 (0.86,10.93)	0.12 (-0.02,0.25)
SD ABA SC + MTX		2.64 (0.60,11.90)	2.38 (0.64,9.48)	0.08 (-0.06,0.23)
SD GOLI SC + MTX		7.34 (1.40,36.77)	5.19 (1.31,19.86)	0.26 (0.04,0.52)
SD ADA SC + MTX		3.25 (0.63,18.48)	2.83 (0.67,12.57)	0.11 (-0.05,0.35)
SD INF IV + MTX		2.76 (0.64,12.20)	2.47 (0.68,9.65)	0.09 (-0.05,0.24)

(Continued)

SD RITUX IV + MTX		1.57 (0.34,7.38)	1.51 (0.37,6.31)	0.03 (-0.10,0.15)
SD GOLI IV + MTX		2.60 (0.82,8.89)	2.35 (0.84,7.13)	0.08 (-0.02,0.23)
SD CERTO + MTX		2.21 (0.47,10.55)	2.05 (0.51,8.45)	0.06 (-0.08,0.22)
SD TOFA PO + MTX		3.09 (0.43,26.32)	2.70 (0.47,14.75)	0.10 (-0.07,0.48)
LD GOLI IV		1.55 (0.46,5.56)	1.49 (0.49,4.77)	0.03 (-0.06,0.16)
LD RITUX IV + MTX		1.05 (0.22,4.98)	1.04 (0.25,4.51)	0.00 (-0.12,0.10)
LD ETN SC + MTX		2.06 (0.41,10.12)	1.93 (0.45,8.15)	0.06 (-0.08,0.22)
LD GOLI IV + MTX		0.93 (0.26,3.38)	0.93 (0.28,3.10)	0.00 (-0.10,0.09)
HD TOCI IV		4.85 (0.77,30.70)	3.85 (0.80,16.78)	0.17 (-0.03,0.49)
HD GOLI SC		3.23 (0.49,20.08)	2.81 (0.53,13.04)	0.11 (-0.07,0.39)
HD TOCI IV + MTX		8.85 (1.63,52.81)	5.80 (1.47,22.87)	0.30 (0.06,0.61)
HD GOLI SC + MTX		6.52 (1.24,33.35)	4.79 (1.20,18.81)	0.23 (0.03,0.48)
HD INF IV + MTX		2.44 (0.49,11.97)	2.23 (0.53,9.24)	0.07 (-0.07,0.25)
HD TOFA PO + MTX		7.74 (1.11,64.66)	5.28 (1.09,23.09)	0.27 (0.01,0.68)
SD ETN SC + MTX	SD GOLI SC	0.93 (0.09,10.54)	0.94 (0.18,8.90)	-0.01 (-0.47,0.16)
SD ABA IV + MTX		1.44 (0.14,15.64)	1.35 (0.27,12.31)	0.05 (-0.41,0.23)
SD ABA SC + MTX		1.12 (0.10,12.39)	1.11 (0.20,10.17)	0.01 (-0.45,0.20)
SD GOLI SC + MTX		3.11 (0.37,27.05)	2.37 (0.55,17.83)	0.17 (-0.23,0.42)
SD ADA SC + MTX		1.39 (0.11,17.51)	1.31 (0.21,13.03)	0.04 (-0.43,0.31)
SD INF IV + MTX		1.18 (0.11,13.44)	1.15 (0.21,10.99)	0.02 (-0.44,0.21)
SD RITUX IV + MTX		0.67 (0.06,8.08)	0.70 (0.12,7.10)	-0.04 (-0.50,0.13)
SD GOLI IV + MTX		1.09 (0.10,14.45)	1.08 (0.19,11.23)	0.01 (-0.45,0.24)
SD CERTO + MTX		0.93 (0.08,11.91)	0.94 (0.16,9.80)	-0.01 (-0.47,0.20)
SD TOFA PO + MTX		1.33 (0.08,22.74)	1.26 (0.16,14.42)	0.03 (-0.44,0.42)
LD GOLI IV		0.64 (0.05,9.43)	0.68 (0.10,7.97)	-0.04 (-0.50,0.17)
LD RITUX IV + MTX		0.44 (0.04,5.28)	0.48 (0.08,4.85)	-0.07 (-0.53,0.08)
LD ETN SC + MTX		0.87 (0.07,10.81)	0.89 (0.15,8.85)	-0.01 (-0.48,0.19)
LD GOLI IV + MTX		0.39 (0.03,5.66)	0.43 (0.06,5.13)	-0.07 (-0.53,0.10)

(Continued)

HD TOCI IV		2.03 (0.14,30.73)	1.75 (0.26,18.67)	0.09 (-0.38,0.45)
HD GOLI SC		1.33 (0.23,8.13)	1.26 (0.37,6.82)	0.03 (-0.29,0.22)
HD TOCI IV + MTX		3.74 (0.29,53.12)	2.66 (0.47,26.15)	0.22 (-0.27,0.57)
HD GOLI SC + MTX		2.75 (0.32,23.94)	2.18 (0.51,16.38)	0.15 (-0.25,0.39)
HD INF IV + MTX		1.04 (0.09,12.54)	1.03 (0.17,10.17)	0.00 (-0.46,0.22)
HD TOFA PO + MTX		3.32 (0.21,55.39)	2.43 (0.36,24.14)	0.18 (-0.32,0.63)
SD ABA IV + MTX	SD ETN SC + MTX	1.52 (0.58,4.26)	1.42 (0.63,3.42)	0.05 (-0.08,0.19)
SD ABA SC + MTX		1.19 (0.39,3.74)	1.16 (0.45,3.07)	0.02 (-0.11,0.17)
SD GOLI SC + MTX		3.31 (0.92,12.29)	2.53 (0.93,6.45)	0.19 (-0.01,0.46)
SD ADA SC + MTX		1.46 (0.40,6.15)	1.37 (0.45,4.25)	0.05 (-0.11,0.29)
SD INF IV + MTX		1.24 (0.42,3.88)	1.20 (0.48,3.16)	0.03 (-0.11,0.18)
SD RITUX IV + MTX		0.71 (0.21,2.35)	0.74 (0.25,2.11)	-0.03 (-0.16,0.10)
SD GOLI IV + MTX		1.18 (0.34,4.34)	1.15 (0.39,3.38)	0.02 (-0.12,0.21)
SD CERTO + MTX		1.00 (0.30,3.51)	1.00 (0.35,2.90)	0.00 (-0.13,0.16)
SD TOFA PO + MTX		1.39 (0.24,9.76)	1.32 (0.28,5.30)	0.04 (-0.13,0.42)
LD GOLI IV		0.70 (0.17,3.03)	0.73 (0.20,2.55)	-0.03 (-0.16,0.14)
LD RITUX IV + MTX		0.47 (0.14,1.62)	0.51 (0.17,1.54)	-0.06 (-0.18,0.04)
LD ETN SC + MTX		0.93 (0.33,2.61)	0.94 (0.37,2.22)	-0.01 (-0.11,0.13)
LD GOLI IV + MTX		0.42 (0.10,1.85)	0.45 (0.12,1.71)	-0.07 (-0.19,0.06)
HD TOCI IV		2.18 (0.47,10.79)	1.88 (0.53,5.79)	0.11 (-0.09,0.43)
HD GOLI SC		1.43 (0.30,7.10)	1.35 (0.35,4.57)	0.04 (-0.12,0.33)
HD TOCI IV + MTX		3.98 (1.00,18.03)	2.85 (1.00,7.54)	0.24 (0.00,0.55)
HD GOLI SC + MTX		2.93 (0.83,10.84)	2.33 (0.86,6.07)	0.17 (-0.03,0.43)
HD INF IV + MTX		1.10 (0.31,3.96)	1.09 (0.36,3.14)	0.01 (-0.13,0.19)
HD TOFA PO + MTX		3.46 (0.64,23.59)	2.59 (0.69,7.83)	0.21 (-0.05,0.62)
SD ABA SC + MTX	SD ABA IV + MTX	0.79 (0.33,1.78)	0.82 (0.39,1.59)	-0.03 (-0.15,0.09)
SD GOLI SC + MTX		2.15 (0.60,7.78)	1.77 (0.67,4.16)	0.14 (-0.08,0.41)
SD ADA SC + MTX		0.97 (0.29,3.26)	0.97 (0.35,2.42)	0.00 (-0.16,0.22)



(Continued)

SD INF IV + MTX		0.82 (0.33,2.05)	0.85 (0.39,1.78)	-0.03 (-0.15,0.11)
SD RITUX IV + MTX		0.46 (0.14,1.45)	0.52 (0.18,1.37)	-0.09 (-0.22,0.05)
SD GOL I IV + MTX		0.77 (0.23,2.64)	0.81 (0.29,2.13)	-0.03 (-0.19,0.16)
SD CERTO + MTX		0.66 (0.20,2.12)	0.70 (0.25,1.84)	-0.05 (-0.20,0.12)
SD TOFA PO + MTX		0.92 (0.17,6.21)	0.93 (0.21,3.47)	-0.01 (-0.20,0.37)
LD GOL I IV		0.46 (0.12,1.82)	0.51 (0.15,1.62)	-0.09 (-0.23,0.09)
LD RITUX IV + MTX		0.31 (0.09,0.99)	0.35 (0.12,0.99)	-0.12 (-0.25,0.00)
LD ETN SC + MTX		0.61 (0.17,2.00)	0.66 (0.22,1.75)	-0.06 (-0.21,0.11)
LD GOL I IV + MTX		0.28 (0.07,1.15)	0.32 (0.08,1.12)	-0.12 (-0.25,0.02)
HD TOCI IV		1.43 (0.31,6.62)	1.32 (0.37,3.72)	0.06 (-0.15,0.38)
HD GOL I SC		0.94 (0.20,4.47)	0.95 (0.25,2.98)	-0.01 (-0.19,0.28)
HD TOCI IV + MTX		2.63 (0.66,11.24)	2.00 (0.72,4.81)	0.18 (-0.07,0.50)
HD GOL I SC + MTX		1.92 (0.54,6.83)	1.64 (0.61,3.91)	0.12 (-0.10,0.38)
HD INF IV + MTX		0.73 (0.22,2.27)	0.77 (0.28,1.91)	-0.04 (-0.19,0.13)
HD TOFA PO + MTX		2.28 (0.43,14.91)	1.83 (0.50,5.03)	0.15 (-0.12,0.57)
SD GOL I SC + MTX	SD ABA SC + MTX	2.75 (0.71,11.09)	2.17 (0.76,5.88)	0.17 (-0.06,0.45)
SD ADA SC + MTX		1.23 (0.48,3.41)	1.19 (0.53,2.58)	0.03 (-0.09,0.22)
SD INF IV + MTX		1.04 (0.35,3.29)	1.03 (0.42,2.72)	0.00 (-0.15,0.16)
SD RITUX IV + MTX		0.59 (0.17,2.13)	0.63 (0.21,1.93)	-0.05 (-0.20,0.09)
SD GOL I IV + MTX		0.99 (0.27,3.78)	0.99 (0.32,2.98)	0.00 (-0.17,0.19)
SD CERTO + MTX		0.84 (0.23,3.09)	0.86 (0.28,2.57)	-0.02 (-0.18,0.15)
SD TOFA PO + MTX		1.17 (0.20,8.65)	1.14 (0.24,4.72)	0.02 (-0.17,0.41)
LD GOL I IV		0.59 (0.14,2.59)	0.63 (0.17,2.23)	-0.05 (-0.21,0.12)
LD RITUX IV + MTX		0.39 (0.11,1.42)	0.44 (0.14,1.36)	-0.08 (-0.23,0.03)
LD ETN SC + MTX		0.78 (0.20,2.92)	0.81 (0.25,2.47)	-0.03 (-0.18,0.14)
LD GOL I IV + MTX		0.35 (0.08,1.63)	0.39 (0.10,1.53)	-0.09 (-0.24,0.05)
HD TOCI IV		1.83 (0.37,9.29)	1.61 (0.43,5.14)	0.09 (-0.13,0.42)
HD GOL I SC		1.20 (0.24,6.15)	1.16 (0.29,4.09)	0.02 (-0.17,0.31)

(Continued)

HD TOCI IV + MTX		3.35 (0.77,15.81)	2.45 (0.82,6.72)	0.22 (-0.04,0.54)
HD GOLI SC + MTX		2.45 (0.63,9.73)	1.99 (0.70,5.52)	0.15 (-0.07,0.41)
HD INF IV + MTX		0.92 (0.25,3.42)	0.93 (0.31,2.78)	-0.01 (-0.17,0.18)
HD TOFA PO + MTX		2.91 (0.51,21.10)	2.23 (0.58,7.09)	0.18 (-0.09,0.60)
SD ADA SC + MTX	SD GOLI SC + MTX	0.45 (0.09,2.18)	0.55 (0.17,1.76)	-0.14 (-0.43,0.15)
SD INF IV + MTX		0.38 (0.10,1.46)	0.48 (0.18,1.34)	-0.17 (-0.44,0.06)
SD RITUX IV + MTX		0.21 (0.05,0.91)	0.29 (0.10,0.92)	-0.23 (-0.49,-0.01)
SD GOLI IV + MTX		0.36 (0.08,1.58)	0.46 (0.15,1.42)	-0.17 (-0.45,0.08)
SD CERTO + MTX		0.30 (0.07,1.30)	0.40 (0.13,1.23)	-0.19 (-0.47,0.04)
SD TOFA PO + MTX		0.42 (0.06,3.35)	0.53 (0.11,2.17)	-0.15 (-0.45,0.26)
LD GOLI IV		0.21 (0.04,1.08)	0.29 (0.08,1.06)	-0.23 (-0.49,0.01)
LD RITUX IV + MTX		0.14 (0.03,0.60)	0.20 (0.06,0.65)	-0.26 (-0.51,-0.06)
LD ETN SC + MTX		0.28 (0.06,1.23)	0.37 (0.12,1.18)	-0.20 (-0.47,0.03)
LD GOLI IV + MTX		0.13 (0.02,0.67)	0.18 (0.04,0.72)	-0.26 (-0.52,-0.05)
HD TOCI IV		0.66 (0.12,3.78)	0.75 (0.20,2.41)	-0.08 (-0.40,0.28)
HD GOLI SC		0.43 (0.13,1.45)	0.54 (0.19,1.29)	-0.14 (-0.35,0.07)
HD TOCI IV + MTX		1.22 (0.24,6.35)	1.13 (0.39,3.15)	0.04 (-0.30,0.41)
HD GOLI SC + MTX		0.89 (0.41,1.95)	0.92 (0.54,1.58)	-0.02 (-0.19,0.14)
HD INF IV + MTX		0.33 (0.07,1.45)	0.43 (0.14,1.33)	-0.18 (-0.45,0.06)
HD TOFA PO + MTX		1.06 (0.16,8.20)	1.04 (0.27,3.31)	0.01 (-0.35,0.47)
SD INF IV + MTX	SD ADA SC + MTX	0.85 (0.20,3.33)	0.87 (0.29,2.78)	-0.02 (-0.27,0.16)
SD RITUX IV + MTX		0.48 (0.10,2.03)	0.53 (0.15,1.85)	-0.08 (-0.32,0.08)
SD GOLI IV + MTX		0.80 (0.17,3.67)	0.83 (0.24,2.95)	-0.03 (-0.28,0.18)
SD CERTO + MTX		0.68 (0.14,2.98)	0.73 (0.21,2.54)	-0.05 (-0.30,0.14)
SD TOFA PO + MTX		0.95 (0.13,7.48)	0.96 (0.18,4.42)	-0.01 (-0.28,0.38)
LD GOLI IV		0.48 (0.09,2.45)	0.53 (0.12,2.14)	-0.08 (-0.33,0.11)
LD RITUX IV + MTX		0.32 (0.07,1.35)	0.37 (0.10,1.31)	-0.11 (-0.35,0.03)
LD ETN SC + MTX		0.63 (0.13,2.83)	0.68 (0.18,2.42)	-0.05 (-0.30,0.13)

(Continued)

LD GOLI IV + MTX		0.29 (0.05,1.56)	0.33 (0.07,1.48)	-0.11 (-0.35,0.04)
HD TOCI IV		1.47 (0.24,8.64)	1.35 (0.32,4.96)	0.06 (-0.23,0.40)
HD GOLI SC		0.97 (0.16,5.74)	0.97 (0.22,3.94)	0.00 (-0.27,0.30)
HD TOCI IV + MTX		2.71 (0.49,14.90)	2.05 (0.60,6.77)	0.19 (-0.13,0.52)
HD GOLI SC + MTX		1.98 (0.41,9.38)	1.68 (0.52,5.54)	0.12 (-0.17,0.40)
HD INF IV + MTX		0.75 (0.16,3.37)	0.79 (0.22,2.74)	-0.04 (-0.29,0.17)
HD TOFA PO + MTX		2.38 (0.34,18.69)	1.88 (0.43,6.82)	0.15 (-0.18,0.58)
SD RITUX IV + MTX	SD INF IV + MTX	0.57 (0.16,1.95)	0.61 (0.21,1.78)	-0.06 (-0.21,0.08)
SD GOLI IV + MTX		0.94 (0.26,3.51)	0.95 (0.31,2.80)	-0.01 (-0.18,0.19)
SD CERTO + MTX		0.80 (0.22,2.85)	0.83 (0.28,2.40)	-0.03 (-0.19,0.14)
SD TOFA PO + MTX		1.11 (0.19,8.08)	1.09 (0.23,4.48)	0.01 (-0.18,0.40)
LD GOLI IV		0.56 (0.13,2.42)	0.60 (0.16,2.10)	-0.06 (-0.22,0.11)
LD RITUX IV + MTX		0.38 (0.11,1.33)	0.42 (0.13,1.28)	-0.09 (-0.24,0.03)
LD ETN SC + MTX		0.75 (0.19,2.67)	0.78 (0.24,2.27)	-0.03 (-0.19,0.14)
LD GOLI IV + MTX		0.34 (0.07,1.51)	0.38 (0.09,1.43)	-0.09 (-0.24,0.04)
HD TOCI IV		1.74 (0.35,8.80)	1.55 (0.41,4.85)	0.08 (-0.14,0.41)
HD GOLI SC		1.16 (0.23,5.75)	1.13 (0.27,3.86)	0.02 (-0.18,0.30)
HD TOCI IV + MTX		3.19 (0.76,14.64)	2.36 (0.81,6.31)	0.21 (-0.04,0.53)
HD GOLI SC + MTX		2.36 (0.61,8.95)	1.93 (0.68,5.10)	0.14 (-0.08,0.40)
HD INF IV + MTX		0.89 (0.31,2.44)	0.90 (0.36,2.08)	-0.01 (-0.15,0.13)
HD TOFA PO + MTX		2.78 (0.50,19.03)	2.15 (0.56,6.62)	0.18 (-0.10,0.59)
SD GOLI IV + MTX	SD RITUX IV + MTX	1.66 (0.42,6.80)	1.56 (0.47,5.23)	0.05 (-0.09,0.24)
SD CERTO + MTX		1.41 (0.37,5.49)	1.36 (0.42,4.41)	0.03 (-0.10,0.19)
SD TOFA PO + MTX		1.95 (0.31,14.95)	1.78 (0.35,8.03)	0.07 (-0.10,0.45)
LD GOLI IV		0.99 (0.22,4.71)	0.99 (0.25,3.87)	0.00 (-0.13,0.17)
LD RITUX IV + MTX		0.67 (0.27,1.65)	0.69 (0.31,1.57)	-0.03 (-0.12,0.04)
LD ETN SC + MTX		1.31 (0.32,5.33)	1.27 (0.36,4.26)	0.02 (-0.11,0.19)
LD GOLI IV + MTX		0.59 (0.12,2.88)	0.62 (0.14,2.59)	-0.03 (-0.16,0.10)

(Continued)

HD TOCI IV		3.08 (0.58,17.34)	2.55 (0.62,9.19)	0.14 (-0.06,0.47)
HD GOLI SC		2.01 (0.37,11.18)	1.82 (0.42,7.17)	0.08 (-0.09,0.37)
HD TOCI IV + MTX		5.62 (1.26,29.31)	3.84 (1.21,12.06)	0.27 (0.03,0.59)
HD GOLI SC + MTX		4.11 (1.00,17.68)	3.14 (1.00,9.76)	0.20 (0.00,0.46)
HD INF IV + MTX		1.56 (0.39,6.21)	1.48 (0.43,4.88)	0.04 (-0.10,0.22)
HD TOFA PO + MTX		4.96 (0.82,35.53)	3.52 (0.85,12.24)	0.24 (-0.02,0.65)
SD CERTO + MTX	SD GOLI IV + MTX	0.85 (0.21,3.44)	0.87 (0.26,2.87)	-0.02 (-0.21,0.16)
SD TOFA PO + MTX		1.18 (0.19,9.19)	1.15 (0.23,5.14)	0.02 (-0.20,0.40)
LD GOLI IV		0.60 (0.19,1.85)	0.64 (0.23,1.68)	-0.05 (-0.20,0.08)
LD RITUX IV + MTX		0.40 (0.10,1.58)	0.44 (0.13,1.50)	-0.08 (-0.26,0.04)
LD ETN SC + MTX		0.79 (0.18,3.32)	0.82 (0.23,2.80)	-0.03 (-0.22,0.15)
LD GOLI IV + MTX		0.36 (0.10,1.17)	0.40 (0.13,1.15)	-0.08 (-0.24,0.02)
HD TOCI IV		1.84 (0.33,10.57)	1.63 (0.40,5.76)	0.09 (-0.15,0.42)
HD GOLI SC		1.22 (0.21,6.51)	1.18 (0.26,4.42)	0.03 (-0.20,0.31)
HD TOCI IV + MTX		3.37 (0.71,17.26)	2.46 (0.77,7.61)	0.22 (-0.06,0.54)
HD GOLI SC + MTX		2.47 (0.57,10.76)	2.01 (0.65,6.17)	0.15 (-0.10,0.42)
HD INF IV + MTX		0.93 (0.22,3.86)	0.94 (0.28,3.12)	-0.01 (-0.20,0.18)
HD TOFA PO + MTX		2.95 (0.47,22.24)	2.25 (0.54,7.71)	0.18 (-0.11,0.60)
SD TOFA PO + MTX	SD CERTO + MTX	1.39 (0.22,10.48)	1.32 (0.26,5.76)	0.04 (-0.16,0.42)
LD GOLI IV		0.70 (0.15,3.29)	0.73 (0.19,2.78)	-0.03 (-0.20,0.14)
LD RITUX IV + MTX		0.47 (0.12,1.82)	0.51 (0.15,1.71)	-0.06 (-0.22,0.05)
LD ETN SC + MTX		0.93 (0.22,3.77)	0.94 (0.27,3.11)	-0.01 (-0.18,0.17)
LD GOLI IV + MTX		0.42 (0.08,2.06)	0.45 (0.11,1.88)	-0.07 (-0.22,0.07)
HD TOCI IV		2.19 (0.42,11.58)	1.89 (0.48,6.34)	0.11 (-0.12,0.44)
HD GOLI SC		1.44 (0.25,7.80)	1.36 (0.30,5.12)	0.04 (-0.16,0.33)
HD TOCI IV + MTX		4.02 (0.87,19.52)	2.85 (0.90,8.47)	0.24 (-0.02,0.55)
HD GOLI SC + MTX		2.93 (0.69,12.45)	2.33 (0.75,7.03)	0.17 (-0.06,0.43)
HD INF IV + MTX		1.11 (0.27,4.48)	1.09 (0.32,3.56)	0.01 (-0.16,0.20)

(Continued)

HD TOFA PO + MTX		3.50 (0.57,25.92)	2.61 (0.63,8.77)	0.20 (-0.08,0.62)
LD GOLI IV	SD TOFA PO + MTX	0.51 (0.06,3.59)	0.56 (0.11,3.10)	-0.07 (-0.45,0.13)
LD RITUX IV + MTX		0.34 (0.04,2.14)	0.38 (0.08,2.01)	-0.10 (-0.48,0.06)
LD ETN SC + MTX		0.67 (0.08,4.23)	0.71 (0.15,3.54)	-0.05 (-0.43,0.16)
LD GOLI IV + MTX		0.30 (0.04,2.17)	0.35 (0.06,2.01)	-0.11 (-0.48,0.06)
HD TOCI IV		1.57 (0.17,12.59)	1.42 (0.27,7.37)	0.07 (-0.34,0.41)
HD GOLI SC		1.01 (0.11,8.36)	1.01 (0.19,5.78)	0.00 (-0.39,0.31)
HD TOCI IV + MTX		2.87 (0.34,21.54)	2.14 (0.50,10.18)	0.19 (-0.23,0.54)
HD GOLI SC + MTX		2.13 (0.27,14.17)	1.77 (0.42,8.28)	0.12 (-0.28,0.42)
HD INF IV + MTX		0.80 (0.10,5.01)	0.83 (0.18,4.09)	-0.03 (-0.41,0.19)
HD TOFA PO + MTX		2.51 (0.78,7.97)	1.91 (0.84,5.02)	0.15 (-0.04,0.40)
LD RITUX IV + MTX	LD GOLI IV	0.67 (0.14,3.16)	0.69 (0.17,2.91)	-0.03 (-0.19,0.08)
LD ETN SC + MTX		1.33 (0.27,6.27)	1.29 (0.31,5.14)	0.03 (-0.15,0.19)
LD GOLI IV + MTX		0.60 (0.17,2.13)	0.62 (0.19,1.99)	-0.03 (-0.17,0.06)
HD TOCI IV		3.09 (0.51,19.56)	2.56 (0.56,10.74)	0.14 (-0.08,0.47)
HD GOLI SC		2.08 (0.31,12.45)	1.87 (0.37,8.26)	0.08 (-0.13,0.36)
HD TOCI IV + MTX		5.69 (1.07,33.26)	3.88 (1.05,14.48)	0.27 (0.01,0.58)
HD GOLI SC + MTX		4.19 (0.83,20.60)	3.20 (0.86,11.72)	0.20 (-0.03,0.46)
HD INF IV + MTX		1.57 (0.32,7.49)	1.49 (0.37,5.88)	0.04 (-0.13,0.23)
HD TOFA PO + MTX		4.98 (0.72,41.12)	3.54 (0.76,14.75)	0.24 (-0.04,0.65)
LD ETN SC + MTX	LD RITUX IV + MTX	1.99 (0.47,8.10)	1.86 (0.50,6.51)	0.05 (-0.06,0.21)
LD GOLI IV + MTX		0.89 (0.18,4.47)	0.90 (0.20,3.94)	-0.01 (-0.10,0.12)
HD TOCI IV		4.64 (0.88,26.29)	3.70 (0.89,13.62)	0.17 (-0.01,0.49)
HD GOLI SC		3.04 (0.55,17.31)	2.66 (0.58,10.88)	0.11 (-0.05,0.39)
HD TOCI IV + MTX		8.48 (1.87,44.14)	5.60 (1.69,18.05)	0.30 (0.07,0.61)
HD GOLI SC + MTX		6.21 (1.48,27.00)	4.58 (1.39,14.77)	0.23 (0.04,0.48)
HD INF IV + MTX		2.34 (0.57,9.51)	2.14 (0.60,7.37)	0.07 (-0.05,0.25)

(Continued)

HD TOFA PO + MTX		7.45 (1.20,54.85)	5.13 (1.18,18.55)	0.27 (0.02,0.68)
LD GOLI IV + MTX	LD ETN SC + MTX	0.45 (0.09,2.36)	0.48 (0.11,2.15)	-0.06 (-0.22,0.08)
HD TOCI IV		2.34 (0.43,13.32)	1.99 (0.49,7.41)	0.12 (-0.11,0.44)
HD GOLI SC		1.54 (0.28,8.83)	1.44 (0.33,5.85)	0.05 (-0.15,0.34)
HD TOCI IV + MTX		4.26 (0.92,23.05)	3.01 (0.93,9.99)	0.24 (-0.01,0.56)
HD GOLI SC + MTX		3.14 (0.72,13.83)	2.47 (0.78,7.96)	0.17 (-0.05,0.43)
HD INF IV + MTX		1.18 (0.28,5.15)	1.16 (0.34,4.06)	0.02 (-0.16,0.20)
HD TOFA PO + MTX		3.72 (0.61,28.41)	2.75 (0.67,10.26)	0.21 (-0.07,0.62)
HD TOCI IV	LD GOLI IV + MTX	5.18 (0.80,34.35)	4.10 (0.83,18.72)	0.18 (-0.02,0.50)
HD GOLI SC		3.45 (0.51,22.27)	2.98 (0.55,14.47)	0.11 (-0.06,0.39)
HD TOCI IV + MTX		9.49 (1.71,57.08)	6.21 (1.55,25.67)	0.30 (0.07,0.61)
HD GOLI SC + MTX		6.98 (1.34,36.74)	5.09 (1.27,20.68)	0.24 (0.04,0.48)
HD INF IV + MTX		2.63 (0.51,13.20)	2.39 (0.56,10.09)	0.08 (-0.06,0.26)
HD TOFA PO + MTX		8.33 (1.18,70.80)	5.66 (1.15,26.06)	0.27 (0.02,0.68)
HD GOLI SC	HD TOCI IV	0.66 (0.09,4.65)	0.73 (0.16,3.30)	-0.06 (-0.41,0.26)
HD TOCI IV + MTX		1.83 (0.81,4.49)	1.49 (0.88,3.09)	0.12 (-0.04,0.30)
HD GOLI SC + MTX		1.34 (0.24,7.54)	1.23 (0.38,4.56)	0.05 (-0.30,0.36)
HD INF IV + MTX		0.51 (0.09,2.83)	0.58 (0.16,2.36)	-0.10 (-0.43,0.14)
HD TOFA PO + MTX		1.61 (0.20,14.77)	1.39 (0.32,5.74)	0.09 (-0.31,0.54)
HD TOCI IV + MTX	HD GOLI SC	2.79 (0.45,18.52)	2.09 (0.57,8.62)	0.19 (-0.16,0.53)
HD GOLI SC + MTX		2.04 (0.62,6.84)	1.70 (0.72,4.85)	0.12 (-0.10,0.32)
HD INF IV + MTX		0.76 (0.14,4.27)	0.80 (0.20,3.48)	-0.03 (-0.32,0.18)
HD TOFA PO + MTX		2.47 (0.31,22.14)	1.92 (0.41,8.54)	0.16 (-0.21,0.59)
HD GOLI SC + MTX	HD TOCI IV + MTX	0.73 (0.14,3.66)	0.81 (0.29,2.43)	-0.07 (-0.43,0.27)
HD INF IV + MTX		0.28 (0.05,1.32)	0.38 (0.12,1.24)	-0.22 (-0.55,0.05)
HD TOFA PO + MTX		0.88 (0.12,7.15)	0.93 (0.24,3.06)	-0.03 (-0.43,0.44)
HD INF IV + MTX	HD GOLI SC + MTX	0.38 (0.08,1.63)	0.47 (0.15,1.45)	-0.16 (-0.42,0.08)
HD TOFA PO + MTX		1.19 (0.19,9.27)	1.13 (0.29,3.57)	0.04 (-0.32,0.49)

(Continued)

HD TOFA PO + MTX	HD INF IV + MTX	3.15 (0.51,24.06)	2.38 (0.58,8.44)	0.19 (-0.10,0.61)
Random-Effect Model	Residual Deviance	77.83 vs 76 data points		
	Deviance Information Criteria	494.211		
Fixed-Effect Model	Residual Deviance	114.7 vs 76 data points		
	Deviance Information Criteria	519.067		
Note:				
Total Patients	14125			
Total Studies	30			
2-arm	17			
3-arm	11			
4-arm	1			
5-arm	1			

## Appendix 20. Remission: Subgroup - Established RA (2 to 10 years)

Remission in Established RA: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX + DMARD	MTX + PL	0.70 (0.22,2.23)	0.71 (0.22,2.11)	-0.01 (-0.04,0.05)
PL		1.02 (0.12,8.51)	1.02 (0.13,6.35)	0.00 (-0.05,0.25)
SD ETN SC		1.79 (0.76,4.33)	1.73 (0.77,3.73)	0.04 (-0.01,0.13)
SD ADA SC		1.22 (0.20,8.20)	1.21 (0.21,6.15)	0.01 (-0.04,0.24)
SD GOLI IV		1.42 (0.41,5.02)	1.39 (0.42,4.22)	0.02 (-0.03,0.15)
SD GOLI SC		3.62 (0.36,35.55)	3.21 (0.38,13.57)	0.11 (-0.03,0.59)
SD ETN SC + MTX		3.21 (1.48,7.01)	2.89 (1.44,5.42)	0.09 (0.02,0.22)
SD ABA IV + MTX		4.73 (2.39,9.83)	3.99 (2.23,6.95)	0.15 (0.06,0.28)

(Continued)

SD ABA SC + MTX	3.50 (1.34,8.74)	3.12 (1.32,6.43)	0.10 (0.02,0.26)	
SD GOLI SC + MTX	10.54 (3.79,32.51)	7.16 (3.30,13.55)	0.30 (0.12,0.56)	
SD ADA SC + MTX	3.94 (1.73,9.61)	3.44 (1.67,6.81)	0.12 (0.03,0.28)	
SD INF IV + MTX	2.26 (0.88,6.08)	2.13 (0.88,4.89)	0.06 (-0.01,0.19)	
SD RITUX IV + MTX	3.63 (1.35,10.50)	3.21 (1.33,7.25)	0.11 (0.02,0.30)	
SD GOLI IV + MTX	3.27 (1.24,8.88)	2.94 (1.22,6.48)	0.09 (0.01,0.26)	
SD CERTO + MTX	10.74 (1.18,283.80)	7.24 (1.17,21.74)	0.31 (0.01,0.88)	
SD TOFA PO + MTX	4.30 (0.91,25.42)	3.69 (0.92,11.98)	0.13 (0.00,0.51)	
LD GOLI IV	2.21 (0.65,7.72)	2.09 (0.66,5.86)	0.05 (-0.02,0.23)	
LD RITUX IV + MTX	1.51 (0.58,4.16)	1.48 (0.59,3.61)	0.02 (-0.02,0.13)	
LD ETN SC + MTX	2.96 (1.03,8.69)	2.70 (1.03,6.35)	0.08 (0.00,0.26)	
LD GOLI IV + MTX	1.31 (0.37,4.63)	1.29 (0.38,3.96)	0.01 (-0.03,0.14)	
HD TOCI IV	7.03 (1.84,31.06)	5.42 (1.76,13.25)	0.22 (0.04,0.55)	
HD GOLI SC	4.69 (1.16,20.27)	3.97 (1.15,10.81)	0.15 (0.01,0.45)	
HD TOCI IV + MTX	12.92 (4.14,49.77)	8.11 (3.56,15.88)	0.35 (0.13,0.66)	
HD GOLI SC + MTX	9.48 (3.37,28.37)	6.67 (2.99,12.84)	0.28 (0.10,0.53)	
HD INF IV + MTX	3.49 (1.22,10.51)	3.11 (1.21,7.20)	0.10 (0.01,0.30)	
HD TOFA PO + MTX	10.91 (2.39,64.71)	7.33 (2.23,16.48)	0.31 (0.06,0.71)	
PL	MTX + DMARD	1.45 (0.13,16.52)	1.42 (0.14,12.42)	0.01 (-0.07,0.26)
SD ETN SC	2.56 (0.89,7.68)	2.42 (0.89,6.93)	0.05 (-0.01,0.13)	
SD ADA SC	1.76 (0.21,16.15)	1.71 (0.22,12.41)	0.02 (-0.06,0.25)	
SD GOLI IV	2.04 (0.37,11.34)	1.96 (0.40,9.70)	0.03 (-0.05,0.17)	
SD GOLI SC	5.22 (0.39,68.59)	4.45 (0.40,30.13)	0.12 (-0.04,0.61)	
SD ETN SC + MTX	4.56 (1.89,11.45)	4.02 (1.76,9.98)	0.10 (0.04,0.20)	
SD ABA IV + MTX	6.74 (1.80,27.16)	5.57 (1.67,20.56)	0.16 (0.05,0.30)	
SD ABA SC + MTX	4.96 (1.09,22.38)	4.33 (1.08,17.14)	0.11 (0.01,0.28)	
SD GOLI SC + MTX	15.31 (3.22,75.02)	10.02 (2.67,37.41)	0.31 (0.12,0.57)	
SD ADA SC + MTX	5.62 (1.39,25.28)	4.81 (1.35,18.90)	0.13 (0.03,0.29)	



(Continued)

SD INF IV + MTX		3.25 (0.73,15.40)	2.99 (0.75,12.72)	0.07 (-0.02,0.20)
SD RITUX IV + MTX		5.18 (1.15,25.60)	4.48 (1.13,19.01)	0.12 (0.01,0.31)
SD GOLIV IV + MTX		4.67 (1.04,22.15)	4.11 (1.04,16.92)	0.11 (0.00,0.28)
SD CERTO + MTX		15.62 (1.25,484.40)	9.93 (1.23,54.76)	0.32 (0.01,0.89)
SD TOFA PO + MTX		6.20 (0.89,51.49)	5.14 (0.90,27.65)	0.14 (-0.01,0.52)
LD GOLIV		3.16 (0.59,17.69)	2.92 (0.61,13.92)	0.06 (-0.03,0.25)
LD RITUX IV + MTX		2.15 (0.48,10.46)	2.06 (0.50,9.20)	0.04 (-0.04,0.14)
LD ETN SC + MTX		4.24 (1.07,17.46)	3.78 (1.07,13.63)	0.09 (0.00,0.26)
LD GOLIV + MTX		1.87 (0.34,10.69)	1.81 (0.36,9.21)	0.03 (-0.05,0.15)
HD TOCI IV		10.18 (1.72,66.28)	7.53 (1.62,32.99)	0.23 (0.04,0.56)
HD GOLIV SC		6.78 (1.08,43.15)	5.55 (1.07,25.91)	0.16 (0.01,0.46)
HD TOCI IV + MTX		18.61 (3.66,112.50)	11.21 (2.96,44.17)	0.36 (0.13,0.67)
HD GOLIV SC + MTX		13.61 (2.86,68.76)	9.29 (2.45,35.46)	0.29 (0.10,0.54)
HD INF IV + MTX		4.98 (1.07,25.53)	4.33 (1.06,18.66)	0.11 (0.00,0.31)
HD TOFA PO + MTX		15.72 (2.31,130.70)	10.00 (2.09,43.78)	0.32 (0.06,0.72)
SD ETN SC	PL	1.76 (0.18,17.32)	1.69 (0.24,15.33)	0.03 (-0.21,0.14)
SD ADA SC		1.21 (0.07,20.18)	1.20 (0.09,16.14)	0.01 (-0.23,0.23)
SD GOLIV		1.41 (0.12,16.35)	1.38 (0.15,14.33)	0.02 (-0.23,0.16)
SD GOLIV SC		3.52 (0.81,16.88)	2.95 (0.83,11.43)	0.09 (-0.01,0.45)
SD ETN SC + MTX		3.14 (0.34,30.37)	2.82 (0.41,24.64)	0.08 (-0.16,0.23)
SD ABA IV + MTX		4.66 (0.50,44.57)	3.92 (0.58,34.30)	0.14 (-0.12,0.29)
SD ABA SC + MTX		3.40 (0.34,34.84)	3.01 (0.42,27.46)	0.09 (-0.15,0.27)
SD GOLIV SC + MTX		10.48 (1.43,79.41)	6.91 (1.28,49.53)	0.29 (0.06,0.52)
SD ADA SC + MTX		3.92 (0.40,39.59)	3.40 (0.47,30.44)	0.11 (-0.14,0.29)
SD INF IV + MTX		2.25 (0.22,23.79)	2.11 (0.28,19.89)	0.05 (-0.20,0.19)
SD RITUX IV + MTX		3.60 (0.34,38.36)	3.15 (0.42,29.24)	0.10 (-0.15,0.30)
SD GOLIV + MTX		3.21 (0.31,33.38)	2.87 (0.39,26.31)	0.09 (-0.16,0.27)
SD CERTO + MTX		11.15 (0.48,564.20)	6.80 (0.54,81.10)	0.29 (-0.09,0.88)

(Continued)

SD TOFA PO + MTX		4.29 (0.30,70.57)	3.60 (0.36,41.14)	0.12 (-0.15,0.50)
LD GOL I IV		2.17 (0.18,25.75)	2.04 (0.23,20.97)	0.05 (-0.20,0.23)
LD RITUX IV + MTX		1.49 (0.15,16.00)	1.45 (0.19,14.02)	0.02 (-0.22,0.14)
LD ETN SC + MTX		2.92 (0.27,31.42)	2.64 (0.33,24.82)	0.08 (-0.17,0.26)
LD GOL I IV + MTX		1.29 (0.11,15.14)	1.27 (0.14,13.32)	0.01 (-0.23,0.15)
HD TOCI IV		7.04 (0.55,89.56)	5.25 (0.62,50.27)	0.20 (-0.09,0.54)
HD GOL I SC		4.55 (1.02,24.12)	3.76 (1.01,19.15)	0.13 (0.00,0.35)
HD TOCI IV + MTX		12.86 (1.15,155.00)	7.82 (1.11,70.11)	0.33 (0.03,0.66)
HD GOL I SC + MTX		9.38 (1.32,73.10)	6.43 (1.21,45.84)	0.26 (0.05,0.50)
HD INF IV + MTX		3.46 (0.32,37.71)	3.04 (0.39,28.79)	0.09 (-0.16,0.30)
HD TOFA PO + MTX		10.89 (0.78,168.40)	6.93 (0.82,67.45)	0.29 (-0.04,0.70)
SD ADA SC	SD ETN SC	0.69 (0.09,5.40)	0.71 (0.10,4.25)	-0.02 (-0.14,0.20)
SD GOL I IV		0.80 (0.17,3.58)	0.81 (0.19,3.12)	-0.01 (-0.12,0.12)
SD GOL I SC		2.02 (0.17,22.98)	1.85 (0.19,9.98)	0.07 (-0.10,0.55)
SD ETN SC + MTX		1.78 (0.98,3.28)	1.66 (0.98,2.89)	0.05 (0.00,0.13)
SD ABA IV + MTX		2.64 (0.86,8.24)	2.31 (0.88,6.23)	0.11 (-0.02,0.25)
SD ABA SC + MTX		1.95 (0.52,6.80)	1.80 (0.56,5.28)	0.07 (-0.06,0.23)
SD GOL I SC + MTX		5.93 (1.54,23.52)	4.14 (1.42,11.54)	0.26 (0.06,0.53)
SD ADA SC + MTX		2.19 (0.66,7.51)	1.98 (0.70,5.75)	0.08 (-0.04,0.25)
SD INF IV + MTX		1.26 (0.35,4.76)	1.23 (0.39,4.03)	0.02 (-0.09,0.16)
SD RITUX IV + MTX		2.03 (0.55,7.94)	1.86 (0.59,5.85)	0.07 (-0.06,0.26)
SD GOL I IV + MTX		1.83 (0.49,6.84)	1.70 (0.53,5.28)	0.06 (-0.07,0.23)
SD CERTO + MTX		6.05 (0.54,173.40)	4.14 (0.58,17.25)	0.27 (-0.05,0.85)
SD TOFA PO + MTX		2.40 (0.41,17.30)	2.13 (0.45,8.97)	0.09 (-0.07,0.47)
LD GOL I IV		1.24 (0.27,5.59)	1.21 (0.30,4.48)	0.02 (-0.10,0.20)
LD RITUX IV + MTX		0.84 (0.23,3.24)	0.85 (0.26,2.91)	-0.01 (-0.12,0.10)
LD ETN SC + MTX		1.65 (0.51,5.30)	1.56 (0.55,4.24)	0.05 (-0.06,0.21)
LD GOL I IV + MTX		0.73 (0.15,3.38)	0.75 (0.18,2.98)	-0.02 (-0.13,0.11)

(Continued)

HD TOCI IV		3.97 (0.79,21.11)	3.13 (0.81,10.30)	0.18 (-0.02,0.52)
HD GOLI SC		2.63 (0.51,13.94)	2.30 (0.55,8.37)	0.11 (-0.06,0.41)
HD TOCI IV + MTX		7.26 (1.70,35.12)	4.66 (1.54,13.53)	0.31 (0.07,0.62)
HD GOLI SC + MTX		5.29 (1.38,21.36)	3.84 (1.31,10.96)	0.24 (0.04,0.50)
HD INF IV + MTX		1.95 (0.50,7.90)	1.80 (0.54,5.80)	0.07 (-0.06,0.27)
HD TOFA PO + MTX		6.14 (1.05,42.98)	4.19 (1.05,13.49)	0.27 (0.01,0.68)
SD GOLI IV	SD ADA SC	1.16 (0.12,10.30)	1.15 (0.15,8.96)	0.01 (-0.22,0.15)
SD GOLI SC		2.93 (0.15,54.59)	2.56 (0.19,26.46)	0.09 (-0.17,0.57)
SD ETN SC + MTX		2.61 (0.34,18.74)	2.38 (0.42,15.27)	0.08 (-0.16,0.22)
SD ABA IV + MTX		3.86 (0.53,27.42)	3.29 (0.61,20.65)	0.13 (-0.10,0.29)
SD ABA SC + MTX		2.85 (0.34,21.22)	2.55 (0.41,16.70)	0.09 (-0.15,0.26)
SD GOLI SC + MTX		8.70 (1.00,72.73)	5.85 (1.00,37.81)	0.28 (0.00,0.56)
SD ADA SC + MTX		3.21 (0.42,24.69)	2.81 (0.50,19.01)	0.10 (-0.13,0.28)
SD INF IV + MTX		1.85 (0.23,14.89)	1.75 (0.28,12.48)	0.04 (-0.19,0.19)
SD RITUX IV + MTX		2.95 (0.36,24.01)	2.63 (0.43,18.22)	0.09 (-0.14,0.29)
SD GOLI IV + MTX		2.65 (0.31,21.24)	2.41 (0.38,16.56)	0.08 (-0.16,0.26)
SD CERTO + MTX		9.30 (0.48,342.30)	5.75 (0.54,50.05)	0.28 (-0.08,0.87)
SD TOFA PO + MTX		3.54 (0.30,45.36)	3.02 (0.36,26.00)	0.11 (-0.14,0.50)
LD GOLI IV		1.78 (0.20,16.52)	1.69 (0.25,13.47)	0.04 (-0.19,0.23)
LD RITUX IV + MTX		1.22 (0.15,9.80)	1.21 (0.19,8.76)	0.01 (-0.21,0.13)
LD ETN SC + MTX		2.42 (0.28,19.81)	2.22 (0.34,15.66)	0.07 (-0.17,0.26)
LD GOLI IV + MTX		1.07 (0.11,9.71)	1.06 (0.14,8.49)	0.00 (-0.22,0.14)
HD TOCI IV		5.76 (1.72,19.49)	4.34 (1.48,14.65)	0.19 (0.05,0.42)
HD GOLI SC		3.83 (0.39,38.62)	3.22 (0.45,25.05)	0.12 (-0.12,0.43)
HD TOCI IV + MTX		10.55 (2.48,49.64)	6.46 (1.81,28.75)	0.32 (0.13,0.57)
HD GOLI SC + MTX		7.76 (0.92,64.05)	5.42 (0.94,35.92)	0.26 (-0.01,0.53)
HD INF IV + MTX		2.84 (0.34,23.63)	2.53 (0.41,17.70)	0.09 (-0.15,0.29)
HD TOFA PO + MTX		9.03 (0.76,112.30)	5.86 (0.81,42.45)	0.29 (-0.04,0.70)

(Continued)

SD GOLI SC	SD GOLI IV	2.54 (0.19,35.63)	2.26 (0.21,15.81)	0.08 (-0.11,0.57)
SD ETN SC + MTX		2.25 (0.52,9.72)	2.06 (0.57,7.98)	0.07 (-0.08,0.20)
SD ABA IV + MTX		3.33 (0.79,14.04)	2.86 (0.82,10.67)	0.12 (-0.03,0.27)
SD ABA SC + MTX		2.45 (0.50,11.43)	2.22 (0.55,8.97)	0.08 (-0.08,0.25)
SD GOLI SC + MTX		7.47 (1.48,40.23)	5.10 (1.36,19.75)	0.28 (0.06,0.55)
SD ADA SC + MTX		2.77 (0.62,12.74)	2.45 (0.67,9.74)	0.10 (-0.06,0.27)
SD INF IV + MTX		1.59 (0.33,7.86)	1.53 (0.38,6.60)	0.03 (-0.11,0.18)
SD RITUX IV + MTX		2.55 (0.78,8.64)	2.29 (0.80,6.92)	0.08 (-0.03,0.24)
SD GOLI IV + MTX		2.31 (0.47,11.30)	2.10 (0.52,8.80)	0.07 (-0.08,0.25)
SD CERTO + MTX		7.77 (0.58,252.40)	5.09 (0.62,27.52)	0.28 (-0.05,0.86)
SD TOFA PO + MTX		3.07 (0.41,26.15)	2.64 (0.45,14.11)	0.11 (-0.08,0.49)
LD GOLI IV		1.55 (0.43,5.55)	1.49 (0.46,4.72)	0.03 (-0.07,0.18)
LD RITUX IV + MTX		1.06 (0.22,5.21)	1.06 (0.25,4.64)	0.00 (-0.13,0.12)
LD ETN SC + MTX		2.09 (0.40,10.76)	1.93 (0.44,8.34)	0.06 (-0.09,0.24)
LD GOLI IV + MTX		0.92 (0.25,3.40)	0.92 (0.27,3.10)	0.00 (-0.11,0.10)
HD TOCI IV		5.02 (0.80,33.52)	3.86 (0.83,17.14)	0.19 (-0.02,0.53)
HD GOLI SC		3.28 (0.50,22.95)	2.80 (0.55,13.84)	0.12 (-0.07,0.43)
HD TOCI IV + MTX		9.19 (1.68,56.26)	5.76 (1.51,22.84)	0.32 (0.07,0.64)
HD GOLI SC + MTX		6.66 (1.27,35.02)	4.72 (1.22,18.47)	0.25 (0.03,0.51)
HD INF IV + MTX		2.44 (0.48,13.07)	2.21 (0.53,9.75)	0.08 (-0.08,0.29)
HD TOFA PO + MTX		7.78 (1.07,64.92)	5.12 (1.06,22.12)	0.28 (0.01,0.69)
SD ETN SC + MTX	SD GOLI SC	0.89 (0.08,10.10)	0.90 (0.18,8.44)	-0.01 (-0.50,0.18)
SD ABA IV + MTX		1.31 (0.12,14.37)	1.24 (0.26,11.15)	0.04 (-0.45,0.25)
SD ABA SC + MTX		0.96 (0.08,11.17)	0.96 (0.18,9.10)	-0.01 (-0.50,0.22)
SD GOLI SC + MTX		2.96 (0.34,25.94)	2.21 (0.56,16.14)	0.18 (-0.24,0.44)
SD ADA SC + MTX		1.10 (0.10,12.89)	1.08 (0.21,10.13)	0.01 (-0.48,0.24)
SD INF IV + MTX		0.63 (0.05,7.62)	0.67 (0.12,6.55)	-0.05 (-0.53,0.15)
SD RITUX IV + MTX		1.01 (0.08,12.47)	1.01 (0.18,9.79)	0.00 (-0.49,0.24)

(Continued)

SD GOLI IV + MTX		0.91 (0.08,11.45)	0.93 (0.17,9.11)	-0.01 (-0.49,0.22)
SD CERTO + MTX		3.11 (0.13,171.40)	2.18 (0.22,26.61)	0.18 (-0.38,0.82)
SD TOFA PO + MTX		1.21 (0.08,21.40)	1.16 (0.15,13.28)	0.02 (-0.47,0.42)
LD GOLI IV		0.61 (0.05,8.20)	0.66 (0.10,6.84)	-0.05 (-0.54,0.18)
LD RITUX IV + MTX		0.42 (0.03,5.11)	0.46 (0.08,4.64)	-0.08 (-0.57,0.10)
LD ETN SC + MTX		0.83 (0.07,10.66)	0.85 (0.15,8.61)	-0.02 (-0.51,0.21)
LD GOLI IV + MTX		0.37 (0.03,4.99)	0.41 (0.06,4.46)	-0.09 (-0.57,0.10)
HD TOCI IV		1.99 (0.14,28.76)	1.69 (0.26,16.67)	0.10 (-0.41,0.48)
HD GOLI SC		1.30 (0.22,8.06)	1.23 (0.37,6.71)	0.03 (-0.32,0.24)
HD TOCI IV + MTX		3.67 (0.27,50.42)	2.51 (0.48,23.04)	0.23 (-0.29,0.59)
HD GOLI SC + MTX		2.62 (0.31,23.79)	2.05 (0.52,15.43)	0.15 (-0.27,0.42)
HD INF IV + MTX		0.98 (0.08,12.35)	0.98 (0.17,9.59)	0.00 (-0.49,0.25)
HD TOFA PO + MTX		3.07 (0.20,54.35)	2.23 (0.36,21.96)	0.18 (-0.34,0.63)
SD ABA IV + MTX	SD ETN SC + MTX	1.48 (0.53,4.24)	1.38 (0.59,3.35)	0.05 (-0.09,0.21)
SD ABA SC + MTX		1.09 (0.31,3.61)	1.08 (0.37,2.92)	0.01 (-0.14,0.18)
SD GOLI SC + MTX		3.32 (0.91,12.57)	2.48 (0.93,6.26)	0.21 (-0.01,0.48)
SD ADA SC + MTX		1.23 (0.40,3.93)	1.19 (0.46,3.09)	0.03 (-0.12,0.20)
SD INF IV + MTX		0.71 (0.21,2.48)	0.74 (0.25,2.17)	-0.04 (-0.17,0.11)
SD RITUX IV + MTX		1.13 (0.32,4.15)	1.11 (0.38,3.22)	0.02 (-0.14,0.21)
SD GOLI IV + MTX		1.02 (0.29,3.55)	1.02 (0.35,2.89)	0.00 (-0.15,0.18)
SD CERTO + MTX		3.40 (0.32,96.36)	2.50 (0.37,9.56)	0.21 (-0.12,0.80)
SD TOFA PO + MTX		1.35 (0.24,9.23)	1.28 (0.28,4.96)	0.04 (-0.15,0.42)
LD GOLI IV		0.69 (0.16,2.98)	0.73 (0.19,2.49)	-0.04 (-0.18,0.15)
LD RITUX IV + MTX		0.47 (0.14,1.68)	0.51 (0.17,1.58)	-0.07 (-0.20,0.05)
LD ETN SC + MTX		0.92 (0.32,2.70)	0.94 (0.37,2.26)	-0.01 (-0.13,0.15)
LD GOLI IV + MTX		0.41 (0.09,1.76)	0.45 (0.11,1.64)	-0.07 (-0.21,0.06)
HD TOCI IV		2.21 (0.46,11.41)	1.88 (0.52,5.73)	0.12 (-0.10,0.47)
HD GOLI SC		1.47 (0.30,7.52)	1.38 (0.35,4.55)	0.05 (-0.14,0.36)

(Continued)

HD TOCI IV + MTX		4.06 (1.01,18.90)	2.80 (1.01,7.22)	0.25 (0.00,0.57)
HD GOLI SC + MTX		2.97 (0.82,11.42)	2.30 (0.85,6.00)	0.18 (-0.03,0.45)
HD INF IV + MTX		1.09 (0.30,4.14)	1.08 (0.35,3.17)	0.01 (-0.14,0.22)
HD TOFA PO + MTX		3.44 (0.61,23.13)	2.52 (0.66,7.40)	0.22 (-0.06,0.62)
SD ABA SC + MTX	SD ABA IV + MTX	0.74 (0.29,1.75)	0.78 (0.35,1.55)	-0.04 (-0.17,0.09)
SD GOLI SC + MTX		2.25 (0.64,8.15)	1.80 (0.71,4.15)	0.15 (-0.08,0.44)
SD ADA SC + MTX		0.83 (0.33,2.17)	0.86 (0.40,1.83)	-0.03 (-0.16,0.13)
SD INF IV + MTX		0.48 (0.15,1.60)	0.53 (0.19,1.48)	-0.09 (-0.24,0.07)
SD RITUX IV + MTX		0.77 (0.22,2.72)	0.81 (0.29,2.19)	-0.04 (-0.20,0.17)
SD GOLI IV + MTX		0.69 (0.21,2.32)	0.74 (0.26,1.95)	-0.05 (-0.21,0.14)
SD CERTO + MTX		2.30 (0.22,64.08)	1.81 (0.27,6.40)	0.16 (-0.19,0.75)
SD TOFA PO + MTX		0.91 (0.17,6.04)	0.92 (0.21,3.36)	-0.01 (-0.21,0.37)
LD GOLI IV		0.46 (0.11,1.93)	0.52 (0.15,1.70)	-0.09 (-0.25,0.10)
LD RITUX IV + MTX		0.32 (0.10,1.08)	0.37 (0.13,1.07)	-0.12 (-0.27,0.01)
LD ETN SC + MTX		0.63 (0.17,2.23)	0.68 (0.22,1.89)	-0.06 (-0.22,0.13)
LD GOLI IV + MTX		0.27 (0.06,1.16)	0.32 (0.09,1.14)	-0.13 (-0.27,0.02)
HD TOCI IV		1.49 (0.32,7.39)	1.36 (0.39,3.84)	0.07 (-0.16,0.42)
HD GOLI SC		0.99 (0.21,4.87)	0.99 (0.26,3.09)	0.00 (-0.20,0.31)
HD TOCI IV + MTX		2.75 (0.71,11.99)	2.03 (0.77,4.78)	0.20 (-0.06,0.53)
HD GOLI SC + MTX		2.02 (0.55,7.41)	1.67 (0.63,4.00)	0.13 (-0.10,0.41)
HD INF IV + MTX		0.74 (0.22,2.50)	0.78 (0.28,2.02)	-0.04 (-0.20,0.16)
HD TOFA PO + MTX		2.31 (0.43,15.08)	1.82 (0.50,4.87)	0.16 (-0.12,0.57)
SD GOLI SC + MTX	SD ABA SC + MTX	3.08 (0.76,13.00)	2.32 (0.81,6.60)	0.20 (-0.05,0.48)
SD ADA SC + MTX		1.13 (0.36,3.92)	1.10 (0.43,3.12)	0.02 (-0.15,0.19)
SD INF IV + MTX		0.65 (0.18,2.58)	0.69 (0.22,2.27)	-0.05 (-0.22,0.11)
SD RITUX IV + MTX		1.04 (0.27,4.32)	1.03 (0.33,3.37)	0.01 (-0.18,0.21)
SD GOLI IV + MTX		0.93 (0.25,3.73)	0.94 (0.31,3.04)	-0.01 (-0.19,0.18)
SD CERTO + MTX		3.14 (0.27,91.33)	2.32 (0.33,9.80)	0.20 (-0.15,0.79)

(Continued)

SD TOFA PO + MTX		1.24 (0.21,9.08)	1.19 (0.26,5.02)	0.03 (-0.18,0.41)
LD GOL I IV		0.63 (0.14,3.03)	0.67 (0.18,2.55)	-0.05 (-0.22,0.15)
LD RITUX IV + MTX		0.43 (0.12,1.76)	0.47 (0.15,1.65)	-0.08 (-0.24,0.06)
LD ETN SC + MTX		0.85 (0.21,3.58)	0.87 (0.26,2.88)	-0.02 (-0.20,0.18)
LD GOL I IV + MTX		0.37 (0.08,1.84)	0.42 (0.10,1.70)	-0.09 (-0.25,0.06)
HD TOCI IV		2.03 (0.39,11.76)	1.74 (0.46,5.96)	0.11 (-0.13,0.46)
HD GOL I SC		1.35 (0.26,7.64)	1.28 (0.31,4.78)	0.04 (-0.17,0.36)
HD TOCI IV + MTX		3.75 (0.85,19.24)	2.60 (0.89,7.76)	0.24 (-0.03,0.57)
HD GOL I SC + MTX		2.75 (0.68,11.78)	2.15 (0.74,6.29)	0.17 (-0.07,0.45)
HD INF IV + MTX		1.00 (0.26,4.19)	1.00 (0.32,3.25)	0.00 (-0.18,0.21)
HD TOFA PO + MTX		3.16 (0.54,22.86)	2.33 (0.61,7.65)	0.20 (-0.09,0.62)
SD ADA SC + MTX	SD GOL I SC + MTX	0.37 (0.09,1.49)	0.48 (0.19,1.35)	-0.18 (-0.46,0.07)
SD INF IV + MTX		0.21 (0.05,0.90)	0.30 (0.10,0.92)	-0.24 (-0.52,-0.02)
SD RITUX IV + MTX		0.34 (0.08,1.49)	0.45 (0.15,1.34)	-0.19 (-0.47,0.07)
SD GOL I IV + MTX		0.31 (0.07,1.31)	0.41 (0.14,1.22)	-0.20 (-0.48,0.05)
SD CERTO + MTX		1.03 (0.08,31.79)	1.02 (0.15,3.86)	0.01 (-0.43,0.64)
SD TOFA PO + MTX		0.41 (0.06,3.16)	0.52 (0.11,2.04)	-0.16 (-0.48,0.26)
LD GOL I IV		0.21 (0.04,1.04)	0.29 (0.08,1.03)	-0.24 (-0.52,0.01)
LD RITUX IV + MTX		0.14 (0.03,0.61)	0.21 (0.07,0.67)	-0.27 (-0.54,-0.07)
LD ETN SC + MTX		0.28 (0.06,1.23)	0.38 (0.12,1.17)	-0.21 (-0.49,0.04)
LD GOL I IV + MTX		0.12 (0.02,0.63)	0.18 (0.05,0.70)	-0.28 (-0.55,-0.06)
HD TOCI IV		0.66 (0.11,3.95)	0.76 (0.21,2.34)	-0.08 (-0.42,0.31)
HD GOL I SC		0.44 (0.13,1.52)	0.56 (0.20,1.31)	-0.15 (-0.37,0.09)
HD TOCI IV + MTX		1.23 (0.24,6.60)	1.13 (0.41,2.97)	0.05 (-0.31,0.42)
HD GOL I SC + MTX		0.89 (0.41,1.99)	0.93 (0.55,1.57)	-0.02 (-0.20,0.15)
HD INF IV + MTX		0.33 (0.07,1.53)	0.43 (0.14,1.36)	-0.19 (-0.47,0.08)
HD TOFA PO + MTX		1.04 (0.16,7.84)	1.03 (0.27,3.02)	0.01 (-0.37,0.46)
SD INF IV + MTX	SD ADA SC + MTX	0.58 (0.16,2.08)	0.62 (0.20,1.86)	-0.06 (-0.24,0.09)

(Continued)

SD RITUX IV + MTX		0.92 (0.24,3.53)	0.94 (0.31,2.77)	-0.01 (-0.20,0.19)
SD GOLI IV + MTX		0.83 (0.22,3.06)	0.85 (0.28,2.51)	-0.02 (-0.21,0.16)
SD CERTO + MTX		2.75 (0.25,80.90)	2.09 (0.30,8.25)	0.18 (-0.17,0.78)
SD TOFA PO + MTX		1.09 (0.18,7.62)	1.08 (0.23,4.23)	0.01 (-0.21,0.40)
LD GOLI IV		0.56 (0.12,2.44)	0.61 (0.16,2.09)	-0.06 (-0.24,0.13)
LD RITUX IV + MTX		0.38 (0.10,1.41)	0.43 (0.14,1.35)	-0.09 (-0.26,0.04)
LD ETN SC + MTX		0.76 (0.19,2.89)	0.79 (0.24,2.38)	-0.03 (-0.22,0.15)
LD GOLI IV + MTX		0.33 (0.07,1.50)	0.38 (0.09,1.42)	-0.10 (-0.27,0.05)
HD TOCI IV		1.80 (0.35,9.44)	1.58 (0.42,4.83)	0.09 (-0.15,0.44)
HD GOLI SC		1.19 (0.23,6.33)	1.15 (0.29,3.95)	0.02 (-0.19,0.34)
HD TOCI IV + MTX		3.30 (0.75,15.65)	2.35 (0.81,6.23)	0.23 (-0.05,0.55)
HD GOLI SC + MTX		2.40 (0.61,9.56)	1.93 (0.69,5.15)	0.15 (-0.09,0.43)
HD INF IV + MTX		0.89 (0.30,2.55)	0.91 (0.36,2.11)	-0.02 (-0.15,0.15)
HD TOFA PO + MTX		2.79 (0.48,18.97)	2.11 (0.55,6.33)	0.19 (-0.11,0.60)
SD RITUX IV + MTX	SD INF IV + MTX	1.61 (0.39,6.53)	1.51 (0.44,4.92)	0.05 (-0.11,0.25)
SD GOLI IV + MTX		1.45 (0.36,5.50)	1.38 (0.41,4.35)	0.04 (-0.12,0.22)
SD CERTO + MTX		4.83 (0.41,139.90)	3.36 (0.46,14.62)	0.25 (-0.09,0.83)
SD TOFA PO + MTX		1.90 (0.30,14.52)	1.73 (0.34,7.58)	0.07 (-0.12,0.46)
LD GOLI IV		0.98 (0.19,4.59)	0.98 (0.23,3.74)	0.00 (-0.15,0.18)
LD RITUX IV + MTX		0.67 (0.26,1.69)	0.69 (0.30,1.60)	-0.03 (-0.13,0.05)
LD ETN SC + MTX		1.31 (0.30,5.36)	1.27 (0.35,4.26)	0.03 (-0.13,0.21)
LD GOLI IV + MTX		0.58 (0.11,2.82)	0.60 (0.13,2.53)	-0.04 (-0.18,0.10)
HD TOCI IV		3.11 (0.58,17.79)	2.52 (0.63,8.80)	0.16 (-0.07,0.50)
HD GOLI SC		2.07 (0.38,11.71)	1.84 (0.43,7.08)	0.09 (-0.10,0.40)
HD TOCI IV + MTX		5.76 (1.23,29.64)	3.78 (1.18,11.45)	0.29 (0.03,0.61)
HD GOLI SC + MTX		4.20 (0.99,17.74)	3.10 (0.99,9.28)	0.22 (0.00,0.48)
HD INF IV + MTX		1.55 (0.37,6.58)	1.46 (0.42,4.93)	0.05 (-0.11,0.25)
HD TOFA PO + MTX		4.86 (0.78,36.18)	3.38 (0.81,11.54)	0.25 (-0.03,0.66)



(Continued)

SD GOLI IV + MTX	SD RITUX IV + MTX	0.90 (0.21,3.64)	0.91 (0.28,2.98)	-0.01 (-0.22,0.18)
SD CERTO + MTX		3.00 (0.26,85.82)	2.23 (0.32,9.56)	0.19 (-0.17,0.79)
SD TOFA PO + MTX		1.19 (0.17,9.07)	1.15 (0.22,5.06)	0.02 (-0.21,0.41)
LD GOLI IV		0.61 (0.19,1.95)	0.65 (0.23,1.76)	-0.05 (-0.21,0.09)
LD RITUX IV + MTX		0.42 (0.10,1.77)	0.46 (0.13,1.66)	-0.08 (-0.28,0.06)
LD ETN SC + MTX		0.82 (0.19,3.57)	0.84 (0.24,2.91)	-0.02 (-0.23,0.17)
LD GOLI IV + MTX		0.36 (0.10,1.22)	0.40 (0.13,1.18)	-0.09 (-0.25,0.02)
HD TOCI IV		1.96 (0.35,10.94)	1.68 (0.43,5.67)	0.10 (-0.16,0.45)
HD GOLI SC		1.28 (0.22,7.76)	1.23 (0.29,4.76)	0.03 (-0.20,0.36)
HD TOCI IV + MTX		3.60 (0.76,18.40)	2.51 (0.81,7.46)	0.24 (-0.05,0.56)
HD GOLI SC + MTX		2.61 (0.59,11.59)	2.06 (0.67,6.26)	0.17 (-0.09,0.44)
HD INF IV + MTX		0.96 (0.22,4.22)	0.97 (0.28,3.26)	0.00 (-0.21,0.21)
HD TOFA PO + MTX		3.03 (0.46,22.18)	2.25 (0.54,7.62)	0.20 (-0.12,0.61)
SD CERTO + MTX	SD GOLI IV + MTX	3.38 (0.30,95.03)	2.47 (0.35,10.37)	0.21 (-0.15,0.80)
SD TOFA PO + MTX		1.33 (0.21,10.15)	1.26 (0.26,5.55)	0.04 (-0.19,0.42)
LD GOLI IV		0.68 (0.14,3.34)	0.71 (0.17,2.77)	-0.04 (-0.22,0.15)
LD RITUX IV + MTX		0.46 (0.12,1.94)	0.50 (0.15,1.80)	-0.07 (-0.24,0.06)
LD ETN SC + MTX		0.91 (0.21,3.88)	0.92 (0.26,3.14)	-0.01 (-0.20,0.18)
LD GOLI IV + MTX		0.40 (0.08,2.00)	0.44 (0.10,1.85)	-0.08 (-0.25,0.07)
HD TOCI IV		2.18 (0.40,12.48)	1.84 (0.48,6.34)	0.12 (-0.13,0.47)
HD GOLI SC		1.43 (0.25,8.39)	1.34 (0.32,5.14)	0.05 (-0.17,0.36)
HD TOCI IV + MTX		3.99 (0.88,20.79)	2.74 (0.91,8.32)	0.25 (-0.02,0.58)
HD GOLI SC + MTX		2.92 (0.68,12.70)	2.27 (0.74,6.77)	0.18 (-0.06,0.45)
HD INF IV + MTX		1.07 (0.25,4.68)	1.06 (0.31,3.59)	0.01 (-0.18,0.22)
HD TOFA PO + MTX		3.37 (0.53,25.33)	2.47 (0.60,8.31)	0.21 (-0.09,0.63)
SD TOFA PO + MTX	SD CERTO + MTX	0.39 (0.01,6.54)	0.53 (0.08,4.31)	-0.16 (-0.78,0.32)
LD GOLI IV		0.20 (0.01,2.58)	0.29 (0.06,2.25)	-0.25 (-0.83,0.10)
LD RITUX IV + MTX		0.14 (0.00,1.63)	0.21 (0.04,1.55)	-0.28 (-0.86,0.04)

(Continued)

LD ETN SC + MTX		0.27 (0.01,3.26)	0.38 (0.08,2.75)	-0.22 (-0.81,0.14)
LD GOL I IV + MTX		0.12 (0.00,1.60)	0.18 (0.03,1.53)	-0.29 (-0.87,0.04)
HD TOCI IV		0.63 (0.02,9.38)	0.74 (0.15,5.59)	-0.09 (-0.72,0.39)
HD GOL I SC		0.43 (0.01,6.41)	0.56 (0.10,4.40)	-0.15 (-0.78,0.29)
HD TOCI IV + MTX		1.18 (0.04,15.85)	1.10 (0.28,7.55)	0.04 (-0.60,0.51)
HD GOL I SC + MTX		0.86 (0.03,10.85)	0.91 (0.23,6.33)	-0.03 (-0.66,0.40)
HD INF IV + MTX		0.32 (0.01,3.83)	0.44 (0.09,3.13)	-0.20 (-0.80,0.17)
HD TOFA PO + MTX		1.00 (0.03,16.78)	1.00 (0.20,7.22)	0.00 (-0.66,0.53)
LD GOL I IV	SD TOFA PO + MTX	0.51 (0.06,3.84)	0.57 (0.11,3.26)	-0.07 (-0.46,0.15)
LD RITUX IV + MTX		0.35 (0.05,2.23)	0.40 (0.09,2.08)	-0.11 (-0.49,0.06)
LD ETN SC + MTX		0.69 (0.09,4.57)	0.73 (0.16,3.73)	-0.05 (-0.43,0.18)
LD GOL I IV + MTX		0.30 (0.03,2.31)	0.35 (0.06,2.12)	-0.11 (-0.49,0.07)
HD TOCI IV		1.63 (0.17,14.23)	1.45 (0.29,7.68)	0.08 (-0.34,0.46)
HD GOL I SC		1.08 (0.12,9.33)	1.06 (0.20,6.10)	0.01 (-0.38,0.35)
HD TOCI IV + MTX		3.03 (0.35,24.24)	2.17 (0.52,10.32)	0.21 (-0.23,0.57)
HD GOL I SC + MTX		2.18 (0.29,14.76)	1.78 (0.45,8.32)	0.14 (-0.27,0.45)
HD INF IV + MTX		0.81 (0.10,5.60)	0.84 (0.19,4.34)	-0.03 (-0.41,0.22)
HD TOFA PO + MTX		2.54 (0.77,8.35)	1.90 (0.84,4.96)	0.16 (-0.05,0.42)
LD RITUX IV + MTX	LD GOL I IV	0.68 (0.14,3.49)	0.70 (0.18,3.15)	-0.03 (-0.21,0.10)
LD ETN SC + MTX		1.34 (0.26,6.97)	1.29 (0.32,5.50)	0.03 (-0.16,0.22)
LD GOL I IV + MTX		0.59 (0.16,2.13)	0.62 (0.19,1.99)	-0.04 (-0.18,0.06)
HD TOCI IV		3.21 (0.52,21.14)	2.57 (0.58,10.98)	0.16 (-0.09,0.50)
HD GOL I SC		2.11 (0.33,14.71)	1.88 (0.39,8.95)	0.09 (-0.13,0.40)
HD TOCI IV + MTX		5.89 (1.07,35.70)	3.84 (1.05,14.58)	0.29 (0.01,0.61)
HD GOL I SC + MTX		4.28 (0.85,22.51)	3.16 (0.88,12.10)	0.22 (-0.03,0.49)
HD INF IV + MTX		1.57 (0.32,8.29)	1.48 (0.38,6.27)	0.05 (-0.15,0.26)
HD TOFA PO + MTX		5.02 (0.68,41.56)	3.45 (0.73,14.51)	0.25 (-0.05,0.66)

(Continued)

LD ETN SC + MTX	LD RITUX IV + MTX	1.97 (0.45,8.35)	1.83 (0.49,6.47)	0.06 (-0.07,0.24)
LD GOLI IV + MTX		0.87 (0.17,4.33)	0.87 (0.19,3.78)	-0.01 (-0.12,0.12)
HD TOCI IV		4.73 (0.84,27.17)	3.68 (0.86,13.18)	0.19 (-0.02,0.53)
HD GOLI SC		3.09 (0.56,17.99)	2.66 (0.59,10.63)	0.12 (-0.05,0.42)
HD TOCI IV + MTX		8.66 (1.83,45.28)	5.47 (1.63,17.09)	0.32 (0.08,0.64)
HD GOLI SC + MTX		6.35 (1.46,27.01)	4.52 (1.36,13.87)	0.25 (0.05,0.51)
HD INF IV + MTX		2.32 (0.54,9.92)	2.11 (0.57,7.28)	0.08 (-0.06,0.28)
HD TOFA PO + MTX		7.28 (1.16,54.51)	4.88 (1.13,17.36)	0.28 (0.02,0.69)
LD GOLI IV + MTX	LD ETN SC + MTX	0.44 (0.08,2.25)	0.48 (0.11,2.06)	-0.07 (-0.25,0.08)
HD TOCI IV		2.39 (0.42,14.52)	2.00 (0.49,7.43)	0.13 (-0.12,0.48)
HD GOLI SC		1.58 (0.27,9.48)	1.46 (0.33,5.95)	0.06 (-0.17,0.37)
HD TOCI IV + MTX		4.41 (0.89,24.33)	2.98 (0.92,9.81)	0.26 (-0.02,0.59)
HD GOLI SC + MTX		3.20 (0.73,14.55)	2.45 (0.79,7.88)	0.19 (-0.05,0.46)
HD INF IV + MTX		1.17 (0.26,5.51)	1.15 (0.32,4.19)	0.02 (-0.18,0.23)
HD TOFA PO + MTX		3.68 (0.58,28.24)	2.65 (0.64,9.74)	0.22 (-0.08,0.63)
HD TOCI IV	LD GOLI IV + MTX	5.42 (0.85,36.93)	4.15 (0.87,18.80)	0.20 (-0.02,0.54)
HD GOLI SC		3.57 (0.54,25.19)	3.03 (0.59,15.30)	0.13 (-0.06,0.43)
HD TOCI IV + MTX		9.93 (1.80,60.87)	6.18 (1.59,25.14)	0.33 (0.08,0.64)
HD GOLI SC + MTX		7.23 (1.42,39.03)	5.08 (1.33,20.87)	0.26 (0.05,0.52)
HD INF IV + MTX		2.67 (0.52,14.26)	2.40 (0.56,10.66)	0.09 (-0.07,0.29)
HD TOFA PO + MTX		8.50 (1.13,72.78)	5.57 (1.11,24.42)	0.29 (0.01,0.70)
HD GOLI SC	HD TOCI IV	0.66 (0.09,4.91)	0.73 (0.17,3.28)	-0.07 (-0.44,0.29)
HD TOCI IV + MTX		1.83 (0.81,4.61)	1.46 (0.88,3.04)	0.12 (-0.05,0.31)
HD GOLI SC + MTX		1.35 (0.23,7.71)	1.23 (0.39,4.44)	0.06 (-0.33,0.39)
HD INF IV + MTX		0.49 (0.08,2.84)	0.58 (0.16,2.31)	-0.11 (-0.46,0.16)
HD TOFA PO + MTX		1.55 (0.18,14.57)	1.33 (0.31,5.42)	0.09 (-0.35,0.55)
HD TOCI IV + MTX	HD GOLI SC	2.78 (0.43,18.85)	2.03 (0.57,8.00)	0.20 (-0.18,0.55)
HD GOLI SC + MTX		2.00 (0.60,7.01)	1.65 (0.71,4.74)	0.12 (-0.11,0.34)

(Continued)

HD INF IV + MTX		0.74 (0.12,4.36)	0.79 (0.20,3.43)	-0.04 (-0.36,0.20)
HD TOFA PO + MTX		2.37 (0.29,21.00)	1.83 (0.41,7.89)	0.16 (-0.23,0.59)
HD GOLI SC + MTX	HD TOCI IV + MTX	0.73 (0.13,3.62)	0.82 (0.30,2.30)	-0.07 (-0.44,0.28)
HD INF IV + MTX		0.27 (0.05,1.32)	0.39 (0.12,1.22)	-0.24 (-0.57,0.05)
HD TOFA PO + MTX		0.84 (0.10,7.14)	0.90 (0.23,2.86)	-0.04 (-0.47,0.44)
HD INF IV + MTX	HD GOLI SC + MTX	0.37 (0.08,1.66)	0.47 (0.15,1.46)	-0.17 (-0.45,0.09)
HD TOFA PO + MTX		1.16 (0.18,8.74)	1.10 (0.29,3.31)	0.03 (-0.34,0.48)
HD TOFA PO + MTX	HD INF IV + MTX	3.12 (0.48,24.05)	2.31 (0.56,8.31)	0.20 (-0.11,0.62)

Random-Effect Model	Residual Deviance	75.74 vs 74 data points
	Deviance Information Criteria	478.266
Fixed-Effect Model	Residual Deviance	113.5 vs 74 data points
	Deviance Information Criteria	504.534

Note:

Total Patients	13479
Total Studies	29
2-arm	16
3-arm	11
4-arm	1
5-arm	1

## Appendix 21. Remission: Subgroup - Trial duration ( $\leq 6$ months) - Network 1

Remission, Short trial duration, Network 1: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
-----------	-----------	--------------	--------------	----------------

**Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis (Review)**

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.

(Continued)

PL	MTX + PL	1.02 (0.13,7.23)	1.02 (0.14,5.92)	0.00 (-0.04,0.17)
SD ADA SC		1.30 (0.23,7.29)	1.29 (0.24,5.96)	0.01 (-0.03,0.17)
SD GOLI IV		1.43 (0.46,4.54)	1.40 (0.47,4.03)	0.02 (-0.02,0.11)
SD GOLI SC		3.56 (0.42,30.78)	3.25 (0.43,15.03)	0.09 (-0.02,0.50)
SD ABA IV + MTX		4.64 (2.54,9.03)	4.07 (2.39,7.01)	0.12 (0.05,0.22)
SD GOLI SC + MTX		10.73 (4.13,31.34)	7.80 (3.64,15.92)	0.26 (0.11,0.49)
SD ABA SC + MTX		3.62 (1.47,8.24)	3.29 (1.44,6.52)	0.09 (0.02,0.21)
SD INF IV + MTX		3.76 (1.87,8.65)	3.40 (1.81,6.79)	0.09 (0.03,0.22)
SD GOLI IV + MTX		3.64 (1.48,9.89)	3.31 (1.45,7.52)	0.09 (0.02,0.24)
SD CERTO + MTX		3.21 (1.36,7.93)	2.96 (1.34,6.33)	0.07 (0.01,0.20)
SD ADA SC + MTX		10.55 (1.27,278.50)	7.69 (1.25,28.95)	0.26 (0.01,0.87)
SD RITUX IV + MTX		4.64 (1.13,21.72)	4.07 (1.13,12.45)	0.12 (0.00,0.41)
LD GOLI IV		2.23 (0.73,6.90)	2.13 (0.74,5.67)	0.04 (-0.01,0.17)
LD RITUX IV + MTX		4.78 (1.18,22.42)	4.18 (1.17,12.68)	0.12 (0.01,0.42)
LD GOLI IV + MTX		1.32 (0.41,4.19)	1.30 (0.42,3.75)	0.01 (-0.02,0.10)
HD TOCI IV		7.52 (2.12,29.66)	6.01 (2.03,15.14)	0.19 (0.04,0.48)
HD GOLI SC		4.61 (1.28,18.39)	4.05 (1.27,11.58)	0.12 (0.01,0.36)
HD TOCI IV + MTX		13.01 (4.27,48.87)	8.89 (3.78,18.95)	0.30 (0.11,0.60)
HD GOLI SC + MTX		9.34 (3.56,27.52)	7.07 (3.21,14.86)	0.23 (0.09,0.46)
HD INF IV + MTX		3.42 (1.37,9.17)	3.13 (1.35,7.04)	0.08 (0.01,0.23)
SD ADA SC	PL	1.32 (0.09,17.85)	1.30 (0.10,15.38)	0.01 (-0.17,0.17)
SD GOLI IV		1.41 (0.14,14.45)	1.39 (0.17,13.08)	0.01 (-0.16,0.11)
SD GOLI SC		3.53 (0.89,15.52)	3.10 (0.90,11.21)	0.08 (-0.01,0.40)
SD ABA IV + MTX		4.61 (0.60,39.26)	4.02 (0.65,31.84)	0.11 (-0.07,0.23)
SD GOLI SC + MTX		10.77 (1.72,70.14)	7.69 (1.51,47.78)	0.25 (0.08,0.45)
SD ABA SC + MTX		3.55 (0.40,31.45)	3.22 (0.45,26.18)	0.08 (-0.10,0.21)
SD INF IV + MTX		3.74 (0.48,33.61)	3.37 (0.53,27.59)	0.09 (-0.09,0.22)
SD GOLI IV + MTX		3.65 (0.43,33.50)	3.29 (0.48,27.39)	0.08 (-0.10,0.24)

(Continued)

SD CERTO + MTX		3.19 (0.37,28.06)	2.92 (0.43,23.81)	0.07 (-0.11,0.20)
SD ADA SC + MTX		11.28 (0.57,490.80)	7.61 (0.61,90.41)	0.25 (-0.05,0.86)
SD RITUX IV + MTX		4.66 (0.41,58.97)	4.01 (0.46,38.62)	0.11 (-0.09,0.41)
LD GOLI IV		2.23 (0.24,21.68)	2.12 (0.28,18.65)	0.04 (-0.13,0.17)
LD RITUX IV + MTX		4.78 (0.43,62.35)	4.10 (0.49,41.53)	0.11 (-0.08,0.42)
LD GOLI IV + MTX		1.31 (0.13,13.37)	1.30 (0.16,12.13)	0.01 (-0.16,0.11)
HD TOCI IV		7.60 (0.68,86.19)	5.93 (0.72,52.77)	0.18 (-0.05,0.48)
HD GOLI SC		4.58 (1.12,21.84)	3.94 (1.10,18.47)	0.11 (0.01,0.29)
HD TOCI IV + MTX		13.21 (1.31,144.40)	8.78 (1.23,74.37)	0.29 (0.04,0.60)
HD GOLI SC + MTX		9.44 (1.55,63.26)	6.98 (1.40,44.69)	0.22 (0.06,0.42)
HD INF IV + MTX		3.40 (0.40,31.17)	3.09 (0.44,25.68)	0.07 (-0.10,0.23)
SD GOLI IV	SD ADA SC	1.11 (0.14,8.73)	1.10 (0.16,7.93)	0.00 (-0.16,0.11)
SD GOLI SC		2.71 (0.19,47.64)	2.47 (0.21,25.90)	0.07 (-0.12,0.49)
SD ABA IV + MTX		3.55 (0.59,23.21)	3.14 (0.65,18.80)	0.10 (-0.07,0.22)
SD GOLI SC + MTX		8.30 (1.14,63.29)	6.02 (1.11,37.52)	0.24 (0.02,0.48)
SD ABA SC + MTX		2.75 (0.41,19.04)	2.52 (0.46,15.52)	0.07 (-0.10,0.20)
SD INF IV + MTX		2.90 (0.47,20.44)	2.64 (0.53,16.67)	0.08 (-0.09,0.21)
SD GOLI IV + MTX		2.82 (0.40,20.17)	2.58 (0.45,16.28)	0.07 (-0.10,0.23)
SD CERTO + MTX		2.48 (0.36,17.55)	2.31 (0.42,14.61)	0.06 (-0.11,0.20)
SD ADA SC + MTX		8.67 (0.54,322.10)	6.02 (0.58,50.30)	0.24 (-0.05,0.86)
SD RITUX IV + MTX		3.58 (0.40,37.56)	3.13 (0.45,24.46)	0.10 (-0.09,0.40)
LD GOLI IV		1.73 (0.22,13.67)	1.66 (0.26,11.58)	0.03 (-0.14,0.17)
LD RITUX IV + MTX		3.67 (0.42,38.80)	3.20 (0.47,25.07)	0.10 (-0.09,0.41)
LD GOLI IV + MTX		1.02 (0.13,7.94)	1.02 (0.15,7.23)	0.00 (-0.16,0.10)
HD TOCI IV		5.86 (1.95,17.74)	4.61 (1.68,14.05)	0.17 (0.05,0.37)
HD GOLI SC		3.52 (0.41,33.97)	3.10 (0.46,23.66)	0.10 (-0.09,0.36)
HD TOCI IV + MTX		10.08 (2.86,42.71)	6.75 (2.14,27.63)	0.28 (0.11,0.51)
HD GOLI SC + MTX		7.19 (1.00,57.28)	5.45 (1.00,35.01)	0.21 (0.00,0.45)

(Continued)

HD INF IV + MTX		2.63 (0.38,19.53)	2.42 (0.44,15.73)	0.07 (-0.10,0.22)
SD GOLI SC	SD GOLI IV	2.50 (0.22,29.37)	2.30 (0.24,15.68)	0.07 (-0.08,0.48)
SD ABA IV + MTX		3.25 (0.91,12.19)	2.89 (0.92,9.88)	0.10 (-0.01,0.21)
SD GOLI SC + MTX		7.64 (1.73,36.50)	5.56 (1.58,20.65)	0.24 (0.07,0.47)
SD ABA SC + MTX		2.51 (0.59,10.11)	2.31 (0.63,8.40)	0.07 (-0.04,0.19)
SD INF IV + MTX		2.66 (0.70,10.96)	2.44 (0.73,8.99)	0.07 (-0.03,0.20)
SD GOLI IV + MTX		2.55 (0.88,7.86)	2.34 (0.90,6.62)	0.07 (-0.01,0.19)
SD CERTO + MTX		2.26 (0.54,9.70)	2.12 (0.57,8.02)	0.06 (-0.05,0.19)
SD ADA SC + MTX		7.71 (0.64,222.50)	5.48 (0.67,31.74)	0.24 (-0.03,0.85)
SD RITUX IV + MTX		3.29 (0.53,22.27)	2.91 (0.56,14.12)	0.10 (-0.05,0.40)
LD GOLI IV		1.56 (0.50,4.98)	1.51 (0.53,4.43)	0.03 (-0.05,0.13)
LD RITUX IV + MTX		3.40 (0.55,23.16)	2.99 (0.58,14.60)	0.10 (-0.04,0.41)
LD GOLI IV + MTX		0.92 (0.28,3.05)	0.93 (0.30,2.87)	0.00 (-0.08,0.07)
HD TOCI IV		5.29 (0.90,31.93)	4.24 (0.92,18.03)	0.17 (-0.01,0.47)
HD GOLI SC		3.25 (0.58,19.52)	2.88 (0.61,13.26)	0.10 (-0.04,0.35)
HD TOCI IV + MTX		9.18 (1.86,52.28)	6.28 (1.67,24.03)	0.28 (0.07,0.59)
HD GOLI SC + MTX		6.61 (1.47,31.64)	5.04 (1.39,19.09)	0.21 (0.04,0.44)
HD INF IV + MTX		2.41 (0.56,10.60)	2.23 (0.59,8.62)	0.06 (-0.05,0.21)
SD ABA IV + MTX	SD GOLI SC	1.31 (0.14,12.45)	1.26 (0.25,10.16)	0.03 (-0.39,0.19)
SD GOLI SC + MTX		3.06 (0.42,22.38)	2.40 (0.58,15.49)	0.16 (-0.19,0.38)
SD ABA SC + MTX		1.01 (0.10,10.03)	1.01 (0.18,8.47)	0.00 (-0.42,0.17)
SD INF IV + MTX		1.07 (0.11,10.50)	1.06 (0.20,8.78)	0.01 (-0.41,0.18)
SD GOLI IV + MTX		1.03 (0.10,10.66)	1.02 (0.18,8.85)	0.00 (-0.41,0.19)
SD CERTO + MTX		0.90 (0.09,9.21)	0.92 (0.16,7.91)	-0.01 (-0.42,0.16)
SD ADA SC + MTX		3.17 (0.15,138.40)	2.36 (0.22,27.91)	0.16 (-0.32,0.79)
SD RITUX IV + MTX		1.30 (0.11,18.12)	1.25 (0.17,12.61)	0.03 (-0.39,0.35)
LD GOLI IV		0.63 (0.06,6.88)	0.66 (0.10,6.07)	-0.04 (-0.45,0.13)
LD RITUX IV + MTX		1.36 (0.11,18.80)	1.29 (0.18,12.79)	0.03 (-0.38,0.36)

(Continued)

LD GOLI IV + MTX		0.37 (0.03,4.33)	0.40 (0.06,4.03)	-0.07 (-0.48,0.07)
HD TOCI IV		2.13 (0.16,25.65)	1.85 (0.27,16.56)	0.10 (-0.35,0.42)
HD GOLI SC		1.30 (0.24,6.99)	1.25 (0.37,5.92)	0.03 (-0.28,0.19)
HD TOCI IV + MTX		3.73 (0.31,45.30)	2.73 (0.46,23.56)	0.20 (-0.25,0.54)
HD GOLI SC + MTX		2.66 (0.36,20.08)	2.17 (0.53,14.30)	0.13 (-0.22,0.35)
HD INF IV + MTX		0.97 (0.09,9.98)	0.97 (0.17,8.40)	0.00 (-0.42,0.18)
SD GOLI SC + MTX	SD ABA IV + MTX	2.31 (0.73,7.75)	1.91 (0.77,4.51)	0.14 (-0.05,0.39)
SD ABA SC + MTX		0.78 (0.33,1.62)	0.81 (0.37,1.49)	-0.03 (-0.13,0.07)
SD INF IV + MTX		0.82 (0.36,1.96)	0.84 (0.41,1.75)	-0.02 (-0.13,0.09)
SD GOLI IV + MTX		0.79 (0.25,2.49)	0.81 (0.30,2.11)	-0.03 (-0.16,0.13)
SD CERTO + MTX		0.69 (0.23,2.03)	0.73 (0.28,1.81)	-0.04 (-0.17,0.09)
SD ADA SC + MTX		2.28 (0.24,61.63)	1.89 (0.29,7.79)	0.14 (-0.15,0.77)
SD RITUX IV + MTX		1.00 (0.21,4.99)	1.00 (0.25,3.30)	0.00 (-0.16,0.30)
LD GOLI IV		0.48 (0.13,1.70)	0.52 (0.16,1.57)	-0.07 (-0.19,0.07)
LD RITUX IV + MTX		1.04 (0.22,5.26)	1.03 (0.26,3.41)	0.00 (-0.16,0.31)
LD GOLI IV + MTX		0.28 (0.07,1.05)	0.32 (0.09,1.04)	-0.10 (-0.22,0.00)
HD TOCI IV		1.63 (0.38,7.24)	1.48 (0.44,4.18)	0.07 (-0.12,0.38)
HD GOLI SC		0.99 (0.24,4.38)	0.99 (0.28,3.13)	0.00 (-0.16,0.26)
HD TOCI IV + MTX		2.80 (0.77,11.87)	2.18 (0.81,5.35)	0.18 (-0.04,0.50)
HD GOLI SC + MTX		2.01 (0.63,6.82)	1.74 (0.69,4.15)	0.11 (-0.07,0.35)
HD INF IV + MTX		0.74 (0.25,2.18)	0.77 (0.30,1.90)	-0.03 (-0.15,0.11)
SD ABA SC + MTX	SD GOLI SC + MTX	0.33 (0.08,1.20)	0.42 (0.14,1.16)	-0.17 (-0.41,0.03)
SD INF IV + MTX		0.35 (0.10,1.25)	0.44 (0.17,1.19)	-0.17 (-0.41,0.03)
SD GOLI IV + MTX		0.33 (0.09,1.35)	0.42 (0.15,1.27)	-0.17 (-0.41,0.05)
SD CERTO + MTX		0.30 (0.08,1.10)	0.38 (0.13,1.08)	-0.18 (-0.43,0.01)
SD ADA SC + MTX		1.02 (0.09,26.57)	1.01 (0.14,4.24)	0.00 (-0.38,0.64)
SD RITUX IV + MTX		0.43 (0.08,2.62)	0.52 (0.13,1.96)	-0.14 (-0.40,0.19)
LD GOLI IV		0.20 (0.05,0.91)	0.27 (0.08,0.92)	-0.21 (-0.45,-0.01)



(Continued)

LD RITUX IV + MTX		0.44 (0.08,2.70)	0.54 (0.13,1.99)	-0.13 (-0.40,0.20)
LD GOLI IV + MTX		0.12 (0.03,0.56)	0.17 (0.04,0.61)	-0.25 (-0.48,-0.07)
HD TOCI IV		0.69 (0.13,3.71)	0.77 (0.21,2.43)	-0.07 (-0.36,0.27)
HD GOLI SC		0.42 (0.14,1.33)	0.52 (0.20,1.22)	-0.14 (-0.32,0.06)
HD TOCI IV + MTX		1.21 (0.26,6.11)	1.14 (0.39,3.14)	0.04 (-0.28,0.39)
HD GOLI SC + MTX		0.87 (0.43,1.82)	0.91 (0.55,1.53)	-0.03 (-0.17,0.12)
HD INF IV + MTX		0.32 (0.08,1.22)	0.40 (0.14,1.17)	-0.18 (-0.42,0.03)
SD INF IV + MTX	SD ABA SC + MTX	1.04 (0.40,3.38)	1.04 (0.45,2.89)	0.00 (-0.11,0.14)
SD GOLI IV + MTX		1.01 (0.30,3.90)	1.01 (0.35,3.22)	0.00 (-0.14,0.16)
SD CERTO + MTX		0.89 (0.27,3.19)	0.90 (0.32,2.76)	-0.01 (-0.15,0.13)
SD ADA SC + MTX		3.03 (0.29,84.52)	2.40 (0.34,11.34)	0.17 (-0.12,0.79)
SD RITUX IV + MTX		1.30 (0.26,7.55)	1.25 (0.30,4.94)	0.03 (-0.13,0.33)
LD GOLI IV		0.62 (0.16,2.62)	0.65 (0.19,2.31)	-0.04 (-0.17,0.10)
LD RITUX IV + MTX		1.34 (0.27,7.82)	1.28 (0.31,5.03)	0.03 (-0.13,0.34)
LD GOLI IV + MTX		0.37 (0.09,1.59)	0.40 (0.11,1.52)	-0.07 (-0.20,0.04)
HD TOCI IV		2.10 (0.46,10.73)	1.84 (0.51,6.23)	0.10 (-0.09,0.41)
HD GOLI SC		1.29 (0.29,6.69)	1.24 (0.33,4.64)	0.03 (-0.13,0.29)
HD TOCI IV + MTX		3.64 (0.92,17.80)	2.72 (0.94,8.17)	0.21 (-0.01,0.53)
HD GOLI SC + MTX		2.63 (0.74,10.50)	2.18 (0.78,6.45)	0.14 (-0.04,0.39)
HD INF IV + MTX		0.95 (0.29,3.51)	0.95 (0.34,2.97)	-0.01 (-0.13,0.15)
SD GOLI IV + MTX	SD INF IV + MTX	0.96 (0.28,3.24)	0.97 (0.33,2.69)	0.00 (-0.15,0.15)
SD CERTO + MTX		0.85 (0.25,2.66)	0.87 (0.30,2.31)	-0.02 (-0.15,0.12)
SD ADA SC + MTX		2.79 (0.27,77.24)	2.24 (0.32,9.97)	0.16 (-0.13,0.78)
SD RITUX IV + MTX		1.23 (0.23,6.51)	1.19 (0.27,4.22)	0.02 (-0.15,0.32)
LD GOLI IV		0.59 (0.14,2.20)	0.62 (0.17,1.97)	-0.05 (-0.18,0.09)
LD RITUX IV + MTX		1.26 (0.24,6.78)	1.22 (0.29,4.30)	0.03 (-0.15,0.33)
LD GOLI IV + MTX		0.35 (0.08,1.32)	0.38 (0.10,1.28)	-0.08 (-0.21,0.03)
HD TOCI IV		2.00 (0.42,9.02)	1.76 (0.48,5.20)	0.10 (-0.11,0.40)

(Continued)

HD GOL I SC		1.22 (0.26,5.62)	1.18 (0.31,3.95)	0.02 (-0.15,0.28)
HD TOCI IV + MTX		3.44 (0.86,15.09)	2.59 (0.89,6.83)	0.21 (-0.02,0.52)
HD GOL I SC + MTX		2.47 (0.70,8.84)	2.06 (0.74,5.39)	0.14 (-0.05,0.38)
HD INF IV + MTX		0.91 (0.35,2.26)	0.92 (0.40,1.98)	-0.01 (-0.12,0.11)
SD CERTO + MTX	SD GOL I IV + MTX	0.88 (0.23,3.24)	0.89 (0.29,2.80)	-0.01 (-0.18,0.13)
SD ADA SC + MTX		2.98 (0.27,81.52)	2.34 (0.32,11.07)	0.17 (-0.14,0.79)
SD RITUX IV + MTX		1.27 (0.23,7.74)	1.23 (0.27,4.98)	0.03 (-0.16,0.33)
LD GOL I IV		0.61 (0.21,1.74)	0.64 (0.24,1.62)	-0.04 (-0.16,0.06)
LD RITUX IV + MTX		1.31 (0.23,7.91)	1.26 (0.28,5.06)	0.03 (-0.16,0.34)
LD GOL I IV + MTX		0.36 (0.12,1.06)	0.40 (0.14,1.05)	-0.07 (-0.20,0.00)
HD TOCI IV		2.07 (0.41,10.99)	1.80 (0.47,6.31)	0.10 (-0.11,0.41)
HD GOL I SC		1.27 (0.25,6.53)	1.23 (0.30,4.60)	0.03 (-0.16,0.29)
HD TOCI IV + MTX		3.57 (0.82,18.21)	2.66 (0.86,8.18)	0.21 (-0.03,0.53)
HD GOL I SC + MTX		2.61 (0.65,10.30)	2.15 (0.71,6.30)	0.14 (-0.07,0.38)
HD INF IV + MTX		0.94 (0.24,3.52)	0.95 (0.30,2.97)	-0.01 (-0.17,0.15)
SD ADA SC + MTX	SD CERTO + MTX	3.34 (0.33,97.49)	2.61 (0.37,12.59)	0.18 (-0.11,0.80)
SD RITUX IV + MTX		1.45 (0.28,8.31)	1.38 (0.32,5.29)	0.04 (-0.12,0.34)
LD GOL I IV		0.70 (0.16,2.87)	0.72 (0.19,2.53)	-0.03 (-0.17,0.11)
LD RITUX IV + MTX		1.49 (0.29,8.70)	1.41 (0.33,5.49)	0.04 (-0.12,0.35)
LD GOL I IV + MTX		0.41 (0.10,1.71)	0.44 (0.11,1.62)	-0.06 (-0.19,0.05)
HD TOCI IV		2.34 (0.49,11.91)	2.02 (0.54,6.76)	0.11 (-0.09,0.42)
HD GOL I SC		1.42 (0.30,7.41)	1.36 (0.35,5.11)	0.04 (-0.13,0.30)
HD TOCI IV + MTX		4.05 (0.97,19.75)	2.98 (0.98,9.09)	0.22 (0.00,0.54)
HD GOL I SC + MTX		2.93 (0.79,11.69)	2.39 (0.83,6.97)	0.15 (-0.03,0.39)
HD INF IV + MTX		1.07 (0.29,3.90)	1.06 (0.34,3.26)	0.01 (-0.13,0.16)
SD RITUX IV + MTX	SD ADA SC + MTX	0.43 (0.01,5.91)	0.53 (0.08,4.32)	-0.13 (-0.77,0.26)
LD GOL I IV		0.20 (0.01,2.39)	0.27 (0.05,2.18)	-0.21 (-0.83,0.08)
LD RITUX IV + MTX		0.44 (0.01,6.24)	0.54 (0.09,4.41)	-0.13 (-0.77,0.26)

(Continued)

LD GOLI IV + MTX		0.12 (0.00,1.42)	0.17 (0.03,1.38)	-0.24 (-0.85,0.02)
HD TOCI IV		0.69 (0.02,8.56)	0.77 (0.14,5.61)	-0.07 (-0.72,0.33)
HD GOLI SC		0.42 (0.01,5.69)	0.52 (0.09,4.24)	-0.14 (-0.77,0.24)
HD TOCI IV + MTX		1.23 (0.04,14.53)	1.14 (0.24,7.79)	0.04 (-0.64,0.46)
HD GOLI SC + MTX		0.87 (0.03,9.72)	0.90 (0.21,6.37)	-0.03 (-0.67,0.35)
HD INF IV + MTX		0.32 (0.01,3.55)	0.40 (0.08,3.05)	-0.17 (-0.80,0.13)
LD GOLI IV	SD RITUX IV + MTX	0.48 (0.07,2.91)	0.53 (0.11,2.59)	-0.07 (-0.37,0.10)
LD RITUX IV + MTX		1.03 (0.32,3.38)	1.03 (0.39,2.72)	0.00 (-0.18,0.19)
LD GOLI IV + MTX		0.28 (0.04,1.72)	0.32 (0.07,1.64)	-0.10 (-0.40,0.04)
HD TOCI IV		1.64 (0.21,10.95)	1.48 (0.30,6.69)	0.07 (-0.28,0.39)
HD GOLI SC		1.00 (0.13,6.82)	1.00 (0.20,4.94)	0.00 (-0.32,0.27)
HD TOCI IV + MTX		2.84 (0.41,18.48)	2.18 (0.54,9.28)	0.18 (-0.17,0.51)
HD GOLI SC + MTX		2.04 (0.33,11.71)	1.74 (0.46,7.51)	0.11 (-0.22,0.37)
HD INF IV + MTX		0.74 (0.12,4.15)	0.77 (0.19,3.51)	-0.03 (-0.34,0.15)
LD RITUX IV + MTX	LD GOLI IV	2.17 (0.36,14.89)	1.97 (0.40,9.39)	0.08 (-0.10,0.38)
LD GOLI IV + MTX		0.59 (0.19,1.89)	0.62 (0.21,1.80)	-0.03 (-0.14,0.04)
HD TOCI IV		3.40 (0.59,19.68)	2.83 (0.64,11.27)	0.14 (-0.06,0.44)
HD GOLI SC		2.10 (0.38,11.85)	1.91 (0.42,8.22)	0.07 (-0.10,0.32)
HD TOCI IV + MTX		5.89 (1.23,32.83)	4.17 (1.18,15.06)	0.25 (0.03,0.56)
HD GOLI SC + MTX		4.29 (0.96,19.28)	3.36 (0.97,11.80)	0.19 (-0.01,0.42)
HD INF IV + MTX		1.54 (0.36,6.75)	1.47 (0.41,5.54)	0.04 (-0.11,0.19)
LD GOLI IV + MTX	LD RITUX IV + MTX	0.27 (0.04,1.68)	0.31 (0.06,1.61)	-0.11 (-0.41,0.04)
HD TOCI IV		1.58 (0.20,10.50)	1.44 (0.29,6.43)	0.07 (-0.28,0.38)
HD GOLI SC		0.96 (0.13,6.78)	0.97 (0.20,4.90)	0.00 (-0.32,0.27)
HD TOCI IV + MTX		2.76 (0.39,17.69)	2.13 (0.53,8.73)	0.17 (-0.19,0.51)
HD GOLI SC + MTX		1.97 (0.33,11.42)	1.70 (0.45,7.20)	0.11 (-0.22,0.37)
HD INF IV + MTX		0.72 (0.12,4.00)	0.75 (0.18,3.37)	-0.04 (-0.35,0.15)

(Continued)

HD TOCI IV	LD GOLI IV + MTX	5.79 (0.98,34.99)	4.60 (0.99,19.95)	0.18 (0.00,0.47)
HD GOLI SC		3.51 (0.62,21.01)	3.10 (0.65,14.48)	0.10 (-0.04,0.35)
HD TOCI IV + MTX		9.97 (2.01,58.65)	6.76 (1.79,26.50)	0.28 (0.08,0.59)
HD GOLI SC + MTX		7.14 (1.56,34.84)	5.40 (1.46,20.76)	0.22 (0.05,0.45)
HD INF IV + MTX		2.60 (0.60,11.86)	2.39 (0.63,9.67)	0.07 (-0.04,0.22)
HD GOLI SC	HD TOCI IV	0.60 (0.09,4.24)	0.67 (0.16,3.11)	-0.07 (-0.39,0.23)
HD TOCI IV + MTX		1.71 (0.85,4.09)	1.45 (0.90,2.96)	0.10 (-0.03,0.27)
HD GOLI SC + MTX		1.24 (0.24,6.87)	1.17 (0.37,4.39)	0.04 (-0.29,0.33)
HD INF IV + MTX		0.45 (0.09,2.37)	0.52 (0.15,2.08)	-0.11 (-0.41,0.11)
HD TOCI IV + MTX	HD GOLI SC	2.91 (0.47,17.65)	2.22 (0.58,8.48)	0.18 (-0.14,0.51)
HD GOLI SC + MTX		2.05 (0.67,6.28)	1.74 (0.75,4.57)	0.11 (-0.07,0.29)
HD INF IV + MTX		0.74 (0.14,3.71)	0.77 (0.20,3.14)	-0.03 (-0.29,0.14)
HD GOLI SC + MTX	HD TOCI IV + MTX	0.71 (0.14,3.45)	0.80 (0.29,2.39)	-0.07 (-0.41,0.25)
HD INF IV + MTX		0.26 (0.05,1.15)	0.35 (0.12,1.12)	-0.22 (-0.52,0.02)
HD INF IV + MTX	HD GOLI SC + MTX	0.36 (0.09,1.39)	0.44 (0.15,1.31)	-0.15 (-0.39,0.05)
Random-Effect Model	Residual Deviance	54.1 vs 52 data points		
	Deviance Information Criteria	326.692		
Fixed-Effect Model	Residual Deviance	67.08 vs 52 data points		
	Deviance Information Criteria	333.907		
Note:				
Total Patients	9626			
Total Studies	20			
2-arm	11			
3-arm	7			

(Continued)

4-arm	1
5-arm	1

## Appendix 22. Remission: Subgroup - Trial duration ( $\leq 6$ months) - Network 2

Remission, Short trial duration, Network 2: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD ETN SC	MTX + DMARD	3.16 (1.02,10.45)	2.59 (1.02,5.96)	0.16 (0.00,0.40)
SD ETN SC + MTX		4.41 (1.96,11.94)	3.29 (1.76,6.51)	0.23 (0.08,0.43)
SD ETN SC + MTX	SD ETN SC	1.39 (0.71,3.08)	1.26 (0.81,2.38)	0.07 (-0.08,0.20)
Random-Effect Model	Residual Deviance	12.14 vs 10 data points		
	Deviance Information Criteria	69.459		
Fixed-Effect Model	Residual Deviance	18.44 vs 10 data points		
	Deviance Information Criteria	73.457		
Note:				
Total Patients	1392			
Total Studies	5			
2-arm	5			

## Appendix 23. Radiographic Progression: Type of medication

Radiographic(Analysis2) :Mean Difference for All Treatment Comparisons-Random Effects Model

Treatment	Reference	MD (95% CrI)
Medications targeting TNF receptor	Comparator: PL, MTX or DMARD	-2.35 (-9.12,3.49)
(MTX or DMARD) + TNF inhibitors		-2.99 (-6.30,-0.55)
(MTX or DMARD) + non-TNF		-2.76 (-10.58,4.12)

(Continued)

(MTX or DMARD) + TNF inhibitors	Medications targeting TNF receptor	-0.64 (-6.82,5.59)
(MTX or DMARD) + non-TNF		-0.44 (-9.57,8.75)
(MTX or DMARD) + non-TNF		0.19 (-6.54,7.01)
Random-Effect Model	Total Residual Deviance	18.4
	Deviance Information Criteria	47.94
Total Studies	8	
2-arm	7	
3-arm	1	

#### Appendix 24. Radiographic Progression: Type of biologics

Radiographic-Analysis3 :Mean Difference for All Treatment Comparisons-Random Effects Model		
Treatment	Reference	MD (95% CrI)
Medications targeting TNF receptor	Comparator: PL, MTX or DMARD	-4.33 (-11.69,2.92)
(MTX or DMARD) + Monoclonal antibodies against TNF		-2.37 (-6.12,0.04)
(MTX or DMARD) + non-TNF		-2.12 (-10.28,4.52)
(MTX or DMARD) + Medications targeting TNF receptor		-6.15 (-13.25,1.04)
(MTX or DMARD) + Monoclonal antibodies against TNF	Medications targeting TNF receptor	1.97 (-6.52,9.35)
(MTX or DMARD) + non-TNF		2.19 (-9.13,12.01)
(MTX or DMARD) + Medications targeting TNF receptor		-1.80 (-8.75,4.66)
(MTX or DMARD) + non-TNF	(MTX or DMARD) + Monoclonal antibodies against TNF	0.21 (-6.67,6.88)
(MTX or DMARD) + Monoclonal antibodies against TNF		-3.80 (-11.12,4.54)
(MTX or DMARD) + Medications targeting TNF receptor	(MTX or DMARD) + non-TNF	-3.96 (-13.74,7.10)

(Continued)

Random-Effect Model	Total Residual Deviance	18.7
	Deviance Information Criteria	48.294
Total Studies	8	
2-arm	7	
3-arm	1	

### Appendix 25. Radiographic Progression: by dose

Radiographic(Analysis4) :Mean Difference for All Treatment Comparisons-Random Effects Model		
Treatment	Reference	MD (95% CrI)
SD biologic	Comparator: PL, MTX or DMARD	-2.23 (-8.32,3.07)
MTXSD biologic		-2.80 (-5.70,-0.47)
MTXHD biologic		-3.70 (-8.27,-0.34)
MTXLD biologic		-1.99 (-7.59,3.28)
MTXSD biologic	SD biologic	-0.57 (-6.02,5.13)
MTXHD biologic		-1.45 (-8.33,4.91)
MTXLD biologic		0.24 (-7.13,8.06)
MTXHD biologic	MTXSD biologic	-0.88 (-5.18,2.72)
MTXLD biologic		0.80 (-4.47,6.38)
MTXLD biologic	MTXHD biologic	1.68 (-4.27,8.66)
Random-Effect Model	Total Residual Deviance	19.23
	Deviance Information Criteria	50.654
Total Studies	7	

(Continued)

2-arm 3

3-arm 4

**Appendix 26. Radiographic Progression: Main analysis**

Radiographic: Mean Difference for All Treatments

Treatment	Reference	MD (95% CrI)
MTX + DMARD	MTX	-5.72 (-13.53,2.31)
SD ETN SC		-4.32 (-11.12,2.40)
SD INF IV + MTX		-6.43 (-13.22,-0.37)
SD ADA SC + MTX		-2.60 (-8.84,3.59)
SD CERTO SC + MTX		-0.99 (-7.19,5.21)
SD ABA SC + MTX		-2.38 (-11.26,6.33)
SD ETN SC + MTX		-6.10 (-12.86,0.67)
LD ADA SC + MTX		-1.90 (-8.14,4.30)
LD CERTO SC + MTX		0.14 (-195.40,196.50)
HD CERTO SC + MTX		-1.61 (-7.78,4.60)
HD INF IV + MTX		-6.75 (-13.30,-1.60)
SD ETN SC	MTX + DMARD	1.39 (-9.06,11.60)
SD INF IV + MTX		-0.64 (-5.79,3.47)
SD ADA SC + MTX		3.15 (-7.06,13.06)
SD CERTO SC + MTX		4.75 (-5.35,14.56)
SD ABA SC + MTX		3.37 (-8.61,15.01)
SD ETN SC + MTX		-0.37 (-10.79,9.83)
LD ADA SC + MTX		3.86 (-6.37,13.74)
LD CERTO SC + MTX		5.70 (-189.80,202.20)
HD CERTO SC + MTX		4.15 (-5.93,13.98)
HD INF IV + MTX		-0.99 (-9.73,5.92)



(Continued)

SD INF IV + MTX	SD ETN SC	-2.09 (-11.71,6.86)
SD ADA SC + MTX		1.75 (-7.44,10.93)
SD CERTO SC + MTX		3.32 (-5.79,12.55)
SD ABA SC + MTX		1.94 (-9.10,12.98)
SD ETN SC + MTX		-1.76 (-8.05,4.61)
LD ADA SC + MTX		2.42 (-6.76,11.69)
LD CERTO SC + MTX		4.46 (-191.10,201.20)
HD CERTO SC + MTX		2.71 (-6.46,11.95)
HD INF IV + MTX		-2.44 (-12.06,5.83)
SD ADA SC + MTX	SD INF IV + MTX	3.82 (-4.77,13.13)
SD CERTO SC + MTX		5.42 (-3.08,14.65)
SD ABA SC + MTX		4.02 (-6.50,15.27)
SD ETN SC + MTX		0.32 (-8.55,9.91)
LD ADA SC + MTX		4.51 (-4.05,13.80)
LD CERTO SC + MTX		6.50 (-189.00,203.10)
HD CERTO SC + MTX		4.80 (-3.70,14.05)
HD INF IV + MTX		-0.30 (-7.03,5.57)
SD CERTO SC + MTX	SD ADA SC + MTX	1.59 (-7.15,10.45)
SD ABA SC + MTX		0.20 (-5.96,6.42)
SD ETN SC + MTX		-3.49 (-12.60,5.71)
LD ADA SC + MTX		0.69 (-5.44,6.93)
LD CERTO SC + MTX		2.74 (-193.00,199.40)
HD CERTO SC + MTX		0.98 (-7.83,9.81)
HD INF IV + MTX		-4.11 (-13.28,3.62)
SD ABA SC + MTX	SD CERTO SC + MTX	-1.39 (-12.21,9.28)
SD ETN SC + MTX		-5.10 (-14.26,4.11)
LD ADA SC + MTX		-0.89 (-9.76,7.88)
LD CERTO SC + MTX		1.14 (-194.50,197.60)

(Continued)

HD CERTO SC + MTX		-0.61 (-6.82,5.60)
HD INF IV + MTX		-5.70 (-14.95,1.96)
SD ETN SC + MTX	SD ABA SC + MTX	-3.69 (-14.76,7.32)
LD ADA SC + MTX		0.50 (-8.19,9.33)
LD CERTO SC + MTX		2.40 (-193.40,199.20)
HD CERTO SC + MTX		0.78 (-9.91,11.55)
HD INF IV + MTX		-4.29 (-15.50,5.40)
LD ADA SC + MTX	SD ETN SC + MTX	4.19 (-4.98,13.39)
LD CERTO SC + MTX		6.34 (-189.20,202.80)
HD CERTO SC + MTX		4.49 (-4.69,13.62)
HD INF IV + MTX		-0.66 (-10.28,7.52)
LD CERTO SC + MTX	LD ADA SC + MTX	2.08 (-193.40,198.80)
HD CERTO SC + MTX		0.28 (-8.50,9.11)
HD INF IV + MTX		-4.81 (-14.08,2.90)
HD CERTO SC + MTX	LD CERTO SC + MTX	-1.79 (-198.40,193.90)
HD INF IV + MTX		-6.93 (-203.50,188.50)
HD INF IV + MTX	HD CERTO SC + MTX	-5.07 (-14.33,2.54)
Random-Effect Model	Total Residual Deviance	20.57 vs 20 data points
	Deviance Information Criteria	52.379
Fixed-Effect Model	Total Residual Deviance	23.04 vs 20 data points
	Deviance Information Criteria	53.62
Note:		
Total Patients	3267	
Total Studies	8	
2-arm	4	

(Continued)

3-arm

4

**Appendix 27. Withdrawals due to AE: Type of medication**

Withdrawals(analysis-2): Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
TNF inhibitors	PL	1.31 (0.95,1.88)	1.30 (0.95,1.84)	0.01 (0.00,0.02)
non-TNF		1.12 (0.68,1.84)	1.12 (0.69,1.80)	0.00 (-0.01,0.02)
TOFA		1.18 (0.27,5.97)	1.17 (0.28,5.30)	0.00 (-0.02,0.11)
ANA		1.67 (0.53,5.86)	1.64 (0.53,5.24)	0.02 (-0.01,0.11)
(MTX or DMARD) + TNF inhibitors		1.25 (0.99,1.59)	1.24 (0.99,1.57)	0.01 (0.00,0.02)
(MTX or DMARD) + non-TNF		1.20 (0.86,1.70)	1.20 (0.87,1.67)	0.00 (0.00,0.02)
(MTX or DMARD) + TOFA		1.56 (0.82,3.02)	1.53 (0.82,2.88)	0.01 (0.00,0.05)
non-TNF	TNF inhibitors	0.85 (0.48,1.48)	0.86 (0.49,1.46)	0.00 (-0.02,0.01)
TOFA		0.89 (0.20,4.62)	0.90 (0.21,4.14)	0.00 (-0.03,0.10)
ANA		1.27 (0.38,4.53)	1.26 (0.39,4.10)	0.01 (-0.02,0.10)
(MTX or DMARD) + TNF inhibitors		0.95 (0.65,1.34)	0.95 (0.66,1.33)	0.00 (-0.02,0.01)
(MTX or DMARD) + non-TNF		0.92 (0.57,1.43)	0.92 (0.58,1.41)	0.00 (-0.02,0.01)
(MTX or DMARD) + TOFA		1.19 (0.57,2.43)	1.18 (0.58,2.34)	0.01 (-0.02,0.04)
TOFA	non-TNF	1.06 (0.23,5.77)	1.05 (0.23,5.14)	0.00 (-0.03,0.10)
ANA		1.50 (0.41,5.60)	1.48 (0.42,5.06)	0.01 (-0.02,0.10)
(MTX or DMARD) + TNF inhibitors		1.12 (0.65,1.90)	1.11 (0.66,1.87)	0.00 (-0.02,0.02)
(MTX or DMARD) + non-TNF		1.08 (0.63,1.81)	1.07 (0.64,1.79)	0.00 (-0.02,0.02)
(MTX or DMARD) + TOFA		1.39 (0.62,3.19)	1.38 (0.63,3.04)	0.01 (-0.01,0.05)
ANA	TOFA	1.40 (0.20,9.45)	1.38 (0.22,8.63)	0.01 (-0.09,0.10)
(MTX or DMARD) + TNF inhibitors		1.06 (0.21,4.62)	1.06 (0.23,4.51)	0.00 (-0.10,0.03)
(MTX or DMARD) + non-TNF		1.02 (0.20,4.60)	1.02 (0.22,4.48)	0.00 (-0.10,0.03)

(Continued)

(MTX or DMARD) + TOFA		1.32 (0.23,6.67)	1.31 (0.26,6.39)	0.01 (-0.09,0.05)
(MTX or DMARD) + TNF inhibitors	ANA	0.75 (0.21,2.45)	0.76 (0.23,2.41)	-0.01 (-0.10,0.02)
(MTX or DMARD) + non-TNF		0.72 (0.20,2.44)	0.73 (0.22,2.38)	-0.01 (-0.10,0.02)
(MTX or DMARD) + TOFA		0.93 (0.23,3.56)	0.93 (0.26,3.42)	0.00 (-0.09,0.04)
(MTX or DMARD) + non-TNF	(MTX or DMARD) + TNF inhibitors	0.97 (0.65,1.42)	0.97 (0.66,1.40)	0.00 (-0.01,0.01)
(MTX or DMARD) + TOFA		1.25 (0.64,2.46)	1.24 (0.65,2.35)	0.01 (-0.01,0.04)
(MTX or DMARD) + TOFA	(MTX or DMARD) + non-TNF	1.29 (0.63,2.69)	1.28 (0.64,2.57)	0.01 (-0.01,0.04)
Random-Effect Model	Residual Deviance	136.7 vs 141 data points		
	Deviance Information Criteria	722.121		
Fixed-Effect Model	Residual Deviance	173.7 vs 141 data points		
	Deviance Information Criteria	739.264		
Note:				
Total Patients	26273			
Total Studies	67			
2-arm	60			
3-arm	7			

## Appendix 28. Withdrawals due to AE: Type of biologics

Withdrawals (Analysis-3): Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
Mono	Comp	1.00 (0.70,1.52)	1.00 (0.70,1.50)	0.00 (-0.01,0.01)
TNF		1.36 (0.82,2.34)	1.35 (0.82,2.27)	0.01 (0.00,0.03)

(Continued)

NonTNF		1.14 (0.72,1.83)	1.14 (0.73,1.79)	0.00 (-0.01,0.02)
TOFA		1.21 (0.29,6.20)	1.20 (0.30,5.51)	0.00 (-0.02,0.11)
ANA		1.69 (0.56,5.55)	1.66 (0.57,5.02)	0.02 (-0.01,0.10)
MTXMono		1.57 (1.19,2.08)	1.54 (1.18,2.03)	0.01 (0.00,0.03)
MTXnon-TNF		1.23 (0.91,1.70)	1.23 (0.91,1.67)	0.01 (0.00,0.02)
MTXTNF		0.79 (0.54,1.16)	0.80 (0.55,1.15)	0.00 (-0.01,0.00)
MTXTOFA		1.67 (0.93,3.05)	1.65 (0.93,2.90)	0.02 (0.00,0.05)
TNF	Mono	1.36 (0.72,2.54)	1.35 (0.72,2.46)	0.01 (-0.01,0.03)
NonTNF		1.13 (0.62,2.05)	1.13 (0.63,2.01)	0.00 (-0.01,0.02)
TOFA		1.19 (0.27,6.38)	1.19 (0.28,5.68)	0.00 (-0.02,0.11)
ANA		1.68 (0.51,5.81)	1.65 (0.52,5.22)	0.02 (-0.01,0.10)
MTXMono		1.56 (0.96,2.45)	1.54 (0.96,2.39)	0.01 (0.00,0.03)
MTXnon-TNF		1.23 (0.73,2.00)	1.23 (0.74,1.96)	0.01 (-0.01,0.02)
MTXTNF		0.79 (0.50,1.20)	0.79 (0.51,1.19)	0.00 (-0.02,0.00)
MTXTOFA		1.67 (0.81,3.35)	1.65 (0.81,3.19)	0.02 (-0.01,0.05)
NonTNF	TNF	0.83 (0.44,1.56)	0.84 (0.46,1.54)	-0.01 (-0.03,0.01)
TOFA		0.89 (0.19,4.82)	0.89 (0.20,4.35)	0.00 (-0.04,0.10)
ANA		1.24 (0.36,4.57)	1.23 (0.37,4.16)	0.01 (-0.03,0.09)
MTXMono		1.15 (0.64,2.05)	1.14 (0.65,2.00)	0.00 (-0.02,0.02)
MTXnon-TNF		0.90 (0.50,1.64)	0.91 (0.51,1.62)	0.00 (-0.03,0.01)
MTXTNF		0.58 (0.32,1.03)	0.59 (0.33,1.03)	-0.01 (-0.04,0.00)
MTXTOFA		1.23 (0.56,2.67)	1.22 (0.57,2.57)	0.01 (-0.02,0.04)
TOFA	NonTNF	1.07 (0.23,5.57)	1.07 (0.24,4.97)	0.00 (-0.03,0.10)
ANA		1.48 (0.44,5.32)	1.46 (0.45,4.83)	0.01 (-0.02,0.10)
MTXMono		1.38 (0.80,2.33)	1.36 (0.81,2.27)	0.01 (-0.01,0.03)
MTXnon-TNF		1.09 (0.66,1.77)	1.09 (0.67,1.74)	0.00 (-0.01,0.02)
MTXTNF		0.69 (0.39,1.25)	0.70 (0.40,1.24)	-0.01 (-0.03,0.00)
MTXTOFA		1.47 (0.68,3.20)	1.45 (0.69,3.05)	0.01 (-0.01,0.05)

(Continued)

ANA	TOFA	1.39 (0.20,8.80)	1.38 (0.22,8.15)	0.01 (-0.09,0.10)
MTXMono		1.30 (0.25,5.60)	1.29 (0.28,5.42)	0.01 (-0.09,0.04)
MTXnon-TNF		1.03 (0.20,4.46)	1.02 (0.22,4.34)	0.00 (-0.10,0.03)
MTXTNF		0.65 (0.12,2.82)	0.66 (0.14,2.79)	-0.01 (-0.11,0.02)
MTXTOFA		1.38 (0.25,6.64)	1.36 (0.28,6.34)	0.01 (-0.09,0.06)
MTXMono	ANA	0.93 (0.27,2.93)	0.93 (0.30,2.85)	0.00 (-0.09,0.03)
MTXnon-TNF		0.73 (0.22,2.32)	0.74 (0.24,2.28)	-0.01 (-0.09,0.02)
MTXTNF		0.47 (0.13,1.51)	0.48 (0.15,1.50)	-0.02 (-0.11,0.01)
MTXTOFA		0.99 (0.26,3.58)	0.99 (0.29,3.44)	0.00 (-0.08,0.05)
MTXnon-TNF	MTXMono	0.79 (0.54,1.18)	0.79 (0.55,1.17)	-0.01 (-0.02,0.01)
MTXTNF		0.51 (0.32,0.80)	0.51 (0.33,0.81)	-0.02 (-0.04,-0.01)
MTXTOFA		1.07 (0.58,1.98)	1.07 (0.59,1.92)	0.00 (-0.02,0.03)
MTXTNF	MTXnon-TNF	0.64 (0.39,1.04)	0.65 (0.40,1.04)	-0.01 (-0.03,0.00)
MTXTOFA		1.36 (0.69,2.67)	1.34 (0.69,2.56)	0.01 (-0.01,0.05)
MTXTOFA	MTXTNF	2.12 (1.05,4.29)	2.08 (1.05,4.07)	0.02 (0.00,0.06)
Random-Effect Model	Residual Deviance	138.8 vs 141 data points		
	Deviance Information Criteria	720.985		
Fixed-Effect Model	Residual Deviance	160.5 vs 141 data points		
	Deviance Information Criteria	728.159		
Note:				
Total Patients	26273			
Total Studies	67			
2-arm	60			

**Appendix 29. Withdrawals due to AE: By dose**

Withdrawals (Analysis-4): Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD	PL	1.32 (1.00,1.80)	1.31 (1.00,1.76)	0.01 (0.00,0.02)
HD		1.23 (0.83,1.84)	1.22 (0.84,1.80)	0.01 (0.00,0.02)
LD		0.94 (0.61,1.44)	0.94 (0.62,1.43)	0.00 (-0.01,0.01)
MTXSD		1.19 (0.98,1.47)	1.19 (0.98,1.45)	0.00 (0.00,0.01)
MTXHD		1.48 (1.08,2.04)	1.47 (1.08,1.99)	0.01 (0.00,0.03)
MTXLD		1.13 (0.69,1.87)	1.13 (0.70,1.83)	0.00 (-0.01,0.02)
HD	SD	0.93 (0.59,1.43)	0.94 (0.60,1.41)	0.00 (-0.02,0.01)
LD		0.71 (0.46,1.07)	0.71 (0.47,1.07)	-0.01 (-0.02,0.00)
MTXSD		0.90 (0.66,1.21)	0.90 (0.67,1.20)	0.00 (-0.01,0.01)
MTXHD		1.13 (0.74,1.65)	1.12 (0.75,1.62)	0.00 (-0.01,0.02)
MTXLD		0.86 (0.49,1.48)	0.86 (0.50,1.46)	0.00 (-0.02,0.01)
LD	HD	0.76 (0.45,1.30)	0.76 (0.46,1.29)	-0.01 (-0.02,0.01)
MTXSD		0.97 (0.63,1.48)	0.97 (0.64,1.46)	0.00 (-0.02,0.01)
MTXHD		1.20 (0.75,1.90)	1.20 (0.76,1.86)	0.01 (-0.01,0.02)
MTXLD		0.92 (0.50,1.70)	0.92 (0.51,1.68)	0.00 (-0.02,0.02)
MTXSD	LD	1.27 (0.81,1.98)	1.27 (0.82,1.95)	0.01 (-0.01,0.02)
MTXHD		1.58 (0.96,2.61)	1.56 (0.96,2.54)	0.01 (0.00,0.03)
MTXLD		1.22 (0.65,2.29)	1.21 (0.65,2.24)	0.00 (-0.01,0.02)
MTXHD	MTXSD	1.25 (0.89,1.72)	1.24 (0.90,1.69)	0.01 (0.00,0.02)
MTXLD		0.95 (0.58,1.56)	0.95 (0.59,1.53)	0.00 (-0.01,0.02)
MTXLD	MTXHD	0.77 (0.44,1.34)	0.77 (0.45,1.33)	-0.01 (-0.03,0.01)
Random-Effect Model	Residual Deviance	155.8 vs 158 data points		
	Deviance Information Criteria	764.003		

(Continued)

Fixed-Effect Model	Residual Deviance	179.6 vs 158 data points
--------------------	-------------------	--------------------------

	Deviance Information Criteria	771.113
--	-------------------------------	---------

Note:

Total Patients	24137
----------------	-------

Total Studies	62
---------------	----

2-arm	38
-------	----

3-arm	17
-------	----

4-arm	6
-------	---

7-arm	1
-------	---

### Appendix 30. Withdrawals due to AE: Main analysis

Withdrawals due to AEs (Analysis 1): Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX	PL	3.10 (1.12,5.73)	2.98 (1.12,5.25)	0.04 (0.00,0.09)
DMARD		1.22 (0.47,2.89)	1.22 (0.48,2.79)	0.00 (-0.01,0.04)
MTX + DMARD		6.88 (2.16,18.40)	6.11 (2.09,13.62)	0.11 (0.03,0.27)
SD ETN SC		2.60 (0.98,4.77)	2.51 (0.98,4.46)	0.03 (0.00,0.07)
SD ADA SC		1.96 (0.95,3.70)	1.92 (0.96,3.52)	0.02 (0.00,0.05)
SD TOCI IV		1.59 (0.61,3.68)	1.57 (0.61,3.50)	0.01 (-0.01,0.05)
SD CERTO SC		2.94 (0.87,16.78)	2.82 (0.87,13.25)	0.04 (0.00,0.22)
SD TOFA		0.27 (0.01,2.00)	0.28 (0.01,1.96)	-0.01 (-0.03,0.02)
SD TOC SC + PL IV		1.15 (0.35,3.23)	1.15 (0.36,3.10)	0.00 (-0.02,0.04)
SD RITUX IV		17.34 (1.88,260.80)	12.73 (1.84,42.45)	0.25 (0.02,0.83)
SD ANA		1.31 (0.38,5.06)	1.30 (0.39,4.69)	0.01 (-0.01,0.08)
SD ETN SC + MTX		2.58 (0.89,5.37)	2.50 (0.89,4.97)	0.03 (0.00,0.08)



(Continued)

SD ADA SC + MTX	4.52 (1.45,9.52)	4.21 (1.43,8.17)	0.07 (0.01,0.16)
SD INF IV + MTX	5.75 (1.89,13.05)	5.22 (1.84,10.50)	0.09 (0.02,0.21)
SD ABA IV + MTX	2.95 (0.96,6.66)	2.83 (0.96,6.01)	0.04 (0.00,0.10)
SD RITUX IV + MTX	3.88 (1.07,17.77)	3.66 (1.07,12.91)	0.06 (0.00,0.27)
SD CERTO SC + MTX	4.31 (1.33,10.05)	4.02 (1.32,8.45)	0.06 (0.01,0.15)
SD GOLI SC + MTX	3.75 (0.88,13.26)	3.55 (0.89,10.46)	0.05 (0.00,0.21)
SD TOFA PO + MTX	5.76 (1.76,13.89)	5.24 (1.73,11.07)	0.09 (0.02,0.21)
SD ABA SC + MTX	1.56 (0.47,4.05)	1.54 (0.48,3.83)	0.01 (-0.01,0.06)
SD TOCI IV + MTX	3.04 (0.88,9.39)	2.92 (0.88,8.03)	0.04 (0.00,0.15)
SD ETN SC + DMARD	1.28 (0.51,2.82)	1.27 (0.52,2.72)	0.01 (-0.01,0.03)
SD CERTO + DMARD	1.73 (0.50,5.05)	1.70 (0.51,4.70)	0.01 (-0.01,0.07)
SD ABA IV + DMARD	1.66 (0.47,4.64)	1.64 (0.47,4.33)	0.01 (-0.01,0.07)
SD ADA SC + DMARD	1.41 (0.30,6.24)	1.40 (0.30,5.66)	0.01 (-0.02,0.10)
SD TOCI SC + DMARD	2.99 (0.53,32.55)	2.87 (0.54,19.83)	0.04 (-0.01,0.39)
LD ETN SC	2.30 (0.84,4.86)	2.24 (0.84,4.54)	0.03 (0.00,0.08)
LD ADA SC	0.68 (0.23,1.93)	0.69 (0.23,1.89)	-0.01 (-0.02,0.02)
LD ANA	0.98 (0.29,3.69)	0.98 (0.30,3.49)	0.00 (-0.02,0.05)
LD TOCI IV	1.85 (0.40,6.07)	1.82 (0.40,5.51)	0.02 (-0.02,0.09)
LD RITUX IV + MTX	5.85 (1.49,28.36)	5.29 (1.47,17.52)	0.09 (0.01,0.37)
LD ABA IV + MTX	3.83 (0.87,12.23)	3.61 (0.88,10.03)	0.05 (0.00,0.19)
LD CERTO SC + MTX	3.49 (0.40,13.84)	3.31 (0.41,11.15)	0.05 (-0.01,0.21)
LD ETN SC + MTX	1.48 (0.32,6.59)	1.47 (0.33,5.93)	0.01 (-0.02,0.10)
LD TOCI IV + MTX	1.27 (0.24,5.29)	1.27 (0.24,4.88)	0.01 (-0.02,0.08)
HD TOCI IV	2.47 (0.88,5.24)	2.39 (0.88,4.86)	0.03 (0.00,0.08)
HD GOLI SC	1.62 (0.18,9.11)	1.59 (0.18,7.88)	0.01 (-0.02,0.14)
HD ADA SC	0.71 (0.23,1.91)	0.72 (0.23,1.87)	-0.01 (-0.02,0.02)
HD TOFA	2.08 (0.51,9.04)	2.03 (0.52,7.87)	0.02 (-0.01,0.13)
HD ANA	2.33 (0.82,7.82)	2.26 (0.82,6.89)	0.03 (0.00,0.12)

(Continued)

HD TOCI IV + MTX		3.17 (1.01,8.67)	3.02 (1.01,7.50)	0.04 (0.00,0.14)
HD GOLI SC + MTX		4.97 (1.35,18.57)	4.58 (1.34,13.50)	0.07 (0.01,0.27)
HD INF IV + MTX		5.25 (1.46,12.43)	4.81 (1.44,10.24)	0.08 (0.01,0.19)
HD TOFA PO + MTX		4.42 (1.38,11.69)	4.13 (1.36,9.66)	0.06 (0.01,0.18)
HD CERTO SC + MTX		4.83 (1.23,13.41)	4.46 (1.22,10.78)	0.07 (0.01,0.20)
HD TOCI IV + DMARD		2.40 (0.75,6.94)	2.33 (0.76,6.20)	0.03 (-0.01,0.11)
DMARD	MTX	0.41 (0.21,0.87)	0.43 (0.22,0.88)	-0.03 (-0.08,0.00)
MTX + DMARD		2.33 (1.13,5.01)	2.14 (1.12,4.13)	0.07 (0.01,0.20)
SD ETN SC		0.85 (0.59,1.28)	0.86 (0.61,1.26)	-0.01 (-0.03,0.01)
SD ADA SC		0.66 (0.31,1.63)	0.67 (0.33,1.59)	-0.02 (-0.07,0.02)
SD TOCI IV		0.55 (0.20,1.45)	0.56 (0.21,1.42)	-0.03 (-0.08,0.02)
SD CERTO SC		1.03 (0.24,6.88)	1.02 (0.26,5.58)	0.00 (-0.08,0.18)
SD TOFA		0.09 (0.00,0.86)	0.09 (0.00,0.86)	-0.05 (-0.11,0.00)
SD TOC SC + PL IV		0.38 (0.13,1.21)	0.40 (0.14,1.21)	-0.03 (-0.09,0.01)
SD RITUX IV		6.00 (0.81,64.99)	4.49 (0.82,15.08)	0.21 (-0.01,0.76)
SD ANA		0.46 (0.10,2.27)	0.48 (0.11,2.15)	-0.03 (-0.09,0.05)
SD ETN SC + MTX		0.84 (0.55,1.33)	0.85 (0.57,1.31)	-0.01 (-0.03,0.02)
SD ADA SC + MTX		1.47 (0.91,2.40)	1.43 (0.91,2.22)	0.02 (0.00,0.08)
SD INF IV + MTX		1.90 (1.14,3.12)	1.80 (1.13,2.78)	0.05 (0.01,0.13)
SD ABA IV + MTX		0.96 (0.52,1.64)	0.97 (0.53,1.59)	0.00 (-0.04,0.03)
SD RITUX IV + MTX		1.35 (0.51,4.96)	1.32 (0.52,3.70)	0.02 (-0.03,0.21)
SD CERTO SC + MTX		1.39 (0.74,2.52)	1.36 (0.76,2.34)	0.02 (-0.02,0.08)
SD GOLI SC + MTX		1.23 (0.46,3.62)	1.21 (0.48,3.11)	0.01 (-0.04,0.14)
SD TOFA PO + MTX		1.91 (1.02,3.27)	1.81 (1.02,2.90)	0.05 (0.00,0.14)
SD ABA SC + MTX		0.52 (0.26,1.05)	0.54 (0.27,1.05)	-0.03 (-0.07,0.00)
SD TOCI IV + MTX		1.04 (0.35,3.03)	1.04 (0.37,2.77)	0.00 (-0.05,0.09)
SD ETN SC + DMARD		0.44 (0.20,0.94)	0.45 (0.21,0.94)	-0.03 (-0.08,0.00)
SD CERTO + DMARD		0.59 (0.19,1.84)	0.60 (0.20,1.76)	-0.02 (-0.07,0.03)

(Continued)

SD ABA IV + DMARD		0.56 (0.21,1.51)	0.57 (0.22,1.47)	-0.02 (-0.07,0.02)
SD ADA SC + DMARD		0.50 (0.12,2.02)	0.51 (0.13,1.91)	-0.03 (-0.08,0.05)
SD TOCI SC + DMARD		1.03 (0.19,9.50)	1.03 (0.21,6.14)	0.00 (-0.07,0.33)
LD ETN SC		0.76 (0.46,1.31)	0.77 (0.47,1.29)	-0.01 (-0.04,0.01)
LD ADA SC		0.23 (0.07,0.89)	0.24 (0.07,0.89)	-0.04 (-0.10,0.00)
LD ANA		0.33 (0.08,1.68)	0.35 (0.09,1.62)	-0.04 (-0.09,0.02)
LD TOCI IV		0.64 (0.17,1.99)	0.65 (0.18,1.89)	-0.02 (-0.08,0.05)
LD RITUX IV + MTX		2.03 (0.76,7.40)	1.90 (0.77,5.06)	0.05 (-0.01,0.31)
LD ABA IV + MTX		1.28 (0.44,3.32)	1.26 (0.45,2.92)	0.01 (-0.04,0.12)
LD CERTO SC + MTX		1.13 (0.20,4.27)	1.12 (0.21,3.55)	0.01 (-0.05,0.15)
LD ETN SC + MTX		0.52 (0.13,1.80)	0.54 (0.14,1.70)	-0.02 (-0.08,0.05)
LD TOCI IV + MTX		0.45 (0.08,1.69)	0.47 (0.09,1.62)	-0.03 (-0.09,0.03)
HD TOCI IV		0.82 (0.44,1.51)	0.82 (0.45,1.48)	-0.01 (-0.05,0.02)
HD GOLI SC		0.54 (0.07,2.76)	0.56 (0.08,2.50)	-0.02 (-0.08,0.09)
HD ADA SC		0.25 (0.06,0.83)	0.26 (0.07,0.84)	-0.04 (-0.10,-0.01)
HD TOFA		0.72 (0.12,3.83)	0.73 (0.13,3.47)	-0.01 (-0.09,0.10)
HD ANA		0.83 (0.21,3.42)	0.84 (0.23,3.12)	-0.01 (-0.08,0.09)
HD TOCI IV + MTX		1.04 (0.46,2.56)	1.04 (0.48,2.36)	0.00 (-0.04,0.08)
HD GOLI SC + MTX		1.70 (0.65,4.99)	1.63 (0.66,3.95)	0.04 (-0.02,0.20)
HD INF IV + MTX		1.69 (0.87,3.17)	1.62 (0.87,2.82)	0.04 (-0.01,0.12)
HD TOFA PO + MTX		1.47 (0.80,2.70)	1.42 (0.81,2.44)	0.02 (-0.01,0.10)
HD CERTO SC + MTX		1.58 (0.63,3.62)	1.52 (0.64,3.14)	0.03 (-0.02,0.14)
HD TOCI IV + DMARD		0.81 (0.33,2.21)	0.82 (0.34,2.09)	-0.01 (-0.06,0.06)
MTX + DMARD	DMARD	5.53 (1.99,14.90)	4.92 (1.92,11.77)	0.10 (0.03,0.26)
SD ETN SC		2.08 (0.99,4.11)	2.02 (0.99,3.91)	0.02 (0.00,0.06)
SD ADA SC		1.60 (0.69,4.02)	1.58 (0.70,3.85)	0.01 (-0.01,0.05)
SD TOCI IV		1.31 (0.48,3.47)	1.30 (0.49,3.33)	0.01 (-0.02,0.04)
SD CERTO SC		2.52 (0.49,16.43)	2.43 (0.50,13.02)	0.03 (-0.03,0.21)

(Continued)

SD TOFA	0.21 (0.00,2.23)	0.21 (0.00,2.19)	-0.02 (-0.06,0.02)
SD TOC SC + PL IV	0.93 (0.29,2.88)	0.93 (0.30,2.79)	0.00 (-0.03,0.04)
SD RITUX IV	14.16 (1.88,174.10)	10.24 (1.84,40.02)	0.25 (0.02,0.82)
SD ANA	1.09 (0.24,5.35)	1.09 (0.25,5.00)	0.00 (-0.04,0.07)
SD ETN SC + MTX	2.05 (0.89,4.39)	2.00 (0.90,4.13)	0.02 (0.00,0.07)
SD ADA SC + MTX	3.55 (1.47,7.89)	3.33 (1.44,7.02)	0.06 (0.01,0.14)
SD INF IV + MTX	4.60 (1.83,10.64)	4.18 (1.77,9.10)	0.08 (0.02,0.19)
SD ABA IV + MTX	2.30 (0.87,5.54)	2.22 (0.88,5.14)	0.03 (0.00,0.09)
SD RITUX IV + MTX	3.21 (0.97,14.89)	3.03 (0.97,10.94)	0.05 (0.00,0.26)
SD CERTO SC + MTX	3.30 (1.40,8.27)	3.10 (1.38,7.41)	0.05 (0.01,0.14)
SD GOLI SC + MTX	2.96 (0.88,10.47)	2.81 (0.88,8.73)	0.05 (0.00,0.20)
SD TOFA PO + MTX	4.57 (1.69,10.85)	4.16 (1.65,9.21)	0.08 (0.02,0.20)
SD ABA SC + MTX	1.26 (0.47,3.42)	1.25 (0.48,3.29)	0.01 (-0.02,0.05)
SD TOCI IV + MTX	2.45 (0.71,7.82)	2.35 (0.72,6.95)	0.03 (-0.01,0.13)
SD ETN SC + DMARD	1.04 (0.56,1.99)	1.04 (0.57,1.96)	0.00 (-0.02,0.02)
SD CERTO + DMARD	1.42 (0.49,3.66)	1.41 (0.50,3.49)	0.01 (-0.02,0.06)
SD ABA IV + DMARD	1.34 (0.69,2.64)	1.33 (0.69,2.54)	0.01 (-0.01,0.05)
SD ADA SC + DMARD	1.18 (0.32,3.95)	1.17 (0.33,3.66)	0.00 (-0.02,0.08)
SD TOCI SC + DMARD	2.45 (0.60,18.52)	2.36 (0.60,11.56)	0.03 (-0.01,0.36)
LD ETN SC	1.83 (0.80,4.24)	1.79 (0.80,4.01)	0.02 (-0.01,0.06)
LD ADA SC	0.56 (0.14,2.27)	0.57 (0.14,2.22)	-0.01 (-0.05,0.02)
LD ANA	0.82 (0.20,3.74)	0.82 (0.20,3.57)	0.00 (-0.04,0.05)
LD TOCI IV	1.50 (0.36,5.38)	1.48 (0.37,4.95)	0.01 (-0.03,0.08)
LD RITUX IV + MTX	4.94 (1.42,22.86)	4.43 (1.40,15.30)	0.09 (0.01,0.36)
LD ABA IV + MTX	3.08 (0.78,10.12)	2.91 (0.78,8.63)	0.05 (-0.01,0.17)
LD CERTO SC + MTX	2.78 (0.44,11.03)	2.63 (0.45,9.07)	0.04 (-0.02,0.20)
LD ETN SC + MTX	1.26 (0.28,4.65)	1.25 (0.28,4.29)	0.01 (-0.03,0.09)
LD TOCI IV + MTX	1.09 (0.19,4.45)	1.09 (0.19,4.11)	0.00 (-0.03,0.07)

(Continued)

HD TOCI IV		1.99 (0.93,3.88)	1.93 (0.93,3.70)	0.02 (0.00,0.06)
HD GOLI SC		1.35 (0.15,8.10)	1.34 (0.15,7.20)	0.01 (-0.04,0.14)
HD ADA SC		0.59 (0.14,2.08)	0.60 (0.15,2.04)	-0.01 (-0.04,0.02)
HD TOFA		1.73 (0.26,9.88)	1.70 (0.27,8.54)	0.02 (-0.04,0.13)
HD ANA		1.97 (0.49,8.48)	1.92 (0.50,7.59)	0.02 (-0.02,0.12)
HD TOCI IV + MTX		2.58 (0.94,6.70)	2.47 (0.95,6.01)	0.04 (0.00,0.12)
HD GOLI SC + MTX		4.10 (1.18,15.88)	3.78 (1.17,12.18)	0.07 (0.01,0.25)
HD INF IV + MTX		4.14 (1.45,9.85)	3.80 (1.43,8.51)	0.07 (0.01,0.18)
HD TOFA PO + MTX		3.54 (1.33,8.88)	3.30 (1.31,7.67)	0.06 (0.01,0.16)
HD CERTO SC + MTX		3.85 (1.19,10.54)	3.55 (1.18,8.78)	0.06 (0.00,0.19)
HD TOCI IV + DMARD		1.95 (1.05,3.79)	1.90 (1.05,3.55)	0.02 (0.00,0.08)
SD ETN SC	MTX + DMARD	0.37 (0.17,0.79)	0.40 (0.21,0.81)	-0.08 (-0.21,-0.01)
SD ADA SC		0.28 (0.10,0.88)	0.31 (0.13,0.89)	-0.09 (-0.24,-0.01)
SD TOCI IV		0.24 (0.07,0.80)	0.26 (0.09,0.81)	-0.09 (-0.26,-0.01)
SD CERTO SC		0.45 (0.09,3.17)	0.49 (0.11,2.70)	-0.06 (-0.25,0.13)
SD TOFA		0.04 (0.00,0.38)	0.05 (0.00,0.40)	-0.12 (-0.29,-0.03)
SD TOC SC + PL IV		0.17 (0.04,0.68)	0.19 (0.05,0.69)	-0.10 (-0.27,-0.02)
SD RITUX IV		2.57 (0.28,29.12)	2.11 (0.31,7.78)	0.14 (-0.12,0.67)
SD ANA		0.20 (0.03,1.19)	0.22 (0.04,1.18)	-0.10 (-0.27,0.01)
SD ETN SC + MTX		0.36 (0.17,0.74)	0.40 (0.21,0.76)	-0.08 (-0.21,-0.01)
SD ADA SC + MTX		0.63 (0.26,1.50)	0.66 (0.31,1.44)	-0.04 (-0.17,0.03)
SD INF IV + MTX		0.83 (0.41,1.53)	0.85 (0.46,1.46)	-0.02 (-0.12,0.04)
SD ABA IV + MTX		0.41 (0.15,1.01)	0.45 (0.18,1.01)	-0.07 (-0.22,0.00)
SD RITUX IV + MTX		0.58 (0.16,2.42)	0.62 (0.19,2.05)	-0.04 (-0.19,0.13)
SD CERTO SC + MTX		0.59 (0.24,1.51)	0.63 (0.28,1.46)	-0.05 (-0.18,0.04)
SD GOLI SC + MTX		0.54 (0.16,2.03)	0.57 (0.19,1.86)	-0.05 (-0.19,0.08)
SD TOFA PO + MTX		0.83 (0.30,2.06)	0.85 (0.36,1.90)	-0.02 (-0.16,0.07)
SD ABA SC + MTX		0.22 (0.08,0.61)	0.25 (0.09,0.63)	-0.09 (-0.25,-0.02)

(Continued)

SD TOCI IV + MTX	0.44 (0.12,1.66)	0.48 (0.15,1.58)	-0.06 (-0.22,0.05)
SD ETN SC + DMARD	0.19 (0.06,0.52)	0.21 (0.08,0.54)	-0.10 (-0.26,-0.02)
SD CERTO + DMARD	0.26 (0.07,0.96)	0.29 (0.08,0.96)	-0.09 (-0.25,0.00)
SD ABA IV + DMARD	0.24 (0.07,0.81)	0.27 (0.09,0.82)	-0.09 (-0.25,-0.01)
SD ADA SC + DMARD	0.21 (0.04,1.02)	0.24 (0.05,1.01)	-0.09 (-0.25,0.00)
SD TOCI SC + DMARD	0.44 (0.08,5.05)	0.47 (0.09,3.48)	-0.06 (-0.23,0.26)
LD ETN SC	0.33 (0.14,0.78)	0.36 (0.17,0.80)	-0.08 (-0.22,-0.01)
LD ADA SC	0.10 (0.02,0.43)	0.12 (0.03,0.45)	-0.11 (-0.27,-0.03)
LD ANA	0.14 (0.03,0.87)	0.16 (0.04,0.88)	-0.10 (-0.27,-0.01)
LD TOCI IV	0.27 (0.05,1.08)	0.30 (0.07,1.08)	-0.09 (-0.26,0.01)
LD RITUX IV + MTX	0.88 (0.25,3.66)	0.90 (0.29,2.76)	-0.01 (-0.16,0.22)
LD ABA IV + MTX	0.54 (0.16,1.87)	0.58 (0.18,1.73)	-0.05 (-0.19,0.06)
LD CERTO SC + MTX	0.48 (0.07,2.19)	0.52 (0.08,1.97)	-0.06 (-0.21,0.09)
LD ETN SC + MTX	0.22 (0.05,0.97)	0.25 (0.06,0.98)	-0.09 (-0.25,0.00)
LD TOCI IV + MTX	0.19 (0.03,0.80)	0.22 (0.04,0.82)	-0.09 (-0.26,-0.01)
HD TOCI IV	0.35 (0.13,0.94)	0.39 (0.17,0.95)	-0.08 (-0.23,0.00)
HD GOLI SC	0.24 (0.02,1.37)	0.27 (0.03,1.32)	-0.09 (-0.25,0.03)
HD ADA SC	0.10 (0.02,0.44)	0.12 (0.03,0.46)	-0.11 (-0.28,-0.03)
HD TOFA	0.31 (0.05,2.02)	0.34 (0.06,1.89)	-0.08 (-0.26,0.06)
HD ANA	0.35 (0.08,1.77)	0.38 (0.10,1.67)	-0.08 (-0.25,0.05)
HD TOCI IV + MTX	0.45 (0.15,1.46)	0.49 (0.18,1.40)	-0.06 (-0.21,0.03)
HD GOLI SC + MTX	0.73 (0.20,2.55)	0.76 (0.24,2.22)	-0.03 (-0.17,0.12)
HD INF IV + MTX	0.73 (0.30,1.70)	0.76 (0.34,1.60)	-0.03 (-0.15,0.05)
HD TOFA PO + MTX	0.63 (0.24,1.67)	0.66 (0.29,1.59)	-0.04 (-0.18,0.05)
HD CERTO SC + MTX	0.66 (0.20,2.10)	0.70 (0.24,1.91)	-0.04 (-0.17,0.08)
HD TOCI IV + DMARD	0.35 (0.11,1.20)	0.39 (0.13,1.18)	-0.07 (-0.24,0.01)
SD ADA SC      SD ETN SC	0.76 (0.37,1.84)	0.77 (0.39,1.79)	-0.01 (-0.05,0.03)
SD TOCI IV	0.64 (0.24,1.60)	0.66 (0.26,1.57)	-0.02 (-0.06,0.02)

(Continued)

SD CERTO SC	1.20 (0.29,7.82)	1.18 (0.31,6.28)	0.01 (-0.06,0.19)
SD TOFA	0.10 (0.00,0.98)	0.11 (0.00,0.98)	-0.04 (-0.09,0.00)
SD TOC SC + PL IV	0.45 (0.15,1.39)	0.47 (0.16,1.37)	-0.03 (-0.07,0.01)
SD RITUX IV	7.02 (0.94,80.12)	5.23 (0.94,17.44)	0.22 (0.00,0.78)
SD ANA	0.54 (0.12,2.57)	0.55 (0.13,2.45)	-0.02 (-0.08,0.05)
SD ETN SC + MTX	0.99 (0.63,1.51)	0.99 (0.64,1.48)	0.00 (-0.02,0.03)
SD ADA SC + MTX	1.72 (0.92,3.17)	1.66 (0.93,2.87)	0.03 (0.00,0.10)
SD INF IV + MTX	2.25 (1.21,4.07)	2.10 (1.20,3.56)	0.06 (0.01,0.15)
SD ABA IV + MTX	1.14 (0.55,2.13)	1.13 (0.56,2.02)	0.01 (-0.03,0.05)
SD RITUX IV + MTX	1.56 (0.57,6.29)	1.51 (0.58,4.73)	0.03 (-0.02,0.22)
SD CERTO SC + MTX	1.62 (0.80,3.28)	1.57 (0.81,2.98)	0.03 (-0.01,0.10)
SD GOLI SC + MTX	1.45 (0.47,4.57)	1.42 (0.49,3.88)	0.02 (-0.03,0.16)
SD TOFA PO + MTX	2.22 (1.08,4.41)	2.08 (1.07,3.77)	0.05 (0.00,0.16)
SD ABA SC + MTX	0.61 (0.27,1.36)	0.62 (0.28,1.34)	-0.02 (-0.06,0.02)
SD TOCI IV + MTX	1.20 (0.38,3.68)	1.19 (0.40,3.30)	0.01 (-0.04,0.11)
SD ETN SC + DMARD	0.51 (0.24,1.04)	0.52 (0.26,1.04)	-0.02 (-0.06,0.00)
SD CERTO + DMARD	0.69 (0.21,2.15)	0.70 (0.23,2.06)	-0.01 (-0.06,0.04)
SD ABA IV + DMARD	0.65 (0.25,1.78)	0.67 (0.26,1.72)	-0.02 (-0.06,0.03)
SD ADA SC + DMARD	0.57 (0.13,2.40)	0.59 (0.14,2.25)	-0.02 (-0.06,0.06)
SD TOCI SC + DMARD	1.19 (0.24,11.56)	1.18 (0.25,7.13)	0.01 (-0.05,0.34)
LD ETN SC	0.90 (0.54,1.49)	0.90 (0.55,1.46)	0.00 (-0.03,0.02)
LD ADA SC	0.28 (0.07,1.01)	0.29 (0.08,1.01)	-0.04 (-0.08,0.00)
LD ANA	0.39 (0.10,1.84)	0.41 (0.11,1.78)	-0.03 (-0.08,0.03)
LD TOCI IV	0.74 (0.19,2.39)	0.75 (0.20,2.25)	-0.01 (-0.06,0.06)
LD RITUX IV + MTX	2.37 (0.84,9.50)	2.20 (0.85,6.26)	0.06 (-0.01,0.32)
LD ABA IV + MTX	1.49 (0.45,4.26)	1.45 (0.46,3.67)	0.02 (-0.03,0.14)
LD CERTO SC + MTX	1.32 (0.23,5.22)	1.30 (0.24,4.36)	0.02 (-0.04,0.17)
LD ETN SC + MTX	0.62 (0.15,2.09)	0.63 (0.16,1.97)	-0.02 (-0.06,0.05)

(Continued)

LD TOCI IV + MTX		0.53 (0.10,2.17)	0.54 (0.10,2.05)	-0.02 (-0.07,0.05)
HD TOCI IV		0.96 (0.48,1.84)	0.96 (0.50,1.78)	0.00 (-0.04,0.03)
HD GOLI SC		0.64 (0.08,3.42)	0.65 (0.08,3.06)	-0.02 (-0.07,0.10)
HD ADA SC		0.29 (0.08,0.98)	0.30 (0.08,0.98)	-0.04 (-0.08,0.00)
HD TOFA		0.84 (0.14,4.49)	0.85 (0.15,4.02)	-0.01 (-0.08,0.11)
HD ANA		0.98 (0.26,3.87)	0.98 (0.27,3.51)	0.00 (-0.06,0.09)
HD TOCI IV + MTX		1.24 (0.52,3.08)	1.23 (0.54,2.82)	0.01 (-0.03,0.09)
HD GOLI SC + MTX		2.01 (0.69,6.29)	1.91 (0.70,4.95)	0.04 (-0.02,0.22)
HD INF IV + MTX		1.99 (0.92,3.94)	1.88 (0.92,3.46)	0.05 (0.00,0.14)
HD TOFA PO + MTX		1.71 (0.83,3.55)	1.65 (0.84,3.14)	0.03 (-0.01,0.13)
HD CERTO SC + MTX		1.86 (0.68,4.63)	1.77 (0.69,3.98)	0.04 (-0.02,0.15)
HD TOCI IV + DMARD		0.96 (0.37,2.54)	0.96 (0.39,2.38)	0.00 (-0.04,0.07)
SD TOCI IV	SD ADA SC	0.81 (0.37,1.75)	0.82 (0.38,1.70)	-0.01 (-0.04,0.03)
SD CERTO SC		1.52 (0.37,9.81)	1.49 (0.38,7.90)	0.02 (-0.04,0.20)
SD TOFA		0.14 (0.00,1.12)	0.14 (0.00,1.11)	-0.03 (-0.07,0.00)
SD TOC SC + PL IV		0.58 (0.21,1.56)	0.59 (0.21,1.54)	-0.02 (-0.05,0.02)
SD RITUX IV		9.13 (1.02,124.00)	6.71 (1.01,23.65)	0.23 (0.00,0.80)
SD ANA		0.67 (0.18,3.07)	0.68 (0.19,2.90)	-0.01 (-0.05,0.06)
SD ETN SC + MTX		1.28 (0.48,3.00)	1.26 (0.49,2.82)	0.01 (-0.03,0.06)
SD ADA SC + MTX		2.19 (0.80,5.46)	2.09 (0.81,4.80)	0.04 (-0.01,0.13)
SD INF IV + MTX		2.89 (1.04,7.38)	2.68 (1.04,6.12)	0.07 (0.00,0.18)
SD ABA IV + MTX		1.46 (0.49,3.64)	1.43 (0.51,3.38)	0.02 (-0.03,0.08)
SD RITUX IV + MTX		2.04 (0.54,10.36)	1.95 (0.55,7.84)	0.04 (-0.02,0.25)
SD CERTO SC + MTX		2.14 (0.71,5.54)	2.04 (0.72,4.87)	0.04 (-0.01,0.13)
SD GOLI SC + MTX		1.90 (0.47,6.64)	1.83 (0.48,5.52)	0.03 (-0.03,0.18)
SD TOFA PO + MTX		2.87 (0.97,7.71)	2.65 (0.98,6.36)	0.07 (0.00,0.19)
SD ABA SC + MTX		0.78 (0.25,2.25)	0.79 (0.26,2.17)	-0.01 (-0.05,0.04)
SD TOCI IV + MTX		1.54 (0.44,4.96)	1.51 (0.45,4.36)	0.02 (-0.03,0.12)



(Continued)

SD ETN SC + DMARD	0.65 (0.30,1.40)	0.66 (0.31,1.39)	-0.01 (-0.04,0.01)
SD CERTO + DMARD	0.89 (0.24,2.86)	0.89 (0.25,2.70)	0.00 (-0.05,0.05)
SD ABA IV + DMARD	0.86 (0.27,2.42)	0.86 (0.28,2.30)	-0.01 (-0.04,0.05)
SD ADA SC + DMARD	0.74 (0.16,3.18)	0.75 (0.17,2.94)	-0.01 (-0.05,0.07)
SD TOCI SC + DMARD	1.54 (0.29,15.81)	1.50 (0.29,9.51)	0.02 (-0.04,0.36)
LD ETN SC	1.16 (0.44,2.74)	1.16 (0.46,2.59)	0.01 (-0.03,0.05)
LD ADA SC	0.35 (0.11,1.01)	0.36 (0.12,1.01)	-0.02 (-0.06,0.00)
LD ANA	0.49 (0.14,2.28)	0.50 (0.15,2.19)	-0.02 (-0.05,0.04)
LD TOCI IV	0.96 (0.21,3.13)	0.96 (0.22,2.90)	0.00 (-0.05,0.07)
LD RITUX IV + MTX	3.08 (0.78,16.12)	2.84 (0.79,10.43)	0.07 (-0.01,0.35)
LD ABA IV + MTX	1.92 (0.46,6.61)	1.85 (0.48,5.54)	0.03 (-0.03,0.16)
LD CERTO SC + MTX	1.71 (0.25,8.18)	1.66 (0.26,6.54)	0.03 (-0.04,0.19)
LD ETN SC + MTX	0.78 (0.16,3.34)	0.79 (0.17,3.07)	-0.01 (-0.05,0.08)
LD TOCI IV + MTX	0.68 (0.13,2.88)	0.69 (0.14,2.69)	-0.01 (-0.05,0.06)
HD TOCI IV	1.26 (0.47,2.57)	1.24 (0.48,2.44)	0.01 (-0.03,0.05)
HD GOLI SC	0.80 (0.09,5.09)	0.80 (0.10,4.48)	-0.01 (-0.05,0.12)
HD ADA SC	0.37 (0.12,0.98)	0.38 (0.12,0.99)	-0.02 (-0.05,0.00)
HD TOFA	1.07 (0.19,5.71)	1.06 (0.20,5.05)	0.00 (-0.05,0.12)
HD ANA	1.20 (0.37,4.77)	1.19 (0.38,4.27)	0.01 (-0.04,0.10)
HD TOCI IV + MTX	1.63 (0.56,4.30)	1.59 (0.58,3.85)	0.02 (-0.02,0.11)
HD GOLI SC + MTX	2.60 (0.71,9.46)	2.43 (0.72,7.29)	0.06 (-0.01,0.24)
HD INF IV + MTX	2.64 (0.81,6.77)	2.47 (0.81,5.71)	0.06 (-0.01,0.17)
HD TOFA PO + MTX	2.21 (0.76,6.31)	2.10 (0.77,5.40)	0.04 (-0.01,0.15)
HD CERTO SC + MTX	2.45 (0.65,7.02)	2.31 (0.66,5.90)	0.05 (-0.02,0.17)
HD TOCI IV + DMARD	1.24 (0.40,3.52)	1.23 (0.41,3.24)	0.01 (-0.03,0.08)
SD CERTO SC      SD TOCI IV	1.94 (0.39,12.65)	1.88 (0.41,10.21)	0.03 (-0.04,0.21)
SD TOFA	0.16 (0.00,1.65)	0.17 (0.00,1.62)	-0.03 (-0.07,0.01)
SD TOC SC + PL IV	0.72 (0.37,1.37)	0.73 (0.37,1.35)	-0.01 (-0.03,0.01)

(Continued)

SD RITUX IV	11.08 (1.26,174.80)	8.04 (1.25,33.84)	0.24 (0.01,0.82)
SD ANA	0.83 (0.21,4.13)	0.84 (0.22,3.87)	-0.01 (-0.05,0.07)
SD ETN SC + MTX	1.52 (0.56,4.60)	1.49 (0.57,4.29)	0.02 (-0.02,0.07)
SD ADA SC + MTX	2.68 (0.92,7.69)	2.53 (0.93,6.71)	0.05 (0.00,0.14)
SD INF IV + MTX	3.45 (1.19,10.63)	3.17 (1.18,9.08)	0.07 (0.01,0.19)
SD ABA IV + MTX	1.78 (0.56,5.40)	1.73 (0.57,4.95)	0.02 (-0.02,0.09)
SD RITUX IV + MTX	2.47 (0.65,14.93)	2.34 (0.66,10.94)	0.04 (-0.02,0.26)
SD CERTO SC + MTX	2.58 (0.81,7.94)	2.44 (0.81,6.99)	0.05 (-0.01,0.14)
SD GOLI SC + MTX	2.31 (0.57,9.13)	2.21 (0.58,7.72)	0.04 (-0.02,0.20)
SD TOFA PO + MTX	3.45 (1.12,11.10)	3.17 (1.11,9.16)	0.07 (0.01,0.20)
SD ABA SC + MTX	0.95 (0.29,3.09)	0.95 (0.30,2.96)	0.00 (-0.04,0.05)
SD TOCI IV + MTX	1.92 (0.60,5.94)	1.86 (0.61,5.30)	0.03 (-0.02,0.12)
SD ETN SC + DMARD	0.79 (0.32,2.13)	0.80 (0.34,2.08)	-0.01 (-0.04,0.02)
SD CERTO + DMARD	1.10 (0.30,3.98)	1.10 (0.31,3.74)	0.00 (-0.04,0.06)
SD ABA IV + DMARD	1.06 (0.32,3.38)	1.06 (0.33,3.24)	0.00 (-0.04,0.05)
SD ADA SC + DMARD	0.91 (0.19,4.20)	0.91 (0.20,3.87)	0.00 (-0.04,0.08)
SD TOCI SC + DMARD	1.91 (0.34,21.36)	1.85 (0.36,12.70)	0.03 (-0.03,0.37)
LD ETN SC	1.41 (0.51,4.14)	1.39 (0.52,3.90)	0.01 (-0.03,0.06)
LD ADA SC	0.44 (0.10,1.65)	0.44 (0.11,1.63)	-0.02 (-0.06,0.01)
LD ANA	0.61 (0.15,3.07)	0.62 (0.16,2.95)	-0.01 (-0.05,0.04)
LD TOCI IV	1.14 (0.28,3.90)	1.13 (0.29,3.63)	0.00 (-0.04,0.07)
LD RITUX IV + MTX	3.74 (0.87,23.98)	3.40 (0.87,15.48)	0.08 (-0.01,0.36)
LD ABA IV + MTX	2.32 (0.60,9.07)	2.21 (0.61,7.69)	0.04 (-0.02,0.17)
LD CERTO SC + MTX	2.11 (0.32,10.24)	2.02 (0.33,8.47)	0.03 (-0.03,0.19)
LD ETN SC + MTX	0.97 (0.18,4.42)	0.97 (0.19,4.00)	0.00 (-0.05,0.09)
LD TOCI IV + MTX	0.82 (0.17,3.29)	0.82 (0.17,3.09)	-0.01 (-0.04,0.06)
HD TOCI IV	1.51 (0.62,3.61)	1.48 (0.63,3.42)	0.02 (-0.02,0.06)
HD GOLI SC	1.01 (0.10,6.70)	1.01 (0.11,5.94)	0.00 (-0.05,0.13)

(Continued)

HD ADA SC		0.46 (0.11,1.57)	0.47 (0.12,1.55)	-0.02 (-0.06,0.01)
HD TOFA		1.34 (0.23,7.74)	1.32 (0.25,6.81)	0.01 (-0.05,0.12)
HD ANA		1.46 (0.40,6.43)	1.44 (0.41,5.82)	0.01 (-0.03,0.11)
HD TOCI IV + MTX		1.98 (0.69,5.77)	1.92 (0.70,5.14)	0.03 (-0.01,0.12)
HD GOLI SC + MTX		3.26 (0.80,11.93)	3.02 (0.81,9.60)	0.06 (-0.01,0.25)
HD INF IV + MTX		3.15 (0.93,9.83)	2.93 (0.93,8.35)	0.06 (0.00,0.18)
HD TOFA PO + MTX		2.65 (0.89,9.57)	2.50 (0.90,8.07)	0.05 (-0.01,0.16)
HD CERTO SC + MTX		2.87 (0.77,9.83)	2.68 (0.78,8.26)	0.06 (-0.01,0.19)
HD TOCI IV + DMARD		1.52 (0.48,4.67)	1.49 (0.49,4.29)	0.02 (-0.03,0.09)
SD TOFA	SD CERTO SC	0.08 (0.00,0.98)	0.08 (0.00,0.98)	-0.05 (-0.22,0.00)
SD TOC SC + PL IV		0.36 (0.05,2.04)	0.38 (0.06,1.98)	-0.04 (-0.21,0.03)
SD RITUX IV		5.72 (0.33,138.30)	4.19 (0.38,26.23)	0.20 (-0.10,0.81)
SD ANA		0.43 (0.06,2.58)	0.45 (0.08,2.47)	-0.03 (-0.20,0.04)
SD ETN SC + MTX		0.83 (0.12,3.49)	0.84 (0.14,3.31)	-0.01 (-0.19,0.06)
SD ADA SC + MTX		1.41 (0.19,6.58)	1.38 (0.22,5.73)	0.02 (-0.17,0.14)
SD INF IV + MTX		1.81 (0.27,8.78)	1.72 (0.32,7.27)	0.04 (-0.14,0.19)
SD ABA IV + MTX		0.92 (0.13,3.90)	0.92 (0.16,3.62)	0.00 (-0.18,0.08)
SD RITUX IV + MTX		1.23 (0.15,9.69)	1.21 (0.19,7.46)	0.01 (-0.17,0.25)
SD CERTO SC + MTX		1.33 (0.20,5.69)	1.30 (0.23,5.05)	0.02 (-0.16,0.12)
SD GOLI SC + MTX		1.16 (0.15,8.47)	1.15 (0.18,6.94)	0.01 (-0.17,0.19)
SD TOFA PO + MTX		1.85 (0.25,8.74)	1.75 (0.30,7.31)	0.04 (-0.15,0.18)
SD ABA SC + MTX		0.50 (0.07,2.26)	0.51 (0.08,2.18)	-0.03 (-0.20,0.03)
SD TOCI IV + MTX		0.99 (0.14,5.92)	0.99 (0.16,5.27)	0.00 (-0.17,0.12)
SD ETN SC + DMARD		0.42 (0.06,1.98)	0.43 (0.08,1.94)	-0.03 (-0.21,0.02)
SD CERTO + DMARD		0.58 (0.08,2.97)	0.59 (0.09,2.81)	-0.02 (-0.20,0.05)
SD ABA IV + DMARD		0.53 (0.07,3.06)	0.55 (0.09,2.90)	-0.03 (-0.20,0.05)
SD ADA SC + DMARD		0.46 (0.05,3.98)	0.48 (0.06,3.65)	-0.03 (-0.20,0.08)
SD TOCI SC + DMARD		0.98 (0.10,15.14)	0.98 (0.11,10.46)	0.00 (-0.18,0.33)

(Continued)

LD ETN SC		0.74 (0.11,3.25)	0.75 (0.14,3.08)	-0.01 (-0.20,0.06)
LD ADA SC		0.22 (0.03,1.25)	0.23 (0.04,1.25)	-0.05 (-0.22,0.01)
LD ANA		0.32 (0.04,1.89)	0.34 (0.05,1.85)	-0.04 (-0.21,0.03)
LD TOCI IV		0.57 (0.07,3.46)	0.59 (0.09,3.23)	-0.02 (-0.20,0.07)
LD RITUX IV + MTX		1.89 (0.26,15.75)	1.78 (0.30,10.34)	0.05 (-0.14,0.35)
LD ABA IV + MTX		1.20 (0.15,6.68)	1.18 (0.17,5.77)	0.01 (-0.17,0.15)
LD CERTO SC + MTX		1.06 (0.09,6.73)	1.06 (0.10,5.65)	0.00 (-0.18,0.17)
LD ETN SC + MTX		0.48 (0.06,3.74)	0.50 (0.07,3.45)	-0.03 (-0.20,0.08)
LD TOCI IV + MTX		0.45 (0.04,3.12)	0.47 (0.04,2.93)	-0.03 (-0.21,0.06)
HD TOCI IV		0.79 (0.12,3.45)	0.80 (0.14,3.26)	-0.01 (-0.19,0.06)
HD GOLI SC		0.52 (0.04,4.22)	0.54 (0.05,3.81)	-0.02 (-0.20,0.10)
HD ADA SC		0.23 (0.03,1.19)	0.24 (0.03,1.18)	-0.04 (-0.22,0.00)
HD TOFA		0.67 (0.09,5.10)	0.68 (0.11,4.58)	-0.02 (-0.19,0.11)
HD ANA		0.76 (0.11,4.16)	0.77 (0.14,3.80)	-0.01 (-0.19,0.09)
HD TOCI IV + MTX		1.02 (0.14,6.37)	1.02 (0.17,5.62)	0.00 (-0.19,0.12)
HD GOLI SC + MTX		1.58 (0.21,10.64)	1.52 (0.25,8.37)	0.03 (-0.15,0.24)
HD INF IV + MTX		1.65 (0.21,8.03)	1.58 (0.26,6.70)	0.03 (-0.16,0.17)
HD TOFA PO + MTX		1.41 (0.20,7.04)	1.38 (0.24,6.02)	0.02 (-0.16,0.15)
HD CERTO SC + MTX		1.51 (0.19,7.72)	1.46 (0.22,6.53)	0.03 (-0.16,0.17)
HD TOCI IV + DMARD		0.80 (0.10,4.54)	0.81 (0.13,4.14)	-0.01 (-0.19,0.09)
SD TOC SC + PL IV	SD TOFA	4.37 (0.39,237.10)	4.27 (0.40,230.40)	0.02 (-0.02,0.06)
SD RITUX IV		90.29 (2.36,2738.00)	51.22 (2.27,1449.00)	0.27 (0.02,0.84)
SD ANA		5.12 (0.51,202.90)	4.96 (0.52,188.50)	0.02 (-0.01,0.09)
SD ETN SC + MTX		9.32 (0.97,538.50)	8.84 (0.97,503.00)	0.04 (0.00,0.10)
SD ADA SC + MTX		17.06 (1.57,1008.00)	15.37 (1.54,889.20)	0.08 (0.02,0.17)
SD INF IV + MTX		21.14 (2.16,1164.00)	18.66 (2.07,1032.00)	0.10 (0.03,0.22)
SD ABA IV + MTX		11.22 (1.08,671.50)	10.51 (1.07,616.10)	0.05 (0.00,0.12)
SD RITUX IV + MTX		16.10 (1.40,919.80)	14.67 (1.38,803.50)	0.07 (0.01,0.28)

(Continued)

SD CERTO SC + MTX	15.61 (1.50,871.80)	14.25 (1.46,783.10)	0.07 (0.01,0.17)
SD GOLI SC + MTX	12.69 (1.27,961.90)	11.72 (1.26,881.00)	0.06 (0.01,0.23)
SD TOFA PO + MTX	21.37 (2.07,1357.00)	18.89 (1.99,1173.00)	0.10 (0.02,0.23)
SD ABA SC + MTX	6.23 (0.56,355.00)	6.02 (0.57,341.50)	0.02 (-0.01,0.07)
SD TOCI IV + MTX	12.02 (0.91,425.90)	11.14 (0.91,397.10)	0.05 (0.00,0.16)
SD ETN SC + DMARD	5.06 (0.48,222.60)	4.94 (0.49,214.90)	0.02 (-0.02,0.05)
SD CERTO + DMARD	6.71 (0.63,291.80)	6.47 (0.64,278.50)	0.03 (-0.01,0.09)
SD ABA IV + DMARD	6.65 (0.56,390.70)	6.40 (0.57,369.70)	0.03 (-0.01,0.09)
SD ADA SC + DMARD	5.92 (0.39,309.10)	5.74 (0.39,294.20)	0.02 (-0.02,0.11)
SD TOCI SC + DMARD	13.23 (0.72,691.70)	12.18 (0.73,511.00)	0.05 (-0.01,0.40)
LD ETN SC	8.60 (0.88,483.30)	8.20 (0.89,457.00)	0.04 (0.00,0.09)
LD ADA SC	2.70 (0.23,151.70)	2.67 (0.24,148.30)	0.01 (-0.03,0.04)
LD ANA	3.58 (0.38,160.00)	3.52 (0.39,156.70)	0.01 (-0.02,0.06)
LD TOCI IV	6.87 (0.54,406.80)	6.62 (0.55,385.60)	0.03 (-0.01,0.11)
LD RITUX IV + MTX	25.15 (1.89,1318.00)	21.63 (1.84,1104.00)	0.11 (0.02,0.38)
LD ABA IV + MTX	15.16 (1.01,766.30)	13.85 (1.01,685.00)	0.07 (0.00,0.20)
LD CERTO SC + MTX	13.36 (0.59,1200.00)	12.17 (0.60,1027.00)	0.06 (-0.01,0.22)
LD ETN SC + MTX	6.03 (0.42,326.80)	5.84 (0.43,313.40)	0.02 (-0.02,0.12)
LD TOCI IV + MTX	4.95 (0.31,384.40)	4.82 (0.32,362.00)	0.02 (-0.02,0.10)
HD TOCI IV	9.13 (0.93,494.60)	8.68 (0.93,464.70)	0.04 (0.00,0.10)
HD GOLI SC	5.91 (0.32,670.90)	5.69 (0.32,609.00)	0.02 (-0.02,0.16)
HD ADA SC	2.64 (0.25,181.10)	2.61 (0.26,175.70)	0.01 (-0.03,0.04)
HD TOFA	7.51 (1.09,383.70)	7.10 (1.08,364.20)	0.03 (0.00,0.14)
HD ANA	8.79 (0.87,362.20)	8.31 (0.87,334.70)	0.04 (0.00,0.13)
HD TOCI IV + MTX	12.29 (1.07,538.20)	11.41 (1.07,498.40)	0.05 (0.00,0.16)
HD GOLI SC + MTX	18.81 (1.79,1361.00)	16.75 (1.74,1194.00)	0.09 (0.02,0.29)
HD INF IV + MTX	19.27 (1.70,1144.00)	17.26 (1.66,1022.00)	0.09 (0.02,0.21)
HD TOFA PO + MTX	16.49 (1.52,1010.00)	15.01 (1.49,906.60)	0.08 (0.01,0.19)

(Continued)

HD CERTO SC + MTX		17.97 (1.58,959.70)	16.16 (1.55,853.10)	0.08 (0.01,0.22)
HD TOCI IV + DMARD		9.42 (0.82,558.60)	8.94 (0.83,522.00)	0.04 (-0.01,0.13)
SD RITUX IV	SD TOC SC + PL IV	15.60 (1.57,249.50)	10.99 (1.55,51.72)	0.25 (0.01,0.83)
SD ANA		1.15 (0.26,6.72)	1.15 (0.27,6.31)	0.00 (-0.04,0.07)
SD ETN SC + MTX		2.15 (0.66,7.39)	2.09 (0.67,6.93)	0.02 (-0.02,0.08)
SD ADA SC + MTX		3.81 (1.07,12.64)	3.56 (1.06,11.19)	0.06 (0.00,0.15)
SD INF IV + MTX		4.91 (1.34,17.81)	4.46 (1.31,14.86)	0.08 (0.01,0.20)
SD ABA IV + MTX		2.48 (0.66,8.85)	2.39 (0.68,8.11)	0.03 (-0.02,0.10)
SD RITUX IV + MTX		3.47 (0.78,21.79)	3.27 (0.79,16.32)	0.05 (-0.01,0.27)
SD CERTO SC + MTX		3.62 (0.97,13.08)	3.39 (0.97,11.55)	0.06 (0.00,0.15)
SD GOLI SC + MTX		3.24 (0.68,14.40)	3.07 (0.69,12.21)	0.05 (-0.01,0.20)
SD TOFA PO + MTX		4.81 (1.33,18.40)	4.38 (1.31,15.04)	0.08 (0.01,0.21)
SD ABA SC + MTX		1.35 (0.35,5.15)	1.34 (0.36,4.91)	0.01 (-0.03,0.06)
SD TOCI IV + MTX		2.65 (0.70,9.57)	2.54 (0.71,8.60)	0.04 (-0.01,0.13)
SD ETN SC + DMARD		1.10 (0.38,3.56)	1.10 (0.40,3.48)	0.00 (-0.03,0.03)
SD CERTO + DMARD		1.51 (0.35,6.42)	1.49 (0.36,5.99)	0.01 (-0.03,0.07)
SD ABA IV + DMARD		1.45 (0.39,5.58)	1.43 (0.40,5.26)	0.01 (-0.03,0.06)
SD ADA SC + DMARD		1.28 (0.25,6.49)	1.27 (0.26,5.95)	0.01 (-0.03,0.09)
SD TOCI SC + DMARD		2.70 (0.44,31.01)	2.58 (0.45,19.46)	0.04 (-0.02,0.38)
LD ETN SC		1.98 (0.59,6.66)	1.93 (0.60,6.27)	0.02 (-0.02,0.07)
LD ADA SC		0.61 (0.13,2.73)	0.62 (0.14,2.68)	-0.01 (-0.05,0.02)
LD ANA		0.86 (0.19,4.86)	0.86 (0.20,4.64)	0.00 (-0.04,0.05)
LD TOCI IV		1.60 (0.34,6.66)	1.58 (0.36,6.18)	0.01 (-0.03,0.09)
LD RITUX IV + MTX		5.29 (1.06,35.09)	4.75 (1.06,22.36)	0.09 (0.00,0.37)
LD ABA IV + MTX		3.26 (0.74,14.34)	3.07 (0.75,12.22)	0.05 (-0.01,0.18)
LD CERTO SC + MTX		2.94 (0.40,16.23)	2.80 (0.41,13.62)	0.04 (-0.02,0.20)
LD ETN SC + MTX		1.37 (0.24,6.62)	1.36 (0.25,6.06)	0.01 (-0.04,0.10)
LD TOCI IV + MTX		1.15 (0.21,5.27)	1.14 (0.22,4.93)	0.00 (-0.04,0.08)

(Continued)

HD TOCI IV		2.13 (0.72,6.03)	2.06 (0.73,5.69)	0.02 (-0.01,0.07)
HD GOLI SC		1.42 (0.14,10.92)	1.41 (0.14,9.53)	0.01 (-0.04,0.14)
HD ADA SC		0.63 (0.15,2.52)	0.64 (0.15,2.47)	-0.01 (-0.05,0.02)
HD TOFA		1.87 (0.29,12.04)	1.83 (0.31,10.73)	0.02 (-0.04,0.13)
HD ANA		2.04 (0.49,10.56)	1.98 (0.50,9.53)	0.02 (-0.02,0.12)
HD TOCI IV + MTX		2.79 (0.80,8.98)	2.66 (0.81,8.07)	0.04 (-0.01,0.13)
HD GOLI SC + MTX		4.52 (0.97,18.85)	4.12 (0.97,15.15)	0.07 (0.00,0.26)
HD INF IV + MTX		4.45 (1.14,15.67)	4.08 (1.13,13.41)	0.07 (0.01,0.19)
HD TOFA PO + MTX		3.74 (1.05,15.53)	3.49 (1.05,13.29)	0.06 (0.00,0.17)
HD CERTO SC + MTX		4.05 (0.93,16.67)	3.75 (0.94,14.04)	0.07 (0.00,0.20)
HD TOCI IV + DMARD		2.12 (0.59,7.72)	2.06 (0.60,7.09)	0.02 (-0.02,0.10)
SD ANA	SD RITUX IV	0.07 (0.00,1.16)	0.10 (0.01,1.15)	-0.24 (-0.83,0.01)
SD ETN SC + MTX		0.14 (0.01,1.09)	0.19 (0.05,1.09)	-0.22 (-0.77,0.00)
SD ADA SC + MTX		0.24 (0.02,1.91)	0.31 (0.09,1.82)	-0.19 (-0.72,0.04)
SD INF IV + MTX		0.32 (0.03,2.44)	0.40 (0.11,2.26)	-0.16 (-0.68,0.07)
SD ABA IV + MTX		0.15 (0.01,1.37)	0.21 (0.06,1.35)	-0.22 (-0.76,0.02)
SD RITUX IV + MTX		0.22 (0.03,1.73)	0.31 (0.07,1.64)	-0.19 (-0.67,0.04)
SD CERTO SC + MTX		0.23 (0.02,1.99)	0.30 (0.07,1.89)	-0.19 (-0.74,0.05)
SD GOLI SC + MTX		0.21 (0.02,2.17)	0.28 (0.06,2.03)	-0.19 (-0.76,0.06)
SD TOFA PO + MTX		0.31 (0.03,2.49)	0.39 (0.10,2.30)	-0.16 (-0.68,0.08)
SD ABA SC + MTX		0.09 (0.01,0.78)	0.12 (0.03,0.79)	-0.24 (-0.80,-0.01)
SD TOCI IV + MTX		0.18 (0.01,1.59)	0.24 (0.05,1.54)	-0.20 (-0.78,0.03)
SD ETN SC + DMARD		0.07 (0.01,0.58)	0.10 (0.03,0.60)	-0.25 (-0.82,-0.02)
SD CERTO + DMARD		0.09 (0.01,1.03)	0.13 (0.03,1.03)	-0.24 (-0.80,0.00)
SD ABA IV + DMARD		0.09 (0.01,0.83)	0.13 (0.03,0.83)	-0.24 (-0.81,-0.01)
SD ADA SC + DMARD		0.09 (0.00,0.88)	0.12 (0.02,0.88)	-0.24 (-0.81,-0.01)
SD TOCI SC + DMARD		0.19 (0.01,2.74)	0.26 (0.03,2.32)	-0.19 (-0.77,0.10)
LD ETN SC		0.13 (0.01,1.02)	0.17 (0.05,1.01)	-0.23 (-0.78,0.00)

(Continued)

LD ADA SC		0.04 (0.00,0.39)	0.06 (0.01,0.41)	-0.26 (-0.84,-0.03)
LD ANA		0.05 (0.00,0.84)	0.08 (0.01,0.85)	-0.25 (-0.83,-0.01)
LD TOCI IV		0.10 (0.01,1.01)	0.14 (0.03,1.01)	-0.23 (-0.80,0.00)
LD RITUX IV + MTX		0.33 (0.04,2.64)	0.44 (0.09,2.38)	-0.15 (-0.61,0.09)
LD ABA IV + MTX		0.21 (0.02,2.01)	0.27 (0.06,1.89)	-0.19 (-0.73,0.06)
LD CERTO SC + MTX		0.17 (0.01,2.03)	0.24 (0.03,1.89)	-0.20 (-0.76,0.06)
LD ETN SC + MTX		0.08 (0.01,0.87)	0.12 (0.02,0.88)	-0.24 (-0.78,-0.01)
LD TOCI IV + MTX		0.07 (0.00,0.86)	0.10 (0.01,0.87)	-0.24 (-0.79,-0.01)
HD TOCI IV		0.13 (0.01,1.05)	0.18 (0.05,1.05)	-0.22 (-0.78,0.00)
HD GOLI SC		0.08 (0.00,1.36)	0.13 (0.01,1.31)	-0.23 (-0.80,0.02)
HD ADA SC		0.04 (0.00,0.40)	0.06 (0.01,0.42)	-0.26 (-0.84,-0.02)
HD TOFA		0.12 (0.01,2.02)	0.17 (0.02,1.90)	-0.22 (-0.81,0.05)
HD ANA		0.14 (0.01,1.78)	0.18 (0.03,1.69)	-0.22 (-0.81,0.03)
HD TOCI IV + MTX		0.18 (0.02,1.42)	0.25 (0.06,1.39)	-0.20 (-0.75,0.02)
HD GOLI SC + MTX		0.28 (0.02,2.84)	0.37 (0.08,2.48)	-0.17 (-0.73,0.11)
HD INF IV + MTX		0.28 (0.02,2.45)	0.36 (0.09,2.27)	-0.17 (-0.71,0.06)
HD TOFA PO + MTX		0.24 (0.02,2.16)	0.31 (0.08,2.04)	-0.19 (-0.72,0.05)
HD CERTO SC + MTX		0.28 (0.02,2.38)	0.35 (0.07,2.23)	-0.17 (-0.73,0.06)
HD TOCI IV + DMARD		0.13 (0.01,1.21)	0.18 (0.04,1.19)	-0.22 (-0.79,0.01)
SD ETN SC + MTX	SD ANA	1.84 (0.37,8.78)	1.79 (0.40,8.13)	0.02 (-0.05,0.08)
SD ADA SC + MTX		3.21 (0.57,17.02)	3.01 (0.60,14.73)	0.05 (-0.03,0.16)
SD INF IV + MTX		4.21 (0.75,22.03)	3.84 (0.76,18.07)	0.08 (-0.02,0.20)
SD ABA IV + MTX		2.06 (0.39,10.94)	1.99 (0.41,9.90)	0.03 (-0.05,0.10)
SD RITUX IV + MTX		2.88 (0.43,27.56)	2.72 (0.45,21.34)	0.05 (-0.04,0.27)
SD CERTO SC + MTX		3.16 (0.54,14.38)	2.97 (0.56,12.58)	0.05 (-0.04,0.15)
SD GOLI SC + MTX		2.79 (0.43,16.71)	2.65 (0.45,14.36)	0.04 (-0.04,0.21)
SD TOFA PO + MTX		4.13 (0.73,23.47)	3.78 (0.74,19.15)	0.08 (-0.02,0.21)
SD ABA SC + MTX		1.13 (0.20,6.18)	1.12 (0.21,5.91)	0.00 (-0.07,0.06)



(Continued)

SD TOCI IV + MTX	2.35 (0.34,11.77)	2.26 (0.36,10.37)	0.03 (-0.05,0.14)	
SD ETN SC + DMARD	0.95 (0.21,4.25)	0.95 (0.23,4.11)	0.00 (-0.07,0.04)	
SD CERTO + DMARD	1.31 (0.22,7.06)	1.30 (0.23,6.66)	0.01 (-0.07,0.07)	
SD ABA IV + DMARD	1.24 (0.21,6.35)	1.23 (0.23,6.03)	0.01 (-0.07,0.07)	
SD ADA SC + DMARD	1.11 (0.15,6.45)	1.11 (0.16,6.00)	0.00 (-0.07,0.09)	
SD TOCI SC + DMARD	2.28 (0.29,39.40)	2.19 (0.31,24.14)	0.03 (-0.05,0.38)	
LD ETN SC	1.68 (0.34,7.96)	1.65 (0.36,7.44)	0.02 (-0.06,0.08)	
LD ADA SC	0.51 (0.09,2.71)	0.52 (0.10,2.66)	-0.01 (-0.08,0.02)	
LD ANA	0.76 (0.23,2.51)	0.77 (0.24,2.44)	-0.01 (-0.06,0.03)	
LD TOCI IV	1.36 (0.20,7.81)	1.34 (0.21,7.22)	0.01 (-0.07,0.09)	
LD RITUX IV + MTX	4.38 (0.68,43.49)	3.97 (0.70,29.32)	0.08 (-0.02,0.37)	
LD ABA IV + MTX	2.85 (0.37,17.37)	2.69 (0.39,14.91)	0.05 (-0.04,0.18)	
LD CERTO SC + MTX	2.50 (0.23,18.65)	2.39 (0.24,15.57)	0.04 (-0.05,0.20)	
LD ETN SC + MTX	1.15 (0.14,7.59)	1.15 (0.15,6.96)	0.00 (-0.07,0.10)	
LD TOCI IV + MTX	0.95 (0.11,7.17)	0.95 (0.12,6.63)	0.00 (-0.08,0.08)	
HD TOCI IV	1.81 (0.34,8.14)	1.76 (0.36,7.62)	0.02 (-0.06,0.08)	
HD GOLI SC	1.21 (0.09,11.22)	1.21 (0.09,10.00)	0.00 (-0.07,0.14)	
HD ADA SC	0.55 (0.08,2.59)	0.56 (0.09,2.55)	-0.01 (-0.08,0.02)	
HD TOFA	1.57 (0.25,11.87)	1.55 (0.26,10.42)	0.01 (-0.06,0.13)	
HD ANA	1.76 (0.63,5.69)	1.71 (0.65,5.33)	0.02 (-0.02,0.08)	
HD TOCI IV + MTX	2.44 (0.41,11.47)	2.34 (0.43,10.27)	0.03 (-0.05,0.13)	
HD GOLI SC + MTX	3.95 (0.58,24.60)	3.63 (0.60,19.54)	0.07 (-0.03,0.27)	
HD INF IV + MTX	3.65 (0.64,20.36)	3.39 (0.66,17.05)	0.07 (-0.03,0.19)	
HD TOFA PO + MTX	3.23 (0.59,19.19)	3.03 (0.61,16.12)	0.05 (-0.03,0.18)	
HD CERTO SC + MTX	3.40 (0.54,18.21)	3.16 (0.56,15.23)	0.06 (-0.03,0.19)	
HD TOCI IV + DMARD	1.78 (0.33,8.84)	1.74 (0.35,8.12)	0.02 (-0.05,0.10)	
SD ADA SC + MTX	SD ETN SC + MTX	1.75 (0.91,3.37)	1.68 (0.92,3.09)	0.03 (0.00,0.10)
SD INF IV + MTX	2.28 (1.20,4.20)	2.12 (1.19,3.71)	0.06 (0.01,0.14)	

(Continued)

SD ABA IV + MTX	1.15 (0.53,2.20)	1.14 (0.54,2.10)	0.01 (-0.03,0.05)
SD RITUX IV + MTX	1.60 (0.56,6.34)	1.55 (0.57,4.96)	0.03 (-0.03,0.22)
SD CERTO SC + MTX	1.65 (0.77,3.49)	1.59 (0.78,3.20)	0.03 (-0.01,0.10)
SD GOLI SC + MTX	1.47 (0.50,4.84)	1.43 (0.52,4.13)	0.02 (-0.03,0.16)
SD TOFA PO + MTX	2.28 (1.05,4.54)	2.13 (1.04,3.99)	0.05 (0.00,0.15)
SD ABA SC + MTX	0.63 (0.26,1.39)	0.64 (0.27,1.37)	-0.02 (-0.06,0.02)
SD TOCI IV + MTX	1.23 (0.38,3.83)	1.21 (0.40,3.46)	0.01 (-0.04,0.11)
SD ETN SC + DMARD	0.51 (0.23,1.20)	0.53 (0.25,1.19)	-0.02 (-0.07,0.01)
SD CERTO + DMARD	0.70 (0.20,2.33)	0.71 (0.21,2.23)	-0.01 (-0.07,0.04)
SD ABA IV + DMARD	0.67 (0.24,1.93)	0.68 (0.25,1.86)	-0.02 (-0.06,0.03)
SD ADA SC + DMARD	0.58 (0.14,2.59)	0.59 (0.15,2.43)	-0.02 (-0.07,0.06)
SD TOCI SC + DMARD	1.21 (0.23,11.79)	1.19 (0.25,7.39)	0.01 (-0.06,0.34)
LD ETN SC	0.91 (0.49,1.73)	0.91 (0.51,1.68)	0.00 (-0.04,0.03)
LD ADA SC	0.28 (0.07,1.09)	0.29 (0.08,1.08)	-0.04 (-0.09,0.00)
LD ANA	0.40 (0.09,1.94)	0.41 (0.10,1.87)	-0.03 (-0.09,0.03)
LD TOCI IV	0.76 (0.18,2.56)	0.77 (0.20,2.40)	-0.01 (-0.07,0.06)
LD RITUX IV + MTX	2.43 (0.78,9.60)	2.25 (0.79,6.75)	0.06 (-0.01,0.32)
LD ABA IV + MTX	1.51 (0.48,4.44)	1.47 (0.49,3.86)	0.02 (-0.03,0.14)
LD CERTO SC + MTX	1.34 (0.22,5.44)	1.31 (0.23,4.55)	0.02 (-0.05,0.17)
LD ETN SC + MTX	0.62 (0.16,2.15)	0.64 (0.17,2.02)	-0.02 (-0.07,0.05)
LD TOCI IV + MTX	0.54 (0.09,2.11)	0.55 (0.10,2.02)	-0.02 (-0.08,0.05)
HD TOCI IV	0.98 (0.46,2.03)	0.98 (0.48,1.96)	0.00 (-0.04,0.04)
HD GOLI SC	0.64 (0.08,3.35)	0.66 (0.09,3.02)	-0.02 (-0.07,0.10)
HD ADA SC	0.29 (0.07,1.05)	0.30 (0.08,1.05)	-0.03 (-0.09,0.00)
HD TOFA	0.84 (0.14,5.02)	0.85 (0.15,4.46)	-0.01 (-0.08,0.11)
HD ANA	0.99 (0.23,4.25)	0.99 (0.25,3.85)	0.00 (-0.07,0.10)
HD TOCI IV + MTX	1.25 (0.49,3.39)	1.24 (0.51,3.09)	0.01 (-0.04,0.09)
HD GOLI SC + MTX	2.01 (0.73,6.45)	1.90 (0.74,5.11)	0.04 (-0.02,0.22)

(Continued)

HD INF IV + MTX		2.04 (0.93,4.21)	1.92 (0.94,3.71)	0.05 (0.00,0.14)
HD TOFA PO + MTX		1.75 (0.80,3.67)	1.68 (0.81,3.27)	0.03 (-0.01,0.12)
HD CERTO SC + MTX		1.92 (0.63,4.93)	1.83 (0.64,4.24)	0.04 (-0.02,0.15)
HD TOCI IV + DMARD		0.97 (0.36,2.71)	0.97 (0.38,2.55)	0.00 (-0.05,0.07)
SD INF IV + MTX	SD ADA SC + MTX	1.31 (0.67,2.57)	1.28 (0.70,2.34)	0.02 (-0.04,0.10)
SD ABA IV + MTX		0.66 (0.32,1.28)	0.68 (0.34,1.26)	-0.03 (-0.09,0.02)
SD RITUX IV + MTX		0.90 (0.31,3.63)	0.91 (0.34,2.93)	-0.01 (-0.08,0.18)
SD CERTO SC + MTX		0.94 (0.44,2.05)	0.95 (0.47,1.92)	0.00 (-0.07,0.06)
SD GOLI SC + MTX		0.84 (0.28,2.69)	0.86 (0.31,2.39)	-0.01 (-0.09,0.11)
SD TOFA PO + MTX		1.28 (0.67,2.52)	1.25 (0.69,2.28)	0.02 (-0.03,0.10)
SD ABA SC + MTX		0.36 (0.18,0.70)	0.38 (0.19,0.72)	-0.05 (-0.12,-0.01)
SD TOCI IV + MTX		0.71 (0.21,2.35)	0.73 (0.23,2.17)	-0.02 (-0.11,0.07)
SD ETN SC + DMARD		0.30 (0.13,0.74)	0.32 (0.14,0.75)	-0.06 (-0.14,-0.01)
SD CERTO + DMARD		0.40 (0.12,1.44)	0.42 (0.13,1.41)	-0.05 (-0.14,0.02)
SD ABA IV + DMARD		0.38 (0.14,1.15)	0.41 (0.15,1.14)	-0.05 (-0.13,0.01)
SD ADA SC + DMARD		0.34 (0.08,1.47)	0.36 (0.09,1.42)	-0.05 (-0.14,0.03)
SD TOCI SC + DMARD		0.70 (0.13,6.98)	0.72 (0.14,4.72)	-0.02 (-0.12,0.31)
LD ETN SC		0.52 (0.26,1.09)	0.54 (0.29,1.09)	-0.04 (-0.11,0.00)
LD ADA SC		0.16 (0.04,0.70)	0.17 (0.05,0.72)	-0.07 (-0.17,-0.01)
LD ANA		0.23 (0.05,1.21)	0.25 (0.06,1.19)	-0.06 (-0.16,0.01)
LD TOCI IV		0.43 (0.11,1.52)	0.45 (0.12,1.47)	-0.04 (-0.14,0.03)
LD RITUX IV + MTX		1.36 (0.46,5.70)	1.32 (0.49,4.11)	0.03 (-0.06,0.28)
LD ABA IV + MTX		0.87 (0.26,2.47)	0.88 (0.28,2.23)	-0.01 (-0.09,0.10)
LD CERTO SC + MTX		0.77 (0.13,3.02)	0.79 (0.14,2.65)	-0.02 (-0.11,0.12)
LD ETN SC + MTX		0.35 (0.09,1.35)	0.38 (0.10,1.31)	-0.05 (-0.13,0.02)
LD TOCI IV + MTX		0.31 (0.05,1.23)	0.33 (0.06,1.21)	-0.05 (-0.14,0.01)
HD TOCI IV		0.56 (0.26,1.20)	0.58 (0.28,1.18)	-0.03 (-0.11,0.01)
HD GOLI SC		0.37 (0.04,2.09)	0.40 (0.05,1.95)	-0.05 (-0.14,0.07)

(Continued)

HD ADA SC		0.16 (0.04,0.67)	0.18 (0.05,0.68)	-0.07 (-0.16,-0.01)
HD TOFA		0.49 (0.09,2.90)	0.51 (0.10,2.66)	-0.04 (-0.15,0.08)
HD ANA		0.57 (0.13,2.57)	0.59 (0.15,2.40)	-0.03 (-0.14,0.07)
HD TOCI IV + MTX		0.72 (0.28,1.92)	0.74 (0.31,1.81)	-0.02 (-0.10,0.06)
HD GOLI SC + MTX		1.15 (0.43,3.51)	1.14 (0.46,2.97)	0.01 (-0.07,0.17)
HD INF IV + MTX		1.17 (0.51,2.47)	1.16 (0.54,2.25)	0.01 (-0.06,0.09)
HD TOFA PO + MTX		0.99 (0.51,2.02)	0.99 (0.54,1.88)	0.00 (-0.06,0.07)
HD CERTO SC + MTX		1.09 (0.38,2.75)	1.08 (0.40,2.45)	0.01 (-0.08,0.11)
HD TOCI IV + DMARD		0.55 (0.20,1.69)	0.58 (0.22,1.62)	-0.03 (-0.12,0.04)
SD ABA IV + MTX	SD INF IV + MTX	0.50 (0.23,1.06)	0.54 (0.26,1.05)	-0.05 (-0.14,0.00)
SD RITUX IV + MTX		0.70 (0.24,2.60)	0.73 (0.27,2.22)	-0.03 (-0.12,0.15)
SD CERTO SC + MTX		0.73 (0.32,1.63)	0.75 (0.35,1.56)	-0.02 (-0.12,0.05)
SD GOLI SC + MTX		0.65 (0.21,2.18)	0.68 (0.23,1.95)	-0.03 (-0.14,0.09)
SD TOFA PO + MTX		1.00 (0.45,2.09)	1.00 (0.49,1.93)	0.00 (-0.09,0.08)
SD ABA SC + MTX		0.27 (0.12,0.66)	0.30 (0.13,0.68)	-0.07 (-0.18,-0.02)
SD TOCI IV + MTX		0.55 (0.15,1.85)	0.58 (0.18,1.74)	-0.04 (-0.16,0.05)
SD ETN SC + DMARD		0.23 (0.09,0.56)	0.25 (0.11,0.58)	-0.08 (-0.19,-0.02)
SD CERTO + DMARD		0.31 (0.09,1.08)	0.34 (0.10,1.07)	-0.07 (-0.19,0.00)
SD ABA IV + DMARD		0.30 (0.10,0.92)	0.32 (0.11,0.93)	-0.07 (-0.18,0.00)
SD ADA SC + DMARD		0.26 (0.06,1.19)	0.29 (0.07,1.17)	-0.07 (-0.18,0.01)
SD TOCI SC + DMARD		0.53 (0.09,5.68)	0.56 (0.11,3.78)	-0.04 (-0.17,0.28)
LD ETN SC		0.40 (0.20,0.82)	0.43 (0.23,0.83)	-0.06 (-0.15,-0.01)
LD ADA SC		0.12 (0.03,0.51)	0.14 (0.04,0.53)	-0.09 (-0.21,-0.02)
LD ANA		0.17 (0.04,1.01)	0.19 (0.05,1.01)	-0.09 (-0.21,0.00)
LD TOCI IV		0.33 (0.07,1.19)	0.36 (0.09,1.18)	-0.07 (-0.19,0.01)
LD RITUX IV + MTX		1.07 (0.35,4.08)	1.07 (0.38,3.02)	0.01 (-0.09,0.23)
LD ABA IV + MTX		0.67 (0.21,1.93)	0.70 (0.23,1.79)	-0.03 (-0.12,0.07)
LD CERTO SC + MTX		0.59 (0.09,2.46)	0.62 (0.10,2.16)	-0.04 (-0.15,0.11)

(Continued)

LD ETN SC + MTX		0.28 (0.07,1.03)	0.30 (0.08,1.02)	-0.07 (-0.18,0.00)
LD TOCI IV + MTX		0.23 (0.04,0.93)	0.26 (0.05,0.94)	-0.08 (-0.19,0.00)
HD TOCI IV		0.43 (0.20,0.96)	0.46 (0.23,0.97)	-0.06 (-0.16,0.00)
HD GOLI SC		0.28 (0.03,1.63)	0.31 (0.04,1.55)	-0.07 (-0.19,0.05)
HD ADA SC		0.13 (0.03,0.49)	0.14 (0.04,0.50)	-0.09 (-0.21,-0.02)
HD TOFA		0.38 (0.06,2.16)	0.41 (0.07,2.01)	-0.06 (-0.20,0.07)
HD ANA		0.42 (0.10,2.01)	0.45 (0.12,1.89)	-0.06 (-0.18,0.06)
HD TOCI IV + MTX		0.56 (0.21,1.51)	0.59 (0.24,1.45)	-0.04 (-0.14,0.04)
HD GOLI SC + MTX		0.90 (0.30,2.87)	0.91 (0.34,2.46)	-0.01 (-0.11,0.14)
HD INF IV + MTX		0.89 (0.44,1.71)	0.90 (0.48,1.60)	-0.01 (-0.08,0.06)
HD TOFA PO + MTX		0.77 (0.36,1.66)	0.79 (0.39,1.57)	-0.02 (-0.10,0.05)
HD CERTO SC + MTX		0.85 (0.30,2.16)	0.86 (0.32,1.96)	-0.01 (-0.11,0.09)
HD TOCI IV + DMARD		0.43 (0.15,1.34)	0.46 (0.17,1.31)	-0.05 (-0.17,0.02)
SD RITUX IV + MTX	SD ABA IV + MTX	1.41 (0.46,5.59)	1.37 (0.48,4.44)	0.02 (-0.04,0.21)
SD CERTO SC + MTX		1.44 (0.65,3.43)	1.40 (0.67,3.16)	0.02 (-0.03,0.10)
SD GOLI SC + MTX		1.30 (0.42,4.51)	1.28 (0.44,3.89)	0.01 (-0.05,0.16)
SD TOFA PO + MTX		1.98 (0.92,4.34)	1.86 (0.92,3.84)	0.05 (0.00,0.15)
SD ABA SC + MTX		0.54 (0.29,1.06)	0.56 (0.31,1.05)	-0.02 (-0.07,0.00)
SD TOCI IV + MTX		1.08 (0.33,3.72)	1.08 (0.35,3.35)	0.00 (-0.06,0.10)
SD ETN SC + DMARD		0.45 (0.18,1.23)	0.47 (0.19,1.22)	-0.03 (-0.09,0.01)
SD CERTO + DMARD		0.61 (0.18,2.27)	0.62 (0.20,2.19)	-0.02 (-0.08,0.04)
SD ABA IV + DMARD		0.59 (0.20,1.92)	0.61 (0.21,1.84)	-0.02 (-0.08,0.03)
SD ADA SC + DMARD		0.51 (0.11,2.48)	0.53 (0.12,2.35)	-0.02 (-0.09,0.06)
SD TOCI SC + DMARD		1.07 (0.18,11.24)	1.07 (0.20,6.98)	0.00 (-0.07,0.34)
LD ETN SC		0.79 (0.37,1.81)	0.80 (0.39,1.75)	-0.01 (-0.06,0.03)
LD ADA SC		0.24 (0.06,1.08)	0.26 (0.07,1.08)	-0.04 (-0.11,0.00)
LD ANA		0.36 (0.08,1.86)	0.37 (0.09,1.81)	-0.03 (-0.11,0.03)
LD TOCI IV		0.65 (0.16,2.50)	0.67 (0.17,2.33)	-0.02 (-0.08,0.06)

(Continued)

LD RITUX IV + MTX		2.12 (0.70,8.53)	1.98 (0.71,6.20)	0.06 (-0.02,0.31)
LD ABA IV + MTX		1.34 (0.47,3.63)	1.31 (0.48,3.21)	0.02 (-0.04,0.13)
LD CERTO SC + MTX		1.19 (0.20,5.06)	1.18 (0.21,4.32)	0.01 (-0.06,0.16)
LD ETN SC + MTX		0.55 (0.12,2.24)	0.57 (0.13,2.10)	-0.02 (-0.09,0.05)
LD TOCI IV + MTX		0.47 (0.08,1.98)	0.49 (0.08,1.88)	-0.03 (-0.09,0.04)
HD TOCI IV		0.85 (0.36,2.06)	0.86 (0.39,1.99)	-0.01 (-0.06,0.04)
HD GOLI SC		0.58 (0.07,3.08)	0.59 (0.08,2.82)	-0.02 (-0.09,0.09)
HD ADA SC		0.26 (0.06,1.02)	0.27 (0.07,1.02)	-0.04 (-0.11,0.00)
HD TOFA		0.75 (0.15,4.54)	0.76 (0.16,4.05)	-0.01 (-0.09,0.10)
HD ANA		0.85 (0.21,4.02)	0.86 (0.22,3.64)	-0.01 (-0.08,0.09)
HD TOCI IV + MTX		1.10 (0.41,3.36)	1.10 (0.43,3.08)	0.01 (-0.05,0.09)
HD GOLI SC + MTX		1.80 (0.58,5.90)	1.71 (0.60,4.89)	0.04 (-0.03,0.21)
HD INF IV + MTX		1.77 (0.76,4.22)	1.69 (0.78,3.71)	0.04 (-0.01,0.14)
HD TOFA PO + MTX		1.53 (0.70,3.53)	1.48 (0.72,3.16)	0.03 (-0.02,0.11)
HD CERTO SC + MTX		1.60 (0.60,4.81)	1.54 (0.62,4.14)	0.03 (-0.03,0.15)
HD TOCI IV + DMARD		0.85 (0.30,2.69)	0.86 (0.32,2.53)	-0.01 (-0.07,0.06)
SD CERTO SC + MTX	SD RITUX IV + MTX	1.02 (0.21,3.21)	1.02 (0.28,2.94)	0.00 (-0.20,0.08)
SD GOLI SC + MTX		0.95 (0.16,4.08)	0.95 (0.21,3.61)	0.00 (-0.20,0.12)
SD TOFA PO + MTX		1.40 (0.37,4.09)	1.36 (0.42,3.69)	0.02 (-0.14,0.12)
SD ABA SC + MTX		0.39 (0.09,1.26)	0.41 (0.12,1.24)	-0.04 (-0.24,0.01)
SD TOCI IV + MTX		0.79 (0.12,3.06)	0.80 (0.16,2.82)	-0.01 (-0.23,0.08)
SD ETN SC + DMARD		0.33 (0.06,1.14)	0.35 (0.08,1.13)	-0.05 (-0.26,0.00)
SD CERTO + DMARD		0.44 (0.08,2.02)	0.46 (0.11,1.95)	-0.04 (-0.25,0.03)
SD ABA IV + DMARD		0.42 (0.09,1.66)	0.44 (0.11,1.63)	-0.04 (-0.25,0.02)
SD ADA SC + DMARD		0.37 (0.05,2.23)	0.39 (0.06,2.11)	-0.04 (-0.26,0.04)
SD TOCI SC + DMARD		0.79 (0.07,8.30)	0.80 (0.09,5.59)	-0.01 (-0.21,0.29)
LD ETN SC		0.57 (0.14,1.71)	0.59 (0.18,1.67)	-0.03 (-0.23,0.02)
LD ADA SC		0.18 (0.03,0.97)	0.19 (0.03,0.97)	-0.06 (-0.28,0.00)

(Continued)

LD ANA		0.25 (0.04,1.64)	0.27 (0.05,1.59)	-0.05 (-0.26,0.02)
LD TOCI IV		0.46 (0.07,2.17)	0.48 (0.09,2.08)	-0.04 (-0.24,0.04)
LD RITUX IV + MTX		1.49 (0.65,3.70)	1.41 (0.67,3.26)	0.03 (-0.04,0.15)
LD ABA IV + MTX		0.92 (0.19,3.72)	0.93 (0.22,3.37)	0.00 (-0.18,0.11)
LD CERTO SC + MTX		0.82 (0.09,4.54)	0.83 (0.11,3.86)	-0.01 (-0.22,0.15)
LD ETN SC + MTX		0.39 (0.05,1.91)	0.42 (0.07,1.84)	-0.04 (-0.24,0.04)
LD TOCI IV + MTX		0.33 (0.04,1.68)	0.35 (0.05,1.63)	-0.04 (-0.25,0.03)
HD TOCI IV		0.61 (0.15,1.88)	0.63 (0.20,1.83)	-0.03 (-0.22,0.03)
HD GOLI SC		0.39 (0.04,2.46)	0.41 (0.05,2.29)	-0.04 (-0.25,0.07)
HD ADA SC		0.18 (0.02,0.93)	0.19 (0.03,0.93)	-0.06 (-0.28,0.00)
HD TOFA		0.52 (0.07,3.62)	0.54 (0.08,3.29)	-0.03 (-0.24,0.09)
HD ANA		0.61 (0.09,3.43)	0.63 (0.12,3.14)	-0.03 (-0.24,0.08)
HD TOCI IV + MTX		0.80 (0.16,2.84)	0.81 (0.20,2.65)	-0.01 (-0.22,0.07)
HD GOLI SC + MTX		1.28 (0.23,5.07)	1.25 (0.29,4.26)	0.02 (-0.19,0.19)
HD INF IV + MTX		1.29 (0.30,4.10)	1.25 (0.37,3.69)	0.02 (-0.17,0.12)
HD TOFA PO + MTX		1.09 (0.28,3.25)	1.09 (0.33,3.00)	0.01 (-0.16,0.09)
HD CERTO SC + MTX		1.16 (0.24,4.11)	1.15 (0.30,3.68)	0.01 (-0.18,0.12)
HD TOCI IV + DMARD		0.61 (0.12,2.47)	0.63 (0.15,2.35)	-0.03 (-0.23,0.05)
SD GOLI SC + MTX	SD CERTO SC + MTX	0.89 (0.28,3.10)	0.90 (0.31,2.73)	-0.01 (-0.09,0.13)
SD TOFA PO + MTX		1.37 (0.61,3.04)	1.32 (0.64,2.73)	0.02 (-0.04,0.12)
SD ABA SC + MTX		0.37 (0.15,0.95)	0.40 (0.16,0.95)	-0.05 (-0.13,0.00)
SD TOCI IV + MTX		0.74 (0.22,2.59)	0.76 (0.24,2.39)	-0.02 (-0.11,0.08)
SD ETN SC + DMARD		0.31 (0.12,0.79)	0.33 (0.14,0.80)	-0.05 (-0.14,-0.01)
SD CERTO + DMARD		0.43 (0.12,1.44)	0.45 (0.14,1.42)	-0.04 (-0.13,0.02)
SD ABA IV + DMARD		0.41 (0.13,1.22)	0.43 (0.15,1.20)	-0.04 (-0.13,0.01)
SD ADA SC + DMARD		0.35 (0.08,1.61)	0.37 (0.09,1.57)	-0.05 (-0.14,0.03)
SD TOCI SC + DMARD		0.76 (0.13,6.94)	0.77 (0.14,4.68)	-0.02 (-0.12,0.31)
LD ETN SC		0.55 (0.26,1.25)	0.57 (0.28,1.23)	-0.03 (-0.11,0.01)

(Continued)

LD ADA SC		0.17 (0.04,0.71)	0.18 (0.05,0.72)	-0.07 (-0.16,-0.01)
LD ANA		0.25 (0.06,1.37)	0.26 (0.06,1.35)	-0.06 (-0.16,0.01)
LD TOCI IV		0.45 (0.10,1.61)	0.48 (0.12,1.56)	-0.04 (-0.13,0.03)
LD RITUX IV + MTX		1.42 (0.49,6.62)	1.37 (0.52,4.65)	0.03 (-0.05,0.28)
LD ABA IV + MTX		0.94 (0.25,2.71)	0.95 (0.28,2.47)	0.00 (-0.09,0.10)
LD CERTO SC + MTX		0.84 (0.14,2.91)	0.86 (0.15,2.55)	-0.01 (-0.10,0.12)
LD ETN SC + MTX		0.37 (0.10,1.57)	0.39 (0.10,1.51)	-0.05 (-0.13,0.03)
LD TOCI IV + MTX		0.32 (0.05,1.45)	0.34 (0.06,1.42)	-0.05 (-0.14,0.02)
HD TOCI IV		0.57 (0.25,1.37)	0.60 (0.28,1.35)	-0.03 (-0.11,0.02)
HD GOLI SC		0.40 (0.04,2.11)	0.43 (0.05,1.96)	-0.04 (-0.14,0.07)
HD ADA SC		0.17 (0.04,0.68)	0.19 (0.05,0.69)	-0.07 (-0.16,-0.01)
HD TOFA		0.52 (0.10,3.16)	0.54 (0.11,2.89)	-0.04 (-0.14,0.09)
HD ANA		0.57 (0.14,2.93)	0.60 (0.15,2.70)	-0.03 (-0.13,0.08)
HD TOCI IV + MTX		0.77 (0.27,2.33)	0.78 (0.30,2.17)	-0.02 (-0.10,0.07)
HD GOLI SC + MTX		1.24 (0.38,3.90)	1.21 (0.41,3.25)	0.01 (-0.08,0.18)
HD INF IV + MTX		1.24 (0.50,2.74)	1.21 (0.53,2.50)	0.02 (-0.06,0.11)
HD TOFA PO + MTX		1.06 (0.47,2.47)	1.06 (0.50,2.29)	0.00 (-0.06,0.09)
HD CERTO SC + MTX		1.13 (0.48,2.54)	1.12 (0.51,2.29)	0.01 (-0.05,0.11)
HD TOCI IV + DMARD		0.59 (0.20,1.82)	0.61 (0.23,1.73)	-0.03 (-0.11,0.04)
SD TOFA PO + MTX	SD GOLI SC + MTX	1.50 (0.43,4.80)	1.45 (0.47,4.22)	0.03 (-0.10,0.14)
SD ABA SC + MTX		0.43 (0.12,1.39)	0.45 (0.14,1.37)	-0.04 (-0.19,0.01)
SD TOCI IV + MTX		0.83 (0.17,3.80)	0.84 (0.20,3.48)	-0.01 (-0.16,0.09)
SD ETN SC + DMARD		0.34 (0.09,1.35)	0.36 (0.11,1.34)	-0.04 (-0.20,0.01)
SD CERTO + DMARD		0.48 (0.10,2.21)	0.50 (0.12,2.13)	-0.03 (-0.19,0.03)
SD ABA IV + DMARD		0.45 (0.11,1.84)	0.47 (0.13,1.79)	-0.04 (-0.19,0.03)
SD ADA SC + DMARD		0.38 (0.07,2.34)	0.40 (0.08,2.21)	-0.04 (-0.18,0.05)
SD TOCI SC + DMARD		0.85 (0.12,9.05)	0.86 (0.14,6.20)	-0.01 (-0.16,0.31)
LD ETN SC		0.61 (0.20,1.97)	0.63 (0.23,1.92)	-0.02 (-0.16,0.03)



(Continued)

LD ADA SC		0.18 (0.04,1.15)	0.19 (0.04,1.14)	-0.06 (-0.21,0.00)
LD ANA		0.26 (0.05,1.85)	0.27 (0.06,1.79)	-0.05 (-0.21,0.02)
LD TOCI IV		0.49 (0.09,2.41)	0.51 (0.11,2.29)	-0.03 (-0.19,0.05)
LD RITUX IV + MTX		1.59 (0.39,8.09)	1.52 (0.43,6.02)	0.03 (-0.10,0.29)
LD ABA IV + MTX		1.05 (0.22,4.07)	1.04 (0.25,3.57)	0.00 (-0.14,0.13)
LD CERTO SC + MTX		0.94 (0.10,4.65)	0.94 (0.11,3.97)	0.00 (-0.14,0.14)
LD ETN SC + MTX		0.42 (0.07,2.04)	0.44 (0.09,1.94)	-0.04 (-0.19,0.05)
LD TOCI IV + MTX		0.34 (0.05,2.00)	0.36 (0.07,1.92)	-0.04 (-0.20,0.03)
HD TOCI IV		0.66 (0.19,2.12)	0.67 (0.22,2.05)	-0.02 (-0.17,0.03)
HD GOLI SC		0.44 (0.06,2.47)	0.46 (0.06,2.28)	-0.03 (-0.18,0.07)
HD ADA SC		0.19 (0.04,0.98)	0.21 (0.05,0.98)	-0.06 (-0.21,0.00)
HD TOFA		0.58 (0.06,4.14)	0.60 (0.07,3.76)	-0.03 (-0.20,0.09)
HD ANA		0.64 (0.13,3.81)	0.66 (0.16,3.49)	-0.02 (-0.19,0.08)
HD TOCI IV + MTX		0.86 (0.21,3.26)	0.87 (0.25,3.04)	-0.01 (-0.15,0.08)
HD GOLI SC + MTX		1.36 (0.52,3.68)	1.32 (0.56,3.27)	0.02 (-0.06,0.14)
HD INF IV + MTX		1.36 (0.39,4.39)	1.32 (0.43,3.98)	0.02 (-0.10,0.12)
HD TOFA PO + MTX		1.15 (0.35,3.84)	1.14 (0.39,3.43)	0.01 (-0.12,0.11)
HD CERTO SC + MTX		1.24 (0.32,4.81)	1.22 (0.36,4.24)	0.01 (-0.11,0.14)
HD TOCI IV + DMARD		0.65 (0.17,2.85)	0.66 (0.20,2.68)	-0.02 (-0.17,0.06)
SD ABA SC + MTX	SD TOFA PO + MTX	0.28 (0.12,0.65)	0.30 (0.14,0.66)	-0.07 (-0.18,-0.02)
SD TOCI IV + MTX		0.55 (0.15,1.91)	0.58 (0.18,1.79)	-0.04 (-0.17,0.05)
SD ETN SC + DMARD		0.23 (0.09,0.63)	0.25 (0.11,0.65)	-0.08 (-0.20,-0.02)
SD CERTO + DMARD		0.31 (0.09,1.17)	0.34 (0.10,1.16)	-0.07 (-0.19,0.01)
SD ABA IV + DMARD		0.29 (0.10,0.96)	0.32 (0.12,0.97)	-0.07 (-0.18,0.00)
SD ADA SC + DMARD		0.26 (0.06,1.28)	0.28 (0.07,1.25)	-0.07 (-0.20,0.02)
SD TOCI SC + DMARD		0.55 (0.10,5.34)	0.58 (0.11,3.62)	-0.04 (-0.17,0.28)
LD ETN SC		0.40 (0.20,0.90)	0.43 (0.23,0.90)	-0.06 (-0.16,-0.01)
LD ADA SC		0.12 (0.03,0.52)	0.14 (0.04,0.54)	-0.09 (-0.22,-0.02)

(Continued)

LD ANA		0.18 (0.04,0.99)	0.19 (0.05,0.99)	-0.08 (-0.21,0.00)
LD TOCI IV		0.33 (0.08,1.19)	0.36 (0.09,1.18)	-0.06 (-0.19,0.01)
LD RITUX IV + MTX		1.06 (0.36,4.40)	1.05 (0.39,3.26)	0.01 (-0.09,0.23)
LD ABA IV + MTX		0.67 (0.20,2.18)	0.70 (0.23,1.99)	-0.03 (-0.13,0.08)
LD CERTO SC + MTX		0.61 (0.09,2.40)	0.64 (0.11,2.13)	-0.03 (-0.15,0.10)
LD ETN SC + MTX		0.28 (0.06,1.10)	0.30 (0.07,1.09)	-0.07 (-0.19,0.01)
LD TOCI IV + MTX		0.24 (0.04,1.01)	0.26 (0.04,1.01)	-0.08 (-0.20,0.00)
HD TOCI IV		0.43 (0.19,1.04)	0.46 (0.22,1.04)	-0.06 (-0.16,0.00)
HD GOLI SC		0.29 (0.03,1.68)	0.31 (0.04,1.59)	-0.07 (-0.19,0.05)
HD ADA SC		0.13 (0.03,0.53)	0.14 (0.04,0.54)	-0.09 (-0.22,-0.02)
HD TOFA		0.37 (0.07,2.34)	0.40 (0.09,2.17)	-0.06 (-0.19,0.07)
HD ANA		0.43 (0.10,2.09)	0.46 (0.11,1.94)	-0.06 (-0.19,0.06)
HD TOCI IV + MTX		0.57 (0.20,1.56)	0.60 (0.23,1.50)	-0.04 (-0.15,0.04)
HD GOLI SC + MTX		0.91 (0.30,2.95)	0.92 (0.33,2.57)	-0.01 (-0.12,0.14)
HD INF IV + MTX		0.89 (0.39,2.13)	0.90 (0.42,1.96)	-0.01 (-0.10,0.08)
HD TOFA PO + MTX		0.78 (0.47,1.32)	0.80 (0.50,1.28)	-0.02 (-0.08,0.02)
HD CERTO SC + MTX		0.83 (0.28,2.37)	0.85 (0.31,2.13)	-0.01 (-0.12,0.10)
HD TOCI IV + DMARD		0.43 (0.15,1.42)	0.46 (0.17,1.38)	-0.06 (-0.17,0.02)
SD TOCI IV + MTX	SD ABA SC + MTX	1.98 (0.54,7.25)	1.92 (0.55,6.45)	0.03 (-0.02,0.13)
SD ETN SC + DMARD		0.83 (0.31,2.44)	0.83 (0.32,2.38)	-0.01 (-0.05,0.02)
SD CERTO + DMARD		1.10 (0.30,4.32)	1.09 (0.31,4.09)	0.00 (-0.04,0.06)
SD ABA IV + DMARD		1.07 (0.33,3.53)	1.07 (0.34,3.37)	0.00 (-0.04,0.05)
SD ADA SC + DMARD		0.94 (0.18,4.61)	0.94 (0.19,4.27)	0.00 (-0.05,0.08)
SD TOCI SC + DMARD		1.94 (0.33,21.80)	1.88 (0.34,13.97)	0.03 (-0.03,0.37)
LD ETN SC		1.45 (0.62,3.58)	1.43 (0.63,3.42)	0.01 (-0.02,0.06)
LD ADA SC		0.44 (0.10,2.10)	0.45 (0.11,2.07)	-0.02 (-0.07,0.02)
LD ANA		0.66 (0.14,3.58)	0.67 (0.15,3.45)	-0.01 (-0.06,0.04)
LD TOCI IV		1.19 (0.28,4.91)	1.18 (0.29,4.51)	0.01 (-0.04,0.08)

(Continued)

LD RITUX IV + MTX		3.86 (1.18,17.07)	3.50 (1.17,11.65)	0.08 (0.01,0.35)
LD ABA IV + MTX		2.45 (0.72,7.32)	2.33 (0.73,6.35)	0.04 (-0.01,0.16)
LD CERTO SC + MTX		2.19 (0.34,9.45)	2.10 (0.34,8.02)	0.03 (-0.03,0.19)
LD ETN SC + MTX		1.00 (0.23,4.25)	1.00 (0.24,3.96)	0.00 (-0.04,0.08)
LD TOCI IV + MTX		0.87 (0.13,3.80)	0.87 (0.13,3.54)	0.00 (-0.05,0.07)
HD TOCI IV		1.55 (0.59,4.07)	1.52 (0.60,3.87)	0.02 (-0.02,0.06)
HD GOLI SC		1.07 (0.12,5.91)	1.07 (0.13,5.34)	0.00 (-0.05,0.12)
HD ADA SC		0.47 (0.10,2.01)	0.48 (0.11,1.97)	-0.02 (-0.06,0.02)
HD TOFA		1.38 (0.26,8.10)	1.36 (0.28,7.27)	0.01 (-0.05,0.12)
HD ANA		1.60 (0.35,7.74)	1.57 (0.37,6.99)	0.02 (-0.04,0.11)
HD TOCI IV + MTX		2.03 (0.67,6.58)	1.96 (0.68,5.95)	0.03 (-0.02,0.12)
HD GOLI SC + MTX		3.20 (1.01,11.32)	2.97 (1.01,9.37)	0.06 (0.00,0.24)
HD INF IV + MTX		3.26 (1.23,8.35)	3.02 (1.21,7.28)	0.06 (0.01,0.17)
HD TOFA PO + MTX		2.82 (1.18,7.00)	2.65 (1.17,6.19)	0.05 (0.01,0.14)
HD CERTO SC + MTX		2.99 (0.95,9.37)	2.80 (0.95,7.92)	0.06 (0.00,0.18)
HD TOCI IV + DMARD		1.56 (0.49,5.11)	1.53 (0.50,4.73)	0.02 (-0.03,0.09)
SD ETN SC + DMARD	SD TOCI IV + MTX	0.42 (0.13,1.48)	0.44 (0.15,1.46)	-0.03 (-0.14,0.01)
SD CERTO + DMARD		0.57 (0.13,2.75)	0.58 (0.15,2.63)	-0.02 (-0.12,0.04)
SD ABA IV + DMARD		0.55 (0.14,2.19)	0.56 (0.16,2.10)	-0.02 (-0.12,0.03)
SD ADA SC + DMARD		0.47 (0.09,2.47)	0.49 (0.10,2.36)	-0.03 (-0.12,0.05)
SD TOCI SC + DMARD		1.02 (0.15,11.97)	1.01 (0.17,7.82)	0.00 (-0.11,0.33)
LD ETN SC		0.75 (0.23,2.33)	0.76 (0.26,2.25)	-0.01 (-0.11,0.04)
LD ADA SC		0.23 (0.05,1.05)	0.24 (0.05,1.05)	-0.04 (-0.15,0.00)
LD ANA		0.32 (0.07,2.09)	0.33 (0.08,2.03)	-0.04 (-0.14,0.03)
LD TOCI IV		0.61 (0.13,2.31)	0.63 (0.15,2.19)	-0.02 (-0.12,0.04)
LD RITUX IV + MTX		1.93 (0.47,13.68)	1.82 (0.50,8.72)	0.05 (-0.06,0.33)
LD ABA IV + MTX		1.20 (0.30,5.18)	1.18 (0.33,4.51)	0.01 (-0.09,0.14)
LD CERTO SC + MTX		1.12 (0.14,6.32)	1.11 (0.15,5.28)	0.01 (-0.11,0.16)

(Continued)

LD ETN SC + MTX		0.48 (0.10,2.96)	0.50 (0.11,2.76)	-0.03 (-0.13,0.07)
LD TOCI IV + MTX		0.44 (0.07,1.86)	0.46 (0.08,1.81)	-0.03 (-0.12,0.03)
HD TOCI IV		0.78 (0.28,2.44)	0.79 (0.31,2.34)	-0.01 (-0.10,0.04)
HD GOLI SC		0.51 (0.06,3.80)	0.53 (0.06,3.42)	-0.02 (-0.13,0.10)
HD ADA SC		0.23 (0.05,1.08)	0.24 (0.05,1.08)	-0.04 (-0.15,0.00)
HD TOFA		0.71 (0.11,4.57)	0.72 (0.13,4.14)	-0.02 (-0.13,0.10)
HD ANA		0.79 (0.16,4.42)	0.80 (0.18,4.00)	-0.01 (-0.12,0.09)
HD TOCI IV + MTX		1.06 (0.34,3.10)	1.05 (0.36,2.90)	0.00 (-0.08,0.08)
HD GOLI SC + MTX		1.68 (0.38,8.14)	1.61 (0.41,6.45)	0.03 (-0.07,0.22)
HD INF IV + MTX		1.64 (0.46,6.02)	1.57 (0.49,5.25)	0.03 (-0.06,0.15)
HD TOFA PO + MTX		1.39 (0.41,5.38)	1.36 (0.44,4.71)	0.02 (-0.07,0.14)
HD CERTO SC + MTX		1.57 (0.34,6.02)	1.52 (0.37,5.28)	0.03 (-0.08,0.15)
HD TOCI IV + DMARD		0.79 (0.22,3.36)	0.80 (0.24,3.14)	-0.01 (-0.11,0.07)
SD CERTO + DMARD	SD ETN SC + DMARD	1.39 (0.40,3.86)	1.38 (0.40,3.65)	0.01 (-0.02,0.06)
SD ABA IV + DMARD		1.30 (0.50,3.23)	1.29 (0.51,3.07)	0.01 (-0.02,0.05)
SD ADA SC + DMARD		1.13 (0.26,4.48)	1.13 (0.27,4.12)	0.00 (-0.03,0.08)
SD TOCI SC + DMARD		2.33 (0.50,21.45)	2.24 (0.51,13.22)	0.03 (-0.02,0.37)
LD ETN SC		1.75 (0.78,4.17)	1.71 (0.79,3.93)	0.02 (-0.01,0.06)
LD ADA SC		0.55 (0.14,1.84)	0.55 (0.14,1.81)	-0.01 (-0.04,0.02)
LD ANA		0.79 (0.19,3.58)	0.80 (0.20,3.43)	-0.01 (-0.04,0.05)
LD TOCI IV		1.43 (0.34,5.30)	1.42 (0.35,4.89)	0.01 (-0.03,0.08)
LD RITUX IV + MTX		4.68 (1.26,23.89)	4.24 (1.25,16.44)	0.09 (0.01,0.36)
LD ABA IV + MTX		2.96 (0.72,10.28)	2.80 (0.72,8.76)	0.05 (-0.01,0.17)
LD CERTO SC + MTX		2.66 (0.40,10.81)	2.53 (0.41,8.85)	0.04 (-0.02,0.20)
LD ETN SC + MTX		1.21 (0.25,4.70)	1.20 (0.26,4.32)	0.00 (-0.03,0.09)
LD TOCI IV + MTX		1.05 (0.18,4.30)	1.05 (0.18,4.00)	0.00 (-0.04,0.08)
HD TOCI IV		1.89 (0.81,4.21)	1.85 (0.81,3.98)	0.02 (-0.01,0.06)
HD GOLI SC		1.24 (0.14,7.96)	1.23 (0.14,6.96)	0.01 (-0.04,0.13)

(Continued)

HD ADA SC		0.57 (0.15,1.87)	0.57 (0.16,1.84)	-0.01 (-0.04,0.01)
HD TOFA		1.67 (0.28,9.51)	1.64 (0.29,8.34)	0.02 (-0.03,0.13)
HD ANA		1.87 (0.46,7.61)	1.83 (0.48,6.80)	0.02 (-0.02,0.12)
HD TOCI IV + MTX		2.46 (0.87,6.60)	2.36 (0.88,5.87)	0.04 (0.00,0.12)
HD GOLI SC + MTX		3.92 (1.14,14.50)	3.62 (1.13,11.20)	0.07 (0.00,0.26)
HD INF IV + MTX		3.92 (1.37,10.22)	3.61 (1.35,8.57)	0.07 (0.01,0.18)
HD TOFA PO + MTX		3.39 (1.22,8.78)	3.19 (1.21,7.60)	0.06 (0.01,0.16)
HD CERTO SC + MTX		3.67 (1.10,11.01)	3.40 (1.09,9.12)	0.06 (0.00,0.19)
HD TOCI IV + DMARD		1.91 (0.75,4.42)	1.86 (0.76,4.08)	0.02 (-0.01,0.09)
SD ABA IV + DMARD	SD CERTO + DMARD	0.94 (0.30,3.33)	0.94 (0.31,3.18)	0.00 (-0.05,0.05)
SD ADA SC + DMARD		0.83 (0.15,4.32)	0.83 (0.16,4.04)	-0.01 (-0.07,0.08)
SD TOCI SC + DMARD		1.85 (0.33,16.46)	1.79 (0.34,10.19)	0.02 (-0.04,0.35)
LD ETN SC		1.31 (0.40,4.34)	1.29 (0.42,4.12)	0.01 (-0.05,0.06)
LD ADA SC		0.39 (0.07,1.94)	0.40 (0.08,1.91)	-0.02 (-0.08,0.02)
LD ANA		0.58 (0.11,3.43)	0.59 (0.12,3.29)	-0.01 (-0.08,0.04)
LD TOCI IV		1.04 (0.21,4.88)	1.03 (0.22,4.56)	0.00 (-0.06,0.08)
LD RITUX IV + MTX		3.60 (0.71,18.43)	3.26 (0.73,13.17)	0.08 (-0.02,0.35)
LD ABA IV + MTX		2.27 (0.40,8.91)	2.16 (0.42,7.70)	0.04 (-0.04,0.16)
LD CERTO SC + MTX		1.98 (0.24,9.17)	1.89 (0.25,7.80)	0.03 (-0.05,0.18)
LD ETN SC + MTX		0.86 (0.17,4.71)	0.87 (0.17,4.31)	0.00 (-0.07,0.09)
LD TOCI IV + MTX		0.74 (0.12,4.29)	0.75 (0.13,4.01)	-0.01 (-0.07,0.07)
HD TOCI IV		1.39 (0.42,4.44)	1.37 (0.43,4.20)	0.01 (-0.04,0.06)
HD GOLI SC		0.91 (0.09,7.34)	0.92 (0.09,6.43)	0.00 (-0.07,0.13)
HD ADA SC		0.41 (0.09,1.89)	0.42 (0.09,1.86)	-0.02 (-0.08,0.01)
HD TOFA		1.25 (0.17,8.18)	1.24 (0.19,7.38)	0.01 (-0.07,0.12)
HD ANA		1.39 (0.30,7.33)	1.37 (0.31,6.54)	0.01 (-0.06,0.11)
HD TOCI IV + MTX		1.85 (0.48,6.83)	1.78 (0.50,6.20)	0.03 (-0.04,0.11)
HD GOLI SC + MTX		2.94 (0.60,15.08)	2.73 (0.62,11.65)	0.06 (-0.03,0.25)

(Continued)

HD INF IV + MTX		2.88 (0.75,10.33)	2.69 (0.76,8.90)	0.06 (-0.01,0.18)
HD TOFA PO + MTX		2.52 (0.67,9.17)	2.38 (0.69,7.95)	0.05 (-0.02,0.16)
HD CERTO SC + MTX		2.69 (0.67,9.81)	2.53 (0.69,8.44)	0.05 (-0.02,0.18)
HD TOCI IV + DMARD		1.35 (0.45,4.64)	1.33 (0.47,4.33)	0.01 (-0.04,0.09)
SD ADA SC + DMARD	SD ABA IV + DMARD	0.88 (0.21,3.50)	0.89 (0.22,3.29)	0.00 (-0.05,0.06)
SD TOCI SC + DMARD		1.84 (0.40,15.36)	1.78 (0.41,10.07)	0.02 (-0.03,0.35)
LD ETN SC		1.35 (0.49,4.05)	1.33 (0.51,3.86)	0.01 (-0.04,0.06)
LD ADA SC		0.41 (0.09,1.97)	0.42 (0.10,1.93)	-0.02 (-0.08,0.02)
LD ANA		0.61 (0.12,3.20)	0.62 (0.13,3.08)	-0.01 (-0.07,0.04)
LD TOCI IV		1.09 (0.25,4.69)	1.08 (0.25,4.37)	0.00 (-0.05,0.07)
LD RITUX IV + MTX		3.63 (0.89,17.74)	3.30 (0.90,12.40)	0.08 (-0.01,0.35)
LD ABA IV + MTX		2.29 (0.50,9.18)	2.18 (0.52,7.94)	0.04 (-0.03,0.17)
LD CERTO SC + MTX		2.03 (0.28,9.64)	1.95 (0.29,8.03)	0.03 (-0.04,0.19)
LD ETN SC + MTX		0.92 (0.18,4.09)	0.92 (0.19,3.80)	0.00 (-0.05,0.08)
LD TOCI IV + MTX		0.80 (0.12,4.04)	0.80 (0.13,3.78)	-0.01 (-0.06,0.07)
HD TOCI IV		1.46 (0.53,3.79)	1.44 (0.55,3.62)	0.01 (-0.03,0.06)
HD GOLI SC		1.00 (0.10,6.64)	1.00 (0.10,6.02)	0.00 (-0.06,0.12)
HD ADA SC		0.43 (0.09,1.89)	0.44 (0.10,1.86)	-0.02 (-0.07,0.01)
HD TOFA		1.27 (0.19,8.28)	1.25 (0.20,7.30)	0.01 (-0.06,0.12)
HD ANA		1.46 (0.33,7.39)	1.44 (0.35,6.66)	0.01 (-0.05,0.11)
HD TOCI IV + MTX		1.91 (0.57,6.17)	1.85 (0.59,5.62)	0.03 (-0.03,0.11)
HD GOLI SC + MTX		3.02 (0.75,12.91)	2.80 (0.76,10.46)	0.06 (-0.01,0.24)
HD INF IV + MTX		3.07 (0.87,9.09)	2.85 (0.88,8.04)	0.06 (-0.01,0.17)
HD TOFA PO + MTX		2.62 (0.82,8.06)	2.47 (0.83,7.11)	0.05 (-0.01,0.15)
HD CERTO SC + MTX		2.82 (0.74,9.54)	2.63 (0.75,8.18)	0.06 (-0.01,0.18)
HD TOCI IV + DMARD		1.45 (0.60,3.77)	1.43 (0.62,3.55)	0.01 (-0.02,0.07)
SD TOCI SC + DMARD	SD ADA SC + DMARD	2.07 (0.34,27.25)	1.98 (0.35,17.22)	0.03 (-0.05,0.37)

(Continued)

LD ETN SC		1.53 (0.35,6.97)	1.51 (0.37,6.62)	0.01 (-0.07,0.07)
LD ADA SC		0.48 (0.07,2.65)	0.49 (0.08,2.60)	-0.01 (-0.10,0.02)
LD ANA		0.68 (0.12,4.95)	0.69 (0.13,4.72)	-0.01 (-0.09,0.05)
LD TOCI IV		1.24 (0.19,7.93)	1.23 (0.21,7.38)	0.01 (-0.07,0.08)
LD RITUX IV + MTX		4.13 (0.69,31.08)	3.74 (0.71,21.92)	0.08 (-0.02,0.35)
LD ABA IV + MTX		2.55 (0.44,14.21)	2.42 (0.46,12.33)	0.04 (-0.05,0.18)
LD CERTO SC + MTX		2.28 (0.25,14.73)	2.17 (0.27,12.41)	0.03 (-0.06,0.19)
LD ETN SC + MTX		1.08 (0.17,6.01)	1.07 (0.18,5.62)	0.00 (-0.08,0.09)
LD TOCI IV + MTX		0.90 (0.11,5.76)	0.90 (0.12,5.41)	0.00 (-0.09,0.07)
HD TOCI IV		1.62 (0.41,7.14)	1.59 (0.43,6.69)	0.02 (-0.06,0.07)
HD GOLI SC		1.11 (0.08,9.24)	1.11 (0.08,8.34)	0.00 (-0.09,0.12)
HD ADA SC		0.49 (0.08,2.76)	0.50 (0.09,2.71)	-0.01 (-0.10,0.02)
HD TOFA		1.42 (0.17,12.52)	1.40 (0.18,11.15)	0.01 (-0.08,0.13)
HD ANA		1.69 (0.28,10.54)	1.65 (0.31,9.64)	0.02 (-0.07,0.11)
HD TOCI IV + MTX		2.17 (0.47,10.43)	2.09 (0.49,9.60)	0.03 (-0.04,0.12)
HD GOLI SC + MTX		3.52 (0.61,20.06)	3.21 (0.64,16.36)	0.06 (-0.03,0.24)
HD INF IV + MTX		3.47 (0.71,15.60)	3.20 (0.73,13.54)	0.06 (-0.02,0.17)
HD TOFA PO + MTX		2.93 (0.64,15.08)	2.75 (0.66,12.86)	0.05 (-0.03,0.16)
HD CERTO SC + MTX		3.26 (0.58,15.34)	3.02 (0.60,13.30)	0.06 (-0.03,0.18)
HD TOCI IV + DMARD		1.66 (0.42,6.93)	1.62 (0.44,6.49)	0.02 (-0.05,0.09)
LD ETN SC	SD TOCI SC + DMARD	0.74 (0.07,3.88)	0.75 (0.12,3.70)	-0.01 (-0.35,0.05)
LD ADA SC		0.24 (0.01,1.58)	0.25 (0.02,1.56)	-0.04 (-0.39,0.01)
LD ANA		0.34 (0.02,2.39)	0.35 (0.03,2.33)	-0.04 (-0.39,0.03)
LD TOCI IV		0.57 (0.04,4.60)	0.59 (0.07,4.32)	-0.02 (-0.35,0.06)
LD RITUX IV + MTX		1.96 (0.19,18.88)	1.83 (0.27,14.50)	0.04 (-0.25,0.30)
LD ABA IV + MTX		1.18 (0.10,9.75)	1.16 (0.15,8.54)	0.01 (-0.33,0.15)
LD CERTO SC + MTX		0.99 (0.09,9.20)	0.99 (0.11,7.69)	0.00 (-0.32,0.17)
LD ETN SC + MTX		0.51 (0.04,3.40)	0.53 (0.06,3.22)	-0.03 (-0.36,0.05)

(Continued)

LD TOCI IV + MTX		0.41 (0.03,3.45)	0.43 (0.04,3.27)	-0.03 (-0.38,0.05)
HD TOCI IV		0.78 (0.09,4.24)	0.79 (0.13,4.04)	-0.01 (-0.34,0.05)
HD GOLI SC		0.49 (0.02,6.37)	0.51 (0.04,5.81)	-0.03 (-0.37,0.11)
HD ADA SC		0.24 (0.02,1.69)	0.25 (0.03,1.67)	-0.04 (-0.39,0.01)
HD TOFA		0.69 (0.03,7.36)	0.70 (0.04,6.68)	-0.02 (-0.38,0.11)
HD ANA		0.76 (0.05,5.66)	0.77 (0.08,5.22)	-0.01 (-0.37,0.09)
HD TOCI IV + MTX		1.02 (0.10,5.63)	1.02 (0.15,5.17)	0.00 (-0.31,0.09)
HD GOLI SC + MTX		1.57 (0.16,11.86)	1.51 (0.22,9.86)	0.03 (-0.28,0.21)
HD INF IV + MTX		1.63 (0.16,8.70)	1.57 (0.24,7.68)	0.03 (-0.29,0.15)
HD TOFA PO + MTX		1.40 (0.15,8.64)	1.36 (0.21,7.45)	0.02 (-0.30,0.14)
HD CERTO SC + MTX		1.43 (0.16,10.29)	1.39 (0.22,8.74)	0.02 (-0.28,0.17)
HD TOCI IV + DMARD		0.79 (0.10,3.53)	0.81 (0.15,3.36)	-0.01 (-0.32,0.06)
LD ADA SC	LD ETN SC	0.30 (0.08,1.22)	0.31 (0.09,1.21)	-0.03 (-0.08,0.01)
LD ANA		0.43 (0.11,2.16)	0.44 (0.12,2.07)	-0.02 (-0.08,0.03)
LD TOCI IV		0.82 (0.20,2.75)	0.83 (0.21,2.57)	-0.01 (-0.06,0.06)
LD RITUX IV + MTX		2.65 (0.85,10.20)	2.45 (0.85,7.18)	0.06 (-0.01,0.33)
LD ABA IV + MTX		1.66 (0.50,5.08)	1.61 (0.51,4.41)	0.03 (-0.03,0.15)
LD CERTO SC + MTX		1.47 (0.24,6.01)	1.44 (0.25,5.04)	0.02 (-0.04,0.17)
LD ETN SC + MTX		0.69 (0.16,2.48)	0.70 (0.17,2.34)	-0.01 (-0.07,0.06)
LD TOCI IV + MTX		0.59 (0.10,2.49)	0.60 (0.10,2.35)	-0.02 (-0.07,0.05)
HD TOCI IV		1.07 (0.49,2.36)	1.07 (0.51,2.27)	0.00 (-0.04,0.04)
HD GOLI SC		0.70 (0.08,4.00)	0.71 (0.09,3.59)	-0.01 (-0.07,0.11)
HD ADA SC		0.32 (0.09,1.19)	0.33 (0.09,1.18)	-0.03 (-0.08,0.00)
HD TOFA		0.96 (0.17,5.29)	0.97 (0.18,4.74)	0.00 (-0.07,0.11)
HD ANA		1.06 (0.26,4.60)	1.06 (0.27,4.15)	0.00 (-0.06,0.10)
HD TOCI IV + MTX		1.38 (0.53,3.94)	1.35 (0.54,3.55)	0.02 (-0.03,0.10)
HD GOLI SC + MTX		2.25 (0.72,7.04)	2.12 (0.74,5.65)	0.05 (-0.01,0.22)
HD INF IV + MTX		2.24 (0.91,5.05)	2.10 (0.92,4.43)	0.05 (0.00,0.15)



(Continued)

HD TOFA PO + MTX		1.94 (0.84,4.19)	1.86 (0.85,3.71)	0.04 (-0.01,0.13)
HD CERTO SC + MTX		2.07 (0.71,5.33)	1.96 (0.73,4.60)	0.04 (-0.01,0.16)
HD TOCI IV + DMARD		1.07 (0.37,3.06)	1.07 (0.39,2.86)	0.00 (-0.05,0.07)
LD ANA	LD ADA SC	1.44 (0.31,8.09)	1.43 (0.31,7.57)	0.01 (-0.02,0.06)
LD TOCI IV		2.66 (0.40,14.95)	2.59 (0.41,13.66)	0.02 (-0.02,0.10)
LD RITUX IV + MTX		8.62 (1.37,57.32)	7.68 (1.35,40.36)	0.10 (0.01,0.38)
LD ABA IV + MTX		5.56 (0.94,24.86)	5.16 (0.94,21.40)	0.06 (0.00,0.19)
LD CERTO SC + MTX		4.88 (0.47,30.85)	4.58 (0.48,25.09)	0.05 (-0.01,0.21)
LD ETN SC + MTX		2.20 (0.37,13.74)	2.15 (0.38,12.44)	0.02 (-0.02,0.11)
LD TOCI IV + MTX		1.92 (0.29,12.66)	1.90 (0.29,11.49)	0.01 (-0.02,0.09)
HD TOCI IV		3.45 (0.85,14.87)	3.32 (0.85,13.75)	0.03 (0.00,0.09)
HD GOLI SC		2.36 (0.20,18.20)	2.30 (0.20,16.26)	0.02 (-0.03,0.14)
HD ADA SC		1.02 (0.28,3.57)	1.02 (0.29,3.50)	0.00 (-0.02,0.02)
HD TOFA		2.99 (0.46,23.86)	2.90 (0.47,21.13)	0.03 (-0.02,0.14)
HD ANA		3.54 (0.81,18.38)	3.41 (0.81,16.47)	0.03 (-0.01,0.13)
HD TOCI IV + MTX		4.59 (1.12,25.04)	4.33 (1.11,21.54)	0.05 (0.00,0.15)
HD GOLI SC + MTX		7.41 (1.26,35.91)	6.72 (1.25,28.23)	0.08 (0.01,0.27)
HD INF IV + MTX		7.39 (1.53,30.49)	6.71 (1.50,25.84)	0.08 (0.01,0.20)
HD TOFA PO + MTX		6.24 (1.50,26.17)	5.79 (1.48,22.53)	0.07 (0.01,0.18)
HD CERTO SC + MTX		6.85 (1.31,32.18)	6.25 (1.29,26.32)	0.08 (0.01,0.21)
HD TOCI IV + DMARD		3.49 (0.83,16.32)	3.37 (0.84,14.62)	0.03 (0.00,0.12)
LD TOCI IV	LD ANA	1.82 (0.25,9.92)	1.79 (0.26,9.13)	0.02 (-0.04,0.10)
LD RITUX IV + MTX		6.14 (0.88,38.40)	5.47 (0.89,27.35)	0.09 (-0.01,0.37)
LD ABA IV + MTX		3.75 (0.56,22.34)	3.53 (0.57,18.83)	0.05 (-0.02,0.19)
LD CERTO SC + MTX		3.29 (0.29,22.13)	3.12 (0.30,18.27)	0.05 (-0.03,0.21)
LD ETN SC + MTX		1.57 (0.19,9.74)	1.55 (0.20,8.84)	0.01 (-0.05,0.10)
LD TOCI IV + MTX		1.28 (0.15,9.16)	1.27 (0.16,8.47)	0.01 (-0.05,0.09)
HD TOCI IV		2.43 (0.48,9.80)	2.36 (0.50,9.15)	0.03 (-0.03,0.08)

(Continued)

HD GOLI SC		1.62 (0.11,13.13)	1.60 (0.12,11.58)	0.01 (-0.05,0.14)
HD ADA SC		0.72 (0.09,3.37)	0.73 (0.10,3.29)	-0.01 (-0.06,0.02)
HD TOFA		2.10 (0.32,16.47)	2.05 (0.34,14.50)	0.02 (-0.04,0.13)
HD ANA		2.32 (0.81,7.38)	2.25 (0.82,6.87)	0.03 (-0.01,0.10)
HD TOCI IV + MTX		3.20 (0.54,15.11)	3.04 (0.56,13.35)	0.04 (-0.03,0.14)
HD GOLI SC + MTX		5.38 (0.80,27.56)	4.89 (0.81,21.65)	0.07 (-0.01,0.27)
HD INF IV + MTX		5.09 (0.89,23.21)	4.66 (0.90,19.49)	0.07 (0.00,0.19)
HD TOFA PO + MTX		4.37 (0.81,22.35)	4.06 (0.82,18.77)	0.06 (-0.01,0.18)
HD CERTO SC + MTX		4.57 (0.79,22.13)	4.21 (0.80,18.75)	0.07 (-0.01,0.20)
HD TOCI IV + DMARD		2.40 (0.47,11.30)	2.32 (0.48,10.27)	0.03 (-0.03,0.11)
LD RITUX IV + MTX	LD TOCI IV	3.28 (0.72,21.10)	2.98 (0.73,15.12)	0.07 (-0.02,0.35)
LD ABA IV + MTX		2.10 (0.37,10.21)	2.01 (0.40,8.71)	0.03 (-0.05,0.16)
LD CERTO SC + MTX		1.78 (0.23,11.92)	1.72 (0.24,9.97)	0.03 (-0.05,0.19)
LD ETN SC + MTX		0.87 (0.15,4.94)	0.87 (0.16,4.57)	0.00 (-0.08,0.08)
LD TOCI IV + MTX		0.73 (0.12,3.60)	0.74 (0.13,3.42)	-0.01 (-0.08,0.06)
HD TOCI IV		1.29 (0.45,4.64)	1.27 (0.47,4.44)	0.01 (-0.05,0.06)
HD GOLI SC		0.89 (0.08,6.92)	0.90 (0.09,6.19)	0.00 (-0.09,0.12)
HD ADA SC		0.39 (0.08,2.25)	0.40 (0.08,2.22)	-0.02 (-0.10,0.02)
HD TOFA		1.16 (0.15,9.94)	1.15 (0.16,8.89)	0.01 (-0.09,0.12)
HD ANA		1.31 (0.26,8.56)	1.29 (0.28,7.68)	0.01 (-0.07,0.11)
HD TOCI IV + MTX		1.70 (0.54,6.34)	1.65 (0.57,5.89)	0.02 (-0.04,0.10)
HD GOLI SC + MTX		2.79 (0.59,13.55)	2.58 (0.62,11.16)	0.06 (-0.03,0.24)
HD INF IV + MTX		2.72 (0.68,11.98)	2.54 (0.70,10.42)	0.06 (-0.03,0.18)
HD TOFA PO + MTX		2.33 (0.65,10.94)	2.21 (0.67,9.58)	0.04 (-0.03,0.15)
HD CERTO SC + MTX		2.50 (0.57,11.84)	2.34 (0.60,10.12)	0.05 (-0.03,0.18)
HD TOCI IV + DMARD		1.30 (0.33,6.43)	1.29 (0.35,5.99)	0.01 (-0.06,0.09)
LD ABA IV + MTX	LD RITUX IV + MTX	0.62 (0.13,2.39)	0.66 (0.16,2.22)	-0.04 (-0.27,0.08)
LD CERTO SC + MTX		0.56 (0.06,3.24)	0.60 (0.07,2.83)	-0.04 (-0.31,0.12)

(Continued)

LD ETN SC + MTX		0.26 (0.04,1.20)	0.29 (0.05,1.19)	-0.08 (-0.35,0.01)
LD TOCI IV + MTX		0.22 (0.03,1.15)	0.24 (0.04,1.14)	-0.08 (-0.35,0.01)
HD TOCI IV		0.40 (0.10,1.34)	0.43 (0.15,1.32)	-0.06 (-0.33,0.01)
HD GOLI SC		0.27 (0.03,1.63)	0.30 (0.03,1.56)	-0.07 (-0.35,0.04)
HD ADA SC		0.12 (0.01,0.64)	0.13 (0.02,0.66)	-0.10 (-0.38,-0.01)
HD TOFA		0.36 (0.05,2.62)	0.39 (0.07,2.41)	-0.06 (-0.35,0.07)
HD ANA		0.40 (0.06,2.30)	0.43 (0.09,2.15)	-0.06 (-0.34,0.06)
HD TOCI IV + MTX		0.54 (0.11,1.99)	0.57 (0.15,1.89)	-0.05 (-0.32,0.05)
HD GOLI SC + MTX		0.83 (0.14,3.38)	0.85 (0.21,2.93)	-0.01 (-0.29,0.15)
HD INF IV + MTX		0.82 (0.20,2.59)	0.84 (0.27,2.38)	-0.02 (-0.26,0.09)
HD TOFA PO + MTX		0.75 (0.18,2.27)	0.77 (0.24,2.13)	-0.02 (-0.25,0.06)
HD CERTO SC + MTX		0.77 (0.17,2.79)	0.79 (0.23,2.51)	-0.02 (-0.28,0.10)
HD TOCI IV + DMARD		0.40 (0.08,1.65)	0.43 (0.12,1.59)	-0.06 (-0.33,0.03)
LD CERTO SC + MTX	LD ABA IV + MTX	0.87 (0.12,5.00)	0.88 (0.14,4.36)	-0.01 (-0.13,0.14)
LD ETN SC + MTX		0.41 (0.08,2.14)	0.43 (0.09,2.03)	-0.04 (-0.17,0.05)
LD TOCI IV + MTX		0.36 (0.05,1.88)	0.38 (0.06,1.81)	-0.04 (-0.18,0.03)
HD TOCI IV		0.63 (0.20,2.35)	0.65 (0.23,2.26)	-0.03 (-0.15,0.04)
HD GOLI SC		0.43 (0.04,3.00)	0.45 (0.04,2.76)	-0.04 (-0.17,0.08)
HD ADA SC		0.19 (0.04,1.04)	0.21 (0.04,1.04)	-0.06 (-0.19,0.00)
HD TOFA		0.58 (0.09,3.96)	0.60 (0.11,3.63)	-0.03 (-0.17,0.09)
HD ANA		0.63 (0.12,3.99)	0.65 (0.15,3.68)	-0.02 (-0.16,0.08)
HD TOCI IV + MTX		0.83 (0.24,3.43)	0.84 (0.27,3.17)	-0.01 (-0.13,0.09)
HD GOLI SC + MTX		1.36 (0.34,5.61)	1.32 (0.38,4.67)	0.02 (-0.10,0.19)
HD INF IV + MTX		1.31 (0.42,4.73)	1.28 (0.45,4.21)	0.02 (-0.08,0.12)
HD TOFA PO + MTX		1.17 (0.35,3.83)	1.15 (0.39,3.53)	0.01 (-0.10,0.10)
HD CERTO SC + MTX		1.18 (0.35,5.34)	1.17 (0.39,4.66)	0.01 (-0.09,0.14)
HD TOCI IV + DMARD		0.64 (0.16,2.81)	0.66 (0.19,2.67)	-0.02 (-0.15,0.06)
LD ETN SC + MTX	LD CERTO SC + MTX	0.46 (0.07,3.96)	0.48 (0.08,3.68)	-0.03 (-0.19,0.06)

(Continued)

LD TOCI IV + MTX		0.40 (0.05,3.88)	0.42 (0.05,3.67)	-0.04 (-0.20,0.05)
HD TOCI IV		0.71 (0.16,4.53)	0.73 (0.19,4.33)	-0.02 (-0.17,0.05)
HD GOLI SC		0.48 (0.03,6.26)	0.51 (0.04,5.75)	-0.03 (-0.19,0.09)
HD ADA SC		0.21 (0.04,2.13)	0.22 (0.05,2.10)	-0.05 (-0.21,0.01)
HD TOFA		0.67 (0.08,8.97)	0.68 (0.09,8.20)	-0.02 (-0.19,0.11)
HD ANA		0.72 (0.12,7.23)	0.73 (0.14,6.73)	-0.02 (-0.18,0.09)
HD TOCI IV + MTX		0.95 (0.18,6.83)	0.95 (0.22,6.35)	0.00 (-0.16,0.10)
HD GOLI SC + MTX		1.54 (0.27,12.02)	1.48 (0.31,10.30)	0.03 (-0.13,0.19)
HD INF IV + MTX		1.54 (0.34,9.25)	1.48 (0.38,8.37)	0.03 (-0.12,0.13)
HD TOFA PO + MTX		1.27 (0.32,8.90)	1.24 (0.37,7.99)	0.02 (-0.12,0.12)
HD CERTO SC + MTX		1.36 (0.38,8.62)	1.32 (0.42,7.83)	0.02 (-0.10,0.13)
HD TOCI IV + DMARD		0.71 (0.17,4.89)	0.73 (0.19,4.59)	-0.02 (-0.17,0.07)
LD TOCI IV + MTX	LD ETN SC + MTX	0.87 (0.12,5.40)	0.88 (0.13,5.11)	0.00 (-0.09,0.06)
HD TOCI IV		1.55 (0.41,6.44)	1.53 (0.44,6.08)	0.02 (-0.06,0.07)
HD GOLI SC		1.09 (0.09,8.28)	1.08 (0.09,7.38)	0.00 (-0.09,0.13)
HD ADA SC		0.47 (0.08,2.82)	0.48 (0.09,2.77)	-0.02 (-0.11,0.02)
HD TOFA		1.30 (0.19,11.98)	1.29 (0.20,10.81)	0.01 (-0.09,0.13)
HD ANA		1.59 (0.24,10.01)	1.56 (0.26,9.11)	0.02 (-0.09,0.11)
HD TOCI IV + MTX		2.11 (0.46,9.23)	2.03 (0.48,8.44)	0.03 (-0.05,0.12)
HD GOLI SC + MTX		3.37 (0.69,15.82)	3.09 (0.71,13.13)	0.06 (-0.02,0.24)
HD INF IV + MTX		3.24 (0.80,12.75)	3.01 (0.82,11.40)	0.06 (-0.01,0.17)
HD TOFA PO + MTX		2.77 (0.72,14.24)	2.61 (0.74,12.29)	0.05 (-0.02,0.16)
HD CERTO SC + MTX		2.99 (0.57,14.18)	2.79 (0.60,12.47)	0.05 (-0.04,0.18)
HD TOCI IV + DMARD		1.57 (0.37,8.18)	1.54 (0.39,7.65)	0.02 (-0.06,0.09)
HD TOCI IV	LD TOCI IV + MTX	1.79 (0.48,9.72)	1.75 (0.50,9.20)	0.02 (-0.05,0.07)
HD GOLI SC		1.15 (0.14,13.22)	1.15 (0.14,11.88)	0.00 (-0.06,0.13)
HD ADA SC		0.52 (0.11,3.57)	0.53 (0.12,3.49)	-0.01 (-0.09,0.02)
HD TOFA		1.65 (0.24,15.03)	1.62 (0.26,13.35)	0.01 (-0.06,0.13)

(Continued)

HD ANA		1.91 (0.27,14.13)	1.86 (0.29,12.88)	0.02 (-0.07,0.12)
HD TOCI IV + MTX		2.34 (0.61,13.07)	2.24 (0.63,11.72)	0.03 (-0.03,0.12)
HD GOLI SC + MTX		3.87 (0.70,28.06)	3.56 (0.72,23.65)	0.06 (-0.02,0.25)
HD INF IV + MTX		3.82 (0.87,22.47)	3.52 (0.88,19.76)	0.07 (-0.01,0.19)
HD TOFA PO + MTX		3.29 (0.75,19.51)	3.08 (0.77,17.42)	0.05 (-0.02,0.16)
HD CERTO SC + MTX		3.57 (0.68,22.55)	3.30 (0.70,19.56)	0.06 (-0.02,0.19)
HD TOCI IV + DMARD		1.81 (0.38,12.15)	1.77 (0.40,11.15)	0.02 (-0.05,0.10)
HD GOLI SC	HD TOCI IV	0.67 (0.08,3.76)	0.68 (0.08,3.37)	-0.01 (-0.07,0.11)
HD ADA SC		0.30 (0.08,1.10)	0.31 (0.08,1.10)	-0.03 (-0.09,0.00)
HD TOFA		0.90 (0.14,5.15)	0.90 (0.15,4.61)	0.00 (-0.08,0.11)
HD ANA		1.02 (0.25,4.24)	1.02 (0.27,3.87)	0.00 (-0.07,0.10)
HD TOCI IV + MTX		1.31 (0.62,2.97)	1.29 (0.64,2.74)	0.01 (-0.02,0.08)
HD GOLI SC + MTX		2.09 (0.65,6.95)	1.97 (0.67,5.57)	0.05 (-0.02,0.22)
HD INF IV + MTX		2.08 (0.82,4.98)	1.97 (0.83,4.36)	0.05 (-0.01,0.15)
HD TOFA PO + MTX		1.77 (0.76,4.46)	1.70 (0.77,3.95)	0.03 (-0.02,0.13)
HD CERTO SC + MTX		1.94 (0.62,5.34)	1.84 (0.63,4.59)	0.04 (-0.02,0.16)
HD TOCI IV + DMARD		0.98 (0.41,2.63)	0.98 (0.42,2.47)	0.00 (-0.04,0.06)
HD ADA SC	HD GOLI SC	0.43 (0.06,4.25)	0.43 (0.07,4.15)	-0.02 (-0.15,0.02)
HD TOFA		1.33 (0.16,16.40)	1.31 (0.18,14.89)	0.01 (-0.12,0.12)
HD ANA		1.48 (0.19,18.42)	1.45 (0.21,16.51)	0.01 (-0.12,0.12)
HD TOCI IV + MTX		1.93 (0.28,17.16)	1.86 (0.31,15.78)	0.03 (-0.10,0.13)
HD GOLI SC + MTX		3.12 (0.64,21.46)	2.88 (0.68,18.85)	0.06 (-0.03,0.22)
HD INF IV + MTX		3.12 (0.53,27.43)	2.88 (0.56,23.72)	0.06 (-0.05,0.17)
HD TOFA PO + MTX		2.69 (0.45,23.24)	2.53 (0.49,20.88)	0.05 (-0.07,0.15)
HD CERTO SC + MTX		2.81 (0.43,27.49)	2.62 (0.46,24.09)	0.05 (-0.07,0.18)
HD TOCI IV + DMARD		1.43 (0.23,14.99)	1.41 (0.25,13.84)	0.01 (-0.11,0.10)
HD TOFA	HD ADA SC	3.13 (0.49,18.47)	3.02 (0.50,16.34)	0.03 (-0.01,0.14)
HD ANA		3.24 (0.79,19.98)	3.12 (0.79,17.83)	0.03 (-0.01,0.13)

(Continued)

HD TOCI IV + MTX		4.33 (1.13,18.72)	4.10 (1.12,16.72)	0.05 (0.00,0.15)
HD GOLI SC + MTX		7.26 (1.58,35.84)	6.56 (1.55,28.74)	0.08 (0.01,0.27)
HD INF IV + MTX		7.15 (1.65,30.74)	6.49 (1.62,26.12)	0.08 (0.01,0.20)
HD TOFA PO + MTX		6.05 (1.50,26.47)	5.57 (1.47,22.99)	0.07 (0.01,0.18)
HD CERTO SC + MTX		6.70 (1.34,28.73)	6.11 (1.33,24.30)	0.08 (0.01,0.21)
HD TOCI IV + DMARD		3.33 (0.83,15.41)	3.21 (0.83,14.08)	0.03 (0.00,0.11)
HD ANA	HD TOFA	1.11 (0.17,6.20)	1.10 (0.19,5.65)	0.00 (-0.11,0.10)
HD TOCI IV + MTX		1.46 (0.22,10.93)	1.43 (0.25,9.74)	0.02 (-0.10,0.13)
HD GOLI SC + MTX		2.32 (0.32,19.22)	2.18 (0.35,14.99)	0.05 (-0.08,0.25)
HD INF IV + MTX		2.32 (0.37,16.42)	2.19 (0.40,13.67)	0.05 (-0.08,0.19)
HD TOFA PO + MTX		2.09 (0.33,10.76)	1.99 (0.36,9.37)	0.04 (-0.08,0.16)
HD CERTO SC + MTX		2.17 (0.31,18.28)	2.06 (0.34,14.85)	0.05 (-0.08,0.20)
HD TOCI IV + DMARD		1.18 (0.17,8.33)	1.17 (0.19,7.64)	0.01 (-0.11,0.10)
HD TOCI IV + MTX	HD ANA	1.32 (0.27,6.07)	1.30 (0.29,5.38)	0.01 (-0.09,0.12)
HD GOLI SC + MTX		2.12 (0.40,11.43)	2.00 (0.43,8.78)	0.04 (-0.07,0.24)
HD INF IV + MTX		2.04 (0.41,9.42)	1.93 (0.44,7.93)	0.04 (-0.07,0.17)
HD TOFA PO + MTX		1.82 (0.39,8.12)	1.74 (0.42,7.03)	0.03 (-0.07,0.15)
HD CERTO SC + MTX		1.97 (0.34,8.66)	1.87 (0.37,7.38)	0.04 (-0.07,0.18)
HD TOCI IV + DMARD		1.02 (0.21,4.29)	1.02 (0.23,3.97)	0.00 (-0.10,0.08)
HD GOLI SC + MTX	HD TOCI IV + MTX	1.54 (0.43,7.13)	1.49 (0.45,5.59)	0.03 (-0.06,0.22)
HD INF IV + MTX		1.59 (0.53,4.84)	1.53 (0.56,4.20)	0.03 (-0.05,0.14)
HD TOFA PO + MTX		1.36 (0.48,4.33)	1.33 (0.51,3.81)	0.02 (-0.06,0.12)
HD CERTO SC + MTX		1.52 (0.39,4.84)	1.47 (0.42,4.24)	0.03 (-0.07,0.14)
HD TOCI IV + DMARD		0.75 (0.25,2.48)	0.76 (0.27,2.33)	-0.01 (-0.10,0.06)
HD INF IV + MTX	HD GOLI SC + MTX	0.99 (0.29,3.09)	0.99 (0.34,2.81)	0.00 (-0.15,0.10)
HD TOFA PO + MTX		0.84 (0.27,2.75)	0.85 (0.32,2.52)	-0.01 (-0.16,0.09)
HD CERTO SC + MTX		0.91 (0.23,3.61)	0.92 (0.27,3.18)	-0.01 (-0.17,0.11)
HD TOCI IV + DMARD		0.47 (0.12,2.10)	0.49 (0.14,2.00)	-0.05 (-0.22,0.04)

(Continued)

HD TOFA PO + MTX	HD INF IV + MTX	0.86 (0.37,2.15)	0.87 (0.41,2.00)	-0.01 (-0.10,0.07)
HD CERTO SC + MTX		0.94 (0.30,2.74)	0.95 (0.33,2.49)	0.00 (-0.11,0.10)
HD TOCI IV + DMARD		0.48 (0.16,1.67)	0.51 (0.19,1.61)	-0.05 (-0.16,0.03)
HD CERTO SC + MTX	HD TOFA PO + MTX	1.08 (0.36,3.03)	1.07 (0.39,2.68)	0.00 (-0.09,0.12)
HD TOCI IV + DMARD		0.55 (0.18,1.81)	0.57 (0.20,1.73)	-0.03 (-0.14,0.04)
HD TOCI IV + DMARD	HD CERTO SC + MTX	0.52 (0.16,2.00)	0.54 (0.18,1.92)	-0.04 (-0.16,0.04)
Random-Effect Model	Residual Deviance	181.1 vs 179 data points		
	Deviance Information Criteria	904.308		
Fixed-Effect Model	Residual Deviance	vs data points		
	Deviance Information Criteria			
Note:				
Total Patients				
Total Studies				
2-arm				

### Appendix 31. Withdrawals due to AE: Subgroup - Established RA (2 to 10 years)

Withdrawals in Established RA: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX	PL	4.16 (1.40,14.34)	3.82 (1.39,11.43)	0.07 (0.01,0.21)
DMARD		1.15 (0.35,3.27)	1.15 (0.35,3.11)	0.00 (-0.02,0.05)
MTX + DMARD		12.33 (3.59,52.86)	9.51 (3.35,26.49)	0.22 (0.05,0.52)
SD ETN SC		4.38 (1.53,13.94)	4.02 (1.51,11.03)	0.07 (0.01,0.23)
SD ADA SC		1.88 (0.74,4.66)	1.83 (0.74,4.34)	0.02 (-0.01,0.07)

(Continued)

SD TOCI IV	1.10 (0.28,4.22)	1.09 (0.28,3.94)	0.00 (-0.02,0.06)
SD CERTO SC	2.79 (0.85,13.90)	2.67 (0.86,11.36)	0.04 (0.00,0.19)
SD TOC SC + PL IV	0.74 (0.16,3.46)	0.74 (0.16,3.29)	-0.01 (-0.03,0.05)
SD ANA	1.33 (0.43,5.50)	1.31 (0.44,4.98)	0.01 (-0.02,0.10)
SD ETN SC + MTX	3.99 (1.26,13.55)	3.71 (1.26,10.84)	0.07 (0.01,0.22)
SD INF IV + MTX	10.77 (3.24,41.96)	8.52 (3.04,23.16)	0.19 (0.05,0.47)
SD ABA IV + MTX	4.10 (1.10,17.02)	3.79 (1.10,12.95)	0.07 (0.00,0.25)
SD CERTO SC + MTX	5.89 (1.67,21.44)	5.22 (1.64,14.98)	0.10 (0.02,0.31)
SD ADA SC + MTX	5.65 (1.51,22.53)	5.05 (1.48,15.90)	0.10 (0.01,0.32)
SD GOLI SC + MTX	6.12 (1.21,34.77)	5.38 (1.20,20.95)	0.11 (0.00,0.42)
SD TOFA PO + MTX	7.66 (2.03,28.75)	6.48 (1.98,18.76)	0.14 (0.02,0.37)
SD ABA SC + MTX	2.35 (0.48,10.73)	2.28 (0.49,8.91)	0.03 (-0.01,0.18)
SD ETN SC + DMARD	2.14 (0.72,6.14)	2.08 (0.73,5.55)	0.03 (-0.01,0.11)
SD CERTO SC + DMARD	1.56 (0.44,5.61)	1.54 (0.45,5.07)	0.01 (-0.02,0.10)
SD ADA SC + DMARD	1.38 (0.24,7.00)	1.37 (0.25,6.12)	0.01 (-0.02,0.12)
LD ETN SC	4.75 (1.40,18.66)	4.33 (1.38,13.86)	0.08 (0.01,0.29)
LD ADA SC	0.67 (0.18,2.27)	0.67 (0.19,2.20)	-0.01 (-0.03,0.03)
LD ANA	1.01 (0.30,3.95)	1.01 (0.30,3.68)	0.00 (-0.02,0.07)
LD ABA IV + MTX	4.98 (1.18,25.38)	4.52 (1.18,17.01)	0.09 (0.00,0.35)
LD CERTO SC + MTX	4.16 (0.64,22.14)	3.85 (0.65,14.79)	0.07 (-0.01,0.34)
LD ETN SC + MTX	2.59 (0.50,12.69)	2.50 (0.51,10.09)	0.04 (-0.01,0.21)
HD TOCI IV	2.73 (0.85,8.26)	2.61 (0.86,7.25)	0.04 (0.00,0.13)
HD ADA SC	0.68 (0.18,2.20)	0.68 (0.19,2.14)	-0.01 (-0.03,0.02)
HD ANA	2.47 (0.84,8.49)	2.39 (0.84,7.29)	0.03 (0.00,0.15)
HD TOCI IV + MTX	3.65 (0.83,15.79)	3.42 (0.83,12.09)	0.06 (0.00,0.25)
HD GOLI SC + MTX	8.63 (1.73,51.09)	7.22 (1.69,25.93)	0.15 (0.02,0.50)
HD TOFA PO + MTX	5.91 (1.60,21.68)	5.21 (1.57,15.42)	0.11 (0.01,0.31)
HD CERTO SC + MTX	6.36 (1.50,25.92)	5.57 (1.48,17.21)	0.11 (0.01,0.36)



(Continued)

HD INF IV + MTX		11.49 (2.97,47.79)	9.00 (2.82,24.75)	0.20 (0.04,0.51)
HD TOCI IV + DMARD		2.26 (0.57,8.05)	2.19 (0.58,6.96)	0.03 (-0.01,0.14)
DMARD	MTX	0.27 (0.10,0.74)	0.30 (0.12,0.75)	-0.06 (-0.19,-0.01)
MTX + DMARD		3.04 (1.41,6.63)	2.48 (1.34,4.54)	0.14 (0.03,0.35)
SD ETN SC		1.06 (0.67,1.79)	1.05 (0.70,1.68)	0.00 (-0.04,0.06)
SD ADA SC		0.44 (0.14,1.36)	0.47 (0.17,1.33)	-0.05 (-0.18,0.02)
SD TOCI IV		0.27 (0.05,1.13)	0.29 (0.06,1.13)	-0.07 (-0.20,0.01)
SD CERTO SC		0.69 (0.13,4.72)	0.71 (0.16,4.09)	-0.03 (-0.18,0.13)
SD TOC SC + PL IV		0.18 (0.03,0.90)	0.20 (0.04,0.91)	-0.07 (-0.21,0.00)
SD ANA		0.32 (0.06,1.80)	0.35 (0.07,1.71)	-0.06 (-0.21,0.04)
SD ETN SC + MTX		0.97 (0.59,1.57)	0.97 (0.62,1.50)	0.00 (-0.05,0.05)
SD INF IV + MTX		2.64 (1.44,4.87)	2.24 (1.37,3.66)	0.12 (0.03,0.29)
SD ABA IV + MTX		0.98 (0.49,1.91)	0.98 (0.51,1.75)	0.00 (-0.05,0.09)
SD CERTO SC + MTX		1.38 (0.78,2.67)	1.32 (0.80,2.34)	0.03 (-0.02,0.14)
SD ADA SC + MTX		1.36 (0.65,3.10)	1.31 (0.67,2.57)	0.03 (-0.04,0.17)
SD GOLI SC + MTX		1.52 (0.39,5.54)	1.43 (0.42,3.94)	0.04 (-0.07,0.29)
SD TOFA PO + MTX		1.82 (0.96,3.36)	1.67 (0.97,2.74)	0.06 (0.00,0.20)
SD ABA SC + MTX		0.55 (0.19,1.57)	0.58 (0.21,1.47)	-0.03 (-0.12,0.05)
SD ETN SC + DMARD		0.52 (0.19,1.31)	0.54 (0.22,1.29)	-0.04 (-0.15,0.02)
SD CERTO SC + DMARD		0.37 (0.09,1.52)	0.39 (0.11,1.48)	-0.05 (-0.19,0.03)
SD ADA SC + DMARD		0.32 (0.07,1.58)	0.35 (0.08,1.51)	-0.06 (-0.19,0.04)
LD ETN SC		1.18 (0.55,2.68)	1.15 (0.58,2.33)	0.01 (-0.05,0.14)
LD ADA SC		0.16 (0.04,0.70)	0.17 (0.04,0.72)	-0.08 (-0.22,-0.01)
LD ANA		0.24 (0.04,1.36)	0.26 (0.05,1.33)	-0.07 (-0.21,0.02)
LD ABA IV + MTX		1.24 (0.45,3.45)	1.20 (0.47,2.83)	0.02 (-0.06,0.19)
LD CERTO SC + MTX		0.97 (0.21,4.35)	0.97 (0.23,3.42)	0.00 (-0.11,0.22)
LD ETN SC + MTX		0.61 (0.17,2.10)	0.64 (0.18,1.92)	-0.03 (-0.13,0.09)
HD TOCI IV		0.66 (0.29,1.33)	0.68 (0.32,1.30)	-0.03 (-0.12,0.02)

(Continued)

HD ADA SC		0.17 (0.03,0.74)	0.18 (0.03,0.75)	-0.08 (-0.22,-0.01)
HD ANA		0.59 (0.11,2.75)	0.62 (0.14,2.51)	-0.03 (-0.19,0.09)
HD TOCI IV + MTX		0.87 (0.26,2.62)	0.89 (0.28,2.30)	-0.01 (-0.11,0.12)
HD GOLI SC + MTX		2.06 (0.61,7.76)	1.84 (0.63,4.84)	0.08 (-0.04,0.37)
HD TOFA PO + MTX		1.40 (0.76,2.63)	1.34 (0.77,2.28)	0.03 (-0.02,0.14)
HD CERTO SC + MTX		1.49 (0.61,3.96)	1.41 (0.64,3.12)	0.04 (-0.04,0.22)
HD INF IV + MTX		2.84 (1.22,6.43)	2.35 (1.19,4.46)	0.13 (0.01,0.34)
HD TOCI IV + DMARD		0.53 (0.17,1.74)	0.56 (0.20,1.66)	-0.04 (-0.15,0.05)
MTX + DMARD	DMARD	11.40 (3.26,38.36)	8.53 (2.95,22.99)	0.21 (0.06,0.50)
SD ETN SC		3.98 (1.50,10.12)	3.64 (1.45,8.55)	0.07 (0.02,0.21)
SD ADA SC		1.66 (0.50,5.14)	1.63 (0.51,4.88)	0.02 (-0.03,0.06)
SD TOCI IV		0.95 (0.21,3.89)	0.95 (0.22,3.69)	0.00 (-0.04,0.06)
SD CERTO SC		2.53 (0.46,16.45)	2.41 (0.47,13.75)	0.04 (-0.03,0.19)
SD TOC SC + PL IV		0.65 (0.12,3.28)	0.65 (0.13,3.12)	-0.01 (-0.05,0.04)
SD ANA		1.20 (0.24,7.26)	1.19 (0.25,6.54)	0.00 (-0.05,0.10)
SD ETN SC + MTX		3.57 (1.22,9.72)	3.31 (1.20,8.18)	0.06 (0.01,0.20)
SD INF IV + MTX		9.77 (3.01,30.69)	7.62 (2.76,20.19)	0.19 (0.05,0.45)
SD ABA IV + MTX		3.60 (1.05,12.86)	3.33 (1.05,10.27)	0.06 (0.00,0.24)
SD CERTO SC + MTX		5.09 (1.64,16.53)	4.53 (1.60,12.70)	0.10 (0.02,0.29)
SD ADA SC + MTX		5.10 (1.47,17.33)	4.53 (1.43,12.98)	0.09 (0.01,0.30)
SD GOLI SC + MTX		5.49 (1.09,29.09)	4.79 (1.09,18.35)	0.10 (0.00,0.42)
SD TOFA PO + MTX		6.59 (1.93,21.27)	5.60 (1.84,15.33)	0.13 (0.03,0.35)
SD ABA SC + MTX		1.98 (0.46,8.73)	1.92 (0.47,7.49)	0.02 (-0.02,0.17)
SD ETN SC + DMARD		1.88 (0.59,5.45)	1.83 (0.60,5.06)	0.02 (-0.02,0.09)
SD CERTO SC + DMARD		1.38 (0.47,4.20)	1.36 (0.48,3.94)	0.01 (-0.03,0.07)
SD ADA SC + DMARD		1.20 (0.35,4.15)	1.19 (0.36,3.76)	0.00 (-0.03,0.10)
LD ETN SC		4.42 (1.34,14.67)	3.99 (1.33,11.28)	0.08 (0.01,0.26)
LD ADA SC		0.59 (0.11,2.75)	0.60 (0.12,2.68)	-0.01 (-0.06,0.02)

(Continued)

LD ANA		0.85 (0.16,5.46)	0.86 (0.17,5.11)	0.00 (-0.05,0.07)
LD ABA IV + MTX		4.52 (1.07,20.02)	4.06 (1.06,14.38)	0.08 (0.00,0.33)
LD CERTO SC + MTX		3.68 (0.56,19.15)	3.39 (0.57,13.89)	0.06 (-0.02,0.32)
LD ETN SC + MTX		2.34 (0.46,10.32)	2.25 (0.47,8.67)	0.03 (-0.02,0.19)
HD TOCI IV		2.36 (0.98,5.77)	2.27 (0.98,5.24)	0.03 (0.00,0.11)
HD ADA SC		0.59 (0.12,2.80)	0.60 (0.12,2.74)	-0.01 (-0.05,0.03)
HD ANA		2.16 (0.46,11.61)	2.09 (0.47,9.96)	0.03 (-0.03,0.15)
HD TOCI IV + MTX		3.16 (0.85,10.58)	2.95 (0.86,8.87)	0.05 (0.00,0.22)
HD GOLI SC + MTX		7.85 (1.73,35.07)	6.42 (1.68,20.82)	0.15 (0.02,0.49)
HD TOFA PO + MTX		5.16 (1.56,15.90)	4.55 (1.52,12.28)	0.10 (0.02,0.29)
HD CERTO SC + MTX		5.60 (1.40,19.90)	4.86 (1.38,14.30)	0.11 (0.01,0.34)
HD INF IV + MTX		10.45 (2.75,36.46)	8.01 (2.55,22.09)	0.20 (0.05,0.49)
HD TOCI IV + DMARD		1.96 (1.04,3.88)	1.90 (1.04,3.58)	0.02 (0.00,0.10)
SD ETN SC	MTX + DMARD	0.35 (0.15,0.82)	0.43 (0.22,0.84)	-0.14 (-0.35,-0.02)
SD ADA SC		0.15 (0.04,0.56)	0.19 (0.07,0.59)	-0.20 (-0.48,-0.04)
SD TOCI IV		0.09 (0.01,0.47)	0.11 (0.02,0.51)	-0.21 (-0.51,-0.05)
SD CERTO SC		0.23 (0.04,1.66)	0.29 (0.07,1.56)	-0.17 (-0.47,0.05)
SD TOC SC + PL IV		0.06 (0.01,0.37)	0.08 (0.01,0.41)	-0.22 (-0.52,-0.05)
SD ANA		0.11 (0.02,0.68)	0.14 (0.03,0.71)	-0.20 (-0.51,-0.03)
SD ETN SC + MTX		0.32 (0.15,0.67)	0.39 (0.21,0.71)	-0.14 (-0.35,-0.03)
SD INF IV + MTX		0.86 (0.43,1.81)	0.90 (0.52,1.59)	-0.02 (-0.17,0.10)
SD ABA IV + MTX		0.32 (0.12,0.92)	0.40 (0.17,0.93)	-0.14 (-0.36,-0.01)
SD CERTO SC + MTX		0.45 (0.18,1.31)	0.53 (0.25,1.25)	-0.11 (-0.31,0.03)
SD ADA SC + MTX		0.45 (0.15,1.34)	0.53 (0.21,1.27)	-0.11 (-0.33,0.04)
SD GOLI SC + MTX		0.50 (0.11,2.13)	0.58 (0.15,1.75)	-0.09 (-0.34,0.13)
SD TOFA PO + MTX		0.60 (0.21,1.60)	0.67 (0.30,1.46)	-0.08 (-0.28,0.07)
SD ABA SC + MTX		0.18 (0.05,0.73)	0.23 (0.07,0.77)	-0.18 (-0.43,-0.03)
SD ETN SC + DMARD		0.17 (0.05,0.54)	0.22 (0.08,0.58)	-0.19 (-0.46,-0.04)

(Continued)

SD CERTO SC + DMARD		0.12 (0.03,0.60)	0.16 (0.05,0.63)	-0.20 (-0.49,-0.03)
SD ADA SC + DMARD		0.10 (0.02,0.65)	0.14 (0.03,0.69)	-0.20 (-0.48,-0.03)
LD ETN SC		0.38 (0.14,1.16)	0.47 (0.19,1.13)	-0.13 (-0.34,0.02)
LD ADA SC		0.05 (0.01,0.27)	0.07 (0.02,0.30)	-0.22 (-0.52,-0.06)
LD ANA		0.08 (0.01,0.49)	0.10 (0.02,0.53)	-0.21 (-0.52,-0.04)
LD ABA IV + MTX		0.41 (0.11,1.50)	0.48 (0.15,1.36)	-0.12 (-0.35,0.06)
LD CERTO SC + MTX		0.32 (0.06,1.72)	0.39 (0.09,1.52)	-0.14 (-0.39,0.09)
LD ETN SC + MTX		0.20 (0.05,0.81)	0.26 (0.07,0.85)	-0.17 (-0.43,-0.02)
HD TOCI IV		0.21 (0.07,0.60)	0.27 (0.11,0.64)	-0.17 (-0.44,-0.03)
HD ADA SC		0.05 (0.01,0.28)	0.07 (0.01,0.31)	-0.22 (-0.52,-0.06)
HD ANA		0.20 (0.03,1.08)	0.25 (0.06,1.07)	-0.17 (-0.49,0.01)
HD TOCI IV + MTX		0.28 (0.07,1.02)	0.35 (0.11,1.02)	-0.15 (-0.42,0.00)
HD GOLI SC + MTX		0.69 (0.16,3.23)	0.75 (0.22,2.35)	-0.05 (-0.29,0.23)
HD TOFA PO + MTX		0.47 (0.17,1.21)	0.55 (0.24,1.17)	-0.10 (-0.31,0.03)
HD CERTO SC + MTX		0.49 (0.15,1.77)	0.57 (0.22,1.56)	-0.10 (-0.32,0.09)
HD INF IV + MTX		0.92 (0.34,2.53)	0.94 (0.43,2.00)	-0.01 (-0.20,0.18)
HD TOCI IV + DMARD		0.17 (0.05,0.69)	0.22 (0.07,0.72)	-0.18 (-0.46,-0.03)
SD ADA SC	SD ETN SC	0.42 (0.14,1.21)	0.45 (0.17,1.19)	-0.05 (-0.19,0.01)
SD TOCI IV		0.25 (0.05,0.97)	0.27 (0.06,0.97)	-0.07 (-0.22,0.00)
SD CERTO SC		0.64 (0.13,4.25)	0.67 (0.15,3.71)	-0.03 (-0.19,0.13)
SD TOC SC + PL IV		0.17 (0.03,0.80)	0.19 (0.04,0.81)	-0.08 (-0.23,-0.01)
SD ANA		0.30 (0.06,1.67)	0.33 (0.07,1.59)	-0.06 (-0.22,0.04)
SD ETN SC + MTX		0.91 (0.54,1.45)	0.92 (0.57,1.39)	-0.01 (-0.06,0.04)
SD INF IV + MTX		2.48 (1.15,5.38)	2.12 (1.12,3.88)	0.11 (0.01,0.30)
SD ABA IV + MTX		0.92 (0.38,2.10)	0.93 (0.41,1.89)	-0.01 (-0.09,0.10)
SD CERTO SC + MTX		1.32 (0.59,2.84)	1.27 (0.62,2.47)	0.03 (-0.05,0.15)
SD ADA SC + MTX		1.29 (0.52,3.11)	1.25 (0.56,2.61)	0.02 (-0.06,0.17)
SD GOLI SC + MTX		1.39 (0.33,5.60)	1.33 (0.36,4.02)	0.03 (-0.08,0.29)

(Continued)

SD TOFA PO + MTX	1.70 (0.76,3.63)	1.58 (0.79,2.93)	0.06 (-0.03,0.20)	
SD ABA SC + MTX	0.52 (0.15,1.66)	0.55 (0.17,1.55)	-0.04 (-0.14,0.06)	
SD ETN SC + DMARD	0.49 (0.20,1.09)	0.52 (0.23,1.08)	-0.05 (-0.16,0.01)	
SD CERTO SC + DMARD	0.34 (0.09,1.40)	0.37 (0.11,1.36)	-0.06 (-0.20,0.02)	
SD ADA SC + DMARD	0.30 (0.07,1.42)	0.32 (0.08,1.38)	-0.06 (-0.20,0.03)	
LD ETN SC	1.11 (0.54,2.35)	1.10 (0.56,2.08)	0.01 (-0.06,0.12)	
LD ADA SC	0.15 (0.03,0.64)	0.17 (0.04,0.66)	-0.08 (-0.23,-0.02)	
LD ANA	0.23 (0.04,1.22)	0.25 (0.05,1.20)	-0.07 (-0.23,0.01)	
LD ABA IV + MTX	1.17 (0.37,3.52)	1.15 (0.40,2.86)	0.01 (-0.08,0.19)	
LD CERTO SC + MTX	0.92 (0.18,4.15)	0.93 (0.20,3.21)	-0.01 (-0.13,0.21)	
LD ETN SC + MTX	0.58 (0.15,2.02)	0.61 (0.17,1.83)	-0.03 (-0.15,0.08)	
HD TOCI IV	0.61 (0.26,1.33)	0.64 (0.30,1.30)	-0.03 (-0.14,0.02)	
HD ADA SC	0.16 (0.03,0.64)	0.17 (0.03,0.65)	-0.08 (-0.23,-0.01)	
HD ANA	0.56 (0.11,2.56)	0.59 (0.13,2.34)	-0.04 (-0.20,0.09)	
HD TOCI IV + MTX	0.82 (0.23,2.51)	0.84 (0.26,2.20)	-0.01 (-0.13,0.12)	
HD GOLI SC + MTX	1.94 (0.52,7.83)	1.74 (0.55,4.94)	0.07 (-0.05,0.37)	
HD TOFA PO + MTX	1.33 (0.60,2.88)	1.28 (0.63,2.46)	0.03 (-0.05,0.15)	
HD CERTO SC + MTX	1.42 (0.51,3.99)	1.35 (0.55,3.15)	0.03 (-0.06,0.22)	
HD INF IV + MTX	2.69 (1.00,6.71)	2.23 (1.00,4.53)	0.12 (0.00,0.35)	
HD TOCI IV + DMARD	0.49 (0.17,1.59)	0.52 (0.19,1.52)	-0.04 (-0.17,0.04)	
SD TOCI IV	SD ADA SC	0.59 (0.18,1.65)	0.60 (0.19,1.60)	-0.02 (-0.06,0.03)
SD CERTO SC		1.52 (0.35,8.50)	1.49 (0.37,7.21)	0.02 (-0.05,0.17)
SD TOC SC + PL IV		0.40 (0.11,1.39)	0.41 (0.11,1.37)	-0.02 (-0.07,0.02)
SD ANA		0.71 (0.16,4.21)	0.72 (0.18,3.82)	-0.01 (-0.07,0.09)
SD ETN SC + MTX		2.20 (0.67,6.68)	2.08 (0.69,5.74)	0.05 (-0.02,0.18)
SD INF IV + MTX		6.02 (1.69,21.72)	4.84 (1.61,13.66)	0.17 (0.03,0.44)
SD ABA IV + MTX		2.22 (0.60,8.65)	2.09 (0.61,7.04)	0.05 (-0.02,0.22)
SD CERTO SC + MTX		3.17 (0.87,11.36)	2.86 (0.87,8.58)	0.08 (-0.01,0.28)

(Continued)

SD ADA SC + MTX		3.09 (0.85,11.78)	2.80 (0.86,8.86)	0.08 (-0.01,0.29)
SD GOLI SC + MTX		3.34 (0.63,19.92)	3.01 (0.65,12.39)	0.09 (-0.02,0.40)
SD TOFA PO + MTX		4.10 (1.07,14.42)	3.56 (1.07,10.15)	0.12 (0.00,0.34)
SD ABA SC + MTX		1.25 (0.24,6.01)	1.24 (0.25,5.06)	0.01 (-0.05,0.16)
SD ETN SC + DMARD		1.16 (0.47,2.78)	1.15 (0.49,2.60)	0.01 (-0.03,0.07)
SD CERTO SC + DMARD		0.83 (0.22,3.65)	0.83 (0.23,3.37)	-0.01 (-0.06,0.08)
SD ADA SC + DMARD		0.72 (0.14,4.11)	0.73 (0.14,3.72)	-0.01 (-0.06,0.10)
LD ETN SC		2.67 (0.77,9.32)	2.48 (0.78,7.28)	0.06 (-0.01,0.25)
LD ADA SC		0.36 (0.11,1.10)	0.37 (0.11,1.09)	-0.03 (-0.07,0.00)
LD ANA		0.53 (0.11,2.91)	0.54 (0.12,2.75)	-0.02 (-0.08,0.05)
LD ABA IV + MTX		2.76 (0.59,13.23)	2.54 (0.60,9.67)	0.07 (-0.02,0.32)
LD CERTO SC + MTX		2.21 (0.30,12.79)	2.09 (0.32,8.93)	0.05 (-0.04,0.31)
LD ETN SC + MTX		1.42 (0.24,6.86)	1.40 (0.25,5.62)	0.02 (-0.05,0.18)
HD TOCI IV		1.43 (0.49,4.51)	1.40 (0.50,4.08)	0.02 (-0.03,0.11)
HD ADA SC		0.36 (0.10,1.12)	0.37 (0.11,1.11)	-0.03 (-0.07,0.00)
HD ANA		1.32 (0.32,5.93)	1.30 (0.34,5.23)	0.01 (-0.05,0.13)
HD TOCI IV + MTX		1.91 (0.47,8.16)	1.82 (0.49,6.50)	0.04 (-0.03,0.21)
HD GOLI SC + MTX		4.72 (0.87,25.90)	3.98 (0.88,14.16)	0.13 (-0.01,0.48)
HD TOFA PO + MTX		3.18 (0.88,11.05)	2.87 (0.88,8.41)	0.08 (-0.01,0.27)
HD CERTO SC + MTX		3.37 (0.79,13.32)	3.01 (0.80,9.47)	0.09 (-0.01,0.33)
HD INF IV + MTX		6.51 (1.52,25.77)	5.11 (1.47,14.75)	0.18 (0.03,0.47)
HD TOCI IV + DMARD		1.20 (0.33,4.67)	1.19 (0.34,4.23)	0.01 (-0.04,0.11)
SD CERTO SC	SD TOCI IV	2.68 (0.41,19.00)	2.55 (0.43,16.33)	0.04 (-0.04,0.19)
SD TOC SC + PL IV		0.68 (0.34,1.37)	0.69 (0.35,1.35)	-0.01 (-0.03,0.01)
SD ANA		1.23 (0.20,9.09)	1.22 (0.21,8.32)	0.01 (-0.06,0.10)
SD ETN SC + MTX		3.66 (0.80,19.86)	3.40 (0.81,16.57)	0.06 (-0.01,0.20)
SD INF IV + MTX		10.03 (1.96,59.04)	7.87 (1.86,38.07)	0.19 (0.04,0.46)
SD ABA IV + MTX		3.73 (0.70,22.24)	3.44 (0.72,17.77)	0.06 (-0.02,0.24)

(Continued)

SD CERTO SC + MTX	5.29 (0.99,31.10)	4.68 (0.99,23.45)	0.10 (0.00,0.30)
SD ADA SC + MTX	5.06 (1.19,30.49)	4.50 (1.18,22.84)	0.09 (0.01,0.31)
SD GOLI SC + MTX	5.65 (0.91,43.68)	4.95 (0.92,28.00)	0.10 (0.00,0.42)
SD TOFA PO + MTX	6.78 (1.52,38.03)	5.78 (1.46,27.53)	0.13 (0.02,0.36)
SD ABA SC + MTX	2.18 (0.29,14.06)	2.10 (0.31,11.88)	0.03 (-0.04,0.18)
SD ETN SC + DMARD	1.98 (0.52,8.46)	1.92 (0.54,7.84)	0.02 (-0.03,0.10)
SD CERTO SC + DMARD	1.47 (0.25,7.41)	1.45 (0.26,6.83)	0.01 (-0.05,0.09)
SD ADA SC + DMARD	1.23 (0.17,9.90)	1.22 (0.19,8.87)	0.01 (-0.05,0.11)
LD ETN SC	4.44 (1.09,25.96)	4.03 (1.08,19.92)	0.08 (0.00,0.27)
LD ADA SC	0.61 (0.13,3.05)	0.62 (0.14,2.98)	-0.01 (-0.07,0.02)
LD ANA	0.90 (0.16,5.80)	0.91 (0.17,5.45)	0.00 (-0.07,0.07)
LD ABA IV + MTX	4.67 (0.74,33.52)	4.18 (0.75,24.35)	0.08 (-0.01,0.34)
LD CERTO SC + MTX	3.87 (0.38,28.37)	3.55 (0.39,20.57)	0.06 (-0.03,0.33)
LD ETN SC + MTX	2.36 (0.35,17.59)	2.26 (0.36,14.29)	0.03 (-0.03,0.20)
HD TOCI IV	2.50 (0.63,10.96)	2.39 (0.65,10.03)	0.04 (-0.02,0.12)
HD ADA SC	0.63 (0.13,2.99)	0.64 (0.14,2.92)	-0.01 (-0.07,0.02)
HD ANA	2.28 (0.38,14.45)	2.20 (0.40,12.67)	0.03 (-0.05,0.15)
HD TOCI IV + MTX	3.28 (0.68,20.69)	3.06 (0.70,17.13)	0.05 (-0.02,0.23)
HD GOLI SC + MTX	8.12 (1.32,66.92)	6.67 (1.30,36.81)	0.15 (0.01,0.49)
HD TOFA PO + MTX	5.31 (1.17,30.10)	4.69 (1.15,23.16)	0.10 (0.01,0.30)
HD CERTO SC + MTX	5.80 (1.02,35.17)	5.03 (1.02,24.92)	0.11 (0.00,0.35)
HD INF IV + MTX	10.98 (1.76,71.90)	8.40 (1.68,41.28)	0.20 (0.03,0.50)
HD TOCI IV + DMARD	2.09 (0.46,10.33)	2.02 (0.48,9.30)	0.03 (-0.03,0.13)
SD TOC SC + PL IV	SD CERTO SC	0.25 (0.03,1.97)	0.27 (0.04,1.92)
SD ANA		0.46 (0.07,2.99)	0.48 (0.09,2.79)
SD ETN SC + MTX		1.40 (0.20,7.14)	1.36 (0.23,5.99)
SD INF IV + MTX		3.85 (0.51,21.76)	3.18 (0.56,13.11)
SD ABA IV + MTX		1.41 (0.17,8.32)	1.37 (0.20,6.72)

(Continued)

SD CERTO SC + MTX	2.04 (0.28,11.93)	1.89 (0.32,8.85)	0.06 (-0.11,0.28)	
SD ADA SC + MTX	2.03 (0.26,11.15)	1.88 (0.29,8.30)	0.06 (-0.11,0.28)	
SD GOLI SC + MTX	2.17 (0.23,16.64)	1.98 (0.26,10.56)	0.06 (-0.11,0.38)	
SD TOFA PO + MTX	2.72 (0.34,13.73)	2.42 (0.38,9.93)	0.09 (-0.10,0.32)	
SD ABA SC + MTX	0.79 (0.09,5.50)	0.80 (0.10,4.78)	-0.01 (-0.16,0.15)	
SD ETN SC + DMARD	0.74 (0.12,3.87)	0.75 (0.14,3.57)	-0.02 (-0.17,0.08)	
SD CERTO SC + DMARD	0.51 (0.08,3.54)	0.53 (0.09,3.29)	-0.03 (-0.17,0.08)	
SD ADA SC + DMARD	0.48 (0.04,3.96)	0.50 (0.05,3.58)	-0.03 (-0.18,0.09)	
LD ETN SC	1.72 (0.23,10.93)	1.63 (0.27,8.27)	0.04 (-0.13,0.25)	
LD ADA SC	0.23 (0.03,1.32)	0.25 (0.04,1.31)	-0.05 (-0.19,0.01)	
LD ANA	0.35 (0.05,2.17)	0.37 (0.06,2.09)	-0.04 (-0.19,0.04)	
LD ABA IV + MTX	1.78 (0.21,12.49)	1.68 (0.24,8.89)	0.04 (-0.13,0.30)	
LD CERTO SC + MTX	1.43 (0.14,11.25)	1.39 (0.17,7.97)	0.02 (-0.14,0.30)	
LD ETN SC + MTX	0.91 (0.09,6.45)	0.92 (0.11,5.41)	0.00 (-0.15,0.17)	
HD TOCI IV	0.95 (0.13,4.84)	0.96 (0.16,4.35)	0.00 (-0.16,0.11)	
HD ADA SC	0.24 (0.03,1.25)	0.26 (0.03,1.24)	-0.05 (-0.19,0.01)	
HD ANA	0.86 (0.13,4.89)	0.87 (0.15,4.35)	-0.01 (-0.16,0.12)	
HD TOCI IV + MTX	1.24 (0.15,8.44)	1.21 (0.17,6.67)	0.01 (-0.14,0.21)	
HD GOLI SC + MTX	3.00 (0.33,23.62)	2.60 (0.37,13.39)	0.10 (-0.09,0.46)	
HD TOFA PO + MTX	2.12 (0.27,10.88)	1.95 (0.30,8.36)	0.06 (-0.11,0.26)	
HD CERTO SC + MTX	2.14 (0.27,14.72)	1.98 (0.31,10.09)	0.06 (-0.11,0.33)	
HD INF IV + MTX	4.07 (0.51,24.65)	3.31 (0.55,14.20)	0.16 (-0.07,0.47)	
HD TOCI IV + DMARD	0.76 (0.10,4.67)	0.78 (0.11,4.20)	-0.01 (-0.16,0.11)	
SD ANA	SD TOC SC + PL IV	1.80 (0.27,14.61)	1.77 (0.28,13.22)	0.01 (-0.05,0.11)
SD ETN SC + MTX		5.49 (1.00,31.67)	5.00 (1.00,26.65)	0.07 (0.00,0.22)
SD INF IV + MTX		14.95 (2.51,95.09)	11.53 (2.31,61.42)	0.20 (0.05,0.47)
SD ABA IV + MTX		5.54 (0.91,35.38)	5.04 (0.92,28.47)	0.07 (0.00,0.25)
SD CERTO SC + MTX		7.83 (1.28,49.12)	6.86 (1.25,37.88)	0.11 (0.01,0.31)



(Continued)

SD ADA SC + MTX		7.49 (1.44,50.57)	6.60 (1.40,37.92)	0.10 (0.01,0.32)
SD GOLI SC + MTX		8.23 (1.19,69.88)	7.17 (1.17,46.33)	0.11 (0.01,0.43)
SD TOFA PO + MTX		9.99 (1.84,62.80)	8.42 (1.75,45.86)	0.14 (0.03,0.37)
SD ABA SC + MTX		3.21 (0.38,22.77)	3.07 (0.40,19.26)	0.04 (-0.03,0.19)
SD ETN SC + DMARD		2.94 (0.63,14.61)	2.83 (0.64,13.47)	0.03 (-0.02,0.11)
SD CERTO SC + DMARD		2.17 (0.31,12.32)	2.11 (0.32,11.32)	0.02 (-0.04,0.10)
SD ADA SC + DMARD		1.82 (0.23,15.61)	1.78 (0.24,13.89)	0.01 (-0.04,0.12)
LD ETN SC		6.63 (1.32,42.11)	5.95 (1.30,32.66)	0.09 (0.01,0.28)
LD ADA SC		0.90 (0.17,5.28)	0.90 (0.18,5.14)	0.00 (-0.05,0.03)
LD ANA		1.34 (0.19,9.24)	1.33 (0.20,8.68)	0.01 (-0.05,0.07)
LD ABA IV + MTX		6.84 (0.99,52.99)	6.10 (0.99,38.94)	0.09 (0.00,0.35)
LD CERTO SC + MTX		5.60 (0.50,46.64)	5.08 (0.52,34.66)	0.07 (-0.02,0.33)
LD ETN SC + MTX		3.44 (0.46,28.88)	3.27 (0.47,24.09)	0.04 (-0.02,0.21)
HD TOCI IV		3.67 (0.78,19.07)	3.48 (0.79,17.25)	0.04 (-0.01,0.13)
HD ADA SC		0.91 (0.16,4.99)	0.91 (0.17,4.81)	0.00 (-0.06,0.03)
HD ANA		3.37 (0.50,23.43)	3.23 (0.51,20.50)	0.04 (-0.03,0.16)
HD TOCI IV + MTX		4.87 (0.80,34.83)	4.49 (0.81,27.96)	0.06 (-0.01,0.24)
HD GOLI SC + MTX		11.77 (1.71,109.60)	9.59 (1.64,62.61)	0.16 (0.02,0.50)
HD TOFA PO + MTX		7.86 (1.40,49.76)	6.88 (1.37,38.21)	0.11 (0.01,0.31)
HD CERTO SC + MTX		8.37 (1.33,55.91)	7.24 (1.30,40.16)	0.12 (0.01,0.36)
HD INF IV + MTX		16.24 (2.30,110.50)	12.33 (2.14,66.29)	0.21 (0.04,0.50)
HD TOCI IV + DMARD		3.05 (0.56,16.80)	2.92 (0.57,15.06)	0.03 (-0.02,0.14)
SD ETN SC + MTX	SD ANA	2.94 (0.51,16.94)	2.75 (0.54,13.83)	0.05 (-0.04,0.21)
SD INF IV + MTX		7.78 (1.37,51.01)	6.27 (1.31,30.15)	0.18 (0.02,0.46)
SD ABA IV + MTX		3.03 (0.47,19.87)	2.83 (0.50,15.70)	0.06 (-0.04,0.25)
SD CERTO SC + MTX		4.42 (0.67,25.87)	3.94 (0.70,19.35)	0.09 (-0.03,0.31)
SD ADA SC + MTX		4.28 (0.61,25.46)	3.82 (0.63,18.80)	0.09 (-0.03,0.31)
SD GOLI SC + MTX		4.72 (0.42,39.83)	4.18 (0.45,24.37)	0.10 (-0.05,0.42)

(Continued)

SD TOFA PO + MTX	5.57 (0.87,33.21)	4.79 (0.88,22.98)	0.12 (-0.01,0.36)	
SD ABA SC + MTX	1.71 (0.23,12.07)	1.67 (0.24,10.10)	0.02 (-0.07,0.18)	
SD ETN SC + DMARD	1.59 (0.26,7.75)	1.55 (0.29,7.09)	0.02 (-0.08,0.10)	
SD CERTO SC + DMARD	1.19 (0.17,7.10)	1.18 (0.18,6.46)	0.01 (-0.09,0.09)	
SD ADA SC + DMARD	1.05 (0.11,7.48)	1.05 (0.12,6.66)	0.00 (-0.10,0.11)	
LD ETN SC	3.64 (0.56,21.91)	3.34 (0.59,16.88)	0.07 (-0.04,0.28)	
LD ADA SC	0.48 (0.08,2.79)	0.49 (0.09,2.72)	-0.02 (-0.11,0.03)	
LD ANA	0.75 (0.21,2.44)	0.75 (0.22,2.36)	-0.01 (-0.07,0.03)	
LD ABA IV + MTX	3.63 (0.53,31.01)	3.32 (0.56,21.28)	0.07 (-0.04,0.34)	
LD CERTO SC + MTX	3.10 (0.29,23.29)	2.88 (0.31,16.91)	0.06 (-0.06,0.32)	
LD ETN SC + MTX	1.90 (0.22,14.40)	1.84 (0.23,11.78)	0.03 (-0.07,0.20)	
HD TOCI IV	2.01 (0.35,10.73)	1.94 (0.37,9.47)	0.03 (-0.07,0.13)	
HD ADA SC	0.50 (0.07,2.65)	0.51 (0.07,2.59)	-0.01 (-0.11,0.03)	
HD ANA	1.80 (0.62,5.47)	1.74 (0.63,5.05)	0.02 (-0.03,0.10)	
HD TOCI IV + MTX	2.65 (0.31,18.29)	2.51 (0.33,14.37)	0.05 (-0.07,0.24)	
HD GOLI SC + MTX	6.47 (0.74,53.84)	5.39 (0.75,30.22)	0.14 (-0.02,0.50)	
HD TOFA PO + MTX	4.32 (0.65,25.79)	3.86 (0.68,19.21)	0.09 (-0.03,0.30)	
HD CERTO SC + MTX	4.72 (0.62,30.94)	4.17 (0.65,21.43)	0.10 (-0.03,0.36)	
HD INF IV + MTX	8.30 (1.37,56.91)	6.57 (1.32,32.12)	0.19 (0.02,0.50)	
HD TOCI IV + DMARD	1.62 (0.25,9.74)	1.58 (0.27,8.41)	0.02 (-0.08,0.13)	
SD INF IV + MTX	SD ETN SC + MTX	2.73 (1.34,5.75)	2.30 (1.29,4.24)	0.12 (0.02,0.31)
SD ABA IV + MTX	1.01 (0.43,2.41)	1.01 (0.46,2.15)	0.00 (-0.07,0.11)	
SD CERTO SC + MTX	1.43 (0.68,3.28)	1.37 (0.71,2.82)	0.03 (-0.04,0.16)	
SD ADA SC + MTX	1.43 (0.57,3.65)	1.37 (0.61,3.00)	0.03 (-0.05,0.18)	
SD GOLI SC + MTX	1.55 (0.36,6.33)	1.47 (0.38,4.54)	0.04 (-0.07,0.30)	
SD TOFA PO + MTX	1.89 (0.83,4.04)	1.73 (0.85,3.31)	0.06 (-0.02,0.21)	
SD ABA SC + MTX	0.57 (0.17,1.90)	0.60 (0.19,1.76)	-0.03 (-0.13,0.07)	
SD ETN SC + DMARD	0.53 (0.20,1.41)	0.56 (0.23,1.37)	-0.04 (-0.16,0.02)	

(Continued)

SD CERTO SC + DMARD		0.38 (0.10,1.69)	0.41 (0.11,1.62)	-0.05 (-0.19,0.04)
SD ADA SC + DMARD		0.33 (0.07,1.71)	0.35 (0.08,1.62)	-0.05 (-0.19,0.04)
LD ETN SC		1.22 (0.53,2.87)	1.20 (0.56,2.53)	0.02 (-0.06,0.14)
LD ADA SC		0.16 (0.04,0.75)	0.18 (0.04,0.76)	-0.07 (-0.22,-0.01)
LD ANA		0.25 (0.04,1.41)	0.27 (0.05,1.38)	-0.06 (-0.22,0.02)
LD ABA IV + MTX		1.28 (0.42,4.02)	1.24 (0.44,3.22)	0.02 (-0.07,0.20)
LD CERTO SC + MTX		1.00 (0.20,4.70)	1.00 (0.22,3.67)	0.00 (-0.12,0.22)
LD ETN SC + MTX		0.63 (0.18,2.13)	0.66 (0.19,1.93)	-0.03 (-0.13,0.09)
HD TOCI IV		0.67 (0.28,1.60)	0.69 (0.31,1.53)	-0.03 (-0.13,0.03)
HD ADA SC		0.17 (0.03,0.80)	0.19 (0.03,0.81)	-0.07 (-0.22,-0.01)
HD ANA		0.62 (0.11,2.93)	0.64 (0.14,2.69)	-0.03 (-0.19,0.09)
HD TOCI IV + MTX		0.90 (0.25,2.94)	0.91 (0.28,2.56)	-0.01 (-0.12,0.13)
HD GOLI SC + MTX		2.12 (0.58,8.85)	1.89 (0.61,5.57)	0.08 (-0.04,0.38)
HD TOFA PO + MTX		1.47 (0.64,3.21)	1.40 (0.67,2.74)	0.03 (-0.04,0.15)
HD CERTO SC + MTX		1.54 (0.55,4.66)	1.46 (0.58,3.63)	0.04 (-0.05,0.23)
HD INF IV + MTX		2.93 (1.15,7.44)	2.43 (1.13,5.14)	0.13 (0.01,0.36)
HD TOCI IV + DMARD		0.54 (0.18,1.92)	0.57 (0.20,1.81)	-0.04 (-0.16,0.05)
SD ABA IV + MTX	SD INF IV + MTX	0.37 (0.16,0.85)	0.44 (0.20,0.88)	-0.12 (-0.30,-0.02)
SD CERTO SC + MTX		0.52 (0.23,1.35)	0.59 (0.30,1.28)	-0.08 (-0.25,0.04)
SD ADA SC + MTX		0.51 (0.19,1.47)	0.58 (0.25,1.37)	-0.08 (-0.28,0.05)
SD GOLI SC + MTX		0.57 (0.13,2.29)	0.64 (0.17,1.87)	-0.07 (-0.29,0.15)
SD TOFA PO + MTX		0.68 (0.28,1.61)	0.74 (0.36,1.47)	-0.05 (-0.23,0.07)
SD ABA SC + MTX		0.21 (0.07,0.67)	0.26 (0.09,0.72)	-0.15 (-0.37,-0.03)
SD ETN SC + DMARD		0.20 (0.06,0.59)	0.24 (0.09,0.62)	-0.16 (-0.41,-0.03)
SD CERTO SC + DMARD		0.14 (0.03,0.65)	0.18 (0.05,0.68)	-0.17 (-0.44,-0.03)
SD ADA SC + DMARD		0.12 (0.02,0.67)	0.15 (0.03,0.71)	-0.18 (-0.43,-0.03)
LD ETN SC		0.44 (0.17,1.29)	0.51 (0.22,1.24)	-0.10 (-0.29,0.03)
LD ADA SC		0.06 (0.01,0.30)	0.08 (0.02,0.32)	-0.20 (-0.47,-0.05)

(Continued)

LD ANA		0.09 (0.01,0.57)	0.12 (0.02,0.60)	-0.19 (-0.47,-0.03)
LD ABA IV + MTX		0.46 (0.14,1.52)	0.53 (0.18,1.39)	-0.09 (-0.29,0.07)
LD CERTO SC + MTX		0.36 (0.07,1.88)	0.43 (0.10,1.62)	-0.11 (-0.34,0.10)
LD ETN SC + MTX		0.23 (0.06,0.94)	0.29 (0.08,0.95)	-0.15 (-0.38,-0.01)
HD TOCI IV		0.25 (0.09,0.62)	0.30 (0.13,0.66)	-0.15 (-0.38,-0.03)
HD ADA SC		0.06 (0.01,0.30)	0.08 (0.02,0.33)	-0.20 (-0.48,-0.05)
HD ANA		0.23 (0.04,1.16)	0.28 (0.06,1.14)	-0.15 (-0.44,0.01)
HD TOCI IV + MTX		0.33 (0.09,1.15)	0.39 (0.12,1.12)	-0.12 (-0.35,0.02)
HD GOLI SC + MTX		0.77 (0.19,3.72)	0.82 (0.25,2.53)	-0.04 (-0.25,0.26)
HD TOFA PO + MTX		0.53 (0.23,1.24)	0.60 (0.29,1.19)	-0.08 (-0.26,0.03)
HD CERTO SC + MTX		0.57 (0.19,1.91)	0.64 (0.24,1.63)	-0.07 (-0.28,0.11)
HD INF IV + MTX		1.07 (0.49,2.28)	1.06 (0.56,1.85)	0.01 (-0.12,0.16)
HD TOCI IV + DMARD		0.20 (0.06,0.79)	0.25 (0.08,0.81)	-0.16 (-0.40,-0.02)
SD CERTO SC + MTX	SD ABA IV + MTX	1.41 (0.56,3.91)	1.35 (0.60,3.37)	0.03 (-0.07,0.16)
SD ADA SC + MTX		1.38 (0.50,4.02)	1.33 (0.55,3.37)	0.03 (-0.08,0.18)
SD GOLI SC + MTX		1.53 (0.30,7.38)	1.44 (0.33,5.22)	0.04 (-0.11,0.30)
SD TOFA PO + MTX		1.83 (0.73,4.69)	1.67 (0.76,3.88)	0.06 (-0.04,0.22)
SD ABA SC + MTX		0.56 (0.25,1.25)	0.59 (0.27,1.21)	-0.03 (-0.13,0.02)
SD ETN SC + DMARD		0.53 (0.14,1.61)	0.56 (0.18,1.56)	-0.04 (-0.20,0.02)
SD CERTO SC + DMARD		0.39 (0.08,1.90)	0.42 (0.09,1.82)	-0.05 (-0.23,0.04)
SD ADA SC + DMARD		0.33 (0.06,1.92)	0.36 (0.07,1.80)	-0.05 (-0.22,0.05)
LD ETN SC		1.19 (0.44,3.64)	1.17 (0.49,3.18)	0.01 (-0.09,0.15)
LD ADA SC		0.17 (0.03,0.82)	0.18 (0.04,0.83)	-0.08 (-0.25,-0.01)
LD ANA		0.25 (0.04,1.69)	0.27 (0.05,1.64)	-0.07 (-0.25,0.03)
LD ABA IV + MTX		1.25 (0.43,3.75)	1.22 (0.46,3.10)	0.02 (-0.07,0.19)
LD CERTO SC + MTX		0.96 (0.19,5.92)	0.96 (0.21,4.52)	0.00 (-0.14,0.23)
LD ETN SC + MTX		0.62 (0.15,2.72)	0.64 (0.17,2.44)	-0.03 (-0.17,0.10)
HD TOCI IV		0.67 (0.21,1.82)	0.69 (0.25,1.74)	-0.03 (-0.17,0.04)

(Continued)

HD ADA SC		0.17 (0.02,0.86)	0.18 (0.03,0.86)	-0.08 (-0.26,0.00)
HD ANA		0.62 (0.10,3.49)	0.64 (0.12,3.15)	-0.03 (-0.22,0.09)
HD TOCI IV + MTX		0.90 (0.20,3.21)	0.91 (0.23,2.82)	-0.01 (-0.15,0.13)
HD GOLI SC + MTX		2.13 (0.48,10.08)	1.89 (0.52,6.28)	0.08 (-0.07,0.38)
HD TOFA PO + MTX		1.43 (0.57,3.62)	1.37 (0.61,3.11)	0.03 (-0.06,0.16)
HD CERTO SC + MTX		1.53 (0.50,5.03)	1.45 (0.54,4.12)	0.04 (-0.07,0.22)
HD INF IV + MTX		2.87 (1.05,8.09)	2.39 (1.04,5.83)	0.13 (0.01,0.35)
HD TOCI IV + DMARD		0.54 (0.14,2.26)	0.57 (0.17,2.12)	-0.04 (-0.20,0.06)
SD ADA SC + MTX	SD CERTO SC + MTX	0.98 (0.37,2.66)	0.98 (0.42,2.30)	0.00 (-0.13,0.14)
SD GOLI SC + MTX		1.07 (0.28,4.14)	1.06 (0.32,3.12)	0.01 (-0.14,0.24)
SD TOFA PO + MTX		1.30 (0.52,3.03)	1.24 (0.58,2.53)	0.03 (-0.09,0.16)
SD ABA SC + MTX		0.40 (0.11,1.27)	0.44 (0.13,1.23)	-0.07 (-0.22,0.02)
SD ETN SC + DMARD		0.37 (0.11,1.09)	0.41 (0.15,1.08)	-0.07 (-0.25,0.01)
SD CERTO SC + DMARD		0.26 (0.06,1.16)	0.30 (0.08,1.15)	-0.08 (-0.29,0.01)
SD ADA SC + DMARD		0.23 (0.04,1.19)	0.26 (0.05,1.18)	-0.09 (-0.28,0.01)
LD ETN SC		0.85 (0.32,2.34)	0.87 (0.37,2.07)	-0.02 (-0.14,0.11)
LD ADA SC		0.11 (0.02,0.54)	0.13 (0.03,0.56)	-0.11 (-0.32,-0.02)
LD ANA		0.17 (0.03,1.09)	0.20 (0.04,1.09)	-0.10 (-0.31,0.00)
LD ABA IV + MTX		0.88 (0.26,2.89)	0.90 (0.30,2.46)	-0.01 (-0.15,0.16)
LD CERTO SC + MTX		0.72 (0.15,2.75)	0.75 (0.18,2.28)	-0.03 (-0.17,0.15)
LD ETN SC + MTX		0.44 (0.11,1.73)	0.48 (0.12,1.61)	-0.06 (-0.23,0.06)
HD TOCI IV		0.47 (0.16,1.14)	0.51 (0.20,1.13)	-0.06 (-0.23,0.01)
HD ADA SC		0.12 (0.02,0.60)	0.14 (0.03,0.62)	-0.11 (-0.32,-0.02)
HD ANA		0.42 (0.07,2.30)	0.46 (0.10,2.12)	-0.07 (-0.29,0.07)
HD TOCI IV + MTX		0.62 (0.16,2.16)	0.66 (0.19,1.94)	-0.04 (-0.21,0.09)
HD GOLI SC + MTX		1.47 (0.42,6.21)	1.37 (0.46,4.06)	0.04 (-0.10,0.33)
HD TOFA PO + MTX		1.01 (0.41,2.38)	1.01 (0.46,2.10)	0.00 (-0.12,0.11)
HD CERTO SC + MTX		1.09 (0.45,2.50)	1.08 (0.50,2.12)	0.01 (-0.10,0.15)

(Continued)

HD INF IV + MTX		2.06 (0.68,5.54)	1.77 (0.72,3.94)	0.10 (-0.05,0.30)
HD TOCI IV + DMARD		0.38 (0.11,1.41)	0.42 (0.13,1.36)	-0.07 (-0.26,0.03)
SD GOLI SC + MTX	SD ADA SC + MTX	1.11 (0.21,5.08)	1.09 (0.25,3.71)	0.01 (-0.17,0.27)
SD TOFA PO + MTX		1.30 (0.61,3.02)	1.24 (0.66,2.57)	0.03 (-0.07,0.16)
SD ABA SC + MTX		0.40 (0.11,1.44)	0.44 (0.13,1.38)	-0.06 (-0.23,0.04)
SD ETN SC + DMARD		0.37 (0.11,1.22)	0.41 (0.14,1.20)	-0.07 (-0.27,0.01)
SD CERTO SC + DMARD		0.27 (0.06,1.35)	0.30 (0.08,1.32)	-0.08 (-0.29,0.02)
SD ADA SC + DMARD		0.24 (0.04,1.32)	0.27 (0.05,1.29)	-0.08 (-0.29,0.02)
LD ETN SC		0.87 (0.30,2.59)	0.89 (0.35,2.27)	-0.01 (-0.16,0.12)
LD ADA SC		0.11 (0.02,0.62)	0.13 (0.03,0.64)	-0.11 (-0.32,-0.02)
LD ANA		0.18 (0.03,1.17)	0.20 (0.04,1.16)	-0.10 (-0.32,0.01)
LD ABA IV + MTX		0.92 (0.24,2.98)	0.93 (0.28,2.52)	-0.01 (-0.17,0.16)
LD CERTO SC + MTX		0.72 (0.13,3.46)	0.75 (0.16,2.86)	-0.03 (-0.21,0.18)
LD ETN SC + MTX		0.45 (0.09,1.92)	0.49 (0.12,1.76)	-0.06 (-0.24,0.07)
HD TOCI IV		0.48 (0.15,1.33)	0.51 (0.19,1.31)	-0.06 (-0.24,0.02)
HD ADA SC		0.12 (0.02,0.67)	0.13 (0.03,0.68)	-0.11 (-0.32,-0.01)
HD ANA		0.44 (0.07,2.46)	0.47 (0.10,2.29)	-0.06 (-0.29,0.08)
HD TOCI IV + MTX		0.63 (0.15,2.43)	0.66 (0.18,2.15)	-0.04 (-0.22,0.10)
HD GOLI SC + MTX		1.53 (0.34,6.42)	1.41 (0.40,4.41)	0.05 (-0.13,0.32)
HD TOFA PO + MTX		1.01 (0.46,2.37)	1.01 (0.52,2.12)	0.00 (-0.11,0.11)
HD CERTO SC + MTX		1.07 (0.34,3.87)	1.06 (0.38,3.09)	0.01 (-0.14,0.20)
HD INF IV + MTX		2.10 (0.61,6.08)	1.80 (0.67,4.32)	0.10 (-0.06,0.31)
HD TOCI IV + DMARD		0.39 (0.10,1.58)	0.43 (0.12,1.51)	-0.07 (-0.26,0.03)
SD TOFA PO + MTX	SD GOLI SC + MTX	1.18 (0.26,5.22)	1.15 (0.35,4.32)	0.02 (-0.24,0.19)
SD ABA SC + MTX		0.37 (0.06,2.32)	0.41 (0.08,2.17)	-0.07 (-0.35,0.06)
SD ETN SC + DMARD		0.35 (0.06,1.73)	0.39 (0.10,1.68)	-0.08 (-0.38,0.03)
SD CERTO SC + DMARD		0.26 (0.04,1.50)	0.29 (0.05,1.46)	-0.09 (-0.41,0.02)
SD ADA SC + DMARD		0.23 (0.02,1.66)	0.26 (0.03,1.59)	-0.09 (-0.41,0.03)

(Continued)

LD ETN SC		0.80 (0.17,3.36)	0.82 (0.24,3.02)	-0.02 (-0.28,0.12)
LD ADA SC		0.10 (0.02,0.69)	0.12 (0.02,0.70)	-0.12 (-0.43,-0.01)
LD ANA		0.16 (0.02,1.65)	0.18 (0.03,1.61)	-0.11 (-0.43,0.02)
LD ABA IV + MTX		0.83 (0.15,4.66)	0.85 (0.20,3.97)	-0.02 (-0.27,0.18)
LD CERTO SC + MTX		0.64 (0.10,4.03)	0.68 (0.13,3.34)	-0.04 (-0.30,0.18)
LD ETN SC + MTX		0.41 (0.07,2.34)	0.45 (0.09,2.16)	-0.07 (-0.34,0.07)
HD TOCI IV		0.43 (0.09,1.94)	0.48 (0.13,1.86)	-0.07 (-0.37,0.04)
HD ADA SC		0.11 (0.01,0.79)	0.13 (0.02,0.79)	-0.12 (-0.43,-0.01)
HD ANA		0.40 (0.05,3.78)	0.43 (0.07,3.42)	-0.07 (-0.39,0.10)
HD TOCI IV + MTX		0.57 (0.10,2.97)	0.61 (0.15,2.64)	-0.05 (-0.33,0.11)
HD GOLI SC + MTX		1.40 (0.43,4.95)	1.31 (0.50,3.80)	0.04 (-0.13,0.25)
HD TOFA PO + MTX		0.93 (0.20,4.03)	0.94 (0.27,3.49)	-0.01 (-0.27,0.15)
HD CERTO SC + MTX		1.02 (0.23,4.37)	1.02 (0.29,3.72)	0.00 (-0.24,0.19)
HD INF IV + MTX		1.87 (0.39,9.22)	1.64 (0.48,6.66)	0.08 (-0.16,0.33)
HD TOCI IV + DMARD		0.36 (0.06,2.02)	0.40 (0.09,1.92)	-0.08 (-0.38,0.04)
SD ABA SC + MTX	SD TOFA PO + MTX	0.31 (0.09,1.05)	0.35 (0.11,1.04)	-0.10 (-0.28,0.01)
SD ETN SC + DMARD		0.28 (0.09,0.92)	0.32 (0.12,0.93)	-0.11 (-0.31,0.00)
SD CERTO SC + DMARD		0.20 (0.05,1.00)	0.24 (0.07,1.00)	-0.12 (-0.34,0.00)
SD ADA SC + DMARD		0.18 (0.03,1.04)	0.21 (0.04,1.04)	-0.12 (-0.34,0.00)
LD ETN SC		0.66 (0.24,1.88)	0.70 (0.29,1.72)	-0.04 (-0.20,0.08)
LD ADA SC		0.09 (0.02,0.45)	0.10 (0.03,0.47)	-0.14 (-0.37,-0.03)
LD ANA		0.13 (0.02,0.88)	0.16 (0.03,0.89)	-0.13 (-0.37,-0.01)
LD ABA IV + MTX		0.68 (0.21,2.22)	0.73 (0.25,1.91)	-0.04 (-0.19,0.13)
LD CERTO SC + MTX		0.54 (0.10,2.69)	0.59 (0.13,2.24)	-0.06 (-0.24,0.15)
LD ETN SC + MTX		0.34 (0.08,1.40)	0.39 (0.10,1.34)	-0.09 (-0.28,0.04)
HD TOCI IV		0.36 (0.13,0.93)	0.41 (0.17,0.94)	-0.09 (-0.28,0.00)
HD ADA SC		0.09 (0.01,0.47)	0.11 (0.02,0.49)	-0.14 (-0.37,-0.03)
HD ANA		0.32 (0.06,1.76)	0.37 (0.08,1.66)	-0.10 (-0.34,0.05)

(Continued)

HD TOCI IV + MTX		0.48 (0.12,1.68)	0.53 (0.15,1.56)	-0.07 (-0.26,0.06)
HD GOLI SC + MTX		1.17 (0.30,4.64)	1.13 (0.35,3.13)	0.02 (-0.15,0.28)
HD TOFA PO + MTX		0.78 (0.46,1.36)	0.81 (0.51,1.29)	-0.03 (-0.12,0.04)
HD CERTO SC + MTX		0.82 (0.28,2.66)	0.85 (0.34,2.19)	-0.02 (-0.18,0.15)
HD INF IV + MTX		1.57 (0.56,4.36)	1.42 (0.62,3.24)	0.06 (-0.08,0.27)
HD TOCI IV + DMARD		0.30 (0.08,1.17)	0.34 (0.11,1.15)	-0.10 (-0.31,0.01)
SD ETN SC + DMARD	SD ABA SC + MTX	0.93 (0.22,3.79)	0.94 (0.25,3.63)	0.00 (-0.14,0.06)
SD CERTO SC + DMARD		0.69 (0.12,4.29)	0.71 (0.14,4.01)	-0.01 (-0.16,0.07)
SD ADA SC + DMARD		0.59 (0.09,4.03)	0.60 (0.10,3.73)	-0.02 (-0.16,0.08)
LD ETN SC		2.13 (0.60,8.40)	1.99 (0.64,7.20)	0.05 (-0.05,0.21)
LD ADA SC		0.30 (0.05,1.87)	0.31 (0.06,1.85)	-0.04 (-0.19,0.01)
LD ANA		0.46 (0.05,3.64)	0.47 (0.06,3.46)	-0.03 (-0.19,0.05)
LD ABA IV + MTX		2.26 (0.59,8.74)	2.08 (0.62,7.19)	0.05 (-0.04,0.25)
LD CERTO SC + MTX		1.71 (0.28,12.60)	1.63 (0.30,9.56)	0.03 (-0.09,0.27)
LD ETN SC + MTX		1.09 (0.22,6.05)	1.08 (0.24,5.23)	0.00 (-0.12,0.15)
HD TOCI IV		1.20 (0.30,4.59)	1.18 (0.33,4.31)	0.01 (-0.12,0.08)
HD ADA SC		0.30 (0.04,2.03)	0.31 (0.05,2.00)	-0.04 (-0.19,0.02)
HD ANA		1.09 (0.16,8.11)	1.09 (0.18,7.29)	0.00 (-0.16,0.12)
HD TOCI IV + MTX		1.62 (0.31,7.06)	1.55 (0.34,6.04)	0.02 (-0.10,0.18)
HD GOLI SC + MTX		3.78 (0.73,21.88)	3.19 (0.76,14.15)	0.11 (-0.02,0.44)
HD TOFA PO + MTX		2.54 (0.77,8.87)	2.30 (0.80,7.40)	0.07 (-0.03,0.22)
HD CERTO SC + MTX		2.71 (0.71,11.35)	2.43 (0.74,9.16)	0.07 (-0.03,0.27)
HD INF IV + MTX		5.13 (1.43,18.96)	4.03 (1.33,13.25)	0.17 (0.03,0.42)
HD TOCI IV + DMARD		0.98 (0.20,4.88)	0.98 (0.23,4.49)	0.00 (-0.13,0.10)
SD CERTO SC + DMARD	SD ETN SC + DMARD	0.73 (0.19,3.11)	0.74 (0.21,2.90)	-0.01 (-0.09,0.07)
SD ADA SC + DMARD		0.63 (0.13,3.47)	0.64 (0.14,3.15)	-0.02 (-0.09,0.08)
LD ETN SC		2.32 (0.79,7.27)	2.16 (0.80,5.78)	0.06 (-0.01,0.23)
LD ADA SC		0.32 (0.07,1.21)	0.33 (0.08,1.20)	-0.03 (-0.11,0.01)



(Continued)

LD ANA		0.47 (0.09,2.82)	0.48 (0.10,2.69)	-0.02 (-0.11,0.05)
LD ABA IV + MTX		2.43 (0.59,10.18)	2.24 (0.60,7.61)	0.06 (-0.03,0.29)
LD CERTO SC + MTX		1.95 (0.32,10.32)	1.85 (0.34,7.67)	0.04 (-0.05,0.29)
LD ETN SC + MTX		1.21 (0.25,5.31)	1.20 (0.26,4.49)	0.01 (-0.06,0.16)
HD TOCI IV		1.26 (0.47,3.72)	1.24 (0.49,3.40)	0.01 (-0.05,0.09)
HD ADA SC		0.32 (0.06,1.26)	0.33 (0.07,1.25)	-0.03 (-0.11,0.01)
HD ANA		1.15 (0.24,5.74)	1.14 (0.26,5.06)	0.01 (-0.08,0.13)
HD TOCI IV + MTX		1.70 (0.43,6.49)	1.64 (0.45,5.33)	0.03 (-0.05,0.19)
HD GOLI SC + MTX		4.11 (0.85,22.42)	3.48 (0.86,12.51)	0.12 (-0.01,0.46)
HD TOFA PO + MTX		2.75 (0.88,8.37)	2.50 (0.88,6.62)	0.07 (-0.01,0.25)
HD CERTO SC + MTX		2.90 (0.80,11.04)	2.62 (0.81,8.10)	0.08 (-0.01,0.31)
HD INF IV + MTX		5.53 (1.54,19.06)	4.37 (1.47,11.80)	0.18 (0.03,0.45)
HD TOCI IV + DMARD		1.06 (0.31,3.76)	1.05 (0.33,3.46)	0.00 (-0.06,0.09)
SD ADA SC + DMARD	SD CERTO SC + DMARD	0.87 (0.17,4.47)	0.87 (0.18,4.08)	0.00 (-0.08,0.10)
LD ETN SC		3.26 (0.68,14.59)	2.98 (0.70,11.42)	0.07 (-0.02,0.26)
LD ADA SC		0.43 (0.06,2.38)	0.44 (0.06,2.34)	-0.02 (-0.11,0.02)
LD ANA		0.64 (0.11,4.35)	0.64 (0.12,4.07)	-0.01 (-0.10,0.06)
LD ABA IV + MTX		3.24 (0.58,19.34)	2.95 (0.60,13.98)	0.07 (-0.03,0.33)
LD CERTO SC + MTX		2.61 (0.34,17.40)	2.43 (0.35,12.75)	0.05 (-0.05,0.32)
LD ETN SC + MTX		1.66 (0.24,9.45)	1.61 (0.25,7.83)	0.02 (-0.07,0.19)
HD TOCI IV		1.75 (0.47,5.92)	1.70 (0.50,5.38)	0.02 (-0.05,0.11)
HD ADA SC		0.42 (0.08,2.44)	0.43 (0.08,2.38)	-0.02 (-0.10,0.02)
HD ANA		1.54 (0.29,10.14)	1.51 (0.32,8.63)	0.02 (-0.07,0.15)
HD TOCI IV + MTX		2.30 (0.47,11.24)	2.18 (0.50,9.15)	0.04 (-0.04,0.22)
HD GOLI SC + MTX		5.61 (0.92,35.60)	4.71 (0.93,21.37)	0.13 (-0.01,0.48)
HD TOFA PO + MTX		3.85 (0.77,16.28)	3.44 (0.79,12.54)	0.09 (-0.02,0.28)
HD CERTO SC + MTX		4.01 (0.77,19.98)	3.55 (0.78,14.41)	0.09 (-0.01,0.34)
HD INF IV + MTX		7.55 (1.54,36.27)	5.86 (1.48,21.72)	0.19 (0.03,0.48)

(Continued)

HD TOCI IV + DMARD		1.42 (0.40,5.17)	1.39 (0.42,4.71)	0.01 (-0.05,0.11)
LD ETN SC	SD ADA SC + DMARD	3.71 (0.67,19.35)	3.36 (0.70,16.02)	0.07 (-0.03,0.26)
LD ADA SC		0.50 (0.07,3.64)	0.51 (0.08,3.57)	-0.02 (-0.13,0.02)
LD ANA		0.71 (0.09,6.60)	0.71 (0.10,6.20)	-0.01 (-0.12,0.07)
LD ABA IV + MTX		3.82 (0.62,22.35)	3.44 (0.65,17.55)	0.07 (-0.03,0.32)
LD CERTO SC + MTX		2.97 (0.33,24.44)	2.75 (0.36,18.94)	0.06 (-0.06,0.30)
LD ETN SC + MTX		1.92 (0.24,13.82)	1.85 (0.27,11.72)	0.02 (-0.08,0.18)
HD TOCI IV		2.00 (0.44,8.92)	1.92 (0.47,8.26)	0.03 (-0.06,0.11)
HD ADA SC		0.50 (0.07,3.63)	0.51 (0.08,3.53)	-0.02 (-0.13,0.02)
HD ANA		1.77 (0.25,14.77)	1.72 (0.28,13.03)	0.02 (-0.09,0.15)
HD TOCI IV + MTX		2.69 (0.44,14.78)	2.52 (0.47,12.76)	0.04 (-0.05,0.21)
HD GOLI SC + MTX		6.44 (0.90,47.97)	5.29 (0.91,31.43)	0.14 (-0.01,0.48)
HD TOFA PO + MTX		4.45 (0.76,22.61)	3.92 (0.77,18.48)	0.09 (-0.02,0.28)
HD CERTO SC + MTX		4.70 (0.78,26.70)	4.09 (0.80,20.69)	0.10 (-0.02,0.33)
HD INF IV + MTX		8.93 (1.42,51.00)	6.82 (1.36,33.32)	0.19 (0.03,0.47)
HD TOCI IV + DMARD		1.64 (0.42,6.67)	1.60 (0.45,6.23)	0.02 (-0.06,0.11)
LD ADA SC	LD ETN SC	0.13 (0.03,0.64)	0.15 (0.04,0.66)	-0.09 (-0.29,-0.01)
LD ANA		0.20 (0.03,1.31)	0.23 (0.04,1.29)	-0.08 (-0.29,0.02)
LD ABA IV + MTX		1.06 (0.28,3.66)	1.05 (0.32,3.03)	0.00 (-0.14,0.18)
LD CERTO SC + MTX		0.82 (0.15,4.12)	0.84 (0.17,3.30)	-0.02 (-0.19,0.20)
LD ETN SC + MTX		0.52 (0.11,2.06)	0.55 (0.13,1.88)	-0.04 (-0.21,0.08)
HD TOCI IV		0.55 (0.19,1.45)	0.58 (0.23,1.40)	-0.04 (-0.21,0.02)
HD ADA SC		0.14 (0.02,0.68)	0.15 (0.03,0.68)	-0.09 (-0.29,-0.01)
HD ANA		0.51 (0.08,2.69)	0.54 (0.11,2.47)	-0.05 (-0.26,0.09)
HD TOCI IV + MTX		0.72 (0.18,2.65)	0.75 (0.21,2.34)	-0.02 (-0.19,0.11)
HD GOLI SC + MTX		1.75 (0.40,8.10)	1.60 (0.45,5.29)	0.06 (-0.10,0.35)
HD TOFA PO + MTX		1.18 (0.42,3.21)	1.15 (0.47,2.76)	0.02 (-0.11,0.15)
HD CERTO SC + MTX		1.27 (0.39,4.03)	1.23 (0.44,3.36)	0.02 (-0.12,0.20)

(Continued)

HD INF IV + MTX		2.41 (0.70,7.54)	2.05 (0.75,5.18)	0.11 (-0.04,0.34)
HD TOCI IV + DMARD		0.45 (0.13,1.70)	0.48 (0.15,1.63)	-0.05 (-0.22,0.04)
LD ANA	LD ADA SC	1.54 (0.27,9.03)	1.53 (0.28,8.47)	0.01 (-0.03,0.08)
LD ABA IV + MTX		7.75 (1.31,43.87)	6.86 (1.30,32.11)	0.10 (0.01,0.35)
LD CERTO SC + MTX		6.18 (0.79,46.45)	5.60 (0.79,33.25)	0.08 (-0.01,0.34)
LD ETN SC + MTX		3.94 (0.57,25.49)	3.73 (0.58,20.90)	0.04 (-0.01,0.21)
HD TOCI IV		4.00 (0.90,19.67)	3.78 (0.91,17.85)	0.05 (0.00,0.14)
HD ADA SC		1.01 (0.24,4.75)	1.01 (0.24,4.65)	0.00 (-0.03,0.03)
HD ANA		3.84 (0.71,17.97)	3.65 (0.72,15.84)	0.04 (-0.01,0.16)
HD TOCI IV + MTX		5.36 (0.87,36.14)	4.96 (0.88,29.48)	0.07 (0.00,0.25)
HD GOLI SC + MTX		13.44 (1.89,96.52)	10.86 (1.83,53.58)	0.16 (0.02,0.51)
HD TOFA PO + MTX		8.95 (1.82,41.65)	7.76 (1.76,31.67)	0.11 (0.02,0.31)
HD CERTO SC + MTX		9.49 (1.74,51.76)	8.16 (1.69,38.07)	0.12 (0.02,0.36)
HD INF IV + MTX		18.00 (3.26,96.45)	13.61 (3.01,58.71)	0.21 (0.05,0.51)
HD TOCI IV + DMARD		3.38 (0.62,18.86)	3.24 (0.63,16.78)	0.03 (-0.01,0.14)
LD ABA IV + MTX	LD ANA	4.88 (0.72,43.50)	4.41 (0.73,30.76)	0.08 (-0.02,0.35)
LD CERTO SC + MTX		4.08 (0.43,36.38)	3.74 (0.45,25.78)	0.07 (-0.03,0.34)
LD ETN SC + MTX		2.55 (0.29,21.37)	2.44 (0.30,17.43)	0.03 (-0.04,0.21)
HD TOCI IV		2.70 (0.45,15.69)	2.59 (0.47,13.98)	0.04 (-0.04,0.14)
HD ADA SC		0.67 (0.10,3.83)	0.68 (0.10,3.69)	-0.01 (-0.08,0.03)
HD ANA		2.43 (0.83,7.61)	2.33 (0.84,6.98)	0.03 (-0.01,0.12)
HD TOCI IV + MTX		3.64 (0.39,24.25)	3.40 (0.41,19.48)	0.06 (-0.04,0.24)
HD GOLI SC + MTX		8.39 (0.98,80.29)	6.96 (0.98,44.53)	0.15 (0.00,0.51)
HD TOFA PO + MTX		5.99 (0.89,36.38)	5.26 (0.90,27.40)	0.10 (-0.01,0.31)
HD CERTO SC + MTX		6.21 (0.90,42.89)	5.44 (0.91,30.30)	0.11 (0.00,0.36)
HD INF IV + MTX		11.36 (1.66,82.92)	8.85 (1.59,46.36)	0.20 (0.03,0.51)
HD TOCI IV + DMARD		2.28 (0.31,13.22)	2.20 (0.33,11.80)	0.03 (-0.05,0.14)
LD CERTO SC + MTX	LD ABA IV + MTX	0.77 (0.12,4.94)	0.80 (0.15,3.92)	-0.02 (-0.24,0.20)

(Continued)

LD ETN SC + MTX		0.49 (0.10,2.67)	0.53 (0.12,2.41)	-0.05 (-0.26,0.09)
HD TOCI IV		0.52 (0.14,1.86)	0.56 (0.19,1.79)	-0.05 (-0.27,0.04)
HD ADA SC		0.13 (0.02,0.82)	0.15 (0.02,0.82)	-0.09 (-0.35,-0.01)
HD ANA		0.51 (0.06,3.18)	0.54 (0.09,2.92)	-0.05 (-0.32,0.08)
HD TOCI IV + MTX		0.71 (0.14,3.06)	0.74 (0.18,2.72)	-0.03 (-0.24,0.11)
HD GOLI SC + MTX		1.68 (0.33,9.35)	1.53 (0.38,6.24)	0.06 (-0.14,0.36)
HD TOFA PO + MTX		1.12 (0.37,3.82)	1.10 (0.43,3.33)	0.01 (-0.16,0.14)
HD CERTO SC + MTX		1.22 (0.30,4.91)	1.19 (0.36,4.04)	0.02 (-0.16,0.20)
HD INF IV + MTX		2.30 (0.60,8.38)	1.95 (0.66,6.14)	0.10 (-0.07,0.33)
HD TOCI IV + DMARD		0.44 (0.09,2.16)	0.47 (0.12,2.05)	-0.05 (-0.29,0.05)
LD ETN SC + MTX	LD CERTO SC + MTX	0.63 (0.09,4.48)	0.66 (0.11,3.95)	-0.03 (-0.25,0.12)
HD TOCI IV		0.64 (0.13,3.64)	0.67 (0.17,3.40)	-0.03 (-0.27,0.07)
HD ADA SC		0.17 (0.02,1.36)	0.18 (0.03,1.35)	-0.08 (-0.34,0.01)
HD ANA		0.60 (0.07,6.05)	0.63 (0.11,5.35)	-0.03 (-0.31,0.12)
HD TOCI IV + MTX		0.87 (0.14,5.80)	0.88 (0.18,5.02)	-0.01 (-0.25,0.15)
HD GOLI SC + MTX		2.13 (0.36,16.41)	1.86 (0.42,10.89)	0.08 (-0.13,0.39)
HD TOFA PO + MTX		1.46 (0.29,7.82)	1.39 (0.35,6.63)	0.03 (-0.18,0.19)
HD CERTO SC + MTX		1.53 (0.38,7.09)	1.44 (0.45,5.81)	0.04 (-0.14,0.21)
HD INF IV + MTX		2.99 (0.50,16.18)	2.45 (0.58,11.51)	0.13 (-0.10,0.38)
HD TOCI IV + DMARD		0.53 (0.10,3.94)	0.56 (0.13,3.66)	-0.04 (-0.28,0.08)
HD TOCI IV	LD ETN SC + MTX	1.04 (0.27,4.60)	1.04 (0.31,4.33)	0.00 (-0.14,0.08)
HD ADA SC		0.25 (0.04,1.96)	0.27 (0.04,1.93)	-0.04 (-0.21,0.01)
HD ANA		0.96 (0.13,7.30)	0.97 (0.16,6.58)	0.00 (-0.18,0.12)
HD TOCI IV + MTX		1.41 (0.26,7.53)	1.36 (0.30,6.43)	0.02 (-0.12,0.17)
HD GOLI SC + MTX		3.42 (0.63,19.26)	2.89 (0.67,13.47)	0.11 (-0.04,0.41)
HD TOFA PO + MTX		2.30 (0.57,9.28)	2.11 (0.61,7.87)	0.06 (-0.06,0.22)
HD CERTO SC + MTX		2.41 (0.55,12.18)	2.18 (0.60,9.63)	0.07 (-0.06,0.28)
HD INF IV + MTX		4.68 (1.01,21.09)	3.70 (1.01,14.81)	0.16 (0.00,0.42)

(Continued)

HD TOCI IV + DMARD		0.87 (0.17,4.86)	0.88 (0.20,4.50)	-0.01 (-0.16,0.09)
HD ADA SC	HD TOCI IV	0.26 (0.05,1.10)	0.27 (0.05,1.10)	-0.05 (-0.14,0.00)
HD ANA		0.94 (0.19,4.46)	0.94 (0.22,3.96)	0.00 (-0.11,0.12)
HD TOCI IV + MTX		1.34 (0.48,3.67)	1.31 (0.50,3.12)	0.02 (-0.04,0.16)
HD GOLI SC + MTX		3.26 (0.80,14.57)	2.80 (0.81,8.80)	0.11 (-0.01,0.43)
HD TOFA PO + MTX		2.14 (0.84,5.92)	1.97 (0.86,4.84)	0.06 (-0.01,0.22)
HD CERTO SC + MTX		2.33 (0.74,7.94)	2.12 (0.76,5.94)	0.07 (-0.02,0.29)
HD INF IV + MTX		4.35 (1.45,14.16)	3.47 (1.39,9.01)	0.16 (0.02,0.42)
HD TOCI IV + DMARD		0.84 (0.29,2.43)	0.85 (0.31,2.28)	-0.01 (-0.08,0.07)
HD ANA	HD ADA SC	3.67 (0.72,21.32)	3.51 (0.73,18.39)	0.04 (-0.01,0.16)
HD TOCI IV + MTX		5.15 (0.96,35.80)	4.76 (0.96,28.99)	0.07 (0.00,0.25)
HD GOLI SC + MTX		12.95 (1.77,115.10)	10.61 (1.72,64.66)	0.16 (0.02,0.51)
HD TOFA PO + MTX		8.79 (1.73,50.82)	7.66 (1.68,39.38)	0.11 (0.02,0.31)
HD CERTO SC + MTX		9.24 (1.63,61.35)	7.95 (1.59,42.40)	0.12 (0.02,0.37)
HD INF IV + MTX		17.57 (3.18,112.80)	13.18 (2.95,66.15)	0.21 (0.05,0.51)
HD TOCI IV + DMARD		3.31 (0.61,19.74)	3.16 (0.62,17.49)	0.04 (-0.01,0.14)
HD TOCI IV + MTX	HD ANA	1.47 (0.20,9.19)	1.42 (0.22,7.27)	0.02 (-0.12,0.22)
HD GOLI SC + MTX		3.36 (0.42,29.91)	2.91 (0.46,16.31)	0.11 (-0.06,0.48)
HD TOFA PO + MTX		2.39 (0.42,13.63)	2.20 (0.46,10.07)	0.07 (-0.07,0.28)
HD CERTO SC + MTX		2.53 (0.41,16.39)	2.30 (0.44,11.42)	0.07 (-0.07,0.33)
HD INF IV + MTX		4.64 (0.83,29.95)	3.77 (0.85,16.58)	0.16 (-0.02,0.48)
HD TOCI IV + DMARD		0.90 (0.15,5.07)	0.91 (0.16,4.53)	0.00 (-0.13,0.11)
HD GOLI SC + MTX	HD TOCI IV + MTX	2.48 (0.44,12.93)	2.17 (0.49,8.68)	0.09 (-0.08,0.40)
HD TOFA PO + MTX		1.63 (0.46,6.29)	1.53 (0.51,5.27)	0.04 (-0.09,0.21)
HD CERTO SC + MTX		1.72 (0.43,7.79)	1.60 (0.48,6.01)	0.05 (-0.09,0.27)
HD INF IV + MTX		3.25 (0.77,13.96)	2.66 (0.81,9.43)	0.14 (-0.03,0.40)
HD TOCI IV + DMARD		0.62 (0.16,2.73)	0.64 (0.19,2.54)	-0.03 (-0.19,0.07)
HD TOFA PO + MTX	HD GOLI SC + MTX	0.68 (0.16,2.60)	0.73 (0.24,2.32)	-0.04 (-0.32,0.11)

(Continued)

HD CERTO SC + MTX		0.71 (0.15,3.14)	0.76 (0.22,2.66)	-0.04 (-0.33,0.15)
HD INF IV + MTX		1.38 (0.25,6.03)	1.28 (0.36,4.39)	0.04 (-0.26,0.30)
HD TOCI IV + DMARD		0.25 (0.05,1.36)	0.30 (0.08,1.32)	-0.12 (-0.44,0.02)
HD CERTO SC + MTX	HD TOFA PO + MTX	1.05 (0.36,3.44)	1.05 (0.41,2.82)	0.01 (-0.12,0.18)
HD INF IV + MTX		2.03 (0.72,5.44)	1.75 (0.76,3.98)	0.10 (-0.04,0.30)
HD TOCI IV + DMARD		0.38 (0.11,1.44)	0.42 (0.13,1.40)	-0.07 (-0.25,0.03)
HD INF IV + MTX	HD CERTO SC + MTX	1.88 (0.50,6.44)	1.65 (0.58,4.56)	0.08 (-0.10,0.31)
HD TOCI IV + DMARD		0.35 (0.09,1.60)	0.39 (0.12,1.54)	-0.08 (-0.30,0.04)
HD TOCI IV + DMARD	HD INF IV + MTX	0.19 (0.04,0.85)	0.24 (0.07,0.86)	-0.17 (-0.45,-0.01)
Random-Effect Model	Residual Deviance	119.1 vs 119 data points		
	Deviance Information Criteria	622.675		
Fixed-Effect Model	Residual Deviance	123.8 vs 119 data points		
	Deviance Information Criteria	622.968		
Note:				
Total Patients	20301			
Total Studies	48			
2-arm	30			
3-arm	13			
4-arm	5			

### Appendix 32. Withdrawals due to AE: Subgroup - Late RA (>10 years)

Withdrawals in Late RA: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
-----------	-----------	--------------	--------------	----------------

**Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis (Review)**

436

(Continued)

MTX + PL	PL	2.70 (0.42,18.18)	2.63 (0.43,15.53)	0.02 (-0.01,0.16)
SD ETN SC		1.24 (0.22,7.53)	1.24 (0.23,7.13)	0.00 (-0.02,0.06)
SD ADA SC		5.91 (0.86,132.50)	5.50 (0.86,89.14)	0.06 (0.00,0.35)
SD RITUX IV		36.20 (1.14,1221.00)	22.61 (1.14,115.20)	0.31 (0.00,0.93)
SD ADA SC + MTX		3.94 (0.51,30.99)	3.75 (0.52,24.30)	0.04 (-0.01,0.26)
SD RITUX IV + MTX		9.81 (0.76,167.10)	8.62 (0.77,64.71)	0.10 (0.00,0.69)
SD ETN SC + MTX		3.63 (0.09,276.70)	3.50 (0.10,61.27)	0.03 (-0.02,0.80)
SD INF IV + MTX		1.84 (0.16,18.50)	1.82 (0.16,15.68)	0.01 (-0.02,0.17)
LD ETN SC		1.27 (0.24,7.42)	1.27 (0.24,6.95)	0.00 (-0.02,0.06)
LD RITUX IV + MTX		6.93 (0.45,113.20)	6.30 (0.46,52.49)	0.07 (-0.01,0.60)
HD INF IV + MTX		1.37 (0.12,15.94)	1.36 (0.12,13.75)	0.00 (-0.02,0.14)
SD ETN SC	MTX + PL	0.47 (0.16,1.27)	0.48 (0.18,1.26)	-0.02 (-0.12,0.00)
SD ADA SC		2.26 (0.15,83.91)	2.15 (0.17,57.17)	0.04 (-0.14,0.35)
SD RITUX IV		12.49 (0.87,298.80)	7.50 (0.88,46.18)	0.27 (0.00,0.87)
SD ADA SC + MTX		1.47 (0.56,3.45)	1.43 (0.58,3.11)	0.01 (-0.02,0.13)
SD RITUX IV + MTX		3.42 (0.63,35.37)	3.02 (0.64,16.33)	0.07 (-0.01,0.61)
SD ETN SC + MTX		1.23 (0.07,71.41)	1.21 (0.07,19.33)	0.01 (-0.07,0.73)
SD INF IV + MTX		0.64 (0.14,2.92)	0.65 (0.15,2.64)	-0.01 (-0.08,0.08)
LD ETN SC		0.47 (0.17,1.37)	0.48 (0.19,1.36)	-0.02 (-0.12,0.01)
LD RITUX IV + MTX		2.53 (0.35,25.06)	2.34 (0.36,13.34)	0.04 (-0.04,0.52)
HD INF IV + MTX		0.51 (0.10,2.39)	0.52 (0.10,2.22)	-0.01 (-0.10,0.06)
SD ADA SC	SD ETN SC	4.96 (0.35,179.90)	4.62 (0.37,117.30)	0.06 (-0.04,0.35)
SD RITUX IV		26.58 (1.53,769.90)	15.92 (1.50,105.40)	0.30 (0.01,0.91)
SD ADA SC + MTX		3.15 (0.81,12.13)	2.99 (0.81,10.21)	0.03 (0.00,0.22)
SD RITUX IV + MTX		7.41 (1.02,95.24)	6.48 (1.01,42.96)	0.09 (0.00,0.67)
SD ETN SC + MTX		2.70 (0.11,176.40)	2.58 (0.11,45.07)	0.02 (-0.03,0.78)
SD INF IV + MTX		1.39 (0.24,9.02)	1.38 (0.24,7.91)	0.01 (-0.03,0.14)
LD ETN SC		0.99 (0.40,2.86)	0.99 (0.41,2.79)	0.00 (-0.03,0.03)

(Continued)

LD RITUX IV + MTX		5.47 (0.56,68.87)	4.93 (0.57,34.34)	0.07 (-0.01,0.58)
HD INF IV + MTX		1.09 (0.16,6.93)	1.08 (0.16,6.27)	0.00 (-0.04,0.12)
SD RITUX IV	SD ADA SC	5.66 (0.06,320.10)	3.86 (0.08,31.65)	0.23 (-0.27,0.88)
SD ADA SC + MTX		0.63 (0.01,11.32)	0.65 (0.02,8.64)	-0.03 (-0.34,0.23)
SD RITUX IV + MTX		1.51 (0.03,55.04)	1.45 (0.04,19.78)	0.03 (-0.32,0.65)
SD ETN SC + MTX		0.51 (0.01,87.27)	0.54 (0.01,19.52)	-0.03 (-0.33,0.75)
SD INF IV + MTX		0.27 (0.01,5.93)	0.29 (0.01,5.05)	-0.05 (-0.35,0.13)
LD ETN SC		0.20 (0.01,3.10)	0.22 (0.01,2.93)	-0.06 (-0.35,0.05)
LD RITUX IV + MTX		1.11 (0.02,39.98)	1.10 (0.03,17.39)	0.01 (-0.32,0.57)
HD INF IV + MTX		0.21 (0.00,5.18)	0.23 (0.01,4.48)	-0.06 (-0.35,0.11)
SD ADA SC + MTX	SD RITUX IV	0.12 (0.00,2.00)	0.19 (0.03,1.88)	-0.25 (-0.85,0.03)
SD RITUX IV + MTX		0.31 (0.01,3.19)	0.48 (0.05,2.70)	-0.15 (-0.71,0.12)
SD ETN SC + MTX		0.11 (0.00,13.37)	0.17 (0.01,5.47)	-0.20 (-0.88,0.42)
SD INF IV + MTX		0.05 (0.00,1.16)	0.09 (0.01,1.14)	-0.28 (-0.90,0.00)
LD ETN SC		0.04 (0.00,0.70)	0.06 (0.01,0.71)	-0.30 (-0.91,-0.01)
LD RITUX IV + MTX		0.21 (0.01,2.60)	0.35 (0.03,2.22)	-0.18 (-0.74,0.09)
HD INF IV + MTX		0.04 (0.00,0.87)	0.07 (0.01,0.88)	-0.29 (-0.90,0.00)
SD RITUX IV + MTX	SD ADA SC + MTX	2.41 (0.35,26.99)	2.17 (0.38,13.90)	0.05 (-0.07,0.58)
SD ETN SC + MTX		0.84 (0.04,57.07)	0.85 (0.04,15.50)	0.00 (-0.15,0.70)
SD INF IV + MTX		0.45 (0.08,2.68)	0.47 (0.09,2.48)	-0.02 (-0.18,0.06)
LD ETN SC		0.31 (0.09,1.38)	0.33 (0.10,1.36)	-0.03 (-0.22,0.01)
LD RITUX IV + MTX		1.75 (0.20,20.27)	1.65 (0.22,11.34)	0.03 (-0.11,0.49)
HD INF IV + MTX		0.34 (0.05,2.21)	0.36 (0.06,2.08)	-0.03 (-0.19,0.04)
SD ETN SC + MTX	SD RITUX IV + MTX	0.38 (0.01,27.97)	0.42 (0.01,8.97)	-0.04 (-0.61,0.58)
SD INF IV + MTX		0.18 (0.01,1.71)	0.21 (0.02,1.63)	-0.08 (-0.63,0.02)
LD ETN SC		0.13 (0.01,1.12)	0.15 (0.02,1.12)	-0.09 (-0.67,0.00)
LD RITUX IV + MTX		0.71 (0.14,3.24)	0.77 (0.17,2.70)	-0.02 (-0.28,0.16)
HD INF IV + MTX		0.14 (0.01,1.39)	0.17 (0.02,1.35)	-0.09 (-0.65,0.01)



(Continued)

SD INF IV + MTX	SD ETN SC + MTX	0.50 (0.01,12.90)	0.52 (0.02,12.19)	-0.02 (-0.75,0.10)
LD ETN SC		0.38 (0.01,8.85)	0.40 (0.02,8.64)	-0.02 (-0.78,0.03)
LD RITUX IV + MTX		1.85 (0.03,106.20)	1.73 (0.08,65.42)	0.02 (-0.63,0.52)
HD INF IV + MTX		0.40 (0.01,11.23)	0.42 (0.02,10.54)	-0.02 (-0.76,0.07)
LD ETN SC	SD INF IV + MTX	0.73 (0.11,4.60)	0.74 (0.13,4.48)	0.00 (-0.14,0.03)
LD RITUX IV + MTX		4.05 (0.35,59.56)	3.61 (0.38,35.42)	0.05 (-0.05,0.55)
HD INF IV + MTX		0.77 (0.14,3.87)	0.78 (0.15,3.66)	0.00 (-0.10,0.06)
LD RITUX IV + MTX	LD ETN SC	5.43 (0.55,68.53)	4.90 (0.55,34.17)	0.07 (-0.01,0.58)
HD INF IV + MTX		1.10 (0.15,6.61)	1.10 (0.15,5.80)	0.00 (-0.04,0.12)
HD INF IV + MTX	LD RITUX IV + MTX	0.19 (0.01,2.60)	0.22 (0.02,2.46)	-0.06 (-0.56,0.04)
Random-Effect Model	Residual Deviance	26.96 vs 24 data points		
	Deviance Information Criteria	122.322		
Fixed-Effect Model	Residual Deviance	27.51 vs 24 data points		
	Deviance Information Criteria	122.485		
Note:				
Total Patients	3276			
Total Studies	9			
2-arm	4			
3-arm	4			
4-arm	1			

### Appendix 33. Withdrawals due to AE: Subgroup - Trial duration ( $\leq 6$ months)

Withdrawals, Short trial duration: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model

(Continued)

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX	PL	1.11 (0.30,3.75)	1.11 (0.31,3.58)	0.00 (-0.02,0.05)
DMARD + PL		3.39 (0.98,11.24)	3.23 (0.98,9.44)	0.05 (0.00,0.17)
MTX + DMARD		3.08 (0.54,14.28)	2.95 (0.55,11.47)	0.04 (-0.01,0.20)
SD ETN SC		1.27 (0.34,4.27)	1.26 (0.35,4.03)	0.01 (-0.02,0.06)
SD ADA SC		2.00 (1.00,4.48)	1.95 (1.00,4.24)	0.02 (0.00,0.06)
SD TOCI IV		0.98 (0.37,2.60)	0.98 (0.38,2.53)	0.00 (-0.02,0.03)
SD CERTO SC		2.92 (0.85,12.52)	2.81 (0.85,10.59)	0.04 (0.00,0.16)
SD TOC SC + PL IV		0.70 (0.20,2.23)	0.70 (0.20,2.18)	-0.01 (-0.02,0.02)
SD RITUX IV		7.58 (0.55,151.10)	6.69 (0.56,38.26)	0.11 (-0.01,0.74)
SD ETN SC + MTX		1.01 (0.22,3.98)	1.01 (0.23,3.81)	0.00 (-0.02,0.05)
SD ADA SC + MTX		1.44 (0.31,6.62)	1.43 (0.32,5.97)	0.01 (-0.02,0.09)
SD INF IV + MTX		2.98 (0.68,11.68)	2.86 (0.68,9.66)	0.04 (-0.01,0.18)
SD ABA IV + MTX		1.09 (0.22,3.96)	1.09 (0.22,3.76)	0.00 (-0.02,0.05)
SD CERTO SC + MTX		1.50 (0.35,6.04)	1.49 (0.36,5.52)	0.01 (-0.02,0.09)
SD RITUX IV + MTX		2.15 (0.38,14.47)	2.10 (0.38,11.41)	0.02 (-0.01,0.20)
SD GOLI SC + MTX		1.16 (0.22,6.22)	1.16 (0.23,5.69)	0.00 (-0.02,0.09)
SD TOFA PO + MTX		1.97 (0.39,10.08)	1.93 (0.39,8.63)	0.02 (-0.01,0.14)
SD ABA SC + MTX		0.61 (0.10,2.67)	0.61 (0.10,2.59)	-0.01 (-0.02,0.03)
SD TOCI IV + MTX		1.24 (0.27,5.65)	1.24 (0.28,5.18)	0.00 (-0.02,0.08)
SD ETN SC + DMARD		2.41 (0.83,7.47)	2.34 (0.83,6.75)	0.03 (0.00,0.11)
SD CERTO SC + DMARD		3.17 (0.85,12.73)	3.03 (0.85,10.52)	0.04 (0.00,0.18)
SD ADA SC + DMARD		4.17 (0.70,22.23)	3.90 (0.70,15.74)	0.06 (-0.01,0.29)
SD TOCI SC + DMARD		9.78 (1.20,77.69)	8.22 (1.20,33.00)	0.15 (0.00,0.59)
LD ADA SC		0.71 (0.17,2.12)	0.72 (0.17,2.08)	-0.01 (-0.02,0.02)
LD ETN SC		2.45 (0.54,11.59)	2.38 (0.55,9.66)	0.03 (-0.01,0.16)
LD TOCI IV		0.75 (0.14,3.61)	0.76 (0.14,3.44)	0.00 (-0.02,0.04)
LD RITUX IV + MTX		1.98 (0.34,14.46)	1.94 (0.35,11.35)	0.02 (-0.02,0.21)

(Continued)

LD ABA IV + MTX	1.36 (0.21,6.99)	1.35 (0.21,6.27)	0.01 (-0.02,0.10)	
LD CERTO SC + MTX	0.98 (0.12,6.19)	0.98 (0.12,5.64)	0.00 (-0.02,0.09)	
LD TOCI IV + MTX	0.53 (0.09,2.70)	0.54 (0.09,2.63)	-0.01 (-0.02,0.03)	
HD TOCI IV	0.89 (0.26,3.16)	0.90 (0.27,3.03)	0.00 (-0.02,0.04)	
HD ADA SC	0.74 (0.20,2.32)	0.74 (0.20,2.26)	-0.01 (-0.02,0.02)	
HD GOLI SC	0.59 (0.05,4.89)	0.59 (0.05,4.53)	-0.01 (-0.03,0.07)	
HD TOCI IV + MTX	1.24 (0.34,4.88)	1.24 (0.35,4.57)	0.00 (-0.02,0.06)	
HD GOLI SC + MTX	1.72 (0.31,8.68)	1.69 (0.32,7.58)	0.01 (-0.02,0.12)	
HD TOFA PO + MTX	1.68 (0.35,9.23)	1.66 (0.35,8.00)	0.01 (-0.02,0.13)	
HD CERTO SC + MTX	1.56 (0.33,7.71)	1.54 (0.34,6.83)	0.01 (-0.02,0.11)	
HD INF IV + MTX	3.17 (0.64,13.94)	3.03 (0.64,11.19)	0.04 (-0.01,0.20)	
HD TOCI IV + DMARD	6.54 (1.64,26.27)	5.85 (1.62,17.84)	0.10 (0.01,0.34)	
DMARD + PL	MTX	3.06 (0.54,23.08)	2.91 (0.55,19.70)	0.04 (-0.02,0.17)
MTX + DMARD		2.92 (0.45,13.15)	2.78 (0.46,11.30)	0.04 (-0.03,0.19)
SD ETN SC	1.20 (0.25,4.31)	1.19 (0.27,4.13)	0.00 (-0.04,0.05)	
SD ADA SC	1.81 (0.50,8.47)	1.77 (0.52,8.10)	0.02 (-0.03,0.06)	
SD TOCI IV	0.89 (0.32,2.89)	0.89 (0.33,2.85)	0.00 (-0.04,0.02)	
SD CERTO SC	2.69 (0.45,21.20)	2.58 (0.46,18.20)	0.03 (-0.03,0.16)	
SD TOC SC + PL IV	0.62 (0.18,2.43)	0.63 (0.19,2.40)	-0.01 (-0.05,0.01)	
SD RITUX IV	6.81 (0.71,93.71)	5.84 (0.72,33.71)	0.11 (-0.01,0.72)	
SD ETN SC + MTX	0.92 (0.20,3.52)	0.92 (0.21,3.39)	0.00 (-0.05,0.04)	
SD ADA SC + MTX	1.28 (0.64,2.91)	1.27 (0.64,2.80)	0.01 (-0.01,0.06)	
SD INF IV + MTX	2.69 (1.30,5.51)	2.58 (1.29,4.92)	0.03 (0.00,0.14)	
SD ABA IV + MTX	0.95 (0.49,1.87)	0.96 (0.50,1.83)	0.00 (-0.02,0.02)	
SD CERTO SC + MTX	1.35 (0.72,2.59)	1.33 (0.72,2.47)	0.01 (-0.01,0.05)	
SD RITUX IV + MTX	1.96 (0.65,7.23)	1.91 (0.66,6.14)	0.02 (-0.01,0.17)	
SD GOLI SC + MTX	1.07 (0.39,3.04)	1.07 (0.40,2.87)	0.00 (-0.02,0.06)	
SD TOFA PO + MTX	1.75 (0.75,4.46)	1.71 (0.75,4.11)	0.02 (-0.01,0.10)	

(Continued)

SD ABA SC + MTX		0.52 (0.19,1.56)	0.53 (0.19,1.54)	-0.01 (-0.04,0.01)
SD TOCI IV + MTX		1.18 (0.34,3.72)	1.17 (0.34,3.55)	0.00 (-0.02,0.06)
SD ETN SC + DMARD		2.20 (0.44,13.50)	2.14 (0.45,12.30)	0.02 (-0.03,0.11)
SD CERTO SC + DMARD		2.71 (0.52,26.30)	2.60 (0.54,21.79)	0.04 (-0.02,0.19)
SD ADA SC + DMARD		3.89 (0.39,40.36)	3.64 (0.41,28.92)	0.06 (-0.03,0.29)
SD TOCI SC + DMARD		9.51 (0.77,96.91)	7.80 (0.78,47.08)	0.15 (-0.01,0.58)
LD ADA SC		0.63 (0.10,3.03)	0.64 (0.10,2.96)	-0.01 (-0.06,0.02)
LD ETN SC		2.24 (0.34,13.33)	2.17 (0.35,11.70)	0.02 (-0.03,0.16)
LD TOCI IV		0.70 (0.16,2.25)	0.70 (0.17,2.21)	-0.01 (-0.04,0.02)
LD RITUX IV + MTX		1.83 (0.55,7.25)	1.79 (0.56,6.33)	0.02 (-0.01,0.16)
LD ABA IV + MTX		1.19 (0.40,3.43)	1.19 (0.41,3.25)	0.00 (-0.02,0.07)
LD CERTO SC + MTX		0.93 (0.17,3.71)	0.93 (0.17,3.51)	0.00 (-0.03,0.07)
LD TOCI IV + MTX		0.49 (0.08,2.06)	0.50 (0.09,2.03)	-0.01 (-0.05,0.02)
HD TOCI IV		0.81 (0.40,1.70)	0.82 (0.41,1.67)	0.00 (-0.03,0.01)
HD ADA SC		0.66 (0.12,3.48)	0.67 (0.13,3.42)	-0.01 (-0.06,0.02)
HD GOLI SC		0.56 (0.05,2.97)	0.57 (0.06,2.83)	-0.01 (-0.04,0.05)
HD TOCI IV + MTX		1.12 (0.48,2.77)	1.12 (0.49,2.70)	0.00 (-0.02,0.04)
HD GOLI SC + MTX		1.50 (0.62,4.60)	1.48 (0.63,4.19)	0.01 (-0.01,0.10)
HD TOFA PO + MTX		1.57 (0.67,4.11)	1.54 (0.68,3.83)	0.01 (-0.01,0.09)
HD CERTO SC + MTX		1.46 (0.62,3.50)	1.44 (0.62,3.29)	0.01 (-0.01,0.08)
HD INF IV + MTX		2.87 (1.22,7.01)	2.73 (1.21,6.14)	0.04 (0.00,0.16)
HD TOCI IV + DMARD		5.90 (0.99,49.48)	5.26 (0.99,34.87)	0.09 (0.00,0.34)
MTX + DMARD	DMARD + PL	0.90 (0.10,6.94)	0.91 (0.12,5.89)	-0.01 (-0.15,0.17)
SD ETN SC		0.38 (0.05,2.53)	0.40 (0.07,2.43)	-0.04 (-0.17,0.04)
SD ADA SC		0.60 (0.19,1.93)	0.62 (0.21,1.89)	-0.02 (-0.14,0.02)
SD TOCI IV		0.29 (0.06,1.44)	0.30 (0.07,1.42)	-0.05 (-0.17,0.01)
SD CERTO SC		0.88 (0.14,5.75)	0.88 (0.17,5.10)	-0.01 (-0.14,0.12)
SD TOC SC + PL IV		0.20 (0.04,1.13)	0.21 (0.04,1.12)	-0.05 (-0.18,0.00)

(Continued)

SD RITUX IV	2.22 (0.10,67.50)	2.03 (0.12,19.44)	0.06 (-0.13,0.70)
SD ETN SC + MTX	0.30 (0.03,1.88)	0.31 (0.04,1.83)	-0.04 (-0.17,0.02)
SD ADA SC + MTX	0.42 (0.05,3.03)	0.44 (0.06,2.81)	-0.03 (-0.17,0.07)
SD INF IV + MTX	0.89 (0.10,6.25)	0.90 (0.12,5.16)	-0.01 (-0.15,0.14)
SD ABA IV + MTX	0.31 (0.03,2.03)	0.33 (0.04,1.96)	-0.04 (-0.17,0.03)
SD CERTO SC + MTX	0.44 (0.06,3.07)	0.46 (0.06,2.87)	-0.03 (-0.17,0.06)
SD RITUX IV + MTX	0.61 (0.07,6.67)	0.63 (0.08,5.53)	-0.02 (-0.16,0.18)
SD GOLI SC + MTX	0.34 (0.04,2.89)	0.36 (0.04,2.69)	-0.04 (-0.17,0.05)
SD TOFA PO + MTX	0.57 (0.06,4.36)	0.59 (0.07,3.86)	-0.02 (-0.16,0.11)
SD ABA SC + MTX	0.18 (0.02,1.27)	0.19 (0.02,1.26)	-0.05 (-0.18,0.01)
SD TOCI IV + MTX	0.36 (0.05,2.45)	0.38 (0.06,2.34)	-0.04 (-0.17,0.05)
SD ETN SC + DMARD	0.71 (0.32,1.70)	0.73 (0.34,1.65)	-0.02 (-0.10,0.03)
SD CERTO SC + DMARD	0.93 (0.30,3.16)	0.93 (0.32,2.90)	0.00 (-0.09,0.10)
SD ADA SC + DMARD	1.27 (0.35,4.05)	1.24 (0.37,3.33)	0.01 (-0.06,0.19)
SD TOCI SC + DMARD	2.74 (0.57,17.79)	2.39 (0.59,9.33)	0.09 (-0.03,0.50)
LD ADA SC	0.20 (0.04,1.08)	0.21 (0.04,1.07)	-0.05 (-0.17,0.00)
LD ETN SC	0.71 (0.10,6.19)	0.73 (0.11,5.42)	-0.02 (-0.15,0.12)
LD TOCI IV	0.22 (0.03,1.87)	0.23 (0.03,1.82)	-0.05 (-0.18,0.02)
LD RITUX IV + MTX	0.55 (0.06,5.59)	0.57 (0.07,4.57)	-0.02 (-0.16,0.17)
LD ABA IV + MTX	0.39 (0.04,3.22)	0.41 (0.04,2.99)	-0.04 (-0.17,0.06)
LD CERTO SC + MTX	0.29 (0.02,2.74)	0.31 (0.03,2.56)	-0.04 (-0.17,0.06)
LD TOCI IV + MTX	0.15 (0.02,1.12)	0.16 (0.02,1.12)	-0.05 (-0.18,0.00)
HD TOCI IV	0.26 (0.04,1.77)	0.27 (0.05,1.73)	-0.05 (-0.17,0.02)
HD ADA SC	0.21 (0.05,1.08)	0.22 (0.05,1.08)	-0.05 (-0.17,0.00)
HD GOLI SC	0.18 (0.01,1.90)	0.19 (0.01,1.83)	-0.05 (-0.18,0.03)
HD TOCI IV + MTX	0.36 (0.06,2.49)	0.38 (0.07,2.39)	-0.04 (-0.17,0.04)
HD GOLI SC + MTX	0.48 (0.06,4.25)	0.50 (0.06,3.81)	-0.03 (-0.16,0.09)
HD TOFA PO + MTX	0.50 (0.06,3.97)	0.52 (0.07,3.54)	-0.03 (-0.16,0.09)

(Continued)

HD CERTO SC + MTX		0.46 (0.05,3.44)	0.47 (0.06,3.17)	-0.03 (-0.16,0.08)
HD INF IV + MTX		0.94 (0.09,6.85)	0.95 (0.11,5.77)	0.00 (-0.15,0.16)
HD TOCI IV + DMARD		1.91 (1.01,3.79)	1.78 (1.01,3.21)	0.05 (0.00,0.20)
SD ETN SC	MTX + DMARD	0.43 (0.12,1.35)	0.45 (0.14,1.34)	-0.03 (-0.18,0.01)
SD ADA SC		0.66 (0.13,4.13)	0.67 (0.15,3.95)	-0.02 (-0.18,0.04)
SD TOCI IV		0.33 (0.06,2.20)	0.35 (0.07,2.16)	-0.04 (-0.21,0.02)
SD CERTO SC		0.99 (0.13,9.94)	0.99 (0.15,8.63)	0.00 (-0.18,0.14)
SD TOC SC + PL IV		0.24 (0.03,1.70)	0.25 (0.04,1.67)	-0.04 (-0.21,0.01)
SD RITUX IV		2.52 (0.15,60.44)	2.26 (0.17,22.31)	0.07 (-0.11,0.69)
SD ETN SC + MTX		0.34 (0.12,0.84)	0.36 (0.14,0.84)	-0.04 (-0.17,0.00)
SD ADA SC + MTX		0.45 (0.09,3.49)	0.47 (0.10,3.22)	-0.03 (-0.18,0.06)
SD INF IV + MTX		0.93 (0.18,6.70)	0.93 (0.21,5.86)	0.00 (-0.15,0.13)
SD ABA IV + MTX		0.33 (0.06,2.27)	0.34 (0.07,2.21)	-0.04 (-0.19,0.03)
SD CERTO SC + MTX		0.47 (0.09,3.17)	0.48 (0.11,3.03)	-0.03 (-0.18,0.05)
SD RITUX IV + MTX		0.66 (0.11,8.71)	0.68 (0.12,7.23)	-0.02 (-0.16,0.17)
SD GOLI SC + MTX		0.37 (0.06,3.20)	0.39 (0.07,3.04)	-0.03 (-0.19,0.05)
SD TOFA PO + MTX		0.62 (0.11,4.75)	0.64 (0.13,4.21)	-0.02 (-0.17,0.09)
SD ABA SC + MTX		0.18 (0.03,1.49)	0.19 (0.03,1.47)	-0.05 (-0.20,0.01)
SD TOCI IV + MTX		0.39 (0.06,3.43)	0.41 (0.08,3.25)	-0.03 (-0.19,0.06)
SD ETN SC + DMARD		0.79 (0.12,5.95)	0.80 (0.14,5.53)	-0.01 (-0.18,0.09)
SD CERTO SC + DMARD		1.03 (0.14,10.75)	1.03 (0.17,9.18)	0.00 (-0.17,0.16)
SD ADA SC + DMARD		1.40 (0.12,16.85)	1.36 (0.14,12.84)	0.02 (-0.16,0.26)
SD TOCI SC + DMARD		3.35 (0.27,42.87)	2.86 (0.30,23.36)	0.10 (-0.10,0.55)
LD ADA SC		0.23 (0.03,1.63)	0.24 (0.04,1.61)	-0.04 (-0.21,0.01)
LD ETN SC		0.82 (0.12,5.84)	0.83 (0.14,5.26)	-0.01 (-0.16,0.11)
LD TOCI IV		0.24 (0.03,2.22)	0.26 (0.04,2.15)	-0.04 (-0.20,0.03)
LD RITUX IV + MTX		0.61 (0.10,7.69)	0.63 (0.11,6.64)	-0.02 (-0.17,0.16)
LD ABA IV + MTX		0.42 (0.06,3.37)	0.44 (0.07,3.17)	-0.03 (-0.18,0.06)

(Continued)

LD CERTO SC + MTX		0.32 (0.03,3.06)	0.34 (0.04,2.85)	-0.03 (-0.19,0.05)
LD TOCI IV + MTX		0.18 (0.02,1.40)	0.19 (0.02,1.39)	-0.05 (-0.21,0.01)
HD TOCI IV		0.29 (0.06,2.22)	0.30 (0.07,2.16)	-0.04 (-0.20,0.02)
HD ADA SC		0.24 (0.03,1.87)	0.25 (0.04,1.84)	-0.04 (-0.21,0.01)
HD GOLI SC		0.20 (0.01,2.18)	0.21 (0.01,2.12)	-0.04 (-0.21,0.03)
HD TOCI IV + MTX		0.40 (0.08,3.22)	0.41 (0.09,3.10)	-0.03 (-0.19,0.04)
HD GOLI SC + MTX		0.55 (0.08,4.15)	0.57 (0.10,3.79)	-0.02 (-0.18,0.08)
HD TOFA PO + MTX		0.56 (0.09,4.34)	0.58 (0.11,3.95)	-0.02 (-0.18,0.08)
HD CERTO SC + MTX		0.51 (0.09,3.71)	0.53 (0.10,3.48)	-0.02 (-0.18,0.07)
HD INF IV + MTX		0.99 (0.17,7.26)	0.99 (0.20,6.40)	0.00 (-0.15,0.16)
HD TOCI IV + DMARD		2.16 (0.24,21.17)	2.00 (0.28,15.79)	0.05 (-0.13,0.30)
SD ADA SC	SD ETN SC	1.62 (0.37,7.02)	1.60 (0.38,6.65)	0.01 (-0.05,0.06)
SD TOCI IV		0.79 (0.19,3.40)	0.79 (0.20,3.30)	-0.01 (-0.06,0.03)
SD CERTO SC		2.32 (0.38,17.04)	2.24 (0.40,14.61)	0.03 (-0.04,0.15)
SD TOC SC + PL IV		0.55 (0.11,2.67)	0.56 (0.11,2.61)	-0.01 (-0.06,0.02)
SD RITUX IV		6.17 (0.39,134.40)	5.35 (0.40,39.89)	0.11 (-0.02,0.74)
SD ETN SC + MTX		0.78 (0.37,1.73)	0.79 (0.38,1.70)	0.00 (-0.03,0.02)
SD ADA SC + MTX		1.10 (0.26,6.30)	1.09 (0.28,5.77)	0.00 (-0.05,0.09)
SD INF IV + MTX		2.30 (0.52,10.85)	2.22 (0.53,9.35)	0.03 (-0.02,0.17)
SD ABA IV + MTX		0.81 (0.19,3.95)	0.81 (0.20,3.78)	0.00 (-0.05,0.05)
SD CERTO SC + MTX		1.11 (0.28,6.13)	1.11 (0.29,5.61)	0.00 (-0.04,0.08)
SD RITUX IV + MTX		1.64 (0.32,16.45)	1.61 (0.33,13.21)	0.01 (-0.03,0.20)
SD GOLI SC + MTX		0.90 (0.18,5.88)	0.90 (0.19,5.40)	0.00 (-0.06,0.08)
SD TOFA PO + MTX		1.49 (0.32,9.16)	1.47 (0.33,8.08)	0.01 (-0.04,0.13)
SD ABA SC + MTX		0.44 (0.09,2.63)	0.45 (0.09,2.56)	-0.01 (-0.06,0.03)
SD TOCI IV + MTX		0.96 (0.20,6.07)	0.96 (0.21,5.69)	0.00 (-0.05,0.08)
SD ETN SC + DMARD		1.90 (0.34,11.43)	1.86 (0.36,10.27)	0.02 (-0.04,0.11)
SD CERTO SC + DMARD		2.44 (0.41,19.48)	2.33 (0.43,16.34)	0.03 (-0.04,0.19)

(Continued)

SD ADA SC + DMARD		3.25 (0.31,31.78)	3.07 (0.32,23.73)	0.05 (-0.04,0.29)
SD TOCI SC + DMARD		7.75 (0.69,93.28)	6.45 (0.70,45.67)	0.14 (-0.01,0.58)
LD ADA SC		0.56 (0.08,2.79)	0.57 (0.09,2.73)	-0.01 (-0.07,0.02)
LD ETN SC		1.93 (0.41,9.68)	1.88 (0.43,8.58)	0.02 (-0.03,0.14)
LD TOCI IV		0.58 (0.09,3.58)	0.59 (0.09,3.44)	-0.01 (-0.06,0.04)
LD RITUX IV + MTX		1.48 (0.29,15.74)	1.46 (0.30,12.57)	0.01 (-0.04,0.20)
LD ABA IV + MTX		0.99 (0.19,6.57)	0.99 (0.19,6.03)	0.00 (-0.05,0.09)
LD CERTO SC + MTX		0.79 (0.09,5.77)	0.79 (0.10,5.33)	0.00 (-0.05,0.08)
LD TOCI IV + MTX		0.43 (0.05,2.85)	0.44 (0.06,2.77)	-0.01 (-0.07,0.03)
HD TOCI IV		0.69 (0.18,3.35)	0.69 (0.19,3.23)	-0.01 (-0.06,0.03)
HD ADA SC		0.58 (0.09,3.10)	0.59 (0.10,3.02)	-0.01 (-0.07,0.02)
HD GOLI SC		0.48 (0.03,4.58)	0.49 (0.03,4.33)	-0.01 (-0.06,0.06)
HD TOCI IV + MTX		0.94 (0.24,4.81)	0.95 (0.25,4.59)	0.00 (-0.05,0.06)
HD GOLI SC + MTX		1.30 (0.26,8.54)	1.29 (0.27,7.57)	0.01 (-0.04,0.12)
HD TOFA PO + MTX		1.34 (0.27,8.65)	1.33 (0.28,7.71)	0.01 (-0.04,0.11)
HD CERTO SC + MTX		1.21 (0.26,7.19)	1.20 (0.27,6.53)	0.00 (-0.04,0.10)
HD INF IV + MTX		2.43 (0.52,12.82)	2.33 (0.54,10.65)	0.03 (-0.02,0.19)
HD TOCI IV + DMARD		4.96 (0.65,42.82)	4.46 (0.67,29.86)	0.09 (-0.02,0.34)
SD TOCI IV	SD ADA SC	0.48 (0.19,1.31)	0.49 (0.20,1.30)	-0.02 (-0.05,0.01)
SD CERTO SC		1.43 (0.32,7.10)	1.41 (0.33,6.07)	0.02 (-0.04,0.14)
SD TOC SC + PL IV		0.34 (0.10,1.17)	0.35 (0.11,1.16)	-0.03 (-0.06,0.00)
SD RITUX IV		3.65 (0.28,85.75)	3.29 (0.30,22.52)	0.09 (-0.04,0.72)
SD ETN SC + MTX		0.48 (0.10,2.30)	0.49 (0.10,2.22)	-0.02 (-0.06,0.03)
SD ADA SC + MTX		0.70 (0.14,3.36)	0.71 (0.15,3.11)	-0.01 (-0.05,0.07)
SD INF IV + MTX		1.47 (0.30,6.43)	1.44 (0.31,5.46)	0.02 (-0.04,0.15)
SD ABA IV + MTX		0.54 (0.10,2.13)	0.55 (0.10,2.05)	-0.02 (-0.06,0.03)
SD CERTO SC + MTX		0.74 (0.15,3.28)	0.75 (0.16,3.05)	-0.01 (-0.05,0.07)
SD RITUX IV + MTX		1.06 (0.17,7.31)	1.05 (0.18,5.98)	0.00 (-0.05,0.18)



(Continued)

SD GOLISERON SC + MTX	0.59 (0.11,3.24)	0.60 (0.11,3.03)	-0.02 (-0.05,0.07)
SD TOFA PO + MTX	0.96 (0.16,4.85)	0.96 (0.17,4.25)	0.00 (-0.05,0.12)
SD ABA SC + MTX	0.30 (0.04,1.36)	0.31 (0.05,1.35)	-0.03 (-0.07,0.01)
SD TOCI IV + MTX	0.62 (0.13,3.12)	0.63 (0.13,2.91)	-0.01 (-0.05,0.06)
SD ETN SC + DMARD	1.20 (0.46,3.11)	1.19 (0.47,2.88)	0.01 (-0.03,0.08)
SD CERTO SC + DMARD	1.55 (0.43,6.48)	1.51 (0.44,5.53)	0.02 (-0.03,0.16)
SD ADA SC + DMARD	2.06 (0.35,11.30)	1.97 (0.37,8.29)	0.04 (-0.03,0.27)
SD TOCI SC + DMARD	4.83 (0.61,35.37)	4.13 (0.62,15.62)	0.13 (-0.02,0.56)
LD ADA SC	0.34 (0.09,0.97)	0.35 (0.10,0.97)	-0.03 (-0.06,0.00)
LD ETN SC	1.21 (0.22,7.27)	1.20 (0.23,6.17)	0.01 (-0.05,0.15)
LD TOCI IV	0.36 (0.07,1.79)	0.37 (0.07,1.74)	-0.02 (-0.06,0.03)
LD RITUX IV + MTX	0.97 (0.16,7.03)	0.97 (0.17,5.65)	0.00 (-0.05,0.19)
LD ABA IV + MTX	0.66 (0.10,3.49)	0.67 (0.10,3.21)	-0.01 (-0.05,0.08)
LD CERTO SC + MTX	0.50 (0.05,3.20)	0.51 (0.06,2.95)	-0.02 (-0.06,0.07)
LD TOCI IV + MTX	0.26 (0.04,1.33)	0.27 (0.04,1.31)	-0.03 (-0.07,0.01)
HD TOCI IV	0.44 (0.12,1.79)	0.45 (0.12,1.75)	-0.02 (-0.06,0.02)
HD ADA SC	0.36 (0.11,1.05)	0.37 (0.12,1.05)	-0.02 (-0.06,0.00)
HD GOLISERON SC	0.29 (0.02,2.64)	0.30 (0.02,2.49)	-0.03 (-0.06,0.05)
HD TOCI IV + MTX	0.60 (0.16,2.47)	0.61 (0.16,2.37)	-0.01 (-0.05,0.04)
HD GOLISERON SC + MTX	0.83 (0.14,4.49)	0.84 (0.15,4.05)	-0.01 (-0.05,0.10)
HD TOFA PO + MTX	0.87 (0.15,4.22)	0.87 (0.16,3.79)	0.00 (-0.05,0.10)
HD CERTO SC + MTX	0.79 (0.15,4.15)	0.79 (0.16,3.78)	-0.01 (-0.05,0.09)
HD INF IV + MTX	1.59 (0.28,7.28)	1.55 (0.29,5.97)	0.02 (-0.04,0.17)
HD TOCI IV + DMARD	3.24 (0.86,12.32)	2.96 (0.87,8.70)	0.08 (-0.01,0.31)
SD CERTO SC      SD TOCI IV	3.02 (0.55,15.80)	2.89 (0.56,13.66)	0.04 (-0.02,0.16)
SD TOC SC + PL IV	0.69 (0.34,1.40)	0.70 (0.34,1.39)	-0.01 (-0.02,0.01)
SD RITUX IV	7.31 (0.68,131.90)	6.42 (0.69,38.38)	0.11 (-0.01,0.74)
SD ETN SC + MTX	0.96 (0.21,5.03)	0.96 (0.22,4.78)	0.00 (-0.03,0.05)

(Continued)

SD ADA SC + MTX	1.46 (0.37,5.37)	1.44 (0.37,4.94)	0.01 (-0.02,0.09)
SD INF IV + MTX	2.99 (0.80,10.91)	2.86 (0.81,9.27)	0.04 (0.00,0.17)
SD ABA IV + MTX	1.09 (0.26,3.56)	1.09 (0.26,3.43)	0.00 (-0.02,0.04)
SD CERTO SC + MTX	1.50 (0.41,5.06)	1.48 (0.41,4.72)	0.01 (-0.02,0.08)
SD RITUX IV + MTX	2.24 (0.45,11.73)	2.18 (0.46,9.67)	0.02 (-0.01,0.19)
SD GOL I SC + MTX	1.17 (0.28,5.58)	1.16 (0.29,5.11)	0.00 (-0.02,0.08)
SD TOFA PO + MTX	1.99 (0.44,8.07)	1.95 (0.44,7.06)	0.02 (-0.02,0.13)
SD ABA SC + MTX	0.60 (0.11,2.59)	0.61 (0.11,2.52)	-0.01 (-0.03,0.03)
SD TOCI IV + MTX	1.28 (0.33,4.58)	1.27 (0.33,4.30)	0.01 (-0.02,0.07)
SD ETN SC + DMARD	2.45 (0.65,9.83)	2.38 (0.66,8.88)	0.03 (-0.01,0.11)
SD CERTO SC + DMARD	3.15 (0.70,17.46)	3.02 (0.71,14.55)	0.04 (-0.01,0.18)
SD ADA SC + DMARD	4.44 (0.56,28.99)	4.15 (0.57,21.07)	0.06 (-0.01,0.29)
SD TOCI SC + DMARD	10.45 (0.99,89.45)	8.62 (0.99,41.13)	0.15 (0.00,0.59)
LD ADA SC	0.71 (0.13,2.55)	0.71 (0.13,2.51)	-0.01 (-0.03,0.02)
LD ETN SC	2.47 (0.45,13.58)	2.39 (0.46,11.51)	0.03 (-0.02,0.16)
LD TOCI IV	0.75 (0.17,2.99)	0.75 (0.17,2.90)	0.00 (-0.03,0.04)
LD RITUX IV + MTX	1.97 (0.40,11.32)	1.93 (0.41,9.46)	0.02 (-0.02,0.20)
LD ABA IV + MTX	1.35 (0.25,5.66)	1.34 (0.26,5.20)	0.01 (-0.02,0.09)
LD CERTO SC + MTX	1.01 (0.13,5.92)	1.01 (0.14,5.40)	0.00 (-0.03,0.09)
LD TOCI IV + MTX	0.53 (0.10,2.50)	0.53 (0.10,2.44)	-0.01 (-0.03,0.03)
HD TOCI IV	0.89 (0.34,2.41)	0.89 (0.34,2.35)	0.00 (-0.02,0.02)
HD ADA SC	0.72 (0.18,2.83)	0.73 (0.18,2.75)	-0.01 (-0.03,0.02)
HD GOL I SC	0.61 (0.05,4.55)	0.62 (0.05,4.23)	-0.01 (-0.03,0.07)
HD TOCI IV + MTX	1.24 (0.42,3.68)	1.23 (0.43,3.51)	0.00 (-0.02,0.05)
HD GOL I SC + MTX	1.66 (0.37,7.62)	1.64 (0.38,6.67)	0.01 (-0.02,0.12)
HD TOFA PO + MTX	1.74 (0.42,7.29)	1.71 (0.42,6.43)	0.01 (-0.02,0.12)
HD CERTO SC + MTX	1.60 (0.39,6.87)	1.58 (0.40,6.15)	0.01 (-0.02,0.10)
HD INF IV + MTX	3.18 (0.76,12.25)	3.03 (0.76,10.30)	0.04 (0.00,0.18)

(Continued)

HD TOCI IV + DMARD		6.64 (1.26,36.78)	5.89 (1.25,25.18)	0.10 (0.01,0.34)
SD TOC SC + PL IV	SD CERTO SC	0.23 (0.04,1.44)	0.24 (0.04,1.43)	-0.04 (-0.16,0.01)
SD RITUX IV		2.44 (0.14,76.28)	2.22 (0.16,21.26)	0.07 (-0.10,0.71)
SD ETN SC + MTX		0.34 (0.04,2.10)	0.35 (0.05,2.04)	-0.04 (-0.16,0.03)
SD ADA SC + MTX		0.48 (0.06,3.27)	0.49 (0.07,3.07)	-0.03 (-0.15,0.06)
SD INF IV + MTX		0.98 (0.11,7.46)	0.98 (0.12,6.43)	0.00 (-0.13,0.15)
SD ABA IV + MTX		0.36 (0.04,2.42)	0.38 (0.04,2.34)	-0.03 (-0.16,0.03)
SD CERTO SC + MTX		0.50 (0.06,3.74)	0.52 (0.07,3.48)	-0.03 (-0.15,0.07)
SD RITUX IV + MTX		0.72 (0.09,6.72)	0.73 (0.10,5.65)	-0.01 (-0.14,0.16)
SD GOLI SC + MTX		0.39 (0.04,3.32)	0.41 (0.05,3.05)	-0.03 (-0.16,0.06)
SD TOFA PO + MTX		0.65 (0.08,5.01)	0.66 (0.09,4.45)	-0.02 (-0.15,0.11)
SD ABA SC + MTX		0.21 (0.02,1.54)	0.22 (0.02,1.51)	-0.04 (-0.17,0.01)
SD TOCI IV + MTX		0.45 (0.05,2.95)	0.46 (0.06,2.76)	-0.03 (-0.16,0.05)
SD ETN SC + DMARD		0.83 (0.15,4.44)	0.84 (0.17,4.10)	-0.01 (-0.13,0.09)
SD CERTO SC + DMARD		1.09 (0.16,7.46)	1.09 (0.18,6.30)	0.00 (-0.13,0.15)
SD ADA SC + DMARD		1.40 (0.16,12.37)	1.36 (0.18,9.47)	0.02 (-0.11,0.26)
SD TOCI SC + DMARD		3.30 (0.29,36.82)	2.86 (0.32,17.86)	0.11 (-0.08,0.55)
LD ADA SC		0.23 (0.03,1.33)	0.24 (0.04,1.32)	-0.04 (-0.17,0.01)
LD ETN SC		0.83 (0.10,6.50)	0.84 (0.11,5.51)	-0.01 (-0.14,0.14)
LD TOCI IV		0.24 (0.03,1.92)	0.25 (0.04,1.86)	-0.04 (-0.16,0.02)
LD RITUX IV + MTX		0.70 (0.08,5.92)	0.71 (0.09,5.04)	-0.01 (-0.14,0.16)
LD ABA IV + MTX		0.45 (0.04,3.83)	0.46 (0.05,3.55)	-0.03 (-0.15,0.07)
LD CERTO SC + MTX		0.33 (0.02,3.24)	0.35 (0.03,3.02)	-0.03 (-0.16,0.06)
LD TOCI IV + MTX		0.18 (0.02,1.28)	0.19 (0.02,1.27)	-0.04 (-0.17,0.01)
HD TOCI IV		0.31 (0.05,1.88)	0.32 (0.05,1.84)	-0.04 (-0.16,0.02)
HD ADA SC		0.25 (0.03,1.38)	0.26 (0.04,1.37)	-0.04 (-0.16,0.01)
HD GOLI SC		0.19 (0.01,2.56)	0.21 (0.01,2.46)	-0.04 (-0.17,0.04)
HD TOCI IV + MTX		0.41 (0.06,2.64)	0.43 (0.07,2.53)	-0.03 (-0.15,0.04)

(Continued)

HD GOLI SC + MTX		0.57 (0.06,4.86)	0.59 (0.07,4.36)	-0.02 (-0.15,0.10)
HD TOFA PO + MTX		0.59 (0.07,4.29)	0.60 (0.08,3.94)	-0.02 (-0.15,0.10)
HD CERTO SC + MTX		0.55 (0.06,4.54)	0.57 (0.07,4.12)	-0.02 (-0.15,0.09)
HD INF IV + MTX		1.05 (0.11,8.22)	1.04 (0.13,6.95)	0.00 (-0.13,0.17)
HD TOCI IV + DMARD		2.17 (0.30,15.51)	2.02 (0.33,11.21)	0.06 (-0.09,0.30)
SD RITUX IV	SD TOC SC + PL IV	10.51 (0.89,207.80)	9.09 (0.89,65.09)	0.12 (0.00,0.74)
SD ETN SC + MTX		1.39 (0.27,8.22)	1.38 (0.28,7.82)	0.00 (-0.03,0.06)
SD ADA SC + MTX		2.09 (0.45,9.00)	2.05 (0.45,8.36)	0.01 (-0.01,0.09)
SD INF IV + MTX		4.26 (0.98,18.60)	4.05 (0.98,16.17)	0.04 (0.00,0.18)
SD ABA IV + MTX		1.56 (0.31,6.10)	1.55 (0.32,5.83)	0.01 (-0.02,0.05)
SD CERTO SC + MTX		2.15 (0.51,8.92)	2.11 (0.52,8.35)	0.01 (-0.01,0.09)
SD RITUX IV + MTX		3.24 (0.57,18.99)	3.12 (0.57,15.36)	0.03 (-0.01,0.20)
SD GOLI SC + MTX		1.69 (0.35,9.56)	1.67 (0.36,8.67)	0.01 (-0.02,0.09)
SD TOFA PO + MTX		2.90 (0.57,13.65)	2.81 (0.58,12.22)	0.02 (-0.01,0.14)
SD ABA SC + MTX		0.86 (0.14,4.47)	0.86 (0.15,4.31)	0.00 (-0.03,0.03)
SD TOCI IV + MTX		1.88 (0.39,7.68)	1.85 (0.40,7.21)	0.01 (-0.01,0.08)
SD ETN SC + DMARD		3.50 (0.79,16.67)	3.37 (0.80,15.21)	0.03 (-0.01,0.12)
SD CERTO SC + DMARD		4.58 (0.91,28.39)	4.34 (0.91,23.91)	0.05 (0.00,0.19)
SD ADA SC + DMARD		6.27 (0.70,48.05)	5.77 (0.70,35.39)	0.06 (-0.01,0.30)
SD TOCI SC + DMARD		14.73 (1.30,149.20)	12.08 (1.29,70.17)	0.15 (0.01,0.59)
LD ADA SC		1.00 (0.16,4.56)	1.00 (0.17,4.44)	0.00 (-0.03,0.03)
LD ETN SC		3.54 (0.57,22.62)	3.39 (0.58,19.49)	0.03 (-0.01,0.17)
LD TOCI IV		1.07 (0.21,5.14)	1.07 (0.22,4.96)	0.00 (-0.02,0.05)
LD RITUX IV + MTX		2.86 (0.49,18.72)	2.77 (0.49,15.58)	0.02 (-0.01,0.21)
LD ABA IV + MTX		1.91 (0.31,10.00)	1.88 (0.32,9.23)	0.01 (-0.02,0.09)
LD CERTO SC + MTX		1.45 (0.17,9.86)	1.44 (0.17,8.96)	0.01 (-0.02,0.09)
LD TOCI IV + MTX		0.76 (0.13,4.19)	0.76 (0.13,4.05)	0.00 (-0.03,0.03)
HD TOCI IV		1.29 (0.39,4.35)	1.28 (0.40,4.25)	0.00 (-0.02,0.03)

(Continued)

HD ADA SC		1.03 (0.23,4.93)	1.03 (0.23,4.79)	0.00 (-0.03,0.03)
HD GOLI SC		0.87 (0.07,7.33)	0.87 (0.07,6.80)	0.00 (-0.03,0.07)
HD TOCI IV + MTX		1.79 (0.50,6.47)	1.77 (0.50,6.14)	0.01 (-0.01,0.06)
HD GOLI SC + MTX		2.42 (0.48,13.41)	2.36 (0.48,11.96)	0.02 (-0.01,0.12)
HD TOFA PO + MTX		2.50 (0.51,12.15)	2.44 (0.52,11.00)	0.02 (-0.01,0.13)
HD CERTO SC + MTX		2.34 (0.49,11.62)	2.29 (0.49,10.60)	0.02 (-0.01,0.11)
HD INF IV + MTX		4.61 (0.93,20.76)	4.35 (0.93,17.43)	0.05 (0.00,0.19)
HD TOCI IV + DMARD		9.62 (1.52,58.01)	8.47 (1.50,42.43)	0.10 (0.01,0.34)
SD ETN SC + MTX	SD RITUX IV	0.13 (0.01,2.02)	0.15 (0.02,1.98)	-0.11 (-0.74,0.01)
SD ADA SC + MTX		0.18 (0.01,2.01)	0.22 (0.04,1.97)	-0.10 (-0.70,0.02)
SD INF IV + MTX		0.39 (0.03,4.05)	0.44 (0.07,3.82)	-0.07 (-0.66,0.06)
SD ABA IV + MTX		0.14 (0.01,1.59)	0.16 (0.02,1.57)	-0.11 (-0.72,0.01)
SD CERTO SC + MTX		0.19 (0.01,2.30)	0.22 (0.04,2.26)	-0.10 (-0.70,0.02)
SD RITUX IV + MTX		0.29 (0.02,2.48)	0.33 (0.06,2.36)	-0.08 (-0.66,0.04)
SD GOLI SC + MTX		0.16 (0.01,1.84)	0.19 (0.02,1.81)	-0.10 (-0.72,0.01)
SD TOFA PO + MTX		0.25 (0.02,3.22)	0.29 (0.04,3.10)	-0.09 (-0.68,0.04)
SD ABA SC + MTX		0.08 (0.00,1.02)	0.09 (0.01,1.02)	-0.12 (-0.74,0.00)
SD TOCI IV + MTX		0.17 (0.01,1.79)	0.19 (0.03,1.75)	-0.10 (-0.72,0.01)
SD ETN SC + DMARD		0.33 (0.01,6.01)	0.36 (0.04,5.45)	-0.08 (-0.72,0.07)
SD CERTO SC + DMARD		0.46 (0.01,8.38)	0.50 (0.05,7.37)	-0.06 (-0.71,0.13)
SD ADA SC + DMARD		0.58 (0.01,13.09)	0.63 (0.04,10.38)	-0.04 (-0.70,0.22)
SD TOCI SC + DMARD		1.28 (0.03,35.73)	1.22 (0.09,20.39)	0.02 (-0.64,0.48)
LD ADA SC		0.10 (0.00,1.35)	0.11 (0.01,1.34)	-0.12 (-0.75,0.00)
LD ETN SC		0.34 (0.01,6.22)	0.38 (0.03,5.53)	-0.08 (-0.72,0.10)
LD TOCI IV		0.10 (0.00,1.21)	0.12 (0.01,1.20)	-0.11 (-0.74,0.00)
LD RITUX IV + MTX		0.26 (0.02,2.38)	0.30 (0.06,2.28)	-0.09 (-0.65,0.03)
LD ABA IV + MTX		0.18 (0.01,2.30)	0.21 (0.02,2.23)	-0.10 (-0.72,0.02)
LD CERTO SC + MTX		0.13 (0.01,1.81)	0.16 (0.02,1.75)	-0.10 (-0.72,0.01)

(Continued)

LD TOCI IV + MTX		0.07 (0.00,0.93)	0.09 (0.01,0.93)	-0.12 (-0.74,0.00)
HD TOCI IV		0.12 (0.01,1.27)	0.14 (0.02,1.26)	-0.11 (-0.73,0.00)
HD ADA SC		0.10 (0.00,1.35)	0.11 (0.01,1.34)	-0.11 (-0.75,0.00)
HD GOLI SC		0.08 (0.00,1.34)	0.09 (0.01,1.33)	-0.11 (-0.74,0.01)
HD TOCI IV + MTX		0.16 (0.01,1.74)	0.19 (0.03,1.72)	-0.10 (-0.72,0.01)
HD GOLI SC + MTX		0.23 (0.01,2.71)	0.26 (0.03,2.60)	-0.09 (-0.70,0.03)
HD TOFA PO + MTX		0.22 (0.01,2.86)	0.26 (0.04,2.80)	-0.09 (-0.69,0.03)
HD CERTO SC + MTX		0.21 (0.01,2.41)	0.24 (0.04,2.34)	-0.10 (-0.70,0.03)
HD INF IV + MTX		0.41 (0.03,4.56)	0.45 (0.07,4.27)	-0.06 (-0.65,0.07)
HD TOCI IV + DMARD		0.87 (0.03,19.65)	0.89 (0.09,14.68)	-0.01 (-0.65,0.27)
SD ADA SC + MTX	SD ETN SC + MTX	1.45 (0.32,8.40)	1.44 (0.33,7.73)	0.01 (-0.04,0.09)
SD INF IV + MTX		2.91 (0.65,14.89)	2.80 (0.66,12.53)	0.03 (-0.02,0.17)
SD ABA IV + MTX		1.03 (0.25,5.18)	1.03 (0.25,4.95)	0.00 (-0.04,0.05)
SD CERTO SC + MTX		1.48 (0.36,7.67)	1.46 (0.37,7.09)	0.01 (-0.04,0.08)
SD RITUX IV + MTX		2.12 (0.39,19.71)	2.06 (0.40,16.29)	0.02 (-0.03,0.20)
SD GOLI SC + MTX		1.16 (0.24,7.64)	1.16 (0.25,7.09)	0.00 (-0.04,0.08)
SD TOFA PO + MTX		1.96 (0.39,10.92)	1.92 (0.40,9.63)	0.02 (-0.03,0.14)
SD ABA SC + MTX		0.57 (0.12,3.64)	0.57 (0.12,3.53)	-0.01 (-0.05,0.03)
SD TOCI IV + MTX		1.25 (0.23,7.97)	1.24 (0.24,7.49)	0.00 (-0.04,0.08)
SD ETN SC + DMARD		2.41 (0.41,17.16)	2.35 (0.42,15.45)	0.03 (-0.03,0.11)
SD CERTO SC + DMARD		3.14 (0.50,28.53)	2.99 (0.52,23.65)	0.04 (-0.02,0.19)
SD ADA SC + DMARD		4.12 (0.40,44.83)	3.85 (0.41,33.49)	0.06 (-0.03,0.29)
SD TOCI SC + DMARD		9.94 (0.85,118.40)	8.15 (0.85,60.89)	0.15 (-0.01,0.59)
LD ADA SC		0.73 (0.11,3.98)	0.73 (0.11,3.89)	-0.01 (-0.05,0.02)
LD ETN SC		2.48 (0.45,14.38)	2.40 (0.46,12.84)	0.03 (-0.02,0.15)
LD TOCI IV		0.75 (0.10,5.00)	0.75 (0.11,4.75)	0.00 (-0.05,0.04)
LD RITUX IV + MTX		1.89 (0.34,18.95)	1.85 (0.35,15.39)	0.02 (-0.03,0.20)
LD ABA IV + MTX		1.29 (0.23,8.26)	1.28 (0.24,7.52)	0.01 (-0.04,0.09)

(Continued)

LD CERTO SC + MTX		1.02 (0.11,7.45)	1.02 (0.11,6.81)	0.00 (-0.05,0.08)
LD TOCI IV + MTX		0.55 (0.06,3.54)	0.56 (0.06,3.43)	-0.01 (-0.06,0.03)
HD TOCI IV		0.89 (0.22,4.38)	0.89 (0.23,4.24)	0.00 (-0.05,0.04)
HD ADA SC		0.74 (0.11,4.66)	0.75 (0.11,4.55)	0.00 (-0.06,0.03)
HD GOLI SC		0.62 (0.04,5.74)	0.62 (0.04,5.46)	-0.01 (-0.06,0.07)
HD TOCI IV + MTX		1.21 (0.28,6.42)	1.21 (0.29,6.10)	0.00 (-0.04,0.06)
HD GOLI SC + MTX		1.68 (0.29,10.64)	1.65 (0.30,9.52)	0.01 (-0.04,0.12)
HD TOFA PO + MTX		1.75 (0.31,10.93)	1.72 (0.32,9.88)	0.01 (-0.04,0.12)
HD CERTO SC + MTX		1.59 (0.32,8.88)	1.57 (0.33,8.04)	0.01 (-0.04,0.10)
HD INF IV + MTX		3.15 (0.58,16.51)	3.01 (0.59,13.91)	0.04 (-0.02,0.19)
HD TOCI IV + DMARD		6.42 (0.89,65.47)	5.72 (0.89,44.98)	0.10 (0.00,0.34)
SD INF IV + MTX	SD ADA SC + MTX	2.10 (0.70,5.68)	2.02 (0.71,5.25)	0.03 (-0.02,0.13)
SD ABA IV + MTX		0.74 (0.25,1.97)	0.75 (0.26,1.94)	-0.01 (-0.06,0.02)
SD CERTO SC + MTX		1.03 (0.38,2.80)	1.03 (0.40,2.71)	0.00 (-0.04,0.04)
SD RITUX IV + MTX		1.51 (0.42,6.65)	1.48 (0.44,5.93)	0.01 (-0.03,0.14)
SD GOLI SC + MTX		0.81 (0.22,3.21)	0.82 (0.23,3.03)	0.00 (-0.06,0.06)
SD TOFA PO + MTX		1.35 (0.58,3.33)	1.33 (0.59,3.16)	0.01 (-0.02,0.08)
SD ABA SC + MTX		0.41 (0.11,1.49)	0.42 (0.11,1.48)	-0.01 (-0.08,0.01)
SD TOCI IV + MTX		0.88 (0.21,3.51)	0.89 (0.22,3.38)	0.00 (-0.06,0.05)
SD ETN SC + DMARD		1.70 (0.27,12.24)	1.67 (0.29,11.07)	0.02 (-0.07,0.11)
SD CERTO SC + DMARD		2.20 (0.32,20.20)	2.12 (0.34,16.83)	0.03 (-0.07,0.18)
SD ADA SC + DMARD		2.99 (0.26,30.76)	2.82 (0.28,22.84)	0.05 (-0.06,0.29)
SD TOCI SC + DMARD		7.15 (0.47,76.37)	5.94 (0.50,39.68)	0.14 (-0.04,0.58)
LD ADA SC		0.50 (0.07,2.67)	0.51 (0.07,2.62)	-0.01 (-0.10,0.02)
LD ETN SC		1.73 (0.22,12.01)	1.69 (0.23,10.59)	0.02 (-0.07,0.15)
LD TOCI IV		0.53 (0.10,2.15)	0.54 (0.11,2.11)	-0.01 (-0.09,0.02)
LD RITUX IV + MTX		1.40 (0.34,6.80)	1.37 (0.35,6.07)	0.01 (-0.03,0.13)
LD ABA IV + MTX		0.92 (0.25,3.29)	0.92 (0.26,3.12)	0.00 (-0.05,0.06)

(Continued)

LD CERTO SC + MTX		0.71 (0.11,3.53)	0.71 (0.11,3.34)	-0.01 (-0.07,0.06)
LD TOCI IV + MTX		0.37 (0.06,1.87)	0.38 (0.06,1.85)	-0.02 (-0.09,0.01)
HD TOCI IV		0.63 (0.22,1.77)	0.64 (0.24,1.75)	-0.01 (-0.08,0.01)
HD ADA SC		0.51 (0.07,2.96)	0.52 (0.08,2.90)	-0.01 (-0.10,0.02)
HD GOLI SC		0.42 (0.04,2.90)	0.43 (0.04,2.74)	-0.01 (-0.08,0.05)
HD TOCI IV + MTX		0.86 (0.27,2.83)	0.86 (0.29,2.75)	0.00 (-0.07,0.03)
HD GOLI SC + MTX		1.16 (0.36,4.50)	1.16 (0.37,4.11)	0.00 (-0.04,0.09)
HD TOFA PO + MTX		1.20 (0.52,3.16)	1.19 (0.53,3.01)	0.00 (-0.02,0.07)
HD CERTO SC + MTX		1.12 (0.36,3.67)	1.11 (0.37,3.43)	0.00 (-0.04,0.07)
HD INF IV + MTX		2.20 (0.66,7.04)	2.11 (0.67,6.33)	0.03 (-0.02,0.15)
HD TOCI IV + DMARD		4.49 (0.61,41.34)	4.04 (0.63,29.17)	0.09 (-0.03,0.33)
SD ABA IV + MTX	SD INF IV + MTX	0.35 (0.14,0.85)	0.37 (0.16,0.86)	-0.03 (-0.14,0.00)
SD CERTO SC + MTX		0.50 (0.18,1.36)	0.52 (0.20,1.34)	-0.03 (-0.13,0.01)
SD RITUX IV + MTX		0.71 (0.19,3.30)	0.73 (0.21,2.91)	-0.01 (-0.11,0.12)
SD GOLI SC + MTX		0.39 (0.12,1.47)	0.41 (0.13,1.43)	-0.03 (-0.14,0.02)
SD TOFA PO + MTX		0.65 (0.21,2.03)	0.66 (0.23,1.93)	-0.02 (-0.11,0.05)
SD ABA SC + MTX		0.20 (0.06,0.64)	0.21 (0.07,0.65)	-0.04 (-0.16,-0.01)
SD TOCI IV + MTX		0.43 (0.10,1.71)	0.45 (0.11,1.66)	-0.03 (-0.15,0.02)
SD ETN SC + DMARD		0.80 (0.14,5.44)	0.81 (0.16,4.95)	-0.01 (-0.15,0.09)
SD CERTO SC + DMARD		1.01 (0.16,11.39)	1.01 (0.19,9.71)	0.00 (-0.14,0.16)
SD ADA SC + DMARD		1.43 (0.13,16.55)	1.39 (0.15,12.63)	0.02 (-0.14,0.26)
SD TOCI SC + DMARD		3.44 (0.27,40.63)	2.93 (0.30,19.51)	0.11 (-0.10,0.54)
LD ADA SC		0.24 (0.03,1.37)	0.25 (0.04,1.36)	-0.04 (-0.18,0.01)
LD ETN SC		0.81 (0.13,5.80)	0.82 (0.15,4.92)	-0.01 (-0.14,0.13)
LD TOCI IV		0.26 (0.05,1.03)	0.27 (0.06,1.03)	-0.04 (-0.16,0.00)
LD RITUX IV + MTX		0.68 (0.15,3.26)	0.69 (0.17,2.87)	-0.02 (-0.11,0.12)
LD ABA IV + MTX		0.44 (0.13,1.51)	0.46 (0.14,1.48)	-0.03 (-0.13,0.02)
LD CERTO SC + MTX		0.33 (0.06,1.63)	0.35 (0.06,1.57)	-0.03 (-0.14,0.03)



(Continued)

LD TOCI IV + MTX		0.18 (0.03,0.95)	0.19 (0.03,0.95)	-0.05 (-0.17,0.00)
HD TOCI IV		0.30 (0.11,0.84)	0.32 (0.12,0.84)	-0.04 (-0.16,0.00)
HD ADA SC		0.24 (0.04,1.50)	0.26 (0.05,1.48)	-0.04 (-0.18,0.01)
HD GOLI SC		0.20 (0.02,1.34)	0.22 (0.02,1.30)	-0.04 (-0.16,0.02)
HD TOCI IV + MTX		0.41 (0.13,1.38)	0.43 (0.14,1.36)	-0.03 (-0.15,0.01)
HD GOLI SC + MTX		0.56 (0.17,2.17)	0.58 (0.19,2.02)	-0.02 (-0.12,0.05)
HD TOFA PO + MTX		0.58 (0.19,1.92)	0.60 (0.21,1.83)	-0.02 (-0.11,0.04)
HD CERTO SC + MTX		0.54 (0.17,1.71)	0.55 (0.19,1.65)	-0.02 (-0.12,0.03)
HD INF IV + MTX		1.08 (0.49,2.25)	1.07 (0.51,2.11)	0.00 (-0.05,0.07)
HD TOCI IV + DMARD		2.19 (0.29,22.07)	2.04 (0.32,15.50)	0.06 (-0.11,0.31)
SD CERTO SC + MTX	SD ABA IV + MTX	1.40 (0.57,3.57)	1.39 (0.57,3.42)	0.01 (-0.02,0.06)
SD RITUX IV + MTX		1.99 (0.55,9.38)	1.94 (0.56,8.14)	0.02 (-0.02,0.18)
SD GOLI SC + MTX		1.14 (0.32,4.03)	1.13 (0.33,3.79)	0.00 (-0.03,0.07)
SD TOFA PO + MTX		1.84 (0.64,5.70)	1.80 (0.65,5.35)	0.02 (-0.01,0.10)
SD ABA SC + MTX		0.55 (0.24,1.27)	0.56 (0.25,1.26)	-0.01 (-0.04,0.01)
SD TOCI IV + MTX		1.22 (0.31,4.69)	1.21 (0.32,4.49)	0.00 (-0.03,0.06)
SD ETN SC + DMARD		2.25 (0.43,16.91)	2.18 (0.45,15.36)	0.02 (-0.03,0.11)
SD CERTO SC + DMARD		2.90 (0.51,33.96)	2.77 (0.53,28.74)	0.04 (-0.02,0.19)
SD ADA SC + DMARD		4.01 (0.36,50.25)	3.74 (0.38,37.99)	0.06 (-0.03,0.29)
SD TOCI SC + DMARD		9.66 (0.78,109.60)	7.90 (0.79,58.74)	0.15 (-0.01,0.58)
LD ADA SC		0.67 (0.09,4.03)	0.67 (0.09,3.94)	-0.01 (-0.06,0.02)
LD ETN SC		2.30 (0.36,17.41)	2.23 (0.38,14.95)	0.02 (-0.03,0.16)
LD TOCI IV		0.73 (0.14,2.85)	0.73 (0.14,2.78)	-0.01 (-0.05,0.03)
LD RITUX IV + MTX		1.90 (0.46,9.12)	1.85 (0.47,8.10)	0.02 (-0.02,0.17)
LD ABA IV + MTX		1.23 (0.45,3.65)	1.23 (0.45,3.49)	0.00 (-0.02,0.07)
LD CERTO SC + MTX		0.95 (0.15,4.55)	0.95 (0.16,4.29)	0.00 (-0.04,0.07)
LD TOCI IV + MTX		0.51 (0.08,2.66)	0.52 (0.08,2.62)	-0.01 (-0.05,0.02)
HD TOCI IV		0.84 (0.32,2.34)	0.84 (0.34,2.31)	0.00 (-0.04,0.02)

(Continued)

HD ADA SC		0.68 (0.12,4.34)	0.69 (0.13,4.24)	-0.01 (-0.06,0.02)
HD GOLI SC		0.57 (0.05,3.42)	0.58 (0.05,3.20)	-0.01 (-0.05,0.06)
HD TOCI IV + MTX		1.16 (0.41,3.87)	1.15 (0.42,3.77)	0.00 (-0.03,0.04)
HD GOLI SC + MTX		1.56 (0.52,5.99)	1.54 (0.53,5.36)	0.01 (-0.02,0.10)
HD TOFA PO + MTX		1.62 (0.57,5.30)	1.59 (0.58,4.92)	0.01 (-0.01,0.09)
HD CERTO SC + MTX		1.53 (0.50,4.70)	1.51 (0.51,4.38)	0.01 (-0.02,0.08)
HD INF IV + MTX		3.03 (1.06,8.79)	2.87 (1.06,7.86)	0.04 (0.00,0.16)
HD TOCI IV + DMARD		6.08 (0.88,65.01)	5.42 (0.88,47.28)	0.09 (0.00,0.34)
SD RITUX IV + MTX	SD CERTO SC + MTX	1.44 (0.39,6.06)	1.42 (0.40,5.29)	0.01 (-0.03,0.15)
SD GOLI SC + MTX		0.81 (0.24,2.77)	0.82 (0.25,2.60)	0.00 (-0.05,0.05)
SD TOFA PO + MTX		1.30 (0.45,3.97)	1.28 (0.46,3.72)	0.01 (-0.03,0.09)
SD ABA SC + MTX		0.39 (0.11,1.39)	0.40 (0.12,1.37)	-0.02 (-0.08,0.01)
SD TOCI IV + MTX		0.86 (0.20,3.23)	0.87 (0.21,3.11)	0.00 (-0.06,0.05)
SD ETN SC + DMARD		1.63 (0.27,10.75)	1.60 (0.30,9.88)	0.02 (-0.07,0.10)
SD CERTO SC + DMARD		2.00 (0.34,20.65)	1.93 (0.36,17.12)	0.03 (-0.06,0.18)
SD ADA SC + DMARD		2.91 (0.24,31.58)	2.73 (0.26,23.67)	0.05 (-0.06,0.28)
SD TOCI SC + DMARD		6.97 (0.49,74.76)	5.73 (0.52,39.56)	0.14 (-0.04,0.57)
LD ADA SC		0.48 (0.06,2.60)	0.48 (0.07,2.56)	-0.01 (-0.09,0.02)
LD ETN SC		1.66 (0.22,10.92)	1.63 (0.23,9.61)	0.02 (-0.07,0.15)
LD TOCI IV		0.51 (0.10,1.96)	0.52 (0.11,1.92)	-0.01 (-0.08,0.02)
LD RITUX IV + MTX		1.33 (0.35,5.87)	1.31 (0.36,5.31)	0.01 (-0.03,0.15)
LD ABA IV + MTX		0.88 (0.25,2.99)	0.89 (0.26,2.87)	0.00 (-0.05,0.05)
LD CERTO SC + MTX		0.68 (0.13,2.60)	0.69 (0.13,2.46)	-0.01 (-0.06,0.05)
LD TOCI IV + MTX		0.36 (0.05,1.75)	0.37 (0.06,1.73)	-0.02 (-0.09,0.01)
HD TOCI IV		0.60 (0.23,1.57)	0.61 (0.24,1.55)	-0.01 (-0.07,0.01)
HD ADA SC		0.49 (0.08,2.82)	0.50 (0.09,2.77)	-0.01 (-0.09,0.02)
HD GOLI SC		0.40 (0.04,2.39)	0.41 (0.04,2.27)	-0.01 (-0.08,0.04)
HD TOCI IV + MTX		0.84 (0.29,2.45)	0.84 (0.30,2.40)	0.00 (-0.06,0.03)

(Continued)

HD GOLI SC + MTX		1.13 (0.36,3.85)	1.12 (0.38,3.52)	0.00 (-0.04,0.08)
HD TOFA PO + MTX		1.17 (0.39,3.71)	1.16 (0.40,3.46)	0.00 (-0.03,0.07)
HD CERTO SC + MTX		1.08 (0.48,2.41)	1.07 (0.49,2.30)	0.00 (-0.03,0.05)
HD INF IV + MTX		2.13 (0.70,6.78)	2.05 (0.71,6.14)	0.03 (-0.01,0.15)
HD TOCI IV + DMARD		4.33 (0.60,39.11)	3.90 (0.62,28.12)	0.08 (-0.03,0.33)
SD GOLI SC + MTX	SD RITUX IV + MTX	0.54 (0.10,2.49)	0.55 (0.12,2.40)	-0.02 (-0.16,0.04)
SD TOFA PO + MTX		0.89 (0.21,3.52)	0.90 (0.23,3.36)	0.00 (-0.13,0.06)
SD ABA SC + MTX		0.27 (0.05,1.32)	0.28 (0.06,1.31)	-0.03 (-0.20,0.00)
SD TOCI IV + MTX		0.60 (0.10,2.89)	0.62 (0.11,2.78)	-0.01 (-0.16,0.03)
SD ETN SC + DMARD		1.15 (0.13,9.29)	1.14 (0.15,8.49)	0.01 (-0.18,0.10)
SD CERTO SC + DMARD		1.42 (0.14,15.13)	1.39 (0.17,12.81)	0.02 (-0.17,0.17)
SD ADA SC + DMARD		2.07 (0.11,22.08)	1.97 (0.14,17.07)	0.04 (-0.17,0.27)
SD TOCI SC + DMARD		4.77 (0.27,60.57)	3.99 (0.30,30.37)	0.12 (-0.13,0.56)
LD ADA SC		0.33 (0.03,2.14)	0.35 (0.04,2.10)	-0.03 (-0.21,0.01)
LD ETN SC		1.11 (0.11,9.72)	1.10 (0.13,8.32)	0.00 (-0.17,0.14)
LD TOCI IV		0.35 (0.05,1.74)	0.36 (0.05,1.72)	-0.03 (-0.19,0.01)
LD RITUX IV + MTX		0.91 (0.28,2.83)	0.91 (0.29,2.67)	0.00 (-0.08,0.07)
LD ABA IV + MTX		0.61 (0.11,2.71)	0.62 (0.12,2.60)	-0.01 (-0.17,0.04)
LD CERTO SC + MTX		0.46 (0.05,2.78)	0.48 (0.05,2.65)	-0.02 (-0.18,0.04)
LD TOCI IV + MTX		0.25 (0.03,1.44)	0.26 (0.03,1.43)	-0.03 (-0.20,0.01)
HD TOCI IV		0.42 (0.09,1.47)	0.43 (0.11,1.46)	-0.02 (-0.19,0.01)
HD ADA SC		0.35 (0.03,2.26)	0.36 (0.04,2.22)	-0.03 (-0.21,0.01)
HD GOLI SC		0.27 (0.02,2.29)	0.28 (0.02,2.20)	-0.03 (-0.19,0.03)
HD TOCI IV + MTX		0.57 (0.12,2.26)	0.58 (0.14,2.22)	-0.02 (-0.17,0.02)
HD GOLI SC + MTX		0.77 (0.15,3.75)	0.78 (0.17,3.46)	-0.01 (-0.15,0.07)
HD TOFA PO + MTX		0.80 (0.18,3.17)	0.81 (0.20,3.01)	-0.01 (-0.13,0.05)
HD CERTO SC + MTX		0.74 (0.16,3.09)	0.75 (0.18,2.96)	-0.01 (-0.14,0.05)
HD INF IV + MTX		1.48 (0.30,5.91)	1.44 (0.34,5.38)	0.01 (-0.11,0.13)

(Continued)

HD TOCI IV + DMARD		3.10 (0.27,32.15)	2.83 (0.32,23.28)	0.07 (-0.14,0.32)
SD TOFA PO + MTX	SD GOLI SC + MTX	1.68 (0.36,6.34)	1.65 (0.37,5.96)	0.01 (-0.05,0.10)
SD ABA SC + MTX		0.49 (0.11,2.38)	0.50 (0.12,2.33)	-0.01 (-0.08,0.02)
SD TOCI IV + MTX		1.11 (0.22,4.32)	1.10 (0.24,4.17)	0.00 (-0.07,0.05)
SD ETN SC + DMARD		2.09 (0.29,14.85)	2.03 (0.31,13.63)	0.02 (-0.06,0.11)
SD CERTO SC + DMARD		2.64 (0.34,25.59)	2.54 (0.36,21.85)	0.03 (-0.06,0.18)
SD ADA SC + DMARD		3.57 (0.28,41.74)	3.31 (0.30,31.20)	0.05 (-0.05,0.29)
SD TOCI SC + DMARD		8.39 (0.61,111.10)	6.85 (0.62,56.25)	0.14 (-0.02,0.58)
LD ADA SC		0.59 (0.07,3.79)	0.59 (0.08,3.73)	-0.01 (-0.09,0.02)
LD ETN SC		2.15 (0.24,16.00)	2.08 (0.26,13.92)	0.02 (-0.07,0.15)
LD TOCI IV		0.64 (0.10,2.90)	0.65 (0.11,2.82)	-0.01 (-0.08,0.03)
LD RITUX IV + MTX		1.71 (0.34,8.96)	1.68 (0.36,8.05)	0.01 (-0.04,0.15)
LD ABA IV + MTX		1.11 (0.24,4.67)	1.11 (0.25,4.45)	0.00 (-0.06,0.07)
LD CERTO SC + MTX		0.85 (0.11,4.67)	0.85 (0.11,4.44)	0.00 (-0.07,0.06)
LD TOCI IV + MTX		0.47 (0.05,2.56)	0.48 (0.05,2.51)	-0.01 (-0.09,0.02)
HD TOCI IV		0.77 (0.21,2.59)	0.78 (0.23,2.54)	0.00 (-0.08,0.02)
HD ADA SC		0.62 (0.09,3.84)	0.63 (0.10,3.75)	-0.01 (-0.09,0.02)
HD GOLI SC		0.50 (0.06,2.96)	0.51 (0.06,2.84)	-0.01 (-0.07,0.04)
HD TOCI IV + MTX		1.07 (0.26,3.67)	1.07 (0.28,3.56)	0.00 (-0.07,0.04)
HD GOLI SC + MTX		1.40 (0.52,4.07)	1.38 (0.54,3.84)	0.01 (-0.02,0.07)
HD TOFA PO + MTX		1.45 (0.34,6.13)	1.42 (0.36,5.71)	0.01 (-0.05,0.09)
HD CERTO SC + MTX		1.33 (0.35,5.21)	1.32 (0.36,4.90)	0.01 (-0.04,0.08)
HD INF IV + MTX		2.71 (0.65,10.12)	2.58 (0.66,8.95)	0.03 (-0.02,0.16)
HD TOCI IV + DMARD		5.45 (0.62,54.43)	4.88 (0.65,39.70)	0.09 (-0.03,0.33)
SD ABA SC + MTX	SD TOFA PO + MTX	0.30 (0.08,1.17)	0.31 (0.08,1.16)	-0.02 (-0.13,0.00)
SD TOCI IV + MTX		0.65 (0.15,2.73)	0.66 (0.16,2.64)	-0.01 (-0.11,0.04)
SD ETN SC + DMARD		1.28 (0.19,9.68)	1.26 (0.21,8.84)	0.01 (-0.12,0.10)

(Continued)

SD CERTO SC + DMARD	1.57 (0.24,16.86)	1.54 (0.27,14.15)	0.02 (-0.10,0.17)	
SD ADA SC + DMARD	2.23 (0.15,22.92)	2.12 (0.17,17.33)	0.04 (-0.11,0.28)	
SD TOCI SC + DMARD	5.24 (0.35,61.42)	4.38 (0.38,31.90)	0.13 (-0.07,0.57)	
LD ADA SC	0.37 (0.04,2.20)	0.38 (0.05,2.16)	-0.02 (-0.15,0.01)	
LD ETN SC	1.28 (0.15,10.16)	1.26 (0.16,8.97)	0.01 (-0.11,0.14)	
LD TOCI IV	0.39 (0.07,1.74)	0.40 (0.08,1.72)	-0.02 (-0.13,0.01)	
LD RITUX IV + MTX	1.05 (0.23,5.10)	1.04 (0.24,4.65)	0.00 (-0.06,0.11)	
LD ABA IV + MTX	0.68 (0.18,2.52)	0.69 (0.19,2.44)	-0.01 (-0.09,0.04)	
LD CERTO SC + MTX	0.51 (0.07,2.95)	0.52 (0.08,2.77)	-0.02 (-0.11,0.05)	
LD TOCI IV + MTX	0.29 (0.04,1.42)	0.29 (0.04,1.40)	-0.02 (-0.14,0.01)	
HD TOCI IV	0.46 (0.15,1.44)	0.47 (0.16,1.43)	-0.02 (-0.12,0.01)	
HD ADA SC	0.38 (0.05,2.35)	0.39 (0.06,2.31)	-0.02 (-0.14,0.02)	
HD GOLI SC	0.31 (0.03,2.23)	0.32 (0.03,2.12)	-0.02 (-0.12,0.04)	
HD TOCI IV + MTX	0.64 (0.18,2.24)	0.65 (0.20,2.19)	-0.01 (-0.11,0.02)	
HD GOLI SC + MTX	0.86 (0.25,3.53)	0.86 (0.27,3.30)	0.00 (-0.08,0.07)	
HD TOFA PO + MTX	0.90 (0.40,2.02)	0.90 (0.42,1.97)	0.00 (-0.05,0.04)	
HD CERTO SC + MTX	0.82 (0.24,2.95)	0.83 (0.26,2.81)	-0.01 (-0.08,0.05)	
HD INF IV + MTX	1.62 (0.48,5.69)	1.57 (0.50,5.11)	0.02 (-0.04,0.13)	
HD TOCI IV + DMARD	3.31 (0.40,34.04)	3.01 (0.44,25.25)	0.08 (-0.08,0.32)	
SD TOCI IV + MTX	SD ABA SC + MTX	2.19 (0.39,10.76)	2.16 (0.40,10.28)	0.01 (-0.02,0.08)
SD ETN SC + DMARD	3.97 (0.68,37.58)	3.82 (0.70,34.13)	0.03 (-0.01,0.12)	
SD CERTO SC + DMARD	5.08 (0.76,70.23)	4.79 (0.77,59.89)	0.05 (-0.01,0.19)	
SD ADA SC + DMARD	7.25 (0.61,104.80)	6.67 (0.62,80.67)	0.06 (-0.01,0.30)	
SD TOCI SC + DMARD	16.82 (1.33,239.10)	13.58 (1.32,133.60)	0.15 (0.01,0.59)	
LD ADA SC	1.19 (0.15,8.61)	1.18 (0.16,8.39)	0.00 (-0.04,0.03)	
LD ETN SC	4.03 (0.55,35.89)	3.87 (0.57,31.34)	0.03 (-0.01,0.17)	
LD TOCI IV	1.32 (0.20,6.33)	1.31 (0.21,6.16)	0.00 (-0.03,0.04)	
LD RITUX IV + MTX	3.43 (0.62,20.07)	3.30 (0.63,18.11)	0.03 (-0.01,0.19)	

(Continued)

LD ABA IV + MTX		2.23 (0.62,9.10)	2.18 (0.62,8.61)	0.01 (-0.01,0.09)
LD CERTO SC + MTX		1.75 (0.21,10.16)	1.74 (0.21,9.45)	0.01 (-0.02,0.09)
LD TOCI IV + MTX		0.91 (0.12,5.85)	0.91 (0.12,5.72)	0.00 (-0.03,0.03)
HD TOCI IV		1.54 (0.41,5.70)	1.52 (0.42,5.59)	0.01 (-0.02,0.03)
HD ADA SC		1.23 (0.20,9.65)	1.23 (0.21,9.42)	0.00 (-0.03,0.03)
HD GOLI SC		1.02 (0.08,6.93)	1.02 (0.08,6.54)	0.00 (-0.03,0.07)
HD TOCI IV + MTX		2.09 (0.52,8.73)	2.06 (0.53,8.45)	0.01 (-0.02,0.06)
HD GOLI SC + MTX		2.86 (0.71,13.35)	2.78 (0.72,12.02)	0.02 (-0.01,0.12)
HD TOFA PO + MTX		2.91 (0.78,11.82)	2.83 (0.78,11.04)	0.02 (0.00,0.12)
HD CERTO SC + MTX		2.76 (0.70,10.72)	2.68 (0.71,9.99)	0.02 (-0.01,0.10)
HD INF IV + MTX		5.40 (1.47,20.63)	5.05 (1.44,18.46)	0.05 (0.01,0.19)
HD TOCI IV + DMARD		10.91 (1.42,138.90)	9.56 (1.40,101.60)	0.10 (0.01,0.35)
SD ETN SC + DMARD	SD TOCI IV + MTX	1.97 (0.32,12.41)	1.92 (0.34,11.26)	0.02 (-0.06,0.10)
SD CERTO SC + DMARD		2.53 (0.36,21.24)	2.43 (0.39,17.95)	0.03 (-0.05,0.18)
SD ADA SC + DMARD		3.49 (0.31,33.03)	3.24 (0.33,24.56)	0.05 (-0.05,0.29)
SD TOCI SC + DMARD		8.22 (0.61,101.50)	6.77 (0.62,49.38)	0.14 (-0.02,0.58)
LD ADA SC		0.56 (0.07,2.99)	0.57 (0.08,2.94)	-0.01 (-0.09,0.02)
LD ETN SC		1.99 (0.24,13.21)	1.94 (0.26,11.45)	0.02 (-0.06,0.16)
LD TOCI IV		0.58 (0.12,2.56)	0.59 (0.12,2.51)	-0.01 (-0.07,0.02)
LD RITUX IV + MTX		1.57 (0.30,9.88)	1.54 (0.31,8.59)	0.01 (-0.04,0.16)
LD ABA IV + MTX		1.03 (0.21,5.12)	1.03 (0.21,4.81)	0.00 (-0.06,0.07)
LD CERTO SC + MTX		0.78 (0.10,5.14)	0.79 (0.11,4.82)	0.00 (-0.06,0.07)
LD TOCI IV + MTX		0.43 (0.07,1.94)	0.43 (0.07,1.91)	-0.01 (-0.08,0.01)
HD TOCI IV		0.71 (0.23,2.39)	0.71 (0.24,2.36)	-0.01 (-0.06,0.02)
HD ADA SC		0.59 (0.08,3.31)	0.60 (0.09,3.27)	-0.01 (-0.09,0.02)
HD GOLI SC		0.46 (0.04,3.78)	0.47 (0.04,3.58)	-0.01 (-0.07,0.05)
HD TOCI IV + MTX		0.97 (0.31,3.59)	0.97 (0.32,3.47)	0.00 (-0.05,0.03)
HD GOLI SC + MTX		1.31 (0.31,6.31)	1.30 (0.32,5.73)	0.01 (-0.04,0.10)

(Continued)

HD TOFA PO + MTX		1.36 (0.32,6.42)	1.35 (0.33,6.00)	0.01 (-0.04,0.10)
HD CERTO SC + MTX		1.25 (0.29,5.96)	1.24 (0.30,5.59)	0.01 (-0.04,0.09)
HD INF IV + MTX		2.46 (0.57,11.59)	2.35 (0.59,10.26)	0.03 (-0.02,0.17)
HD TOCI IV + DMARD		5.23 (0.72,42.60)	4.67 (0.74,31.27)	0.09 (-0.02,0.33)
SD CERTO SC + DMARD	SD ETN SC + DMARD	1.29 (0.37,5.39)	1.27 (0.39,4.66)	0.01 (-0.05,0.13)
SD ADA SC + DMARD		1.74 (0.37,7.43)	1.67 (0.38,5.74)	0.03 (-0.04,0.24)
SD TOCI SC + DMARD		3.92 (0.61,26.92)	3.35 (0.62,13.27)	0.12 (-0.02,0.54)
LD ADA SC		0.28 (0.06,1.21)	0.29 (0.06,1.20)	-0.03 (-0.11,0.00)
LD ETN SC		1.00 (0.14,7.23)	1.00 (0.15,6.28)	0.00 (-0.09,0.14)
LD TOCI IV		0.30 (0.04,2.21)	0.31 (0.05,2.15)	-0.03 (-0.12,0.03)
LD RITUX IV + MTX		0.80 (0.09,7.31)	0.81 (0.10,6.03)	-0.01 (-0.10,0.18)
LD ABA IV + MTX		0.54 (0.06,3.59)	0.55 (0.07,3.34)	-0.02 (-0.11,0.07)
LD CERTO SC + MTX		0.40 (0.04,3.56)	0.42 (0.05,3.26)	-0.03 (-0.11,0.07)
LD TOCI IV + MTX		0.21 (0.03,1.44)	0.22 (0.03,1.42)	-0.03 (-0.12,0.01)
HD TOCI IV		0.36 (0.07,1.92)	0.37 (0.08,1.87)	-0.03 (-0.11,0.02)
HD ADA SC		0.30 (0.07,1.24)	0.31 (0.08,1.23)	-0.03 (-0.11,0.01)
HD GOLI SC		0.25 (0.01,2.71)	0.26 (0.02,2.56)	-0.03 (-0.12,0.05)
HD TOCI IV + MTX		0.50 (0.10,2.74)	0.52 (0.11,2.62)	-0.02 (-0.11,0.04)
HD GOLI SC + MTX		0.68 (0.09,4.95)	0.69 (0.10,4.48)	-0.01 (-0.10,0.10)
HD TOFA PO + MTX		0.70 (0.10,4.95)	0.71 (0.11,4.42)	-0.01 (-0.10,0.10)
HD CERTO SC + MTX		0.65 (0.09,4.34)	0.66 (0.10,3.96)	-0.01 (-0.10,0.09)
HD INF IV + MTX		1.33 (0.17,7.96)	1.31 (0.19,6.75)	0.01 (-0.08,0.17)
HD TOCI IV + DMARD		2.66 (0.92,7.61)	2.44 (0.92,5.92)	0.07 (0.00,0.27)
SD ADA SC + DMARD	SD CERTO SC + DMARD	1.37 (0.21,6.53)	1.34 (0.23,5.15)	0.02 (-0.10,0.22)
SD TOCI SC + DMARD		3.06 (0.38,24.04)	2.65 (0.41,12.27)	0.10 (-0.06,0.52)
LD ADA SC		0.22 (0.03,1.17)	0.24 (0.04,1.16)	-0.05 (-0.19,0.00)
LD ETN SC		0.79 (0.09,6.25)	0.80 (0.10,5.42)	-0.01 (-0.16,0.13)

(Continued)

LD TOCI IV		0.24 (0.03,1.83)	0.25 (0.03,1.79)	-0.04 (-0.19,0.02)
LD RITUX IV + MTX		0.65 (0.06,6.01)	0.67 (0.07,5.07)	-0.02 (-0.17,0.17)
LD ABA IV + MTX		0.44 (0.03,2.82)	0.45 (0.04,2.66)	-0.03 (-0.18,0.05)
LD CERTO SC + MTX		0.32 (0.02,2.84)	0.34 (0.02,2.66)	-0.04 (-0.18,0.06)
LD TOCI IV + MTX		0.16 (0.02,1.27)	0.17 (0.02,1.26)	-0.05 (-0.19,0.01)
HD TOCI IV		0.29 (0.04,1.48)	0.30 (0.05,1.46)	-0.04 (-0.19,0.01)
HD ADA SC		0.23 (0.04,1.26)	0.24 (0.05,1.25)	-0.05 (-0.19,0.01)
HD GOLI SC		0.19 (0.01,2.45)	0.20 (0.01,2.34)	-0.04 (-0.19,0.04)
HD TOCI IV + MTX		0.40 (0.05,2.30)	0.42 (0.06,2.21)	-0.03 (-0.18,0.03)
HD GOLI SC + MTX		0.54 (0.05,4.20)	0.56 (0.06,3.80)	-0.02 (-0.17,0.09)
HD TOFA PO + MTX		0.55 (0.05,3.76)	0.57 (0.07,3.37)	-0.02 (-0.17,0.09)
HD CERTO SC + MTX		0.53 (0.05,3.72)	0.55 (0.06,3.39)	-0.02 (-0.18,0.08)
HD INF IV + MTX		1.04 (0.09,6.44)	1.04 (0.10,5.55)	0.00 (-0.16,0.15)
HD TOCI IV + DMARD		2.08 (0.52,7.65)	1.93 (0.55,6.07)	0.05 (-0.06,0.25)
SD TOCI SC + DMARD	SD ADA SC + DMARD	2.19 (0.34,21.65)	1.94 (0.38,13.85)	0.07 (-0.12,0.48)
LD ADA SC		0.16 (0.02,1.32)	0.17 (0.03,1.30)	-0.06 (-0.30,0.01)
LD ETN SC		0.58 (0.06,7.71)	0.61 (0.08,6.71)	-0.03 (-0.26,0.12)
LD TOCI IV		0.17 (0.02,2.21)	0.18 (0.02,2.15)	-0.06 (-0.30,0.03)
LD RITUX IV + MTX		0.44 (0.04,8.02)	0.47 (0.05,6.54)	-0.04 (-0.27,0.16)
LD ABA IV + MTX		0.30 (0.02,4.07)	0.32 (0.03,3.76)	-0.05 (-0.29,0.07)
LD CERTO SC + MTX		0.22 (0.01,3.43)	0.24 (0.02,3.20)	-0.06 (-0.29,0.05)
LD TOCI IV + MTX		0.12 (0.01,1.49)	0.13 (0.01,1.48)	-0.07 (-0.30,0.01)
HD TOCI IV		0.20 (0.03,2.11)	0.22 (0.03,2.07)	-0.06 (-0.29,0.02)
HD ADA SC		0.17 (0.03,1.29)	0.18 (0.03,1.28)	-0.06 (-0.30,0.01)
HD GOLI SC		0.13 (0.01,2.51)	0.15 (0.01,2.36)	-0.06 (-0.30,0.03)
HD TOCI IV + MTX		0.30 (0.03,2.85)	0.32 (0.05,2.73)	-0.05 (-0.29,0.04)
HD GOLI SC + MTX		0.38 (0.03,5.33)	0.40 (0.04,4.69)	-0.04 (-0.28,0.09)
HD TOFA PO + MTX		0.40 (0.04,5.84)	0.42 (0.05,5.16)	-0.04 (-0.28,0.09)



(Continued)

HD CERTO SC + MTX		0.36 (0.03,4.47)	0.38 (0.04,4.15)	-0.05 (-0.28,0.07)
HD INF IV + MTX		0.74 (0.06,8.95)	0.76 (0.08,7.46)	-0.02 (-0.26,0.16)
HD TOCI IV + DMARD		1.54 (0.40,6.56)	1.46 (0.47,5.47)	0.03 (-0.13,0.20)
LD ADA SC	SD TOCI SC + DMARD	0.07 (0.01,0.80)	0.08 (0.01,0.81)	-0.15 (-0.59,-0.01)
LD ETN SC		0.25 (0.02,3.29)	0.29 (0.04,2.99)	-0.11 (-0.57,0.09)
LD TOCI IV		0.07 (0.01,1.06)	0.09 (0.01,1.06)	-0.15 (-0.59,0.00)
LD RITUX IV + MTX		0.20 (0.01,3.64)	0.24 (0.03,3.22)	-0.12 (-0.57,0.11)
LD ABA IV + MTX		0.13 (0.01,2.02)	0.16 (0.02,1.92)	-0.14 (-0.58,0.04)
LD CERTO SC + MTX		0.09 (0.01,1.81)	0.12 (0.01,1.73)	-0.14 (-0.58,0.03)
LD TOCI IV + MTX		0.05 (0.00,0.82)	0.06 (0.01,0.83)	-0.16 (-0.60,-0.01)
HD TOCI IV		0.08 (0.01,1.05)	0.10 (0.02,1.04)	-0.15 (-0.59,0.00)
HD ADA SC		0.07 (0.01,0.74)	0.09 (0.02,0.75)	-0.15 (-0.59,-0.01)
HD GOLI SC		0.06 (0.00,1.19)	0.08 (0.00,1.18)	-0.15 (-0.59,0.01)
HD TOCI IV + MTX		0.12 (0.01,1.52)	0.15 (0.02,1.48)	-0.14 (-0.58,0.02)
HD GOLI SC + MTX		0.17 (0.01,2.41)	0.20 (0.03,2.28)	-0.13 (-0.57,0.05)
HD TOFA PO + MTX		0.17 (0.02,2.64)	0.20 (0.03,2.42)	-0.13 (-0.56,0.06)
HD CERTO SC + MTX		0.16 (0.01,2.27)	0.19 (0.03,2.13)	-0.13 (-0.57,0.05)
HD INF IV + MTX		0.31 (0.03,4.12)	0.36 (0.05,3.63)	-0.10 (-0.54,0.12)
HD TOCI IV + DMARD		0.69 (0.10,3.93)	0.73 (0.17,3.47)	-0.04 (-0.43,0.14)
LD ETN SC	LD ADA SC	3.55 (0.54,22.64)	3.41 (0.55,19.87)	0.03 (-0.01,0.17)
LD TOCI IV		1.09 (0.15,7.77)	1.09 (0.16,7.44)	0.00 (-0.03,0.05)
LD RITUX IV + MTX		2.66 (0.43,29.58)	2.59 (0.44,24.04)	0.02 (-0.02,0.22)
LD ABA IV + MTX		1.90 (0.25,16.00)	1.87 (0.25,14.73)	0.01 (-0.02,0.10)
LD CERTO SC + MTX		1.41 (0.15,13.12)	1.40 (0.15,12.07)	0.01 (-0.02,0.10)
LD TOCI IV + MTX		0.73 (0.10,6.56)	0.73 (0.10,6.29)	0.00 (-0.03,0.04)
HD TOCI IV		1.23 (0.29,8.12)	1.22 (0.29,7.76)	0.00 (-0.02,0.04)
HD ADA SC		1.04 (0.28,4.33)	1.04 (0.28,4.24)	0.00 (-0.02,0.03)
HD GOLI SC		0.83 (0.06,12.86)	0.83 (0.06,12.01)	0.00 (-0.03,0.08)

(Continued)

HD TOCI IV + MTX		1.69 (0.38,11.29)	1.67 (0.39,10.64)	0.01 (-0.02,0.07)
HD GOLI SC + MTX		2.41 (0.35,20.58)	2.36 (0.35,18.19)	0.02 (-0.02,0.13)
HD TOFA PO + MTX		2.37 (0.42,25.52)	2.33 (0.43,22.58)	0.02 (-0.01,0.14)
HD CERTO SC + MTX		2.19 (0.38,19.66)	2.15 (0.39,17.88)	0.02 (-0.02,0.12)
HD INF IV + MTX		4.40 (0.73,36.52)	4.16 (0.74,30.80)	0.05 (-0.01,0.20)
HD TOCI IV + DMARD		9.65 (1.66,55.55)	8.50 (1.63,41.19)	0.10 (0.01,0.34)
LD TOCI IV	LD ETN SC	0.31 (0.03,2.07)	0.32 (0.04,2.02)	-0.03 (-0.17,0.02)
LD RITUX IV + MTX		0.79 (0.10,8.70)	0.80 (0.11,7.21)	-0.01 (-0.14,0.18)
LD ABA IV + MTX		0.54 (0.06,4.59)	0.55 (0.07,4.33)	-0.02 (-0.15,0.07)
LD CERTO SC + MTX		0.41 (0.04,3.60)	0.43 (0.04,3.32)	-0.02 (-0.15,0.06)
LD TOCI IV + MTX		0.21 (0.02,2.05)	0.22 (0.03,2.01)	-0.04 (-0.17,0.02)
HD TOCI IV		0.36 (0.06,2.20)	0.38 (0.07,2.17)	-0.03 (-0.16,0.02)
HD ADA SC		0.30 (0.04,2.09)	0.31 (0.05,2.05)	-0.03 (-0.17,0.01)
HD GOLI SC		0.24 (0.01,2.81)	0.26 (0.02,2.68)	-0.03 (-0.16,0.04)
HD TOCI IV + MTX		0.52 (0.08,3.07)	0.53 (0.09,2.95)	-0.02 (-0.16,0.04)
HD GOLI SC + MTX		0.67 (0.09,6.12)	0.68 (0.10,5.53)	-0.01 (-0.14,0.10)
HD TOFA PO + MTX		0.71 (0.09,6.08)	0.72 (0.11,5.57)	-0.01 (-0.14,0.10)
HD CERTO SC + MTX		0.64 (0.10,5.01)	0.65 (0.11,4.62)	-0.01 (-0.14,0.09)
HD INF IV + MTX		1.28 (0.18,8.98)	1.26 (0.21,7.63)	0.01 (-0.12,0.16)
HD TOCI IV + DMARD		2.58 (0.27,22.63)	2.38 (0.30,16.75)	0.06 (-0.10,0.31)
LD RITUX IV + MTX	LD TOCI IV	2.54 (0.49,21.10)	2.46 (0.50,18.63)	0.02 (-0.02,0.19)
LD ABA IV + MTX		1.75 (0.34,10.05)	1.72 (0.35,9.37)	0.01 (-0.02,0.08)
LD CERTO SC + MTX		1.30 (0.18,9.93)	1.30 (0.19,9.41)	0.00 (-0.03,0.08)
LD TOCI IV + MTX		0.71 (0.11,3.93)	0.72 (0.11,3.86)	0.00 (-0.04,0.03)
HD TOCI IV		1.18 (0.38,4.93)	1.18 (0.39,4.86)	0.00 (-0.03,0.03)
HD ADA SC		0.99 (0.15,6.59)	0.99 (0.15,6.46)	0.00 (-0.05,0.03)
HD GOLI SC		0.80 (0.07,6.92)	0.80 (0.07,6.65)	0.00 (-0.04,0.06)
HD TOCI IV + MTX		1.66 (0.50,6.99)	1.64 (0.51,6.77)	0.01 (-0.02,0.05)

(Continued)

HD GOLI SC + MTX		2.23 (0.51,12.84)	2.17 (0.52,11.56)	0.02 (-0.01,0.11)
HD TOFA PO + MTX		2.26 (0.52,13.28)	2.21 (0.53,11.95)	0.02 (-0.02,0.12)
HD CERTO SC + MTX		2.13 (0.48,11.19)	2.08 (0.49,10.39)	0.01 (-0.02,0.10)
HD INF IV + MTX		4.12 (0.94,22.44)	3.90 (0.94,20.02)	0.04 (0.00,0.18)
HD TOCI IV + DMARD		9.02 (0.98,83.30)	7.89 (0.98,60.86)	0.10 (0.00,0.34)
LD ABA IV + MTX	LD RITUX IV + MTX	0.67 (0.11,3.36)	0.68 (0.12,3.21)	-0.01 (-0.15,0.05)
LD CERTO SC + MTX		0.50 (0.05,3.42)	0.52 (0.06,3.28)	-0.02 (-0.17,0.05)
LD TOCI IV + MTX		0.27 (0.03,1.61)	0.28 (0.04,1.60)	-0.03 (-0.19,0.01)
HD TOCI IV		0.45 (0.09,1.82)	0.46 (0.11,1.80)	-0.02 (-0.18,0.01)
HD ADA SC		0.38 (0.04,2.46)	0.39 (0.05,2.42)	-0.02 (-0.21,0.02)
HD GOLI SC		0.31 (0.02,2.34)	0.32 (0.03,2.23)	-0.02 (-0.19,0.03)
HD TOCI IV + MTX		0.61 (0.13,2.72)	0.63 (0.14,2.66)	-0.01 (-0.17,0.03)
HD GOLI SC + MTX		0.85 (0.15,4.06)	0.86 (0.17,3.81)	0.00 (-0.14,0.07)
HD TOFA PO + MTX		0.85 (0.17,4.17)	0.86 (0.19,3.94)	0.00 (-0.12,0.06)
HD CERTO SC + MTX		0.81 (0.16,3.57)	0.82 (0.18,3.39)	-0.01 (-0.14,0.06)
HD INF IV + MTX		1.58 (0.31,7.33)	1.54 (0.35,6.63)	0.02 (-0.10,0.13)
HD TOCI IV + DMARD		3.45 (0.31,36.59)	3.11 (0.36,26.63)	0.07 (-0.12,0.32)
LD CERTO SC + MTX	LD ABA IV + MTX	0.77 (0.09,4.51)	0.78 (0.10,4.25)	0.00 (-0.08,0.06)
LD TOCI IV + MTX		0.41 (0.05,2.61)	0.42 (0.06,2.56)	-0.01 (-0.09,0.02)
HD TOCI IV		0.68 (0.20,2.62)	0.69 (0.21,2.60)	-0.01 (-0.08,0.02)
HD ADA SC		0.54 (0.08,4.28)	0.55 (0.09,4.16)	-0.01 (-0.10,0.02)
HD GOLI SC		0.46 (0.04,3.35)	0.47 (0.04,3.17)	-0.01 (-0.09,0.05)
HD TOCI IV + MTX		0.93 (0.25,3.85)	0.93 (0.27,3.73)	0.00 (-0.07,0.04)
HD GOLI SC + MTX		1.27 (0.32,5.68)	1.26 (0.34,5.22)	0.01 (-0.05,0.09)
HD TOFA PO + MTX		1.33 (0.35,5.24)	1.31 (0.36,4.90)	0.01 (-0.05,0.09)
HD CERTO SC + MTX		1.22 (0.31,4.90)	1.21 (0.33,4.62)	0.00 (-0.05,0.08)
HD INF IV + MTX		2.40 (0.63,8.96)	2.29 (0.65,8.15)	0.03 (-0.02,0.15)
HD TOCI IV + DMARD		4.92 (0.56,58.39)	4.40 (0.58,42.34)	0.09 (-0.03,0.33)

(Continued)

LD TOCI IV + MTX	LD CERTO SC + MTX	0.54 (0.06,4.77)	0.55 (0.07,4.66)	-0.01 (-0.09,0.03)
HD TOCI IV		0.91 (0.18,5.50)	0.91 (0.19,5.39)	0.00 (-0.08,0.02)
HD ADA SC		0.74 (0.08,6.79)	0.75 (0.09,6.66)	0.00 (-0.10,0.03)
HD GOLI SC		0.62 (0.04,5.52)	0.63 (0.04,5.25)	-0.01 (-0.08,0.05)
HD TOCI IV + MTX		1.24 (0.23,8.46)	1.23 (0.25,8.19)	0.00 (-0.07,0.04)
HD GOLI SC + MTX		1.66 (0.31,13.02)	1.63 (0.33,12.31)	0.01 (-0.05,0.10)
HD TOFA PO + MTX		1.71 (0.32,13.32)	1.68 (0.34,11.98)	0.01 (-0.05,0.10)
HD CERTO SC + MTX		1.57 (0.38,8.66)	1.55 (0.39,8.27)	0.01 (-0.04,0.08)
HD INF IV + MTX		3.24 (0.61,21.17)	3.06 (0.63,19.24)	0.04 (-0.02,0.17)
HD TOCI IV + DMARD		6.84 (0.65,88.72)	6.04 (0.67,65.43)	0.09 (-0.03,0.34)
HD TOCI IV	LD TOCI IV + MTX	1.64 (0.43,8.55)	1.62 (0.44,8.34)	0.01 (-0.02,0.03)
HD ADA SC		1.35 (0.21,10.50)	1.34 (0.22,10.18)	0.00 (-0.04,0.03)
HD GOLI SC		1.11 (0.09,12.12)	1.11 (0.09,11.47)	0.00 (-0.03,0.07)
HD TOCI IV + MTX		2.29 (0.57,13.30)	2.26 (0.58,12.88)	0.01 (-0.01,0.06)
HD GOLI SC + MTX		3.20 (0.52,25.25)	3.10 (0.53,22.96)	0.02 (-0.01,0.12)
HD TOFA PO + MTX		3.19 (0.55,22.26)	3.09 (0.56,20.61)	0.02 (-0.01,0.13)
HD CERTO SC + MTX		2.98 (0.54,23.00)	2.91 (0.55,21.48)	0.02 (-0.01,0.11)
HD INF IV + MTX		5.91 (1.03,40.58)	5.53 (1.03,35.84)	0.05 (0.00,0.19)
HD TOCI IV + DMARD		12.37 (1.61,104.90)	10.84 (1.58,78.96)	0.10 (0.01,0.35)
HD ADA SC	HD TOCI IV	0.83 (0.17,3.61)	0.83 (0.17,3.53)	0.00 (-0.04,0.03)
HD GOLI SC		0.66 (0.07,4.19)	0.66 (0.07,3.90)	-0.01 (-0.03,0.06)
HD TOCI IV + MTX		1.39 (0.64,2.92)	1.37 (0.65,2.86)	0.01 (-0.01,0.04)
HD GOLI SC + MTX		1.86 (0.60,6.64)	1.83 (0.61,5.79)	0.01 (-0.01,0.11)
HD TOFA PO + MTX		1.96 (0.62,6.46)	1.92 (0.63,5.86)	0.02 (-0.01,0.11)
HD CERTO SC + MTX		1.77 (0.58,5.60)	1.74 (0.59,5.16)	0.01 (-0.01,0.09)
HD INF IV + MTX		3.51 (1.17,10.94)	3.33 (1.17,9.37)	0.04 (0.00,0.18)
HD TOCI IV + DMARD		7.28 (1.06,52.01)	6.47 (1.06,36.95)	0.10 (0.00,0.34)
HD GOLI SC	HD ADA SC	0.79 (0.05,8.97)	0.79 (0.06,8.35)	0.00 (-0.03,0.08)

(Continued)

HD TOCI IV + MTX		1.66 (0.34,8.86)	1.64 (0.35,8.37)	0.01 (-0.02,0.06)
HD GOLI SC + MTX		2.37 (0.35,15.50)	2.31 (0.35,13.80)	0.02 (-0.02,0.13)
HD TOFA PO + MTX		2.33 (0.38,17.76)	2.28 (0.39,15.68)	0.02 (-0.02,0.13)
HD CERTO SC + MTX		2.14 (0.35,14.86)	2.10 (0.35,13.44)	0.01 (-0.02,0.11)
HD INF IV + MTX		4.42 (0.67,26.42)	4.17 (0.68,22.23)	0.05 (-0.01,0.20)
HD TOCI IV + DMARD		9.33 (1.63,49.48)	8.25 (1.60,35.54)	0.10 (0.01,0.34)
HD TOCI IV + MTX	HD GOLI SC	2.12 (0.32,21.15)	2.09 (0.34,20.51)	0.01 (-0.05,0.05)
HD GOLI SC + MTX		2.69 (0.59,24.71)	2.60 (0.60,23.79)	0.02 (-0.02,0.10)
HD TOFA PO + MTX		2.94 (0.38,37.19)	2.85 (0.41,34.95)	0.02 (-0.04,0.11)
HD CERTO SC + MTX		2.63 (0.43,27.76)	2.57 (0.45,26.47)	0.02 (-0.03,0.09)
HD INF IV + MTX		5.22 (0.76,61.62)	4.89 (0.77,56.54)	0.04 (-0.01,0.18)
HD TOCI IV + DMARD		10.78 (0.86,228.60)	9.41 (0.87,171.10)	0.10 (-0.01,0.34)
HD GOLI SC + MTX	HD TOCI IV + MTX	1.38 (0.39,5.21)	1.37 (0.40,4.67)	0.01 (-0.03,0.10)
HD TOFA PO + MTX		1.39 (0.40,5.14)	1.38 (0.41,4.60)	0.01 (-0.03,0.10)
HD CERTO SC + MTX		1.30 (0.35,4.44)	1.29 (0.36,4.08)	0.01 (-0.03,0.08)
HD INF IV + MTX		2.60 (0.72,8.87)	2.49 (0.73,7.77)	0.04 (-0.01,0.17)
HD TOCI IV + DMARD		5.27 (0.75,37.47)	4.71 (0.76,26.81)	0.09 (-0.02,0.33)
HD TOFA PO + MTX	HD GOLI SC + MTX	1.04 (0.26,3.64)	1.04 (0.28,3.43)	0.00 (-0.08,0.07)
HD CERTO SC + MTX		0.97 (0.24,3.38)	0.97 (0.26,3.22)	0.00 (-0.08,0.06)
HD INF IV + MTX		1.90 (0.44,6.86)	1.84 (0.47,6.16)	0.02 (-0.05,0.14)
HD TOCI IV + DMARD		3.96 (0.40,39.07)	3.58 (0.44,28.51)	0.08 (-0.06,0.32)
HD CERTO SC + MTX	HD TOFA PO + MTX	0.91 (0.26,3.43)	0.92 (0.27,3.24)	0.00 (-0.07,0.06)
HD INF IV + MTX		1.82 (0.52,6.26)	1.76 (0.54,5.62)	0.02 (-0.04,0.14)
HD TOCI IV + DMARD		3.85 (0.42,36.87)	3.47 (0.46,26.58)	0.08 (-0.07,0.32)
HD INF IV + MTX	HD CERTO SC + MTX	2.00 (0.55,6.87)	1.92 (0.56,6.22)	0.03 (-0.03,0.14)
HD TOCI IV + DMARD		4.22 (0.52,38.97)	3.79 (0.54,28.18)	0.08 (-0.05,0.33)
HD TOCI IV + DMARD	HD INF IV + MTX	2.01 (0.26,22.03)	1.88 (0.30,16.07)	0.05 (-0.13,0.30)

(Continued)

Random-Effect Model	Residual Deviance	128 vs 132 data points
	Deviance Information Criteria	641.601
Fixed-Effect Model	Residual Deviance	131 vs 132 data points
	Deviance Information Criteria	641.171
Note:		
Total Patients	20850	
Total Studies	52	
2-arm	34	
3-arm	11	
4-arm	6	
7-arm	1	

### Appendix 34. Withdrawals due to AE: Subgroup - Trial duration (6 to 12 months)

Withdrawals, Intermediate trial duration : Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD ETN SC	MTX + PL	1.99 (0.58,6.33)	1.91 (0.59,5.20)	0.04 (-0.02,0.18)
SD ETN SC + MTX		1.43 (0.34,6.31)	1.41 (0.35,5.26)	0.02 (-0.03,0.17)
SD ADA SC + MTX		1.63 (0.54,5.06)	1.59 (0.55,4.32)	0.03 (-0.02,0.14)
SD INF IV + MTX		0.64 (0.14,2.88)	0.65 (0.15,2.68)	-0.02 (-0.04,0.07)
SD RITUX IV + MTX		0.25 (0.01,2.63)	0.26 (0.01,2.49)	-0.03 (-0.05,0.06)
SD TOFA PO + MTX		1.74 (0.56,5.52)	1.69 (0.57,4.65)	0.03 (-0.02,0.16)
LD ETN SC		1.78 (0.58,6.22)	1.72 (0.59,5.12)	0.03 (-0.02,0.17)
LD RITUX IV + MTX		1.89 (0.36,12.55)	1.82 (0.37,8.63)	0.04 (-0.03,0.29)

(Continued)

LD ETN SC + MTX		0.76 (0.13,3.84)	0.77 (0.14,3.46)	-0.01 (-0.04,0.10)
HD INF IV + MTX		0.51 (0.10,2.39)	0.52 (0.10,2.26)	-0.02 (-0.05,0.05)
HD TOFA PO + MTX		1.23 (0.38,3.95)	1.22 (0.39,3.52)	0.01 (-0.03,0.11)
SD ETN SC + MTX	SD ETN SC	0.73 (0.12,4.66)	0.75 (0.14,4.02)	-0.02 (-0.17,0.13)
SD ADA SC + MTX		0.81 (0.18,4.57)	0.82 (0.21,3.97)	-0.01 (-0.15,0.12)
SD INF IV + MTX		0.32 (0.05,2.28)	0.34 (0.06,2.14)	-0.05 (-0.19,0.05)
SD RITUX IV + MTX		0.13 (0.00,1.87)	0.14 (0.00,1.79)	-0.07 (-0.21,0.03)
SD TOFA PO + MTX		0.87 (0.18,4.77)	0.88 (0.21,4.08)	-0.01 (-0.15,0.13)
LD ETN SC		0.90 (0.37,2.59)	0.91 (0.41,2.36)	-0.01 (-0.09,0.08)
LD RITUX IV + MTX		0.95 (0.12,8.78)	0.96 (0.15,6.44)	0.00 (-0.16,0.25)
LD ETN SC + MTX		0.38 (0.05,2.81)	0.40 (0.06,2.58)	-0.05 (-0.19,0.07)
HD INF IV + MTX		0.25 (0.04,1.89)	0.27 (0.04,1.81)	-0.06 (-0.20,0.03)
HD TOFA PO + MTX		0.61 (0.12,3.45)	0.63 (0.15,3.12)	-0.03 (-0.17,0.08)
SD ADA SC + MTX	SD ETN SC + MTX	1.14 (0.18,7.31)	1.13 (0.21,6.24)	0.01 (-0.15,0.13)
SD INF IV + MTX		0.45 (0.06,3.66)	0.47 (0.07,3.37)	-0.03 (-0.18,0.06)
SD RITUX IV + MTX		0.17 (0.00,2.77)	0.18 (0.00,2.60)	-0.05 (-0.19,0.05)
SD TOFA PO + MTX		1.23 (0.19,7.83)	1.22 (0.22,6.65)	0.01 (-0.14,0.14)
LD ETN SC		1.25 (0.21,8.21)	1.23 (0.24,6.99)	0.01 (-0.14,0.16)
LD RITUX IV + MTX		1.33 (0.14,14.20)	1.30 (0.16,10.48)	0.02 (-0.14,0.27)
LD ETN SC + MTX		0.53 (0.10,2.49)	0.55 (0.12,2.37)	-0.03 (-0.14,0.05)
HD INF IV + MTX		0.36 (0.04,2.95)	0.37 (0.05,2.81)	-0.04 (-0.18,0.04)
HD TOFA PO + MTX		0.88 (0.13,5.64)	0.88 (0.15,5.03)	-0.01 (-0.16,0.10)
SD INF IV + MTX	SD ADA SC + MTX	0.39 (0.06,2.49)	0.41 (0.07,2.33)	-0.04 (-0.16,0.05)
SD RITUX IV + MTX		0.15 (0.00,2.02)	0.16 (0.00,1.92)	-0.06 (-0.17,0.04)
SD TOFA PO + MTX		1.08 (0.21,5.10)	1.07 (0.24,4.39)	0.00 (-0.12,0.13)
LD ETN SC		1.10 (0.22,5.67)	1.09 (0.26,4.78)	0.01 (-0.12,0.15)
LD RITUX IV + MTX		1.17 (0.16,10.34)	1.15 (0.18,7.56)	0.01 (-0.12,0.27)
LD ETN SC + MTX		0.46 (0.06,3.13)	0.48 (0.07,2.86)	-0.03 (-0.15,0.08)

(Continued)

HD INF IV + MTX		0.31 (0.04,1.93)	0.33 (0.05,1.85)	-0.04 (-0.16,0.03)
HD TOFA PO + MTX		0.76 (0.15,3.56)	0.77 (0.17,3.22)	-0.02 (-0.14,0.09)
SD RITUX IV + MTX	SD INF IV + MTX	0.38 (0.01,6.14)	0.39 (0.01,5.73)	-0.02 (-0.10,0.07)
SD TOFA PO + MTX		2.74 (0.41,17.55)	2.59 (0.43,15.01)	0.04 (-0.05,0.17)
LD ETN SC		2.78 (0.45,19.95)	2.64 (0.47,16.66)	0.04 (-0.05,0.19)
LD RITUX IV + MTX		2.92 (0.32,32.83)	2.74 (0.34,24.34)	0.05 (-0.05,0.30)
LD ETN SC + MTX		1.20 (0.12,10.87)	1.19 (0.13,9.61)	0.00 (-0.08,0.11)
HD INF IV + MTX		0.79 (0.14,3.96)	0.80 (0.15,3.80)	-0.01 (-0.07,0.05)
HD TOFA PO + MTX		1.94 (0.28,12.38)	1.88 (0.30,11.03)	0.02 (-0.07,0.12)
SD TOFA PO + MTX	SD RITUX IV + MTX	7.15 (0.48,331.20)	6.62 (0.51,287.70)	0.06 (-0.04,0.19)
LD ETN SC		7.24 (0.50,284.80)	6.67 (0.53,240.60)	0.06 (-0.04,0.20)
LD RITUX IV + MTX		7.53 (0.85,282.10)	6.80 (0.86,238.80)	0.06 (-0.01,0.28)
LD ETN SC + MTX		3.23 (0.15,137.40)	3.13 (0.16,122.50)	0.02 (-0.07,0.13)
HD INF IV + MTX		2.10 (0.12,91.78)	2.07 (0.13,86.53)	0.01 (-0.08,0.08)
HD TOFA PO + MTX		4.97 (0.34,226.00)	4.73 (0.36,203.00)	0.04 (-0.05,0.14)
LD ETN SC	SD TOFA PO + MTX	1.03 (0.21,5.39)	1.03 (0.24,4.59)	0.00 (-0.13,0.15)
LD RITUX IV + MTX		1.08 (0.14,10.04)	1.08 (0.16,7.20)	0.01 (-0.14,0.27)
LD ETN SC + MTX		0.43 (0.06,3.17)	0.45 (0.07,2.90)	-0.04 (-0.17,0.08)
HD INF IV + MTX		0.29 (0.04,1.99)	0.30 (0.04,1.91)	-0.05 (-0.18,0.04)
HD TOFA PO + MTX		0.71 (0.24,1.98)	0.72 (0.27,1.87)	-0.02 (-0.11,0.04)
LD RITUX IV + MTX	LD ETN SC	1.04 (0.13,9.29)	1.03 (0.15,6.80)	0.00 (-0.15,0.26)
LD ETN SC + MTX		0.42 (0.05,3.01)	0.44 (0.06,2.74)	-0.04 (-0.18,0.07)
HD INF IV + MTX		0.28 (0.04,1.94)	0.30 (0.04,1.86)	-0.05 (-0.19,0.03)
HD TOFA PO + MTX		0.69 (0.12,3.47)	0.71 (0.15,3.16)	-0.02 (-0.17,0.08)
LD ETN SC + MTX	LD RITUX IV + MTX	0.40 (0.03,4.13)	0.43 (0.04,3.79)	-0.04 (-0.30,0.08)
HD INF IV + MTX		0.27 (0.02,2.52)	0.29 (0.03,2.40)	-0.05 (-0.31,0.04)
HD TOFA PO + MTX		0.65 (0.07,5.02)	0.67 (0.09,4.56)	-0.03 (-0.28,0.09)



(Continued)

HD INF IV + MTX	LD ETN SC + MTX	0.68 (0.07,6.41)	0.69 (0.08,5.95)	-0.01 (-0.12,0.06)
HD TOFA PO + MTX		1.63 (0.22,12.55)	1.59 (0.24,11.11)	0.02 (-0.09,0.12)
HD TOFA PO + MTX	HD INF IV + MTX	2.48 (0.35,17.87)	2.39 (0.37,15.96)	0.03 (-0.05,0.13)
Random-Effect Model	Residual Deviance	19.23 vs 19 data points		
	Deviance Information Criteria	109.73		
Fixed-Effect Model	Residual Deviance	19.57 vs 19 data points		
	Deviance Information Criteria	109.933		
Note:				
Total Patients	3279			
Total Studies	7			
2-arm	2			
3-arm	5			

### Appendix 35. Serious Adverse Events: Type of medication

SAEs Analysis 2: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
TNF	Comp	1.24 (0.94,1.64)	1.23 (0.94,1.59)	0.01 (0.00,0.03)
non-TNF		1.22 (0.82,1.78)	1.21 (0.83,1.72)	0.01 (-0.01,0.04)
TOFA		0.48 (0.23,1.06)	0.50 (0.24,1.06)	-0.03 (-0.04,0.00)
MTXTNF		1.21 (1.01,1.47)	1.20 (1.01,1.43)	0.01 (0.00,0.02)
MTXnon-TNF		1.07 (0.89,1.31)	1.07 (0.89,1.29)	0.00 (-0.01,0.01)
MTXTOFA		2.06 (1.03,4.35)	1.96 (1.03,3.72)	0.05 (0.00,0.14)
MTXANA		1.06 (0.64,1.83)	1.06 (0.65,1.75)	0.00 (-0.02,0.04)
non-TNF	TNF	0.98 (0.63,1.50)	0.98 (0.65,1.46)	0.00 (-0.03,0.03)

(Continued)

TOFA		0.39 (0.18,0.89)	0.40 (0.19,0.89)	-0.04 (-0.06,-0.01)
MTXTNF		0.97 (0.73,1.32)	0.98 (0.74,1.30)	0.00 (-0.02,0.02)
MTXnon-TNF		0.86 (0.63,1.21)	0.87 (0.64,1.19)	-0.01 (-0.03,0.01)
MTXTOFA		1.66 (0.80,3.68)	1.59 (0.81,3.19)	0.04 (-0.01,0.13)
MTXANA		0.86 (0.48,1.55)	0.87 (0.50,1.51)	-0.01 (-0.04,0.03)
TOFA	non-TNF	0.39 (0.17,0.96)	0.41 (0.18,0.96)	-0.04 (-0.07,0.00)
MTXTNF		0.99 (0.66,1.54)	0.99 (0.68,1.50)	0.00 (-0.03,0.02)
MTXnon-TNF		0.88 (0.59,1.33)	0.89 (0.61,1.31)	-0.01 (-0.03,0.01)
MTXTOFA		1.69 (0.77,3.94)	1.62 (0.78,3.42)	0.04 (-0.02,0.13)
MTXANA		0.87 (0.46,1.70)	0.88 (0.48,1.64)	-0.01 (-0.04,0.03)
MTXTNF	TOFA	2.51 (1.12,5.37)	2.42 (1.12,5.09)	0.04 (0.01,0.05)
MTXnon-TNF		2.23 (1.00,4.78)	2.16 (1.00,4.56)	0.03 (0.00,0.05)
MTXTOFA		4.26 (1.49,12.33)	3.93 (1.46,10.47)	0.07 (0.02,0.16)
MTXANA		2.21 (0.87,5.55)	2.14 (0.88,5.21)	0.03 (-0.01,0.07)
MTXnon-TNF	MTXTNF	0.89 (0.69,1.14)	0.89 (0.70,1.13)	-0.01 (-0.02,0.01)
MTXTOFA		1.70 (0.85,3.60)	1.63 (0.86,3.11)	0.04 (-0.01,0.13)
MTXANA		0.88 (0.51,1.55)	0.89 (0.52,1.50)	-0.01 (-0.03,0.03)
MTXTOFA	MTXnon-TNF	1.92 (0.94,4.12)	1.83 (0.94,3.54)	0.05 (0.00,0.13)
MTXANA		0.99 (0.57,1.77)	0.99 (0.58,1.70)	0.00 (-0.02,0.04)
MTXANA	MTXTOFA	0.52 (0.20,1.25)	0.54 (0.24,1.23)	-0.05 (-0.14,0.01)
Random-Effect Model	Residual Deviance	127.5 vs 122 data points		
	Deviance Information Criteria	677.34		
Fixed-Effect Model	Residual Deviance	135.1 vs 122 data points		
	Deviance Information Criteria	677.585		
Note:				

(Continued)

Total Patients	25872
Total Studies	58
2-arm	52
3-arm	6

### Appendix 36. Serious Adverse Events: Type of biologics

SAEs Analysis 3: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
Mono	comp	1.16 (0.84,1.63)	1.15 (0.84,1.58)	0.01 (-0.01,0.03)
TNF		1.53 (0.92,2.59)	1.49 (0.92,2.40)	0.03 (0.00,0.07)
non-TNF		1.19 (0.80,1.78)	1.18 (0.81,1.71)	0.01 (-0.01,0.04)
TOFA		0.48 (0.23,1.05)	0.50 (0.24,1.05)	-0.03 (-0.04,0.00)
MTXMono		1.18 (0.95,1.48)	1.17 (0.96,1.45)	0.01 (0.00,0.02)
MTXnon-TNF		1.07 (0.88,1.30)	1.06 (0.88,1.29)	0.00 (-0.01,0.01)
MTXTNF		1.33 (0.91,2.00)	1.31 (0.91,1.91)	0.02 (0.00,0.05)
MTXTOFA		2.04 (1.03,4.41)	1.94 (1.03,3.77)	0.05 (0.00,0.14)
MTXANA		1.07 (0.64,1.83)	1.06 (0.65,1.75)	0.00 (-0.02,0.04)
TNF	Mono	1.31 (0.72,2.43)	1.29 (0.74,2.26)	0.02 (-0.02,0.07)
non-TNF		1.02 (0.64,1.62)	1.02 (0.66,1.57)	0.00 (-0.02,0.03)
TOFA		0.42 (0.18,0.96)	0.43 (0.20,0.96)	-0.03 (-0.06,0.00)
MTXMono		1.02 (0.70,1.48)	1.02 (0.72,1.45)	0.00 (-0.02,0.02)
MTXnon-TNF		0.92 (0.63,1.33)	0.92 (0.65,1.31)	0.00 (-0.03,0.01)
MTXTNF		1.15 (0.71,1.91)	1.14 (0.72,1.83)	0.01 (-0.02,0.04)
MTXTOFA		1.76 (0.82,4.06)	1.68 (0.83,3.50)	0.04 (-0.01,0.13)
MTXANA		0.92 (0.50,1.72)	0.92 (0.52,1.66)	0.00 (-0.03,0.03)
non-TNF	TNF	0.78 (0.40,1.49)	0.79 (0.43,1.45)	-0.02 (-0.07,0.02)

(Continued)

TOFA		0.32 (0.13,0.81)	0.33 (0.14,0.82)	-0.05 (-0.10,-0.01)
MTXMono		0.77 (0.44,1.35)	0.79 (0.47,1.33)	-0.02 (-0.06,0.02)
MTXnon-TNF		0.70 (0.40,1.21)	0.72 (0.43,1.20)	-0.02 (-0.07,0.01)
MTXTNF		0.88 (0.53,1.44)	0.88 (0.56,1.40)	-0.01 (-0.05,0.02)
MTXTOFA		1.34 (0.56,3.36)	1.31 (0.59,2.95)	0.02 (-0.04,0.12)
MTXANA		0.70 (0.33,1.47)	0.71 (0.36,1.43)	-0.02 (-0.07,0.02)
TOFA	non-TNF	0.41 (0.18,0.97)	0.42 (0.19,0.97)	-0.03 (-0.07,0.00)
MTXMono		1.00 (0.64,1.56)	1.00 (0.66,1.52)	0.00 (-0.03,0.02)
MTXnon-TNF		0.90 (0.59,1.37)	0.90 (0.61,1.35)	-0.01 (-0.03,0.02)
MTXTNF		1.12 (0.65,1.98)	1.12 (0.66,1.90)	0.01 (-0.03,0.04)
MTXTOFA		1.72 (0.78,4.10)	1.65 (0.80,3.54)	0.04 (-0.02,0.13)
MTXANA		0.90 (0.47,1.74)	0.90 (0.49,1.68)	-0.01 (-0.04,0.03)
MTXMono	TOFA	2.44 (1.10,5.31)	2.36 (1.10,5.03)	0.03 (0.00,0.05)
MTXnon-TNF		2.21 (0.99,4.71)	2.14 (0.99,4.49)	0.03 (0.00,0.05)
MTXTNF		2.77 (1.17,6.34)	2.64 (1.16,5.90)	0.04 (0.01,0.07)
MTXTOFA		4.23 (1.49,12.66)	3.90 (1.46,10.72)	0.07 (0.02,0.17)
MTXANA		2.21 (0.87,5.50)	2.14 (0.88,5.16)	0.03 (-0.01,0.07)
MTXnon-TNF	MTXMono	0.90 (0.69,1.18)	0.91 (0.70,1.16)	-0.01 (-0.02,0.01)
MTXTNF		1.13 (0.72,1.78)	1.12 (0.73,1.70)	0.01 (-0.02,0.04)
MTXTOFA		1.72 (0.87,3.74)	1.65 (0.87,3.22)	0.04 (-0.01,0.13)
MTXANA		0.90 (0.52,1.61)	0.90 (0.53,1.56)	-0.01 (-0.03,0.03)
MTXTNF	MTXnon-TNF	1.25 (0.81,1.96)	1.23 (0.82,1.87)	0.01 (-0.01,0.04)
MTXTOFA		1.91 (0.94,4.22)	1.82 (0.95,3.62)	0.04 (0.00,0.14)
MTXANA		1.00 (0.57,1.77)	1.00 (0.59,1.70)	0.00 (-0.02,0.04)
MTXTOFA	MTXTNF	1.53 (0.69,3.67)	1.48 (0.70,3.18)	0.03 (-0.02,0.13)
MTXANA		0.80 (0.41,1.56)	0.81 (0.43,1.51)	-0.01 (-0.05,0.03)
MTXANA	MTXTOFA	0.52 (0.21,1.25)	0.55 (0.24,1.23)	-0.04 (-0.14,0.01)

(Continued)

Random-Effect Model	Residual Deviance	128.1 vs 122 data points
	Deviance Information Criteria	680.036
Fixed-Effect Model	Residual Deviance	136.1 vs 122 data points
	Deviance Information Criteria	680.533
Note:		
Total Patients	25872	
Total Studies	58	
2-arm	52	
3-arm	6	

### Appendix 37. Serious Adverse Events: By dose

SAEs Analysis 4 : Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD	PL	1.28 (0.96,1.75)	1.26 (0.96,1.68)	0.01 (0.00,0.04)
HD		1.21 (0.85,1.72)	1.20 (0.86,1.66)	0.01 (-0.01,0.04)
LD		1.00 (0.60,1.61)	1.00 (0.62,1.56)	0.00 (-0.02,0.03)
MTXSD		1.11 (0.95,1.28)	1.10 (0.96,1.27)	0.01 (0.00,0.01)
MTXLD		1.09 (0.81,1.47)	1.08 (0.81,1.43)	0.00 (-0.01,0.02)
MTXHD		1.33 (1.02,1.74)	1.30 (1.02,1.68)	0.02 (0.00,0.04)
HD	SD	0.94 (0.62,1.44)	0.95 (0.64,1.40)	0.00 (-0.03,0.02)
LD		0.78 (0.47,1.28)	0.79 (0.49,1.26)	-0.01 (-0.04,0.02)
MTXSD		0.86 (0.63,1.16)	0.87 (0.65,1.15)	-0.01 (-0.03,0.01)
MTXLD		0.85 (0.57,1.26)	0.86 (0.59,1.24)	-0.01 (-0.03,0.01)
MTXHD		1.03 (0.71,1.52)	1.03 (0.72,1.47)	0.00 (-0.02,0.03)
LD	HD	0.82 (0.47,1.43)	0.83 (0.49,1.39)	-0.01 (-0.04,0.02)

(Continued)

MTXSD		0.91 (0.63,1.32)	0.92 (0.66,1.30)	-0.01 (-0.03,0.01)
MTXLD		0.90 (0.57,1.40)	0.90 (0.59,1.37)	-0.01 (-0.03,0.02)
MTXHD		1.10 (0.73,1.65)	1.09 (0.75,1.60)	0.01 (-0.02,0.03)
MTXSD	LD	1.11 (0.68,1.83)	1.10 (0.70,1.78)	0.01 (-0.03,0.03)
MTXLD		1.09 (0.62,1.93)	1.09 (0.64,1.87)	0.00 (-0.03,0.03)
MTXHD		1.33 (0.78,2.32)	1.31 (0.79,2.22)	0.02 (-0.02,0.05)
MTXLD	MTXSD	0.98 (0.73,1.33)	0.99 (0.74,1.31)	0.00 (-0.02,0.02)
MTXHD		1.20 (0.91,1.59)	1.19 (0.91,1.54)	0.01 (-0.01,0.03)
MTXHD	MTXLD	1.22 (0.83,1.80)	1.21 (0.84,1.73)	0.01 (-0.01,0.04)

Random-Effect Model	Residual Deviance	137.2 vs 131 data points
	Deviance Information Criteria	692.326
Fixed-Effect Model	Residual Deviance	143.1 vs 131 data points
	Deviance Information Criteria	691.715

Note:

Total Patients	22337
Total Studies	53
2-arm	35
3-arm	12
4-arm	5
5-arm	1

### Appendix 38. Serious Adverse Events: Main analysis

SAEs (Analysis 1): Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
-----------	-----------	--------------	--------------	----------------

**Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis (Review)**

476

(Continued)

MTX	PL	1.32 (0.38,6.19)	1.30 (0.39,5.23)	0.01 (-0.03,0.15)
DMARD		0.63 (0.20,2.49)	0.63 (0.21,2.37)	-0.01 (-0.04,0.05)
MTX + DMARD		0.74 (0.14,4.06)	0.75 (0.14,3.67)	-0.01 (-0.04,0.09)
SD ETN SC		1.55 (0.50,6.08)	1.52 (0.51,5.18)	0.02 (-0.02,0.14)
SD ADA SC		1.08 (0.66,1.94)	1.08 (0.67,1.88)	0.00 (-0.01,0.03)
SD TOCI IV		1.22 (0.47,3.38)	1.21 (0.48,3.10)	0.01 (-0.02,0.08)
SD TOFA PO		0.38 (0.15,0.93)	0.39 (0.15,0.94)	-0.02 (-0.04,0.00)
SD TOCI SC		1.07 (0.33,3.70)	1.07 (0.34,3.39)	0.00 (-0.03,0.09)
SD CERTO SC		4.67 (1.33,19.91)	4.11 (1.31,12.87)	0.11 (0.01,0.35)
SD GOLI IV		1.46 (0.17,14.63)	1.43 (0.18,9.91)	0.01 (-0.03,0.32)
SD RITUX IV		0.55 (0.07,5.11)	0.56 (0.07,4.50)	-0.01 (-0.04,0.13)
SD INF IV + MTX		1.16 (0.31,5.32)	1.15 (0.32,4.67)	0.01 (-0.03,0.13)
SD ETN SC + MTX		1.28 (0.34,5.50)	1.27 (0.35,4.80)	0.01 (-0.03,0.14)
SD ADA SC + MTX		1.20 (0.34,5.99)	1.19 (0.35,5.12)	0.01 (-0.03,0.14)
SD ABA IV + MTX		1.07 (0.30,4.66)	1.06 (0.30,4.17)	0.00 (-0.03,0.11)
SD RITUX IV + MTX		1.43 (0.37,7.39)	1.40 (0.38,6.09)	0.01 (-0.03,0.17)
SD ABA SC + MTX		0.89 (0.24,4.28)	0.89 (0.25,3.87)	0.00 (-0.03,0.10)
SD GOLI SC + MTX		2.75 (0.52,20.39)	2.58 (0.53,12.10)	0.06 (-0.02,0.39)
SD CERTO SC + MTX		2.02 (0.54,11.76)	1.94 (0.55,8.55)	0.03 (-0.02,0.26)
SD TOFA PO + MTX		2.59 (0.63,14.30)	2.44 (0.64,9.80)	0.05 (-0.01,0.31)
SD GOLI IV + MTX		4.39 (0.59,34.27)	3.89 (0.60,16.03)	0.10 (-0.01,0.53)
SD ANA SC + MTX		1.80 (0.35,12.98)	1.75 (0.36,9.03)	0.03 (-0.02,0.28)
SD ETN SC + DMARD		1.28 (0.44,4.62)	1.26 (0.45,4.11)	0.01 (-0.02,0.10)
SD ABA IV + DMARD		0.67 (0.18,2.94)	0.68 (0.19,2.77)	-0.01 (-0.04,0.06)
SD ADA SC + DMARD		0.45 (0.10,2.35)	0.46 (0.11,2.25)	-0.02 (-0.04,0.04)
SD ANA + DMARD		0.64 (0.17,2.85)	0.65 (0.17,2.67)	-0.01 (-0.04,0.06)
SD CERTO SC + DMARD		0.44 (0.08,2.73)	0.45 (0.08,2.57)	-0.02 (-0.04,0.06)
SD TOCI SC + DMARD		0.81 (0.18,4.36)	0.81 (0.19,3.89)	-0.01 (-0.04,0.10)

(Continued)

LD ADA SC		0.64 (0.30,1.38)	0.65 (0.30,1.36)	-0.01 (-0.03,0.01)
LD ETN SC		0.99 (0.21,5.85)	0.99 (0.22,5.04)	0.00 (-0.04,0.14)
LD GOL I IV		6.90 (1.23,55.27)	5.64 (1.22,19.92)	0.17 (0.01,0.64)
LD RITUX IV + MTX		1.23 (0.31,6.12)	1.22 (0.31,5.22)	0.01 (-0.03,0.15)
LD ABA IV + MTX		1.67 (0.38,8.47)	1.63 (0.39,6.78)	0.02 (-0.02,0.20)
LD CERTO SC + MTX		2.27 (0.26,18.03)	2.16 (0.26,11.59)	0.04 (-0.03,0.36)
LD ETN SC + MTX		0.64 (0.13,3.60)	0.65 (0.13,3.31)	-0.01 (-0.04,0.08)
LD GOL I IV + MTX		3.95 (0.66,32.35)	3.55 (0.67,15.74)	0.09 (-0.01,0.51)
HD TOCI IV		1.24 (0.34,5.83)	1.23 (0.35,5.01)	0.01 (-0.03,0.14)
HD TOFA PO		0.52 (0.23,1.24)	0.53 (0.24,1.23)	-0.02 (-0.04,0.01)
HD GOL I SC		1.78 (0.34,12.98)	1.73 (0.35,9.30)	0.03 (-0.03,0.28)
HD ADA SC		0.96 (0.48,2.09)	0.96 (0.49,2.02)	0.00 (-0.02,0.03)
HD GOL I SC + MTX		3.85 (0.63,25.39)	3.49 (0.64,14.17)	0.09 (-0.01,0.44)
HD TOCI IV + MTX		1.44 (0.34,7.89)	1.42 (0.35,6.47)	0.01 (-0.03,0.19)
HD TOFA PO + MTX		2.11 (0.52,12.09)	2.02 (0.53,8.78)	0.04 (-0.02,0.27)
HD INF IV + MTX		1.37 (0.35,6.87)	1.36 (0.35,5.76)	0.01 (-0.03,0.17)
HD CERTO SC + MTX		2.54 (0.59,16.81)	2.40 (0.60,10.92)	0.05 (-0.02,0.34)
HD TOCI IV + DMARD		0.95 (0.27,3.95)	0.96 (0.28,3.57)	0.00 (-0.03,0.09)
DMARD	MTX	0.46 (0.20,1.02)	0.47 (0.22,1.02)	-0.02 (-0.12,0.00)
MTX + DMARD		0.55 (0.14,1.81)	0.57 (0.15,1.76)	-0.02 (-0.12,0.03)
SD ETN SC		1.14 (0.58,2.31)	1.13 (0.60,2.23)	0.01 (-0.05,0.05)
SD ADA SC		0.82 (0.19,2.78)	0.82 (0.22,2.69)	-0.01 (-0.14,0.03)
SD TOCI IV		0.88 (0.19,4.16)	0.88 (0.21,3.92)	-0.01 (-0.13,0.06)
SD TOFA PO		0.29 (0.05,1.22)	0.30 (0.06,1.22)	-0.03 (-0.17,0.00)
SD TOCI SC		0.77 (0.14,4.64)	0.78 (0.16,4.27)	-0.01 (-0.13,0.08)
SD CERTO SC		3.34 (0.45,28.48)	2.98 (0.49,19.53)	0.09 (-0.07,0.34)
SD GOL I IV		1.04 (0.13,7.94)	1.04 (0.14,6.09)	0.00 (-0.09,0.25)
SD RITUX IV		0.42 (0.07,1.90)	0.44 (0.08,1.80)	-0.02 (-0.11,0.05)



(Continued)

SD INF IV + MTX	0.89 (0.55,1.34)	0.89 (0.57,1.31)	0.00 (-0.04,0.02)
SD ETN SC + MTX	0.97 (0.43,1.95)	0.97 (0.46,1.86)	0.00 (-0.06,0.05)
SD ADA SC + MTX	0.92 (0.48,1.67)	0.92 (0.50,1.61)	0.00 (-0.05,0.04)
SD ABA IV + MTX	0.80 (0.51,1.20)	0.81 (0.53,1.19)	-0.01 (-0.05,0.01)
SD RITUX IV + MTX	1.05 (0.65,1.79)	1.05 (0.66,1.70)	0.00 (-0.03,0.05)
SD ABA SC + MTX	0.68 (0.36,1.20)	0.69 (0.37,1.18)	-0.01 (-0.07,0.01)
SD GOLI SC + MTX	1.99 (0.68,6.54)	1.87 (0.69,5.14)	0.04 (-0.02,0.28)
SD CERTO SC + MTX	1.55 (0.91,2.73)	1.50 (0.91,2.47)	0.02 (0.00,0.13)
SD TOFA PO + MTX	1.93 (0.88,4.43)	1.83 (0.89,3.79)	0.04 (-0.01,0.20)
SD GOLI IV + MTX	3.06 (0.54,19.59)	2.68 (0.55,12.28)	0.08 (-0.03,0.45)
SD ANA SC + MTX	1.32 (0.45,4.19)	1.30 (0.46,3.53)	0.01 (-0.04,0.18)
SD ETN SC + DMARD	0.93 (0.39,2.13)	0.94 (0.42,2.07)	0.00 (-0.08,0.04)
SD ABA IV + DMARD	0.49 (0.18,1.33)	0.51 (0.19,1.31)	-0.02 (-0.12,0.01)
SD ADA SC + DMARD	0.33 (0.09,1.06)	0.34 (0.10,1.06)	-0.03 (-0.13,0.00)
SD ANA + DMARD	0.47 (0.15,1.31)	0.48 (0.16,1.29)	-0.02 (-0.12,0.01)
SD CERTO SC + DMARD	0.32 (0.06,1.43)	0.33 (0.07,1.40)	-0.03 (-0.14,0.02)
SD TOCI SC + DMARD	0.61 (0.16,2.08)	0.62 (0.17,1.99)	-0.02 (-0.11,0.05)
LD ADA SC	0.46 (0.09,2.07)	0.48 (0.11,2.04)	-0.02 (-0.16,0.02)
LD ETN SC	0.75 (0.28,2.04)	0.76 (0.30,1.93)	-0.01 (-0.08,0.05)
LD GOLI IV	5.07 (0.99,30.48)	3.97 (0.99,15.67)	0.15 (0.00,0.57)
LD RITUX IV + MTX	0.90 (0.55,1.57)	0.91 (0.56,1.52)	0.00 (-0.04,0.04)
LD ABA IV + MTX	1.23 (0.56,2.58)	1.21 (0.58,2.38)	0.01 (-0.03,0.10)
LD CERTO SC + MTX	1.57 (0.36,6.28)	1.51 (0.37,4.91)	0.02 (-0.05,0.27)
LD ETN SC + MTX	0.48 (0.16,1.34)	0.49 (0.17,1.31)	-0.02 (-0.10,0.01)
LD GOLI IV + MTX	2.88 (0.52,16.55)	2.56 (0.54,11.00)	0.07 (-0.03,0.43)
HD TOCI IV	0.91 (0.44,1.90)	0.91 (0.46,1.82)	0.00 (-0.06,0.05)
HD TOFA PO	0.39 (0.07,1.82)	0.41 (0.08,1.80)	-0.03 (-0.17,0.01)
HD GOLI SC	1.30 (0.36,4.60)	1.28 (0.37,3.89)	0.01 (-0.05,0.19)

(Continued)

HD ADA SC		0.73 (0.16,2.78)	0.74 (0.18,2.69)	-0.01 (-0.14,0.03)
HD GOLI SC + MTX		2.77 (0.98,8.62)	2.48 (0.99,6.04)	0.07 (0.00,0.34)
HD TOCI IV + MTX		1.04 (0.41,2.80)	1.04 (0.43,2.56)	0.00 (-0.05,0.10)
HD TOFA PO + MTX		1.62 (0.71,3.71)	1.56 (0.73,3.23)	0.02 (-0.02,0.16)
HD INF IV + MTX		1.03 (0.59,1.77)	1.03 (0.60,1.68)	0.00 (-0.03,0.05)
HD CERTO SC + MTX		1.90 (0.89,4.37)	1.80 (0.90,3.55)	0.04 (0.00,0.22)
HD TOCI IV + DMARD		0.69 (0.26,1.84)	0.71 (0.28,1.79)	-0.01 (-0.10,0.03)
MTX + DMARD	DMARD	1.23 (0.26,4.52)	1.23 (0.27,4.20)	0.00 (-0.03,0.08)
SD ETN SC		2.47 (1.21,5.34)	2.38 (1.20,4.94)	0.03 (0.01,0.11)
SD ADA SC		1.75 (0.48,5.24)	1.72 (0.50,5.03)	0.02 (-0.04,0.05)
SD TOCI IV		1.88 (0.43,7.81)	1.83 (0.45,7.34)	0.02 (-0.04,0.09)
SD TOFA PO		0.61 (0.11,2.37)	0.62 (0.12,2.34)	-0.01 (-0.07,0.01)
SD TOCI SC		1.67 (0.34,8.83)	1.64 (0.35,8.08)	0.01 (-0.04,0.10)
SD CERTO SC		7.36 (1.10,47.68)	6.36 (1.09,33.14)	0.12 (0.00,0.36)
SD GOLI IV		2.34 (0.26,17.59)	2.25 (0.27,13.34)	0.03 (-0.03,0.31)
SD RITUX IV		0.93 (0.13,5.38)	0.93 (0.13,4.80)	0.00 (-0.04,0.12)
SD INF IV + MTX		1.91 (0.78,4.86)	1.87 (0.79,4.43)	0.02 (-0.01,0.11)
SD ETN SC + MTX		2.10 (0.75,5.64)	2.04 (0.76,5.14)	0.02 (-0.01,0.12)
SD ADA SC + MTX		1.97 (0.74,5.38)	1.92 (0.75,4.85)	0.02 (-0.01,0.12)
SD ABA IV + MTX		1.73 (0.72,4.31)	1.69 (0.73,4.00)	0.01 (-0.01,0.09)
SD RITUX IV + MTX		2.27 (0.89,6.25)	2.19 (0.90,5.56)	0.03 (0.00,0.15)
SD ABA SC + MTX		1.47 (0.55,3.88)	1.45 (0.56,3.61)	0.01 (-0.02,0.08)
SD GOLI SC + MTX		4.31 (1.18,18.62)	3.93 (1.17,13.56)	0.07 (0.00,0.37)
SD CERTO SC + MTX		3.40 (1.24,9.31)	3.18 (1.23,7.77)	0.05 (0.00,0.23)
SD TOFA PO + MTX		4.19 (1.43,12.67)	3.83 (1.41,10.16)	0.06 (0.01,0.29)
SD GOLI IV + MTX		6.65 (1.04,48.72)	5.71 (1.04,29.61)	0.11 (0.00,0.52)
SD ANA SC + MTX		2.83 (0.75,12.17)	2.70 (0.76,9.57)	0.04 (-0.01,0.27)
SD ETN SC + DMARD		2.01 (1.07,3.92)	1.95 (1.07,3.73)	0.02 (0.00,0.08)

(Continued)

SD ABA IV + DMARD	1.06 (0.58,1.94)	1.06 (0.59,1.88)	0.00 (-0.02,0.03)	
SD ADA SC + DMARD	0.70 (0.30,1.67)	0.70 (0.31,1.64)	-0.01 (-0.03,0.02)	
SD ANA + DMARD	1.00 (0.50,2.08)	1.00 (0.50,2.00)	0.00 (-0.02,0.03)	
SD CERTO SC + DMARD	0.69 (0.18,2.56)	0.69 (0.18,2.44)	-0.01 (-0.04,0.04)	
SD TOCI SC + DMARD	1.28 (0.48,3.49)	1.27 (0.49,3.26)	0.01 (-0.02,0.08)	
LD ADA SC	1.00 (0.22,3.79)	1.00 (0.24,3.68)	0.00 (-0.06,0.03)	
LD ETN SC	1.61 (0.52,5.00)	1.58 (0.53,4.49)	0.01 (-0.02,0.12)	
LD GOL I IV	10.93 (1.79,72.89)	8.52 (1.74,36.66)	0.18 (0.02,0.63)	
LD RITUX IV + MTX	1.93 (0.77,5.40)	1.88 (0.77,4.86)	0.02 (-0.01,0.12)	
LD ABA IV + MTX	2.66 (0.90,8.38)	2.54 (0.90,7.24)	0.03 (0.00,0.18)	
LD CERTO SC + MTX	3.33 (0.61,18.14)	3.11 (0.61,12.90)	0.05 (-0.01,0.34)	
LD ETN SC + MTX	1.05 (0.27,3.72)	1.05 (0.28,3.53)	0.00 (-0.03,0.07)	
LD GOL I IV + MTX	6.26 (0.97,42.72)	5.46 (0.97,25.22)	0.10 (0.00,0.50)	
HD TOCI IV	1.95 (1.00,4.21)	1.90 (1.00,3.89)	0.02 (0.00,0.11)	
HD TOFA PO	0.83 (0.18,3.68)	0.83 (0.19,3.60)	0.00 (-0.06,0.02)	
HD GOL I SC	2.76 (0.71,12.48)	2.62 (0.72,9.84)	0.04 (-0.01,0.26)	
HD ADA SC	1.56 (0.38,5.47)	1.54 (0.40,5.21)	0.01 (-0.04,0.05)	
HD GOL I SC + MTX	6.03 (1.61,24.27)	5.27 (1.58,16.49)	0.10 (0.01,0.42)	
HD TOCI IV + MTX	2.25 (0.85,6.67)	2.18 (0.85,5.70)	0.03 (0.00,0.16)	
HD TOFA PO + MTX	3.49 (1.15,10.74)	3.26 (1.14,8.78)	0.05 (0.00,0.25)	
HD INF IV + MTX	2.21 (0.84,6.17)	2.14 (0.84,5.57)	0.02 (0.00,0.14)	
HD CERTO SC + MTX	4.14 (1.31,13.83)	3.79 (1.30,10.42)	0.06 (0.01,0.32)	
HD TOCI IV + DMARD	1.51 (0.87,2.64)	1.49 (0.88,2.52)	0.01 (0.00,0.06)	
SD ETN SC	MTX + DMARD	2.07 (0.61,8.51)	1.99 (0.63,7.91)	0.02 (-0.03,0.11)
SD ADA SC		1.45 (0.29,7.77)	1.44 (0.32,7.46)	0.01 (-0.09,0.05)
SD TOCI IV		1.62 (0.28,9.88)	1.59 (0.30,9.28)	0.01 (-0.08,0.08)
SD TOFA PO		0.51 (0.07,3.22)	0.52 (0.08,3.17)	-0.01 (-0.12,0.02)
SD TOCI SC		1.41 (0.22,10.26)	1.39 (0.23,9.55)	0.01 (-0.09,0.09)

(Continued)

SD CERTO SC	6.03 (0.71,62.12)	5.22 (0.74,44.98)	0.11 (-0.03,0.35)
SD GOLI IV	1.88 (0.17,22.71)	1.82 (0.18,17.86)	0.02 (-0.06,0.30)
SD RITUX IV	0.77 (0.09,5.73)	0.78 (0.10,5.25)	0.00 (-0.08,0.11)
SD INF IV + MTX	1.59 (0.48,6.58)	1.56 (0.50,6.12)	0.01 (-0.04,0.10)
SD ETN SC + MTX	1.72 (0.66,5.48)	1.68 (0.67,5.18)	0.02 (-0.02,0.09)
SD ADA SC + MTX	1.64 (0.46,7.91)	1.61 (0.48,7.20)	0.01 (-0.04,0.12)
SD ABA IV + MTX	1.44 (0.41,6.00)	1.41 (0.42,5.69)	0.01 (-0.05,0.09)
SD RITUX IV + MTX	1.89 (0.55,8.74)	1.83 (0.57,8.00)	0.02 (-0.03,0.14)
SD ABA SC + MTX	1.21 (0.32,5.57)	1.20 (0.34,5.24)	0.00 (-0.06,0.08)
SD GOLI SC + MTX	3.67 (0.71,22.21)	3.33 (0.73,17.24)	0.06 (-0.01,0.35)
SD CERTO SC + MTX	2.81 (0.73,13.04)	2.64 (0.76,11.29)	0.04 (-0.01,0.23)
SD TOFA PO + MTX	3.53 (0.79,17.73)	3.23 (0.80,14.86)	0.06 (-0.01,0.28)
SD GOLI IV + MTX	5.66 (0.71,56.08)	4.81 (0.73,34.07)	0.10 (-0.02,0.51)
SD ANA SC + MTX	2.41 (0.48,13.72)	2.29 (0.50,11.11)	0.03 (-0.03,0.24)
SD ETN SC + DMARD	1.65 (0.44,7.67)	1.62 (0.46,7.31)	0.01 (-0.05,0.08)
SD ABA IV + DMARD	0.87 (0.20,4.57)	0.87 (0.21,4.41)	0.00 (-0.08,0.05)
SD ADA SC + DMARD	0.59 (0.11,3.41)	0.60 (0.12,3.35)	-0.01 (-0.10,0.03)
SD ANA + DMARD	0.82 (0.19,4.49)	0.83 (0.20,4.36)	0.00 (-0.08,0.05)
SD CERTO SC + DMARD	0.59 (0.08,4.47)	0.60 (0.09,4.23)	-0.01 (-0.10,0.05)
SD TOCI SC + DMARD	1.08 (0.20,6.42)	1.08 (0.21,5.99)	0.00 (-0.08,0.08)
LD ADA SC	0.85 (0.14,5.65)	0.85 (0.16,5.47)	0.00 (-0.10,0.03)
LD ETN SC	1.39 (0.28,6.71)	1.36 (0.30,6.18)	0.01 (-0.06,0.11)
LD GOLI IV	8.93 (1.27,83.42)	6.96 (1.25,44.05)	0.17 (0.01,0.62)
LD RITUX IV + MTX	1.63 (0.44,7.33)	1.59 (0.46,6.82)	0.01 (-0.04,0.12)
LD ABA IV + MTX	2.25 (0.55,10.90)	2.16 (0.57,9.69)	0.03 (-0.03,0.17)
LD CERTO SC + MTX	2.90 (0.38,20.52)	2.72 (0.39,15.39)	0.04 (-0.03,0.34)
LD ETN SC + MTX	0.86 (0.20,4.02)	0.87 (0.21,3.83)	0.00 (-0.07,0.06)
LD GOLI IV + MTX	5.16 (0.64,51.52)	4.50 (0.66,31.65)	0.09 (-0.02,0.49)

(Continued)

HD TOCI IV		1.62 (0.43,7.95)	1.59 (0.45,7.35)	0.01 (-0.05,0.11)
HD TOFA PO		0.71 (0.11,4.62)	0.72 (0.12,4.56)	-0.01 (-0.11,0.03)
HD GOLI SC		2.32 (0.42,14.31)	2.22 (0.44,11.65)	0.03 (-0.04,0.25)
HD ADA SC		1.27 (0.23,7.35)	1.26 (0.25,7.04)	0.01 (-0.09,0.05)
HD GOLI SC + MTX		5.02 (1.02,28.62)	4.36 (1.02,20.17)	0.09 (0.00,0.40)
HD TOCI IV + MTX		1.89 (0.46,10.81)	1.83 (0.48,9.52)	0.02 (-0.04,0.16)
HD TOFA PO + MTX		2.94 (0.63,15.21)	2.76 (0.65,12.87)	0.04 (-0.02,0.24)
HD INF IV + MTX		1.84 (0.52,8.32)	1.79 (0.54,7.66)	0.02 (-0.03,0.13)
HD CERTO SC + MTX		3.39 (0.85,17.96)	3.11 (0.86,14.44)	0.05 (-0.01,0.31)
HD TOCI IV + DMARD		1.26 (0.29,6.68)	1.25 (0.31,6.34)	0.01 (-0.07,0.07)
SD ADA SC	SD ETN SC	0.70 (0.20,2.02)	0.71 (0.24,1.98)	-0.02 (-0.13,0.02)
SD TOCI IV		0.77 (0.19,2.97)	0.78 (0.21,2.82)	-0.01 (-0.12,0.06)
SD TOFA PO		0.25 (0.05,0.90)	0.26 (0.06,0.90)	-0.04 (-0.16,0.00)
SD TOCI SC		0.68 (0.14,3.30)	0.69 (0.16,3.04)	-0.02 (-0.13,0.07)
SD CERTO SC		3.00 (0.44,17.80)	2.69 (0.49,12.42)	0.09 (-0.07,0.33)
SD GOLI IV		0.95 (0.11,6.84)	0.96 (0.12,5.27)	0.00 (-0.09,0.25)
SD RITUX IV		0.37 (0.05,2.05)	0.39 (0.06,1.91)	-0.03 (-0.11,0.06)
SD INF IV + MTX		0.77 (0.34,1.74)	0.78 (0.35,1.66)	-0.01 (-0.07,0.04)
SD ETN SC + MTX		0.84 (0.35,1.88)	0.85 (0.37,1.77)	-0.01 (-0.06,0.05)
SD ADA SC + MTX		0.79 (0.33,1.98)	0.80 (0.35,1.86)	-0.01 (-0.06,0.06)
SD ABA IV + MTX		0.69 (0.32,1.55)	0.70 (0.33,1.50)	-0.01 (-0.07,0.03)
SD RITUX IV + MTX		0.92 (0.39,2.26)	0.93 (0.40,2.09)	0.00 (-0.05,0.08)
SD ABA SC + MTX		0.58 (0.25,1.43)	0.60 (0.26,1.40)	-0.02 (-0.08,0.02)
SD GOLI SC + MTX		1.73 (0.50,6.33)	1.64 (0.51,4.73)	0.03 (-0.03,0.29)
SD CERTO SC + MTX		1.36 (0.57,3.20)	1.33 (0.58,2.78)	0.02 (-0.03,0.15)
SD TOFA PO + MTX		1.66 (0.63,4.87)	1.59 (0.64,4.06)	0.03 (-0.03,0.22)
SD GOLI IV + MTX		2.73 (0.45,18.38)	2.42 (0.46,10.85)	0.08 (-0.04,0.46)
SD ANA SC + MTX		1.15 (0.32,4.39)	1.14 (0.34,3.61)	0.01 (-0.06,0.20)

(Continued)

SD ETN SC + DMARD	0.80 (0.41,1.58)	0.81 (0.43,1.54)	-0.01 (-0.07,0.03)	
SD ABA IV + DMARD	0.43 (0.16,1.06)	0.44 (0.18,1.06)	-0.03 (-0.11,0.00)	
SD ADA SC + DMARD	0.28 (0.09,0.87)	0.30 (0.09,0.88)	-0.04 (-0.13,0.00)	
SD ANA + DMARD	0.41 (0.14,1.06)	0.42 (0.15,1.06)	-0.03 (-0.12,0.00)	
SD CERTO SC + DMARD	0.28 (0.06,1.17)	0.30 (0.06,1.15)	-0.03 (-0.13,0.01)	
SD TOCI SC + DMARD	0.51 (0.15,1.80)	0.53 (0.16,1.71)	-0.02 (-0.11,0.04)	
LD ADA SC	0.41 (0.10,1.42)	0.42 (0.11,1.41)	-0.03 (-0.15,0.01)	
LD ETN SC	0.65 (0.24,1.75)	0.67 (0.25,1.66)	-0.02 (-0.07,0.05)	
LD GOLIV	4.37 (0.83,26.03)	3.51 (0.84,13.41)	0.14 (-0.01,0.56)	
LD RITUX IV + MTX	0.79 (0.32,1.93)	0.80 (0.34,1.82)	-0.01 (-0.06,0.06)	
LD ABA IV + MTX	1.07 (0.38,2.98)	1.06 (0.40,2.63)	0.00 (-0.05,0.12)	
LD CERTO SC + MTX	1.36 (0.26,6.57)	1.33 (0.27,4.86)	0.02 (-0.06,0.27)	
LD ETN SC + MTX	0.42 (0.12,1.33)	0.44 (0.13,1.30)	-0.03 (-0.10,0.02)	
LD GOLIV + MTX	2.56 (0.41,15.02)	2.32 (0.43,9.33)	0.07 (-0.04,0.44)	
HD TOCI IV	0.79 (0.34,1.92)	0.80 (0.35,1.82)	-0.01 (-0.07,0.05)	
HD TOFA PO	0.33 (0.07,1.28)	0.35 (0.09,1.27)	-0.03 (-0.16,0.01)	
HD GOLIV SC	1.13 (0.28,4.72)	1.12 (0.30,3.82)	0.01 (-0.06,0.19)	
HD ADA SC	0.61 (0.16,2.11)	0.63 (0.18,2.06)	-0.02 (-0.14,0.03)	
HD GOLIV SC + MTX	2.49 (0.69,8.84)	2.26 (0.70,6.11)	0.06 (-0.02,0.35)	
HD TOCI IV + MTX	0.91 (0.31,2.82)	0.92 (0.33,2.53)	0.00 (-0.06,0.11)	
HD TOFA PO + MTX	1.36 (0.50,4.12)	1.33 (0.52,3.53)	0.02 (-0.04,0.18)	
HD INF IV + MTX	0.89 (0.36,2.23)	0.89 (0.37,2.07)	-0.01 (-0.06,0.08)	
HD CERTO SC + MTX	1.65 (0.59,4.87)	1.58 (0.60,3.85)	0.03 (-0.02,0.24)	
HD TOCI IV + DMARD	0.62 (0.24,1.47)	0.63 (0.25,1.43)	-0.02 (-0.09,0.02)	
SD TOCI IV	SD ADA SC	1.11 (0.50,2.57)	1.11 (0.51,2.40)	0.00 (-0.02,0.06)
SD TOFA PO		0.35 (0.12,0.97)	0.36 (0.12,0.97)	-0.02 (-0.06,0.00)
SD TOCI SC		0.98 (0.34,2.96)	0.98 (0.35,2.75)	0.00 (-0.03,0.07)
SD CERTO SC		4.27 (1.05,18.66)	3.78 (1.05,12.53)	0.11 (0.00,0.34)

(Continued)

SD GOLII IV	1.32 (0.15,13.23)	1.30 (0.16,9.17)	0.01 (-0.04,0.31)
SD RITUX IV	0.51 (0.06,4.56)	0.52 (0.07,4.00)	-0.02 (-0.05,0.12)
SD INF IV + MTX	1.09 (0.29,4.61)	1.08 (0.30,4.07)	0.00 (-0.03,0.12)
SD ETN SC + MTX	1.18 (0.32,4.97)	1.17 (0.33,4.34)	0.01 (-0.03,0.13)
SD ADA SC + MTX	1.12 (0.31,5.13)	1.12 (0.32,4.44)	0.00 (-0.04,0.14)
SD ABA IV + MTX	0.98 (0.27,3.98)	0.98 (0.28,3.60)	0.00 (-0.04,0.10)
SD RITUX IV + MTX	1.33 (0.34,6.06)	1.31 (0.35,5.04)	0.01 (-0.03,0.16)
SD ABA SC + MTX	0.83 (0.22,3.65)	0.84 (0.23,3.33)	-0.01 (-0.04,0.09)
SD GOLII SC + MTX	2.57 (0.47,17.20)	2.42 (0.48,10.44)	0.05 (-0.02,0.38)
SD CERTO SC + MTX	1.89 (0.50,9.64)	1.82 (0.51,7.22)	0.03 (-0.02,0.25)
SD TOFA PO + MTX	2.38 (0.62,11.91)	2.25 (0.64,8.45)	0.05 (-0.02,0.30)
SD GOLII IV + MTX	4.04 (0.52,33.18)	3.59 (0.54,15.66)	0.10 (-0.02,0.53)
SD ANA SC + MTX	1.65 (0.33,10.63)	1.61 (0.34,7.73)	0.02 (-0.03,0.27)
SD ETN SC + DMARD	1.17 (0.41,3.76)	1.16 (0.42,3.42)	0.01 (-0.03,0.10)
SD ABA IV + DMARD	0.61 (0.17,2.53)	0.62 (0.18,2.40)	-0.01 (-0.05,0.05)
SD ADA SC + DMARD	0.41 (0.10,2.04)	0.42 (0.10,1.96)	-0.02 (-0.05,0.04)
SD ANA + DMARD	0.59 (0.15,2.47)	0.60 (0.16,2.33)	-0.01 (-0.05,0.05)
SD CERTO SC + DMARD	0.40 (0.07,2.51)	0.41 (0.07,2.36)	-0.02 (-0.05,0.05)
SD TOCI SC + DMARD	0.73 (0.17,3.86)	0.74 (0.18,3.45)	-0.01 (-0.04,0.10)
LD ADA SC	0.59 (0.26,1.29)	0.60 (0.27,1.28)	-0.01 (-0.04,0.01)
LD ETN SC	0.93 (0.20,4.96)	0.93 (0.20,4.30)	0.00 (-0.04,0.13)
LD GOLII IV	6.29 (1.07,49.60)	5.15 (1.07,18.65)	0.16 (0.00,0.64)
LD RITUX IV + MTX	1.14 (0.28,5.13)	1.14 (0.29,4.36)	0.01 (-0.03,0.14)
LD ABA IV + MTX	1.54 (0.36,7.36)	1.51 (0.37,6.00)	0.02 (-0.03,0.19)
LD CERTO SC + MTX	2.06 (0.25,15.74)	1.97 (0.25,10.23)	0.04 (-0.04,0.35)
LD ETN SC + MTX	0.59 (0.12,3.21)	0.60 (0.12,2.95)	-0.01 (-0.05,0.08)
LD GOLII IV + MTX	3.65 (0.56,29.09)	3.29 (0.57,14.53)	0.09 (-0.02,0.50)
HD TOCI IV	1.13 (0.31,4.81)	1.13 (0.32,4.20)	0.00 (-0.03,0.13)

(Continued)

HD TOFA PO		0.48 (0.18,1.33)	0.49 (0.18,1.32)	-0.02 (-0.05,0.01)
HD GOLI SC		1.68 (0.32,10.68)	1.63 (0.33,7.71)	0.02 (-0.03,0.27)
HD ADA SC		0.89 (0.45,1.82)	0.90 (0.46,1.77)	0.00 (-0.03,0.03)
HD GOLI SC + MTX		3.54 (0.62,20.74)	3.20 (0.64,11.83)	0.08 (-0.01,0.43)
HD TOCI IV + MTX		1.30 (0.31,6.77)	1.28 (0.32,5.57)	0.01 (-0.03,0.18)
HD TOFA PO + MTX		1.98 (0.50,10.20)	1.90 (0.51,7.58)	0.03 (-0.02,0.26)
HD INF IV + MTX		1.27 (0.33,5.82)	1.26 (0.34,4.91)	0.01 (-0.03,0.16)
HD CERTO SC + MTX		2.34 (0.56,13.33)	2.22 (0.57,9.02)	0.05 (-0.02,0.33)
HD TOCI IV + DMARD		0.87 (0.25,3.30)	0.88 (0.26,3.04)	0.00 (-0.04,0.08)
SD TOFA PO	SD TOCI IV	0.31 (0.08,1.15)	0.32 (0.08,1.15)	-0.03 (-0.10,0.00)
SD TOCI SC		0.88 (0.44,1.81)	0.89 (0.45,1.73)	0.00 (-0.04,0.04)
SD CERTO SC		3.92 (0.73,21.61)	3.45 (0.75,15.00)	0.10 (-0.02,0.34)
SD GOLI IV		1.16 (0.11,13.04)	1.15 (0.12,9.53)	0.01 (-0.08,0.30)
SD RITUX IV		0.45 (0.05,4.54)	0.46 (0.06,4.04)	-0.02 (-0.09,0.11)
SD INF IV + MTX		1.01 (0.21,4.72)	1.01 (0.22,4.24)	0.00 (-0.07,0.11)
SD ETN SC + MTX		1.07 (0.24,5.27)	1.06 (0.25,4.66)	0.00 (-0.07,0.12)
SD ADA SC + MTX		1.05 (0.22,5.40)	1.05 (0.23,4.74)	0.00 (-0.07,0.13)
SD ABA IV + MTX		0.92 (0.19,4.16)	0.93 (0.20,3.80)	0.00 (-0.07,0.09)
SD RITUX IV + MTX		1.21 (0.24,6.23)	1.19 (0.26,5.32)	0.01 (-0.06,0.15)
SD ABA SC + MTX		0.78 (0.15,3.75)	0.79 (0.16,3.46)	-0.01 (-0.08,0.08)
SD GOLI SC + MTX		2.31 (0.36,17.01)	2.18 (0.38,11.04)	0.05 (-0.05,0.37)
SD CERTO SC + MTX		1.72 (0.34,9.55)	1.67 (0.36,7.47)	0.03 (-0.05,0.24)
SD TOFA PO + MTX		2.21 (0.45,11.93)	2.09 (0.47,8.99)	0.04 (-0.04,0.29)
SD GOLI IV + MTX		3.63 (0.36,32.71)	3.20 (0.38,17.27)	0.09 (-0.05,0.52)
SD ANA SC + MTX		1.50 (0.25,10.21)	1.46 (0.26,7.55)	0.02 (-0.06,0.27)
SD ETN SC + DMARD		1.05 (0.28,4.15)	1.05 (0.30,3.82)	0.00 (-0.06,0.09)
SD ABA IV + DMARD		0.56 (0.12,2.74)	0.57 (0.13,2.62)	-0.02 (-0.09,0.05)
SD ADA SC + DMARD		0.38 (0.07,2.10)	0.39 (0.08,2.01)	-0.02 (-0.09,0.03)



(Continued)

SD ANA + DMARD		0.53 (0.11,2.65)	0.54 (0.12,2.53)	-0.02 (-0.09,0.05)
SD CERTO SC + DMARD		0.36 (0.05,2.78)	0.37 (0.06,2.65)	-0.02 (-0.09,0.05)
SD TOCI SC + DMARD		0.66 (0.12,4.24)	0.67 (0.13,3.84)	-0.01 (-0.08,0.09)
LD ADA SC		0.53 (0.16,1.61)	0.55 (0.18,1.59)	-0.02 (-0.09,0.01)
LD ETN SC		0.84 (0.15,5.15)	0.84 (0.16,4.48)	-0.01 (-0.08,0.12)
LD GOLIV		5.66 (0.78,51.04)	4.61 (0.79,21.30)	0.16 (-0.01,0.63)
LD RITUX IV + MTX		1.04 (0.20,5.24)	1.04 (0.21,4.63)	0.00 (-0.07,0.13)
LD ABA IV + MTX		1.42 (0.25,7.65)	1.39 (0.27,6.38)	0.02 (-0.06,0.18)
LD CERTO SC + MTX		1.84 (0.19,15.72)	1.76 (0.20,10.42)	0.03 (-0.06,0.34)
LD ETN SC + MTX		0.55 (0.08,3.39)	0.56 (0.09,3.15)	-0.02 (-0.09,0.07)
LD GOLIV + MTX		3.26 (0.40,30.45)	2.92 (0.42,16.40)	0.08 (-0.04,0.50)
HD TOCI IV		1.04 (0.22,5.24)	1.03 (0.24,4.64)	0.00 (-0.07,0.12)
HD TOFA PO		0.43 (0.12,1.55)	0.44 (0.13,1.53)	-0.02 (-0.10,0.01)
HD GOLIV SC		1.49 (0.21,10.95)	1.46 (0.22,8.15)	0.02 (-0.06,0.26)
HD ADA SC		0.80 (0.27,2.38)	0.81 (0.29,2.31)	-0.01 (-0.07,0.03)
HD GOLIV SC + MTX		3.20 (0.46,21.06)	2.89 (0.48,13.02)	0.08 (-0.03,0.42)
HD TOCI IV + MTX		1.18 (0.22,7.12)	1.17 (0.24,5.82)	0.01 (-0.07,0.17)
HD TOFA PO + MTX		1.84 (0.37,10.27)	1.77 (0.39,7.89)	0.03 (-0.05,0.26)
HD INF IV + MTX		1.19 (0.23,5.88)	1.18 (0.24,5.10)	0.01 (-0.06,0.15)
HD CERTO SC + MTX		2.09 (0.37,13.28)	1.99 (0.39,9.35)	0.04 (-0.05,0.32)
HD TOCI IV + DMARD		0.80 (0.17,3.74)	0.81 (0.18,3.44)	-0.01 (-0.08,0.08)
SD TOCI SC	SD TOFA PO	2.84 (0.63,13.82)	2.76 (0.64,12.44)	0.02 (-0.01,0.11)
SD CERTO SC		12.27 (2.90,70.20)	10.49 (2.78,46.77)	0.13 (0.03,0.37)
SD GOLIV		3.97 (0.39,46.38)	3.80 (0.40,31.97)	0.04 (-0.01,0.34)
SD RITUX IV		1.45 (0.16,15.81)	1.44 (0.16,13.70)	0.01 (-0.02,0.15)
SD INF IV + MTX		3.08 (0.68,19.11)	2.98 (0.68,16.68)	0.03 (-0.01,0.15)
SD ETN SC + MTX		3.40 (0.73,20.80)	3.29 (0.73,18.03)	0.03 (-0.01,0.16)
SD ADA SC + MTX		3.16 (0.73,20.78)	3.06 (0.74,17.66)	0.03 (-0.01,0.17)

(Continued)

SD ABA IV + MTX	2.77 (0.64,16.88)	2.69 (0.65,14.98)	0.02 (-0.01,0.13)
SD RITUX IV + MTX	3.78 (0.83,24.29)	3.63 (0.83,20.20)	0.04 (0.00,0.20)
SD ABA SC + MTX	2.36 (0.54,14.79)	2.31 (0.55,13.28)	0.02 (-0.01,0.12)
SD GOL I SC + MTX	7.05 (1.17,68.25)	6.49 (1.16,41.07)	0.08 (0.00,0.41)
SD CERTO SC + MTX	5.42 (1.18,37.02)	5.09 (1.17,27.85)	0.06 (0.00,0.28)
SD TOFA PO + MTX	6.80 (1.55,46.08)	6.25 (1.53,32.52)	0.07 (0.01,0.33)
SD GOL I IV + MTX	11.17 (1.38,111.20)	9.61 (1.37,56.64)	0.13 (0.01,0.55)
SD ANA SC + MTX	4.71 (0.79,41.17)	4.45 (0.79,29.17)	0.05 (0.00,0.31)
SD ETN SC + DMARD	3.33 (0.93,16.14)	3.21 (0.94,14.62)	0.03 (0.00,0.13)
SD ABA IV + DMARD	1.70 (0.40,10.47)	1.68 (0.40,9.72)	0.01 (-0.01,0.08)
SD ADA SC + DMARD	1.18 (0.24,7.51)	1.17 (0.24,7.06)	0.00 (-0.02,0.06)
SD ANA + DMARD	1.64 (0.35,9.45)	1.62 (0.36,8.73)	0.01 (-0.02,0.08)
SD CERTO SC + DMARD	1.11 (0.18,9.34)	1.11 (0.19,8.48)	0.00 (-0.02,0.08)
SD TOCI SC + DMARD	2.10 (0.39,13.79)	2.06 (0.40,12.27)	0.01 (-0.01,0.13)
LD ADA SC	1.69 (0.51,6.16)	1.67 (0.52,5.95)	0.01 (-0.01,0.04)
LD ETN SC	2.60 (0.51,19.38)	2.53 (0.52,16.63)	0.02 (-0.01,0.16)
LD GOL I IV	18.17 (2.62,186.60)	14.36 (2.54,74.34)	0.19 (0.02,0.66)
LD RITUX IV + MTX	3.20 (0.70,21.37)	3.10 (0.71,18.13)	0.03 (-0.01,0.17)
LD ABA IV + MTX	4.31 (0.87,29.92)	4.11 (0.88,24.05)	0.04 (0.00,0.22)
LD CERTO SC + MTX	5.77 (0.69,54.24)	5.35 (0.70,35.20)	0.06 (-0.01,0.38)
LD ETN SC + MTX	1.71 (0.28,12.36)	1.69 (0.28,11.15)	0.01 (-0.02,0.11)
LD GOL I IV + MTX	10.45 (1.43,104.60)	9.13 (1.42,55.26)	0.11 (0.01,0.53)
HD TOCI IV	3.24 (0.76,20.29)	3.12 (0.76,17.30)	0.03 (0.00,0.16)
HD TOFA PO	1.38 (0.54,3.62)	1.37 (0.54,3.55)	0.00 (-0.01,0.03)
HD GOL I SC	4.68 (0.74,38.28)	4.40 (0.75,28.30)	0.05 (0.00,0.30)
HD ADA SC	2.56 (0.81,8.50)	2.51 (0.81,8.09)	0.02 (-0.01,0.06)
HD GOL I SC + MTX	9.72 (1.53,81.82)	8.60 (1.52,47.54)	0.11 (0.01,0.46)
HD TOCI IV + MTX	3.74 (0.74,27.08)	3.59 (0.74,22.00)	0.04 (-0.01,0.21)

(Continued)

HD TOFA PO + MTX		5.59 (1.34,40.53)	5.22 (1.33,29.59)	0.06 (0.01,0.30)
HD INF IV + MTX		3.67 (0.80,23.77)	3.53 (0.80,19.77)	0.03 (0.00,0.19)
HD CERTO SC + MTX		6.58 (1.28,50.90)	6.04 (1.27,34.89)	0.07 (0.01,0.36)
HD TOCI IV + DMARD		2.51 (0.55,13.87)	2.45 (0.55,12.66)	0.02 (-0.01,0.11)
SD CERTO SC	SD TOCI SC	4.45 (0.71,28.16)	3.90 (0.73,19.68)	0.11 (-0.03,0.35)
SD GOL I IV		1.30 (0.11,16.36)	1.28 (0.12,11.99)	0.01 (-0.08,0.31)
SD RITUX IV		0.51 (0.05,5.93)	0.53 (0.05,5.21)	-0.01 (-0.10,0.12)
SD INF IV + MTX		1.15 (0.19,6.36)	1.14 (0.20,5.67)	0.00 (-0.08,0.12)
SD ETN SC + MTX		1.23 (0.21,7.03)	1.22 (0.23,6.16)	0.01 (-0.08,0.13)
SD ADA SC + MTX		1.20 (0.20,6.90)	1.19 (0.22,6.10)	0.01 (-0.08,0.14)
SD ABA IV + MTX		1.04 (0.17,5.48)	1.04 (0.18,5.01)	0.00 (-0.08,0.10)
SD RITUX IV + MTX		1.38 (0.21,8.05)	1.35 (0.23,6.98)	0.01 (-0.08,0.16)
SD ABA SC + MTX		0.89 (0.14,4.93)	0.89 (0.15,4.54)	0.00 (-0.09,0.09)
SD GOL I SC + MTX		2.63 (0.34,21.44)	2.46 (0.36,14.39)	0.05 (-0.06,0.38)
SD CERTO SC + MTX		1.96 (0.33,12.48)	1.88 (0.35,9.94)	0.03 (-0.06,0.24)
SD TOFA PO + MTX		2.54 (0.41,15.93)	2.39 (0.43,11.97)	0.05 (-0.05,0.30)
SD GOL I IV + MTX		4.02 (0.36,43.09)	3.52 (0.38,23.51)	0.10 (-0.05,0.52)
SD ANA SC + MTX		1.72 (0.22,13.22)	1.67 (0.24,9.98)	0.02 (-0.07,0.27)
SD ETN SC + DMARD		1.19 (0.25,5.55)	1.18 (0.27,5.08)	0.01 (-0.07,0.10)
SD ABA IV + DMARD		0.64 (0.11,3.62)	0.65 (0.12,3.43)	-0.01 (-0.10,0.06)
SD ADA SC + DMARD		0.43 (0.07,2.68)	0.44 (0.07,2.56)	-0.02 (-0.10,0.04)
SD ANA + DMARD		0.60 (0.10,3.41)	0.61 (0.11,3.21)	-0.01 (-0.10,0.05)
SD CERTO SC + DMARD		0.41 (0.05,3.40)	0.42 (0.06,3.22)	-0.02 (-0.10,0.06)
SD TOCI SC + DMARD		0.76 (0.12,5.40)	0.76 (0.13,4.91)	-0.01 (-0.09,0.10)
LD ADA SC		0.60 (0.15,2.23)	0.61 (0.17,2.19)	-0.01 (-0.10,0.02)
LD ETN SC		0.96 (0.13,6.45)	0.96 (0.15,5.69)	0.00 (-0.09,0.13)
LD GOL I IV		6.55 (0.75,67.05)	5.21 (0.77,28.89)	0.16 (-0.02,0.63)
LD RITUX IV + MTX		1.17 (0.18,6.85)	1.16 (0.20,6.08)	0.01 (-0.08,0.13)

(Continued)

LD ABA IV + MTX		1.63 (0.23,10.03)	1.59 (0.25,8.48)	0.02 (-0.07,0.19)
LD CERTO SC + MTX		2.08 (0.18,19.56)	1.97 (0.20,13.31)	0.04 (-0.07,0.35)
LD ETN SC + MTX		0.61 (0.08,4.40)	0.62 (0.09,4.02)	-0.01 (-0.10,0.08)
LD GOLI IV + MTX		3.63 (0.39,39.12)	3.24 (0.41,21.84)	0.08 (-0.05,0.50)
HD TOCI IV		1.17 (0.21,6.70)	1.17 (0.22,5.87)	0.01 (-0.08,0.13)
HD TOFA PO		0.49 (0.11,2.09)	0.50 (0.12,2.05)	-0.02 (-0.10,0.02)
HD GOLI SC		1.65 (0.20,14.59)	1.60 (0.21,10.90)	0.02 (-0.07,0.27)
HD ADA SC		0.92 (0.25,3.19)	0.92 (0.28,3.07)	0.00 (-0.08,0.04)
HD GOLI SC + MTX		3.62 (0.45,27.61)	3.23 (0.48,17.42)	0.08 (-0.04,0.42)
HD TOCI IV + MTX		1.34 (0.21,9.16)	1.33 (0.23,7.69)	0.01 (-0.08,0.17)
HD TOFA PO + MTX		2.06 (0.34,13.42)	1.98 (0.37,10.48)	0.03 (-0.06,0.26)
HD INF IV + MTX		1.35 (0.21,7.75)	1.33 (0.23,6.77)	0.01 (-0.08,0.16)
HD CERTO SC + MTX		2.41 (0.34,16.62)	2.27 (0.37,12.03)	0.04 (-0.06,0.33)
HD TOCI IV + DMARD		0.91 (0.16,4.82)	0.92 (0.17,4.42)	0.00 (-0.09,0.09)
SD GOLI IV	SD CERTO SC	0.32 (0.02,4.48)	0.36 (0.03,3.45)	-0.08 (-0.34,0.22)
SD RITUX IV		0.12 (0.01,1.83)	0.14 (0.01,1.72)	-0.12 (-0.36,0.06)
SD INF IV + MTX		0.27 (0.03,2.00)	0.31 (0.04,1.84)	-0.10 (-0.34,0.06)
SD ETN SC + MTX		0.28 (0.03,2.10)	0.31 (0.05,1.92)	-0.10 (-0.34,0.07)
SD ADA SC + MTX		0.27 (0.04,2.22)	0.30 (0.05,2.00)	-0.10 (-0.34,0.08)
SD ABA IV + MTX		0.24 (0.03,1.75)	0.28 (0.04,1.66)	-0.10 (-0.35,0.05)
SD RITUX IV + MTX		0.32 (0.03,2.58)	0.36 (0.05,2.28)	-0.09 (-0.34,0.10)
SD ABA SC + MTX		0.20 (0.03,1.53)	0.23 (0.04,1.48)	-0.11 (-0.35,0.03)
SD GOLI SC + MTX		0.59 (0.05,7.42)	0.63 (0.08,4.77)	-0.05 (-0.32,0.33)
SD CERTO SC + MTX		0.45 (0.05,4.23)	0.49 (0.07,3.38)	-0.07 (-0.33,0.19)
SD TOFA PO + MTX		0.57 (0.07,5.23)	0.61 (0.10,3.92)	-0.05 (-0.32,0.24)
SD GOLI IV + MTX		0.91 (0.07,10.37)	0.92 (0.09,5.76)	-0.01 (-0.29,0.43)
SD ANA SC + MTX		0.38 (0.04,4.46)	0.42 (0.06,3.50)	-0.08 (-0.33,0.20)
SD ETN SC + DMARD		0.27 (0.05,1.73)	0.30 (0.07,1.62)	-0.10 (-0.34,0.04)

(Continued)

SD ABA IV + DMARD	0.14 (0.02,1.07)	0.17 (0.03,1.06)	-0.12 (-0.36,0.00)
SD ADA SC + DMARD	0.09 (0.01,0.83)	0.11 (0.02,0.84)	-0.13 (-0.36,-0.01)
SD ANA + DMARD	0.14 (0.02,1.04)	0.16 (0.03,1.03)	-0.12 (-0.36,0.00)
SD CERTO SC + DMARD	0.09 (0.01,0.93)	0.10 (0.01,0.94)	-0.13 (-0.36,0.00)
SD TOCI SC + DMARD	0.17 (0.02,1.47)	0.20 (0.03,1.42)	-0.11 (-0.35,0.03)
LD ADA SC	0.14 (0.03,0.65)	0.16 (0.04,0.67)	-0.12 (-0.36,-0.02)
LD ETN SC	0.21 (0.03,2.01)	0.24 (0.04,1.85)	-0.11 (-0.35,0.07)
LD GOLI IV	1.51 (0.12,17.57)	1.38 (0.17,7.40)	0.05 (-0.26,0.55)
LD RITUX IV + MTX	0.27 (0.03,2.17)	0.30 (0.04,1.99)	-0.10 (-0.34,0.08)
LD ABA IV + MTX	0.36 (0.04,3.05)	0.40 (0.06,2.63)	-0.08 (-0.33,0.13)
LD CERTO SC + MTX	0.46 (0.04,6.19)	0.51 (0.05,4.20)	-0.07 (-0.32,0.28)
LD ETN SC + MTX	0.14 (0.01,1.31)	0.16 (0.02,1.28)	-0.12 (-0.36,0.02)
LD GOLI IV + MTX	0.84 (0.08,9.26)	0.86 (0.10,5.38)	-0.02 (-0.29,0.40)
HD TOCI IV	0.27 (0.03,2.08)	0.30 (0.05,1.92)	-0.10 (-0.34,0.07)
HD TOFA PO	0.11 (0.02,0.51)	0.13 (0.03,0.53)	-0.13 (-0.36,-0.03)
HD GOLI SC	0.38 (0.03,4.22)	0.42 (0.05,3.28)	-0.08 (-0.34,0.20)
HD ADA SC	0.21 (0.05,0.93)	0.24 (0.07,0.94)	-0.11 (-0.35,0.00)
HD GOLI SC + MTX	0.81 (0.06,9.63)	0.83 (0.09,5.72)	-0.02 (-0.31,0.37)
HD TOCI IV + MTX	0.30 (0.04,2.71)	0.34 (0.06,2.39)	-0.09 (-0.34,0.11)
HD TOFA PO + MTX	0.44 (0.06,4.61)	0.49 (0.09,3.62)	-0.07 (-0.32,0.20)
HD INF IV + MTX	0.31 (0.03,2.44)	0.35 (0.04,2.17)	-0.09 (-0.34,0.09)
HD CERTO SC + MTX	0.56 (0.05,5.92)	0.60 (0.08,4.22)	-0.06 (-0.32,0.27)
HD TOCI IV + DMARD	0.20 (0.03,1.43)	0.23 (0.04,1.38)	-0.11 (-0.35,0.03)
SD RITUX IV	SD GOLI IV	0.38 (0.03,5.73)	0.40 (0.03,5.39)
SD INF IV + MTX		0.84 (0.10,6.86)	0.85 (0.13,6.52)
SD ETN SC + MTX		0.91 (0.12,8.29)	0.92 (0.15,7.71)
SD ADA SC + MTX		0.82 (0.11,7.87)	0.83 (0.14,7.37)
SD ABA IV + MTX		0.76 (0.09,6.22)	0.77 (0.12,5.85)

(Continued)

SD RITUX IV + MTX	1.00 (0.13,8.42)	1.00 (0.17,7.81)	0.00 (-0.24,0.11)
SD ABA SC + MTX	0.63 (0.08,5.56)	0.64 (0.10,5.34)	-0.02 (-0.28,0.06)
SD GOLI SC + MTX	1.98 (0.19,22.32)	1.85 (0.23,17.70)	0.03 (-0.20,0.29)
SD CERTO SC + MTX	1.51 (0.18,13.58)	1.46 (0.23,11.67)	0.02 (-0.21,0.18)
SD TOFA PO + MTX	1.81 (0.23,17.33)	1.71 (0.29,14.57)	0.03 (-0.20,0.24)
SD GOLI IV + MTX	2.83 (0.50,21.68)	2.45 (0.54,16.80)	0.07 (-0.08,0.37)
SD ANA SC + MTX	1.25 (0.12,11.97)	1.23 (0.16,10.38)	0.01 (-0.23,0.21)
SD ETN SC + DMARD	0.85 (0.12,7.56)	0.86 (0.16,7.17)	-0.01 (-0.27,0.07)
SD ABA IV + DMARD	0.46 (0.06,4.38)	0.47 (0.07,4.25)	-0.02 (-0.30,0.04)
SD ADA SC + DMARD	0.30 (0.03,3.25)	0.32 (0.04,3.17)	-0.03 (-0.32,0.02)
SD ANA + DMARD	0.43 (0.05,4.27)	0.44 (0.07,4.18)	-0.03 (-0.30,0.04)
SD CERTO SC + DMARD	0.30 (0.03,3.86)	0.32 (0.03,3.67)	-0.03 (-0.32,0.04)
SD TOCI SC + DMARD	0.57 (0.06,5.87)	0.58 (0.08,5.48)	-0.02 (-0.29,0.07)
LD ADA SC	0.48 (0.04,4.31)	0.49 (0.05,4.21)	-0.03 (-0.33,0.03)
LD ETN SC	0.70 (0.08,7.60)	0.71 (0.10,7.20)	-0.01 (-0.27,0.10)
LD GOLI IV	4.58 (1.04,30.01)	3.62 (1.03,21.69)	0.13 (0.00,0.48)
LD RITUX IV + MTX	0.83 (0.11,7.49)	0.84 (0.14,7.01)	-0.01 (-0.25,0.09)
LD ABA IV + MTX	1.14 (0.13,10.94)	1.13 (0.17,9.94)	0.01 (-0.24,0.14)
LD CERTO SC + MTX	1.46 (0.11,22.72)	1.41 (0.13,17.78)	0.02 (-0.24,0.30)
LD ETN SC + MTX	0.46 (0.05,4.79)	0.48 (0.06,4.49)	-0.02 (-0.30,0.05)
LD GOLI IV + MTX	2.69 (0.51,18.96)	2.35 (0.56,14.97)	0.06 (-0.07,0.36)
HD TOCI IV	0.83 (0.11,7.70)	0.84 (0.15,7.24)	-0.01 (-0.26,0.09)
HD TOFA PO	0.36 (0.03,3.75)	0.38 (0.04,3.67)	-0.03 (-0.34,0.02)
HD GOLI SC	1.20 (0.12,15.08)	1.19 (0.15,12.76)	0.01 (-0.23,0.21)
HD ADA SC	0.68 (0.06,6.47)	0.70 (0.09,6.25)	-0.02 (-0.32,0.04)
HD GOLI SC + MTX	2.78 (0.28,30.13)	2.49 (0.34,22.16)	0.06 (-0.16,0.37)
HD TOCI IV + MTX	0.92 (0.12,10.84)	0.93 (0.15,9.73)	0.00 (-0.24,0.14)
HD TOFA PO + MTX	1.46 (0.19,14.57)	1.41 (0.24,12.41)	0.02 (-0.21,0.20)

(Continued)

HD INF IV + MTX		0.97 (0.12,8.78)	0.98 (0.15,8.09)	0.00 (-0.25,0.11)
HD CERTO SC + MTX		1.83 (0.19,18.85)	1.73 (0.24,15.58)	0.03 (-0.20,0.27)
HD TOCI IV + DMARD		0.63 (0.08,6.18)	0.65 (0.11,5.85)	-0.02 (-0.28,0.06)
SD INF IV + MTX	SD RITUX IV	2.12 (0.42,12.74)	2.05 (0.45,11.91)	0.02 (-0.06,0.10)
SD ETN SC + MTX		2.27 (0.41,15.08)	2.20 (0.44,14.09)	0.02 (-0.07,0.12)
SD ADA SC + MTX		2.16 (0.41,13.79)	2.09 (0.43,13.07)	0.02 (-0.07,0.12)
SD ABA IV + MTX		1.88 (0.39,11.60)	1.84 (0.42,11.02)	0.01 (-0.07,0.09)
SD RITUX IV + MTX		2.49 (0.57,15.78)	2.39 (0.60,14.65)	0.02 (-0.04,0.13)
SD ABA SC + MTX		1.59 (0.30,9.80)	1.56 (0.33,9.43)	0.01 (-0.09,0.07)
SD GOLI SC + MTX		4.90 (0.68,36.64)	4.39 (0.70,30.32)	0.06 (-0.02,0.35)
SD CERTO SC + MTX		3.82 (0.70,22.45)	3.53 (0.73,19.95)	0.04 (-0.03,0.22)
SD TOFA PO + MTX		4.55 (0.79,32.27)	4.15 (0.81,27.50)	0.06 (-0.02,0.28)
SD GOLI IV + MTX		7.54 (0.65,97.23)	6.30 (0.67,65.26)	0.11 (-0.02,0.51)
SD ANA SC + MTX		3.15 (0.43,22.82)	2.95 (0.46,20.15)	0.03 (-0.05,0.24)
SD ETN SC + DMARD		2.24 (0.38,16.18)	2.16 (0.42,15.52)	0.02 (-0.08,0.09)
SD ABA IV + DMARD		1.16 (0.18,8.50)	1.15 (0.20,8.21)	0.00 (-0.12,0.05)
SD ADA SC + DMARD		0.76 (0.11,6.61)	0.77 (0.12,6.44)	0.00 (-0.13,0.04)
SD ANA + DMARD		1.10 (0.16,8.53)	1.10 (0.18,8.27)	0.00 (-0.12,0.05)
SD CERTO SC + DMARD		0.75 (0.08,8.38)	0.76 (0.09,8.13)	0.00 (-0.13,0.05)
SD TOCI SC + DMARD		1.44 (0.18,12.21)	1.42 (0.20,11.52)	0.01 (-0.11,0.09)
LD ADA SC		1.13 (0.11,10.42)	1.13 (0.12,10.16)	0.00 (-0.14,0.04)
LD ETN SC		1.80 (0.29,12.98)	1.76 (0.32,12.29)	0.01 (-0.08,0.11)
LD GOLI IV		12.36 (1.19,152.20)	9.52 (1.18,85.34)	0.17 (0.01,0.61)
LD RITUX IV + MTX		2.10 (0.49,12.69)	2.04 (0.52,11.93)	0.02 (-0.05,0.11)
LD ABA IV + MTX		2.90 (0.50,19.26)	2.75 (0.53,17.83)	0.03 (-0.05,0.17)
LD CERTO SC + MTX		3.72 (0.44,32.20)	3.43 (0.46,25.64)	0.04 (-0.05,0.34)
LD ETN SC + MTX		1.14 (0.18,8.36)	1.14 (0.20,8.08)	0.00 (-0.11,0.07)
LD GOLI IV + MTX		7.10 (0.57,85.63)	6.03 (0.60,61.31)	0.10 (-0.03,0.48)

(Continued)

HD TOCI IV		2.13 (0.39,15.30)	2.07 (0.42,14.36)	0.02 (-0.07,0.11)
HD TOFA PO		0.96 (0.09,8.01)	0.96 (0.10,7.79)	0.00 (-0.15,0.03)
HD GOLI SC		3.17 (0.41,27.83)	2.97 (0.43,23.50)	0.03 (-0.06,0.25)
HD ADA SC		1.73 (0.19,16.10)	1.71 (0.22,15.40)	0.01 (-0.12,0.06)
HD GOLI SC + MTX		6.60 (0.99,50.10)	5.68 (0.99,37.38)	0.09 (0.00,0.40)
HD TOCI IV + MTX		2.41 (0.43,20.11)	2.32 (0.46,18.37)	0.02 (-0.06,0.16)
HD TOFA PO + MTX		3.77 (0.62,26.53)	3.52 (0.65,23.64)	0.05 (-0.03,0.24)
HD INF IV + MTX		2.48 (0.48,15.41)	2.39 (0.50,14.33)	0.02 (-0.06,0.13)
HD CERTO SC + MTX		4.61 (0.78,29.98)	4.19 (0.80,25.76)	0.06 (-0.02,0.29)
HD TOCI IV + DMARD		1.63 (0.27,13.23)	1.60 (0.30,12.58)	0.01 (-0.10,0.08)
SD ETN SC + MTX	SD INF IV + MTX	1.09 (0.46,2.51)	1.09 (0.48,2.39)	0.00 (-0.05,0.07)
SD ADA SC + MTX		1.05 (0.49,2.21)	1.04 (0.50,2.10)	0.00 (-0.04,0.06)
SD ABA IV + MTX		0.90 (0.52,1.58)	0.91 (0.54,1.54)	0.00 (-0.05,0.02)
SD RITUX IV + MTX		1.19 (0.64,2.42)	1.18 (0.65,2.27)	0.01 (-0.03,0.07)
SD ABA SC + MTX		0.76 (0.36,1.54)	0.77 (0.38,1.51)	-0.01 (-0.06,0.02)
SD GOLI SC + MTX		2.26 (0.69,7.83)	2.11 (0.70,6.17)	0.05 (-0.01,0.30)
SD CERTO SC + MTX		1.76 (0.88,3.73)	1.69 (0.88,3.31)	0.03 (-0.01,0.15)
SD TOFA PO + MTX		2.18 (0.91,5.69)	2.04 (0.91,4.73)	0.04 (0.00,0.22)
SD GOLI IV + MTX		3.52 (0.58,24.65)	3.04 (0.60,15.51)	0.09 (-0.02,0.47)
SD ANA SC + MTX		1.51 (0.47,4.87)	1.47 (0.49,4.08)	0.02 (-0.04,0.19)
SD ETN SC + DMARD		1.05 (0.41,2.72)	1.05 (0.43,2.62)	0.00 (-0.07,0.05)
SD ABA IV + DMARD		0.56 (0.19,1.65)	0.57 (0.20,1.62)	-0.02 (-0.10,0.02)
SD ADA SC + DMARD		0.37 (0.10,1.33)	0.38 (0.11,1.31)	-0.02 (-0.12,0.01)
SD ANA + DMARD		0.53 (0.16,1.61)	0.54 (0.17,1.58)	-0.02 (-0.11,0.02)
SD CERTO SC + DMARD		0.37 (0.07,1.78)	0.38 (0.07,1.72)	-0.02 (-0.13,0.02)
SD TOCI SC + DMARD		0.69 (0.18,2.53)	0.70 (0.19,2.39)	-0.01 (-0.10,0.05)
LD ADA SC		0.52 (0.10,2.43)	0.54 (0.12,2.38)	-0.02 (-0.14,0.02)
LD ETN SC		0.85 (0.28,2.61)	0.86 (0.30,2.47)	0.00 (-0.07,0.07)



(Continued)

LD GOLIV		5.64 (1.13,36.21)	4.42 (1.11,18.80)	0.15 (0.01,0.58)
LD RITUX IV + MTX		1.02 (0.54,2.09)	1.02 (0.56,1.98)	0.00 (-0.04,0.05)
LD ABA IV + MTX		1.39 (0.60,3.29)	1.36 (0.62,2.99)	0.01 (-0.03,0.12)
LD CERTO SC + MTX		1.75 (0.40,7.77)	1.68 (0.41,5.96)	0.03 (-0.04,0.29)
LD ETN SC + MTX		0.54 (0.17,1.69)	0.56 (0.18,1.66)	-0.02 (-0.09,0.03)
LD GOLIV + MTX		3.27 (0.57,20.03)	2.88 (0.59,12.96)	0.08 (-0.02,0.45)
HD TOCI IV		1.02 (0.44,2.46)	1.02 (0.46,2.33)	0.00 (-0.05,0.06)
HD TOFA PO		0.45 (0.08,2.13)	0.46 (0.09,2.10)	-0.02 (-0.15,0.02)
HD GOLIV SC		1.46 (0.37,5.86)	1.43 (0.39,4.80)	0.02 (-0.05,0.21)
HD ADA SC		0.83 (0.18,3.35)	0.84 (0.21,3.24)	-0.01 (-0.12,0.04)
HD GOLIV SC + MTX		3.15 (1.02,10.20)	2.80 (1.02,7.42)	0.08 (0.00,0.36)
HD TOCI IV + MTX		1.17 (0.43,3.54)	1.16 (0.45,3.20)	0.01 (-0.05,0.11)
HD TOFA PO + MTX		1.84 (0.77,4.74)	1.76 (0.78,4.14)	0.03 (-0.01,0.18)
HD INF IV + MTX		1.16 (0.67,2.08)	1.15 (0.68,1.96)	0.01 (-0.02,0.06)
HD CERTO SC + MTX		2.16 (0.89,5.72)	2.02 (0.89,4.69)	0.04 (0.00,0.25)
HD TOCI IV + DMARD		0.79 (0.27,2.28)	0.80 (0.29,2.19)	-0.01 (-0.09,0.04)
SD ADA SC + MTX	SD ETN SC + MTX	0.94 (0.37,2.65)	0.94 (0.39,2.48)	0.00 (-0.07,0.07)
SD ABA IV + MTX		0.82 (0.35,2.07)	0.83 (0.38,1.98)	-0.01 (-0.08,0.04)
SD RITUX IV + MTX		1.09 (0.46,3.00)	1.09 (0.48,2.73)	0.00 (-0.05,0.09)
SD ABA SC + MTX		0.70 (0.27,1.95)	0.71 (0.29,1.87)	-0.01 (-0.09,0.04)
SD GOLIV SC + MTX		2.06 (0.57,8.59)	1.94 (0.59,6.64)	0.04 (-0.03,0.30)
SD CERTO SC + MTX		1.63 (0.66,4.15)	1.57 (0.68,3.61)	0.02 (-0.02,0.16)
SD TOFA PO + MTX		2.01 (0.73,6.26)	1.90 (0.74,5.24)	0.04 (-0.02,0.22)
SD GOLIV IV + MTX		3.25 (0.48,21.79)	2.85 (0.50,13.68)	0.08 (-0.04,0.47)
SD ANA SC + MTX		1.39 (0.36,5.36)	1.36 (0.38,4.47)	0.01 (-0.05,0.20)
SD ETN SC + DMARD		0.95 (0.37,2.65)	0.96 (0.40,2.55)	0.00 (-0.08,0.05)
SD ABA IV + DMARD		0.50 (0.16,1.65)	0.52 (0.18,1.61)	-0.02 (-0.12,0.02)
SD ADA SC + DMARD		0.34 (0.09,1.28)	0.35 (0.10,1.27)	-0.03 (-0.13,0.01)

(Continued)

SD ANA + DMARD		0.49 (0.14,1.67)	0.50 (0.16,1.64)	-0.02 (-0.12,0.02)
SD CERTO SC + DMARD		0.34 (0.06,1.67)	0.35 (0.06,1.63)	-0.03 (-0.13,0.02)
SD TOCI SC + DMARD		0.62 (0.15,2.46)	0.64 (0.17,2.31)	-0.01 (-0.11,0.05)
LD ADA SC		0.49 (0.09,2.25)	0.50 (0.11,2.21)	-0.02 (-0.15,0.02)
LD ETN SC		0.79 (0.24,2.43)	0.80 (0.25,2.28)	-0.01 (-0.09,0.06)
LD GOLIV IV		5.29 (0.89,34.38)	4.18 (0.90,17.42)	0.15 (-0.01,0.58)
LD RITUX IV + MTX		0.93 (0.40,2.53)	0.93 (0.42,2.34)	0.00 (-0.06,0.07)
LD ABA IV + MTX		1.27 (0.43,3.97)	1.25 (0.46,3.53)	0.01 (-0.06,0.13)
LD CERTO SC + MTX		1.66 (0.31,7.96)	1.59 (0.33,5.90)	0.02 (-0.05,0.28)
LD ETN SC + MTX		0.51 (0.16,1.39)	0.52 (0.16,1.35)	-0.02 (-0.10,0.02)
LD GOLIV IV + MTX		3.13 (0.45,19.11)	2.75 (0.47,12.09)	0.08 (-0.04,0.44)
HD TOCI IV		0.94 (0.36,2.72)	0.95 (0.38,2.56)	0.00 (-0.07,0.07)
HD TOFA PO		0.41 (0.08,1.95)	0.42 (0.09,1.91)	-0.03 (-0.15,0.02)
HD GOLIV SC		1.39 (0.31,5.82)	1.36 (0.33,4.69)	0.01 (-0.07,0.20)
HD ADA SC		0.75 (0.16,2.90)	0.76 (0.18,2.80)	-0.01 (-0.14,0.03)
HD GOLIV SC + MTX		2.89 (0.80,11.15)	2.59 (0.82,7.80)	0.07 (-0.01,0.36)
HD TOCI IV + MTX		1.08 (0.34,3.80)	1.08 (0.36,3.37)	0.00 (-0.06,0.12)
HD TOFA PO + MTX		1.68 (0.57,5.29)	1.61 (0.59,4.55)	0.02 (-0.03,0.19)
HD INF IV + MTX		1.07 (0.45,2.78)	1.06 (0.47,2.57)	0.00 (-0.06,0.08)
HD CERTO SC + MTX		1.95 (0.73,6.04)	1.85 (0.75,4.92)	0.04 (-0.02,0.25)
HD TOCI IV + DMARD		0.73 (0.23,2.33)	0.74 (0.25,2.24)	-0.01 (-0.10,0.04)
SD ABA IV + MTX	SD ADA SC + MTX	0.87 (0.45,1.69)	0.88 (0.47,1.65)	0.00 (-0.06,0.03)
SD RITUX IV + MTX		1.16 (0.53,2.65)	1.15 (0.55,2.51)	0.01 (-0.04,0.07)
SD ABA SC + MTX		0.74 (0.41,1.29)	0.75 (0.43,1.27)	-0.01 (-0.07,0.01)
SD GOLIV SC + MTX		2.20 (0.65,8.78)	2.05 (0.66,6.93)	0.04 (-0.02,0.30)
SD CERTO SC + MTX		1.69 (0.78,4.13)	1.62 (0.79,3.72)	0.03 (-0.01,0.15)
SD TOFA PO + MTX		2.12 (0.93,5.06)	1.98 (0.93,4.34)	0.04 (0.00,0.21)
SD GOLIV IV + MTX		3.45 (0.53,22.58)	3.03 (0.55,14.59)	0.09 (-0.03,0.47)

(Continued)

SD ANA SC + MTX	1.45 (0.39,5.40)	1.41 (0.41,4.60)	0.02 (-0.05,0.19)	
SD ETN SC + DMARD	1.02 (0.37,2.72)	1.02 (0.40,2.62)	0.00 (-0.09,0.05)	
SD ABA IV + DMARD	0.54 (0.17,1.69)	0.55 (0.19,1.66)	-0.02 (-0.12,0.02)	
SD ADA SC + DMARD	0.36 (0.09,1.30)	0.37 (0.10,1.30)	-0.02 (-0.14,0.01)	
SD ANA + DMARD	0.51 (0.14,1.68)	0.52 (0.16,1.65)	-0.02 (-0.13,0.02)	
SD CERTO SC + DMARD	0.35 (0.06,1.74)	0.36 (0.07,1.69)	-0.02 (-0.14,0.02)	
SD TOCI SC + DMARD	0.66 (0.16,2.68)	0.67 (0.18,2.50)	-0.01 (-0.11,0.05)	
LD ADA SC	0.52 (0.09,2.35)	0.53 (0.11,2.30)	-0.02 (-0.16,0.02)	
LD ETN SC	0.82 (0.26,2.61)	0.83 (0.29,2.47)	-0.01 (-0.09,0.07)	
LD GOL I IV	5.68 (1.01,36.39)	4.44 (1.01,18.67)	0.15 (0.00,0.57)	
LD RITUX IV + MTX	0.99 (0.44,2.29)	0.99 (0.46,2.18)	0.00 (-0.06,0.06)	
LD ABA IV + MTX	1.35 (0.51,3.37)	1.33 (0.53,3.08)	0.01 (-0.04,0.11)	
LD CERTO SC + MTX	1.69 (0.34,8.53)	1.62 (0.36,6.60)	0.03 (-0.05,0.28)	
LD ETN SC + MTX	0.52 (0.15,1.74)	0.54 (0.17,1.69)	-0.02 (-0.11,0.03)	
LD GOL I IV + MTX	3.22 (0.51,20.51)	2.86 (0.54,13.14)	0.08 (-0.04,0.45)	
HD TOCI IV	0.98 (0.40,2.65)	0.98 (0.43,2.51)	0.00 (-0.07,0.06)	
HD TOFA PO	0.42 (0.07,1.97)	0.43 (0.08,1.94)	-0.02 (-0.16,0.01)	
HD GOL I SC	1.42 (0.34,5.82)	1.39 (0.36,4.85)	0.02 (-0.06,0.20)	
HD ADA SC	0.80 (0.15,3.29)	0.80 (0.18,3.17)	-0.01 (-0.14,0.04)	
HD GOL I SC + MTX	3.01 (0.90,11.42)	2.69 (0.91,8.50)	0.07 (0.00,0.35)	
HD TOCI IV + MTX	1.13 (0.39,3.69)	1.12 (0.41,3.32)	0.00 (-0.06,0.11)	
HD TOFA PO + MTX	1.76 (0.77,4.21)	1.69 (0.78,3.70)	0.03 (-0.01,0.16)	
HD INF IV + MTX	1.12 (0.49,2.57)	1.11 (0.51,2.41)	0.00 (-0.05,0.07)	
HD CERTO SC + MTX	2.06 (0.79,6.21)	1.93 (0.81,5.24)	0.04 (-0.01,0.24)	
HD TOCI IV + DMARD	0.76 (0.25,2.35)	0.77 (0.27,2.26)	-0.01 (-0.10,0.04)	
SD RITUX IV + MTX	SD ABA IV + MTX	1.33 (0.69,2.68)	1.31 (0.71,2.50)	0.01 (-0.02,0.09)
SD ABA SC + MTX		0.84 (0.47,1.48)	0.85 (0.49,1.45)	0.00 (-0.04,0.02)
SD GOL I SC + MTX		2.48 (0.78,9.26)	2.31 (0.79,6.89)	0.05 (-0.01,0.31)

(Continued)

SD CERTO SC + MTX	1.94 (1.00,4.06)	1.85 (1.00,3.58)	0.03 (0.00,0.16)
SD TOFA PO + MTX	2.43 (1.05,5.95)	2.26 (1.05,5.08)	0.05 (0.00,0.23)
SD GOLI IV + MTX	3.89 (0.67,26.04)	3.35 (0.68,16.14)	0.09 (-0.02,0.48)
SD ANA SC + MTX	1.66 (0.51,5.57)	1.60 (0.53,4.63)	0.02 (-0.03,0.21)
SD ETN SC + DMARD	1.18 (0.47,2.92)	1.17 (0.49,2.81)	0.01 (-0.05,0.05)
SD ABA IV + DMARD	0.61 (0.21,1.79)	0.62 (0.22,1.74)	-0.01 (-0.09,0.02)
SD ADA SC + DMARD	0.40 (0.12,1.43)	0.42 (0.13,1.41)	-0.02 (-0.11,0.01)
SD ANA + DMARD	0.59 (0.18,1.80)	0.60 (0.19,1.75)	-0.01 (-0.09,0.02)
SD CERTO SC + DMARD	0.40 (0.07,1.92)	0.41 (0.08,1.84)	-0.02 (-0.11,0.03)
SD TOCI SC + DMARD	0.76 (0.20,2.90)	0.77 (0.21,2.70)	-0.01 (-0.08,0.06)
LD ADA SC	0.58 (0.12,2.61)	0.59 (0.13,2.55)	-0.01 (-0.12,0.02)
LD ETN SC	0.93 (0.32,2.84)	0.94 (0.34,2.66)	0.00 (-0.06,0.08)
LD GOLI IV	6.30 (1.24,40.25)	4.95 (1.22,19.94)	0.16 (0.01,0.58)
LD RITUX IV + MTX	1.13 (0.60,2.34)	1.12 (0.62,2.20)	0.00 (-0.03,0.07)
LD ABA IV + MTX	1.53 (0.72,3.35)	1.49 (0.73,3.06)	0.02 (-0.01,0.12)
LD CERTO SC + MTX	1.94 (0.43,8.74)	1.86 (0.45,6.53)	0.03 (-0.03,0.30)
LD ETN SC + MTX	0.60 (0.18,1.86)	0.61 (0.19,1.81)	-0.01 (-0.08,0.03)
LD GOLI IV + MTX	3.58 (0.63,22.53)	3.16 (0.65,14.45)	0.08 (-0.02,0.46)
HD TOCI IV	1.13 (0.50,2.76)	1.12 (0.53,2.58)	0.00 (-0.04,0.07)
HD TOFA PO	0.49 (0.09,2.31)	0.50 (0.10,2.27)	-0.02 (-0.13,0.02)
HD GOLI SC	1.63 (0.41,6.48)	1.58 (0.42,5.26)	0.02 (-0.04,0.22)
HD ADA SC	0.90 (0.20,3.69)	0.91 (0.22,3.52)	0.00 (-0.11,0.04)
HD GOLI SC + MTX	3.46 (1.09,12.03)	3.05 (1.09,8.52)	0.08 (0.00,0.36)
HD TOCI IV + MTX	1.30 (0.49,3.82)	1.28 (0.50,3.47)	0.01 (-0.03,0.12)
HD TOFA PO + MTX	2.03 (0.85,5.12)	1.94 (0.86,4.38)	0.03 (-0.01,0.19)
HD INF IV + MTX	1.29 (0.67,2.56)	1.27 (0.68,2.38)	0.01 (-0.02,0.08)
HD CERTO SC + MTX	2.36 (0.99,6.39)	2.20 (0.99,5.15)	0.05 (0.00,0.26)
HD TOCI IV + DMARD	0.87 (0.31,2.49)	0.88 (0.33,2.39)	0.00 (-0.07,0.05)

(Continued)

SD ABA SC + MTX	SD RITUX IV + MTX	0.64 (0.28,1.37)	0.65 (0.30,1.35)	-0.02 (-0.10,0.01)
SD GOL I SC + MTX		1.86 (0.56,6.73)	1.76 (0.58,5.32)	0.04 (-0.03,0.27)
SD CERTO SC + MTX		1.48 (0.70,3.10)	1.43 (0.72,2.81)	0.02 (-0.02,0.13)
SD TOFA PO + MTX		1.84 (0.70,4.82)	1.75 (0.73,4.19)	0.03 (-0.02,0.20)
SD GOL I IV + MTX		2.92 (0.46,20.20)	2.57 (0.48,12.96)	0.08 (-0.04,0.45)
SD ANA SC + MTX		1.25 (0.37,4.20)	1.24 (0.39,3.58)	0.01 (-0.06,0.17)
SD ETN SC + DMARD		0.88 (0.31,2.27)	0.88 (0.34,2.20)	-0.01 (-0.11,0.04)
SD ABA IV + DMARD		0.47 (0.14,1.36)	0.48 (0.16,1.34)	-0.02 (-0.15,0.01)
SD ADA SC + DMARD		0.31 (0.08,1.09)	0.33 (0.09,1.08)	-0.03 (-0.16,0.00)
SD ANA + DMARD		0.45 (0.13,1.39)	0.47 (0.14,1.37)	-0.03 (-0.15,0.01)
SD CERTO SC + DMARD		0.30 (0.05,1.46)	0.32 (0.06,1.44)	-0.03 (-0.16,0.02)
SD TOCI SC + DMARD		0.58 (0.13,2.10)	0.59 (0.15,2.00)	-0.02 (-0.14,0.04)
LD ADA SC		0.43 (0.08,2.19)	0.45 (0.09,2.16)	-0.03 (-0.18,0.02)
LD ETN SC		0.71 (0.24,2.06)	0.72 (0.26,1.97)	-0.01 (-0.10,0.05)
LD GOL I IV		4.74 (0.90,29.07)	3.81 (0.91,16.09)	0.14 (-0.01,0.56)
LD RITUX IV + MTX		0.85 (0.51,1.45)	0.86 (0.54,1.41)	-0.01 (-0.05,0.02)
LD ABA IV + MTX		1.16 (0.45,2.80)	1.15 (0.48,2.59)	0.01 (-0.06,0.10)
LD CERTO SC + MTX		1.48 (0.31,6.46)	1.44 (0.33,4.91)	0.02 (-0.07,0.26)
LD ETN SC + MTX		0.45 (0.13,1.40)	0.47 (0.14,1.37)	-0.02 (-0.13,0.02)
LD GOL I IV + MTX		2.73 (0.43,16.96)	2.44 (0.46,11.26)	0.07 (-0.04,0.43)
HD TOCI IV		0.86 (0.34,2.04)	0.87 (0.37,1.95)	-0.01 (-0.09,0.05)
HD TOFA PO		0.37 (0.06,1.82)	0.38 (0.07,1.80)	-0.03 (-0.19,0.01)
HD GOL I SC		1.22 (0.31,4.73)	1.21 (0.33,3.88)	0.01 (-0.07,0.19)
HD ADA SC		0.68 (0.14,2.96)	0.69 (0.16,2.85)	-0.01 (-0.17,0.03)
HD GOL I SC + MTX		2.59 (0.83,9.14)	2.33 (0.84,6.53)	0.07 (-0.01,0.33)
HD TOCI IV + MTX		0.98 (0.35,2.96)	0.98 (0.37,2.72)	0.00 (-0.08,0.09)
HD TOFA PO + MTX		1.53 (0.60,3.96)	1.47 (0.62,3.50)	0.02 (-0.04,0.16)
HD INF IV + MTX		0.98 (0.45,2.01)	0.98 (0.47,1.92)	0.00 (-0.06,0.05)

(Continued)

HD CERTO SC + MTX		1.81 (0.73,4.73)	1.72 (0.74,3.87)	0.03 (-0.02,0.21)
HD TOCI IV + DMARD		0.67 (0.22,1.93)	0.68 (0.24,1.86)	-0.01 (-0.12,0.03)
SD GOLI SC + MTX	SD ABA SC + MTX	2.95 (0.88,11.72)	2.71 (0.89,8.91)	0.06 (0.00,0.33)
SD CERTO SC + MTX		2.28 (1.07,5.45)	2.15 (1.07,4.78)	0.04 (0.00,0.18)
SD TOFA PO + MTX		2.86 (1.22,7.48)	2.65 (1.21,6.30)	0.05 (0.01,0.24)
SD GOLI IV + MTX		4.71 (0.76,32.59)	4.00 (0.77,19.95)	0.10 (-0.01,0.49)
SD ANA SC + MTX		1.95 (0.57,7.11)	1.88 (0.58,5.89)	0.03 (-0.02,0.22)
SD ETN SC + DMARD		1.39 (0.50,3.77)	1.36 (0.53,3.59)	0.01 (-0.04,0.06)
SD ABA IV + DMARD		0.72 (0.23,2.28)	0.73 (0.25,2.20)	-0.01 (-0.08,0.03)
SD ADA SC + DMARD		0.49 (0.13,1.81)	0.50 (0.14,1.78)	-0.01 (-0.09,0.02)
SD ANA + DMARD		0.70 (0.20,2.30)	0.71 (0.21,2.22)	-0.01 (-0.08,0.03)
SD CERTO SC + DMARD		0.48 (0.09,2.32)	0.49 (0.09,2.25)	-0.01 (-0.09,0.03)
SD TOCI SC + DMARD		0.88 (0.22,3.64)	0.89 (0.24,3.41)	0.00 (-0.07,0.07)
LD ADA SC		0.69 (0.13,3.15)	0.70 (0.14,3.08)	-0.01 (-0.11,0.03)
LD ETN SC		1.11 (0.36,3.59)	1.10 (0.37,3.35)	0.00 (-0.05,0.09)
LD GOLI IV		7.54 (1.41,50.69)	5.85 (1.37,26.19)	0.16 (0.01,0.60)
LD RITUX IV + MTX		1.33 (0.61,3.19)	1.31 (0.63,3.02)	0.01 (-0.02,0.08)
LD ABA IV + MTX		1.82 (0.73,4.57)	1.76 (0.75,4.10)	0.02 (-0.01,0.14)
LD CERTO SC + MTX		2.28 (0.49,10.87)	2.16 (0.50,8.46)	0.04 (-0.02,0.31)
LD ETN SC + MTX		0.71 (0.21,2.36)	0.72 (0.22,2.28)	-0.01 (-0.07,0.04)
LD GOLI IV + MTX		4.26 (0.70,28.12)	3.73 (0.71,18.64)	0.09 (-0.01,0.47)
HD TOCI IV		1.33 (0.55,3.61)	1.31 (0.57,3.37)	0.01 (-0.03,0.08)
HD TOFA PO		0.58 (0.10,2.72)	0.59 (0.12,2.66)	-0.01 (-0.12,0.02)
HD GOLI SC		1.97 (0.46,7.91)	1.89 (0.47,6.46)	0.03 (-0.03,0.23)
HD ADA SC		1.07 (0.22,4.64)	1.07 (0.24,4.44)	0.00 (-0.09,0.05)
HD GOLI SC + MTX		4.09 (1.26,15.06)	3.59 (1.24,10.89)	0.09 (0.01,0.38)
HD TOCI IV + MTX		1.54 (0.53,5.07)	1.51 (0.54,4.49)	0.01 (-0.03,0.14)
HD TOFA PO + MTX		2.39 (0.98,6.30)	2.26 (0.98,5.41)	0.04 (0.00,0.20)

(Continued)

HD INF IV + MTX		1.52 (0.70,3.53)	1.48 (0.71,3.26)	0.01 (-0.02,0.10)
HD CERTO SC + MTX		2.81 (1.07,8.50)	2.59 (1.07,6.85)	0.05 (0.00,0.27)
HD TOCI IV + DMARD		1.03 (0.34,3.18)	1.03 (0.35,3.03)	0.00 (-0.06,0.06)
SD CERTO SC + MTX	SD GOLI SC + MTX	0.78 (0.22,2.53)	0.80 (0.27,2.31)	-0.02 (-0.23,0.09)
SD TOFA PO + MTX		0.97 (0.22,3.91)	0.97 (0.28,3.46)	0.00 (-0.22,0.15)
SD GOLI IV + MTX		1.55 (0.18,12.61)	1.44 (0.21,8.27)	0.04 (-0.19,0.39)
SD ANA SC + MTX		0.66 (0.14,3.21)	0.69 (0.17,2.82)	-0.02 (-0.25,0.11)
SD ETN SC + DMARD		0.47 (0.11,1.80)	0.50 (0.15,1.74)	-0.04 (-0.33,0.02)
SD ABA IV + DMARD		0.24 (0.05,1.02)	0.27 (0.07,1.02)	-0.06 (-0.37,0.00)
SD ADA SC + DMARD		0.16 (0.03,0.78)	0.18 (0.04,0.79)	-0.07 (-0.39,0.00)
SD ANA + DMARD		0.23 (0.05,1.04)	0.25 (0.06,1.04)	-0.07 (-0.37,0.00)
SD CERTO SC + DMARD		0.16 (0.02,1.09)	0.18 (0.02,1.09)	-0.07 (-0.39,0.00)
SD TOCI SC + DMARD		0.30 (0.05,1.50)	0.33 (0.07,1.46)	-0.06 (-0.35,0.02)
LD ADA SC		0.22 (0.03,1.44)	0.24 (0.05,1.43)	-0.07 (-0.40,0.01)
LD ETN SC		0.36 (0.09,1.68)	0.39 (0.11,1.62)	-0.05 (-0.31,0.03)
LD GOLI IV		2.62 (0.35,18.37)	2.17 (0.41,10.49)	0.09 (-0.13,0.50)
LD RITUX IV + MTX		0.46 (0.12,1.54)	0.49 (0.15,1.51)	-0.04 (-0.30,0.02)
LD ABA IV + MTX		0.62 (0.14,2.30)	0.65 (0.17,2.15)	-0.03 (-0.27,0.06)
LD CERTO SC + MTX		0.75 (0.12,4.20)	0.78 (0.15,3.47)	-0.02 (-0.23,0.20)
LD ETN SC + MTX		0.24 (0.05,1.02)	0.26 (0.06,1.02)	-0.06 (-0.35,0.00)
LD GOLI IV + MTX		1.51 (0.17,11.67)	1.42 (0.20,7.80)	0.03 (-0.19,0.37)
HD TOCI IV		0.46 (0.11,1.63)	0.49 (0.15,1.59)	-0.04 (-0.31,0.02)
HD TOFA PO		0.19 (0.02,1.22)	0.20 (0.04,1.21)	-0.07 (-0.41,0.01)
HD GOLI SC		0.62 (0.18,2.32)	0.66 (0.21,2.14)	-0.03 (-0.22,0.08)
HD ADA SC		0.35 (0.05,2.18)	0.37 (0.08,2.11)	-0.06 (-0.39,0.02)
HD GOLI SC + MTX		1.36 (0.53,3.57)	1.30 (0.58,2.98)	0.02 (-0.09,0.20)
HD TOCI IV + MTX		0.53 (0.11,2.19)	0.56 (0.14,2.08)	-0.04 (-0.29,0.05)
HD TOFA PO + MTX		0.82 (0.18,3.20)	0.84 (0.22,2.90)	-0.01 (-0.23,0.11)

(Continued)

HD INF IV + MTX		0.52 (0.14,1.76)	0.55 (0.18,1.70)	-0.04 (-0.29,0.03)
HD CERTO SC + MTX		0.93 (0.23,3.46)	0.94 (0.29,3.02)	0.00 (-0.20,0.15)
HD TOCI IV + DMARD		0.35 (0.07,1.39)	0.38 (0.09,1.37)	-0.05 (-0.34,0.01)
SD TOFA PO + MTX	SD CERTO SC + MTX	1.24 (0.47,3.28)	1.21 (0.51,2.93)	0.01 (-0.07,0.14)
SD GOL I IV + MTX		1.97 (0.32,14.28)	1.79 (0.36,8.69)	0.06 (-0.10,0.42)
SD ANA SC + MTX		0.85 (0.25,3.00)	0.86 (0.28,2.58)	-0.01 (-0.12,0.12)
SD ETN SC + DMARD		0.59 (0.21,1.59)	0.61 (0.25,1.55)	-0.03 (-0.18,0.02)
SD ABA IV + DMARD		0.31 (0.10,0.99)	0.33 (0.12,0.99)	-0.05 (-0.23,0.00)
SD ADA SC + DMARD		0.21 (0.05,0.78)	0.23 (0.07,0.79)	-0.05 (-0.24,-0.01)
SD ANA + DMARD		0.30 (0.08,0.99)	0.32 (0.10,0.99)	-0.05 (-0.23,0.00)
SD CERTO SC + DMARD		0.20 (0.04,1.03)	0.22 (0.04,1.02)	-0.05 (-0.25,0.00)
SD TOCI SC + DMARD		0.39 (0.09,1.49)	0.41 (0.11,1.46)	-0.04 (-0.22,0.02)
LD ADA SC		0.31 (0.05,1.46)	0.32 (0.07,1.45)	-0.05 (-0.27,0.01)
LD ETN SC		0.48 (0.15,1.51)	0.51 (0.17,1.47)	-0.03 (-0.18,0.03)
LD GOL I IV		3.16 (0.59,22.08)	2.63 (0.63,11.15)	0.11 (-0.04,0.53)
LD RITUX IV + MTX		0.58 (0.27,1.25)	0.60 (0.30,1.23)	-0.03 (-0.15,0.01)
LD ABA IV + MTX		0.78 (0.30,1.96)	0.80 (0.33,1.85)	-0.01 (-0.13,0.06)
LD CERTO SC + MTX		1.02 (0.22,3.73)	1.02 (0.24,3.07)	0.00 (-0.11,0.20)
LD ETN SC + MTX		0.31 (0.09,0.96)	0.33 (0.10,0.96)	-0.04 (-0.21,0.00)
LD GOL I IV + MTX		1.80 (0.30,12.15)	1.67 (0.34,7.95)	0.05 (-0.10,0.40)
HD TOCI IV		0.58 (0.23,1.47)	0.60 (0.26,1.43)	-0.03 (-0.16,0.02)
HD TOFA PO		0.26 (0.04,1.29)	0.27 (0.05,1.28)	-0.05 (-0.28,0.01)
HD GOL I SC		0.84 (0.20,3.36)	0.86 (0.22,2.83)	-0.01 (-0.14,0.15)
HD ADA SC		0.46 (0.09,1.99)	0.48 (0.12,1.94)	-0.04 (-0.26,0.02)
HD GOL I SC + MTX		1.76 (0.53,6.62)	1.63 (0.57,4.72)	0.04 (-0.05,0.29)
HD TOCI IV + MTX		0.65 (0.23,2.10)	0.68 (0.26,1.97)	-0.02 (-0.15,0.06)
HD TOFA PO + MTX		1.04 (0.38,2.78)	1.03 (0.41,2.53)	0.00 (-0.09,0.11)
HD INF IV + MTX		0.66 (0.30,1.40)	0.68 (0.34,1.35)	-0.02 (-0.13,0.02)



(Continued)

HD CERTO SC + MTX		1.22 (0.61,2.45)	1.19 (0.63,2.19)	0.01 (-0.04,0.13)
HD TOCI IV + DMARD		0.44 (0.14,1.42)	0.47 (0.17,1.40)	-0.04 (-0.21,0.02)
SD GOLI IV + MTX	SD TOFA PO + MTX	1.63 (0.26,10.42)	1.50 (0.29,6.85)	0.04 (-0.14,0.38)
SD ANA SC + MTX		0.68 (0.17,2.72)	0.71 (0.20,2.41)	-0.02 (-0.18,0.11)
SD ETN SC + DMARD		0.49 (0.15,1.37)	0.51 (0.19,1.35)	-0.04 (-0.24,0.02)
SD ABA IV + DMARD		0.26 (0.07,0.85)	0.28 (0.09,0.86)	-0.06 (-0.28,-0.01)
SD ADA SC + DMARD		0.17 (0.04,0.64)	0.19 (0.05,0.65)	-0.07 (-0.30,-0.01)
SD ANA + DMARD		0.24 (0.06,0.85)	0.27 (0.08,0.86)	-0.06 (-0.29,-0.01)
SD CERTO SC + DMARD		0.17 (0.03,0.85)	0.18 (0.03,0.86)	-0.07 (-0.30,-0.01)
SD TOCI SC + DMARD		0.31 (0.07,1.34)	0.33 (0.08,1.31)	-0.06 (-0.27,0.02)
LD ADA SC		0.25 (0.04,1.17)	0.26 (0.06,1.16)	-0.06 (-0.32,0.00)
LD ETN SC		0.39 (0.10,1.26)	0.42 (0.12,1.24)	-0.05 (-0.24,0.01)
LD GOLI IV		2.70 (0.43,16.94)	2.26 (0.49,9.26)	0.10 (-0.09,0.50)
LD RITUX IV + MTX		0.47 (0.18,1.21)	0.50 (0.21,1.19)	-0.04 (-0.21,0.01)
LD ABA IV + MTX		0.63 (0.20,1.86)	0.66 (0.23,1.77)	-0.03 (-0.19,0.05)
LD CERTO SC + MTX		0.80 (0.14,4.11)	0.82 (0.16,3.27)	-0.01 (-0.19,0.20)
LD ETN SC + MTX		0.24 (0.06,0.93)	0.27 (0.07,0.93)	-0.06 (-0.27,0.00)
LD GOLI IV + MTX		1.53 (0.23,9.91)	1.43 (0.26,6.41)	0.03 (-0.15,0.36)
HD TOCI IV		0.46 (0.17,1.36)	0.49 (0.20,1.33)	-0.04 (-0.22,0.02)
HD TOFA PO		0.20 (0.03,0.97)	0.22 (0.04,0.97)	-0.07 (-0.33,0.00)
HD GOLI SC		0.66 (0.15,3.17)	0.69 (0.18,2.72)	-0.02 (-0.21,0.13)
HD ADA SC		0.38 (0.07,1.52)	0.40 (0.09,1.49)	-0.05 (-0.31,0.02)
HD GOLI SC + MTX		1.44 (0.37,5.51)	1.36 (0.41,4.24)	0.03 (-0.11,0.26)
HD TOCI IV + MTX		0.54 (0.17,1.89)	0.57 (0.19,1.77)	-0.03 (-0.20,0.05)
HD TOFA PO + MTX		0.83 (0.41,1.71)	0.85 (0.45,1.60)	-0.01 (-0.11,0.05)
HD INF IV + MTX		0.53 (0.20,1.36)	0.56 (0.23,1.33)	-0.03 (-0.20,0.02)
HD CERTO SC + MTX		0.97 (0.32,3.10)	0.98 (0.35,2.68)	0.00 (-0.13,0.14)
HD TOCI IV + DMARD		0.36 (0.10,1.20)	0.39 (0.13,1.18)	-0.05 (-0.26,0.01)

(Continued)

SD ANA SC + MTX	SD GOLI IV + MTX	0.43 (0.05,3.71)	0.48 (0.08,3.16)	-0.06 (-0.43,0.13)
SD ETN SC + DMARD		0.30 (0.04,1.95)	0.33 (0.07,1.88)	-0.09 (-0.48,0.03)
SD ABA IV + DMARD		0.16 (0.02,1.13)	0.19 (0.03,1.13)	-0.11 (-0.52,0.00)
SD ADA SC + DMARD		0.10 (0.01,0.80)	0.12 (0.02,0.81)	-0.12 (-0.53,0.00)
SD ANA + DMARD		0.15 (0.02,1.06)	0.18 (0.03,1.06)	-0.11 (-0.51,0.00)
SD CERTO SC + DMARD		0.10 (0.01,1.04)	0.12 (0.02,1.04)	-0.12 (-0.52,0.00)
SD TOCI SC + DMARD		0.20 (0.02,1.52)	0.23 (0.03,1.46)	-0.10 (-0.51,0.02)
LD ADA SC		0.15 (0.02,1.22)	0.17 (0.03,1.21)	-0.12 (-0.54,0.00)
LD ETN SC		0.24 (0.03,1.76)	0.28 (0.05,1.70)	-0.09 (-0.48,0.03)
LD GOLI IV		1.66 (0.47,6.30)	1.46 (0.55,4.85)	0.06 (-0.12,0.31)
LD RITUX IV + MTX		0.29 (0.04,1.86)	0.34 (0.07,1.80)	-0.09 (-0.46,0.03)
LD ABA IV + MTX		0.40 (0.05,2.91)	0.45 (0.09,2.66)	-0.07 (-0.45,0.07)
LD CERTO SC + MTX		0.51 (0.05,5.40)	0.56 (0.07,4.23)	-0.05 (-0.42,0.19)
LD ETN SC + MTX		0.16 (0.02,1.06)	0.19 (0.03,1.05)	-0.11 (-0.51,0.00)
LD GOLI IV + MTX		0.93 (0.25,3.96)	0.94 (0.31,3.35)	-0.01 (-0.22,0.20)
HD TOCI IV		0.29 (0.04,1.99)	0.34 (0.07,1.92)	-0.09 (-0.47,0.03)
HD TOFA PO		0.12 (0.01,1.05)	0.14 (0.03,1.05)	-0.12 (-0.55,0.00)
HD GOLI SC		0.41 (0.05,3.42)	0.46 (0.07,3.01)	-0.07 (-0.43,0.13)
HD ADA SC		0.23 (0.02,1.84)	0.25 (0.05,1.80)	-0.10 (-0.53,0.02)
HD GOLI SC + MTX		0.91 (0.12,7.69)	0.92 (0.17,5.80)	-0.01 (-0.35,0.26)
HD TOCI IV + MTX		0.34 (0.04,2.45)	0.38 (0.07,2.26)	-0.08 (-0.45,0.06)
HD TOFA PO + MTX		0.51 (0.08,3.53)	0.56 (0.13,3.18)	-0.05 (-0.40,0.12)
HD INF IV + MTX		0.34 (0.05,2.09)	0.38 (0.07,2.00)	-0.08 (-0.45,0.04)
HD CERTO SC + MTX		0.62 (0.08,4.49)	0.66 (0.12,3.83)	-0.04 (-0.39,0.16)
HD TOCI IV + DMARD		0.23 (0.03,1.53)	0.26 (0.05,1.50)	-0.10 (-0.49,0.02)
SD ETN SC + DMARD	SD ANA SC + MTX	0.70 (0.17,2.81)	0.72 (0.22,2.69)	-0.02 (-0.22,0.04)
SD ABA IV + DMARD		0.37 (0.08,1.65)	0.39 (0.10,1.61)	-0.04 (-0.26,0.01)
SD ADA SC + DMARD		0.25 (0.05,1.26)	0.26 (0.06,1.25)	-0.04 (-0.27,0.01)

(Continued)

SD ANA + DMARD		0.35 (0.07,1.57)	0.37 (0.09,1.53)	-0.04 (-0.26,0.01)
SD CERTO SC + DMARD		0.25 (0.03,1.62)	0.26 (0.04,1.57)	-0.04 (-0.27,0.02)
SD TOCI SC + DMARD		0.46 (0.08,2.37)	0.48 (0.10,2.25)	-0.03 (-0.25,0.04)
LD ADA SC		0.36 (0.04,2.25)	0.37 (0.06,2.21)	-0.04 (-0.30,0.02)
LD ETN SC		0.56 (0.12,2.51)	0.58 (0.14,2.35)	-0.02 (-0.22,0.05)
LD GOLIV		3.83 (0.55,31.58)	3.09 (0.61,17.01)	0.12 (-0.06,0.55)
LD RITUX IV + MTX		0.68 (0.18,2.40)	0.70 (0.22,2.30)	-0.02 (-0.19,0.05)
LD ABA IV + MTX		0.93 (0.23,3.40)	0.93 (0.26,3.15)	0.00 (-0.16,0.09)
LD CERTO SC + MTX		1.19 (0.19,6.81)	1.17 (0.22,5.50)	0.01 (-0.14,0.24)
LD ETN SC + MTX		0.36 (0.08,1.61)	0.38 (0.09,1.58)	-0.04 (-0.24,0.02)
LD GOLIV + MTX		2.20 (0.28,17.70)	1.99 (0.33,11.53)	0.06 (-0.13,0.42)
HD TOCI IV		0.68 (0.18,2.73)	0.70 (0.21,2.61)	-0.02 (-0.20,0.05)
HD TOFA PO		0.28 (0.04,1.92)	0.30 (0.05,1.89)	-0.04 (-0.30,0.01)
HD GOLIV SC		0.99 (0.18,5.06)	1.00 (0.20,4.43)	0.00 (-0.16,0.16)
HD ADA SC		0.55 (0.08,2.91)	0.56 (0.11,2.82)	-0.03 (-0.28,0.03)
HD GOLIV SC + MTX		2.07 (0.47,9.26)	1.88 (0.52,7.19)	0.05 (-0.07,0.31)
HD TOCI IV + MTX		0.80 (0.18,3.42)	0.81 (0.21,3.13)	-0.01 (-0.18,0.09)
HD TOFA PO + MTX		1.22 (0.30,4.91)	1.20 (0.34,4.34)	0.01 (-0.13,0.15)
HD INF IV + MTX		0.78 (0.22,2.66)	0.79 (0.26,2.52)	-0.01 (-0.18,0.06)
HD CERTO SC + MTX		1.42 (0.35,5.88)	1.37 (0.41,5.02)	0.02 (-0.11,0.20)
HD TOCI IV + DMARD		0.53 (0.11,2.29)	0.55 (0.14,2.22)	-0.03 (-0.24,0.03)
SD ABA IV + DMARD	SD ETN SC + DMARD	0.53 (0.22,1.24)	0.54 (0.23,1.22)	-0.02 (-0.08,0.01)
SD ADA SC + DMARD		0.35 (0.12,0.99)	0.36 (0.13,0.99)	-0.03 (-0.10,0.00)
SD ANA + DMARD		0.50 (0.19,1.28)	0.51 (0.20,1.26)	-0.02 (-0.08,0.01)
SD CERTO SC + DMARD		0.35 (0.08,1.42)	0.36 (0.08,1.37)	-0.03 (-0.10,0.02)
SD TOCI SC + DMARD		0.63 (0.20,2.22)	0.64 (0.21,2.11)	-0.01 (-0.07,0.05)
LD ADA SC		0.50 (0.12,1.77)	0.51 (0.14,1.74)	-0.02 (-0.12,0.02)
LD ETN SC		0.81 (0.26,2.48)	0.82 (0.27,2.31)	-0.01 (-0.06,0.08)

(Continued)

LD GOLIV		5.45 (0.94,33.63)	4.39 (0.95,16.67)	0.15 (0.00,0.59)
LD RITUX IV + MTX		0.97 (0.36,2.72)	0.97 (0.37,2.49)	0.00 (-0.05,0.08)
LD ABA IV + MTX		1.30 (0.43,4.19)	1.28 (0.45,3.57)	0.01 (-0.04,0.14)
LD CERTO SC + MTX		1.68 (0.29,9.16)	1.62 (0.31,6.62)	0.03 (-0.05,0.30)
LD ETN SC + MTX		0.53 (0.13,1.80)	0.54 (0.14,1.73)	-0.02 (-0.08,0.04)
LD GOLIV + MTX		3.12 (0.47,20.12)	2.80 (0.49,12.01)	0.08 (-0.03,0.47)
HD TOCI IV		0.97 (0.41,2.40)	0.97 (0.43,2.24)	0.00 (-0.04,0.07)
HD TOFA PO		0.42 (0.09,1.53)	0.43 (0.11,1.52)	-0.02 (-0.12,0.01)
HD GOLIV SC		1.40 (0.32,6.48)	1.37 (0.34,5.09)	0.02 (-0.05,0.22)
HD ADA SC		0.77 (0.21,2.41)	0.78 (0.23,2.33)	-0.01 (-0.10,0.03)
HD GOLIV SC + MTX		3.00 (0.79,11.92)	2.70 (0.80,8.13)	0.07 (-0.01,0.38)
HD TOCI IV + MTX		1.13 (0.37,3.53)	1.12 (0.38,3.09)	0.00 (-0.05,0.13)
HD TOFA PO + MTX		1.72 (0.59,5.47)	1.66 (0.60,4.62)	0.03 (-0.03,0.20)
HD INF IV + MTX		1.11 (0.40,3.12)	1.10 (0.41,2.83)	0.00 (-0.04,0.10)
HD CERTO SC + MTX		2.05 (0.66,6.90)	1.94 (0.68,5.29)	0.04 (-0.02,0.27)
HD TOCI IV + DMARD		0.76 (0.32,1.69)	0.77 (0.33,1.65)	-0.01 (-0.06,0.03)
SD ADA SC + DMARD	SD ABA IV + DMARD	0.66 (0.23,1.89)	0.67 (0.24,1.85)	-0.01 (-0.05,0.02)
SD ANA + DMARD		0.95 (0.37,2.40)	0.95 (0.39,2.31)	0.00 (-0.04,0.03)
SD CERTO SC + DMARD		0.66 (0.15,2.70)	0.66 (0.16,2.59)	-0.01 (-0.05,0.04)
SD TOCI SC + DMARD		1.21 (0.39,3.91)	1.20 (0.40,3.66)	0.00 (-0.03,0.08)
LD ADA SC		0.94 (0.19,4.08)	0.94 (0.20,3.95)	0.00 (-0.07,0.03)
LD ETN SC		1.51 (0.43,5.52)	1.49 (0.45,5.09)	0.01 (-0.03,0.12)
LD GOLIV		10.09 (1.53,75.14)	7.91 (1.50,38.29)	0.17 (0.02,0.62)
LD RITUX IV + MTX		1.82 (0.61,6.07)	1.78 (0.63,5.55)	0.02 (-0.02,0.12)
LD ABA IV + MTX		2.51 (0.70,9.02)	2.40 (0.72,7.73)	0.03 (-0.01,0.18)
LD CERTO SC + MTX		3.14 (0.52,18.76)	2.93 (0.53,13.87)	0.05 (-0.02,0.34)
LD ETN SC + MTX		0.98 (0.22,4.02)	0.98 (0.23,3.80)	0.00 (-0.05,0.07)
LD GOLIV + MTX		5.91 (0.83,45.07)	5.13 (0.84,27.29)	0.10 (-0.01,0.49)

(Continued)

HD TOCI IV		1.82 (0.77,5.12)	1.78 (0.78,4.68)	0.02 (-0.01,0.10)
HD TOFA PO		0.78 (0.15,3.82)	0.79 (0.16,3.74)	0.00 (-0.08,0.03)
HD GOLI SC		2.62 (0.58,12.98)	2.49 (0.59,10.41)	0.03 (-0.02,0.26)
HD ADA SC		1.47 (0.32,5.79)	1.45 (0.34,5.55)	0.01 (-0.06,0.05)
HD GOLI SC + MTX		5.69 (1.34,26.59)	4.95 (1.32,17.60)	0.10 (0.01,0.42)
HD TOCI IV + MTX		2.13 (0.68,7.44)	2.05 (0.69,6.54)	0.02 (-0.01,0.16)
HD TOFA PO + MTX		3.29 (0.97,11.66)	3.07 (0.97,9.70)	0.05 (0.00,0.24)
HD INF IV + MTX		2.09 (0.69,6.86)	2.02 (0.70,6.22)	0.02 (-0.01,0.14)
HD CERTO SC + MTX		3.91 (1.09,15.15)	3.58 (1.08,11.68)	0.06 (0.00,0.31)
HD TOCI IV + DMARD		1.44 (0.63,3.23)	1.42 (0.65,3.10)	0.01 (-0.02,0.06)
SD ANA + DMARD	SD ADA SC + DMARD	1.43 (0.46,4.34)	1.42 (0.48,4.20)	0.01 (-0.02,0.05)
SD CERTO SC + DMARD		0.98 (0.20,4.76)	0.98 (0.20,4.51)	0.00 (-0.04,0.05)
SD TOCI SC + DMARD		1.81 (0.48,6.66)	1.78 (0.49,6.24)	0.01 (-0.02,0.09)
LD ADA SC		1.44 (0.24,7.20)	1.43 (0.25,6.94)	0.01 (-0.06,0.04)
LD ETN SC		2.25 (0.55,9.63)	2.20 (0.56,8.79)	0.02 (-0.02,0.13)
LD GOLI IV		16.15 (1.98,122.00)	12.22 (1.91,62.43)	0.18 (0.02,0.64)
LD RITUX IV + MTX		2.75 (0.78,10.76)	2.65 (0.79,9.78)	0.03 (-0.01,0.14)
LD ABA IV + MTX		3.77 (0.94,15.63)	3.58 (0.94,13.76)	0.04 (0.00,0.19)
LD CERTO SC + MTX		4.77 (0.70,32.76)	4.40 (0.71,23.85)	0.06 (-0.01,0.36)
LD ETN SC + MTX		1.47 (0.29,6.93)	1.46 (0.30,6.51)	0.01 (-0.03,0.08)
LD GOLI IV + MTX		9.17 (1.06,72.09)	7.80 (1.06,45.57)	0.11 (0.00,0.51)
HD TOCI IV		2.75 (0.97,9.19)	2.66 (0.97,8.40)	0.03 (0.00,0.12)
HD TOFA PO		1.18 (0.19,6.10)	1.17 (0.20,5.97)	0.00 (-0.06,0.03)
HD GOLI SC		3.93 (0.76,23.07)	3.67 (0.77,18.71)	0.04 (-0.01,0.27)
HD ADA SC		2.20 (0.41,9.67)	2.16 (0.43,9.22)	0.02 (-0.04,0.06)
HD GOLI SC + MTX		8.53 (1.73,46.07)	7.31 (1.68,31.81)	0.10 (0.01,0.43)
HD TOCI IV + MTX		3.19 (0.88,12.82)	3.05 (0.89,11.09)	0.03 (0.00,0.18)
HD TOFA PO + MTX		4.88 (1.33,21.39)	4.52 (1.31,17.87)	0.05 (0.01,0.26)

(Continued)

HD INF IV + MTX		3.18 (0.84,12.23)	3.03 (0.85,11.01)	0.03 (0.00,0.16)
HD CERTO SC + MTX		5.81 (1.42,26.15)	5.28 (1.39,20.12)	0.07 (0.01,0.33)
HD TOCI IV + DMARD		2.16 (0.76,5.90)	2.11 (0.76,5.65)	0.02 (-0.01,0.08)
SD CERTO SC + DMARD	SD ANA + DMARD	0.70 (0.15,3.00)	0.71 (0.15,2.89)	-0.01 (-0.05,0.04)
SD TOCI SC + DMARD		1.25 (0.39,4.40)	1.25 (0.40,4.08)	0.00 (-0.03,0.08)
LD ADA SC		1.01 (0.20,4.45)	1.01 (0.21,4.33)	0.00 (-0.07,0.03)
LD ETN SC		1.57 (0.45,6.44)	1.55 (0.46,5.94)	0.01 (-0.03,0.12)
LD GOL I IV		11.02 (1.58,82.43)	8.43 (1.54,41.91)	0.18 (0.02,0.62)
LD RITUX IV + MTX		1.92 (0.61,6.90)	1.86 (0.62,6.33)	0.02 (-0.02,0.13)
LD ABA IV + MTX		2.64 (0.73,10.38)	2.52 (0.74,8.95)	0.03 (-0.01,0.18)
LD CERTO SC + MTX		3.37 (0.52,21.60)	3.14 (0.53,15.79)	0.05 (-0.02,0.34)
LD ETN SC + MTX		1.04 (0.22,4.60)	1.04 (0.23,4.33)	0.00 (-0.04,0.07)
LD GOL I IV + MTX		6.34 (0.82,49.57)	5.47 (0.84,29.87)	0.10 (-0.01,0.50)
HD TOCI IV		1.95 (0.72,5.47)	1.90 (0.73,5.06)	0.02 (-0.01,0.11)
HD TOFA PO		0.82 (0.15,4.15)	0.83 (0.17,4.04)	0.00 (-0.08,0.03)
HD GOL I SC		2.80 (0.59,14.12)	2.66 (0.61,11.41)	0.04 (-0.02,0.26)
HD ADA SC		1.54 (0.32,6.46)	1.52 (0.34,6.24)	0.01 (-0.06,0.05)
HD GOL I SC + MTX		6.05 (1.41,29.32)	5.25 (1.38,19.59)	0.10 (0.01,0.42)
HD TOCI IV + MTX		2.23 (0.66,8.36)	2.16 (0.67,7.30)	0.02 (-0.01,0.16)
HD TOFA PO + MTX		3.46 (0.97,13.39)	3.21 (0.97,11.04)	0.05 (0.00,0.25)
HD INF IV + MTX		2.19 (0.66,7.82)	2.12 (0.68,7.05)	0.02 (-0.01,0.15)
HD CERTO SC + MTX		4.07 (1.07,16.84)	3.73 (1.06,13.00)	0.06 (0.00,0.32)
HD TOCI IV + DMARD		1.51 (0.60,3.67)	1.49 (0.61,3.51)	0.01 (-0.02,0.06)
SD TOCI SC + DMARD	SD CERTO SC + DMARD	1.84 (0.36,10.22)	1.81 (0.37,9.67)	0.01 (-0.04,0.10)
LD ADA SC		1.45 (0.21,10.21)	1.44 (0.22,9.85)	0.01 (-0.07,0.04)
LD ETN SC		2.35 (0.40,13.39)	2.29 (0.42,12.27)	0.02 (-0.03,0.13)
LD GOL I IV		16.49 (1.62,145.80)	12.41 (1.56,80.73)	0.18 (0.02,0.64)
LD RITUX IV + MTX		2.81 (0.58,15.17)	2.71 (0.60,13.86)	0.02 (-0.02,0.14)

(Continued)

LD ABA IV + MTX		3.91 (0.69,22.50)	3.69 (0.71,19.30)	0.04 (-0.01,0.19)
LD CERTO SC + MTX		4.84 (0.51,48.28)	4.41 (0.53,35.63)	0.05 (-0.02,0.36)
LD ETN SC + MTX		1.46 (0.23,9.21)	1.45 (0.25,8.69)	0.01 (-0.05,0.09)
LD GOLI IV + MTX		9.44 (0.88,90.20)	7.94 (0.88,56.94)	0.11 (0.00,0.50)
HD TOCI IV		2.88 (0.64,13.40)	2.77 (0.66,12.30)	0.02 (-0.02,0.13)
HD TOFA PO		1.21 (0.16,8.49)	1.21 (0.17,8.27)	0.00 (-0.08,0.03)
HD GOLI SC		3.93 (0.55,34.46)	3.71 (0.57,27.35)	0.04 (-0.02,0.28)
HD ADA SC		2.22 (0.34,14.61)	2.17 (0.36,13.97)	0.02 (-0.06,0.06)
HD GOLI SC + MTX		8.51 (1.28,71.10)	7.35 (1.25,48.69)	0.10 (0.01,0.44)
HD TOCI IV + MTX		3.25 (0.63,19.14)	3.10 (0.65,16.82)	0.03 (-0.02,0.18)
HD TOFA PO + MTX		5.08 (0.98,28.44)	4.67 (0.98,24.43)	0.05 (0.00,0.26)
HD INF IV + MTX		3.24 (0.65,18.74)	3.09 (0.67,16.57)	0.03 (-0.02,0.16)
HD CERTO SC + MTX		5.91 (1.05,37.13)	5.38 (1.04,28.90)	0.07 (0.00,0.33)
HD TOCI IV + DMARD		2.18 (0.52,9.76)	2.13 (0.54,9.11)	0.02 (-0.03,0.08)
LD ADA SC	SD TOCI SC + DMARD	0.80 (0.13,4.09)	0.80 (0.14,3.96)	-0.01 (-0.12,0.03)
LD ETN SC		1.25 (0.27,5.83)	1.24 (0.30,5.30)	0.01 (-0.07,0.11)
LD GOLI IV		8.47 (1.16,73.25)	6.58 (1.15,38.20)	0.17 (0.01,0.61)
LD RITUX IV + MTX		1.50 (0.41,6.39)	1.48 (0.43,5.83)	0.01 (-0.05,0.11)
LD ABA IV + MTX		2.02 (0.49,9.52)	1.95 (0.51,8.30)	0.02 (-0.04,0.17)
LD CERTO SC + MTX		2.62 (0.37,19.05)	2.46 (0.39,13.89)	0.04 (-0.04,0.33)
LD ETN SC + MTX		0.81 (0.16,4.16)	0.82 (0.17,3.96)	0.00 (-0.08,0.06)
LD GOLI IV + MTX		4.74 (0.59,42.79)	4.18 (0.61,26.98)	0.09 (-0.02,0.48)
HD TOCI IV		1.51 (0.47,5.54)	1.48 (0.49,5.16)	0.01 (-0.05,0.10)
HD TOFA PO		0.65 (0.10,3.67)	0.66 (0.11,3.62)	-0.01 (-0.12,0.02)
HD GOLI SC		2.17 (0.39,12.49)	2.08 (0.41,10.37)	0.03 (-0.05,0.25)
HD ADA SC		1.22 (0.22,5.82)	1.21 (0.24,5.60)	0.01 (-0.10,0.05)
HD GOLI SC + MTX		4.65 (0.93,26.84)	4.06 (0.94,18.35)	0.09 (0.00,0.41)
HD TOCI IV + MTX		1.76 (0.44,7.85)	1.71 (0.45,7.03)	0.02 (-0.04,0.15)

(Continued)

HD TOFA PO + MTX		2.76 (0.60,12.01)	2.58 (0.62,10.29)	0.04 (-0.03,0.23)
HD INF IV + MTX		1.70 (0.46,7.43)	1.66 (0.48,6.67)	0.02 (-0.05,0.13)
HD CERTO SC + MTX		3.15 (0.73,15.95)	2.90 (0.75,12.41)	0.05 (-0.02,0.30)
HD TOCI IV + DMARD		1.19 (0.39,3.55)	1.18 (0.41,3.42)	0.00 (-0.06,0.05)
LD ETN SC	LD ADA SC	1.59 (0.28,9.81)	1.57 (0.29,8.54)	0.01 (-0.03,0.15)
LD GOLIV IV		10.84 (1.75,102.40)	8.64 (1.71,38.74)	0.18 (0.02,0.65)
LD RITUX IV + MTX		1.96 (0.39,10.77)	1.92 (0.41,9.33)	0.02 (-0.02,0.16)
LD ABA IV + MTX		2.71 (0.51,16.21)	2.61 (0.52,13.13)	0.03 (-0.02,0.21)
LD CERTO SC + MTX		3.47 (0.36,31.74)	3.24 (0.37,20.74)	0.05 (-0.02,0.37)
LD ETN SC + MTX		1.00 (0.17,6.54)	1.00 (0.18,5.97)	0.00 (-0.03,0.10)
LD GOLIV IV + MTX		6.27 (0.89,56.60)	5.54 (0.90,29.64)	0.10 (0.00,0.52)
HD TOCI IV		1.94 (0.44,10.37)	1.89 (0.45,9.01)	0.02 (-0.02,0.15)
HD TOFA PO		0.81 (0.25,2.64)	0.81 (0.26,2.59)	0.00 (-0.04,0.02)
HD GOLIV SC		2.75 (0.43,22.86)	2.63 (0.44,16.38)	0.04 (-0.02,0.29)
HD ADA SC		1.53 (0.64,3.69)	1.51 (0.64,3.55)	0.01 (-0.02,0.04)
HD GOLIV SC + MTX		5.87 (0.92,45.19)	5.19 (0.92,26.11)	0.10 (0.00,0.46)
HD TOCI IV + MTX		2.28 (0.40,14.43)	2.21 (0.41,11.61)	0.03 (-0.03,0.20)
HD TOFA PO + MTX		3.38 (0.66,22.14)	3.20 (0.67,16.02)	0.05 (-0.01,0.29)
HD INF IV + MTX		2.24 (0.46,12.53)	2.18 (0.47,10.32)	0.03 (-0.02,0.18)
HD CERTO SC + MTX		3.96 (0.72,27.13)	3.69 (0.73,18.22)	0.06 (-0.01,0.35)
HD TOCI IV + DMARD		1.51 (0.32,7.27)	1.49 (0.33,6.63)	0.01 (-0.03,0.10)
LD GOLIV IV	LD ETN SC	6.83 (1.04,49.43)	5.29 (1.03,27.62)	0.16 (0.00,0.59)
LD RITUX IV + MTX		1.21 (0.41,3.66)	1.20 (0.44,3.44)	0.01 (-0.06,0.08)
LD ABA IV + MTX		1.63 (0.46,5.83)	1.59 (0.49,5.26)	0.02 (-0.05,0.14)
LD CERTO SC + MTX		2.07 (0.34,11.64)	1.97 (0.36,8.95)	0.03 (-0.05,0.30)
LD ETN SC + MTX		0.63 (0.14,2.73)	0.65 (0.15,2.64)	-0.01 (-0.11,0.05)
LD GOLIV IV + MTX		3.93 (0.50,27.79)	3.41 (0.52,19.30)	0.08 (-0.03,0.46)
HD TOCI IV		1.22 (0.38,4.00)	1.21 (0.41,3.73)	0.01 (-0.07,0.08)



(Continued)

HD TOFA PO		0.51 (0.08,2.75)	0.52 (0.09,2.69)	-0.02 (-0.15,0.02)
HD GOLI SC		1.76 (0.37,7.99)	1.68 (0.38,6.77)	0.02 (-0.06,0.21)
HD ADA SC		0.96 (0.17,4.65)	0.96 (0.19,4.47)	0.00 (-0.14,0.04)
HD GOLI SC + MTX		3.83 (0.85,15.86)	3.35 (0.86,11.52)	0.08 (-0.01,0.37)
HD TOCI IV + MTX		1.41 (0.37,5.43)	1.39 (0.39,4.85)	0.01 (-0.06,0.14)
HD TOFA PO + MTX		2.14 (0.66,7.89)	2.03 (0.68,6.92)	0.03 (-0.03,0.20)
HD INF IV + MTX		1.38 (0.42,4.39)	1.36 (0.45,4.10)	0.01 (-0.06,0.10)
HD CERTO SC + MTX		2.55 (0.72,9.23)	2.35 (0.74,7.73)	0.05 (-0.02,0.26)
HD TOCI IV + DMARD		0.95 (0.26,3.27)	0.95 (0.29,3.11)	0.00 (-0.10,0.05)
LD RITUX IV + MTX	LD GOLI IV	0.17 (0.03,1.00)	0.22 (0.06,1.00)	-0.15 (-0.57,0.00)
LD ABA IV + MTX		0.24 (0.03,1.45)	0.30 (0.07,1.39)	-0.13 (-0.56,0.03)
LD CERTO SC + MTX		0.30 (0.03,2.89)	0.37 (0.05,2.40)	-0.11 (-0.54,0.13)
LD ETN SC + MTX		0.09 (0.01,0.61)	0.12 (0.02,0.64)	-0.17 (-0.62,-0.02)
LD GOLI IV + MTX		0.56 (0.17,2.02)	0.64 (0.22,1.76)	-0.06 (-0.32,0.11)
HD TOCI IV		0.17 (0.03,1.09)	0.22 (0.05,1.08)	-0.15 (-0.58,0.00)
HD TOFA PO		0.08 (0.01,0.54)	0.10 (0.02,0.55)	-0.18 (-0.66,-0.02)
HD GOLI SC		0.25 (0.03,2.00)	0.31 (0.06,1.80)	-0.13 (-0.55,0.07)
HD ADA SC		0.14 (0.02,0.86)	0.18 (0.04,0.86)	-0.17 (-0.64,-0.01)
HD GOLI SC + MTX		0.54 (0.08,4.00)	0.61 (0.13,3.18)	-0.06 (-0.46,0.21)
HD TOCI IV + MTX		0.20 (0.03,1.35)	0.26 (0.05,1.31)	-0.14 (-0.56,0.02)
HD TOFA PO + MTX		0.31 (0.05,1.96)	0.38 (0.09,1.79)	-0.12 (-0.52,0.06)
HD INF IV + MTX		0.20 (0.03,1.12)	0.26 (0.06,1.11)	-0.14 (-0.56,0.01)
HD CERTO SC + MTX		0.38 (0.05,2.33)	0.45 (0.10,2.05)	-0.10 (-0.51,0.10)
HD TOCI IV + DMARD		0.14 (0.02,0.88)	0.17 (0.04,0.89)	-0.16 (-0.60,-0.01)
LD ABA IV + MTX	LD RITUX IV + MTX	1.36 (0.52,3.30)	1.33 (0.54,3.04)	0.01 (-0.04,0.11)
LD CERTO SC + MTX		1.71 (0.36,7.85)	1.64 (0.38,6.18)	0.03 (-0.05,0.28)
LD ETN SC + MTX		0.52 (0.16,1.67)	0.53 (0.17,1.62)	-0.02 (-0.11,0.02)
LD GOLI IV + MTX		3.25 (0.50,19.21)	2.87 (0.51,12.56)	0.08 (-0.03,0.44)

(Continued)

HD TOCI IV		1.03 (0.39,2.39)	1.02 (0.42,2.28)	0.00 (-0.07,0.06)
HD TOFA PO		0.43 (0.07,2.03)	0.45 (0.09,2.00)	-0.02 (-0.16,0.02)
HD GOLI SC		1.42 (0.35,5.66)	1.38 (0.37,4.70)	0.01 (-0.06,0.21)
HD ADA SC		0.79 (0.16,3.43)	0.80 (0.19,3.31)	-0.01 (-0.14,0.04)
HD GOLI SC + MTX		3.03 (0.94,11.06)	2.71 (0.94,8.04)	0.07 (0.00,0.35)
HD TOCI IV + MTX		1.15 (0.39,3.49)	1.15 (0.41,3.18)	0.01 (-0.06,0.11)
HD TOFA PO + MTX		1.78 (0.69,4.56)	1.70 (0.71,4.01)	0.03 (-0.02,0.18)
HD INF IV + MTX		1.15 (0.53,2.34)	1.14 (0.55,2.20)	0.00 (-0.04,0.07)
HD CERTO SC + MTX		2.10 (0.84,5.76)	1.97 (0.85,4.67)	0.04 (-0.01,0.24)
HD TOCI IV + DMARD		0.77 (0.26,2.20)	0.78 (0.28,2.12)	-0.01 (-0.10,0.04)
LD CERTO SC + MTX	LD ABA IV + MTX	1.26 (0.24,6.61)	1.23 (0.26,5.30)	0.01 (-0.10,0.25)
LD ETN SC + MTX		0.39 (0.10,1.49)	0.41 (0.11,1.46)	-0.03 (-0.17,0.02)
LD GOLI IV + MTX		2.37 (0.35,16.71)	2.14 (0.39,10.92)	0.06 (-0.07,0.42)
HD TOCI IV		0.74 (0.26,2.18)	0.75 (0.30,2.09)	-0.01 (-0.12,0.05)
HD TOFA PO		0.31 (0.05,1.76)	0.32 (0.07,1.73)	-0.04 (-0.22,0.01)
HD GOLI SC		1.05 (0.23,4.85)	1.05 (0.25,3.97)	0.00 (-0.11,0.18)
HD ADA SC		0.58 (0.11,2.69)	0.60 (0.13,2.61)	-0.02 (-0.20,0.03)
HD GOLI SC + MTX		2.22 (0.61,9.17)	2.02 (0.64,6.89)	0.06 (-0.04,0.33)
HD TOCI IV + MTX		0.83 (0.27,2.90)	0.85 (0.29,2.68)	-0.01 (-0.11,0.09)
HD TOFA PO + MTX		1.32 (0.46,4.03)	1.28 (0.49,3.58)	0.01 (-0.07,0.16)
HD INF IV + MTX		0.84 (0.33,2.15)	0.85 (0.36,2.03)	-0.01 (-0.10,0.05)
HD CERTO SC + MTX		1.55 (0.52,4.90)	1.49 (0.54,4.11)	0.03 (-0.05,0.20)
HD TOCI IV + DMARD		0.56 (0.16,1.93)	0.58 (0.19,1.89)	-0.02 (-0.16,0.03)
LD ETN SC + MTX	LD CERTO SC + MTX	0.30 (0.05,1.92)	0.32 (0.07,1.86)	-0.05 (-0.33,0.02)
LD GOLI IV + MTX		1.88 (0.19,18.68)	1.71 (0.24,12.62)	0.05 (-0.20,0.41)
HD TOCI IV		0.59 (0.11,3.13)	0.61 (0.15,2.96)	-0.03 (-0.28,0.05)
HD TOFA PO		0.23 (0.03,1.92)	0.25 (0.04,1.90)	-0.06 (-0.37,0.01)
HD GOLI SC		0.83 (0.11,5.66)	0.84 (0.14,4.82)	-0.01 (-0.26,0.16)

(Continued)

HD ADA SC		0.44 (0.06,3.66)	0.46 (0.09,3.55)	-0.04 (-0.35,0.03)
HD GOLI SC + MTX		1.78 (0.32,10.84)	1.64 (0.39,8.10)	0.04 (-0.15,0.31)
HD TOCI IV + MTX		0.68 (0.11,4.01)	0.70 (0.15,3.74)	-0.02 (-0.27,0.09)
HD TOFA PO + MTX		1.04 (0.19,6.11)	1.03 (0.24,5.45)	0.00 (-0.22,0.15)
HD INF IV + MTX		0.66 (0.15,3.06)	0.69 (0.19,2.93)	-0.02 (-0.26,0.06)
HD CERTO SC + MTX		1.20 (0.31,5.73)	1.17 (0.37,5.12)	0.01 (-0.16,0.17)
HD TOCI IV + DMARD		0.46 (0.07,2.65)	0.48 (0.10,2.57)	-0.04 (-0.32,0.03)
LD GOLI IV + MTX	LD ETN SC + MTX	6.13 (0.83,43.62)	5.25 (0.84,29.87)	0.10 (-0.01,0.48)
HD TOCI IV		1.88 (0.56,7.62)	1.83 (0.58,7.10)	0.02 (-0.03,0.11)
HD TOFA PO		0.82 (0.12,5.16)	0.83 (0.13,5.03)	0.00 (-0.10,0.03)
HD GOLI SC		2.74 (0.49,14.78)	2.60 (0.51,12.17)	0.03 (-0.03,0.25)
HD ADA SC		1.46 (0.26,8.32)	1.44 (0.28,7.97)	0.01 (-0.08,0.05)
HD GOLI SC + MTX		5.83 (1.36,27.75)	5.02 (1.32,20.70)	0.09 (0.01,0.41)
HD TOCI IV + MTX		2.19 (0.52,10.32)	2.11 (0.54,9.41)	0.02 (-0.03,0.16)
HD TOFA PO + MTX		3.42 (0.87,13.28)	3.18 (0.88,11.55)	0.05 (-0.01,0.23)
HD INF IV + MTX		2.17 (0.65,7.50)	2.09 (0.67,6.91)	0.02 (-0.02,0.13)
HD CERTO SC + MTX		3.95 (1.14,15.46)	3.60 (1.13,12.95)	0.06 (0.00,0.29)
HD TOCI IV + DMARD		1.46 (0.35,6.28)	1.44 (0.37,5.99)	0.01 (-0.05,0.07)
HD TOCI IV	LD GOLI IV + MTX	0.30 (0.05,2.05)	0.34 (0.08,1.97)	-0.08 (-0.45,0.03)
HD TOFA PO		0.14 (0.01,1.02)	0.15 (0.03,1.02)	-0.11 (-0.53,0.00)
HD GOLI SC		0.44 (0.05,3.88)	0.48 (0.08,3.35)	-0.06 (-0.42,0.14)
HD ADA SC		0.24 (0.03,1.75)	0.27 (0.06,1.71)	-0.09 (-0.50,0.02)
HD GOLI SC + MTX		0.94 (0.12,8.65)	0.94 (0.17,6.55)	-0.01 (-0.33,0.27)
HD TOCI IV + MTX		0.34 (0.05,2.58)	0.39 (0.08,2.40)	-0.07 (-0.43,0.06)
HD TOFA PO + MTX		0.54 (0.09,3.74)	0.59 (0.13,3.25)	-0.05 (-0.38,0.13)
HD INF IV + MTX		0.36 (0.06,2.22)	0.40 (0.09,2.10)	-0.07 (-0.43,0.04)
HD CERTO SC + MTX		0.67 (0.09,4.60)	0.71 (0.14,3.79)	-0.03 (-0.37,0.16)
HD TOCI IV + DMARD		0.24 (0.03,1.69)	0.27 (0.06,1.63)	-0.09 (-0.47,0.02)

(Continued)

HD TOFA PO	HD TOCI IV	0.43 (0.08,1.99)	0.44 (0.09,1.96)	-0.02 (-0.16,0.01)
HD GOLI SC		1.39 (0.35,6.05)	1.36 (0.37,4.99)	0.01 (-0.06,0.21)
HD ADA SC		0.80 (0.17,3.09)	0.81 (0.19,2.99)	-0.01 (-0.13,0.04)
HD GOLI SC + MTX		3.05 (0.89,11.48)	2.72 (0.89,8.07)	0.07 (-0.01,0.36)
HD TOCI IV + MTX		1.15 (0.53,2.56)	1.14 (0.55,2.36)	0.01 (-0.04,0.09)
HD TOFA PO + MTX		1.80 (0.61,4.93)	1.72 (0.63,4.32)	0.03 (-0.03,0.18)
HD INF IV + MTX		1.14 (0.45,2.80)	1.13 (0.47,2.64)	0.00 (-0.05,0.08)
HD CERTO SC + MTX		2.11 (0.73,6.38)	1.98 (0.75,5.17)	0.04 (-0.02,0.25)
HD TOCI IV + DMARD		0.77 (0.31,1.88)	0.78 (0.33,1.81)	-0.01 (-0.08,0.03)
HD GOLI SC	HD TOFA PO	3.40 (0.52,26.74)	3.23 (0.53,18.87)	0.04 (-0.01,0.30)
HD ADA SC		1.83 (0.61,5.97)	1.80 (0.62,5.68)	0.01 (-0.01,0.06)
HD GOLI SC + MTX		7.54 (1.02,53.03)	6.65 (1.02,30.60)	0.10 (0.00,0.46)
HD TOCI IV + MTX		2.71 (0.52,18.48)	2.62 (0.53,14.87)	0.03 (-0.01,0.21)
HD TOFA PO + MTX		4.18 (0.88,27.29)	3.94 (0.88,20.32)	0.05 (0.00,0.29)
HD INF IV + MTX		2.59 (0.53,15.27)	2.51 (0.54,12.69)	0.03 (-0.01,0.18)
HD CERTO SC + MTX		4.75 (0.85,34.40)	4.42 (0.85,23.12)	0.06 (0.00,0.36)
HD TOCI IV + DMARD		1.83 (0.38,9.43)	1.80 (0.39,8.52)	0.01 (-0.02,0.11)
HD ADA SC	HD GOLI SC	0.53 (0.08,3.39)	0.54 (0.11,3.27)	-0.03 (-0.28,0.04)
HD GOLI SC + MTX		2.14 (0.65,7.60)	1.95 (0.69,6.20)	0.06 (-0.04,0.28)
HD TOCI IV + MTX		0.81 (0.16,4.00)	0.82 (0.19,3.64)	-0.01 (-0.20,0.11)
HD TOFA PO + MTX		1.26 (0.27,5.74)	1.24 (0.32,4.99)	0.01 (-0.15,0.17)
HD INF IV + MTX		0.79 (0.20,3.25)	0.80 (0.24,3.05)	-0.01 (-0.19,0.07)
HD CERTO SC + MTX		1.44 (0.34,7.29)	1.39 (0.39,6.22)	0.02 (-0.13,0.22)
HD TOCI IV + DMARD		0.55 (0.11,2.33)	0.57 (0.14,2.26)	-0.02 (-0.24,0.04)
HD GOLI SC + MTX	HD ADA SC	3.96 (0.66,25.40)	3.58 (0.67,14.63)	0.09 (-0.01,0.43)
HD TOCI IV + MTX		1.43 (0.31,8.45)	1.41 (0.32,6.87)	0.01 (-0.04,0.19)
HD TOFA PO + MTX		2.20 (0.53,12.89)	2.11 (0.55,9.58)	0.04 (-0.02,0.27)
HD INF IV + MTX		1.42 (0.32,7.34)	1.40 (0.34,6.12)	0.01 (-0.04,0.16)

(Continued)

HD CERTO SC + MTX		2.62 (0.57,15.86)	2.47 (0.58,10.84)	0.05 (-0.02,0.34)
HD TOCI IV + DMARD		0.97 (0.25,4.31)	0.97 (0.26,3.94)	0.00 (-0.04,0.09)
HD TOCI IV + MTX	HD GOLI SC + MTX	0.37 (0.09,1.50)	0.42 (0.12,1.45)	-0.06 (-0.35,0.03)
HD TOFA PO + MTX		0.59 (0.14,2.27)	0.64 (0.18,2.10)	-0.04 (-0.28,0.08)
HD INF IV + MTX		0.38 (0.11,1.22)	0.42 (0.15,1.20)	-0.07 (-0.33,0.01)
HD CERTO SC + MTX		0.69 (0.17,2.72)	0.73 (0.23,2.42)	-0.03 (-0.27,0.10)
HD TOCI IV + DMARD		0.25 (0.06,1.03)	0.28 (0.08,1.03)	-0.08 (-0.40,0.00)
HD TOFA PO + MTX	HD TOCI IV + MTX	1.54 (0.46,5.11)	1.48 (0.49,4.51)	0.02 (-0.06,0.17)
HD INF IV + MTX		1.00 (0.31,2.85)	1.00 (0.34,2.69)	0.00 (-0.10,0.07)
HD CERTO SC + MTX		1.83 (0.51,6.30)	1.74 (0.54,5.27)	0.03 (-0.05,0.23)
HD TOCI IV + DMARD		0.67 (0.21,2.15)	0.68 (0.23,2.06)	-0.01 (-0.14,0.03)
HD INF IV + MTX	HD TOFA PO + MTX	0.63 (0.24,1.64)	0.66 (0.27,1.60)	-0.02 (-0.17,0.03)
HD CERTO SC + MTX		1.15 (0.37,3.77)	1.13 (0.41,3.25)	0.01 (-0.10,0.17)
HD TOCI IV + DMARD		0.43 (0.12,1.46)	0.46 (0.15,1.44)	-0.04 (-0.22,0.02)
HD CERTO SC + MTX	HD INF IV + MTX	1.85 (0.72,5.14)	1.75 (0.74,4.24)	0.03 (-0.02,0.22)
HD TOCI IV + DMARD		0.67 (0.21,2.04)	0.69 (0.24,1.98)	-0.01 (-0.12,0.03)
HD TOCI IV + DMARD	HD CERTO SC + MTX	0.37 (0.10,1.33)	0.40 (0.13,1.31)	-0.05 (-0.29,0.01)
Random-Effect Model	Residual Deviance	152 vs 153 data points		
	Deviance Information Criteria	843.894		
Fixed-Effect Model	Residual Deviance	161.1 vs 153 data points		
	Deviance Information Criteria	845.774		
Note:				
Total Patients	28661			

(Continued)

Total Studies	61
2-arm	38
3-arm	16
4-arm	6
5-arm	1

### Appendix 39. Serious Adverse Events: Subgroup - Established RA (2 to 10 years)

SAEs in Established RA: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
MTX	PL	1.96 (0.39,5.90)	1.90 (0.39,5.24)	0.02 (-0.02,0.12)
DMARD		0.76 (0.20,2.86)	0.76 (0.20,2.73)	-0.01 (-0.03,0.05)
MTX + DMARD		1.08 (0.19,4.61)	1.08 (0.20,4.15)	0.00 (-0.03,0.09)
SD ETN SC		2.30 (0.66,6.73)	2.22 (0.67,5.90)	0.04 (-0.01,0.14)
SD ADA SC		1.52 (0.73,3.04)	1.49 (0.73,2.90)	0.01 (-0.01,0.05)
SD TOCI IV		1.69 (0.57,4.79)	1.65 (0.58,4.33)	0.02 (-0.01,0.10)
SD TOFA PO		0.37 (0.15,0.95)	0.38 (0.16,0.95)	-0.02 (-0.04,0.00)
SD CERTO SC		4.55 (1.35,24.41)	4.09 (1.34,16.75)	0.09 (0.01,0.31)
SD TOC SC + PL IV		1.46 (0.40,5.21)	1.44 (0.41,4.65)	0.01 (-0.02,0.11)
SD GOL I IV		1.88 (0.12,52.25)	1.83 (0.12,24.92)	0.02 (-0.03,0.51)
SD INF IV + MTX		1.89 (0.45,6.27)	1.84 (0.46,5.47)	0.02 (-0.02,0.13)
SD ETN SC + MTX		1.85 (0.37,6.22)	1.81 (0.38,5.44)	0.02 (-0.02,0.13)
SD ABA IV + MTX		1.52 (0.30,5.17)	1.50 (0.31,4.64)	0.01 (-0.02,0.11)
SD CERTO SC + MTX		2.78 (0.59,10.08)	2.64 (0.60,8.00)	0.05 (-0.01,0.21)
SD ADA SC + MTX		2.30 (0.36,7.68)	2.22 (0.37,6.52)	0.03 (-0.02,0.16)
SD ABA SC + MTX		1.10 (0.21,4.40)	1.09 (0.22,4.02)	0.00 (-0.03,0.09)
SD GOL I SC + MTX		4.26 (0.71,17.63)	3.89 (0.71,12.29)	0.08 (-0.01,0.33)
SD RITUX IV + MTX		1.59 (0.31,5.87)	1.56 (0.31,5.16)	0.02 (-0.02,0.12)

(Continued)

SD TOFA PO + MTX	4.59 (0.80,17.14)	4.14 (0.81,11.97)	0.09 (-0.01,0.31)
SD GOL I IV + MTX	5.40 (0.45,107.10)	4.77 (0.46,32.58)	0.11 (-0.02,0.71)
SD ETN SC + DMARD	2.12 (0.67,6.42)	2.05 (0.68,5.62)	0.03 (-0.01,0.13)
SD ADA SC + DMARD	0.54 (0.11,2.58)	0.55 (0.12,2.47)	-0.01 (-0.04,0.04)
SD CERTO SC + DMARD	0.52 (0.09,3.17)	0.53 (0.09,2.99)	-0.01 (-0.04,0.05)
LD ADA SC	0.77 (0.30,1.68)	0.78 (0.31,1.65)	-0.01 (-0.03,0.02)
LD ETN SC	1.51 (0.33,6.09)	1.48 (0.34,5.28)	0.01 (-0.02,0.13)
LD GOL I IV	9.67 (0.64,176.00)	7.62 (0.65,38.84)	0.20 (-0.01,0.77)
LD RITUX IV + MTX	1.03 (0.19,3.98)	1.03 (0.20,3.67)	0.00 (-0.03,0.08)
LD ABA IV + MTX	2.31 (0.39,9.43)	2.23 (0.40,7.69)	0.03 (-0.02,0.20)
LD CERTO SC + MTX	2.65 (0.32,13.80)	2.52 (0.33,9.96)	0.04 (-0.02,0.28)
LD ETN SC + MTX	0.94 (0.18,4.22)	0.94 (0.19,3.86)	0.00 (-0.03,0.09)
LD GOL I IV + MTX	5.28 (0.35,98.46)	4.68 (0.36,33.02)	0.11 (-0.02,0.67)
HD TOCI IV	1.62 (0.39,6.09)	1.59 (0.40,5.38)	0.02 (-0.02,0.13)
HD TOFA PO	0.49 (0.20,1.18)	0.50 (0.21,1.17)	-0.01 (-0.03,0.00)
HD ADA SC	1.17 (0.51,2.71)	1.16 (0.52,2.61)	0.00 (-0.02,0.04)
HD GOL I SC	2.50 (0.38,12.40)	2.39 (0.39,9.42)	0.04 (-0.02,0.25)
HD GOL I SC + MTX	5.84 (0.85,23.62)	5.10 (0.86,14.31)	0.12 (0.00,0.40)
HD TOCI IV + MTX	1.98 (0.41,8.14)	1.92 (0.42,6.85)	0.03 (-0.02,0.17)
HD TOFA PO + MTX	3.77 (0.70,14.44)	3.47 (0.71,10.70)	0.07 (-0.01,0.28)
HD CERTO SC + MTX	3.56 (0.84,13.69)	3.31 (0.85,9.97)	0.07 (-0.01,0.27)
HD INF IV + MTX	1.84 (0.36,6.84)	1.79 (0.37,5.88)	0.02 (-0.02,0.14)
HD TOCI IV + DMARD	1.16 (0.27,5.05)	1.15 (0.27,4.52)	0.00 (-0.03,0.10)
DMARD	MTX	0.41 (0.16,0.98)	0.42 (0.17,0.98)
MTX + DMARD		0.57 (0.18,1.64)	0.58 (0.19,1.59)
SD ETN SC		1.23 (0.58,2.42)	1.21 (0.60,2.32)
SD ADA SC		0.82 (0.22,3.48)	0.83 (0.25,3.36)
SD TOCI IV		0.89 (0.21,4.69)	0.90 (0.23,4.41)

(Continued)

SD TOFA PO	0.19 (0.05,1.01)	0.20 (0.06,1.01)	-0.04 (-0.15,0.00)
SD CERTO SC	2.31 (0.42,19.65)	2.15 (0.46,14.43)	0.06 (-0.07,0.30)
SD TOC SC + PL IV	0.78 (0.15,4.75)	0.79 (0.17,4.40)	-0.01 (-0.11,0.08)
SD GOLI IV	0.93 (0.07,23.30)	0.94 (0.07,11.95)	0.00 (-0.10,0.49)
SD INF IV + MTX	1.00 (0.62,1.57)	1.00 (0.64,1.54)	0.00 (-0.03,0.04)
SD ETN SC + MTX	0.95 (0.47,1.96)	0.95 (0.49,1.87)	0.00 (-0.05,0.05)
SD ABA IV + MTX	0.80 (0.49,1.19)	0.81 (0.51,1.18)	-0.01 (-0.05,0.01)
SD CERTO SC + MTX	1.51 (0.92,2.49)	1.46 (0.92,2.29)	0.02 (0.00,0.11)
SD ADA SC + MTX	1.11 (0.49,2.42)	1.11 (0.51,2.25)	0.00 (-0.04,0.08)
SD ABA SC + MTX	0.59 (0.27,1.18)	0.60 (0.28,1.17)	-0.02 (-0.07,0.01)
SD GOLI SC + MTX	2.22 (0.64,6.56)	2.06 (0.66,5.32)	0.05 (-0.02,0.26)
SD RITUX IV + MTX	0.85 (0.46,1.57)	0.86 (0.48,1.52)	-0.01 (-0.05,0.04)
SD TOFA PO + MTX	2.23 (0.97,5.52)	2.06 (0.98,4.48)	0.06 (0.00,0.22)
SD GOLI IV + MTX	2.67 (0.43,47.82)	2.40 (0.45,16.29)	0.08 (-0.03,0.67)
SD ETN SC + DMARD	1.14 (0.43,2.79)	1.13 (0.45,2.67)	0.01 (-0.06,0.07)
SD ADA SC + DMARD	0.29 (0.09,0.96)	0.31 (0.09,0.96)	-0.03 (-0.12,0.00)
SD CERTO SC + DMARD	0.28 (0.06,1.45)	0.29 (0.06,1.43)	-0.03 (-0.12,0.01)
LD ADA SC	0.42 (0.09,1.60)	0.43 (0.11,1.59)	-0.03 (-0.14,0.01)
LD ETN SC	0.80 (0.30,1.90)	0.81 (0.31,1.81)	-0.01 (-0.07,0.05)
LD GOLI IV	4.77 (0.85,81.13)	3.72 (0.86,19.33)	0.17 (-0.01,0.73)
LD RITUX IV + MTX	0.56 (0.29,1.06)	0.57 (0.30,1.06)	-0.02 (-0.07,0.00)
LD ABA IV + MTX	1.19 (0.56,2.57)	1.18 (0.57,2.33)	0.01 (-0.03,0.10)
LD CERTO SC + MTX	1.45 (0.24,5.28)	1.41 (0.25,4.30)	0.02 (-0.05,0.21)
LD ETN SC + MTX	0.50 (0.17,1.32)	0.52 (0.18,1.29)	-0.02 (-0.09,0.02)
LD GOLI IV + MTX	2.68 (0.49,45.71)	2.42 (0.51,16.27)	0.08 (-0.03,0.62)
HD TOCI IV	0.87 (0.41,1.83)	0.88 (0.43,1.75)	-0.01 (-0.06,0.05)
HD TOFA PO	0.26 (0.07,1.26)	0.27 (0.07,1.25)	-0.04 (-0.14,0.00)
HD ADA SC	0.61 (0.16,2.93)	0.63 (0.18,2.83)	-0.02 (-0.12,0.03)



(Continued)

HD GOLI SC		1.32 (0.35,4.40)	1.29 (0.36,3.74)	0.01 (-0.05,0.17)
HD GOLI SC + MTX		3.00 (1.10,8.04)	2.64 (1.09,5.79)	0.09 (0.00,0.33)
HD TOCI IV + MTX		1.05 (0.42,2.61)	1.04 (0.44,2.41)	0.00 (-0.05,0.09)
HD TOFA PO + MTX		1.88 (0.73,4.58)	1.77 (0.74,3.90)	0.04 (-0.01,0.19)
HD CERTO SC + MTX		1.88 (0.89,3.98)	1.78 (0.90,3.50)	0.04 (-0.01,0.18)
HD INF IV + MTX		0.97 (0.49,1.89)	0.97 (0.51,1.79)	0.00 (-0.04,0.05)
HD TOCI IV + DMARD		0.62 (0.21,1.71)	0.64 (0.23,1.64)	-0.02 (-0.09,0.03)
MTX + DMARD	DMARD	1.36 (0.35,4.84)	1.35 (0.36,4.47)	0.01 (-0.03,0.08)
SD ETN SC		2.95 (1.26,7.79)	2.80 (1.24,7.26)	0.04 (0.01,0.12)
SD ADA SC		1.98 (0.52,7.97)	1.93 (0.54,7.59)	0.02 (-0.03,0.06)
SD TOCI IV		2.15 (0.48,10.49)	2.09 (0.50,9.63)	0.02 (-0.03,0.10)
SD TOFA PO		0.47 (0.11,2.81)	0.48 (0.12,2.76)	-0.01 (-0.07,0.01)
SD CERTO SC		6.23 (0.92,44.44)	5.53 (0.92,32.46)	0.10 (0.00,0.31)
SD TOC SC + PL IV		1.94 (0.36,10.55)	1.89 (0.37,9.48)	0.02 (-0.04,0.11)
SD GOLI IV		2.27 (0.18,57.03)	2.17 (0.18,27.77)	0.03 (-0.04,0.51)
SD INF IV + MTX		2.45 (0.90,6.95)	2.35 (0.91,6.35)	0.03 (0.00,0.12)
SD ETN SC + MTX		2.34 (0.86,6.83)	2.25 (0.86,6.27)	0.03 (-0.01,0.11)
SD ABA IV + MTX		1.90 (0.71,5.44)	1.86 (0.72,5.06)	0.02 (-0.01,0.09)
SD CERTO SC + MTX		3.70 (1.33,10.74)	3.46 (1.31,9.24)	0.05 (0.01,0.19)
SD ADA SC + MTX		2.77 (0.81,8.47)	2.64 (0.82,7.66)	0.04 (-0.01,0.15)
SD ABA SC + MTX		1.41 (0.44,4.63)	1.40 (0.45,4.36)	0.01 (-0.03,0.08)
SD GOLI SC + MTX		5.36 (1.32,21.74)	4.75 (1.31,16.88)	0.09 (0.01,0.32)
SD RITUX IV + MTX		2.07 (0.65,6.43)	2.01 (0.66,5.91)	0.02 (-0.01,0.11)
SD TOFA PO + MTX		5.58 (1.73,18.92)	4.94 (1.67,14.94)	0.09 (0.01,0.29)
SD GOLI IV + MTX		6.73 (0.82,121.50)	5.74 (0.82,37.64)	0.11 (0.00,0.71)
SD ETN SC + DMARD		2.72 (1.02,7.85)	2.61 (1.02,7.26)	0.03 (0.00,0.11)
SD ADA SC + DMARD		0.74 (0.31,1.65)	0.74 (0.31,1.62)	0.00 (-0.03,0.02)
SD CERTO SC + DMARD		0.70 (0.18,2.38)	0.71 (0.18,2.29)	-0.01 (-0.04,0.04)

(Continued)

LD ADA SC		1.03 (0.21,4.28)	1.03 (0.22,4.17)	0.00 (-0.06,0.03)
LD ETN SC		1.88 (0.61,6.75)	1.84 (0.62,6.19)	0.02 (-0.02,0.11)
LD GOL I V		11.82 (1.38,182.20)	8.82 (1.37,46.95)	0.20 (0.01,0.77)
LD RITUX IV + MTX		1.38 (0.43,4.39)	1.37 (0.44,4.15)	0.01 (-0.03,0.07)
LD ABA IV + MTX		2.92 (0.88,10.07)	2.78 (0.88,8.61)	0.04 (0.00,0.18)
LD CERTO SC + MTX		3.43 (0.45,16.59)	3.22 (0.46,13.21)	0.05 (-0.02,0.27)
LD ETN SC + MTX		1.20 (0.33,4.69)	1.19 (0.34,4.41)	0.00 (-0.04,0.08)
LD GOL I V + MTX		6.52 (0.76,107.20)	5.63 (0.77,38.47)	0.11 (0.00,0.67)
HD TOCI IV		2.12 (1.07,4.54)	2.06 (1.06,4.29)	0.02 (0.00,0.10)
HD TOFA PO		0.63 (0.14,3.48)	0.64 (0.16,3.42)	-0.01 (-0.06,0.02)
HD ADA SC		1.56 (0.34,6.43)	1.54 (0.35,6.19)	0.01 (-0.05,0.05)
HD GOL I SC		3.21 (0.60,16.83)	3.02 (0.61,13.75)	0.04 (-0.01,0.24)
HD GOL I SC + MTX		7.20 (1.84,31.16)	6.09 (1.78,22.25)	0.12 (0.01,0.39)
HD TOCI IV + MTX		2.52 (0.93,7.29)	2.43 (0.93,6.54)	0.03 (0.00,0.15)
HD TOFA PO + MTX		4.63 (1.38,16.09)	4.20 (1.36,12.91)	0.07 (0.01,0.26)
HD CERTO SC + MTX		4.71 (1.42,14.36)	4.29 (1.39,11.75)	0.07 (0.01,0.26)
HD INF IV + MTX		2.36 (0.75,7.70)	2.27 (0.76,7.03)	0.03 (-0.01,0.13)
HD TOCI IV + DMARD		1.51 (0.90,2.62)	1.49 (0.90,2.52)	0.01 (0.00,0.06)
SD ETN SC	MTX + DMARD	2.14 (0.69,7.09)	2.05 (0.71,6.66)	0.03 (-0.02,0.10)
SD ADA SC		1.45 (0.30,7.18)	1.43 (0.32,6.81)	0.01 (-0.08,0.06)
SD TOCI IV		1.60 (0.28,9.19)	1.57 (0.30,8.53)	0.02 (-0.07,0.10)
SD TOFA PO		0.35 (0.07,2.21)	0.36 (0.07,2.18)	-0.02 (-0.11,0.01)
SD CERTO SC		4.18 (0.54,46.06)	3.77 (0.57,33.19)	0.09 (-0.05,0.31)
SD TOC SC + PL IV		1.42 (0.22,9.70)	1.40 (0.24,8.97)	0.01 (-0.08,0.10)
SD GOL I V		1.69 (0.10,61.18)	1.65 (0.11,31.36)	0.02 (-0.08,0.51)
SD INF IV + MTX		1.78 (0.57,5.86)	1.72 (0.59,5.43)	0.02 (-0.03,0.10)
SD ETN SC + MTX		1.71 (0.64,4.59)	1.66 (0.67,4.35)	0.02 (-0.03,0.08)
SD ABA IV + MTX		1.41 (0.43,4.65)	1.39 (0.45,4.41)	0.01 (-0.05,0.07)

(Continued)

SD CERTO SC + MTX	2.69 (0.83,9.40)	2.52 (0.84,8.55)	0.04 (-0.01,0.17)
SD ADA SC + MTX	2.00 (0.52,8.04)	1.92 (0.54,7.30)	0.03 (-0.03,0.13)
SD ABA SC + MTX	1.07 (0.28,3.91)	1.07 (0.30,3.72)	0.00 (-0.07,0.06)
SD GOLI SC + MTX	3.87 (0.80,22.09)	3.46 (0.81,17.69)	0.07 (-0.01,0.31)
SD RITUX IV + MTX	1.50 (0.44,5.59)	1.47 (0.46,5.23)	0.01 (-0.05,0.10)
SD TOFA PO + MTX	4.05 (1.05,17.25)	3.66 (1.04,14.00)	0.08 (0.00,0.28)
SD GOLI IV + MTX	4.85 (0.64,118.10)	4.14 (0.66,42.92)	0.10 (-0.01,0.71)
SD ETN SC + DMARD	2.00 (0.54,7.48)	1.93 (0.57,7.01)	0.02 (-0.04,0.10)
SD ADA SC + DMARD	0.52 (0.12,2.69)	0.53 (0.12,2.63)	-0.01 (-0.09,0.03)
SD CERTO SC + DMARD	0.50 (0.09,3.53)	0.51 (0.09,3.37)	-0.01 (-0.10,0.04)
LD ADA SC	0.75 (0.13,3.80)	0.75 (0.14,3.72)	-0.01 (-0.10,0.03)
LD ETN SC	1.42 (0.36,5.64)	1.39 (0.38,5.33)	0.01 (-0.05,0.09)
LD GOLI IV	8.77 (1.13,208.10)	6.47 (1.13,53.45)	0.19 (0.00,0.76)
LD RITUX IV + MTX	0.99 (0.29,3.92)	0.99 (0.31,3.74)	0.00 (-0.07,0.06)
LD ABA IV + MTX	2.12 (0.56,8.51)	2.02 (0.58,7.49)	0.03 (-0.03,0.16)
LD CERTO SC + MTX	2.65 (0.32,14.88)	2.49 (0.33,12.20)	0.04 (-0.04,0.25)
LD ETN SC + MTX	0.89 (0.22,3.61)	0.89 (0.23,3.47)	0.00 (-0.08,0.06)
LD GOLI IV + MTX	4.84 (0.71,118.60)	4.13 (0.72,42.49)	0.10 (-0.01,0.65)
HD TOCI IV	1.58 (0.46,5.65)	1.55 (0.48,5.24)	0.01 (-0.04,0.10)
HD TOFA PO	0.48 (0.09,2.82)	0.49 (0.09,2.77)	-0.02 (-0.11,0.02)
HD ADA SC	1.11 (0.22,6.26)	1.11 (0.24,6.00)	0.00 (-0.09,0.05)
HD GOLI SC	2.28 (0.40,14.03)	2.17 (0.42,11.53)	0.03 (-0.04,0.22)
HD GOLI SC + MTX	5.21 (1.22,28.19)	4.44 (1.20,20.46)	0.11 (0.01,0.38)
HD TOCI IV + MTX	1.84 (0.45,7.48)	1.78 (0.47,6.76)	0.02 (-0.05,0.14)
HD TOFA PO + MTX	3.36 (0.85,14.74)	3.08 (0.86,12.33)	0.06 (-0.01,0.25)
HD CERTO SC + MTX	3.33 (0.94,13.50)	3.05 (0.95,11.55)	0.06 (0.00,0.23)
HD INF IV + MTX	1.72 (0.50,6.42)	1.67 (0.53,5.91)	0.02 (-0.04,0.11)
HD TOCI IV + DMARD	1.11 (0.29,4.52)	1.10 (0.31,4.32)	0.00 (-0.07,0.07)

(Continued)

SD ADA SC	SD ETN SC	0.68 (0.21,2.00)	0.69 (0.24,1.94)	-0.02 (-0.12,0.03)
SD TOCI IV		0.72 (0.19,2.97)	0.73 (0.21,2.78)	-0.02 (-0.12,0.07)
SD TOFA PO		0.16 (0.04,0.74)	0.17 (0.05,0.75)	-0.05 (-0.16,-0.01)
SD CERTO SC		2.02 (0.37,13.99)	1.88 (0.40,10.33)	0.06 (-0.09,0.29)
SD TOC SC + PL IV		0.64 (0.14,3.14)	0.66 (0.15,2.91)	-0.02 (-0.13,0.08)
SD GOLI IV		0.79 (0.05,19.56)	0.81 (0.06,9.33)	-0.01 (-0.12,0.48)
SD INF IV + MTX		0.82 (0.36,1.94)	0.83 (0.37,1.84)	-0.01 (-0.07,0.06)
SD ETN SC + MTX		0.78 (0.38,1.69)	0.79 (0.40,1.61)	-0.01 (-0.06,0.04)
SD ABA IV + MTX		0.65 (0.28,1.59)	0.67 (0.30,1.52)	-0.02 (-0.08,0.03)
SD CERTO SC + MTX		1.24 (0.53,3.02)	1.22 (0.55,2.69)	0.01 (-0.04,0.12)
SD ADA SC + MTX		0.92 (0.32,2.57)	0.93 (0.33,2.38)	0.00 (-0.06,0.08)
SD ABA SC + MTX		0.48 (0.17,1.37)	0.50 (0.19,1.34)	-0.03 (-0.10,0.02)
SD GOLI SC + MTX		1.80 (0.45,6.53)	1.70 (0.47,4.91)	0.04 (-0.04,0.26)
SD RITUX IV + MTX		0.69 (0.28,1.85)	0.71 (0.29,1.76)	-0.02 (-0.08,0.05)
SD TOFA PO + MTX		1.88 (0.64,5.53)	1.75 (0.66,4.39)	0.05 (-0.02,0.23)
SD GOLI IV + MTX		2.24 (0.31,43.59)	2.03 (0.33,13.85)	0.07 (-0.05,0.66)
SD ETN SC + DMARD		0.92 (0.45,1.90)	0.93 (0.47,1.82)	0.00 (-0.06,0.05)
SD ADA SC + DMARD		0.24 (0.07,0.79)	0.26 (0.08,0.81)	-0.05 (-0.13,-0.01)
SD CERTO SC + DMARD		0.23 (0.05,1.09)	0.25 (0.05,1.09)	-0.04 (-0.14,0.00)
LD ADA SC		0.35 (0.09,1.16)	0.36 (0.10,1.15)	-0.04 (-0.15,0.00)
LD ETN SC		0.65 (0.25,1.65)	0.67 (0.27,1.58)	-0.02 (-0.08,0.04)
LD GOLI IV		3.94 (0.51,64.81)	3.19 (0.52,15.77)	0.15 (-0.03,0.73)
LD RITUX IV + MTX		0.46 (0.18,1.25)	0.48 (0.19,1.22)	-0.03 (-0.10,0.01)
LD ABA IV + MTX		1.00 (0.34,2.96)	1.00 (0.36,2.64)	0.00 (-0.06,0.11)
LD CERTO SC + MTX		1.22 (0.17,4.95)	1.20 (0.18,3.97)	0.01 (-0.08,0.21)
LD ETN SC + MTX		0.41 (0.13,1.36)	0.43 (0.14,1.33)	-0.03 (-0.11,0.02)
LD GOLI IV + MTX		2.20 (0.28,34.53)	2.02 (0.29,13.51)	0.06 (-0.05,0.62)
HD TOCI IV		0.72 (0.29,1.74)	0.73 (0.31,1.66)	-0.01 (-0.07,0.04)

(Continued)

HD TOFA PO		0.21 (0.06,0.92)	0.22 (0.07,0.93)	-0.05 (-0.15,0.00)
HD ADA SC		0.51 (0.14,1.82)	0.53 (0.16,1.78)	-0.03 (-0.14,0.02)
HD GOLI SC		1.09 (0.23,4.28)	1.08 (0.25,3.57)	0.00 (-0.08,0.17)
HD GOLI SC + MTX		2.40 (0.73,8.31)	2.17 (0.75,5.84)	0.07 (-0.02,0.33)
HD TOCI IV + MTX		0.86 (0.28,2.55)	0.87 (0.30,2.34)	-0.01 (-0.08,0.08)
HD TOFA PO + MTX		1.56 (0.47,4.79)	1.50 (0.49,3.89)	0.03 (-0.04,0.20)
HD CERTO SC + MTX		1.53 (0.59,4.30)	1.47 (0.61,3.63)	0.03 (-0.03,0.19)
HD INF IV + MTX		0.79 (0.30,2.16)	0.81 (0.32,2.02)	-0.01 (-0.07,0.07)
HD TOCI IV + DMARD		0.52 (0.18,1.43)	0.53 (0.19,1.39)	-0.03 (-0.10,0.02)
SD TOCI IV	SD ADA SC	1.09 (0.50,2.49)	1.08 (0.52,2.33)	0.00 (-0.02,0.07)
SD TOFA PO		0.24 (0.08,0.76)	0.25 (0.09,0.77)	-0.03 (-0.08,-0.01)
SD CERTO SC		3.06 (0.75,17.88)	2.79 (0.76,12.62)	0.08 (-0.02,0.30)
SD TOC SC + PL IV		0.97 (0.34,2.76)	0.97 (0.35,2.54)	0.00 (-0.04,0.08)
SD GOLI IV		1.27 (0.07,27.30)	1.25 (0.08,12.99)	0.01 (-0.06,0.50)
SD INF IV + MTX		1.20 (0.33,4.77)	1.19 (0.34,4.25)	0.01 (-0.04,0.12)
SD ETN SC + MTX		1.14 (0.29,4.42)	1.14 (0.30,3.95)	0.01 (-0.04,0.11)
SD ABA IV + MTX		0.96 (0.23,3.86)	0.96 (0.24,3.51)	0.00 (-0.05,0.09)
SD CERTO SC + MTX		1.80 (0.45,7.39)	1.74 (0.46,6.04)	0.03 (-0.03,0.19)
SD ADA SC + MTX		1.42 (0.26,5.81)	1.39 (0.27,4.99)	0.02 (-0.04,0.14)
SD ABA SC + MTX		0.70 (0.16,3.29)	0.71 (0.17,3.03)	-0.01 (-0.06,0.07)
SD GOLI SC + MTX		2.82 (0.51,12.81)	2.59 (0.52,8.93)	0.07 (-0.03,0.32)
SD RITUX IV + MTX		1.04 (0.23,4.37)	1.04 (0.24,3.93)	0.00 (-0.05,0.11)
SD TOFA PO + MTX		2.96 (0.57,11.61)	2.71 (0.59,8.51)	0.07 (-0.02,0.29)
SD GOLI IV + MTX		3.68 (0.31,60.18)	3.28 (0.32,18.17)	0.10 (-0.04,0.69)
SD ETN SC + DMARD		1.37 (0.52,3.89)	1.35 (0.54,3.51)	0.01 (-0.03,0.10)
SD ADA SC + DMARD		0.37 (0.08,1.81)	0.38 (0.08,1.76)	-0.03 (-0.07,0.03)
SD CERTO SC + DMARD		0.36 (0.06,2.04)	0.37 (0.06,1.95)	-0.03 (-0.07,0.04)
LD ADA SC		0.50 (0.22,1.07)	0.51 (0.23,1.06)	-0.02 (-0.06,0.00)

(Continued)

LD ETN SC		0.97 (0.22,4.50)	0.97 (0.23,4.00)	0.00 (-0.05,0.11)
LD GOLI IV		6.59 (0.46,83.79)	5.19 (0.47,21.73)	0.18 (-0.02,0.75)
LD RITUX IV + MTX		0.68 (0.15,3.18)	0.69 (0.15,2.96)	-0.01 (-0.06,0.07)
LD ABA IV + MTX		1.47 (0.27,6.54)	1.44 (0.28,5.50)	0.02 (-0.04,0.18)
LD CERTO SC + MTX		1.74 (0.20,10.56)	1.68 (0.21,7.95)	0.03 (-0.05,0.26)
LD ETN SC + MTX		0.60 (0.12,2.94)	0.61 (0.13,2.72)	-0.02 (-0.06,0.07)
LD GOLI IV + MTX		3.63 (0.24,51.00)	3.22 (0.25,18.00)	0.09 (-0.04,0.65)
HD TOCI IV		1.07 (0.28,4.37)	1.07 (0.29,3.89)	0.00 (-0.04,0.11)
HD TOFA PO		0.32 (0.11,0.99)	0.33 (0.12,0.99)	-0.03 (-0.07,0.00)
HD ADA SC		0.78 (0.37,1.59)	0.79 (0.38,1.57)	-0.01 (-0.04,0.02)
HD GOLI SC		1.64 (0.26,8.47)	1.59 (0.27,6.60)	0.02 (-0.04,0.23)
HD GOLI SC + MTX		3.70 (0.65,16.83)	3.30 (0.66,10.82)	0.10 (-0.02,0.38)
HD TOCI IV + MTX		1.28 (0.27,6.06)	1.26 (0.28,5.17)	0.01 (-0.04,0.15)
HD TOFA PO + MTX		2.42 (0.47,10.13)	2.26 (0.48,7.76)	0.06 (-0.03,0.26)
HD CERTO SC + MTX		2.28 (0.57,10.24)	2.14 (0.58,7.74)	0.05 (-0.02,0.26)
HD INF IV + MTX		1.20 (0.25,5.10)	1.18 (0.26,4.46)	0.01 (-0.04,0.13)
HD TOCI IV + DMARD		0.78 (0.17,3.23)	0.79 (0.18,2.99)	-0.01 (-0.05,0.08)
SD TOFA PO	SD TOCI IV	0.22 (0.05,0.91)	0.23 (0.06,0.91)	-0.04 (-0.12,0.00)
SD CERTO SC		2.75 (0.54,20.04)	2.52 (0.57,14.46)	0.07 (-0.05,0.30)
SD TOC SC + PL IV		0.88 (0.43,1.74)	0.88 (0.45,1.67)	0.00 (-0.04,0.04)
SD GOLI IV		1.16 (0.06,27.62)	1.15 (0.07,13.48)	0.01 (-0.09,0.49)
SD INF IV + MTX		1.12 (0.24,5.05)	1.11 (0.25,4.53)	0.00 (-0.08,0.12)
SD ETN SC + MTX		1.06 (0.22,4.62)	1.06 (0.23,4.14)	0.00 (-0.08,0.11)
SD ABA IV + MTX		0.89 (0.17,4.18)	0.90 (0.18,3.81)	0.00 (-0.09,0.09)
SD CERTO SC + MTX		1.67 (0.34,7.87)	1.61 (0.36,6.57)	0.03 (-0.06,0.19)
SD ADA SC + MTX		1.28 (0.20,6.39)	1.26 (0.21,5.59)	0.01 (-0.07,0.14)
SD ABA SC + MTX		0.65 (0.12,3.39)	0.66 (0.13,3.14)	-0.01 (-0.10,0.08)
SD GOLI SC + MTX		2.56 (0.40,13.46)	2.35 (0.42,9.78)	0.06 (-0.05,0.31)

(Continued)

SD RITUX IV + MTX	0.97 (0.18,4.75)	0.97 (0.19,4.30)	0.00 (-0.08,0.11)	
SD TOFA PO + MTX	2.64 (0.42,12.84)	2.41 (0.44,9.51)	0.07 (-0.05,0.28)	
SD GOL I IV + MTX	3.41 (0.22,61.85)	3.02 (0.24,19.34)	0.09 (-0.06,0.69)	
SD ETN SC + DMARD	1.27 (0.34,4.44)	1.26 (0.36,4.01)	0.01 (-0.06,0.10)	
SD ADA SC + DMARD	0.34 (0.06,1.91)	0.35 (0.06,1.86)	-0.03 (-0.11,0.03)	
SD CERTO SC + DMARD	0.32 (0.04,2.17)	0.33 (0.05,2.07)	-0.03 (-0.11,0.03)	
LD ADA SC	0.46 (0.15,1.35)	0.48 (0.16,1.34)	-0.02 (-0.10,0.01)	
LD ETN SC	0.89 (0.16,4.48)	0.90 (0.18,4.08)	0.00 (-0.09,0.10)	
LD GOL I IV	5.99 (0.36,88.57)	4.66 (0.38,23.50)	0.18 (-0.04,0.74)	
LD RITUX IV + MTX	0.63 (0.11,3.31)	0.65 (0.12,3.11)	-0.01 (-0.10,0.07)	
LD ABA IV + MTX	1.35 (0.20,7.19)	1.33 (0.21,6.07)	0.01 (-0.07,0.18)	
LD CERTO SC + MTX	1.61 (0.15,10.72)	1.55 (0.16,8.10)	0.03 (-0.07,0.25)	
LD ETN SC + MTX	0.55 (0.09,3.13)	0.57 (0.10,2.94)	-0.02 (-0.10,0.07)	
LD GOL I IV + MTX	3.24 (0.19,51.29)	2.87 (0.20,18.93)	0.09 (-0.06,0.64)	
HD TOCI IV	1.00 (0.21,4.73)	1.00 (0.22,4.29)	0.00 (-0.08,0.11)	
HD TOFA PO	0.29 (0.08,1.15)	0.30 (0.08,1.15)	-0.03 (-0.12,0.00)	
HD ADA SC	0.71 (0.24,2.05)	0.72 (0.26,2.00)	-0.01 (-0.09,0.03)	
HD GOL I SC	1.49 (0.20,8.95)	1.46 (0.21,7.38)	0.02 (-0.08,0.22)	
HD GOL I SC + MTX	3.39 (0.47,18.48)	3.00 (0.50,12.23)	0.09 (-0.04,0.37)	
HD TOCI IV + MTX	1.18 (0.22,6.35)	1.17 (0.23,5.49)	0.01 (-0.08,0.15)	
HD TOFA PO + MTX	2.17 (0.35,10.99)	2.03 (0.37,8.57)	0.05 (-0.06,0.25)	
HD CERTO SC + MTX	2.09 (0.45,10.78)	1.97 (0.47,8.32)	0.05 (-0.05,0.25)	
HD INF IV + MTX	1.10 (0.18,5.34)	1.09 (0.20,4.74)	0.00 (-0.08,0.13)	
HD TOCI IV + DMARD	0.72 (0.13,3.49)	0.73 (0.14,3.22)	-0.01 (-0.09,0.07)	
SD CERTO SC	SD TOFA PO	12.44 (2.55,73.20)	10.94 (2.45,52.33)	0.11 (0.03,0.32)
SD TOC SC + PL IV	3.99 (0.81,18.05)	3.85 (0.81,16.08)	0.03 (0.00,0.13)	
SD GOL I IV	5.00 (0.25,137.40)	4.75 (0.25,67.34)	0.04 (-0.01,0.53)	
SD INF IV + MTX	5.05 (0.92,20.77)	4.83 (0.92,18.27)	0.04 (0.00,0.15)	

(Continued)

SD ETN SC + MTX	4.93 (0.93,20.71)	4.71 (0.94,18.23)	0.04 (0.00,0.15)
SD ABA IV + MTX	4.04 (0.73,16.71)	3.90 (0.74,15.08)	0.03 (0.00,0.13)
SD CERTO SC + MTX	7.49 (1.44,33.76)	6.94 (1.43,27.00)	0.07 (0.01,0.23)
SD ADA SC + MTX	5.98 (0.93,25.95)	5.63 (0.93,21.85)	0.05 (0.00,0.18)
SD ABA SC + MTX	2.96 (0.49,15.03)	2.89 (0.50,13.55)	0.02 (-0.01,0.11)
SD GOLI SC + MTX	11.33 (1.54,60.51)	10.03 (1.53,42.27)	0.10 (0.01,0.35)
SD RITUX IV + MTX	4.23 (0.77,19.73)	4.07 (0.77,17.37)	0.03 (0.00,0.14)
SD TOFA PO + MTX	12.35 (1.88,52.11)	10.85 (1.85,37.92)	0.11 (0.01,0.33)
SD GOLI IV + MTX	14.11 (1.10,325.50)	12.12 (1.09,104.00)	0.13 (0.00,0.73)
SD ETN SC + DMARD	5.66 (1.30,21.61)	5.35 (1.30,18.91)	0.05 (0.01,0.15)
SD ADA SC + DMARD	1.51 (0.24,7.91)	1.50 (0.24,7.46)	0.01 (-0.02,0.06)
SD CERTO SC + DMARD	1.44 (0.18,9.45)	1.44 (0.19,8.88)	0.00 (-0.02,0.07)
LD ADA SC	2.05 (0.59,6.36)	2.03 (0.60,6.19)	0.01 (-0.01,0.04)
LD ETN SC	4.04 (0.69,18.56)	3.90 (0.70,16.21)	0.03 (-0.01,0.14)
LD GOLI IV	24.13 (1.44,460.60)	18.77 (1.43,115.20)	0.21 (0.01,0.78)
LD RITUX IV + MTX	2.78 (0.50,13.35)	2.73 (0.50,12.22)	0.02 (-0.01,0.10)
LD ABA IV + MTX	6.20 (0.89,30.14)	5.85 (0.89,24.31)	0.05 (0.00,0.22)
LD CERTO SC + MTX	7.22 (0.69,46.10)	6.70 (0.69,33.71)	0.06 (0.00,0.30)
LD ETN SC + MTX	2.49 (0.39,14.93)	2.45 (0.40,13.39)	0.02 (-0.01,0.11)
LD GOLI IV + MTX	13.82 (0.71,270.00)	11.89 (0.72,95.32)	0.13 (0.00,0.69)
HD TOCI IV	4.39 (0.80,20.33)	4.22 (0.81,17.98)	0.04 (0.00,0.15)
HD TOFA PO	1.31 (0.54,3.37)	1.31 (0.54,3.31)	0.00 (-0.01,0.02)
HD ADA SC	3.22 (0.94,9.73)	3.14 (0.94,9.28)	0.02 (0.00,0.06)
HD GOLI SC	6.55 (0.89,38.98)	6.14 (0.89,30.39)	0.06 (0.00,0.27)
HD GOLI SC + MTX	15.78 (2.00,79.86)	13.36 (1.96,50.15)	0.13 (0.01,0.42)
HD TOCI IV + MTX	5.32 (0.84,26.88)	5.05 (0.84,22.38)	0.04 (0.00,0.19)
HD TOFA PO + MTX	10.06 (1.46,44.56)	9.05 (1.45,33.23)	0.09 (0.01,0.30)
HD CERTO SC + MTX	9.49 (1.66,44.50)	8.60 (1.64,33.59)	0.09 (0.01,0.30)



(Continued)

HD INF IV + MTX		4.87 (0.82,21.86)	4.66 (0.82,18.99)	0.04 (0.00,0.17)
HD TOCI IV + DMARD		3.25 (0.54,16.14)	3.16 (0.54,14.37)	0.02 (-0.01,0.12)
SD TOC SC + PL IV	SD CERTO SC	0.32 (0.04,1.88)	0.35 (0.05,1.77)	-0.08 (-0.30,0.05)
SD GOLI IV		0.39 (0.02,7.16)	0.43 (0.02,4.77)	-0.06 (-0.28,0.34)
SD INF IV + MTX		0.43 (0.05,2.44)	0.46 (0.07,2.23)	-0.06 (-0.30,0.08)
SD ETN SC + MTX		0.41 (0.05,2.40)	0.44 (0.06,2.19)	-0.07 (-0.30,0.08)
SD ABA IV + MTX		0.34 (0.04,1.98)	0.37 (0.05,1.87)	-0.07 (-0.30,0.05)
SD CERTO SC + MTX		0.65 (0.07,4.07)	0.68 (0.10,3.40)	-0.04 (-0.28,0.16)
SD ADA SC + MTX		0.45 (0.05,3.02)	0.49 (0.07,2.67)	-0.06 (-0.29,0.11)
SD ABA SC + MTX		0.25 (0.03,1.71)	0.27 (0.04,1.64)	-0.08 (-0.31,0.04)
SD GOLI SC + MTX		0.88 (0.08,6.96)	0.89 (0.11,5.01)	-0.01 (-0.25,0.27)
SD RITUX IV + MTX		0.36 (0.04,2.25)	0.40 (0.05,2.09)	-0.07 (-0.30,0.07)
SD TOFA PO + MTX		0.97 (0.10,6.22)	0.97 (0.13,4.70)	0.00 (-0.26,0.24)
SD GOLI IV + MTX		1.22 (0.07,21.66)	1.19 (0.08,8.54)	0.02 (-0.24,0.58)
SD ETN SC + DMARD		0.46 (0.07,2.53)	0.49 (0.09,2.30)	-0.06 (-0.29,0.08)
SD ADA SC + DMARD		0.11 (0.01,0.92)	0.13 (0.02,0.93)	-0.10 (-0.32,-0.01)
SD CERTO SC + DMARD		0.11 (0.01,0.96)	0.13 (0.01,0.96)	-0.10 (-0.31,0.00)
LD ADA SC		0.16 (0.03,0.75)	0.18 (0.04,0.76)	-0.10 (-0.32,-0.01)
LD ETN SC		0.33 (0.04,2.29)	0.36 (0.05,2.10)	-0.07 (-0.30,0.07)
LD GOLI IV		2.16 (0.09,35.08)	1.87 (0.11,10.26)	0.10 (-0.22,0.66)
LD RITUX IV + MTX		0.24 (0.03,1.49)	0.27 (0.03,1.44)	-0.09 (-0.31,0.03)
LD ABA IV + MTX		0.51 (0.05,3.43)	0.54 (0.07,2.96)	-0.05 (-0.29,0.13)
LD CERTO SC + MTX		0.58 (0.04,5.23)	0.61 (0.05,4.03)	-0.04 (-0.29,0.21)
LD ETN SC + MTX		0.21 (0.02,1.44)	0.24 (0.03,1.39)	-0.09 (-0.31,0.03)
LD GOLI IV + MTX		1.20 (0.05,21.01)	1.17 (0.06,8.42)	0.02 (-0.25,0.57)
HD TOCI IV		0.36 (0.05,2.32)	0.39 (0.06,2.13)	-0.07 (-0.30,0.07)
HD TOFA PO		0.11 (0.02,0.50)	0.12 (0.03,0.51)	-0.11 (-0.32,-0.02)
HD ADA SC		0.25 (0.04,1.10)	0.28 (0.06,1.09)	-0.09 (-0.30,0.00)

(Continued)

HD GOLI SC		0.51 (0.05,4.48)	0.55 (0.06,3.58)	-0.05 (-0.29,0.18)
HD GOLI SC + MTX		1.26 (0.12,9.71)	1.22 (0.16,6.04)	0.02 (-0.24,0.35)
HD TOCI IV + MTX		0.42 (0.05,3.00)	0.46 (0.07,2.63)	-0.06 (-0.29,0.11)
HD TOFA PO + MTX		0.79 (0.08,5.26)	0.81 (0.10,4.15)	-0.02 (-0.27,0.21)
HD CERTO SC + MTX		0.78 (0.09,5.39)	0.81 (0.12,4.17)	-0.02 (-0.28,0.22)
HD INF IV + MTX		0.41 (0.05,2.60)	0.45 (0.06,2.36)	-0.06 (-0.30,0.09)
HD TOCI IV + DMARD		0.25 (0.03,1.71)	0.27 (0.04,1.63)	-0.08 (-0.31,0.04)
SD GOLI IV	SD TOC SC + PL IV	1.31 (0.06,35.13)	1.29 (0.07,17.60)	0.01 (-0.09,0.50)
SD INF IV + MTX		1.28 (0.23,6.92)	1.26 (0.25,6.17)	0.01 (-0.09,0.12)
SD ETN SC + MTX		1.20 (0.20,6.39)	1.19 (0.22,5.75)	0.01 (-0.08,0.11)
SD ABA IV + MTX		1.02 (0.16,5.64)	1.02 (0.17,5.09)	0.00 (-0.09,0.10)
SD CERTO SC + MTX		1.93 (0.33,10.52)	1.85 (0.35,8.85)	0.03 (-0.07,0.20)
SD ADA SC + MTX		1.45 (0.20,8.80)	1.42 (0.21,7.63)	0.02 (-0.08,0.15)
SD ABA SC + MTX		0.75 (0.11,4.55)	0.76 (0.12,4.20)	-0.01 (-0.11,0.08)
SD GOLI SC + MTX		2.87 (0.40,18.47)	2.63 (0.42,13.74)	0.07 (-0.05,0.32)
SD RITUX IV + MTX		1.10 (0.16,6.25)	1.10 (0.18,5.60)	0.00 (-0.09,0.11)
SD TOFA PO + MTX		3.00 (0.41,17.48)	2.73 (0.43,13.40)	0.07 (-0.05,0.29)
SD GOLI IV + MTX		3.87 (0.23,79.95)	3.35 (0.25,25.62)	0.09 (-0.06,0.70)
SD ETN SC + DMARD		1.43 (0.33,6.22)	1.40 (0.36,5.65)	0.02 (-0.07,0.11)
SD ADA SC + DMARD		0.37 (0.06,2.54)	0.38 (0.06,2.46)	-0.02 (-0.12,0.03)
SD CERTO SC + DMARD		0.36 (0.05,2.86)	0.37 (0.05,2.73)	-0.02 (-0.12,0.04)
LD ADA SC		0.52 (0.14,1.88)	0.53 (0.15,1.86)	-0.02 (-0.11,0.01)
LD ETN SC		1.02 (0.16,6.15)	1.02 (0.17,5.56)	0.00 (-0.09,0.11)
LD GOLI IV		6.71 (0.39,114.40)	5.16 (0.41,31.45)	0.18 (-0.04,0.75)
LD RITUX IV + MTX		0.73 (0.11,4.41)	0.74 (0.11,4.07)	-0.01 (-0.11,0.07)
LD ABA IV + MTX		1.56 (0.20,9.63)	1.52 (0.21,8.15)	0.02 (-0.08,0.18)
LD CERTO SC + MTX		1.80 (0.16,13.73)	1.73 (0.17,10.47)	0.03 (-0.08,0.26)
LD ETN SC + MTX		0.63 (0.09,4.02)	0.64 (0.10,3.74)	-0.01 (-0.11,0.07)

(Continued)

LD GOLI IV + MTX		3.69 (0.22,64.74)	3.23 (0.23,25.19)	0.09 (-0.06,0.65)
HD TOCI IV		1.11 (0.19,6.52)	1.10 (0.21,5.79)	0.00 (-0.09,0.12)
HD TOFA PO		0.33 (0.08,1.57)	0.34 (0.08,1.55)	-0.03 (-0.12,0.01)
HD ADA SC		0.79 (0.22,2.79)	0.80 (0.24,2.71)	-0.01 (-0.10,0.03)
HD GOLI SC		1.71 (0.20,12.11)	1.65 (0.22,9.83)	0.02 (-0.08,0.22)
HD GOLI SC + MTX		3.84 (0.46,24.30)	3.38 (0.48,16.34)	0.10 (-0.04,0.38)
HD TOCI IV + MTX		1.31 (0.20,8.60)	1.29 (0.22,7.37)	0.01 (-0.08,0.15)
HD TOFA PO + MTX		2.48 (0.34,14.84)	2.29 (0.36,11.67)	0.05 (-0.06,0.26)
HD CERTO SC + MTX		2.37 (0.42,14.34)	2.21 (0.45,11.46)	0.05 (-0.05,0.26)
HD INF IV + MTX		1.24 (0.18,7.29)	1.23 (0.20,6.48)	0.01 (-0.09,0.13)
HD TOCI IV + DMARD		0.79 (0.14,4.68)	0.80 (0.15,4.35)	-0.01 (-0.10,0.08)
SD INF IV + MTX	SD GOLI IV	1.06 (0.04,14.72)	1.06 (0.08,13.26)	0.00 (-0.49,0.11)
SD ETN SC + MTX		1.00 (0.04,15.05)	1.00 (0.07,13.60)	0.00 (-0.49,0.10)
SD ABA IV + MTX		0.84 (0.03,13.09)	0.85 (0.07,11.96)	-0.01 (-0.49,0.09)
SD CERTO SC + MTX		1.61 (0.05,25.92)	1.55 (0.10,22.04)	0.02 (-0.47,0.18)
SD ADA SC + MTX		1.14 (0.05,16.99)	1.13 (0.10,15.00)	0.00 (-0.47,0.14)
SD ABA SC + MTX		0.64 (0.02,9.88)	0.65 (0.04,9.23)	-0.02 (-0.50,0.07)
SD GOLI SC + MTX		2.20 (0.14,25.21)	2.03 (0.24,21.07)	0.04 (-0.39,0.28)
SD RITUX IV + MTX		0.92 (0.03,12.15)	0.93 (0.05,11.13)	0.00 (-0.49,0.09)
SD TOFA PO + MTX		2.29 (0.08,34.30)	2.11 (0.16,27.82)	0.04 (-0.43,0.27)
SD GOLI IV + MTX		2.89 (0.49,28.72)	2.37 (0.53,22.84)	0.07 (-0.07,0.44)
SD ETN SC + DMARD		1.16 (0.05,16.68)	1.15 (0.10,15.28)	0.01 (-0.48,0.11)
SD ADA SC + DMARD		0.32 (0.01,5.03)	0.33 (0.02,4.87)	-0.03 (-0.52,0.03)
SD CERTO SC + DMARD		0.29 (0.01,4.92)	0.30 (0.02,4.77)	-0.03 (-0.51,0.03)
LD ADA SC		0.39 (0.02,6.60)	0.41 (0.04,6.44)	-0.03 (-0.51,0.03)
LD ETN SC		0.85 (0.03,14.28)	0.86 (0.06,13.00)	-0.01 (-0.49,0.10)
LD GOLI IV		4.52 (1.07,55.75)	3.34 (1.05,37.84)	0.14 (0.00,0.53)
LD RITUX IV + MTX		0.62 (0.02,8.93)	0.63 (0.04,8.43)	-0.02 (-0.50,0.06)

(Continued)

LD ABA IV + MTX		1.29 (0.06,18.60)	1.27 (0.11,16.42)	0.01 (-0.47,0.16)
LD CERTO SC + MTX		1.51 (0.03,30.51)	1.46 (0.05,25.29)	0.02 (-0.48,0.24)
LD ETN SC + MTX		0.53 (0.02,7.96)	0.55 (0.03,7.55)	-0.02 (-0.51,0.06)
LD GOLI IV + MTX		2.67 (0.51,27.32)	2.29 (0.56,21.59)	0.06 (-0.08,0.45)
HD TOCI IV		0.93 (0.04,12.50)	0.94 (0.07,11.45)	0.00 (-0.49,0.10)
HD TOFA PO		0.26 (0.01,5.24)	0.27 (0.02,5.12)	-0.04 (-0.52,0.02)
HD ADA SC		0.61 (0.03,10.74)	0.62 (0.06,10.32)	-0.02 (-0.50,0.05)
HD GOLI SC		1.40 (0.05,17.22)	1.36 (0.10,15.33)	0.01 (-0.45,0.19)
HD GOLI SC + MTX		3.15 (0.16,34.11)	2.76 (0.27,27.90)	0.07 (-0.37,0.34)
HD TOCI IV + MTX		1.11 (0.04,16.32)	1.10 (0.08,14.56)	0.00 (-0.48,0.14)
HD TOFA PO + MTX		1.91 (0.07,28.08)	1.80 (0.13,23.61)	0.03 (-0.44,0.24)
HD CERTO SC + MTX		2.04 (0.05,31.07)	1.91 (0.11,25.09)	0.03 (-0.46,0.22)
HD INF IV + MTX		1.05 (0.04,13.99)	1.04 (0.07,12.82)	0.00 (-0.49,0.11)
HD TOCI IV + DMARD		0.68 (0.03,8.51)	0.70 (0.05,7.99)	-0.01 (-0.50,0.07)
SD ETN SC + MTX	SD INF IV + MTX	0.95 (0.42,2.16)	0.95 (0.44,2.06)	0.00 (-0.06,0.05)
SD ABA IV + MTX		0.80 (0.45,1.39)	0.81 (0.47,1.36)	-0.01 (-0.06,0.02)
SD CERTO SC + MTX		1.50 (0.75,3.07)	1.46 (0.77,2.81)	0.02 (-0.02,0.11)
SD ADA SC + MTX		1.10 (0.45,2.72)	1.09 (0.47,2.52)	0.00 (-0.05,0.09)
SD ABA SC + MTX		0.59 (0.25,1.32)	0.61 (0.26,1.29)	-0.02 (-0.08,0.01)
SD GOLI SC + MTX		2.16 (0.66,7.28)	2.00 (0.68,5.93)	0.05 (-0.02,0.26)
SD RITUX IV + MTX		0.84 (0.40,1.87)	0.85 (0.42,1.79)	-0.01 (-0.07,0.04)
SD TOFA PO + MTX		2.21 (0.87,6.63)	2.04 (0.87,5.27)	0.06 (-0.01,0.23)
SD GOLI IV + MTX		2.74 (0.41,48.63)	2.44 (0.42,17.20)	0.08 (-0.04,0.67)
SD ETN SC + DMARD		1.14 (0.40,3.16)	1.13 (0.43,2.96)	0.01 (-0.07,0.07)
SD ADA SC + DMARD		0.30 (0.08,1.09)	0.31 (0.09,1.09)	-0.03 (-0.13,0.00)
SD CERTO SC + DMARD		0.28 (0.06,1.46)	0.29 (0.06,1.44)	-0.03 (-0.13,0.02)
LD ADA SC		0.42 (0.09,1.74)	0.43 (0.10,1.71)	-0.03 (-0.15,0.01)
LD ETN SC		0.79 (0.28,2.14)	0.80 (0.30,2.04)	-0.01 (-0.08,0.05)

(Continued)

LD GOLIV		4.85 (0.72,82.94)	3.81 (0.73,20.70)	0.16 (-0.01,0.73)
LD RITUX IV + MTX		0.55 (0.26,1.27)	0.57 (0.27,1.25)	-0.02 (-0.09,0.01)
LD ABA IV + MTX		1.21 (0.50,2.89)	1.19 (0.52,2.62)	0.01 (-0.04,0.11)
LD CERTO SC + MTX		1.45 (0.24,5.89)	1.41 (0.25,4.84)	0.02 (-0.06,0.21)
LD ETN SC + MTX		0.50 (0.16,1.42)	0.51 (0.17,1.39)	-0.02 (-0.10,0.02)
LD GOLIV + MTX		2.69 (0.43,50.10)	2.43 (0.45,17.39)	0.08 (-0.04,0.62)
HD TOCI IV		0.88 (0.36,2.18)	0.89 (0.38,2.08)	0.00 (-0.07,0.05)
HD TOFA PO		0.26 (0.06,1.33)	0.27 (0.07,1.33)	-0.04 (-0.15,0.01)
HD ADA SC		0.62 (0.15,2.63)	0.63 (0.17,2.56)	-0.02 (-0.13,0.03)
HD GOLIV SC		1.29 (0.33,4.74)	1.27 (0.35,4.04)	0.01 (-0.06,0.18)
HD GOLIV SC + MTX		2.93 (1.03,8.58)	2.59 (1.03,6.38)	0.09 (0.00,0.33)
HD TOCI IV + MTX		1.03 (0.37,3.07)	1.03 (0.39,2.81)	0.00 (-0.07,0.09)
HD TOFA PO + MTX		1.86 (0.68,5.16)	1.76 (0.68,4.36)	0.04 (-0.02,0.20)
HD CERTO SC + MTX		1.87 (0.80,4.58)	1.77 (0.81,3.97)	0.04 (-0.01,0.18)
HD INF IV + MTX		0.97 (0.50,1.92)	0.97 (0.51,1.83)	0.00 (-0.04,0.05)
HD TOCI IV + DMARD		0.62 (0.20,1.93)	0.64 (0.22,1.86)	-0.02 (-0.10,0.04)
SD ABA IV + MTX	SD ETN SC + MTX	0.84 (0.35,1.84)	0.85 (0.37,1.78)	-0.01 (-0.07,0.04)
SD CERTO SC + MTX		1.57 (0.68,3.73)	1.52 (0.70,3.40)	0.02 (-0.03,0.13)
SD ADA SC + MTX		1.17 (0.41,3.58)	1.16 (0.42,3.22)	0.01 (-0.06,0.10)
SD ABA SC + MTX		0.63 (0.21,1.64)	0.65 (0.23,1.60)	-0.02 (-0.09,0.03)
SD GOLIV SC + MTX		2.28 (0.56,8.90)	2.12 (0.59,6.95)	0.05 (-0.03,0.28)
SD RITUX IV + MTX		0.87 (0.36,2.32)	0.88 (0.38,2.18)	0.00 (-0.07,0.06)
SD TOFA PO + MTX		2.37 (0.78,7.41)	2.20 (0.80,6.04)	0.06 (-0.01,0.24)
SD GOLIV IV + MTX		2.72 (0.45,58.61)	2.45 (0.46,20.08)	0.08 (-0.04,0.68)
SD ETN SC + DMARD		1.18 (0.45,3.04)	1.17 (0.47,2.86)	0.01 (-0.06,0.07)
SD ADA SC + DMARD		0.31 (0.08,1.11)	0.32 (0.09,1.10)	-0.03 (-0.12,0.00)
SD CERTO SC + DMARD		0.30 (0.06,1.55)	0.31 (0.06,1.53)	-0.03 (-0.13,0.02)
LD ADA SC		0.44 (0.09,1.71)	0.45 (0.11,1.68)	-0.03 (-0.14,0.01)

(Continued)

LD ETN SC		0.84 (0.28,2.41)	0.85 (0.30,2.29)	-0.01 (-0.08,0.06)
LD GOLI IV		5.01 (0.75,96.66)	3.88 (0.76,22.99)	0.17 (-0.01,0.74)
LD RITUX IV + MTX		0.58 (0.23,1.56)	0.60 (0.25,1.53)	-0.02 (-0.09,0.02)
LD ABA IV + MTX		1.27 (0.43,3.63)	1.24 (0.45,3.25)	0.01 (-0.05,0.12)
LD CERTO SC + MTX		1.51 (0.21,6.24)	1.46 (0.23,5.18)	0.02 (-0.06,0.21)
LD ETN SC + MTX		0.52 (0.18,1.40)	0.54 (0.19,1.37)	-0.02 (-0.09,0.02)
LD GOLI IV + MTX		2.83 (0.44,53.74)	2.53 (0.45,20.04)	0.08 (-0.04,0.63)
HD TOCI IV		0.92 (0.36,2.38)	0.93 (0.38,2.26)	0.00 (-0.07,0.06)
HD TOFA PO		0.28 (0.06,1.33)	0.29 (0.07,1.32)	-0.04 (-0.15,0.01)
HD ADA SC		0.65 (0.16,3.13)	0.66 (0.18,3.03)	-0.02 (-0.13,0.03)
HD GOLI SC		1.37 (0.29,5.77)	1.35 (0.30,4.81)	0.01 (-0.07,0.19)
HD GOLI SC + MTX		3.07 (0.90,11.35)	2.71 (0.91,8.03)	0.09 (-0.01,0.34)
HD TOCI IV + MTX		1.08 (0.36,3.51)	1.07 (0.38,3.18)	0.00 (-0.06,0.10)
HD TOFA PO + MTX		2.01 (0.60,6.31)	1.88 (0.62,5.17)	0.04 (-0.03,0.21)
HD CERTO SC + MTX		1.98 (0.74,5.48)	1.85 (0.76,4.67)	0.04 (-0.02,0.19)
HD INF IV + MTX		1.01 (0.40,2.69)	1.01 (0.42,2.52)	0.00 (-0.06,0.07)
HD TOCI IV + DMARD		0.65 (0.21,2.04)	0.67 (0.22,1.95)	-0.01 (-0.10,0.04)
SD CERTO SC + MTX	SD ABA IV + MTX	1.90 (1.00,3.75)	1.81 (1.00,3.43)	0.03 (0.00,0.13)
SD ADA SC + MTX		1.38 (0.57,3.64)	1.36 (0.59,3.28)	0.01 (-0.03,0.10)
SD ABA SC + MTX		0.74 (0.39,1.36)	0.75 (0.41,1.34)	-0.01 (-0.05,0.02)
SD GOLI SC + MTX		2.74 (0.82,9.31)	2.52 (0.83,7.34)	0.06 (-0.01,0.28)
SD RITUX IV + MTX		1.08 (0.50,2.33)	1.07 (0.52,2.22)	0.00 (-0.04,0.06)
SD TOFA PO + MTX		2.83 (1.12,7.91)	2.58 (1.12,6.37)	0.07 (0.00,0.25)
SD GOLI IV + MTX		3.47 (0.51,60.68)	3.05 (0.52,20.36)	0.09 (-0.02,0.69)
SD ETN SC + DMARD		1.44 (0.49,3.89)	1.41 (0.52,3.64)	0.02 (-0.05,0.09)
SD ADA SC + DMARD		0.38 (0.10,1.31)	0.39 (0.11,1.30)	-0.02 (-0.10,0.01)
SD CERTO SC + DMARD		0.35 (0.07,1.90)	0.36 (0.08,1.85)	-0.02 (-0.11,0.02)
LD ADA SC		0.53 (0.11,2.17)	0.54 (0.12,2.15)	-0.02 (-0.12,0.02)

(Continued)

LD ETN SC		1.01 (0.35,2.66)	1.00 (0.37,2.52)	0.00 (-0.05,0.07)
LD GOL I IV		6.15 (1.03,98.16)	4.73 (1.02,24.52)	0.18 (0.00,0.74)
LD RITUX IV + MTX		0.70 (0.33,1.60)	0.71 (0.35,1.55)	-0.01 (-0.06,0.02)
LD ABA IV + MTX		1.51 (0.72,3.34)	1.47 (0.73,3.01)	0.02 (-0.01,0.12)
LD CERTO SC + MTX		1.86 (0.30,7.15)	1.78 (0.31,5.90)	0.03 (-0.04,0.22)
LD ETN SC + MTX		0.63 (0.21,1.82)	0.65 (0.22,1.76)	-0.01 (-0.08,0.03)
LD GOL I IV + MTX		3.47 (0.60,57.15)	3.08 (0.61,20.44)	0.09 (-0.02,0.64)
HD TOCI IV		1.12 (0.44,2.77)	1.11 (0.46,2.62)	0.00 (-0.05,0.07)
HD TOFA PO		0.33 (0.07,1.69)	0.34 (0.08,1.67)	-0.03 (-0.12,0.01)
HD ADA SC		0.78 (0.18,3.81)	0.79 (0.20,3.66)	-0.01 (-0.10,0.04)
HD GOL I SC		1.62 (0.42,6.28)	1.57 (0.43,5.32)	0.02 (-0.04,0.19)
HD GOL I SC + MTX		3.65 (1.36,11.85)	3.20 (1.32,8.55)	0.09 (0.01,0.35)
HD TOCI IV + MTX		1.31 (0.49,3.78)	1.29 (0.50,3.44)	0.01 (-0.04,0.11)
HD TOFA PO + MTX		2.34 (0.85,6.64)	2.19 (0.86,5.59)	0.05 (-0.01,0.21)
HD CERTO SC + MTX		2.37 (1.05,5.68)	2.20 (1.05,4.92)	0.05 (0.00,0.20)
HD INF IV + MTX		1.22 (0.57,2.71)	1.21 (0.59,2.54)	0.01 (-0.03,0.08)
HD TOCI IV + DMARD		0.80 (0.26,2.46)	0.81 (0.28,2.32)	-0.01 (-0.08,0.05)
SD ADA SC + MTX	SD CERTO SC + MTX	0.73 (0.28,1.92)	0.75 (0.31,1.82)	-0.02 (-0.11,0.05)
SD ABA SC + MTX		0.39 (0.15,0.93)	0.42 (0.17,0.94)	-0.04 (-0.15,0.00)
SD GOL I SC + MTX		1.45 (0.41,4.99)	1.39 (0.44,3.99)	0.03 (-0.08,0.23)
SD RITUX IV + MTX		0.56 (0.26,1.24)	0.58 (0.29,1.22)	-0.03 (-0.14,0.02)
SD TOFA PO + MTX		1.48 (0.54,4.28)	1.42 (0.57,3.55)	0.03 (-0.05,0.19)
SD GOL I IV + MTX		1.78 (0.27,40.10)	1.66 (0.29,13.19)	0.05 (-0.09,0.65)
SD ETN SC + DMARD		0.76 (0.26,1.99)	0.78 (0.29,1.90)	-0.02 (-0.14,0.05)
SD ADA SC + DMARD		0.20 (0.05,0.71)	0.21 (0.06,0.73)	-0.06 (-0.21,-0.01)
SD CERTO SC + DMARD		0.19 (0.04,0.96)	0.20 (0.04,0.96)	-0.06 (-0.21,0.00)
LD ADA SC		0.28 (0.05,1.11)	0.30 (0.07,1.11)	-0.05 (-0.22,0.00)
LD ETN SC		0.53 (0.18,1.50)	0.56 (0.20,1.45)	-0.03 (-0.15,0.03)

(Continued)

LD GOLIV		3.11 (0.53,62.39)	2.57 (0.54,15.29)	0.13 (-0.04,0.72)
LD RITUX IV + MTX		0.36 (0.16,0.85)	0.39 (0.18,0.86)	-0.04 (-0.16,-0.01)
LD ABA IV + MTX		0.80 (0.32,1.99)	0.82 (0.34,1.86)	-0.01 (-0.10,0.07)
LD CERTO SC + MTX		0.97 (0.17,3.36)	0.97 (0.19,2.87)	0.00 (-0.10,0.15)
LD ETN SC + MTX		0.33 (0.10,1.03)	0.35 (0.11,1.03)	-0.05 (-0.18,0.00)
LD GOLIV + MTX		1.78 (0.30,34.81)	1.67 (0.31,12.62)	0.05 (-0.08,0.60)
HD TOCI IV		0.59 (0.23,1.40)	0.62 (0.26,1.36)	-0.03 (-0.14,0.02)
HD TOFA PO		0.17 (0.04,0.88)	0.18 (0.05,0.88)	-0.06 (-0.23,0.00)
HD ADA SC		0.41 (0.09,1.95)	0.43 (0.12,1.90)	-0.04 (-0.21,0.02)
HD GOLIV SC		0.88 (0.20,3.24)	0.89 (0.23,2.78)	-0.01 (-0.13,0.14)
HD GOLIV SC + MTX		1.99 (0.63,6.11)	1.81 (0.66,4.57)	0.06 (-0.04,0.29)
HD TOCI IV + MTX		0.69 (0.24,1.93)	0.71 (0.27,1.80)	-0.02 (-0.13,0.06)
HD TOFA PO + MTX		1.25 (0.43,3.53)	1.22 (0.46,3.02)	0.02 (-0.06,0.16)
HD CERTO SC + MTX		1.26 (0.62,2.45)	1.23 (0.65,2.20)	0.02 (-0.04,0.12)
HD INF IV + MTX		0.65 (0.27,1.47)	0.67 (0.30,1.42)	-0.02 (-0.12,0.03)
HD TOCI IV + DMARD		0.42 (0.13,1.31)	0.44 (0.15,1.28)	-0.04 (-0.17,0.01)
SD ABA SC + MTX	SD ADA SC + MTX	0.53 (0.17,1.57)	0.55 (0.19,1.54)	-0.02 (-0.12,0.02)
SD GOLIV SC + MTX		2.01 (0.43,7.61)	1.86 (0.45,6.26)	0.05 (-0.05,0.25)
SD RITUX IV + MTX		0.76 (0.28,2.16)	0.77 (0.31,2.07)	-0.01 (-0.10,0.05)
SD TOFA PO + MTX		2.03 (0.84,5.26)	1.89 (0.86,4.45)	0.05 (-0.01,0.21)
SD GOLIV IV + MTX		2.55 (0.29,45.08)	2.29 (0.31,15.26)	0.07 (-0.07,0.66)
SD ETN SC + DMARD		1.00 (0.30,3.39)	1.00 (0.33,3.24)	0.00 (-0.10,0.07)
SD ADA SC + DMARD		0.26 (0.07,1.10)	0.28 (0.07,1.10)	-0.04 (-0.16,0.00)
SD CERTO SC + DMARD		0.25 (0.05,1.58)	0.27 (0.05,1.55)	-0.04 (-0.16,0.01)
LD ADA SC		0.36 (0.07,1.97)	0.38 (0.09,1.94)	-0.04 (-0.17,0.02)
LD ETN SC		0.72 (0.20,2.36)	0.73 (0.22,2.26)	-0.01 (-0.11,0.05)
LD GOLIV		4.47 (0.59,68.73)	3.51 (0.61,18.38)	0.16 (-0.04,0.72)
LD RITUX IV + MTX		0.51 (0.18,1.44)	0.53 (0.20,1.42)	-0.03 (-0.12,0.01)



(Continued)

LD ABA IV + MTX		1.08 (0.35,3.32)	1.08 (0.38,3.03)	0.00 (-0.08,0.11)
LD CERTO SC + MTX		1.31 (0.21,5.45)	1.28 (0.23,4.55)	0.01 (-0.09,0.20)
LD ETN SC + MTX		0.44 (0.11,1.54)	0.46 (0.13,1.50)	-0.03 (-0.14,0.02)
LD GOLI IV + MTX		2.49 (0.38,38.28)	2.23 (0.40,15.17)	0.07 (-0.06,0.61)
HD TOCI IV		0.79 (0.28,2.40)	0.80 (0.30,2.27)	-0.01 (-0.10,0.05)
HD TOFA PO		0.22 (0.05,1.42)	0.24 (0.06,1.41)	-0.05 (-0.18,0.01)
HD ADA SC		0.54 (0.12,3.30)	0.55 (0.14,3.17)	-0.03 (-0.16,0.04)
HD GOLI SC		1.19 (0.24,5.36)	1.17 (0.26,4.56)	0.01 (-0.09,0.17)
HD GOLI SC + MTX		2.65 (0.74,10.32)	2.34 (0.76,7.75)	0.08 (-0.02,0.33)
HD TOCI IV + MTX		0.93 (0.28,3.19)	0.93 (0.30,2.92)	0.00 (-0.09,0.09)
HD TOFA PO + MTX		1.68 (0.67,4.64)	1.60 (0.68,3.99)	0.03 (-0.03,0.18)
HD CERTO SC + MTX		1.70 (0.57,5.21)	1.61 (0.59,4.53)	0.03 (-0.04,0.17)
HD INF IV + MTX		0.87 (0.31,2.44)	0.88 (0.34,2.33)	-0.01 (-0.09,0.06)
HD TOCI IV + DMARD		0.55 (0.16,2.05)	0.57 (0.17,1.96)	-0.02 (-0.13,0.04)
SD GOLI SC + MTX	SD ABA SC + MTX	3.69 (0.99,15.15)	3.31 (0.99,12.09)	0.07 (0.00,0.30)
SD RITUX IV + MTX		1.42 (0.57,4.03)	1.40 (0.59,3.76)	0.01 (-0.03,0.08)
SD TOFA PO + MTX		3.83 (1.26,12.32)	3.44 (1.24,10.14)	0.08 (0.01,0.26)
SD GOLI IV + MTX		4.73 (0.63,90.95)	4.07 (0.64,32.54)	0.10 (-0.01,0.70)
SD ETN SC + DMARD		1.92 (0.57,6.26)	1.86 (0.60,5.76)	0.02 (-0.04,0.10)
SD ADA SC + DMARD		0.51 (0.13,2.07)	0.52 (0.14,2.03)	-0.01 (-0.09,0.02)
SD CERTO SC + DMARD		0.47 (0.09,2.76)	0.48 (0.10,2.68)	-0.01 (-0.09,0.04)
LD ADA SC		0.72 (0.13,3.27)	0.73 (0.14,3.20)	-0.01 (-0.10,0.02)
LD ETN SC		1.36 (0.44,4.27)	1.34 (0.46,4.00)	0.01 (-0.04,0.09)
LD GOLI IV		8.24 (1.28,164.20)	6.26 (1.26,40.30)	0.19 (0.00,0.76)
LD RITUX IV + MTX		0.92 (0.37,2.60)	0.93 (0.39,2.51)	0.00 (-0.05,0.04)
LD ABA IV + MTX		2.05 (0.78,5.69)	1.97 (0.79,5.18)	0.03 (-0.01,0.15)
LD CERTO SC + MTX		2.49 (0.38,10.82)	2.32 (0.39,9.07)	0.04 (-0.03,0.24)
LD ETN SC + MTX		0.85 (0.25,2.92)	0.85 (0.26,2.79)	0.00 (-0.06,0.05)

(Continued)

LD GOLI IV + MTX		4.69 (0.74,95.89)	4.05 (0.74,33.23)	0.10 (-0.01,0.65)
HD TOCI IV		1.49 (0.50,4.41)	1.47 (0.53,4.14)	0.01 (-0.04,0.09)
HD TOFA PO		0.45 (0.08,2.61)	0.45 (0.09,2.58)	-0.02 (-0.11,0.01)
HD ADA SC		1.06 (0.21,5.46)	1.06 (0.23,5.26)	0.00 (-0.09,0.05)
HD GOLI SC		2.18 (0.50,9.75)	2.08 (0.51,8.02)	0.03 (-0.03,0.21)
HD GOLI SC + MTX		4.91 (1.55,18.50)	4.24 (1.48,13.49)	0.11 (0.01,0.37)
HD TOCI IV + MTX		1.76 (0.57,5.91)	1.71 (0.58,5.43)	0.02 (-0.03,0.13)
HD TOFA PO + MTX		3.23 (0.98,10.47)	2.97 (0.98,8.68)	0.06 (0.00,0.23)
HD CERTO SC + MTX		3.19 (1.18,9.28)	2.92 (1.17,7.96)	0.06 (0.01,0.22)
HD INF IV + MTX		1.61 (0.65,4.64)	1.57 (0.67,4.33)	0.02 (-0.02,0.10)
HD TOCI IV + DMARD		1.07 (0.30,3.84)	1.07 (0.32,3.58)	0.00 (-0.06,0.07)
SD RITUX IV + MTX	SD GOLI SC + MTX	0.38 (0.10,1.47)	0.42 (0.12,1.44)	-0.06 (-0.27,0.02)
SD TOFA PO + MTX		1.00 (0.27,6.16)	1.00 (0.32,4.94)	0.00 (-0.17,0.19)
SD GOLI IV + MTX		1.36 (0.16,17.59)	1.30 (0.19,6.69)	0.03 (-0.20,0.58)
SD ETN SC + DMARD		0.51 (0.13,2.10)	0.54 (0.17,2.02)	-0.05 (-0.28,0.04)
SD ADA SC + DMARD		0.14 (0.03,0.64)	0.16 (0.03,0.65)	-0.09 (-0.34,-0.01)
SD CERTO SC + DMARD		0.13 (0.02,0.86)	0.14 (0.02,0.88)	-0.09 (-0.33,0.00)
LD ADA SC		0.18 (0.03,1.02)	0.20 (0.05,1.02)	-0.09 (-0.34,0.00)
LD ETN SC		0.37 (0.08,1.52)	0.40 (0.11,1.48)	-0.06 (-0.28,0.02)
LD GOLI IV		2.28 (0.32,25.66)	1.93 (0.34,8.10)	0.10 (-0.14,0.65)
LD RITUX IV + MTX		0.26 (0.06,0.91)	0.29 (0.08,0.92)	-0.08 (-0.30,0.00)
LD ABA IV + MTX		0.55 (0.15,2.13)	0.59 (0.18,2.00)	-0.04 (-0.25,0.06)
LD CERTO SC + MTX		0.67 (0.08,3.57)	0.70 (0.09,3.12)	-0.03 (-0.24,0.15)
LD ETN SC + MTX		0.23 (0.05,1.05)	0.25 (0.06,1.04)	-0.08 (-0.32,0.00)
LD GOLI IV + MTX		1.33 (0.16,15.12)	1.28 (0.18,6.26)	0.02 (-0.20,0.54)
HD TOCI IV		0.40 (0.11,1.47)	0.44 (0.14,1.44)	-0.06 (-0.27,0.02)
HD TOFA PO		0.12 (0.02,0.79)	0.13 (0.03,0.79)	-0.10 (-0.35,0.00)
HD ADA SC		0.27 (0.06,1.64)	0.30 (0.08,1.62)	-0.08 (-0.33,0.02)

(Continued)

HD GOLI SC		0.60 (0.14,2.04)	0.64 (0.17,1.88)	-0.03 (-0.21,0.08)
HD GOLI SC + MTX		1.36 (0.55,3.67)	1.29 (0.60,3.09)	0.03 (-0.08,0.19)
HD TOCI IV + MTX		0.48 (0.12,2.02)	0.51 (0.14,1.93)	-0.05 (-0.27,0.05)
HD TOFA PO + MTX		0.83 (0.21,4.16)	0.85 (0.25,3.65)	-0.01 (-0.19,0.14)
HD CERTO SC + MTX		0.87 (0.21,3.58)	0.89 (0.26,3.19)	-0.01 (-0.21,0.13)
HD INF IV + MTX		0.44 (0.12,1.70)	0.48 (0.14,1.64)	-0.05 (-0.26,0.03)
HD TOCI IV + DMARD		0.29 (0.06,1.27)	0.32 (0.08,1.25)	-0.07 (-0.30,0.01)
SD TOFA PO + MTX	SD RITUX IV + MTX	2.72 (0.89,7.80)	2.47 (0.90,6.36)	0.07 (-0.01,0.24)
SD GOLI IV + MTX		3.12 (0.48,76.53)	2.79 (0.49,25.89)	0.08 (-0.03,0.68)
SD ETN SC + DMARD		1.33 (0.42,3.98)	1.31 (0.45,3.75)	0.01 (-0.07,0.08)
SD ADA SC + DMARD		0.35 (0.09,1.52)	0.36 (0.10,1.49)	-0.03 (-0.12,0.01)
SD CERTO SC + DMARD		0.32 (0.06,2.05)	0.34 (0.07,2.00)	-0.03 (-0.12,0.03)
LD ADA SC		0.49 (0.10,2.03)	0.50 (0.11,2.00)	-0.02 (-0.13,0.02)
LD ETN SC		0.96 (0.29,2.70)	0.96 (0.31,2.55)	0.00 (-0.08,0.06)
LD GOLI IV		5.72 (0.93,126.70)	4.39 (0.94,32.30)	0.17 (0.00,0.75)
LD RITUX IV + MTX		0.66 (0.33,1.27)	0.67 (0.35,1.25)	-0.01 (-0.07,0.01)
LD ABA IV + MTX		1.42 (0.51,3.91)	1.39 (0.54,3.60)	0.02 (-0.04,0.13)
LD CERTO SC + MTX		1.70 (0.25,6.95)	1.64 (0.27,5.60)	0.02 (-0.06,0.23)
LD ETN SC + MTX		0.61 (0.17,1.78)	0.62 (0.18,1.73)	-0.02 (-0.10,0.03)
LD GOLI IV + MTX		3.15 (0.53,72.16)	2.81 (0.54,27.02)	0.08 (-0.02,0.64)
HD TOCI IV		1.03 (0.39,2.94)	1.02 (0.42,2.78)	0.00 (-0.06,0.06)
HD TOFA PO		0.31 (0.07,1.63)	0.32 (0.08,1.61)	-0.03 (-0.14,0.01)
HD ADA SC		0.71 (0.17,3.74)	0.72 (0.19,3.62)	-0.01 (-0.12,0.04)
HD GOLI SC		1.54 (0.36,6.06)	1.50 (0.38,5.04)	0.02 (-0.05,0.19)
HD GOLI SC + MTX		3.45 (1.07,11.28)	3.02 (1.06,8.47)	0.09 (0.00,0.34)
HD TOCI IV + MTX		1.23 (0.41,3.76)	1.21 (0.43,3.45)	0.01 (-0.05,0.10)
HD TOFA PO + MTX		2.32 (0.68,6.53)	2.15 (0.69,5.46)	0.05 (-0.02,0.21)
HD CERTO SC + MTX		2.25 (0.83,5.74)	2.11 (0.84,4.92)	0.05 (-0.01,0.20)

(Continued)

HD INF IV + MTX		1.14 (0.46,2.79)	1.13 (0.48,2.61)	0.00 (-0.05,0.08)
HD TOCI IV + DMARD		0.73 (0.21,2.45)	0.74 (0.23,2.36)	-0.01 (-0.09,0.05)
SD GOLI IV + MTX	SD TOFA PO + MTX	1.24 (0.14,25.44)	1.19 (0.17,9.33)	0.02 (-0.18,0.60)
SD ETN SC + DMARD		0.50 (0.14,1.67)	0.54 (0.17,1.62)	-0.05 (-0.25,0.03)
SD ADA SC + DMARD		0.13 (0.03,0.53)	0.15 (0.04,0.56)	-0.10 (-0.30,-0.01)
SD CERTO SC + DMARD		0.12 (0.02,0.73)	0.14 (0.02,0.75)	-0.10 (-0.30,-0.01)
LD ADA SC		0.17 (0.04,0.97)	0.19 (0.05,0.97)	-0.09 (-0.32,0.00)
LD ETN SC		0.36 (0.09,1.23)	0.39 (0.11,1.22)	-0.07 (-0.26,0.01)
LD GOLI IV		2.22 (0.23,37.58)	1.88 (0.27,10.55)	0.10 (-0.16,0.68)
LD RITUX IV + MTX		0.25 (0.08,0.73)	0.28 (0.10,0.75)	-0.08 (-0.27,-0.01)
LD ABA IV + MTX		0.54 (0.17,1.69)	0.58 (0.20,1.62)	-0.04 (-0.22,0.04)
LD CERTO SC + MTX		0.62 (0.09,3.08)	0.66 (0.11,2.64)	-0.03 (-0.23,0.14)
LD ETN SC + MTX		0.22 (0.05,0.77)	0.25 (0.06,0.79)	-0.08 (-0.28,-0.01)
LD GOLI IV + MTX		1.20 (0.17,22.16)	1.17 (0.19,8.91)	0.02 (-0.19,0.57)
HD TOCI IV		0.39 (0.13,1.19)	0.42 (0.16,1.17)	-0.06 (-0.24,0.01)
HD TOFA PO		0.11 (0.02,0.71)	0.12 (0.03,0.71)	-0.10 (-0.33,-0.01)
HD ADA SC		0.26 (0.06,1.51)	0.28 (0.08,1.49)	-0.08 (-0.30,0.01)
HD GOLI SC		0.58 (0.09,2.55)	0.62 (0.12,2.31)	-0.04 (-0.23,0.10)
HD GOLI SC + MTX		1.32 (0.31,4.99)	1.27 (0.36,3.95)	0.03 (-0.15,0.25)
HD TOCI IV + MTX		0.45 (0.13,1.68)	0.49 (0.16,1.59)	-0.05 (-0.23,0.04)
HD TOFA PO + MTX		0.83 (0.42,1.64)	0.85 (0.46,1.53)	-0.01 (-0.11,0.06)
HD CERTO SC + MTX		0.84 (0.27,2.51)	0.86 (0.32,2.28)	-0.01 (-0.17,0.10)
HD INF IV + MTX		0.42 (0.14,1.25)	0.46 (0.17,1.23)	-0.06 (-0.23,0.01)
HD TOCI IV + DMARD		0.27 (0.07,0.98)	0.31 (0.09,0.98)	-0.08 (-0.27,0.00)
SD ETN SC + DMARD	SD GOLI IV + MTX	0.41 (0.02,3.36)	0.45 (0.07,3.18)	-0.07 (-0.67,0.06)
SD ADA SC + DMARD		0.11 (0.01,1.01)	0.13 (0.02,1.01)	-0.12 (-0.72,0.00)
SD CERTO SC + DMARD		0.09 (0.01,1.10)	0.11 (0.01,1.09)	-0.12 (-0.72,0.00)
LD ADA SC		0.13 (0.01,1.67)	0.16 (0.03,1.65)	-0.12 (-0.71,0.01)

(Continued)

LD ETN SC		0.30 (0.01,2.23)	0.34 (0.04,2.16)	-0.08 (-0.69,0.04)
LD GOL I IV		1.62 (0.50,6.95)	1.39 (0.57,5.18)	0.05 (-0.12,0.33)
LD RITUX IV + MTX		0.21 (0.01,1.46)	0.24 (0.03,1.44)	-0.10 (-0.69,0.01)
LD ABA IV + MTX		0.44 (0.02,3.24)	0.48 (0.07,3.03)	-0.06 (-0.66,0.08)
LD CERTO SC + MTX		0.50 (0.01,5.23)	0.55 (0.03,4.67)	-0.05 (-0.67,0.15)
LD ETN SC + MTX		0.18 (0.01,1.35)	0.21 (0.02,1.33)	-0.11 (-0.70,0.01)
LD GOL I IV + MTX		0.93 (0.23,4.35)	0.95 (0.28,3.54)	-0.01 (-0.26,0.22)
HD TOCI IV		0.33 (0.02,2.36)	0.37 (0.05,2.28)	-0.08 (-0.68,0.03)
HD TOFA PO		0.09 (0.00,1.15)	0.10 (0.01,1.14)	-0.12 (-0.73,0.00)
HD ADA SC		0.20 (0.01,2.59)	0.23 (0.04,2.52)	-0.11 (-0.70,0.03)
HD GOL I SC		0.46 (0.02,4.11)	0.51 (0.06,3.64)	-0.06 (-0.65,0.12)
HD GOL I SC + MTX		1.07 (0.06,8.37)	1.06 (0.17,6.75)	0.00 (-0.56,0.26)
HD TOCI IV + MTX		0.38 (0.02,3.04)	0.43 (0.05,2.86)	-0.07 (-0.68,0.06)
HD TOFA PO + MTX		0.66 (0.04,6.57)	0.71 (0.09,5.59)	-0.04 (-0.61,0.16)
HD CERTO SC + MTX		0.72 (0.03,4.74)	0.76 (0.08,4.30)	-0.03 (-0.64,0.13)
HD INF IV + MTX		0.36 (0.02,2.66)	0.40 (0.05,2.55)	-0.08 (-0.67,0.04)
HD TOCI IV + DMARD		0.23 (0.01,2.02)	0.26 (0.04,1.96)	-0.10 (-0.70,0.03)
SD ADA SC + DMARD	SD ETN SC + DMARD	0.27 (0.07,0.92)	0.28 (0.08,0.92)	-0.04 (-0.12,0.00)
SD CERTO SC + DMARD		0.26 (0.05,1.22)	0.27 (0.05,1.20)	-0.04 (-0.13,0.01)
LD ADA SC		0.37 (0.10,1.16)	0.39 (0.11,1.15)	-0.04 (-0.14,0.00)
LD ETN SC		0.69 (0.22,2.35)	0.71 (0.24,2.20)	-0.01 (-0.09,0.06)
LD GOL I IV		4.34 (0.47,70.46)	3.48 (0.49,17.47)	0.16 (-0.02,0.73)
LD RITUX IV + MTX		0.49 (0.16,1.62)	0.51 (0.17,1.57)	-0.03 (-0.10,0.03)
LD ABA IV + MTX		1.06 (0.31,3.65)	1.06 (0.32,3.22)	0.00 (-0.07,0.13)
LD CERTO SC + MTX		1.27 (0.16,6.01)	1.25 (0.17,4.79)	0.01 (-0.08,0.22)
LD ETN SC + MTX		0.44 (0.12,1.66)	0.46 (0.13,1.60)	-0.03 (-0.11,0.03)
LD GOL I IV + MTX		2.40 (0.27,37.95)	2.18 (0.29,14.36)	0.07 (-0.04,0.62)
HD TOCI IV		0.78 (0.28,2.22)	0.79 (0.30,2.09)	-0.01 (-0.08,0.06)

(Continued)

HD TOFA PO		0.23 (0.06,0.95)	0.24 (0.07,0.95)	-0.04 (-0.15,0.00)
HD ADA SC		0.56 (0.16,1.80)	0.58 (0.18,1.76)	-0.02 (-0.12,0.02)
HD GOLI SC		1.20 (0.23,5.00)	1.18 (0.24,4.19)	0.01 (-0.08,0.18)
HD GOLI SC + MTX		2.59 (0.65,10.42)	2.33 (0.66,7.23)	0.08 (-0.02,0.34)
HD TOCI IV + MTX		0.90 (0.28,3.12)	0.91 (0.29,2.81)	0.00 (-0.07,0.10)
HD TOFA PO + MTX		1.68 (0.46,6.35)	1.60 (0.47,5.13)	0.03 (-0.04,0.21)
HD CERTO SC + MTX		1.67 (0.56,5.34)	1.59 (0.58,4.41)	0.03 (-0.04,0.20)
HD INF IV + MTX		0.86 (0.27,2.78)	0.86 (0.29,2.57)	-0.01 (-0.08,0.09)
HD TOCI IV + DMARD		0.56 (0.17,1.71)	0.58 (0.18,1.64)	-0.02 (-0.09,0.04)
SD CERTO SC + DMARD	SD ADA SC + DMARD	0.96 (0.21,4.43)	0.96 (0.22,4.25)	0.00 (-0.04,0.05)
LD ADA SC		1.42 (0.23,7.43)	1.41 (0.24,7.19)	0.01 (-0.05,0.04)
LD ETN SC		2.62 (0.66,11.84)	2.53 (0.67,10.82)	0.02 (-0.01,0.12)
LD GOLI IV		16.18 (1.71,259.20)	12.00 (1.68,79.82)	0.21 (0.01,0.77)
LD RITUX IV + MTX		1.90 (0.46,7.60)	1.86 (0.47,7.17)	0.01 (-0.02,0.08)
LD ABA IV + MTX		4.02 (1.00,17.26)	3.79 (1.00,15.13)	0.04 (0.00,0.19)
LD CERTO SC + MTX		4.78 (0.53,27.51)	4.41 (0.54,22.26)	0.05 (-0.01,0.28)
LD ETN SC + MTX		1.66 (0.37,8.11)	1.64 (0.37,7.66)	0.01 (-0.03,0.09)
LD GOLI IV + MTX		9.11 (0.93,166.80)	7.76 (0.94,66.04)	0.12 (0.00,0.68)
HD TOCI IV		2.93 (1.03,9.02)	2.82 (1.03,8.43)	0.03 (0.00,0.11)
HD TOFA PO		0.90 (0.16,5.31)	0.91 (0.17,5.21)	0.00 (-0.06,0.02)
HD ADA SC		2.14 (0.38,10.97)	2.09 (0.40,10.50)	0.02 (-0.04,0.06)
HD GOLI SC		4.36 (0.71,27.18)	4.07 (0.72,21.91)	0.05 (-0.01,0.25)
HD GOLI SC + MTX		9.74 (2.04,52.03)	8.24 (1.95,37.68)	0.12 (0.02,0.40)
HD TOCI IV + MTX		3.47 (0.97,13.17)	3.28 (0.97,11.99)	0.04 (0.00,0.16)
HD TOFA PO + MTX		6.38 (1.50,28.50)	5.71 (1.47,22.87)	0.08 (0.01,0.27)
HD CERTO SC + MTX		6.48 (1.48,26.19)	5.82 (1.45,21.42)	0.08 (0.01,0.27)
HD INF IV + MTX		3.28 (0.81,13.81)	3.14 (0.81,12.75)	0.03 (-0.01,0.14)
HD TOCI IV + DMARD		2.08 (0.79,5.83)	2.04 (0.80,5.57)	0.02 (-0.01,0.08)

(Continued)

LD ADA SC	SD CERTO SC + DMARD	1.43 (0.20,9.17)	1.42 (0.21,8.89)	0.01 (-0.06,0.04)
LD ETN SC		2.83 (0.50,17.09)	2.73 (0.51,15.83)	0.02 (-0.03,0.13)
LD GOL I V		17.55 (1.27,287.30)	12.83 (1.26,94.88)	0.20 (0.00,0.77)
LD RITUX IV + MTX		2.03 (0.33,10.35)	1.99 (0.34,9.84)	0.01 (-0.04,0.08)
LD ABA IV + MTX		4.36 (0.63,25.11)	4.09 (0.64,21.71)	0.04 (-0.01,0.20)
LD CERTO SC + MTX		4.87 (0.42,40.97)	4.50 (0.43,32.29)	0.05 (-0.02,0.29)
LD ETN SC + MTX		1.74 (0.28,11.44)	1.72 (0.29,10.66)	0.01 (-0.04,0.09)
LD GOL I V + MTX		10.24 (0.72,172.80)	8.78 (0.73,73.72)	0.12 (-0.01,0.67)
HD TOCI IV		3.11 (0.74,13.65)	2.98 (0.75,12.82)	0.03 (-0.01,0.12)
HD TOFA PO		0.89 (0.14,6.81)	0.90 (0.15,6.69)	0.00 (-0.07,0.02)
HD ADA SC		2.20 (0.35,13.64)	2.16 (0.36,13.11)	0.02 (-0.05,0.06)
HD GOL I SC		4.77 (0.54,33.58)	4.46 (0.55,28.50)	0.05 (-0.02,0.25)
HD GOL I SC + MTX		10.91 (1.43,69.85)	9.17 (1.39,51.80)	0.12 (0.01,0.40)
HD TOCI IV + MTX		3.60 (0.73,19.77)	3.42 (0.74,17.76)	0.04 (-0.01,0.16)
HD TOFA PO + MTX		6.65 (1.16,39.61)	5.97 (1.15,33.50)	0.08 (0.00,0.27)
HD CERTO SC + MTX		6.65 (1.12,35.45)	6.00 (1.11,29.35)	0.08 (0.00,0.27)
HD INF IV + MTX		3.54 (0.55,18.29)	3.37 (0.56,16.76)	0.03 (-0.02,0.14)
HD TOCI IV + DMARD		2.20 (0.57,9.58)	2.14 (0.58,9.14)	0.02 (-0.02,0.08)
LD ETN SC	LD ADA SC	1.89 (0.42,10.33)	1.85 (0.43,9.07)	0.02 (-0.02,0.13)
LD GOL I V		13.34 (0.97,180.00)	10.13 (0.97,49.19)	0.20 (0.00,0.77)
LD RITUX IV + MTX		1.35 (0.30,7.16)	1.34 (0.31,6.55)	0.01 (-0.03,0.09)
LD ABA IV + MTX		2.89 (0.58,15.87)	2.76 (0.59,13.02)	0.04 (-0.01,0.20)
LD CERTO SC + MTX		3.42 (0.37,24.54)	3.21 (0.38,17.98)	0.05 (-0.02,0.29)
LD ETN SC + MTX		1.16 (0.23,6.78)	1.16 (0.23,6.22)	0.00 (-0.03,0.09)
LD GOL I V + MTX		7.43 (0.45,113.80)	6.40 (0.46,40.22)	0.12 (-0.01,0.67)
HD TOCI IV		2.10 (0.51,10.85)	2.05 (0.52,9.53)	0.02 (-0.02,0.14)
HD TOFA PO		0.64 (0.21,2.12)	0.64 (0.21,2.08)	-0.01 (-0.04,0.01)
HD ADA SC		1.53 (0.68,3.54)	1.51 (0.69,3.40)	0.01 (-0.01,0.04)

(Continued)

HD GOLI SC		3.25 (0.50,19.74)	3.07 (0.51,15.16)	0.05 (-0.02,0.25)
HD GOLI SC + MTX		7.31 (1.33,41.87)	6.35 (1.32,26.06)	0.12 (0.01,0.41)
HD TOCI IV + MTX		2.46 (0.52,14.10)	2.38 (0.53,11.88)	0.03 (-0.01,0.18)
HD TOFA PO + MTX		4.64 (0.90,24.96)	4.24 (0.90,18.78)	0.08 (0.00,0.28)
HD CERTO SC + MTX		4.57 (1.08,25.10)	4.20 (1.08,18.91)	0.07 (0.00,0.28)
HD INF IV + MTX		2.34 (0.52,12.01)	2.27 (0.53,10.29)	0.03 (-0.01,0.16)
HD TOCI IV + DMARD		1.49 (0.32,8.08)	1.48 (0.33,7.24)	0.01 (-0.02,0.11)
LD GOLI IV	LD ETN SC	5.85 (0.87,122.00)	4.57 (0.87,31.29)	0.17 (0.00,0.75)
LD RITUX IV + MTX		0.68 (0.24,2.34)	0.69 (0.26,2.23)	-0.01 (-0.09,0.04)
LD ABA IV + MTX		1.49 (0.47,5.17)	1.45 (0.49,4.57)	0.02 (-0.05,0.14)
LD CERTO SC + MTX		1.85 (0.25,8.58)	1.77 (0.26,7.16)	0.03 (-0.06,0.23)
LD ETN SC + MTX		0.62 (0.16,2.50)	0.63 (0.18,2.40)	-0.01 (-0.10,0.05)
LD GOLI IV + MTX		3.32 (0.45,69.20)	2.95 (0.47,25.84)	0.08 (-0.03,0.64)
HD TOCI IV		1.11 (0.36,3.54)	1.10 (0.38,3.31)	0.00 (-0.07,0.08)
HD TOFA PO		0.33 (0.07,1.76)	0.34 (0.08,1.73)	-0.03 (-0.14,0.01)
HD ADA SC		0.80 (0.15,3.82)	0.80 (0.17,3.69)	-0.01 (-0.12,0.04)
HD GOLI SC		1.59 (0.33,7.69)	1.54 (0.35,6.42)	0.02 (-0.06,0.20)
HD GOLI SC + MTX		3.67 (0.94,15.33)	3.20 (0.95,11.05)	0.09 (0.00,0.35)
HD TOCI IV + MTX		1.29 (0.37,4.83)	1.27 (0.39,4.39)	0.01 (-0.06,0.12)
HD TOFA PO + MTX		2.34 (0.64,8.99)	2.19 (0.66,7.42)	0.05 (-0.02,0.23)
HD CERTO SC + MTX		2.38 (0.72,7.52)	2.22 (0.75,6.48)	0.05 (-0.02,0.21)
HD INF IV + MTX		1.20 (0.41,3.91)	1.19 (0.44,3.64)	0.01 (-0.06,0.09)
HD TOCI IV + DMARD		0.81 (0.21,2.75)	0.82 (0.23,2.61)	-0.01 (-0.09,0.05)
LD RITUX IV + MTX	LD GOLI IV	0.12 (0.01,0.67)	0.16 (0.02,0.68)	-0.19 (-0.76,-0.01)
LD ABA IV + MTX		0.25 (0.02,1.57)	0.31 (0.06,1.51)	-0.15 (-0.72,0.03)
LD CERTO SC + MTX		0.29 (0.01,2.81)	0.37 (0.03,2.66)	-0.13 (-0.74,0.10)
LD ETN SC + MTX		0.10 (0.00,0.76)	0.14 (0.02,0.77)	-0.19 (-0.77,0.00)
LD GOLI IV + MTX		0.59 (0.15,1.96)	0.69 (0.22,1.66)	-0.06 (-0.34,0.11)



(Continued)

HD TOCI IV		0.19 (0.01,1.30)	0.24 (0.04,1.29)	-0.17 (-0.74,0.01)
HD TOFA PO		0.05 (0.00,0.85)	0.07 (0.01,0.85)	-0.21 (-0.78,0.00)
HD ADA SC		0.11 (0.01,1.72)	0.15 (0.04,1.69)	-0.19 (-0.75,0.02)
HD GOLI SC		0.27 (0.02,1.97)	0.34 (0.04,1.83)	-0.14 (-0.71,0.06)
HD GOLI SC + MTX		0.61 (0.04,3.92)	0.69 (0.15,3.19)	-0.06 (-0.63,0.19)
HD TOCI IV + MTX		0.22 (0.01,1.51)	0.28 (0.04,1.48)	-0.16 (-0.74,0.02)
HD TOFA PO + MTX		0.38 (0.02,3.10)	0.47 (0.08,2.83)	-0.12 (-0.70,0.10)
HD CERTO SC + MTX		0.40 (0.02,2.81)	0.48 (0.07,2.58)	-0.11 (-0.71,0.08)
HD INF IV + MTX		0.20 (0.01,1.24)	0.26 (0.04,1.22)	-0.17 (-0.74,0.01)
HD TOCI IV + DMARD		0.13 (0.01,1.13)	0.17 (0.03,1.13)	-0.18 (-0.75,0.00)
LD ABA IV + MTX	LD RITUX IV + MTX	2.17 (0.77,6.04)	2.08 (0.78,5.48)	0.03 (-0.01,0.15)
LD CERTO SC + MTX		2.60 (0.36,10.41)	2.45 (0.37,8.54)	0.04 (-0.03,0.24)
LD ETN SC + MTX		0.91 (0.25,2.83)	0.92 (0.26,2.71)	0.00 (-0.06,0.05)
LD GOLI IV + MTX		4.82 (0.79,95.19)	4.16 (0.80,34.24)	0.10 (0.00,0.66)
HD TOCI IV		1.58 (0.58,4.42)	1.54 (0.60,4.17)	0.01 (-0.03,0.09)
HD TOFA PO		0.47 (0.10,2.50)	0.47 (0.11,2.47)	-0.01 (-0.10,0.01)
HD ADA SC		1.12 (0.23,5.97)	1.11 (0.25,5.74)	0.00 (-0.08,0.05)
HD GOLI SC		2.36 (0.53,9.25)	2.24 (0.54,7.73)	0.03 (-0.02,0.21)
HD GOLI SC + MTX		5.23 (1.59,18.35)	4.50 (1.54,13.09)	0.11 (0.01,0.37)
HD TOCI IV + MTX		1.86 (0.62,5.73)	1.80 (0.63,5.25)	0.02 (-0.02,0.13)
HD TOFA PO + MTX		3.43 (1.05,10.42)	3.14 (1.04,8.72)	0.07 (0.00,0.24)
HD CERTO SC + MTX		3.44 (1.27,9.01)	3.15 (1.25,7.74)	0.06 (0.01,0.23)
HD INF IV + MTX		1.75 (0.67,4.42)	1.70 (0.68,4.11)	0.02 (-0.02,0.10)
HD TOCI IV + DMARD		1.12 (0.31,3.79)	1.11 (0.32,3.58)	0.00 (-0.05,0.07)
LD CERTO SC + MTX	LD ABA IV + MTX	1.20 (0.17,5.21)	1.18 (0.18,4.38)	0.01 (-0.11,0.19)
LD ETN SC + MTX		0.41 (0.11,1.43)	0.43 (0.13,1.40)	-0.03 (-0.16,0.02)
LD GOLI IV + MTX		2.28 (0.37,32.76)	2.08 (0.40,12.94)	0.06 (-0.08,0.61)
HD TOCI IV		0.73 (0.24,2.17)	0.75 (0.27,2.08)	-0.01 (-0.13,0.05)

(Continued)

HD TOFA PO		0.21 (0.04,1.39)	0.22 (0.05,1.39)	-0.05 (-0.21,0.01)
HD ADA SC		0.52 (0.10,3.23)	0.54 (0.12,3.11)	-0.03 (-0.19,0.03)
HD GOLI SC		1.08 (0.24,4.61)	1.08 (0.27,3.93)	0.00 (-0.11,0.16)
HD GOLI SC + MTX		2.42 (0.71,8.77)	2.17 (0.74,6.58)	0.07 (-0.03,0.32)
HD TOCI IV + MTX		0.86 (0.26,2.93)	0.87 (0.28,2.71)	-0.01 (-0.12,0.08)
HD TOFA PO + MTX		1.58 (0.46,5.21)	1.50 (0.49,4.41)	0.03 (-0.06,0.18)
HD CERTO SC + MTX		1.56 (0.55,4.52)	1.49 (0.58,3.98)	0.03 (-0.06,0.17)
HD INF IV + MTX		0.81 (0.29,2.28)	0.82 (0.32,2.16)	-0.01 (-0.11,0.05)
HD TOCI IV + DMARD		0.52 (0.13,1.90)	0.54 (0.15,1.84)	-0.03 (-0.16,0.03)
LD ETN SC + MTX	LD CERTO SC + MTX	0.34 (0.07,2.73)	0.36 (0.09,2.64)	-0.04 (-0.25,0.03)
LD GOLI IV + MTX		1.95 (0.20,68.80)	1.79 (0.23,28.25)	0.05 (-0.16,0.63)
HD TOCI IV		0.61 (0.14,4.32)	0.63 (0.17,4.11)	-0.02 (-0.23,0.07)
HD TOFA PO		0.19 (0.03,1.86)	0.20 (0.03,1.84)	-0.06 (-0.30,0.01)
HD ADA SC		0.44 (0.07,4.81)	0.46 (0.09,4.54)	-0.04 (-0.28,0.04)
HD GOLI SC		0.94 (0.14,8.93)	0.94 (0.16,7.66)	0.00 (-0.20,0.16)
HD GOLI SC + MTX		2.09 (0.37,17.72)	1.88 (0.42,13.69)	0.06 (-0.12,0.31)
HD TOCI IV + MTX		0.72 (0.15,4.92)	0.74 (0.18,4.57)	-0.02 (-0.22,0.09)
HD TOFA PO + MTX		1.33 (0.26,9.72)	1.29 (0.30,8.11)	0.02 (-0.16,0.20)
HD CERTO SC + MTX		1.29 (0.38,6.96)	1.26 (0.43,6.26)	0.02 (-0.12,0.15)
HD INF IV + MTX		0.67 (0.16,4.26)	0.70 (0.19,3.98)	-0.02 (-0.21,0.07)
HD TOCI IV + DMARD		0.44 (0.09,3.58)	0.46 (0.11,3.45)	-0.04 (-0.25,0.04)
LD GOLI IV + MTX	LD ETN SC + MTX	5.52 (0.74,109.30)	4.70 (0.74,40.75)	0.10 (-0.01,0.66)
HD TOCI IV		1.79 (0.49,6.20)	1.74 (0.51,5.76)	0.02 (-0.04,0.10)
HD TOFA PO		0.55 (0.08,3.44)	0.55 (0.09,3.39)	-0.01 (-0.10,0.02)
HD ADA SC		1.28 (0.24,6.59)	1.27 (0.26,6.37)	0.01 (-0.08,0.05)
HD GOLI SC		2.57 (0.48,14.56)	2.44 (0.50,12.02)	0.04 (-0.03,0.23)
HD GOLI SC + MTX		5.95 (1.41,26.39)	5.10 (1.38,19.11)	0.11 (0.01,0.38)
HD TOCI IV + MTX		2.11 (0.52,8.39)	2.03 (0.54,7.44)	0.02 (-0.03,0.14)

(Continued)

HD TOFA PO + MTX		3.80 (1.00,16.97)	3.45 (1.00,13.75)	0.07 (0.00,0.25)
HD CERTO SC + MTX		3.74 (1.16,14.09)	3.42 (1.15,12.04)	0.06 (0.01,0.24)
HD INF IV + MTX		1.90 (0.62,6.79)	1.85 (0.63,6.26)	0.02 (-0.02,0.11)
HD TOCI IV + DMARD		1.27 (0.30,5.18)	1.26 (0.32,4.84)	0.01 (-0.06,0.08)
HD TOCI IV	LD GOLI IV + MTX	0.33 (0.02,2.33)	0.37 (0.05,2.28)	-0.08 (-0.64,0.03)
HD TOFA PO		0.09 (0.01,1.73)	0.10 (0.01,1.72)	-0.12 (-0.69,0.01)
HD ADA SC		0.21 (0.02,3.37)	0.24 (0.04,3.27)	-0.10 (-0.66,0.03)
HD GOLI SC		0.48 (0.03,3.51)	0.52 (0.06,3.22)	-0.05 (-0.61,0.11)
HD GOLI SC + MTX		1.11 (0.08,7.30)	1.09 (0.18,5.87)	0.01 (-0.52,0.26)
HD TOCI IV + MTX		0.39 (0.02,2.70)	0.43 (0.05,2.60)	-0.07 (-0.64,0.05)
HD TOFA PO + MTX		0.67 (0.03,5.31)	0.71 (0.09,4.94)	-0.03 (-0.59,0.15)
HD CERTO SC + MTX		0.69 (0.03,5.01)	0.73 (0.08,4.55)	-0.03 (-0.60,0.13)
HD INF IV + MTX		0.36 (0.02,2.11)	0.40 (0.05,2.03)	-0.08 (-0.62,0.04)
HD TOCI IV + DMARD		0.23 (0.01,2.04)	0.27 (0.04,2.00)	-0.10 (-0.66,0.02)
HD TOFA PO	HD TOCI IV	0.29 (0.07,1.56)	0.30 (0.08,1.55)	-0.03 (-0.14,0.01)
HD ADA SC		0.72 (0.16,3.15)	0.73 (0.18,3.03)	-0.01 (-0.12,0.04)
HD GOLI SC		1.49 (0.31,6.74)	1.45 (0.32,5.68)	0.02 (-0.06,0.19)
HD GOLI SC + MTX		3.31 (0.97,12.50)	2.91 (0.98,8.99)	0.09 (0.00,0.35)
HD TOCI IV + MTX		1.16 (0.55,2.52)	1.15 (0.57,2.34)	0.01 (-0.04,0.08)
HD TOFA PO + MTX		2.16 (0.68,6.69)	2.02 (0.70,5.58)	0.05 (-0.02,0.22)
HD CERTO SC + MTX		2.19 (0.73,6.02)	2.06 (0.74,5.12)	0.04 (-0.02,0.21)
HD INF IV + MTX		1.10 (0.39,3.12)	1.10 (0.41,2.85)	0.00 (-0.06,0.09)
HD TOCI IV + DMARD		0.72 (0.28,1.73)	0.73 (0.30,1.67)	-0.01 (-0.08,0.03)
HD ADA SC	HD TOFA PO	2.36 (0.77,7.53)	2.32 (0.77,7.13)	0.02 (-0.01,0.06)
HD GOLI SC		5.11 (0.67,28.98)	4.80 (0.68,22.31)	0.05 (-0.01,0.26)
HD GOLI SC + MTX		11.88 (1.52,62.49)	10.12 (1.50,40.49)	0.13 (0.01,0.42)
HD TOCI IV + MTX		4.05 (0.67,19.24)	3.85 (0.68,16.06)	0.04 (-0.01,0.18)
HD TOFA PO + MTX		7.48 (1.14,35.73)	6.75 (1.14,27.02)	0.09 (0.00,0.29)

(Continued)

HD CERTO SC + MTX		7.27 (1.36,33.78)	6.61 (1.35,25.82)	0.08 (0.01,0.29)
HD INF IV + MTX		3.73 (0.64,18.72)	3.58 (0.65,16.11)	0.04 (-0.01,0.16)
HD TOCI IV + DMARD		2.47 (0.42,11.88)	2.41 (0.43,10.69)	0.02 (-0.01,0.11)
HD GOLI SC	HD ADA SC	2.15 (0.30,12.14)	2.07 (0.31,9.45)	0.03 (-0.03,0.24)
HD GOLI SC + MTX		4.89 (0.75,23.04)	4.28 (0.75,15.01)	0.11 (-0.01,0.40)
HD TOCI IV + MTX		1.66 (0.32,8.66)	1.63 (0.33,7.37)	0.02 (-0.03,0.17)
HD TOFA PO + MTX		3.17 (0.57,14.30)	2.92 (0.58,10.85)	0.07 (-0.02,0.27)
HD CERTO SC + MTX		3.05 (0.68,14.59)	2.82 (0.69,10.97)	0.06 (-0.01,0.27)
HD INF IV + MTX		1.57 (0.30,7.33)	1.54 (0.31,6.34)	0.02 (-0.04,0.14)
HD TOCI IV + DMARD		0.99 (0.22,4.96)	0.99 (0.23,4.47)	0.00 (-0.04,0.09)
HD GOLI SC + MTX	HD GOLI SC	2.28 (0.71,8.29)	2.04 (0.75,6.87)	0.07 (-0.03,0.28)
HD TOCI IV + MTX		0.80 (0.16,4.19)	0.81 (0.19,3.84)	-0.01 (-0.18,0.10)
HD TOFA PO + MTX		1.47 (0.31,7.45)	1.40 (0.35,6.40)	0.02 (-0.12,0.19)
HD CERTO SC + MTX		1.44 (0.34,6.72)	1.38 (0.38,5.78)	0.02 (-0.12,0.18)
HD INF IV + MTX		0.74 (0.19,3.34)	0.76 (0.22,3.13)	-0.01 (-0.18,0.07)
HD TOCI IV + DMARD		0.47 (0.09,2.69)	0.49 (0.10,2.57)	-0.03 (-0.22,0.04)
HD TOCI IV + MTX	HD GOLI SC + MTX	0.36 (0.08,1.32)	0.40 (0.12,1.28)	-0.08 (-0.34,0.02)
HD TOFA PO + MTX		0.62 (0.16,2.68)	0.67 (0.20,2.37)	-0.04 (-0.26,0.12)
HD CERTO SC + MTX		0.63 (0.18,2.17)	0.67 (0.23,1.99)	-0.04 (-0.27,0.09)
HD INF IV + MTX		0.33 (0.10,1.06)	0.38 (0.13,1.06)	-0.09 (-0.33,0.00)
HD TOCI IV + DMARD		0.21 (0.05,0.91)	0.25 (0.06,0.91)	-0.10 (-0.37,0.00)
HD TOFA PO + MTX	HD TOCI IV + MTX	1.88 (0.49,6.42)	1.77 (0.51,5.44)	0.04 (-0.05,0.21)
HD CERTO SC + MTX		1.84 (0.57,5.76)	1.74 (0.60,4.89)	0.04 (-0.04,0.19)
HD INF IV + MTX		0.93 (0.30,2.85)	0.93 (0.32,2.68)	0.00 (-0.10,0.08)
HD TOCI IV + DMARD		0.61 (0.19,1.90)	0.62 (0.21,1.83)	-0.02 (-0.12,0.03)
HD CERTO SC + MTX	HD TOFA PO + MTX	1.00 (0.31,3.23)	1.00 (0.37,2.90)	0.00 (-0.14,0.12)
HD INF IV + MTX		0.51 (0.17,1.59)	0.54 (0.21,1.54)	-0.04 (-0.20,0.02)

(Continued)

HD TOCI IV + DMARD		0.33 (0.09,1.24)	0.36 (0.11,1.23)	-0.06 (-0.24,0.01)
HD INF IV + MTX	HD CERTO SC + MTX	0.51 (0.19,1.40)	0.55 (0.22,1.36)	-0.04 (-0.19,0.02)
HD TOCI IV + DMARD		0.33 (0.09,1.13)	0.35 (0.11,1.12)	-0.06 (-0.24,0.01)
HD TOCI IV + DMARD	HD INF IV + MTX	0.65 (0.18,2.20)	0.67 (0.20,2.11)	-0.01 (-0.11,0.04)

Random-Effect Model	Residual Deviance	125.1 vs 127 data points
	Deviance Information Criteria	688.58
Fixed-Effect Model	Residual Deviance	130.2 vs 127 data points
	Deviance Information Criteria	689.019

Note:

Total Patients	22022
Total Studies	50
2-arm	30
3-arm	14
4-arm	5
5-arm	1

#### Appendix 40. Serious Adverse Events: Subgroup - Late RA (> 10 years)

SAEs in Late RA: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD RITUX IV	MTX + PL	0.79 (0.09,4.27)	0.80 (0.09,3.70)	-0.01 (-0.06,0.13)
SD RITUX IV + MTX		2.02 (0.71,5.91)	1.90 (0.72,4.90)	0.05 (-0.02,0.17)
SD INF IV + MTX		0.48 (0.16,1.42)	0.50 (0.17,1.39)	-0.03 (-0.06,0.02)
SD ANA SC + MTX		1.26 (0.39,4.26)	1.24 (0.41,3.65)	0.01 (-0.04,0.14)

(Continued)

LD RITUX IV + MTX		2.67 (0.96,7.84)	2.43 (0.96,6.09)	0.08 (0.00,0.22)
HD INF IV + MTX		0.94 (0.35,2.57)	0.94 (0.36,2.37)	0.00 (-0.04,0.07)
SD RITUX IV + MTX	SD RITUX IV	2.56 (0.50,21.54)	2.38 (0.55,18.75)	0.06 (-0.07,0.17)
SD INF IV + MTX		0.61 (0.08,6.91)	0.62 (0.10,6.58)	-0.02 (-0.15,0.05)
SD ANA SC + MTX		1.61 (0.20,19.67)	1.56 (0.23,17.05)	0.02 (-0.12,0.16)
LD RITUX IV + MTX		3.39 (0.68,28.39)	3.03 (0.72,23.75)	0.09 (-0.04,0.22)
HD INF IV + MTX		1.20 (0.17,12.80)	1.19 (0.19,11.66)	0.01 (-0.13,0.10)
SD INF IV + MTX	SD RITUX IV + MTX	0.24 (0.05,1.10)	0.26 (0.06,1.09)	-0.08 (-0.19,0.01)
SD ANA SC + MTX		0.63 (0.13,3.18)	0.65 (0.15,2.79)	-0.04 (-0.17,0.11)
LD RITUX IV + MTX		1.32 (0.54,3.31)	1.27 (0.58,2.84)	0.03 (-0.07,0.14)
HD INF IV + MTX		0.47 (0.11,1.98)	0.50 (0.13,1.87)	-0.05 (-0.18,0.05)
SD ANA SC + MTX	SD INF IV + MTX	2.61 (0.54,13.70)	2.49 (0.56,11.58)	0.04 (-0.03,0.17)
LD RITUX IV + MTX		5.58 (1.23,25.49)	4.91 (1.21,19.87)	0.11 (0.01,0.25)
HD INF IV + MTX		1.95 (0.65,5.91)	1.89 (0.67,5.46)	0.02 (-0.02,0.09)
LD RITUX IV + MTX	SD ANA SC + MTX	2.13 (0.43,10.31)	1.97 (0.48,8.18)	0.07 (-0.09,0.22)
HD INF IV + MTX		0.74 (0.15,3.47)	0.76 (0.18,3.20)	-0.02 (-0.15,0.08)
HD INF IV + MTX	LD RITUX IV + MTX	0.35 (0.08,1.48)	0.39 (0.10,1.42)	-0.08 (-0.23,0.03)
<hr/>				
Random-Effect Model	Residual Deviance	11.23 vs 12 data points		
	Deviance Information Criteria	65.874		
Fixed-Effect Model	Residual Deviance	11.24 vs 12 data points		
	Deviance Information Criteria	65.611		
Note:				
<hr/>				
Total Patients	1390			

(Continued)

Total Studies	4
2-arm	1
3-arm	2
4-arm	1

**Appendix 41. Serious Adverse Events: Subgroup - Trial duration ( $\leq$  6 months) - Network 1**

SAEs, Short trial duration, Network 1: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
DMARD + PL	PL	0.96 (0.14,6.18)	0.96 (0.15,5.17)	0.00 (-0.04,0.15)
MTX + DMARD		0.93 (0.06,13.23)	0.93 (0.06,9.40)	0.00 (-0.04,0.28)
SD ADA SC		1.11 (0.59,2.11)	1.11 (0.60,2.04)	0.00 (-0.02,0.04)
SD ETN SC		1.62 (0.21,13.99)	1.58 (0.22,9.90)	0.02 (-0.03,0.29)
SD TOC IV + PL SC		1.27 (0.41,3.80)	1.26 (0.42,3.48)	0.01 (-0.02,0.09)
SD TOFA PO		0.39 (0.14,1.05)	0.40 (0.14,1.05)	-0.02 (-0.04,0.00)
SD CERTO SC		4.43 (1.10,21.91)	3.94 (1.10,13.92)	0.10 (0.00,0.37)
SD TOC SC + PL IV		1.10 (0.26,4.60)	1.09 (0.27,4.06)	0.00 (-0.03,0.11)
SD ETN SC + MTX		1.66 (0.15,21.12)	1.62 (0.16,13.16)	0.02 (-0.04,0.38)
SD ETN SC + DMARD		1.45 (0.29,6.57)	1.42 (0.30,5.47)	0.01 (-0.03,0.16)
SD ADA SC + DMARD		0.67 (0.08,5.30)	0.68 (0.08,4.61)	-0.01 (-0.04,0.13)
SD ANA + DMARD		0.95 (0.12,7.22)	0.95 (0.12,5.96)	0.00 (-0.04,0.18)
SD CERTO SC + DMARD		0.66 (0.06,6.85)	0.67 (0.06,5.67)	-0.01 (-0.04,0.17)
SD TOCI SC + DMARD		1.25 (0.14,10.79)	1.23 (0.14,8.01)	0.01 (-0.04,0.25)
LD ADA SC		0.65 (0.25,1.49)	0.66 (0.26,1.47)	-0.01 (-0.03,0.02)
HD TOFA PO		0.53 (0.22,1.37)	0.54 (0.22,1.35)	-0.02 (-0.04,0.01)
HD ADA SC		1.00 (0.45,2.30)	1.00 (0.46,2.21)	0.00 (-0.02,0.04)
HD TOCI IV + DMARD		1.47 (0.20,10.44)	1.45 (0.21,7.81)	0.02 (-0.03,0.25)
MTX + DMARD	DMARD + PL	0.91 (0.04,25.54)	0.91 (0.04,19.57)	0.00 (-0.15,0.27)

(Continued)

SD ADA SC		1.18 (0.20,7.16)	1.18 (0.24,6.85)	0.01 (-0.14,0.05)
SD ETN SC		1.63 (0.11,29.72)	1.59 (0.13,22.57)	0.02 (-0.13,0.28)
SD TOC IV + PL SC		1.34 (0.18,10.39)	1.33 (0.21,9.65)	0.01 (-0.13,0.09)
SD TOFA PO		0.40 (0.04,3.31)	0.41 (0.05,3.25)	-0.02 (-0.18,0.02)
SD CERTO SC		4.76 (0.43,57.12)	4.15 (0.49,40.20)	0.10 (-0.08,0.37)
SD TOC SC + PL IV		1.18 (0.14,10.56)	1.17 (0.16,9.81)	0.00 (-0.14,0.10)
SD ETN SC + MTX		1.71 (0.09,40.13)	1.65 (0.10,28.01)	0.02 (-0.12,0.37)
SD ETN SC + DMARD		1.52 (0.57,4.02)	1.48 (0.60,3.82)	0.01 (-0.04,0.08)
SD ADA SC + DMARD		0.70 (0.25,1.88)	0.71 (0.26,1.80)	-0.01 (-0.07,0.04)
SD ANA + DMARD		1.00 (0.42,2.36)	1.00 (0.44,2.21)	0.00 (-0.04,0.07)
SD CERTO SC + DMARD		0.69 (0.15,2.76)	0.71 (0.16,2.55)	-0.01 (-0.08,0.08)
SD TOCI SC + DMARD		1.29 (0.46,4.02)	1.28 (0.47,3.50)	0.01 (-0.03,0.15)
LD ADA SC		0.68 (0.09,5.06)	0.69 (0.11,4.90)	-0.01 (-0.16,0.03)
HD TOFA PO		0.56 (0.06,4.78)	0.57 (0.08,4.64)	-0.01 (-0.17,0.03)
HD ADA SC		1.04 (0.16,7.57)	1.04 (0.19,7.26)	0.00 (-0.15,0.05)
HD TOCI IV + DMARD		1.52 (0.81,2.99)	1.48 (0.82,2.76)	0.01 (-0.01,0.12)
SD ADA SC	MTX + DMARD	1.22 (0.08,20.81)	1.21 (0.11,19.91)	0.01 (-0.27,0.06)
SD ETN SC		1.76 (0.38,9.71)	1.68 (0.44,9.08)	0.02 (-0.11,0.15)
SD TOC IV + PL SC		1.39 (0.08,26.66)	1.37 (0.11,24.75)	0.01 (-0.26,0.10)
SD TOFA PO		0.42 (0.02,8.11)	0.43 (0.03,7.96)	-0.02 (-0.30,0.02)
SD CERTO SC		4.76 (0.23,123.50)	4.17 (0.30,86.98)	0.10 (-0.19,0.37)
SD TOC SC + PL IV		1.22 (0.06,26.45)	1.21 (0.08,24.20)	0.01 (-0.26,0.11)
SD ETN SC + MTX		1.81 (0.63,6.63)	1.73 (0.66,6.05)	0.02 (-0.04,0.18)
SD ETN SC + DMARD		1.64 (0.07,34.32)	1.60 (0.10,30.75)	0.02 (-0.25,0.16)
SD ADA SC + DMARD		0.74 (0.02,20.69)	0.75 (0.03,18.63)	-0.01 (-0.28,0.13)
SD ANA + DMARD		1.12 (0.04,27.80)	1.12 (0.05,24.55)	0.00 (-0.27,0.17)
SD CERTO SC + DMARD		0.74 (0.02,25.08)	0.75 (0.02,21.69)	-0.01 (-0.28,0.17)
SD TOCI SC + DMARD		1.44 (0.04,39.90)	1.41 (0.05,33.84)	0.01 (-0.26,0.24)



(Continued)

LD ADA SC		0.69 (0.04,12.56)	0.70 (0.06,12.17)	-0.01 (-0.29,0.04)
HD TOFA PO		0.58 (0.03,10.77)	0.59 (0.05,10.42)	-0.01 (-0.29,0.03)
HD ADA SC		1.09 (0.07,21.03)	1.08 (0.09,19.95)	0.00 (-0.28,0.06)
HD TOCI IV + DMARD		1.68 (0.06,42.31)	1.64 (0.08,35.79)	0.02 (-0.25,0.24)
SD ETN SC	SD ADA SC	1.47 (0.17,13.61)	1.44 (0.17,9.75)	0.02 (-0.05,0.28)
SD TOC IV + PL SC		1.14 (0.45,2.86)	1.13 (0.46,2.66)	0.00 (-0.02,0.07)
SD TOFA PO		0.35 (0.10,1.12)	0.36 (0.11,1.12)	-0.02 (-0.06,0.00)
SD CERTO SC		3.98 (0.83,23.16)	3.55 (0.84,14.95)	0.10 (-0.01,0.37)
SD TOC SC + PL IV		0.99 (0.28,3.51)	1.00 (0.28,3.18)	0.00 (-0.04,0.09)
SD ETN SC + MTX		1.50 (0.12,19.86)	1.47 (0.13,12.19)	0.02 (-0.05,0.38)
SD ETN SC + DMARD		1.31 (0.30,5.28)	1.29 (0.31,4.51)	0.01 (-0.03,0.15)
SD ADA SC + DMARD		0.60 (0.08,4.43)	0.61 (0.08,3.83)	-0.01 (-0.05,0.12)
SD ANA + DMARD		0.85 (0.12,6.02)	0.85 (0.12,4.95)	-0.01 (-0.05,0.17)
SD CERTO SC + DMARD		0.58 (0.06,5.65)	0.59 (0.06,4.77)	-0.01 (-0.05,0.16)
SD TOCI SC + DMARD		1.11 (0.14,8.73)	1.10 (0.14,6.65)	0.00 (-0.04,0.23)
LD ADA SC		0.58 (0.23,1.32)	0.59 (0.24,1.30)	-0.02 (-0.05,0.01)
HD TOFA PO		0.47 (0.16,1.47)	0.49 (0.16,1.44)	-0.02 (-0.06,0.01)
HD ADA SC		0.90 (0.41,1.99)	0.90 (0.42,1.93)	0.00 (-0.03,0.03)
HD TOCI IV + DMARD		1.31 (0.20,8.63)	1.29 (0.20,6.50)	0.01 (-0.04,0.24)
SD TOC IV + PL SC	SD ETN SC	0.76 (0.07,7.99)	0.77 (0.10,7.32)	-0.01 (-0.28,0.09)
SD TOFA PO		0.23 (0.02,2.47)	0.25 (0.03,2.43)	-0.04 (-0.31,0.01)
SD CERTO SC		2.71 (0.21,39.52)	2.44 (0.27,27.00)	0.07 (-0.21,0.36)
SD TOC SC + PL IV		0.66 (0.05,7.95)	0.67 (0.07,7.18)	-0.02 (-0.28,0.10)
SD ETN SC + MTX		1.04 (0.33,3.10)	1.03 (0.35,2.65)	0.00 (-0.07,0.16)
SD ETN SC + DMARD		0.90 (0.06,11.09)	0.91 (0.09,9.54)	0.00 (-0.27,0.15)
SD ADA SC + DMARD		0.42 (0.02,7.51)	0.44 (0.03,6.63)	-0.03 (-0.29,0.11)
SD ANA + DMARD		0.60 (0.03,9.77)	0.62 (0.04,8.48)	-0.02 (-0.28,0.15)
SD CERTO SC + DMARD		0.41 (0.02,9.20)	0.42 (0.02,7.82)	-0.03 (-0.29,0.15)

(Continued)

SD TOCI SC + DMARD		0.78 (0.04,14.46)	0.79 (0.04,11.43)	-0.01 (-0.27,0.22)
LD ADA SC		0.39 (0.04,3.55)	0.41 (0.05,3.45)	-0.03 (-0.30,0.03)
HD TOFA PO		0.32 (0.03,3.15)	0.33 (0.05,3.09)	-0.04 (-0.30,0.02)
HD ADA SC		0.60 (0.06,5.72)	0.62 (0.09,5.48)	-0.02 (-0.29,0.05)
HD TOCI IV + DMARD		0.94 (0.05,14.51)	0.94 (0.06,11.74)	0.00 (-0.27,0.21)
SD TOFA PO	SD TOC IV + PL SC	0.31 (0.07,1.32)	0.32 (0.07,1.31)	-0.03 (-0.11,0.01)
SD CERTO SC		3.51 (0.60,25.56)	3.13 (0.62,17.15)	0.09 (-0.03,0.36)
SD TOC SC + PL IV		0.87 (0.37,2.09)	0.88 (0.38,1.98)	0.00 (-0.04,0.05)
SD ETN SC + MTX		1.35 (0.10,19.89)	1.33 (0.10,12.73)	0.01 (-0.09,0.36)
SD ETN SC + DMARD		1.14 (0.20,6.39)	1.14 (0.21,5.47)	0.01 (-0.07,0.15)
SD ADA SC + DMARD		0.53 (0.05,4.81)	0.54 (0.06,4.23)	-0.02 (-0.10,0.11)
SD ANA + DMARD		0.75 (0.08,6.39)	0.76 (0.09,5.39)	-0.01 (-0.09,0.16)
SD CERTO SC + DMARD		0.51 (0.04,5.99)	0.53 (0.05,5.09)	-0.02 (-0.10,0.15)
SD TOCI SC + DMARD		0.97 (0.10,9.56)	0.98 (0.11,7.46)	0.00 (-0.08,0.23)
LD ADA SC		0.51 (0.14,1.74)	0.52 (0.15,1.71)	-0.02 (-0.10,0.01)
HD TOFA PO		0.42 (0.10,1.83)	0.43 (0.11,1.81)	-0.02 (-0.11,0.01)
HD ADA SC		0.79 (0.24,2.69)	0.80 (0.26,2.60)	-0.01 (-0.08,0.04)
HD TOCI IV + DMARD		1.15 (0.14,8.99)	1.14 (0.15,7.16)	0.01 (-0.08,0.23)
SD CERTO SC	SD TOFA PO	11.21 (2.11,79.76)	9.71 (2.05,51.52)	0.12 (0.02,0.39)
SD TOC SC + PL IV		2.80 (0.52,16.83)	2.72 (0.52,14.73)	0.02 (-0.01,0.13)
SD ETN SC + MTX		4.42 (0.32,64.65)	4.20 (0.33,40.39)	0.04 (-0.02,0.40)
SD ETN SC + DMARD		3.74 (0.58,23.89)	3.59 (0.58,19.88)	0.04 (-0.01,0.19)
SD ADA SC + DMARD		1.74 (0.17,18.47)	1.72 (0.17,15.85)	0.01 (-0.02,0.15)
SD ANA + DMARD		2.46 (0.25,25.78)	2.40 (0.26,20.60)	0.02 (-0.02,0.21)
SD CERTO SC + DMARD		1.69 (0.12,22.75)	1.67 (0.12,18.34)	0.01 (-0.02,0.19)
SD TOCI SC + DMARD		3.20 (0.29,36.23)	3.09 (0.30,26.52)	0.03 (-0.02,0.27)
LD ADA SC		1.65 (0.45,6.49)	1.64 (0.46,6.22)	0.01 (-0.02,0.04)
HD TOFA PO		1.36 (0.51,3.82)	1.35 (0.52,3.74)	0.00 (-0.01,0.03)

(Continued)

HD ADA SC		2.53 (0.75,9.86)	2.47 (0.75,9.32)	0.02 (-0.01,0.07)
HD TOCI IV + DMARD		3.79 (0.42,38.62)	3.63 (0.42,28.27)	0.04 (-0.01,0.27)
SD TOC SC + PL IV	SD CERTO SC	0.25 (0.03,1.75)	0.28 (0.04,1.65)	-0.10 (-0.36,0.04)
SD ETN SC + MTX		0.38 (0.02,6.87)	0.42 (0.03,4.60)	-0.07 (-0.35,0.30)
SD ETN SC + DMARD		0.32 (0.03,2.65)	0.36 (0.05,2.36)	-0.08 (-0.35,0.09)
SD ADA SC + DMARD		0.15 (0.01,1.89)	0.17 (0.01,1.76)	-0.11 (-0.37,0.06)
SD ANA + DMARD		0.21 (0.01,2.69)	0.24 (0.02,2.33)	-0.10 (-0.37,0.10)
SD CERTO SC + DMARD		0.15 (0.01,2.31)	0.17 (0.01,2.09)	-0.11 (-0.37,0.09)
SD TOCI SC + DMARD		0.28 (0.02,3.62)	0.32 (0.03,2.96)	-0.09 (-0.36,0.16)
LD ADA SC		0.14 (0.02,0.73)	0.17 (0.03,0.74)	-0.12 (-0.38,-0.01)
HD TOFA PO		0.12 (0.02,0.68)	0.14 (0.03,0.69)	-0.12 (-0.38,-0.01)
HD ADA SC		0.22 (0.03,1.18)	0.25 (0.05,1.17)	-0.10 (-0.37,0.01)
HD TOCI IV + DMARD		0.32 (0.02,3.90)	0.36 (0.03,3.14)	-0.08 (-0.35,0.17)
SD ETN SC + MTX	SD TOC SC + PL IV	1.57 (0.10,26.25)	1.53 (0.11,17.17)	0.02 (-0.10,0.37)
SD ETN SC + DMARD		1.31 (0.19,8.95)	1.29 (0.21,7.69)	0.01 (-0.09,0.15)
SD ADA SC + DMARD		0.61 (0.05,6.35)	0.62 (0.06,5.57)	-0.01 (-0.11,0.11)
SD ANA + DMARD		0.86 (0.08,8.52)	0.87 (0.09,7.35)	0.00 (-0.10,0.17)
SD CERTO SC + DMARD		0.59 (0.04,8.07)	0.60 (0.05,6.79)	-0.01 (-0.11,0.16)
SD TOCI SC + DMARD		1.11 (0.10,12.81)	1.10 (0.11,10.24)	0.00 (-0.10,0.23)
LD ADA SC		0.58 (0.12,2.68)	0.59 (0.14,2.61)	-0.01 (-0.12,0.02)
HD TOFA PO		0.48 (0.09,2.65)	0.49 (0.10,2.59)	-0.02 (-0.13,0.02)
HD ADA SC		0.91 (0.21,4.07)	0.91 (0.23,3.91)	0.00 (-0.10,0.04)
HD TOCI IV + DMARD		1.30 (0.14,12.44)	1.28 (0.15,9.98)	0.01 (-0.09,0.23)
SD ETN SC + DMARD	SD ETN SC + MTX	0.87 (0.05,14.52)	0.88 (0.07,12.70)	-0.01 (-0.36,0.14)
SD ADA SC + DMARD		0.40 (0.02,8.85)	0.42 (0.02,8.05)	-0.03 (-0.38,0.11)
SD ANA + DMARD		0.58 (0.02,11.97)	0.60 (0.03,10.31)	-0.02 (-0.37,0.15)
SD CERTO SC + DMARD		0.40 (0.01,10.37)	0.42 (0.02,8.96)	-0.03 (-0.38,0.14)
SD TOCI SC + DMARD		0.75 (0.03,17.16)	0.76 (0.04,13.90)	-0.01 (-0.36,0.21)

(Continued)

LD ADA SC		0.37 (0.03,4.99)	0.39 (0.04,4.85)	-0.03 (-0.39,0.03)
HD TOFA PO		0.31 (0.02,4.21)	0.33 (0.04,4.10)	-0.04 (-0.39,0.02)
HD ADA SC		0.60 (0.04,7.95)	0.61 (0.07,7.59)	-0.02 (-0.38,0.05)
HD TOCI IV + DMARD		0.90 (0.04,17.66)	0.91 (0.05,14.64)	0.00 (-0.36,0.21)
SD ADA SC + DMARD	SD ETN SC + DMARD	0.47 (0.11,1.82)	0.48 (0.12,1.72)	-0.02 (-0.11,0.04)
SD ANA + DMARD		0.66 (0.18,2.43)	0.67 (0.19,2.21)	-0.01 (-0.09,0.08)
SD CERTO SC + DMARD		0.46 (0.08,2.47)	0.48 (0.08,2.22)	-0.02 (-0.12,0.08)
SD TOCI SC + DMARD		0.85 (0.21,3.82)	0.86 (0.22,3.21)	0.00 (-0.08,0.15)
LD ADA SC		0.44 (0.08,2.38)	0.46 (0.10,2.34)	-0.03 (-0.18,0.02)
HD TOFA PO		0.37 (0.06,2.42)	0.38 (0.07,2.38)	-0.03 (-0.18,0.02)
HD ADA SC		0.68 (0.14,3.82)	0.70 (0.17,3.67)	-0.01 (-0.16,0.04)
HD TOCI IV + DMARD		1.01 (0.32,3.26)	1.01 (0.33,2.86)	0.00 (-0.06,0.14)
SD ANA + DMARD	SD ADA SC + DMARD	1.43 (0.38,5.47)	1.40 (0.40,5.10)	0.01 (-0.05,0.11)
SD CERTO SC + DMARD		1.00 (0.16,5.64)	1.00 (0.17,5.15)	0.00 (-0.08,0.11)
SD TOCI SC + DMARD		1.87 (0.43,8.46)	1.81 (0.45,7.40)	0.02 (-0.04,0.18)
LD ADA SC		0.95 (0.11,9.15)	0.95 (0.12,8.93)	0.00 (-0.14,0.04)
HD TOFA PO		0.80 (0.08,8.40)	0.80 (0.09,8.19)	0.00 (-0.15,0.03)
HD ADA SC		1.46 (0.18,14.45)	1.44 (0.21,13.87)	0.01 (-0.13,0.06)
HD TOCI IV + DMARD		2.18 (0.68,7.44)	2.09 (0.70,6.80)	0.02 (-0.02,0.16)
SD CERTO SC + DMARD	SD ANA + DMARD	0.68 (0.12,3.59)	0.70 (0.13,3.29)	-0.01 (-0.11,0.08)
SD TOCI SC + DMARD		1.30 (0.33,5.29)	1.28 (0.35,4.65)	0.01 (-0.07,0.15)
LD ADA SC		0.68 (0.08,5.77)	0.69 (0.10,5.61)	-0.01 (-0.19,0.03)
HD TOFA PO		0.56 (0.05,5.63)	0.57 (0.07,5.47)	-0.01 (-0.20,0.03)
HD ADA SC		1.05 (0.13,8.86)	1.05 (0.16,8.49)	0.00 (-0.17,0.05)
HD TOCI IV + DMARD		1.53 (0.54,4.55)	1.49 (0.56,4.16)	0.01 (-0.04,0.13)
SD TOCI SC + DMARD	SD CERTO SC + DMARD	1.90 (0.33,11.57)	1.83 (0.36,10.40)	0.01 (-0.07,0.18)
LD ADA SC		0.98 (0.08,12.31)	0.98 (0.10,11.89)	0.00 (-0.18,0.04)

(Continued)

HD TOFA PO		0.81 (0.07,12.06)	0.81 (0.08,11.72)	0.00 (-0.19,0.03)
HD ADA SC		1.51 (0.14,18.93)	1.49 (0.17,18.07)	0.01 (-0.16,0.06)
HD TOCI IV + DMARD		2.21 (0.47,11.44)	2.10 (0.51,10.48)	0.02 (-0.05,0.17)
LD ADA SC	SD TOCI SC + DMARD	0.52 (0.05,4.94)	0.53 (0.07,4.78)	-0.02 (-0.26,0.03)
HD TOFA PO		0.43 (0.04,4.68)	0.44 (0.06,4.56)	-0.02 (-0.26,0.03)
HD ADA SC		0.81 (0.09,7.72)	0.82 (0.12,7.37)	-0.01 (-0.24,0.05)
HD TOCI IV + DMARD		1.17 (0.33,4.05)	1.16 (0.37,3.75)	0.00 (-0.11,0.12)
HD TOFA PO	LD ADA SC	0.82 (0.24,2.89)	0.82 (0.25,2.82)	0.00 (-0.04,0.03)
HD ADA SC		1.54 (0.64,4.18)	1.52 (0.65,4.01)	0.01 (-0.01,0.05)
HD TOCI IV + DMARD		2.27 (0.27,18.38)	2.20 (0.28,13.99)	0.03 (-0.03,0.26)
HD ADA SC	HD TOFA PO	1.90 (0.55,6.60)	1.86 (0.56,6.22)	0.02 (-0.02,0.06)
HD TOCI IV + DMARD		2.71 (0.30,26.42)	2.61 (0.30,19.47)	0.03 (-0.02,0.27)
HD TOCI IV + DMARD	HD ADA SC	1.47 (0.18,10.69)	1.45 (0.19,8.12)	0.01 (-0.05,0.24)
Random-Effect Model	Residual Deviance	54.1 vs 52 data points		
	Deviance Information Criteria	294.538		
Fixed-Effect Model	Residual Deviance	56.54 vs 52 data points		
	Deviance Information Criteria	294.2		
Note:				
Total Patients	11146			
Total Studies	23			
2-arm	19			
3-arm	2			
4-arm	2			

**Appendix 42. Serious Adverse Events: Subgroup - Trial duration ( $\leq 6$  months) - Network 2**

SAE, Short trial duration, Network 2: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model

Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD GOLI IV	MTX	0.95 (0.08,10.49)	0.96 (0.09,7.69)	0.00 (-0.04,0.26)
SD RITUX IV		0.49 (0.06,2.35)	0.50 (0.07,2.23)	-0.02 (-0.04,0.05)
SD CERTO SC + MTX		1.49 (0.88,2.73)	1.46 (0.88,2.55)	0.02 (0.00,0.06)
SD INF IV + MTX		1.08 (0.60,1.86)	1.08 (0.61,1.80)	0.00 (-0.02,0.03)
SD ADA SC + MTX		1.10 (0.46,2.50)	1.09 (0.47,2.36)	0.00 (-0.02,0.05)
SD ABA SC + MTX		0.61 (0.21,1.34)	0.62 (0.22,1.32)	-0.02 (-0.03,0.01)
SD ABA IV + MTX		0.80 (0.40,1.36)	0.81 (0.41,1.34)	-0.01 (-0.02,0.01)
SD RITUX IV + MTX		1.36 (0.69,2.65)	1.34 (0.70,2.49)	0.01 (-0.01,0.06)
SD GOLI SC + MTX		2.15 (0.71,7.89)	2.06 (0.72,6.26)	0.04 (-0.01,0.20)
SD TOFA PO + MTX		2.15 (0.88,5.43)	2.05 (0.89,4.64)	0.04 (0.00,0.14)
SD GOLI IV + MTX		2.91 (0.54,24.54)	2.70 (0.55,12.82)	0.07 (-0.02,0.46)
SD ANA SC + MTX		1.28 (0.43,4.20)	1.26 (0.44,3.72)	0.01 (-0.02,0.11)
LD GOLI IV		4.76 (0.99,38.40)	4.12 (0.99,15.69)	0.13 (0.00,0.57)
LD RITUX IV + MTX		1.08 (0.55,2.28)	1.07 (0.56,2.18)	0.00 (-0.02,0.05)
LD CERTO SC + MTX		1.58 (0.27,8.35)	1.55 (0.28,6.47)	0.02 (-0.03,0.21)
LD GOLI IV + MTX		2.81 (0.53,22.70)	2.62 (0.54,12.34)	0.07 (-0.02,0.44)
HD TOCI IV		1.39 (0.54,3.71)	1.36 (0.55,3.34)	0.01 (-0.02,0.09)
HD GOLI SC		1.30 (0.32,5.56)	1.28 (0.33,4.73)	0.01 (-0.03,0.14)
HD GOLI SC + MTX		2.90 (0.99,9.95)	2.69 (0.99,7.48)	0.07 (0.00,0.24)
HD TOCI IV + MTX		1.48 (0.50,4.45)	1.45 (0.52,3.91)	0.02 (-0.02,0.12)
HD TOFA PO + MTX		1.83 (0.73,4.62)	1.77 (0.74,4.07)	0.03 (-0.01,0.12)
HD INF IV + MTX		1.03 (0.46,2.17)	1.03 (0.47,2.07)	0.00 (-0.02,0.04)
HD CERTO SC + MTX		2.33 (0.59,11.61)	2.21 (0.60,8.17)	0.05 (-0.02,0.28)
HD CERTO + MTX		1.70 (0.67,4.47)	1.65 (0.68,3.93)	0.03 (-0.01,0.12)
SD RITUX IV	SD GOLI IV	0.50 (0.02,9.39)	0.51 (0.03,8.89)	-0.02 (-0.28,0.06)

(Continued)

SD CERTO SC + MTX	1.57 (0.15,20.71)	1.54 (0.19,19.14)	0.02 (-0.23,0.08)	
SD INF IV + MTX	1.14 (0.10,13.44)	1.13 (0.13,12.80)	0.00 (-0.25,0.05)	
SD ADA SC + MTX	1.16 (0.09,14.40)	1.15 (0.12,13.64)	0.01 (-0.26,0.07)	
SD ABA SC + MTX	0.62 (0.05,8.33)	0.63 (0.06,8.03)	-0.01 (-0.27,0.03)	
SD ABA IV + MTX	0.83 (0.07,10.06)	0.84 (0.10,9.73)	-0.01 (-0.26,0.04)	
SD RITUX IV + MTX	1.46 (0.12,17.67)	1.43 (0.17,16.53)	0.02 (-0.24,0.08)	
SD GOL I SC + MTX	2.40 (0.16,36.31)	2.26 (0.21,32.04)	0.04 (-0.22,0.20)	
SD TOFA PO + MTX	2.33 (0.17,30.02)	2.21 (0.23,26.61)	0.04 (-0.22,0.15)	
SD GOL I IV + MTX	3.05 (0.52,39.86)	2.71 (0.55,30.57)	0.06 (-0.05,0.34)	
SD ANA SC + MTX	1.36 (0.10,21.91)	1.34 (0.13,19.64)	0.01 (-0.25,0.12)	
LD GOL I IV	5.03 (1.01,54.83)	4.10 (1.01,38.98)	0.12 (0.00,0.44)	
LD RITUX IV + MTX	1.17 (0.10,14.55)	1.16 (0.14,13.83)	0.01 (-0.25,0.06)	
LD CERTO SC + MTX	1.70 (0.10,31.87)	1.65 (0.12,26.33)	0.02 (-0.23,0.21)	
LD GOL I IV + MTX	3.01 (0.49,33.93)	2.66 (0.52,27.76)	0.06 (-0.05,0.31)	
HD TOCI IV	1.48 (0.11,20.90)	1.45 (0.14,19.03)	0.02 (-0.24,0.11)	
HD GOL I SC	1.41 (0.09,27.43)	1.39 (0.12,24.34)	0.01 (-0.24,0.15)	
HD GOL I SC + MTX	3.13 (0.22,54.92)	2.87 (0.28,44.48)	0.07 (-0.20,0.24)	
HD TOCI IV + MTX	1.62 (0.12,22.86)	1.57 (0.15,20.53)	0.02 (-0.23,0.13)	
HD TOFA PO + MTX	1.96 (0.14,26.74)	1.88 (0.19,23.80)	0.03 (-0.23,0.13)	
HD INF IV + MTX	1.09 (0.09,13.72)	1.08 (0.12,13.02)	0.00 (-0.26,0.06)	
HD CERTO SC + MTX	2.53 (0.16,48.64)	2.36 (0.20,37.83)	0.05 (-0.21,0.28)	
HD CERTO + MTX	1.84 (0.16,27.40)	1.78 (0.20,24.59)	0.03 (-0.22,0.12)	
SD CERTO SC + MTX	SD RITUX IV	3.08 (0.59,24.72)	2.96 (0.61,23.13)	0.04 (-0.03,0.09)
SD INF IV + MTX		2.24 (0.40,18.26)	2.19 (0.42,17.40)	0.02 (-0.05,0.06)
SD ADA SC + MTX		2.29 (0.36,22.59)	2.23 (0.38,21.25)	0.02 (-0.05,0.08)
SD ABA SC + MTX		1.26 (0.18,10.83)	1.25 (0.20,10.47)	0.00 (-0.07,0.04)
SD ABA IV + MTX		1.65 (0.29,13.43)	1.63 (0.31,12.97)	0.01 (-0.06,0.04)
SD RITUX IV + MTX		2.76 (0.58,22.50)	2.66 (0.60,21.05)	0.03 (-0.03,0.08)

(Continued)

SD GOL1 SC + MTX		4.58 (0.69,45.04)	4.25 (0.70,38.73)	0.06 (-0.02,0.21)
SD TOFA PO + MTX		4.53 (0.71,43.46)	4.21 (0.73,38.18)	0.06 (-0.02,0.16)
SD GOL1 IV + MTX		6.47 (0.54,111.50)	5.73 (0.56,67.91)	0.09 (-0.03,0.48)
SD ANA SC + MTX		2.76 (0.39,26.18)	2.66 (0.41,23.71)	0.03 (-0.04,0.13)
LD GOL1 IV		10.40 (1.11,164.90)	8.52 (1.10,89.52)	0.14 (0.00,0.59)
LD RITUX IV + MTX		2.19 (0.47,17.80)	2.14 (0.49,16.85)	0.02 (-0.04,0.07)
LD CERTO SC + MTX		3.40 (0.31,44.12)	3.21 (0.32,36.77)	0.04 (-0.05,0.23)
LD GOL1 IV + MTX		6.24 (0.58,104.50)	5.58 (0.59,63.30)	0.08 (-0.02,0.46)
HD TOCI IV		2.88 (0.47,26.87)	2.77 (0.49,24.52)	0.03 (-0.04,0.12)
HD GOL1 SC		2.73 (0.36,30.48)	2.63 (0.38,26.94)	0.03 (-0.04,0.16)
HD GOL1 SC + MTX		6.22 (0.87,59.87)	5.57 (0.87,48.16)	0.09 (-0.01,0.26)
HD TOCI IV + MTX		3.10 (0.46,30.30)	2.96 (0.48,27.39)	0.04 (-0.04,0.14)
HD TOFA PO + MTX		3.87 (0.56,36.71)	3.65 (0.58,32.83)	0.05 (-0.03,0.14)
HD INF IV + MTX		2.13 (0.35,19.07)	2.08 (0.37,18.11)	0.02 (-0.05,0.07)
HD CERTO SC + MTX		4.95 (0.60,66.80)	4.53 (0.61,51.60)	0.07 (-0.02,0.30)
HD CERTO + MTX		3.50 (0.56,32.87)	3.32 (0.58,29.51)	0.04 (-0.03,0.14)
SD INF IV + MTX	SD CERTO SC + MTX	0.72 (0.30,1.54)	0.74 (0.32,1.50)	-0.02 (-0.06,0.02)
SD ADA SC + MTX		0.72 (0.26,1.96)	0.74 (0.27,1.88)	-0.02 (-0.07,0.04)
SD ABA SC + MTX		0.40 (0.11,1.05)	0.42 (0.12,1.05)	-0.03 (-0.08,0.00)
SD ABA IV + MTX		0.53 (0.21,1.14)	0.55 (0.22,1.13)	-0.03 (-0.07,0.01)
SD RITUX IV + MTX		0.92 (0.36,2.10)	0.92 (0.38,2.00)	0.00 (-0.06,0.05)
SD GOL1 SC + MTX		1.45 (0.42,5.66)	1.41 (0.45,4.63)	0.02 (-0.05,0.18)
SD TOFA PO + MTX		1.44 (0.49,4.19)	1.40 (0.51,3.65)	0.02 (-0.04,0.12)
SD GOL1 IV + MTX		1.97 (0.32,16.73)	1.86 (0.34,9.14)	0.05 (-0.05,0.44)
SD ANA SC + MTX		0.86 (0.24,3.11)	0.87 (0.26,2.81)	-0.01 (-0.06,0.09)
LD GOL1 IV		3.21 (0.57,27.22)	2.83 (0.59,11.63)	0.11 (-0.03,0.55)
LD RITUX IV + MTX		0.72 (0.30,1.77)	0.74 (0.32,1.71)	-0.02 (-0.06,0.03)
LD CERTO SC + MTX		1.07 (0.18,5.18)	1.06 (0.19,4.18)	0.00 (-0.06,0.19)



(Continued)

LD GOL I IV + MTX		1.91 (0.32,15.94)	1.81 (0.33,8.87)	0.05 (-0.05,0.42)
HD TOCI IV		0.92 (0.30,2.82)	0.92 (0.32,2.59)	0.00 (-0.06,0.08)
HD GOL I SC		0.87 (0.19,4.04)	0.88 (0.21,3.51)	-0.01 (-0.07,0.13)
HD GOL I SC + MTX		1.97 (0.57,7.23)	1.86 (0.59,5.59)	0.05 (-0.03,0.22)
HD TOCI IV + MTX		0.98 (0.29,3.33)	0.98 (0.30,2.98)	0.00 (-0.06,0.10)
HD TOFA PO + MTX		1.23 (0.40,3.56)	1.21 (0.42,3.19)	0.01 (-0.05,0.10)
HD INF IV + MTX		0.69 (0.25,1.68)	0.70 (0.27,1.63)	-0.02 (-0.07,0.03)
HD CERTO SC + MTX		1.57 (0.39,7.23)	1.51 (0.41,5.32)	0.03 (-0.04,0.25)
HD CERTO + MTX		1.14 (0.48,2.71)	1.13 (0.50,2.48)	0.01 (-0.04,0.09)
SD ADA SC + MTX	SD INF IV + MTX	1.01 (0.37,2.81)	1.01 (0.39,2.67)	0.00 (-0.04,0.05)
SD ABA SC + MTX		0.56 (0.19,1.41)	0.57 (0.19,1.39)	-0.02 (-0.05,0.01)
SD ABA IV + MTX		0.74 (0.34,1.47)	0.74 (0.36,1.45)	-0.01 (-0.04,0.01)
SD RITUX IV + MTX		1.25 (0.53,3.11)	1.24 (0.54,2.92)	0.01 (-0.03,0.06)
SD GOL I SC + MTX		1.99 (0.63,8.32)	1.91 (0.64,6.65)	0.04 (-0.02,0.20)
SD TOFA PO + MTX		2.00 (0.72,5.98)	1.92 (0.73,5.19)	0.04 (-0.02,0.14)
SD GOL I IV + MTX		2.72 (0.45,24.78)	2.52 (0.47,13.37)	0.07 (-0.03,0.46)
SD ANA SC + MTX		1.19 (0.35,4.60)	1.18 (0.37,4.10)	0.01 (-0.04,0.11)
LD GOL I IV		4.46 (0.85,40.18)	3.86 (0.85,16.61)	0.12 (-0.01,0.57)
LD RITUX IV + MTX		1.00 (0.43,2.65)	1.00 (0.44,2.53)	0.00 (-0.04,0.05)
LD CERTO SC + MTX		1.46 (0.24,8.65)	1.43 (0.24,6.78)	0.02 (-0.04,0.21)
LD GOL I IV + MTX		2.61 (0.45,23.29)	2.44 (0.47,12.83)	0.06 (-0.03,0.44)
HD TOCI IV		1.27 (0.43,4.06)	1.26 (0.45,3.68)	0.01 (-0.03,0.09)
HD GOL I SC		1.21 (0.27,5.82)	1.20 (0.28,4.99)	0.01 (-0.04,0.14)
HD GOL I SC + MTX		2.70 (0.84,10.95)	2.51 (0.85,8.27)	0.07 (-0.01,0.24)
HD TOCI IV + MTX		1.36 (0.41,4.85)	1.34 (0.43,4.27)	0.01 (-0.03,0.12)
HD TOFA PO + MTX		1.70 (0.59,5.03)	1.65 (0.61,4.47)	0.03 (-0.02,0.12)
HD INF IV + MTX		0.95 (0.44,2.07)	0.95 (0.45,1.99)	0.00 (-0.03,0.04)
HD CERTO SC + MTX		2.17 (0.49,11.88)	2.06 (0.50,8.58)	0.05 (-0.03,0.28)

(Continued)

HD CERTO + MTX		1.57 (0.54,4.97)	1.53 (0.56,4.41)	0.02 (-0.03,0.12)
SD ABA SC + MTX	SD ADA SC + MTX	0.54 (0.15,1.76)	0.55 (0.16,1.73)	-0.02 (-0.07,0.02)
SD ABA IV + MTX		0.72 (0.25,1.98)	0.73 (0.26,1.94)	-0.01 (-0.06,0.02)
SD RITUX IV + MTX		1.25 (0.43,3.71)	1.23 (0.45,3.49)	0.01 (-0.05,0.06)
SD GOLI SC + MTX		1.99 (0.50,9.13)	1.90 (0.52,7.48)	0.04 (-0.04,0.19)
SD TOFA PO + MTX		1.98 (0.77,5.34)	1.90 (0.78,4.73)	0.04 (-0.01,0.13)
SD GOLI IV + MTX		2.70 (0.42,27.86)	2.50 (0.44,15.01)	0.07 (-0.04,0.45)
SD ANA SC + MTX		1.18 (0.29,5.25)	1.17 (0.30,4.70)	0.01 (-0.05,0.11)
LD GOLI IV		4.41 (0.74,40.46)	3.79 (0.75,18.28)	0.12 (-0.02,0.56)
LD RITUX IV + MTX		1.00 (0.34,3.09)	1.00 (0.36,2.93)	0.00 (-0.05,0.05)
LD CERTO SC + MTX		1.49 (0.21,9.09)	1.46 (0.22,7.21)	0.02 (-0.06,0.21)
LD GOLI IV + MTX		2.61 (0.40,24.70)	2.42 (0.42,14.06)	0.06 (-0.04,0.44)
HD TOCI IV		1.26 (0.36,4.73)	1.24 (0.38,4.30)	0.01 (-0.05,0.09)
HD GOLI SC		1.19 (0.25,6.36)	1.18 (0.26,5.46)	0.01 (-0.06,0.14)
HD GOLI SC + MTX		2.67 (0.70,12.09)	2.48 (0.71,9.27)	0.06 (-0.02,0.24)
HD TOCI IV + MTX		1.36 (0.34,5.65)	1.33 (0.36,4.99)	0.01 (-0.05,0.12)
HD TOFA PO + MTX		1.69 (0.64,4.55)	1.63 (0.66,4.12)	0.03 (-0.02,0.11)
HD INF IV + MTX		0.94 (0.30,2.93)	0.94 (0.32,2.79)	0.00 (-0.05,0.05)
HD CERTO SC + MTX		2.16 (0.44,12.68)	2.05 (0.46,9.32)	0.04 (-0.04,0.27)
HD CERTO + MTX		1.58 (0.44,5.72)	1.54 (0.46,5.05)	0.02 (-0.04,0.12)
SD ABA IV + MTX	SD ABA SC + MTX	1.32 (0.67,2.91)	1.31 (0.68,2.85)	0.01 (-0.01,0.03)
SD RITUX IV + MTX		2.27 (0.79,7.79)	2.20 (0.80,7.27)	0.03 (-0.01,0.08)
SD GOLI SC + MTX		3.67 (0.94,17.64)	3.43 (0.94,14.25)	0.06 (0.00,0.21)
SD TOFA PO + MTX		3.61 (1.11,14.60)	3.38 (1.11,12.47)	0.06 (0.00,0.16)
SD GOLI IV + MTX		4.91 (0.78,51.18)	4.44 (0.79,28.37)	0.08 (-0.01,0.48)
SD ANA SC + MTX		2.19 (0.54,10.29)	2.12 (0.55,9.13)	0.03 (-0.02,0.13)
LD GOLI IV		8.06 (1.38,80.92)	6.82 (1.36,35.50)	0.14 (0.01,0.59)
LD RITUX IV + MTX		1.79 (0.64,6.57)	1.76 (0.65,6.22)	0.02 (-0.02,0.07)

(Continued)

LD CERTO SC + MTX		2.65 (0.39,19.16)	2.54 (0.40,15.15)	0.04 (-0.02,0.23)
LD GOLI IV + MTX		4.78 (0.76,50.17)	4.34 (0.77,27.75)	0.08 (-0.01,0.46)
HD TOCI IV		2.30 (0.68,9.67)	2.23 (0.69,8.73)	0.03 (-0.01,0.11)
HD GOLI SC		2.21 (0.45,12.33)	2.14 (0.46,10.59)	0.03 (-0.02,0.16)
HD GOLI SC + MTX		4.94 (1.27,24.28)	4.49 (1.25,18.21)	0.08 (0.01,0.26)
HD TOCI IV + MTX		2.47 (0.65,11.42)	2.38 (0.66,10.08)	0.03 (-0.01,0.13)
HD TOFA PO + MTX		3.07 (0.88,12.42)	2.92 (0.88,10.92)	0.05 (-0.01,0.14)
HD INF IV + MTX		1.70 (0.59,6.08)	1.67 (0.60,5.73)	0.02 (-0.02,0.06)
HD CERTO SC + MTX		3.99 (0.81,25.92)	3.70 (0.82,18.92)	0.06 (-0.01,0.30)
HD CERTO + MTX		2.82 (0.84,12.46)	2.69 (0.85,10.93)	0.04 (-0.01,0.14)
SD RITUX IV + MTX	SD ABA IV + MTX	1.70 (0.73,4.42)	1.67 (0.74,4.14)	0.02 (-0.01,0.07)
SD GOLI SC + MTX		2.73 (0.82,11.35)	2.58 (0.83,9.11)	0.05 (-0.01,0.21)
SD TOFA PO + MTX		2.71 (0.98,8.73)	2.56 (0.99,7.48)	0.05 (0.00,0.15)
SD GOLI IV + MTX		3.71 (0.65,33.56)	3.41 (0.66,17.95)	0.08 (-0.01,0.47)
SD ANA SC + MTX		1.63 (0.48,6.36)	1.60 (0.49,5.62)	0.02 (-0.02,0.12)
LD GOLI IV		6.05 (1.16,54.64)	5.18 (1.15,22.43)	0.14 (0.01,0.58)
LD RITUX IV + MTX		1.37 (0.57,3.86)	1.35 (0.59,3.63)	0.01 (-0.02,0.06)
LD CERTO SC + MTX		2.01 (0.32,12.28)	1.94 (0.32,9.59)	0.03 (-0.03,0.22)
LD GOLI IV + MTX		3.58 (0.62,32.54)	3.31 (0.63,17.38)	0.07 (-0.01,0.45)
HD TOCI IV		1.74 (0.59,5.78)	1.70 (0.60,5.22)	0.02 (-0.02,0.11)
HD GOLI SC		1.66 (0.38,8.06)	1.62 (0.39,6.83)	0.02 (-0.03,0.15)
HD GOLI SC + MTX		3.69 (1.11,14.81)	3.38 (1.10,11.22)	0.08 (0.00,0.25)
HD TOCI IV + MTX		1.85 (0.56,6.95)	1.80 (0.57,6.08)	0.03 (-0.02,0.13)
HD TOFA PO + MTX		2.31 (0.78,7.33)	2.22 (0.79,6.48)	0.04 (-0.01,0.13)
HD INF IV + MTX		1.28 (0.52,3.46)	1.27 (0.53,3.28)	0.01 (-0.02,0.05)
HD CERTO SC + MTX		2.98 (0.68,16.76)	2.80 (0.69,11.93)	0.06 (-0.01,0.29)
HD CERTO + MTX		2.13 (0.75,7.20)	2.05 (0.76,6.37)	0.03 (-0.01,0.13)
SD GOLI SC + MTX	SD RITUX IV + MTX	1.60 (0.44,6.74)	1.55 (0.46,5.48)	0.03 (-0.04,0.19)

(Continued)

SD TOFA PO + MTX		1.58 (0.53,5.03)	1.53 (0.56,4.37)	0.03 (-0.04,0.13)
SD GOLI IV + MTX		2.16 (0.35,19.22)	2.02 (0.37,10.50)	0.05 (-0.05,0.45)
SD ANA SC + MTX		0.94 (0.26,3.76)	0.95 (0.27,3.38)	0.00 (-0.06,0.10)
LD GOLI IV		3.53 (0.66,29.62)	3.09 (0.68,13.17)	0.11 (-0.02,0.55)
LD RITUX IV + MTX		0.80 (0.41,1.62)	0.81 (0.43,1.58)	-0.01 (-0.05,0.02)
LD CERTO SC + MTX		1.17 (0.18,7.05)	1.16 (0.19,5.62)	0.01 (-0.06,0.20)
LD GOLI IV + MTX		2.06 (0.35,18.28)	1.94 (0.37,10.36)	0.05 (-0.05,0.43)
HD TOCI IV		1.02 (0.32,3.32)	1.02 (0.34,3.06)	0.00 (-0.06,0.09)
HD GOLI SC		0.96 (0.20,4.79)	0.97 (0.22,4.17)	0.00 (-0.06,0.13)
HD GOLI SC + MTX		2.15 (0.59,9.11)	2.02 (0.61,6.97)	0.05 (-0.03,0.23)
HD TOCI IV + MTX		1.09 (0.30,3.97)	1.09 (0.32,3.54)	0.00 (-0.06,0.11)
HD TOFA PO + MTX		1.35 (0.43,4.24)	1.32 (0.46,3.79)	0.02 (-0.05,0.11)
HD INF IV + MTX		0.75 (0.27,2.08)	0.76 (0.29,2.00)	-0.01 (-0.06,0.04)
HD CERTO SC + MTX		1.73 (0.37,9.58)	1.66 (0.39,7.09)	0.04 (-0.05,0.27)
HD CERTO + MTX		1.24 (0.41,4.12)	1.23 (0.43,3.70)	0.01 (-0.05,0.11)
SD TOFA PO + MTX	SD GOLI SC + MTX	0.98 (0.21,4.23)	0.99 (0.24,3.76)	0.00 (-0.16,0.11)
SD GOLI IV + MTX		1.32 (0.16,14.51)	1.28 (0.19,8.33)	0.02 (-0.15,0.42)
SD ANA SC + MTX		0.59 (0.11,3.10)	0.61 (0.14,2.83)	-0.03 (-0.19,0.08)
LD GOLI IV		2.20 (0.30,25.05)	1.99 (0.34,11.21)	0.08 (-0.13,0.53)
LD RITUX IV + MTX		0.51 (0.11,1.86)	0.53 (0.14,1.80)	-0.04 (-0.20,0.03)
LD CERTO SC + MTX		0.70 (0.09,5.67)	0.72 (0.10,4.66)	-0.02 (-0.18,0.18)
LD GOLI IV + MTX		1.29 (0.16,14.85)	1.25 (0.19,8.50)	0.02 (-0.16,0.41)
HD TOCI IV		0.63 (0.13,2.77)	0.65 (0.16,2.58)	-0.03 (-0.19,0.07)
HD GOLI SC		0.59 (0.15,2.18)	0.62 (0.17,2.03)	-0.03 (-0.14,0.06)
HD GOLI SC + MTX		1.35 (0.50,3.55)	1.31 (0.53,3.15)	0.02 (-0.07,0.14)
HD TOCI IV + MTX		0.67 (0.13,3.09)	0.69 (0.16,2.82)	-0.02 (-0.18,0.09)
HD TOFA PO + MTX		0.84 (0.16,3.56)	0.85 (0.20,3.23)	-0.01 (-0.17,0.09)
HD INF IV + MTX		0.47 (0.11,1.70)	0.49 (0.13,1.65)	-0.04 (-0.20,0.03)

(Continued)

HD CERTO SC + MTX		1.09 (0.16,7.45)	1.08 (0.19,5.64)	0.01 (-0.16,0.25)
HD CERTO + MTX		0.77 (0.17,3.41)	0.79 (0.20,3.11)	-0.02 (-0.17,0.09)
SD GOLI IV + MTX	SD TOFA PO + MTX	1.35 (0.19,13.94)	1.31 (0.22,7.95)	0.03 (-0.11,0.42)
SD ANA SC + MTX		0.60 (0.14,2.62)	0.62 (0.16,2.42)	-0.03 (-0.13,0.08)
LD GOLI IV		2.21 (0.35,20.86)	1.99 (0.38,9.63)	0.08 (-0.08,0.53)
LD RITUX IV + MTX		0.50 (0.16,1.58)	0.52 (0.19,1.54)	-0.04 (-0.14,0.02)
LD CERTO SC + MTX		0.75 (0.10,4.70)	0.77 (0.11,3.88)	-0.02 (-0.13,0.17)
LD GOLI IV + MTX		1.28 (0.20,12.91)	1.25 (0.22,7.62)	0.02 (-0.11,0.40)
HD TOCI IV		0.64 (0.17,2.42)	0.66 (0.19,2.27)	-0.03 (-0.13,0.06)
HD GOLI SC		0.59 (0.12,3.36)	0.62 (0.13,2.99)	-0.03 (-0.14,0.11)
HD GOLI SC + MTX		1.36 (0.34,6.29)	1.32 (0.37,5.01)	0.03 (-0.09,0.21)
HD TOCI IV + MTX		0.68 (0.16,2.87)	0.70 (0.18,2.61)	-0.02 (-0.13,0.09)
HD TOFA PO + MTX		0.85 (0.40,1.75)	0.86 (0.43,1.68)	-0.01 (-0.08,0.04)
HD INF IV + MTX		0.47 (0.14,1.53)	0.50 (0.16,1.49)	-0.04 (-0.14,0.02)
HD CERTO SC + MTX		1.09 (0.21,6.80)	1.08 (0.23,5.12)	0.01 (-0.11,0.24)
HD CERTO + MTX		0.80 (0.21,2.92)	0.81 (0.24,2.67)	-0.02 (-0.12,0.09)
SD ANA SC + MTX	SD GOLI IV + MTX	0.44 (0.04,3.50)	0.47 (0.07,3.22)	-0.06 (-0.45,0.08)
LD GOLI IV		1.62 (0.46,6.80)	1.48 (0.53,5.24)	0.05 (-0.11,0.29)
LD RITUX IV + MTX		0.37 (0.04,2.39)	0.40 (0.08,2.30)	-0.06 (-0.45,0.03)
LD CERTO SC + MTX		0.54 (0.04,5.87)	0.58 (0.06,4.88)	-0.04 (-0.43,0.16)
LD GOLI IV + MTX		0.97 (0.21,4.31)	0.98 (0.25,3.62)	0.00 (-0.20,0.18)
HD TOCI IV		0.47 (0.05,3.34)	0.50 (0.08,3.11)	-0.05 (-0.44,0.07)
HD GOLI SC		0.45 (0.03,4.21)	0.48 (0.06,3.77)	-0.05 (-0.45,0.10)
HD GOLI SC + MTX		1.03 (0.09,8.26)	1.02 (0.16,6.68)	0.00 (-0.40,0.20)
HD TOCI IV + MTX		0.49 (0.05,3.86)	0.53 (0.09,3.54)	-0.05 (-0.43,0.09)
HD TOFA PO + MTX		0.62 (0.06,4.38)	0.65 (0.11,3.99)	-0.04 (-0.43,0.09)
HD INF IV + MTX		0.35 (0.04,2.22)	0.38 (0.07,2.15)	-0.07 (-0.46,0.03)
HD CERTO SC + MTX		0.80 (0.07,8.10)	0.82 (0.11,6.35)	-0.02 (-0.40,0.23)

(Continued)

HD CERTO + MTX		0.58 (0.06,4.16)	0.61 (0.11,3.77)	-0.04 (-0.43,0.09)
LD GOLI IV	SD ANA SC + MTX	3.84 (0.51,38.84)	3.30 (0.54,17.85)	0.11 (-0.05,0.56)
LD RITUX IV + MTX		0.83 (0.22,3.22)	0.84 (0.25,3.06)	-0.01 (-0.11,0.05)
LD CERTO SC + MTX		1.21 (0.16,9.34)	1.19 (0.17,7.59)	0.01 (-0.10,0.20)
LD GOLI IV + MTX		2.22 (0.28,23.97)	2.07 (0.31,13.81)	0.05 (-0.08,0.43)
HD TOCI IV		1.08 (0.23,4.68)	1.07 (0.26,4.32)	0.00 (-0.10,0.09)
HD GOLI SC		1.01 (0.15,6.05)	1.01 (0.17,5.29)	0.00 (-0.11,0.13)
HD GOLI SC + MTX		2.27 (0.48,11.71)	2.12 (0.51,9.10)	0.06 (-0.06,0.23)
HD TOCI IV + MTX		1.15 (0.23,5.51)	1.14 (0.25,4.89)	0.01 (-0.10,0.11)
HD TOFA PO + MTX		1.43 (0.31,5.87)	1.40 (0.35,5.25)	0.02 (-0.09,0.11)
HD INF IV + MTX		0.79 (0.20,2.97)	0.80 (0.22,2.84)	-0.01 (-0.11,0.04)
HD CERTO SC + MTX		1.84 (0.29,13.10)	1.75 (0.32,9.85)	0.04 (-0.08,0.27)
HD CERTO + MTX		1.32 (0.30,5.81)	1.30 (0.33,5.22)	0.01 (-0.09,0.11)
LD RITUX IV + MTX	LD GOLI IV	0.23 (0.03,1.27)	0.26 (0.06,1.26)	-0.12 (-0.56,0.01)
LD CERTO SC + MTX		0.32 (0.02,3.22)	0.37 (0.04,2.78)	-0.10 (-0.54,0.12)
LD GOLI IV + MTX		0.59 (0.14,2.18)	0.65 (0.19,1.89)	-0.05 (-0.29,0.11)
HD TOCI IV		0.28 (0.03,1.90)	0.33 (0.06,1.81)	-0.11 (-0.55,0.04)
HD GOLI SC		0.27 (0.02,2.17)	0.31 (0.05,2.02)	-0.11 (-0.56,0.07)
HD GOLI SC + MTX		0.62 (0.06,4.45)	0.66 (0.13,3.69)	-0.05 (-0.51,0.17)
HD TOCI IV + MTX		0.31 (0.03,2.13)	0.35 (0.07,1.99)	-0.10 (-0.55,0.06)
HD TOFA PO + MTX		0.38 (0.04,2.45)	0.43 (0.09,2.27)	-0.09 (-0.54,0.06)
HD INF IV + MTX		0.21 (0.02,1.21)	0.24 (0.05,1.20)	-0.13 (-0.57,0.01)
HD CERTO SC + MTX		0.48 (0.04,4.63)	0.53 (0.09,3.70)	-0.07 (-0.52,0.19)
HD CERTO + MTX		0.35 (0.04,2.39)	0.40 (0.08,2.22)	-0.10 (-0.54,0.06)
LD CERTO SC + MTX	LD RITUX IV + MTX	1.46 (0.22,8.69)	1.43 (0.24,6.92)	0.02 (-0.05,0.21)
LD GOLI IV + MTX		2.59 (0.42,23.11)	2.41 (0.44,12.92)	0.06 (-0.03,0.44)
HD TOCI IV		1.28 (0.37,4.36)	1.26 (0.39,3.94)	0.01 (-0.04,0.09)
HD GOLI SC		1.20 (0.25,6.18)	1.19 (0.27,5.29)	0.01 (-0.05,0.14)

(Continued)

HD GOLI SC + MTX		2.68 (0.74,11.68)	2.49 (0.76,8.92)	0.06 (-0.02,0.24)
HD TOCI IV + MTX		1.37 (0.35,5.10)	1.34 (0.37,4.52)	0.01 (-0.05,0.12)
HD TOFA PO + MTX		1.70 (0.52,5.30)	1.65 (0.54,4.68)	0.03 (-0.03,0.12)
HD INF IV + MTX		0.95 (0.31,2.62)	0.95 (0.33,2.49)	0.00 (-0.05,0.04)
HD CERTO SC + MTX		2.16 (0.45,11.99)	2.04 (0.47,8.72)	0.05 (-0.03,0.28)
HD CERTO + MTX		1.57 (0.48,5.00)	1.53 (0.50,4.41)	0.02 (-0.04,0.11)
LD GOLI IV + MTX	LD CERTO SC + MTX	1.82 (0.17,25.58)	1.72 (0.21,16.06)	0.04 (-0.16,0.41)
HD TOCI IV		0.86 (0.13,6.63)	0.87 (0.17,6.13)	-0.01 (-0.20,0.09)
HD GOLI SC		0.84 (0.09,7.69)	0.85 (0.12,6.82)	-0.01 (-0.20,0.13)
HD GOLI SC + MTX		1.93 (0.24,15.70)	1.81 (0.29,12.44)	0.05 (-0.16,0.22)
HD TOCI IV + MTX		0.93 (0.13,7.66)	0.93 (0.16,6.90)	0.00 (-0.20,0.11)
HD TOFA PO + MTX		1.13 (0.18,8.34)	1.12 (0.22,7.53)	0.01 (-0.18,0.11)
HD INF IV + MTX		0.65 (0.10,4.22)	0.67 (0.13,4.04)	-0.02 (-0.21,0.05)
HD CERTO SC + MTX		1.52 (0.32,8.76)	1.46 (0.35,7.48)	0.03 (-0.11,0.20)
HD CERTO + MTX		1.07 (0.18,7.47)	1.06 (0.22,6.82)	0.00 (-0.18,0.10)
HD TOCI IV	LD GOLI IV + MTX	0.49 (0.05,3.43)	0.52 (0.09,3.16)	-0.05 (-0.42,0.07)
HD GOLI SC		0.47 (0.04,4.33)	0.51 (0.06,3.84)	-0.05 (-0.43,0.11)
HD GOLI SC + MTX		1.05 (0.10,8.70)	1.05 (0.16,6.87)	0.00 (-0.38,0.20)
HD TOCI IV + MTX		0.52 (0.05,3.97)	0.55 (0.09,3.62)	-0.05 (-0.41,0.09)
HD TOFA PO + MTX		0.67 (0.07,4.37)	0.70 (0.11,4.00)	-0.03 (-0.41,0.09)
HD INF IV + MTX		0.36 (0.04,2.29)	0.39 (0.07,2.21)	-0.06 (-0.44,0.03)
HD CERTO SC + MTX		0.83 (0.07,8.30)	0.85 (0.12,6.57)	-0.01 (-0.39,0.23)
HD CERTO + MTX		0.59 (0.06,4.34)	0.62 (0.11,3.97)	-0.04 (-0.41,0.09)
HD GOLI SC	HD TOCI IV	0.95 (0.16,5.40)	0.96 (0.18,4.70)	0.00 (-0.09,0.13)
HD GOLI SC + MTX		2.14 (0.50,10.16)	2.00 (0.53,7.91)	0.05 (-0.05,0.23)
HD TOCI IV + MTX		1.07 (0.46,2.52)	1.07 (0.48,2.35)	0.00 (-0.05,0.07)
HD TOFA PO + MTX		1.34 (0.34,5.09)	1.31 (0.37,4.53)	0.02 (-0.07,0.11)
HD INF IV + MTX		0.74 (0.21,2.49)	0.76 (0.23,2.39)	-0.01 (-0.10,0.04)

(Continued)

HD CERTO SC + MTX		1.71 (0.30,10.93)	1.64 (0.33,8.02)	0.03 (-0.07,0.27)
HD CERTO + MTX		1.24 (0.31,4.81)	1.23 (0.34,4.34)	0.01 (-0.08,0.11)
HD GOLI SC + MTX	HD GOLI SC	2.23 (0.65,8.53)	2.08 (0.68,7.39)	0.05 (-0.04,0.19)
HD TOCI IV + MTX		1.12 (0.19,7.26)	1.11 (0.22,6.47)	0.01 (-0.13,0.12)
HD TOFA PO + MTX		1.42 (0.25,7.47)	1.39 (0.28,6.68)	0.02 (-0.12,0.12)
HD INF IV + MTX		0.78 (0.15,3.89)	0.79 (0.17,3.71)	-0.01 (-0.14,0.05)
HD CERTO SC + MTX		1.82 (0.25,15.28)	1.74 (0.27,11.49)	0.04 (-0.11,0.27)
HD CERTO + MTX		1.30 (0.23,7.11)	1.28 (0.27,6.33)	0.01 (-0.12,0.11)
HD TOCI IV + MTX	HD GOLI SC + MTX	0.50 (0.10,2.26)	0.53 (0.13,2.09)	-0.05 (-0.23,0.07)
HD TOFA PO + MTX		0.63 (0.12,2.48)	0.66 (0.16,2.31)	-0.04 (-0.22,0.07)
HD INF IV + MTX		0.35 (0.08,1.27)	0.38 (0.10,1.25)	-0.07 (-0.24,0.01)
HD CERTO SC + MTX		0.80 (0.13,5.61)	0.82 (0.16,4.30)	-0.02 (-0.21,0.22)
HD CERTO + MTX		0.57 (0.13,2.54)	0.60 (0.16,2.34)	-0.04 (-0.22,0.08)
HD TOFA PO + MTX	HD TOCI IV + MTX	1.25 (0.29,5.36)	1.23 (0.32,4.82)	0.01 (-0.10,0.11)
HD INF IV + MTX		0.70 (0.18,2.55)	0.71 (0.20,2.46)	-0.02 (-0.12,0.04)
HD CERTO SC + MTX		1.58 (0.26,10.73)	1.52 (0.29,8.08)	0.03 (-0.09,0.26)
HD CERTO + MTX		1.15 (0.27,4.95)	1.14 (0.30,4.47)	0.01 (-0.10,0.11)
HD INF IV + MTX	HD TOFA PO + MTX	0.56 (0.17,1.89)	0.58 (0.19,1.83)	-0.03 (-0.12,0.03)
HD CERTO SC + MTX		1.28 (0.25,8.06)	1.25 (0.27,6.01)	0.02 (-0.09,0.25)
HD CERTO + MTX		0.94 (0.24,3.46)	0.94 (0.27,3.14)	0.00 (-0.10,0.09)
HD CERTO SC + MTX	HD INF IV + MTX	2.28 (0.48,13.55)	2.15 (0.49,9.88)	0.05 (-0.03,0.28)
HD CERTO + MTX		1.66 (0.51,5.89)	1.61 (0.53,5.23)	0.02 (-0.03,0.12)
HD CERTO + MTX	HD CERTO SC + MTX	0.72 (0.13,3.65)	0.74 (0.17,3.35)	-0.02 (-0.25,0.08)
Random-Effect Model	Residual De- viance	70 vs 71 data points		
	Deviance Infor- mation Criteria	380.174		



(Continued)

Fixed-Effect Model	Residual Deviance	75.17 vs 71 data points
	Deviance Information Criteria	381.124
Note:		
Total Patients	12263	
Total Studies	26	
2-arm	13	
3-arm	8	
4-arm	4	
5-arm	1	

#### Appendix 43. Serious Adverse Events: Subgroup - Trial duration (6 to 12 months)

SAEs, Intermediate trial duration: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD ETN SC + PL	MTX + PL	1.06 (0.34,3.38)	1.06 (0.37,2.68)	0.01 (-0.08,0.19)
SD INF IV + MTX		0.52 (0.22,1.19)	0.55 (0.25,1.16)	-0.05 (-0.10,0.02)
SD ETN SC + MTX		0.77 (0.27,2.20)	0.79 (0.30,1.94)	-0.02 (-0.09,0.11)
SD ABA IV + MTX		0.73 (0.26,1.99)	0.76 (0.29,1.78)	-0.03 (-0.09,0.09)
SD RITUX IV + MTX		0.74 (0.27,1.96)	0.76 (0.30,1.76)	-0.03 (-0.09,0.09)
LD ETN SC + PL		0.72 (0.22,2.50)	0.75 (0.24,2.13)	-0.03 (-0.10,0.13)
LD RITUX IV + MTX		0.70 (0.25,1.86)	0.73 (0.28,1.69)	-0.03 (-0.09,0.08)
LD ABA IV + MTX		1.16 (0.44,3.19)	1.14 (0.47,2.55)	0.02 (-0.07,0.18)
LD ETN SC + MTX		0.42 (0.12,1.34)	0.46 (0.14,1.29)	-0.06 (-0.11,0.03)
HD INF IV + MTX		0.96 (0.37,2.51)	0.96 (0.40,2.14)	0.00 (-0.08,0.13)
SD INF IV + MTX	SD ETN SC + PL	0.49 (0.12,1.98)	0.52 (0.15,1.87)	-0.06 (-0.24,0.05)
SD ETN SC + MTX		0.74 (0.15,3.24)	0.76 (0.20,2.84)	-0.03 (-0.21,0.12)

(Continued)

SD ABA IV + MTX		0.68 (0.15,3.17)	0.72 (0.20,2.78)	-0.04 (-0.22,0.11)
SD RITUX IV + MTX		0.69 (0.15,3.08)	0.72 (0.20,2.72)	-0.03 (-0.22,0.11)
LD ETN SC + PL		0.69 (0.20,2.19)	0.72 (0.24,1.98)	-0.03 (-0.18,0.08)
LD RITUX IV + MTX		0.65 (0.14,2.89)	0.68 (0.19,2.56)	-0.04 (-0.22,0.10)
LD ABA IV + MTX		1.10 (0.25,4.94)	1.08 (0.31,4.01)	0.01 (-0.18,0.19)
LD ETN SC + MTX		0.40 (0.08,2.05)	0.43 (0.10,1.91)	-0.07 (-0.25,0.05)
HD INF IV + MTX		0.90 (0.20,4.07)	0.91 (0.25,3.43)	-0.01 (-0.20,0.15)
SD ETN SC + MTX	SD INF IV + MTX	1.46 (0.40,5.88)	1.42 (0.42,4.88)	0.03 (-0.06,0.17)
SD ABA IV + MTX		1.42 (0.38,5.13)	1.38 (0.41,4.38)	0.02 (-0.06,0.15)
SD RITUX IV + MTX		1.42 (0.39,5.12)	1.38 (0.42,4.36)	0.02 (-0.06,0.15)
LD ETN SC + PL		1.40 (0.31,6.27)	1.36 (0.34,5.13)	0.02 (-0.07,0.18)
LD RITUX IV + MTX		1.36 (0.37,4.84)	1.33 (0.40,4.16)	0.02 (-0.07,0.14)
LD ABA IV + MTX		2.26 (0.63,8.37)	2.09 (0.66,6.45)	0.07 (-0.03,0.23)
LD ETN SC + MTX		0.82 (0.19,3.39)	0.83 (0.21,3.09)	-0.01 (-0.09,0.09)
HD INF IV + MTX		1.86 (0.65,5.30)	1.75 (0.68,4.44)	0.05 (-0.03,0.17)
SD ABA IV + MTX	SD ETN SC + MTX	0.94 (0.22,4.00)	0.94 (0.26,3.47)	-0.01 (-0.14,0.13)
SD RITUX IV + MTX		0.94 (0.22,3.95)	0.95 (0.26,3.44)	0.00 (-0.14,0.13)
LD ETN SC + PL		0.93 (0.20,4.50)	0.94 (0.23,3.79)	-0.01 (-0.15,0.16)
LD RITUX IV + MTX		0.92 (0.22,3.75)	0.92 (0.25,3.28)	-0.01 (-0.15,0.12)
LD ABA IV + MTX		1.51 (0.36,6.41)	1.43 (0.41,5.12)	0.04 (-0.11,0.21)
LD ETN SC + MTX		0.55 (0.16,1.81)	0.58 (0.18,1.72)	-0.04 (-0.15,0.04)
HD INF IV + MTX		1.25 (0.30,5.12)	1.22 (0.34,4.29)	0.02 (-0.13,0.16)
SD RITUX IV + MTX	SD ABA IV + MTX	0.99 (0.25,4.19)	0.99 (0.29,3.63)	0.00 (-0.13,0.13)
LD ETN SC + PL		1.00 (0.21,4.82)	1.00 (0.24,3.99)	0.00 (-0.14,0.16)
LD RITUX IV + MTX		0.94 (0.24,4.00)	0.95 (0.28,3.49)	0.00 (-0.13,0.12)
LD ABA IV + MTX		1.61 (0.60,4.49)	1.52 (0.64,3.74)	0.05 (-0.05,0.18)
LD ETN SC + MTX		0.58 (0.12,2.77)	0.60 (0.14,2.54)	-0.03 (-0.16,0.08)
HD INF IV + MTX		1.30 (0.33,5.25)	1.26 (0.37,4.39)	0.02 (-0.11,0.17)

(Continued)

LD ETN SC + PL	SD RITUX IV + MTX	0.98 (0.21,4.73)	0.99 (0.24,3.95)	0.00 (-0.13,0.16)
LD RITUX IV + MTX		0.95 (0.35,2.71)	0.96 (0.39,2.46)	0.00 (-0.09,0.09)
LD ABA IV + MTX		1.61 (0.41,6.48)	1.52 (0.45,5.08)	0.05 (-0.09,0.22)
LD ETN SC + MTX		0.58 (0.12,2.63)	0.60 (0.14,2.42)	-0.03 (-0.16,0.07)
HD INF IV + MTX		1.30 (0.34,5.23)	1.26 (0.38,4.30)	0.02 (-0.11,0.17)
LD RITUX IV + MTX	LD ETN SC + PL	0.98 (0.19,4.42)	0.98 (0.24,3.88)	0.00 (-0.17,0.12)
LD ABA IV + MTX		1.61 (0.34,7.65)	1.52 (0.40,6.07)	0.04 (-0.12,0.22)
LD ETN SC + MTX		0.60 (0.12,3.00)	0.62 (0.14,2.76)	-0.03 (-0.19,0.08)
HD INF IV + MTX		1.33 (0.28,6.29)	1.29 (0.33,5.20)	0.03 (-0.14,0.17)
LD ABA IV + MTX	LD RITUX IV + MTX	1.67 (0.42,6.88)	1.58 (0.47,5.38)	0.05 (-0.09,0.22)
LD ETN SC + MTX		0.60 (0.13,2.82)	0.62 (0.15,2.58)	-0.03 (-0.15,0.08)
HD INF IV + MTX		1.35 (0.35,5.49)	1.31 (0.39,4.57)	0.03 (-0.10,0.17)
LD ETN SC + MTX	LD ABA IV + MTX	0.36 (0.07,1.68)	0.40 (0.10,1.59)	-0.08 (-0.25,0.04)
HD INF IV + MTX		0.82 (0.21,3.17)	0.84 (0.26,2.71)	-0.02 (-0.19,0.13)
HD INF IV + MTX	LD ETN SC + MTX	2.26 (0.52,10.49)	2.11 (0.56,8.68)	0.06 (-0.06,0.20)
Random-Effect Model	Residual Deviance	16.48 vs 17 data points		
	Deviance Information Criteria	105.18		
Fixed-Effect Model	Residual Deviance	16.25 vs 17 data points		
	Deviance Information Criteria	104.718		
Note:				
Total Patients	2277			
Total Studies	6			
2-arm	1			

(Continued)

5-arm

5

**Appendix 44. Cancer: Type of medications**

Remission (Analysis4): Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
TNF	PL	1.32 (0.63,3.02)	1.31 (0.63,2.98)	0.00 (0.00,0.01)
non-TNF		1.25 (0.36,5.05)	1.25 (0.36,4.92)	0.00 (-0.01,0.03)
MTXTNF		1.21 (0.63,2.40)	1.21 (0.63,2.38)	0.00 (0.00,0.01)
MTXnon-TNF		0.99 (0.58,1.79)	0.99 (0.58,1.78)	0.00 (0.00,0.01)
non-TNF	TNF	0.95 (0.22,4.35)	0.95 (0.23,4.25)	0.00 (-0.01,0.03)
MTXTNF		0.91 (0.39,2.16)	0.91 (0.40,2.15)	0.00 (-0.01,0.01)
MTXnon-TNF		0.75 (0.29,1.84)	0.75 (0.30,1.83)	0.00 (-0.01,0.01)
MTXTNF	non-TNF	0.97 (0.21,3.77)	0.97 (0.22,3.73)	0.00 (-0.03,0.01)
MTXnon-TNF		0.79 (0.18,3.07)	0.79 (0.18,3.05)	0.00 (-0.03,0.01)
MTXnon-TNF	MTXTNF	0.83 (0.38,1.71)	0.83 (0.39,1.70)	0.00 (-0.01,0.00)
Random-Effect Model	Residual Deviance	38.11 vs 49 data points		
	Deviance Information Criteria	180.758		
Fixed-Effect Model	Residual Deviance	38.09 vs 49 data points		
	Deviance Information Criteria	179.805		
Note:				
Total Patients	9386			
Total Studies	23			
2-arm	20			
3-arm	3			

**Appendix 45. Cancer: Type of biologics**

Cancer (Analysis 3): Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
TNF	PL	1.43 (0.62,3.54)	1.43 (0.62,3.48)	0.00 (0.00,0.02)
non-TNF		1.31 (0.31,5.92)	1.30 (0.32,5.72)	0.00 (-0.01,0.04)
Mono		1.31 (0.10,17.94)	1.31 (0.10,15.86)	0.00 (-0.01,0.11)
MTXnon-TNF		0.92 (0.52,1.70)	0.92 (0.52,1.69)	0.00 (0.00,0.00)
MTXTNF		1.42 (0.62,3.52)	1.42 (0.62,3.46)	0.00 (0.00,0.02)
MTXMono		0.93 (0.33,2.55)	0.93 (0.33,2.53)	0.00 (-0.01,0.01)
non-TNF	TNF	0.91 (0.17,5.40)	0.91 (0.17,5.22)	0.00 (-0.02,0.03)
Mono		0.91 (0.06,13.28)	0.91 (0.07,11.82)	0.00 (-0.02,0.11)
MTXnon-TNF		0.64 (0.22,1.80)	0.64 (0.22,1.79)	0.00 (-0.02,0.00)
MTXTNF		0.99 (0.39,2.62)	0.99 (0.39,2.59)	0.00 (-0.01,0.01)
MTXMono		0.65 (0.16,2.33)	0.65 (0.16,2.31)	0.00 (-0.02,0.01)
Mono	non-TNF	0.97 (0.09,12.11)	0.97 (0.09,11.11)	0.00 (-0.03,0.10)
MTXnon-TNF		0.71 (0.14,3.14)	0.71 (0.15,3.13)	0.00 (-0.04,0.01)
MTXTNF		1.09 (0.20,5.80)	1.09 (0.21,5.70)	0.00 (-0.03,0.02)
MTXMono		0.71 (0.11,4.09)	0.71 (0.12,4.05)	0.00 (-0.04,0.01)
MTXnon-TNF	Mono	0.70 (0.05,9.51)	0.71 (0.05,9.44)	0.00 (-0.12,0.01)
MTXTNF		1.07 (0.09,14.19)	1.07 (0.10,14.03)	0.00 (-0.11,0.02)
MTXMono		0.71 (0.04,11.12)	0.72 (0.05,11.01)	0.00 (-0.12,0.01)
MTXTNF	MTXnon-TNF	1.54 (0.56,4.51)	1.54 (0.56,4.43)	0.00 (0.00,0.02)
MTXMono		1.00 (0.38,2.62)	1.00 (0.38,2.60)	0.00 (-0.01,0.01)
MTXMono	MTXTNF	0.65 (0.16,2.42)	0.65 (0.16,2.40)	0.00 (-0.02,0.01)
Random-Effect Model	Residual Deviance	39.55 vs 49 data points		
	Deviance Information Criteria	184.079		

(Continued)

Fixed-Effect Model	Residual Deviance	39.64 vs 49 data points
	Deviance Information Criteria	183.351
Note:		
Total Patients	9386	
Total Studies	23	
2-arm	20	
3-arm	3	

#### Appendix 46. Cancer: By dose

Cancer Analysis 4: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD	PL	1.40 (0.63,3.00)	1.40 (0.63,2.96)	0.00 (0.00,0.01)
HD		1.35 (0.35,5.77)	1.35 (0.35,5.58)	0.00 (-0.01,0.03)
LD		0.64 (0.13,2.33)	0.64 (0.13,2.31)	0.00 (-0.01,0.01)
MTXSD		1.05 (0.65,1.71)	1.05 (0.65,1.70)	0.00 (0.00,0.00)
MTXLD		1.37 (0.42,4.05)	1.36 (0.43,3.97)	0.00 (-0.01,0.02)
HD	SD	0.97 (0.22,4.53)	0.97 (0.23,4.40)	0.00 (-0.01,0.03)
LD		0.46 (0.10,1.68)	0.46 (0.10,1.67)	-0.01 (-0.02,0.01)
MTXSD		0.75 (0.34,1.69)	0.75 (0.35,1.68)	0.00 (-0.01,0.00)
MTXLD		0.98 (0.25,3.60)	0.98 (0.26,3.53)	0.00 (-0.01,0.02)
LD	HD	0.47 (0.06,3.15)	0.47 (0.06,3.11)	-0.01 (-0.04,0.01)
MTXSD		0.79 (0.17,3.14)	0.79 (0.18,3.12)	0.00 (-0.03,0.01)
MTXLD		1.02 (0.17,5.56)	1.02 (0.17,5.45)	0.00 (-0.03,0.02)
MTXSD	LD	1.63 (0.42,8.73)	1.63 (0.43,8.65)	0.00 (-0.01,0.01)
MTXLD		2.13 (0.39,14.46)	2.11 (0.39,14.17)	0.01 (-0.01,0.03)

(Continued)

MTXLD	MTXSD	1.31 (0.40,3.77)	1.30 (0.40,3.69)	0.00 (-0.01,0.02)
Random-Effect Model	Residual Deviance	39.23 vs 51 data points		
	Deviance Information Criteria	181.671		
Fixed-Effect Model	Residual Deviance	39.27 vs 51 data points		
	Deviance Information Criteria	180.863		
Note:				
Total Patients	8740			
Total Studies	22			
2-arm	15			
3-arm	7			

## Appendix 47. Cancer: Main analysis

Cancer (Analysis 1): Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
DMARD	MTX	0.11 (0.01,1.07)	0.11 (0.01,1.07)	-0.01 (-0.01,0.00)
SD ETN SC		1.44 (0.54,4.04)	1.44 (0.54,3.96)	0.00 (0.00,0.02)
SD ADA SC		0.19 (0.01,3.31)	0.19 (0.01,3.25)	-0.01 (-0.01,0.02)
SD ABA IV + MTX		0.69 (0.14,3.11)	0.69 (0.14,3.07)	0.00 (-0.01,0.01)
SD ABA SC + MTX		0.47 (0.07,2.70)	0.48 (0.07,2.67)	0.00 (-0.01,0.01)
SD ADA SC + MTX		0.51 (0.06,3.76)	0.51 (0.06,3.69)	0.00 (-0.01,0.02)
SD ETN SC + MTX		1.99 (0.59,7.18)	1.97 (0.59,6.87)	0.01 (0.00,0.05)
SD INF IV + MTX		0.80 (0.13,5.22)	0.80 (0.13,5.08)	0.00 (-0.01,0.03)
SD RITUX IV + MTX		0.92 (0.15,5.66)	0.92 (0.15,5.47)	0.00 (-0.01,0.03)
SD ETN SC + DMARD		0.09 (0.00,1.04)	0.09 (0.00,1.04)	-0.01 (-0.01,0.00)

(Continued)

SD ABA IV + DMARD		0.11 (0.00,1.33)	0.11 (0.00,1.32)	-0.01 (-0.01,0.00)
LD ETN SC		0.60 (0.11,2.67)	0.60 (0.12,2.63)	0.00 (-0.01,0.01)
LD RITUX IV + MTX		0.59 (0.06,4.03)	0.59 (0.06,3.95)	0.00 (-0.01,0.02)
LD ETN SC + MTX		4.34 (0.58,31.67)	4.23 (0.58,25.72)	0.03 (0.00,0.19)
HD TOCI IV		0.39 (0.03,2.63)	0.39 (0.04,2.60)	0.00 (-0.01,0.01)
SD ETN SC	DMARD	13.86 (1.28,256.80)	13.69 (1.28,252.60)	0.01 (0.00,0.03)
SD ADA SC		1.78 (0.12,35.45)	1.78 (0.12,34.93)	0.00 (0.00,0.02)
SD ABA IV + MTX		6.72 (0.33,176.20)	6.68 (0.33,174.30)	0.00 (0.00,0.02)
SD ABA SC + MTX		4.59 (0.18,131.60)	4.57 (0.18,130.50)	0.00 (-0.01,0.02)
SD ADA SC + MTX		4.98 (0.17,173.70)	4.95 (0.17,170.90)	0.00 (-0.01,0.02)
SD ETN SC + MTX		18.62 (1.52,383.20)	18.30 (1.52,370.80)	0.01 (0.00,0.05)
SD INF IV + MTX		7.56 (0.44,241.20)	7.51 (0.44,236.90)	0.01 (0.00,0.03)
SD RITUX IV + MTX		8.97 (0.40,259.70)	8.89 (0.40,253.70)	0.01 (0.00,0.04)
SD ETN SC + DMARD		0.90 (0.14,6.08)	0.90 (0.14,6.06)	0.00 (0.00,0.00)
SD ABA IV + DMARD		1.00 (0.36,2.93)	1.00 (0.36,2.92)	0.00 (0.00,0.00)
LD ETN SC		5.56 (0.35,127.80)	5.53 (0.35,126.40)	0.00 (0.00,0.02)
LD RITUX IV + MTX		5.23 (0.24,189.60)	5.21 (0.24,185.20)	0.00 (-0.01,0.03)
LD ETN SC + MTX		40.81 (1.88,1326.00)	38.78 (1.88,1162.00)	0.03 (0.00,0.20)
HD TOCI IV		3.43 (0.51,37.98)	3.41 (0.51,37.66)	0.00 (0.00,0.02)
SD ADA SC	SD ETN SC	0.13 (0.00,2.48)	0.13 (0.00,2.44)	-0.01 (-0.03,0.01)
SD ABA IV + MTX		0.48 (0.07,2.75)	0.48 (0.07,2.73)	-0.01 (-0.03,0.01)
SD ABA SC + MTX		0.33 (0.04,2.37)	0.34 (0.04,2.35)	-0.01 (-0.03,0.01)
SD ADA SC + MTX		0.36 (0.03,3.36)	0.36 (0.03,3.31)	-0.01 (-0.03,0.02)
SD ETN SC + MTX		1.37 (0.39,4.94)	1.36 (0.40,4.78)	0.00 (-0.01,0.04)
SD INF IV + MTX		0.56 (0.06,4.28)	0.56 (0.06,4.18)	0.00 (-0.03,0.02)
SD RITUX IV + MTX		0.64 (0.07,5.43)	0.64 (0.07,5.24)	0.00 (-0.03,0.03)
SD ETN SC + DMARD		0.06 (0.00,0.74)	0.06 (0.00,0.74)	-0.01 (-0.03,0.00)
SD ABA IV + DMARD		0.07 (0.00,0.97)	0.07 (0.00,0.97)	-0.01 (-0.03,0.00)



(Continued)

LD ETN SC		0.41 (0.08,1.68)	0.42 (0.09,1.67)	-0.01 (-0.02,0.01)
LD RITUX IV + MTX		0.41 (0.03,3.46)	0.42 (0.03,3.39)	-0.01 (-0.03,0.02)
LD ETN SC + MTX		2.99 (0.36,22.54)	2.91 (0.37,18.66)	0.02 (-0.01,0.19)
HD TOCI IV		0.26 (0.02,2.07)	0.26 (0.02,2.05)	-0.01 (-0.03,0.01)
SD ABA IV + MTX	SD ADA SC	3.64 (0.12,133.50)	3.62 (0.12,132.00)	0.00 (-0.02,0.02)
SD ABA SC + MTX		2.53 (0.07,111.90)	2.52 (0.07,110.80)	0.00 (-0.02,0.02)
SD ADA SC + MTX		2.75 (0.07,141.30)	2.74 (0.08,139.30)	0.00 (-0.02,0.02)
SD ETN SC + MTX		10.74 (0.47,343.40)	10.53 (0.47,333.70)	0.01 (-0.01,0.05)
SD INF IV + MTX		4.07 (0.14,175.40)	4.04 (0.14,171.80)	0.00 (-0.02,0.03)
SD RITUX IV + MTX		4.95 (0.16,210.00)	4.92 (0.16,205.60)	0.00 (-0.02,0.04)
SD ETN SC + DMARD		0.54 (0.03,6.33)	0.54 (0.03,6.32)	0.00 (-0.02,0.00)
SD ABA IV + DMARD		0.58 (0.03,10.26)	0.58 (0.03,10.22)	0.00 (-0.02,0.01)
LD ETN SC		3.22 (0.12,111.50)	3.21 (0.12,110.40)	0.00 (-0.02,0.02)
LD RITUX IV + MTX		3.06 (0.08,161.40)	3.04 (0.08,158.90)	0.00 (-0.02,0.03)
LD ETN SC + MTX		22.80 (0.79,1116.00)	21.68 (0.80,992.50)	0.03 (0.00,0.20)
HD TOCI IV		2.00 (0.15,27.53)	2.00 (0.15,27.33)	0.00 (-0.02,0.02)
SD ABA SC + MTX	SD ABA IV + MTX	0.69 (0.15,3.16)	0.69 (0.15,3.13)	0.00 (-0.01,0.01)
SD ADA SC + MTX		0.74 (0.12,5.36)	0.74 (0.12,5.30)	0.00 (-0.01,0.02)
SD ETN SC + MTX		2.97 (0.41,22.99)	2.93 (0.41,22.11)	0.01 (-0.01,0.05)
SD INF IV + MTX		1.17 (0.16,9.26)	1.16 (0.16,9.06)	0.00 (-0.01,0.03)
SD RITUX IV + MTX		1.33 (0.13,14.46)	1.33 (0.13,13.96)	0.00 (-0.02,0.04)
SD ETN SC + DMARD		0.14 (0.00,2.83)	0.14 (0.00,2.82)	0.00 (-0.02,0.00)
SD ABA IV + DMARD		0.15 (0.00,3.67)	0.15 (0.00,3.64)	0.00 (-0.02,0.01)
LD ETN SC		0.86 (0.09,7.50)	0.86 (0.10,7.39)	0.00 (-0.02,0.02)
LD RITUX IV + MTX		0.85 (0.06,10.44)	0.85 (0.06,10.16)	0.00 (-0.02,0.02)
LD ETN SC + MTX		6.30 (0.56,94.02)	6.08 (0.57,77.80)	0.03 (-0.01,0.20)
HD TOCI IV		0.55 (0.03,7.57)	0.55 (0.03,7.43)	0.00 (-0.02,0.02)
SD ADA SC + MTX	SD ABA SC + MTX	1.08 (0.31,4.13)	1.08 (0.32,4.08)	0.00 (-0.01,0.01)

(Continued)

SD ETN SC + MTX		4.19 (0.51,46.24)	4.13 (0.51,44.65)	0.01 (-0.01,0.05)
SD INF IV + MTX		1.70 (0.17,18.51)	1.69 (0.17,18.06)	0.00 (-0.01,0.03)
SD RITUX IV + MTX		1.93 (0.16,25.05)	1.92 (0.16,24.22)	0.00 (-0.01,0.04)
SD ETN SC + DMARD		0.20 (0.01,4.89)	0.20 (0.01,4.85)	0.00 (-0.02,0.01)
SD ABA IV + DMARD		0.23 (0.01,6.55)	0.23 (0.01,6.51)	0.00 (-0.02,0.01)
LD ETN SC		1.22 (0.12,15.79)	1.22 (0.12,15.59)	0.00 (-0.01,0.02)
LD RITUX IV + MTX		1.26 (0.08,17.13)	1.26 (0.08,16.78)	0.00 (-0.01,0.03)
LD ETN SC + MTX		8.93 (0.69,159.80)	8.61 (0.70,134.80)	0.03 (0.00,0.20)
HD TOCI IV		0.79 (0.04,13.43)	0.79 (0.04,13.21)	0.00 (-0.01,0.02)
SD ETN SC + MTX	SD ADA SC + MTX	3.93 (0.38,49.01)	3.88 (0.38,47.02)	0.01 (-0.01,0.05)
SD INF IV + MTX		1.63 (0.12,17.80)	1.62 (0.12,17.48)	0.00 (-0.02,0.03)
SD RITUX IV + MTX		1.78 (0.12,24.81)	1.77 (0.13,24.14)	0.00 (-0.02,0.04)
SD ETN SC + DMARD		0.18 (0.00,4.97)	0.18 (0.00,4.94)	0.00 (-0.02,0.01)
SD ABA IV + DMARD		0.20 (0.00,6.76)	0.21 (0.01,6.71)	0.00 (-0.02,0.01)
LD ETN SC		1.11 (0.09,15.89)	1.11 (0.09,15.63)	0.00 (-0.02,0.02)
LD RITUX IV + MTX		1.15 (0.06,16.48)	1.15 (0.06,16.09)	0.00 (-0.02,0.03)
LD ETN SC + MTX		8.53 (0.46,164.50)	8.21 (0.47,140.20)	0.03 (-0.01,0.20)
HD TOCI IV		0.73 (0.03,14.83)	0.73 (0.03,14.60)	0.00 (-0.02,0.02)
SD INF IV + MTX	SD ETN SC + MTX	0.39 (0.04,3.52)	0.40 (0.05,3.45)	-0.01 (-0.05,0.02)
SD RITUX IV + MTX		0.46 (0.05,4.10)	0.46 (0.05,4.00)	-0.01 (-0.05,0.03)
SD ETN SC + DMARD		0.05 (0.00,0.65)	0.05 (0.00,0.66)	-0.01 (-0.05,0.00)
SD ABA IV + DMARD		0.05 (0.00,0.83)	0.05 (0.00,0.83)	-0.01 (-0.05,0.00)
LD ETN SC		0.30 (0.04,1.76)	0.30 (0.05,1.75)	-0.01 (-0.05,0.01)
LD RITUX IV + MTX		0.29 (0.02,2.63)	0.30 (0.02,2.59)	-0.01 (-0.05,0.02)
LD ETN SC + MTX		2.18 (0.36,13.13)	2.13 (0.37,11.26)	0.02 (-0.02,0.17)
HD TOCI IV		0.19 (0.01,1.78)	0.19 (0.01,1.77)	-0.01 (-0.05,0.01)
SD RITUX IV + MTX	SD INF IV + MTX	1.13 (0.08,15.99)	1.13 (0.08,15.50)	0.00 (-0.03,0.04)
SD ETN SC + DMARD		0.12 (0.00,2.35)	0.12 (0.00,2.34)	-0.01 (-0.03,0.00)

(Continued)

SD ABA IV + DMARD		0.13 (0.00,2.83)	0.13 (0.00,2.81)	-0.01 (-0.03,0.01)
LD ETN SC		0.73 (0.07,8.35)	0.73 (0.07,8.24)	0.00 (-0.03,0.02)
LD RITUX IV + MTX		0.72 (0.04,9.82)	0.72 (0.04,9.64)	0.00 (-0.03,0.02)
LD ETN SC + MTX		5.44 (0.41,75.23)	5.26 (0.41,63.70)	0.03 (-0.01,0.20)
HD TOCI IV		0.49 (0.02,6.73)	0.49 (0.02,6.63)	0.00 (-0.03,0.02)
SD ETN SC + DMARD	SD RITUX IV + MTX	0.10 (0.00,2.43)	0.10 (0.00,2.42)	-0.01 (-0.04,0.00)
SD ABA IV + DMARD		0.11 (0.00,2.96)	0.11 (0.00,2.94)	-0.01 (-0.04,0.01)
LD ETN SC		0.65 (0.05,7.28)	0.66 (0.06,7.18)	0.00 (-0.04,0.02)
LD RITUX IV + MTX		0.63 (0.06,4.55)	0.63 (0.06,4.50)	0.00 (-0.03,0.01)
LD ETN SC + MTX		4.74 (0.31,76.08)	4.58 (0.32,63.38)	0.02 (-0.02,0.19)
HD TOCI IV		0.41 (0.02,6.31)	0.41 (0.02,6.23)	0.00 (-0.04,0.01)
SD ABA IV + DMARD	SD ETN SC + DMARD	1.14 (0.13,9.36)	1.14 (0.13,9.33)	0.00 (0.00,0.01)
LD ETN SC		6.66 (0.37,163.90)	6.63 (0.37,162.00)	0.00 (0.00,0.02)
LD RITUX IV + MTX		6.29 (0.22,240.90)	6.26 (0.22,237.30)	0.00 (0.00,0.03)
LD ETN SC + MTX		47.44 (2.15,1487.00)	45.16 (2.14,1309.00)	0.03 (0.00,0.20)
HD TOCI IV		3.98 (0.41,52.17)	3.97 (0.41,51.60)	0.00 (0.00,0.02)
LD ETN SC	SD ABA IV + DMARD	5.70 (0.29,150.80)	5.67 (0.30,149.00)	0.00 (-0.01,0.02)
LD RITUX IV + MTX		5.12 (0.20,213.20)	5.10 (0.20,210.50)	0.00 (-0.01,0.03)
LD ETN SC + MTX		40.87 (1.75,1502.00)	38.93 (1.74,1347.00)	0.03 (0.00,0.20)
HD TOCI IV		3.49 (0.38,46.06)	3.47 (0.38,45.72)	0.00 (0.00,0.02)
LD RITUX IV + MTX	LD ETN SC	1.00 (0.06,12.70)	1.00 (0.06,12.38)	0.00 (-0.02,0.03)
LD ETN SC + MTX		7.24 (0.63,85.94)	6.98 (0.63,72.53)	0.03 (0.00,0.20)
HD TOCI IV		0.63 (0.04,8.20)	0.63 (0.04,8.05)	0.00 (-0.02,0.02)
LD ETN SC + MTX	LD RITUX IV + MTX	7.45 (0.46,147.40)	7.16 (0.47,125.70)	0.03 (-0.01,0.20)
HD TOCI IV		0.67 (0.03,12.35)	0.67 (0.03,12.16)	0.00 (-0.03,0.02)
HD TOCI IV	LD ETN SC + MTX	0.09 (0.00,1.55)	0.09 (0.00,1.54)	-0.03 (-0.20,0.00)

(Continued)

Random-Effect Model	Residual Deviance	43.47 vs 56 datapoint
	Deviance Information Criteria	213.751
Fixed-Effect Model	Residual Deviance	43.15 vs 56 datapoint
	Deviance Information Criteria	212.255
Total Patients	10843	
Total Studies	24	
2-arm	16	
3-arm	8	

#### Appendix 48. Cancer: Subgroup - Established RA (2 to 10 years)

Cancer in Established RA: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD ETN SC	MTX	2.33 (0.46,14.33)	2.31 (0.47,13.27)	0.01 (0.00,0.08)
SD ABA IV + MTX		0.64 (0.11,3.33)	0.65 (0.11,3.29)	0.00 (-0.01,0.01)
SD ETN SC + MTX		2.74 (0.69,15.56)	2.70 (0.69,14.38)	0.01 (0.00,0.08)
SD INF IV + MTX		0.86 (0.15,5.23)	0.86 (0.15,5.13)	0.00 (-0.01,0.02)
SD ABA SC + MTX		0.40 (0.04,3.16)	0.40 (0.04,3.12)	0.00 (-0.01,0.01)
SD RITUX IV + MTX		0.98 (0.16,6.79)	0.98 (0.16,6.57)	0.00 (-0.01,0.03)
LD RITUX IV + MTX		0.63 (0.06,4.29)	0.64 (0.06,4.21)	0.00 (-0.01,0.02)
LD ETN SC + MTX		5.55 (0.81,53.48)	5.37 (0.81,41.14)	0.03 (0.00,0.24)
HD TOCI IV		0.24 (0.01,2.58)	0.25 (0.01,2.56)	0.00 (-0.01,0.01)
SD ABA IV + MTX	SD ETN SC	0.27 (0.02,2.86)	0.27 (0.02,2.83)	-0.01 (-0.08,0.01)
SD ETN SC + MTX		1.18 (0.34,4.40)	1.18 (0.35,4.27)	0.00 (-0.03,0.04)
SD INF IV + MTX		0.37 (0.03,4.06)	0.37 (0.03,4.01)	-0.01 (-0.08,0.02)

(Continued)

SD ABA SC + MTX		0.17 (0.01,2.36)	0.17 (0.01,2.34)	-0.01 (-0.08,0.01)
SD RITUX IV + MTX		0.42 (0.03,5.21)	0.42 (0.03,5.08)	-0.01 (-0.08,0.03)
LD RITUX IV + MTX		0.26 (0.01,3.20)	0.27 (0.01,3.16)	-0.01 (-0.08,0.01)
LD ETN SC + MTX		2.38 (0.30,22.42)	2.32 (0.30,18.84)	0.02 (-0.03,0.20)
HD TOCI IV		0.10 (0.00,1.88)	0.10 (0.00,1.87)	-0.01 (-0.08,0.01)
SD ETN SC + MTX	SD ABA IV + MTX	4.45 (0.50,46.49)	4.37 (0.50,43.50)	0.01 (-0.01,0.08)
SD INF IV + MTX		1.34 (0.16,12.75)	1.34 (0.17,12.51)	0.00 (-0.01,0.02)
SD ABA SC + MTX		0.62 (0.11,2.82)	0.62 (0.11,2.80)	0.00 (-0.01,0.01)
SD RITUX IV + MTX		1.54 (0.13,20.39)	1.54 (0.13,19.65)	0.00 (-0.01,0.04)
LD RITUX IV + MTX		0.98 (0.06,12.64)	0.98 (0.06,12.41)	0.00 (-0.01,0.02)
LD ETN SC + MTX		9.00 (0.69,131.50)	8.66 (0.70,105.40)	0.03 (0.00,0.24)
HD TOCI IV		0.36 (0.01,6.96)	0.36 (0.01,6.88)	0.00 (-0.02,0.01)
SD INF IV + MTX	SD ETN SC + MTX	0.31 (0.03,2.90)	0.32 (0.03,2.87)	-0.01 (-0.08,0.01)
SD ABA SC + MTX		0.14 (0.01,1.79)	0.14 (0.01,1.78)	-0.02 (-0.08,0.01)
SD RITUX IV + MTX		0.35 (0.03,3.80)	0.35 (0.03,3.70)	-0.01 (-0.08,0.02)
LD RITUX IV + MTX		0.22 (0.01,2.42)	0.22 (0.01,2.39)	-0.01 (-0.08,0.01)
LD ETN SC + MTX		1.99 (0.33,13.37)	1.94 (0.34,11.30)	0.02 (-0.03,0.19)
HD TOCI IV		0.09 (0.00,1.37)	0.09 (0.00,1.37)	-0.02 (-0.08,0.00)
SD ABA SC + MTX	SD INF IV + MTX	0.45 (0.03,5.71)	0.45 (0.03,5.63)	0.00 (-0.02,0.01)
SD RITUX IV + MTX		1.13 (0.09,14.61)	1.13 (0.09,14.22)	0.00 (-0.02,0.03)
LD RITUX IV + MTX		0.71 (0.04,9.81)	0.71 (0.04,9.60)	0.00 (-0.02,0.02)
LD ETN SC + MTX		6.32 (0.50,104.40)	6.09 (0.51,84.16)	0.03 (-0.01,0.24)
HD TOCI IV		0.26 (0.01,5.97)	0.27 (0.01,5.90)	0.00 (-0.02,0.01)
SD RITUX IV + MTX	SD ABA SC + MTX	2.49 (0.15,53.39)	2.48 (0.16,51.97)	0.00 (-0.01,0.04)
LD RITUX IV + MTX		1.60 (0.07,32.68)	1.59 (0.07,32.08)	0.00 (-0.01,0.02)
LD ETN SC + MTX		14.80 (0.86,336.80)	14.14 (0.86,276.00)	0.03 (0.00,0.24)
HD TOCI IV		0.60 (0.01,16.38)	0.60 (0.01,16.17)	0.00 (-0.02,0.01)
LD RITUX IV + MTX	SD RITUX IV + MTX	0.63 (0.06,4.34)	0.64 (0.06,4.30)	0.00 (-0.03,0.01)

(Continued)

LD ETN SC + MTX		5.70 (0.38,104.80)	5.49 (0.39,84.29)	0.03 (-0.02,0.23)
HD TOCI IV		0.24 (0.00,5.04)	0.24 (0.00,4.99)	0.00 (-0.04,0.01)
LD ETN SC + MTX	LD RITUX IV + MTX	9.11 (0.58,216.70)	8.73 (0.58,178.10)	0.03 (-0.01,0.24)
HD TOCI IV		0.39 (0.01,9.91)	0.39 (0.01,9.78)	0.00 (-0.02,0.01)
HD TOCI IV	LD ETN SC + MTX	0.04 (0.00,0.97)	0.04 (0.00,0.98)	-0.03 (-0.24,0.00)
Random-Effect Model	Residual Deviance	23.95 vs data points 31		
	Deviance Information Criteria	115.121		
Fixed-Effect Model	Residual Deviance	23.65 vs 31 data points		
	Deviance Information Criteria	114.266		
Note:				
Total Studies	13			
2-arm	8			
3-arm	5			

#### Appendix 49. Cancer: Subgroup - Trial Duration ( $\leq 6$ months)

Cancer, Short trial duration: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons-Random Effects Model				
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% CrI)
SD ABA IV + MTX	MTX	0.72 (0.11,4.57)	0.73 (0.11,4.52)	0.00 (-0.01,0.01)
SD ABA SC + MTX		0.44 (0.04,3.99)	0.44 (0.04,3.95)	0.00 (-0.01,0.01)
SD INF IV + MTX		1.45 (0.16,16.43)	1.44 (0.16,15.69)	0.00 (-0.01,0.05)
SD RITUX IV + MTX		2.39 (0.19,69.59)	2.37 (0.19,53.42)	0.01 (-0.01,0.22)
LD RITUX IV + MTX		0.94 (0.03,30.30)	0.94 (0.03,26.84)	0.00 (-0.01,0.12)

(Continued)

HD TOCI IV		0.25 (0.01,2.66)	0.26 (0.01,2.64)	0.00 (-0.01,0.01)
SD ABA SC + MTX	SD ABA IV + MTX	0.61 (0.11,2.89)	0.61 (0.11,2.86)	0.00 (-0.01,0.01)
SD INF IV + MTX		2.02 (0.21,24.23)	2.01 (0.21,23.28)	0.00 (-0.01,0.05)
SD RITUX IV + MTX		3.45 (0.13,139.90)	3.41 (0.13,110.00)	0.01 (-0.01,0.22)
LD RITUX IV + MTX		1.35 (0.02,67.15)	1.35 (0.02,59.70)	0.00 (-0.01,0.12)
HD TOCI IV		0.34 (0.01,6.62)	0.34 (0.01,6.53)	0.00 (-0.01,0.01)
SD INF IV + MTX	SD ABA SC + MTX	3.40 (0.23,58.33)	3.38 (0.23,56.39)	0.00 (-0.01,0.05)
SD RITUX IV + MTX		5.71 (0.18,315.00)	5.62 (0.19,251.50)	0.01 (-0.01,0.22)
LD RITUX IV + MTX		2.25 (0.03,143.80)	2.24 (0.03,126.20)	0.00 (-0.01,0.12)
HD TOCI IV		0.57 (0.01,16.97)	0.57 (0.01,16.74)	0.00 (-0.01,0.01)
SD RITUX IV + MTX	SD INF IV + MTX	1.67 (0.05,92.96)	1.66 (0.05,73.20)	0.00 (-0.04,0.22)
LD RITUX IV + MTX		0.64 (0.01,43.56)	0.64 (0.01,38.58)	0.00 (-0.05,0.12)
HD TOCI IV		0.16 (0.00,4.88)	0.16 (0.00,4.83)	-0.01 (-0.05,0.01)
LD RITUX IV + MTX	SD RITUX IV + MTX	0.40 (0.01,5.52)	0.41 (0.02,5.32)	-0.01 (-0.15,0.04)
HD TOCI IV		0.10 (0.00,3.61)	0.10 (0.00,3.57)	-0.01 (-0.22,0.01)
HD TOCI IV	LD RITUX IV + MTX	0.26 (0.00,15.60)	0.26 (0.00,15.50)	0.00 (-0.12,0.01)
Random-Effect Model	Residual Deviance	13.3 vs 18 data points		
	Deviance Information Criteria	64.955		
Fixed-Effect Model	Residual Deviance	13.33 vs 18 data points		
	Deviance Information Criteria	65.149		
Note:				
Total Patients	3895			
Total Studies	8			

(Continued)

2-arm	6
3-arm	2

## Appendix 50. Characteristics of excluded studies

Study	Reason for exclusion
Axelsen 2015	Duplicate of Horslev 2014
Bathon 2000	Duplicate of Genovese 2002
Bejarano 2008	Wrong drug exposure
Bonafede 2015	Not a RCT
Boyle 2015	Wrong drug exposure
Breedveld 2006	Wrong drug exposure
Bresnihan 1998	Wrong drug exposure
Burmester 2014	Comparing two routes of administration of a biologic
Burmester 2015	Wrong drug exposure
Cheng 2014	Conference abstract
Cohen 2003	Wrong drug exposure
Cohen 2006	Wrong drug exposure
Coombs 2009	Wrong drug exposure
Conaghan 2014	Sub-study of Huizinga 2015
Dougados 2014	Duplicate of Huizinga 2015
Doyle 2013	Wrong drug exposure
Durez 2004	Wrong drug exposure
Emery 2008	Wrong drug exposure
Emery 2014a	Duplicate
Emery 2014b	Conference abstract
Erickson 2015	Follow-up at two years of Vollenhoven 2012 NCT00764725
Fleischmann 2012a	Comparing multiple doses of a biologic



(Continued)

Fleischmann 2012b	Comparing multiple doses of biologics
Fleischmann 2013	Conference abstract
Furst 2015	Open label study
Gabay 2013	Comparing two doses of a biologic
Genovese 2002	Wrong drug exposure
Genovese 2005	Wrong drug exposure
Genovese 2015	Wrong drug exposure
Gherge 2014	Conference abstract
Haroui 2014	Duplicate of Pope 2014
Heimans 2014	Wrong drug exposure
Hobbs 2015	Wrong drug exposure
Hørslev-Petersen 2014	Open label study
Iannone 2014	Open label study
Johnsen 2006	Wrong drug exposure
Jones 2010	Wrong drug exposure
Kameda 2011	Wrong drug exposure
Kavanaugh 2014	Conference abstract
Kennedy 2014	Wrong drug exposure
Keystone 2014	Conference abstract
Koroleva 2014a	Conference abstract
Koroleva 2014b	Conference abstract
Kremer 2015	Cross over study design
Kremer 2009	Wrong drug exposure
Kremer 2013	Wrong drug exposure
Landewe 2015	Conference abstract
Manders 2015	Trial patients switched therapy within one year/before completion of study period
Mathias 2000	Wrong drug exposure
McInnes 2015	Compares lipid levels in those randomized to CZP or PL, in MTX-IR patients

(Continued)

Miyasaka 2008	Wrong drug exposure
Moreland 1999	Wrong drug exposure
Moreland 2002	Wrong drug exposure
Navarro 2014	Conference abstract
Nishimoto 2004	Wrong drug exposure
Nishimoto 2007	Wrong drug exposure
Oakley 2014	Conference abstract
Ostergaard 2015	Wrong drug exposure
Quinn 2005	Wrong drug exposure
Pavelka 2013	Sub-group analysis of Smolen 2013 NCT00565409
Smolen 2014	Patients in the control group also received the intervention
Sonomoto 2014	Open label study
St Clair 2004	Wrong drug exposure
Tada 2012	Wrong drug exposure
Takeuchi 2013a	Wrong drug exposure
Takeuchi 2013b	Wrong drug exposure
Takeuchi 2013c	Wrong drug exposure
Takeuchi 2014	Wrong drug exposure
Van de Putte 2003	Wrong drug exposure
Van de Putte 2004	Wrong drug exposure
Van Vollenhoven 2009	Duplicate of Van Vollenhoven 2012
Vital 2015	B cell depletion study
Weinblatt 2007	Wrong drug exposure
Weinblatt 2014	Results at 1 year of Weinblatt 2013b GO-FURTHER trial, NCT00973479
Westhovens 2014	Conference abstract
Yamamoto 2014b	Wrong drug exposure
Yamanaka 2014	Post hoc analysis of Takeuchi 2014

## WHAT'S NEW

Date	Event	Description
22 June 2015	New search has been performed	New citation: conclusions changed, description: Original review split into four by patient populations (1) MTX/DMARD-naive; (2) MTX/DMARD-experienced; and (3) biologic-experienced. This review will focus on RA patients who are MTX/DMARD-experienced (i.e., MTX/DMARD-incomplete responders)
22 June 2015	New citation required and conclusions have changed	Updated, description: New search with 73 new studies

## HISTORY

Review first published: Issue 5, 2016

Date	Event	Description
1 March 2010	Amended	Odds ratios have been used in the network meta-analyses.  See 'Published notes' for details.
25 February 2010	Amended	CMSG ID: C187-R

## CONTRIBUTIONS OF AUTHORS

JS, GW - study concept

JS, GW - protocol development

JS, RC, PT, GW, ETG - protocol editing

JS, GW, ETG - data extraction

AM - data programming

AK, AH, GW, AM, JS- data analysis

JS - first draft of the review and NMA; major revision

LM - draft of SOF table, abstract and PLS

NS - data abstraction and risk of bias assessment for 2014/2015 studies

All authors - revision of the manuscript, and approval of the final version

## DECLARATIONS OF INTEREST

JS - JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta and Allergan pharmaceuticals, WebMD, UBM LLC and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c)(3) entity. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee.

RC - research grant and consultant fee (paid to his institution) from Abbott/Abbvie, MSD, Norpharma/Mundipharma, Roche

GW - research grant and consultant fee from Bristol-Myers Squibb

AK - none

AH - none

AM - none

LM - none

ETG - none

NS - none

PT - grants/honoraria from Bristol Myers, Chiltern International, and UCB

## SOURCES OF SUPPORT

### Internal sources

- The Oak Foundation, Switzerland.

Provide support for The Parker Institute: Musculoskeletal Statistics Unit.

- Birmingham VA Medical Center, USA.

JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA.

### External sources

- Jasvinder Singh, USA.

This work was supported in part by resources provided to the UAB Cochrane NMA Satellite by the Rheumatology division at University of Alabama at Birmingham (UAB). JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging (NIA) U01 AG018947, National Cancer Institute (NCI) U10 CA149950, and research contract CE-1304-6631 from the Patient Centered Outcomes Research Institute (PCORI). JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA.

## NOTES

This original 2006 version was co-published in the Canadian Medical Association Journal (CMAJ 2009 DOI:10.1503/cmaj.091391) and because of separate review processes, both versions were substantively different - risk ratios were used in the network meta-analyses in the Cochrane version and odds ratios in the CMAJ version. Since the indirect comparisons approach used requires odds ratios, we have now harmonized the network meta-analyses using odds ratios in the Cochrane version as well. We also provide risk ratio (RR) in the abstract, since these are easier to understand for patients and clinicians.

## INDEX TERMS

### Medical Subject Headings (MeSH)

Adalimumab [therapeutic use]; Antibodies, Monoclonal [therapeutic use]; Antibodies, Monoclonal, Humanized [therapeutic use]; Antirheumatic Agents [\*therapeutic use]; Arthritis, Rheumatoid [\*drug therapy]; Biological Products [\*therapeutic use]; Certolizumab Pegol [therapeutic use]; Etanercept [therapeutic use]; Infliximab [therapeutic use]; Interleukin 1 Receptor Antagonist Protein [therapeutic use]; Methotrexate [therapeutic use]; Piperidines [\*therapeutic use]; Protein Kinase Inhibitors [\*therapeutic use]; Pyrimidines [\*therapeutic use]; Pyrroles [\*therapeutic use]; Randomized Controlled Trials as Topic; Rituximab [therapeutic use]

### MeSH check words

Humans